<!DOCTYPE html>
<html>
<head><meta charset="utf-8" />
<meta http-equiv="X-UA-Compatible" content="chrome=1" />

<meta name="apple-mobile-web-app-capable" content="yes" />
<meta name="apple-mobile-web-app-status-bar-style" content="black-translucent" />


<title>Gr2_MAPDB_Presentation slides</title><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/2.0.3/jquery.min.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/require.js/2.1.10/require.min.js"></script>

<!-- General and theme style sheets -->
<link rel="stylesheet" href="https://unpkg.com/reveal.js@4.0.2/dist/reveal.css">
<link rel="stylesheet" href="https://unpkg.com/reveal.js@4.0.2/dist/theme/simple.css" id="theme">

<!-- If the query includes 'print-pdf', include the PDF print sheet -->
<script>
if( window.location.search.match( /print-pdf/gi ) ) {
        var link = document.createElement( 'link' );
        link.rel = 'stylesheet';
        link.type = 'text/css';
        document.getElementsByTagName( 'head' )[0].appendChild( link );
}
</script>

<!-- Loading the mathjax macro -->
<!-- Load mathjax -->
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.7/latest.js?config=TeX-MML-AM_CHTML-full,Safe"> </script>
    <!-- MathJax configuration -->
    <script type="text/x-mathjax-config">
    init_mathjax = function() {
        if (window.MathJax) {
        // MathJax loaded
            MathJax.Hub.Config({
                TeX: {
                    equationNumbers: {
                    autoNumber: "AMS",
                    useLabelIds: true
                    }
                },
                tex2jax: {
                    inlineMath: [ ['$','$'], ["\\(","\\)"] ],
                    displayMath: [ ['$$','$$'], ["\\[","\\]"] ],
                    processEscapes: true,
                    processEnvironments: true
                },
                displayAlign: 'center',
                CommonHTML: {
                    linebreaks: { 
                    automatic: true 
                    }
                },
                "HTML-CSS": {
                    linebreaks: { 
                    automatic: true 
                    }
                }
            });
        
            MathJax.Hub.Queue(["Typeset", MathJax.Hub]);
        }
    }
    init_mathjax();
    </script>
    <!-- End of mathjax configuration -->

<style type="text/css">
    pre { line-height: 125%; }
td.linenos .normal { color: inherit; background-color: transparent; padding-left: 5px; padding-right: 5px; }
span.linenos { color: inherit; background-color: transparent; padding-left: 5px; padding-right: 5px; }
td.linenos .special { color: #000000; background-color: #ffffc0; padding-left: 5px; padding-right: 5px; }
span.linenos.special { color: #000000; background-color: #ffffc0; padding-left: 5px; padding-right: 5px; }
.highlight .hll { background-color: var(--jp-cell-editor-active-background) }
.highlight { background: var(--jp-cell-editor-background); color: var(--jp-mirror-editor-variable-color) }
.highlight .c { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment */
.highlight .err { color: var(--jp-mirror-editor-error-color) } /* Error */
.highlight .k { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword */
.highlight .o { color: var(--jp-mirror-editor-operator-color); font-weight: bold } /* Operator */
.highlight .p { color: var(--jp-mirror-editor-punctuation-color) } /* Punctuation */
.highlight .ch { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Hashbang */
.highlight .cm { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Multiline */
.highlight .cp { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Preproc */
.highlight .cpf { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.PreprocFile */
.highlight .c1 { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Single */
.highlight .cs { color: var(--jp-mirror-editor-comment-color); font-style: italic } /* Comment.Special */
.highlight .kc { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Constant */
.highlight .kd { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Declaration */
.highlight .kn { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Namespace */
.highlight .kp { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Pseudo */
.highlight .kr { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Reserved */
.highlight .kt { color: var(--jp-mirror-editor-keyword-color); font-weight: bold } /* Keyword.Type */
.highlight .m { color: var(--jp-mirror-editor-number-color) } /* Literal.Number */
.highlight .s { color: var(--jp-mirror-editor-string-color) } /* Literal.String */
.highlight .ow { color: var(--jp-mirror-editor-operator-color); font-weight: bold } /* Operator.Word */
.highlight .w { color: var(--jp-mirror-editor-variable-color) } /* Text.Whitespace */
.highlight .mb { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Bin */
.highlight .mf { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Float */
.highlight .mh { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Hex */
.highlight .mi { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Integer */
.highlight .mo { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Oct */
.highlight .sa { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Affix */
.highlight .sb { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Backtick */
.highlight .sc { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Char */
.highlight .dl { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Delimiter */
.highlight .sd { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Doc */
.highlight .s2 { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Double */
.highlight .se { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Escape */
.highlight .sh { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Heredoc */
.highlight .si { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Interpol */
.highlight .sx { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Other */
.highlight .sr { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Regex */
.highlight .s1 { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Single */
.highlight .ss { color: var(--jp-mirror-editor-string-color) } /* Literal.String.Symbol */
.highlight .il { color: var(--jp-mirror-editor-number-color) } /* Literal.Number.Integer.Long */
  </style>
<style type="text/css">
    /*This file contains any manual css for this page that needs to override the global styles.
This is only required when different pages style the same element differently. This is just
a hack to deal with our current css styles and no new styling should be added in this file.*/

#ipython-main-app {
    position: relative;
}
#jupyter-main-app {
    position: relative;
}

  </style>



<style type="text/css">
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*
 * Mozilla scrollbar styling
 */

/* use standard opaque scrollbars for most nodes */
[data-jp-theme-scrollbars='true'] {
  scrollbar-color: rgb(var(--jp-scrollbar-thumb-color))
    var(--jp-scrollbar-background-color);
}

/* for code nodes, use a transparent style of scrollbar. These selectors
 * will match lower in the tree, and so will override the above */
[data-jp-theme-scrollbars='true'] .CodeMirror-hscrollbar,
[data-jp-theme-scrollbars='true'] .CodeMirror-vscrollbar {
  scrollbar-color: rgba(var(--jp-scrollbar-thumb-color), 0.5) transparent;
}

/*
 * Webkit scrollbar styling
 */

/* use standard opaque scrollbars for most nodes */

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar,
[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-corner {
  background: var(--jp-scrollbar-background-color);
}

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-thumb {
  background: rgb(var(--jp-scrollbar-thumb-color));
  border: var(--jp-scrollbar-thumb-margin) solid transparent;
  background-clip: content-box;
  border-radius: var(--jp-scrollbar-thumb-radius);
}

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-track:horizontal {
  border-left: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
  border-right: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
}

[data-jp-theme-scrollbars='true'] ::-webkit-scrollbar-track:vertical {
  border-top: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
  border-bottom: var(--jp-scrollbar-endpad) solid
    var(--jp-scrollbar-background-color);
}

/* for code nodes, use a transparent style of scrollbar */

[data-jp-theme-scrollbars='true'] .CodeMirror-hscrollbar::-webkit-scrollbar,
[data-jp-theme-scrollbars='true'] .CodeMirror-vscrollbar::-webkit-scrollbar,
[data-jp-theme-scrollbars='true']
  .CodeMirror-hscrollbar::-webkit-scrollbar-corner,
[data-jp-theme-scrollbars='true']
  .CodeMirror-vscrollbar::-webkit-scrollbar-corner {
  background-color: transparent;
}

[data-jp-theme-scrollbars='true']
  .CodeMirror-hscrollbar::-webkit-scrollbar-thumb,
[data-jp-theme-scrollbars='true']
  .CodeMirror-vscrollbar::-webkit-scrollbar-thumb {
  background: rgba(var(--jp-scrollbar-thumb-color), 0.5);
  border: var(--jp-scrollbar-thumb-margin) solid transparent;
  background-clip: content-box;
  border-radius: var(--jp-scrollbar-thumb-radius);
}

[data-jp-theme-scrollbars='true']
  .CodeMirror-hscrollbar::-webkit-scrollbar-track:horizontal {
  border-left: var(--jp-scrollbar-endpad) solid transparent;
  border-right: var(--jp-scrollbar-endpad) solid transparent;
}

[data-jp-theme-scrollbars='true']
  .CodeMirror-vscrollbar::-webkit-scrollbar-track:vertical {
  border-top: var(--jp-scrollbar-endpad) solid transparent;
  border-bottom: var(--jp-scrollbar-endpad) solid transparent;
}

/*
 * Phosphor
 */

.lm-ScrollBar[data-orientation='horizontal'] {
  min-height: 16px;
  max-height: 16px;
  min-width: 45px;
  border-top: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='vertical'] {
  min-width: 16px;
  max-width: 16px;
  min-height: 45px;
  border-left: 1px solid #a0a0a0;
}

.lm-ScrollBar-button {
  background-color: #f0f0f0;
  background-position: center center;
  min-height: 15px;
  max-height: 15px;
  min-width: 15px;
  max-width: 15px;
}

.lm-ScrollBar-button:hover {
  background-color: #dadada;
}

.lm-ScrollBar-button.lm-mod-active {
  background-color: #cdcdcd;
}

.lm-ScrollBar-track {
  background: #f0f0f0;
}

.lm-ScrollBar-thumb {
  background: #cdcdcd;
}

.lm-ScrollBar-thumb:hover {
  background: #bababa;
}

.lm-ScrollBar-thumb.lm-mod-active {
  background: #a0a0a0;
}

.lm-ScrollBar[data-orientation='horizontal'] .lm-ScrollBar-thumb {
  height: 100%;
  min-width: 15px;
  border-left: 1px solid #a0a0a0;
  border-right: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='vertical'] .lm-ScrollBar-thumb {
  width: 100%;
  min-height: 15px;
  border-top: 1px solid #a0a0a0;
  border-bottom: 1px solid #a0a0a0;
}

.lm-ScrollBar[data-orientation='horizontal']
  .lm-ScrollBar-button[data-action='decrement'] {
  background-image: var(--jp-icon-caret-left);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='horizontal']
  .lm-ScrollBar-button[data-action='increment'] {
  background-image: var(--jp-icon-caret-right);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='vertical']
  .lm-ScrollBar-button[data-action='decrement'] {
  background-image: var(--jp-icon-caret-up);
  background-size: 17px;
}

.lm-ScrollBar[data-orientation='vertical']
  .lm-ScrollBar-button[data-action='increment'] {
  background-image: var(--jp-icon-caret-down);
  background-size: 17px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-Widget, /* </DEPRECATED> */
.lm-Widget {
  box-sizing: border-box;
  position: relative;
  overflow: hidden;
  cursor: default;
}


/* <DEPRECATED> */ .p-Widget.p-mod-hidden, /* </DEPRECATED> */
.lm-Widget.lm-mod-hidden {
  display: none !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-CommandPalette, /* </DEPRECATED> */
.lm-CommandPalette {
  display: flex;
  flex-direction: column;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-CommandPalette-search, /* </DEPRECATED> */
.lm-CommandPalette-search {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-CommandPalette-content, /* </DEPRECATED> */
.lm-CommandPalette-content {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  min-height: 0;
  overflow: auto;
  list-style-type: none;
}


/* <DEPRECATED> */ .p-CommandPalette-header, /* </DEPRECATED> */
.lm-CommandPalette-header {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}


/* <DEPRECATED> */ .p-CommandPalette-item, /* </DEPRECATED> */
.lm-CommandPalette-item {
  display: flex;
  flex-direction: row;
}


/* <DEPRECATED> */ .p-CommandPalette-itemIcon, /* </DEPRECATED> */
.lm-CommandPalette-itemIcon {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-CommandPalette-itemContent, /* </DEPRECATED> */
.lm-CommandPalette-itemContent {
  flex: 1 1 auto;
  overflow: hidden;
}


/* <DEPRECATED> */ .p-CommandPalette-itemShortcut, /* </DEPRECATED> */
.lm-CommandPalette-itemShortcut {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-CommandPalette-itemLabel, /* </DEPRECATED> */
.lm-CommandPalette-itemLabel {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-DockPanel, /* </DEPRECATED> */
.lm-DockPanel {
  z-index: 0;
}


/* <DEPRECATED> */ .p-DockPanel-widget, /* </DEPRECATED> */
.lm-DockPanel-widget {
  z-index: 0;
}


/* <DEPRECATED> */ .p-DockPanel-tabBar, /* </DEPRECATED> */
.lm-DockPanel-tabBar {
  z-index: 1;
}


/* <DEPRECATED> */ .p-DockPanel-handle, /* </DEPRECATED> */
.lm-DockPanel-handle {
  z-index: 2;
}


/* <DEPRECATED> */ .p-DockPanel-handle.p-mod-hidden, /* </DEPRECATED> */
.lm-DockPanel-handle.lm-mod-hidden {
  display: none !important;
}


/* <DEPRECATED> */ .p-DockPanel-handle:after, /* </DEPRECATED> */
.lm-DockPanel-handle:after {
  position: absolute;
  top: 0;
  left: 0;
  width: 100%;
  height: 100%;
  content: '';
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='horizontal'],
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='horizontal'] {
  cursor: ew-resize;
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='vertical'],
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='vertical'] {
  cursor: ns-resize;
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='horizontal']:after,
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='horizontal']:after {
  left: 50%;
  min-width: 8px;
  transform: translateX(-50%);
}


/* <DEPRECATED> */
.p-DockPanel-handle[data-orientation='vertical']:after,
/* </DEPRECATED> */
.lm-DockPanel-handle[data-orientation='vertical']:after {
  top: 50%;
  min-height: 8px;
  transform: translateY(-50%);
}


/* <DEPRECATED> */ .p-DockPanel-overlay, /* </DEPRECATED> */
.lm-DockPanel-overlay {
  z-index: 3;
  box-sizing: border-box;
  pointer-events: none;
}


/* <DEPRECATED> */ .p-DockPanel-overlay.p-mod-hidden, /* </DEPRECATED> */
.lm-DockPanel-overlay.lm-mod-hidden {
  display: none !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-Menu, /* </DEPRECATED> */
.lm-Menu {
  z-index: 10000;
  position: absolute;
  white-space: nowrap;
  overflow-x: hidden;
  overflow-y: auto;
  outline: none;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-Menu-content, /* </DEPRECATED> */
.lm-Menu-content {
  margin: 0;
  padding: 0;
  display: table;
  list-style-type: none;
}


/* <DEPRECATED> */ .p-Menu-item, /* </DEPRECATED> */
.lm-Menu-item {
  display: table-row;
}


/* <DEPRECATED> */
.p-Menu-item.p-mod-hidden,
.p-Menu-item.p-mod-collapsed,
/* </DEPRECATED> */
.lm-Menu-item.lm-mod-hidden,
.lm-Menu-item.lm-mod-collapsed {
  display: none !important;
}


/* <DEPRECATED> */
.p-Menu-itemIcon,
.p-Menu-itemSubmenuIcon,
/* </DEPRECATED> */
.lm-Menu-itemIcon,
.lm-Menu-itemSubmenuIcon {
  display: table-cell;
  text-align: center;
}


/* <DEPRECATED> */ .p-Menu-itemLabel, /* </DEPRECATED> */
.lm-Menu-itemLabel {
  display: table-cell;
  text-align: left;
}


/* <DEPRECATED> */ .p-Menu-itemShortcut, /* </DEPRECATED> */
.lm-Menu-itemShortcut {
  display: table-cell;
  text-align: right;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-MenuBar, /* </DEPRECATED> */
.lm-MenuBar {
  outline: none;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-MenuBar-content, /* </DEPRECATED> */
.lm-MenuBar-content {
  margin: 0;
  padding: 0;
  display: flex;
  flex-direction: row;
  list-style-type: none;
}


/* <DEPRECATED> */ .p--MenuBar-item, /* </DEPRECATED> */
.lm-MenuBar-item {
  box-sizing: border-box;
}


/* <DEPRECATED> */
.p-MenuBar-itemIcon,
.p-MenuBar-itemLabel,
/* </DEPRECATED> */
.lm-MenuBar-itemIcon,
.lm-MenuBar-itemLabel {
  display: inline-block;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-ScrollBar, /* </DEPRECATED> */
.lm-ScrollBar {
  display: flex;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */
.p-ScrollBar[data-orientation='horizontal'],
/* </DEPRECATED> */
.lm-ScrollBar[data-orientation='horizontal'] {
  flex-direction: row;
}


/* <DEPRECATED> */
.p-ScrollBar[data-orientation='vertical'],
/* </DEPRECATED> */
.lm-ScrollBar[data-orientation='vertical'] {
  flex-direction: column;
}


/* <DEPRECATED> */ .p-ScrollBar-button, /* </DEPRECATED> */
.lm-ScrollBar-button {
  box-sizing: border-box;
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-ScrollBar-track, /* </DEPRECATED> */
.lm-ScrollBar-track {
  box-sizing: border-box;
  position: relative;
  overflow: hidden;
  flex: 1 1 auto;
}


/* <DEPRECATED> */ .p-ScrollBar-thumb, /* </DEPRECATED> */
.lm-ScrollBar-thumb {
  box-sizing: border-box;
  position: absolute;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-SplitPanel-child, /* </DEPRECATED> */
.lm-SplitPanel-child {
  z-index: 0;
}


/* <DEPRECATED> */ .p-SplitPanel-handle, /* </DEPRECATED> */
.lm-SplitPanel-handle {
  z-index: 1;
}


/* <DEPRECATED> */ .p-SplitPanel-handle.p-mod-hidden, /* </DEPRECATED> */
.lm-SplitPanel-handle.lm-mod-hidden {
  display: none !important;
}


/* <DEPRECATED> */ .p-SplitPanel-handle:after, /* </DEPRECATED> */
.lm-SplitPanel-handle:after {
  position: absolute;
  top: 0;
  left: 0;
  width: 100%;
  height: 100%;
  content: '';
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='horizontal'] > .p-SplitPanel-handle,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='horizontal'] > .lm-SplitPanel-handle {
  cursor: ew-resize;
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='vertical'] > .p-SplitPanel-handle,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='vertical'] > .lm-SplitPanel-handle {
  cursor: ns-resize;
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='horizontal'] > .p-SplitPanel-handle:after,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='horizontal'] > .lm-SplitPanel-handle:after {
  left: 50%;
  min-width: 8px;
  transform: translateX(-50%);
}


/* <DEPRECATED> */
.p-SplitPanel[data-orientation='vertical'] > .p-SplitPanel-handle:after,
/* </DEPRECATED> */
.lm-SplitPanel[data-orientation='vertical'] > .lm-SplitPanel-handle:after {
  top: 50%;
  min-height: 8px;
  transform: translateY(-50%);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-TabBar, /* </DEPRECATED> */
.lm-TabBar {
  display: flex;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}


/* <DEPRECATED> */ .p-TabBar[data-orientation='horizontal'], /* </DEPRECATED> */
.lm-TabBar[data-orientation='horizontal'] {
  flex-direction: row;
}


/* <DEPRECATED> */ .p-TabBar[data-orientation='vertical'], /* </DEPRECATED> */
.lm-TabBar[data-orientation='vertical'] {
  flex-direction: column;
}


/* <DEPRECATED> */ .p-TabBar-content, /* </DEPRECATED> */
.lm-TabBar-content {
  margin: 0;
  padding: 0;
  display: flex;
  flex: 1 1 auto;
  list-style-type: none;
}


/* <DEPRECATED> */
.p-TabBar[data-orientation='horizontal'] > .p-TabBar-content,
/* </DEPRECATED> */
.lm-TabBar[data-orientation='horizontal'] > .lm-TabBar-content {
  flex-direction: row;
}


/* <DEPRECATED> */
.p-TabBar[data-orientation='vertical'] > .p-TabBar-content,
/* </DEPRECATED> */
.lm-TabBar[data-orientation='vertical'] > .lm-TabBar-content {
  flex-direction: column;
}


/* <DEPRECATED> */ .p-TabBar-tab, /* </DEPRECATED> */
.lm-TabBar-tab {
  display: flex;
  flex-direction: row;
  box-sizing: border-box;
  overflow: hidden;
}


/* <DEPRECATED> */
.p-TabBar-tabIcon,
.p-TabBar-tabCloseIcon,
/* </DEPRECATED> */
.lm-TabBar-tabIcon,
.lm-TabBar-tabCloseIcon {
  flex: 0 0 auto;
}


/* <DEPRECATED> */ .p-TabBar-tabLabel, /* </DEPRECATED> */
.lm-TabBar-tabLabel {
  flex: 1 1 auto;
  overflow: hidden;
  white-space: nowrap;
}


/* <DEPRECATED> */ .p-TabBar-tab.p-mod-hidden, /* </DEPRECATED> */
.lm-TabBar-tab.lm-mod-hidden {
  display: none !important;
}


/* <DEPRECATED> */ .p-TabBar.p-mod-dragging .p-TabBar-tab, /* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging .lm-TabBar-tab {
  position: relative;
}


/* <DEPRECATED> */
.p-TabBar.p-mod-dragging[data-orientation='horizontal'] .p-TabBar-tab,
/* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging[data-orientation='horizontal'] .lm-TabBar-tab {
  left: 0;
  transition: left 150ms ease;
}


/* <DEPRECATED> */
.p-TabBar.p-mod-dragging[data-orientation='vertical'] .p-TabBar-tab,
/* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging[data-orientation='vertical'] .lm-TabBar-tab {
  top: 0;
  transition: top 150ms ease;
}


/* <DEPRECATED> */
.p-TabBar.p-mod-dragging .p-TabBar-tab.p-mod-dragging
/* </DEPRECATED> */
.lm-TabBar.lm-mod-dragging .lm-TabBar-tab.lm-mod-dragging {
  transition: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ .p-TabPanel-tabBar, /* </DEPRECATED> */
.lm-TabPanel-tabBar {
  z-index: 1;
}


/* <DEPRECATED> */ .p-TabPanel-stackedPanel, /* </DEPRECATED> */
.lm-TabPanel-stackedPanel {
  z-index: 0;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/

@charset "UTF-8";
/*!

Copyright 2015-present Palantir Technologies, Inc. All rights reserved.
Licensed under the Apache License, Version 2.0.

*/
html{
  -webkit-box-sizing:border-box;
          box-sizing:border-box; }

*,
*::before,
*::after{
  -webkit-box-sizing:inherit;
          box-sizing:inherit; }

body{
  text-transform:none;
  line-height:1.28581;
  letter-spacing:0;
  font-size:14px;
  font-weight:400;
  color:#182026;
  font-family:-apple-system, "BlinkMacSystemFont", "Segoe UI", "Roboto", "Oxygen", "Ubuntu", "Cantarell", "Open Sans", "Helvetica Neue", "Icons16", sans-serif; }

p{
  margin-top:0;
  margin-bottom:10px; }

small{
  font-size:12px; }

strong{
  font-weight:600; }

::-moz-selection{
  background:rgba(125, 188, 255, 0.6); }

::selection{
  background:rgba(125, 188, 255, 0.6); }
.bp3-heading{
  color:#182026;
  font-weight:600;
  margin:0 0 10px;
  padding:0; }
  .bp3-dark .bp3-heading{
    color:#f5f8fa; }

h1.bp3-heading, .bp3-running-text h1{
  line-height:40px;
  font-size:36px; }

h2.bp3-heading, .bp3-running-text h2{
  line-height:32px;
  font-size:28px; }

h3.bp3-heading, .bp3-running-text h3{
  line-height:25px;
  font-size:22px; }

h4.bp3-heading, .bp3-running-text h4{
  line-height:21px;
  font-size:18px; }

h5.bp3-heading, .bp3-running-text h5{
  line-height:19px;
  font-size:16px; }

h6.bp3-heading, .bp3-running-text h6{
  line-height:16px;
  font-size:14px; }
.bp3-ui-text{
  text-transform:none;
  line-height:1.28581;
  letter-spacing:0;
  font-size:14px;
  font-weight:400; }

.bp3-monospace-text{
  text-transform:none;
  font-family:monospace; }

.bp3-text-muted{
  color:#5c7080; }
  .bp3-dark .bp3-text-muted{
    color:#a7b6c2; }

.bp3-text-disabled{
  color:rgba(92, 112, 128, 0.6); }
  .bp3-dark .bp3-text-disabled{
    color:rgba(167, 182, 194, 0.6); }

.bp3-text-overflow-ellipsis{
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal; }
.bp3-running-text{
  line-height:1.5;
  font-size:14px; }
  .bp3-running-text h1{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h1{
      color:#f5f8fa; }
  .bp3-running-text h2{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h2{
      color:#f5f8fa; }
  .bp3-running-text h3{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h3{
      color:#f5f8fa; }
  .bp3-running-text h4{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h4{
      color:#f5f8fa; }
  .bp3-running-text h5{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h5{
      color:#f5f8fa; }
  .bp3-running-text h6{
    color:#182026;
    font-weight:600;
    margin-top:40px;
    margin-bottom:20px; }
    .bp3-dark .bp3-running-text h6{
      color:#f5f8fa; }
  .bp3-running-text hr{
    margin:20px 0;
    border:none;
    border-bottom:1px solid rgba(16, 22, 26, 0.15); }
    .bp3-dark .bp3-running-text hr{
      border-color:rgba(255, 255, 255, 0.15); }
  .bp3-running-text p{
    margin:0 0 10px;
    padding:0; }

.bp3-text-large{
  font-size:16px; }

.bp3-text-small{
  font-size:12px; }
a{
  text-decoration:none;
  color:#106ba3; }
  a:hover{
    cursor:pointer;
    text-decoration:underline;
    color:#106ba3; }
  a .bp3-icon, a .bp3-icon-standard, a .bp3-icon-large{
    color:inherit; }
  a code,
  .bp3-dark a code{
    color:inherit; }
  .bp3-dark a,
  .bp3-dark a:hover{
    color:#48aff0; }
    .bp3-dark a .bp3-icon, .bp3-dark a .bp3-icon-standard, .bp3-dark a .bp3-icon-large,
    .bp3-dark a:hover .bp3-icon,
    .bp3-dark a:hover .bp3-icon-standard,
    .bp3-dark a:hover .bp3-icon-large{
      color:inherit; }
.bp3-running-text code, .bp3-code{
  text-transform:none;
  font-family:monospace;
  border-radius:3px;
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2);
  background:rgba(255, 255, 255, 0.7);
  padding:2px 5px;
  color:#5c7080;
  font-size:smaller; }
  .bp3-dark .bp3-running-text code, .bp3-running-text .bp3-dark code, .bp3-dark .bp3-code{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#a7b6c2; }
  .bp3-running-text a > code, a > .bp3-code{
    color:#137cbd; }
    .bp3-dark .bp3-running-text a > code, .bp3-running-text .bp3-dark a > code, .bp3-dark a > .bp3-code{
      color:inherit; }

.bp3-running-text pre, .bp3-code-block{
  text-transform:none;
  font-family:monospace;
  display:block;
  margin:10px 0;
  border-radius:3px;
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
  background:rgba(255, 255, 255, 0.7);
  padding:13px 15px 12px;
  line-height:1.4;
  color:#182026;
  font-size:13px;
  word-break:break-all;
  word-wrap:break-word; }
  .bp3-dark .bp3-running-text pre, .bp3-running-text .bp3-dark pre, .bp3-dark .bp3-code-block{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa; }
  .bp3-running-text pre > code, .bp3-code-block > code{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none;
    padding:0;
    color:inherit;
    font-size:inherit; }

.bp3-running-text kbd, .bp3-key{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  min-width:24px;
  height:24px;
  padding:3px 6px;
  vertical-align:middle;
  line-height:24px;
  color:#5c7080;
  font-family:inherit;
  font-size:12px; }
  .bp3-running-text kbd .bp3-icon, .bp3-key .bp3-icon, .bp3-running-text kbd .bp3-icon-standard, .bp3-key .bp3-icon-standard, .bp3-running-text kbd .bp3-icon-large, .bp3-key .bp3-icon-large{
    margin-right:5px; }
  .bp3-dark .bp3-running-text kbd, .bp3-running-text .bp3-dark kbd, .bp3-dark .bp3-key{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
    background:#394b59;
    color:#a7b6c2; }
.bp3-running-text blockquote, .bp3-blockquote{
  margin:0 0 10px;
  border-left:solid 4px rgba(167, 182, 194, 0.5);
  padding:0 20px; }
  .bp3-dark .bp3-running-text blockquote, .bp3-running-text .bp3-dark blockquote, .bp3-dark .bp3-blockquote{
    border-color:rgba(115, 134, 148, 0.5); }
.bp3-running-text ul,
.bp3-running-text ol, .bp3-list{
  margin:10px 0;
  padding-left:30px; }
  .bp3-running-text ul li:not(:last-child), .bp3-running-text ol li:not(:last-child), .bp3-list li:not(:last-child){
    margin-bottom:5px; }
  .bp3-running-text ul ol, .bp3-running-text ol ol, .bp3-list ol,
  .bp3-running-text ul ul,
  .bp3-running-text ol ul,
  .bp3-list ul{
    margin-top:5px; }

.bp3-list-unstyled{
  margin:0;
  padding:0;
  list-style:none; }
  .bp3-list-unstyled li{
    padding:0; }
.bp3-rtl{
  text-align:right; }

.bp3-dark{
  color:#f5f8fa; }

:focus{
  outline:rgba(19, 124, 189, 0.6) auto 2px;
  outline-offset:2px;
  -moz-outline-radius:6px; }

.bp3-focus-disabled :focus{
  outline:none !important; }
  .bp3-focus-disabled :focus ~ .bp3-control-indicator{
    outline:none !important; }

.bp3-alert{
  max-width:400px;
  padding:20px; }

.bp3-alert-body{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex; }
  .bp3-alert-body .bp3-icon{
    margin-top:0;
    margin-right:20px;
    font-size:40px; }

.bp3-alert-footer{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:reverse;
      -ms-flex-direction:row-reverse;
          flex-direction:row-reverse;
  margin-top:10px; }
  .bp3-alert-footer .bp3-button{
    margin-left:10px; }
.bp3-breadcrumbs{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -ms-flex-wrap:wrap;
      flex-wrap:wrap;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  margin:0;
  cursor:default;
  height:30px;
  padding:0;
  list-style:none; }
  .bp3-breadcrumbs > li{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-align:center;
        -ms-flex-align:center;
            align-items:center; }
    .bp3-breadcrumbs > li::after{
      display:block;
      margin:0 5px;
      background:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cpath fill-rule='evenodd' clip-rule='evenodd' d='M10.71 7.29l-4-4a1.003 1.003 0 0 0-1.42 1.42L8.59 8 5.3 11.29c-.19.18-.3.43-.3.71a1.003 1.003 0 0 0 1.71.71l4-4c.18-.18.29-.43.29-.71 0-.28-.11-.53-.29-.71z' fill='%235C7080'/%3e%3c/svg%3e");
      width:16px;
      height:16px;
      content:""; }
    .bp3-breadcrumbs > li:last-of-type::after{
      display:none; }

.bp3-breadcrumb,
.bp3-breadcrumb-current,
.bp3-breadcrumbs-collapsed{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  font-size:16px; }

.bp3-breadcrumb,
.bp3-breadcrumbs-collapsed{
  color:#5c7080; }

.bp3-breadcrumb:hover{
  text-decoration:none; }

.bp3-breadcrumb.bp3-disabled{
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-breadcrumb .bp3-icon{
  margin-right:5px; }

.bp3-breadcrumb-current{
  color:inherit;
  font-weight:600; }
  .bp3-breadcrumb-current .bp3-input{
    vertical-align:baseline;
    font-size:inherit;
    font-weight:inherit; }

.bp3-breadcrumbs-collapsed{
  margin-right:2px;
  border:none;
  border-radius:3px;
  background:#ced9e0;
  cursor:pointer;
  padding:1px 5px;
  vertical-align:text-bottom; }
  .bp3-breadcrumbs-collapsed::before{
    display:block;
    background:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cg fill='%235C7080'%3e%3ccircle cx='2' cy='8.03' r='2'/%3e%3ccircle cx='14' cy='8.03' r='2'/%3e%3ccircle cx='8' cy='8.03' r='2'/%3e%3c/g%3e%3c/svg%3e") center no-repeat;
    width:16px;
    height:16px;
    content:""; }
  .bp3-breadcrumbs-collapsed:hover{
    background:#bfccd6;
    text-decoration:none;
    color:#182026; }

.bp3-dark .bp3-breadcrumb,
.bp3-dark .bp3-breadcrumbs-collapsed{
  color:#a7b6c2; }

.bp3-dark .bp3-breadcrumbs > li::after{
  color:#a7b6c2; }

.bp3-dark .bp3-breadcrumb.bp3-disabled{
  color:rgba(167, 182, 194, 0.6); }

.bp3-dark .bp3-breadcrumb-current{
  color:#f5f8fa; }

.bp3-dark .bp3-breadcrumbs-collapsed{
  background:rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-breadcrumbs-collapsed:hover{
    background:rgba(16, 22, 26, 0.6);
    color:#f5f8fa; }
.bp3-button{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  border:none;
  border-radius:3px;
  cursor:pointer;
  padding:5px 10px;
  vertical-align:middle;
  text-align:left;
  font-size:14px;
  min-width:30px;
  min-height:30px; }
  .bp3-button > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-button > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-button::before,
  .bp3-button > *{
    margin-right:7px; }
  .bp3-button:empty::before,
  .bp3-button > :last-child{
    margin-right:0; }
  .bp3-button:empty{
    padding:0 !important; }
  .bp3-button:disabled, .bp3-button.bp3-disabled{
    cursor:not-allowed; }
  .bp3-button.bp3-fill{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    width:100%; }
  .bp3-button.bp3-align-right,
  .bp3-align-right .bp3-button{
    text-align:right; }
  .bp3-button.bp3-align-left,
  .bp3-align-left .bp3-button{
    text-align:left; }
  .bp3-button:not([class*="bp3-intent-"]){
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-color:#f5f8fa;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
    color:#182026; }
    .bp3-button:not([class*="bp3-intent-"]):hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
      background-clip:padding-box;
      background-color:#ebf1f5; }
    .bp3-button:not([class*="bp3-intent-"]):active, .bp3-button:not([class*="bp3-intent-"]).bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#d8e1e8;
      background-image:none; }
    .bp3-button:not([class*="bp3-intent-"]):disabled, .bp3-button:not([class*="bp3-intent-"]).bp3-disabled{
      outline:none;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(206, 217, 224, 0.5);
      background-image:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-button:not([class*="bp3-intent-"]):disabled.bp3-active, .bp3-button:not([class*="bp3-intent-"]):disabled.bp3-active:hover, .bp3-button:not([class*="bp3-intent-"]).bp3-disabled.bp3-active, .bp3-button:not([class*="bp3-intent-"]).bp3-disabled.bp3-active:hover{
        background:rgba(206, 217, 224, 0.7); }
  .bp3-button.bp3-intent-primary{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#137cbd;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-primary:hover, .bp3-button.bp3-intent-primary:active, .bp3-button.bp3-intent-primary.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-primary:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#106ba3; }
    .bp3-button.bp3-intent-primary:active, .bp3-button.bp3-intent-primary.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#0e5a8a;
      background-image:none; }
    .bp3-button.bp3-intent-primary:disabled, .bp3-button.bp3-intent-primary.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(19, 124, 189, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button.bp3-intent-success{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#0f9960;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-success:hover, .bp3-button.bp3-intent-success:active, .bp3-button.bp3-intent-success.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-success:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#0d8050; }
    .bp3-button.bp3-intent-success:active, .bp3-button.bp3-intent-success.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#0a6640;
      background-image:none; }
    .bp3-button.bp3-intent-success:disabled, .bp3-button.bp3-intent-success.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(15, 153, 96, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button.bp3-intent-warning{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#d9822b;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-warning:hover, .bp3-button.bp3-intent-warning:active, .bp3-button.bp3-intent-warning.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-warning:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#bf7326; }
    .bp3-button.bp3-intent-warning:active, .bp3-button.bp3-intent-warning.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#a66321;
      background-image:none; }
    .bp3-button.bp3-intent-warning:disabled, .bp3-button.bp3-intent-warning.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(217, 130, 43, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button.bp3-intent-danger{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#db3737;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
    .bp3-button.bp3-intent-danger:hover, .bp3-button.bp3-intent-danger:active, .bp3-button.bp3-intent-danger.bp3-active{
      color:#ffffff; }
    .bp3-button.bp3-intent-danger:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
      background-color:#c23030; }
    .bp3-button.bp3-intent-danger:active, .bp3-button.bp3-intent-danger.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#a82a2a;
      background-image:none; }
    .bp3-button.bp3-intent-danger:disabled, .bp3-button.bp3-intent-danger.bp3-disabled{
      border-color:transparent;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(219, 55, 55, 0.5);
      background-image:none;
      color:rgba(255, 255, 255, 0.6); }
  .bp3-button[class*="bp3-intent-"] .bp3-button-spinner .bp3-spinner-head{
    stroke:#ffffff; }
  .bp3-button.bp3-large,
  .bp3-large .bp3-button{
    min-width:40px;
    min-height:40px;
    padding:5px 15px;
    font-size:16px; }
    .bp3-button.bp3-large::before,
    .bp3-button.bp3-large > *,
    .bp3-large .bp3-button::before,
    .bp3-large .bp3-button > *{
      margin-right:10px; }
    .bp3-button.bp3-large:empty::before,
    .bp3-button.bp3-large > :last-child,
    .bp3-large .bp3-button:empty::before,
    .bp3-large .bp3-button > :last-child{
      margin-right:0; }
  .bp3-button.bp3-small,
  .bp3-small .bp3-button{
    min-width:24px;
    min-height:24px;
    padding:0 7px; }
  .bp3-button.bp3-loading{
    position:relative; }
    .bp3-button.bp3-loading[class*="bp3-icon-"]::before{
      visibility:hidden; }
    .bp3-button.bp3-loading .bp3-button-spinner{
      position:absolute;
      margin:0; }
    .bp3-button.bp3-loading > :not(.bp3-button-spinner){
      visibility:hidden; }
  .bp3-button[class*="bp3-icon-"]::before{
    line-height:1;
    font-family:"Icons16", sans-serif;
    font-size:16px;
    font-weight:400;
    font-style:normal;
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased;
    color:#5c7080; }
  .bp3-button .bp3-icon, .bp3-button .bp3-icon-standard, .bp3-button .bp3-icon-large{
    color:#5c7080; }
    .bp3-button .bp3-icon.bp3-align-right, .bp3-button .bp3-icon-standard.bp3-align-right, .bp3-button .bp3-icon-large.bp3-align-right{
      margin-left:7px; }
  .bp3-button .bp3-icon:first-child:last-child,
  .bp3-button .bp3-spinner + .bp3-icon:last-child{
    margin:0 -7px; }
  .bp3-dark .bp3-button:not([class*="bp3-intent-"]){
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#394b59;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
    color:#f5f8fa; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):hover, .bp3-dark .bp3-button:not([class*="bp3-intent-"]):active, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-active{
      color:#f5f8fa; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):hover{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#30404d; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):active, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-active{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#202b33;
      background-image:none; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]):disabled, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(57, 75, 89, 0.5);
      background-image:none;
      color:rgba(167, 182, 194, 0.6); }
      .bp3-dark .bp3-button:not([class*="bp3-intent-"]):disabled.bp3-active, .bp3-dark .bp3-button:not([class*="bp3-intent-"]).bp3-disabled.bp3-active{
        background:rgba(57, 75, 89, 0.7); }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-button-spinner .bp3-spinner-head{
      background:rgba(16, 22, 26, 0.5);
      stroke:#8a9ba8; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"])[class*="bp3-icon-"]::before{
      color:#a7b6c2; }
    .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-icon, .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-icon-standard, .bp3-dark .bp3-button:not([class*="bp3-intent-"]) .bp3-icon-large{
      color:#a7b6c2; }
  .bp3-dark .bp3-button[class*="bp3-intent-"]{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-button[class*="bp3-intent-"]:hover{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-button[class*="bp3-intent-"]:active, .bp3-dark .bp3-button[class*="bp3-intent-"].bp3-active{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2); }
    .bp3-dark .bp3-button[class*="bp3-intent-"]:disabled, .bp3-dark .bp3-button[class*="bp3-intent-"].bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background-image:none;
      color:rgba(255, 255, 255, 0.3); }
    .bp3-dark .bp3-button[class*="bp3-intent-"] .bp3-button-spinner .bp3-spinner-head{
      stroke:#8a9ba8; }
  .bp3-button:disabled::before,
  .bp3-button:disabled .bp3-icon, .bp3-button:disabled .bp3-icon-standard, .bp3-button:disabled .bp3-icon-large, .bp3-button.bp3-disabled::before,
  .bp3-button.bp3-disabled .bp3-icon, .bp3-button.bp3-disabled .bp3-icon-standard, .bp3-button.bp3-disabled .bp3-icon-large, .bp3-button[class*="bp3-intent-"]::before,
  .bp3-button[class*="bp3-intent-"] .bp3-icon, .bp3-button[class*="bp3-intent-"] .bp3-icon-standard, .bp3-button[class*="bp3-intent-"] .bp3-icon-large{
    color:inherit !important; }
  .bp3-button.bp3-minimal{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none; }
    .bp3-button.bp3-minimal:hover{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(167, 182, 194, 0.3);
      text-decoration:none;
      color:#182026; }
    .bp3-button.bp3-minimal:active, .bp3-button.bp3-minimal.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(115, 134, 148, 0.3);
      color:#182026; }
    .bp3-button.bp3-minimal:disabled, .bp3-button.bp3-minimal:disabled:hover, .bp3-button.bp3-minimal.bp3-disabled, .bp3-button.bp3-minimal.bp3-disabled:hover{
      background:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-button.bp3-minimal:disabled.bp3-active, .bp3-button.bp3-minimal:disabled:hover.bp3-active, .bp3-button.bp3-minimal.bp3-disabled.bp3-active, .bp3-button.bp3-minimal.bp3-disabled:hover.bp3-active{
        background:rgba(115, 134, 148, 0.3); }
    .bp3-dark .bp3-button.bp3-minimal{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:inherit; }
      .bp3-dark .bp3-button.bp3-minimal:hover, .bp3-dark .bp3-button.bp3-minimal:active, .bp3-dark .bp3-button.bp3-minimal.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none; }
      .bp3-dark .bp3-button.bp3-minimal:hover{
        background:rgba(138, 155, 168, 0.15); }
      .bp3-dark .bp3-button.bp3-minimal:active, .bp3-dark .bp3-button.bp3-minimal.bp3-active{
        background:rgba(138, 155, 168, 0.3);
        color:#f5f8fa; }
      .bp3-dark .bp3-button.bp3-minimal:disabled, .bp3-dark .bp3-button.bp3-minimal:disabled:hover, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled:hover{
        background:none;
        cursor:not-allowed;
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-button.bp3-minimal:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal:disabled:hover.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-disabled:hover.bp3-active{
          background:rgba(138, 155, 168, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-primary{
      color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:hover, .bp3-button.bp3-minimal.bp3-intent-primary:active, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:hover{
        background:rgba(19, 124, 189, 0.15);
        color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:active, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-active{
        background:rgba(19, 124, 189, 0.3);
        color:#106ba3; }
      .bp3-button.bp3-minimal.bp3-intent-primary:disabled, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled{
        background:none;
        color:rgba(16, 107, 163, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-primary:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled.bp3-active{
          background:rgba(19, 124, 189, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head{
        stroke:#106ba3; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary{
        color:#48aff0; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:hover{
          background:rgba(19, 124, 189, 0.2);
          color:#48aff0; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary.bp3-active{
          background:rgba(19, 124, 189, 0.3);
          color:#48aff0; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled{
          background:none;
          color:rgba(72, 175, 240, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-primary.bp3-disabled.bp3-active{
            background:rgba(19, 124, 189, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-success{
      color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:hover, .bp3-button.bp3-minimal.bp3-intent-success:active, .bp3-button.bp3-minimal.bp3-intent-success.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:hover{
        background:rgba(15, 153, 96, 0.15);
        color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:active, .bp3-button.bp3-minimal.bp3-intent-success.bp3-active{
        background:rgba(15, 153, 96, 0.3);
        color:#0d8050; }
      .bp3-button.bp3-minimal.bp3-intent-success:disabled, .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled{
        background:none;
        color:rgba(13, 128, 80, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-success:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled.bp3-active{
          background:rgba(15, 153, 96, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-success .bp3-button-spinner .bp3-spinner-head{
        stroke:#0d8050; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success{
        color:#3dcc91; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:hover{
          background:rgba(15, 153, 96, 0.2);
          color:#3dcc91; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success.bp3-active{
          background:rgba(15, 153, 96, 0.3);
          color:#3dcc91; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled{
          background:none;
          color:rgba(61, 204, 145, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-success.bp3-disabled.bp3-active{
            background:rgba(15, 153, 96, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-warning{
      color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:hover, .bp3-button.bp3-minimal.bp3-intent-warning:active, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:hover{
        background:rgba(217, 130, 43, 0.15);
        color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:active, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-active{
        background:rgba(217, 130, 43, 0.3);
        color:#bf7326; }
      .bp3-button.bp3-minimal.bp3-intent-warning:disabled, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled{
        background:none;
        color:rgba(191, 115, 38, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-warning:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled.bp3-active{
          background:rgba(217, 130, 43, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head{
        stroke:#bf7326; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning{
        color:#ffb366; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:hover{
          background:rgba(217, 130, 43, 0.2);
          color:#ffb366; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning.bp3-active{
          background:rgba(217, 130, 43, 0.3);
          color:#ffb366; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled{
          background:none;
          color:rgba(255, 179, 102, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-warning.bp3-disabled.bp3-active{
            background:rgba(217, 130, 43, 0.3); }
    .bp3-button.bp3-minimal.bp3-intent-danger{
      color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:hover, .bp3-button.bp3-minimal.bp3-intent-danger:active, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:hover{
        background:rgba(219, 55, 55, 0.15);
        color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:active, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-active{
        background:rgba(219, 55, 55, 0.3);
        color:#c23030; }
      .bp3-button.bp3-minimal.bp3-intent-danger:disabled, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled{
        background:none;
        color:rgba(194, 48, 48, 0.5); }
        .bp3-button.bp3-minimal.bp3-intent-danger:disabled.bp3-active, .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled.bp3-active{
          background:rgba(219, 55, 55, 0.3); }
      .bp3-button.bp3-minimal.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head{
        stroke:#c23030; }
      .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger{
        color:#ff7373; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:hover{
          background:rgba(219, 55, 55, 0.2);
          color:#ff7373; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger.bp3-active{
          background:rgba(219, 55, 55, 0.3);
          color:#ff7373; }
        .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:disabled, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled{
          background:none;
          color:rgba(255, 115, 115, 0.5); }
          .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger:disabled.bp3-active, .bp3-dark .bp3-button.bp3-minimal.bp3-intent-danger.bp3-disabled.bp3-active{
            background:rgba(219, 55, 55, 0.3); }

a.bp3-button{
  text-align:center;
  text-decoration:none;
  -webkit-transition:none;
  transition:none; }
  a.bp3-button, a.bp3-button:hover, a.bp3-button:active{
    color:#182026; }
  a.bp3-button.bp3-disabled{
    color:rgba(92, 112, 128, 0.6); }

.bp3-button-text{
  -webkit-box-flex:0;
      -ms-flex:0 1 auto;
          flex:0 1 auto; }

.bp3-button.bp3-align-left .bp3-button-text, .bp3-button.bp3-align-right .bp3-button-text,
.bp3-button-group.bp3-align-left .bp3-button-text,
.bp3-button-group.bp3-align-right .bp3-button-text{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto; }
.bp3-button-group{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex; }
  .bp3-button-group .bp3-button{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    position:relative;
    z-index:4; }
    .bp3-button-group .bp3-button:focus{
      z-index:5; }
    .bp3-button-group .bp3-button:hover{
      z-index:6; }
    .bp3-button-group .bp3-button:active, .bp3-button-group .bp3-button.bp3-active{
      z-index:7; }
    .bp3-button-group .bp3-button:disabled, .bp3-button-group .bp3-button.bp3-disabled{
      z-index:3; }
    .bp3-button-group .bp3-button[class*="bp3-intent-"]{
      z-index:9; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:focus{
        z-index:10; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:hover{
        z-index:11; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:active, .bp3-button-group .bp3-button[class*="bp3-intent-"].bp3-active{
        z-index:12; }
      .bp3-button-group .bp3-button[class*="bp3-intent-"]:disabled, .bp3-button-group .bp3-button[class*="bp3-intent-"].bp3-disabled{
        z-index:8; }
  .bp3-button-group:not(.bp3-minimal) > .bp3-popover-wrapper:not(:first-child) .bp3-button,
  .bp3-button-group:not(.bp3-minimal) > .bp3-button:not(:first-child){
    border-top-left-radius:0;
    border-bottom-left-radius:0; }
  .bp3-button-group:not(.bp3-minimal) > .bp3-popover-wrapper:not(:last-child) .bp3-button,
  .bp3-button-group:not(.bp3-minimal) > .bp3-button:not(:last-child){
    margin-right:-1px;
    border-top-right-radius:0;
    border-bottom-right-radius:0; }
  .bp3-button-group.bp3-minimal .bp3-button{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none; }
    .bp3-button-group.bp3-minimal .bp3-button:hover{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(167, 182, 194, 0.3);
      text-decoration:none;
      color:#182026; }
    .bp3-button-group.bp3-minimal .bp3-button:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(115, 134, 148, 0.3);
      color:#182026; }
    .bp3-button-group.bp3-minimal .bp3-button:disabled, .bp3-button-group.bp3-minimal .bp3-button:disabled:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover{
      background:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-button-group.bp3-minimal .bp3-button:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button:disabled:hover.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover.bp3-active{
        background:rgba(115, 134, 148, 0.3); }
    .bp3-dark .bp3-button-group.bp3-minimal .bp3-button{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:inherit; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:hover, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:hover{
        background:rgba(138, 155, 168, 0.15); }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-active{
        background:rgba(138, 155, 168, 0.3);
        color:#f5f8fa; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled:hover, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover{
        background:none;
        cursor:not-allowed;
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button:disabled:hover.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-disabled:hover.bp3-active{
          background:rgba(138, 155, 168, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary{
      color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:hover{
        background:rgba(19, 124, 189, 0.15);
        color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-active{
        background:rgba(19, 124, 189, 0.3);
        color:#106ba3; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled{
        background:none;
        color:rgba(16, 107, 163, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled.bp3-active{
          background:rgba(19, 124, 189, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head{
        stroke:#106ba3; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary{
        color:#48aff0; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:hover{
          background:rgba(19, 124, 189, 0.2);
          color:#48aff0; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-active{
          background:rgba(19, 124, 189, 0.3);
          color:#48aff0; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled{
          background:none;
          color:rgba(72, 175, 240, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-primary.bp3-disabled.bp3-active{
            background:rgba(19, 124, 189, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success{
      color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:hover{
        background:rgba(15, 153, 96, 0.15);
        color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-active{
        background:rgba(15, 153, 96, 0.3);
        color:#0d8050; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled{
        background:none;
        color:rgba(13, 128, 80, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled.bp3-active{
          background:rgba(15, 153, 96, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success .bp3-button-spinner .bp3-spinner-head{
        stroke:#0d8050; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success{
        color:#3dcc91; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:hover{
          background:rgba(15, 153, 96, 0.2);
          color:#3dcc91; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-active{
          background:rgba(15, 153, 96, 0.3);
          color:#3dcc91; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled{
          background:none;
          color:rgba(61, 204, 145, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-success.bp3-disabled.bp3-active{
            background:rgba(15, 153, 96, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning{
      color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:hover{
        background:rgba(217, 130, 43, 0.15);
        color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-active{
        background:rgba(217, 130, 43, 0.3);
        color:#bf7326; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled{
        background:none;
        color:rgba(191, 115, 38, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled.bp3-active{
          background:rgba(217, 130, 43, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head{
        stroke:#bf7326; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning{
        color:#ffb366; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:hover{
          background:rgba(217, 130, 43, 0.2);
          color:#ffb366; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-active{
          background:rgba(217, 130, 43, 0.3);
          color:#ffb366; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled{
          background:none;
          color:rgba(255, 179, 102, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-warning.bp3-disabled.bp3-active{
            background:rgba(217, 130, 43, 0.3); }
    .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger{
      color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:hover, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-active{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:none;
        color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:hover{
        background:rgba(219, 55, 55, 0.15);
        color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-active{
        background:rgba(219, 55, 55, 0.3);
        color:#c23030; }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled{
        background:none;
        color:rgba(194, 48, 48, 0.5); }
        .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled.bp3-active, .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled.bp3-active{
          background:rgba(219, 55, 55, 0.3); }
      .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head{
        stroke:#c23030; }
      .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger{
        color:#ff7373; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:hover{
          background:rgba(219, 55, 55, 0.2);
          color:#ff7373; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-active{
          background:rgba(219, 55, 55, 0.3);
          color:#ff7373; }
        .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled{
          background:none;
          color:rgba(255, 115, 115, 0.5); }
          .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger:disabled.bp3-active, .bp3-dark .bp3-button-group.bp3-minimal .bp3-button.bp3-intent-danger.bp3-disabled.bp3-active{
            background:rgba(219, 55, 55, 0.3); }
  .bp3-button-group .bp3-popover-wrapper,
  .bp3-button-group .bp3-popover-target{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-button-group.bp3-fill{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    width:100%; }
  .bp3-button-group .bp3-button.bp3-fill,
  .bp3-button-group.bp3-fill .bp3-button:not(.bp3-fixed){
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-button-group.bp3-vertical{
    -webkit-box-orient:vertical;
    -webkit-box-direction:normal;
        -ms-flex-direction:column;
            flex-direction:column;
    -webkit-box-align:stretch;
        -ms-flex-align:stretch;
            align-items:stretch;
    vertical-align:top; }
    .bp3-button-group.bp3-vertical.bp3-fill{
      width:unset;
      height:100%; }
    .bp3-button-group.bp3-vertical .bp3-button{
      margin-right:0 !important;
      width:100%; }
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-popover-wrapper:first-child .bp3-button,
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-button:first-child{
      border-radius:3px 3px 0 0; }
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-popover-wrapper:last-child .bp3-button,
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-button:last-child{
      border-radius:0 0 3px 3px; }
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-popover-wrapper:not(:last-child) .bp3-button,
    .bp3-button-group.bp3-vertical:not(.bp3-minimal) > .bp3-button:not(:last-child){
      margin-bottom:-1px; }
  .bp3-button-group.bp3-align-left .bp3-button{
    text-align:left; }
  .bp3-dark .bp3-button-group:not(.bp3-minimal) > .bp3-popover-wrapper:not(:last-child) .bp3-button,
  .bp3-dark .bp3-button-group:not(.bp3-minimal) > .bp3-button:not(:last-child){
    margin-right:1px; }
  .bp3-dark .bp3-button-group.bp3-vertical > .bp3-popover-wrapper:not(:last-child) .bp3-button,
  .bp3-dark .bp3-button-group.bp3-vertical > .bp3-button:not(:last-child){
    margin-bottom:1px; }
.bp3-callout{
  line-height:1.5;
  font-size:14px;
  position:relative;
  border-radius:3px;
  background-color:rgba(138, 155, 168, 0.15);
  width:100%;
  padding:10px 12px 9px; }
  .bp3-callout[class*="bp3-icon-"]{
    padding-left:40px; }
    .bp3-callout[class*="bp3-icon-"]::before{
      line-height:1;
      font-family:"Icons20", sans-serif;
      font-size:20px;
      font-weight:400;
      font-style:normal;
      -moz-osx-font-smoothing:grayscale;
      -webkit-font-smoothing:antialiased;
      position:absolute;
      top:10px;
      left:10px;
      color:#5c7080; }
  .bp3-callout.bp3-callout-icon{
    padding-left:40px; }
    .bp3-callout.bp3-callout-icon > .bp3-icon:first-child{
      position:absolute;
      top:10px;
      left:10px;
      color:#5c7080; }
  .bp3-callout .bp3-heading{
    margin-top:0;
    margin-bottom:5px;
    line-height:20px; }
    .bp3-callout .bp3-heading:last-child{
      margin-bottom:0; }
  .bp3-dark .bp3-callout{
    background-color:rgba(138, 155, 168, 0.2); }
    .bp3-dark .bp3-callout[class*="bp3-icon-"]::before{
      color:#a7b6c2; }
  .bp3-callout.bp3-intent-primary{
    background-color:rgba(19, 124, 189, 0.15); }
    .bp3-callout.bp3-intent-primary[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-primary > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-primary .bp3-heading{
      color:#106ba3; }
    .bp3-dark .bp3-callout.bp3-intent-primary{
      background-color:rgba(19, 124, 189, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-primary[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-primary > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-primary .bp3-heading{
        color:#48aff0; }
  .bp3-callout.bp3-intent-success{
    background-color:rgba(15, 153, 96, 0.15); }
    .bp3-callout.bp3-intent-success[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-success > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-success .bp3-heading{
      color:#0d8050; }
    .bp3-dark .bp3-callout.bp3-intent-success{
      background-color:rgba(15, 153, 96, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-success[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-success > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-success .bp3-heading{
        color:#3dcc91; }
  .bp3-callout.bp3-intent-warning{
    background-color:rgba(217, 130, 43, 0.15); }
    .bp3-callout.bp3-intent-warning[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-warning > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-warning .bp3-heading{
      color:#bf7326; }
    .bp3-dark .bp3-callout.bp3-intent-warning{
      background-color:rgba(217, 130, 43, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-warning[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-warning > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-warning .bp3-heading{
        color:#ffb366; }
  .bp3-callout.bp3-intent-danger{
    background-color:rgba(219, 55, 55, 0.15); }
    .bp3-callout.bp3-intent-danger[class*="bp3-icon-"]::before,
    .bp3-callout.bp3-intent-danger > .bp3-icon:first-child,
    .bp3-callout.bp3-intent-danger .bp3-heading{
      color:#c23030; }
    .bp3-dark .bp3-callout.bp3-intent-danger{
      background-color:rgba(219, 55, 55, 0.25); }
      .bp3-dark .bp3-callout.bp3-intent-danger[class*="bp3-icon-"]::before,
      .bp3-dark .bp3-callout.bp3-intent-danger > .bp3-icon:first-child,
      .bp3-dark .bp3-callout.bp3-intent-danger .bp3-heading{
        color:#ff7373; }
  .bp3-running-text .bp3-callout{
    margin:20px 0; }
.bp3-card{
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
  background-color:#ffffff;
  padding:20px;
  -webkit-transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-card.bp3-dark,
  .bp3-dark .bp3-card{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
    background-color:#30404d; }

.bp3-elevation-0{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.15), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0); }
  .bp3-elevation-0.bp3-dark,
  .bp3-dark .bp3-elevation-0{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), 0 0 0 rgba(16, 22, 26, 0), 0 0 0 rgba(16, 22, 26, 0); }

.bp3-elevation-1{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-1.bp3-dark,
  .bp3-dark .bp3-elevation-1{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-elevation-2{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 1px 1px rgba(16, 22, 26, 0.2), 0 2px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 1px 1px rgba(16, 22, 26, 0.2), 0 2px 6px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-2.bp3-dark,
  .bp3-dark .bp3-elevation-2{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.4), 0 2px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.4), 0 2px 6px rgba(16, 22, 26, 0.4); }

.bp3-elevation-3{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-3.bp3-dark,
  .bp3-dark .bp3-elevation-3{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }

.bp3-elevation-4{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2); }
  .bp3-elevation-4.bp3-dark,
  .bp3-dark .bp3-elevation-4{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4); }

.bp3-card.bp3-interactive:hover{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  cursor:pointer; }
  .bp3-card.bp3-interactive:hover.bp3-dark,
  .bp3-dark .bp3-card.bp3-interactive:hover{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }

.bp3-card.bp3-interactive:active{
  opacity:0.9;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
  -webkit-transition-duration:0;
          transition-duration:0; }
  .bp3-card.bp3-interactive:active.bp3-dark,
  .bp3-dark .bp3-card.bp3-interactive:active{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-collapse{
  height:0;
  overflow-y:hidden;
  -webkit-transition:height 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:height 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-collapse .bp3-collapse-body{
    -webkit-transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
    .bp3-collapse .bp3-collapse-body[aria-hidden="true"]{
      display:none; }

.bp3-context-menu .bp3-popover-target{
  display:block; }

.bp3-context-menu-popover-target{
  position:fixed; }

.bp3-divider{
  margin:5px;
  border-right:1px solid rgba(16, 22, 26, 0.15);
  border-bottom:1px solid rgba(16, 22, 26, 0.15); }
  .bp3-dark .bp3-divider{
    border-color:rgba(16, 22, 26, 0.4); }
.bp3-dialog-container{
  opacity:1;
  -webkit-transform:scale(1);
          transform:scale(1);
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  width:100%;
  min-height:100%;
  pointer-events:none;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-dialog-container.bp3-overlay-enter > .bp3-dialog, .bp3-dialog-container.bp3-overlay-appear > .bp3-dialog{
    opacity:0;
    -webkit-transform:scale(0.5);
            transform:scale(0.5); }
  .bp3-dialog-container.bp3-overlay-enter-active > .bp3-dialog, .bp3-dialog-container.bp3-overlay-appear-active > .bp3-dialog{
    opacity:1;
    -webkit-transform:scale(1);
            transform:scale(1);
    -webkit-transition-property:opacity, -webkit-transform;
    transition-property:opacity, -webkit-transform;
    transition-property:opacity, transform;
    transition-property:opacity, transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-dialog-container.bp3-overlay-exit > .bp3-dialog{
    opacity:1;
    -webkit-transform:scale(1);
            transform:scale(1); }
  .bp3-dialog-container.bp3-overlay-exit-active > .bp3-dialog{
    opacity:0;
    -webkit-transform:scale(0.5);
            transform:scale(0.5);
    -webkit-transition-property:opacity, -webkit-transform;
    transition-property:opacity, -webkit-transform;
    transition-property:opacity, transform;
    transition-property:opacity, transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }

.bp3-dialog{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin:30px 0;
  border-radius:6px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
  background:#ebf1f5;
  width:500px;
  padding-bottom:20px;
  pointer-events:all;
  -webkit-user-select:text;
     -moz-user-select:text;
      -ms-user-select:text;
          user-select:text; }
  .bp3-dialog:focus{
    outline:0; }
  .bp3-dialog.bp3-dark,
  .bp3-dark .bp3-dialog{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
    background:#293742;
    color:#f5f8fa; }

.bp3-dialog-header{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  border-radius:6px 6px 0 0;
  -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
          box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
  background:#ffffff;
  min-height:40px;
  padding-right:5px;
  padding-left:20px; }
  .bp3-dialog-header .bp3-icon-large,
  .bp3-dialog-header .bp3-icon{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    margin-right:10px;
    color:#5c7080; }
  .bp3-dialog-header .bp3-heading{
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    margin:0;
    line-height:inherit; }
    .bp3-dialog-header .bp3-heading:last-child{
      margin-right:20px; }
  .bp3-dark .bp3-dialog-header{
    -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.4);
            box-shadow:0 1px 0 rgba(16, 22, 26, 0.4);
    background:#30404d; }
    .bp3-dark .bp3-dialog-header .bp3-icon-large,
    .bp3-dark .bp3-dialog-header .bp3-icon{
      color:#a7b6c2; }

.bp3-dialog-body{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  margin:20px;
  line-height:18px; }

.bp3-dialog-footer{
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  margin:0 20px; }

.bp3-dialog-footer-actions{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-pack:end;
      -ms-flex-pack:end;
          justify-content:flex-end; }
  .bp3-dialog-footer-actions .bp3-button{
    margin-left:10px; }
.bp3-drawer{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin:0;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  padding:0; }
  .bp3-drawer:focus{
    outline:0; }
  .bp3-drawer.bp3-position-top{
    top:0;
    right:0;
    left:0;
    height:50%; }
    .bp3-drawer.bp3-position-top.bp3-overlay-enter, .bp3-drawer.bp3-position-top.bp3-overlay-appear{
      -webkit-transform:translateY(-100%);
              transform:translateY(-100%); }
    .bp3-drawer.bp3-position-top.bp3-overlay-enter-active, .bp3-drawer.bp3-position-top.bp3-overlay-appear-active{
      -webkit-transform:translateY(0);
              transform:translateY(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-top.bp3-overlay-exit{
      -webkit-transform:translateY(0);
              transform:translateY(0); }
    .bp3-drawer.bp3-position-top.bp3-overlay-exit-active{
      -webkit-transform:translateY(-100%);
              transform:translateY(-100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-position-bottom{
    right:0;
    bottom:0;
    left:0;
    height:50%; }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-enter, .bp3-drawer.bp3-position-bottom.bp3-overlay-appear{
      -webkit-transform:translateY(100%);
              transform:translateY(100%); }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-enter-active, .bp3-drawer.bp3-position-bottom.bp3-overlay-appear-active{
      -webkit-transform:translateY(0);
              transform:translateY(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-exit{
      -webkit-transform:translateY(0);
              transform:translateY(0); }
    .bp3-drawer.bp3-position-bottom.bp3-overlay-exit-active{
      -webkit-transform:translateY(100%);
              transform:translateY(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-position-left{
    top:0;
    bottom:0;
    left:0;
    width:50%; }
    .bp3-drawer.bp3-position-left.bp3-overlay-enter, .bp3-drawer.bp3-position-left.bp3-overlay-appear{
      -webkit-transform:translateX(-100%);
              transform:translateX(-100%); }
    .bp3-drawer.bp3-position-left.bp3-overlay-enter-active, .bp3-drawer.bp3-position-left.bp3-overlay-appear-active{
      -webkit-transform:translateX(0);
              transform:translateX(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-left.bp3-overlay-exit{
      -webkit-transform:translateX(0);
              transform:translateX(0); }
    .bp3-drawer.bp3-position-left.bp3-overlay-exit-active{
      -webkit-transform:translateX(-100%);
              transform:translateX(-100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-position-right{
    top:0;
    right:0;
    bottom:0;
    width:50%; }
    .bp3-drawer.bp3-position-right.bp3-overlay-enter, .bp3-drawer.bp3-position-right.bp3-overlay-appear{
      -webkit-transform:translateX(100%);
              transform:translateX(100%); }
    .bp3-drawer.bp3-position-right.bp3-overlay-enter-active, .bp3-drawer.bp3-position-right.bp3-overlay-appear-active{
      -webkit-transform:translateX(0);
              transform:translateX(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer.bp3-position-right.bp3-overlay-exit{
      -webkit-transform:translateX(0);
              transform:translateX(0); }
    .bp3-drawer.bp3-position-right.bp3-overlay-exit-active{
      -webkit-transform:translateX(100%);
              transform:translateX(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
  .bp3-position-right):not(.bp3-vertical){
    top:0;
    right:0;
    bottom:0;
    width:50%; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-enter, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-appear{
      -webkit-transform:translateX(100%);
              transform:translateX(100%); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-enter-active, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-appear-active{
      -webkit-transform:translateX(0);
              transform:translateX(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-exit{
      -webkit-transform:translateX(0);
              transform:translateX(0); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right):not(.bp3-vertical).bp3-overlay-exit-active{
      -webkit-transform:translateX(100%);
              transform:translateX(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
  .bp3-position-right).bp3-vertical{
    right:0;
    bottom:0;
    left:0;
    height:50%; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-enter, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-appear{
      -webkit-transform:translateY(100%);
              transform:translateY(100%); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-enter-active, .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-appear-active{
      -webkit-transform:translateY(0);
              transform:translateY(0);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:200ms;
              transition-duration:200ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-exit{
      -webkit-transform:translateY(0);
              transform:translateY(0); }
    .bp3-drawer:not(.bp3-position-top):not(.bp3-position-bottom):not(.bp3-position-left):not(
    .bp3-position-right).bp3-vertical.bp3-overlay-exit-active{
      -webkit-transform:translateY(100%);
              transform:translateY(100%);
      -webkit-transition-property:-webkit-transform;
      transition-property:-webkit-transform;
      transition-property:transform;
      transition-property:transform, -webkit-transform;
      -webkit-transition-duration:100ms;
              transition-duration:100ms;
      -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
              transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
      -webkit-transition-delay:0;
              transition-delay:0; }
  .bp3-drawer.bp3-dark,
  .bp3-dark .bp3-drawer{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
    background:#30404d;
    color:#f5f8fa; }

.bp3-drawer-header{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  position:relative;
  border-radius:0;
  -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
          box-shadow:0 1px 0 rgba(16, 22, 26, 0.15);
  min-height:40px;
  padding:5px;
  padding-left:20px; }
  .bp3-drawer-header .bp3-icon-large,
  .bp3-drawer-header .bp3-icon{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    margin-right:10px;
    color:#5c7080; }
  .bp3-drawer-header .bp3-heading{
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    margin:0;
    line-height:inherit; }
    .bp3-drawer-header .bp3-heading:last-child{
      margin-right:20px; }
  .bp3-dark .bp3-drawer-header{
    -webkit-box-shadow:0 1px 0 rgba(16, 22, 26, 0.4);
            box-shadow:0 1px 0 rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-drawer-header .bp3-icon-large,
    .bp3-dark .bp3-drawer-header .bp3-icon{
      color:#a7b6c2; }

.bp3-drawer-body{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  overflow:auto;
  line-height:18px; }

.bp3-drawer-footer{
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  position:relative;
  -webkit-box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
          box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
  padding:10px 20px; }
  .bp3-dark .bp3-drawer-footer{
    -webkit-box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.4); }
.bp3-editable-text{
  display:inline-block;
  position:relative;
  cursor:text;
  max-width:100%;
  vertical-align:top;
  white-space:nowrap; }
  .bp3-editable-text::before{
    position:absolute;
    top:-3px;
    right:-3px;
    bottom:-3px;
    left:-3px;
    border-radius:3px;
    content:"";
    -webkit-transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9), box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-editable-text:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15); }
  .bp3-editable-text.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
    background-color:#ffffff; }
  .bp3-editable-text.bp3-disabled::before{
    -webkit-box-shadow:none;
            box-shadow:none; }
  .bp3-editable-text.bp3-intent-primary .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-primary .bp3-editable-text-content{
    color:#137cbd; }
  .bp3-editable-text.bp3-intent-primary:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(19, 124, 189, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(19, 124, 189, 0.4); }
  .bp3-editable-text.bp3-intent-primary.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-editable-text.bp3-intent-success .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-success .bp3-editable-text-content{
    color:#0f9960; }
  .bp3-editable-text.bp3-intent-success:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px rgba(15, 153, 96, 0.4);
            box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px rgba(15, 153, 96, 0.4); }
  .bp3-editable-text.bp3-intent-success.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-editable-text.bp3-intent-warning .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-warning .bp3-editable-text-content{
    color:#d9822b; }
  .bp3-editable-text.bp3-intent-warning:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px rgba(217, 130, 43, 0.4);
            box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px rgba(217, 130, 43, 0.4); }
  .bp3-editable-text.bp3-intent-warning.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-editable-text.bp3-intent-danger .bp3-editable-text-input,
  .bp3-editable-text.bp3-intent-danger .bp3-editable-text-content{
    color:#db3737; }
  .bp3-editable-text.bp3-intent-danger:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px rgba(219, 55, 55, 0.4);
            box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px rgba(219, 55, 55, 0.4); }
  .bp3-editable-text.bp3-intent-danger.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-dark .bp3-editable-text:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(255, 255, 255, 0.15);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(255, 255, 255, 0.15); }
  .bp3-dark .bp3-editable-text.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background-color:rgba(16, 22, 26, 0.3); }
  .bp3-dark .bp3-editable-text.bp3-disabled::before{
    -webkit-box-shadow:none;
            box-shadow:none; }
  .bp3-dark .bp3-editable-text.bp3-intent-primary .bp3-editable-text-content{
    color:#48aff0; }
  .bp3-dark .bp3-editable-text.bp3-intent-primary:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(72, 175, 240, 0), 0 0 0 0 rgba(72, 175, 240, 0), inset 0 0 0 1px rgba(72, 175, 240, 0.4);
            box-shadow:0 0 0 0 rgba(72, 175, 240, 0), 0 0 0 0 rgba(72, 175, 240, 0), inset 0 0 0 1px rgba(72, 175, 240, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-primary.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #48aff0, 0 0 0 3px rgba(72, 175, 240, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #48aff0, 0 0 0 3px rgba(72, 175, 240, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-success .bp3-editable-text-content{
    color:#3dcc91; }
  .bp3-dark .bp3-editable-text.bp3-intent-success:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(61, 204, 145, 0), 0 0 0 0 rgba(61, 204, 145, 0), inset 0 0 0 1px rgba(61, 204, 145, 0.4);
            box-shadow:0 0 0 0 rgba(61, 204, 145, 0), 0 0 0 0 rgba(61, 204, 145, 0), inset 0 0 0 1px rgba(61, 204, 145, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-success.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #3dcc91, 0 0 0 3px rgba(61, 204, 145, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #3dcc91, 0 0 0 3px rgba(61, 204, 145, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-warning .bp3-editable-text-content{
    color:#ffb366; }
  .bp3-dark .bp3-editable-text.bp3-intent-warning:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(255, 179, 102, 0), 0 0 0 0 rgba(255, 179, 102, 0), inset 0 0 0 1px rgba(255, 179, 102, 0.4);
            box-shadow:0 0 0 0 rgba(255, 179, 102, 0), 0 0 0 0 rgba(255, 179, 102, 0), inset 0 0 0 1px rgba(255, 179, 102, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-warning.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #ffb366, 0 0 0 3px rgba(255, 179, 102, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #ffb366, 0 0 0 3px rgba(255, 179, 102, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-danger .bp3-editable-text-content{
    color:#ff7373; }
  .bp3-dark .bp3-editable-text.bp3-intent-danger:hover::before{
    -webkit-box-shadow:0 0 0 0 rgba(255, 115, 115, 0), 0 0 0 0 rgba(255, 115, 115, 0), inset 0 0 0 1px rgba(255, 115, 115, 0.4);
            box-shadow:0 0 0 0 rgba(255, 115, 115, 0), 0 0 0 0 rgba(255, 115, 115, 0), inset 0 0 0 1px rgba(255, 115, 115, 0.4); }
  .bp3-dark .bp3-editable-text.bp3-intent-danger.bp3-editable-text-editing::before{
    -webkit-box-shadow:0 0 0 1px #ff7373, 0 0 0 3px rgba(255, 115, 115, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #ff7373, 0 0 0 3px rgba(255, 115, 115, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-editable-text-input,
.bp3-editable-text-content{
  display:inherit;
  position:relative;
  min-width:inherit;
  max-width:inherit;
  vertical-align:top;
  text-transform:inherit;
  letter-spacing:inherit;
  color:inherit;
  font:inherit;
  resize:none; }

.bp3-editable-text-input{
  border:none;
  -webkit-box-shadow:none;
          box-shadow:none;
  background:none;
  width:100%;
  padding:0;
  white-space:pre-wrap; }
  .bp3-editable-text-input::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-editable-text-input:focus{
    outline:none; }
  .bp3-editable-text-input::-ms-clear{
    display:none; }

.bp3-editable-text-content{
  overflow:hidden;
  padding-right:2px;
  text-overflow:ellipsis;
  white-space:pre; }
  .bp3-editable-text-editing > .bp3-editable-text-content{
    position:absolute;
    left:0;
    visibility:hidden; }
  .bp3-editable-text-placeholder > .bp3-editable-text-content{
    color:rgba(92, 112, 128, 0.6); }
    .bp3-dark .bp3-editable-text-placeholder > .bp3-editable-text-content{
      color:rgba(167, 182, 194, 0.6); }

.bp3-editable-text.bp3-multiline{
  display:block; }
  .bp3-editable-text.bp3-multiline .bp3-editable-text-content{
    overflow:auto;
    white-space:pre-wrap;
    word-wrap:break-word; }
.bp3-control-group{
  -webkit-transform:translateZ(0);
          transform:translateZ(0);
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:stretch;
      -ms-flex-align:stretch;
          align-items:stretch; }
  .bp3-control-group > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-control-group > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-control-group .bp3-button,
  .bp3-control-group .bp3-html-select,
  .bp3-control-group .bp3-input,
  .bp3-control-group .bp3-select{
    position:relative; }
  .bp3-control-group .bp3-input{
    z-index:2;
    border-radius:inherit; }
    .bp3-control-group .bp3-input:focus{
      z-index:14;
      border-radius:3px; }
    .bp3-control-group .bp3-input[class*="bp3-intent"]{
      z-index:13; }
      .bp3-control-group .bp3-input[class*="bp3-intent"]:focus{
        z-index:15; }
    .bp3-control-group .bp3-input[readonly], .bp3-control-group .bp3-input:disabled, .bp3-control-group .bp3-input.bp3-disabled{
      z-index:1; }
  .bp3-control-group .bp3-input-group[class*="bp3-intent"] .bp3-input{
    z-index:13; }
    .bp3-control-group .bp3-input-group[class*="bp3-intent"] .bp3-input:focus{
      z-index:15; }
  .bp3-control-group .bp3-button,
  .bp3-control-group .bp3-html-select select,
  .bp3-control-group .bp3-select select{
    -webkit-transform:translateZ(0);
            transform:translateZ(0);
    z-index:4;
    border-radius:inherit; }
    .bp3-control-group .bp3-button:focus,
    .bp3-control-group .bp3-html-select select:focus,
    .bp3-control-group .bp3-select select:focus{
      z-index:5; }
    .bp3-control-group .bp3-button:hover,
    .bp3-control-group .bp3-html-select select:hover,
    .bp3-control-group .bp3-select select:hover{
      z-index:6; }
    .bp3-control-group .bp3-button:active,
    .bp3-control-group .bp3-html-select select:active,
    .bp3-control-group .bp3-select select:active{
      z-index:7; }
    .bp3-control-group .bp3-button[readonly], .bp3-control-group .bp3-button:disabled, .bp3-control-group .bp3-button.bp3-disabled,
    .bp3-control-group .bp3-html-select select[readonly],
    .bp3-control-group .bp3-html-select select:disabled,
    .bp3-control-group .bp3-html-select select.bp3-disabled,
    .bp3-control-group .bp3-select select[readonly],
    .bp3-control-group .bp3-select select:disabled,
    .bp3-control-group .bp3-select select.bp3-disabled{
      z-index:3; }
    .bp3-control-group .bp3-button[class*="bp3-intent"],
    .bp3-control-group .bp3-html-select select[class*="bp3-intent"],
    .bp3-control-group .bp3-select select[class*="bp3-intent"]{
      z-index:9; }
      .bp3-control-group .bp3-button[class*="bp3-intent"]:focus,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:focus,
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:focus{
        z-index:10; }
      .bp3-control-group .bp3-button[class*="bp3-intent"]:hover,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:hover,
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:hover{
        z-index:11; }
      .bp3-control-group .bp3-button[class*="bp3-intent"]:active,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:active,
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:active{
        z-index:12; }
      .bp3-control-group .bp3-button[class*="bp3-intent"][readonly], .bp3-control-group .bp3-button[class*="bp3-intent"]:disabled, .bp3-control-group .bp3-button[class*="bp3-intent"].bp3-disabled,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"][readonly],
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"]:disabled,
      .bp3-control-group .bp3-html-select select[class*="bp3-intent"].bp3-disabled,
      .bp3-control-group .bp3-select select[class*="bp3-intent"][readonly],
      .bp3-control-group .bp3-select select[class*="bp3-intent"]:disabled,
      .bp3-control-group .bp3-select select[class*="bp3-intent"].bp3-disabled{
        z-index:8; }
  .bp3-control-group .bp3-input-group > .bp3-icon,
  .bp3-control-group .bp3-input-group > .bp3-button,
  .bp3-control-group .bp3-input-group > .bp3-input-action{
    z-index:16; }
  .bp3-control-group .bp3-select::after,
  .bp3-control-group .bp3-html-select::after,
  .bp3-control-group .bp3-select > .bp3-icon,
  .bp3-control-group .bp3-html-select > .bp3-icon{
    z-index:17; }
  .bp3-control-group:not(.bp3-vertical) > *{
    margin-right:-1px; }
  .bp3-dark .bp3-control-group:not(.bp3-vertical) > *{
    margin-right:0; }
  .bp3-dark .bp3-control-group:not(.bp3-vertical) > .bp3-button + .bp3-button{
    margin-left:1px; }
  .bp3-control-group .bp3-popover-wrapper,
  .bp3-control-group .bp3-popover-target{
    border-radius:inherit; }
  .bp3-control-group > :first-child{
    border-radius:3px 0 0 3px; }
  .bp3-control-group > :last-child{
    margin-right:0;
    border-radius:0 3px 3px 0; }
  .bp3-control-group > :only-child{
    margin-right:0;
    border-radius:3px; }
  .bp3-control-group .bp3-input-group .bp3-button{
    border-radius:3px; }
  .bp3-control-group > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-control-group.bp3-fill > *:not(.bp3-fixed){
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto; }
  .bp3-control-group.bp3-vertical{
    -webkit-box-orient:vertical;
    -webkit-box-direction:normal;
        -ms-flex-direction:column;
            flex-direction:column; }
    .bp3-control-group.bp3-vertical > *{
      margin-top:-1px; }
    .bp3-control-group.bp3-vertical > :first-child{
      margin-top:0;
      border-radius:3px 3px 0 0; }
    .bp3-control-group.bp3-vertical > :last-child{
      border-radius:0 0 3px 3px; }
.bp3-control{
  display:block;
  position:relative;
  margin-bottom:10px;
  cursor:pointer;
  text-transform:none; }
  .bp3-control input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#137cbd;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
  .bp3-control:hover input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#106ba3; }
  .bp3-control input:not(:disabled):active:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background:#0e5a8a; }
  .bp3-control input:disabled:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(19, 124, 189, 0.5); }
  .bp3-dark .bp3-control input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control:hover input:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#106ba3; }
  .bp3-dark .bp3-control input:not(:disabled):active:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#0e5a8a; }
  .bp3-dark .bp3-control input:disabled:checked ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(14, 90, 138, 0.5); }
  .bp3-control:not(.bp3-align-right){
    padding-left:26px; }
    .bp3-control:not(.bp3-align-right) .bp3-control-indicator{
      margin-left:-26px; }
  .bp3-control.bp3-align-right{
    padding-right:26px; }
    .bp3-control.bp3-align-right .bp3-control-indicator{
      margin-right:-26px; }
  .bp3-control.bp3-disabled{
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-control.bp3-inline{
    display:inline-block;
    margin-right:20px; }
  .bp3-control input{
    position:absolute;
    top:0;
    left:0;
    opacity:0;
    z-index:-1; }
  .bp3-control .bp3-control-indicator{
    display:inline-block;
    position:relative;
    margin-top:-3px;
    margin-right:10px;
    border:none;
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#f5f8fa;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
    cursor:pointer;
    width:1em;
    height:1em;
    vertical-align:middle;
    font-size:16px;
    -webkit-user-select:none;
       -moz-user-select:none;
        -ms-user-select:none;
            user-select:none; }
    .bp3-control .bp3-control-indicator::before{
      display:block;
      width:1em;
      height:1em;
      content:""; }
  .bp3-control:hover .bp3-control-indicator{
    background-color:#ebf1f5; }
  .bp3-control input:not(:disabled):active ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background:#d8e1e8; }
  .bp3-control input:disabled ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(206, 217, 224, 0.5);
    cursor:not-allowed; }
  .bp3-control input:focus ~ .bp3-control-indicator{
    outline:rgba(19, 124, 189, 0.6) auto 2px;
    outline-offset:2px;
    -moz-outline-radius:6px; }
  .bp3-control.bp3-align-right .bp3-control-indicator{
    float:right;
    margin-top:1px;
    margin-left:10px; }
  .bp3-control.bp3-large{
    font-size:16px; }
    .bp3-control.bp3-large:not(.bp3-align-right){
      padding-left:30px; }
      .bp3-control.bp3-large:not(.bp3-align-right) .bp3-control-indicator{
        margin-left:-30px; }
    .bp3-control.bp3-large.bp3-align-right{
      padding-right:30px; }
      .bp3-control.bp3-large.bp3-align-right .bp3-control-indicator{
        margin-right:-30px; }
    .bp3-control.bp3-large .bp3-control-indicator{
      font-size:20px; }
    .bp3-control.bp3-large.bp3-align-right .bp3-control-indicator{
      margin-top:0; }
  .bp3-control.bp3-checkbox input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#137cbd;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.1)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.1), rgba(255, 255, 255, 0));
    color:#ffffff; }
  .bp3-control.bp3-checkbox:hover input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 -1px 0 rgba(16, 22, 26, 0.2);
    background-color:#106ba3; }
  .bp3-control.bp3-checkbox input:not(:disabled):active:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background:#0e5a8a; }
  .bp3-control.bp3-checkbox input:disabled:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(19, 124, 189, 0.5); }
  .bp3-dark .bp3-control.bp3-checkbox input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control.bp3-checkbox:hover input:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#106ba3; }
  .bp3-dark .bp3-control.bp3-checkbox input:not(:disabled):active:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#0e5a8a; }
  .bp3-dark .bp3-control.bp3-checkbox input:disabled:indeterminate ~ .bp3-control-indicator{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(14, 90, 138, 0.5); }
  .bp3-control.bp3-checkbox .bp3-control-indicator{
    border-radius:3px; }
  .bp3-control.bp3-checkbox input:checked ~ .bp3-control-indicator::before{
    background-image:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cpath fill-rule='evenodd' clip-rule='evenodd' d='M12 5c-.28 0-.53.11-.71.29L7 9.59l-2.29-2.3a1.003 1.003 0 0 0-1.42 1.42l3 3c.18.18.43.29.71.29s.53-.11.71-.29l5-5A1.003 1.003 0 0 0 12 5z' fill='white'/%3e%3c/svg%3e"); }
  .bp3-control.bp3-checkbox input:indeterminate ~ .bp3-control-indicator::before{
    background-image:url("data:image/svg+xml,%3csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 16 16'%3e%3cpath fill-rule='evenodd' clip-rule='evenodd' d='M11 7H5c-.55 0-1 .45-1 1s.45 1 1 1h6c.55 0 1-.45 1-1s-.45-1-1-1z' fill='white'/%3e%3c/svg%3e"); }
  .bp3-control.bp3-radio .bp3-control-indicator{
    border-radius:50%; }
  .bp3-control.bp3-radio input:checked ~ .bp3-control-indicator::before{
    background-image:radial-gradient(#ffffff, #ffffff 28%, transparent 32%); }
  .bp3-control.bp3-radio input:checked:disabled ~ .bp3-control-indicator::before{
    opacity:0.5; }
  .bp3-control.bp3-radio input:focus ~ .bp3-control-indicator{
    -moz-outline-radius:16px; }
  .bp3-control.bp3-switch input ~ .bp3-control-indicator{
    background:rgba(167, 182, 194, 0.5); }
  .bp3-control.bp3-switch:hover input ~ .bp3-control-indicator{
    background:rgba(115, 134, 148, 0.5); }
  .bp3-control.bp3-switch input:not(:disabled):active ~ .bp3-control-indicator{
    background:rgba(92, 112, 128, 0.5); }
  .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator{
    background:rgba(206, 217, 224, 0.5); }
    .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator::before{
      background:rgba(255, 255, 255, 0.8); }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator{
    background:#137cbd; }
  .bp3-control.bp3-switch:hover input:checked ~ .bp3-control-indicator{
    background:#106ba3; }
  .bp3-control.bp3-switch input:checked:not(:disabled):active ~ .bp3-control-indicator{
    background:#0e5a8a; }
  .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator{
    background:rgba(19, 124, 189, 0.5); }
    .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator::before{
      background:rgba(255, 255, 255, 0.8); }
  .bp3-control.bp3-switch:not(.bp3-align-right){
    padding-left:38px; }
    .bp3-control.bp3-switch:not(.bp3-align-right) .bp3-control-indicator{
      margin-left:-38px; }
  .bp3-control.bp3-switch.bp3-align-right{
    padding-right:38px; }
    .bp3-control.bp3-switch.bp3-align-right .bp3-control-indicator{
      margin-right:-38px; }
  .bp3-control.bp3-switch .bp3-control-indicator{
    border:none;
    border-radius:1.75em;
    -webkit-box-shadow:none !important;
            box-shadow:none !important;
    width:auto;
    min-width:1.75em;
    -webkit-transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:background-color 100ms cubic-bezier(0.4, 1, 0.75, 0.9); }
    .bp3-control.bp3-switch .bp3-control-indicator::before{
      position:absolute;
      left:0;
      margin:2px;
      border-radius:50%;
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
      background:#ffffff;
      width:calc(1em - 4px);
      height:calc(1em - 4px);
      -webkit-transition:left 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
      transition:left 100ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator::before{
    left:calc(100% - 1em); }
  .bp3-control.bp3-switch.bp3-large:not(.bp3-align-right){
    padding-left:45px; }
    .bp3-control.bp3-switch.bp3-large:not(.bp3-align-right) .bp3-control-indicator{
      margin-left:-45px; }
  .bp3-control.bp3-switch.bp3-large.bp3-align-right{
    padding-right:45px; }
    .bp3-control.bp3-switch.bp3-large.bp3-align-right .bp3-control-indicator{
      margin-right:-45px; }
  .bp3-dark .bp3-control.bp3-switch input ~ .bp3-control-indicator{
    background:rgba(16, 22, 26, 0.5); }
  .bp3-dark .bp3-control.bp3-switch:hover input ~ .bp3-control-indicator{
    background:rgba(16, 22, 26, 0.7); }
  .bp3-dark .bp3-control.bp3-switch input:not(:disabled):active ~ .bp3-control-indicator{
    background:rgba(16, 22, 26, 0.9); }
  .bp3-dark .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator{
    background:rgba(57, 75, 89, 0.5); }
    .bp3-dark .bp3-control.bp3-switch input:disabled ~ .bp3-control-indicator::before{
      background:rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator{
    background:#137cbd; }
  .bp3-dark .bp3-control.bp3-switch:hover input:checked ~ .bp3-control-indicator{
    background:#106ba3; }
  .bp3-dark .bp3-control.bp3-switch input:checked:not(:disabled):active ~ .bp3-control-indicator{
    background:#0e5a8a; }
  .bp3-dark .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator{
    background:rgba(14, 90, 138, 0.5); }
    .bp3-dark .bp3-control.bp3-switch input:checked:disabled ~ .bp3-control-indicator::before{
      background:rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-control.bp3-switch .bp3-control-indicator::before{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background:#394b59; }
  .bp3-dark .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator::before{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
  .bp3-control.bp3-switch .bp3-switch-inner-text{
    text-align:center;
    font-size:0.7em; }
  .bp3-control.bp3-switch .bp3-control-indicator-child:first-child{
    visibility:hidden;
    margin-right:1.2em;
    margin-left:0.5em;
    line-height:0; }
  .bp3-control.bp3-switch .bp3-control-indicator-child:last-child{
    visibility:visible;
    margin-right:0.5em;
    margin-left:1.2em;
    line-height:1em; }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator .bp3-control-indicator-child:first-child{
    visibility:visible;
    line-height:1em; }
  .bp3-control.bp3-switch input:checked ~ .bp3-control-indicator .bp3-control-indicator-child:last-child{
    visibility:hidden;
    line-height:0; }
  .bp3-dark .bp3-control{
    color:#f5f8fa; }
    .bp3-dark .bp3-control.bp3-disabled{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-control .bp3-control-indicator{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#394b59;
      background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
      background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0)); }
    .bp3-dark .bp3-control:hover .bp3-control-indicator{
      background-color:#30404d; }
    .bp3-dark .bp3-control input:not(:disabled):active ~ .bp3-control-indicator{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background:#202b33; }
    .bp3-dark .bp3-control input:disabled ~ .bp3-control-indicator{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      cursor:not-allowed; }
    .bp3-dark .bp3-control.bp3-checkbox input:disabled:checked ~ .bp3-control-indicator, .bp3-dark .bp3-control.bp3-checkbox input:disabled:indeterminate ~ .bp3-control-indicator{
      color:rgba(167, 182, 194, 0.6); }
.bp3-file-input{
  display:inline-block;
  position:relative;
  cursor:pointer;
  height:30px; }
  .bp3-file-input input{
    opacity:0;
    margin:0;
    min-width:200px; }
    .bp3-file-input input:disabled + .bp3-file-upload-input,
    .bp3-file-input input.bp3-disabled + .bp3-file-upload-input{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(206, 217, 224, 0.5);
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6);
      resize:none; }
      .bp3-file-input input:disabled + .bp3-file-upload-input::after,
      .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after{
        outline:none;
        -webkit-box-shadow:none;
                box-shadow:none;
        background-color:rgba(206, 217, 224, 0.5);
        background-image:none;
        cursor:not-allowed;
        color:rgba(92, 112, 128, 0.6); }
        .bp3-file-input input:disabled + .bp3-file-upload-input::after.bp3-active, .bp3-file-input input:disabled + .bp3-file-upload-input::after.bp3-active:hover,
        .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after.bp3-active,
        .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after.bp3-active:hover{
          background:rgba(206, 217, 224, 0.7); }
      .bp3-dark .bp3-file-input input:disabled + .bp3-file-upload-input, .bp3-dark
      .bp3-file-input input.bp3-disabled + .bp3-file-upload-input{
        -webkit-box-shadow:none;
                box-shadow:none;
        background:rgba(57, 75, 89, 0.5);
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-file-input input:disabled + .bp3-file-upload-input::after, .bp3-dark
        .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after{
          -webkit-box-shadow:none;
                  box-shadow:none;
          background-color:rgba(57, 75, 89, 0.5);
          background-image:none;
          color:rgba(167, 182, 194, 0.6); }
          .bp3-dark .bp3-file-input input:disabled + .bp3-file-upload-input::after.bp3-active, .bp3-dark
          .bp3-file-input input.bp3-disabled + .bp3-file-upload-input::after.bp3-active{
            background:rgba(57, 75, 89, 0.7); }
  .bp3-file-input.bp3-file-input-has-selection .bp3-file-upload-input{
    color:#182026; }
  .bp3-dark .bp3-file-input.bp3-file-input-has-selection .bp3-file-upload-input{
    color:#f5f8fa; }
  .bp3-file-input.bp3-fill{
    width:100%; }
  .bp3-file-input.bp3-large,
  .bp3-large .bp3-file-input{
    height:40px; }
  .bp3-file-input .bp3-file-upload-input-custom-text::after{
    content:attr(bp3-button-text); }

.bp3-file-upload-input{
  outline:none;
  border:none;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  height:30px;
  padding:0 10px;
  vertical-align:middle;
  line-height:30px;
  color:#182026;
  font-size:14px;
  font-weight:400;
  -webkit-transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  -webkit-appearance:none;
     -moz-appearance:none;
          appearance:none;
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal;
  position:absolute;
  top:0;
  right:0;
  left:0;
  padding-right:80px;
  color:rgba(92, 112, 128, 0.6);
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-file-upload-input::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-file-upload-input:focus, .bp3-file-upload-input.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-file-upload-input[type="search"], .bp3-file-upload-input.bp3-round{
    border-radius:30px;
    -webkit-box-sizing:border-box;
            box-sizing:border-box;
    padding-left:10px; }
  .bp3-file-upload-input[readonly]{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15); }
  .bp3-file-upload-input:disabled, .bp3-file-upload-input.bp3-disabled{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(206, 217, 224, 0.5);
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6);
    resize:none; }
  .bp3-file-upload-input::after{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-color:#f5f8fa;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
    color:#182026;
    min-width:24px;
    min-height:24px;
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    position:absolute;
    top:0;
    right:0;
    margin:3px;
    border-radius:3px;
    width:70px;
    text-align:center;
    line-height:24px;
    content:"Browse"; }
    .bp3-file-upload-input::after:hover{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
      background-clip:padding-box;
      background-color:#ebf1f5; }
    .bp3-file-upload-input::after:active, .bp3-file-upload-input::after.bp3-active{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#d8e1e8;
      background-image:none; }
    .bp3-file-upload-input::after:disabled, .bp3-file-upload-input::after.bp3-disabled{
      outline:none;
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(206, 217, 224, 0.5);
      background-image:none;
      cursor:not-allowed;
      color:rgba(92, 112, 128, 0.6); }
      .bp3-file-upload-input::after:disabled.bp3-active, .bp3-file-upload-input::after:disabled.bp3-active:hover, .bp3-file-upload-input::after.bp3-disabled.bp3-active, .bp3-file-upload-input::after.bp3-disabled.bp3-active:hover{
        background:rgba(206, 217, 224, 0.7); }
  .bp3-file-upload-input:hover::after{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5; }
  .bp3-file-upload-input:active::after{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none; }
  .bp3-large .bp3-file-upload-input{
    height:40px;
    line-height:40px;
    font-size:16px;
    padding-right:95px; }
    .bp3-large .bp3-file-upload-input[type="search"], .bp3-large .bp3-file-upload-input.bp3-round{
      padding:0 15px; }
    .bp3-large .bp3-file-upload-input::after{
      min-width:30px;
      min-height:30px;
      margin:5px;
      width:85px;
      line-height:30px; }
  .bp3-dark .bp3-file-upload-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa;
    color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-file-upload-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-file-upload-input:disabled, .bp3-dark .bp3-file-upload-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-file-upload-input::after{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#394b59;
      background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
      background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
      color:#f5f8fa; }
      .bp3-dark .bp3-file-upload-input::after:hover, .bp3-dark .bp3-file-upload-input::after:active, .bp3-dark .bp3-file-upload-input::after.bp3-active{
        color:#f5f8fa; }
      .bp3-dark .bp3-file-upload-input::after:hover{
        -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
        background-color:#30404d; }
      .bp3-dark .bp3-file-upload-input::after:active, .bp3-dark .bp3-file-upload-input::after.bp3-active{
        -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
                box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
        background-color:#202b33;
        background-image:none; }
      .bp3-dark .bp3-file-upload-input::after:disabled, .bp3-dark .bp3-file-upload-input::after.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none;
        background-color:rgba(57, 75, 89, 0.5);
        background-image:none;
        color:rgba(167, 182, 194, 0.6); }
        .bp3-dark .bp3-file-upload-input::after:disabled.bp3-active, .bp3-dark .bp3-file-upload-input::after.bp3-disabled.bp3-active{
          background:rgba(57, 75, 89, 0.7); }
      .bp3-dark .bp3-file-upload-input::after .bp3-button-spinner .bp3-spinner-head{
        background:rgba(16, 22, 26, 0.5);
        stroke:#8a9ba8; }
    .bp3-dark .bp3-file-upload-input:hover::after{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#30404d; }
    .bp3-dark .bp3-file-upload-input:active::after{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#202b33;
      background-image:none; }

.bp3-file-upload-input::after{
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1); }
.bp3-form-group{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin:0 0 15px; }
  .bp3-form-group label.bp3-label{
    margin-bottom:5px; }
  .bp3-form-group .bp3-control{
    margin-top:7px; }
  .bp3-form-group .bp3-form-helper-text{
    margin-top:5px;
    color:#5c7080;
    font-size:12px; }
  .bp3-form-group.bp3-intent-primary .bp3-form-helper-text{
    color:#106ba3; }
  .bp3-form-group.bp3-intent-success .bp3-form-helper-text{
    color:#0d8050; }
  .bp3-form-group.bp3-intent-warning .bp3-form-helper-text{
    color:#bf7326; }
  .bp3-form-group.bp3-intent-danger .bp3-form-helper-text{
    color:#c23030; }
  .bp3-form-group.bp3-inline{
    -webkit-box-orient:horizontal;
    -webkit-box-direction:normal;
        -ms-flex-direction:row;
            flex-direction:row;
    -webkit-box-align:start;
        -ms-flex-align:start;
            align-items:flex-start; }
    .bp3-form-group.bp3-inline.bp3-large label.bp3-label{
      margin:0 10px 0 0;
      line-height:40px; }
    .bp3-form-group.bp3-inline label.bp3-label{
      margin:0 10px 0 0;
      line-height:30px; }
  .bp3-form-group.bp3-disabled .bp3-label,
  .bp3-form-group.bp3-disabled .bp3-text-muted,
  .bp3-form-group.bp3-disabled .bp3-form-helper-text{
    color:rgba(92, 112, 128, 0.6) !important; }
  .bp3-dark .bp3-form-group.bp3-intent-primary .bp3-form-helper-text{
    color:#48aff0; }
  .bp3-dark .bp3-form-group.bp3-intent-success .bp3-form-helper-text{
    color:#3dcc91; }
  .bp3-dark .bp3-form-group.bp3-intent-warning .bp3-form-helper-text{
    color:#ffb366; }
  .bp3-dark .bp3-form-group.bp3-intent-danger .bp3-form-helper-text{
    color:#ff7373; }
  .bp3-dark .bp3-form-group .bp3-form-helper-text{
    color:#a7b6c2; }
  .bp3-dark .bp3-form-group.bp3-disabled .bp3-label,
  .bp3-dark .bp3-form-group.bp3-disabled .bp3-text-muted,
  .bp3-dark .bp3-form-group.bp3-disabled .bp3-form-helper-text{
    color:rgba(167, 182, 194, 0.6) !important; }
.bp3-input-group{
  display:block;
  position:relative; }
  .bp3-input-group .bp3-input{
    position:relative;
    width:100%; }
    .bp3-input-group .bp3-input:not(:first-child){
      padding-left:30px; }
    .bp3-input-group .bp3-input:not(:last-child){
      padding-right:30px; }
  .bp3-input-group .bp3-input-action,
  .bp3-input-group > .bp3-button,
  .bp3-input-group > .bp3-icon{
    position:absolute;
    top:0; }
    .bp3-input-group .bp3-input-action:first-child,
    .bp3-input-group > .bp3-button:first-child,
    .bp3-input-group > .bp3-icon:first-child{
      left:0; }
    .bp3-input-group .bp3-input-action:last-child,
    .bp3-input-group > .bp3-button:last-child,
    .bp3-input-group > .bp3-icon:last-child{
      right:0; }
  .bp3-input-group .bp3-button{
    min-width:24px;
    min-height:24px;
    margin:3px;
    padding:0 7px; }
    .bp3-input-group .bp3-button:empty{
      padding:0; }
  .bp3-input-group > .bp3-icon{
    z-index:1;
    color:#5c7080; }
    .bp3-input-group > .bp3-icon:empty{
      line-height:1;
      font-family:"Icons16", sans-serif;
      font-size:16px;
      font-weight:400;
      font-style:normal;
      -moz-osx-font-smoothing:grayscale;
      -webkit-font-smoothing:antialiased; }
  .bp3-input-group > .bp3-icon,
  .bp3-input-group .bp3-input-action > .bp3-spinner{
    margin:7px; }
  .bp3-input-group .bp3-tag{
    margin:5px; }
  .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus),
  .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus){
    color:#5c7080; }
    .bp3-dark .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus), .bp3-dark
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus){
      color:#a7b6c2; }
    .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-standard, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-large,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-standard,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:not(:hover):not(:focus) .bp3-icon-large{
      color:#5c7080; }
  .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled,
  .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled{
    color:rgba(92, 112, 128, 0.6) !important; }
    .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled .bp3-icon, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled .bp3-icon-standard, .bp3-input-group .bp3-input:not(:focus) + .bp3-button.bp3-minimal:disabled .bp3-icon-large,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled .bp3-icon,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled .bp3-icon-standard,
    .bp3-input-group .bp3-input:not(:focus) + .bp3-input-action .bp3-button.bp3-minimal:disabled .bp3-icon-large{
      color:rgba(92, 112, 128, 0.6) !important; }
  .bp3-input-group.bp3-disabled{
    cursor:not-allowed; }
    .bp3-input-group.bp3-disabled .bp3-icon{
      color:rgba(92, 112, 128, 0.6); }
  .bp3-input-group.bp3-large .bp3-button{
    min-width:30px;
    min-height:30px;
    margin:5px; }
  .bp3-input-group.bp3-large > .bp3-icon,
  .bp3-input-group.bp3-large .bp3-input-action > .bp3-spinner{
    margin:12px; }
  .bp3-input-group.bp3-large .bp3-input{
    height:40px;
    line-height:40px;
    font-size:16px; }
    .bp3-input-group.bp3-large .bp3-input[type="search"], .bp3-input-group.bp3-large .bp3-input.bp3-round{
      padding:0 15px; }
    .bp3-input-group.bp3-large .bp3-input:not(:first-child){
      padding-left:40px; }
    .bp3-input-group.bp3-large .bp3-input:not(:last-child){
      padding-right:40px; }
  .bp3-input-group.bp3-small .bp3-button{
    min-width:20px;
    min-height:20px;
    margin:2px; }
  .bp3-input-group.bp3-small .bp3-tag{
    min-width:20px;
    min-height:20px;
    margin:2px; }
  .bp3-input-group.bp3-small > .bp3-icon,
  .bp3-input-group.bp3-small .bp3-input-action > .bp3-spinner{
    margin:4px; }
  .bp3-input-group.bp3-small .bp3-input{
    height:24px;
    padding-right:8px;
    padding-left:8px;
    line-height:24px;
    font-size:12px; }
    .bp3-input-group.bp3-small .bp3-input[type="search"], .bp3-input-group.bp3-small .bp3-input.bp3-round{
      padding:0 12px; }
    .bp3-input-group.bp3-small .bp3-input:not(:first-child){
      padding-left:24px; }
    .bp3-input-group.bp3-small .bp3-input:not(:last-child){
      padding-right:24px; }
  .bp3-input-group.bp3-fill{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    width:100%; }
  .bp3-input-group.bp3-round .bp3-button,
  .bp3-input-group.bp3-round .bp3-input,
  .bp3-input-group.bp3-round .bp3-tag{
    border-radius:30px; }
  .bp3-dark .bp3-input-group .bp3-icon{
    color:#a7b6c2; }
  .bp3-dark .bp3-input-group.bp3-disabled .bp3-icon{
    color:rgba(167, 182, 194, 0.6); }
  .bp3-input-group.bp3-intent-primary .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-primary .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-primary .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #137cbd;
              box-shadow:inset 0 0 0 1px #137cbd; }
    .bp3-input-group.bp3-intent-primary .bp3-input:disabled, .bp3-input-group.bp3-intent-primary .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-primary > .bp3-icon{
    color:#106ba3; }
    .bp3-dark .bp3-input-group.bp3-intent-primary > .bp3-icon{
      color:#48aff0; }
  .bp3-input-group.bp3-intent-success .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-success .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-success .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #0f9960;
              box-shadow:inset 0 0 0 1px #0f9960; }
    .bp3-input-group.bp3-intent-success .bp3-input:disabled, .bp3-input-group.bp3-intent-success .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-success > .bp3-icon{
    color:#0d8050; }
    .bp3-dark .bp3-input-group.bp3-intent-success > .bp3-icon{
      color:#3dcc91; }
  .bp3-input-group.bp3-intent-warning .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-warning .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-warning .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #d9822b;
              box-shadow:inset 0 0 0 1px #d9822b; }
    .bp3-input-group.bp3-intent-warning .bp3-input:disabled, .bp3-input-group.bp3-intent-warning .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-warning > .bp3-icon{
    color:#bf7326; }
    .bp3-dark .bp3-input-group.bp3-intent-warning > .bp3-icon{
      color:#ffb366; }
  .bp3-input-group.bp3-intent-danger .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-danger .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input-group.bp3-intent-danger .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #db3737;
              box-shadow:inset 0 0 0 1px #db3737; }
    .bp3-input-group.bp3-intent-danger .bp3-input:disabled, .bp3-input-group.bp3-intent-danger .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-input-group.bp3-intent-danger > .bp3-icon{
    color:#c23030; }
    .bp3-dark .bp3-input-group.bp3-intent-danger > .bp3-icon{
      color:#ff7373; }
.bp3-input{
  outline:none;
  border:none;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
  background:#ffffff;
  height:30px;
  padding:0 10px;
  vertical-align:middle;
  line-height:30px;
  color:#182026;
  font-size:14px;
  font-weight:400;
  -webkit-transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-box-shadow 100ms cubic-bezier(0.4, 1, 0.75, 0.9);
  -webkit-appearance:none;
     -moz-appearance:none;
          appearance:none; }
  .bp3-input::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input:focus, .bp3-input.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-input[type="search"], .bp3-input.bp3-round{
    border-radius:30px;
    -webkit-box-sizing:border-box;
            box-sizing:border-box;
    padding-left:10px; }
  .bp3-input[readonly]{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.15); }
  .bp3-input:disabled, .bp3-input.bp3-disabled{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(206, 217, 224, 0.5);
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6);
    resize:none; }
  .bp3-input.bp3-large{
    height:40px;
    line-height:40px;
    font-size:16px; }
    .bp3-input.bp3-large[type="search"], .bp3-input.bp3-large.bp3-round{
      padding:0 15px; }
  .bp3-input.bp3-small{
    height:24px;
    padding-right:8px;
    padding-left:8px;
    line-height:24px;
    font-size:12px; }
    .bp3-input.bp3-small[type="search"], .bp3-input.bp3-small.bp3-round{
      padding:0 12px; }
  .bp3-input.bp3-fill{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    width:100%; }
  .bp3-dark .bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa; }
    .bp3-dark .bp3-input::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input::placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-input:disabled, .bp3-dark .bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      color:rgba(167, 182, 194, 0.6); }
  .bp3-input.bp3-intent-primary{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-primary:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-primary[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #137cbd;
              box-shadow:inset 0 0 0 1px #137cbd; }
    .bp3-input.bp3-intent-primary:disabled, .bp3-input.bp3-intent-primary.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-primary{
      -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px #137cbd, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-primary:focus{
        -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-primary[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #137cbd;
                box-shadow:inset 0 0 0 1px #137cbd; }
      .bp3-dark .bp3-input.bp3-intent-primary:disabled, .bp3-dark .bp3-input.bp3-intent-primary.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input.bp3-intent-success{
    -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-success:focus{
      -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-success[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #0f9960;
              box-shadow:inset 0 0 0 1px #0f9960; }
    .bp3-input.bp3-intent-success:disabled, .bp3-input.bp3-intent-success.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-success{
      -webkit-box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), 0 0 0 0 rgba(15, 153, 96, 0), inset 0 0 0 1px #0f9960, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-success:focus{
        -webkit-box-shadow:0 0 0 1px #0f9960, 0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #0f9960, 0 0 0 1px #0f9960, 0 0 0 3px rgba(15, 153, 96, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-success[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #0f9960;
                box-shadow:inset 0 0 0 1px #0f9960; }
      .bp3-dark .bp3-input.bp3-intent-success:disabled, .bp3-dark .bp3-input.bp3-intent-success.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input.bp3-intent-warning{
    -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-warning:focus{
      -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-warning[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #d9822b;
              box-shadow:inset 0 0 0 1px #d9822b; }
    .bp3-input.bp3-intent-warning:disabled, .bp3-input.bp3-intent-warning.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-warning{
      -webkit-box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), 0 0 0 0 rgba(217, 130, 43, 0), inset 0 0 0 1px #d9822b, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-warning:focus{
        -webkit-box-shadow:0 0 0 1px #d9822b, 0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #d9822b, 0 0 0 1px #d9822b, 0 0 0 3px rgba(217, 130, 43, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-warning[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #d9822b;
                box-shadow:inset 0 0 0 1px #d9822b; }
      .bp3-dark .bp3-input.bp3-intent-warning:disabled, .bp3-dark .bp3-input.bp3-intent-warning.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input.bp3-intent-danger{
    -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.15), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-danger:focus{
      -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-input.bp3-intent-danger[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px #db3737;
              box-shadow:inset 0 0 0 1px #db3737; }
    .bp3-input.bp3-intent-danger:disabled, .bp3-input.bp3-intent-danger.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none; }
    .bp3-dark .bp3-input.bp3-intent-danger{
      -webkit-box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), 0 0 0 0 rgba(219, 55, 55, 0), inset 0 0 0 1px #db3737, inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-danger:focus{
        -webkit-box-shadow:0 0 0 1px #db3737, 0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
                box-shadow:0 0 0 1px #db3737, 0 0 0 1px #db3737, 0 0 0 3px rgba(219, 55, 55, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
      .bp3-dark .bp3-input.bp3-intent-danger[readonly]{
        -webkit-box-shadow:inset 0 0 0 1px #db3737;
                box-shadow:inset 0 0 0 1px #db3737; }
      .bp3-dark .bp3-input.bp3-intent-danger:disabled, .bp3-dark .bp3-input.bp3-intent-danger.bp3-disabled{
        -webkit-box-shadow:none;
                box-shadow:none; }
  .bp3-input::-ms-clear{
    display:none; }
textarea.bp3-input{
  max-width:100%;
  padding:10px; }
  textarea.bp3-input, textarea.bp3-input.bp3-large, textarea.bp3-input.bp3-small{
    height:auto;
    line-height:inherit; }
  textarea.bp3-input.bp3-small{
    padding:8px; }
  .bp3-dark textarea.bp3-input{
    -webkit-box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), 0 0 0 0 rgba(19, 124, 189, 0), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background:rgba(16, 22, 26, 0.3);
    color:#f5f8fa; }
    .bp3-dark textarea.bp3-input::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input::placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark textarea.bp3-input:focus{
      -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark textarea.bp3-input[readonly]{
      -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark textarea.bp3-input:disabled, .bp3-dark textarea.bp3-input.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:rgba(57, 75, 89, 0.5);
      color:rgba(167, 182, 194, 0.6); }
label.bp3-label{
  display:block;
  margin-top:0;
  margin-bottom:15px; }
  label.bp3-label .bp3-html-select,
  label.bp3-label .bp3-input,
  label.bp3-label .bp3-select,
  label.bp3-label .bp3-slider,
  label.bp3-label .bp3-popover-wrapper{
    display:block;
    margin-top:5px;
    text-transform:none; }
  label.bp3-label .bp3-button-group{
    margin-top:5px; }
  label.bp3-label .bp3-select select,
  label.bp3-label .bp3-html-select select{
    width:100%;
    vertical-align:top;
    font-weight:400; }
  label.bp3-label.bp3-disabled,
  label.bp3-label.bp3-disabled .bp3-text-muted{
    color:rgba(92, 112, 128, 0.6); }
  label.bp3-label.bp3-inline{
    line-height:30px; }
    label.bp3-label.bp3-inline .bp3-html-select,
    label.bp3-label.bp3-inline .bp3-input,
    label.bp3-label.bp3-inline .bp3-input-group,
    label.bp3-label.bp3-inline .bp3-select,
    label.bp3-label.bp3-inline .bp3-popover-wrapper{
      display:inline-block;
      margin:0 0 0 5px;
      vertical-align:top; }
    label.bp3-label.bp3-inline .bp3-button-group{
      margin:0 0 0 5px; }
    label.bp3-label.bp3-inline .bp3-input-group .bp3-input{
      margin-left:0; }
    label.bp3-label.bp3-inline.bp3-large{
      line-height:40px; }
  label.bp3-label:not(.bp3-inline) .bp3-popover-target{
    display:block; }
  .bp3-dark label.bp3-label{
    color:#f5f8fa; }
    .bp3-dark label.bp3-label.bp3-disabled,
    .bp3-dark label.bp3-label.bp3-disabled .bp3-text-muted{
      color:rgba(167, 182, 194, 0.6); }
.bp3-numeric-input .bp3-button-group.bp3-vertical > .bp3-button{
  -webkit-box-flex:1;
      -ms-flex:1 1 14px;
          flex:1 1 14px;
  width:30px;
  min-height:0;
  padding:0; }
  .bp3-numeric-input .bp3-button-group.bp3-vertical > .bp3-button:first-child{
    border-radius:0 3px 0 0; }
  .bp3-numeric-input .bp3-button-group.bp3-vertical > .bp3-button:last-child{
    border-radius:0 0 3px 0; }

.bp3-numeric-input .bp3-button-group.bp3-vertical:first-child > .bp3-button:first-child{
  border-radius:3px 0 0 0; }

.bp3-numeric-input .bp3-button-group.bp3-vertical:first-child > .bp3-button:last-child{
  border-radius:0 0 0 3px; }

.bp3-numeric-input.bp3-large .bp3-button-group.bp3-vertical > .bp3-button{
  width:40px; }

form{
  display:block; }
.bp3-html-select select,
.bp3-select select{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  border:none;
  border-radius:3px;
  cursor:pointer;
  padding:5px 10px;
  vertical-align:middle;
  text-align:left;
  font-size:14px;
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
  background-color:#f5f8fa;
  background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
  background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
  color:#182026;
  border-radius:3px;
  width:100%;
  height:30px;
  padding:0 25px 0 10px;
  -moz-appearance:none;
  -webkit-appearance:none; }
  .bp3-html-select select > *, .bp3-select select > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-html-select select > .bp3-fill, .bp3-select select > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-html-select select::before,
  .bp3-select select::before, .bp3-html-select select > *, .bp3-select select > *{
    margin-right:7px; }
  .bp3-html-select select:empty::before,
  .bp3-select select:empty::before,
  .bp3-html-select select > :last-child,
  .bp3-select select > :last-child{
    margin-right:0; }
  .bp3-html-select select:hover,
  .bp3-select select:hover{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5; }
  .bp3-html-select select:active,
  .bp3-select select:active, .bp3-html-select select.bp3-active,
  .bp3-select select.bp3-active{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none; }
  .bp3-html-select select:disabled,
  .bp3-select select:disabled, .bp3-html-select select.bp3-disabled,
  .bp3-select select.bp3-disabled{
    outline:none;
    -webkit-box-shadow:none;
            box-shadow:none;
    background-color:rgba(206, 217, 224, 0.5);
    background-image:none;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
    .bp3-html-select select:disabled.bp3-active,
    .bp3-select select:disabled.bp3-active, .bp3-html-select select:disabled.bp3-active:hover,
    .bp3-select select:disabled.bp3-active:hover, .bp3-html-select select.bp3-disabled.bp3-active,
    .bp3-select select.bp3-disabled.bp3-active, .bp3-html-select select.bp3-disabled.bp3-active:hover,
    .bp3-select select.bp3-disabled.bp3-active:hover{
      background:rgba(206, 217, 224, 0.7); }

.bp3-html-select.bp3-minimal select,
.bp3-select.bp3-minimal select{
  -webkit-box-shadow:none;
          box-shadow:none;
  background:none; }
  .bp3-html-select.bp3-minimal select:hover,
  .bp3-select.bp3-minimal select:hover{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(167, 182, 194, 0.3);
    text-decoration:none;
    color:#182026; }
  .bp3-html-select.bp3-minimal select:active,
  .bp3-select.bp3-minimal select:active, .bp3-html-select.bp3-minimal select.bp3-active,
  .bp3-select.bp3-minimal select.bp3-active{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:rgba(115, 134, 148, 0.3);
    color:#182026; }
  .bp3-html-select.bp3-minimal select:disabled,
  .bp3-select.bp3-minimal select:disabled, .bp3-html-select.bp3-minimal select:disabled:hover,
  .bp3-select.bp3-minimal select:disabled:hover, .bp3-html-select.bp3-minimal select.bp3-disabled,
  .bp3-select.bp3-minimal select.bp3-disabled, .bp3-html-select.bp3-minimal select.bp3-disabled:hover,
  .bp3-select.bp3-minimal select.bp3-disabled:hover{
    background:none;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
    .bp3-html-select.bp3-minimal select:disabled.bp3-active,
    .bp3-select.bp3-minimal select:disabled.bp3-active, .bp3-html-select.bp3-minimal select:disabled:hover.bp3-active,
    .bp3-select.bp3-minimal select:disabled:hover.bp3-active, .bp3-html-select.bp3-minimal select.bp3-disabled.bp3-active,
    .bp3-select.bp3-minimal select.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-disabled:hover.bp3-active,
    .bp3-select.bp3-minimal select.bp3-disabled:hover.bp3-active{
      background:rgba(115, 134, 148, 0.3); }
  .bp3-dark .bp3-html-select.bp3-minimal select, .bp3-html-select.bp3-minimal .bp3-dark select,
  .bp3-dark .bp3-select.bp3-minimal select, .bp3-select.bp3-minimal .bp3-dark select{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:none;
    color:inherit; }
    .bp3-dark .bp3-html-select.bp3-minimal select:hover, .bp3-html-select.bp3-minimal .bp3-dark select:hover,
    .bp3-dark .bp3-select.bp3-minimal select:hover, .bp3-select.bp3-minimal .bp3-dark select:hover, .bp3-dark .bp3-html-select.bp3-minimal select:active, .bp3-html-select.bp3-minimal .bp3-dark select:active,
    .bp3-dark .bp3-select.bp3-minimal select:active, .bp3-select.bp3-minimal .bp3-dark select:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-active,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none; }
    .bp3-dark .bp3-html-select.bp3-minimal select:hover, .bp3-html-select.bp3-minimal .bp3-dark select:hover,
    .bp3-dark .bp3-select.bp3-minimal select:hover, .bp3-select.bp3-minimal .bp3-dark select:hover{
      background:rgba(138, 155, 168, 0.15); }
    .bp3-dark .bp3-html-select.bp3-minimal select:active, .bp3-html-select.bp3-minimal .bp3-dark select:active,
    .bp3-dark .bp3-select.bp3-minimal select:active, .bp3-select.bp3-minimal .bp3-dark select:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-active,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-active{
      background:rgba(138, 155, 168, 0.3);
      color:#f5f8fa; }
    .bp3-dark .bp3-html-select.bp3-minimal select:disabled, .bp3-html-select.bp3-minimal .bp3-dark select:disabled,
    .bp3-dark .bp3-select.bp3-minimal select:disabled, .bp3-select.bp3-minimal .bp3-dark select:disabled, .bp3-dark .bp3-html-select.bp3-minimal select:disabled:hover, .bp3-html-select.bp3-minimal .bp3-dark select:disabled:hover,
    .bp3-dark .bp3-select.bp3-minimal select:disabled:hover, .bp3-select.bp3-minimal .bp3-dark select:disabled:hover, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled:hover,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled:hover{
      background:none;
      cursor:not-allowed;
      color:rgba(167, 182, 194, 0.6); }
      .bp3-dark .bp3-html-select.bp3-minimal select:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select:disabled.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select:disabled:hover.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select:disabled:hover.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select:disabled:hover.bp3-active, .bp3-select.bp3-minimal .bp3-dark select:disabled:hover.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-disabled:hover.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-disabled:hover.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-disabled:hover.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-disabled:hover.bp3-active{
        background:rgba(138, 155, 168, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-primary,
  .bp3-select.bp3-minimal select.bp3-intent-primary{
    color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:hover,
    .bp3-select.bp3-minimal select.bp3-intent-primary:hover, .bp3-html-select.bp3-minimal select.bp3-intent-primary:active,
    .bp3-select.bp3-minimal select.bp3-intent-primary:active, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:hover,
    .bp3-select.bp3-minimal select.bp3-intent-primary:hover{
      background:rgba(19, 124, 189, 0.15);
      color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:active,
    .bp3-select.bp3-minimal select.bp3-intent-primary:active, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-active{
      background:rgba(19, 124, 189, 0.3);
      color:#106ba3; }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-primary:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled{
      background:none;
      color:rgba(16, 107, 163, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active{
        background:rgba(19, 124, 189, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-primary .bp3-button-spinner .bp3-spinner-head{
      stroke:#106ba3; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary{
      color:#48aff0; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:hover{
        background:rgba(19, 124, 189, 0.2);
        color:#48aff0; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-active{
        background:rgba(19, 124, 189, 0.3);
        color:#48aff0; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled{
        background:none;
        color:rgba(72, 175, 240, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-primary.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-primary.bp3-disabled.bp3-active{
          background:rgba(19, 124, 189, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-success,
  .bp3-select.bp3-minimal select.bp3-intent-success{
    color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:hover,
    .bp3-select.bp3-minimal select.bp3-intent-success:hover, .bp3-html-select.bp3-minimal select.bp3-intent-success:active,
    .bp3-select.bp3-minimal select.bp3-intent-success:active, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-success.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:hover,
    .bp3-select.bp3-minimal select.bp3-intent-success:hover{
      background:rgba(15, 153, 96, 0.15);
      color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:active,
    .bp3-select.bp3-minimal select.bp3-intent-success:active, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-success.bp3-active{
      background:rgba(15, 153, 96, 0.3);
      color:#0d8050; }
    .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-success:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled{
      background:none;
      color:rgba(13, 128, 80, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active{
        background:rgba(15, 153, 96, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-success .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-success .bp3-button-spinner .bp3-spinner-head{
      stroke:#0d8050; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success{
      color:#3dcc91; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:hover{
        background:rgba(15, 153, 96, 0.2);
        color:#3dcc91; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-active{
        background:rgba(15, 153, 96, 0.3);
        color:#3dcc91; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled{
        background:none;
        color:rgba(61, 204, 145, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-success.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-success.bp3-disabled.bp3-active{
          background:rgba(15, 153, 96, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-warning,
  .bp3-select.bp3-minimal select.bp3-intent-warning{
    color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:hover,
    .bp3-select.bp3-minimal select.bp3-intent-warning:hover, .bp3-html-select.bp3-minimal select.bp3-intent-warning:active,
    .bp3-select.bp3-minimal select.bp3-intent-warning:active, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:hover,
    .bp3-select.bp3-minimal select.bp3-intent-warning:hover{
      background:rgba(217, 130, 43, 0.15);
      color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:active,
    .bp3-select.bp3-minimal select.bp3-intent-warning:active, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-active{
      background:rgba(217, 130, 43, 0.3);
      color:#bf7326; }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-warning:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled{
      background:none;
      color:rgba(191, 115, 38, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active{
        background:rgba(217, 130, 43, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-warning .bp3-button-spinner .bp3-spinner-head{
      stroke:#bf7326; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning{
      color:#ffb366; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:hover{
        background:rgba(217, 130, 43, 0.2);
        color:#ffb366; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-active{
        background:rgba(217, 130, 43, 0.3);
        color:#ffb366; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled{
        background:none;
        color:rgba(255, 179, 102, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-warning.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-warning.bp3-disabled.bp3-active{
          background:rgba(217, 130, 43, 0.3); }
  .bp3-html-select.bp3-minimal select.bp3-intent-danger,
  .bp3-select.bp3-minimal select.bp3-intent-danger{
    color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:hover,
    .bp3-select.bp3-minimal select.bp3-intent-danger:hover, .bp3-html-select.bp3-minimal select.bp3-intent-danger:active,
    .bp3-select.bp3-minimal select.bp3-intent-danger:active, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-active{
      -webkit-box-shadow:none;
              box-shadow:none;
      background:none;
      color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:hover,
    .bp3-select.bp3-minimal select.bp3-intent-danger:hover{
      background:rgba(219, 55, 55, 0.15);
      color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:active,
    .bp3-select.bp3-minimal select.bp3-intent-danger:active, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-active,
    .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-active{
      background:rgba(219, 55, 55, 0.3);
      color:#c23030; }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled,
    .bp3-select.bp3-minimal select.bp3-intent-danger:disabled, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled,
    .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled{
      background:none;
      color:rgba(194, 48, 48, 0.5); }
      .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active, .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active,
      .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active{
        background:rgba(219, 55, 55, 0.3); }
    .bp3-html-select.bp3-minimal select.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head, .bp3-select.bp3-minimal select.bp3-intent-danger .bp3-button-spinner .bp3-spinner-head{
      stroke:#c23030; }
    .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger,
    .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger{
      color:#ff7373; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:hover, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:hover,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:hover, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:hover{
        background:rgba(219, 55, 55, 0.2);
        color:#ff7373; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-active,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-active{
        background:rgba(219, 55, 55, 0.3);
        color:#ff7373; }
      .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled,
      .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled{
        background:none;
        color:rgba(255, 115, 115, 0.5); }
        .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger:disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger:disabled.bp3-active, .bp3-dark .bp3-html-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active, .bp3-html-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled.bp3-active,
        .bp3-dark .bp3-select.bp3-minimal select.bp3-intent-danger.bp3-disabled.bp3-active, .bp3-select.bp3-minimal .bp3-dark select.bp3-intent-danger.bp3-disabled.bp3-active{
          background:rgba(219, 55, 55, 0.3); }

.bp3-html-select.bp3-large select,
.bp3-select.bp3-large select{
  height:40px;
  padding-right:35px;
  font-size:16px; }

.bp3-dark .bp3-html-select select, .bp3-dark .bp3-select select{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
  background-color:#394b59;
  background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
  background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
  color:#f5f8fa; }
  .bp3-dark .bp3-html-select select:hover, .bp3-dark .bp3-select select:hover, .bp3-dark .bp3-html-select select:active, .bp3-dark .bp3-select select:active, .bp3-dark .bp3-html-select select.bp3-active, .bp3-dark .bp3-select select.bp3-active{
    color:#f5f8fa; }
  .bp3-dark .bp3-html-select select:hover, .bp3-dark .bp3-select select:hover{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#30404d; }
  .bp3-dark .bp3-html-select select:active, .bp3-dark .bp3-select select:active, .bp3-dark .bp3-html-select select.bp3-active, .bp3-dark .bp3-select select.bp3-active{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#202b33;
    background-image:none; }
  .bp3-dark .bp3-html-select select:disabled, .bp3-dark .bp3-select select:disabled, .bp3-dark .bp3-html-select select.bp3-disabled, .bp3-dark .bp3-select select.bp3-disabled{
    -webkit-box-shadow:none;
            box-shadow:none;
    background-color:rgba(57, 75, 89, 0.5);
    background-image:none;
    color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-html-select select:disabled.bp3-active, .bp3-dark .bp3-select select:disabled.bp3-active, .bp3-dark .bp3-html-select select.bp3-disabled.bp3-active, .bp3-dark .bp3-select select.bp3-disabled.bp3-active{
      background:rgba(57, 75, 89, 0.7); }
  .bp3-dark .bp3-html-select select .bp3-button-spinner .bp3-spinner-head, .bp3-dark .bp3-select select .bp3-button-spinner .bp3-spinner-head{
    background:rgba(16, 22, 26, 0.5);
    stroke:#8a9ba8; }

.bp3-html-select select:disabled,
.bp3-select select:disabled{
  -webkit-box-shadow:none;
          box-shadow:none;
  background-color:rgba(206, 217, 224, 0.5);
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-html-select .bp3-icon,
.bp3-select .bp3-icon, .bp3-select::after{
  position:absolute;
  top:7px;
  right:7px;
  color:#5c7080;
  pointer-events:none; }
  .bp3-html-select .bp3-disabled.bp3-icon,
  .bp3-select .bp3-disabled.bp3-icon, .bp3-disabled.bp3-select::after{
    color:rgba(92, 112, 128, 0.6); }
.bp3-html-select,
.bp3-select{
  display:inline-block;
  position:relative;
  vertical-align:middle;
  letter-spacing:normal; }
  .bp3-html-select select::-ms-expand,
  .bp3-select select::-ms-expand{
    display:none; }
  .bp3-html-select .bp3-icon,
  .bp3-select .bp3-icon{
    color:#5c7080; }
    .bp3-html-select .bp3-icon:hover,
    .bp3-select .bp3-icon:hover{
      color:#182026; }
    .bp3-dark .bp3-html-select .bp3-icon, .bp3-dark
    .bp3-select .bp3-icon{
      color:#a7b6c2; }
      .bp3-dark .bp3-html-select .bp3-icon:hover, .bp3-dark
      .bp3-select .bp3-icon:hover{
        color:#f5f8fa; }
  .bp3-html-select.bp3-large::after,
  .bp3-html-select.bp3-large .bp3-icon,
  .bp3-select.bp3-large::after,
  .bp3-select.bp3-large .bp3-icon{
    top:12px;
    right:12px; }
  .bp3-html-select.bp3-fill,
  .bp3-html-select.bp3-fill select,
  .bp3-select.bp3-fill,
  .bp3-select.bp3-fill select{
    width:100%; }
  .bp3-dark .bp3-html-select option, .bp3-dark
  .bp3-select option{
    background-color:#30404d;
    color:#f5f8fa; }
  .bp3-dark .bp3-html-select::after, .bp3-dark
  .bp3-select::after{
    color:#a7b6c2; }

.bp3-select::after{
  line-height:1;
  font-family:"Icons16", sans-serif;
  font-size:16px;
  font-weight:400;
  font-style:normal;
  -moz-osx-font-smoothing:grayscale;
  -webkit-font-smoothing:antialiased;
  content:""; }
.bp3-running-text table, table.bp3-html-table{
  border-spacing:0;
  font-size:14px; }
  .bp3-running-text table th, table.bp3-html-table th,
  .bp3-running-text table td,
  table.bp3-html-table td{
    padding:11px;
    vertical-align:top;
    text-align:left; }
  .bp3-running-text table th, table.bp3-html-table th{
    color:#182026;
    font-weight:600; }
  
  .bp3-running-text table td,
  table.bp3-html-table td{
    color:#182026; }
  .bp3-running-text table tbody tr:first-child th, table.bp3-html-table tbody tr:first-child th,
  .bp3-running-text table tbody tr:first-child td,
  table.bp3-html-table tbody tr:first-child td{
    -webkit-box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15); }
  .bp3-dark .bp3-running-text table th, .bp3-running-text .bp3-dark table th, .bp3-dark table.bp3-html-table th{
    color:#f5f8fa; }
  .bp3-dark .bp3-running-text table td, .bp3-running-text .bp3-dark table td, .bp3-dark table.bp3-html-table td{
    color:#f5f8fa; }
  .bp3-dark .bp3-running-text table tbody tr:first-child th, .bp3-running-text .bp3-dark table tbody tr:first-child th, .bp3-dark table.bp3-html-table tbody tr:first-child th,
  .bp3-dark .bp3-running-text table tbody tr:first-child td,
  .bp3-running-text .bp3-dark table tbody tr:first-child td,
  .bp3-dark table.bp3-html-table tbody tr:first-child td{
    -webkit-box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15);
            box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15); }

table.bp3-html-table.bp3-html-table-condensed th,
table.bp3-html-table.bp3-html-table-condensed td, table.bp3-html-table.bp3-small th,
table.bp3-html-table.bp3-small td{
  padding-top:6px;
  padding-bottom:6px; }

table.bp3-html-table.bp3-html-table-striped tbody tr:nth-child(odd) td{
  background:rgba(191, 204, 214, 0.15); }

table.bp3-html-table.bp3-html-table-bordered th:not(:first-child){
  -webkit-box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15);
          box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15); }

table.bp3-html-table.bp3-html-table-bordered tbody tr td{
  -webkit-box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15);
          box-shadow:inset 0 1px 0 0 rgba(16, 22, 26, 0.15); }
  table.bp3-html-table.bp3-html-table-bordered tbody tr td:not(:first-child){
    -webkit-box-shadow:inset 1px 1px 0 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 1px 1px 0 0 rgba(16, 22, 26, 0.15); }

table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td{
  -webkit-box-shadow:none;
          box-shadow:none; }
  table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td:not(:first-child){
    -webkit-box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 1px 0 0 0 rgba(16, 22, 26, 0.15); }

table.bp3-html-table.bp3-interactive tbody tr:hover td{
  background-color:rgba(191, 204, 214, 0.3);
  cursor:pointer; }

table.bp3-html-table.bp3-interactive tbody tr:active td{
  background-color:rgba(191, 204, 214, 0.4); }

.bp3-dark table.bp3-html-table.bp3-html-table-striped tbody tr:nth-child(odd) td{
  background:rgba(92, 112, 128, 0.15); }

.bp3-dark table.bp3-html-table.bp3-html-table-bordered th:not(:first-child){
  -webkit-box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15);
          box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15); }

.bp3-dark table.bp3-html-table.bp3-html-table-bordered tbody tr td{
  -webkit-box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15);
          box-shadow:inset 0 1px 0 0 rgba(255, 255, 255, 0.15); }
  .bp3-dark table.bp3-html-table.bp3-html-table-bordered tbody tr td:not(:first-child){
    -webkit-box-shadow:inset 1px 1px 0 0 rgba(255, 255, 255, 0.15);
            box-shadow:inset 1px 1px 0 0 rgba(255, 255, 255, 0.15); }

.bp3-dark table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td{
  -webkit-box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15);
          box-shadow:inset 1px 0 0 0 rgba(255, 255, 255, 0.15); }
  .bp3-dark table.bp3-html-table.bp3-html-table-bordered.bp3-html-table-striped tbody tr:not(:first-child) td:first-child{
    -webkit-box-shadow:none;
            box-shadow:none; }

.bp3-dark table.bp3-html-table.bp3-interactive tbody tr:hover td{
  background-color:rgba(92, 112, 128, 0.3);
  cursor:pointer; }

.bp3-dark table.bp3-html-table.bp3-interactive tbody tr:active td{
  background-color:rgba(92, 112, 128, 0.4); }

.bp3-key-combo{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center; }
  .bp3-key-combo > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-key-combo > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-key-combo::before,
  .bp3-key-combo > *{
    margin-right:5px; }
  .bp3-key-combo:empty::before,
  .bp3-key-combo > :last-child{
    margin-right:0; }

.bp3-hotkey-dialog{
  top:40px;
  padding-bottom:0; }
  .bp3-hotkey-dialog .bp3-dialog-body{
    margin:0;
    padding:0; }
  .bp3-hotkey-dialog .bp3-hotkey-label{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1; }

.bp3-hotkey-column{
  margin:auto;
  max-height:80vh;
  overflow-y:auto;
  padding:30px; }
  .bp3-hotkey-column .bp3-heading{
    margin-bottom:20px; }
    .bp3-hotkey-column .bp3-heading:not(:first-child){
      margin-top:40px; }

.bp3-hotkey{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:justify;
      -ms-flex-pack:justify;
          justify-content:space-between;
  margin-right:0;
  margin-left:0; }
  .bp3-hotkey:not(:last-child){
    margin-bottom:10px; }
.bp3-icon{
  display:inline-block;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  vertical-align:text-bottom; }
  .bp3-icon:not(:empty)::before{
    content:"" !important;
    content:unset !important; }
  .bp3-icon > svg{
    display:block; }
    .bp3-icon > svg:not([fill]){
      fill:currentColor; }

.bp3-icon.bp3-intent-primary, .bp3-icon-standard.bp3-intent-primary, .bp3-icon-large.bp3-intent-primary{
  color:#106ba3; }
  .bp3-dark .bp3-icon.bp3-intent-primary, .bp3-dark .bp3-icon-standard.bp3-intent-primary, .bp3-dark .bp3-icon-large.bp3-intent-primary{
    color:#48aff0; }

.bp3-icon.bp3-intent-success, .bp3-icon-standard.bp3-intent-success, .bp3-icon-large.bp3-intent-success{
  color:#0d8050; }
  .bp3-dark .bp3-icon.bp3-intent-success, .bp3-dark .bp3-icon-standard.bp3-intent-success, .bp3-dark .bp3-icon-large.bp3-intent-success{
    color:#3dcc91; }

.bp3-icon.bp3-intent-warning, .bp3-icon-standard.bp3-intent-warning, .bp3-icon-large.bp3-intent-warning{
  color:#bf7326; }
  .bp3-dark .bp3-icon.bp3-intent-warning, .bp3-dark .bp3-icon-standard.bp3-intent-warning, .bp3-dark .bp3-icon-large.bp3-intent-warning{
    color:#ffb366; }

.bp3-icon.bp3-intent-danger, .bp3-icon-standard.bp3-intent-danger, .bp3-icon-large.bp3-intent-danger{
  color:#c23030; }
  .bp3-dark .bp3-icon.bp3-intent-danger, .bp3-dark .bp3-icon-standard.bp3-intent-danger, .bp3-dark .bp3-icon-large.bp3-intent-danger{
    color:#ff7373; }

span.bp3-icon-standard{
  line-height:1;
  font-family:"Icons16", sans-serif;
  font-size:16px;
  font-weight:400;
  font-style:normal;
  -moz-osx-font-smoothing:grayscale;
  -webkit-font-smoothing:antialiased;
  display:inline-block; }

span.bp3-icon-large{
  line-height:1;
  font-family:"Icons20", sans-serif;
  font-size:20px;
  font-weight:400;
  font-style:normal;
  -moz-osx-font-smoothing:grayscale;
  -webkit-font-smoothing:antialiased;
  display:inline-block; }

span.bp3-icon:empty{
  line-height:1;
  font-family:"Icons20";
  font-size:inherit;
  font-weight:400;
  font-style:normal; }
  span.bp3-icon:empty::before{
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased; }

.bp3-icon-add::before{
  content:""; }

.bp3-icon-add-column-left::before{
  content:""; }

.bp3-icon-add-column-right::before{
  content:""; }

.bp3-icon-add-row-bottom::before{
  content:""; }

.bp3-icon-add-row-top::before{
  content:""; }

.bp3-icon-add-to-artifact::before{
  content:""; }

.bp3-icon-add-to-folder::before{
  content:""; }

.bp3-icon-airplane::before{
  content:""; }

.bp3-icon-align-center::before{
  content:""; }

.bp3-icon-align-justify::before{
  content:""; }

.bp3-icon-align-left::before{
  content:""; }

.bp3-icon-align-right::before{
  content:""; }

.bp3-icon-alignment-bottom::before{
  content:""; }

.bp3-icon-alignment-horizontal-center::before{
  content:""; }

.bp3-icon-alignment-left::before{
  content:""; }

.bp3-icon-alignment-right::before{
  content:""; }

.bp3-icon-alignment-top::before{
  content:""; }

.bp3-icon-alignment-vertical-center::before{
  content:""; }

.bp3-icon-annotation::before{
  content:""; }

.bp3-icon-application::before{
  content:""; }

.bp3-icon-applications::before{
  content:""; }

.bp3-icon-archive::before{
  content:""; }

.bp3-icon-arrow-bottom-left::before{
  content:""; }

.bp3-icon-arrow-bottom-right::before{
  content:""; }

.bp3-icon-arrow-down::before{
  content:""; }

.bp3-icon-arrow-left::before{
  content:""; }

.bp3-icon-arrow-right::before{
  content:""; }

.bp3-icon-arrow-top-left::before{
  content:""; }

.bp3-icon-arrow-top-right::before{
  content:""; }

.bp3-icon-arrow-up::before{
  content:""; }

.bp3-icon-arrows-horizontal::before{
  content:""; }

.bp3-icon-arrows-vertical::before{
  content:""; }

.bp3-icon-asterisk::before{
  content:"*"; }

.bp3-icon-automatic-updates::before{
  content:""; }

.bp3-icon-badge::before{
  content:""; }

.bp3-icon-ban-circle::before{
  content:""; }

.bp3-icon-bank-account::before{
  content:""; }

.bp3-icon-barcode::before{
  content:""; }

.bp3-icon-blank::before{
  content:""; }

.bp3-icon-blocked-person::before{
  content:""; }

.bp3-icon-bold::before{
  content:""; }

.bp3-icon-book::before{
  content:""; }

.bp3-icon-bookmark::before{
  content:""; }

.bp3-icon-box::before{
  content:""; }

.bp3-icon-briefcase::before{
  content:""; }

.bp3-icon-bring-data::before{
  content:""; }

.bp3-icon-build::before{
  content:""; }

.bp3-icon-calculator::before{
  content:""; }

.bp3-icon-calendar::before{
  content:""; }

.bp3-icon-camera::before{
  content:""; }

.bp3-icon-caret-down::before{
  content:""; }

.bp3-icon-caret-left::before{
  content:""; }

.bp3-icon-caret-right::before{
  content:""; }

.bp3-icon-caret-up::before{
  content:""; }

.bp3-icon-cell-tower::before{
  content:""; }

.bp3-icon-changes::before{
  content:""; }

.bp3-icon-chart::before{
  content:""; }

.bp3-icon-chat::before{
  content:""; }

.bp3-icon-chevron-backward::before{
  content:""; }

.bp3-icon-chevron-down::before{
  content:""; }

.bp3-icon-chevron-forward::before{
  content:""; }

.bp3-icon-chevron-left::before{
  content:""; }

.bp3-icon-chevron-right::before{
  content:""; }

.bp3-icon-chevron-up::before{
  content:""; }

.bp3-icon-circle::before{
  content:""; }

.bp3-icon-circle-arrow-down::before{
  content:""; }

.bp3-icon-circle-arrow-left::before{
  content:""; }

.bp3-icon-circle-arrow-right::before{
  content:""; }

.bp3-icon-circle-arrow-up::before{
  content:""; }

.bp3-icon-citation::before{
  content:""; }

.bp3-icon-clean::before{
  content:""; }

.bp3-icon-clipboard::before{
  content:""; }

.bp3-icon-cloud::before{
  content:""; }

.bp3-icon-cloud-download::before{
  content:""; }

.bp3-icon-cloud-upload::before{
  content:""; }

.bp3-icon-code::before{
  content:""; }

.bp3-icon-code-block::before{
  content:""; }

.bp3-icon-cog::before{
  content:""; }

.bp3-icon-collapse-all::before{
  content:""; }

.bp3-icon-column-layout::before{
  content:""; }

.bp3-icon-comment::before{
  content:""; }

.bp3-icon-comparison::before{
  content:""; }

.bp3-icon-compass::before{
  content:""; }

.bp3-icon-compressed::before{
  content:""; }

.bp3-icon-confirm::before{
  content:""; }

.bp3-icon-console::before{
  content:""; }

.bp3-icon-contrast::before{
  content:""; }

.bp3-icon-control::before{
  content:""; }

.bp3-icon-credit-card::before{
  content:""; }

.bp3-icon-cross::before{
  content:""; }

.bp3-icon-crown::before{
  content:""; }

.bp3-icon-cube::before{
  content:""; }

.bp3-icon-cube-add::before{
  content:""; }

.bp3-icon-cube-remove::before{
  content:""; }

.bp3-icon-curved-range-chart::before{
  content:""; }

.bp3-icon-cut::before{
  content:""; }

.bp3-icon-dashboard::before{
  content:""; }

.bp3-icon-data-lineage::before{
  content:""; }

.bp3-icon-database::before{
  content:""; }

.bp3-icon-delete::before{
  content:""; }

.bp3-icon-delta::before{
  content:""; }

.bp3-icon-derive-column::before{
  content:""; }

.bp3-icon-desktop::before{
  content:""; }

.bp3-icon-diagram-tree::before{
  content:""; }

.bp3-icon-direction-left::before{
  content:""; }

.bp3-icon-direction-right::before{
  content:""; }

.bp3-icon-disable::before{
  content:""; }

.bp3-icon-document::before{
  content:""; }

.bp3-icon-document-open::before{
  content:""; }

.bp3-icon-document-share::before{
  content:""; }

.bp3-icon-dollar::before{
  content:"$"; }

.bp3-icon-dot::before{
  content:""; }

.bp3-icon-double-caret-horizontal::before{
  content:""; }

.bp3-icon-double-caret-vertical::before{
  content:""; }

.bp3-icon-double-chevron-down::before{
  content:""; }

.bp3-icon-double-chevron-left::before{
  content:""; }

.bp3-icon-double-chevron-right::before{
  content:""; }

.bp3-icon-double-chevron-up::before{
  content:""; }

.bp3-icon-doughnut-chart::before{
  content:""; }

.bp3-icon-download::before{
  content:""; }

.bp3-icon-drag-handle-horizontal::before{
  content:""; }

.bp3-icon-drag-handle-vertical::before{
  content:""; }

.bp3-icon-draw::before{
  content:""; }

.bp3-icon-drive-time::before{
  content:""; }

.bp3-icon-duplicate::before{
  content:""; }

.bp3-icon-edit::before{
  content:""; }

.bp3-icon-eject::before{
  content:""; }

.bp3-icon-endorsed::before{
  content:""; }

.bp3-icon-envelope::before{
  content:""; }

.bp3-icon-equals::before{
  content:""; }

.bp3-icon-eraser::before{
  content:""; }

.bp3-icon-error::before{
  content:""; }

.bp3-icon-euro::before{
  content:""; }

.bp3-icon-exchange::before{
  content:""; }

.bp3-icon-exclude-row::before{
  content:""; }

.bp3-icon-expand-all::before{
  content:""; }

.bp3-icon-export::before{
  content:""; }

.bp3-icon-eye-off::before{
  content:""; }

.bp3-icon-eye-on::before{
  content:""; }

.bp3-icon-eye-open::before{
  content:""; }

.bp3-icon-fast-backward::before{
  content:""; }

.bp3-icon-fast-forward::before{
  content:""; }

.bp3-icon-feed::before{
  content:""; }

.bp3-icon-feed-subscribed::before{
  content:""; }

.bp3-icon-film::before{
  content:""; }

.bp3-icon-filter::before{
  content:""; }

.bp3-icon-filter-keep::before{
  content:""; }

.bp3-icon-filter-list::before{
  content:""; }

.bp3-icon-filter-open::before{
  content:""; }

.bp3-icon-filter-remove::before{
  content:""; }

.bp3-icon-flag::before{
  content:""; }

.bp3-icon-flame::before{
  content:""; }

.bp3-icon-flash::before{
  content:""; }

.bp3-icon-floppy-disk::before{
  content:""; }

.bp3-icon-flow-branch::before{
  content:""; }

.bp3-icon-flow-end::before{
  content:""; }

.bp3-icon-flow-linear::before{
  content:""; }

.bp3-icon-flow-review::before{
  content:""; }

.bp3-icon-flow-review-branch::before{
  content:""; }

.bp3-icon-flows::before{
  content:""; }

.bp3-icon-folder-close::before{
  content:""; }

.bp3-icon-folder-new::before{
  content:""; }

.bp3-icon-folder-open::before{
  content:""; }

.bp3-icon-folder-shared::before{
  content:""; }

.bp3-icon-folder-shared-open::before{
  content:""; }

.bp3-icon-follower::before{
  content:""; }

.bp3-icon-following::before{
  content:""; }

.bp3-icon-font::before{
  content:""; }

.bp3-icon-fork::before{
  content:""; }

.bp3-icon-form::before{
  content:""; }

.bp3-icon-full-circle::before{
  content:""; }

.bp3-icon-full-stacked-chart::before{
  content:""; }

.bp3-icon-fullscreen::before{
  content:""; }

.bp3-icon-function::before{
  content:""; }

.bp3-icon-gantt-chart::before{
  content:""; }

.bp3-icon-geolocation::before{
  content:""; }

.bp3-icon-geosearch::before{
  content:""; }

.bp3-icon-git-branch::before{
  content:""; }

.bp3-icon-git-commit::before{
  content:""; }

.bp3-icon-git-merge::before{
  content:""; }

.bp3-icon-git-new-branch::before{
  content:""; }

.bp3-icon-git-pull::before{
  content:""; }

.bp3-icon-git-push::before{
  content:""; }

.bp3-icon-git-repo::before{
  content:""; }

.bp3-icon-glass::before{
  content:""; }

.bp3-icon-globe::before{
  content:""; }

.bp3-icon-globe-network::before{
  content:""; }

.bp3-icon-graph::before{
  content:""; }

.bp3-icon-graph-remove::before{
  content:""; }

.bp3-icon-greater-than::before{
  content:""; }

.bp3-icon-greater-than-or-equal-to::before{
  content:""; }

.bp3-icon-grid::before{
  content:""; }

.bp3-icon-grid-view::before{
  content:""; }

.bp3-icon-group-objects::before{
  content:""; }

.bp3-icon-grouped-bar-chart::before{
  content:""; }

.bp3-icon-hand::before{
  content:""; }

.bp3-icon-hand-down::before{
  content:""; }

.bp3-icon-hand-left::before{
  content:""; }

.bp3-icon-hand-right::before{
  content:""; }

.bp3-icon-hand-up::before{
  content:""; }

.bp3-icon-header::before{
  content:""; }

.bp3-icon-header-one::before{
  content:""; }

.bp3-icon-header-two::before{
  content:""; }

.bp3-icon-headset::before{
  content:""; }

.bp3-icon-heart::before{
  content:""; }

.bp3-icon-heart-broken::before{
  content:""; }

.bp3-icon-heat-grid::before{
  content:""; }

.bp3-icon-heatmap::before{
  content:""; }

.bp3-icon-help::before{
  content:"?"; }

.bp3-icon-helper-management::before{
  content:""; }

.bp3-icon-highlight::before{
  content:""; }

.bp3-icon-history::before{
  content:""; }

.bp3-icon-home::before{
  content:""; }

.bp3-icon-horizontal-bar-chart::before{
  content:""; }

.bp3-icon-horizontal-bar-chart-asc::before{
  content:""; }

.bp3-icon-horizontal-bar-chart-desc::before{
  content:""; }

.bp3-icon-horizontal-distribution::before{
  content:""; }

.bp3-icon-id-number::before{
  content:""; }

.bp3-icon-image-rotate-left::before{
  content:""; }

.bp3-icon-image-rotate-right::before{
  content:""; }

.bp3-icon-import::before{
  content:""; }

.bp3-icon-inbox::before{
  content:""; }

.bp3-icon-inbox-filtered::before{
  content:""; }

.bp3-icon-inbox-geo::before{
  content:""; }

.bp3-icon-inbox-search::before{
  content:""; }

.bp3-icon-inbox-update::before{
  content:""; }

.bp3-icon-info-sign::before{
  content:""; }

.bp3-icon-inheritance::before{
  content:""; }

.bp3-icon-inner-join::before{
  content:""; }

.bp3-icon-insert::before{
  content:""; }

.bp3-icon-intersection::before{
  content:""; }

.bp3-icon-ip-address::before{
  content:""; }

.bp3-icon-issue::before{
  content:""; }

.bp3-icon-issue-closed::before{
  content:""; }

.bp3-icon-issue-new::before{
  content:""; }

.bp3-icon-italic::before{
  content:""; }

.bp3-icon-join-table::before{
  content:""; }

.bp3-icon-key::before{
  content:""; }

.bp3-icon-key-backspace::before{
  content:""; }

.bp3-icon-key-command::before{
  content:""; }

.bp3-icon-key-control::before{
  content:""; }

.bp3-icon-key-delete::before{
  content:""; }

.bp3-icon-key-enter::before{
  content:""; }

.bp3-icon-key-escape::before{
  content:""; }

.bp3-icon-key-option::before{
  content:""; }

.bp3-icon-key-shift::before{
  content:""; }

.bp3-icon-key-tab::before{
  content:""; }

.bp3-icon-known-vehicle::before{
  content:""; }

.bp3-icon-label::before{
  content:""; }

.bp3-icon-layer::before{
  content:""; }

.bp3-icon-layers::before{
  content:""; }

.bp3-icon-layout::before{
  content:""; }

.bp3-icon-layout-auto::before{
  content:""; }

.bp3-icon-layout-balloon::before{
  content:""; }

.bp3-icon-layout-circle::before{
  content:""; }

.bp3-icon-layout-grid::before{
  content:""; }

.bp3-icon-layout-group-by::before{
  content:""; }

.bp3-icon-layout-hierarchy::before{
  content:""; }

.bp3-icon-layout-linear::before{
  content:""; }

.bp3-icon-layout-skew-grid::before{
  content:""; }

.bp3-icon-layout-sorted-clusters::before{
  content:""; }

.bp3-icon-learning::before{
  content:""; }

.bp3-icon-left-join::before{
  content:""; }

.bp3-icon-less-than::before{
  content:""; }

.bp3-icon-less-than-or-equal-to::before{
  content:""; }

.bp3-icon-lifesaver::before{
  content:""; }

.bp3-icon-lightbulb::before{
  content:""; }

.bp3-icon-link::before{
  content:""; }

.bp3-icon-list::before{
  content:""; }

.bp3-icon-list-columns::before{
  content:""; }

.bp3-icon-list-detail-view::before{
  content:""; }

.bp3-icon-locate::before{
  content:""; }

.bp3-icon-lock::before{
  content:""; }

.bp3-icon-log-in::before{
  content:""; }

.bp3-icon-log-out::before{
  content:""; }

.bp3-icon-manual::before{
  content:""; }

.bp3-icon-manually-entered-data::before{
  content:""; }

.bp3-icon-map::before{
  content:""; }

.bp3-icon-map-create::before{
  content:""; }

.bp3-icon-map-marker::before{
  content:""; }

.bp3-icon-maximize::before{
  content:""; }

.bp3-icon-media::before{
  content:""; }

.bp3-icon-menu::before{
  content:""; }

.bp3-icon-menu-closed::before{
  content:""; }

.bp3-icon-menu-open::before{
  content:""; }

.bp3-icon-merge-columns::before{
  content:""; }

.bp3-icon-merge-links::before{
  content:""; }

.bp3-icon-minimize::before{
  content:""; }

.bp3-icon-minus::before{
  content:""; }

.bp3-icon-mobile-phone::before{
  content:""; }

.bp3-icon-mobile-video::before{
  content:""; }

.bp3-icon-moon::before{
  content:""; }

.bp3-icon-more::before{
  content:""; }

.bp3-icon-mountain::before{
  content:""; }

.bp3-icon-move::before{
  content:""; }

.bp3-icon-mugshot::before{
  content:""; }

.bp3-icon-multi-select::before{
  content:""; }

.bp3-icon-music::before{
  content:""; }

.bp3-icon-new-drawing::before{
  content:""; }

.bp3-icon-new-grid-item::before{
  content:""; }

.bp3-icon-new-layer::before{
  content:""; }

.bp3-icon-new-layers::before{
  content:""; }

.bp3-icon-new-link::before{
  content:""; }

.bp3-icon-new-object::before{
  content:""; }

.bp3-icon-new-person::before{
  content:""; }

.bp3-icon-new-prescription::before{
  content:""; }

.bp3-icon-new-text-box::before{
  content:""; }

.bp3-icon-ninja::before{
  content:""; }

.bp3-icon-not-equal-to::before{
  content:""; }

.bp3-icon-notifications::before{
  content:""; }

.bp3-icon-notifications-updated::before{
  content:""; }

.bp3-icon-numbered-list::before{
  content:""; }

.bp3-icon-numerical::before{
  content:""; }

.bp3-icon-office::before{
  content:""; }

.bp3-icon-offline::before{
  content:""; }

.bp3-icon-oil-field::before{
  content:""; }

.bp3-icon-one-column::before{
  content:""; }

.bp3-icon-outdated::before{
  content:""; }

.bp3-icon-page-layout::before{
  content:""; }

.bp3-icon-panel-stats::before{
  content:""; }

.bp3-icon-panel-table::before{
  content:""; }

.bp3-icon-paperclip::before{
  content:""; }

.bp3-icon-paragraph::before{
  content:""; }

.bp3-icon-path::before{
  content:""; }

.bp3-icon-path-search::before{
  content:""; }

.bp3-icon-pause::before{
  content:""; }

.bp3-icon-people::before{
  content:""; }

.bp3-icon-percentage::before{
  content:""; }

.bp3-icon-person::before{
  content:""; }

.bp3-icon-phone::before{
  content:""; }

.bp3-icon-pie-chart::before{
  content:""; }

.bp3-icon-pin::before{
  content:""; }

.bp3-icon-pivot::before{
  content:""; }

.bp3-icon-pivot-table::before{
  content:""; }

.bp3-icon-play::before{
  content:""; }

.bp3-icon-plus::before{
  content:"+"; }

.bp3-icon-polygon-filter::before{
  content:""; }

.bp3-icon-power::before{
  content:""; }

.bp3-icon-predictive-analysis::before{
  content:""; }

.bp3-icon-prescription::before{
  content:""; }

.bp3-icon-presentation::before{
  content:""; }

.bp3-icon-print::before{
  content:""; }

.bp3-icon-projects::before{
  content:""; }

.bp3-icon-properties::before{
  content:""; }

.bp3-icon-property::before{
  content:""; }

.bp3-icon-publish-function::before{
  content:""; }

.bp3-icon-pulse::before{
  content:""; }

.bp3-icon-random::before{
  content:""; }

.bp3-icon-record::before{
  content:""; }

.bp3-icon-redo::before{
  content:""; }

.bp3-icon-refresh::before{
  content:""; }

.bp3-icon-regression-chart::before{
  content:""; }

.bp3-icon-remove::before{
  content:""; }

.bp3-icon-remove-column::before{
  content:""; }

.bp3-icon-remove-column-left::before{
  content:""; }

.bp3-icon-remove-column-right::before{
  content:""; }

.bp3-icon-remove-row-bottom::before{
  content:""; }

.bp3-icon-remove-row-top::before{
  content:""; }

.bp3-icon-repeat::before{
  content:""; }

.bp3-icon-reset::before{
  content:""; }

.bp3-icon-resolve::before{
  content:""; }

.bp3-icon-rig::before{
  content:""; }

.bp3-icon-right-join::before{
  content:""; }

.bp3-icon-ring::before{
  content:""; }

.bp3-icon-rotate-document::before{
  content:""; }

.bp3-icon-rotate-page::before{
  content:""; }

.bp3-icon-satellite::before{
  content:""; }

.bp3-icon-saved::before{
  content:""; }

.bp3-icon-scatter-plot::before{
  content:""; }

.bp3-icon-search::before{
  content:""; }

.bp3-icon-search-around::before{
  content:""; }

.bp3-icon-search-template::before{
  content:""; }

.bp3-icon-search-text::before{
  content:""; }

.bp3-icon-segmented-control::before{
  content:""; }

.bp3-icon-select::before{
  content:""; }

.bp3-icon-selection::before{
  content:""; }

.bp3-icon-send-to::before{
  content:""; }

.bp3-icon-send-to-graph::before{
  content:""; }

.bp3-icon-send-to-map::before{
  content:""; }

.bp3-icon-series-add::before{
  content:""; }

.bp3-icon-series-configuration::before{
  content:""; }

.bp3-icon-series-derived::before{
  content:""; }

.bp3-icon-series-filtered::before{
  content:""; }

.bp3-icon-series-search::before{
  content:""; }

.bp3-icon-settings::before{
  content:""; }

.bp3-icon-share::before{
  content:""; }

.bp3-icon-shield::before{
  content:""; }

.bp3-icon-shop::before{
  content:""; }

.bp3-icon-shopping-cart::before{
  content:""; }

.bp3-icon-signal-search::before{
  content:""; }

.bp3-icon-sim-card::before{
  content:""; }

.bp3-icon-slash::before{
  content:""; }

.bp3-icon-small-cross::before{
  content:""; }

.bp3-icon-small-minus::before{
  content:""; }

.bp3-icon-small-plus::before{
  content:""; }

.bp3-icon-small-tick::before{
  content:""; }

.bp3-icon-snowflake::before{
  content:""; }

.bp3-icon-social-media::before{
  content:""; }

.bp3-icon-sort::before{
  content:""; }

.bp3-icon-sort-alphabetical::before{
  content:""; }

.bp3-icon-sort-alphabetical-desc::before{
  content:""; }

.bp3-icon-sort-asc::before{
  content:""; }

.bp3-icon-sort-desc::before{
  content:""; }

.bp3-icon-sort-numerical::before{
  content:""; }

.bp3-icon-sort-numerical-desc::before{
  content:""; }

.bp3-icon-split-columns::before{
  content:""; }

.bp3-icon-square::before{
  content:""; }

.bp3-icon-stacked-chart::before{
  content:""; }

.bp3-icon-star::before{
  content:""; }

.bp3-icon-star-empty::before{
  content:""; }

.bp3-icon-step-backward::before{
  content:""; }

.bp3-icon-step-chart::before{
  content:""; }

.bp3-icon-step-forward::before{
  content:""; }

.bp3-icon-stop::before{
  content:""; }

.bp3-icon-stopwatch::before{
  content:""; }

.bp3-icon-strikethrough::before{
  content:""; }

.bp3-icon-style::before{
  content:""; }

.bp3-icon-swap-horizontal::before{
  content:""; }

.bp3-icon-swap-vertical::before{
  content:""; }

.bp3-icon-symbol-circle::before{
  content:""; }

.bp3-icon-symbol-cross::before{
  content:""; }

.bp3-icon-symbol-diamond::before{
  content:""; }

.bp3-icon-symbol-square::before{
  content:""; }

.bp3-icon-symbol-triangle-down::before{
  content:""; }

.bp3-icon-symbol-triangle-up::before{
  content:""; }

.bp3-icon-tag::before{
  content:""; }

.bp3-icon-take-action::before{
  content:""; }

.bp3-icon-taxi::before{
  content:""; }

.bp3-icon-text-highlight::before{
  content:""; }

.bp3-icon-th::before{
  content:""; }

.bp3-icon-th-derived::before{
  content:""; }

.bp3-icon-th-disconnect::before{
  content:""; }

.bp3-icon-th-filtered::before{
  content:""; }

.bp3-icon-th-list::before{
  content:""; }

.bp3-icon-thumbs-down::before{
  content:""; }

.bp3-icon-thumbs-up::before{
  content:""; }

.bp3-icon-tick::before{
  content:""; }

.bp3-icon-tick-circle::before{
  content:""; }

.bp3-icon-time::before{
  content:""; }

.bp3-icon-timeline-area-chart::before{
  content:""; }

.bp3-icon-timeline-bar-chart::before{
  content:""; }

.bp3-icon-timeline-events::before{
  content:""; }

.bp3-icon-timeline-line-chart::before{
  content:""; }

.bp3-icon-tint::before{
  content:""; }

.bp3-icon-torch::before{
  content:""; }

.bp3-icon-tractor::before{
  content:""; }

.bp3-icon-train::before{
  content:""; }

.bp3-icon-translate::before{
  content:""; }

.bp3-icon-trash::before{
  content:""; }

.bp3-icon-tree::before{
  content:""; }

.bp3-icon-trending-down::before{
  content:""; }

.bp3-icon-trending-up::before{
  content:""; }

.bp3-icon-truck::before{
  content:""; }

.bp3-icon-two-columns::before{
  content:""; }

.bp3-icon-unarchive::before{
  content:""; }

.bp3-icon-underline::before{
  content:""; }

.bp3-icon-undo::before{
  content:""; }

.bp3-icon-ungroup-objects::before{
  content:""; }

.bp3-icon-unknown-vehicle::before{
  content:""; }

.bp3-icon-unlock::before{
  content:""; }

.bp3-icon-unpin::before{
  content:""; }

.bp3-icon-unresolve::before{
  content:""; }

.bp3-icon-updated::before{
  content:""; }

.bp3-icon-upload::before{
  content:""; }

.bp3-icon-user::before{
  content:""; }

.bp3-icon-variable::before{
  content:""; }

.bp3-icon-vertical-bar-chart-asc::before{
  content:""; }

.bp3-icon-vertical-bar-chart-desc::before{
  content:""; }

.bp3-icon-vertical-distribution::before{
  content:""; }

.bp3-icon-video::before{
  content:""; }

.bp3-icon-volume-down::before{
  content:""; }

.bp3-icon-volume-off::before{
  content:""; }

.bp3-icon-volume-up::before{
  content:""; }

.bp3-icon-walk::before{
  content:""; }

.bp3-icon-warning-sign::before{
  content:""; }

.bp3-icon-waterfall-chart::before{
  content:""; }

.bp3-icon-widget::before{
  content:""; }

.bp3-icon-widget-button::before{
  content:""; }

.bp3-icon-widget-footer::before{
  content:""; }

.bp3-icon-widget-header::before{
  content:""; }

.bp3-icon-wrench::before{
  content:""; }

.bp3-icon-zoom-in::before{
  content:""; }

.bp3-icon-zoom-out::before{
  content:""; }

.bp3-icon-zoom-to-fit::before{
  content:""; }
.bp3-submenu > .bp3-popover-wrapper{
  display:block; }

.bp3-submenu .bp3-popover-target{
  display:block; }

.bp3-submenu.bp3-popover{
  -webkit-box-shadow:none;
          box-shadow:none;
  padding:0 5px; }
  .bp3-submenu.bp3-popover > .bp3-popover-content{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2); }
  .bp3-dark .bp3-submenu.bp3-popover, .bp3-submenu.bp3-popover.bp3-dark{
    -webkit-box-shadow:none;
            box-shadow:none; }
    .bp3-dark .bp3-submenu.bp3-popover > .bp3-popover-content, .bp3-submenu.bp3-popover.bp3-dark > .bp3-popover-content{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }
.bp3-menu{
  margin:0;
  border-radius:3px;
  background:#ffffff;
  min-width:180px;
  padding:5px;
  list-style:none;
  text-align:left;
  color:#182026; }

.bp3-menu-divider{
  display:block;
  margin:5px;
  border-top:1px solid rgba(16, 22, 26, 0.15); }
  .bp3-dark .bp3-menu-divider{
    border-top-color:rgba(255, 255, 255, 0.15); }

.bp3-menu-item{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:start;
      -ms-flex-align:start;
          align-items:flex-start;
  border-radius:2px;
  padding:5px 7px;
  text-decoration:none;
  line-height:20px;
  color:inherit;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-menu-item > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-menu-item > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-menu-item::before,
  .bp3-menu-item > *{
    margin-right:7px; }
  .bp3-menu-item:empty::before,
  .bp3-menu-item > :last-child{
    margin-right:0; }
  .bp3-menu-item > .bp3-fill{
    word-break:break-word; }
  .bp3-menu-item:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-menu-item{
    background-color:rgba(167, 182, 194, 0.3);
    cursor:pointer;
    text-decoration:none; }
  .bp3-menu-item.bp3-disabled{
    background-color:inherit;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-dark .bp3-menu-item{
    color:inherit; }
    .bp3-dark .bp3-menu-item:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-menu-item{
      background-color:rgba(138, 155, 168, 0.15);
      color:inherit; }
    .bp3-dark .bp3-menu-item.bp3-disabled{
      background-color:inherit;
      color:rgba(167, 182, 194, 0.6); }
  .bp3-menu-item.bp3-intent-primary{
    color:#106ba3; }
    .bp3-menu-item.bp3-intent-primary .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-primary::before, .bp3-menu-item.bp3-intent-primary::after,
    .bp3-menu-item.bp3-intent-primary .bp3-menu-item-label{
      color:#106ba3; }
    .bp3-menu-item.bp3-intent-primary:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-menu-item.bp3-intent-primary.bp3-active{
      background-color:#137cbd; }
    .bp3-menu-item.bp3-intent-primary:active{
      background-color:#106ba3; }
    .bp3-menu-item.bp3-intent-primary:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-menu-item.bp3-intent-primary:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::before, .bp3-menu-item.bp3-intent-primary:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-primary:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-primary:active, .bp3-menu-item.bp3-intent-primary:active::before, .bp3-menu-item.bp3-intent-primary:active::after,
    .bp3-menu-item.bp3-intent-primary:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-primary.bp3-active, .bp3-menu-item.bp3-intent-primary.bp3-active::before, .bp3-menu-item.bp3-intent-primary.bp3-active::after,
    .bp3-menu-item.bp3-intent-primary.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item.bp3-intent-success{
    color:#0d8050; }
    .bp3-menu-item.bp3-intent-success .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-success::before, .bp3-menu-item.bp3-intent-success::after,
    .bp3-menu-item.bp3-intent-success .bp3-menu-item-label{
      color:#0d8050; }
    .bp3-menu-item.bp3-intent-success:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-menu-item.bp3-intent-success.bp3-active{
      background-color:#0f9960; }
    .bp3-menu-item.bp3-intent-success:active{
      background-color:#0d8050; }
    .bp3-menu-item.bp3-intent-success:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-menu-item.bp3-intent-success:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::before, .bp3-menu-item.bp3-intent-success:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-success:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-success:active, .bp3-menu-item.bp3-intent-success:active::before, .bp3-menu-item.bp3-intent-success:active::after,
    .bp3-menu-item.bp3-intent-success:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-success.bp3-active, .bp3-menu-item.bp3-intent-success.bp3-active::before, .bp3-menu-item.bp3-intent-success.bp3-active::after,
    .bp3-menu-item.bp3-intent-success.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item.bp3-intent-warning{
    color:#bf7326; }
    .bp3-menu-item.bp3-intent-warning .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-warning::before, .bp3-menu-item.bp3-intent-warning::after,
    .bp3-menu-item.bp3-intent-warning .bp3-menu-item-label{
      color:#bf7326; }
    .bp3-menu-item.bp3-intent-warning:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-menu-item.bp3-intent-warning.bp3-active{
      background-color:#d9822b; }
    .bp3-menu-item.bp3-intent-warning:active{
      background-color:#bf7326; }
    .bp3-menu-item.bp3-intent-warning:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-menu-item.bp3-intent-warning:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::before, .bp3-menu-item.bp3-intent-warning:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-warning:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-warning:active, .bp3-menu-item.bp3-intent-warning:active::before, .bp3-menu-item.bp3-intent-warning:active::after,
    .bp3-menu-item.bp3-intent-warning:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-warning.bp3-active, .bp3-menu-item.bp3-intent-warning.bp3-active::before, .bp3-menu-item.bp3-intent-warning.bp3-active::after,
    .bp3-menu-item.bp3-intent-warning.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item.bp3-intent-danger{
    color:#c23030; }
    .bp3-menu-item.bp3-intent-danger .bp3-icon{
      color:inherit; }
    .bp3-menu-item.bp3-intent-danger::before, .bp3-menu-item.bp3-intent-danger::after,
    .bp3-menu-item.bp3-intent-danger .bp3-menu-item-label{
      color:#c23030; }
    .bp3-menu-item.bp3-intent-danger:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-menu-item.bp3-intent-danger.bp3-active{
      background-color:#db3737; }
    .bp3-menu-item.bp3-intent-danger:active{
      background-color:#c23030; }
    .bp3-menu-item.bp3-intent-danger:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-menu-item.bp3-intent-danger:hover::before, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::before, .bp3-menu-item.bp3-intent-danger:hover::after, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::after,
    .bp3-menu-item.bp3-intent-danger:hover .bp3-menu-item-label,
    .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item .bp3-menu-item-label, .bp3-menu-item.bp3-intent-danger:active, .bp3-menu-item.bp3-intent-danger:active::before, .bp3-menu-item.bp3-intent-danger:active::after,
    .bp3-menu-item.bp3-intent-danger:active .bp3-menu-item-label, .bp3-menu-item.bp3-intent-danger.bp3-active, .bp3-menu-item.bp3-intent-danger.bp3-active::before, .bp3-menu-item.bp3-intent-danger.bp3-active::after,
    .bp3-menu-item.bp3-intent-danger.bp3-active .bp3-menu-item-label{
      color:#ffffff; }
  .bp3-menu-item::before{
    line-height:1;
    font-family:"Icons16", sans-serif;
    font-size:16px;
    font-weight:400;
    font-style:normal;
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased;
    margin-right:7px; }
  .bp3-menu-item::before,
  .bp3-menu-item > .bp3-icon{
    margin-top:2px;
    color:#5c7080; }
  .bp3-menu-item .bp3-menu-item-label{
    color:#5c7080; }
  .bp3-menu-item:hover, .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-menu-item{
    color:inherit; }
  .bp3-menu-item.bp3-active, .bp3-menu-item:active{
    background-color:rgba(115, 134, 148, 0.3); }
  .bp3-menu-item.bp3-disabled{
    outline:none !important;
    background-color:inherit !important;
    cursor:not-allowed !important;
    color:rgba(92, 112, 128, 0.6) !important; }
    .bp3-menu-item.bp3-disabled::before,
    .bp3-menu-item.bp3-disabled > .bp3-icon,
    .bp3-menu-item.bp3-disabled .bp3-menu-item-label{
      color:rgba(92, 112, 128, 0.6) !important; }
  .bp3-large .bp3-menu-item{
    padding:9px 7px;
    line-height:22px;
    font-size:16px; }
    .bp3-large .bp3-menu-item .bp3-icon{
      margin-top:3px; }
    .bp3-large .bp3-menu-item::before{
      line-height:1;
      font-family:"Icons20", sans-serif;
      font-size:20px;
      font-weight:400;
      font-style:normal;
      -moz-osx-font-smoothing:grayscale;
      -webkit-font-smoothing:antialiased;
      margin-top:1px;
      margin-right:10px; }

button.bp3-menu-item{
  border:none;
  background:none;
  width:100%;
  text-align:left; }
.bp3-menu-header{
  display:block;
  margin:5px;
  border-top:1px solid rgba(16, 22, 26, 0.15);
  cursor:default;
  padding-left:2px; }
  .bp3-dark .bp3-menu-header{
    border-top-color:rgba(255, 255, 255, 0.15); }
  .bp3-menu-header:first-of-type{
    border-top:none; }
  .bp3-menu-header > h6{
    color:#182026;
    font-weight:600;
    overflow:hidden;
    text-overflow:ellipsis;
    white-space:nowrap;
    word-wrap:normal;
    margin:0;
    padding:10px 7px 0 1px;
    line-height:17px; }
    .bp3-dark .bp3-menu-header > h6{
      color:#f5f8fa; }
  .bp3-menu-header:first-of-type > h6{
    padding-top:0; }
  .bp3-large .bp3-menu-header > h6{
    padding-top:15px;
    padding-bottom:5px;
    font-size:18px; }
  .bp3-large .bp3-menu-header:first-of-type > h6{
    padding-top:0; }

.bp3-dark .bp3-menu{
  background:#30404d;
  color:#f5f8fa; }

.bp3-dark .bp3-menu-item.bp3-intent-primary{
  color:#48aff0; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary::before, .bp3-dark .bp3-menu-item.bp3-intent-primary::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary .bp3-menu-item-label{
    color:#48aff0; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active{
    background-color:#137cbd; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary:active{
    background-color:#106ba3; }
  .bp3-dark .bp3-menu-item.bp3-intent-primary:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-primary:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-primary:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-primary.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-primary:active, .bp3-dark .bp3-menu-item.bp3-intent-primary:active::before, .bp3-dark .bp3-menu-item.bp3-intent-primary:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-primary.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item.bp3-intent-success{
  color:#3dcc91; }
  .bp3-dark .bp3-menu-item.bp3-intent-success .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-success::before, .bp3-dark .bp3-menu-item.bp3-intent-success::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success .bp3-menu-item-label{
    color:#3dcc91; }
  .bp3-dark .bp3-menu-item.bp3-intent-success:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active{
    background-color:#0f9960; }
  .bp3-dark .bp3-menu-item.bp3-intent-success:active{
    background-color:#0d8050; }
  .bp3-dark .bp3-menu-item.bp3-intent-success:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-success:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-success:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-success.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-success:active, .bp3-dark .bp3-menu-item.bp3-intent-success:active::before, .bp3-dark .bp3-menu-item.bp3-intent-success:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-success.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item.bp3-intent-warning{
  color:#ffb366; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning::before, .bp3-dark .bp3-menu-item.bp3-intent-warning::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning .bp3-menu-item-label{
    color:#ffb366; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active{
    background-color:#d9822b; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning:active{
    background-color:#bf7326; }
  .bp3-dark .bp3-menu-item.bp3-intent-warning:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-warning:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-warning:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-warning.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-warning:active, .bp3-dark .bp3-menu-item.bp3-intent-warning:active::before, .bp3-dark .bp3-menu-item.bp3-intent-warning:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-warning.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item.bp3-intent-danger{
  color:#ff7373; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger .bp3-icon{
    color:inherit; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger::before, .bp3-dark .bp3-menu-item.bp3-intent-danger::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger .bp3-menu-item-label{
    color:#ff7373; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active{
    background-color:#db3737; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger:active{
    background-color:#c23030; }
  .bp3-dark .bp3-menu-item.bp3-intent-danger:hover, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item, .bp3-dark .bp3-menu-item.bp3-intent-danger:hover::before, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::before, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::before, .bp3-dark .bp3-menu-item.bp3-intent-danger:hover::after, .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::after, .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger:hover .bp3-menu-item-label,
  .bp3-dark .bp3-submenu .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item .bp3-menu-item-label,
  .bp3-submenu .bp3-dark .bp3-popover-target.bp3-popover-open > .bp3-intent-danger.bp3-menu-item .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-danger:active, .bp3-dark .bp3-menu-item.bp3-intent-danger:active::before, .bp3-dark .bp3-menu-item.bp3-intent-danger:active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger:active .bp3-menu-item-label, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active::before, .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active::after,
  .bp3-dark .bp3-menu-item.bp3-intent-danger.bp3-active .bp3-menu-item-label{
    color:#ffffff; }

.bp3-dark .bp3-menu-item::before,
.bp3-dark .bp3-menu-item > .bp3-icon{
  color:#a7b6c2; }

.bp3-dark .bp3-menu-item .bp3-menu-item-label{
  color:#a7b6c2; }

.bp3-dark .bp3-menu-item.bp3-active, .bp3-dark .bp3-menu-item:active{
  background-color:rgba(138, 155, 168, 0.3); }

.bp3-dark .bp3-menu-item.bp3-disabled{
  color:rgba(167, 182, 194, 0.6) !important; }
  .bp3-dark .bp3-menu-item.bp3-disabled::before,
  .bp3-dark .bp3-menu-item.bp3-disabled > .bp3-icon,
  .bp3-dark .bp3-menu-item.bp3-disabled .bp3-menu-item-label{
    color:rgba(167, 182, 194, 0.6) !important; }

.bp3-dark .bp3-menu-divider,
.bp3-dark .bp3-menu-header{
  border-color:rgba(255, 255, 255, 0.15); }

.bp3-dark .bp3-menu-header > h6{
  color:#f5f8fa; }

.bp3-label .bp3-menu{
  margin-top:5px; }
.bp3-navbar{
  position:relative;
  z-index:10;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.2);
  background-color:#ffffff;
  width:100%;
  height:50px;
  padding:0 15px; }
  .bp3-navbar.bp3-dark,
  .bp3-dark .bp3-navbar{
    background-color:#394b59; }
  .bp3-navbar.bp3-dark{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-dark .bp3-navbar{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 0 0 rgba(16, 22, 26, 0), 0 1px 1px rgba(16, 22, 26, 0.4); }
  .bp3-navbar.bp3-fixed-top{
    position:fixed;
    top:0;
    right:0;
    left:0; }

.bp3-navbar-heading{
  margin-right:15px;
  font-size:16px; }

.bp3-navbar-group{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  height:50px; }
  .bp3-navbar-group.bp3-align-left{
    float:left; }
  .bp3-navbar-group.bp3-align-right{
    float:right; }

.bp3-navbar-divider{
  margin:0 10px;
  border-left:1px solid rgba(16, 22, 26, 0.15);
  height:20px; }
  .bp3-dark .bp3-navbar-divider{
    border-left-color:rgba(255, 255, 255, 0.15); }
.bp3-non-ideal-state{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  width:100%;
  height:100%;
  text-align:center; }
  .bp3-non-ideal-state > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-non-ideal-state > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-non-ideal-state::before,
  .bp3-non-ideal-state > *{
    margin-bottom:20px; }
  .bp3-non-ideal-state:empty::before,
  .bp3-non-ideal-state > :last-child{
    margin-bottom:0; }
  .bp3-non-ideal-state > *{
    max-width:400px; }

.bp3-non-ideal-state-visual{
  color:rgba(92, 112, 128, 0.6);
  font-size:60px; }
  .bp3-dark .bp3-non-ideal-state-visual{
    color:rgba(167, 182, 194, 0.6); }

.bp3-overflow-list{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -ms-flex-wrap:nowrap;
      flex-wrap:nowrap;
  min-width:0; }

.bp3-overflow-list-spacer{
  -ms-flex-negative:1;
      flex-shrink:1;
  width:1px; }

body.bp3-overlay-open{
  overflow:hidden; }

.bp3-overlay{
  position:static;
  top:0;
  right:0;
  bottom:0;
  left:0;
  z-index:20; }
  .bp3-overlay:not(.bp3-overlay-open){
    pointer-events:none; }
  .bp3-overlay.bp3-overlay-container{
    position:fixed;
    overflow:hidden; }
    .bp3-overlay.bp3-overlay-container.bp3-overlay-inline{
      position:absolute; }
  .bp3-overlay.bp3-overlay-scroll-container{
    position:fixed;
    overflow:auto; }
    .bp3-overlay.bp3-overlay-scroll-container.bp3-overlay-inline{
      position:absolute; }
  .bp3-overlay.bp3-overlay-inline{
    display:inline;
    overflow:visible; }

.bp3-overlay-content{
  position:fixed;
  z-index:20; }
  .bp3-overlay-inline .bp3-overlay-content,
  .bp3-overlay-scroll-container .bp3-overlay-content{
    position:absolute; }

.bp3-overlay-backdrop{
  position:fixed;
  top:0;
  right:0;
  bottom:0;
  left:0;
  opacity:1;
  z-index:20;
  background-color:rgba(16, 22, 26, 0.7);
  overflow:auto;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-overlay-backdrop.bp3-overlay-enter, .bp3-overlay-backdrop.bp3-overlay-appear{
    opacity:0; }
  .bp3-overlay-backdrop.bp3-overlay-enter-active, .bp3-overlay-backdrop.bp3-overlay-appear-active{
    opacity:1;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-overlay-backdrop.bp3-overlay-exit{
    opacity:1; }
  .bp3-overlay-backdrop.bp3-overlay-exit-active{
    opacity:0;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-overlay-backdrop:focus{
    outline:none; }
  .bp3-overlay-inline .bp3-overlay-backdrop{
    position:absolute; }
.bp3-panel-stack{
  position:relative;
  overflow:hidden; }

.bp3-panel-stack-header{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -ms-flex-negative:0;
      flex-shrink:0;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  z-index:1;
  -webkit-box-shadow:0 1px rgba(16, 22, 26, 0.15);
          box-shadow:0 1px rgba(16, 22, 26, 0.15);
  height:30px; }
  .bp3-dark .bp3-panel-stack-header{
    -webkit-box-shadow:0 1px rgba(255, 255, 255, 0.15);
            box-shadow:0 1px rgba(255, 255, 255, 0.15); }
  .bp3-panel-stack-header > span{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-flex:1;
        -ms-flex:1;
            flex:1;
    -webkit-box-align:stretch;
        -ms-flex-align:stretch;
            align-items:stretch; }
  .bp3-panel-stack-header .bp3-heading{
    margin:0 5px; }

.bp3-button.bp3-panel-stack-header-back{
  margin-left:5px;
  padding-left:0;
  white-space:nowrap; }
  .bp3-button.bp3-panel-stack-header-back .bp3-icon{
    margin:0 2px; }

.bp3-panel-stack-view{
  position:absolute;
  top:0;
  right:0;
  bottom:0;
  left:0;
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  margin-right:-1px;
  border-right:1px solid rgba(16, 22, 26, 0.15);
  background-color:#ffffff;
  overflow-y:auto; }
  .bp3-dark .bp3-panel-stack-view{
    background-color:#30404d; }

.bp3-panel-stack-push .bp3-panel-stack-enter, .bp3-panel-stack-push .bp3-panel-stack-appear{
  -webkit-transform:translateX(100%);
          transform:translateX(100%);
  opacity:0; }

.bp3-panel-stack-push .bp3-panel-stack-enter-active, .bp3-panel-stack-push .bp3-panel-stack-appear-active{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }

.bp3-panel-stack-push .bp3-panel-stack-exit{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1; }

.bp3-panel-stack-push .bp3-panel-stack-exit-active{
  -webkit-transform:translateX(-50%);
          transform:translateX(-50%);
  opacity:0;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }

.bp3-panel-stack-pop .bp3-panel-stack-enter, .bp3-panel-stack-pop .bp3-panel-stack-appear{
  -webkit-transform:translateX(-50%);
          transform:translateX(-50%);
  opacity:0; }

.bp3-panel-stack-pop .bp3-panel-stack-enter-active, .bp3-panel-stack-pop .bp3-panel-stack-appear-active{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }

.bp3-panel-stack-pop .bp3-panel-stack-exit{
  -webkit-transform:translate(0%);
          transform:translate(0%);
  opacity:1; }

.bp3-panel-stack-pop .bp3-panel-stack-exit-active{
  -webkit-transform:translateX(100%);
          transform:translateX(100%);
  opacity:0;
  -webkit-transition-property:opacity, -webkit-transform;
  transition-property:opacity, -webkit-transform;
  transition-property:transform, opacity;
  transition-property:transform, opacity, -webkit-transform;
  -webkit-transition-duration:400ms;
          transition-duration:400ms;
  -webkit-transition-timing-function:ease;
          transition-timing-function:ease;
  -webkit-transition-delay:0;
          transition-delay:0; }
.bp3-popover{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  -webkit-transform:scale(1);
          transform:scale(1);
  display:inline-block;
  z-index:20;
  border-radius:3px; }
  .bp3-popover .bp3-popover-arrow{
    position:absolute;
    width:30px;
    height:30px; }
    .bp3-popover .bp3-popover-arrow::before{
      margin:5px;
      width:20px;
      height:20px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-popover{
    margin-top:-17px;
    margin-bottom:17px; }
    .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-popover > .bp3-popover-arrow{
      bottom:-11px; }
      .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(-90deg);
                transform:rotate(-90deg); }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-popover{
    margin-left:17px; }
    .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-popover > .bp3-popover-arrow{
      left:-11px; }
      .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(0);
                transform:rotate(0); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-popover{
    margin-top:17px; }
    .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-popover > .bp3-popover-arrow{
      top:-11px; }
      .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(90deg);
                transform:rotate(90deg); }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-popover{
    margin-right:17px;
    margin-left:-17px; }
    .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-popover > .bp3-popover-arrow{
      right:-11px; }
      .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-popover > .bp3-popover-arrow svg{
        -webkit-transform:rotate(180deg);
                transform:rotate(180deg); }
  .bp3-tether-element-attached-middle > .bp3-popover > .bp3-popover-arrow{
    top:50%;
    -webkit-transform:translateY(-50%);
            transform:translateY(-50%); }
  .bp3-tether-element-attached-center > .bp3-popover > .bp3-popover-arrow{
    right:50%;
    -webkit-transform:translateX(50%);
            transform:translateX(50%); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-top > .bp3-popover > .bp3-popover-arrow{
    top:-0.3934px; }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-right > .bp3-popover > .bp3-popover-arrow{
    right:-0.3934px; }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-left > .bp3-popover > .bp3-popover-arrow{
    left:-0.3934px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-bottom > .bp3-popover > .bp3-popover-arrow{
    bottom:-0.3934px; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-left > .bp3-popover{
    -webkit-transform-origin:top left;
            transform-origin:top left; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-center > .bp3-popover{
    -webkit-transform-origin:top center;
            transform-origin:top center; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-right > .bp3-popover{
    -webkit-transform-origin:top right;
            transform-origin:top right; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-left > .bp3-popover{
    -webkit-transform-origin:center left;
            transform-origin:center left; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-center > .bp3-popover{
    -webkit-transform-origin:center center;
            transform-origin:center center; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-right > .bp3-popover{
    -webkit-transform-origin:center right;
            transform-origin:center right; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-left > .bp3-popover{
    -webkit-transform-origin:bottom left;
            transform-origin:bottom left; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-center > .bp3-popover{
    -webkit-transform-origin:bottom center;
            transform-origin:bottom center; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-right > .bp3-popover{
    -webkit-transform-origin:bottom right;
            transform-origin:bottom right; }
  .bp3-popover .bp3-popover-content{
    background:#ffffff;
    color:inherit; }
  .bp3-popover .bp3-popover-arrow::before{
    -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2);
            box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2); }
  .bp3-popover .bp3-popover-arrow-border{
    fill:#10161a;
    fill-opacity:0.1; }
  .bp3-popover .bp3-popover-arrow-fill{
    fill:#ffffff; }
  .bp3-popover-enter > .bp3-popover, .bp3-popover-appear > .bp3-popover{
    -webkit-transform:scale(0.3);
            transform:scale(0.3); }
  .bp3-popover-enter-active > .bp3-popover, .bp3-popover-appear-active > .bp3-popover{
    -webkit-transform:scale(1);
            transform:scale(1);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-popover-exit > .bp3-popover{
    -webkit-transform:scale(1);
            transform:scale(1); }
  .bp3-popover-exit-active > .bp3-popover{
    -webkit-transform:scale(0.3);
            transform:scale(0.3);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-popover .bp3-popover-content{
    position:relative;
    border-radius:3px; }
  .bp3-popover.bp3-popover-content-sizing .bp3-popover-content{
    max-width:350px;
    padding:20px; }
  .bp3-popover-target + .bp3-overlay .bp3-popover.bp3-popover-content-sizing{
    width:350px; }
  .bp3-popover.bp3-minimal{
    margin:0 !important; }
    .bp3-popover.bp3-minimal .bp3-popover-arrow{
      display:none; }
    .bp3-popover.bp3-minimal.bp3-popover{
      -webkit-transform:scale(1);
              transform:scale(1); }
      .bp3-popover-enter > .bp3-popover.bp3-minimal.bp3-popover, .bp3-popover-appear > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1); }
      .bp3-popover-enter-active > .bp3-popover.bp3-minimal.bp3-popover, .bp3-popover-appear-active > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1);
        -webkit-transition-property:-webkit-transform;
        transition-property:-webkit-transform;
        transition-property:transform;
        transition-property:transform, -webkit-transform;
        -webkit-transition-duration:100ms;
                transition-duration:100ms;
        -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
                transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
        -webkit-transition-delay:0;
                transition-delay:0; }
      .bp3-popover-exit > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1); }
      .bp3-popover-exit-active > .bp3-popover.bp3-minimal.bp3-popover{
        -webkit-transform:scale(1);
                transform:scale(1);
        -webkit-transition-property:-webkit-transform;
        transition-property:-webkit-transform;
        transition-property:transform;
        transition-property:transform, -webkit-transform;
        -webkit-transition-duration:100ms;
                transition-duration:100ms;
        -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
                transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
        -webkit-transition-delay:0;
                transition-delay:0; }
  .bp3-popover.bp3-dark,
  .bp3-dark .bp3-popover{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }
    .bp3-popover.bp3-dark .bp3-popover-content,
    .bp3-dark .bp3-popover .bp3-popover-content{
      background:#30404d;
      color:inherit; }
    .bp3-popover.bp3-dark .bp3-popover-arrow::before,
    .bp3-dark .bp3-popover .bp3-popover-arrow::before{
      -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4);
              box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4); }
    .bp3-popover.bp3-dark .bp3-popover-arrow-border,
    .bp3-dark .bp3-popover .bp3-popover-arrow-border{
      fill:#10161a;
      fill-opacity:0.2; }
    .bp3-popover.bp3-dark .bp3-popover-arrow-fill,
    .bp3-dark .bp3-popover .bp3-popover-arrow-fill{
      fill:#30404d; }

.bp3-popover-arrow::before{
  display:block;
  position:absolute;
  -webkit-transform:rotate(45deg);
          transform:rotate(45deg);
  border-radius:2px;
  content:""; }

.bp3-tether-pinned .bp3-popover-arrow{
  display:none; }

.bp3-popover-backdrop{
  background:rgba(255, 255, 255, 0); }

.bp3-transition-container{
  opacity:1;
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  z-index:20; }
  .bp3-transition-container.bp3-popover-enter, .bp3-transition-container.bp3-popover-appear{
    opacity:0; }
  .bp3-transition-container.bp3-popover-enter-active, .bp3-transition-container.bp3-popover-appear-active{
    opacity:1;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-transition-container.bp3-popover-exit{
    opacity:1; }
  .bp3-transition-container.bp3-popover-exit-active{
    opacity:0;
    -webkit-transition-property:opacity;
    transition-property:opacity;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-transition-container:focus{
    outline:none; }
  .bp3-transition-container.bp3-popover-leave .bp3-popover-content{
    pointer-events:none; }
  .bp3-transition-container[data-x-out-of-boundaries]{
    display:none; }

span.bp3-popover-target{
  display:inline-block; }

.bp3-popover-wrapper.bp3-fill{
  width:100%; }

.bp3-portal{
  position:absolute;
  top:0;
  right:0;
  left:0; }
@-webkit-keyframes linear-progress-bar-stripes{
  from{
    background-position:0 0; }
  to{
    background-position:30px 0; } }
@keyframes linear-progress-bar-stripes{
  from{
    background-position:0 0; }
  to{
    background-position:30px 0; } }

.bp3-progress-bar{
  display:block;
  position:relative;
  border-radius:40px;
  background:rgba(92, 112, 128, 0.2);
  width:100%;
  height:8px;
  overflow:hidden; }
  .bp3-progress-bar .bp3-progress-meter{
    position:absolute;
    border-radius:40px;
    background:linear-gradient(-45deg, rgba(255, 255, 255, 0.2) 25%, transparent 25%, transparent 50%, rgba(255, 255, 255, 0.2) 50%, rgba(255, 255, 255, 0.2) 75%, transparent 75%);
    background-color:rgba(92, 112, 128, 0.8);
    background-size:30px 30px;
    width:100%;
    height:100%;
    -webkit-transition:width 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:width 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-progress-bar:not(.bp3-no-animation):not(.bp3-no-stripes) .bp3-progress-meter{
    animation:linear-progress-bar-stripes 300ms linear infinite reverse; }
  .bp3-progress-bar.bp3-no-stripes .bp3-progress-meter{
    background-image:none; }

.bp3-dark .bp3-progress-bar{
  background:rgba(16, 22, 26, 0.5); }
  .bp3-dark .bp3-progress-bar .bp3-progress-meter{
    background-color:#8a9ba8; }

.bp3-progress-bar.bp3-intent-primary .bp3-progress-meter{
  background-color:#137cbd; }

.bp3-progress-bar.bp3-intent-success .bp3-progress-meter{
  background-color:#0f9960; }

.bp3-progress-bar.bp3-intent-warning .bp3-progress-meter{
  background-color:#d9822b; }

.bp3-progress-bar.bp3-intent-danger .bp3-progress-meter{
  background-color:#db3737; }
@-webkit-keyframes skeleton-glow{
  from{
    border-color:rgba(206, 217, 224, 0.2);
    background:rgba(206, 217, 224, 0.2); }
  to{
    border-color:rgba(92, 112, 128, 0.2);
    background:rgba(92, 112, 128, 0.2); } }
@keyframes skeleton-glow{
  from{
    border-color:rgba(206, 217, 224, 0.2);
    background:rgba(206, 217, 224, 0.2); }
  to{
    border-color:rgba(92, 112, 128, 0.2);
    background:rgba(92, 112, 128, 0.2); } }
.bp3-skeleton{
  border-color:rgba(206, 217, 224, 0.2) !important;
  border-radius:2px;
  -webkit-box-shadow:none !important;
          box-shadow:none !important;
  background:rgba(206, 217, 224, 0.2);
  background-clip:padding-box !important;
  cursor:default;
  color:transparent !important;
  -webkit-animation:1000ms linear infinite alternate skeleton-glow;
          animation:1000ms linear infinite alternate skeleton-glow;
  pointer-events:none;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-skeleton::before, .bp3-skeleton::after,
  .bp3-skeleton *{
    visibility:hidden !important; }
.bp3-slider{
  width:100%;
  min-width:150px;
  height:40px;
  position:relative;
  outline:none;
  cursor:default;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-slider:hover{
    cursor:pointer; }
  .bp3-slider:active{
    cursor:-webkit-grabbing;
    cursor:grabbing; }
  .bp3-slider.bp3-disabled{
    opacity:0.5;
    cursor:not-allowed; }
  .bp3-slider.bp3-slider-unlabeled{
    height:16px; }

.bp3-slider-track,
.bp3-slider-progress{
  top:5px;
  right:0;
  left:0;
  height:6px;
  position:absolute; }

.bp3-slider-track{
  border-radius:3px;
  overflow:hidden; }

.bp3-slider-progress{
  background:rgba(92, 112, 128, 0.2); }
  .bp3-dark .bp3-slider-progress{
    background:rgba(16, 22, 26, 0.5); }
  .bp3-slider-progress.bp3-intent-primary{
    background-color:#137cbd; }
  .bp3-slider-progress.bp3-intent-success{
    background-color:#0f9960; }
  .bp3-slider-progress.bp3-intent-warning{
    background-color:#d9822b; }
  .bp3-slider-progress.bp3-intent-danger{
    background-color:#db3737; }

.bp3-slider-handle{
  -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
          box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
  background-color:#f5f8fa;
  background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.8)), to(rgba(255, 255, 255, 0)));
  background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.8), rgba(255, 255, 255, 0));
  color:#182026;
  position:absolute;
  top:0;
  left:0;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
  cursor:pointer;
  width:16px;
  height:16px; }
  .bp3-slider-handle:hover{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5; }
  .bp3-slider-handle:active, .bp3-slider-handle.bp3-active{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none; }
  .bp3-slider-handle:disabled, .bp3-slider-handle.bp3-disabled{
    outline:none;
    -webkit-box-shadow:none;
            box-shadow:none;
    background-color:rgba(206, 217, 224, 0.5);
    background-image:none;
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
    .bp3-slider-handle:disabled.bp3-active, .bp3-slider-handle:disabled.bp3-active:hover, .bp3-slider-handle.bp3-disabled.bp3-active, .bp3-slider-handle.bp3-disabled.bp3-active:hover{
      background:rgba(206, 217, 224, 0.7); }
  .bp3-slider-handle:focus{
    z-index:1; }
  .bp3-slider-handle:hover{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 -1px 0 rgba(16, 22, 26, 0.1);
    background-clip:padding-box;
    background-color:#ebf1f5;
    z-index:2;
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 1px 1px rgba(16, 22, 26, 0.2);
    cursor:-webkit-grab;
    cursor:grab; }
  .bp3-slider-handle.bp3-active{
    -webkit-box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
            box-shadow:inset 0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 2px rgba(16, 22, 26, 0.2);
    background-color:#d8e1e8;
    background-image:none;
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 1px rgba(16, 22, 26, 0.1);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), inset 0 1px 1px rgba(16, 22, 26, 0.1);
    cursor:-webkit-grabbing;
    cursor:grabbing; }
  .bp3-disabled .bp3-slider-handle{
    -webkit-box-shadow:none;
            box-shadow:none;
    background:#bfccd6;
    pointer-events:none; }
  .bp3-dark .bp3-slider-handle{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
    background-color:#394b59;
    background-image:-webkit-gradient(linear, left top, left bottom, from(rgba(255, 255, 255, 0.05)), to(rgba(255, 255, 255, 0)));
    background-image:linear-gradient(to bottom, rgba(255, 255, 255, 0.05), rgba(255, 255, 255, 0));
    color:#f5f8fa; }
    .bp3-dark .bp3-slider-handle:hover, .bp3-dark .bp3-slider-handle:active, .bp3-dark .bp3-slider-handle.bp3-active{
      color:#f5f8fa; }
    .bp3-dark .bp3-slider-handle:hover{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.4);
      background-color:#30404d; }
    .bp3-dark .bp3-slider-handle:active, .bp3-dark .bp3-slider-handle.bp3-active{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.6), inset 0 1px 2px rgba(16, 22, 26, 0.2);
      background-color:#202b33;
      background-image:none; }
    .bp3-dark .bp3-slider-handle:disabled, .bp3-dark .bp3-slider-handle.bp3-disabled{
      -webkit-box-shadow:none;
              box-shadow:none;
      background-color:rgba(57, 75, 89, 0.5);
      background-image:none;
      color:rgba(167, 182, 194, 0.6); }
      .bp3-dark .bp3-slider-handle:disabled.bp3-active, .bp3-dark .bp3-slider-handle.bp3-disabled.bp3-active{
        background:rgba(57, 75, 89, 0.7); }
    .bp3-dark .bp3-slider-handle .bp3-button-spinner .bp3-spinner-head{
      background:rgba(16, 22, 26, 0.5);
      stroke:#8a9ba8; }
    .bp3-dark .bp3-slider-handle, .bp3-dark .bp3-slider-handle:hover{
      background-color:#394b59; }
    .bp3-dark .bp3-slider-handle.bp3-active{
      background-color:#293742; }
  .bp3-dark .bp3-disabled .bp3-slider-handle{
    border-color:#5c7080;
    -webkit-box-shadow:none;
            box-shadow:none;
    background:#5c7080; }
  .bp3-slider-handle .bp3-slider-label{
    margin-left:8px;
    border-radius:3px;
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
    background:#394b59;
    color:#f5f8fa; }
    .bp3-dark .bp3-slider-handle .bp3-slider-label{
      -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
      background:#e1e8ed;
      color:#394b59; }
    .bp3-disabled .bp3-slider-handle .bp3-slider-label{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-slider-handle.bp3-start, .bp3-slider-handle.bp3-end{
    width:8px; }
  .bp3-slider-handle.bp3-start{
    border-top-right-radius:0;
    border-bottom-right-radius:0; }
  .bp3-slider-handle.bp3-end{
    margin-left:8px;
    border-top-left-radius:0;
    border-bottom-left-radius:0; }
    .bp3-slider-handle.bp3-end .bp3-slider-label{
      margin-left:0; }

.bp3-slider-label{
  -webkit-transform:translate(-50%, 20px);
          transform:translate(-50%, 20px);
  display:inline-block;
  position:absolute;
  padding:2px 5px;
  vertical-align:top;
  line-height:1;
  font-size:12px; }

.bp3-slider.bp3-vertical{
  width:40px;
  min-width:40px;
  height:150px; }
  .bp3-slider.bp3-vertical .bp3-slider-track,
  .bp3-slider.bp3-vertical .bp3-slider-progress{
    top:0;
    bottom:0;
    left:5px;
    width:6px;
    height:auto; }
  .bp3-slider.bp3-vertical .bp3-slider-progress{
    top:auto; }
  .bp3-slider.bp3-vertical .bp3-slider-label{
    -webkit-transform:translate(20px, 50%);
            transform:translate(20px, 50%); }
  .bp3-slider.bp3-vertical .bp3-slider-handle{
    top:auto; }
    .bp3-slider.bp3-vertical .bp3-slider-handle .bp3-slider-label{
      margin-top:-8px;
      margin-left:0; }
    .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-end, .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-start{
      margin-left:0;
      width:16px;
      height:8px; }
    .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-start{
      border-top-left-radius:0;
      border-bottom-right-radius:3px; }
      .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-start .bp3-slider-label{
        -webkit-transform:translate(20px);
                transform:translate(20px); }
    .bp3-slider.bp3-vertical .bp3-slider-handle.bp3-end{
      margin-bottom:8px;
      border-top-left-radius:3px;
      border-bottom-left-radius:0;
      border-bottom-right-radius:0; }

@-webkit-keyframes pt-spinner-animation{
  from{
    -webkit-transform:rotate(0deg);
            transform:rotate(0deg); }
  to{
    -webkit-transform:rotate(360deg);
            transform:rotate(360deg); } }

@keyframes pt-spinner-animation{
  from{
    -webkit-transform:rotate(0deg);
            transform:rotate(0deg); }
  to{
    -webkit-transform:rotate(360deg);
            transform:rotate(360deg); } }

.bp3-spinner{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  -webkit-box-pack:center;
      -ms-flex-pack:center;
          justify-content:center;
  overflow:visible;
  vertical-align:middle; }
  .bp3-spinner svg{
    display:block; }
  .bp3-spinner path{
    fill-opacity:0; }
  .bp3-spinner .bp3-spinner-head{
    -webkit-transform-origin:center;
            transform-origin:center;
    -webkit-transition:stroke-dashoffset 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    transition:stroke-dashoffset 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
    stroke:rgba(92, 112, 128, 0.8);
    stroke-linecap:round; }
  .bp3-spinner .bp3-spinner-track{
    stroke:rgba(92, 112, 128, 0.2); }

.bp3-spinner-animation{
  -webkit-animation:pt-spinner-animation 500ms linear infinite;
          animation:pt-spinner-animation 500ms linear infinite; }
  .bp3-no-spin > .bp3-spinner-animation{
    -webkit-animation:none;
            animation:none; }

.bp3-dark .bp3-spinner .bp3-spinner-head{
  stroke:#8a9ba8; }

.bp3-dark .bp3-spinner .bp3-spinner-track{
  stroke:rgba(16, 22, 26, 0.5); }

.bp3-spinner.bp3-intent-primary .bp3-spinner-head{
  stroke:#137cbd; }

.bp3-spinner.bp3-intent-success .bp3-spinner-head{
  stroke:#0f9960; }

.bp3-spinner.bp3-intent-warning .bp3-spinner-head{
  stroke:#d9822b; }

.bp3-spinner.bp3-intent-danger .bp3-spinner-head{
  stroke:#db3737; }
.bp3-tabs.bp3-vertical{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex; }
  .bp3-tabs.bp3-vertical > .bp3-tab-list{
    -webkit-box-orient:vertical;
    -webkit-box-direction:normal;
        -ms-flex-direction:column;
            flex-direction:column;
    -webkit-box-align:start;
        -ms-flex-align:start;
            align-items:flex-start; }
    .bp3-tabs.bp3-vertical > .bp3-tab-list .bp3-tab{
      border-radius:3px;
      width:100%;
      padding:0 10px; }
      .bp3-tabs.bp3-vertical > .bp3-tab-list .bp3-tab[aria-selected="true"]{
        -webkit-box-shadow:none;
                box-shadow:none;
        background-color:rgba(19, 124, 189, 0.2); }
    .bp3-tabs.bp3-vertical > .bp3-tab-list .bp3-tab-indicator-wrapper .bp3-tab-indicator{
      top:0;
      right:0;
      bottom:0;
      left:0;
      border-radius:3px;
      background-color:rgba(19, 124, 189, 0.2);
      height:auto; }
  .bp3-tabs.bp3-vertical > .bp3-tab-panel{
    margin-top:0;
    padding-left:20px; }

.bp3-tab-list{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  -webkit-box-align:end;
      -ms-flex-align:end;
          align-items:flex-end;
  position:relative;
  margin:0;
  border:none;
  padding:0;
  list-style:none; }
  .bp3-tab-list > *:not(:last-child){
    margin-right:20px; }

.bp3-tab{
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal;
  -webkit-box-flex:0;
      -ms-flex:0 0 auto;
          flex:0 0 auto;
  position:relative;
  cursor:pointer;
  max-width:100%;
  vertical-align:top;
  line-height:30px;
  color:#182026;
  font-size:14px; }
  .bp3-tab a{
    display:block;
    text-decoration:none;
    color:inherit; }
  .bp3-tab-indicator-wrapper ~ .bp3-tab{
    -webkit-box-shadow:none !important;
            box-shadow:none !important;
    background-color:transparent !important; }
  .bp3-tab[aria-disabled="true"]{
    cursor:not-allowed;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-tab[aria-selected="true"]{
    border-radius:0;
    -webkit-box-shadow:inset 0 -3px 0 #106ba3;
            box-shadow:inset 0 -3px 0 #106ba3; }
  .bp3-tab[aria-selected="true"], .bp3-tab:not([aria-disabled="true"]):hover{
    color:#106ba3; }
  .bp3-tab:focus{
    -moz-outline-radius:0; }
  .bp3-large > .bp3-tab{
    line-height:40px;
    font-size:16px; }

.bp3-tab-panel{
  margin-top:20px; }
  .bp3-tab-panel[aria-hidden="true"]{
    display:none; }

.bp3-tab-indicator-wrapper{
  position:absolute;
  top:0;
  left:0;
  -webkit-transform:translateX(0), translateY(0);
          transform:translateX(0), translateY(0);
  -webkit-transition:height, width, -webkit-transform;
  transition:height, width, -webkit-transform;
  transition:height, transform, width;
  transition:height, transform, width, -webkit-transform;
  -webkit-transition-duration:200ms;
          transition-duration:200ms;
  -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
          transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
  pointer-events:none; }
  .bp3-tab-indicator-wrapper .bp3-tab-indicator{
    position:absolute;
    right:0;
    bottom:0;
    left:0;
    background-color:#106ba3;
    height:3px; }
  .bp3-tab-indicator-wrapper.bp3-no-animation{
    -webkit-transition:none;
    transition:none; }

.bp3-dark .bp3-tab{
  color:#f5f8fa; }
  .bp3-dark .bp3-tab[aria-disabled="true"]{
    color:rgba(167, 182, 194, 0.6); }
  .bp3-dark .bp3-tab[aria-selected="true"]{
    -webkit-box-shadow:inset 0 -3px 0 #48aff0;
            box-shadow:inset 0 -3px 0 #48aff0; }
  .bp3-dark .bp3-tab[aria-selected="true"], .bp3-dark .bp3-tab:not([aria-disabled="true"]):hover{
    color:#48aff0; }

.bp3-dark .bp3-tab-indicator{
  background-color:#48aff0; }

.bp3-flex-expander{
  -webkit-box-flex:1;
      -ms-flex:1 1;
          flex:1 1; }
.bp3-tag{
  display:-webkit-inline-box;
  display:-ms-inline-flexbox;
  display:inline-flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  position:relative;
  border:none;
  border-radius:3px;
  -webkit-box-shadow:none;
          box-shadow:none;
  background-color:#5c7080;
  min-width:20px;
  max-width:100%;
  min-height:20px;
  padding:2px 6px;
  line-height:16px;
  color:#f5f8fa;
  font-size:12px; }
  .bp3-tag.bp3-interactive{
    cursor:pointer; }
    .bp3-tag.bp3-interactive:hover{
      background-color:rgba(92, 112, 128, 0.85); }
    .bp3-tag.bp3-interactive.bp3-active, .bp3-tag.bp3-interactive:active{
      background-color:rgba(92, 112, 128, 0.7); }
  .bp3-tag > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-tag > .bp3-fill{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-tag::before,
  .bp3-tag > *{
    margin-right:4px; }
  .bp3-tag:empty::before,
  .bp3-tag > :last-child{
    margin-right:0; }
  .bp3-tag:focus{
    outline:rgba(19, 124, 189, 0.6) auto 2px;
    outline-offset:0;
    -moz-outline-radius:6px; }
  .bp3-tag.bp3-round{
    border-radius:30px;
    padding-right:8px;
    padding-left:8px; }
  .bp3-dark .bp3-tag{
    background-color:#bfccd6;
    color:#182026; }
    .bp3-dark .bp3-tag.bp3-interactive{
      cursor:pointer; }
      .bp3-dark .bp3-tag.bp3-interactive:hover{
        background-color:rgba(191, 204, 214, 0.85); }
      .bp3-dark .bp3-tag.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-interactive:active{
        background-color:rgba(191, 204, 214, 0.7); }
    .bp3-dark .bp3-tag > .bp3-icon, .bp3-dark .bp3-tag .bp3-icon-standard, .bp3-dark .bp3-tag .bp3-icon-large{
      fill:currentColor; }
  .bp3-tag > .bp3-icon, .bp3-tag .bp3-icon-standard, .bp3-tag .bp3-icon-large{
    fill:#ffffff; }
  .bp3-tag.bp3-large,
  .bp3-large .bp3-tag{
    min-width:30px;
    min-height:30px;
    padding:0 10px;
    line-height:20px;
    font-size:14px; }
    .bp3-tag.bp3-large::before,
    .bp3-tag.bp3-large > *,
    .bp3-large .bp3-tag::before,
    .bp3-large .bp3-tag > *{
      margin-right:7px; }
    .bp3-tag.bp3-large:empty::before,
    .bp3-tag.bp3-large > :last-child,
    .bp3-large .bp3-tag:empty::before,
    .bp3-large .bp3-tag > :last-child{
      margin-right:0; }
    .bp3-tag.bp3-large.bp3-round,
    .bp3-large .bp3-tag.bp3-round{
      padding-right:12px;
      padding-left:12px; }
  .bp3-tag.bp3-intent-primary{
    background:#137cbd;
    color:#ffffff; }
    .bp3-tag.bp3-intent-primary.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-primary.bp3-interactive:hover{
        background-color:rgba(19, 124, 189, 0.85); }
      .bp3-tag.bp3-intent-primary.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-primary.bp3-interactive:active{
        background-color:rgba(19, 124, 189, 0.7); }
  .bp3-tag.bp3-intent-success{
    background:#0f9960;
    color:#ffffff; }
    .bp3-tag.bp3-intent-success.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-success.bp3-interactive:hover{
        background-color:rgba(15, 153, 96, 0.85); }
      .bp3-tag.bp3-intent-success.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-success.bp3-interactive:active{
        background-color:rgba(15, 153, 96, 0.7); }
  .bp3-tag.bp3-intent-warning{
    background:#d9822b;
    color:#ffffff; }
    .bp3-tag.bp3-intent-warning.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-warning.bp3-interactive:hover{
        background-color:rgba(217, 130, 43, 0.85); }
      .bp3-tag.bp3-intent-warning.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-warning.bp3-interactive:active{
        background-color:rgba(217, 130, 43, 0.7); }
  .bp3-tag.bp3-intent-danger{
    background:#db3737;
    color:#ffffff; }
    .bp3-tag.bp3-intent-danger.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-intent-danger.bp3-interactive:hover{
        background-color:rgba(219, 55, 55, 0.85); }
      .bp3-tag.bp3-intent-danger.bp3-interactive.bp3-active, .bp3-tag.bp3-intent-danger.bp3-interactive:active{
        background-color:rgba(219, 55, 55, 0.7); }
  .bp3-tag.bp3-fill{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    width:100%; }
  .bp3-tag.bp3-minimal > .bp3-icon, .bp3-tag.bp3-minimal .bp3-icon-standard, .bp3-tag.bp3-minimal .bp3-icon-large{
    fill:#5c7080; }
  .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]){
    background-color:rgba(138, 155, 168, 0.2);
    color:#182026; }
    .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:hover{
        background-color:rgba(92, 112, 128, 0.3); }
      .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive.bp3-active, .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:active{
        background-color:rgba(92, 112, 128, 0.4); }
    .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]){
      color:#f5f8fa; }
      .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:hover{
          background-color:rgba(191, 204, 214, 0.3); }
        .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]).bp3-interactive:active{
          background-color:rgba(191, 204, 214, 0.4); }
      .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]) > .bp3-icon, .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]) .bp3-icon-standard, .bp3-dark .bp3-tag.bp3-minimal:not([class*="bp3-intent-"]) .bp3-icon-large{
        fill:#a7b6c2; }
  .bp3-tag.bp3-minimal.bp3-intent-primary{
    background-color:rgba(19, 124, 189, 0.15);
    color:#106ba3; }
    .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:hover{
        background-color:rgba(19, 124, 189, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:active{
        background-color:rgba(19, 124, 189, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-primary > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-primary .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-primary .bp3-icon-large{
      fill:#137cbd; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary{
      background-color:rgba(19, 124, 189, 0.25);
      color:#48aff0; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:hover{
          background-color:rgba(19, 124, 189, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-primary.bp3-interactive:active{
          background-color:rgba(19, 124, 189, 0.45); }
  .bp3-tag.bp3-minimal.bp3-intent-success{
    background-color:rgba(15, 153, 96, 0.15);
    color:#0d8050; }
    .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:hover{
        background-color:rgba(15, 153, 96, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:active{
        background-color:rgba(15, 153, 96, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-success > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-success .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-success .bp3-icon-large{
      fill:#0f9960; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success{
      background-color:rgba(15, 153, 96, 0.25);
      color:#3dcc91; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:hover{
          background-color:rgba(15, 153, 96, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-success.bp3-interactive:active{
          background-color:rgba(15, 153, 96, 0.45); }
  .bp3-tag.bp3-minimal.bp3-intent-warning{
    background-color:rgba(217, 130, 43, 0.15);
    color:#bf7326; }
    .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:hover{
        background-color:rgba(217, 130, 43, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:active{
        background-color:rgba(217, 130, 43, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-warning > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-warning .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-warning .bp3-icon-large{
      fill:#d9822b; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning{
      background-color:rgba(217, 130, 43, 0.25);
      color:#ffb366; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:hover{
          background-color:rgba(217, 130, 43, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-warning.bp3-interactive:active{
          background-color:rgba(217, 130, 43, 0.45); }
  .bp3-tag.bp3-minimal.bp3-intent-danger{
    background-color:rgba(219, 55, 55, 0.15);
    color:#c23030; }
    .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive{
      cursor:pointer; }
      .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:hover{
        background-color:rgba(219, 55, 55, 0.25); }
      .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive.bp3-active, .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:active{
        background-color:rgba(219, 55, 55, 0.35); }
    .bp3-tag.bp3-minimal.bp3-intent-danger > .bp3-icon, .bp3-tag.bp3-minimal.bp3-intent-danger .bp3-icon-standard, .bp3-tag.bp3-minimal.bp3-intent-danger .bp3-icon-large{
      fill:#db3737; }
    .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger{
      background-color:rgba(219, 55, 55, 0.25);
      color:#ff7373; }
      .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive{
        cursor:pointer; }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:hover{
          background-color:rgba(219, 55, 55, 0.35); }
        .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive.bp3-active, .bp3-dark .bp3-tag.bp3-minimal.bp3-intent-danger.bp3-interactive:active{
          background-color:rgba(219, 55, 55, 0.45); }

.bp3-tag-remove{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  opacity:0.5;
  margin-top:-2px;
  margin-right:-6px !important;
  margin-bottom:-2px;
  border:none;
  background:none;
  cursor:pointer;
  padding:2px;
  padding-left:0;
  color:inherit; }
  .bp3-tag-remove:hover{
    opacity:0.8;
    background:none;
    text-decoration:none; }
  .bp3-tag-remove:active{
    opacity:1; }
  .bp3-tag-remove:empty::before{
    line-height:1;
    font-family:"Icons16", sans-serif;
    font-size:16px;
    font-weight:400;
    font-style:normal;
    -moz-osx-font-smoothing:grayscale;
    -webkit-font-smoothing:antialiased;
    content:""; }
  .bp3-large .bp3-tag-remove{
    margin-right:-10px !important;
    padding:5px;
    padding-left:0; }
    .bp3-large .bp3-tag-remove:empty::before{
      line-height:1;
      font-family:"Icons20", sans-serif;
      font-size:20px;
      font-weight:400;
      font-style:normal; }
.bp3-tag-input{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-orient:horizontal;
  -webkit-box-direction:normal;
      -ms-flex-direction:row;
          flex-direction:row;
  -webkit-box-align:start;
      -ms-flex-align:start;
          align-items:flex-start;
  cursor:text;
  height:auto;
  min-height:30px;
  padding-right:0;
  padding-left:5px;
  line-height:inherit; }
  .bp3-tag-input > *{
    -webkit-box-flex:0;
        -ms-flex-positive:0;
            flex-grow:0;
    -ms-flex-negative:0;
        flex-shrink:0; }
  .bp3-tag-input > .bp3-tag-input-values{
    -webkit-box-flex:1;
        -ms-flex-positive:1;
            flex-grow:1;
    -ms-flex-negative:1;
        flex-shrink:1; }
  .bp3-tag-input .bp3-tag-input-icon{
    margin-top:7px;
    margin-right:7px;
    margin-left:2px;
    color:#5c7080; }
  .bp3-tag-input .bp3-tag-input-values{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-orient:horizontal;
    -webkit-box-direction:normal;
        -ms-flex-direction:row;
            flex-direction:row;
    -ms-flex-wrap:wrap;
        flex-wrap:wrap;
    -webkit-box-align:center;
        -ms-flex-align:center;
            align-items:center;
    -ms-flex-item-align:stretch;
        align-self:stretch;
    margin-top:5px;
    margin-right:7px;
    min-width:0; }
    .bp3-tag-input .bp3-tag-input-values > *{
      -webkit-box-flex:0;
          -ms-flex-positive:0;
              flex-grow:0;
      -ms-flex-negative:0;
          flex-shrink:0; }
    .bp3-tag-input .bp3-tag-input-values > .bp3-fill{
      -webkit-box-flex:1;
          -ms-flex-positive:1;
              flex-grow:1;
      -ms-flex-negative:1;
          flex-shrink:1; }
    .bp3-tag-input .bp3-tag-input-values::before,
    .bp3-tag-input .bp3-tag-input-values > *{
      margin-right:5px; }
    .bp3-tag-input .bp3-tag-input-values:empty::before,
    .bp3-tag-input .bp3-tag-input-values > :last-child{
      margin-right:0; }
    .bp3-tag-input .bp3-tag-input-values:first-child .bp3-input-ghost:first-child{
      padding-left:5px; }
    .bp3-tag-input .bp3-tag-input-values > *{
      margin-bottom:5px; }
  .bp3-tag-input .bp3-tag{
    overflow-wrap:break-word; }
    .bp3-tag-input .bp3-tag.bp3-active{
      outline:rgba(19, 124, 189, 0.6) auto 2px;
      outline-offset:0;
      -moz-outline-radius:6px; }
  .bp3-tag-input .bp3-input-ghost{
    -webkit-box-flex:1;
        -ms-flex:1 1 auto;
            flex:1 1 auto;
    width:80px;
    line-height:20px; }
    .bp3-tag-input .bp3-input-ghost:disabled, .bp3-tag-input .bp3-input-ghost.bp3-disabled{
      cursor:not-allowed; }
  .bp3-tag-input .bp3-button,
  .bp3-tag-input .bp3-spinner{
    margin:3px;
    margin-left:0; }
  .bp3-tag-input .bp3-button{
    min-width:24px;
    min-height:24px;
    padding:0 7px; }
  .bp3-tag-input.bp3-large{
    height:auto;
    min-height:40px; }
    .bp3-tag-input.bp3-large::before,
    .bp3-tag-input.bp3-large > *{
      margin-right:10px; }
    .bp3-tag-input.bp3-large:empty::before,
    .bp3-tag-input.bp3-large > :last-child{
      margin-right:0; }
    .bp3-tag-input.bp3-large .bp3-tag-input-icon{
      margin-top:10px;
      margin-left:5px; }
    .bp3-tag-input.bp3-large .bp3-input-ghost{
      line-height:30px; }
    .bp3-tag-input.bp3-large .bp3-button{
      min-width:30px;
      min-height:30px;
      padding:5px 10px;
      margin:5px;
      margin-left:0; }
    .bp3-tag-input.bp3-large .bp3-spinner{
      margin:8px;
      margin-left:0; }
  .bp3-tag-input.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
    background-color:#ffffff; }
    .bp3-tag-input.bp3-active.bp3-intent-primary{
      -webkit-box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-tag-input.bp3-active.bp3-intent-success{
      -webkit-box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-tag-input.bp3-active.bp3-intent-warning{
      -webkit-box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
    .bp3-tag-input.bp3-active.bp3-intent-danger{
      -webkit-box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2);
              box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.2); }
  .bp3-dark .bp3-tag-input .bp3-tag-input-icon, .bp3-tag-input.bp3-dark .bp3-tag-input-icon{
    color:#a7b6c2; }
  .bp3-dark .bp3-tag-input .bp3-input-ghost, .bp3-tag-input.bp3-dark .bp3-input-ghost{
    color:#f5f8fa; }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::-webkit-input-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::-webkit-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::-moz-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::-moz-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost:-ms-input-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost:-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::-ms-input-placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::-ms-input-placeholder{
      color:rgba(167, 182, 194, 0.6); }
    .bp3-dark .bp3-tag-input .bp3-input-ghost::placeholder, .bp3-tag-input.bp3-dark .bp3-input-ghost::placeholder{
      color:rgba(167, 182, 194, 0.6); }
  .bp3-dark .bp3-tag-input.bp3-active, .bp3-tag-input.bp3-dark.bp3-active{
    -webkit-box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px #137cbd, 0 0 0 1px #137cbd, 0 0 0 3px rgba(19, 124, 189, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
    background-color:rgba(16, 22, 26, 0.3); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-primary, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-primary{
      -webkit-box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #106ba3, 0 0 0 3px rgba(16, 107, 163, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-success, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-success{
      -webkit-box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #0d8050, 0 0 0 3px rgba(13, 128, 80, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-warning, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-warning{
      -webkit-box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #bf7326, 0 0 0 3px rgba(191, 115, 38, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }
    .bp3-dark .bp3-tag-input.bp3-active.bp3-intent-danger, .bp3-tag-input.bp3-dark.bp3-active.bp3-intent-danger{
      -webkit-box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4);
              box-shadow:0 0 0 1px #c23030, 0 0 0 3px rgba(194, 48, 48, 0.3), inset 0 0 0 1px rgba(16, 22, 26, 0.3), inset 0 1px 1px rgba(16, 22, 26, 0.4); }

.bp3-input-ghost{
  border:none;
  -webkit-box-shadow:none;
          box-shadow:none;
  background:none;
  padding:0; }
  .bp3-input-ghost::-webkit-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost::-moz-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost:-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost::-ms-input-placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost::placeholder{
    opacity:1;
    color:rgba(92, 112, 128, 0.6); }
  .bp3-input-ghost:focus{
    outline:none !important; }
.bp3-toast{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:start;
      -ms-flex-align:start;
          align-items:flex-start;
  position:relative !important;
  margin:20px 0 0;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  background-color:#ffffff;
  min-width:300px;
  max-width:500px;
  pointer-events:all; }
  .bp3-toast.bp3-toast-enter, .bp3-toast.bp3-toast-appear{
    -webkit-transform:translateY(-40px);
            transform:translateY(-40px); }
  .bp3-toast.bp3-toast-enter-active, .bp3-toast.bp3-toast-appear-active{
    -webkit-transform:translateY(0);
            transform:translateY(0);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-toast.bp3-toast-enter ~ .bp3-toast, .bp3-toast.bp3-toast-appear ~ .bp3-toast{
    -webkit-transform:translateY(-40px);
            transform:translateY(-40px); }
  .bp3-toast.bp3-toast-enter-active ~ .bp3-toast, .bp3-toast.bp3-toast-appear-active ~ .bp3-toast{
    -webkit-transform:translateY(0);
            transform:translateY(0);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
            transition-timing-function:cubic-bezier(0.54, 1.12, 0.38, 1.11);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-toast.bp3-toast-exit{
    opacity:1;
    -webkit-filter:blur(0);
            filter:blur(0); }
  .bp3-toast.bp3-toast-exit-active{
    opacity:0;
    -webkit-filter:blur(10px);
            filter:blur(10px);
    -webkit-transition-property:opacity, -webkit-filter;
    transition-property:opacity, -webkit-filter;
    transition-property:opacity, filter;
    transition-property:opacity, filter, -webkit-filter;
    -webkit-transition-duration:300ms;
            transition-duration:300ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-toast.bp3-toast-exit ~ .bp3-toast{
    -webkit-transform:translateY(0);
            transform:translateY(0); }
  .bp3-toast.bp3-toast-exit-active ~ .bp3-toast{
    -webkit-transform:translateY(-40px);
            transform:translateY(-40px);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:50ms;
            transition-delay:50ms; }
  .bp3-toast .bp3-button-group{
    -webkit-box-flex:0;
        -ms-flex:0 0 auto;
            flex:0 0 auto;
    padding:5px;
    padding-left:0; }
  .bp3-toast > .bp3-icon{
    margin:12px;
    margin-right:0;
    color:#5c7080; }
  .bp3-toast.bp3-dark,
  .bp3-dark .bp3-toast{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
    background-color:#394b59; }
    .bp3-toast.bp3-dark > .bp3-icon,
    .bp3-dark .bp3-toast > .bp3-icon{
      color:#a7b6c2; }
  .bp3-toast[class*="bp3-intent-"] a{
    color:rgba(255, 255, 255, 0.7); }
    .bp3-toast[class*="bp3-intent-"] a:hover{
      color:#ffffff; }
  .bp3-toast[class*="bp3-intent-"] > .bp3-icon{
    color:#ffffff; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button, .bp3-toast[class*="bp3-intent-"] .bp3-button::before,
  .bp3-toast[class*="bp3-intent-"] .bp3-button .bp3-icon, .bp3-toast[class*="bp3-intent-"] .bp3-button:active{
    color:rgba(255, 255, 255, 0.7) !important; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button:focus{
    outline-color:rgba(255, 255, 255, 0.5); }
  .bp3-toast[class*="bp3-intent-"] .bp3-button:hover{
    background-color:rgba(255, 255, 255, 0.15) !important;
    color:#ffffff !important; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button:active{
    background-color:rgba(255, 255, 255, 0.3) !important;
    color:#ffffff !important; }
  .bp3-toast[class*="bp3-intent-"] .bp3-button::after{
    background:rgba(255, 255, 255, 0.3) !important; }
  .bp3-toast.bp3-intent-primary{
    background-color:#137cbd;
    color:#ffffff; }
  .bp3-toast.bp3-intent-success{
    background-color:#0f9960;
    color:#ffffff; }
  .bp3-toast.bp3-intent-warning{
    background-color:#d9822b;
    color:#ffffff; }
  .bp3-toast.bp3-intent-danger{
    background-color:#db3737;
    color:#ffffff; }

.bp3-toast-message{
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  padding:11px;
  word-break:break-word; }

.bp3-toast-container{
  display:-webkit-box !important;
  display:-ms-flexbox !important;
  display:flex !important;
  -webkit-box-orient:vertical;
  -webkit-box-direction:normal;
      -ms-flex-direction:column;
          flex-direction:column;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  position:fixed;
  right:0;
  left:0;
  z-index:40;
  overflow:hidden;
  padding:0 20px 20px;
  pointer-events:none; }
  .bp3-toast-container.bp3-toast-container-top{
    top:0;
    bottom:auto; }
  .bp3-toast-container.bp3-toast-container-bottom{
    -webkit-box-orient:vertical;
    -webkit-box-direction:reverse;
        -ms-flex-direction:column-reverse;
            flex-direction:column-reverse;
    top:auto;
    bottom:0; }
  .bp3-toast-container.bp3-toast-container-left{
    -webkit-box-align:start;
        -ms-flex-align:start;
            align-items:flex-start; }
  .bp3-toast-container.bp3-toast-container-right{
    -webkit-box-align:end;
        -ms-flex-align:end;
            align-items:flex-end; }

.bp3-toast-container-bottom .bp3-toast.bp3-toast-enter:not(.bp3-toast-enter-active),
.bp3-toast-container-bottom .bp3-toast.bp3-toast-enter:not(.bp3-toast-enter-active) ~ .bp3-toast, .bp3-toast-container-bottom .bp3-toast.bp3-toast-appear:not(.bp3-toast-appear-active),
.bp3-toast-container-bottom .bp3-toast.bp3-toast-appear:not(.bp3-toast-appear-active) ~ .bp3-toast,
.bp3-toast-container-bottom .bp3-toast.bp3-toast-leave-active ~ .bp3-toast{
  -webkit-transform:translateY(60px);
          transform:translateY(60px); }
.bp3-tooltip{
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 2px 4px rgba(16, 22, 26, 0.2), 0 8px 24px rgba(16, 22, 26, 0.2);
  -webkit-transform:scale(1);
          transform:scale(1); }
  .bp3-tooltip .bp3-popover-arrow{
    position:absolute;
    width:22px;
    height:22px; }
    .bp3-tooltip .bp3-popover-arrow::before{
      margin:4px;
      width:14px;
      height:14px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-tooltip{
    margin-top:-11px;
    margin-bottom:11px; }
    .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-tooltip > .bp3-popover-arrow{
      bottom:-8px; }
      .bp3-tether-element-attached-bottom.bp3-tether-target-attached-top > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(-90deg);
                transform:rotate(-90deg); }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-tooltip{
    margin-left:11px; }
    .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-tooltip > .bp3-popover-arrow{
      left:-8px; }
      .bp3-tether-element-attached-left.bp3-tether-target-attached-right > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(0);
                transform:rotate(0); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-tooltip{
    margin-top:11px; }
    .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-tooltip > .bp3-popover-arrow{
      top:-8px; }
      .bp3-tether-element-attached-top.bp3-tether-target-attached-bottom > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(90deg);
                transform:rotate(90deg); }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-tooltip{
    margin-right:11px;
    margin-left:-11px; }
    .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-tooltip > .bp3-popover-arrow{
      right:-8px; }
      .bp3-tether-element-attached-right.bp3-tether-target-attached-left > .bp3-tooltip > .bp3-popover-arrow svg{
        -webkit-transform:rotate(180deg);
                transform:rotate(180deg); }
  .bp3-tether-element-attached-middle > .bp3-tooltip > .bp3-popover-arrow{
    top:50%;
    -webkit-transform:translateY(-50%);
            transform:translateY(-50%); }
  .bp3-tether-element-attached-center > .bp3-tooltip > .bp3-popover-arrow{
    right:50%;
    -webkit-transform:translateX(50%);
            transform:translateX(50%); }
  .bp3-tether-element-attached-top.bp3-tether-target-attached-top > .bp3-tooltip > .bp3-popover-arrow{
    top:-0.22183px; }
  .bp3-tether-element-attached-right.bp3-tether-target-attached-right > .bp3-tooltip > .bp3-popover-arrow{
    right:-0.22183px; }
  .bp3-tether-element-attached-left.bp3-tether-target-attached-left > .bp3-tooltip > .bp3-popover-arrow{
    left:-0.22183px; }
  .bp3-tether-element-attached-bottom.bp3-tether-target-attached-bottom > .bp3-tooltip > .bp3-popover-arrow{
    bottom:-0.22183px; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-left > .bp3-tooltip{
    -webkit-transform-origin:top left;
            transform-origin:top left; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-center > .bp3-tooltip{
    -webkit-transform-origin:top center;
            transform-origin:top center; }
  .bp3-tether-element-attached-top.bp3-tether-element-attached-right > .bp3-tooltip{
    -webkit-transform-origin:top right;
            transform-origin:top right; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-left > .bp3-tooltip{
    -webkit-transform-origin:center left;
            transform-origin:center left; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-center > .bp3-tooltip{
    -webkit-transform-origin:center center;
            transform-origin:center center; }
  .bp3-tether-element-attached-middle.bp3-tether-element-attached-right > .bp3-tooltip{
    -webkit-transform-origin:center right;
            transform-origin:center right; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-left > .bp3-tooltip{
    -webkit-transform-origin:bottom left;
            transform-origin:bottom left; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-center > .bp3-tooltip{
    -webkit-transform-origin:bottom center;
            transform-origin:bottom center; }
  .bp3-tether-element-attached-bottom.bp3-tether-element-attached-right > .bp3-tooltip{
    -webkit-transform-origin:bottom right;
            transform-origin:bottom right; }
  .bp3-tooltip .bp3-popover-content{
    background:#394b59;
    color:#f5f8fa; }
  .bp3-tooltip .bp3-popover-arrow::before{
    -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2);
            box-shadow:1px 1px 6px rgba(16, 22, 26, 0.2); }
  .bp3-tooltip .bp3-popover-arrow-border{
    fill:#10161a;
    fill-opacity:0.1; }
  .bp3-tooltip .bp3-popover-arrow-fill{
    fill:#394b59; }
  .bp3-popover-enter > .bp3-tooltip, .bp3-popover-appear > .bp3-tooltip{
    -webkit-transform:scale(0.8);
            transform:scale(0.8); }
  .bp3-popover-enter-active > .bp3-tooltip, .bp3-popover-appear-active > .bp3-tooltip{
    -webkit-transform:scale(1);
            transform:scale(1);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-popover-exit > .bp3-tooltip{
    -webkit-transform:scale(1);
            transform:scale(1); }
  .bp3-popover-exit-active > .bp3-tooltip{
    -webkit-transform:scale(0.8);
            transform:scale(0.8);
    -webkit-transition-property:-webkit-transform;
    transition-property:-webkit-transform;
    transition-property:transform;
    transition-property:transform, -webkit-transform;
    -webkit-transition-duration:100ms;
            transition-duration:100ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-tooltip .bp3-popover-content{
    padding:10px 12px; }
  .bp3-tooltip.bp3-dark,
  .bp3-dark .bp3-tooltip{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 2px 4px rgba(16, 22, 26, 0.4), 0 8px 24px rgba(16, 22, 26, 0.4); }
    .bp3-tooltip.bp3-dark .bp3-popover-content,
    .bp3-dark .bp3-tooltip .bp3-popover-content{
      background:#e1e8ed;
      color:#394b59; }
    .bp3-tooltip.bp3-dark .bp3-popover-arrow::before,
    .bp3-dark .bp3-tooltip .bp3-popover-arrow::before{
      -webkit-box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4);
              box-shadow:1px 1px 6px rgba(16, 22, 26, 0.4); }
    .bp3-tooltip.bp3-dark .bp3-popover-arrow-border,
    .bp3-dark .bp3-tooltip .bp3-popover-arrow-border{
      fill:#10161a;
      fill-opacity:0.2; }
    .bp3-tooltip.bp3-dark .bp3-popover-arrow-fill,
    .bp3-dark .bp3-tooltip .bp3-popover-arrow-fill{
      fill:#e1e8ed; }
  .bp3-tooltip.bp3-intent-primary .bp3-popover-content{
    background:#137cbd;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-primary .bp3-popover-arrow-fill{
    fill:#137cbd; }
  .bp3-tooltip.bp3-intent-success .bp3-popover-content{
    background:#0f9960;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-success .bp3-popover-arrow-fill{
    fill:#0f9960; }
  .bp3-tooltip.bp3-intent-warning .bp3-popover-content{
    background:#d9822b;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-warning .bp3-popover-arrow-fill{
    fill:#d9822b; }
  .bp3-tooltip.bp3-intent-danger .bp3-popover-content{
    background:#db3737;
    color:#ffffff; }
  .bp3-tooltip.bp3-intent-danger .bp3-popover-arrow-fill{
    fill:#db3737; }

.bp3-tooltip-indicator{
  border-bottom:dotted 1px;
  cursor:help; }
.bp3-tree .bp3-icon, .bp3-tree .bp3-icon-standard, .bp3-tree .bp3-icon-large{
  color:#5c7080; }
  .bp3-tree .bp3-icon.bp3-intent-primary, .bp3-tree .bp3-icon-standard.bp3-intent-primary, .bp3-tree .bp3-icon-large.bp3-intent-primary{
    color:#137cbd; }
  .bp3-tree .bp3-icon.bp3-intent-success, .bp3-tree .bp3-icon-standard.bp3-intent-success, .bp3-tree .bp3-icon-large.bp3-intent-success{
    color:#0f9960; }
  .bp3-tree .bp3-icon.bp3-intent-warning, .bp3-tree .bp3-icon-standard.bp3-intent-warning, .bp3-tree .bp3-icon-large.bp3-intent-warning{
    color:#d9822b; }
  .bp3-tree .bp3-icon.bp3-intent-danger, .bp3-tree .bp3-icon-standard.bp3-intent-danger, .bp3-tree .bp3-icon-large.bp3-intent-danger{
    color:#db3737; }

.bp3-tree-node-list{
  margin:0;
  padding-left:0;
  list-style:none; }

.bp3-tree-root{
  position:relative;
  background-color:transparent;
  cursor:default;
  padding-left:0; }

.bp3-tree-node-content-0{
  padding-left:0px; }

.bp3-tree-node-content-1{
  padding-left:23px; }

.bp3-tree-node-content-2{
  padding-left:46px; }

.bp3-tree-node-content-3{
  padding-left:69px; }

.bp3-tree-node-content-4{
  padding-left:92px; }

.bp3-tree-node-content-5{
  padding-left:115px; }

.bp3-tree-node-content-6{
  padding-left:138px; }

.bp3-tree-node-content-7{
  padding-left:161px; }

.bp3-tree-node-content-8{
  padding-left:184px; }

.bp3-tree-node-content-9{
  padding-left:207px; }

.bp3-tree-node-content-10{
  padding-left:230px; }

.bp3-tree-node-content-11{
  padding-left:253px; }

.bp3-tree-node-content-12{
  padding-left:276px; }

.bp3-tree-node-content-13{
  padding-left:299px; }

.bp3-tree-node-content-14{
  padding-left:322px; }

.bp3-tree-node-content-15{
  padding-left:345px; }

.bp3-tree-node-content-16{
  padding-left:368px; }

.bp3-tree-node-content-17{
  padding-left:391px; }

.bp3-tree-node-content-18{
  padding-left:414px; }

.bp3-tree-node-content-19{
  padding-left:437px; }

.bp3-tree-node-content-20{
  padding-left:460px; }

.bp3-tree-node-content{
  display:-webkit-box;
  display:-ms-flexbox;
  display:flex;
  -webkit-box-align:center;
      -ms-flex-align:center;
          align-items:center;
  width:100%;
  height:30px;
  padding-right:5px; }
  .bp3-tree-node-content:hover{
    background-color:rgba(191, 204, 214, 0.4); }

.bp3-tree-node-caret,
.bp3-tree-node-caret-none{
  min-width:30px; }

.bp3-tree-node-caret{
  color:#5c7080;
  -webkit-transform:rotate(0deg);
          transform:rotate(0deg);
  cursor:pointer;
  padding:7px;
  -webkit-transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:-webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9);
  transition:transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9), -webkit-transform 200ms cubic-bezier(0.4, 1, 0.75, 0.9); }
  .bp3-tree-node-caret:hover{
    color:#182026; }
  .bp3-dark .bp3-tree-node-caret{
    color:#a7b6c2; }
    .bp3-dark .bp3-tree-node-caret:hover{
      color:#f5f8fa; }
  .bp3-tree-node-caret.bp3-tree-node-caret-open{
    -webkit-transform:rotate(90deg);
            transform:rotate(90deg); }
  .bp3-tree-node-caret.bp3-icon-standard::before{
    content:""; }

.bp3-tree-node-icon{
  position:relative;
  margin-right:7px; }

.bp3-tree-node-label{
  overflow:hidden;
  text-overflow:ellipsis;
  white-space:nowrap;
  word-wrap:normal;
  -webkit-box-flex:1;
      -ms-flex:1 1 auto;
          flex:1 1 auto;
  position:relative;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-tree-node-label span{
    display:inline; }

.bp3-tree-node-secondary-label{
  padding:0 5px;
  -webkit-user-select:none;
     -moz-user-select:none;
      -ms-user-select:none;
          user-select:none; }
  .bp3-tree-node-secondary-label .bp3-popover-wrapper,
  .bp3-tree-node-secondary-label .bp3-popover-target{
    display:-webkit-box;
    display:-ms-flexbox;
    display:flex;
    -webkit-box-align:center;
        -ms-flex-align:center;
            align-items:center; }

.bp3-tree-node.bp3-disabled .bp3-tree-node-content{
  background-color:inherit;
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-tree-node.bp3-disabled .bp3-tree-node-caret,
.bp3-tree-node.bp3-disabled .bp3-tree-node-icon{
  cursor:not-allowed;
  color:rgba(92, 112, 128, 0.6); }

.bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content{
  background-color:#137cbd; }
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content,
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-icon, .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-icon-standard, .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-icon-large{
    color:#ffffff; }
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-tree-node-caret::before{
    color:rgba(255, 255, 255, 0.7); }
  .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content .bp3-tree-node-caret:hover::before{
    color:#ffffff; }

.bp3-dark .bp3-tree-node-content:hover{
  background-color:rgba(92, 112, 128, 0.3); }

.bp3-dark .bp3-tree .bp3-icon, .bp3-dark .bp3-tree .bp3-icon-standard, .bp3-dark .bp3-tree .bp3-icon-large{
  color:#a7b6c2; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-primary, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-primary, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-primary{
    color:#137cbd; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-success, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-success, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-success{
    color:#0f9960; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-warning, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-warning, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-warning{
    color:#d9822b; }
  .bp3-dark .bp3-tree .bp3-icon.bp3-intent-danger, .bp3-dark .bp3-tree .bp3-icon-standard.bp3-intent-danger, .bp3-dark .bp3-tree .bp3-icon-large.bp3-intent-danger{
    color:#db3737; }

.bp3-dark .bp3-tree-node.bp3-tree-node-selected > .bp3-tree-node-content{
  background-color:#137cbd; }
/*!

Copyright 2017-present Palantir Technologies, Inc. All rights reserved.
Licensed under the Apache License, Version 2.0.

*/
.bp3-omnibar{
  -webkit-filter:blur(0);
          filter:blur(0);
  opacity:1;
  top:20vh;
  left:calc(50% - 250px);
  z-index:21;
  border-radius:3px;
  -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
          box-shadow:0 0 0 1px rgba(16, 22, 26, 0.1), 0 4px 8px rgba(16, 22, 26, 0.2), 0 18px 46px 6px rgba(16, 22, 26, 0.2);
  background-color:#ffffff;
  width:500px; }
  .bp3-omnibar.bp3-overlay-enter, .bp3-omnibar.bp3-overlay-appear{
    -webkit-filter:blur(20px);
            filter:blur(20px);
    opacity:0.2; }
  .bp3-omnibar.bp3-overlay-enter-active, .bp3-omnibar.bp3-overlay-appear-active{
    -webkit-filter:blur(0);
            filter:blur(0);
    opacity:1;
    -webkit-transition-property:opacity, -webkit-filter;
    transition-property:opacity, -webkit-filter;
    transition-property:filter, opacity;
    transition-property:filter, opacity, -webkit-filter;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-omnibar.bp3-overlay-exit{
    -webkit-filter:blur(0);
            filter:blur(0);
    opacity:1; }
  .bp3-omnibar.bp3-overlay-exit-active{
    -webkit-filter:blur(20px);
            filter:blur(20px);
    opacity:0.2;
    -webkit-transition-property:opacity, -webkit-filter;
    transition-property:opacity, -webkit-filter;
    transition-property:filter, opacity;
    transition-property:filter, opacity, -webkit-filter;
    -webkit-transition-duration:200ms;
            transition-duration:200ms;
    -webkit-transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
            transition-timing-function:cubic-bezier(0.4, 1, 0.75, 0.9);
    -webkit-transition-delay:0;
            transition-delay:0; }
  .bp3-omnibar .bp3-input{
    border-radius:0;
    background-color:transparent; }
    .bp3-omnibar .bp3-input, .bp3-omnibar .bp3-input:focus{
      -webkit-box-shadow:none;
              box-shadow:none; }
  .bp3-omnibar .bp3-menu{
    border-radius:0;
    -webkit-box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
            box-shadow:inset 0 1px 0 rgba(16, 22, 26, 0.15);
    background-color:transparent;
    max-height:calc(60vh - 40px);
    overflow:auto; }
    .bp3-omnibar .bp3-menu:empty{
      display:none; }
  .bp3-dark .bp3-omnibar, .bp3-omnibar.bp3-dark{
    -webkit-box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
            box-shadow:0 0 0 1px rgba(16, 22, 26, 0.2), 0 4px 8px rgba(16, 22, 26, 0.4), 0 18px 46px 6px rgba(16, 22, 26, 0.4);
    background-color:#30404d; }

.bp3-omnibar-overlay .bp3-overlay-backdrop{
  background-color:rgba(16, 22, 26, 0.2); }

.bp3-select-popover .bp3-popover-content{
  padding:5px; }

.bp3-select-popover .bp3-input-group{
  margin-bottom:0; }

.bp3-select-popover .bp3-menu{
  max-width:400px;
  max-height:300px;
  overflow:auto;
  padding:0; }
  .bp3-select-popover .bp3-menu:not(:first-child){
    padding-top:5px; }

.bp3-multi-select{
  min-width:150px; }

.bp3-multi-select-popover .bp3-menu{
  max-width:400px;
  max-height:300px;
  overflow:auto; }

.bp3-select-popover .bp3-popover-content{
  padding:5px; }

.bp3-select-popover .bp3-input-group{
  margin-bottom:0; }

.bp3-select-popover .bp3-menu{
  max-width:400px;
  max-height:300px;
  overflow:auto;
  padding:0; }
  .bp3-select-popover .bp3-menu:not(:first-child){
    padding-top:5px; }
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensureUiComponents() in @jupyterlab/buildutils */

/**
 * (DEPRECATED) Support for consuming icons as CSS background images
 */

/* Icons urls */

:root {
  --jp-icon-add: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE5IDEzaC02djZoLTJ2LTZINXYtMmg2VjVoMnY2aDZ2MnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-bug: url(data:image/svg+xml;base64,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);
  --jp-icon-build: url(data:image/svg+xml;base64,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);
  --jp-icon-caret-down-empty-thin: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwIDIwIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwb2x5Z29uIGNsYXNzPSJzdDEiIHBvaW50cz0iOS45LDEzLjYgMy42LDcuNCA0LjQsNi42IDkuOSwxMi4yIDE1LjQsNi43IDE2LjEsNy40ICIvPgoJPC9nPgo8L3N2Zz4K);
  --jp-icon-caret-down-empty: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik01LjIsNS45TDksOS43bDMuOC0zLjhsMS4yLDEuMmwtNC45LDVsLTQuOS01TDUuMiw1Ljl6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-caret-down: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik01LjIsNy41TDksMTEuMmwzLjgtMy44SDUuMnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-caret-left: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwYXRoIGQ9Ik0xMC44LDEyLjhMNy4xLDlsMy44LTMuOGwwLDcuNkgxMC44eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-caret-right: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiIHNoYXBlLXJlbmRlcmluZz0iZ2VvbWV0cmljUHJlY2lzaW9uIj4KICAgIDxwYXRoIGQ9Ik03LjIsNS4yTDEwLjksOWwtMy44LDMuOFY1LjJINy4yeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-caret-up-empty-thin: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwIDIwIj4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwb2x5Z29uIGNsYXNzPSJzdDEiIHBvaW50cz0iMTUuNCwxMy4zIDkuOSw3LjcgNC40LDEzLjIgMy42LDEyLjUgOS45LDYuMyAxNi4xLDEyLjYgIi8+Cgk8L2c+Cjwvc3ZnPgo=);
  --jp-icon-caret-up: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KCTxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSIgc2hhcGUtcmVuZGVyaW5nPSJnZW9tZXRyaWNQcmVjaXNpb24iPgoJCTxwYXRoIGQ9Ik01LjIsMTAuNUw5LDYuOGwzLjgsMy44SDUuMnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-case-sensitive: url(data:image/svg+xml;base64,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);
  --jp-icon-check: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTkgMTYuMTdMNC44MyAxMmwtMS40MiAxLjQxTDkgMTkgMjEgN2wtMS40MS0xLjQxeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-circle-empty: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyIDJDNi40NyAyIDIgNi40NyAyIDEyczQuNDcgMTAgMTAgMTAgMTAtNC40NyAxMC0xMFMxNy41MyAyIDEyIDJ6bTAgMThjLTQuNDEgMC04LTMuNTktOC04czMuNTktOCA4LTggOCAzLjU5IDggOC0zLjU5IDgtOCA4eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-circle: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMTggMTgiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPGNpcmNsZSBjeD0iOSIgY3k9IjkiIHI9IjgiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-clear: url(data:image/svg+xml;base64,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);
  --jp-icon-close: url(data:image/svg+xml;base64,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);
  --jp-icon-console: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIwMCAyMDAiPgogIDxnIGNsYXNzPSJqcC1pY29uLWJyYW5kMSBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiMwMjg4RDEiPgogICAgPHBhdGggZD0iTTIwIDE5LjhoMTYwdjE1OS45SDIweiIvPgogIDwvZz4KICA8ZyBjbGFzcz0ianAtaWNvbi1zZWxlY3RhYmxlLWludmVyc2UiIGZpbGw9IiNmZmYiPgogICAgPHBhdGggZD0iTTEwNSAxMjcuM2g0MHYxMi44aC00MHpNNTEuMSA3N0w3NCA5OS45bC0yMy4zIDIzLjMgMTAuNSAxMC41IDIzLjMtMjMuM0w5NSA5OS45IDg0LjUgODkuNCA2MS42IDY2LjV6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-copy: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMTggMTgiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTExLjksMUgzLjJDMi40LDEsMS43LDEuNywxLjcsMi41djEwLjJoMS41VjIuNWg4LjdWMXogTTE0LjEsMy45aC04Yy0wLjgsMC0xLjUsMC43LTEuNSwxLjV2MTAuMmMwLDAuOCwwLjcsMS41LDEuNSwxLjVoOCBjMC44LDAsMS41LTAuNywxLjUtMS41VjUuNEMxNS41LDQuNiwxNC45LDMuOSwxNC4xLDMuOXogTTE0LjEsMTUuNWgtOFY1LjRoOFYxNS41eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-cut: url(data:image/svg+xml;base64,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);
  --jp-icon-download: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTE5IDloLTRWM0g5djZINWw3IDcgNy03ek01IDE4djJoMTR2LTJINXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-edit: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTMgMTcuMjVWMjFoMy43NUwxNy44MSA5Ljk0bC0zLjc1LTMuNzVMMyAxNy4yNXpNMjAuNzEgNy4wNGMuMzktLjM5LjM5LTEuMDIgMC0xLjQxbC0yLjM0LTIuMzRjLS4zOS0uMzktMS4wMi0uMzktMS40MSAwbC0xLjgzIDEuODMgMy43NSAzLjc1IDEuODMtMS44M3oiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-ellipses: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPGNpcmNsZSBjeD0iNSIgY3k9IjEyIiByPSIyIi8+CiAgICA8Y2lyY2xlIGN4PSIxMiIgY3k9IjEyIiByPSIyIi8+CiAgICA8Y2lyY2xlIGN4PSIxOSIgY3k9IjEyIiByPSIyIi8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-extension: url(data:image/svg+xml;base64,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);
  --jp-icon-fast-forward: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyNCIgaGVpZ2h0PSIyNCIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTQgMThsOC41LTZMNCA2djEyem05LTEydjEybDguNS02TDEzIDZ6Ii8+CiAgICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-file-upload: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTkgMTZoNnYtNmg0bC03LTctNyA3aDR6bS00IDJoMTR2Mkg1eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-file: url(data:image/svg+xml;base64,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);
  --jp-icon-filter-list: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEwIDE4aDR2LTJoLTR2MnpNMyA2djJoMThWNkgzem0zIDdoMTJ2LTJINnYyeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-folder: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTAgNEg0Yy0xLjEgMC0xLjk5LjktMS45OSAyTDIgMThjMCAxLjEuOSAyIDIgMmgxNmMxLjEgMCAyLS45IDItMlY4YzAtMS4xLS45LTItMi0yaC04bC0yLTJ6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-html5: url(data:image/svg+xml;base64,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);
  --jp-icon-image: url(data:image/svg+xml;base64,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);
  --jp-icon-inspector: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMjAgNEg0Yy0xLjEgMC0xLjk5LjktMS45OSAyTDIgMThjMCAxLjEuOSAyIDIgMmgxNmMxLjEgMCAyLS45IDItMlY2YzAtMS4xLS45LTItMi0yem0tNSAxNEg0di00aDExdjR6bTAtNUg0VjloMTF2NHptNSA1aC00VjloNHY5eiIvPgo8L3N2Zz4K);
  --jp-icon-json: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyter-favicon: url(data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUyIiBoZWlnaHQ9IjE2NSIgdmlld0JveD0iMCAwIDE1MiAxNjUiIHZlcnNpb249IjEuMSIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbi13YXJuMCIgZmlsbD0iI0YzNzcyNiI+CiAgICA8cGF0aCB0cmFuc2Zvcm09InRyYW5zbGF0ZSgwLjA3ODk0NywgMTEwLjU4MjkyNykiIGQ9Ik03NS45NDIyODQyLDI5LjU4MDQ1NjEgQzQzLjMwMjM5NDcsMjkuNTgwNDU2MSAxNC43OTY3ODMyLDE3LjY1MzQ2MzQgMCwwIEM1LjUxMDgzMjExLDE1Ljg0MDY4MjkgMTUuNzgxNTM4OSwyOS41NjY3NzMyIDI5LjM5MDQ5NDcsMzkuMjc4NDE3MSBDNDIuOTk5Nyw0OC45ODk4NTM3IDU5LjI3MzcsNTQuMjA2NzgwNSA3NS45NjA1Nzg5LDU0LjIwNjc4MDUgQzkyLjY0NzQ1NzksNTQuMjA2NzgwNSAxMDguOTIxNDU4LDQ4Ljk4OTg1MzcgMTIyLjUzMDY2MywzOS4yNzg0MTcxIEMxMzYuMTM5NDUzLDI5LjU2Njc3MzIgMTQ2LjQxMDI4NCwxNS44NDA2ODI5IDE1MS45MjExNTgsMCBDMTM3LjA4Nzg2OCwxNy42NTM0NjM0IDEwOC41ODI1ODksMjkuNTgwNDU2MSA3NS45NDIyODQyLDI5LjU4MDQ1NjEgTDc1Ljk0MjI4NDIsMjkuNTgwNDU2MSBaIiAvPgogICAgPHBhdGggdHJhbnNmb3JtPSJ0cmFuc2xhdGUoMC4wMzczNjgsIDAuNzA0ODc4KSIgZD0iTTc1Ljk3ODQ1NzksMjQuNjI2NDA3MyBDMTA4LjYxODc2MywyNC42MjY0MDczIDEzNy4xMjQ0NTgsMzYuNTUzNDQxNSAxNTEuOTIxMTU4LDU0LjIwNjc4MDUgQzE0Ni40MTAyODQsMzguMzY2MjIyIDEzNi4xMzk0NTMsMjQuNjQwMTMxNyAxMjIuNTMwNjYzLDE0LjkyODQ4NzggQzEwOC45MjE0NTgsNS4yMTY4NDM5IDkyLjY0NzQ1NzksMCA3NS45NjA1Nzg5LDAgQzU5LjI3MzcsMCA0Mi45OTk3LDUuMjE2ODQzOSAyOS4zOTA0OTQ3LDE0LjkyODQ4NzggQzE1Ljc4MTUzODksMjQuNjQwMTMxNyA1LjUxMDgzMjExLDM4LjM2NjIyMiAwLDU0LjIwNjc4MDUgQzE0LjgzMzA4MTYsMzYuNTg5OTI5MyA0My4zMzg1Njg0LDI0LjYyNjQwNzMgNzUuOTc4NDU3OSwyNC42MjY0MDczIEw3NS45Nzg0NTc5LDI0LjYyNjQwNzMgWiIgLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-jupyter: url(data:image/svg+xml;base64,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);
  --jp-icon-jupyterlab-wordmark: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyMDAiIHZpZXdCb3g9IjAgMCAxODYwLjggNDc1Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjIiIGZpbGw9IiM0RTRFNEUiIHRyYW5zZm9ybT0idHJhbnNsYXRlKDQ4MC4xMzY0MDEsIDY0LjI3MTQ5MykiPgogICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoMC4wMDAwMDAsIDU4Ljg3NTU2NikiPgogICAgICA8ZyB0cmFuc2Zvcm09InRyYW5zbGF0ZSgwLjA4NzYwMywgMC4xNDAyOTQpIj4KICAgICAgICA8cGF0aCBkPSJNLTQyNi45LDE2OS44YzAsNDguNy0zLjcsNjQuNy0xMy42LDc2LjRjLTEwLjgsMTAtMjUsMTUuNS0zOS43LDE1LjVsMy43LDI5IGMyMi44LDAuMyw0NC44LTcuOSw2MS45LTIzLjFjMTcuOC0xOC41LDI0LTQ0LjEsMjQtODMuM1YwSC00Mjd2MTcwLjFMLTQyNi45LDE2OS44TC00MjYuOSwxNjkuOHoiLz4KICAgICAgPC9nPgogICAgPC9nPgogICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoMTU1LjA0NTI5NiwgNTYuODM3MTA0KSI+CiAgICAgIDxnIHRyYW5zZm9ybT0idHJhbnNsYXRlKDEuNTYyNDUzLCAxLjc5OTg0MikiPgogICAgICAgIDxwYXRoIGQ9Ik0tMzEyLDE0OGMwLDIxLDAsMzkuNSwxLjcsNTUuNGgtMzEuOGwtMi4xLTMzLjNoLTAuOGMtNi43LDExLjYtMTYuNCwyMS4zLTI4LDI3LjkgYy0xMS42LDYuNi0yNC44LDEwLTM4LjIsOS44Yy0zMS40LDAtNjktMTcuNy02OS04OVYwaDM2LjR2MTEyLjdjMCwzOC43LDExLjYsNjQuNyw0NC42LDY0LjdjMTAuMy0wLjIsMjAuNC0zLjUsMjguOS05LjQgYzguNS01LjksMTUuMS0xNC4zLDE4LjktMjMuOWMyLjItNi4xLDMuMy0xMi41LDMuMy0xOC45VjAuMmgzNi40VjE0OEgtMzEyTC0zMTIsMTQ4eiIvPgogICAgICA8L2c+CiAgICA8L2c+CiAgICA8ZyB0cmFuc2Zvcm09InRyYW5zbGF0ZSgzOTAuMDEzMzIyLCA1My40Nzk2MzgpIj4KICAgICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoMS43MDY0NTgsIDAuMjMxNDI1KSI+CiAgICAgICAgPHBhdGggZD0iTS00NzguNiw3MS40YzAtMjYtMC44LTQ3LTEuNy02Ni43aDMyLjdsMS43LDM0LjhoMC44YzcuMS0xMi41LDE3LjUtMjIuOCwzMC4xLTI5LjcgYzEyLjUtNywyNi43LTEwLjMsNDEtOS44YzQ4LjMsMCw4NC43LDQxLjcsODQuNywxMDMuM2MwLDczLjEtNDMuNywxMDkuMi05MSwxMDkuMmMtMTIuMSwwLjUtMjQuMi0yLjItMzUtNy44IGMtMTAuOC01LjYtMTkuOS0xMy45LTI2LjYtMjQuMmgtMC44VjI5MWgtMzZ2LTIyMEwtNDc4LjYsNzEuNEwtNDc4LjYsNzEuNHogTS00NDIuNiwxMjUuNmMwLjEsNS4xLDAuNiwxMC4xLDEuNywxNS4xIGMzLDEyLjMsOS45LDIzLjMsMTkuOCwzMS4xYzkuOSw3LjgsMjIuMSwxMi4xLDM0LjcsMTIuMWMzOC41LDAsNjAuNy0zMS45LDYwLjctNzguNWMwLTQwLjctMjEuMS03NS42LTU5LjUtNzUuNiBjLTEyLjksMC40LTI1LjMsNS4xLTM1LjMsMTMuNGMtOS45LDguMy0xNi45LDE5LjctMTkuNiwzMi40Yy0xLjUsNC45LTIuMywxMC0yLjUsMTUuMVYxMjUuNkwtNDQyLjYsMTI1LjZMLTQ0Mi42LDEyNS42eiIvPgogICAgICA8L2c+CiAgICA8L2c+CiAgICA8ZyB0cmFuc2Zvcm09InRyYW5zbGF0ZSg2MDYuNzQwNzI2LCA1Ni44MzcxMDQpIj4KICAgICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoMC43NTEyMjYsIDEuOTg5Mjk5KSI+CiAgICAgICAgPHBhdGggZD0iTS00NDAuOCwwbDQzLjcsMTIwLjFjNC41LDEzLjQsOS41LDI5LjQsMTIuOCw0MS43aDAuOGMzLjctMTIuMiw3LjktMjcuNywxMi44LTQyLjQgbDM5LjctMTE5LjJoMzguNUwtMzQ2LjksMTQ1Yy0yNiw2OS43LTQzLjcsMTA1LjQtNjguNiwxMjcuMmMtMTIuNSwxMS43LTI3LjksMjAtNDQuNiwyMy45bC05LjEtMzEuMSBjMTEuNy0zLjksMjIuNS0xMC4xLDMxLjgtMTguMWMxMy4yLTExLjEsMjMuNy0yNS4yLDMwLjYtNDEuMmMxLjUtMi44LDIuNS01LjcsMi45LTguOGMtMC4zLTMuMy0xLjItNi42LTIuNS05LjdMLTQ4MC4yLDAuMSBoMzkuN0wtNDQwLjgsMEwtNDQwLjgsMHoiLz4KICAgICAgPC9nPgogICAgPC9nPgogICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoODIyLjc0ODEwNCwgMC4wMDAwMDApIj4KICAgICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoMS40NjQwNTAsIDAuMzc4OTE0KSI+CiAgICAgICAgPHBhdGggZD0iTS00MTMuNywwdjU4LjNoNTJ2MjguMmgtNTJWMTk2YzAsMjUsNywzOS41LDI3LjMsMzkuNWM3LjEsMC4xLDE0LjItMC43LDIxLjEtMi41IGwxLjcsMjcuN2MtMTAuMywzLjctMjEuMyw1LjQtMzIuMiw1Yy03LjMsMC40LTE0LjYtMC43LTIxLjMtMy40Yy02LjgtMi43LTEyLjktNi44LTE3LjktMTIuMWMtMTAuMy0xMC45LTE0LjEtMjktMTQuMS01Mi45IFY4Ni41aC0zMVY1OC4zaDMxVjkuNkwtNDEzLjcsMEwtNDEzLjcsMHoiLz4KICAgICAgPC9nPgogICAgPC9nPgogICAgPGcgdHJhbnNmb3JtPSJ0cmFuc2xhdGUoOTc0LjQzMzI4NiwgNTMuNDc5NjM4KSI+CiAgICAgIDxnIHRyYW5zZm9ybT0idHJhbnNsYXRlKDAuOTkwMDM0LCAwLjYxMDMzOSkiPgogICAgICAgIDxwYXRoIGQ9Ik0tNDQ1LjgsMTEzYzAuOCw1MCwzMi4yLDcwLjYsNjguNiw3MC42YzE5LDAuNiwzNy45LTMsNTUuMy0xMC41bDYuMiwyNi40IGMtMjAuOSw4LjktNDMuNSwxMy4xLTY2LjIsMTIuNmMtNjEuNSwwLTk4LjMtNDEuMi05OC4zLTEwMi41Qy00ODAuMiw0OC4yLTQ0NC43LDAtMzg2LjUsMGM2NS4yLDAsODIuNyw1OC4zLDgyLjcsOTUuNyBjLTAuMSw1LjgtMC41LDExLjUtMS4yLDE3LjJoLTE0MC42SC00NDUuOEwtNDQ1LjgsMTEzeiBNLTMzOS4yLDg2LjZjMC40LTIzLjUtOS41LTYwLjEtNTAuNC02MC4xIGMtMzYuOCwwLTUyLjgsMzQuNC01NS43LDYwLjFILTMzOS4yTC0zMzkuMiw4Ni42TC0zMzkuMiw4Ni42eiIvPgogICAgICA8L2c+CiAgICA8L2c+CiAgICA8ZyB0cmFuc2Zvcm09InRyYW5zbGF0ZSgxMjAxLjk2MTA1OCwgNTMuNDc5NjM4KSI+CiAgICAgIDxnIHRyYW5zZm9ybT0idHJhbnNsYXRlKDEuMTc5NjQwLCAwLjcwNTA2OCkiPgogICAgICAgIDxwYXRoIGQ9Ik0tNDc4LjYsNjhjMC0yMy45LTAuNC00NC41LTEuNy02My40aDMxLjhsMS4yLDM5LjloMS43YzkuMS0yNy4zLDMxLTQ0LjUsNTUuMy00NC41IGMzLjUtMC4xLDcsMC40LDEwLjMsMS4ydjM0LjhjLTQuMS0wLjktOC4yLTEuMy0xMi40LTEuMmMtMjUuNiwwLTQzLjcsMTkuNy00OC43LDQ3LjRjLTEsNS43LTEuNiwxMS41LTEuNywxNy4ydjEwOC4zaC0zNlY2OCBMLTQ3OC42LDY4eiIvPgogICAgICA8L2c+CiAgICA8L2c+CiAgPC9nPgoKICA8ZyBjbGFzcz0ianAtaWNvbi13YXJuMCIgZmlsbD0iI0YzNzcyNiI+CiAgICA8cGF0aCBkPSJNMTM1Mi4zLDMyNi4yaDM3VjI4aC0zN1YzMjYuMnogTTE2MDQuOCwzMjYuMmMtMi41LTEzLjktMy40LTMxLjEtMy40LTQ4Ljd2LTc2IGMwLTQwLjctMTUuMS04My4xLTc3LjMtODMuMWMtMjUuNiwwLTUwLDcuMS02Ni44LDE4LjFsOC40LDI0LjRjMTQuMy05LjIsMzQtMTUuMSw1My0xNS4xYzQxLjYsMCw0Ni4yLDMwLjIsNDYuMiw0N3Y0LjIgYy03OC42LTAuNC0xMjIuMywyNi41LTEyMi4zLDc1LjZjMCwyOS40LDIxLDU4LjQsNjIuMiw1OC40YzI5LDAsNTAuOS0xNC4zLDYyLjItMzAuMmgxLjNsMi45LDI1LjZIMTYwNC44eiBNMTU2NS43LDI1Ny43IGMwLDMuOC0wLjgsOC0yLjEsMTEuOGMtNS45LDE3LjItMjIuNywzNC00OS4yLDM0Yy0xOC45LDAtMzQuOS0xMS4zLTM0LjktMzUuM2MwLTM5LjUsNDUuOC00Ni42LDg2LjItNDUuOFYyNTcuN3ogTTE2OTguNSwzMjYuMiBsMS43LTMzLjZoMS4zYzE1LjEsMjYuOSwzOC43LDM4LjIsNjguMSwzOC4yYzQ1LjQsMCw5MS4yLTM2LjEsOTEuMi0xMDguOGMwLjQtNjEuNy0zNS4zLTEwMy43LTg1LjctMTAzLjcgYy0zMi44LDAtNTYuMywxNC43LTY5LjMsMzcuNGgtMC44VjI4aC0zNi42djI0NS43YzAsMTguMS0wLjgsMzguNi0xLjcsNTIuNUgxNjk4LjV6IE0xNzA0LjgsMjA4LjJjMC01LjksMS4zLTEwLjksMi4xLTE1LjEgYzcuNi0yOC4xLDMxLjEtNDUuNCw1Ni4zLTQ1LjRjMzkuNSwwLDYwLjUsMzQuOSw2MC41LDc1LjZjMCw0Ni42LTIzLjEsNzguMS02MS44LDc4LjFjLTI2LjksMC00OC4zLTE3LjYtNTUuNS00My4zIGMtMC44LTQuMi0xLjctOC44LTEuNy0xMy40VjIwOC4yeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-kernel: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiIgZmlsbD0iIzYxNjE2MSIgZD0iTTE1IDlIOXY2aDZWOXptLTIgNGgtMnYtMmgydjJ6bTgtMlY5aC0yVjdjMC0xLjEtLjktMi0yLTJoLTJWM2gtMnYyaC0yVjNIOXYySDdjLTEuMSAwLTIgLjktMiAydjJIM3YyaDJ2MkgzdjJoMnYyYzAgMS4xLjkgMiAyIDJoMnYyaDJ2LTJoMnYyaDJ2LTJoMmMxLjEgMCAyLS45IDItMnYtMmgydi0yaC0ydi0yaDJ6bS00IDZIN1Y3aDEwdjEweiIvPgo8L3N2Zz4K);
  --jp-icon-keyboard: url(data:image/svg+xml;base64,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);
  --jp-icon-launcher: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTkgMTlINVY1aDdWM0g1YTIgMiAwIDAwLTIgMnYxNGEyIDIgMCAwMDIgMmgxNGMxLjEgMCAyLS45IDItMnYtN2gtMnY3ek0xNCAzdjJoMy41OWwtOS44MyA5LjgzIDEuNDEgMS40MUwxOSA2LjQxVjEwaDJWM2gtN3oiLz4KPC9zdmc+Cg==);
  --jp-icon-line-form: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGZpbGw9IndoaXRlIiBkPSJNNS44OCA0LjEyTDEzLjc2IDEybC03Ljg4IDcuODhMOCAyMmwxMC0xMEw4IDJ6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-link: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTMuOSAxMmMwLTEuNzEgMS4zOS0zLjEgMy4xLTMuMWg0VjdIN2MtMi43NiAwLTUgMi4yNC01IDVzMi4yNCA1IDUgNWg0di0xLjlIN2MtMS43MSAwLTMuMS0xLjM5LTMuMS0zLjF6TTggMTNoOHYtMkg4djJ6bTktNmgtNHYxLjloNGMxLjcxIDAgMy4xIDEuMzkgMy4xIDMuMXMtMS4zOSAzLjEtMy4xIDMuMWgtNFYxN2g0YzIuNzYgMCA1LTIuMjQgNS01cy0yLjI0LTUtNS01eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-list: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICAgIDxwYXRoIGNsYXNzPSJqcC1pY29uMiBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiM2MTYxNjEiIGQ9Ik0xOSA1djE0SDVWNWgxNG0xLjEtMkgzLjljLS41IDAtLjkuNC0uOS45djE2LjJjMCAuNC40LjkuOS45aDE2LjJjLjQgMCAuOS0uNS45LS45VjMuOWMwLS41LS41LS45LS45LS45ek0xMSA3aDZ2MmgtNlY3em0wIDRoNnYyaC02di0yem0wIDRoNnYyaC02ek03IDdoMnYySDd6bTAgNGgydjJIN3ptMCA0aDJ2Mkg3eiIvPgo8L3N2Zz4=);
  --jp-icon-listings-info: url(data:image/svg+xml;base64,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);
  --jp-icon-markdown: url(data:image/svg+xml;base64,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);
  --jp-icon-new-folder: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTIwIDZoLThsLTItMkg0Yy0xLjExIDAtMS45OS44OS0xLjk5IDJMMiAxOGMwIDEuMTEuODkgMiAyIDJoMTZjMS4xMSAwIDItLjg5IDItMlY4YzAtMS4xMS0uODktMi0yLTJ6bS0xIDhoLTN2M2gtMnYtM2gtM3YtMmgzVjloMnYzaDN2MnoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-not-trusted: url(data:image/svg+xml;base64,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);
  --jp-icon-notebook: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtaWNvbi13YXJuMCBqcC1pY29uLXNlbGVjdGFibGUiIGZpbGw9IiNFRjZDMDAiPgogICAgPHBhdGggZD0iTTE4LjcgMy4zdjE1LjRIMy4zVjMuM2gxNS40bTEuNS0xLjVIMS44djE4LjNoMTguM2wuMS0xOC4zeiIvPgogICAgPHBhdGggZD0iTTE2LjUgMTYuNWwtNS40LTQuMy01LjYgNC4zdi0xMWgxMXoiLz4KICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-palette: url(data:image/svg+xml;base64,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);
  --jp-icon-paste: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTE5IDJoLTQuMThDMTQuNC44NCAxMy4zIDAgMTIgMGMtMS4zIDAtMi40Ljg0LTIuODIgMkg1Yy0xLjEgMC0yIC45LTIgMnYxNmMwIDEuMS45IDIgMiAyaDE0YzEuMSAwIDItLjkgMi0yVjRjMC0xLjEtLjktMi0yLTJ6bS03IDBjLjU1IDAgMSAuNDUgMSAxcy0uNDUgMS0xIDEtMS0uNDUtMS0xIC40NS0xIDEtMXptNyAxOEg1VjRoMnYzaDEwVjRoMnYxNnoiLz4KICAgIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-python: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtaWNvbi1icmFuZDAganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjMEQ0N0ExIj4KICAgIDxwYXRoIGQ9Ik0xMS4xIDYuOVY1LjhINi45YzAtLjUgMC0xLjMuMi0xLjYuNC0uNy44LTEuMSAxLjctMS40IDEuNy0uMyAyLjUtLjMgMy45LS4xIDEgLjEgMS45LjkgMS45IDEuOXY0LjJjMCAuNS0uOSAxLjYtMiAxLjZIOC44Yy0xLjUgMC0yLjQgMS40LTIuNCAyLjh2Mi4ySDQuN0MzLjUgMTUuMSAzIDE0IDMgMTMuMVY5Yy0uMS0xIC42LTIgMS44LTIgMS41LS4xIDYuMy0uMSA2LjMtLjF6Ii8+CiAgICA8cGF0aCBkPSJNMTAuOSAxNS4xdjEuMWg0LjJjMCAuNSAwIDEuMy0uMiAxLjYtLjQuNy0uOCAxLjEtMS43IDEuNC0xLjcuMy0yLjUuMy0zLjkuMS0xLS4xLTEuOS0uOS0xLjktMS45di00LjJjMC0uNS45LTEuNiAyLTEuNmgzLjhjMS41IDAgMi40LTEuNCAyLjQtMi44VjYuNmgxLjdDMTguNSA2LjkgMTkgOCAxOSA4LjlWMTNjMCAxLS43IDIuMS0xLjkgMi4xaC02LjJ6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-r-kernel: url(data:image/svg+xml;base64,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);
  --jp-icon-react: url(data:image/svg+xml;base64,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);
  --jp-icon-refresh: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDE4IDE4Ij4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTkgMTMuNWMtMi40OSAwLTQuNS0yLjAxLTQuNS00LjVTNi41MSA0LjUgOSA0LjVjMS4yNCAwIDIuMzYuNTIgMy4xNyAxLjMzTDEwIDhoNVYzbC0xLjc2IDEuNzZDMTIuMTUgMy42OCAxMC42NiAzIDkgMyA1LjY5IDMgMy4wMSA1LjY5IDMuMDEgOVM1LjY5IDE1IDkgMTVjMi45NyAwIDUuNDMtMi4xNiA1LjktNWgtMS41MmMtLjQ2IDItMi4yNCAzLjUtNC4zOCAzLjV6Ii8+CiAgICA8L2c+Cjwvc3ZnPgo=);
  --jp-icon-regex: url(data:image/svg+xml;base64,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);
  --jp-icon-run: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTggNXYxNGwxMS03eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-running: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDUxMiA1MTIiPgogIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICA8cGF0aCBkPSJNMjU2IDhDMTE5IDggOCAxMTkgOCAyNTZzMTExIDI0OCAyNDggMjQ4IDI0OC0xMTEgMjQ4LTI0OFMzOTMgOCAyNTYgOHptOTYgMzI4YzAgOC44LTcuMiAxNi0xNiAxNkgxNzZjLTguOCAwLTE2LTcuMi0xNi0xNlYxNzZjMC04LjggNy4yLTE2IDE2LTE2aDE2MGM4LjggMCAxNiA3LjIgMTYgMTZ2MTYweiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-save: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTE3IDNINWMtMS4xMSAwLTIgLjktMiAydjE0YzAgMS4xLjg5IDIgMiAyaDE0YzEuMSAwIDItLjkgMi0yVjdsLTQtNHptLTUgMTZjLTEuNjYgMC0zLTEuMzQtMy0zczEuMzQtMyAzLTMgMyAxLjM0IDMgMy0xLjM0IDMtMyAzem0zLTEwSDVWNWgxMHY0eiIvPgogICAgPC9nPgo8L3N2Zz4K);
  --jp-icon-search: url(data:image/svg+xml;base64,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);
  --jp-icon-settings: url(data:image/svg+xml;base64,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);
  --jp-icon-spreadsheet: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8cGF0aCBjbGFzcz0ianAtaWNvbi1jb250cmFzdDEganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNENBRjUwIiBkPSJNMi4yIDIuMnYxNy42aDE3LjZWMi4ySDIuMnptMTUuNCA3LjdoLTUuNVY0LjRoNS41djUuNXpNOS45IDQuNHY1LjVINC40VjQuNGg1LjV6bS01LjUgNy43aDUuNXY1LjVINC40di01LjV6bTcuNyA1LjV2LTUuNWg1LjV2NS41aC01LjV6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-stop: url(data:image/svg+xml;base64,PHN2ZyBoZWlnaHQ9IjI0IiB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIyNCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICAgIDxnIGNsYXNzPSJqcC1pY29uMyIgZmlsbD0iIzYxNjE2MSI+CiAgICAgICAgPHBhdGggZD0iTTAgMGgyNHYyNEgweiIgZmlsbD0ibm9uZSIvPgogICAgICAgIDxwYXRoIGQ9Ik02IDZoMTJ2MTJINnoiLz4KICAgIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-tab: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTIxIDNIM2MtMS4xIDAtMiAuOS0yIDJ2MTRjMCAxLjEuOSAyIDIgMmgxOGMxLjEgMCAyLS45IDItMlY1YzAtMS4xLS45LTItMi0yem0wIDE2SDNWNWgxMHY0aDh2MTB6Ii8+CiAgPC9nPgo8L3N2Zz4K);
  --jp-icon-terminal: url(data:image/svg+xml;base64,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);
  --jp-icon-text-editor: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDI0IDI0Ij4KICA8cGF0aCBjbGFzcz0ianAtaWNvbjMganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjNjE2MTYxIiBkPSJNMTUgMTVIM3YyaDEydi0yem0wLThIM3YyaDEyVjd6TTMgMTNoMTh2LTJIM3Yyem0wIDhoMTh2LTJIM3Yyek0zIDN2MmgxOFYzSDN6Ii8+Cjwvc3ZnPgo=);
  --jp-icon-trusted: url(data:image/svg+xml;base64,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);
  --jp-icon-undo: url(data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjQgMjQiIHdpZHRoPSIxNiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KICA8ZyBjbGFzcz0ianAtaWNvbjMiIGZpbGw9IiM2MTYxNjEiPgogICAgPHBhdGggZD0iTTEyLjUgOGMtMi42NSAwLTUuMDUuOTktNi45IDIuNkwyIDd2OWg5bC0zLjYyLTMuNjJjMS4zOS0xLjE2IDMuMTYtMS44OCA1LjEyLTEuODggMy41NCAwIDYuNTUgMi4zMSA3LjYgNS41bDIuMzctLjc4QzIxLjA4IDExLjAzIDE3LjE1IDggMTIuNSA4eiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-vega: url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIxNiIgdmlld0JveD0iMCAwIDIyIDIyIj4KICA8ZyBjbGFzcz0ianAtaWNvbjEganAtaWNvbi1zZWxlY3RhYmxlIiBmaWxsPSIjMjEyMTIxIj4KICAgIDxwYXRoIGQ9Ik0xMC42IDUuNGwyLjItMy4ySDIuMnY3LjNsNC02LjZ6Ii8+CiAgICA8cGF0aCBkPSJNMTUuOCAyLjJsLTQuNCA2LjZMNyA2LjNsLTQuOCA4djUuNWgxNy42VjIuMmgtNHptLTcgMTUuNEg1LjV2LTQuNGgzLjN2NC40em00LjQgMEg5LjhWOS44aDMuNHY3Ljh6bTQuNCAwaC0zLjRWNi41aDMuNHYxMS4xeiIvPgogIDwvZz4KPC9zdmc+Cg==);
  --jp-icon-yaml: url(data:image/svg+xml;base64,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);
}

/* Icon CSS class declarations */

.jp-AddIcon {
  background-image: var(--jp-icon-add);
}
.jp-BugIcon {
  background-image: var(--jp-icon-bug);
}
.jp-BuildIcon {
  background-image: var(--jp-icon-build);
}
.jp-CaretDownEmptyIcon {
  background-image: var(--jp-icon-caret-down-empty);
}
.jp-CaretDownEmptyThinIcon {
  background-image: var(--jp-icon-caret-down-empty-thin);
}
.jp-CaretDownIcon {
  background-image: var(--jp-icon-caret-down);
}
.jp-CaretLeftIcon {
  background-image: var(--jp-icon-caret-left);
}
.jp-CaretRightIcon {
  background-image: var(--jp-icon-caret-right);
}
.jp-CaretUpEmptyThinIcon {
  background-image: var(--jp-icon-caret-up-empty-thin);
}
.jp-CaretUpIcon {
  background-image: var(--jp-icon-caret-up);
}
.jp-CaseSensitiveIcon {
  background-image: var(--jp-icon-case-sensitive);
}
.jp-CheckIcon {
  background-image: var(--jp-icon-check);
}
.jp-CircleEmptyIcon {
  background-image: var(--jp-icon-circle-empty);
}
.jp-CircleIcon {
  background-image: var(--jp-icon-circle);
}
.jp-ClearIcon {
  background-image: var(--jp-icon-clear);
}
.jp-CloseIcon {
  background-image: var(--jp-icon-close);
}
.jp-ConsoleIcon {
  background-image: var(--jp-icon-console);
}
.jp-CopyIcon {
  background-image: var(--jp-icon-copy);
}
.jp-CutIcon {
  background-image: var(--jp-icon-cut);
}
.jp-DownloadIcon {
  background-image: var(--jp-icon-download);
}
.jp-EditIcon {
  background-image: var(--jp-icon-edit);
}
.jp-EllipsesIcon {
  background-image: var(--jp-icon-ellipses);
}
.jp-ExtensionIcon {
  background-image: var(--jp-icon-extension);
}
.jp-FastForwardIcon {
  background-image: var(--jp-icon-fast-forward);
}
.jp-FileIcon {
  background-image: var(--jp-icon-file);
}
.jp-FileUploadIcon {
  background-image: var(--jp-icon-file-upload);
}
.jp-FilterListIcon {
  background-image: var(--jp-icon-filter-list);
}
.jp-FolderIcon {
  background-image: var(--jp-icon-folder);
}
.jp-Html5Icon {
  background-image: var(--jp-icon-html5);
}
.jp-ImageIcon {
  background-image: var(--jp-icon-image);
}
.jp-InspectorIcon {
  background-image: var(--jp-icon-inspector);
}
.jp-JsonIcon {
  background-image: var(--jp-icon-json);
}
.jp-JupyterFaviconIcon {
  background-image: var(--jp-icon-jupyter-favicon);
}
.jp-JupyterIcon {
  background-image: var(--jp-icon-jupyter);
}
.jp-JupyterlabWordmarkIcon {
  background-image: var(--jp-icon-jupyterlab-wordmark);
}
.jp-KernelIcon {
  background-image: var(--jp-icon-kernel);
}
.jp-KeyboardIcon {
  background-image: var(--jp-icon-keyboard);
}
.jp-LauncherIcon {
  background-image: var(--jp-icon-launcher);
}
.jp-LineFormIcon {
  background-image: var(--jp-icon-line-form);
}
.jp-LinkIcon {
  background-image: var(--jp-icon-link);
}
.jp-ListIcon {
  background-image: var(--jp-icon-list);
}
.jp-ListingsInfoIcon {
  background-image: var(--jp-icon-listings-info);
}
.jp-MarkdownIcon {
  background-image: var(--jp-icon-markdown);
}
.jp-NewFolderIcon {
  background-image: var(--jp-icon-new-folder);
}
.jp-NotTrustedIcon {
  background-image: var(--jp-icon-not-trusted);
}
.jp-NotebookIcon {
  background-image: var(--jp-icon-notebook);
}
.jp-PaletteIcon {
  background-image: var(--jp-icon-palette);
}
.jp-PasteIcon {
  background-image: var(--jp-icon-paste);
}
.jp-PythonIcon {
  background-image: var(--jp-icon-python);
}
.jp-RKernelIcon {
  background-image: var(--jp-icon-r-kernel);
}
.jp-ReactIcon {
  background-image: var(--jp-icon-react);
}
.jp-RefreshIcon {
  background-image: var(--jp-icon-refresh);
}
.jp-RegexIcon {
  background-image: var(--jp-icon-regex);
}
.jp-RunIcon {
  background-image: var(--jp-icon-run);
}
.jp-RunningIcon {
  background-image: var(--jp-icon-running);
}
.jp-SaveIcon {
  background-image: var(--jp-icon-save);
}
.jp-SearchIcon {
  background-image: var(--jp-icon-search);
}
.jp-SettingsIcon {
  background-image: var(--jp-icon-settings);
}
.jp-SpreadsheetIcon {
  background-image: var(--jp-icon-spreadsheet);
}
.jp-StopIcon {
  background-image: var(--jp-icon-stop);
}
.jp-TabIcon {
  background-image: var(--jp-icon-tab);
}
.jp-TerminalIcon {
  background-image: var(--jp-icon-terminal);
}
.jp-TextEditorIcon {
  background-image: var(--jp-icon-text-editor);
}
.jp-TrustedIcon {
  background-image: var(--jp-icon-trusted);
}
.jp-UndoIcon {
  background-image: var(--jp-icon-undo);
}
.jp-VegaIcon {
  background-image: var(--jp-icon-vega);
}
.jp-YamlIcon {
  background-image: var(--jp-icon-yaml);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * (DEPRECATED) Support for consuming icons as CSS background images
 */

:root {
  --jp-icon-search-white: url(data:image/svg+xml;base64,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);
}

.jp-Icon,
.jp-MaterialIcon {
  background-position: center;
  background-repeat: no-repeat;
  background-size: 16px;
  min-width: 16px;
  min-height: 16px;
}

.jp-Icon-cover {
  background-position: center;
  background-repeat: no-repeat;
  background-size: cover;
}

/**
 * (DEPRECATED) Support for specific CSS icon sizes
 */

.jp-Icon-16 {
  background-size: 16px;
  min-width: 16px;
  min-height: 16px;
}

.jp-Icon-18 {
  background-size: 18px;
  min-width: 18px;
  min-height: 18px;
}

.jp-Icon-20 {
  background-size: 20px;
  min-width: 20px;
  min-height: 20px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * Support for icons as inline SVG HTMLElements
 */

/* recolor the primary elements of an icon */
.jp-icon0[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon1[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon2[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon3[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon4[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon0[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon1[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon2[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon3[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon4[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}
/* recolor the accent elements of an icon */
.jp-icon-accent0[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-accent1[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-accent2[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-accent3[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-accent4[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-accent0[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-accent1[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-accent2[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-accent3[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-accent4[stroke] {
  stroke: var(--jp-layout-color4);
}
/* set the color of an icon to transparent */
.jp-icon-none[fill] {
  fill: none;
}

.jp-icon-none[stroke] {
  stroke: none;
}
/* brand icon colors. Same for light and dark */
.jp-icon-brand0[fill] {
  fill: var(--jp-brand-color0);
}
.jp-icon-brand1[fill] {
  fill: var(--jp-brand-color1);
}
.jp-icon-brand2[fill] {
  fill: var(--jp-brand-color2);
}
.jp-icon-brand3[fill] {
  fill: var(--jp-brand-color3);
}
.jp-icon-brand4[fill] {
  fill: var(--jp-brand-color4);
}

.jp-icon-brand0[stroke] {
  stroke: var(--jp-brand-color0);
}
.jp-icon-brand1[stroke] {
  stroke: var(--jp-brand-color1);
}
.jp-icon-brand2[stroke] {
  stroke: var(--jp-brand-color2);
}
.jp-icon-brand3[stroke] {
  stroke: var(--jp-brand-color3);
}
.jp-icon-brand4[stroke] {
  stroke: var(--jp-brand-color4);
}
/* warn icon colors. Same for light and dark */
.jp-icon-warn0[fill] {
  fill: var(--jp-warn-color0);
}
.jp-icon-warn1[fill] {
  fill: var(--jp-warn-color1);
}
.jp-icon-warn2[fill] {
  fill: var(--jp-warn-color2);
}
.jp-icon-warn3[fill] {
  fill: var(--jp-warn-color3);
}

.jp-icon-warn0[stroke] {
  stroke: var(--jp-warn-color0);
}
.jp-icon-warn1[stroke] {
  stroke: var(--jp-warn-color1);
}
.jp-icon-warn2[stroke] {
  stroke: var(--jp-warn-color2);
}
.jp-icon-warn3[stroke] {
  stroke: var(--jp-warn-color3);
}
/* icon colors that contrast well with each other and most backgrounds */
.jp-icon-contrast0[fill] {
  fill: var(--jp-icon-contrast-color0);
}
.jp-icon-contrast1[fill] {
  fill: var(--jp-icon-contrast-color1);
}
.jp-icon-contrast2[fill] {
  fill: var(--jp-icon-contrast-color2);
}
.jp-icon-contrast3[fill] {
  fill: var(--jp-icon-contrast-color3);
}

.jp-icon-contrast0[stroke] {
  stroke: var(--jp-icon-contrast-color0);
}
.jp-icon-contrast1[stroke] {
  stroke: var(--jp-icon-contrast-color1);
}
.jp-icon-contrast2[stroke] {
  stroke: var(--jp-icon-contrast-color2);
}
.jp-icon-contrast3[stroke] {
  stroke: var(--jp-icon-contrast-color3);
}

/* CSS for icons in selected items in the settings editor */
#setting-editor .jp-PluginList .jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}
#setting-editor
  .jp-PluginList
  .jp-mod-selected
  .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}

/* CSS for icons in selected filebrowser listing items */
.jp-DirListing-item.jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}
.jp-DirListing-item.jp-mod-selected .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}

/* CSS for icons in selected tabs in the sidebar tab manager */
#tab-manager .lm-TabBar-tab.jp-mod-active .jp-icon-selectable[fill] {
  fill: #fff;
}

#tab-manager .lm-TabBar-tab.jp-mod-active .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}
#tab-manager
  .lm-TabBar-tab.jp-mod-active
  .jp-icon-hover
  :hover
  .jp-icon-selectable[fill] {
  fill: var(--jp-brand-color1);
}

#tab-manager
  .lm-TabBar-tab.jp-mod-active
  .jp-icon-hover
  :hover
  .jp-icon-selectable-inverse[fill] {
  fill: #fff;
}

/**
 * TODO: come up with non css-hack solution for showing the busy icon on top
 *  of the close icon
 * CSS for complex behavior of close icon of tabs in the sidebar tab manager
 */
#tab-manager
  .lm-TabBar-tab.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon3[fill] {
  fill: none;
}
#tab-manager
  .lm-TabBar-tab.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: var(--jp-inverse-layout-color3);
}

#tab-manager
  .lm-TabBar-tab.jp-mod-dirty.jp-mod-active
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: #fff;
}

/**
* TODO: come up with non css-hack solution for showing the busy icon on top
*  of the close icon
* CSS for complex behavior of close icon of tabs in the main area tabbar
*/
.lm-DockPanel-tabBar
  .lm-TabBar-tab.lm-mod-closable.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon3[fill] {
  fill: none;
}
.lm-DockPanel-tabBar
  .lm-TabBar-tab.lm-mod-closable.jp-mod-dirty
  > .lm-TabBar-tabCloseIcon
  > :not(:hover)
  > .jp-icon-busy[fill] {
  fill: var(--jp-inverse-layout-color3);
}

/* CSS for icons in status bar */
#jp-main-statusbar .jp-mod-selected .jp-icon-selectable[fill] {
  fill: #fff;
}

#jp-main-statusbar .jp-mod-selected .jp-icon-selectable-inverse[fill] {
  fill: var(--jp-brand-color1);
}
/* special handling for splash icon CSS. While the theme CSS reloads during
   splash, the splash icon can loose theming. To prevent that, we set a
   default for its color variable */
:root {
  --jp-warn-color0: var(--md-orange-700);
}

/* not sure what to do with this one, used in filebrowser listing */
.jp-DragIcon {
  margin-right: 4px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/**
 * Support for alt colors for icons as inline SVG HTMLElements
 */

/* alt recolor the primary elements of an icon */
.jp-icon-alt .jp-icon0[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-alt .jp-icon1[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-alt .jp-icon2[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-alt .jp-icon3[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-alt .jp-icon4[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-alt .jp-icon0[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-alt .jp-icon1[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-alt .jp-icon2[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-alt .jp-icon3[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-alt .jp-icon4[stroke] {
  stroke: var(--jp-layout-color4);
}

/* alt recolor the accent elements of an icon */
.jp-icon-alt .jp-icon-accent0[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon-alt .jp-icon-accent1[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon-alt .jp-icon-accent2[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon-alt .jp-icon-accent3[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon-alt .jp-icon-accent4[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-alt .jp-icon-accent0[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon-alt .jp-icon-accent1[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon-alt .jp-icon-accent2[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon-alt .jp-icon-accent3[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon-alt .jp-icon-accent4[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-icon-hoverShow:not(:hover) svg {
  display: none !important;
}

/**
 * Support for hover colors for icons as inline SVG HTMLElements
 */

/**
 * regular colors
 */

/* recolor the primary elements of an icon */
.jp-icon-hover :hover .jp-icon0-hover[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon-hover :hover .jp-icon1-hover[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon-hover :hover .jp-icon2-hover[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon-hover :hover .jp-icon3-hover[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon-hover :hover .jp-icon4-hover[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-hover :hover .jp-icon0-hover[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon-hover :hover .jp-icon1-hover[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon-hover :hover .jp-icon2-hover[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon-hover :hover .jp-icon3-hover[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon-hover :hover .jp-icon4-hover[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/* recolor the accent elements of an icon */
.jp-icon-hover :hover .jp-icon-accent0-hover[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-hover :hover .jp-icon-accent1-hover[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-hover :hover .jp-icon-accent2-hover[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-hover :hover .jp-icon-accent3-hover[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-hover :hover .jp-icon-accent4-hover[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-hover :hover .jp-icon-accent0-hover[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-hover :hover .jp-icon-accent1-hover[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-hover :hover .jp-icon-accent2-hover[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-hover :hover .jp-icon-accent3-hover[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-hover :hover .jp-icon-accent4-hover[stroke] {
  stroke: var(--jp-layout-color4);
}

/* set the color of an icon to transparent */
.jp-icon-hover :hover .jp-icon-none-hover[fill] {
  fill: none;
}

.jp-icon-hover :hover .jp-icon-none-hover[stroke] {
  stroke: none;
}

/**
 * inverse colors
 */

/* inverse recolor the primary elements of an icon */
.jp-icon-hover.jp-icon-alt :hover .jp-icon0-hover[fill] {
  fill: var(--jp-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon1-hover[fill] {
  fill: var(--jp-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon2-hover[fill] {
  fill: var(--jp-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon3-hover[fill] {
  fill: var(--jp-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon4-hover[fill] {
  fill: var(--jp-layout-color4);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon0-hover[stroke] {
  stroke: var(--jp-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon1-hover[stroke] {
  stroke: var(--jp-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon2-hover[stroke] {
  stroke: var(--jp-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon3-hover[stroke] {
  stroke: var(--jp-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon4-hover[stroke] {
  stroke: var(--jp-layout-color4);
}

/* inverse recolor the accent elements of an icon */
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent0-hover[fill] {
  fill: var(--jp-inverse-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent1-hover[fill] {
  fill: var(--jp-inverse-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent2-hover[fill] {
  fill: var(--jp-inverse-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent3-hover[fill] {
  fill: var(--jp-inverse-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent4-hover[fill] {
  fill: var(--jp-inverse-layout-color4);
}

.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent0-hover[stroke] {
  stroke: var(--jp-inverse-layout-color0);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent1-hover[stroke] {
  stroke: var(--jp-inverse-layout-color1);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent2-hover[stroke] {
  stroke: var(--jp-inverse-layout-color2);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent3-hover[stroke] {
  stroke: var(--jp-inverse-layout-color3);
}
.jp-icon-hover.jp-icon-alt :hover .jp-icon-accent4-hover[stroke] {
  stroke: var(--jp-inverse-layout-color4);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* Sibling imports */

/* Override Blueprint's _reset.scss styles */
html {
  box-sizing: unset;
}

*,
*::before,
*::after {
  box-sizing: unset;
}

body {
  color: unset;
  font-family: var(--jp-ui-font-family);
}

p {
  margin-top: unset;
  margin-bottom: unset;
}

small {
  font-size: unset;
}

strong {
  font-weight: unset;
}

/* Override Blueprint's _typography.scss styles */
a {
  text-decoration: unset;
  color: unset;
}
a:hover {
  text-decoration: unset;
  color: unset;
}

/* Override Blueprint's _accessibility.scss styles */
:focus {
  outline: unset;
  outline-offset: unset;
  -moz-outline-radius: unset;
}

/* Styles for ui-components */
.jp-Button {
  border-radius: var(--jp-border-radius);
  padding: 0px 12px;
  font-size: var(--jp-ui-font-size1);
}

/* Use our own theme for hover styles */
button.jp-Button.bp3-button.bp3-minimal:hover {
  background-color: var(--jp-layout-color2);
}
.jp-Button.minimal {
  color: unset !important;
}

.jp-Button.jp-ToolbarButtonComponent {
  text-transform: none;
}

.jp-InputGroup input {
  box-sizing: border-box;
  border-radius: 0;
  background-color: transparent;
  color: var(--jp-ui-font-color0);
  box-shadow: inset 0 0 0 var(--jp-border-width) var(--jp-input-border-color);
}

.jp-InputGroup input:focus {
  box-shadow: inset 0 0 0 var(--jp-border-width)
      var(--jp-input-active-box-shadow-color),
    inset 0 0 0 3px var(--jp-input-active-box-shadow-color);
}

.jp-InputGroup input::placeholder,
input::placeholder {
  color: var(--jp-ui-font-color3);
}

.jp-BPIcon {
  display: inline-block;
  vertical-align: middle;
  margin: auto;
}

/* Stop blueprint futzing with our icon fills */
.bp3-icon.jp-BPIcon > svg:not([fill]) {
  fill: var(--jp-inverse-layout-color3);
}

.jp-InputGroupAction {
  padding: 6px;
}

.jp-HTMLSelect.jp-DefaultStyle select {
  background-color: initial;
  border: none;
  border-radius: 0;
  box-shadow: none;
  color: var(--jp-ui-font-color0);
  display: block;
  font-size: var(--jp-ui-font-size1);
  height: 24px;
  line-height: 14px;
  padding: 0 25px 0 10px;
  text-align: left;
  -moz-appearance: none;
  -webkit-appearance: none;
}

/* Use our own theme for hover and option styles */
.jp-HTMLSelect.jp-DefaultStyle select:hover,
.jp-HTMLSelect.jp-DefaultStyle select > option {
  background-color: var(--jp-layout-color2);
  color: var(--jp-ui-font-color0);
}
select {
  box-sizing: border-box;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Collapse {
  display: flex;
  flex-direction: column;
  align-items: stretch;
  border-top: 1px solid var(--jp-border-color2);
  border-bottom: 1px solid var(--jp-border-color2);
}

.jp-Collapse-header {
  padding: 1px 12px;
  color: var(--jp-ui-font-color1);
  background-color: var(--jp-layout-color1);
  font-size: var(--jp-ui-font-size2);
}

.jp-Collapse-header:hover {
  background-color: var(--jp-layout-color2);
}

.jp-Collapse-contents {
  padding: 0px 12px 0px 12px;
  background-color: var(--jp-layout-color1);
  color: var(--jp-ui-font-color1);
  overflow: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-commandpalette-search-height: 28px;
}

/*-----------------------------------------------------------------------------
| Overall styles
|----------------------------------------------------------------------------*/

.lm-CommandPalette {
  padding-bottom: 0px;
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
}

/*-----------------------------------------------------------------------------
| Search
|----------------------------------------------------------------------------*/

.lm-CommandPalette-search {
  padding: 4px;
  background-color: var(--jp-layout-color1);
  z-index: 2;
}

.lm-CommandPalette-wrapper {
  overflow: overlay;
  padding: 0px 9px;
  background-color: var(--jp-input-active-background);
  height: 30px;
  box-shadow: inset 0 0 0 var(--jp-border-width) var(--jp-input-border-color);
}

.lm-CommandPalette.lm-mod-focused .lm-CommandPalette-wrapper {
  box-shadow: inset 0 0 0 1px var(--jp-input-active-box-shadow-color),
    inset 0 0 0 3px var(--jp-input-active-box-shadow-color);
}

.lm-CommandPalette-wrapper::after {
  content: ' ';
  color: white;
  background-color: var(--jp-brand-color1);
  position: absolute;
  top: 4px;
  right: 4px;
  height: 30px;
  width: 10px;
  padding: 0px 10px;
  background-image: var(--jp-icon-search-white);
  background-size: 20px;
  background-repeat: no-repeat;
  background-position: center;
}

.lm-CommandPalette-input {
  background: transparent;
  width: calc(100% - 18px);
  float: left;
  border: none;
  outline: none;
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  line-height: var(--jp-private-commandpalette-search-height);
}

.lm-CommandPalette-input::-webkit-input-placeholder,
.lm-CommandPalette-input::-moz-placeholder,
.lm-CommandPalette-input:-ms-input-placeholder {
  color: var(--jp-ui-font-color3);
  font-size: var(--jp-ui-font-size1);
}

/*-----------------------------------------------------------------------------
| Results
|----------------------------------------------------------------------------*/

.lm-CommandPalette-header:first-child {
  margin-top: 0px;
}

.lm-CommandPalette-header {
  border-bottom: solid var(--jp-border-width) var(--jp-border-color2);
  color: var(--jp-ui-font-color1);
  cursor: pointer;
  display: flex;
  font-size: var(--jp-ui-font-size0);
  font-weight: 600;
  letter-spacing: 1px;
  margin-top: 8px;
  padding: 8px 0 8px 12px;
  text-transform: uppercase;
}

.lm-CommandPalette-header.lm-mod-active {
  background: var(--jp-layout-color2);
}

.lm-CommandPalette-header > mark {
  background-color: transparent;
  font-weight: bold;
  color: var(--jp-ui-font-color1);
}

.lm-CommandPalette-item {
  padding: 4px 12px 4px 4px;
  color: var(--jp-ui-font-color1);
  font-size: var(--jp-ui-font-size1);
  font-weight: 400;
  display: flex;
}

.lm-CommandPalette-item.lm-mod-disabled {
  color: var(--jp-ui-font-color3);
}

.lm-CommandPalette-item.lm-mod-active {
  background: var(--jp-layout-color3);
}

.lm-CommandPalette-item.lm-mod-active:hover:not(.lm-mod-disabled) {
  background: var(--jp-layout-color4);
}

.lm-CommandPalette-item:hover:not(.lm-mod-active):not(.lm-mod-disabled) {
  background: var(--jp-layout-color2);
}

.lm-CommandPalette-itemContent {
  overflow: hidden;
}

.lm-CommandPalette-itemLabel > mark {
  color: var(--jp-ui-font-color0);
  background-color: transparent;
  font-weight: bold;
}

.lm-CommandPalette-item.lm-mod-disabled mark {
  color: var(--jp-ui-font-color3);
}

.lm-CommandPalette-item .lm-CommandPalette-itemIcon {
  margin: 0 4px 0 0;
  position: relative;
  width: 16px;
  top: 2px;
  flex: 0 0 auto;
}

.lm-CommandPalette-item.lm-mod-disabled .lm-CommandPalette-itemIcon {
  opacity: 0.4;
}

.lm-CommandPalette-item .lm-CommandPalette-itemShortcut {
  flex: 0 0 auto;
}

.lm-CommandPalette-itemCaption {
  display: none;
}

.lm-CommandPalette-content {
  background-color: var(--jp-layout-color1);
}

.lm-CommandPalette-content:empty:after {
  content: 'No results';
  margin: auto;
  margin-top: 20px;
  width: 100px;
  display: block;
  font-size: var(--jp-ui-font-size2);
  font-family: var(--jp-ui-font-family);
  font-weight: lighter;
}

.lm-CommandPalette-emptyMessage {
  text-align: center;
  margin-top: 24px;
  line-height: 1.32;
  padding: 0px 8px;
  color: var(--jp-content-font-color3);
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Dialog {
  position: absolute;
  z-index: 10000;
  display: flex;
  flex-direction: column;
  align-items: center;
  justify-content: center;
  top: 0px;
  left: 0px;
  margin: 0;
  padding: 0;
  width: 100%;
  height: 100%;
  background: var(--jp-dialog-background);
}

.jp-Dialog-content {
  display: flex;
  flex-direction: column;
  margin-left: auto;
  margin-right: auto;
  background: var(--jp-layout-color1);
  padding: 24px;
  padding-bottom: 12px;
  min-width: 300px;
  min-height: 150px;
  max-width: 1000px;
  max-height: 500px;
  box-sizing: border-box;
  box-shadow: var(--jp-elevation-z20);
  word-wrap: break-word;
  border-radius: var(--jp-border-radius);
  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color1);
}

.jp-Dialog-button {
  overflow: visible;
}

button.jp-Dialog-button:focus {
  outline: 1px solid var(--jp-brand-color1);
  outline-offset: 4px;
  -moz-outline-radius: 0px;
}

button.jp-Dialog-button:focus::-moz-focus-inner {
  border: 0;
}

.jp-Dialog-header {
  flex: 0 0 auto;
  padding-bottom: 12px;
  font-size: var(--jp-ui-font-size3);
  font-weight: 400;
  color: var(--jp-ui-font-color0);
}

.jp-Dialog-body {
  display: flex;
  flex-direction: column;
  flex: 1 1 auto;
  font-size: var(--jp-ui-font-size1);
  background: var(--jp-layout-color1);
  overflow: auto;
}

.jp-Dialog-footer {
  display: flex;
  flex-direction: row;
  justify-content: flex-end;
  flex: 0 0 auto;
  margin-left: -12px;
  margin-right: -12px;
  padding: 12px;
}

.jp-Dialog-title {
  overflow: hidden;
  white-space: nowrap;
  text-overflow: ellipsis;
}

.jp-Dialog-body > .jp-select-wrapper {
  width: 100%;
}

.jp-Dialog-body > button {
  padding: 0px 16px;
}

.jp-Dialog-body > label {
  line-height: 1.4;
  color: var(--jp-ui-font-color0);
}

.jp-Dialog-button.jp-mod-styled:not(:last-child) {
  margin-right: 12px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-HoverBox {
  position: fixed;
}

.jp-HoverBox.jp-mod-outofview {
  display: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-IFrame {
  width: 100%;
  height: 100%;
}

.jp-IFrame > iframe {
  border: none;
}

/*
When drag events occur, `p-mod-override-cursor` is added to the body.
Because iframes steal all cursor events, the following two rules are necessary
to suppress pointer events while resize drags are occurring. There may be a
better solution to this problem.
*/
body.lm-mod-override-cursor .jp-IFrame {
  position: relative;
}

body.lm-mod-override-cursor .jp-IFrame:before {
  content: '';
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-MainAreaWidget > :focus {
  outline: none;
}

/**
 * google-material-color v1.2.6
 * https://github.com/danlevan/google-material-color
 */
:root {
  --md-red-50: #ffebee;
  --md-red-100: #ffcdd2;
  --md-red-200: #ef9a9a;
  --md-red-300: #e57373;
  --md-red-400: #ef5350;
  --md-red-500: #f44336;
  --md-red-600: #e53935;
  --md-red-700: #d32f2f;
  --md-red-800: #c62828;
  --md-red-900: #b71c1c;
  --md-red-A100: #ff8a80;
  --md-red-A200: #ff5252;
  --md-red-A400: #ff1744;
  --md-red-A700: #d50000;

  --md-pink-50: #fce4ec;
  --md-pink-100: #f8bbd0;
  --md-pink-200: #f48fb1;
  --md-pink-300: #f06292;
  --md-pink-400: #ec407a;
  --md-pink-500: #e91e63;
  --md-pink-600: #d81b60;
  --md-pink-700: #c2185b;
  --md-pink-800: #ad1457;
  --md-pink-900: #880e4f;
  --md-pink-A100: #ff80ab;
  --md-pink-A200: #ff4081;
  --md-pink-A400: #f50057;
  --md-pink-A700: #c51162;

  --md-purple-50: #f3e5f5;
  --md-purple-100: #e1bee7;
  --md-purple-200: #ce93d8;
  --md-purple-300: #ba68c8;
  --md-purple-400: #ab47bc;
  --md-purple-500: #9c27b0;
  --md-purple-600: #8e24aa;
  --md-purple-700: #7b1fa2;
  --md-purple-800: #6a1b9a;
  --md-purple-900: #4a148c;
  --md-purple-A100: #ea80fc;
  --md-purple-A200: #e040fb;
  --md-purple-A400: #d500f9;
  --md-purple-A700: #aa00ff;

  --md-deep-purple-50: #ede7f6;
  --md-deep-purple-100: #d1c4e9;
  --md-deep-purple-200: #b39ddb;
  --md-deep-purple-300: #9575cd;
  --md-deep-purple-400: #7e57c2;
  --md-deep-purple-500: #673ab7;
  --md-deep-purple-600: #5e35b1;
  --md-deep-purple-700: #512da8;
  --md-deep-purple-800: #4527a0;
  --md-deep-purple-900: #311b92;
  --md-deep-purple-A100: #b388ff;
  --md-deep-purple-A200: #7c4dff;
  --md-deep-purple-A400: #651fff;
  --md-deep-purple-A700: #6200ea;

  --md-indigo-50: #e8eaf6;
  --md-indigo-100: #c5cae9;
  --md-indigo-200: #9fa8da;
  --md-indigo-300: #7986cb;
  --md-indigo-400: #5c6bc0;
  --md-indigo-500: #3f51b5;
  --md-indigo-600: #3949ab;
  --md-indigo-700: #303f9f;
  --md-indigo-800: #283593;
  --md-indigo-900: #1a237e;
  --md-indigo-A100: #8c9eff;
  --md-indigo-A200: #536dfe;
  --md-indigo-A400: #3d5afe;
  --md-indigo-A700: #304ffe;

  --md-blue-50: #e3f2fd;
  --md-blue-100: #bbdefb;
  --md-blue-200: #90caf9;
  --md-blue-300: #64b5f6;
  --md-blue-400: #42a5f5;
  --md-blue-500: #2196f3;
  --md-blue-600: #1e88e5;
  --md-blue-700: #1976d2;
  --md-blue-800: #1565c0;
  --md-blue-900: #0d47a1;
  --md-blue-A100: #82b1ff;
  --md-blue-A200: #448aff;
  --md-blue-A400: #2979ff;
  --md-blue-A700: #2962ff;

  --md-light-blue-50: #e1f5fe;
  --md-light-blue-100: #b3e5fc;
  --md-light-blue-200: #81d4fa;
  --md-light-blue-300: #4fc3f7;
  --md-light-blue-400: #29b6f6;
  --md-light-blue-500: #03a9f4;
  --md-light-blue-600: #039be5;
  --md-light-blue-700: #0288d1;
  --md-light-blue-800: #0277bd;
  --md-light-blue-900: #01579b;
  --md-light-blue-A100: #80d8ff;
  --md-light-blue-A200: #40c4ff;
  --md-light-blue-A400: #00b0ff;
  --md-light-blue-A700: #0091ea;

  --md-cyan-50: #e0f7fa;
  --md-cyan-100: #b2ebf2;
  --md-cyan-200: #80deea;
  --md-cyan-300: #4dd0e1;
  --md-cyan-400: #26c6da;
  --md-cyan-500: #00bcd4;
  --md-cyan-600: #00acc1;
  --md-cyan-700: #0097a7;
  --md-cyan-800: #00838f;
  --md-cyan-900: #006064;
  --md-cyan-A100: #84ffff;
  --md-cyan-A200: #18ffff;
  --md-cyan-A400: #00e5ff;
  --md-cyan-A700: #00b8d4;

  --md-teal-50: #e0f2f1;
  --md-teal-100: #b2dfdb;
  --md-teal-200: #80cbc4;
  --md-teal-300: #4db6ac;
  --md-teal-400: #26a69a;
  --md-teal-500: #009688;
  --md-teal-600: #00897b;
  --md-teal-700: #00796b;
  --md-teal-800: #00695c;
  --md-teal-900: #004d40;
  --md-teal-A100: #a7ffeb;
  --md-teal-A200: #64ffda;
  --md-teal-A400: #1de9b6;
  --md-teal-A700: #00bfa5;

  --md-green-50: #e8f5e9;
  --md-green-100: #c8e6c9;
  --md-green-200: #a5d6a7;
  --md-green-300: #81c784;
  --md-green-400: #66bb6a;
  --md-green-500: #4caf50;
  --md-green-600: #43a047;
  --md-green-700: #388e3c;
  --md-green-800: #2e7d32;
  --md-green-900: #1b5e20;
  --md-green-A100: #b9f6ca;
  --md-green-A200: #69f0ae;
  --md-green-A400: #00e676;
  --md-green-A700: #00c853;

  --md-light-green-50: #f1f8e9;
  --md-light-green-100: #dcedc8;
  --md-light-green-200: #c5e1a5;
  --md-light-green-300: #aed581;
  --md-light-green-400: #9ccc65;
  --md-light-green-500: #8bc34a;
  --md-light-green-600: #7cb342;
  --md-light-green-700: #689f38;
  --md-light-green-800: #558b2f;
  --md-light-green-900: #33691e;
  --md-light-green-A100: #ccff90;
  --md-light-green-A200: #b2ff59;
  --md-light-green-A400: #76ff03;
  --md-light-green-A700: #64dd17;

  --md-lime-50: #f9fbe7;
  --md-lime-100: #f0f4c3;
  --md-lime-200: #e6ee9c;
  --md-lime-300: #dce775;
  --md-lime-400: #d4e157;
  --md-lime-500: #cddc39;
  --md-lime-600: #c0ca33;
  --md-lime-700: #afb42b;
  --md-lime-800: #9e9d24;
  --md-lime-900: #827717;
  --md-lime-A100: #f4ff81;
  --md-lime-A200: #eeff41;
  --md-lime-A400: #c6ff00;
  --md-lime-A700: #aeea00;

  --md-yellow-50: #fffde7;
  --md-yellow-100: #fff9c4;
  --md-yellow-200: #fff59d;
  --md-yellow-300: #fff176;
  --md-yellow-400: #ffee58;
  --md-yellow-500: #ffeb3b;
  --md-yellow-600: #fdd835;
  --md-yellow-700: #fbc02d;
  --md-yellow-800: #f9a825;
  --md-yellow-900: #f57f17;
  --md-yellow-A100: #ffff8d;
  --md-yellow-A200: #ffff00;
  --md-yellow-A400: #ffea00;
  --md-yellow-A700: #ffd600;

  --md-amber-50: #fff8e1;
  --md-amber-100: #ffecb3;
  --md-amber-200: #ffe082;
  --md-amber-300: #ffd54f;
  --md-amber-400: #ffca28;
  --md-amber-500: #ffc107;
  --md-amber-600: #ffb300;
  --md-amber-700: #ffa000;
  --md-amber-800: #ff8f00;
  --md-amber-900: #ff6f00;
  --md-amber-A100: #ffe57f;
  --md-amber-A200: #ffd740;
  --md-amber-A400: #ffc400;
  --md-amber-A700: #ffab00;

  --md-orange-50: #fff3e0;
  --md-orange-100: #ffe0b2;
  --md-orange-200: #ffcc80;
  --md-orange-300: #ffb74d;
  --md-orange-400: #ffa726;
  --md-orange-500: #ff9800;
  --md-orange-600: #fb8c00;
  --md-orange-700: #f57c00;
  --md-orange-800: #ef6c00;
  --md-orange-900: #e65100;
  --md-orange-A100: #ffd180;
  --md-orange-A200: #ffab40;
  --md-orange-A400: #ff9100;
  --md-orange-A700: #ff6d00;

  --md-deep-orange-50: #fbe9e7;
  --md-deep-orange-100: #ffccbc;
  --md-deep-orange-200: #ffab91;
  --md-deep-orange-300: #ff8a65;
  --md-deep-orange-400: #ff7043;
  --md-deep-orange-500: #ff5722;
  --md-deep-orange-600: #f4511e;
  --md-deep-orange-700: #e64a19;
  --md-deep-orange-800: #d84315;
  --md-deep-orange-900: #bf360c;
  --md-deep-orange-A100: #ff9e80;
  --md-deep-orange-A200: #ff6e40;
  --md-deep-orange-A400: #ff3d00;
  --md-deep-orange-A700: #dd2c00;

  --md-brown-50: #efebe9;
  --md-brown-100: #d7ccc8;
  --md-brown-200: #bcaaa4;
  --md-brown-300: #a1887f;
  --md-brown-400: #8d6e63;
  --md-brown-500: #795548;
  --md-brown-600: #6d4c41;
  --md-brown-700: #5d4037;
  --md-brown-800: #4e342e;
  --md-brown-900: #3e2723;

  --md-grey-50: #fafafa;
  --md-grey-100: #f5f5f5;
  --md-grey-200: #eeeeee;
  --md-grey-300: #e0e0e0;
  --md-grey-400: #bdbdbd;
  --md-grey-500: #9e9e9e;
  --md-grey-600: #757575;
  --md-grey-700: #616161;
  --md-grey-800: #424242;
  --md-grey-900: #212121;

  --md-blue-grey-50: #eceff1;
  --md-blue-grey-100: #cfd8dc;
  --md-blue-grey-200: #b0bec5;
  --md-blue-grey-300: #90a4ae;
  --md-blue-grey-400: #78909c;
  --md-blue-grey-500: #607d8b;
  --md-blue-grey-600: #546e7a;
  --md-blue-grey-700: #455a64;
  --md-blue-grey-800: #37474f;
  --md-blue-grey-900: #263238;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Spinner {
  position: absolute;
  display: flex;
  justify-content: center;
  align-items: center;
  z-index: 10;
  left: 0;
  top: 0;
  width: 100%;
  height: 100%;
  background: var(--jp-layout-color0);
  outline: none;
}

.jp-SpinnerContent {
  font-size: 10px;
  margin: 50px auto;
  text-indent: -9999em;
  width: 3em;
  height: 3em;
  border-radius: 50%;
  background: var(--jp-brand-color3);
  background: linear-gradient(
    to right,
    #f37626 10%,
    rgba(255, 255, 255, 0) 42%
  );
  position: relative;
  animation: load3 1s infinite linear, fadeIn 1s;
}

.jp-SpinnerContent:before {
  width: 50%;
  height: 50%;
  background: #f37626;
  border-radius: 100% 0 0 0;
  position: absolute;
  top: 0;
  left: 0;
  content: '';
}

.jp-SpinnerContent:after {
  background: var(--jp-layout-color0);
  width: 75%;
  height: 75%;
  border-radius: 50%;
  content: '';
  margin: auto;
  position: absolute;
  top: 0;
  left: 0;
  bottom: 0;
  right: 0;
}

@keyframes fadeIn {
  0% {
    opacity: 0;
  }
  100% {
    opacity: 1;
  }
}

@keyframes load3 {
  0% {
    transform: rotate(0deg);
  }
  100% {
    transform: rotate(360deg);
  }
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

button.jp-mod-styled {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  border: none;
  box-sizing: border-box;
  text-align: center;
  line-height: 32px;
  height: 32px;
  padding: 0px 12px;
  letter-spacing: 0.8px;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

input.jp-mod-styled {
  background: var(--jp-input-background);
  height: 28px;
  box-sizing: border-box;
  border: var(--jp-border-width) solid var(--jp-border-color1);
  padding-left: 7px;
  padding-right: 7px;
  font-size: var(--jp-ui-font-size2);
  color: var(--jp-ui-font-color0);
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

input.jp-mod-styled:focus {
  border: var(--jp-border-width) solid var(--md-blue-500);
  box-shadow: inset 0 0 4px var(--md-blue-300);
}

.jp-select-wrapper {
  display: flex;
  position: relative;
  flex-direction: column;
  padding: 1px;
  background-color: var(--jp-layout-color1);
  height: 28px;
  box-sizing: border-box;
  margin-bottom: 12px;
}

.jp-select-wrapper.jp-mod-focused select.jp-mod-styled {
  border: var(--jp-border-width) solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
  background-color: var(--jp-input-active-background);
}

select.jp-mod-styled:hover {
  background-color: var(--jp-layout-color1);
  cursor: pointer;
  color: var(--jp-ui-font-color0);
  background-color: var(--jp-input-hover-background);
  box-shadow: inset 0 0px 1px rgba(0, 0, 0, 0.5);
}

select.jp-mod-styled {
  flex: 1 1 auto;
  height: 32px;
  width: 100%;
  font-size: var(--jp-ui-font-size2);
  background: var(--jp-input-background);
  color: var(--jp-ui-font-color0);
  padding: 0 25px 0 8px;
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  border-radius: 0px;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

:root {
  --jp-private-toolbar-height: calc(
    28px + var(--jp-border-width)
  ); /* leave 28px for content */
}

.jp-Toolbar {
  color: var(--jp-ui-font-color1);
  flex: 0 0 auto;
  display: flex;
  flex-direction: row;
  border-bottom: var(--jp-border-width) solid var(--jp-toolbar-border-color);
  box-shadow: var(--jp-toolbar-box-shadow);
  background: var(--jp-toolbar-background);
  min-height: var(--jp-toolbar-micro-height);
  padding: 2px;
  z-index: 1;
}

/* Toolbar items */

.jp-Toolbar > .jp-Toolbar-item.jp-Toolbar-spacer {
  flex-grow: 1;
  flex-shrink: 1;
}

.jp-Toolbar-item.jp-Toolbar-kernelStatus {
  display: inline-block;
  width: 32px;
  background-repeat: no-repeat;
  background-position: center;
  background-size: 16px;
}

.jp-Toolbar > .jp-Toolbar-item {
  flex: 0 0 auto;
  display: flex;
  padding-left: 1px;
  padding-right: 1px;
  font-size: var(--jp-ui-font-size1);
  line-height: var(--jp-private-toolbar-height);
  height: 100%;
}

/* Toolbar buttons */

/* This is the div we use to wrap the react component into a Widget */
div.jp-ToolbarButton {
  color: transparent;
  border: none;
  box-sizing: border-box;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
  padding: 0px;
  margin: 0px;
}

button.jp-ToolbarButtonComponent {
  background: var(--jp-layout-color1);
  border: none;
  box-sizing: border-box;
  outline: none;
  appearance: none;
  -webkit-appearance: none;
  -moz-appearance: none;
  padding: 0px 6px;
  margin: 0px;
  height: 24px;
  border-radius: var(--jp-border-radius);
  display: flex;
  align-items: center;
  text-align: center;
  font-size: 14px;
  min-width: unset;
  min-height: unset;
}

button.jp-ToolbarButtonComponent:disabled {
  opacity: 0.4;
}

button.jp-ToolbarButtonComponent span {
  padding: 0px;
  flex: 0 0 auto;
}

button.jp-ToolbarButtonComponent .jp-ToolbarButtonComponent-label {
  font-size: var(--jp-ui-font-size1);
  line-height: 100%;
  padding-left: 2px;
  color: var(--jp-ui-font-color1);
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2017, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Copyright (c) 2014-2017, PhosphorJS Contributors
|
| Distributed under the terms of the BSD 3-Clause License.
|
| The full license is in the file LICENSE, distributed with this software.
|----------------------------------------------------------------------------*/


/* <DEPRECATED> */ body.p-mod-override-cursor *, /* </DEPRECATED> */
body.lm-mod-override-cursor * {
  cursor: inherit !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) 2014-2016, Jupyter Development Team.
|
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-JSONEditor {
  display: flex;
  flex-direction: column;
  width: 100%;
}

.jp-JSONEditor-host {
  flex: 1 1 auto;
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  border-radius: 0px;
  background: var(--jp-layout-color0);
  min-height: 50px;
  padding: 1px;
}

.jp-JSONEditor.jp-mod-error .jp-JSONEditor-host {
  border-color: red;
  outline-color: red;
}

.jp-JSONEditor-header {
  display: flex;
  flex: 1 0 auto;
  padding: 0 0 0 12px;
}

.jp-JSONEditor-header label {
  flex: 0 0 auto;
}

.jp-JSONEditor-commitButton {
  height: 16px;
  width: 16px;
  background-size: 18px;
  background-repeat: no-repeat;
  background-position: center;
}

.jp-JSONEditor-host.jp-mod-focused {
  background-color: var(--jp-input-active-background);
  border: 1px solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
}

.jp-Editor.jp-mod-dropTarget {
  border: var(--jp-border-width) solid var(--jp-input-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* BASICS */

.CodeMirror {
  /* Set height, width, borders, and global font properties here */
  font-family: monospace;
  height: 300px;
  color: black;
  direction: ltr;
}

/* PADDING */

.CodeMirror-lines {
  padding: 4px 0; /* Vertical padding around content */
}
.CodeMirror pre.CodeMirror-line,
.CodeMirror pre.CodeMirror-line-like {
  padding: 0 4px; /* Horizontal padding of content */
}

.CodeMirror-scrollbar-filler, .CodeMirror-gutter-filler {
  background-color: white; /* The little square between H and V scrollbars */
}

/* GUTTER */

.CodeMirror-gutters {
  border-right: 1px solid #ddd;
  background-color: #f7f7f7;
  white-space: nowrap;
}
.CodeMirror-linenumbers {}
.CodeMirror-linenumber {
  padding: 0 3px 0 5px;
  min-width: 20px;
  text-align: right;
  color: #999;
  white-space: nowrap;
}

.CodeMirror-guttermarker { color: black; }
.CodeMirror-guttermarker-subtle { color: #999; }

/* CURSOR */

.CodeMirror-cursor {
  border-left: 1px solid black;
  border-right: none;
  width: 0;
}
/* Shown when moving in bi-directional text */
.CodeMirror div.CodeMirror-secondarycursor {
  border-left: 1px solid silver;
}
.cm-fat-cursor .CodeMirror-cursor {
  width: auto;
  border: 0 !important;
  background: #7e7;
}
.cm-fat-cursor div.CodeMirror-cursors {
  z-index: 1;
}
.cm-fat-cursor-mark {
  background-color: rgba(20, 255, 20, 0.5);
  -webkit-animation: blink 1.06s steps(1) infinite;
  -moz-animation: blink 1.06s steps(1) infinite;
  animation: blink 1.06s steps(1) infinite;
}
.cm-animate-fat-cursor {
  width: auto;
  border: 0;
  -webkit-animation: blink 1.06s steps(1) infinite;
  -moz-animation: blink 1.06s steps(1) infinite;
  animation: blink 1.06s steps(1) infinite;
  background-color: #7e7;
}
@-moz-keyframes blink {
  0% {}
  50% { background-color: transparent; }
  100% {}
}
@-webkit-keyframes blink {
  0% {}
  50% { background-color: transparent; }
  100% {}
}
@keyframes blink {
  0% {}
  50% { background-color: transparent; }
  100% {}
}

/* Can style cursor different in overwrite (non-insert) mode */
.CodeMirror-overwrite .CodeMirror-cursor {}

.cm-tab { display: inline-block; text-decoration: inherit; }

.CodeMirror-rulers {
  position: absolute;
  left: 0; right: 0; top: -50px; bottom: 0;
  overflow: hidden;
}
.CodeMirror-ruler {
  border-left: 1px solid #ccc;
  top: 0; bottom: 0;
  position: absolute;
}

/* DEFAULT THEME */

.cm-s-default .cm-header {color: blue;}
.cm-s-default .cm-quote {color: #090;}
.cm-negative {color: #d44;}
.cm-positive {color: #292;}
.cm-header, .cm-strong {font-weight: bold;}
.cm-em {font-style: italic;}
.cm-link {text-decoration: underline;}
.cm-strikethrough {text-decoration: line-through;}

.cm-s-default .cm-keyword {color: #708;}
.cm-s-default .cm-atom {color: #219;}
.cm-s-default .cm-number {color: #164;}
.cm-s-default .cm-def {color: #00f;}
.cm-s-default .cm-variable,
.cm-s-default .cm-punctuation,
.cm-s-default .cm-property,
.cm-s-default .cm-operator {}
.cm-s-default .cm-variable-2 {color: #05a;}
.cm-s-default .cm-variable-3, .cm-s-default .cm-type {color: #085;}
.cm-s-default .cm-comment {color: #a50;}
.cm-s-default .cm-string {color: #a11;}
.cm-s-default .cm-string-2 {color: #f50;}
.cm-s-default .cm-meta {color: #555;}
.cm-s-default .cm-qualifier {color: #555;}
.cm-s-default .cm-builtin {color: #30a;}
.cm-s-default .cm-bracket {color: #997;}
.cm-s-default .cm-tag {color: #170;}
.cm-s-default .cm-attribute {color: #00c;}
.cm-s-default .cm-hr {color: #999;}
.cm-s-default .cm-link {color: #00c;}

.cm-s-default .cm-error {color: #f00;}
.cm-invalidchar {color: #f00;}

.CodeMirror-composing { border-bottom: 2px solid; }

/* Default styles for common addons */

div.CodeMirror span.CodeMirror-matchingbracket {color: #0b0;}
div.CodeMirror span.CodeMirror-nonmatchingbracket {color: #a22;}
.CodeMirror-matchingtag { background: rgba(255, 150, 0, .3); }
.CodeMirror-activeline-background {background: #e8f2ff;}

/* STOP */

/* The rest of this file contains styles related to the mechanics of
   the editor. You probably shouldn't touch them. */

.CodeMirror {
  position: relative;
  overflow: hidden;
  background: white;
}

.CodeMirror-scroll {
  overflow: scroll !important; /* Things will break if this is overridden */
  /* 30px is the magic margin used to hide the element's real scrollbars */
  /* See overflow: hidden in .CodeMirror */
  margin-bottom: -30px; margin-right: -30px;
  padding-bottom: 30px;
  height: 100%;
  outline: none; /* Prevent dragging from highlighting the element */
  position: relative;
}
.CodeMirror-sizer {
  position: relative;
  border-right: 30px solid transparent;
}

/* The fake, visible scrollbars. Used to force redraw during scrolling
   before actual scrolling happens, thus preventing shaking and
   flickering artifacts. */
.CodeMirror-vscrollbar, .CodeMirror-hscrollbar, .CodeMirror-scrollbar-filler, .CodeMirror-gutter-filler {
  position: absolute;
  z-index: 6;
  display: none;
}
.CodeMirror-vscrollbar {
  right: 0; top: 0;
  overflow-x: hidden;
  overflow-y: scroll;
}
.CodeMirror-hscrollbar {
  bottom: 0; left: 0;
  overflow-y: hidden;
  overflow-x: scroll;
}
.CodeMirror-scrollbar-filler {
  right: 0; bottom: 0;
}
.CodeMirror-gutter-filler {
  left: 0; bottom: 0;
}

.CodeMirror-gutters {
  position: absolute; left: 0; top: 0;
  min-height: 100%;
  z-index: 3;
}
.CodeMirror-gutter {
  white-space: normal;
  height: 100%;
  display: inline-block;
  vertical-align: top;
  margin-bottom: -30px;
}
.CodeMirror-gutter-wrapper {
  position: absolute;
  z-index: 4;
  background: none !important;
  border: none !important;
}
.CodeMirror-gutter-background {
  position: absolute;
  top: 0; bottom: 0;
  z-index: 4;
}
.CodeMirror-gutter-elt {
  position: absolute;
  cursor: default;
  z-index: 4;
}
.CodeMirror-gutter-wrapper ::selection { background-color: transparent }
.CodeMirror-gutter-wrapper ::-moz-selection { background-color: transparent }

.CodeMirror-lines {
  cursor: text;
  min-height: 1px; /* prevents collapsing before first draw */
}
.CodeMirror pre.CodeMirror-line,
.CodeMirror pre.CodeMirror-line-like {
  /* Reset some styles that the rest of the page might have set */
  -moz-border-radius: 0; -webkit-border-radius: 0; border-radius: 0;
  border-width: 0;
  background: transparent;
  font-family: inherit;
  font-size: inherit;
  margin: 0;
  white-space: pre;
  word-wrap: normal;
  line-height: inherit;
  color: inherit;
  z-index: 2;
  position: relative;
  overflow: visible;
  -webkit-tap-highlight-color: transparent;
  -webkit-font-variant-ligatures: contextual;
  font-variant-ligatures: contextual;
}
.CodeMirror-wrap pre.CodeMirror-line,
.CodeMirror-wrap pre.CodeMirror-line-like {
  word-wrap: break-word;
  white-space: pre-wrap;
  word-break: normal;
}

.CodeMirror-linebackground {
  position: absolute;
  left: 0; right: 0; top: 0; bottom: 0;
  z-index: 0;
}

.CodeMirror-linewidget {
  position: relative;
  z-index: 2;
  padding: 0.1px; /* Force widget margins to stay inside of the container */
}

.CodeMirror-widget {}

.CodeMirror-rtl pre { direction: rtl; }

.CodeMirror-code {
  outline: none;
}

/* Force content-box sizing for the elements where we expect it */
.CodeMirror-scroll,
.CodeMirror-sizer,
.CodeMirror-gutter,
.CodeMirror-gutters,
.CodeMirror-linenumber {
  -moz-box-sizing: content-box;
  box-sizing: content-box;
}

.CodeMirror-measure {
  position: absolute;
  width: 100%;
  height: 0;
  overflow: hidden;
  visibility: hidden;
}

.CodeMirror-cursor {
  position: absolute;
  pointer-events: none;
}
.CodeMirror-measure pre { position: static; }

div.CodeMirror-cursors {
  visibility: hidden;
  position: relative;
  z-index: 3;
}
div.CodeMirror-dragcursors {
  visibility: visible;
}

.CodeMirror-focused div.CodeMirror-cursors {
  visibility: visible;
}

.CodeMirror-selected { background: #d9d9d9; }
.CodeMirror-focused .CodeMirror-selected { background: #d7d4f0; }
.CodeMirror-crosshair { cursor: crosshair; }
.CodeMirror-line::selection, .CodeMirror-line > span::selection, .CodeMirror-line > span > span::selection { background: #d7d4f0; }
.CodeMirror-line::-moz-selection, .CodeMirror-line > span::-moz-selection, .CodeMirror-line > span > span::-moz-selection { background: #d7d4f0; }

.cm-searching {
  background-color: #ffa;
  background-color: rgba(255, 255, 0, .4);
}

/* Used to force a border model for a node */
.cm-force-border { padding-right: .1px; }

@media print {
  /* Hide the cursor when printing */
  .CodeMirror div.CodeMirror-cursors {
    visibility: hidden;
  }
}

/* See issue #2901 */
.cm-tab-wrap-hack:after { content: ''; }

/* Help users use markselection to safely style text background */
span.CodeMirror-selectedtext { background: none; }

.CodeMirror-dialog {
  position: absolute;
  left: 0; right: 0;
  background: inherit;
  z-index: 15;
  padding: .1em .8em;
  overflow: hidden;
  color: inherit;
}

.CodeMirror-dialog-top {
  border-bottom: 1px solid #eee;
  top: 0;
}

.CodeMirror-dialog-bottom {
  border-top: 1px solid #eee;
  bottom: 0;
}

.CodeMirror-dialog input {
  border: none;
  outline: none;
  background: transparent;
  width: 20em;
  color: inherit;
  font-family: monospace;
}

.CodeMirror-dialog button {
  font-size: 70%;
}

.CodeMirror-foldmarker {
  color: blue;
  text-shadow: #b9f 1px 1px 2px, #b9f -1px -1px 2px, #b9f 1px -1px 2px, #b9f -1px 1px 2px;
  font-family: arial;
  line-height: .3;
  cursor: pointer;
}
.CodeMirror-foldgutter {
  width: .7em;
}
.CodeMirror-foldgutter-open,
.CodeMirror-foldgutter-folded {
  cursor: pointer;
}
.CodeMirror-foldgutter-open:after {
  content: "\25BE";
}
.CodeMirror-foldgutter-folded:after {
  content: "\25B8";
}

/*
  Name:       material
  Author:     Mattia Astorino (http://github.com/equinusocio)
  Website:    https://material-theme.site/
*/

.cm-s-material.CodeMirror {
  background-color: #263238;
  color: #EEFFFF;
}

.cm-s-material .CodeMirror-gutters {
  background: #263238;
  color: #546E7A;
  border: none;
}

.cm-s-material .CodeMirror-guttermarker,
.cm-s-material .CodeMirror-guttermarker-subtle,
.cm-s-material .CodeMirror-linenumber {
  color: #546E7A;
}

.cm-s-material .CodeMirror-cursor {
  border-left: 1px solid #FFCC00;
}

.cm-s-material div.CodeMirror-selected {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material.CodeMirror-focused div.CodeMirror-selected {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material .CodeMirror-line::selection,
.cm-s-material .CodeMirror-line>span::selection,
.cm-s-material .CodeMirror-line>span>span::selection {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material .CodeMirror-line::-moz-selection,
.cm-s-material .CodeMirror-line>span::-moz-selection,
.cm-s-material .CodeMirror-line>span>span::-moz-selection {
  background: rgba(128, 203, 196, 0.2);
}

.cm-s-material .CodeMirror-activeline-background {
  background: rgba(0, 0, 0, 0.5);
}

.cm-s-material .cm-keyword {
  color: #C792EA;
}

.cm-s-material .cm-operator {
  color: #89DDFF;
}

.cm-s-material .cm-variable-2 {
  color: #EEFFFF;
}

.cm-s-material .cm-variable-3,
.cm-s-material .cm-type {
  color: #f07178;
}

.cm-s-material .cm-builtin {
  color: #FFCB6B;
}

.cm-s-material .cm-atom {
  color: #F78C6C;
}

.cm-s-material .cm-number {
  color: #FF5370;
}

.cm-s-material .cm-def {
  color: #82AAFF;
}

.cm-s-material .cm-string {
  color: #C3E88D;
}

.cm-s-material .cm-string-2 {
  color: #f07178;
}

.cm-s-material .cm-comment {
  color: #546E7A;
}

.cm-s-material .cm-variable {
  color: #f07178;
}

.cm-s-material .cm-tag {
  color: #FF5370;
}

.cm-s-material .cm-meta {
  color: #FFCB6B;
}

.cm-s-material .cm-attribute {
  color: #C792EA;
}

.cm-s-material .cm-property {
  color: #C792EA;
}

.cm-s-material .cm-qualifier {
  color: #DECB6B;
}

.cm-s-material .cm-variable-3,
.cm-s-material .cm-type {
  color: #DECB6B;
}


.cm-s-material .cm-error {
  color: rgba(255, 255, 255, 1.0);
  background-color: #FF5370;
}

.cm-s-material .CodeMirror-matchingbracket {
  text-decoration: underline;
  color: white !important;
}
/**
 * "
 *  Using Zenburn color palette from the Emacs Zenburn Theme
 *  https://github.com/bbatsov/zenburn-emacs/blob/master/zenburn-theme.el
 *
 *  Also using parts of https://github.com/xavi/coderay-lighttable-theme
 * "
 * From: https://github.com/wisenomad/zenburn-lighttable-theme/blob/master/zenburn.css
 */

.cm-s-zenburn .CodeMirror-gutters { background: #3f3f3f !important; }
.cm-s-zenburn .CodeMirror-foldgutter-open, .CodeMirror-foldgutter-folded { color: #999; }
.cm-s-zenburn .CodeMirror-cursor { border-left: 1px solid white; }
.cm-s-zenburn { background-color: #3f3f3f; color: #dcdccc; }
.cm-s-zenburn span.cm-builtin { color: #dcdccc; font-weight: bold; }
.cm-s-zenburn span.cm-comment { color: #7f9f7f; }
.cm-s-zenburn span.cm-keyword { color: #f0dfaf; font-weight: bold; }
.cm-s-zenburn span.cm-atom { color: #bfebbf; }
.cm-s-zenburn span.cm-def { color: #dcdccc; }
.cm-s-zenburn span.cm-variable { color: #dfaf8f; }
.cm-s-zenburn span.cm-variable-2 { color: #dcdccc; }
.cm-s-zenburn span.cm-string { color: #cc9393; }
.cm-s-zenburn span.cm-string-2 { color: #cc9393; }
.cm-s-zenburn span.cm-number { color: #dcdccc; }
.cm-s-zenburn span.cm-tag { color: #93e0e3; }
.cm-s-zenburn span.cm-property { color: #dfaf8f; }
.cm-s-zenburn span.cm-attribute { color: #dfaf8f; }
.cm-s-zenburn span.cm-qualifier { color: #7cb8bb; }
.cm-s-zenburn span.cm-meta { color: #f0dfaf; }
.cm-s-zenburn span.cm-header { color: #f0efd0; }
.cm-s-zenburn span.cm-operator { color: #f0efd0; }
.cm-s-zenburn span.CodeMirror-matchingbracket { box-sizing: border-box; background: transparent; border-bottom: 1px solid; }
.cm-s-zenburn span.CodeMirror-nonmatchingbracket { border-bottom: 1px solid; background: none; }
.cm-s-zenburn .CodeMirror-activeline { background: #000000; }
.cm-s-zenburn .CodeMirror-activeline-background { background: #000000; }
.cm-s-zenburn div.CodeMirror-selected { background: #545454; }
.cm-s-zenburn .CodeMirror-focused div.CodeMirror-selected { background: #4f4f4f; }

.cm-s-abcdef.CodeMirror { background: #0f0f0f; color: #defdef; }
.cm-s-abcdef div.CodeMirror-selected { background: #515151; }
.cm-s-abcdef .CodeMirror-line::selection, .cm-s-abcdef .CodeMirror-line > span::selection, .cm-s-abcdef .CodeMirror-line > span > span::selection { background: rgba(56, 56, 56, 0.99); }
.cm-s-abcdef .CodeMirror-line::-moz-selection, .cm-s-abcdef .CodeMirror-line > span::-moz-selection, .cm-s-abcdef .CodeMirror-line > span > span::-moz-selection { background: rgba(56, 56, 56, 0.99); }
.cm-s-abcdef .CodeMirror-gutters { background: #555; border-right: 2px solid #314151; }
.cm-s-abcdef .CodeMirror-guttermarker { color: #222; }
.cm-s-abcdef .CodeMirror-guttermarker-subtle { color: azure; }
.cm-s-abcdef .CodeMirror-linenumber { color: #FFFFFF; }
.cm-s-abcdef .CodeMirror-cursor { border-left: 1px solid #00FF00; }

.cm-s-abcdef span.cm-keyword { color: darkgoldenrod; font-weight: bold; }
.cm-s-abcdef span.cm-atom { color: #77F; }
.cm-s-abcdef span.cm-number { color: violet; }
.cm-s-abcdef span.cm-def { color: #fffabc; }
.cm-s-abcdef span.cm-variable { color: #abcdef; }
.cm-s-abcdef span.cm-variable-2 { color: #cacbcc; }
.cm-s-abcdef span.cm-variable-3, .cm-s-abcdef span.cm-type { color: #def; }
.cm-s-abcdef span.cm-property { color: #fedcba; }
.cm-s-abcdef span.cm-operator { color: #ff0; }
.cm-s-abcdef span.cm-comment { color: #7a7b7c; font-style: italic;}
.cm-s-abcdef span.cm-string { color: #2b4; }
.cm-s-abcdef span.cm-meta { color: #C9F; }
.cm-s-abcdef span.cm-qualifier { color: #FFF700; }
.cm-s-abcdef span.cm-builtin { color: #30aabc; }
.cm-s-abcdef span.cm-bracket { color: #8a8a8a; }
.cm-s-abcdef span.cm-tag { color: #FFDD44; }
.cm-s-abcdef span.cm-attribute { color: #DDFF00; }
.cm-s-abcdef span.cm-error { color: #FF0000; }
.cm-s-abcdef span.cm-header { color: aquamarine; font-weight: bold; }
.cm-s-abcdef span.cm-link { color: blueviolet; }

.cm-s-abcdef .CodeMirror-activeline-background { background: #314151; }

/*

    Name:       Base16 Default Light
    Author:     Chris Kempson (http://chriskempson.com)

    CodeMirror template by Jan T. Sott (https://github.com/idleberg/base16-codemirror)
    Original Base16 color scheme by Chris Kempson (https://github.com/chriskempson/base16)

*/

.cm-s-base16-light.CodeMirror { background: #f5f5f5; color: #202020; }
.cm-s-base16-light div.CodeMirror-selected { background: #e0e0e0; }
.cm-s-base16-light .CodeMirror-line::selection, .cm-s-base16-light .CodeMirror-line > span::selection, .cm-s-base16-light .CodeMirror-line > span > span::selection { background: #e0e0e0; }
.cm-s-base16-light .CodeMirror-line::-moz-selection, .cm-s-base16-light .CodeMirror-line > span::-moz-selection, .cm-s-base16-light .CodeMirror-line > span > span::-moz-selection { background: #e0e0e0; }
.cm-s-base16-light .CodeMirror-gutters { background: #f5f5f5; border-right: 0px; }
.cm-s-base16-light .CodeMirror-guttermarker { color: #ac4142; }
.cm-s-base16-light .CodeMirror-guttermarker-subtle { color: #b0b0b0; }
.cm-s-base16-light .CodeMirror-linenumber { color: #b0b0b0; }
.cm-s-base16-light .CodeMirror-cursor { border-left: 1px solid #505050; }

.cm-s-base16-light span.cm-comment { color: #8f5536; }
.cm-s-base16-light span.cm-atom { color: #aa759f; }
.cm-s-base16-light span.cm-number { color: #aa759f; }

.cm-s-base16-light span.cm-property, .cm-s-base16-light span.cm-attribute { color: #90a959; }
.cm-s-base16-light span.cm-keyword { color: #ac4142; }
.cm-s-base16-light span.cm-string { color: #f4bf75; }

.cm-s-base16-light span.cm-variable { color: #90a959; }
.cm-s-base16-light span.cm-variable-2 { color: #6a9fb5; }
.cm-s-base16-light span.cm-def { color: #d28445; }
.cm-s-base16-light span.cm-bracket { color: #202020; }
.cm-s-base16-light span.cm-tag { color: #ac4142; }
.cm-s-base16-light span.cm-link { color: #aa759f; }
.cm-s-base16-light span.cm-error { background: #ac4142; color: #505050; }

.cm-s-base16-light .CodeMirror-activeline-background { background: #DDDCDC; }
.cm-s-base16-light .CodeMirror-matchingbracket { color: #f5f5f5 !important; background-color: #6A9FB5 !important}

/*

    Name:       Base16 Default Dark
    Author:     Chris Kempson (http://chriskempson.com)

    CodeMirror template by Jan T. Sott (https://github.com/idleberg/base16-codemirror)
    Original Base16 color scheme by Chris Kempson (https://github.com/chriskempson/base16)

*/

.cm-s-base16-dark.CodeMirror { background: #151515; color: #e0e0e0; }
.cm-s-base16-dark div.CodeMirror-selected { background: #303030; }
.cm-s-base16-dark .CodeMirror-line::selection, .cm-s-base16-dark .CodeMirror-line > span::selection, .cm-s-base16-dark .CodeMirror-line > span > span::selection { background: rgba(48, 48, 48, .99); }
.cm-s-base16-dark .CodeMirror-line::-moz-selection, .cm-s-base16-dark .CodeMirror-line > span::-moz-selection, .cm-s-base16-dark .CodeMirror-line > span > span::-moz-selection { background: rgba(48, 48, 48, .99); }
.cm-s-base16-dark .CodeMirror-gutters { background: #151515; border-right: 0px; }
.cm-s-base16-dark .CodeMirror-guttermarker { color: #ac4142; }
.cm-s-base16-dark .CodeMirror-guttermarker-subtle { color: #505050; }
.cm-s-base16-dark .CodeMirror-linenumber { color: #505050; }
.cm-s-base16-dark .CodeMirror-cursor { border-left: 1px solid #b0b0b0; }

.cm-s-base16-dark span.cm-comment { color: #8f5536; }
.cm-s-base16-dark span.cm-atom { color: #aa759f; }
.cm-s-base16-dark span.cm-number { color: #aa759f; }

.cm-s-base16-dark span.cm-property, .cm-s-base16-dark span.cm-attribute { color: #90a959; }
.cm-s-base16-dark span.cm-keyword { color: #ac4142; }
.cm-s-base16-dark span.cm-string { color: #f4bf75; }

.cm-s-base16-dark span.cm-variable { color: #90a959; }
.cm-s-base16-dark span.cm-variable-2 { color: #6a9fb5; }
.cm-s-base16-dark span.cm-def { color: #d28445; }
.cm-s-base16-dark span.cm-bracket { color: #e0e0e0; }
.cm-s-base16-dark span.cm-tag { color: #ac4142; }
.cm-s-base16-dark span.cm-link { color: #aa759f; }
.cm-s-base16-dark span.cm-error { background: #ac4142; color: #b0b0b0; }

.cm-s-base16-dark .CodeMirror-activeline-background { background: #202020; }
.cm-s-base16-dark .CodeMirror-matchingbracket { text-decoration: underline; color: white !important; }

/*

    Name:       dracula
    Author:     Michael Kaminsky (http://github.com/mkaminsky11)

    Original dracula color scheme by Zeno Rocha (https://github.com/zenorocha/dracula-theme)

*/


.cm-s-dracula.CodeMirror, .cm-s-dracula .CodeMirror-gutters {
  background-color: #282a36 !important;
  color: #f8f8f2 !important;
  border: none;
}
.cm-s-dracula .CodeMirror-gutters { color: #282a36; }
.cm-s-dracula .CodeMirror-cursor { border-left: solid thin #f8f8f0; }
.cm-s-dracula .CodeMirror-linenumber { color: #6D8A88; }
.cm-s-dracula .CodeMirror-selected { background: rgba(255, 255, 255, 0.10); }
.cm-s-dracula .CodeMirror-line::selection, .cm-s-dracula .CodeMirror-line > span::selection, .cm-s-dracula .CodeMirror-line > span > span::selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-dracula .CodeMirror-line::-moz-selection, .cm-s-dracula .CodeMirror-line > span::-moz-selection, .cm-s-dracula .CodeMirror-line > span > span::-moz-selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-dracula span.cm-comment { color: #6272a4; }
.cm-s-dracula span.cm-string, .cm-s-dracula span.cm-string-2 { color: #f1fa8c; }
.cm-s-dracula span.cm-number { color: #bd93f9; }
.cm-s-dracula span.cm-variable { color: #50fa7b; }
.cm-s-dracula span.cm-variable-2 { color: white; }
.cm-s-dracula span.cm-def { color: #50fa7b; }
.cm-s-dracula span.cm-operator { color: #ff79c6; }
.cm-s-dracula span.cm-keyword { color: #ff79c6; }
.cm-s-dracula span.cm-atom { color: #bd93f9; }
.cm-s-dracula span.cm-meta { color: #f8f8f2; }
.cm-s-dracula span.cm-tag { color: #ff79c6; }
.cm-s-dracula span.cm-attribute { color: #50fa7b; }
.cm-s-dracula span.cm-qualifier { color: #50fa7b; }
.cm-s-dracula span.cm-property { color: #66d9ef; }
.cm-s-dracula span.cm-builtin { color: #50fa7b; }
.cm-s-dracula span.cm-variable-3, .cm-s-dracula span.cm-type { color: #ffb86c; }

.cm-s-dracula .CodeMirror-activeline-background { background: rgba(255,255,255,0.1); }
.cm-s-dracula .CodeMirror-matchingbracket { text-decoration: underline; color: white !important; }

/*

    Name:       Hopscotch
    Author:     Jan T. Sott

    CodeMirror template by Jan T. Sott (https://github.com/idleberg/base16-codemirror)
    Original Base16 color scheme by Chris Kempson (https://github.com/chriskempson/base16)

*/

.cm-s-hopscotch.CodeMirror {background: #322931; color: #d5d3d5;}
.cm-s-hopscotch div.CodeMirror-selected {background: #433b42 !important;}
.cm-s-hopscotch .CodeMirror-gutters {background: #322931; border-right: 0px;}
.cm-s-hopscotch .CodeMirror-linenumber {color: #797379;}
.cm-s-hopscotch .CodeMirror-cursor {border-left: 1px solid #989498 !important;}

.cm-s-hopscotch span.cm-comment {color: #b33508;}
.cm-s-hopscotch span.cm-atom {color: #c85e7c;}
.cm-s-hopscotch span.cm-number {color: #c85e7c;}

.cm-s-hopscotch span.cm-property, .cm-s-hopscotch span.cm-attribute {color: #8fc13e;}
.cm-s-hopscotch span.cm-keyword {color: #dd464c;}
.cm-s-hopscotch span.cm-string {color: #fdcc59;}

.cm-s-hopscotch span.cm-variable {color: #8fc13e;}
.cm-s-hopscotch span.cm-variable-2 {color: #1290bf;}
.cm-s-hopscotch span.cm-def {color: #fd8b19;}
.cm-s-hopscotch span.cm-error {background: #dd464c; color: #989498;}
.cm-s-hopscotch span.cm-bracket {color: #d5d3d5;}
.cm-s-hopscotch span.cm-tag {color: #dd464c;}
.cm-s-hopscotch span.cm-link {color: #c85e7c;}

.cm-s-hopscotch .CodeMirror-matchingbracket { text-decoration: underline; color: white !important;}
.cm-s-hopscotch .CodeMirror-activeline-background { background: #302020; }

/****************************************************************/
/*   Based on mbonaci's Brackets mbo theme                      */
/*   https://github.com/mbonaci/global/blob/master/Mbo.tmTheme  */
/*   Create your own: http://tmtheme-editor.herokuapp.com       */
/****************************************************************/

.cm-s-mbo.CodeMirror { background: #2c2c2c; color: #ffffec; }
.cm-s-mbo div.CodeMirror-selected { background: #716C62; }
.cm-s-mbo .CodeMirror-line::selection, .cm-s-mbo .CodeMirror-line > span::selection, .cm-s-mbo .CodeMirror-line > span > span::selection { background: rgba(113, 108, 98, .99); }
.cm-s-mbo .CodeMirror-line::-moz-selection, .cm-s-mbo .CodeMirror-line > span::-moz-selection, .cm-s-mbo .CodeMirror-line > span > span::-moz-selection { background: rgba(113, 108, 98, .99); }
.cm-s-mbo .CodeMirror-gutters { background: #4e4e4e; border-right: 0px; }
.cm-s-mbo .CodeMirror-guttermarker { color: white; }
.cm-s-mbo .CodeMirror-guttermarker-subtle { color: grey; }
.cm-s-mbo .CodeMirror-linenumber { color: #dadada; }
.cm-s-mbo .CodeMirror-cursor { border-left: 1px solid #ffffec; }

.cm-s-mbo span.cm-comment { color: #95958a; }
.cm-s-mbo span.cm-atom { color: #00a8c6; }
.cm-s-mbo span.cm-number { color: #00a8c6; }

.cm-s-mbo span.cm-property, .cm-s-mbo span.cm-attribute { color: #9ddfe9; }
.cm-s-mbo span.cm-keyword { color: #ffb928; }
.cm-s-mbo span.cm-string { color: #ffcf6c; }
.cm-s-mbo span.cm-string.cm-property { color: #ffffec; }

.cm-s-mbo span.cm-variable { color: #ffffec; }
.cm-s-mbo span.cm-variable-2 { color: #00a8c6; }
.cm-s-mbo span.cm-def { color: #ffffec; }
.cm-s-mbo span.cm-bracket { color: #fffffc; font-weight: bold; }
.cm-s-mbo span.cm-tag { color: #9ddfe9; }
.cm-s-mbo span.cm-link { color: #f54b07; }
.cm-s-mbo span.cm-error { border-bottom: #636363; color: #ffffec; }
.cm-s-mbo span.cm-qualifier { color: #ffffec; }

.cm-s-mbo .CodeMirror-activeline-background { background: #494b41; }
.cm-s-mbo .CodeMirror-matchingbracket { color: #ffb928 !important; }
.cm-s-mbo .CodeMirror-matchingtag { background: rgba(255, 255, 255, .37); }

/*
  MDN-LIKE Theme - Mozilla
  Ported to CodeMirror by Peter Kroon <plakroon@gmail.com>
  Report bugs/issues here: https://github.com/codemirror/CodeMirror/issues
  GitHub: @peterkroon

  The mdn-like theme is inspired on the displayed code examples at: https://developer.mozilla.org/en-US/docs/Web/CSS/animation

*/
.cm-s-mdn-like.CodeMirror { color: #999; background-color: #fff; }
.cm-s-mdn-like div.CodeMirror-selected { background: #cfc; }
.cm-s-mdn-like .CodeMirror-line::selection, .cm-s-mdn-like .CodeMirror-line > span::selection, .cm-s-mdn-like .CodeMirror-line > span > span::selection { background: #cfc; }
.cm-s-mdn-like .CodeMirror-line::-moz-selection, .cm-s-mdn-like .CodeMirror-line > span::-moz-selection, .cm-s-mdn-like .CodeMirror-line > span > span::-moz-selection { background: #cfc; }

.cm-s-mdn-like .CodeMirror-gutters { background: #f8f8f8; border-left: 6px solid rgba(0,83,159,0.65); color: #333; }
.cm-s-mdn-like .CodeMirror-linenumber { color: #aaa; padding-left: 8px; }
.cm-s-mdn-like .CodeMirror-cursor { border-left: 2px solid #222; }

.cm-s-mdn-like .cm-keyword { color: #6262FF; }
.cm-s-mdn-like .cm-atom { color: #F90; }
.cm-s-mdn-like .cm-number { color:  #ca7841; }
.cm-s-mdn-like .cm-def { color: #8DA6CE; }
.cm-s-mdn-like span.cm-variable-2, .cm-s-mdn-like span.cm-tag { color: #690; }
.cm-s-mdn-like span.cm-variable-3, .cm-s-mdn-like span.cm-def, .cm-s-mdn-like span.cm-type { color: #07a; }

.cm-s-mdn-like .cm-variable { color: #07a; }
.cm-s-mdn-like .cm-property { color: #905; }
.cm-s-mdn-like .cm-qualifier { color: #690; }

.cm-s-mdn-like .cm-operator { color: #cda869; }
.cm-s-mdn-like .cm-comment { color:#777; font-weight:normal; }
.cm-s-mdn-like .cm-string { color:#07a; font-style:italic; }
.cm-s-mdn-like .cm-string-2 { color:#bd6b18; } /*?*/
.cm-s-mdn-like .cm-meta { color: #000; } /*?*/
.cm-s-mdn-like .cm-builtin { color: #9B7536; } /*?*/
.cm-s-mdn-like .cm-tag { color: #997643; }
.cm-s-mdn-like .cm-attribute { color: #d6bb6d; } /*?*/
.cm-s-mdn-like .cm-header { color: #FF6400; }
.cm-s-mdn-like .cm-hr { color: #AEAEAE; }
.cm-s-mdn-like .cm-link { color:#ad9361; font-style:italic; text-decoration:none; }
.cm-s-mdn-like .cm-error { border-bottom: 1px solid red; }

div.cm-s-mdn-like .CodeMirror-activeline-background { background: #efefff; }
div.cm-s-mdn-like span.CodeMirror-matchingbracket { outline:1px solid grey; color: inherit; }

.cm-s-mdn-like.CodeMirror { background-image: url(data:image/png;base64,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); }

/*

    Name:       seti
    Author:     Michael Kaminsky (http://github.com/mkaminsky11)

    Original seti color scheme by Jesse Weed (https://github.com/jesseweed/seti-syntax)

*/


.cm-s-seti.CodeMirror {
  background-color: #151718 !important;
  color: #CFD2D1 !important;
  border: none;
}
.cm-s-seti .CodeMirror-gutters {
  color: #404b53;
  background-color: #0E1112;
  border: none;
}
.cm-s-seti .CodeMirror-cursor { border-left: solid thin #f8f8f0; }
.cm-s-seti .CodeMirror-linenumber { color: #6D8A88; }
.cm-s-seti.CodeMirror-focused div.CodeMirror-selected { background: rgba(255, 255, 255, 0.10); }
.cm-s-seti .CodeMirror-line::selection, .cm-s-seti .CodeMirror-line > span::selection, .cm-s-seti .CodeMirror-line > span > span::selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-seti .CodeMirror-line::-moz-selection, .cm-s-seti .CodeMirror-line > span::-moz-selection, .cm-s-seti .CodeMirror-line > span > span::-moz-selection { background: rgba(255, 255, 255, 0.10); }
.cm-s-seti span.cm-comment { color: #41535b; }
.cm-s-seti span.cm-string, .cm-s-seti span.cm-string-2 { color: #55b5db; }
.cm-s-seti span.cm-number { color: #cd3f45; }
.cm-s-seti span.cm-variable { color: #55b5db; }
.cm-s-seti span.cm-variable-2 { color: #a074c4; }
.cm-s-seti span.cm-def { color: #55b5db; }
.cm-s-seti span.cm-keyword { color: #ff79c6; }
.cm-s-seti span.cm-operator { color: #9fca56; }
.cm-s-seti span.cm-keyword { color: #e6cd69; }
.cm-s-seti span.cm-atom { color: #cd3f45; }
.cm-s-seti span.cm-meta { color: #55b5db; }
.cm-s-seti span.cm-tag { color: #55b5db; }
.cm-s-seti span.cm-attribute { color: #9fca56; }
.cm-s-seti span.cm-qualifier { color: #9fca56; }
.cm-s-seti span.cm-property { color: #a074c4; }
.cm-s-seti span.cm-variable-3, .cm-s-seti span.cm-type { color: #9fca56; }
.cm-s-seti span.cm-builtin { color: #9fca56; }
.cm-s-seti .CodeMirror-activeline-background { background: #101213; }
.cm-s-seti .CodeMirror-matchingbracket { text-decoration: underline; color: white !important; }

/*
Solarized theme for code-mirror
http://ethanschoonover.com/solarized
*/

/*
Solarized color palette
http://ethanschoonover.com/solarized/img/solarized-palette.png
*/

.solarized.base03 { color: #002b36; }
.solarized.base02 { color: #073642; }
.solarized.base01 { color: #586e75; }
.solarized.base00 { color: #657b83; }
.solarized.base0 { color: #839496; }
.solarized.base1 { color: #93a1a1; }
.solarized.base2 { color: #eee8d5; }
.solarized.base3  { color: #fdf6e3; }
.solarized.solar-yellow  { color: #b58900; }
.solarized.solar-orange  { color: #cb4b16; }
.solarized.solar-red { color: #dc322f; }
.solarized.solar-magenta { color: #d33682; }
.solarized.solar-violet  { color: #6c71c4; }
.solarized.solar-blue { color: #268bd2; }
.solarized.solar-cyan { color: #2aa198; }
.solarized.solar-green { color: #859900; }

/* Color scheme for code-mirror */

.cm-s-solarized {
  line-height: 1.45em;
  color-profile: sRGB;
  rendering-intent: auto;
}
.cm-s-solarized.cm-s-dark {
  color: #839496;
  background-color: #002b36;
  text-shadow: #002b36 0 1px;
}
.cm-s-solarized.cm-s-light {
  background-color: #fdf6e3;
  color: #657b83;
  text-shadow: #eee8d5 0 1px;
}

.cm-s-solarized .CodeMirror-widget {
  text-shadow: none;
}

.cm-s-solarized .cm-header { color: #586e75; }
.cm-s-solarized .cm-quote { color: #93a1a1; }

.cm-s-solarized .cm-keyword { color: #cb4b16; }
.cm-s-solarized .cm-atom { color: #d33682; }
.cm-s-solarized .cm-number { color: #d33682; }
.cm-s-solarized .cm-def { color: #2aa198; }

.cm-s-solarized .cm-variable { color: #839496; }
.cm-s-solarized .cm-variable-2 { color: #b58900; }
.cm-s-solarized .cm-variable-3, .cm-s-solarized .cm-type { color: #6c71c4; }

.cm-s-solarized .cm-property { color: #2aa198; }
.cm-s-solarized .cm-operator { color: #6c71c4; }

.cm-s-solarized .cm-comment { color: #586e75; font-style:italic; }

.cm-s-solarized .cm-string { color: #859900; }
.cm-s-solarized .cm-string-2 { color: #b58900; }

.cm-s-solarized .cm-meta { color: #859900; }
.cm-s-solarized .cm-qualifier { color: #b58900; }
.cm-s-solarized .cm-builtin { color: #d33682; }
.cm-s-solarized .cm-bracket { color: #cb4b16; }
.cm-s-solarized .CodeMirror-matchingbracket { color: #859900; }
.cm-s-solarized .CodeMirror-nonmatchingbracket { color: #dc322f; }
.cm-s-solarized .cm-tag { color: #93a1a1; }
.cm-s-solarized .cm-attribute { color: #2aa198; }
.cm-s-solarized .cm-hr {
  color: transparent;
  border-top: 1px solid #586e75;
  display: block;
}
.cm-s-solarized .cm-link { color: #93a1a1; cursor: pointer; }
.cm-s-solarized .cm-special { color: #6c71c4; }
.cm-s-solarized .cm-em {
  color: #999;
  text-decoration: underline;
  text-decoration-style: dotted;
}
.cm-s-solarized .cm-error,
.cm-s-solarized .cm-invalidchar {
  color: #586e75;
  border-bottom: 1px dotted #dc322f;
}

.cm-s-solarized.cm-s-dark div.CodeMirror-selected { background: #073642; }
.cm-s-solarized.cm-s-dark.CodeMirror ::selection { background: rgba(7, 54, 66, 0.99); }
.cm-s-solarized.cm-s-dark .CodeMirror-line::-moz-selection, .cm-s-dark .CodeMirror-line > span::-moz-selection, .cm-s-dark .CodeMirror-line > span > span::-moz-selection { background: rgba(7, 54, 66, 0.99); }

.cm-s-solarized.cm-s-light div.CodeMirror-selected { background: #eee8d5; }
.cm-s-solarized.cm-s-light .CodeMirror-line::selection, .cm-s-light .CodeMirror-line > span::selection, .cm-s-light .CodeMirror-line > span > span::selection { background: #eee8d5; }
.cm-s-solarized.cm-s-light .CodeMirror-line::-moz-selection, .cm-s-ligh .CodeMirror-line > span::-moz-selection, .cm-s-ligh .CodeMirror-line > span > span::-moz-selection { background: #eee8d5; }

/* Editor styling */



/* Little shadow on the view-port of the buffer view */
.cm-s-solarized.CodeMirror {
  -moz-box-shadow: inset 7px 0 12px -6px #000;
  -webkit-box-shadow: inset 7px 0 12px -6px #000;
  box-shadow: inset 7px 0 12px -6px #000;
}

/* Remove gutter border */
.cm-s-solarized .CodeMirror-gutters {
  border-right: 0;
}

/* Gutter colors and line number styling based of color scheme (dark / light) */

/* Dark */
.cm-s-solarized.cm-s-dark .CodeMirror-gutters {
  background-color: #073642;
}

.cm-s-solarized.cm-s-dark .CodeMirror-linenumber {
  color: #586e75;
  text-shadow: #021014 0 -1px;
}

/* Light */
.cm-s-solarized.cm-s-light .CodeMirror-gutters {
  background-color: #eee8d5;
}

.cm-s-solarized.cm-s-light .CodeMirror-linenumber {
  color: #839496;
}

/* Common */
.cm-s-solarized .CodeMirror-linenumber {
  padding: 0 5px;
}
.cm-s-solarized .CodeMirror-guttermarker-subtle { color: #586e75; }
.cm-s-solarized.cm-s-dark .CodeMirror-guttermarker { color: #ddd; }
.cm-s-solarized.cm-s-light .CodeMirror-guttermarker { color: #cb4b16; }

.cm-s-solarized .CodeMirror-gutter .CodeMirror-gutter-text {
  color: #586e75;
}

/* Cursor */
.cm-s-solarized .CodeMirror-cursor { border-left: 1px solid #819090; }

/* Fat cursor */
.cm-s-solarized.cm-s-light.cm-fat-cursor .CodeMirror-cursor { background: #77ee77; }
.cm-s-solarized.cm-s-light .cm-animate-fat-cursor { background-color: #77ee77; }
.cm-s-solarized.cm-s-dark.cm-fat-cursor .CodeMirror-cursor { background: #586e75; }
.cm-s-solarized.cm-s-dark .cm-animate-fat-cursor { background-color: #586e75; }

/* Active line */
.cm-s-solarized.cm-s-dark .CodeMirror-activeline-background {
  background: rgba(255, 255, 255, 0.06);
}
.cm-s-solarized.cm-s-light .CodeMirror-activeline-background {
  background: rgba(0, 0, 0, 0.06);
}

.cm-s-the-matrix.CodeMirror { background: #000000; color: #00FF00; }
.cm-s-the-matrix div.CodeMirror-selected { background: #2D2D2D; }
.cm-s-the-matrix .CodeMirror-line::selection, .cm-s-the-matrix .CodeMirror-line > span::selection, .cm-s-the-matrix .CodeMirror-line > span > span::selection { background: rgba(45, 45, 45, 0.99); }
.cm-s-the-matrix .CodeMirror-line::-moz-selection, .cm-s-the-matrix .CodeMirror-line > span::-moz-selection, .cm-s-the-matrix .CodeMirror-line > span > span::-moz-selection { background: rgba(45, 45, 45, 0.99); }
.cm-s-the-matrix .CodeMirror-gutters { background: #060; border-right: 2px solid #00FF00; }
.cm-s-the-matrix .CodeMirror-guttermarker { color: #0f0; }
.cm-s-the-matrix .CodeMirror-guttermarker-subtle { color: white; }
.cm-s-the-matrix .CodeMirror-linenumber { color: #FFFFFF; }
.cm-s-the-matrix .CodeMirror-cursor { border-left: 1px solid #00FF00; }

.cm-s-the-matrix span.cm-keyword { color: #008803; font-weight: bold; }
.cm-s-the-matrix span.cm-atom { color: #3FF; }
.cm-s-the-matrix span.cm-number { color: #FFB94F; }
.cm-s-the-matrix span.cm-def { color: #99C; }
.cm-s-the-matrix span.cm-variable { color: #F6C; }
.cm-s-the-matrix span.cm-variable-2 { color: #C6F; }
.cm-s-the-matrix span.cm-variable-3, .cm-s-the-matrix span.cm-type { color: #96F; }
.cm-s-the-matrix span.cm-property { color: #62FFA0; }
.cm-s-the-matrix span.cm-operator { color: #999; }
.cm-s-the-matrix span.cm-comment { color: #CCCCCC; }
.cm-s-the-matrix span.cm-string { color: #39C; }
.cm-s-the-matrix span.cm-meta { color: #C9F; }
.cm-s-the-matrix span.cm-qualifier { color: #FFF700; }
.cm-s-the-matrix span.cm-builtin { color: #30a; }
.cm-s-the-matrix span.cm-bracket { color: #cc7; }
.cm-s-the-matrix span.cm-tag { color: #FFBD40; }
.cm-s-the-matrix span.cm-attribute { color: #FFF700; }
.cm-s-the-matrix span.cm-error { color: #FF0000; }

.cm-s-the-matrix .CodeMirror-activeline-background { background: #040; }

/*
Copyright (C) 2011 by MarkLogic Corporation
Author: Mike Brevoort <mike@brevoort.com>

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in
all copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN
THE SOFTWARE.
*/
.cm-s-xq-light span.cm-keyword { line-height: 1em; font-weight: bold; color: #5A5CAD; }
.cm-s-xq-light span.cm-atom { color: #6C8CD5; }
.cm-s-xq-light span.cm-number { color: #164; }
.cm-s-xq-light span.cm-def { text-decoration:underline; }
.cm-s-xq-light span.cm-variable { color: black; }
.cm-s-xq-light span.cm-variable-2 { color:black; }
.cm-s-xq-light span.cm-variable-3, .cm-s-xq-light span.cm-type { color: black; }
.cm-s-xq-light span.cm-property {}
.cm-s-xq-light span.cm-operator {}
.cm-s-xq-light span.cm-comment { color: #0080FF; font-style: italic; }
.cm-s-xq-light span.cm-string { color: red; }
.cm-s-xq-light span.cm-meta { color: yellow; }
.cm-s-xq-light span.cm-qualifier { color: grey; }
.cm-s-xq-light span.cm-builtin { color: #7EA656; }
.cm-s-xq-light span.cm-bracket { color: #cc7; }
.cm-s-xq-light span.cm-tag { color: #3F7F7F; }
.cm-s-xq-light span.cm-attribute { color: #7F007F; }
.cm-s-xq-light span.cm-error { color: #f00; }

.cm-s-xq-light .CodeMirror-activeline-background { background: #e8f2ff; }
.cm-s-xq-light .CodeMirror-matchingbracket { outline:1px solid grey;color:black !important;background:yellow; }

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.CodeMirror {
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  font-family: var(--jp-code-font-family);
  border: 0;
  border-radius: 0;
  height: auto;
  /* Changed to auto to autogrow */
}

.CodeMirror pre {
  padding: 0 var(--jp-code-padding);
}

.jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-dialog {
  background-color: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
}

/* This causes https://github.com/jupyter/jupyterlab/issues/522 */
/* May not cause it not because we changed it! */
.CodeMirror-lines {
  padding: var(--jp-code-padding) 0;
}

.CodeMirror-linenumber {
  padding: 0 8px;
}

.jp-CodeMirrorEditor-static {
  margin: var(--jp-code-padding);
}

.jp-CodeMirrorEditor,
.jp-CodeMirrorEditor-static {
  cursor: text;
}

.jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-cursor {
  border-left: var(--jp-code-cursor-width0) solid var(--jp-editor-cursor-color);
}

/* When zoomed out 67% and 33% on a screen of 1440 width x 900 height */
@media screen and (min-width: 2138px) and (max-width: 4319px) {
  .jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-cursor {
    border-left: var(--jp-code-cursor-width1) solid
      var(--jp-editor-cursor-color);
  }
}

/* When zoomed out less than 33% */
@media screen and (min-width: 4320px) {
  .jp-CodeMirrorEditor[data-type='inline'] .CodeMirror-cursor {
    border-left: var(--jp-code-cursor-width2) solid
      var(--jp-editor-cursor-color);
  }
}

.CodeMirror.jp-mod-readOnly .CodeMirror-cursor {
  display: none;
}

.CodeMirror-gutters {
  border-right: 1px solid var(--jp-border-color2);
  background-color: var(--jp-layout-color0);
}

.jp-CollaboratorCursor {
  border-left: 5px solid transparent;
  border-right: 5px solid transparent;
  border-top: none;
  border-bottom: 3px solid;
  background-clip: content-box;
  margin-left: -5px;
  margin-right: -5px;
}

.CodeMirror-selectedtext.cm-searching {
  background-color: var(--jp-search-selected-match-background-color) !important;
  color: var(--jp-search-selected-match-color) !important;
}

.cm-searching {
  background-color: var(
    --jp-search-unselected-match-background-color
  ) !important;
  color: var(--jp-search-unselected-match-color) !important;
}

.CodeMirror-focused .CodeMirror-selected {
  background-color: var(--jp-editor-selected-focused-background);
}

.CodeMirror-selected {
  background-color: var(--jp-editor-selected-background);
}

.jp-CollaboratorCursor-hover {
  position: absolute;
  z-index: 1;
  transform: translateX(-50%);
  color: white;
  border-radius: 3px;
  padding-left: 4px;
  padding-right: 4px;
  padding-top: 1px;
  padding-bottom: 1px;
  text-align: center;
  font-size: var(--jp-ui-font-size1);
  white-space: nowrap;
}

.jp-CodeMirror-ruler {
  border-left: 1px dashed var(--jp-border-color2);
}

/**
 * Here is our jupyter theme for CodeMirror syntax highlighting
 * This is used in our marked.js syntax highlighting and CodeMirror itself
 * The string "jupyter" is set in ../codemirror/widget.DEFAULT_CODEMIRROR_THEME
 * This came from the classic notebook, which came form highlight.js/GitHub
 */

/**
 * CodeMirror themes are handling the background/color in this way. This works
 * fine for CodeMirror editors outside the notebook, but the notebook styles
 * these things differently.
 */
.CodeMirror.cm-s-jupyter {
  background: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
}

/* In the notebook, we want this styling to be handled by its container */
.jp-CodeConsole .CodeMirror.cm-s-jupyter,
.jp-Notebook .CodeMirror.cm-s-jupyter {
  background: transparent;
}

.cm-s-jupyter .CodeMirror-cursor {
  border-left: var(--jp-code-cursor-width0) solid var(--jp-editor-cursor-color);
}
.cm-s-jupyter span.cm-keyword {
  color: var(--jp-mirror-editor-keyword-color);
  font-weight: bold;
}
.cm-s-jupyter span.cm-atom {
  color: var(--jp-mirror-editor-atom-color);
}
.cm-s-jupyter span.cm-number {
  color: var(--jp-mirror-editor-number-color);
}
.cm-s-jupyter span.cm-def {
  color: var(--jp-mirror-editor-def-color);
}
.cm-s-jupyter span.cm-variable {
  color: var(--jp-mirror-editor-variable-color);
}
.cm-s-jupyter span.cm-variable-2 {
  color: var(--jp-mirror-editor-variable-2-color);
}
.cm-s-jupyter span.cm-variable-3 {
  color: var(--jp-mirror-editor-variable-3-color);
}
.cm-s-jupyter span.cm-punctuation {
  color: var(--jp-mirror-editor-punctuation-color);
}
.cm-s-jupyter span.cm-property {
  color: var(--jp-mirror-editor-property-color);
}
.cm-s-jupyter span.cm-operator {
  color: var(--jp-mirror-editor-operator-color);
  font-weight: bold;
}
.cm-s-jupyter span.cm-comment {
  color: var(--jp-mirror-editor-comment-color);
  font-style: italic;
}
.cm-s-jupyter span.cm-string {
  color: var(--jp-mirror-editor-string-color);
}
.cm-s-jupyter span.cm-string-2 {
  color: var(--jp-mirror-editor-string-2-color);
}
.cm-s-jupyter span.cm-meta {
  color: var(--jp-mirror-editor-meta-color);
}
.cm-s-jupyter span.cm-qualifier {
  color: var(--jp-mirror-editor-qualifier-color);
}
.cm-s-jupyter span.cm-builtin {
  color: var(--jp-mirror-editor-builtin-color);
}
.cm-s-jupyter span.cm-bracket {
  color: var(--jp-mirror-editor-bracket-color);
}
.cm-s-jupyter span.cm-tag {
  color: var(--jp-mirror-editor-tag-color);
}
.cm-s-jupyter span.cm-attribute {
  color: var(--jp-mirror-editor-attribute-color);
}
.cm-s-jupyter span.cm-header {
  color: var(--jp-mirror-editor-header-color);
}
.cm-s-jupyter span.cm-quote {
  color: var(--jp-mirror-editor-quote-color);
}
.cm-s-jupyter span.cm-link {
  color: var(--jp-mirror-editor-link-color);
}
.cm-s-jupyter span.cm-error {
  color: var(--jp-mirror-editor-error-color);
}
.cm-s-jupyter span.cm-hr {
  color: #999;
}

.cm-s-jupyter span.cm-tab {
  background: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADAAAAAMCAYAAAAkuj5RAAAAAXNSR0IArs4c6QAAAGFJREFUSMft1LsRQFAQheHPowAKoACx3IgEKtaEHujDjORSgWTH/ZOdnZOcM/sgk/kFFWY0qV8foQwS4MKBCS3qR6ixBJvElOobYAtivseIE120FaowJPN75GMu8j/LfMwNjh4HUpwg4LUAAAAASUVORK5CYII=);
  background-position: right;
  background-repeat: no-repeat;
}

.cm-s-jupyter .CodeMirror-activeline-background,
.cm-s-jupyter .CodeMirror-gutter {
  background-color: var(--jp-layout-color2);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| RenderedText
|----------------------------------------------------------------------------*/

.jp-RenderedText {
  text-align: left;
  padding-left: var(--jp-code-padding);
  line-height: var(--jp-code-line-height);
  font-family: var(--jp-code-font-family);
}

.jp-RenderedText pre,
.jp-RenderedJavaScript pre,
.jp-RenderedHTMLCommon pre {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-code-font-size);
  border: none;
  margin: 0px;
  padding: 0px;
  line-height: normal;
}

.jp-RenderedText pre a:link {
  text-decoration: none;
  color: var(--jp-content-link-color);
}
.jp-RenderedText pre a:hover {
  text-decoration: underline;
  color: var(--jp-content-link-color);
}
.jp-RenderedText pre a:visited {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

/* console foregrounds and backgrounds */
.jp-RenderedText pre .ansi-black-fg {
  color: #3e424d;
}
.jp-RenderedText pre .ansi-red-fg {
  color: #e75c58;
}
.jp-RenderedText pre .ansi-green-fg {
  color: #00a250;
}
.jp-RenderedText pre .ansi-yellow-fg {
  color: #ddb62b;
}
.jp-RenderedText pre .ansi-blue-fg {
  color: #208ffb;
}
.jp-RenderedText pre .ansi-magenta-fg {
  color: #d160c4;
}
.jp-RenderedText pre .ansi-cyan-fg {
  color: #60c6c8;
}
.jp-RenderedText pre .ansi-white-fg {
  color: #c5c1b4;
}

.jp-RenderedText pre .ansi-black-bg {
  background-color: #3e424d;
}
.jp-RenderedText pre .ansi-red-bg {
  background-color: #e75c58;
}
.jp-RenderedText pre .ansi-green-bg {
  background-color: #00a250;
}
.jp-RenderedText pre .ansi-yellow-bg {
  background-color: #ddb62b;
}
.jp-RenderedText pre .ansi-blue-bg {
  background-color: #208ffb;
}
.jp-RenderedText pre .ansi-magenta-bg {
  background-color: #d160c4;
}
.jp-RenderedText pre .ansi-cyan-bg {
  background-color: #60c6c8;
}
.jp-RenderedText pre .ansi-white-bg {
  background-color: #c5c1b4;
}

.jp-RenderedText pre .ansi-black-intense-fg {
  color: #282c36;
}
.jp-RenderedText pre .ansi-red-intense-fg {
  color: #b22b31;
}
.jp-RenderedText pre .ansi-green-intense-fg {
  color: #007427;
}
.jp-RenderedText pre .ansi-yellow-intense-fg {
  color: #b27d12;
}
.jp-RenderedText pre .ansi-blue-intense-fg {
  color: #0065ca;
}
.jp-RenderedText pre .ansi-magenta-intense-fg {
  color: #a03196;
}
.jp-RenderedText pre .ansi-cyan-intense-fg {
  color: #258f8f;
}
.jp-RenderedText pre .ansi-white-intense-fg {
  color: #a1a6b2;
}

.jp-RenderedText pre .ansi-black-intense-bg {
  background-color: #282c36;
}
.jp-RenderedText pre .ansi-red-intense-bg {
  background-color: #b22b31;
}
.jp-RenderedText pre .ansi-green-intense-bg {
  background-color: #007427;
}
.jp-RenderedText pre .ansi-yellow-intense-bg {
  background-color: #b27d12;
}
.jp-RenderedText pre .ansi-blue-intense-bg {
  background-color: #0065ca;
}
.jp-RenderedText pre .ansi-magenta-intense-bg {
  background-color: #a03196;
}
.jp-RenderedText pre .ansi-cyan-intense-bg {
  background-color: #258f8f;
}
.jp-RenderedText pre .ansi-white-intense-bg {
  background-color: #a1a6b2;
}

.jp-RenderedText pre .ansi-default-inverse-fg {
  color: var(--jp-ui-inverse-font-color0);
}
.jp-RenderedText pre .ansi-default-inverse-bg {
  background-color: var(--jp-inverse-layout-color0);
}

.jp-RenderedText pre .ansi-bold {
  font-weight: bold;
}
.jp-RenderedText pre .ansi-underline {
  text-decoration: underline;
}

.jp-RenderedText[data-mime-type='application/vnd.jupyter.stderr'] {
  background: var(--jp-rendermime-error-background);
  padding-top: var(--jp-code-padding);
}

/*-----------------------------------------------------------------------------
| RenderedLatex
|----------------------------------------------------------------------------*/

.jp-RenderedLatex {
  color: var(--jp-content-font-color1);
  font-size: var(--jp-content-font-size1);
  line-height: var(--jp-content-line-height);
}

/* Left-justify outputs.*/
.jp-OutputArea-output.jp-RenderedLatex {
  padding: var(--jp-code-padding);
  text-align: left;
}

/*-----------------------------------------------------------------------------
| RenderedHTML
|----------------------------------------------------------------------------*/

.jp-RenderedHTMLCommon {
  color: var(--jp-content-font-color1);
  font-family: var(--jp-content-font-family);
  font-size: var(--jp-content-font-size1);
  line-height: var(--jp-content-line-height);
  /* Give a bit more R padding on Markdown text to keep line lengths reasonable */
  padding-right: 20px;
}

.jp-RenderedHTMLCommon em {
  font-style: italic;
}

.jp-RenderedHTMLCommon strong {
  font-weight: bold;
}

.jp-RenderedHTMLCommon u {
  text-decoration: underline;
}

.jp-RenderedHTMLCommon a:link {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

.jp-RenderedHTMLCommon a:hover {
  text-decoration: underline;
  color: var(--jp-content-link-color);
}

.jp-RenderedHTMLCommon a:visited {
  text-decoration: none;
  color: var(--jp-content-link-color);
}

/* Headings */

.jp-RenderedHTMLCommon h1,
.jp-RenderedHTMLCommon h2,
.jp-RenderedHTMLCommon h3,
.jp-RenderedHTMLCommon h4,
.jp-RenderedHTMLCommon h5,
.jp-RenderedHTMLCommon h6 {
  line-height: var(--jp-content-heading-line-height);
  font-weight: var(--jp-content-heading-font-weight);
  font-style: normal;
  margin: var(--jp-content-heading-margin-top) 0
    var(--jp-content-heading-margin-bottom) 0;
}

.jp-RenderedHTMLCommon h1:first-child,
.jp-RenderedHTMLCommon h2:first-child,
.jp-RenderedHTMLCommon h3:first-child,
.jp-RenderedHTMLCommon h4:first-child,
.jp-RenderedHTMLCommon h5:first-child,
.jp-RenderedHTMLCommon h6:first-child {
  margin-top: calc(0.5 * var(--jp-content-heading-margin-top));
}

.jp-RenderedHTMLCommon h1:last-child,
.jp-RenderedHTMLCommon h2:last-child,
.jp-RenderedHTMLCommon h3:last-child,
.jp-RenderedHTMLCommon h4:last-child,
.jp-RenderedHTMLCommon h5:last-child,
.jp-RenderedHTMLCommon h6:last-child {
  margin-bottom: calc(0.5 * var(--jp-content-heading-margin-bottom));
}

.jp-RenderedHTMLCommon h1 {
  font-size: var(--jp-content-font-size5);
}

.jp-RenderedHTMLCommon h2 {
  font-size: var(--jp-content-font-size4);
}

.jp-RenderedHTMLCommon h3 {
  font-size: var(--jp-content-font-size3);
}

.jp-RenderedHTMLCommon h4 {
  font-size: var(--jp-content-font-size2);
}

.jp-RenderedHTMLCommon h5 {
  font-size: var(--jp-content-font-size1);
}

.jp-RenderedHTMLCommon h6 {
  font-size: var(--jp-content-font-size0);
}

/* Lists */

.jp-RenderedHTMLCommon ul:not(.list-inline),
.jp-RenderedHTMLCommon ol:not(.list-inline) {
  padding-left: 2em;
}

.jp-RenderedHTMLCommon ul {
  list-style: disc;
}

.jp-RenderedHTMLCommon ul ul {
  list-style: square;
}

.jp-RenderedHTMLCommon ul ul ul {
  list-style: circle;
}

.jp-RenderedHTMLCommon ol {
  list-style: decimal;
}

.jp-RenderedHTMLCommon ol ol {
  list-style: upper-alpha;
}

.jp-RenderedHTMLCommon ol ol ol {
  list-style: lower-alpha;
}

.jp-RenderedHTMLCommon ol ol ol ol {
  list-style: lower-roman;
}

.jp-RenderedHTMLCommon ol ol ol ol ol {
  list-style: decimal;
}

.jp-RenderedHTMLCommon ol,
.jp-RenderedHTMLCommon ul {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon ul ul,
.jp-RenderedHTMLCommon ul ol,
.jp-RenderedHTMLCommon ol ul,
.jp-RenderedHTMLCommon ol ol {
  margin-bottom: 0em;
}

.jp-RenderedHTMLCommon hr {
  color: var(--jp-border-color2);
  background-color: var(--jp-border-color1);
  margin-top: 1em;
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon > pre {
  margin: 1.5em 2em;
}

.jp-RenderedHTMLCommon pre,
.jp-RenderedHTMLCommon code {
  border: 0;
  background-color: var(--jp-layout-color0);
  color: var(--jp-content-font-color1);
  font-family: var(--jp-code-font-family);
  font-size: inherit;
  line-height: var(--jp-code-line-height);
  padding: 0;
  white-space: pre-wrap;
}

.jp-RenderedHTMLCommon :not(pre) > code {
  background-color: var(--jp-layout-color2);
  padding: 1px 5px;
}

/* Tables */

.jp-RenderedHTMLCommon table {
  border-collapse: collapse;
  border-spacing: 0;
  border: none;
  color: var(--jp-ui-font-color1);
  font-size: 12px;
  table-layout: fixed;
  margin-left: auto;
  margin-right: auto;
}

.jp-RenderedHTMLCommon thead {
  border-bottom: var(--jp-border-width) solid var(--jp-border-color1);
  vertical-align: bottom;
}

.jp-RenderedHTMLCommon td,
.jp-RenderedHTMLCommon th,
.jp-RenderedHTMLCommon tr {
  vertical-align: middle;
  padding: 0.5em 0.5em;
  line-height: normal;
  white-space: normal;
  max-width: none;
  border: none;
}

.jp-RenderedMarkdown.jp-RenderedHTMLCommon td,
.jp-RenderedMarkdown.jp-RenderedHTMLCommon th {
  max-width: none;
}

:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon td,
:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon th,
:not(.jp-RenderedMarkdown).jp-RenderedHTMLCommon tr {
  text-align: right;
}

.jp-RenderedHTMLCommon th {
  font-weight: bold;
}

.jp-RenderedHTMLCommon tbody tr:nth-child(odd) {
  background: var(--jp-layout-color0);
}

.jp-RenderedHTMLCommon tbody tr:nth-child(even) {
  background: var(--jp-rendermime-table-row-background);
}

.jp-RenderedHTMLCommon tbody tr:hover {
  background: var(--jp-rendermime-table-row-hover-background);
}

.jp-RenderedHTMLCommon table {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon p {
  text-align: left;
  margin: 0px;
}

.jp-RenderedHTMLCommon p {
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon img {
  -moz-force-broken-image-icon: 1;
}

/* Restrict to direct children as other images could be nested in other content. */
.jp-RenderedHTMLCommon > img {
  display: block;
  margin-left: 0;
  margin-right: 0;
  margin-bottom: 1em;
}

/* Change color behind transparent images if they need it... */
[data-jp-theme-light='false'] .jp-RenderedImage img.jp-needs-light-background {
  background-color: var(--jp-inverse-layout-color1);
}
[data-jp-theme-light='true'] .jp-RenderedImage img.jp-needs-dark-background {
  background-color: var(--jp-inverse-layout-color1);
}
/* ...or leave it untouched if they don't */
[data-jp-theme-light='false'] .jp-RenderedImage img.jp-needs-dark-background {
}
[data-jp-theme-light='true'] .jp-RenderedImage img.jp-needs-light-background {
}

.jp-RenderedHTMLCommon img,
.jp-RenderedImage img,
.jp-RenderedHTMLCommon svg,
.jp-RenderedSVG svg {
  max-width: 100%;
  height: auto;
}

.jp-RenderedHTMLCommon img.jp-mod-unconfined,
.jp-RenderedImage img.jp-mod-unconfined,
.jp-RenderedHTMLCommon svg.jp-mod-unconfined,
.jp-RenderedSVG svg.jp-mod-unconfined {
  max-width: none;
}

.jp-RenderedHTMLCommon .alert {
  padding: var(--jp-notebook-padding);
  border: var(--jp-border-width) solid transparent;
  border-radius: var(--jp-border-radius);
  margin-bottom: 1em;
}

.jp-RenderedHTMLCommon .alert-info {
  color: var(--jp-info-color0);
  background-color: var(--jp-info-color3);
  border-color: var(--jp-info-color2);
}
.jp-RenderedHTMLCommon .alert-info hr {
  border-color: var(--jp-info-color3);
}
.jp-RenderedHTMLCommon .alert-info > p:last-child,
.jp-RenderedHTMLCommon .alert-info > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-warning {
  color: var(--jp-warn-color0);
  background-color: var(--jp-warn-color3);
  border-color: var(--jp-warn-color2);
}
.jp-RenderedHTMLCommon .alert-warning hr {
  border-color: var(--jp-warn-color3);
}
.jp-RenderedHTMLCommon .alert-warning > p:last-child,
.jp-RenderedHTMLCommon .alert-warning > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-success {
  color: var(--jp-success-color0);
  background-color: var(--jp-success-color3);
  border-color: var(--jp-success-color2);
}
.jp-RenderedHTMLCommon .alert-success hr {
  border-color: var(--jp-success-color3);
}
.jp-RenderedHTMLCommon .alert-success > p:last-child,
.jp-RenderedHTMLCommon .alert-success > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon .alert-danger {
  color: var(--jp-error-color0);
  background-color: var(--jp-error-color3);
  border-color: var(--jp-error-color2);
}
.jp-RenderedHTMLCommon .alert-danger hr {
  border-color: var(--jp-error-color3);
}
.jp-RenderedHTMLCommon .alert-danger > p:last-child,
.jp-RenderedHTMLCommon .alert-danger > ul:last-child {
  margin-bottom: 0;
}

.jp-RenderedHTMLCommon blockquote {
  margin: 1em 2em;
  padding: 0 1em;
  border-left: 5px solid var(--jp-border-color2);
}

a.jp-InternalAnchorLink {
  visibility: hidden;
  margin-left: 8px;
  color: var(--md-blue-800);
}

h1:hover .jp-InternalAnchorLink,
h2:hover .jp-InternalAnchorLink,
h3:hover .jp-InternalAnchorLink,
h4:hover .jp-InternalAnchorLink,
h5:hover .jp-InternalAnchorLink,
h6:hover .jp-InternalAnchorLink {
  visibility: visible;
}

.jp-RenderedHTMLCommon kbd {
  background-color: var(--jp-rendermime-table-row-background);
  border: 1px solid var(--jp-border-color0);
  border-bottom-color: var(--jp-border-color2);
  border-radius: 3px;
  box-shadow: inset 0 -1px 0 rgba(0, 0, 0, 0.25);
  display: inline-block;
  font-size: 0.8em;
  line-height: 1em;
  padding: 0.2em 0.5em;
}

/* Most direct children of .jp-RenderedHTMLCommon have a margin-bottom of 1.0.
 * At the bottom of cells this is a bit too much as there is also spacing
 * between cells. Going all the way to 0 gets too tight between markdown and
 * code cells.
 */
.jp-RenderedHTMLCommon > *:last-child {
  margin-bottom: 0.5em;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-MimeDocument {
  outline: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-filebrowser-button-height: 28px;
  --jp-private-filebrowser-button-width: 48px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-FileBrowser {
  display: flex;
  flex-direction: column;
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  /* This is needed so that all font sizing of children done in ems is
   * relative to this base size */
  font-size: var(--jp-ui-font-size1);
}

.jp-FileBrowser-toolbar.jp-Toolbar {
  border-bottom: none;
  height: auto;
  margin: var(--jp-toolbar-header-margin);
  box-shadow: none;
}

.jp-BreadCrumbs {
  flex: 0 0 auto;
  margin: 4px 12px;
}

.jp-BreadCrumbs-item {
  margin: 0px 2px;
  padding: 0px 2px;
  border-radius: var(--jp-border-radius);
  cursor: pointer;
}

.jp-BreadCrumbs-item:hover {
  background-color: var(--jp-layout-color2);
}

.jp-BreadCrumbs-item:first-child {
  margin-left: 0px;
}

.jp-BreadCrumbs-item.jp-mod-dropTarget {
  background-color: var(--jp-brand-color2);
  opacity: 0.7;
}

/*-----------------------------------------------------------------------------
| Buttons
|----------------------------------------------------------------------------*/

.jp-FileBrowser-toolbar.jp-Toolbar {
  padding: 0px;
}

.jp-FileBrowser-toolbar.jp-Toolbar {
  justify-content: space-evenly;
}

.jp-FileBrowser-toolbar.jp-Toolbar .jp-Toolbar-item {
  flex: 1;
}

.jp-FileBrowser-toolbar.jp-Toolbar .jp-ToolbarButtonComponent {
  width: 100%;
}

/*-----------------------------------------------------------------------------
| DirListing
|----------------------------------------------------------------------------*/

.jp-DirListing {
  flex: 1 1 auto;
  display: flex;
  flex-direction: column;
  outline: 0;
}

.jp-DirListing-header {
  flex: 0 0 auto;
  display: flex;
  flex-direction: row;
  overflow: hidden;
  border-top: var(--jp-border-width) solid var(--jp-border-color2);
  border-bottom: var(--jp-border-width) solid var(--jp-border-color1);
  box-shadow: var(--jp-toolbar-box-shadow);
  z-index: 2;
}

.jp-DirListing-headerItem {
  padding: 4px 12px 2px 12px;
  font-weight: 500;
}

.jp-DirListing-headerItem:hover {
  background: var(--jp-layout-color2);
}

.jp-DirListing-headerItem.jp-id-name {
  flex: 1 0 84px;
}

.jp-DirListing-headerItem.jp-id-modified {
  flex: 0 0 112px;
  border-left: var(--jp-border-width) solid var(--jp-border-color2);
  text-align: right;
}

.jp-DirListing-narrow .jp-id-modified,
.jp-DirListing-narrow .jp-DirListing-itemModified {
  display: none;
}

.jp-DirListing-headerItem.jp-mod-selected {
  font-weight: 600;
}

/* increase specificity to override bundled default */
.jp-DirListing-content {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  list-style-type: none;
  overflow: auto;
  background-color: var(--jp-layout-color1);
}

/* Style the directory listing content when a user drops a file to upload */
.jp-DirListing.jp-mod-native-drop .jp-DirListing-content {
  outline: 5px dashed rgba(128, 128, 128, 0.5);
  outline-offset: -10px;
  cursor: copy;
}

.jp-DirListing-item {
  display: flex;
  flex-direction: row;
  padding: 4px 12px;
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-DirListing-item.jp-mod-selected {
  color: white;
  background: var(--jp-brand-color1);
}

.jp-DirListing-item.jp-mod-dropTarget {
  background: var(--jp-brand-color3);
}

.jp-DirListing-item:hover:not(.jp-mod-selected) {
  background: var(--jp-layout-color2);
}

.jp-DirListing-itemIcon {
  flex: 0 0 20px;
  margin-right: 4px;
}

.jp-DirListing-itemText {
  flex: 1 0 64px;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  user-select: none;
}

.jp-DirListing-itemModified {
  flex: 0 0 125px;
  text-align: right;
}

.jp-DirListing-editor {
  flex: 1 0 64px;
  outline: none;
  border: none;
}

.jp-DirListing-item.jp-mod-running .jp-DirListing-itemIcon:before {
  color: limegreen;
  content: '\25CF';
  font-size: 8px;
  position: absolute;
  left: -8px;
}

.jp-DirListing-item.lm-mod-drag-image,
.jp-DirListing-item.jp-mod-selected.lm-mod-drag-image {
  font-size: var(--jp-ui-font-size1);
  padding-left: 4px;
  margin-left: 4px;
  width: 160px;
  background-color: var(--jp-ui-inverse-font-color2);
  box-shadow: var(--jp-elevation-z2);
  border-radius: 0px;
  color: var(--jp-ui-font-color1);
  transform: translateX(-40%) translateY(-58%);
}

.jp-DirListing-deadSpace {
  flex: 1 1 auto;
  margin: 0;
  padding: 0;
  list-style-type: none;
  overflow: auto;
  background-color: var(--jp-layout-color1);
}

.jp-Document {
  min-width: 120px;
  min-height: 120px;
  outline: none;
}

.jp-FileDialog.jp-mod-conflict input {
  color: red;
}

.jp-FileDialog .jp-new-name-title {
  margin-top: 12px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
}

/*-----------------------------------------------------------------------------
| Main OutputArea
| OutputArea has a list of Outputs
|----------------------------------------------------------------------------*/

.jp-OutputArea {
  overflow-y: auto;
}

.jp-OutputArea-child {
  display: flex;
  flex-direction: row;
}

.jp-OutputPrompt {
  flex: 0 0 var(--jp-cell-prompt-width);
  color: var(--jp-cell-outprompt-font-color);
  font-family: var(--jp-cell-prompt-font-family);
  padding: var(--jp-code-padding);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
  opacity: var(--jp-cell-prompt-opacity);
  /* Right align prompt text, don't wrap to handle large prompt numbers */
  text-align: right;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  /* Disable text selection */
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

.jp-OutputArea-output {
  height: auto;
  overflow: auto;
  user-select: text;
  -moz-user-select: text;
  -webkit-user-select: text;
  -ms-user-select: text;
}

.jp-OutputArea-child .jp-OutputArea-output {
  flex-grow: 1;
  flex-shrink: 1;
}

/**
 * Isolated output.
 */
.jp-OutputArea-output.jp-mod-isolated {
  width: 100%;
  display: block;
}

/*
When drag events occur, `p-mod-override-cursor` is added to the body.
Because iframes steal all cursor events, the following two rules are necessary
to suppress pointer events while resize drags are occurring. There may be a
better solution to this problem.
*/
body.lm-mod-override-cursor .jp-OutputArea-output.jp-mod-isolated {
  position: relative;
}

body.lm-mod-override-cursor .jp-OutputArea-output.jp-mod-isolated:before {
  content: '';
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  background: transparent;
}

/* pre */

.jp-OutputArea-output pre {
  border: none;
  margin: 0px;
  padding: 0px;
  overflow-x: auto;
  overflow-y: auto;
  word-break: break-all;
  word-wrap: break-word;
  white-space: pre-wrap;
}

/* tables */

.jp-OutputArea-output.jp-RenderedHTMLCommon table {
  margin-left: 0;
  margin-right: 0;
}

/* description lists */

.jp-OutputArea-output dl,
.jp-OutputArea-output dt,
.jp-OutputArea-output dd {
  display: block;
}

.jp-OutputArea-output dl {
  width: 100%;
  overflow: hidden;
  padding: 0;
  margin: 0;
}

.jp-OutputArea-output dt {
  font-weight: bold;
  float: left;
  width: 20%;
  padding: 0;
  margin: 0;
}

.jp-OutputArea-output dd {
  float: left;
  width: 80%;
  padding: 0;
  margin: 0;
}

/* Hide the gutter in case of
 *  - nested output areas (e.g. in the case of output widgets)
 *  - mirrored output areas
 */
.jp-OutputArea .jp-OutputArea .jp-OutputArea-prompt {
  display: none;
}

/*-----------------------------------------------------------------------------
| executeResult is added to any Output-result for the display of the object
| returned by a cell
|----------------------------------------------------------------------------*/

.jp-OutputArea-output.jp-OutputArea-executeResult {
  margin-left: 0px;
  flex: 1 1 auto;
}

.jp-OutputArea-executeResult.jp-RenderedText {
  padding-top: var(--jp-code-padding);
}

/*-----------------------------------------------------------------------------
| The Stdin output
|----------------------------------------------------------------------------*/

.jp-OutputArea-stdin {
  line-height: var(--jp-code-line-height);
  padding-top: var(--jp-code-padding);
  display: flex;
}

.jp-Stdin-prompt {
  color: var(--jp-content-font-color0);
  padding-right: var(--jp-code-padding);
  vertical-align: baseline;
  flex: 0 0 auto;
}

.jp-Stdin-input {
  font-family: var(--jp-code-font-family);
  font-size: inherit;
  color: inherit;
  background-color: inherit;
  width: 42%;
  min-width: 200px;
  /* make sure input baseline aligns with prompt */
  vertical-align: baseline;
  /* padding + margin = 0.5em between prompt and cursor */
  padding: 0em 0.25em;
  margin: 0em 0.25em;
  flex: 0 0 70%;
}

.jp-Stdin-input:focus {
  box-shadow: none;
}

/*-----------------------------------------------------------------------------
| Output Area View
|----------------------------------------------------------------------------*/

.jp-LinkedOutputView .jp-OutputArea {
  height: 100%;
  display: block;
}

.jp-LinkedOutputView .jp-OutputArea-output:only-child {
  height: 100%;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

.jp-Collapser {
  flex: 0 0 var(--jp-cell-collapser-width);
  padding: 0px;
  margin: 0px;
  border: none;
  outline: none;
  background: transparent;
  border-radius: var(--jp-border-radius);
  opacity: 1;
}

.jp-Collapser-child {
  display: block;
  width: 100%;
  box-sizing: border-box;
  /* height: 100% doesn't work because the height of its parent is computed from content */
  position: absolute;
  top: 0px;
  bottom: 0px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Header/Footer
|----------------------------------------------------------------------------*/

/* Hidden by zero height by default */
.jp-CellHeader,
.jp-CellFooter {
  height: 0px;
  width: 100%;
  padding: 0px;
  margin: 0px;
  border: none;
  outline: none;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Input
|----------------------------------------------------------------------------*/

/* All input areas */
.jp-InputArea {
  display: flex;
  flex-direction: row;
}

.jp-InputArea-editor {
  flex: 1 1 auto;
}

.jp-InputArea-editor {
  /* This is the non-active, default styling */
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  border-radius: 0px;
  background: var(--jp-cell-editor-background);
}

.jp-InputPrompt {
  flex: 0 0 var(--jp-cell-prompt-width);
  color: var(--jp-cell-inprompt-font-color);
  font-family: var(--jp-cell-prompt-font-family);
  padding: var(--jp-code-padding);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  opacity: var(--jp-cell-prompt-opacity);
  line-height: var(--jp-code-line-height);
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
  opacity: var(--jp-cell-prompt-opacity);
  /* Right align prompt text, don't wrap to handle large prompt numbers */
  text-align: right;
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  /* Disable text selection */
  -webkit-user-select: none;
  -moz-user-select: none;
  -ms-user-select: none;
  user-select: none;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Placeholder
|----------------------------------------------------------------------------*/

.jp-Placeholder {
  display: flex;
  flex-direction: row;
  flex: 1 1 auto;
}

.jp-Placeholder-prompt {
  box-sizing: border-box;
}

.jp-Placeholder-content {
  flex: 1 1 auto;
  border: none;
  background: transparent;
  height: 20px;
  box-sizing: border-box;
}

.jp-Placeholder-content .jp-MoreHorizIcon {
  width: 32px;
  height: 16px;
  border: 1px solid transparent;
  border-radius: var(--jp-border-radius);
}

.jp-Placeholder-content .jp-MoreHorizIcon:hover {
  border: 1px solid var(--jp-border-color1);
  box-shadow: 0px 0px 2px 0px rgba(0, 0, 0, 0.25);
  background-color: var(--jp-layout-color0);
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-cell-scrolling-output-offset: 5px;
}

/*-----------------------------------------------------------------------------
| Cell
|----------------------------------------------------------------------------*/

.jp-Cell {
  padding: var(--jp-cell-padding);
  margin: 0px;
  border: none;
  outline: none;
  background: transparent;
}

/*-----------------------------------------------------------------------------
| Common input/output
|----------------------------------------------------------------------------*/

.jp-Cell-inputWrapper,
.jp-Cell-outputWrapper {
  display: flex;
  flex-direction: row;
  padding: 0px;
  margin: 0px;
  /* Added to reveal the box-shadow on the input and output collapsers. */
  overflow: visible;
}

/* Only input/output areas inside cells */
.jp-Cell-inputArea,
.jp-Cell-outputArea {
  flex: 1 1 auto;
}

/*-----------------------------------------------------------------------------
| Collapser
|----------------------------------------------------------------------------*/

/* Make the output collapser disappear when there is not output, but do so
 * in a manner that leaves it in the layout and preserves its width.
 */
.jp-Cell.jp-mod-noOutputs .jp-Cell-outputCollapser {
  border: none !important;
  background: transparent !important;
}

.jp-Cell:not(.jp-mod-noOutputs) .jp-Cell-outputCollapser {
  min-height: var(--jp-cell-collapser-min-height);
}

/*-----------------------------------------------------------------------------
| Output
|----------------------------------------------------------------------------*/

/* Put a space between input and output when there IS output */
.jp-Cell:not(.jp-mod-noOutputs) .jp-Cell-outputWrapper {
  margin-top: 5px;
}

/* Text output with the Out[] prompt needs a top padding to match the
 * alignment of the Out[] prompt itself.
 */
.jp-OutputArea-executeResult .jp-RenderedText.jp-OutputArea-output {
  padding-top: var(--jp-code-padding);
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-Cell-outputArea {
  overflow-y: auto;
  max-height: 200px;
  box-shadow: inset 0 0 6px 2px rgba(0, 0, 0, 0.3);
  margin-left: var(--jp-private-cell-scrolling-output-offset);
}

.jp-CodeCell.jp-mod-outputsScrolled .jp-OutputArea-prompt {
  flex: 0 0
    calc(
      var(--jp-cell-prompt-width) -
        var(--jp-private-cell-scrolling-output-offset)
    );
}

/*-----------------------------------------------------------------------------
| CodeCell
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| MarkdownCell
|----------------------------------------------------------------------------*/

.jp-MarkdownOutput {
  flex: 1 1 auto;
  margin-top: 0;
  margin-bottom: 0;
  padding-left: var(--jp-code-padding);
}

.jp-MarkdownOutput.jp-RenderedHTMLCommon {
  overflow: auto;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Variables
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------

/*-----------------------------------------------------------------------------
| Styles
|----------------------------------------------------------------------------*/

.jp-NotebookPanel-toolbar {
  padding: 2px;
}

.jp-Toolbar-item.jp-Notebook-toolbarCellType .jp-select-wrapper.jp-mod-focused {
  border: none;
  box-shadow: none;
}

.jp-Notebook-toolbarCellTypeDropdown select {
  height: 24px;
  font-size: var(--jp-ui-font-size1);
  line-height: 14px;
  border-radius: 0;
  display: block;
}

.jp-Notebook-toolbarCellTypeDropdown span {
  top: 5px !important;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Private CSS variables
|----------------------------------------------------------------------------*/

:root {
  --jp-private-notebook-dragImage-width: 304px;
  --jp-private-notebook-dragImage-height: 36px;
  --jp-private-notebook-selected-color: var(--md-blue-400);
  --jp-private-notebook-active-color: var(--md-green-400);
}

/*-----------------------------------------------------------------------------
| Imports
|----------------------------------------------------------------------------*/

/*-----------------------------------------------------------------------------
| Notebook
|----------------------------------------------------------------------------*/

.jp-NotebookPanel {
  display: block;
  height: 100%;
}

.jp-NotebookPanel.jp-Document {
  min-width: 240px;
  min-height: 120px;
}

.jp-Notebook {
  padding: var(--jp-notebook-padding);
  outline: none;
  overflow: auto;
  background: var(--jp-layout-color0);
}

.jp-Notebook.jp-mod-scrollPastEnd::after {
  display: block;
  content: '';
  min-height: var(--jp-notebook-scroll-padding);
}

.jp-Notebook .jp-Cell {
  overflow: visible;
}

.jp-Notebook .jp-Cell .jp-InputPrompt {
  cursor: move;
}

/*-----------------------------------------------------------------------------
| Notebook state related styling
|
| The notebook and cells each have states, here are the possibilities:
|
| - Notebook
|   - Command
|   - Edit
| - Cell
|   - None
|   - Active (only one can be active)
|   - Selected (the cells actions are applied to)
|   - Multiselected (when multiple selected, the cursor)
|   - No outputs
|----------------------------------------------------------------------------*/

/* Command or edit modes */

.jp-Notebook .jp-Cell:not(.jp-mod-active) .jp-InputPrompt {
  opacity: var(--jp-cell-prompt-not-active-opacity);
  color: var(--jp-cell-prompt-not-active-font-color);
}

.jp-Notebook .jp-Cell:not(.jp-mod-active) .jp-OutputPrompt {
  opacity: var(--jp-cell-prompt-not-active-opacity);
  color: var(--jp-cell-prompt-not-active-font-color);
}

/* cell is active */
.jp-Notebook .jp-Cell.jp-mod-active .jp-Collapser {
  background: var(--jp-brand-color1);
}

/* collapser is hovered */
.jp-Notebook .jp-Cell .jp-Collapser:hover {
  box-shadow: var(--jp-elevation-z2);
  background: var(--jp-brand-color1);
  opacity: var(--jp-cell-collapser-not-active-hover-opacity);
}

/* cell is active and collapser is hovered */
.jp-Notebook .jp-Cell.jp-mod-active .jp-Collapser:hover {
  background: var(--jp-brand-color0);
  opacity: 1;
}

/* Command mode */

.jp-Notebook.jp-mod-commandMode .jp-Cell.jp-mod-selected {
  background: var(--jp-notebook-multiselected-color);
}

.jp-Notebook.jp-mod-commandMode
  .jp-Cell.jp-mod-active.jp-mod-selected:not(.jp-mod-multiSelected) {
  background: transparent;
}

/* Edit mode */

.jp-Notebook.jp-mod-editMode .jp-Cell.jp-mod-active .jp-InputArea-editor {
  border: var(--jp-border-width) solid var(--jp-cell-editor-active-border-color);
  box-shadow: var(--jp-input-box-shadow);
  background-color: var(--jp-cell-editor-active-background);
}

/*-----------------------------------------------------------------------------
| Notebook drag and drop
|----------------------------------------------------------------------------*/

.jp-Notebook-cell.jp-mod-dropSource {
  opacity: 0.5;
}

.jp-Notebook-cell.jp-mod-dropTarget,
.jp-Notebook.jp-mod-commandMode
  .jp-Notebook-cell.jp-mod-active.jp-mod-selected.jp-mod-dropTarget {
  border-top-color: var(--jp-private-notebook-selected-color);
  border-top-style: solid;
  border-top-width: 2px;
}

.jp-dragImage {
  display: flex;
  flex-direction: row;
  width: var(--jp-private-notebook-dragImage-width);
  height: var(--jp-private-notebook-dragImage-height);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background);
  overflow: visible;
}

.jp-dragImage-singlePrompt {
  box-shadow: 2px 2px 4px 0px rgba(0, 0, 0, 0.12);
}

.jp-dragImage .jp-dragImage-content {
  flex: 1 1 auto;
  z-index: 2;
  font-size: var(--jp-code-font-size);
  font-family: var(--jp-code-font-family);
  line-height: var(--jp-code-line-height);
  padding: var(--jp-code-padding);
  border: var(--jp-border-width) solid var(--jp-cell-editor-border-color);
  background: var(--jp-cell-editor-background-color);
  color: var(--jp-content-font-color3);
  text-align: left;
  margin: 4px 4px 4px 0px;
}

.jp-dragImage .jp-dragImage-prompt {
  flex: 0 0 auto;
  min-width: 36px;
  color: var(--jp-cell-inprompt-font-color);
  padding: var(--jp-code-padding);
  padding-left: 12px;
  font-family: var(--jp-cell-prompt-font-family);
  letter-spacing: var(--jp-cell-prompt-letter-spacing);
  line-height: 1.9;
  font-size: var(--jp-code-font-size);
  border: var(--jp-border-width) solid transparent;
}

.jp-dragImage-multipleBack {
  z-index: -1;
  position: absolute;
  height: 32px;
  width: 300px;
  top: 8px;
  left: 8px;
  background: var(--jp-layout-color2);
  border: var(--jp-border-width) solid var(--jp-input-border-color);
  box-shadow: 2px 2px 4px 0px rgba(0, 0, 0, 0.12);
}

/*-----------------------------------------------------------------------------
| Cell toolbar
|----------------------------------------------------------------------------*/

.jp-NotebookTools {
  display: block;
  min-width: var(--jp-sidebar-min-width);
  color: var(--jp-ui-font-color1);
  background: var(--jp-layout-color1);
  /* This is needed so that all font sizing of children done in ems is
    * relative to this base size */
  font-size: var(--jp-ui-font-size1);
  overflow: auto;
}

.jp-NotebookTools-tool {
  padding: 0px 12px 0 12px;
}

.jp-ActiveCellTool {
  padding: 12px;
  background-color: var(--jp-layout-color1);
  border-top: none !important;
}

.jp-ActiveCellTool .jp-InputArea-prompt {
  flex: 0 0 auto;
  padding-left: 0px;
}

.jp-ActiveCellTool .jp-InputArea-editor {
  flex: 1 1 auto;
  background: var(--jp-cell-editor-background);
  border-color: var(--jp-cell-editor-border-color);
}

.jp-ActiveCellTool .jp-InputArea-editor .CodeMirror {
  background: transparent;
}

.jp-MetadataEditorTool {
  flex-direction: column;
  padding: 12px 0px 12px 0px;
}

.jp-RankedPanel > :not(:first-child) {
  margin-top: 12px;
}

.jp-KeySelector select.jp-mod-styled {
  font-size: var(--jp-ui-font-size1);
  color: var(--jp-ui-font-color0);
  border: var(--jp-border-width) solid var(--jp-border-color1);
}

.jp-KeySelector label,
.jp-MetadataEditorTool label {
  line-height: 1.4;
}

/*-----------------------------------------------------------------------------
| Presentation Mode (.jp-mod-presentationMode)
|----------------------------------------------------------------------------*/

.jp-mod-presentationMode .jp-Notebook {
  --jp-content-font-size1: var(--jp-content-presentation-font-size1);
  --jp-code-font-size: var(--jp-code-presentation-font-size);
}

.jp-mod-presentationMode .jp-Notebook .jp-Cell .jp-InputPrompt,
.jp-mod-presentationMode .jp-Notebook .jp-Cell .jp-OutputPrompt {
  flex: 0 0 110px;
}

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/* This file was auto-generated by ensurePackage() in @jupyterlab/buildutils */

/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

</style>

    <style type="text/css">
/*-----------------------------------------------------------------------------
| Copyright (c) Jupyter Development Team.
| Distributed under the terms of the Modified BSD License.
|----------------------------------------------------------------------------*/

/*
The following CSS variables define the main, public API for styling JupyterLab.
These variables should be used by all plugins wherever possible. In other
words, plugins should not define custom colors, sizes, etc unless absolutely
necessary. This enables users to change the visual theme of JupyterLab
by changing these variables.

Many variables appear in an ordered sequence (0,1,2,3). These sequences
are designed to work well together, so for example, `--jp-border-color1` should
be used with `--jp-layout-color1`. The numbers have the following meanings:

* 0: super-primary, reserved for special emphasis
* 1: primary, most important under normal situations
* 2: secondary, next most important under normal situations
* 3: tertiary, next most important under normal situations

Throughout JupyterLab, we are mostly following principles from Google's
Material Design when selecting colors. We are not, however, following
all of MD as it is not optimized for dense, information rich UIs.
*/

:root {
  /* Elevation
   *
   * We style box-shadows using Material Design's idea of elevation. These particular numbers are taken from here:
   *
   * https://github.com/material-components/material-components-web
   * https://material-components-web.appspot.com/elevation.html
   */

  --jp-shadow-base-lightness: 0;
  --jp-shadow-umbra-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.2
  );
  --jp-shadow-penumbra-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.14
  );
  --jp-shadow-ambient-color: rgba(
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    var(--jp-shadow-base-lightness),
    0.12
  );
  --jp-elevation-z0: none;
  --jp-elevation-z1: 0px 2px 1px -1px var(--jp-shadow-umbra-color),
    0px 1px 1px 0px var(--jp-shadow-penumbra-color),
    0px 1px 3px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z2: 0px 3px 1px -2px var(--jp-shadow-umbra-color),
    0px 2px 2px 0px var(--jp-shadow-penumbra-color),
    0px 1px 5px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z4: 0px 2px 4px -1px var(--jp-shadow-umbra-color),
    0px 4px 5px 0px var(--jp-shadow-penumbra-color),
    0px 1px 10px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z6: 0px 3px 5px -1px var(--jp-shadow-umbra-color),
    0px 6px 10px 0px var(--jp-shadow-penumbra-color),
    0px 1px 18px 0px var(--jp-shadow-ambient-color);
  --jp-elevation-z8: 0px 5px 5px -3px var(--jp-shadow-umbra-color),
    0px 8px 10px 1px var(--jp-shadow-penumbra-color),
    0px 3px 14px 2px var(--jp-shadow-ambient-color);
  --jp-elevation-z12: 0px 7px 8px -4px var(--jp-shadow-umbra-color),
    0px 12px 17px 2px var(--jp-shadow-penumbra-color),
    0px 5px 22px 4px var(--jp-shadow-ambient-color);
  --jp-elevation-z16: 0px 8px 10px -5px var(--jp-shadow-umbra-color),
    0px 16px 24px 2px var(--jp-shadow-penumbra-color),
    0px 6px 30px 5px var(--jp-shadow-ambient-color);
  --jp-elevation-z20: 0px 10px 13px -6px var(--jp-shadow-umbra-color),
    0px 20px 31px 3px var(--jp-shadow-penumbra-color),
    0px 8px 38px 7px var(--jp-shadow-ambient-color);
  --jp-elevation-z24: 0px 11px 15px -7px var(--jp-shadow-umbra-color),
    0px 24px 38px 3px var(--jp-shadow-penumbra-color),
    0px 9px 46px 8px var(--jp-shadow-ambient-color);

  /* Borders
   *
   * The following variables, specify the visual styling of borders in JupyterLab.
   */

  --jp-border-width: 1px;
  --jp-border-color0: var(--md-grey-400);
  --jp-border-color1: var(--md-grey-400);
  --jp-border-color2: var(--md-grey-300);
  --jp-border-color3: var(--md-grey-200);
  --jp-border-radius: 2px;

  /* UI Fonts
   *
   * The UI font CSS variables are used for the typography all of the JupyterLab
   * user interface elements that are not directly user generated content.
   *
   * The font sizing here is done assuming that the body font size of --jp-ui-font-size1
   * is applied to a parent element. When children elements, such as headings, are sized
   * in em all things will be computed relative to that body size.
   */

  --jp-ui-font-scale-factor: 1.2;
  --jp-ui-font-size0: 0.83333em;
  --jp-ui-font-size1: 13px; /* Base font size */
  --jp-ui-font-size2: 1.2em;
  --jp-ui-font-size3: 1.44em;

  --jp-ui-font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica,
    Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol';

  /*
   * Use these font colors against the corresponding main layout colors.
   * In a light theme, these go from dark to light.
   */

  /* Defaults use Material Design specification */
  --jp-ui-font-color0: rgba(0, 0, 0, 1);
  --jp-ui-font-color1: rgba(0, 0, 0, 0.87);
  --jp-ui-font-color2: rgba(0, 0, 0, 0.54);
  --jp-ui-font-color3: rgba(0, 0, 0, 0.38);

  /*
   * Use these against the brand/accent/warn/error colors.
   * These will typically go from light to darker, in both a dark and light theme.
   */

  --jp-ui-inverse-font-color0: rgba(255, 255, 255, 1);
  --jp-ui-inverse-font-color1: rgba(255, 255, 255, 1);
  --jp-ui-inverse-font-color2: rgba(255, 255, 255, 0.7);
  --jp-ui-inverse-font-color3: rgba(255, 255, 255, 0.5);

  /* Content Fonts
   *
   * Content font variables are used for typography of user generated content.
   *
   * The font sizing here is done assuming that the body font size of --jp-content-font-size1
   * is applied to a parent element. When children elements, such as headings, are sized
   * in em all things will be computed relative to that body size.
   */

  --jp-content-line-height: 1.6;
  --jp-content-font-scale-factor: 1.2;
  --jp-content-font-size0: 0.83333em;
  --jp-content-font-size1: 14px; /* Base font size */
  --jp-content-font-size2: 1.2em;
  --jp-content-font-size3: 1.44em;
  --jp-content-font-size4: 1.728em;
  --jp-content-font-size5: 2.0736em;

  /* This gives a magnification of about 125% in presentation mode over normal. */
  --jp-content-presentation-font-size1: 17px;

  --jp-content-heading-line-height: 1;
  --jp-content-heading-margin-top: 1.2em;
  --jp-content-heading-margin-bottom: 0.8em;
  --jp-content-heading-font-weight: 500;

  /* Defaults use Material Design specification */
  --jp-content-font-color0: rgba(0, 0, 0, 1);
  --jp-content-font-color1: rgba(0, 0, 0, 0.87);
  --jp-content-font-color2: rgba(0, 0, 0, 0.54);
  --jp-content-font-color3: rgba(0, 0, 0, 0.38);

  --jp-content-link-color: var(--md-blue-700);

  --jp-content-font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI',
    Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji',
    'Segoe UI Symbol';

  /*
   * Code Fonts
   *
   * Code font variables are used for typography of code and other monospaces content.
   */

  --jp-code-font-size: 13px;
  --jp-code-line-height: 1.3077; /* 17px for 13px base */
  --jp-code-padding: 5px; /* 5px for 13px base, codemirror highlighting needs integer px value */
  --jp-code-font-family-default: Menlo, Consolas, 'DejaVu Sans Mono', monospace;
  --jp-code-font-family: var(--jp-code-font-family-default);

  /* This gives a magnification of about 125% in presentation mode over normal. */
  --jp-code-presentation-font-size: 16px;

  /* may need to tweak cursor width if you change font size */
  --jp-code-cursor-width0: 1.4px;
  --jp-code-cursor-width1: 2px;
  --jp-code-cursor-width2: 4px;

  /* Layout
   *
   * The following are the main layout colors use in JupyterLab. In a light
   * theme these would go from light to dark.
   */

  --jp-layout-color0: white;
  --jp-layout-color1: white;
  --jp-layout-color2: var(--md-grey-200);
  --jp-layout-color3: var(--md-grey-400);
  --jp-layout-color4: var(--md-grey-600);

  /* Inverse Layout
   *
   * The following are the inverse layout colors use in JupyterLab. In a light
   * theme these would go from dark to light.
   */

  --jp-inverse-layout-color0: #111111;
  --jp-inverse-layout-color1: var(--md-grey-900);
  --jp-inverse-layout-color2: var(--md-grey-800);
  --jp-inverse-layout-color3: var(--md-grey-700);
  --jp-inverse-layout-color4: var(--md-grey-600);

  /* Brand/accent */

  --jp-brand-color0: var(--md-blue-700);
  --jp-brand-color1: var(--md-blue-500);
  --jp-brand-color2: var(--md-blue-300);
  --jp-brand-color3: var(--md-blue-100);
  --jp-brand-color4: var(--md-blue-50);

  --jp-accent-color0: var(--md-green-700);
  --jp-accent-color1: var(--md-green-500);
  --jp-accent-color2: var(--md-green-300);
  --jp-accent-color3: var(--md-green-100);

  /* State colors (warn, error, success, info) */

  --jp-warn-color0: var(--md-orange-700);
  --jp-warn-color1: var(--md-orange-500);
  --jp-warn-color2: var(--md-orange-300);
  --jp-warn-color3: var(--md-orange-100);

  --jp-error-color0: var(--md-red-700);
  --jp-error-color1: var(--md-red-500);
  --jp-error-color2: var(--md-red-300);
  --jp-error-color3: var(--md-red-100);

  --jp-success-color0: var(--md-green-700);
  --jp-success-color1: var(--md-green-500);
  --jp-success-color2: var(--md-green-300);
  --jp-success-color3: var(--md-green-100);

  --jp-info-color0: var(--md-cyan-700);
  --jp-info-color1: var(--md-cyan-500);
  --jp-info-color2: var(--md-cyan-300);
  --jp-info-color3: var(--md-cyan-100);

  /* Cell specific styles */

  --jp-cell-padding: 5px;

  --jp-cell-collapser-width: 8px;
  --jp-cell-collapser-min-height: 20px;
  --jp-cell-collapser-not-active-hover-opacity: 0.6;

  --jp-cell-editor-background: var(--md-grey-100);
  --jp-cell-editor-border-color: var(--md-grey-300);
  --jp-cell-editor-box-shadow: inset 0 0 2px var(--md-blue-300);
  --jp-cell-editor-active-background: var(--jp-layout-color0);
  --jp-cell-editor-active-border-color: var(--jp-brand-color1);

  --jp-cell-prompt-width: 64px;
  --jp-cell-prompt-font-family: 'Source Code Pro', monospace;
  --jp-cell-prompt-letter-spacing: 0px;
  --jp-cell-prompt-opacity: 1;
  --jp-cell-prompt-not-active-opacity: 0.5;
  --jp-cell-prompt-not-active-font-color: var(--md-grey-700);
  /* A custom blend of MD grey and blue 600
   * See https://meyerweb.com/eric/tools/color-blend/#546E7A:1E88E5:5:hex */
  --jp-cell-inprompt-font-color: #307fc1;
  /* A custom blend of MD grey and orange 600
   * https://meyerweb.com/eric/tools/color-blend/#546E7A:F4511E:5:hex */
  --jp-cell-outprompt-font-color: #bf5b3d;

  /* Notebook specific styles */

  --jp-notebook-padding: 10px;
  --jp-notebook-select-background: var(--jp-layout-color1);
  --jp-notebook-multiselected-color: var(--md-blue-50);

  /* The scroll padding is calculated to fill enough space at the bottom of the
  notebook to show one single-line cell (with appropriate padding) at the top
  when the notebook is scrolled all the way to the bottom. We also subtract one
  pixel so that no scrollbar appears if we have just one single-line cell in the
  notebook. This padding is to enable a 'scroll past end' feature in a notebook.
  */
  --jp-notebook-scroll-padding: calc(
    100% - var(--jp-code-font-size) * var(--jp-code-line-height) -
      var(--jp-code-padding) - var(--jp-cell-padding) - 1px
  );

  /* Rendermime styles */

  --jp-rendermime-error-background: #fdd;
  --jp-rendermime-table-row-background: var(--md-grey-100);
  --jp-rendermime-table-row-hover-background: var(--md-light-blue-50);

  /* Dialog specific styles */

  --jp-dialog-background: rgba(0, 0, 0, 0.25);

  /* Console specific styles */

  --jp-console-padding: 10px;

  /* Toolbar specific styles */

  --jp-toolbar-border-color: var(--jp-border-color1);
  --jp-toolbar-micro-height: 8px;
  --jp-toolbar-background: var(--jp-layout-color1);
  --jp-toolbar-box-shadow: 0px 0px 2px 0px rgba(0, 0, 0, 0.24);
  --jp-toolbar-header-margin: 4px 4px 0px 4px;
  --jp-toolbar-active-background: var(--md-grey-300);

  /* Input field styles */

  --jp-input-box-shadow: inset 0 0 2px var(--md-blue-300);
  --jp-input-active-background: var(--jp-layout-color1);
  --jp-input-hover-background: var(--jp-layout-color1);
  --jp-input-background: var(--md-grey-100);
  --jp-input-border-color: var(--jp-border-color1);
  --jp-input-active-border-color: var(--jp-brand-color1);
  --jp-input-active-box-shadow-color: rgba(19, 124, 189, 0.3);

  /* General editor styles */

  --jp-editor-selected-background: #d9d9d9;
  --jp-editor-selected-focused-background: #d7d4f0;
  --jp-editor-cursor-color: var(--jp-ui-font-color0);

  /* Code mirror specific styles */

  --jp-mirror-editor-keyword-color: #008000;
  --jp-mirror-editor-atom-color: #88f;
  --jp-mirror-editor-number-color: #080;
  --jp-mirror-editor-def-color: #00f;
  --jp-mirror-editor-variable-color: var(--md-grey-900);
  --jp-mirror-editor-variable-2-color: #05a;
  --jp-mirror-editor-variable-3-color: #085;
  --jp-mirror-editor-punctuation-color: #05a;
  --jp-mirror-editor-property-color: #05a;
  --jp-mirror-editor-operator-color: #aa22ff;
  --jp-mirror-editor-comment-color: #408080;
  --jp-mirror-editor-string-color: #ba2121;
  --jp-mirror-editor-string-2-color: #708;
  --jp-mirror-editor-meta-color: #aa22ff;
  --jp-mirror-editor-qualifier-color: #555;
  --jp-mirror-editor-builtin-color: #008000;
  --jp-mirror-editor-bracket-color: #997;
  --jp-mirror-editor-tag-color: #170;
  --jp-mirror-editor-attribute-color: #00c;
  --jp-mirror-editor-header-color: blue;
  --jp-mirror-editor-quote-color: #090;
  --jp-mirror-editor-link-color: #00c;
  --jp-mirror-editor-error-color: #f00;
  --jp-mirror-editor-hr-color: #999;

  /* Vega extension styles */

  --jp-vega-background: white;

  /* Sidebar-related styles */

  --jp-sidebar-min-width: 180px;

  /* Search-related styles */

  --jp-search-toggle-off-opacity: 0.5;
  --jp-search-toggle-hover-opacity: 0.8;
  --jp-search-toggle-on-opacity: 1;
  --jp-search-selected-match-background-color: rgb(245, 200, 0);
  --jp-search-selected-match-color: black;
  --jp-search-unselected-match-background-color: var(
    --jp-inverse-layout-color0
  );
  --jp-search-unselected-match-color: var(--jp-ui-inverse-font-color0);

  /* Icon colors that work well with light or dark backgrounds */
  --jp-icon-contrast-color0: var(--md-purple-600);
  --jp-icon-contrast-color1: var(--md-green-600);
  --jp-icon-contrast-color2: var(--md-pink-600);
  --jp-icon-contrast-color3: var(--md-blue-600);
}
</style>

<style type="text/css">
a.anchor-link {
   display: none;
}
.highlight  {
    margin: 0.4em;
}
.jp-Notebook {
    padding: 0;
}
:root {
    --jp-ui-font-size1: 20px;       /* instead of 14px */
    --jp-content-font-size1: 20px;  /* instead of 14px */
    --jp-code-font-size: 19px;      /* instead of 13px */
    --jp-cell-prompt-width: 110px;  /* instead of 64px */
}
@media print {
  body {
    margin: 0;
  }
}
</style>

<style type="text/css">
/* Overrides of notebook CSS for static HTML export */
.reveal {
  font-size: 160%;
}
.reveal pre {
  width: inherit;
  padding: 0.4em;
  margin: 0px;
  font-family: monospace, sans-serif;
  font-size: 80%;
  box-shadow: 0px 0px 0px rgba(0, 0, 0, 0);
}
.reveal pre code {
  padding: 0px;
}
.reveal section img {
  border: 0px solid black;
  box-shadow: 0 0 10px rgba(0, 0, 0, 0);
}
.reveal i {
  font-style: normal;
  font-family: FontAwesome;
  font-size: 2em;
}
.reveal .slides {
  text-align: left;
}
.reveal.fade {
  opacity: 1;
}
.reveal .progress {
  position: static;
}

div.jp-InputArea-editor {
  padding: 0.06em;
}

div.code_cell {
  background-color: transparent;
}

div.output_area pre {
  font-family: monospace, sans-serif;
  font-size: 80%;
}

div.jp-OutputPrompt {
  /* 5px right shift to account for margin in parent container */
  margin: 5px 5px 0 0;
}

/* Reveal navigation controls */

.reveal .controls .navigate-left,
.reveal .controls .navigate-left.enabled {
  border-right-color: #727272;
}
.reveal .controls .navigate-left.enabled:hover,
.reveal .controls .navigate-left.enabled.enabled:hover {
  border-right-color: #dfdfdf;
}
.reveal .controls .navigate-right,
.reveal .controls .navigate-right.enabled {
  border-left-color: #727272;
}
.reveal .controls .navigate-right.enabled:hover,
.reveal .controls .navigate-right.enabled.enabled:hover {
  border-left-color: #dfdfdf;
}
.reveal .controls .navigate-up,
.reveal .controls .navigate-up.enabled {
  border-bottom-color: #727272;
}
.reveal .controls .navigate-up.enabled:hover,
.reveal .controls .navigate-up.enabled.enabled:hover {
  border-bottom-color: #dfdfdf;
}
.reveal .controls .navigate-down,
.reveal .controls .navigate-down.enabled {
  border-top-color: #727272;
}
.reveal .controls .navigate-down.enabled:hover,
.reveal .controls .navigate-down.enabled.enabled:hover {
  border-top-color: #dfdfdf;
}
.reveal .progress span {
  background: #727272;
}

/* Scrollbars */

::-webkit-scrollbar
{
  width: 6px;
  height: 6px;
}
::-webkit-scrollbar *
{
  background:transparent;
}
::-webkit-scrollbar-thumb
{
  background: #727272 !important;
}
</style>

</head>

<body class="jp-Notebook" data-jp-theme-light="true" data-jp-theme-name="JupyterLab Light">

<div class="reveal">
<div class="slides"><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="MAPD-B-Distribute-Processing-Project">MAPD-B Distribute Processing Project<a class="anchor-link" href="#MAPD-B-Distribute-Processing-Project">&#182;</a></h1><h1 id="Analysis-of-Covid-19-papers">Analysis of Covid-19 papers<a class="anchor-link" href="#Analysis-of-Covid-19-papers">&#182;</a></h1><p>This distributed computing project will focus on the analysis of $1000$ papers about COVID-19, SARS-CoV-2 and related corona viruses. The dataset is a sub-sample of $1000$ items taken from the original dataset that is composed of more than $75000$ papers. This dataset is a part of real-world research on COVID-19 named COVID-19 Open Research Dataset Challenge (CORD-19). The research and related challenges are available on the dedicated page on Kaggle: <a href="https://www.kaggle.com/allen-institute-for-ai/CORD-19-research-challenge">https://www.kaggle.com/allen-institute-for-ai/CORD-19-research-challenge</a></p>

</div>
</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="Introduction">Introduction<a class="anchor-link" href="#Introduction">&#182;</a></h1><p>For the purpose of this assignment, we have relied on CloudVeneto.</p>
<p>We have created a cluster using the $3$ machine available on the server. One machine is the <code>dask-scheduler</code>, the other $2$ are the <code>dask-worker</code>.</p>
<p>In order to make the cluster working, the same Dask and Distributed version should be installed in every machine. Also, the Python's packages used should be the same.</p>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>We access the machine via <code>ssh</code>:</p>
<div class="highlight"><pre><span></span>ssh -t -L port:127.0.0.1:port username@gate.cloudveneto.it ssh -L port:127.0.0.1:port root@ip-machine
</pre></div>
<p><code>username</code>, <code>ip-machine</code>, <code>port</code> need to be changed. In our case, we have the following ip-address:</p>
<ul>
<li><code>10.67.22.115</code> first machine</li>
<li><code>10.67.22.202</code> second machine</li>
<li><code>10.67.22.125</code> third machine</li>
</ul>

</div>
</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Internal-connection">Internal connection<a class="anchor-link" href="#Internal-connection">&#182;</a></h2><p>In order to create the cluster the three machine need to communicate and "see" each other without password request.</p>
<p>The three machines see each other out-of-the-box because they are in the same network (we need to open a gate to Cloud Veneto server in order to see them).</p>
<p>The main problem is the <code>ssh</code> connection, because this type of connection always ask for a password and Dask can not automatically satisfy this request. To overcome this we make all the machines "SSH known host", making the login password-less.
For each machine we create a SSH key using the command <code>ssh-keygen</code>, and copy it to all the other machines (include the machine itself) using the following command:</p>
<div class="highlight"><pre><span></span>ssh-copy-id <span class="m">10</span>.67.22.<span class="o">{</span><span class="m">115</span>,202,125<span class="o">}</span>
</pre></div>
<p>So all the machines now can communicate each other without asking the password.</p>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Cluster-creation">Cluster creation<a class="anchor-link" href="#Cluster-creation">&#182;</a></h2><p>We access the first machine using <code>port-7000</code>:</p>
<div class="highlight"><pre><span></span>ssh -t -L <span class="m">7000</span>:127.0.0.1:7000 username@gate.cloudveneto.it ssh -L <span class="m">7000</span>:127.0.0.1:7000 root@10.67.22.115
</pre></div>
<p>Then we use <code>dask-ssh</code> to create the cluster. After the command we have to specify the ip-address of the machines used. The first one is used for the scheduler, the following for the workers. 
The output will show the port of the scheduler and the workers. In this case we have created a cluster with 3 workers.</p>
<div class="highlight"><pre><span></span>dask-ssh <span class="m">10</span>.67.22.115 <span class="m">10</span>.67.22.202 <span class="m">10</span>.67.22.125
</pre></div>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>Next step is to create a ssh tunnel for the dask dashboard, which usually is by default in the <code>port-8787</code>. This will make the dask dashboard visible at <code>localhost:8787</code>:</p>
<div class="highlight"><pre><span></span>ssh -t -L <span class="m">8787</span>:127.0.0.1:8787 username@gate.cloudveneto.it ssh -L <span class="m">8787</span>:127.0.0.1:8787 root@10.67.22.115
</pre></div>
<p>Then we need to connect to the cluster via Jupyter Notebook.</p>
<div class="highlight"><pre><span></span>jupyter notebook --ip <span class="m">127</span>.0.0.1 --port <span class="m">7000</span> --no-browser --allow-root
</pre></div>
<p>Inside Jupyter Notebook, we start the cluster (specifying the scheduler address).</p>
<div class="highlight"><pre><span></span>Client<span class="o">(</span><span class="s2">&quot;tcp://10.67.22.115:8786&quot;</span><span class="o">)</span>
</pre></div>

</div>
</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>All documents are structured in this way:</p>
<div class="highlight"><pre><span></span><span class="o">{</span>
    <span class="s2">&quot;paper_id&quot;</span>: &lt;str&gt;,                      <span class="c1"># 40-character sha1 of the PDF</span>
    <span class="s2">&quot;metadata&quot;</span>: <span class="o">{</span>
        <span class="s2">&quot;title&quot;</span>: &lt;str&gt;,
        <span class="s2">&quot;authors&quot;</span>: <span class="o">[</span>                        <span class="c1"># list of author dicts, in order</span>
            <span class="o">{</span>
                <span class="s2">&quot;first&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;middle&quot;</span>: &lt;list of str&gt;,
                <span class="s2">&quot;last&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;suffix&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;affiliation&quot;</span>: &lt;dict&gt;,
                <span class="s2">&quot;email&quot;</span>: &lt;str&gt;
            <span class="o">}</span>,
            ...
        <span class="o">]</span>,
        <span class="s2">&quot;abstract&quot;</span>: <span class="o">[</span>                       <span class="c1"># list of paragraphs in the abstract</span>
            <span class="o">{</span>
                <span class="s2">&quot;text&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;cite_spans&quot;</span>: <span class="o">[</span>             <span class="c1"># list of character indices of inline citations</span>
                                            <span class="c1"># e.g. citation &quot;[7]&quot; occurs at positions 151-154 in &quot;text&quot;</span>
                                            <span class="c1">#      linked to bibliography entry BIBREF3</span>
                    <span class="o">{</span>
                        <span class="s2">&quot;start&quot;</span>: <span class="m">151</span>,
                        <span class="s2">&quot;end&quot;</span>: <span class="m">154</span>,
                        <span class="s2">&quot;text&quot;</span>: <span class="s2">&quot;[7]&quot;</span>,
                        <span class="s2">&quot;ref_id&quot;</span>: <span class="s2">&quot;BIBREF3&quot;</span>
                    <span class="o">}</span>,
                    ...
                <span class="o">]</span>,
                <span class="s2">&quot;ref_spans&quot;</span>: &lt;list of dicts similar to cite_spans&gt;,     <span class="c1"># e.g. inline reference to &quot;Table 1&quot;</span>
                <span class="s2">&quot;section&quot;</span>: <span class="s2">&quot;Abstract&quot;</span>
            <span class="o">}</span>,
            ...
        <span class="o">]</span>,
        <span class="s2">&quot;body_text&quot;</span>: <span class="o">[</span>                      <span class="c1"># list of paragraphs in full body</span>
                                            <span class="c1"># paragraph dicts look the same as above</span>
            <span class="o">{</span>
                <span class="s2">&quot;text&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;cite_spans&quot;</span>: <span class="o">[]</span>,
                <span class="s2">&quot;ref_spans&quot;</span>: <span class="o">[]</span>,
                <span class="s2">&quot;eq_spans&quot;</span>: <span class="o">[]</span>,
                <span class="s2">&quot;section&quot;</span>: <span class="s2">&quot;Introduction&quot;</span>
            <span class="o">}</span>,
            ...
            <span class="o">{</span>
                ...,
                <span class="s2">&quot;section&quot;</span>: <span class="s2">&quot;Conclusion&quot;</span>
            <span class="o">}</span>
        <span class="o">]</span>,
        <span class="s2">&quot;bib_entries&quot;</span>: <span class="o">{</span>
            <span class="s2">&quot;BIBREF0&quot;</span>: <span class="o">{</span>
                <span class="s2">&quot;ref_id&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;title&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;authors&quot;</span>: &lt;list of dict&gt;       <span class="c1"># same structure as earlier,</span>
                                                <span class="c1"># but without `affiliation` or `email`</span>
                <span class="s2">&quot;year&quot;</span>: &lt;int&gt;,
                <span class="s2">&quot;venue&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;volume&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;issn&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;pages&quot;</span>: &lt;str&gt;,
                <span class="s2">&quot;other_ids&quot;</span>: <span class="o">{</span>
                    <span class="s2">&quot;DOI&quot;</span>: <span class="o">[</span>
                        &lt;str&gt;
                    <span class="o">]</span>
                <span class="o">}</span>
            <span class="o">}</span>,
            <span class="s2">&quot;BIBREF1&quot;</span>: <span class="o">{}</span>,
            ...
            <span class="s2">&quot;BIBREF25&quot;</span>: <span class="o">{}</span>
        <span class="o">}</span>,
        <span class="s2">&quot;ref_entries&quot;</span>:
            <span class="s2">&quot;FIGREF0&quot;</span>: <span class="o">{</span>
                <span class="s2">&quot;text&quot;</span>: &lt;str&gt;,                  <span class="c1"># figure caption text</span>
                <span class="s2">&quot;type&quot;</span>: <span class="s2">&quot;figure&quot;</span>
            <span class="o">}</span>,
            ...
            <span class="s2">&quot;TABREF13&quot;</span>: <span class="o">{</span>
                <span class="s2">&quot;text&quot;</span>: &lt;str&gt;,                  <span class="c1"># table caption text</span>
                <span class="s2">&quot;type&quot;</span>: <span class="s2">&quot;table&quot;</span>
            <span class="o">}</span>
        <span class="o">}</span>,
        <span class="s2">&quot;back_matter&quot;</span>: &lt;list of dict&gt;           <span class="c1"># same structure as body_text</span>
    <span class="o">}</span>
<span class="o">}</span>
</pre></div>
<p>We have to be careful because in some papers there could be missing values.</p>

</div>
</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>Prepare the <code>JSON</code> files.</p>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[&nbsp;]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">directory</span> <span class="o">=</span> <span class="s2">&quot;./kaggle/working/&quot;</span>
<span class="n">file_names</span> <span class="o">=</span> <span class="n">gl</span><span class="o">.</span><span class="n">glob</span><span class="p">(</span><span class="n">directory</span> <span class="o">+</span> <span class="s1">&#39;*.json&#39;</span><span class="p">)</span>
<span class="k">for</span> <span class="n">files</span> <span class="ow">in</span> <span class="n">file_names</span><span class="p">:</span>
    <span class="n">os</span><span class="o">.</span><span class="n">system</span><span class="p">(</span><span class="sa">f</span><span class="s2">&quot;jq -c . </span><span class="si">{</span><span class="n">files</span><span class="si">}</span><span class="s2"> &gt; ./json_singleline/</span><span class="si">{</span><span class="n">files</span><span class="p">[</span><span class="mi">17</span><span class="p">:]</span><span class="si">}</span><span class="s2">&quot;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="2-Word-counter-distributed-algorithm">2 Word counter distributed algorithm<a class="anchor-link" href="#2-Word-counter-distributed-algorithm">&#182;</a></h1><p>We implemented a distributed algorithm to count the occurrences of all the words inside a list of documents.</p>
<p>The algorithm is defined as follow:</p>
<ul>
<li>Map phase : For each document $D_i$, produce the set of intermediate pairs $(w,cp(w))$, one for each word $w  D_i$, where $cp(w)$ is the number of occurrences of $w$ in $D_i$. E.g.: (hello,3)</li>
<li>Reduce phase : For each word $w$, gather all the previous pairs $(w,cp(w))$ and return the final pair $(w,c(w))$ where $c(w)$ is the number of occurrences of $w$ for all the Documents. In other words, $c(w)$ is equal to $^n_{k=1} cp_k(w)$</li>
</ul>

</div>
</div><div class="fragment">
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="2.1-Word-Count">2.1 Word Count<a class="anchor-link" href="#2.1-Word-Count">&#182;</a></h2><p>In this section we define a function which will do 3 things:</p>
<ul>
<li>Concatenate the text of the body (<code>body_text</code>) of a paper in a single string.</li>
<li>Counts the number of occurrences of a word in that document (i.e. the <code>map phase</code>).</li>
<li>Add all the occurence of a single word in all the documents (i.e. the <code>reduce phase</code>). </li>
</ul>

</div>
</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Clean-Phase">Clean Phase<a class="anchor-link" href="#Clean-Phase">&#182;</a></h2>
</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[&nbsp;]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">string</span> <span class="o">=</span> <span class="s1">&#39;&#39;</span>
<span class="k">for</span> <span class="n">txt</span> <span class="ow">in</span> <span class="n">body_text</span><span class="p">:</span>
    <span class="n">string</span> <span class="o">+=</span> <span class="n">txt</span><span class="p">[</span><span class="s2">&quot;text&quot;</span><span class="p">]</span>
        
<span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>
    

<span class="n">remove_symbols</span> <span class="o">=</span><span class="s2">&quot;1 2 3 4 5 6 9 8 7 0 . / * - + ! &#39; ? ^ } @ #  ] { [ ` ) ( = !   $ % &amp; / &lt; &gt; \ | , ; . : - _ &lt; &gt;&quot;</span>
<span class="n">remove_symbols</span> <span class="o">=</span> <span class="n">remove_symbols</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    
<span class="k">for</span> <span class="n">symbol</span> <span class="ow">in</span> <span class="n">remove_symbols</span><span class="p">:</span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">symbol</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>
    
<span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="s1">&#39;&quot;&#39;</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>

<span class="n">remove_words</span> <span class="o">=</span> <span class="n">stopwords</span><span class="o">.</span><span class="n">words</span><span class="p">(</span><span class="s2">&quot;english&quot;</span><span class="p">)</span> <span class="o">+</span> <span class="p">[</span><span class="s2">&quot;et&quot;</span><span class="p">,</span><span class="s2">&quot;al&quot;</span><span class="p">,</span><span class="s2">&quot;may&quot;</span><span class="p">,</span><span class="s2">&quot;figure&quot;</span><span class="p">,</span><span class="s2">&quot;results&quot;</span><span class="p">,</span><span class="s2">&quot;however&quot;</span><span class="p">,</span><span class="s2">&quot;fig&quot;</span><span class="p">]</span>
<span class="n">remove_words</span> <span class="o">+=</span> <span class="s2">&quot;q w e r t y u i o p l k j h g f d s a z x c v b n m&quot;</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
<span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    
<span class="n">string</span> <span class="o">=</span> <span class="p">[</span><span class="n">word</span> <span class="k">for</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">string</span> <span class="k">if</span> <span class="ow">not</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">remove_words</span><span class="p">]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Count-phase">Count phase<a class="anchor-link" href="#Count-phase">&#182;</a></h2>
</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[&nbsp;]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">words</span><span class="p">,</span><span class="n">counts</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">unique</span><span class="p">(</span><span class="n">string</span><span class="p">,</span><span class="n">return_counts</span><span class="o">=</span><span class="kc">True</span><span class="p">)</span>

<span class="k">return</span> <span class="p">[{</span><span class="s2">&quot;word&quot;</span><span class="p">:</span><span class="n">i</span> <span class="p">,</span> <span class="s2">&quot;n_counts&quot;</span><span class="p">:</span> <span class="n">j</span><span class="p">}</span> <span class="k">for</span> <span class="n">i</span><span class="p">,</span><span class="n">j</span> <span class="ow">in</span> <span class="nb">zip</span><span class="p">(</span><span class="n">words</span><span class="p">,</span><span class="n">counts</span><span class="p">)]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="All-together">All together<a class="anchor-link" href="#All-together">&#182;</a></h2>
</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[6]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">counts_of_word</span><span class="p">(</span><span class="n">body_text</span><span class="p">):</span>

    <span class="c1">##  Begin clean phase</span>
    <span class="n">string</span> <span class="o">=</span> <span class="s1">&#39;&#39;</span>
    <span class="k">for</span> <span class="n">txt</span> <span class="ow">in</span> <span class="n">body_text</span><span class="p">:</span>
        <span class="n">string</span> <span class="o">+=</span> <span class="n">txt</span><span class="p">[</span><span class="s2">&quot;text&quot;</span><span class="p">]</span>
        
    <span class="c1"># Now we have the string which contains the full body text of the documents in input, we &quot;lower&quot; it  </span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>
    
    <span class="c1"># We need to clean it up from the stop words and 1,2,3,4,5,6,7,8,9,0,?,^,:,.,-,_,!,&quot;,,$,%,&amp;,/,(,),=,?&lt;,&gt; and ,</span>
    <span class="n">remove_symbols</span> <span class="o">=</span><span class="s2">&quot;1 2 3 4 5 6 9 8 7 0 . / * - + ! &#39; ? ^ } @ #  ] { [ ` ) ( = !   $ % &amp; / &lt; &gt; \ | , ; . : - _ &lt; &gt;&quot;</span>
    <span class="n">remove_symbols</span> <span class="o">=</span> <span class="n">remove_symbols</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    
    <span class="k">for</span> <span class="n">symbol</span> <span class="ow">in</span> <span class="n">remove_symbols</span><span class="p">:</span>
        <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">symbol</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>
    
    <span class="c1"># The last symbol to clean is the &quot;, because we use it to create the string remove_symbols</span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="s1">&#39;&quot;&#39;</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>
    <span class="c1"># We have run the algorithm and we found out that some useless words appear (also the alphabet)</span>
    <span class="c1"># however we remove it now </span>
    <span class="n">remove_words</span> <span class="o">=</span> <span class="n">stopwords</span><span class="o">.</span><span class="n">words</span><span class="p">(</span><span class="s2">&quot;english&quot;</span><span class="p">)</span> <span class="o">+</span> <span class="p">[</span><span class="s2">&quot;et&quot;</span><span class="p">,</span><span class="s2">&quot;al&quot;</span><span class="p">,</span><span class="s2">&quot;may&quot;</span><span class="p">,</span><span class="s2">&quot;figure&quot;</span><span class="p">,</span><span class="s2">&quot;results&quot;</span><span class="p">,</span><span class="s2">&quot;however&quot;</span><span class="p">,</span><span class="s2">&quot;fig&quot;</span><span class="p">]</span>
    <span class="n">remove_words</span> <span class="o">+=</span> <span class="s2">&quot;q w e r t y u i o p l k j h g f d s a z x c v b n m&quot;</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    
    <span class="n">string</span> <span class="o">=</span> <span class="p">[</span><span class="n">word</span> <span class="k">for</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">string</span> <span class="k">if</span> <span class="ow">not</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">remove_words</span><span class="p">]</span>
    
    <span class="c1">## End clean phase</span>
    
    <span class="c1">## Count phase</span>
    <span class="c1"># In this phase we count the single words using the numpy function unique</span>
    
    <span class="n">words</span><span class="p">,</span><span class="n">counts</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">unique</span><span class="p">(</span><span class="n">string</span><span class="p">,</span><span class="n">return_counts</span><span class="o">=</span><span class="kc">True</span><span class="p">)</span>
    <span class="c1">## The Output will be the follow : [(word1,frequencies1)...(wordn,frequenciesn)]</span>
    <span class="k">return</span> <span class="p">[{</span><span class="s2">&quot;word&quot;</span><span class="p">:</span><span class="n">i</span> <span class="p">,</span> <span class="s2">&quot;n_counts&quot;</span><span class="p">:</span> <span class="n">j</span><span class="p">}</span> <span class="k">for</span> <span class="n">i</span><span class="p">,</span><span class="n">j</span> <span class="ow">in</span> <span class="nb">zip</span><span class="p">(</span><span class="n">words</span><span class="p">,</span><span class="n">counts</span><span class="p">)]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Input-the-bag-and-apply-the-map_phase-function">Input the bag and apply the map_phase function<a class="anchor-link" href="#Input-the-bag-and-apply-the-map_phase-function">&#182;</a></h2>
</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[7]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;./json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="mi">20</span><span class="p">)</span>
<span class="n">words_counted_map</span> <span class="o">=</span> <span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;body_text&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">counts_of_word</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>Example for one document.</p>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[8]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">words_counted_map</span><span class="o">.</span><span class="n">take</span><span class="p">(</span><span class="mi">1</span><span class="p">)[</span><span class="mi">0</span><span class="p">][</span><span class="mi">0</span><span class="p">:</span><span class="mi">10</span><span class="p">]</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[8]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>[{&#39;word&#39;: &#39;adapted&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;admitted&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;advocate&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;aerosol&#39;, &#39;n_counts&#39;: 2},
 {&#39;word&#39;: &#39;aerosolization&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;aimed&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;airborne&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;airflow&#39;, &#39;n_counts&#39;: 2},
 {&#39;word&#39;: &#39;already&#39;, &#39;n_counts&#39;: 1},
 {&#39;word&#39;: &#39;alternatives&#39;, &#39;n_counts&#39;: 1}]</pre>
</div>

</div>

</div>

</div>

</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="2.2-Reduce-Phase">2.2 Reduce Phase<a class="anchor-link" href="#2.2-Reduce-Phase">&#182;</a></h2><p>In this phase we took all the pairs $\{(word_i,n\_counts_i)\}_{i=1\dots n}$ and sum up the counts of the same word. We choose to use the <code>foldby</code> method to group the mapped pairs in each partition.</p>
<h3 id="The-foldby-method-in-dask">The <code>foldby</code> method in dask<a class="anchor-link" href="#The-foldby-method-in-dask">&#182;</a></h3><p>The <code>foldby</code> method require five arguments, in order "left to right":</p>
<ul>
<li><code>key</code> function which determine how to group the elements in the bag.</li>
<li><code>binop</code> this operator takes a "running total" and sum it up with a new element and produces a new total.</li>
<li><code>initial</code> initial value of the <code>binop</code>'s total.</li>
<li><code>combine</code> in this case the binary operator takes "two totals" and sum it up together.</li>
<li><code>combine_initial</code> initial value of the <code>combine</code>'s total.</li>
</ul>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[9]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">increment</span><span class="p">(</span><span class="n">tot</span><span class="p">,</span> <span class="n">x</span><span class="p">):</span>
    <span class="k">return</span> <span class="n">tot</span> <span class="o">+</span> <span class="n">x</span><span class="p">[</span><span class="s1">&#39;n_counts&#39;</span><span class="p">]</span>

<span class="n">words_counted_reduce</span> <span class="o">=</span> <span class="n">words_counted_map</span><span class="o">.</span><span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">foldby</span><span class="p">(</span><span class="s1">&#39;word&#39;</span><span class="p">,</span> <span class="n">binop</span><span class="o">=</span><span class="n">increment</span><span class="p">,</span> 
                                      <span class="n">initial</span><span class="o">=</span><span class="mi">0</span><span class="p">,</span> <span class="n">combine</span> <span class="o">=</span> <span class="k">lambda</span> <span class="n">x</span><span class="p">,</span><span class="n">y</span><span class="p">:</span> <span class="n">x</span><span class="o">+</span><span class="n">y</span><span class="p">,</span> 
                                      <span class="n">combine_initial</span><span class="o">=</span><span class="mi">0</span><span class="p">)</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
<span class="n">words_counted_reduce</span><span class="p">[</span><span class="mi">0</span><span class="p">:</span><span class="mi">10</span><span class="p">]</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[9]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>[(&#39;adapted&#39;, 230),
 (&#39;admitted&#39;, 442),
 (&#39;advocate&#39;, 36),
 (&#39;aerosol&#39;, 256),
 (&#39;aerosolization&#39;, 28),
 (&#39;aimed&#39;, 273),
 (&#39;airborne&#39;, 207),
 (&#39;airflow&#39;, 32),
 (&#39;already&#39;, 632),
 (&#39;alternatives&#39;, 73)]</pre>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>To simplify the bar plot procedure we sort the list by the counts values</p>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[10]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">words_counted_reduce</span><span class="o">.</span><span class="n">sort</span><span class="p">(</span><span class="n">key</span> <span class="o">=</span> <span class="k">lambda</span> <span class="n">tup</span><span class="p">:</span> <span class="n">tup</span><span class="p">[</span><span class="mi">1</span><span class="p">],</span> <span class="n">reverse</span><span class="o">=</span><span class="kc">True</span><span class="p">)</span> 
<span class="n">words_counted_reduce</span><span class="p">[</span><span class="mi">0</span><span class="p">:</span><span class="mi">10</span><span class="p">]</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[10]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>[(&#39;patients&#39;, 13337),
 (&#39;covid&#39;, 10094),
 (&#39;study&#39;, 8496),
 (&#39;also&#39;, 8370),
 (&#39;cells&#39;, 7006),
 (&#39;data&#39;, 6849),
 (&#39;used&#39;, 5842),
 (&#39;using&#39;, 5747),
 (&#39;infection&#39;, 5608),
 (&#39;health&#39;, 5171)]</pre>
</div>

</div>

</div>

</div>

</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="2.3-Top-words">2.3 Top words<a class="anchor-link" href="#2.3-Top-words">&#182;</a></h2><p>Let's see the most frequent words in all the papers.</p>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[12]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">top_words</span><span class="p">(</span><span class="n">sorted_list</span><span class="p">,</span> <span class="n">n</span><span class="p">,</span> <span class="n">title</span><span class="p">):</span>
    
    <span class="n">bars</span> <span class="o">=</span> <span class="p">[</span><span class="n">sorted_list</span><span class="p">[</span><span class="n">i</span><span class="p">][</span><span class="mi">0</span><span class="p">]</span> <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">n</span><span class="p">)]</span>
    <span class="n">values</span> <span class="o">=</span> <span class="p">[</span><span class="n">sorted_list</span><span class="p">[</span><span class="n">i</span><span class="p">][</span><span class="mi">1</span><span class="p">]</span> <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">n</span><span class="p">)]</span>
    
    <span class="n">y</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">arange</span><span class="p">(</span><span class="n">n</span><span class="p">)</span>
    
    <span class="n">fig</span><span class="p">,</span> <span class="n">ax</span> <span class="o">=</span> <span class="n">plt</span><span class="o">.</span><span class="n">subplots</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">20</span><span class="p">,</span> <span class="nb">int</span><span class="p">(</span><span class="n">n</span><span class="o">*</span><span class="mf">0.5</span><span class="p">)))</span>
    
    <span class="n">ax</span><span class="o">.</span><span class="n">grid</span><span class="p">(</span><span class="kc">True</span><span class="p">,</span> <span class="n">color</span> <span class="o">=</span> <span class="s2">&quot;#C688EB&quot;</span><span class="p">)</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">barh</span><span class="p">(</span><span class="n">bars</span><span class="p">,</span> <span class="n">values</span><span class="p">,</span> <span class="n">color</span> <span class="o">=</span> <span class="s2">&quot;#6C7EE1&quot;</span><span class="p">)</span> 
    <span class="n">ax</span><span class="o">.</span><span class="n">set_axisbelow</span><span class="p">(</span><span class="kc">True</span><span class="p">)</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">xaxis</span><span class="o">.</span><span class="n">set_minor_locator</span><span class="p">(</span><span class="n">MultipleLocator</span><span class="p">(</span><span class="mi">1000</span><span class="p">))</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">grid</span><span class="p">(</span><span class="kc">True</span><span class="p">,</span> <span class="s2">&quot;minor&quot;</span><span class="p">,</span> <span class="n">linestyle</span><span class="o">=</span><span class="s2">&quot;--&quot;</span><span class="p">,</span> <span class="n">color</span> <span class="o">=</span> <span class="s2">&quot;#C688EB&quot;</span><span class="p">)</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">set_title</span><span class="p">(</span><span class="n">title</span><span class="p">,</span> <span class="n">fontdict</span> <span class="o">=</span> <span class="p">{</span><span class="s1">&#39;fontsize&#39;</span> <span class="p">:</span> <span class="mi">20</span><span class="p">})</span>

<span class="n">n</span> <span class="o">=</span> <span class="mi">15</span>
<span class="n">top_words</span><span class="p">(</span><span class="n">words_counted_reduce</span><span class="p">,</span> <span class="n">n</span><span class="p">,</span> <span class="sa">f</span><span class="s2">&quot;top </span><span class="si">{</span><span class="n">n</span><span class="si">}</span><span class="s2"> words&quot;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="2.3-Grid-seach-on-number-of-workers-and-number-of-partitions">2.3 Grid-seach on number of workers and number of partitions<a class="anchor-link" href="#2.3-Grid-seach-on-number-of-workers-and-number-of-partitions">&#182;</a></h2><p>We have run the algorithm several times by changing the number of workers and the number of partitions in order to visualize the execution time.</p>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[22]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">grid_search_counts</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">):</span>

    <span class="n">start</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;./json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">)</span>
    <span class="n">words_counted_map</span> <span class="o">=</span> <span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;body_text&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">counts_of_word</span><span class="p">)</span>
    
    <span class="n">words_counted_reduce</span> <span class="o">=</span> <span class="n">words_counted_map</span><span class="o">.</span><span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">foldby</span><span class="p">(</span><span class="s1">&#39;word&#39;</span><span class="p">,</span> <span class="n">binop</span><span class="o">=</span><span class="n">increment</span><span class="p">,</span> 
                                      <span class="n">initial</span><span class="o">=</span><span class="mi">0</span><span class="p">,</span> <span class="n">combine</span> <span class="o">=</span> <span class="k">lambda</span> <span class="n">x</span><span class="p">,</span><span class="n">y</span><span class="p">:</span> <span class="n">x</span><span class="o">+</span><span class="n">y</span><span class="p">,</span> 
                                      <span class="n">combine_initial</span><span class="o">=</span><span class="mi">0</span><span class="p">)</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
    <span class="n">end</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">diff</span> <span class="o">=</span> <span class="n">end</span> <span class="o">-</span> <span class="n">start</span>
    
    <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;For </span><span class="si">{}</span><span class="s2"> partitions, computational time: </span><span class="si">{}</span><span class="s2">&quot;</span><span class="o">.</span><span class="n">format</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">,</span> <span class="n">diff</span><span class="p">))</span>
    <span class="k">del</span> <span class="n">words_counted_map</span>
    <span class="k">del</span> <span class="n">words_counted_reduce</span>
    <span class="k">del</span> <span class="n">input_bag</span>
    <span class="k">return</span> <span class="n">diff</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></div></section></section><section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[&nbsp;]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_matrix_counts</span> <span class="o">=</span> <span class="p">[]</span>
<span class="n">n_partitions</span> <span class="o">=</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span> <span class="mi">10</span><span class="p">,</span> <span class="mi">20</span><span class="p">,</span> <span class="mi">50</span><span class="p">,</span> <span class="mi">100</span><span class="p">,</span> <span class="mi">500</span><span class="p">]</span>

<span class="n">time_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">part</span> <span class="ow">in</span> <span class="n">n_partitions</span><span class="p">:</span>
    <span class="n">time_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">grid_search_counts</span><span class="p">(</span> <span class="n">part</span><span class="p">))</span>
<span class="n">time_matrix_counts</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">time_list</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[3]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df_cm</span> <span class="o">=</span> <span class="n">pd</span><span class="o">.</span><span class="n">DataFrame</span><span class="p">(</span><span class="n">time_matrix_counts</span><span class="p">,</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span><span class="mi">2</span><span class="p">,</span><span class="mi">3</span><span class="p">,</span><span class="mi">4</span><span class="p">,</span><span class="mi">5</span><span class="p">,</span><span class="mi">6</span><span class="p">])</span>
<span class="n">plt</span><span class="o">.</span><span class="n">figure</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">16</span><span class="p">,</span><span class="mi">10</span><span class="p">))</span>
<span class="n">sn</span><span class="o">.</span><span class="n">set</span><span class="p">(</span><span class="n">font_scale</span><span class="o">=</span><span class="mf">1.7</span><span class="p">)</span> 
<span class="n">sn</span><span class="o">.</span><span class="n">heatmap</span><span class="p">(</span><span class="n">df_cm</span><span class="p">,</span> <span class="n">annot</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span> <span class="n">annot_kws</span><span class="o">=</span><span class="p">{</span><span class="s2">&quot;size&quot;</span><span class="p">:</span> <span class="mi">16</span><span class="p">},</span><span class="n">fmt</span><span class="o">=</span><span class="s2">&quot;.3f&quot;</span><span class="p">,</span>
               <span class="n">cbar_kws</span><span class="o">=</span><span class="p">{</span><span class="s1">&#39;label&#39;</span><span class="p">:</span><span class="s1">&#39;Execution time [s]&#39;</span><span class="p">},</span><span class="n">cmap</span><span class="o">=</span><span class="n">sn</span><span class="o">.</span><span class="n">color_palette</span><span class="p">(</span><span class="s2">&quot;inferno_r&quot;</span><span class="p">,</span><span class="mi">40</span><span class="p">))</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">&#39;workers&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">&#39;partitions&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">&quot;Computational time words counts algorithm search&quot;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">20</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
<span class="n">plt</span><span class="o">.</span><span class="n">style</span><span class="o">.</span><span class="n">use</span><span class="p">(</span><span class="s1">&#39;default&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAA5oAAAJyCAYAAACllb/QAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADl0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uIDIuMi4zLCBodHRwOi8vbWF0cGxvdGxpYi5vcmcvIxREBQAAIABJREFUeJzs3Xd4FNUexvFvCiQk1NA7CHhQQJoFFJAiVRGk2UVUrihWBLuCBVFRr4r9omJBxYqCoqJIVekWBA69dwglJIS0+8eZhM1mU1mIwPt5Hp4lM2fOnJ2dnZ3fnBaSlpaGiIiIiIiISLCEFnYBRERERERE5OSiQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQkqBZoiIiIiIiISVAo0RUREREREJKgUaIqcoowx44wxacaYWoVdltwYY6YbY4I2F5P3vqcHKz/JzBizzhizrrDLIXnzb/68CvJdPZGubScLY8z13jG/vrDLIiL/HuGFXQA5NRlj6gODgXZAdaAYsAtYDHwJjLfWHiq8Eh5/3s3UhdbakCDlNwIYDrSz1k4PRp4nivSbZmttrUItiIgfnZtH71S+tomInEgUaMpxZ4x5FHeTEAr8DrwHxAEVgbbAWOAW4OxCKuKp4gHgaWBzYRekEJwBxBd2IUQkV/quioicoBRoynFljHkQeAzYCPS11s4NkOYS4J7jXbZTjbV2K7C1sMtRGKy1ywu7DCKSO31XRUROXAo05bjx+suMAJKAbtbaJYHSWWsnG2OmBti+H3Ab0BgoCqwCPgJesNYm+qVd5/23IfAE0AcoB1hghLV2ojEmHLgXGIBrvrsZ+K+19hW/vNoCv+AC5B+8/M7B1cj+CjxkrV3gt804oD9Q21q7zm9dRn7W2hHecVnrs963L+IMa21bb3k74EqgFVANKAKsBj4DnvFtauy9/5ren78YYzIyTG+am0sZC3Ksz/SO0eW42umNwP+AZ621aX7bXA90B5oClXHnxN/A69baDykgn2Ob/rfvft+z1l7vszzj2HrLRuA1x/PKNBRXm7IX+AR4wFqbaIxpDzwKNANSgMnAXdba3QHKUw24H+gGVMXV3M8BnrDWzs/D+ykO7AHmW2sv8FleDIgFIoDrrLUf+Ky7FXgVuNFa+47P8nrAI0AHoDyuqfpPXllW+u3X91hUAe4EGgC70pt8GmNCcM3fbwHqALuBr4CHsnkvRYFBwPVAba/sO4A/gTHW2p9yOx5ePlHA7UBfwAAhuHNtKjDSWrvdJ21l4GHgYu997ANmeekWZvee/Ztj+nxHM84hb/k4vO8Q0Bn3nann7edrYJi1dp+Xti15Ozdb465LTXGfUyywDphirX0sD8enKPAf3DnXAKgEHAQWAc9ba6fklodPXqVw3+n06+c64C1gIu7ak+l4eNvk55hfD7yLuwZvw31XmgIlfa5Tmb6rebm2+e3jZnL4XHzSrfP+e9S/GTkxxpyFa03SEned2Y87f2d65UrySRuO+yyvw11fw73yvA28Zq1N9cv7evJxXU3vroH7Lt4PXA3UAj72O88v98rRFIjCfVa/4c6nTL99Xvp2uO9ScyAN9/kPtdYuy+NhEpGThAJNOZ4G4IKjT7ILMtMFCGaewv0478IFPHFAV+ApoLMxpqPvD7SnCO7mMwZ3c1EUF6h9YYzpBNwKnAdMARJxN65jjDE7rbUTAhTrPK8MP+Fu5OsCvYA2xphO1tpZeToKWe3F3cxdj7uB8r2ZXOfz//uA+rjg9lsgErgAF7y3NcZcZK1N8dK+CPTE3US855dPjo7iWP+Iu7GcAiR7+3/aK6f/DfLrwFLczdVWoCzuxvgDY4yx1j6S1/L6Weft6y7v7xd91v2Rxzxux73ficB0oBNwNxBjjPkaF3R+i7vhPh+4BndD2tU3E2NMM9wxicE9oPjSS9cTmG2Mucxa+11OBbHWxhlj5gHnGWNKWGsPeKsuwN0cggscP/DZrL33+rNPWc7BnbclgG9wx74+7sayhzGmQ6AbRlzLgo7AJFyQVMpn3YvAHbjP7y3cTW0P3PekKHDYL69xuO/fEuB9IAF3vrQCunjly5ExpoxXjsa4G+53vP3UAW7AHePtXtrawGxvH9OAj3HBQV/gYmNMb2vt5Nz2mUfP4gLNSbjPvB0wEHeNSP881pHLuWmM6YI7t/bjPqfNuPPnDNz1KtdA00v/Eu46MRXYiQs6ugPfGWMGWmvH5paJMSYSd9ya4frOj8d9/g8BrbPZpqDHvA/uHJgCvIELdrKTn2tbXj4XX8H+zcjECzLn4oKvb3APL0p65bkVF6AneWmLeOXujDvXPwIOee9hjFeOa/12UdDr6he4h6dTcNe9HV4ZQnAPAvrjfg++xJ1P1bxyWMD/unEJ7jqQ/lme6ZXhHGPMmdbaXbkdJxE5eSjQlOOplff6c46p/BhjWuICn43Audbabd7yB3A1KJcAw3CBkK8quKf4bdMDV2PMB7gf4c9wT+QbWmv3euteAJbjnuwGumnoAtzu+/TaGNMD98P8jvdDnhpguxx5+x/h1XjUtNaOyCbprcDaALWDT+BuUPqkl9ta+6IxpjTuZmxcXgfMOMpj/SfQ0Vqb4G3zGLACuNsY85RfcNrQWrvab99FcTcn9xtj3rDW5rvvqFczOyJ95MMcjmVOLgKapz99N8ZE4M6ja3E3652stTO8daG4ILKLMaaJtTY9YAgHPgWK42rIZvi8zyrAfOBtY0wt/4cqAUzDBZZtcEEIuOAyBXcud/DJOxTXz3mNtXa9tywEF9iVBK6x1o73SX85LnD+0LsJ9D9/2wMtrbWLfRcaY87HBZmrcefJHm/5Q7hAsDKw3id9KeAKYCFwns8DkfT1ZXM5BulexQWZbwCDfctrjClB5pHU38Cdlw9ba0f6pHsNd9zeM8bUtNbG5XHfOWkBNLLWbvD2EY773NoZY8611s7L47k50HsPba21f/quMMaUy2NZYnHXkU1+25fC1aY/a4wZn/49zcEwXJD5CXBV+nXHGDMS930IpKDHvBuulcv3ub25fF7bcv1c/NIH+zfDX3/cg7ee1tqvfVd4D1F8+6I+hAsyX8G1mEjx0oXhHuzcYIz53C+fgl5Xa3rb+geBA70yz8dd2zNqgb1yVAiQV0+gs7XW90HXKNwxugEX/IvIKULTm8jxVNl73ZRjqqxu8F6fTA98AKy1ybgal1Tgpmy2vcv3Rt6rdVwLlAHuS79h8Natwd2INfJ+RP2tAl7zXeD9yM/APZEO+JQ/WKy1a/yDTE96zUjnIOzmaI71Hb43r9baHbhagVK4Jo74rFvtty3W2sO4QCIcn+CpELzs28TLO38m4K6X3/oGjV6gk94krbFPHhfjatnG+Kb3ttmCu9mqRN7eZ/oNm2/aDrig7QugmjHmdG95E1wthu/DnPNxtZe/+QaZXlkm4GqgDEceBPl6yz/I9AzwXkemB5lefodwDyr8peGauCbizqFMbIBmx/6MMRVwzbK34prhZcrHWnvAp5lqNVxN9Ab8bmyttb/iatpicC0SguHx9GDG20cyriYI4NwC5JclCMxrTZC1NtE/yPSW78PVAJfB1V7lpj/us3rA97pjrd1I5tpY4KiP+dd5CTILoCCfSzB/M7IT6PONTT+nvQdGt+GaqN7t+2DG+/89uO/U1X55FPS6+kg259ft3uvN1q+psbU2xbp+/v4+8Q0yPW95rwX5LojICUw1mnI8pfefye98iM2812n+K6y1K4wxm4DaxpjSvjcBwN5AP7zAFlyfqoUB1m0GwnBBgP+T31nZ1FhOxz1db4oLOo8JY0w0rq/cZcDpuGaQvn2SqgZhNwU91vustasC5LfRey3ju9AYUwPXFLgDUAM3vY2vYLyXggrUhHSL95rdOQOuOVm6lt5rTa/vn7963usZQI7NZ3F9oRLwbhK9mqlmuJv59M+pA672OL05oO/nl+1n6rO8Fe78nem3zr/Gxz/PQOf7LFzT6QzW2v3GmEm4GuE/jDFfeOnmWmvzOqJoer/omdbag7mkbZpeFpu1mTe493yNl+79PO4/J4HOmYDnfi7G4wKxucaYCbja4TmBAsecGGMa4Gok2+Ae8EX6Jcnx+2WMKYl7ULLR+vXf9swOsOxojnl259nRyu/nEuzfDH8TcNfwicaYz3HNxecE2OfpuAdGK4GHffuh+kjAXT8yHMV1Ncvx935vGgLbs3nYlJ1gfRdE5CSgQFOOpy24mpVquSX0k94vLLsRUrfiflRL4fo7ptsXOLm7CfZ/Quu7DtdXx9/2AMvAPXX2LWfQef11puGeCC/B3bDsxOvPgxt4ISLw1vlS0GO9N3DyjOOZ8bTfGHMa7samDC7Y+BH3WaXg+mb1JzjvpaByOi/yes6kNwXtm8u+iudWGGvtYWPMbOAir1avJe54/mytXWaM2YK7sXzde00jc1CZl88UoHSAddsCLPPNM8t3wlqbYowJVEN5Oe4m+CqO9DU85N1wD7U+g/hkI718eWlSfTTvuSACnf9Zzv3cWGu/NEdG3b4BuBnAGLMQV7OYZZA0f8aYFrjPPxxXs/0Nrs9nKq7Guwe5f79Keq/ZfSaBlh+L8+xo5fdzCfZvRibW2nnGDfb0EK6rw7UAxhiLGxzuYy9p+vWjHu7anp2M68dRXlcDHf/8fN98ZTnm1tpkL1jOT62viJwEFGjK8TQbV+PSATdqXl6l/7hXwvWR8VfZL92xUjGb5ZUC7D+95jPQd6wgN7c9cEFmdqM85nQzkh/H41gPwd1IDbDWjvNdYYy5EndDdKJLPz49rLXfBCG/abhBedrjmsIm4prsgav16ur1JW0N/OM1W/YvSyUCy+kzza71QXraisAa3xVeE8Ky+N2ges2qR+D6KVbH1bZdj6vlqkXuTc/Tb2DzUttdkPcc7O9sgVhrvwW+9WqUzsP1i74FmGyMaWqtXZpLFg/jarICjZ77AO5akpv93mt217xAy4/FeXbSsdb+BlzifV+b4/X9Bz7yBhX6iSPH6CtrbV6bdxf4uppNl4z8fN9ERAJSH005nt7F1cD1NsacmVNC70c4XXqznbYB0tXF1ZCu9WvKeSy08vrO+Esvl2/zoljvtXqA9Gdnk7/vYA/+6nqvXwRYd2FO+ZG/p8jH41gX5L3kVwqF+/T8d+81WP12fftptsc1tzvksy4GF4xEk3WwrWw/U7/l2Q3wEkh62kCfV2tyeYhprd3o9RftjGse2CoPAwLNwwWDbbwgLCfp77mVNwCMv3beq+97Lsh3tiDydG5aaw9aa6dZa4fgBt8qit/IxtmoC+zJZpCcPH2/rLX7cQ8Qqho3tYu/QP15C3LMC6og17Z/Fa8v7a/W2kdxA2vBkYcAy3GBXguvNUteBPW66jVPXwJUNMY0zS29iEggCjTluPH6+ozA3TB9a4wJePNm3BD/vnO9pc8F+LAxprxPujDgOdx5nJ8a0oKqhxv5NYM36uyFuIGCfKc3Se/zMtAvfSNcH51A0psb1giwbp332tYvv9OAZwqQX3aOx7Fe57229V1ojOlM9gMN5dduoLxx800Whq9xNcKDjTHdAiUwxrQ0bk7IvFiIu/HsgZsb0TeYTP9/+iA8/n0x5+CmIWhljOnjV4Y+uJrFFQTud5edcd7rQ8aYGJ/8IoFR/omNMeWNMecFyCca19c4mazToWRird2JGwG1MvCc/0MfY0xxr/8qXp/Gqbia0rv80p2Ha74bixtJOV36d3aAb6Dk1b4+mlPZ8inbc9MY0yGbcza9BjEv/VnX4abiOcsv7xvJ34Bh7+O+76O8kYvT86mO3zGFAh/zgirIta3QGWNap5+jfjJ9vt6gRWNw5/rL2Zwrlf0e2K7zXtv6pTua6+rL3uub/uU2xoR6rWlERLKlprNyXFlrn/Ju4oYD840xv+IGD4jD/di2wQV0C3y2+dUY8yxuouwlXp+ug7in+w1xN8ijj0PxvweeN8Z0xU3lkT6P5iHgRr+Bgr7G1dRc6Y3GOBd3U9TDW9cvQP4/4/r0fWmM+Q432MN6a+0HuPnUVgFDvGB1sZffJbgpLwLdcP2CqwEaZYxpiFdjY619Mrs3eJyO9Wu4UUs/8waF2ezl3QU3JcjlR5k/uGN5DvC9MWYmrqnpn9baSUHIO1fW2iRjTC/c1Cffeuf5H7gbyepe2U7D3UjmGjxYa1ONMTM4UuPxs8+6DcaY1bjBW1LwG6DHWptmjOmPCwImGDcX6HLcSLM9gQPAddkMdJVdeeYYY8bgmvylnyfp82jGkrWfXlXgd2PMMlyN1kZcP8BLcE0tX7ZH5gjNyW24c2UQbu7YH3ABam1cEHUpbnAuvDRzgNHGzYG4gCNzOqbimhhm7NNaO9c7V9oA84wx03DXpO64zzFQTWdB5HRuPg/UMsZMxwUOh3HNK9vjpov5JA/5v4g7FrONMZ/immGejauF/BzXNzAvnsWdH1cAxhjzI64fZj/coFE9yTqCcL6O+VHI97XtX+IeoJP3+a7B/e41wF1fYzkyOivAE7iRrAcB3b3zcTNuSpF6uCmPHsLNmwnH5ro6FnfeXAes9K4dO3HTwLTHPZgcUYB8ReQUoRpNOe6stY/jfgBfwd24DMCNkHgxrhboJvyaZllr78NNnL0S96N3B+78fRg3v1eOtSFBMhf3tDgCd8PbFVd71MZam2m0Tq9ZYwfcD3xDL/1puKf6r2eT/1hcbVApXKD3BHCjl99B3A/7R7gbkzuAs7w01wTKzLopOvrjBnq41Uv7RG5v8lgfa2vtX7hmdL/i5s+7BRd09MLNwxcMT3p51cHV9D0B9A5S3nnivc/GuBrn9PP8FlzgsBg3EEh+Ji9PDy73k3Vkx/R1CwMNWGKtnYsLbj7CDSY0DNfX82PgHG99ft2JCzT34QatuRIXkF1E1trJdbiHS9twn/0Q3Oe9FvedyFJDFoi1NtYrd/rE9v/BHdMGuJvepT5p1+ACrDdwQfVQ3Hf2e+AC6zePoacH7ntYzXtvTXHfxfvyUr48yuncfArXmqMB7jo4CBfsPoX7nGKz5ObHmyakO+5YXI67hiTijvu3OWzqn0+Ct80Y3MOAu72/n+JIrfV+v20KcszzraDXtn+B13ADudXCff9vx40w+xrQ1Hf0WW/k3p64a7DFPZS5Bxc4hgKP4EYpTk8f9OuqtTbNWtsf9xuzDPeQYQiuFc8s3EBTIiLZCklLO2X64IsUiDGmLe4J+mM28CTrIiKnDGPMQFzt2yBr7ZuFXR4REfl3Uo2miIiIZGGMqRJgWXVcbVoyMPm4F0pERE4Y6qMpIiIigXzhjXqaPhhVLVwTzijcvJ75nWNRREROIQo0RUREJJAPcH0Je+P6Gcfh+qq/Yq39sjALJiIi/37qoykiIiIiIiJBpT6aIiIiIiIiElQnddPZWiW6qrr2JPRD27zMWS4non821SzsIsgxMmjlisIughwjuxOWFXYR5Bi5q9L1hV0EOYae3/xSSGGXIb/Cwkodt3v7lJR9J9zx+bc5qQNNERERERGRY8kYUw031+wluHmEywPbganAE9batT5pa+Hmkc7OGdba5XncbxHc3NgDgOrADtx8vSO8OdgLlQJNERERERGRgrsNuA9YBkwC9gFn4wLAy4wxray1//ht8ycwMUBeu/Kx3w9xAe4C4AvgTGAo0MIY095am5SvdxFkCjRFREREREQKbi5wvrX2N9+Fxpi7gReA54Cuftv8Ya0dUdAdGmO64YLMH4Fu1toUb/njuPmObwTeKGj+waDBgERERERERArIWvuVf5DpeQmIB1ofg90O8F6HpweZnqdx01HdcAz2mS+q0RQRERERETk2koFAgxhVMcYMBkoCG4AfrbU785Fva1xAOc93obU23hjzG9DBGFPMWptQwHIfNQWaIiIiIiIiPowxpYHSAVbttdbuzWM2PXCB5FcB1nX0/qVLMMY8aK19MQ9lKw5UBP621qYGSLLay7s2sDSPZQ06NZ0VERERERHJ7C7c6LD+/+7Ky8bGmIrAGCAReNRnVTwwAmgMlAAqA1cBu4H/GmOuzEP2Jb3X/dmsT19eKi9lPVZUoykiIiIiIpLZi8C4AMtzrc00xkTjRpStCgy01i5JX2et3QE85pM8DvjYGPMPMB83kM/HuewifY7P4zavaEEo0BQREREREfHhNY/NaxPZDMaYSOBroAUwzFo7No/7+8sYsxBoaYwpaa3NrrYS3PQpkH2NZUm/dIVCTWdFRERERESOkjGmKG4+yw640WCfy2cW6XNoRueUyFobB2wHahtjAsVzdYBUXFPfQqNAU0RERERE5CgYY8KBCUA34Flr7eMF2L4Jrg9nXkafnQUUB871yycKaAksLMwRZ0GBpoiIiIiISIF5tYofAj2BMdba+3JI29yr+fRdFoab/7I68KW1NtlnXZQxpr4xprJfVu96r49526e7HxeAvkshUx9NERERERGRghsOXI5r+hprjBnhn8Bam77sEVw/zBm4+TOjgAuBM4FVwFC/Tc8FfgHeA673ye87Y8ynQD/gd2PMz14e3YE5QJ76hh5LCjRFRERERORfr0hYicIuQnZqeq/lyDyVia8R3utnQFHcYEHdcSPHrgZGAqOttfkZwOca4C9gAHA3sAN4Htc/NCkf+RwTCjRFREREREQKyFp7PT61jbmkHQ+Mz0fe0zkynYn/uiRcgDoyr/kdT+qjKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQkqBZoiIiIiIiISVAo0RUREREREJKgUaIqIiIiIiEhQKdAUERERERGRoFKgKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBFV4YRdAREREREQkN0XDShZ2ESQfVKMpIiIiIiIiQaVAU0RERERERIJKgaaIiIiIiIgElQJNERERERERCSoFmiIiIiIiIhJUCjRFREREREQkqBRoioiIiIiISFAp0BQREREREZGgUqApIiIiIiIiQaVAU0RERERERIIqvLALcDLr2qMVl/a9kEZN61GufGk2b9rJD9/M4dXnJnAwLgGAhk3qMuzR/pgGtSgTU5L9++JY8sdqxjz7EYvmLc91H1WqleeeR66jReuziClbkq1bdvHtl7N47fkJJMQnZqSLLBbBsEf7c3Gv1pSJKcna1Zt5/YXP+PrTXzLlFxoayuChl9Pv2k5UqFyWLRt38MH/JvPOaxODe3BOAuFlyxPT+yoi6xkiatchNCKS1TdeTvKObRlpyl55PeWuGhBw+9TDiazs3Snb/Is1bEKNUS9lu3790Fs4ZJe6P0JDKdv3Gkp27EZ4TFmSd+5g77dfEfvN55m2KdOjLyUuvIiiFSsTEhlJ8q6dxM2dw+7PPiT1wP58vPuTW7EKZTh9wCWUPrM2pepVJ7xYBN93G0L81l2Z0kVVKUeju6+g/HkNCA0PJ3bJav5+cQJ7l67NdR/NR9xEmUZ1KVahDCGhIcRt2sG6r2aw5tOfIDUtI13r/z1A+bPPyLL9n6PHs/qjHzItq9y2GWfcfBklalcmcc9+1n45HfvOpEz5neou6dmOXn070bhpfcqVL8Pmjdv59pvpvPjcexyMiwfgrCaGB4cP4owGdSgTU4r9++L46w/LC8+8w4J5S3LdR42alRk+8nbatD2H8CLhLF64lMceGsOfi49c0y+/+mLGvPlItnk0PK0bO3bsoULFsgy8pR8Xtj+X0+pU53BSEkuXrOK5UW/z+5w/jv6AnER69+7BFVf0oXnzJlSoUJ4NGzbx1VeTGDXqeeLi4gCoWbMGa9b8HXD7mJga7Nu3L8d93HXXYNq1a03z5k2pXLkSjz02iscffzpg2sjISO699y6uuqofNWpUY+/efSxYsIjeva8hKSmJ0NBQ7rprMF27dqJBg/pERRVj5co1vP76/3j33Q9JS9P3Nt1ZFzemaY/mVGtcnRJlixO7JZa/v/uLn8dMJfGgu9eJiI6g05AuVDurOtUaVSeyRCSv9RnD6t9W5WkfZ/c9hwYdG1GtcXViqsUw/9O5fHL3R5nShISGcOHAttTvcCaVTq9MkWJF2LV2J3PGzWb+hLlZPrOzLm7MRXd0okLdiiTsT+Cvb//gu1GTM8oscrJToHkM/efO3mzeuIPRj73Hts27aNC4Dnc9cDUt2zSmV4chpKWlUbJUcdat2cLn439ix7Y9lC1fihtvu4xPpjxL305D+XPhimzzLxYVwYeTnqJIeDgvPPkBWzbu4Kzmp3P3g9dQu04Vbrv+yI/fm+Mfpum5Z/D8E++zZuUmulx6Pi+9fS+hoSF89cm0jHRP/ncwva/uyJhnPuKPBZaWbc7iwZE3ERUdySujPzmmx+tEU6RyVUq0asuh1StI+OcvopudmyXNvh+/5eCieZmWhUZEUu2x0cTN+zXH/BNXr2D90FuyLK90x72EFS/JoZVHblor3nI3JTt0Yfcn73NoxTKiGjWl/A23EBJZjD2ffnBk38VLEPfrTBLXryU1IZ7IOvUoe0V/os5qyvq7/wO6sQEgunpFqnY8l73L1rF78Qoqnt8oS5qipYpz4bsPk3zwEIufHEfKoUTqXdOF1m/dz/RrH+PA2i057iM0sihrPplK3KYdkJZGxfMb0XjY1RSvXoG/Ro/PlHbvig0sfvLdTMvit2QOeiu0bESL5+5g3cQZ/PX8R5SuX5MGt/UhPCqSf17+tIBH4uRz6x1Xs3nTNp4a8QZbtuyg0VmnM+zBm7igTXMu7jCQtLQ0SpUuwdo1m/hk/Lds37abcuXLMGjwFUz8/nW6d7yZxQuXZpt/mZiSTJr6JnFx8Qy98xkS4g8x6PYr+eq7V+nc9kZW2nUA/PTDHLq2uzHTtiEhIXzw2XOsX7uZHTv2ANC4aX169r6Ijz+czMJ5/1CkaDgDBvZm4pTXuLbfMKZ+P+eYHasTzZAht7Nx4yYefvhxNm3aQpMmZzF8+P20bduaVq06ZgoCRo16nkmTvsu0/YEDB3Ldx0039Wf//gN8/fW3DBp0Y7bpwsPD+fbbz6lduybPPPNfli5dTvny5bjoonaEhYWRlJREsWLFeOihoXzwwSeMGfM6cXEH6dq1I2+++TLGnM5992X/IOJU03ZQe2I3xzLl6cns3bqXqg3dveZrAAAgAElEQVSr0XlIF+peUI8xl75IWloaUWWiOffy89i0ZBMrZlrOurhxvvbRvNc5RJeNZuVMy1mXNAmYpkhkES66sxMLPp/PrLEzOBx/mPrtz6Tv6MupULcCk5/8JiNt0x7NuOa1/sz/dC7fPjWJmBpl6XrfxVSoU5E3r3ztqI6HyIlCgeYxdGO/EezZdeTp6Nw5f7M39gAvvDWUFq3P4reZf/LrjD/4dUbmp9IzflrIonUTuOyKDjkGmme3aMBpdatxbY+HmDVtEQC/zfqL0mVKMPCO3kQWi+BQQiJnt2zAhR3PZuig5/l8/E8AzJq2iEpVy3H/4zfw9afTSU1NpUq18lzevzNjnvk4I6ic/ctiipeI4rZhV/DB2Mnsi40L9mE6YSX88yerr7sMgFKdLg4YaCbv3kny7p2ZlpVs14mQ8HD2//x9jvmnJsQfqbH0hJevSNFqNYmdOAFSU71lFSjV8WJ2T3g/I6iM/2MBoVFRlO13LXu/m0hqnLuB2j3+nczvYckfpCYeotLgoUScVo/E1dmfb6eSXYss3110OwC1LrswYKBZu297ImJKMfOmpzi4cQcAO+ctpfPk5zlj0GXMu+/VHPcx//7MNxo7fl9CZPnS1OzRJkugmXzwELF/r84xv4Z39GPXHysyAtJdC5YRHhVB/Zt6sGr8DyTuzrmm5lRxbb+h7N61N+Pv32YvZm/sfl7533AuaNOM2TMWMmv6AmZNX5Bpu2lTf2f5+u/pe2XXHAPN62/qTfkKMfTscitr12wCYPaMBcxf8iX3PnQTA697GIDdu/ZmKgfAeec3pmzZ0owe+b+MZXN/+5MWTfqRkpKSseyXn+Yya/5H3Hb3NQo0ffTocTm7du3O+HvmzDnExsYybtybtG3bml9+mZmxbu3adcyduyBQNjlq1Og80tLSCAsLyzHQHDLkdpo1a0yjRi3YtGlzxvIvvzwSiCQkJFC3bhNiY2Mzlk2bNoMyZUpz223/YfjwkRw6dCjfZTwZvd3/LQ7uOZjx95rfVxO/N56rXrqGOufXZdWclcRu2sMjDR8EoF7r0/MdaL511esZDyNMu6ytSACSDiUx8vwnSNgbn7Fs5ewVRJUqRqsBbfj+uSkkH0oCoMuwbqz6dWWmWtGDe+Lo/9YN1G9/JsunZX8dETlZqI/mMeQbZKb7c5G7ka9UpWy228UfPMThxCSSk5NzzL9IUfecIO5AfKbl+/fFERoaQkiI+7vpOfUBmP5j5h/VGVMXUrFyWZqe69Y3bm4ICwtj+lS/dD8tJLJYBG07npNjeU45Baz9K9m+M8mxuzm4aH7+t23XiZDQUPb9fKTJZGS9MwgJC+PgwrmZ0h5cNI/QiAiim5+XY54p+70msyk5n2+nlDx8tjGN6hK3YXtGkAmQcugwuxdbKrVuQkhY/i+vh/fGkZaSmu/tilWMoXT9mmz8NnMt+YbJcwgtEk6lC87Kd54nK//gDmDxomUAVK5cPtvt4g8muOtyUs7fk+bnNGDN6k0ZQSZAfPwhfv/1Dzp2aUVYWFi2215+1cUkJh7mq8+nZizbvy8uU5AJkJKSwpK/V+ZY3lORb5CZbv589xC2atXKQdlHXpuz3nLLjXz++deZgkx/qampmYLMdAsWLCYyMpJy5bK/TzjV+AaZ6Tb+sQGAUpVKBWUfefls01LTMgWZ6Tb8uYEikUUoHhMNQHSZaMrVLs/yX5ZlSpf+d6MuWR9eSt5EhpU8bv/k6P3rA01jTIwxpkZhlyNYWlzgLi6r7MZMy0NCQggPD6NKtfI8/vytAHwy7ocs2/ua88ti1qzaxP2P30BdU4Oo6EhatmnMgFt6Mv7t7zL6aKZ6NymH/W6QDh92T93MGTVdOq+GLOmwX7pEL92ZNfP3ZiWL8LLliWrUlP3Tf4LUlNw38FOqfWcOrbIc3uDTB9D73NL8HkykJbnPLaJm7awZhYYREhFBpDmTclcP4OAfC0hctybf5TmVpaWmkhrgYVDK4WTCi0UQXa1CnvIJCQulSPEoqnQ4mxrdW7Hqw6w13aXr16T7zDfoOe8dOkx4kpo922RaX7JOVQD2r96UaXn8ll0kJyRS4rSqeX1bp6TzWzUFYIXXrDVd+nW5arWKPP3CUAA+fO/rHPNKSUklybu2+jqcmERUVCS1svksIiMjuPSy9kz9fg6xe3LuL12kSDhnn9swS3klqwsvbAXAsmWZW2uMHDmcxMTd7NmzgYkTP6ZhwzODts/q1atRo0Z11qxZx5tvvkxs7EYOHtzOjz9+Q+PGuQcYbdpcQGzsXrZu3ZZr2lNZnZZ1Adi+cnshlwTqtKhL/N549m933930+6mUJL+HRMkppKamUql+cB58iPzbnQhNZ58HruXEKGuOKlYuy90PX8usaYv4e/HKTOteff9BuvV0P4g7d8QyoM+jrLIbcswvMTGJvh2H8vr4h/lpwZsZyz8eN4VH7znSLG/1SvdEtdk59TPVVjY71zUNKR1TwqVb4W5Sm55Tn3/+Wp01XZkS+XvDkkXJdp0ICQtj/7Scm80GEmkaULRqdba/9XKm5Yc3u/OkmDmTxDVHzqti9RsAEFYi81O5kMhinP7Zkf0fXDiXzc8Mz3d5TnVx67ZS4bwGFC1VnMP7vCblISHENDwNcH04c1OpdRPOf3kI4ALXFe9OZvn/MgcyuxZZNn73G3EbtlKkRDQ1LrmA5sNvIrJcaexY1wyvSEm3r8P7sz71T9p/kKKlogv8Pk92lSqX596HBzJj2rxMg/UAjP1gJN17tgdg5449XNV7CCuWr8sxv9UrN3Bh+3MpE1MyI2AMCQmhaXMXyJQpE/gpedfubShZqjgTxn8XcL2vYQ/eRJWqFbjlRn1vc1KlSmVGjHiQn376hYULFwOQmJjIm2++w9Sp09i5cxf165/O/fffw+zZP9KiRXuWLz/67gNVqlQC4N5772T+/MVcddUNREREMHz4A0ybNpkmTS5g48ZNAbft1KkDfftexqOPjsxSky1HlKxUis5Du7JipmXTXxtz3+AYMhfWp3H3Jnw/+jtSvRYpCfsSOLDrADWbZX5AX7NpLUJDQ4kqHVUYRRU57v71NZqekMIuwNGKio7kf588SkpyCsNu+W+W9aMeeZtLL7yTm69+ghVL1/POpyNo1LRejnlGRBThlfceoGz50tx107P06zKMkQ+N5ZJeF/LEC4Mz0s36eSErl29g+LODaHZufUqWLk6/6zpxaZ8LAUj1RqRcZTcw8+dF3PXQNbTp0IySpaLp3P18bri1Z6Z0UnAl23fm0OoVBao9LNWhM2lJSRyY8VOm5Yc3rufg4vmUvWoAUU3PITS6OMVbtKbMpX1cAr/PLS3xEOvu/g8b7ruN7W++RMRpdan2yCgIzb5Jn2S15vNphISGcPYT/yG6WgUiy5Wi8b3XEFXFNWdMS829CeyuxZZpVw9n1s1Ps+LdydS7rhtnDu6TKc2y179k3VfT2bXQsnX6IuYOHcOWaQuof+OlhBWLAMhoJh+wye8Jf/U8dqKji/H+hGdJSU7hjkFPZFn/+MOv0KnNAAZcdT/Llq7mw8+eo3HT+jnm+d7bXxIaGsIrbw2nVu2qVKhYlqeeG0KNWq4GI7vr6OVXdWPnzj389EPOg4T16tuJO+65jheeeYe5v/6Zx3d66omOjuarrz4mOTmZG264NWP5tm3bufXWu/nqq0nMnv0bY8e+R9u2XUlLS+PBB4cGZd+hoe7WKj4+gR49LmfKlKlMnDiZ7t37UaxYMW69dWDA7c44wzB+/NtMnz6bZ5/Nep8gTtGootzwzk2kJqfyyZDxuW9wDFWsV5FrXr2O1b+t4pdXf860btbbMzjr4iZccH1ripWOolqjavQe1ZeU5BTSdD8lp4jjXktojMlvcHvC3yZFRBRh7ITh1KhVmcu73ss2v9EiATau28bGddv4a9EKpk2Zxw/zXmfoI9fRv1f2o871u64zLds0ps1ZN7Bh7VYA5s1ZwoH9B3l6zJ2Mf/tbli1ZS0pKKrdcM5KX37mXL392P147t+/h2RHjePSZm9mxbU9GnsNueYGX3r6X9yeOBGD/voM8/cjbPPXyHZnSSf5F1qtPRPWaWWok8yIkvAglWrUjbsHvpOzP2vd324tPU3now1R//DkAUg7GsXPcG1QaPJTkWL9+S2lpJK6yACQs/ZvEdWuoMeolSlxwIQdmTfPPWrIRv3kn8x96gyb3X0fnSe64xy5dy6rxP3B6/24cCtBH219yXELGVCg75y0lNSmF+gN7sObTnzm0M2vfrXQbv/+dKu3PplS96uz5a1VGTWagWtQiJaI5vC9rTeepLiKiKO9/OpqatarQs+utbN2yM0ua9eu2sH7dFv5YtIwfp8xm5ryPeODRm7nisruzzXf9ui3ceuMInn5hKPP+/gKAPxcv581XPmHwXdewfVvW63+FimVp0+4cxr7xWY61WJ26tuLlNx9h/HuTeHbk2AK861NDREQEEyd+wmmn1aJdu25s3pzzCNCbNm1mzpzfOfvsZkHZ/+7d7rfy11/nkpCQkGk/y5evoGnTrH2ma9euxQ8/TGTt2vX06nWVajOzER4Rzg3jBlK2Rlle7TOGfVsLb5CzmBplufnjW9m9cQ/v3jA2ozYz3fTXp1Gmahl6PHYZvUb2ISUphTnvzSLpUBKH4jTIk5waCqM5atbOKyex8PAwXh//MI2bG6659EHs0nW5bpOUlMzyJes4s9FpOaar36AWe/ccyAgy0/25wAURdU0Nli1xN7Gr7Aa6XXAb1WpUoFhUJGtXbabLpRcAsOD3IyOfbd+6myu63UeFSjGULlOC9Wu3ckZD18dv/m//5Pl9S1YlO3QhLTk5S41kXkSfdwFhJUpm2+Q2ec8uNj54F2ExZQkrXpKkbZuJqFUHgISlf+WY9yEv6CxSWf348mvLzwvY8stCStSsTGpSMgc37aDJg/2J37qbhG1ZBybJTezStYSEhRJdtXyOgWZ6FWb64BX7V7vm8SXrVGXPX0fmjIuqXI7wYhEcWJP9gCSnovDwMN4ZP4pmzc+kT/fbWfZPziP6grsuL/1nFQ0b5dzSBGDy17/w3aQZ1KlXg6TDSaxbu5lnX7yXTRu3sXlT1v5kfa/oQnh4OJ/m0Gy2dduzGfvBSL6bNIOhdwSet1HctCKff/4B557bjE6derBkSd5G9gwJCQnavJVr1qwjPj4+YH4hISEZ/ffSVa1ahalTv2H//gN069YrT9OsnIpCw0Pp/78bqNGkJm9c8Srblm/NfaNjpFTlUgyaMJhDcYf439WvkxiXdV7MlKQUPr/vUyaPnESZqmXYu3UviXGHePzvp5j19oxCKLXI8VdY/R73Ajnf/R5RH8jbqBr/MiEhIbz49r1ccGETBvQZzuL5y3PfCIgsFsFZTeuxZmXgPhzpdm6PpXRMCWqeVpn1a45ccJt4o8xu25r1yfmmDW6EzPDwMK67uTszf1qYJVAF2LFtT0YN5g239mSV3cDvs/L6kUkW4eGUbN0+2xrJ3JTq0Jnk/XuJm/9bjulS9uwmZY8LcMpc2pfEjeuJ/zvnSd2jGroh4JO25fzUX7KRmpYxZ2Zk+dJU63QeK97PvZ9dIOWa1yctNZWDm3fkmK5615YkJySyf6Xrm5SwbTd77Xqqd23Juq+O3MBUv/h8UpOS2TZH3910ISEhvP7OY7RuezZX97mHhfPz9gCtWLEIGjc9g9Ur1+cpfWpqasacmRUrlaNHrw68+lLgZn59r+rKP3+vZMnfKwOuP/vchrz/ybPMmr6AW28cHrSA6GQTEhLChx+OpX37C+nevV+epy+pXr0a559/HhMnTg5KOZKTk/nuux9p3fp8oqKiiI+Pz9iPMfX45psj14dy5cry44+uX3bnzj0Djpwr7rO9+pXrqHfB6bzd/y02LMrb9/BYiI6JZtAnrnvSm1e+FnBEXF+H9iewdb+r2W557QWEFw1n3idzc9xG5GRRGIHmCiDCWtsuL4mNMe8C1x3bIh0bT7wwmEt6tWHMsx+TEH8oY5oRgK2bd7Ftyy6eeul29sYe4K9FK4ndvZ+qNSpw3X+6U75SDHf/Z3RG+qrVKzDjr3d4+emPePkZNyfT5+OncuNtvXj3i8d5dfQEtmzcQaNm9bj93qv4a9EKFvx25Enurff0Y9OGHezYupsq1Stw3cBLqFK9Ar073pOpzNfc6IbX37huG+UrxtD7qg6c3bIBV3d/QDc3ARQ/3/Vzjaxj3N/NzyN5315S9u8lYcmR/lPFz2lJWMlSOQ4CVPvN8STt3M6mh4dkWh5WqjTRTc9l75SvIZvmVKW79iD18GGStm8lvEwMJTt0IeqMRmx8+O6MfnuhUdFUe2w0+6dP5fCWTUAakfXOIKZnPw6tWUncrzMD5n2qqnKRm86n9Bm1AKjY6iwSYw9wOHY/uxZaQsLDaHjn5exauJzkgwmUqFMNc8Ml7F+9mZXvT8mUV6evRxO/dRezBz0DQKVWjanZozVbZ/5B/NbdFImOpOIFZ1G7VzvWfvELh3a6KTjKNj0dM+ASNk9bQPyWXRQpHkWN7q2o0rYZS16aQMqhwxn7+OeVzzj/pSE0feh6Nn7/O6Xr16T+TZey6qMfNYemj2f+O4wevS7ihWffJf5gAs3PaZCxbsvmHWzdspPnXr6P2D37+XPxcnbv3kv16pW44eY+VKxUlsEDR2Skr1a9EvP+/pznn36H5592c9SGh4fx6JO38dvsxRw4cBBzxmncec912OVref3lj/yLQ6PGhjMb1OXR+18KWN66p9dk/OfPs3v3Pl59aXyWPqJ5DZRPBa+88jx9+17GyJGjOXjwIOedd3bGuk2btrB58xZGj36S0NBQfv99Pjt37sKYetx3392kpqYyatTzmfJLTNzN++9/zMCBt2Usa968KbVq1cjoh3nmmfXp3bsHAN9992NGU9kRI57i99+nMWnSp/z3v68QGRnJI4/cx969+3j11bcAiIyMZMqUr6hVqwY33TSYatWqUK1alYx9LV1qVbvp6fVUH5p0b8rUl34gMT6RGj6D7OzbujejCW39dmdQNKooleu741inRV2iY6I5HH8401QjD8x+mNjNsbxx+ZH5jivWq0jF091ATkUii1CmWkzGXJyrf1vFwT0HCY8swn8+uoUy1WKYcM/HlKpcmlKVS2fksX3FtozazdNbGyrVr8y25VsJjwzHtKnP+f1b8dUjXxC7SV2R5NRQGIHmfOBqY0xZa+1J/eiubUf3I3f7vVdy+71XZlr34lMf8uKo8SxeYLmif2euHNCVqKhItm3ZzR8LlnPf4BczNbMNCXE3MKGhR7qsbtqwg8va381dD17NPY9cR0zZkmzZvJOPx03hldGfZAoMi0VFMuzR/lSoXJb9++KY+dNCbrl2JFs3Z671DA0LZdCQflSrXoGE+ER+n/0Xl7W/m5XLcx4B91RV9YHHM/1d8VYXJMb/vZiND96Vsbxk+y6k7N+XY41kSFgYIaFZuzCXbNuRkPBw9v2cw0i1oaGU7XMV4RUqkpaYSPzff7B+2C0c3rAuI0na4cMc3rieMt17E162HGkpKSTt2MaeiROInfQFacmnVKv2XLUYfXumv5s+eD0AOxcsY9bAUZCWRvEalajetSVFSkSRsH0P6yfOxL4zibTkzA8EQsJDM82rGbdpB4SEcuatvYmIKUnSgXjiNmxnwSNvsvH73zPSHdq1F0JDOPOWXhQtXYK05BT2rdzIvAdeY5NPOoDts/9i7rBXqH9zT2pc2prE3fux70xi+dhvkCPad2wJwJB7BzDk3gGZ1o1+aiyjnxrLwvn/cE3/S7l2QE+ioiPZtmUnCxf8w92Dn8rUzNZNfxKeEXSAe65zWp3q9O7XmZKlirN18w4++mAyL40eR1KAOTgvv7obSUnJfPFp4Omsmp/TkDIxpSgTU4qJU17Lsr5C8RYFOg4noy5dLgLgoYeG8dBDwzKte+yxUTz++NMsXbqcm2++kf79r6ZEieLs2rWbX36ZyeOPP82KFasybRMeHk6Y33y4gwcPpH//qzP+7tv3Mvr2vQyA005rxPr17rdy2TLLRRd1Z9Sox/j443dJSkpi+vRZ9Op1NTt2uP7AFStWoFkzF8h8+OHbWd5P+/YXM2PG7KM5JCeN+u3c6Pcd7+xMxzs7Z1r3w/NT+PEF9/vYe1RfYqofmX+089CuAOzZuJuRLY78XoeGhxISmnkIkMbdm9L5nq4Zf9c9vx51z3dN5V/rM4bVv62iRLkSVGtUHYBrXs1aB5KeDiA5KZmmPZtToW4FQkJD2PLPZt69cSxLp+rhkJw6Qo53LZUx5g7gRaCbtTbXOR6MMfcBXfJaA+qrVomuqoI7Cf3QNutkyXJy+GeT5mo9WQ1aefTTRsi/0+6EZbknkhPSXZWuL+wiyDH0/OaXTrgBNysUb3Hc7u13xP1+wh2ff5vjXqNprX0ZyPOwm9baZ4Bnjl2JREREREREJJhOlHk0RURERERE5AShQFNERERERESCSoGmiIiIiIiIBFVhzaMpIiIiIiKSZ1EhZQq7CJIPqtEUERERERGRoFKgKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQkqBZoiIiIiIiISVAo0RUREREREJKgUaIqIiIiIiEhQKdAUERERERGRoFKgKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBFV4YRdAREREREQkN1FpJQq7CJIPqtEUERERERGRoFKgKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQkqBZoiIiIiIiISVAo0RUREREREJKgUaIqIiIiIiEhQKdAUERERERGRoFKgKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQmq8MIugIiIiIiISG6i06IKuwiSD6rRFBERERERkaBSoCkiIiIiIiJBpUBTREREREREgkqBpoiIiIiIiASVAk0REREREREJKgWaIiIiIiIiElQKNEVERERERCSoTup5NKPSShR2EeQYqFRneWEXQY6RkmX2FXYR5BjZMnhZYRdBjpEb7htU2EWQY2TnocIugYicyFSjKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQmqk3owIBEREREROTlEpUUUdhEkH1SjKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQkqBZoiIiIiIiISVAo0RUREREREJKgUaIqIiIiIiEhQKdAUERERERGRoFKgKSIiIiIiIkGlQFNERERERESCSoGmiIiIiIiIBJUCTREREREREQkqBZoiIiIiIiISVOGFXQAREREREZHcFA8rUthFkHxQoCkiIiIiIlJAxphqQD/gEsAA5YHtwFTgCWvtWp+0pwOXA12AukBpYBMwGXjSWrszj/u8Hng3m9XbrbWVCvRmgkiBpoiIiIiISMHdBtwHLAMmAfuAs4EBwGXGmFbW2n+8tI/jAs1FwKdAItAauMNLe561dms+9v018IffsriCvpFgUqApIiIiIiJScHOB8621v/kuNMbcDbwAPAd09RZPwdVy/uOX9iVcsPkocEs+9j3RWjuugOU+phRoioiIiIiIFJC19qtsVr0EPImrsUxP+142aUfhAs3W2aw/4SjQFBEREREROTaSgbQ8pEvySZ8fTY0xZXGziSwHplprD+Uzj2NCgaaIiIiIiIgPY0xp3EA9/vZaa/fmMZseQEkguxpPX9d5r9PymHe6O/z+3mqMudpa+0s+8wk6zaMpIiIiIiKS2V3A2gD/7srLxsaYisAY3GA/j+aStj7wGLAbeDaP5VsDDALqAMW81wdxwfEkY0zdPOZzzKhGU0REREREJLMXgXEBludam2mMiQYmAlWBgdbaJTmkrYgbqTYS6Get3ZaXwllrZwIzfRatAUYZY/YAbwBDgFvzktexokBTRERERETEh9c8Nq9NZDMYYyJxU460AIZZa8fmkDYG+BGoDVxtrf2+gMX19R7wmrf/QqWmsyIiIiIiIkfJGFMU+ALoAAy31j6XQ9pSuCCzEXCTtXZCMMrgDQQUB0QHI7+joUBTRERERETkKBhjwoEJQDfgWWvt4zmkLQF8DzQHbgvmPJjGmNNxAxCtD1aeBaVAU0REREREpICMMaHAh0BPYIy19r4c0hYDJuOatg611r6WS95Rxpj6xpjKfstbBkhbCnjL+zMoNaRHQ300RURERERECm44cDmwC4g1xozwT2CtTV/2BtAGWA2UCJB2r7X2RZ+/zwV+wfW9vN5n+RRjzFZgPrAFqAR0BSrg+oiOO4r3ExQKNEVERERE5F8vKuxf2xizpvdajuynMhnhl7YOLkD1tx434m1uXgbaA52AGCAB+Bt4BBhrrU3NQx7HlAJNERERERGRArLWXk/m2sac0rbNZ97TgZAAyx8ll/k5C9u/9rGAiIiIiIiInJgUaIqIiIiIiEhQKdAUERERERGRoFKgKSIiIiIiIkGlwYCOsU49z6Nb31Y0bHoaMeVLsXXjLn76Zi5vPvcV8XGHADizSW3uHH4lpzeoQemY4hzYF8/SP9bw+jNf8Oe8lfna38B7enL3Y1ex8NflXNvpSP/gnldfyFNvDs52uzanDWTXjn0Zf/e5vgPX33EJ1WpWYPP6nbz/6rdMeHtqPt/9yS2kVCUiOgwirEYjwqqcQUjRYux/vBVpezZnSRtasQ6RXYcQVrcFIUWjSN27hcOzP+DwzHF53l9YrWZE3/EZIaGh7BtSF1JTAperbHVK3PcDIUWLceDJtqTuOjJfb0SXO4nscleWbZL+/pH4t2/Oc1lOdqFlKlD8kgEUqX0mRaqfTkhEMXYM6UbKri0ZaYpfNogSlw0KuH3a4US23XRe9vmXKkd0pysp2rAF4RVrkJacRPLGlcRNfJPDdlGW9BHN2pKYQecAACAASURBVFHispsJr1yblP27SZj+JXGT3oE0b0C5kFCiu1xDRONWhFetQ0jRSFK2b+DgTxNImPU1pKUd3QE5iWw7EMbbc0vxz7ai2J1FOZQcyo//2UTVUsmZ0jUYXSvg9p9ft4UzKh7O8/4Wb47g2o8qkUYIf96zjnCfx7u/rCrGd8uj+WdbBBtiwzm7eiLjrtgWMJ9Vu4rwzLQYFm+JoGhYGu3qxjOsbSylixX6oIL/Gud0b0yL3s2p3aQ6JcsVZ/fmWBZM/otJ/53KobhEACKLR9BzWBdqN6lOrcbVKVYikqcuHcPyOavytI+ixYrQ56FLOLdnE4qXiWb7mp1Mfuknfvt8YUaayBIRdL65LWd1OIPKdSsQEhbCFrudb8f8zKLv/s6UX+dBbWnZpzkVapalaFRRYrfsZdGUJUz674/ExcYH7+Cc4I7XZ3vxHRfRslczYqqW5sCegyybvZIvR01h18Y9mdK2H3ABnW6+kPI1yrJ/5wFmfzKPiaO/JyU56/fxgsvPoePANlQ1lUg+nMzm5dsYN/RTNi3bevQHRuRfToHmMTbgju5s3bSbF0d8zLYtuznjrNoMfrAv57ZpwFUdHiEtLY2SpaPZsGYbE8dPZ+e2WMqWL8V1gy/m/e8f45qOj/D3wtV52le1WhW4eVgvdu3Ym2XdjB8WcUW7hzItCwmB1z67j41rd2QJMke8PJD/PT+R3375mxZtG/LIf2+EEJgwVsFmutDyNSnS9GJSNv5N8pr5FKnfJmC6sOqNiB48nuRVc0mYcD9pCQcILV+bkIiofOwsnGL9RpJ2YBchpSrkmLRYnydISzhASNFi2aaJe6lPpkA1LX5ftmlPReEVaxB5bieS1i3j8IrFRDQ6P0ua+OlfkvjXnEzLQiKKETP0Vf7P3l3HSVXvfxx/TW0Hu0vD0nIApUMpUTEREEExfiZ2yzXwXvXaAnZig62ImHgVlVARCYOGQ3dvsD079fvjbA1bM7i4xPv5eOwD5pzv+Z7vzuyZmc/5fKPgr5+qrN/Vsj1Rx59B/i9fkr12KTani5iBI0n+95tkPHcb7kW/lJSN6NibpFufIv+nL8j68ClczdsRf94t2KJiyf7keeu8EZHEDb2G/F+/Jvf7DwkU5BHZuR+Jo/6Ls3FLsj9+tgaelSPD5gwX081YOjRw062pm7kbK79Ohh2XzcjOOUHbWiR7Qj6XxwcPfZ9CSqyPvbnlP25nro1h1e4IOjdy4/aWm1CwxO4cB1d83JCWyR6ePWcP2QV2nv4piZs+c/HexTuxV37oUeWsm08hbWsGUx6dRvr2TFp0bMqwMWfSvt8xPHLmcwQCAeKSYjnx/45n05KtLJtt0nNI57DOces7V9GmZwumPv4NO9bspsfgztzw2mXY7DbmfvI7AClNkhk4qh+/fDSfL5+aTsAf4IQR3bj9vat55+4pzHhrTkl9cUkx/D5tMVtX7qAgx03zjk0ZdtcZtO/XhgcGPk1AN4mAf+a1veq5i+g2qCOfj/+WDYs2k9I0iXPHnMWYz2/ivgHjcedaN5gG334q5917NtNf+YklM1fS/LgmnDvmLBIbJDDx9o+D6jzvvsGccd0A/vfiDCY/+CUR0RG06taciJiIGntuRA5lCjQPshtHjidjb3bJ49/nrGRfRg7j3riZXid2YP5Py5k3exnzZi8LOu6XHxYxd9NbDL3oxJADzf8+dzXTPvmFFsc0xuFwBO3L2Jsd1A6A7n3akZSSwEuPTSnZ5nDYue2BC/nqo194/iHrDXPBz8up3zCZW++/gKlvz8TrrTiTdrTxrVtA9v09AXCdcEHFgabNRvTFT+FdPZe8iaXZL9/aeWGdK/KUa8Fmo3D+FKJOrzwz7eo2FEfTY3H/OIHocyuf8dq3aVGlGVGBQvMPdt8yEIDoAedWGGj6M3bjz9gdtC26z9nYnC7y53xddf2rF7Hn7nOCXgP30rnUGzuV2EFXBAWaCSNvo3D1X+yb9Ih17MrfsUXGEHfONeROfx//vjQChW5233k2gdys0nOsWIA9NoHYUy8ke+oE8LjDfyKOQD1SC/j5pi0AfLokrspAs36cj86ND/x5m7QwkQAwvGMOr8+rU27/Q2eklQSJl3zYsNJ6Ji5IwOu38fLw3SRE+Yva5uXyjxsxY00Mp7VV5gvg2YtfJzstt+SxOXcdOZl5XDfhEtr1a8PKX9awd0s6N7b5DwDHDmgbVjDS9vhWdBrYntdv/oA5Hy0AYNlsk+TGdbjggaH89ukfBPwB9mxO487uD1OYX3pTYumsVSQ3SWLwracGBZpTx/4v6Byrfl1LYX4hVz5zAc07NWHj4q0H9FwcaQ72a+uKctFrWBe+eXEm/3tpZsn2fbuzuWvKDbTt1Yqls1bhinQyZPRp/Dp5IR/99wsAls82CQQCXPDgUKa/MpttptUroU2PFgy+bSAvXD4xKJO9+IcVf+u5EDmc1OoYTcMwEgzDOM0wjOsNwxhT9HN90baE2mxbTdk/uANY9qcVONZvlFzpcfm5bgrdHjye0IKBs8/vS4curXj2gQ9Dbts5Fw+g0O3hf5+WZmW6HN+WlHqJfP3xz0Flv/r4Z5JSEujWp13I9R/xQrjT7GhzAo5GbXHPfuuAT2NPaUbkaTeRP+W/4K8imxKdQNSw+yj48nEC+VmVl5PqHWAWIbr/EHyZe3EvnVt19XnZ5QN9vw/PZhNHUmnG2p7cAFfzduTPDf4ymv/rNGxOF5Gd+hVV6A8KMot51i/HFhGJPb58kHO0+qeyf5sznLw+L5H7T00L6i57IG2ZvTaGE1vllQSZAD1S3TRK8DJzbRg9I45wZQORYhv+2gxAUqPEv11/6x7WGutLflwZtH3JzJUkNUykTY8WABTmFQYFmSVtWbSZOg2r/2qTk279Hj6PukUXO9ivrcNpx+F0UJBdELQ9LysfAFvRxdq0fSOi46LK/w3MWIXdbqfb2R1Ltp0yqi97NqWX6y4tcjSplYymYRipwHhgOOCi/CKkAcBjGMZnwBjTNLf8w008qHr26wDAejN4LJ/NZsPhsFOvYR2uvmMYAFPfmVFtfQl1Yhkz/nKevu999mWUfzOuSGSUizPO7c3s7/5kX3pp17A27VMBWLMi+Clfu9J63LpdUxb8vDykcwg4W/UAwOaMJPb2z3CkHkcgbx+ev6ZR8PW4kLJMUec/imfxt/jWL8DZtnel5aKH/hv/7nV4fv8cV68RVdYZ/8BcbPEpBDJ34vnrawq+e04Zr7/JnlSfiPY9yZ3+wYFlix1OItp0wrOldFy2q0lrALxbg8cY+fZux+/Ox9mkVZVVRrTrjj83C3/m3vDbI0xeFM+khYk4bAE6NXZzc99MujcN7Tp55IcUTmubR49UN/M3V541rU6Bx8bWfU5GdMopt69NSiHr0lwHXPfRwOjTBoAdq3f97br8PusGlLcweDyv1209btq+EWsWbKj0+Ha9W7Njze4K99kddpwRDlKPbcy595zF8p9MtqzYXmFZsdTka1uQ42bO5AWcdu2JrPtjI+v/2kzdpslc+OA5bFq6leU/rwbA77OCf+9+SYDiv4mm7RqVbGt7fCs2L9vGoFtO4fTrBpBYL54da3bz+RPfsfCrRX+7zSKHg3880DQMozkwD6gPzAZ+BNYBxbfjE4DWwGnABcDJhmGcYJrmpvK1HX7qN0ri5vtGMnfmEpb/tT5o3zPvjeaMYScAsHd3JtePGMu6VeUnltnfnY9ewqa1O/j8/dkht2PgkF7EJ8bw5QfBxyQmxQGQlRkcsBYHo8X7JTS2hAYARF/+IoVz3qVg2ngcqZ2IOms09jqNgrrTVsTVfRiO1I7kjD21ynKOlj1w9TyXnCcHV1nOv2cT+V+Pw791BQQCONv1J2LAKOxNjyPvlUvD++UkSHTfwdjsjmq7zVYm/twbsCc1IOeV/5Rss8VZd+r9FWQrA7lZ2GMrz45EdOxNVK/TyZk6Qd2kD8CQDjkMaJ1H/Tgf2/c5mbgwkVGTG/LG+bvo1aygymO/Xh7Lsl0RTDu7+vfv6mS57QSwBWUziyVG+dmYrkCzMkmNEhlxz1ksm22yYdHfv1+9Y60VJLbp0YIlM0ozWm16tgAgNqny7PJJl/WmTc+WvHLdu+X2RcZG8MbmJ0seL5mxkpdGTfrb7T2S1fRrC/DGzR9y6bgR/PvLW0q2rf19I0+MmICvKLDcuX4Pfp+f1j2a88c3S0rKFf8NxJX5G6jTMJH4lDiad2zK5Ae+Iisth5Mv680tk67kuUve4M9vg4dMiRyJaiOjOR5IBE4zTXNmFeXGGoYxEPgKGAdc9E807mCKiY3kpcl34/P6uPf6CeX2P33f+7z1zJc0bJrCxdeewYQp93DVkEfKBaRlde/TjnMuHsCIfmPCass5Fw8gbc8+fp7+V9B2W1FuWRMQ1Aybzeoz5/njC9zfWhOy+NbOB7ud6CH3YG/QBv+uimfEs8UkEjXsXtzfPEkgJ63ykzhcRI98DPfsiZXWVczzxxdBj72r5+DP3EH08AdwtO2Lb/WvlRwp1YnpNxjPxpV4t4Q3UzRAVO+ziB18JTlfvoFnddlrsuSCrOCoyvtdOhu3IumGcRSu+p2cb/SF9UCMO7s0C9y9qZtTjsnjnElNeGFOHd6/uOKZYQEy8+08OTuZ2/tnkhL797s+Fr/0Nsr/DehdunKRsRHc/v7V+Hx+3rjlgxqpc9msVWwzd3LJ2BG8fuP7bF+zix6DO3PC8G4ABPwVvyLt+rbhkrEjmDN5QdDstMUK8zw8MPApXJEumndqwpDRpzP6g2sYP3xCSQZNSh2M1xbgvHvPps/5Pfjw/i/Y8Jc1GdCwu87kzk+u57EhL1KYV4g7t5CfP5jHaVf1Z9OSrSydsYrmnZpw/v2D8Xl9+Mv8DdjtNiKKZr7dtMQaa7vip9U0btuQIaNPU6ApR4XaGKM5EPigmiATANM0ZwAfY2U3D2sRkS5e+mQMqS0acM2wx9i1Pb1cma0bd7Psz3X8+NUCrjv3cdL37OPW/15YZb0PvnAtU9+dya5tacQnxhCfGIPD4cDhsBOfGIMrovy9hLoN6tD75I5MmzwH334fYpkZFWcuE5Otx/syynffksr58zIA8JpzgrZ7V1mTvTiadKj02MhBdxDI3otn0TcQHW/9OCMBsEXFQ9GsshEDRmGLqWMtlVJUzuYq6qoXGWv9VMHzp5WBczbrFPbvJxZXq+NwNm5F3gFkMyO7nEidax4m/+cvyPn8laB9gVxrNmB7XPkxSLbY+AoznY56TUi++1V8e7aR8dxoZTNrSGxEgBNb5bFsZ2SV5V6YU4eUGB9nGLlkFdjJKrCXzCib47aTVxjeINGEKD82AuwrcJTbl1VgJ0HLm5TjinQy+oNrqNc8hSfPe4WM7TUzq7bf5+fFKyfiznPz3+mjeXX9OM6792ymPDINgMxd5a/Hll2bMfqDa1j5yxreuvWjCusNBAJsWLSF1fPX88MbvzDhmndo3+8Yeg4Nb9bUo8HBem2bGA0ZcvtpfHjfF3w3YRbmb+uYO+V3nr7wNVp2acZJl5QOW/nwv1+wdNYqbnj9Ml7dMI47Pr6O71/9idzMfPaV+RvISc8lJz23JMgE67Ve/vNqmh3XtEbafTSKdtj+sR/5+2ojoxkDhPPOkAEc+ACXQ4DT6eD5D+6gU/c2jBryCGuWV9/Nw+PxYS7fTPuOLaos17pdU1q3a8qFV59ebt/8bW8z9u63eW9C8EQiQy/sj9PpKNdtFmDtSusN8Zj2qezdVbpMSut21pviulWaAS8c/h1F2a39M1IlqePKvyQ6Gh6Do3E7Eh4vP5Yj4fG/Sta+dDRsgz2xPgkPzy9XLv6ub/BtW0HOk2dX31hlsQ9YdL8hBLweCn77NqzjIjr0IunmJyn4Y2bJrLJlebZZE4c5m7TGs7a0m5ajbmPskdF4twX3drAn1Sf5ntcJFOSQ/tRNBApCG7MtIQpUlUe2rE+LYPXeCPq+1Kzcvr4vNeOUNnm8eG7F4/QqEu0K0CTRy9q95bvIrkuLoEdq1d14jzYOp51b3h5Fq67NGT/i5Rpfq3C7uYv7T3qSuqnJRMZEsHOdtcQJwJr5wddj0/aNuGvK9WxaupUXrphY4RqLFdmwyJrkpkGrejXa9sPdwXxtm3awxlYWTzBUbNf6PeRm5tG4bYOSbQXZbl64fCLxKbEk1k9g75Z0IqIjuPChc1g9r/RvYJu5k2bHNSl3LptNvcbk6FEbgeZyYKRhGGNN06yiPyAYhlEPa5zmYdu/wGaz8cTEWznhpOO44bxxLFkYWre6qOgIjuvaig1rqp4M4PKzHiy37d/jr8DusPPYnRPZvK58F6+hFw9g1dKNrFpaftjr4vmrSd+bxeAL+vHb7NKZ0oZc0J/MtGz++m1VSO0Xi3flbAIeN872A/CuKE3iFy+F4ttS+Wx0+Z8/jC06eAxeRK/ziOh1Hjkv/x+BbKtrn/vHVyhc8GlQOWe7AUSdegN5792Of3flXa8BXN3Psdq6SZMTHBCHk+gTzsC9ZA7+7IyQD3O16UTS7c/hXrGAzFfvrTDQ96ftxLPJJLr3IPJ/+rxke3SfQQS8HtxLSjPl9vgkUsa8BkDa+OvDaotUL8dt46f1MXRqVPVkQGNOTifbHdxZ6ItlcXy5PI63Ru4kJSb8DPNJbfL5alks2W4b8ZHW38kfWyPZnuXk5NZa2qSYzWbj+tcuo8OJbXnmotdZ9/vBm9ph7xarV5LDaefUq/uzdOZKdm8s/UrToFU97p56I3s2pfHMxa/jKQh9/dV2RZPc7N6gSbyKHezXdt9ua4WAVt2aBU3C1LB1PWLrxJCxo/z65NlpuSWz4Q791+lk7c1hQZlJfn7/ZgnHDjBo2SW1ZBypzWbj2AFGuYBW5EhVG4Hmk8BkYLFhGM8DM6l4MqCBwK1AI2B0LbSzRtz/7FWcObw3rz4xlbxcN516HlOyb9e2NHZtT+fBF65hX3oOy/5aT0ZaFo1T63HxdWdSr2ES91zzUkn5xql1+W7pi7wy7lNeGTcVgIW/lF+PKWtfLg6Ho8J97Tu3pO2xzRh/zzsVttfr9fHiI5O5/9mr2LUjnd9mLeX4Accx/LKTeezOSSEvt3K0cHY+CwBH6nEAuNqfhD8nnUBOOr518wnkZeL+cQKRp99CoCAb75rfcKZ2JPL0Wylc8Cn+vaUflnH3ziKQsY3cCZcA4N+2stz5/G2syaJ86+aXdIn0714P+wWT9mQrA+3btCj4HHdOo3DhZ0XBZwCn0Y+I/pfjWTk77LU9j3RRPa0JmFwt2gMQ2akv/uwM/FkZFJql46yiup6IPa5OlZMA1XvyK3x7d5A+/joAHI1akPyvF/FnZ5L7v3dKzlHMs670BkT2lBdJ+tcLJFxxHwXzvsPVvB1xQ68h9/sP8e8r+mLriiT5rgk46jYm860HcSQ3wJFcegfeu229sptlTDetCTtW7LQWTf9lfTRJMT6SY3z0THUzaUECGzJc9EotsCYDynLw9sJE9uY6eGLwnqC6znyjCY0TvEy8wJr5sn2DwnLnW7glCrDW8Cy71Mn2fQ6WFnXF3Zdvx2YrbVvHhm4aJ1rX+Kie+5i2IpabP2vA1SfsI8dt4+mfkunYyM2pWkOzxGVPnsfxw7ry5dPTcee5S5YjAUjfnlnSzbLTwPZExkTQtENjwArs4pNjcecVBk3y8+TC+9i7NYPx575csm3w7aeStiWDjJ37SGmaxKlX9SOlSRKPDHq+pEx83TjunnoDzggHn437liZG8Bqpm5ZsxVvoIzo+irumXM/cT/9g17o9BAIBWnVvzpk3nMSmpVv5fdrig/I8HY4O9mtr/raOTUu3ctEjw4itE8OGRdYYzaH/OoPcfXnM+XhhybHHD+tKbFIMO9buJrZODN3P7sTxw7ry4hUTKcgpvRH18/vzOPWq/tzy9ig+ffwbctJyOenyPjRqU58nzgseJiFypPrHA03TNKcYhlEXeAJrYqDK+g/YgFzgZtM0P62kzCGv/2ldALj+7hFcf3fwkhMvPz6Flx+fwpKFaxlx+Smcf+WpRMdGsmt7Okt+X8v9N70S3M3WZsPpdGC3H/jQ2mH/NwCPx8u0T+ZUWmbyWz8QCAS44pbBjLptKDu27OXROyby8RvfH/B5j1SxVwZP6hR9/qMAeNfOI/cla/4q9/QXCLhzieh7CZEnX0Mgaw/uWa/jnv5i0LE2h5OAvfw4rJrk272eiP6XYU+oD3Y7/r2bcU9/EfeM1w7qeQ9HSbc8FfQ48Yp7AXCv/J30sVeXbI/uNwR/TiYFfwWvPRvE7oQyr21E607Y4xKxxyWS8p83yxXfcVmXkv+7l8wh86U7iRt2HTH9h+LPSiPn67fI+ar0OEdiSkmwmnTD2HL1pT1+NYWrfq/mNz56/Our+kGPH/kxBYCeqQW8feFOWiR7+HFNDDPWxJDjthMb4adrEzcPn7mXTo2CA0mf34Y/cGBjeeZviea+b+tW2LZHz9rLuYnWmPgG8T4mXbCTJ2YlM/rLerjsAU5uk8/dJ6f/Y+uCHg46DbSugXPuOINz7jgjaN/n47/l8ye+A+Dyp86nXrOUkn3D77FuGO7ZnMYdXR8u2W532rHv9wRHxkRw3r1nU6dhInn78lk6cyUvXjGJ9O2lGa8mRsOS+u/4+Lpy7fxXl4fYuyUdj9vD9tW7OP2aE0lqlIjP52fv5nS+nTCLH17/GW+hbuwWO9ivbcAfYPy5LzNk9OmcdFkfht9zFtnpuaxdsIGp474lbVtpD5FAIMDAUf2o36Iufp+ftb9vZOzQF8stbeNxexl37stc+NA5XPL4cCKiI9i8dCtPjXyVFUXLpYgc6Wy11U+8KNi8AOgHtMHKZNqwxm+uBX4BPjFN84D7jnSIG6lO8Eeg365eWH0hOSzlpf/9hbfl0FTvxPIZejkyjBpT9TJNInJoejft+cPuVtVlKbf9Y9/tD8fn51BTG11nASgKIF8u+hEREREREZEjRG0sbyIiIiIiIiJHsEM+0DQMI9kwjPLzxIuIiIiIiMgh6ZAPNIGngarXZxAREREREZFDxuEQaEL1a2SLiIiIiIjIIeIfnwzIMIxwg1sFmSIiIiIiIoeR2ph11lML5xQREREREZF/SG0tb5IJLAmxbDugfrWlRERERERE5JBQG4HmaiDSNM2TQylsGMYk4LKD2yQRERERETmUxdRWikwOSG1MBrQQaG4YRkotnFtEREREREQOstoINH/HmuCnZ4jlVwE/H7zmiIiIiIiISE36xxPQpmm+ALwQRvnxwPiD1yIRERERERGpSYfLOpoiIiIiIiJymFCgKSIiIiIiIjVKgaaIiIiIiIjUKAWaIiIiIiIiUqMUaIqIiIiIiEiNUqApIiIiIiIiNUqBpoiIiIiIiNQoBZoiIiIiIiJSoxRoioiIiIiISI1y1nYDREREREREqhOryOWwooymiIiIiIiI1CgFmiIiIiIiIlKjFGiKiIiIiIhIjVKgKSIiIiIiIjVKgaaIiIiIiIjUKAWaIiIiIiIiUqMUaIqIiIiIiEiNUqApIiIiIiIiNUqBpoiIiIiIiNQoBZoiIiIiIiJSoxRoioiIiIiISI1SoCkiIiIiIiI1SoGmiIiIiIiI1ChnbTdARERERESkOjGOQG03QcKgjKaIiIiIiIjUKAWaIiIiIiIiUqOO6K6zxzob1nYT5CCIvqRebTdBDpLYRYtruwlykPi7dK7tJshB8uoNk2u7CXKQRHbMq+0myEH1fG03QGqBYRjNaqou0zQ3V7X/iA40RUREREREpMRGoCYGuwaoJpZUoCkiIiIiInL02A2s+hvHtwPqV1dIgaaIiIiIiMjR41vTNEcd6MGGYUwCLquunCYDEhERERERkVDZin6qpIymiIiIiIjI0aElkPM367gDeKC6Qgo0RUREREREjgKmaW6qgTrSgLTqyqnrrIiIiIiIiNQoZTRFRERERESOQoZhNAQ6ACtM09xZZntr4DHgOGAz8Ihpmr+FU7cymiIiIiIiIkenfwM/APHFGwzDSADmACOxgtAzgRmGYRjhVKyMpoiIiIiIHPKinf7absKRaACw3DTNNWW2XQE0ACYCDwGDgFeAO4FrQq1YGU0REREREZGjUxNg/X7bzgY8wJ2maW4xTfM14A/gxHAqVqApIiIiIiJydIoF8osfGIbhBHoDC0zTzCxTbg3QNJyKFWiKiIiIiIgcnbYCbcs87gfEATP3KxcJ5IVTscZoioiIiIiIHJ1+AkYZhnErMAt4FAgAX+5XriNWUBoyZTRFRERERESOTo8DWcCzwCKgDzDVNM0/iwsYhtEBaAP8Gk7FymiKiIiIiIgchUzT3GAYRmfgKqAu8Cfw9n7FumJlOCeHU7cCTRERERERkaOUaZqbgQeq2P8B8EG49arrrIiIiIiIiNQoBZoiIiIiIiJHAcMwTjEMo93frKOdYRinVFdOgaaIiIiIiMjR4Ufg7r9Zxxjgh+oKKdAUERERERGRGqXJgERERERERI4e5xmGcdLfOL5uKIUUaIqIiIiIiBw94op+/o5AdQUUaIqIiIiIyCEvxuGv7SYc9kzT/MeGTmqMpoiIiIiIiNQoBZoiIiIiIiJSoxRoioiIiIiISI1SoCkiIiIiIiI1SoGmiIiIiIiI1CgFmiIiIiIiIlKjFGiKiIiIiIhIjVKgKSIiIiIiIjXKWdsNEBERERERkdpjGIYLGAz0BFKA+aZpTiza1xioC6wwTdMbap0KNEVERERERI5ShmGcArwLNAJsQABwAROLipwCvAOMBKaGWq+6zoqIiIiIiByFDMPoAkzDymI+B5yPFWyWNRXIK9oXMmU0RUREREREjk7/xcpenmqa5k8AhmEEFTBNM98wjBVAl3AqVkZTRERERETk6NQfmFccZFZhM9A4nIqV0RQRERERkUNerDPkeWgkdHHAzhDKxVC+S22VFGgel1lBjQAAIABJREFUZCcM7ULf87rRumszEuvGsXdrBvO/XsJnz3xPQY4bgONObMvJ/3c8bXu1JLlhAuk7s1gycxWTx/6PrL05VdYfFRfJDS9eTKvOTanTIAGf18f2Nbv59vWf+eWT3w9aOYGdaX4mTnOzfL2P1Zt9FBTCd8/F06ReaUeB7Xv8jH03H3OTj/SsANGRNtqk2hk1OJL+XVzVniMj288zHxXw059e8goCtG3m4KbzIunbKfjYfHeAFz4p4Pv5HjJzAjRrYOeqoZEM7htRUiYnL8B737n5dYmXjTv8+P0BWjVxcOXgSAb2qL4tR5Od2Q7emp/I8p0RmHsiKPDa+f7arTRJDP6AO/bJFhUe/+ll22nfoLDKc9z7bQpLtkeyK8eJPwCpdbyc1ymbC7tk46ikr8lf2yK59MOGBLCx+I6NOIvK5bhtvPtHAr9uiGZDugt/wEbrlEJG9cpi4DF54f76R7RQrtv9vfllAc9/4qZrWwfvPhBXZf17Mvx8ML2Q35Z52bzTh8tpo20zO9efG0WP9qUfueFej3+aXp75qIBVG33ExdgY1MfFrSOjiIoI6zP/iGZLaISz/83Ym3TG3rADtogY8p/qSSBzS/my9Y7BNfBuHC37QEQMgcxteBe8jfe3Nys/QVx9XL2vxt5mAPaUluDz4N+5As+sp/FvnFdad51Uou9cWGk17snX4Vv6JdjsOPtch8MYiL2+Aa5oAmnr8cyfhO/PjyEQ+FvPx5Fk5z47b86JY/k2F+YuFwUeGz+M3k2TJF9QuQ7/bVTh8VNv2EP7RtUHKFN+j+btuXFszXDQpI6Py/rkcmHP4PfQ/3yWyBeLYsode+kJufx7UFbQto8XxPDevFi2ZjhIifMzrEseN5yUg8tRbVPkMGMYRlOsiXIGAwZQD9gF/AA8YprmhgqOOR+4CzgOa/zjDGCMaZobwzivq6iOK4FUYDcwGXjQNM3cEKvZChxbzXnsQEdgfahtAwWaB92QW05h79YMPnx4GunbM2nRqSkj7zmTY/sfw32nP0sgEOD0UX2Jio1k6lPT2b0xjYat6nHBv8+i88B23Nl3HAW5lX9hdboc+L0+Pn/2B3ZvSscV6aTP8K7c+vplJNSN45sJsw9KOYEtu/xMn+ehQ0sH3Qwnc5eW/xDLcwdIirdxy/lRNEi2k5MfYOqsQm58Mo9nb4/h1J6VB3iFngBXPZZLZnaA0RdFUTfRxuezC7n5qTxevyeWnh1KL9/Rz+WxeI2Xm8+PomUjOz8u9PLvCfkE/DCkvxVs7kjzM/nHQoadGMF1wxzY7fC/uR5ufzaP/1wexUWnR9b8k3SY2pzhYroZS4cGbro1dTN3Y3SlZYcdl83IzsE3hFoke6o9h9tr5+Ju2aTW8WADft0YzdgZyWzOcPHvgenlynt88ND3KaTE+tibG/zWvSPLycd/JXBux2yu770Pmy3A/1bGcesX9bl3YBoXd8sO7Rc/CoRy3QaV3+3n9S/dJCeEFtCt2ODju3mFDBsQQac2kXi98PGPhYx6LJcX/xXDgG7WNR/O9Whu9nHt2Fz6dHLy0p2xbNvj5+kP89mdHuCpW8t/4T1a2VJa4uw4FP+2Jfg3zcdxzMkVlrM37kzkqE/xbZhL4Rd3ECjIxpbSEltEbJX125t0xtHxHLx/foxnyx/giMB1/BVEjvoM9weX4zd/ACCQvYuCVweVO9512j3Ym/XCt7aod5orCtdJt+NdNAXv3DcIFObiaHsqEec8jbfuMXimP/z3npAjyOZ0J9OXRdGhsYfuzQr5dV3ln1fDuuZxQY/g4LBFSmhB5oNfJ3JN/1x6t3Izb30Ej0xLgABc2Cu4vuRYHy9fnBG0rW68P+jx6z/H8vyMeC7rnUv/Nm5W7nTx8qx49mQ7eGTYvmrbI4edm4ExwErga2Af0AMrADzXMIx+pmkuLy5sGMYNwARgG/AqkAhcDJxkGEYv0zQ3hXje97EC3N+xJuzpANwJnGAYximmaVb/hcSaCOhWwzCuME3z7UrK3AQ0BSaF2C5AgeZBN/7C18lKK/0SuuLXteRk5HLLq5dybP82LPt5DW/eMaVcmR3rdvPw/26j97ndmPX+vIqqBiAnI4/nr3k3aNtfP6ygcev6nPJ/J5QEhjVdTqB7Owc/vZIAwNRZhRV+YW3T1MHD1wZ/ETyxq5Mzb8/mi58Kqww0p8/3sGaLn4n3lgaV/To7GfHvHJ75qICPHrEyK3+aXn5d4uWRa6MZNsAKKvt0crEr3c+zHxcwqK8Lh91Gk3p2vn02nujI0i/MfTu52JWew8RpbgWaZfRILeDnm6wsyKdL4qoMNOvH+ejc2B32OZ4asifocd+WBezOcfDZ0rgKA81JCxMJAMM75vD6vDpB+5okepl+7VaiXaUZkH4tC6zM7IJEBZplhHLdlvXoxHzO7hvBxh0+fL4qiwLQ1XAy7el4nI7S66xPJyfnjrGus+JAM5zrccLUAhok23n61hhcTqu8ywn3vprPqA0+OrRUegTAv/E38sd1BMDR/eKKA02bjYgRL+Bb/wuFH44q3b7h1+rr3zSfguf6gL/0D8G9dhZRt/yEq/+NuIsCTXyF+Lf+GXywKxp7k674zB8gP9Pa5ikg/5njSx8D/vVzsEUn4jxhFJ4ZT4C3ILRf/gjXo3khv4zZDcCnf0RXGWg2iPfROTWU79alvD54fkY8Qzvnc/up1vvl8a0K2Z3t4IWZ8YzonheUhXQ5qPIcbg+8/nMc53TOZ8yZVn192hRiA57+IZ7L+uRyTH11AT3CzAf6mKb5W9mNhmGMBp4BngLOKtpWD3gSq7tqN9M0dxdt/xArAzoeuLC6ExqGMQgryPweGGSapq9o+8PA/cBVWEFsdcYWne9NwzD6AF8VbU8xDONU4BzgemAL1qy0IdNkQAdZ2QCy2Lo/NwOQ3KhOCGUSD+i82em5eL3Vfyuq6XJHE7v9wLqsOR024mNsOKv5brhkrY+oCOjRvrSgzWajT0cny9b72JXuLykH0K9L8H2jvp2d7MkMsGSNtT8myhb0pbZYh5YO9mSoi1ZZB/jS/m11ov047eVfi80ZTl6fl8j9p6aVdJctKyYiEBRkFju2YSF7chSElBXOdfvNr4Ws3Ojj9gtCvwmTEGsLCjLBuuaNZg52l7nOQr0ePd4Avy72csYJrpIgE+CM4124nDDrj/C+UB/RQuhqam/ZB3sDA++vr4Vff0FWUJAJgN+Hf+dybAkVd9ks5ugwCFtUPN6/PinTXn9QkFlS5bZF2FxR2GKTw2/jEcp+kL+tLtriIj3XwZBO+UHbh3bOJzPPzp+bIio5smJrdrvIK7TT/5jgm5D9j3ETCNiYsTLqb7dZDi2maX6+f5BZ5HmsbrH9y2wbCcQCzxcHmUV1zABmA8MNwwi+o1yxK4v+faA4yCwyDsgBRpU/pMK27wYGAquBq4Evi3YNBqZjZTPXAWeapplRYSWVqNWMpmEYCcDxQGuslDFYqeZ1wHzTNLMqO/Zw1qFvGwC2mpWPuy0us83cFXK9doedmIQoThjahc4D2/PKLR/+I+Wken5/AH8AMrMDfDqrkI07/Iy5tPIsGYDDDk6HFVyWFeGyHq/d6qNBsr3kA7jsl1CAiKLHa7b66GpUfqn/scpHy8a653SgJi+KZ9LCRBy2AJ0au7m5bybdm4aW4QwEwBeAvEI78zZF8eWyOEb1Kt+l6pEfUjitbR49Ut3M31z1301Zf2yJpGWKApEDsS83wBPvFzD6oigS4/7e9eHxBli81kvb1OqD/v2vxy27/bg90KZpcBsiI2yk1rezbptuAIbD3vx46z/OSCKv+wZ7406Qvw/v0i/wTH80/Ayiw4U9tTuBnSurLObsOpJAzh78a2ZW38YWvQnkZxLIDv3zX0p9vDCWib/G4bBD56aF3HRyNj1aVP0+uHaP1dPgmAbBWcY2RVnHdXucHN+qdBhTWq6dPuMakF1go2mSjxHd8riyb27J+Hp70Q1DlyP45ofLaT1eu1sdCo8yXqDsH0Nx0DmjgrI/AidjxUfTq6m3P1ZAuaDsRtM08wzD+A0YaBhGtGma+RUeHXzMCsMwOgLDsILO5lgJya1FbZpqmmbYafha+Us3DCMVKy08HGvdlv1v6wYAj2EYn2ENii0/kv8wldwokQv+M4gls1axflHFv1ZUXCRXjB3O1lU7WfDNkpDqPfOa/lz1pLWGqrfQy6R7pvLzx+UnI6jpchKaZz4q4J3/WR9SMVHw5C0xnHBc1Zdfi0Z2cvJh/TYfrZqUfkFdvMa6zvflBErKASxZ4w2aYGjxWqtcVk7ld/mnzCxkyVofY28MPXiRUkM65DCgdR7143xs3+dk4sJERk1uyBvn76JXs+q/sP60PpqbPmsAgI0AVx+/jxv6BAeaXy+PZdmuCKadvS2stn2yOI7FO6IYf/ae6gtLOc98mE+LRnaGnfj3J8qaMNXNrvQA426sOjNa0fVYfP0mxJbPfibG2cjKVW+EcNjirest8oLX8M6fhOf7x7A37oxr4F3YEhsHd6cNgeuUO7ElNKZwyk1VnLMh9lb98P72RvmM6H7sbU7CcdxQPDPGV1tWyhvSOY+T2rqpF2+9J0+aE8uot1N48/J0erWsfL6LfXnW9ZUQFTzOMjHaerwvv/RGT7uGHjo09tCmvhe318pOPvtjPJvSnCVjL5sn+7DbAizeGsGpHUpvPC7eElF0Pt3cPRwUZRUryixmmqZZvjtCxc4BEoDPy2xrU/TvugrKF29rXU3b4oAGwFLTNP0VFFkHnAa0BFaE0tCirOjUop8a8Y8HmoZhNAfmAfWx0sM/Yj0ZxdnLBKwn9zTgAuBkwzBOCGNQ7CErKjaCuz+8Bp/Xz8s3VZ5FvP3Ny0lulMh9Zz6H31fR3055cz/7i9ULN5KQEkePs47jqifOw+/z8+Pbcw9qOQnNJWdGclZvF3szA3w1x8OYl/N45tbSiUEqMqhPBK985ubeV/N56Jpo6iXZ+HRmIX+ssr58FPcA7NPRSavGdsa9W0B8rI2WjR3MWOjh27nWHVxbJV0FF67wMu7dfIb0cwXNTiuhG3f23pL/d2/q5pRj8jhnUhNemFOH9y+ufqbw7k0LmHzpdnLcVkZz0sJEbDa4rb/1+ZWZb+fJ2cnc3j+TlNjQ3gsAFmyOYuyMFIZ2yGFwh1AnnZNif6zy8tUvHj55LK5cj4JwffNrIW997ea6YZF0b1f5R25l12Nxb9CKmqFJScNns1lf8L2Lp1pjIAH/hrlgdxBxxn146rUlsGd1SHU5Op2Ls/8teGc/i3/T/MrLdT0Pm90R3G22orbVa0vkyFfwb5yL95eXQvyNpKzxI8reqPMwsF0BQ1+qywsz4nn/6rRKjwsU5TtCudwv6xM8MdCAtm5iIvy8+1scV/XPoUWKj9jIAMO75fPh/BjaN/LQr42blTtcPPtDPA57AJtNF+9h4nbggQq2PwQ8WN3BhmE0AF4E3MB/y+xKKPq3op6bxduqGztXVR3h1HNQ1UZGczzWL32aaZpV9SEZaxjGQKwBqeOAi/6Jxh0srkgnYz66lgYtUnjg7BdI317+RojNZuPmVy6h40kGY0e+xubl20OuPystp2Ss56IZK4mMieCyR4Yx6/15+Lz+g1ZOQtMwxU7DFOsLzoBuLq58NIenPiyoMtBMiLXxzG0x3PtqHiP+bb0WqQ3s3DA8kpc+dVO3jlWf02GVG/NyHpc+aAUVKYk2brsgiifeL6BenfKfnMvWebnl6Vx6dXDy0DXKZtaU2IgAJ7bK47Ol8SGVj48McFxD6y77Cc0LcDng1d8SubBLNg3ifbwwpw4pMT7OMHLJKrBeb7fXej1z3HYiHAFiIoK/sCzdEcHNn9fn+Gb5PHzmXiR8D7+Vz/CTImiQbC/JGPp84PNDVm6AqIjSLuxVmf2nh/tey2f4ABc3nVf5mKyqrsfEOOs8+yromZCVG6B1kjIj4QjkWcOL/MUzvxbxrZ0NZ9yHvdGx+EIINB3GaUQMfx7fnx/imflklWWdXUbi376UwM7Kkwq2pGZEXjmZQMZm3B9coWxmDYmNDDCgrZupf1Y9O3OdMpnLemVmjy3OZBZnNiszqGMB7/5mLb/SIsV67e4+I4vMPDt3fVqHQMBGpDPAzadkM3FObNA55JD2HPB2BdurzWYahhELfAE0Aa4xTXNZmd01MRNEcR01dteiqM3dgUZApV1wTNN8t7J9+6uNQHMg8EE1QSZgDYo1DONjrLTzYcvhtHPnu1fRpltzHh72MptX7Kiw3LXPjqTP8K48fflElv0c2h3Vyqz7azMnXXw8ifUTKgxqD1Y5Cc2xLR28/13V6ywCdG/n5Ntn49m8y4/PDy0a2pn0TSFREQTNNNm6qYNPx8azbY+ffHeA5g3tzFhoZTS7tg0eF7Z6s4/rxudhNHfw7O0x5cZ2yt8UOPBPkGMbuvEHbGzd56RBvI/1aRGs3htB35ealSvb96VmnNImjxfPLZlHgNV7XFz7aQPa1S/kuXP2aK22A7R+u5/12wv5ZEb5a7TvtVncfUkUl55VdTfYecu83PFCHgN7uPjvVZXfzKnuekxtYCfCBWu3Bn8xdRcG2LrHz+nHaw3ccPh3m0BF38yKnvdA9QGAvVU/Ii58A9/Kbyn88q6qyzbpgr1+Wwq/ub/SMraERkSO+hQKsil452JwV71+toQnQPWZyuKxmGt2O6kXX3rdr9tjfU1uXa/qoWkV9TyIiwrwwkUZpOfa2Ztjp0kdH/keG09/n0C35tV//kvtK+oeG/aXXsMworAm1DkBuMs0zf0X6C1OvScA+08zn7BfmcoU768sYxlqPcVrZD4K3ApUlX2wYV1Sh3SgGUMIv3QZGVT9Sx/SbDYbt75xOccNaMvYka+x5veNFZa77NFhnHJZb16+4QMWfrP0b5+3Q9825GcXkLWn6mUNarqcVM/vD/CX6SO1QWiZCJvNRvOGVsSQV2Ctwzm4XwQxUeU/OYsXnfd4A3z0QyF9OjpJbVAabWza6ePacbk0rW/n5Ttjtdh7Dctx2/hpfQydGoW/3AnA71uisBEgtY71pWbMyelku4P/Tr5YFseXy+N4a+ROUmJKsx6bMpxc/UlDUhO9TBi+i6gKZqGV0Ey8t/x6iuPfy8fnh/9cHl3ttbtojZdbn8nl+GOdjL0xutKZbkO5Hl1OG307Ofl+vocbR0SWzGj7/QIPhR44qbsCzXD4Vs8k4CnAcczJJeteAjiOOQkA/7bFVR5vT+1O5P+9g3/9HGtcZjX9lx1dRxLwefAu+bziAjEpRF5pdal1v30B5FXevVPCl1Ng46fVUXRqUnVg1zm1kKQYH9OWRNOndWnZrxdHkxjtp2uzqo//Zmk0NluA45qUn3QoOdZPctHQh9d+iiMpxseZx2rZmiOVYRgRWGMcB2LNBvtUBcXWYmUOW1M+0Cwem1nR+M0SpmnmGIaxC2hpGIa9gnGarQE/sCGEZj8E3AMUYmVh1wE1Mu6mNgLN5cBIwzDGmqZZ5Ttq0TozFwDLqip3KLv6qfPpc25Xpj45HXdeIcf0aFGyL217JunbMznntlMZcvMpzHzvN3as2xNUJmtvDrs2lnZ/+3jvs/z00QJeueUjAE69og9te7ZgyezVpG/PJC45hj7DutJ7WFfef+ArvB7fQSknlu/nWx8qKzZYz8ucxR6S4u0kJdjo2d7JhKkF7MsJ0LWtg5Q6dtIy/Xw228PS9T7G3xR8/6TLpfsY2t8VtO7mcx8X0KGlg6R4G5t3+Xn7GzdOB+WWW3jzywIa1bVTP8nOjjQ/H/9QyI40P+8+EFdSJm2fn2vH5uLxwk0jIsvNVtm+hSOk7oBHi+mm9Tqs2GmNl/tlfTRJMT6SY3z0THUzaUECGzJc9EotsCYDynLw9sJE9uY6eGJw8AQ8Z77RhMYJXiZeYM0i+dO6aD5fFsdJrfNolOAjt9DGnPXRTFkSz8jO2dSPs16b9g3Kf7lZuMXqgtkjtaBkqZO0XDtXf9IQjx9u6pvJurTgMbft67uJ0CSHJaq7bovXrS0rPtaGz0e5fYP+lU3jujbe/I91ra3f7uOmJ/NIirdx5dmRJeco1vkY6/hwrscbh0dxyYM53PlCHheeFsn2vX6e/rCA03o5OVZraAZxHDsYAHvjztbjtqcQyE0jkJuGf+NvkJ+B5+cXcZ00GtzZ+NbPwd6kM66T/4X3z8kE0jeW1BU1+jcCmVtxT7ImxrPVbUPkpe8TyEvHM2eCNWNtGeXWzrQ7cXY8B9/qmZBbQTd2ZxRRV3yErU4qhZ+PxpbQKGiZFP+e1cpuljF9ufXet3y7dXPllzWRJMX6SY7x07NlIRPnxLIxzUmvlm7qx/vZnulg0q+x7M2x88SI4JvkZzxXj8aJPiZdaX3HdzngloE5PDItgQbxPnq3LmT++gg++yuaewdllbx/bst0cM/URAZ1LKBZspdCr40fV0bxxaJoRvbIo1ly6XX87dIo9uXbaVHXS1a+nR9XRvHdsiieuzCD2EjdCDwSGYbhBCYDg4AnTNN8uJKiv2DFNwOB/WfaPBXwYK3LWZ1fgPOAXljz3xS3IwboDfwRyoyzWMuk7AN6m6a5KoTyIauNrx5PYr0Iiw3DeB6YScWTAQ3ESuE2AkbXQjtrRJfT2gMw4q4zGHHXGUH7Phn3LVPGfUvXojKnXNqbUy7tHVRm9ofzefnGD0oeO5wO7I7Su+mbV+yg56COXPbIOcQlxZKdlsPW1bsYO/JV/vx+xUErJ5Y7XgieFODRSdZdyh7tHUy6L472LRy8/52b7+Z5yM4LUDfRhtHcwTv3x5ZbcsTnt37KSsvyM/69QtKzAiQn2BjY08VNIyLLLbeQ54YXpxSwOyNAfIyNfp2dPHNbTMm4UID12/xs32t9uN30VHC7Ab57Lp4m9RRoFvvXV/WDHj/yYwoAPVMLePvCnbRI9vDjmhhmrIkhx20nNsJP1yZuHj5zL50aBQeIPr8Nf6D0uU2t4yUQgBfnJJGW5yAh0k+zJA9jB+1lUPvwbyKuS4tge5b193Rj0Sy2ZX1/7VaaJGpx8GLVXbfh8PkC+Pylr+2SNT6ycgNk5cKox8q/lks/sHo5hXM9tmvh4NUxsTz7cQE3PZVLXLSNof1d3DpSa/HtL/Ki4B5qEUPHA+DbMBf3W8MB8M56Gtw5OI+/AmffGwjk7MY75xU8s54JrszuBHtpIG9P7Y4tJglbTBJRV31W7tx59zUMeuwwTsMWm4KvkkmAbHH1SoLVyJGvlNtf8NZwa6IiAWD05KSgxw9Ps66lni3cvNMynZZ1vcxYGcWPK6PIKbARGxmgW7NCHhm2j05NgzONPj/494v1LuyZhw14e661PEqjRB/3nZ3FRb1Kr8/YCD+J0QHe/CWWtFwHNqBVPS//GZTFRT33u45t8NGCGLZkOHHYA3Ru6uHtK9Po1lxLTh2Jirqfvo+1PMiLpmmOqaL4J1hz1txqGMbE4rU0i+amOQmYUnZW26LAsRmwzzTNsuPvJmEFmg8ZhjGozFqa9wBxRftDkQR8X9NBJoAtUAvT1hmGcQPwBNZipZU1wIaVtr3bNM3y78AhOL/OrbpldAT64Md51ReSw5J9UdXd1uTw5e/SubabIAeJ94vNtd0EOUgiO5a/CSJHDscFWYfd3eX3O476x77bX7J0YsjPj2EYD2HNLLsXmEAF8Y1pmg+WKX8j8DKwDSsBVwdr4tMcoGfZ1TYMwzgJmAW8Y5rmFfuddzIwEvgda13ODsAQ4FfgZNM0q72zYRjG70CeaZonhvr7hqpWOlOZpvmKYRhTsNLG/bDWk0nACi73YfVd/gX4xDRNTZsoIiIiIiKHquZF/9YleCmTsh4s/o9pmhMMw9gL3AXcCOQD04AxYS7peAmwBKv762hgN/A01vjQUNPnTwNvG4bRyzTNBWGcu1q1ktH8pyijeWRSRvPIpYzmkUsZzSOXMppHLmU0j2zKaFYtnIzm4c4wjLuwgt4XsIY1bqOSXqemaYb8pq/pIURERERERI5ei7GWcnmo6KcyAcKIH2sl0DQMoz3wFNAf8GL1KX7ANM1ys80YhvEAcL9pmgqKRUREREREaohhGOdiTVDkAPYAmzhclzcxDKMFMAdrhqM8wA6MAM42DOMm0zQrmiHpqEldi4iIiIiI/EMeLPr3SuBd0zRrrHtyWIGmYRh9gGTTNKcVPU4BXgKOA6ZjDWCtbqHF+7GCzNFY/YChaCpg4E3DMOqYpvlsOO0SERERERGRsB0DzDZN852arthefZEg44DuZR4/ibUo6WrgBuA/IdRxGjDDNM3nTdMMFP18DnQDFgBPGYZxb5jtEhERERERkfDsxBqfWePCDTTbY63TgmEYLqxFQkebpjkCuBe4OIQ6GhTXUVbRYqUDsdaJedgwjMfDbJuIiIiIiIiE7j3gZMMw6tR0xeEGmnFAVtH/ewGxWGu+APwJNAuhjj1AYkU7TNPMA84GvgPGGIbxLBqfKSIiIiIicjA8AvwCzDQM48SarDjcyYC2AZ2LGnMWsKwoEwmlk/tUxwQq/SVM03QbhjEMa/ajW4G9YbZRREREREREqrcaK7HXDJhlGEYhVnfaiiYFCpim2TrUisPNaH4EPG4YxqfAv4D3y+zrBqwJoY5vgPaGYRxfWQHTND1Y3XKnAPXCbKOIiIiIiIhUrwXQHCvYtAGRRY9bVPDTMpyKw81oPggUACdgTQz0TJl9nbECw+pMxgoeG1ZVyDRNn2EYF2FlQEPpkisiIiIiIiIhMk0z3MRjyMIKNIuWLnmskn3DQqxjG/DvEMsGgAdCbqCIiIiIiIjUunAzmiIiIiIiIv+4GKe3tpsgYQgr0DQMIwIrG3kRVnfWyP2KBEzTVPAqIiIiIiJyiCkzs+wC0zQLwp1p1jTNn0MtG25Q+CRwE/At8BngDvN4ERERERERqR2zsWaUbY8142zx41A5Qi0YbqB5HvAdatPaAAAgAElEQVSAaZoVjtMUERERERGRQ9a7WIHlvv0e17hwA8044LeD0RARERERERE5eEzTvKKqxzUp3OlsvwbC6scrIiIiIiIiR5dwM5ovAu8ahuEH/gek71/ANM31NdEwEREREREROXgMw/ABb5umeVU15d4Argxn4tdwA83ibrMPUvn6liEPEBUREREREZFaYyv6CbVsyMINNEdxkAaLioiIiIiIyCEpBSgI54CwAk3TNN8Op7yIiIiIiIgcOipYO7NhFetpOgEDOBMwwzlPuBlNAAzDsAEdgGQgDVhpmqYynSIiIiIiIoe22QT3Uj2j6KcyxV1mnw3nJGEHmoZhXA08CtQrs3m3YRj3mab5Vrj1iYiIiIiIyD+m7NqZlwPrgF8rKesBdgDfmKa5IJyThBVoGobxf8DrwAzgfWAn0BD4P+B1wzDyTNP8KJw6RURERERE5J9Rdu1MwzAuB+aYpjmqps8TbkbzbuAD0zQv3W/7O4ZhvAeMARRoioiIiIhIjYp2emq7CUcc0zTtB6vucCs2sDKZFXm/aL+IiIiIiIgcxcINNLOBppXsa1q0X0RERERERI5i4Qaa3wKPG4bRv+xGwzB6Y00Q9G1NNUxEREREREQOTwcyRvMEYLZhGNuwZiBqiJXNXFu0X0RERERERI5iYWU0TdPcCXQBbgN+A7KAecAtQFfTNHfVeAtFRERERETksBL2OpqmaeYBLxX9iIiIiIiIiAQ5aNPZioiIiIiIyNGp2oymYRjrgXNN01xsGMYGIFBF8YBpmq1rrHUiIiIiIiJy0BmG0RxoBERUVsY0zZ9DrS+UrrM/YY3FLP5/VYGmiIiIiIiIHCYMw7gW+A+QGkJxR6j1VhtomqZ5ZZn/XxFqxSIiIiIiInLoKgoyXy16uARYA+TURN1hTQZkGP/P3n2HV1Xkfxx/35IeAqH3DkMRka6ISlGxoKDoKhYUsesq6Lq66s+1u8ha0FXXBriKDRURFRApCoKoiFIdeg8dAoG0e+/5/XEuCSH1QiBIPq/nyZOcc+bMzE3/npn5jnkEeMtau6mAa7WAm6y1j5dGx0REREREROSoGgJkA/2stRNLs+JIkwH9E3fPzILUDl8XERERERGR419j4PvSDjIh8u1NPEVcSwYyj6AvpS7OV1R3ReR446kQU9ZdkKPEsy+1rLsgIhEKbc4u6y7IUVTihXZyotsKpB+NikuSdbY70POgU7cYY/ocUiwOuBBYXHpdExERERERccVHH1djWieKj4GBxpgka+2eYktHoCQjmmcBD4c/doBBBZTJApYAd5VSv0REREREROTo+j/gVOAzY8xN1trVpVVxSbLOPgY8BmCMCQGnWmt/Kq0OiIiIiIiISJn4Kvy+B7DMGLMG2AiECijrWGt7lbTiiNZoWmsjTR4kIiIiIiIix6fuB33sA5qE3wriRFJxSdZo1gdSrLXZ4Y+LZK1dF0kHREREREREpEw0OloVl2REczVwGvATsIbiI1klsRIRERERETnOWWvXHq26SxJo3gCsPOjjiIZMRUREREREpHwpSTKgdw76ePRR7Y2IiIiIiIgcU8aYusCNQDegVvh0CjATGGmtXR9pnREl9zHGTDPGtCjkWnNjzLRIOyAiIiIiIiJlwxgzEPgDd6uTnkDL8FtP4J/AUmPMtZHWG2kW2e5AUiHXKuDuuSkiIiIiIiLHOWPMGcBI3Jmub+HGew1xkwR1B97AzcEz0hjTLZK6I9reJKywNZpNgLTDqE9ERERERESOvQdw47vzrLUzDrm2FvjeGPMB8G24bJ+SVlyS7U0GAYPChw7whjFm7yHF4oCTgKklbVhERERERETK1KnAdwUEmTmstd8ZY77D3YmkxEoydTYEBMNvnkOOD7ztAF4DBkfSuIiIiIiIiJSZeGBrCcptC5ctsZJmnX0HwBgzHbjNWvtHJI2IiIiIiIjIcWct0M0YE22tzSqogDEmGjg9XLbESrxGM9xARaA+blYiERERERGRYyI2qsA4SI7MJ8CDwIfGmL9aazcefNEYUwt4CagDPB1JxSUONK21WcaYRkAgkgZERERERETkuPQv4GKgH3CBMWYW7silAzQAzgCigQXAsEgqjnR7kynAuRHeIyIiIiIiIscZa20abjD5Jm4unp64iWBvAHqFz70BnBUuW2KRbm/yMvCeMcYPfA6kcMh2J9baVRHWKSIiIiIiImXAWpsK3GKMuQfoANTCTQK7CZhnrd13OPVGGmh+F35/DzC0kDK+w+mIiIiIiIiIlI1wQPl9adUXaaA5qPgiIiIiIiIiUp5FFGiGtzoRERERERGRPxljzEjcpY8PWmu3hI9LyrHWDi5p4UhHNEVEREREROTP6XrcQHMYsCV8XFIOcPQCTWNMdWAAYIDYQxuPJMoVERERERGRY6ZH+P26Q45LXUSBpjHGAD/iJvxJALYDlcPHu4DU0u6giIiIiIiIHDlr7XdFHZemSPfRHA78BNTATXl7PhAH3AjsBy4p1d6JiIiIiIjIUWGMGWiM6VqCcqcaYwZGUnekgWYn4FUg88D91tqAtXYk7h6bL0ZYn4iIiIiIiJSN0biDhsUZDIyKpOJIA81EYKe1NoQ7TbbqQdd+wQ1ERURERERE5MThw00GVGKRJgNaA9QMf2yBy4FJ4eM+wO4I6xMRERERESlWbHRWWXehPGtJhLFepIHmFOAcYCzwPPChMaYbEABaAE9FWJ+IiIiIiIgcIwXsndmtiP00/bi7jXQEvoqknUgDzX8AMQDW2o+NMfuBK4F4YATwZoT1iYiIiIiIyLFz/UEfO0DT8FtRlgJ/i6SRiAJNa20mkGmMSQJOws04+yqwyFq7J5K6RERERERE5Jg7sHemB5iGuxRyWCFls4EUa+3qSBuJdEQTY8wjwL24iYE8uFFwmjFmuLX2yUjrExERERERkWPj4L0zjTHvADOPxn6aEQWaxpjHgP8D3gI+BLbg7qk5AHjMGOO31j5a2p0UERERERGR0mWtHXS06o50RPMm4Dlr7X0HnVsMTDPGpAI3A4+WUt9ERERERETkTyjSQLMiMLmQa5OA246sOyIiIiIiInIsGGOCERR3rLUljh8jDTTnAp2Abwu41il8XURERERERI5/63Fz7hzKC9QEosLHayOtONJA8y5gnDEmgLuX5oE1mn8BbgD6GmO8Bwpba0ORdkhERERERESOPmttw8KuheO67rjbWC7BzctTYpEGmgvC7/8VfjuYB1h40LFzGPWLiIiIiIhIGQsPGk4zxlwALAIeBEq8y0ikgeDjFDy0KgXodFFbTu3fgUan1COpaiI7Nu7ily8XMOGFKWSkZQIQmxhDv/vOo9Ep9WjYth5xFWJ5+uKX+eOHFSVqIzouisse6kPnfqeQmJzAllXb+HLEt8z5ZF5Omar1KvP8b/8stI5XbhzN3HHzAbjk7+dxyf3n5ysz7+sFjLj27Uhe/glv844QI7/MZPGqIMvWBcnIgkkvVqBONW+h97w1PoMRH2fSrrmP//0zsdg2xn+fxYxfs1m8KkjKDoeLz4jiqVvj85X71Qb4dHoWS1YHWb0pRI3KHiaPSCq038++m86cRQEcB049yc/918ZRq2rh/S5vNqd6eWtWIos3RmG3RJGR7WHK0K3USc67jKHVI7UKvP/T27bRslagyDY+nx/HdBvDoo1RpKT66XfKfp6+NDVfuXdmJ/DVgljW7/KTnu2hRlKQni0yuOXMNCrF5/11PG9tFM99k8TSlCgSY0P0aZPO3WfvJTYqX7Xl1uZdMHISLF4Ldj1kZMPkp6FO1cLveXMijBgH7ZrAu/dH1t78lTDwWXAc+O018Ptyrz00CsbPyX/PNb3ggStyj0+6ufD6h1wCN+b/lV0ueZJq4T/jTrx12uKt2QpPdDzp/+6Es3t9/rLVmhHV6+/4GnWF6Hic3RsJ/DSawJy3Cm8gsTpRp92It+lZeKs0gmA2oc1LyJ7+HKE1P+aWi0nE3/VmfM164K3aBDw+QtuWEZj5CsGlk/JU6e96M76TL8VbuT5ExePsSSG4dDLZ342A9F2l9an580usg7fDvXhqtMdTtQ2eqHiyRxrYuy5Psai70wu8PXtMF9i+oMBrecRUwtvlIbxN+0JcdUjfjrN+GsEpB/0Qerx4T7kDb6vroGJDyNqDk/IzwblPwPZFOcX8g/7Ak9SgwGaCC98kNO2u4vsjcpyw1q43xvwIDOJoBZrauiQy59/Zkx0bdjH2yS/ZuWk3DdvUpd/959GyWzOeOO9FHMchMTmBM6/uwtoFG1g0w9LporYRtXHXO4Np2qkhnz79FSnLt9KxT1tue30gHq+H2R//AsDuLak81vv5fPde9uCFNOvSmEXTbb5rT5z/IqFQ7sznfbv2R/jqT3zrt4SY/GM2rRr5aG/8zF5YdGCxfmuIN8ZnUjnJU+I2vvwhm117QpzWxs83c7MLLTd3UYBfbZDWjdz/YvdnFPw8KD3TYfBT+4iOgidvjccDvDw2gxue2senzyQSH1vyvp3I1u30M3lRLK1qZ9OhfhY/rIwptGy/dvu5omPen4+GVYr+XgCY8HscO/d76doki8mLCw/yU9M9nN0qg2bVAyTEOCxNieK1GYn8tDqGsbdsxxu+1W72c+M7VTi9aSavXr2Tjbt9/HtyElv2+nj+L7tL9sLLgXVbYdIv0LoBtG8Gs5cUXX79Nnjja6hcIfK2sgPw+LtQpQJs31NwmcoV4OU78p6rVjHv8ZgH8t/3wXT4ci50j+xPxgnNU6UR/jYXE9q4gNDaufia9SiwnLd2W2Ju+ITg6tlkfX4vTsZePFUa4YlOKLJ+b522+Nr0JfDrh2Svnwe+aKK6XE/MDZ+ROeY6QnaK24+KdYnqfL1bbvoL4ITwn3wJMVePJmvCPwjMHZXb57hKBJd8RWDLHzhZ+/DWOomoHvfga9yVjNd6u08oBE/FxnibX4qzdT7Oph/wNDin0LKhJf8jtPCQB+O7lxffSEwl/JdPBcchOPtR2LMWEmvjqXVanmLe0/6Jt8O9hH4ZjrN+BsRVxdf5fvyXTiLwfhdI2whA4Msr8Pjy/u3wNOmLr+M9OKu+KsnLFjneZAN1IrlBU1uPoheueoO9O/blHNvZK0nbvZ9bXr2GFt2asnTmcrav38ntTR8EoPVZzSMKNJt3aczJvVryxp1jmPXBTwAsmmGpXLsSV/zzYuZ8Mg8n5BDICrLyl7zrd6PjomjcvgG/TV7Evt35g8iV89YSCmqJbVE6tPDx3WvuqOGn07OKDTSfHJnOhadHsyYlSLCE+b1evz8er9cN/mb9Xsh/qsAtl8RwW/9YAB54dT/zbcF9+XR6Fhu2hpjw70Tq13SD0ub1ffS5dy9jp2Vx3QWFB1TlSccGWcy8fysAn8yLKzLQrFEhSNt6hT8EKMybA3fmBImzVhRe/1290vIcd26URWyUw2MTKrJ0s5/Wtd2v9X+mV6BGUpAXrthFVHjULMoH//isEjd2S6NV7eKD3/KgYzP4/jn3409mFh9oPjEG+nSG1Vso8c/tAaO+cacAXXK6OypakCgftG1cdD0FXX/gbTdYblo7sj6dyEJr5pD+rzYA+DpcVXCg6fEQ3f8lgqtmkvX+DbnnV/9QfP1r55LxYlcI5X4jZK6YTuxfvyPqjNvJDAeazq51pD/fBbJzR9eyVszAU7E2/jPuyBNoZk99Nm8bq2dDdjrRfYfjqdUGZ1MJRuHKAWfjLAJvNgTA0/p6vEUEmk7aJpzNP0Xchvf0xyEqkcCYjpC1N7e+ZWPzlmt5Lc7yTwjNeSznXGD7QqIG/o634XmEFoWD3G2/55sC6O36KM6+FJy1UyLun0hZMsacjLtWc2Mk9ynQPIoODjIPWD3fneaRXKtivmuRatLRnZKx4Nulec4vmLaUU3q3pmnHhiz/aXWB93bs05a4CrHM+vDnI+5HeXUgACyJr37IYumaIM/eGceQF0s+OlzSNkpabsav2Zzc1JcTZALUre7llOY+ps/LVqAZ5j0Gs4iPpI1K8e5DIH+4juwgzFoew3Vd9+UEmQDntU7nkfEVmfpHLK1qpxVQU/kTyef9q7mwdB0Mvwnufi2ydtZthTe/htfugrl/RHZvcX5d7o60Pnhl6db7p1eC0T9vo654axiyvvh75PVnFPCwLxQktHkx3joHPSTOLvh3fGjj7/gbnlbgtYM5+8NTZoORP8A6cR3lkV1/PN4WVxP6ZXieILNAviicrEO+FzLDyx48RfyCqVAPT92zCP36Ejh6kH+4YmMyy7oLJxxjzCNFXE4EmgHn42afLWJ9QX5lGmgaY5KALkAT3D06AVKBlcBca23hQzh/UqZrUwBSlm054rpCQfcXbyAr70hFINM9rtuyVqGBZrcrO5O6dS8Lpi4t8PqLCx4lqVoFdm7azY/jfmXcsElkZ+iP3uFI3efw7HsZDB0QS8XEsl0HuWJDiB4d8i/Ya1rXV+TUXCnchz8nMPKHRHxeaFs3izt67KVjw9L/XAaCbkC5bEsU/5mWyKmNMzE13Z/19Tt9ZAY8NKuet92YKKhXOcDKbXqmGKnUfTDsY7inP1QsekZlgZ4YA+d0gI7Niw40d+yFbkNhbzrUrQqXdoPrzwVfEb8qxs+BKD9c0DnyfpV33gZd3A/8McTc8hXe2idDeiqBhZ+TPflJCGREVqEvCm+9DjibC/5bmqfthqfibC8k/4LXB75ovDVaEtXzPoIrv8fZUnydkp+3zU142w8FJ4iz+SdCPz6Js6noEWtP9XZ4ouJx9m/Fd8H7eBqdB6EgzvrpBL+/z51GGxZa8AbednfhrPkGZ8N3EFsF3xn/wtm7gdCyTwrvV4sBeDxeQkvfK7XXKlJKHsV9mlPUqEUG8Ky19plIKi6T/z6MMfWAYcCluNHxoS/MAbKNMZ8B91tr86/k/xNKrlWR/g+cz6IZltW/HflLSlnhTu1r2rFhnoCxaaeGACQk508ac6Afrc5oxjevf5dveuyW1dv56LEvWLtgAw7QprvhvFu70/Dkejzb/9Uj7nN59Pz76TSs5aXfmWWfkSU1zSEpIf/vkaQED3v2aS1QpC5qu5/uzTOpViHIplQ/o2YlcMPoKrx13U46N8oqtXb2ZXro9FTNnONuTTN44YrcdZep6W5UkhSX/2tYKc4hdb8SPUXquU+hYQ3o1zXyeyf86CYbmjC46HIt6kGr8PTXzGyYOh9eHAdrt8LjAwu+JzMbvpkHZ7aBSsXnE5NDeCrUACDmitcJzB1F9jdP4a3dlqhe9+GpWDvvdNoSiOr5NzxJtckae0eR5Xwdr8FXvyOZY2/PfzE6nvhHVuUcBpdNI/PDmyLqh7hCS98ntHoi7EuBCvXwdRiK79KJBMddiLNxZuE3Jrpz0H3dnsFZ+w3BCZdBXDV8XR/H3/8bAu91gGx3VkjoxycgmInvwg/xeN0pJM6uZQQ+PRcyC0/g5G1xFc7W+bBjcem9YJHSMaiIa1nAZuBna23EU6OOeaBpjGkA/AhUB2YA3+KOYB4YvUzCHeE8B7gC6GGMOdVaG/EmoceTmIRohrx3I8FgiDf/OqZU6lw0/Q822s1c80x/3rj9PTYt30LHPm059dL2ADihggOH0//SCa/Py8wP869hmD32lzzHi2dYdm5K5ZpnLqX1Wc1Z/N2yUul7eTHvjwBfzMzm46cS8XiOj0Q7x0cvTgzD+h+cJTabXi0yuPg/VXlpagXeu3FHqbUTF+Xw8S3byQzA0pQoXv8+kdvHJPP2dTvx+3JnDHoKmF6mXCKRm7ccvpgDYx+GSH9sU/fB8LFw9yVQpeDEzzmuPTvv8ZltID4G3p0Kg3tDgxr575k63x397Ff8DEwpgCc8tTHw+6c56yNDq2eD10d074fJrtYcZ1vJ/s75Tr4E/xl/JTDjBUJr5xZaztuoK9EXPklg/liCv3+Wv0B2Ohmv9oaoGLy12hB11t3EXPsumaMuz7MeVIoX/Cbv053Aqi/xXzMPb9dHCY7tVfiNB6a87llDcOK1ufXtXoX/yu/xthhAaOGbQHjEtPMDhH7+F8767yCuKt6O9+Lv9yWBT852g9xDq6/ZGU9lQ3DGvUf+IkVKmbX2naNVd1mMaA7DnSZ7jrV2WhHlnjHG9AK+wN2zM6INQo8nUTF+ho65iWoNqvD0RS+za1P+LQwORygY4uVBI7nt9YE8MnkoALu37GHsE19y9dOXsntLwTOPT7+iE2sXbGD94k0lamfOZ/O45plLadSuvgLNCD3+djqXdo+mRmVvzohhMAjBEOzZ5xAbDdFRxy70S0rwkFrAyOWefQWPdEpkEmIczmqeyae/Fjyb4HB5vXBSHXdabIcG2TSvEeD6UVX4ZkksF7TJoGJ4m5MDI5sHS83w0LS6/lmNxGPvuVNYayTDnvByu2AQQo57HBsF0YVMUHjpczfAPK9j7r0HVjekpbv3xRexFPqCzm6guXhtwYHmhB/dTLXdTjr811eeHVj/GFrxXZ7zwRUzoPfDeGu1JliCQNNnziH60hEEf32f7GnDCy3nrXMKMVe/Q2jVD2SNG1pIpxxCm353+7X2J0JblhI7+DN8rfsQXDi+ZC9MCpadRmjNRLytri+6XLr7YDC0fnqe086Wn3EyU/FUC6/BjUnGe+azhOa9QOjH3B0egutn4B/0B94OQwl9n3/9r6flVTjBLELLPj6ilyPyZ1MWgWYvYEwxQSYA1tqpxpgPgb5Hv1tHh8/v5a+jb6BxuwYM6/8KG5bmf9J1JDbZLfxf9+FUrVeZmPhoNq90tzgBWD53Vb7yjdrVp46pyZgHC3iqWhyNjERs1aYQqzZl8fHU/NMoT795D3+/JpZrzz92CXia1vWyckP+oGPlxiCN62h6ZWlwiHwULFKta7tB57od7q/weskBov0OK7bm/ZWemQ0bdvnp3TrCdWfl3KoU9+3j7/Jf6zoE7v9L/tHIA1amwPKNcHoBMUW3e6BnW3ipiFmWRY1Ab091s+QO6OGu0ZTIhba623nl/zSHf2hLkKTF27gb0Ve+SXDpRLLG31doOU+NFsRc9wGhzYvI/GAwhEqW+Tm08Tf3/iqNSlReiuOhuH9gnJ3h5UeF/AA6uN8XnuRmePyxOFvm5S2QuQtSV+FJNvlv9kXjbXYZzprJkL490s6LHHXGmA7A1cAH1toCs4QaYzrhDvr9z1r7W0nrLos/VfG4CX9KahcQd5T6clR5PB5ufX0grc5szvMD3si3xUhp2r5+J+AGtmffeAYLpy1l65r8U/e6XdmJQHaQ2Z/Oy3etMF0v6wjAynlrSqWv5cnIh/JnERn2bjrBEDx4XRz1ahzb4K57+yieez+D9VtD1Kvutr1xW4jflgUZckXsMe3LiSgtw8N3y2I5uU7prc8syC9rogE30Q9AtB+6Nc1k0uI47uiRhj+ceXbykjiyAh56tlCgGYmRBcxuG/YRhELwjwFQv3rh9z5wRe5I5gHjZ7sJfN4aWvx02q9+ch9UnNQw/7UJc93ZEH01bfawBZdNw8nOwNesR86+lwC+Zt0BNzNsUbz1OoRHKGe56zILCUw8VRoRe/3HhHatI/PdayNKMuRt6C4MdnauKfE9UojoCngbnY+zuZgM+2kbCW2Zh7dBL0Kzck97anbBE1MxJ7B09m0On++Is/qgvTBjkqFSE9iW//9vT6ML8cRVIagkQHL8uhu4DHiqiDKrgdtwZ6UWk4EgV1kEmouBvxhjnrHWFrmIyRhTDXed5qJj0rNSNnD4ZXTp147xz00mc39mznYkADs37c6ZQntyr5bExEdTt5W7GL1F16ZUqJxA5v6sPEl+hv/8MNs37GLYJa/knOsz5Gx2rN/Frs2pVKmbzNmDu1GlTjJPXDAiX398fi+nXtKeBd8uYe/2gtfzPjH9PmZ99LObaMhxOKm74eybzuT3b5ewdFYh2fLKsQOZWpesdkcJZ/2eTXIFL8lJHjq19NOpVf4fsQoJHoJB8l274J691K7q4a0HczN8rNwQZOVG90lqZjakbA/ltNmxpY/KSW6wuHNPiF+Wun1I2R4iIyu3b03qeGlS1408+veI5oMpWdz13D7+enksHg/855MMalT2cHmv6FL7vJwIJi92A+/Fm9w5kjOXx5CcEKJyfIhOjbIYOSuBNTv8dG6USfUKITbt9jHqhwS2p3l5tn/e9Pi9X6xG7YpBRg3amXNuxVZ/TjbYjGwPm3b7ctrs1DCLygkh9mZ4uPl/lenTNp0GlQN4PLBwQzSj5yRgamZzTqvcf17v6LGXq96syj0fJzOg8z427fYx/Jskzm2dnrPXpri+CT9nW+LuNsXMRe501ORE6GSgcwGDEhXi3emzh147/yGoXQXevsc9blEv/70/u4NodGxOzkOATTvgHyPh/E5QrxpkB+Db+W5AevmZBQezX8yBZnWgZf3IX3N54WvdBwBvbXdmj695T5x9O3D27SC0Zg6k7yL7+5eJ6j4UMvcSXDULb522RPW4h8CvH+UJ7mKHzsHZvcFdKwl4qjYl5tr3cPbvJHvWq27G2oOENvzqfpBQlZjrPwZfFNlTh+Ot1jxvuZRFEMyCmArEXPcBwd8/I7RjFeDgrduOqK63EEpZRHDx10fnk/Qn5Wl6ifu+ejsAvA1746Rvh/RtOBtn4W0/BE9yM0Ibvoe0TZBUH1/7IRBfg9CkvLlO/Nctwtm7juBnF+ScC/3wML5+E/Bd+AGhRaMgriq+ro/h7PwD54+P3EJ71xFa9VU4q23ITTAUWwVvh6HgiyG04M18/fa2vAonfTvO6kI20xUpe12B+UXFZdba7caYecCZkVRcFoHmcOAj4HdjzAhgGgUnA+oF3AXUAgpZ2HB8O7lXSwD63tubvvf2znNt3LCJjHt2EgDX/ftyqtWvknPt0gfOB2Dbuh3c2+7xnPNevzfffokx8dFc9tCFVKpZkf2p6SyctpSXrx/Fzk27OdQpvU+iQpVEZn1U+FuP4CEAACAASURBVJO9lBVbOfvGM6hUIwmvz8vWNdsZP3wSX708NcJXXz7c+1LeoYsnR7n/+Hds6WPUw5GlhAwGHYKhvF/fyXOzee2z3D2jfl4a5OelbpsjH0qgcis30Fy5IZSvLweOb7s0htvDgWZ8rIe3H0zg2ffSefC1/ThAl9Z+7r82jvhYrdE82NCPkvMcP/6luwNTp4aZvNNoJ42qBpi6NJZvl8aSluEhIcahff0snuiXysl1824zEgy56/sONmlRLK/OqJBz/NOaGH5a406jHj1oB50bZRHjd2hcLcB7PyawdY8XnxfqVApyfdd9XHvqPqIP+g3eslaANwfu5LlvKnDbmMpUiAnRt206Q84+4XaJOmL3vJ73+Mn33fcdm8PoAoLMogRD7lukEmKhYjy8PQl27HFHMRvXhH9cAVd2z19+6Tp3Su7fLou8rfIkZkDeLd6iLx4GQHD1bDLfvhSAwPTnIDMNf5fr8Z9+G07aVgKzXiN7+vN5K/P63W1HDhzW64AnPhlPfDKxg/MvP9n/sJsZ2lu9Od5k94lD7MD8o1jp/+6Es3s9BDJxti3Hf9pgPEm1IBTA2bWe7B/+S2DOW24wKjn8F76f59jX8yUAQhu+J/hpb5xdy/A0uRhfk4shuiJk7cFJmUPo29twtuRNdIjXDx5fnlPO+hkEv+iP97RH8PX5CLL34ayZRHDWgxDMfagXnHgt3vZ3423+F2h/t9vO1t8Iju2Fs/XXvO3EVcXToDehhW9BSFuIyXGrDpA/Q2h+64B2kVTsccogJaEx5jbgWSCBwifOe4B9wN+ttRFule0aWOVurSo8Ab01eU5Zd0GOEt/KUt7ZXo4boZq1yroLcpRkTymdBHdy/Imqpq/tiSzq7vQ/3RNme9FZx+x/ezPhuz/d5+dwGGO2A79ZawvJPpBT7lugg7U2uahyByuT7B/hwLER8FfgY+BXYAXuyOav4XN3Ao0ON8gUERERERGRIv0KdDPGNC6sQPhaN2B+JBWXWd46a+124JXwm4iIiIiIiBxbrwFnA5OMMXdYe1CmNMAYcw7wHyAqXLbEjqsE6cYYH9ASd0rtWmvt5jLukoiIiIiIyAnJWjvOGPM6cAtusLkRd5apAzTFXcPpAd6y1o6NpO5jHmgaY84FVlhrVx1y/n7gAdxkQAfOzQRusdbaY9tLERERERE5nsTGabuuo8Fae5sx5ifgfqA5UPfgy8Bwa+3ISOstixHNicBjQE46VWPMMOBvwG7gQ2A70Ak3he4MY8wp1totZdBXERERERGRE5q1dhQwyhhTC6iHO4q53lq76XDrLItAM08GJ2NMXdztS5YCZx88XdYYczfwAm50fc+x7KSIiIiIiEhxjDF34Q6SdcIdEfQAUdbafBtZG2NGA9cVU2V9a+36Ytq8HhhVyOUt1tqaxbRRIGttCpByOPce6nhYo3k24APuO3RNprV2hDHmKuACFGiKiIiIiMjxZ0T4/VogFahURNnPgTUFnK+Ju05yWXFB5iHGA78dci4tgvtzGGPa4QbLVYDF1tovwudjgBhrbUSbcx8PgeaBzdV+LOT6j8BNx6gvIiIiIiIikbgQ+Nlau80YMwM4q7CC1trPcYPNPML5agDeibDtz621oyO859C2T8IdHW1/0Ol3gC/CHw8CXjHG9LHWTixpvWWyj+YhtoXf5xtaDguG30RERERERI4r1tqvrbXbii9ZpOuAEPC/UuhSiYX3yPwO6IAbAP+dQ5Y64ubQyQIuj6TushrRvN4Y0z388YGh5Wa4G4YeqgGw9Vh0SkRERERE5FgyxnTC3eLxW2vthghvb2eMqYI7gPgHMMVaG0l63kdx47GrrbUfhPsz/OAC1trdxpglQOdIOlZWgWbD8NvB/sIhgaYxJgHoBXx7THolIiIiIiLlnjGmEgWvtdxtrd1dys0dSA40+jDuveuQ4xRjzNXW2uklvP8cYN6BILMIa4EekXTsmAea1tpIpus2wp0vXOK5wCIiIiIiIkdoCPDPAs4/hjsKWCqMMdHAlcBeYFwEt64CbgWmAJuA2sAVwP8BE8LbQ64oQT3JwPclKOcFoiPo33GRDKhQ1tpFuFufiIiIiIiIHCsvUvAIY2mPZvbBzfL6trV2f0lvstZ+T94AcRXwjDFmJ/Bf3B07bi9BVVtwlzAWpzWwrqT9g+M80BQRERERETnWwtNjSzuoLMiBabORZpstzDvAq8CpJSw/BRhkjOltrZ1cUAFjzBVAE9zgu8QUaIqIiIiIiBxjxphqwPnASmvtzNKo01qbYYxJAxJKeMtTuLlyPjPGPEXuliYxxpimQF/cqcK7gOci6cvxsL2JiIiIiIhIeXMVEEUpbmlijGkOJOEm7ymWtXY17vTdNOBJ4HfAwV03aoHhQDrQz1q7MZK+KNAUERERERE59q7DDeoKDTSNMfHGmBbGmFqHnD+tgLIVgTfChx+VtBPh9Z7NgfuAybjbpCwDpgH/AMzhjLhq6qyIiIiIiBz3omMzy7oLBTLGPAC0CB8eeP+2McYJf/w3a+32Q+5pA7QDZlhr1xRRfWdgOu7ay+sPOj/RGJMC/IybdbYm7jTc6sB4ItwqxVqbijs1NqLpsUVRoCkiIiIiInL4zgPOOuTcwIM+fhTYfsj1I9k7E+AloCdwLlAZd3rrQtztTd6y1oYOs95CGWMSrbVpJS2vQFNEREREROQwWWu7H8Y9fwP+VoJyMwBPAecfAR6JtN1DGWO+AgZZa7cWU+4sYBTQuKR1a42miIiIiIhI+XQ+sMgY07+gi8aYKGPMcGAqUC+SihVoioiIiIiIlE/3AonAx8aY/xljkg5cMMa0BeaFy6zFnapbYgo0RUREREREyiFr7QtAB2A+cA2w0BhzrjHmH8Bc4CTgLeDkSDPPao2miIiIiIhIOWWtXWqM6QL8E3c7k4nhSynATdbaiYXeXASNaIqIiIiIiJRj1tog7jYpmbjJhzy4+2nOP9w6FWiKiIiIiIiUU8aYmsaYr4FXgCzgdmAa7prMhcaYyw+nXgWaIiIiIiIi5ZAx5i+4+2+eB0zHXYv5X2vt2cBQIB740BgzxhhTKZK6FWiKiIiIiIiUTx8CCcBQa+3Z1toNBy5Ya0cA7XEzzw4AFkRSsQJNERERERGR8mk+0D4cVOZjrbXAacDjQM1IKlbWWRERERERkfKpi7U2UFSBcKKgR40xEyKpWCOaIiIiIiIi5VBxQeYhZedFUrdGNEVERERE5LgXFZdZ1l340zPGDARWWGtnF3AtCciy1mYUcG0A0Mlae09J29KIpoiIiIiISPkwGrixkGu7cLc4Kci5wN2RNKRAU0RERERERDzht1KhQFNERERERERKlQJNERERERERKVUKNEVERERERKRUKdAUERERERGRUqVAU0REREREREqV9tGUPx3PDwvLugtylIROqV/WXZCjxJu2p6y7IEfJ+t9NWXdBjpI6rzco6y7IURRV1h2QsnSdMea6As47RVyLmAJNERERERGR8uNwtzBxIimsQFNERERERKQcsNYes6WTWqMpIiIiIiIipUqBpoiIiIiIiJQqTZ0VEREREZHjXlRcRll3QSKgEU0REREREREpVQo0RUREREREpFQp0BQREREREZFSpUBTRERERERESpUCTRERERERESlVCjRFRERERESkVCnQFBERERERkVKlQFNERERERERKlQJNERERERERKVUKNEVERERERKRUKdAUERERERGRUqVAU0REREREREqVAk0REREREREpVf6y7oCIiIiIiEhxohLTy7oLEgGNaIqIiIiIiEipUqApIiIiIiIipUqBpoiIiIiIiJQqBZoiIiIiIiJSqhRoioiIiIiISKlSoCkiIiIiIiKlSoGmiIiIiIiIlCoFmiIiIiIiIlKqFGiKiIiIiIhIqVKgKSIiIiIiIqVKgaaIiIiIiIiUKgWaIiIiIiIiUqr8Zd0BERERERGR4vjiM8q6CxIBjWiKiIiIiIhIqVKgKSIiIiIiIqVKgaaIiIiIiIiUKgWaIiIiIiIiUqoUaIqIiIiIiEipUtbZo6jTRW05tX8HGp1Sj6SqiezYuItfvlzAhBemkJGWCUBsYgz97juPRqfUo2HbesRViOXpi1/mjx9WlKiN6LgoLnuoD537nUJicgJbVm3jyxHfMueTeXnKebwezr35LM665lSq1a9M+t4MVsxby7h/TWT9kk15yp5ybmv63H02tU0NPB4PG+1mvn55Kr9OXFQ6n5gTRWIdvB3uxVOjPZ6qbfBExZM90sDedXmKRd2dXuDt2WO6wPYFxbcTUwlvl4fwNu0LcdUhfTvO+mkEp9yct5wvFm/He/G2uBIS60HWbpwt8wh+eSWEsvPXG10R/8Df8CTUJPDZBTjrp5f0lZ/wNu+CkZNg8Vqw6yEjGyY/DXWqFn7PmxNhxDho1wTevT+y9uavhIHPguPAb6+B35d7LRiCMVPhsx9g43ZIiIWTG8MdF4Opm1vu89nw8Oj8dZu68OkjkfXnRLZ5t4e3psWweL0Xu8lHRraHKQ/vpU5lp9B73vg2mhe/jqV9owDv/XV/idpJ3Q+vTo5hysIoduz1UDnR4bTmAZ4e4GZMTMuA/30XzSzrZ/VWL6GQhyY1g9zQI4uz2wTy1NXqnqRC2xl6YQY39coqUZ9OdP4q1ajc/ypimxliGjXBGxPLysFXENi6OadMlQHXU/WqQQXeH8rKZHn/cwutP+6kU6j/zIhCr6/9221k2CUA1BzyABV7nZ+vzM7xY9n21n9y62zVhornXkhsU0N03foEtm9j1Y1XFvtay5st2zJ554MUlth9LFu5n8zMEBM+OIXaNWNyyqRszmT4y2uwK/eza1c2sbE+mjaK47oBtTm9S6WI2ps0dTsPPbmS6lWjmDi2faHlfl+0l8F3LcFxYO63nfH7PDnXgkGHDz/bzPivt7FxcyYJ8T7atErk1uvr0qxJfOSfBJE/IQWaR9H5d/Zkx4ZdjH3yS3Zu2k3DNnXpd/95tOzWjCfOexHHcUhMTuDMq7uwdsEGFs2wdLqobURt3PXOYJp2asinT39FyvKtdOzTltteH4jH62H2x7/klOv/4IX0uasXE16cwpKZy6lQOYGL7+3NP8bfyUNnDWPXplQA2vRswZAxN/LLlwv44vlvAOg+8DTu+t9gXrjqTX6fsqT0PkF/cp6KjfE2vxRn63ycTT/gaXBOoWVDS/5HaOHbeU/uXl58IzGV8F8+FRyH4OxHYc9aSKyNp9Zpect5/fj6jceT1JDQL8NxdiyF+Gp46vcEjw/IH2h6uz0JFP7PdXm2bitM+gVaN4D2zWB2Md/267fBG19D5QqRt5UdgMffhSoVYPue/NdfHu8GvTeeD11awK40eP0ruOE5N4CsmZy3/PO3QI2DzsVFR96nE9m67V4m/+anVd0gHRoH+cEW/Wdw/Q4Pr38bQ5XEUInbSN0P17ycgMcDd5+fSZ3KIbbu8fDr6ty2UnZ5+WB2NJd0yubWc7Lwehy+nh/FXaPiefjSdK7qlvsz+8Fd+/K18f4PUUyYF0331oF818qrqFp1qNCtOxkrl5G+eAEJ7TvnK5P6zVfs+/WnPOe8MbHUfWw4aT/NLrL+zJXLWPu32/Kdr3nX3/ElJpGx/I885wO7d7HxyQfzntu5I89x/MntiWt1MhkrLDjgjYsrsg/l1fqNmUyZsYOWzRNo16YCP/6Smq/M/vQglSpGcfsNdaleLZp9+4KM+2obdz1gGf5YM3qeWblEbe1NC/D8K+uoUjmqyHLZgRBPPb+ayslR7NiZ/2/sayM38M6Hmxh0VW06tktid2qAt9/byC33LOWDt06iRrWYAmoVObEo0DyKXrjqDfbuyP0Hwc5eSdru/dzy6jW06NaUpTOXs339Tm5v6v4han1W84gCzeZdGnNyr5a8cecYZn3g/uFcNMNSuXYlrvjnxcz5ZB5OyA0kzhjQmbnj5vPp01/n3L9+ySaG/fgQp5zTmunvuH9gu13RmV0pqbwyeHTOvQun/8ELvz9K18s7KtA8iLNxFoE3GwLgaX093iICTSdtE87mnwq9Xhjv6Y9DVCKBMR0ha29ufcvG5i3XfgieaqcQeK8DpG3ILbfi8wLr9dQ6DW+LAQRn3IP/nNcj7teJrmMz+P459+NPZhYfaD4xBvp0htVbIBiMrK1R37jh/iWnu6Oihxo/G87rBHf1yz3XvA5c/E/4fgH85ay85VvUg/rVI+tDedKxcZCZj6cB8MmPUcUGmo9/Ekef9tms2eYlWMJY84WvYtmf5WH8fWkkxuaev6BdblBYp3KIbx5Ky/MgoFuLICm7vbw1LSZPoNm2Yf5vqr+PieOkekGa1Sx5AHyiS1/8OysHXgJAxXMvLDDQDOzYRmDHtjznknqci8fvZ8/USUXWH0rfnzNieYC/Wg2i6zZg1+cfQSjv18IJZOcrf6gdH/2PHR++A0Ctex4irlWbIsuXV+1PrsCUzzoAMO6rrQUGmk0axfPI3xvnOdfttGQuHvAbX0zaVuJAc8R/19GsSTxVq0Tx07z87Rzw7ocp4EDf86sxcsymfNcnTN7GOd2rcPvgejnnmjWJ57LrFjBrzm76X1yjRP0R+TPTGs2j6OAg84DV891plcm1Kh5x/U06NgBgwbdL85xfMG0pyTUr0rRjw5xz/igf6XvzbnK7P9Wd0unx5k718EX7yNyflRNkAjghh4x9mXgPKidw1EcD/fF4W1xNaPGoPEFmQbwn34yz4rM8QWbhhf34er5M6Jd/Q+rqUursicUbwW/Gr+bC0nUw5NLI21m3Fd78Gh6+Ku902YNlB9zpsgdLCs+6CmlAOmKRfG2/nOdnyQYvQy8s+Qbh+zPhi1+iuKxLVp4g81DxMQWPNp9UN8i2PUX/rp23ysf6HV76dtSU2Tycw/uBSOrZm8CuHez79efI7+1xLh6vl9Spkw+r7cPtc3lzuP9/+H0eEhN8+P0lu/+3hXv5+tsdPDCkYZHl1m/M4O0xm3hgSMNC687OdkhMyPuLvUKie6zf3VJelPmIpjGmGdAEOBB5pQIrrbUlmFf452O6NgUgZdmWI64rFHR/UwWy8k6dCmS6x3Vb1mL5T24gMXXkLM67rQcLpi5hyazlVKicyIDH+7Jj4y7mjpufc++Md2Zz70e3cNE95zB99Gw8Hug5qBtV61Vm5JAPj7jP5ZW3zU142w8FJ4iz+SdCPz6Js+mHIu/xVG+HJyoeZ/9WfBe8j6fReRAK4qyfTvD7+9xptAAV6uGpUI9Q6mp8vV7B0+wy8EXjpMwh+P0D+daBejvcA75oQvOex1Ozy9F6yeVC6j4Y9jHc0x8qJkR+/xNj4JwO0LE5zP2j4DJXdod3voUzToLOxp06++9P3Omx53fKX/7aZ2HXXncab49TYMglh9e38i51PwwbH8u9F2VSKYLP35IN7rrPKhUchoyO47slfrxeOK15gAf6ZlC3StH/Yf6yykej6kWPUo7/OYoon8OF7TVt9kj5q1Qjvk07dn3xCYQinI4AVOzZm4wVlqx1+R/a+Ssm02TMeHwJiWRvTiF1ylfsHJd/5FNKVyjkEHJgd2o2477cxtoNGfztzgbF3pcdCPHUc6sZeEUt6tUp4ikR8MyLq+l1ZmXat03i5/kFrHkALu9bgzFjU+jauWLO1NkX/7uOGtWiObdHlcN6bSJ/NmUSaBpjkoAHgOuBAucOGGO2AKOBf1lrC/4p/pNJrlWR/g+cz6IZltW/rT/i+lJWbAWgaceGLJiaO6rZtFNDABKScxebf/aviWRnBbjrncF4fd7w/Vt45uKX2bc7N7nFohmWF65+i9tev5bLH+oDQPreDF66biTLflx1xH0uj0JL3ye0eiLsS4EK9fB1GIrv0okEx12Is3Fm4Tcm1gbA1+0ZnLXfEJxwGcRVw9f1cfz9v3GnyWan4UmoBYC3w704W+cRnDQQfDH4Tn0Y/2WTCYzpDHvD328VG+Pt/IBbV1CjIUfquU+hYQ3o1zXyeyf86CYbmjC46HJ39oUoPwx5LfcpeMMaMOrevAFktYpwax84uRHERrkJht6eBL+tgA8fgpiilxvJIf49IZYG1UJc0qmARFpF2BoejRz+RSxntAzwyuD97Ezz8MLXsVz3agJf3JeWb4T6gI/nRPH7Wj/Dri484VBmNkz+PYqzWgWolKBhkSOV1ONcPD4fe6YVPW22ILGmNdF16rHljZfyXctctYKtK5aRtW41nqhoEk87k6oDbyaqdl22vDy8NLouhRjx+jre+9hNABUf5+WZ/2tK5w7FzyJ754MUsrJDDLq6dpHlvp6ynaV2H5++07TIcrfdUJfoaA/3/XN5zrOFBvVief2FllRMKvNxHpFj4ph/pxtjqgAzgRbAKuAtYCVwIJhMwh3h7IkbjPYzxpxhrd1RQHV/GjEJ0Qx570aCwRBv/nVMqdS5aPofbLSbueaZ/rxx+3tsWr6Fjn3acuqlboa0g6e/9hx0On3vOZfxz33D0lluMqA+Q87mvk9u56k+I9i92f30N+nYgFv/ew2/T1nCDx//DA50G9CZv468nueveoOls0qWDVdyBb/JG0kEVn2J/5p5eLs+SnBsr8Jv9ITn+O1ZQ3Ditbn17V6F/8rv8bYYQGjhm7nlAvsJftEfAu6U6MCWX/FftwjvybcQ+uFhAHw9X8JZ+SXOumml9wLLqXnL4Ys5MPZh8EQ4qyt1HwwfC3dfAlUKTygKwIcz3ERDN1/ojmjuToO3JsHNL8L//g7Vw8kUT2/tvh3QuQU0qwN3veoGtZedEVkfy7NfVvkY/0sUn96zL+Kv7YF/KOtWDvHctek599erms6AEQlMmBfFlafnD15/WuHj6XGxXNwxi4s6FD5SOXWRn70ZHvpFGABLwZJ69iZj5TIy10T+ILVir9442dns/e7bfNd2ffFJnuN98+YSythP5b5/Yecn75OdsvGw+yxFu+qymvTuWYXtO7P5avJ2HnpyBcMea8aZpyUXes/6jRmMfG8j/36iOTHRhc+vT90T4IXX1nLHjfWonFz007ux47fw9rsbGXxNnfCIZjaj30/hjr//wdsjWlGtqjK1yYmvLB6pPA00AwZba0cVVdAYcwPwOvAUcOsx6NtRERXjZ+iYm6jWoApPX/RyTobXIxUKhnh50Ehue30gj0weCsDuLXsY+8SXXP30peze4gaPCZXiuerJS5j4n2mMG5abbWTJzOU8/9s/ueDOXrz/8DgArv3XZWz8YzP/vfXdnHILp//Bw1/dzVVPXML/9dCT2COWnUZozUS8ra4vuly6+2wldMi2I86Wn3EyU/FUcxNHOeFyTsqPOUEm4K7X3GVzynma9cdT6zQCH54O0eGnu9GJ7vuoBIhOgqwTYvLAMfHYe3BpN3cK657wAFQw6I467tnvjipGF/J/yEufuwHmeR1z7z0wAz4t3b0vPsYNSJ/9GAb1hjsvzr2/Sws49x8wajLcf0XhfezRFuJiYPEaBZqReHRsLP27ZFOjUog94R+pYMh925Me/toW8tfzwCjjqc0DeYLUtg2CJMY6LN2YPwv0wnVe7ng7ni5NAzxxRdHrQcf/HEXlxBBntNS02SMV26wFMfUaFDgiWRyPP4oK3XqQ9suPBPeU7G/63u+mUrnvX4ht1kKB5lFUo1pMTkbXM09L5uYhS3jxtXVFBprDX15Dx3YVadMqkb1p7s9WdraDg5uFNirKS2yMl1ffXk/l5CjO6V4lp1xmlvt0KS0tQEy0l7g4H6l7Ajz/ylquvbIWtw7K3YeqU7uKXDRgPv/7KIV77yh+Oq/In11ZBJoXAR8XF2QCWGtHGmPOAS7mTxpo+vxe/jr6Bhq3a8Cw/q+wYWlKqda/yW7h/7oPp2q9ysTER7N5pbvFCcDyue4T2ppNqxEdG8Wq+Xn3d9y3ez9bV2+ndvPc2ct1W9Zi2shZ+dpZNX8dPQedXqp9L988FJdMyNkZng5dSLIIh/DQyZ7VONn7Cy7n8YDjlvNUboEnKp6oa+fnK+a/aCxO5m4C/61V4ldQ3q1Kcd8+/i7/ta5D4P6/wLVnF3zvyhRYvhFOH5r/Wrd7oGdbeOkOWLPFDUBPOuT/kYoJUK8arNqc//4CKY9XRFZt8bFqi4+PZucfcTj1oSQe6JvBwLMKnnreNJwFtrCR0EPPL9vk5abXE2hRJ8iI69OJKiQpFMC2PR5mL/Nz1elZRZaTkknqdR5OIFDgiGRxErqcjq9CUmRTbg988ZUA6JhqaRL44JOif1muWpNOypYsul80L9+17hfNY0D/mvztzgasXpvOilXp9Oybv1yvfr9y1unJPP9kc9ZtSCcr26G1ScxTpmKSn7q1Y1m9tuD9taV43oTMsu6CRKAsAs1kIJIFiuuAyHbaPU54PB5ufX0grc5szvMD3mDlL2uPWlvb1+8E3MD27BvPYOG0pWxd4450pW5xM5Y2bl+f+ZMW5dyTUCme6o2rsmZBbqbS1K17aNSufr76G7evz66U0hmJLfeiK+BtdD7O5mIyHKZtJLRlHt4GvQgdFPt7anbBE1MRZ0v4D10ogLNmEp46p4M/HgLhIbIK9aBSc5yVX7rFlryLs+H7PE14qrXFd9Zwgt8/gLMl8oyL5dnIe/OfGxbO8/GPAUVvMfLAFbkjmQeMnw3j58BbQ3On01YNv1+4xk3sc0DqPjdjbcv8P6p5TP0N0jPddZtScqNvz58x/JnPYwmF4KFLM6hftfBkLjUrOZxUL8hs68dxMnNii9/W+EjL8NCmXm7CmTXbvAx+PZ56VUK8duN+YouZSTdhXhTBkIe+mjZ75Px+ks7oGdGI5MEq9upNYM9u0n6eU+J7ks46GycUyrffphw9oZDDbwv3Ure45D6PNCUzK+8DgNHvb2Lpsn0Me7QZNaq5P5z33tmAvWl5k0ZNmLSNLydv57V/t6ByeO/NKpXd8ov/SOOs03NHUlP3BFi/T457nwAAIABJREFUMYMWzZShTcqHsgg0lwN9jTGPWmuLnCNkjInDHc38Uy4MHDj8Mrr0a8f45yaTuT8zZzsSgJ2bdudMoT25V0ti4qOp28pdgN6ia1MqVE4gc39WniQ/w39+mO0bdjHskldyzvUZcjY71u9i1+ZUqtRN5uzB3ahSJ5knLhiRU2b7+p3Mn7SIC+7shRNy+GP2ShKT47nwrl5ERfuZNio3ipny5kyueqIft70+kB/G/gJAtys60bxLY979x6dH5xP1J+Zp6u7Z5qneDgBvw9446dshfRvOxlnu/pbJzQht+B7SNkFSfXzth0B8DUKTBuWpy3/dIpy96wh+dkHOudAPD+PrNwHfhR8QWjQK4qri6/oYzs4/cP74KKdc8Mcn8F8xE1/fcYR+HQG+WHxdHoSs3YQW/NcttHcdzt68o9oHONsX4GwqerPy8uabcBy/JPwpm7nIzeSanAidjLte8lAV4t3ps4deO/8hqF0F3r7HPW5RL/+9P1v3fcfmuVud1KkKZ53s7rXp9bjXdu+DkZPdkc4rDtpD88YX3Hab1YaYaJi/AkZPAVMXLsy/nWC5Nvl390/f4g3uJ3rmUj/JiQ6VExw6NQ3SuWn+7KNJcQ7BEPmu9X4qkdqVQ4y6LffJwdALM7j5jXiGjI6j/6nZ7ErzMGJiDI2rB7mwvRsk7tjr4cb/xpMd8PD/7d13eFRl2sfx72QmDUISekf6A4h0kCpNBUTs4lpWsayKstZ1dfe1rRVQ1t4L2HtZC0WKqFQpCgjy0HsvaZSUmXn/OJMyaZAwyRD4fa4r1yTnPHPOPXMyydxzP2XU4MOs3RFcomzdwFuge+43CyNpWddLmwaatbQocT2dF0VMM+dFGNf5dLKSk/CmJHHojyW57br2wB2fUGxFsslrH5C5eydb7r8raLs7IZHKHbuRNOl/hS6c66lZm7p3/R+pv8wgY/sWXJ4oqvToQ/zAwSRP/pbMHblrLrrjE4ht2yHnfq7omJzHkLF5Axmby+4D6opm2k/Oh+d/rnI+CJo9P4mqiR6qJkTSuUM8r03YQnJKFh3aVqF6tUj27svk60m7WL7yAI/fHzxxT7eB8zl3UM2cdTdPa1OlwPm+nbybqEgXXTrkDqQ3zQsmiIt+d4acdOoQj8ftfLJUr040fXok8u4n23G5XHRuX4WklCze/Xg7GZl+Ljlfix3LySEciebLga+5xpgngBn5J/oJTBg0EPg30BK4pdyjDIF2A1sDcP7dgzj/7kFB+74aM4mvxjr/4K55+lJqNsqd6vqi+4YAsHvTXu7u+EjO9ghPRIG1pKIrRXHJ/w0lsU4CB5MPsWzGn7wwYjz7tiUFtXvphgkMuaU/3S/uzJBb+nMo9TAblm7hnXueC5oBd/LLP5K8K4WzbzyDka85E9DsWLuLl//2DvO+XHysT8kJxzP0w6Cf3QOcsT6+LT/j/WIQ/v2rcDU7D3ez85xxkRkp+LfPxTdtJP6dC4MPFuEBV/CbTf/mmXi/uZiIHg/iPvcTyDyAf8NkvLP+Dd48n9PsW4n3yyFE9HoM95D3wJeJf8vPeL8bDgd3lcljP9Hd9Vrwz48FLnWXljChkCSzONnj+0rj6b/BO1Nh4gLntnKMU8l875/QtnFuu+b1nEl/du53ktA6VWH4GXDz0KLHip6s7nynUtDPj3wRC0DXZlm807zoGV8L4/UVXK2iR0svL11/iBcnR3Pb+Fhio/z0bZPFP4al51Qt1+6MYNt+Z9KRkW9WIr+p96dSv1puhWXFlghWbXdzz3lHv6bnyaj+vx4J+rn2LU6SeHDZb2z+9x052+MHDMabklxsRdLlduMqZOHV+H5n4fJ4SJ5eeJLqO3QQb1oK1S6+HHdiVfBDxpaN7Hr9eZImfh3UNqpRkwIxZ/+858Px7P1oQtEP9iRz78PBNYfRz24AoHP7Krz+bBtatajMh1/s4Icf95J2wEv1apG0bFaJN59rQ4fTghNJ529y2XZhfvLB5rz/6Q6mzNjD+59tp3IlN61aVOat59vQJl+XWpETlcsfhrECxpgxwN3kjhxKxZl11o+znmb2XwQ/MM5ae29pznN19ds1EOIE9NaDr4c7BCkrHY7QF1QqrIg0TTR1olrzastwhyBlpP5rmrDmRBZX790KN4I/87nYcntvH3n7oQr3/Bxvip7DuQwFEsf2wH+BX3Gm4KsN1Al8/yswDmhf2iRTREREREREwiNsK8Zaa5cD94Tr/CIiIiIiIlI2wlLRFBERERERkRNX2CqaAMaYeOB0oBnO2EyAZGAtMN9aq0E9IiIiIiIiFUxYEk1jTENgDHAREEnB5cT9QKYx5kvgXmttSdbdFBERERERkTAq90TTGHMKMA+oBcwEpuFUMLOrl/E4Fc6zgMuA/saY7tZaLSYlIiIiIiJSAYSjojkGp5vsWdbaGcW0e9IYMxD4BhgNXF4ewYmIiIiIiMixCcdkQAOBD46QZAJgrZ0OfIxT3RQREREREZEKIBwVzUo4E/4crf1AbBnFIiIiIiIiFYCrsi/cIUgJhKOiuRwYboypfqSGxpiaOOM0/yjzqERERERERCQkwlHRfAr4BFhijHkOmEHhkwENBG4D6gJ3hiFOERERERERKYVyTzSttZ8ZY2oAY3EmBvIX0dQFHABGWWs/L6/4RERERERE5NiEZR1Na+0rxpjPcLrF9gaa41QyXTjjN9cAvwCfWmv3hCNGERERERERKZ2wJJoAgQTypcCXiIiIiIiInCDCMRmQiIiIiIiInMCO+0TTGFPNGNMo3HGIiIiIiIjI0TnuE01gHLAu3EGIiIiIiIjI0akIiSY4kwSJiIiIiIhIBVDukwEZY0qa3CrJFBERERERqUDCMetsZhjOKSIiIiIiIuUkXMubJAFLj7JtK6BWGcYiIiIiIiIiIRSORHMVEG2t7X80jY0x44GryzYkERERERERCZVwJJoLgCuNMdWttXvDcH4REREREalgXFWiwx2ClEA4Zp1diDPBT9ejbL8S+LnswhEREREREZFQKveKprX2eeD5ErQfA4wpu4hERERERERKxxhzG04RrSvQEqeoFmmtzSqkbWNgfTGHa22tXXmU540E7gGuBRoCu4BPgIettQdK8hjKQrgmAxIRERERETkRPBe43QgkA4lHcZ8lwNeFbN9TgvO+DwzH6TH6BdAG+AfQ3RgzwFob1tU+lGiKiIiIiIiU3lBggbV2tzFmJtD3KO7zu7X24dKe0BhzDk6S+QNwjrXWG9j+CPAAcD3wammPHwrhGKMpIiIiIiJyQrDWTrTW7i7n014buH0oO8kMGA2kAdeVczwFqKIpIiIiIiJSvuoZY24F4oFNwA8lTFb74CSUv+bdaK09aIyZCww0xsRaaw+FLOISUqIpIiIiIiKShzEmkcLHWiZZa5NCcIqzAl/ZDhlj/m2tffYoYosDagPLrLW+QpqsDRy7CbAiBLGWirrOioiIiIiIBLsDZ3bY/F93HONxDwIPA+2BKkBd4ApgL/CMMebyozhGfOA2pYj92dsTSh/msVNFU0REREREJNizwIRCth9TNdNauwv4T55NacBHxpjlwAKciXw+OsJhXIFb/7HEUtaUaIqIiIiIiOQR6B4bii6yR3u+pcaYRUAPY0y8tbaoaiU4S6hA0RXL+HztwkJdZ0VERERERMIvew3NysU1stamATuBJsaYwvK5ZoAPp6tv2CjRFBERERERCSNjjAfogDOG82hmn/0FiAO65TtOJaAHsCicM86CEk0REREREZFyYYzpbIyJyrfNjbP+ZUPgS2ttVp59lYwxrYwxdfMdanzg9j+B+2e7DycBHU+YaYymiIiIiIgc/+KK7VEaNsaY+4BWgR+zb98yxmRP1vMPa212t9gHcMZh/oSzfmYloC/QBlgD/CPf4bsBPwLvACOyN1prJxpjPgWGA/OMMdMDxxgGzAbeDNkDLCUlmiIiIiIiIqU3GCdZzOvqPN8/TO74y8+AKKA7TlLox1n38nHgKWttSSbwuQpYClwL3AnsAsYBD1lrM0v2EEJPiaaIiIiIiEgpWWv7laDtB8AHJWg/k9zlTPLvy8RJUB8/2uOVpxM60dx46HC4Q5AykHHzE+EOQURKyHtoe7hDkDLScO674Q5BykjUxHnhDkHK0g167UrZ0mRAIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBERERERkZBSoikiIiIiIiIhpURTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElKecAcgIiIiIiJyJL64+HI7l7vcznTiUkVTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBERERERkZBSoikiIiIiIiIhpURTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElJKNEVERERERCSkPOEOQERERERE5Ej8lRPCHYKUgCqaIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBERERERkZBSoikiIiIiIiIhpURTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBERERERkZDyhDsAERERERGRI8mKr1Fu54oqtzOduFTRFBERERERkZBSRbMM9b2gEwOHd8V0OoWqNauwc/M+fv7fb7z/1CQOpaUD0KlfK4b8tSennt6UGnUT2LM9mYXTV/D2Y9+StDu12OMPvqoH/3p9RJH7L2xyD/t2plCtTjwXjxxAl4FtaNCsFlkZWaz9YysTnviOpbNX57Sv06g6n6x8osjj/efqN5jx+cKSPQknsJ070pgw/ndWLN/N6lV7OXw4i+8mXUG9+vE5bVYs38UXn//Jb4u2s2NHGomJMXTsVIdbRnWjfoP4Yo7uOHQokwlv/86UyWvYGbh/l671GXlrl6DzAPy2eDvPPTMPu3IPcXFRDD6nBbf+vRsxMYW/zDMzvVx52ResWbOPBx7qy4UXtz62J+QEUtbXduGCrdx4/bdF7p/w3oW0a1875+cfZ6zn9VcXsn5dEtWqx3LRxa259vqOuN25nxW+/94SJk9cw9YtKRw6lEWt2pXp178x193QicTEmNI/GSeYnTsP8e57q/nzzyRWrU4hPd3L/746i3r1KuW02b79IE+PW8aq1cns359OTIyHZs2qcPVfW9CrZ+1ijg4HDmTy2OO/s9Ims2fPYTweF6ecEsfwS5tyzpCGQW19Pj/vvLuar77ewN696ZzSKI4brjcMGFAvp82iRXu4+ZbZRZ7v7Tf7cNpp1Ur5bJxYXPF18fQZRUT99kTUaYMrqhKHnu6KP2lzwbY1WxA58J+4m/SEqEr4k7aS9esEsua+Wew5oi56logGnXDF1wVXBP59G8ha9CFZ88eD35fbMDKWyD6jcLe7AFdCPfwH9+FbN4fM6WNz43FF4Ol5E24zkIhaBiJj8e9dR+b88XgXfwx+fyifngptR6qbt+YnsHxHFHZ3FIezIvjhxi3UT8gKanfqU40Lvf/nV2+jde2MIo+/O83N+4urMHdDLBv3RxLp9tOyZga39EyiS8P0nHZp6S7eXRTP7PWxrN8Xic/voln1DK7rlsLAFgcLHNfrgw8Wx/PFsjg27Y8kNtJH61oZjB66h5px3tI9GSIViBLNMnTZHWexa/M+3njoa3Zv3U+L9o0Y8X/n0rGv4db+Y/H7/Zx/wxnExkXz3piJbFu/mwbNa3Ht/cPoemYbruv2KIcOpBd5/LmTlzGy7+igbS6Xiyc+v5XtG3azb2cKAKbjKQy4pAuT3pvDil/X44lyc8GN/Xhuyl38+9KXmTtpGQB7dyQXOB7A9Q+dz2k9m7Ng+ooQPjsV3+bNyUydspbWbWrQoVMd5s3ZUqDNlElrWbd2H3+5oi3Nmldj184DvPH6Iq66/As++uxS6tSJK/Ycjz78EzN/3MBNI7vQ5tSa7NiexquvLODmv33Hx59fSqVKkQCsWrWXW276jh49G/LsC0PYtjWVZ/87l127DjDmqbMKPfZ77ywhKenwsT8RJ6CyvratWtdkwnsXFtj+yMMzSUlO59S2NXO2zZm9mXvu+oHzL2zFXf/oiV25hxef/5UDBzK5/c7uOe1SktMZMLAJzZpXo3LlSFau3MMbry5i4a/beP/ji4mIcB3js3Ji2LLlANOmbaNVqwQ6dqjGvPm7C7Q5eCiLxMQoRt7Umlq1YjhwIIuv/7eRO+6cx5jRXRnQv14hR3ZkZvlxu12MuKYFdetWIjPDx9RpW3no4cUkJWVwxeXNctq++tqfvP/BWkbe3JrWrRL4YepW7vv3Ap4Z151evZyE1pgE3n6zT4HzPPr476SkZNCmTdUQPCsnBlf1JnhOOw/f1qX4Ns7H3aJ/oe0i6rUn+rrP8a6fQ8bXd+M/nIqrehNcUZWPfBJPDFnz3sa3bwPgx928P5HnPIqrWmMyJz6Q0yzqgnG4Ww8mc8bT+LYuwZVYn8gB9xB93WccfnEAZByEyBgi+91B1u+fkTXnDfwZB3C3PJOo88eRVaMFmVMeCc0TcwLYtD+SKbYybWqn06lBOnM2xBbZ9oK2qQxvnxa0rXG1zGKPv3xnFJNXVuaCtmm0r5dOptfFx79XYcTHdXjxol30a3YIgO0pHj7+LZ4LT0vl5h7JuFx+Jv4Zx21f1+L/Bu7lik7BBYL7JtZg9vpYbuyezKl10klNj2Dh5hjSs/T3WE4OSjTL0L8ueYnkPbl/7JbMWk3q/gP8+81r6XBGS377yfLfOz4s0Gbz6l28MPUf9L+4MxPfnVPk8ZP3pAXdF6Bdz+Yk1ohj/OO51ZJlc9ZwVbsH8XpzP21dMHUFExY9xOV3DspJNDMzslixYH3Q8aJjI2ndpTFzJy4ldX/BT+tOZp0612PazGsA+OqLPwtNRkZc14Gq1YL/IbbvWIdhQz7gqy/+ZOStXYs8/uHDWUz9YS1Xj+jANdd2yNlerXosf79lIr//toOevZwKyWsvL6BW7cqMefosIiPdAERGRvDg/T8y4toOtG5TM+jYW7ak8Obri7n/oTO4/18zSvcEnMDK+trGxUUFVSwBtm1LZf26/Vx1dfugSuULz82jQ8c6PPBQXwC6dqvPwYOZvPn6Yq78aztq1HAqcbeM6hZ0vC5d6xMTE8kTj/7MypV7aJPvd+Bk1bFjdaZMHgzA1//bWGii2axpPA/c3zFoW69etTn/wql8+92mYhPNxIQoHnu0S4H7btqUxjffbsxJNPftS+f9D9ZyzdUt+OtVzQHo0qUmm7cc4MWXV+QkmnFxkQUqltu3H2TDhlSuvKI5brfesGbzbZjLodGnAeDufEXhiabLRdTFz+Nd9wsZH16Xu3190VXjvDI+vTn4nGt+whVfG0/ny3MTTU8M7rbnkTXrJbJmvZzT1p+2m5hrPiKiUTd8a2ZC5mEO/fd0OJSUe7x1s3DFJuDpfh2Z08dClj4MBOjS8DA/3+pUgj9fGldsolkrzkv7ekV/SF+YTvXT+f6GrXjyDCjr1eQQ579dn7d/TchJNOsnZDHlxi3ERuZWm3s3OexUXH9NCEo0J/5ZmSkrK/PRVds5tU5uNXVA80Mlik2kItMYzTKUPwkEWLloAwA16yUesU2NQJuSGHRVDzLSM5nx2YKcbWnJh4KSTACv18eapVuOeI4zzu9E5fhYJn8wt8SxnOiOpkKUPxEBqFevClWrxrJr14Fi7+v1+vB6/cTFBQ9Hr1IlGgC/z/lHl5npZc7szZx1drOcJBPgrEHNiIyMYOaPGwoc+4nHfmbQkOZ06FDniI/hZFTW17YwE79bhd8Pw84zOdt27EjDrtzLOUNbBLUdem5LsrJ8zJ61qdhjJiY4vysej/7UZyttZdfjiSAuLrLUz2VCQlTQfefN20Vmpo8hgxsEtRsyuAFr1qSwdVvRv0MTJ23G74ehQxsW2eakdBRdTSOa9CSitiFr9muhO+3B/eDL04Uzwo3L7cGfnm/4y6Fk59YV+D3w+4KSzGy+rb/jiozBVVldorOVdYeM+Bgf+V/anghoVSuDXam5/1crRfmDksxsp9bJYHeaO2jbx79XoUvDw0FJpsjJJuwVTWNMC6AZkBDYlAystdauLvpeFVf7Pi0B2Gh3FNmmQ3ablUW3KUxUTCT9LuzM3EnLSNlX/BtdT6SbU09vyto/ClZq8hp8ZXf27Uzh1x+WlygWKdq6dfvZt+8QTZoUn+RXrhzF0HNb8tGHy2h7Wi1ObVuL7ducLrEtTXW6da8PONXJ9HQvzZsHvymJjvbQoGEC69ftD9o+8ftV/Ll8N48/OZBDB4vvTiQlc7TXtjDffbuKVq1r0LxF7nVcu2YfAM1aBF/b+g3iiYnxsG5t8LUFyMrykZnpZfWqfbz6ykK6nV6fli2rlzgeccZQ+nx+kpIz+PrrjWzalMbdd512VPf1+/14vX7SDmQxY8Y25s7bxQP35/ZMWLs+haioCBo2DO6u2aypM753/bpU6tcrvCvnxImbaWUSaN7syOO8JVjEKac733iiib7peyLqtYNDyWQt+5rMKY8dfQUxwg1RlXE37YOn43Ayf3kpd1/GAbJ++wxP9xvwbf4N39bfcCU2JHLwg/i2/4Fv3S/FH7pxD/yHkvCn7izlozy5ffJ7FcYvSMDt8tOuXjqjeiXRuUHJKpwAGV74fVs0puaRE8VFm6NpUj33/2mmF5Zuj2Z4+1SenlmVr/6IIy09gta1M7ijz366n6JKtZwcwpJoGmPigfuAEUChMysYY3YCE4DR1tqUcguuDNWol8h19w9j4fQV2MUbC20TGxfNqLHD2fDnNmZ9+3uJjt9nWAfiEo6u+njt/cOoWT+Rx659q9h4O/ZrxRcvzShQEZXSycry8cSjP1O1agwXXHTkyXcefrQfY0fP5qYbcrtCtz2tFq+8dm5O9TIl2fkHWiU+usD9ExKiSU7O/QebkpLOf5+ay213dKdq1VglmiFU0mub15IlO9i0MZl77u0VtD372sYXcm3j46NJSQl+83TwYCa9u+e+pnv0bMjYcYWP0ZUje/6F5Xzw4VoAKlVy8/hjXejW9ei6IH/2+XqeetoZluDxuLj7rtMYek6jnP0pyZnExUXicgWXauLjnXHXKSmFvzaXLtvHps0HuPuutiV+PAKuKs5bjujLXiNr/ngyf3iciHrtiRx4D66EesHdaYsQYc4i5q/vAeD3+cj65QWyZj4T1Cbjy9uJHPo4Mdd/kbPNu3kRh8dfBt6i/+5GNO+Hu+15ZE4fAz5NFlNSw9qk0bfZQWrFedmW7OHtBQlc90kd3rh0J90alSy5e3l2IjtT3Yw9N7nYdp8uiWPJ9hjGDM3thp90yE2m18XXf8TRICGL/5y9lyiPn7d/jeemz2vzwZXbaatKp5wEyj3RNMZUB34BWgHrgDeBtUB2MhmPU+EcgJOMXmCM6WOt3VvesYZSbOVoHv/0FrxeH6NvfqfQNm53BA++cwM16yVy68CxJU7uBl3Vg/27Upg/+Y9i2505vCtX3D2Id0dPZOmcNUW2O/vy03G7I9RtNoTGPDmLpUt28tyLQwpNHvJ7+cUFTPp+NXfe3cOZDGhHGq+/upBRt0zkzbfPI7ZSJP5Ad7H8b1iBnH3Znh03lwYN47ngolaheUCSo6TXNq/vvlmFxxPB4HOaB233E7i2FHJtKdh9KybGw/sfXUR6uhe7cg9vvbGYO/4+iVdeH6bus6Vw+V+acfbZ9dm7N52JEzfzwIOLiHwygj69j9zl/Kwz69O2bVWSkjL4+ZcdPD1uKe4IFxdd1BgAP1DIS/aIvT+//34zHo+LwYMaFN9QCuUKdFvNWvKFMwYS8K2fAxFuogbdT2bNlvh3ryr2GL4N8zj88iCIqYK7WR88vUaC30/mtNzJ9CLPvA9Ph4vJmPSw0xU2oT6R/e8m+poPSX/zQsgsOOeBq2ZLooe/gm/DHLJ+eTGEj/rkMXronpzvOzdIZ0CLg5w/vj7Pz0rk/SuOvpfYdysq8+b8BG7ukVxsNfTXTTE8Ob0657VJ49w2uT3Jsl/GWT549ZKd1ArMMNu5wWEGv9GA8b8mMO68guPDRU404ahoPgG0AK631o4vrqEx5jrgNeBx4Obi2h7PoqI9PPHZLdRrXIPbBz3N7q0Fx2S4XC7+9cYIOvdvzX0Xvci6P7aW6BzV6sTTuX8rvnzlx2IT1J7ntOO+10cw8Z3ZjH+s6OUVAAZd0Z3VSzaxdlnx3Wvl6Lzw3Hy+/HwF/3lsAD16Hnls1do1+xj/1m88+HDfoArZaafV4oJhH/PVl39yxVXtiE9wlq5ISS74aW1KSgbNmjnd75Yt3cm331hefWMYaanOJ6lpB5xP1tPTs0hNSSeuSlShCasUr6TXNq+MDC9Tp6ylzxmNqFo1eNxnQrxzbZNTCl7b1JSMAgltRISLNqfWAqBjp7o0b1GNG6//lulT1zFoSPMCx5Di1a4dS+3azjXp07sON42cxXPPLz+qRLNq1WiqVnWuT88etTl82MtzL/zBeec1wuOJICE+ktTUTPx+f9BrLjXVeU1mVzbzysjwMm36Vnr3qk1iYsk+zBCH/6DT3dy35qeg7d41M2HQ/UTUPRXvERJN0lPxbVviHGfdLPBm4ul3J1nzJ+BP3YGrliGy722kf3Un3kUf5dzNt2UxsXfOxdPligLLqLiqNiL62k/w799E+gcjVM0MkcpRfs5oepAvl1U56vv8uCaW/5tUg4vapTGqd8H3a9mWbY9i1Fe1OL3RIR4ZvCdoX3y0Dxd+mlXPzEkys+NpXy+dP3dF5T+cyAkpHB9xDwM+PVKSCWCtfRv4HDivzKMqI25PBI98dDOtujTm3gtfYN3ybYW2u/uFK+l/SRceueYNFs9cWeLznP2+m+RLAAAXX0lEQVSX7ng8bqYUU33s1K8VD79/I7988ztPj/qg2OO16nwKjVvXY/L780ocixT05uuLGP/Wb9xzby/OHdbyqO6zZrUzPq9N21pB2xudkkiVKlGsX+/8A2zYMJ6oKDdr843XS0/PYuuWFJo0dZY/WL9+P16vn79d9w19e4+nb+/x/OWSzwAYO3o2fXuPz0lA5eiV5trm9dPMDaSkpHNunkmAsjVt7ly7dWuCr+22rSkcPpxF02bFL22RnXRu3lx81y85Oq1bJbJlS8knegJo0zqRgwe97N3rVEeaNq1CRoavwPHWrXcmkGnStOAb459/2UFKSiZDhzYqsE+Ojm+XBSikP0Ag2feXfJiId+sSXBFuXNWc6xJR2+kx4tsSPPzFv3c9/kNJuGoGT+7liq9L9HWfw+FUDr9zBaQXnCRQjoGfQvqEFG7exhju+qYWZ7Y4yMNnF92RbtXuSG78vDatamXw7Pm7iQyeB4iYSD8NErMKPa/fX/aTG4kcL8KRaFYFCq6eXLRNQMln1jgOuFwuHhh/PZ36teL/hr9SYOmQbLc8eQlDR/RizE3vMOvbJaU616ArurNm6WbWLC28+nhqt6Y8/ulIFs9cyWPXvVWgS2WB413Zg6xML9M+/bVU8Uiujz5YxssvLuDWv3fjL1cc3UQiANVrOJWU5ct2BW3fuCGJ1NQMatVyKpWRkW569mrI1B/WkpWV+yZp2tR1ZGR46du/MQA9ezXi9beGBX09OeZMAP56TXtef2sYsZUKVlGkaKW9tnl9+40lMTGG3n0KJg9161ahpanOpInBc6NN/H41Hk8EvXoXn3AsWuh8sNWggSaNOVY+n58lS/ZRv36lUt1/8eK9VKrkplo1pxLZo3ttIiMjmDwl+G/2pMmbadasSqETAX3//WYSEqLo3avQqQ3kKHhXzcCfebjA0ifuFv0A8G0t+f9gd+Me+H0+/PucuRf8aU6XyIgGwUvkuKo3xRWbiD8lTxfOStWJvvZTANInXAYHK/QooeNOWrqLn9ZVol3dI08G9PvWaEZ9VYvupxxi9NDdRSaDG/d7uOHTOjRMyOLli3YSU8gstABntjjI6j1R7Mgza+2BDBdLtkXTtk7JJycSqYjC0XV2NXC+MeZha22xI7ONMbE41cyiBxIex+589nL6X9yFd8dM5PCBdNp0bZKzb/e2/ezemsTldw3istvP4vt3ZrFlza6gNkl7Utm2Prc7xvSUl5nywVzGjnwv6DwtOjSkadv6vHTvZ4XG0ahlbUZ/OYrkvWl8/MwPmI6nBO3PnwC7PREMuKQr83/4g6Td+aZnlyDTfnAmCvlzhfPGYvaszVStGkPVarF07lKPKZPW8PTY2fTs1ZCu3eqzdEnuLIJxcZE0bZY7m+h5Qz+kbt0qvPbmMMDp+tjSVOeZcXNJSUl3xmhuT+PNNxYRVyWKc8/LrZ7dNLILI/76FffeM5Xhl50amJ12Hmee1TRn/cQaNSrlrLmYbdtWZ2h048aJdOlavwyeoYqrLK9ttn17DzFvzhYuGd4maGmavEbd1o3bR03isUd+YvCQ5qxcuYc3X1/M5VeelnM9U1PTGTVyIkOGtqBRowRcLlj+xy7ef3cpLU11BpzZNKTPTUU3fbqTgK9c6fQKmDN3J1UTo0msGkXnTjV4/Y2VpKRk0K5ddapXj2bv3nS++WYjy1fs57FHOgcdq3vPbxh6TsOcdTe//HIDy/7YR7duNalVK5bk5AymTdvG9BnbGHVrGyIjnc93q1WL5vLLmzLhndVUquShlUlk6rStLFy4h6efOr1AzPv2pTN33i4uubixxtsWw33quQBE1Gvv/NxyAP4De/Ef2Itvw1w4tJ/Mn18gst+dkJ6Kd90sIuq3J7L/XWQt/gT/vg05x4q5cy7+pC2kj7/UOWbLM/F0+gte+wP+pK24oisT0WIgnq5XkbXgvZxZYn0b5uHb/gdRQx4mMzYR39YluBLrE9n3DvyHkvH+5iSWeGKIGfERrsSGZHx1J674urji6+ac37d7laqbeUyxzt+7FTucbqe/rIulaiUv1Sp56downfG/xrN+fyTdGh52JgNKcTNhQQJ7DrgZe27weMjBb9SnXnwWb1/mXLN1eyMZ+WUtqsb6uLZrCit2BndNz16Xc++BCG74tA6ZPri1VxJr9wZ3gW1dK52owDvrEV2T+WZ5HCM/r83NPZOIdPuZsCCBw1kubjhdvUzk5BCORPPlwNdcY8wTwIz8E/0EJgwaCPwbaAncUu5RhkC3s08F4Op7z+Hqe88J2jf+8W+Z8Ph3nB5oM/Sa3gy9pndQm0nvzWH0TbkTB3k8biIiCr7BGByoPk79ZH6hcbTp1pT4apWJr1aZ56bcXWB/30o3Bf3c85x2JNaIY/L7mgToSP75j6lBPz/5uDNtfecudXnj7fOZM3sTfj/Mmb2ZObODC/nZbbJ5vT58vtyKpNsdwatvDOPtNxfz5RcrePXlAyQmxtCuQx1G3tKVunVzu9aZVjV48ZWhPP/sfG4fNYm4uCiGDmvJqNu6lcXDPimU5bXNNnHiKrKyfIV2m83Wu88pjB13Nq+/uohv/2epXr0S193Qkev/1imnTXS0hyZNE/n4w2Xs2nkAjyeCuvWqcNXV7bj8ytOIiio8iT1Z3ffvBUE/jxm7FIBOnarz2iu9MSaBjz9exw9Tt5KWlkX16tG0aJHAG6/1pn374KVivF4/Xl9uRaNZ83h++nk7zz2/nJSUTBITo2jcOI5nxp1O73xjO2+5uQ2VYj18/Mk69u5N55RT4njy8a6c0afgGNDJU7bg9fqDZq6VgqIvDx77GHXeGAC86+eQ/tZFAGT9OA7S0/CcPgJPr5H403aRNesVMn/8b/DBIjzOMiYB/n0bwOUi8sx7cVWuAYdT8O1dR8YXf8e79Kvc+/l9HH77UiL73o6ny1W4Bt6D/+A+fJsWkjl9LP5kZw4GV1xNZ3kVIHr4KwUey+G3LnImKhIA7vomeBjJo9Oc12LXhoeZ8JcdNK6WybTVlZi+uhJp6RFUjvLRsX46jwzeQ7u6wcNCvD4XPn9uyXLJ9mhSDrtJOQzXflLw9bf8ng0ArN0bxbYU563zLV8W7Fnww41bqJ/grKlao7KPdy/fztiZ1bh/Ug38QPu66Uz4yw6a19CM73JycB2pC2VZMMaMAe4mt9t8Ks6ss36c9TSz30H7gXHW2ntLc56+lW4q/wcnZW7ifs2YKlLReA9tD3cIUkY8T78b7hCkjEQ1LrhWr5w4PDekV7jRomnbri639/Zx9d6tcM/P8SYs/W8CiWN74L/Ar0AmznqadQLf/wqMA9qXNskUERERERGR8AhH11kArLXLgXvCdX4REREREREpG5pRQEREREREREIqbBVNAGNMPHA60AxnbCZAMrAWmG+tTQlXbCIiIiIiIlI6YUk0jTENgTHARUAkBdfS9QOZxpgvgXuttSVZd1NERERERETCqNwTTWPMKcA8oBYwE5iGU8HMrl7G41Q4zwIuA/obY7pbazeWd6wiIiIiIiJScuGoaI7B6SZ7lrV2RjHtnjTGDAS+AUYDl5dHcCIiIiIiInJswjEZ0EDggyMkmQBYa6cDH+NUN0VERERERKQCCEeiWQlnwp+jtR+ILaNYREREREREJMTCkWguB4YbY6ofqaExpibOOM0/yjwqERERERERCYlwjNF8CvgEWGKMeQ6YQeGTAQ0EbgPqAneGIU4REREREREphXJPNK21nxljagBjcSYG8hfR1AUcAEZZaz8vr/hERERERETk2IRlHU1r7SvGmM9wusX2BprjVDJdOOM31wC/AJ9aa/eEI0YREREREREpnbAkmgCBBPKlwJeIiIiIiEiRfJXqhDsEKYGwJZqFMca4gdZAZWCjtXZHmEMSERERERGREir3WWeNMWcbY5oWsv1eYA+wBJgDbDXGzDTGmPKOUUREREREREovHMubTAKuyrvBGDMGeALwAR8DLwLzgTOAmcaY2uUdpIiIiIiIiJROOLrOuvL+YIxpgLN8yZ/AmXm7yxpjbgeeAe4F7irPIEVERERERKR0wlHRzO9MwA3ck39MprX2OWABcE44AhMREREREZGSOx4SzbqB23lF7J8HNCqnWEREREREROQYHQ+J5u7AbVYR+72BLxEREREREakAwrW8yQhjTL/A94mB2xbA4kLangLsKo+gRERERERE5NiFK9FsHPjKazj5Ek1jTGVgIDCtXKISERERERGRY1buiaa1tiTddZsA43GWRBEREREREZEKIFwVzaNirf0DZ+kTERERERERqSCOh8mARERERERE5ARyXFc0RUREREREANyxdY/cSI4bqmiKiIiIiIhISCnRFBERERERkZBSoikiIiIiIiIhpURTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBERERERkZBSoikiIiIiIiIhpURTREREREREQsrl9/vDHYOIiIiIiIicQFTRFBERERERkZBSoikiIiIiIiIhpURTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBERERERkZBSoikiIiIiIiIh5Ql3AFI6xpjbgK6Br5aAC4i01maFNTA5ZsaYBsBw4FzAADWBncBU4FFr7fowhifHwBhTDfgPcDrQGEgAtgELgSettYvDF52EkjHGDcwDugCzrbW9wxySHANjjL+Y3UOstZPLLRgJOWNMFHA7cCXQAsgAVgMTrLUvhzM2kYpMiWbF9VzgdiOQDCSGMRYJrVHAvcCfwLc417cLcC1woTGmt7V2eRjjk9KrBYwA5uAkl8nAKcD5ONf2Emvt1+ELT0LoTqB1uIOQkNoITChk+5pyjkNCyBhTBZgC9ABmBL6PwXn9DgWUaIqUkhLNimsosMBau9sYMxPoG+Z4JHTmAz2ttXPzbjTG3An8F3gaGBKOwOSYrQGq5u95YIxpBfwGjAaUaFZwxphmOJXrB4BxYQ5HQmeDtfbhcAchIfcsTi+Ti6y1X+XdYYzR+2SRY6AXUAVlrZ0Y7hikbOT/R5fHc8BjQJ9yDEdCqKiu7dbalcaYP4G25RySlI3XAIvzmlWiKXKcMsY0xuktNKGw/70ajiRybJRoilQsWUBxY4WkAgq82WkJrAhzKHKMjDHXA/2A0621XmNMmCOSEEo0xvwNZ9z8dmCatXZzmGOSY3MRzhwXXxpjauMMY6iG0/tkorX2YDiDE6nolGiKVBznA/FAURVPqSCMMfWAGwE30BC4APDhTEYhFZQxpg5O1/YXrLWLwh2PhFx74PU8P2cZY54B7rXW6gPAiqlj4LY18BEQl2ffFmPM+ZqkTaT0tLyJSAUQ+KT1BSAdeDDM4cixqwc8BNwPXIMzw+HF1tqfwhqVHKuXgFScsZlyYnkKZ5b3RKAGzqzgq4F7gPvCGJccm5qB2yeBd4BGOJO2/Rvn7/Q3xphKYYpNpMJTRVPkOGeMqYwzQUx94G/W2j/CHJIcI2vtQsAVmFK/GXA3MMkYM8pa+2p4o5PSMMZciNMN7zxrbVq445HQstb+M9+m740xi4HlwH3GmKettZlhCE2OjTtwu8BaOyrP9ieNMafiLHdyCfBuuUcmcgJQRVPkOGaMiQH+B3QH7rHWvhnmkCSErLUZ1to/rbU3AD8Azxpj6oc7LimZwIdBLwFfWGu/DXc8Uj6stduByThDGrSUTcWUHLgtbILF7G2dyikWkROOKpoix6lAtesLYCDwkLX26TCHJGVrGs6yNd3QONyKpiZQF7jYGFPYWL1ege0/WWv7lWtkUtb2BG4rhzUKKa3VgdvkQvYlBW5jyykWkROOEk2R41Bg7a5PgHOAsdbaR8IckpS9eoFbTadf8aQCbxWx73pgJ/AdzpIncmLpErjdGNYopLR+whlj26qQfdlV6k3lF47IiUWJpshxxhgTAbyPMxPpC9bae8MckoSIMaY9sM5am5pv+2nA34CDwKxwxCalZ63dC9xQ2L7AcidrAt2jpQIKvD7X5x97a4y5HegBzLLWbgtLcHKspgMbgKuNMf+11q4BMMbUAP6Os5yYepiIlJISzQrKGJP3E7js27fydNv6h7V2T8F7SgXwEHAZTpes/caYh/M3sNYW2CYVwrXAdcaYGThvbrw462cOwVnL7QZr7f7whScihbgeuNYYMx2ncunGGTffFdiNs1SRVEDW2szA2qiTgIXGmM9xZnc/H2cCviettVrfWKSUlGhWXIOBvvm2XZ3n+4fJHTsiFcspgdsaFL2UycPlE4qE2OdAVZwqyEAgCtgBfAo8a639NYyxiUjhJuMse9ERGISTaG4CngdGByYFkgrKWjvNGNMH5//qpTh/l1cA91trJ4QxNJEKz+X3a41hERERERERCR0tbyIiIiIiIiIhpURTREREREREQkqJpoiIiIiIiISUEk0REREREREJKSWaIiIiIiIiElJKNEVERERERCSklGiKiIiIiIhISCnRFBGRMmeM2WCMeT/ccYiIiEj5UKIpIiIiIiIiIaVEU0REyowxJvpEOo+IiIgcHU+4AxARkfJjjOkCLAD6WGtnBbb9HXgeeNxae39gWwtgFTDUWjvRGNMNeALoDriAecC/rLW/5jn2BOBM4FJgHNAReB24vZA43MArwF+AC6210wPb2wOPAn2AGGAxcJ+19pejOY8x5grgHqAF4AU2AS9aa187ludNRERESkYVTRGRk8tiIAkYkGfbAOBQIdu8wC/GmHbAT0BVYARwNRAP/BRIDPNKAD4GPgKGAB/mD8AYEwt8AZwP9MuTZHYC5gDVgL8BFwN7gWnGmM5HOo8xpjfwfiDWC3AS0TeAxCM/LSIiIhJKqmiKiJxErLU+Y8zPQH/gEWNMBNAXp7p4mzEmzlqbFti/0Fqbaox5EEgHBlprkwCMMVOBDcBDwEV5ThEHXGWt/V9h5zfGVAW+AeoBvay1a/LsfgqnAjnAWpsRaD8F+AN4ACd5LPI8xph/AEnW2jvytPvh6J8dERERCRVVNEVETj4/Aj2MMTFAB5yK31icZLJPoE0/YEbg+zOA77KTTABrbQpOwtg337GzgO+KOG894BecJDEoyQxUOfsCnwE+Y4zHGOPB6aY7LRDDkc6zAKhqjHnfGHOuMUaVTBERkTBRoikicvKZAUQDPXEql0ustTuBWUB/Y8ypQG2chBScrqzbCznODpzutHntstZ6izhvO+BU4GNr7Y58+6oBbpzKZWa+r1E4CWTe/1kFzmOt/Qmnu2xD4CtgtzFmWqDrr4iIiJQjJZoiIiefZcAenHGYA8itXM7Isy0DmB3Yvg+oU8hx6gT25eUv5ryTgX8Co40x+ScISgJ8wAtA18K+rLW+I53HWvu5tbYvTgJ8IVAXmJwvSRUREZEypjGaIiInGWut3xjzE3AW0Bp4ObBrBvAkkALMt9YeDGz/CRhqjKlirU0FMMZUAYYBM0t47qeMMVnAs8aYCGvtM4HtB4wxvwDtgcX5ksrSPMY04DtjTFPgOaA6sPtYjikiIiJHT4mmiMjJaQbwEoGZZQPbFuMkmf2BR/K0fRQ4F5hujBmDU028F6iUr91RsdY+Y4zx4iSbbmvt04FddwE/A1OMMW/hdNetAXQC3Nba+4o7rjHmEXK7/G4DGgC3Ab9ba5VkioiIlCN1JRIROTllj79cGJjYh0AV8ed8+7HWLsWZHCgFeAd4D0gD+lprl5Tm5Nba54G/A2ONMf8MbFuM0012L866nj/gVCNPyxNXceYDjYFngKnAGALV2NLEKCIiIqXn8vuLG04jIiIiIiIiUjKqaIqIiIiIiEhIKdEUERERERGRkFKiKSIiIiIiIiGlRFNERERERERCSommiIiIiIiIhJQSTREREREREQkpJZoiIiIiIiISUko0RUREREREJKSUaIqIiIiIiEhI/T/0/7USJD77hwAAAABJRU5ErkJggg==
"
>
</div>

</div>

</div>

</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="3-Which-are-the-worst-and-best-represented-countries/universities-in-the-research?">3 Which are the worst and best represented countries/universities in the research?<a class="anchor-link" href="#3-Which-are-the-worst-and-best-represented-countries/universities-in-the-research?">&#182;</a></h1>
</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>In this part we have converted each document in usable DataFrame data structure in order to figure out:</p>
<ul>
<li>the countries that are most and less active in the research (for this purpose we have used the country of the authors)</li>
<li>the universities that are most and less active in the research.</li>
</ul>
<p>As before, we run the algorithms with different number of partitions and workers and keep track of the computational time.</p>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="3.1-Countries-most-and-less-active-in-research">3.1 Countries most and less active in research<a class="anchor-link" href="#3.1-Countries-most-and-less-active-in-research">&#182;</a></h2>
</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[13]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Take json_singleline files in input</span>
<span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;./json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="mi">20</span><span class="p">)</span>
<span class="n">input_bag</span><span class="o">.</span><span class="n">take</span><span class="p">(</span><span class="mi">1</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[13]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>({&#39;paper_id&#39;: &#39;00c75478b9f6b815f8b552a50fd5e20a6d10e9f4&#39;,
  &#39;metadata&#39;: {&#39;title&#39;: &#39;Journal Pre-proof Fighting COVID-19 Hypoxia with One Hand Tied Behind Our Back: Blanket Prohibition of High Flow Oxygen and Non-Invasive Positive End-Expiratory Pressure in United States Hospitals Fighting COVID-19 Hypoxia with One Hand Tied Behind Our Back: Blanket Prohibition of High Flow Oxygen and Non-Invasive Positive End-Expiratory Pressure in United States Hospitals Fighting COVID-19 Hypoxia with One Hand Tied Behind Our Back: Blanket Prohibition of High Flow Oxygen and Non-Invasive Positive End-Expiratory Pressure in United States Hospitals&#39;,
   &#39;authors&#39;: [{&#39;first&#39;: &#39;Joseph&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Colla&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {&#39;laboratory&#39;: &#39;&#39;,
      &#39;institution&#39;: &#39;University of Illinois&#39;,
      &#39;location&#39;: {&#39;settlement&#39;: &#39;Chicago&#39;, &#39;region&#39;: &#39;IL&#39;, &#39;country&#39;: &#39;USA&#39;}},
     &#39;email&#39;: &#39;&#39;},
    {&#39;first&#39;: &#39;Adam&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Rodos&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {&#39;laboratory&#39;: &#39;&#39;,
      &#39;institution&#39;: &#39;University of Illinois&#39;,
      &#39;location&#39;: {&#39;settlement&#39;: &#39;Chicago&#39;, &#39;region&#39;: &#39;IL&#39;, &#39;country&#39;: &#39;USA&#39;}},
     &#39;email&#39;: &#39;&#39;},
    {&#39;first&#39;: &#39;Hannah&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Seyller&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {&#39;laboratory&#39;: &#39;&#39;,
      &#39;institution&#39;: &#39;University of Illinois at Chicago College of Medicine&#39;,
      &#39;location&#39;: {&#39;settlement&#39;: &#39;Chicago&#39;, &#39;region&#39;: &#39;IL&#39;, &#39;country&#39;: &#39;USA&#39;}},
     &#39;email&#39;: &#39;&#39;},
    {&#39;first&#39;: &#39;Scott&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Weingart&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {},
     &#39;email&#39;: &#39;&#39;}]},
  &#39;abstract&#39;: [],
  &#39;body_text&#39;: [{&#39;text&#39;: &#39;Before COVID-19 pandemic, patients with hypoxia failing low flow oxygen via nasal cannula were treated using non-invasive positive pressure ventilation (NIPPV) or high flow nasal cannula (HFNC) oxygen, aimed at delivering higher concentration and flow of oxygen to match patient demand, decreasing anatomical dead space by preventing rebreathing, and recruiting alveoli using positive end-expiratory pressure (PEEP). Many emergency medicine physicians began their fight against COVID-19 with both of these options off the table due to concerns of exposure to staff and other patients from virus aerosolization. Instead, early endotracheal intubation (ETI) has been the suggested option for a patient failing nasal cannula. Often this is the correct answer, but not always.&#39;,
    &#39;cite_spans&#39;: [],
    &#39;ref_spans&#39;: [],
    &#39;section&#39;: &#39;Dear Editor:&#39;},
   {&#39;text&#39;: &#39;There is a cost to staff and patients from over-utilization of ETI. ETI is an extremely high aerosol generating event. A systematic review of aerosol generating procedures and their risk of transmission of SARS transmission to health care workers found ETI to be an odds ratio of 6.6 compared to 2.2 for NIPPV 1 . Plus, many hospitals face the risk of running out of ventilators and ICU beds. Once intubated, COVID-19 patients tend to remain on mechanical ventilation for over one week with poor outcomes. In vitro studies have demonstrated less airflow dispersal from HFNC or CPAP using sealed masks than from nasal cannula 2 .&#39;,
    &#39;cite_spans&#39;: [],
    &#39;ref_spans&#39;: [],
    &#39;section&#39;: &#39;Dear Editor:&#39;},
   {&#39;text&#39;: &#34;Furthermore, data coming from overseas indicates an important role for NIPPV and HFNC in managing COVID-19 patients. Retrospective data from China demonstrates that approximately 21% of patients required HFNC and 14% of patients required NIPPV. 3 Among admitted patients in Italy, about 30% required ventilation support beyond oxygen therapy. Of those given ventilation support, 89% were assisted with NIPPV compared to 12% on invasive ventilation. 4 The Chinese Handbook on COVID-19 Prevention and Management recommends the use of HFNC for hypoxic patients not tolerating nasal cannula. 5 We advocate early planning with colleagues from critical care, respiratory therapy, and nursing to develop protocols that mitigate risk associated with HFNC and NIPPV rather than prohibiting the use of these critical alternatives to ETI. Ideally these interventions should be performed in negative airflow rooms, but most ED&#39;s have a limited number of these. We are recommending use of these interventions in closed isolation rooms with staff in full airborne PPE. HFNC should be performed with surgical mask over patients mouth or high flow oxygen could be provided using a non-vented sealed CPAP mask attached to self-inflating bag plus viral filter with dual oxygen source see https://emcrit.org/emcrit/covid-airway-management/ CPAP should be provided via helmeted set-up or non-vented CPAP masks with viral filter attached to expiratory port. Policies can be rapidly adapted as more data emerges regarding COVID-19, but it&#39;s already clear that we must find safe and creative ways to expand, not limit, our armamentarium during this pandemic.&#34;,
    &#39;cite_spans&#39;: [{&#39;start&#39;: 245,
      &#39;end&#39;: 246,
      &#39;text&#39;: &#39;3&#39;,
      &#39;ref_id&#39;: &#39;BIBREF2&#39;},
     {&#39;start&#39;: 449, &#39;end&#39;: 450, &#39;text&#39;: &#39;4&#39;, &#39;ref_id&#39;: &#39;BIBREF3&#39;},
     {&#39;start&#39;: 588, &#39;end&#39;: 589, &#39;text&#39;: &#39;5&#39;, &#39;ref_id&#39;: &#39;BIBREF4&#39;}],
    &#39;ref_spans&#39;: [],
    &#39;section&#39;: &#39;Dear Editor:&#39;}],
  &#39;bib_entries&#39;: {&#39;BIBREF0&#39;: {&#39;ref_id&#39;: &#39;b0&#39;,
    &#39;title&#39;: &#39;Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;K&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Tran&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;K&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Cimon&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;M&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Severn&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;C&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Pessoa-Silva&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;J&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Conly&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2012,
    &#39;venue&#39;: &#39;PLoS One&#39;,
    &#39;volume&#39;: &#39;7&#39;,
    &#39;issn&#39;: &#39;4&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF1&#39;: {&#39;ref_id&#39;: &#39;b1&#39;,
    &#39;title&#39;: &#39;Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;D&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Hui&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;B&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Chow&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;T&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Lo&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2019,
    &#39;venue&#39;: &#39;European Respiratory Journal&#39;,
    &#39;volume&#39;: &#39;53&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF2&#39;: {&#39;ref_id&#39;: &#39;b2&#39;,
    &#39;title&#39;: &#39;Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;F&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Zhou&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;T&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Yu&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;R&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Du&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;G&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Fan&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;Y&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Liu&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;Z&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Liu&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2020,
    &#39;venue&#39;: &#39;&#39;,
    &#39;volume&#39;: &#39;395&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;1054--1062&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF3&#39;: {&#39;ref_id&#39;: &#39;b3&#39;,
    &#39;title&#39;: &#39;Novel 2019 Coronavirus SARS-CoV-2 (COVID-19): An Updated Overview for Emergency Clinicians. EB Medicine&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;A&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Giwa&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;A&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Desai&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;A&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Duca&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2020,
    &#39;venue&#39;: &#39;&#39;,
    &#39;volume&#39;: &#39;&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF4&#39;: {&#39;ref_id&#39;: &#39;b4&#39;,
    &#39;title&#39;: &#39;Handbook of COVID-19 Prevention and Treatment&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;T&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Liang&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: None,
    &#39;venue&#39;: &#39;&#39;,
    &#39;volume&#39;: &#39;&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}}},
  &#39;ref_entries&#39;: {},
  &#39;back_matter&#39;: []},)</pre>
</div>

</div>

</div>

</div>

</div></div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>As we can see from the structure of the JSON file, we have to:</p>
<ul>
<li><code>pluck</code> in 'metadata'</li>
<li><code>pluck</code> in 'authors'</li>
<li><code>flatten</code> the results in order to get rid of the list</li>
<li><code>pluck</code> in 'affiliation'</li>
<li><code>filter</code> None values in order to get rid of the empty <code>dict</code></li>
<li><code>pluck</code> in 'location'</li>
</ul>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[14]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">data_country</span> <span class="o">=</span> <span class="p">(</span><span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;metadata&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;authors&#39;</span><span class="p">)</span>
                <span class="o">.</span><span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;affiliation&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="kc">None</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;location&#39;</span><span class="p">))</span>
<span class="c1"># Conversion to DataFrame</span>
<span class="n">data_country</span> <span class="o">=</span> <span class="n">data_country</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
<span class="n">data_country</span><span class="o">.</span><span class="n">head</span><span class="p">(</span><span class="mi">10</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[14]:</div>



<div class="jp-RenderedHTMLCommon jp-RenderedHTML jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/html">
<div>
<style scoped>
    .dataframe tbody tr th:only-of-type {
        vertical-align: middle;
    }

    .dataframe tbody tr th {
        vertical-align: top;
    }

    .dataframe thead th {
        text-align: right;
    }
</style>
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>settlement</th>
      <th>region</th>
      <th>country</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>Chicago</td>
      <td>IL</td>
      <td>USA</td>
    </tr>
    <tr>
      <th>1</th>
      <td>Chicago</td>
      <td>IL</td>
      <td>USA</td>
    </tr>
    <tr>
      <th>2</th>
      <td>Chicago</td>
      <td>IL</td>
      <td>USA</td>
    </tr>
    <tr>
      <th>3</th>
      <td>Athens</td>
      <td>NaN</td>
      <td>Greece</td>
    </tr>
    <tr>
      <th>4</th>
      <td>Urayasu</td>
      <td>Chiba</td>
      <td>Japan</td>
    </tr>
    <tr>
      <th>5</th>
      <td>Urayasu</td>
      <td>Chiba</td>
      <td>Japan</td>
    </tr>
    <tr>
      <th>6</th>
      <td>Urayasu</td>
      <td>Chiba</td>
      <td>Japan</td>
    </tr>
    <tr>
      <th>7</th>
      <td>Urayasu</td>
      <td>Chiba</td>
      <td>Japan</td>
    </tr>
    <tr>
      <th>8</th>
      <td>Urayasu</td>
      <td>Chiba</td>
      <td>Japan</td>
    </tr>
    <tr>
      <th>9</th>
      <td>Hamedan</td>
      <td>NaN</td>
      <td>Iran</td>
    </tr>
  </tbody>
</table>
</div>
</div>

</div>

</div>

</div>

</div></div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[15]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">data_country</span><span class="o">.</span><span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;country&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span><span class="o">.</span><span class="n">sort_values</span><span class="p">(</span><span class="n">ascending</span> <span class="o">=</span> <span class="kc">False</span><span class="p">)[</span><span class="mi">0</span><span class="p">:</span><span class="mi">20</span><span class="p">]</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[15]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>country
China                         455
USA                           417
Italy                         207
Germany                       165
Spain                         125
France                        117
UK                            107
Brazil                         96
United States                  94
Australia                      88
Japan                          83
India                          76
Canada                         71
Sweden                         56
Iran                           47
People&#39;s Republic of China     47
The Netherlands                45
PR China                       37
Portugal                       32
Belgium                        30
dtype: int64</pre>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>We can see that some countries are represented with different names, so we replace them.</p>
<p>After this cleaning procedure, we compute the count of the occurrence for each country using <code>size</code>.</p>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[&nbsp;]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">list_USA</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;United States&#39;</span><span class="p">,</span><span class="s1">&#39;California&#39;</span><span class="p">,</span><span class="s1">&#39;United States, USA&#39;</span><span class="p">,</span><span class="s1">&#39;United States, United States&#39;</span><span class="p">,</span><span class="s1">&#39;USA., China&#39;</span><span class="p">,</span><span class="s1">&#39;U S. A&#39;</span><span class="p">,</span>
           <span class="s1">&#39;USA;&#39;</span><span class="p">,</span><span class="s1">&#39;Usa&#39;</span><span class="p">,</span><span class="s1">&#39;United States, France&#39;</span><span class="p">,</span> <span class="s1">&#39;US), Greece, GR), UK), US), UK), UK&#39;</span><span class="p">,</span>  <span class="s1">&#39;Bulgaria, USA, USA&#39;</span><span class="p">]</span>
<span class="n">list_China</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;PR China&#39;</span><span class="p">,</span><span class="s1">&#39;P.R. China&#39;</span><span class="p">,</span> <span class="s1">&#39;P.R. China, PR China&#39;</span><span class="p">,</span> <span class="s1">&#39;China., China&#39;</span><span class="p">,</span> <span class="s2">&quot;People&#39;s Republic of China&quot;</span><span class="p">,</span>
              <span class="s1">&#39;China;&#39;</span><span class="p">,</span> <span class="s1">&#39;China aa, USA ab&#39;</span><span class="p">,</span><span class="s1">&#39;China-Japan, China&#39;</span><span class="p">,</span> <span class="s2">&quot;People&#39;s Republic of China., China&quot;</span><span class="p">,</span>
             <span class="s2">&quot;People&#39; s Republic of China&quot;</span><span class="p">]</span>
<span class="n">list_UK</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;UK, UK&#39;</span><span class="p">,</span><span class="s1">&#39;UK&#39;</span><span class="p">,</span> <span class="s1">&#39;UK, China&#39;</span><span class="p">,</span> <span class="s1">&#39;UK A R&#39;</span><span class="p">,</span> <span class="s1">&#39;United Kingdom., United Kingdom&#39;</span><span class="p">,</span> <span class="s1">&#39;7 UK&#39;</span><span class="p">,</span><span class="s1">&#39;England&#39;</span><span class="p">]</span>
<span class="n">list_Spain</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Espaa&#39;</span><span class="p">,</span><span class="s1">&#39;Espaa, Spain&#39;</span><span class="p">,</span> <span class="s1">&#39;Spain;&#39;</span><span class="p">,</span><span class="s1">&#39;Spain. 19&#39;</span> <span class="s1">&#39;Spain., Italy&#39;</span><span class="p">,</span> <span class="s1">&#39;Spain., Spain&#39;</span><span class="p">,</span> <span class="s1">&#39;Spain., Italy&#39;</span><span class="p">,</span> <span class="s1">&#39;Spain. 19&#39;</span><span class="p">]</span>
<span class="n">list_Iran</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Iran, Iran&#39;</span><span class="p">,</span> <span class="s1">&#39;Iran A R&#39;</span><span class="p">]</span>
<span class="n">list_Brazil</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Brasil. CEP&#39;</span><span class="p">,</span><span class="s1">&#39;Brazil., Brazil&#39;</span><span class="p">]</span>
<span class="n">list_Italy</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Italy ; 27&#39;</span><span class="p">,</span> <span class="s1">&#39;Italy; 16&#39;</span><span class="p">,</span> <span class="s1">&#39;Italy;, Italy&#39;</span><span class="p">,</span> <span class="s1">&#39;Italy Neurological Sciences&#39;</span><span class="p">,</span> <span class="s1">&#39;Italy. (&#39;</span><span class="p">,</span> <span class="s1">&#39;10 Italy&#39;</span><span class="p">,</span>
             <span class="s1">&#39;Italy, Italy&#39;</span><span class="p">]</span>
<span class="n">list_Germany</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Germany, United States&#39;</span><span class="p">,</span> <span class="s1">&#39;Germany Schlsselwrter&#39;</span><span class="p">,</span> <span class="s1">&#39;South Korea, Germany&#39;</span><span class="p">]</span>
<span class="n">list_Russia</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;127051 Russia&#39;</span><span class="p">,</span><span class="s1">&#39;127051 Russia&#39;</span><span class="p">,</span> <span class="s1">&#39;119991 Russia&#39;</span><span class="p">]</span>
<span class="n">list_Greece</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Greece, Austria&#39;</span><span class="p">]</span>
<span class="n">list_France</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Guadeloupe, France&#39;</span><span class="p">,</span> <span class="s1">&#39;France, France, France&#39;</span><span class="p">,</span> <span class="s1">&#39;France, France&#39;</span><span class="p">,</span> <span class="s1">&#39;France, Singapore&#39;</span><span class="p">]</span>
<span class="n">list_Sing</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Singapore, Singapore&#39;</span><span class="p">]</span>
<span class="n">list_Japan</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Japan, Japan&#39;</span><span class="p">,</span> <span class="s1">&#39;JAPAN, JAPAN&#39;</span><span class="p">]</span>
<span class="n">list_Austria</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Austria Opinion&#39;</span><span class="p">,</span> <span class="s1">&#39;Austria, Austria&#39;</span><span class="p">]</span>
<span class="n">list_Ireland</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Ireland; C.OTOOLE9@nuigalway.ie (C.O.&#39;</span><span class="p">]</span>
<span class="n">list_Finland</span> <span class="o">=</span> <span class="p">[</span><span class="s1">&#39;Finland;, Finland&#39;</span><span class="p">]</span>

<span class="n">country</span> <span class="o">=</span> <span class="p">(</span><span class="n">data_country</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_USA</span><span class="p">,</span> <span class="s1">&#39;USA&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_China</span><span class="p">,</span> <span class="s1">&#39;China&#39;</span><span class="p">)</span><span class="o">.</span>
           <span class="n">replace</span><span class="p">(</span><span class="n">list_UK</span><span class="p">,</span> <span class="s1">&#39;United Kingdom&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Spain</span><span class="p">,</span><span class="s1">&#39;Spain&#39;</span><span class="p">)</span><span class="o">.</span>
           <span class="n">replace</span><span class="p">(</span><span class="n">list_Iran</span><span class="p">,</span> <span class="s1">&#39;Iran&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Brazil</span><span class="p">,</span> <span class="s1">&#39;Brazil&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Italy</span><span class="p">,</span> <span class="s1">&#39;Italy&#39;</span><span class="p">)</span><span class="o">.</span>
           <span class="n">replace</span><span class="p">(</span><span class="n">list_Germany</span><span class="p">,</span> <span class="s1">&#39;Germany&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Russia</span><span class="p">,</span> <span class="s1">&#39;Russia&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Greece</span><span class="p">,</span> <span class="s1">&#39;Greece&#39;</span><span class="p">)</span><span class="o">.</span>
           <span class="n">replace</span><span class="p">(</span><span class="n">list_France</span><span class="p">,</span> <span class="s1">&#39;France&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Sing</span><span class="p">,</span> <span class="s1">&#39;Singapore&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Japan</span><span class="p">,</span> <span class="s1">&#39;Japan&#39;</span><span class="p">)</span><span class="o">.</span>
           <span class="n">replace</span><span class="p">(</span><span class="n">list_Austria</span><span class="p">,</span> <span class="s1">&#39;Austria&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Ireland</span><span class="p">,</span> <span class="s1">&#39;Ireland&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">list_Finland</span><span class="p">,</span> <span class="s1">&#39;Finland&#39;</span><span class="p">)</span><span class="o">.</span>
           <span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;country&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span><span class="o">.</span><span class="n">sort_values</span><span class="p">(</span><span class="n">ascending</span> <span class="o">=</span> <span class="kc">False</span><span class="p">))</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[23]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">top_active</span><span class="p">(</span><span class="n">sorted_list</span><span class="p">,</span> <span class="n">n</span><span class="p">,</span> <span class="n">title</span><span class="p">,</span><span class="n">initial_pos</span><span class="o">=</span><span class="mi">0</span><span class="p">):</span>
    
    <span class="n">bars</span> <span class="o">=</span> <span class="p">[</span><span class="n">sorted_list</span><span class="o">.</span><span class="n">index</span><span class="p">[</span><span class="n">i</span><span class="p">]</span> <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="n">initial_pos</span><span class="p">,</span> <span class="n">n</span><span class="p">)]</span>
    <span class="n">values</span> <span class="o">=</span> <span class="p">[</span><span class="n">sorted_list</span><span class="p">[</span><span class="n">i</span><span class="p">]</span> <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="n">initial_pos</span><span class="p">,</span> <span class="n">n</span><span class="p">)]</span>
    
    <span class="n">y</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">arange</span><span class="p">(</span><span class="nb">len</span><span class="p">(</span><span class="n">bars</span><span class="p">))</span>

    <span class="n">fig</span><span class="p">,</span> <span class="n">ax</span> <span class="o">=</span> <span class="n">plt</span><span class="o">.</span><span class="n">subplots</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">20</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">y</span><span class="p">)</span><span class="o">*</span><span class="mf">0.5</span><span class="p">))</span>
    
    <span class="n">ax</span><span class="o">.</span><span class="n">grid</span><span class="p">(</span><span class="kc">True</span><span class="p">,</span> <span class="n">color</span> <span class="o">=</span> <span class="s2">&quot;#C688EB&quot;</span><span class="p">)</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">barh</span><span class="p">(</span><span class="n">bars</span><span class="p">,</span> <span class="n">values</span><span class="p">,</span> <span class="n">color</span> <span class="o">=</span> <span class="s2">&quot;#6C7EE1&quot;</span><span class="p">)</span> 
    <span class="n">ax</span><span class="o">.</span><span class="n">set_axisbelow</span><span class="p">(</span><span class="kc">True</span><span class="p">)</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">xaxis</span><span class="o">.</span><span class="n">set_minor_locator</span><span class="p">(</span><span class="n">MultipleLocator</span><span class="p">(</span><span class="mi">1000</span><span class="p">))</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">grid</span><span class="p">(</span><span class="kc">True</span><span class="p">,</span> <span class="s2">&quot;minor&quot;</span><span class="p">,</span> <span class="n">linestyle</span><span class="o">=</span><span class="s2">&quot;--&quot;</span><span class="p">,</span> <span class="n">color</span> <span class="o">=</span> <span class="s2">&quot;#C688EB&quot;</span><span class="p">)</span>
    <span class="n">ax</span><span class="o">.</span><span class="n">set_title</span><span class="p">(</span><span class="n">title</span><span class="p">,</span> <span class="n">fontdict</span> <span class="o">=</span> <span class="p">{</span><span class="s1">&#39;fontsize&#39;</span> <span class="p">:</span> <span class="mi">20</span><span class="p">})</span>

<span class="c1"># Top 15 active countries</span>
<span class="n">top_active</span><span class="p">(</span><span class="n">country</span><span class="p">,</span> <span class="mi">15</span><span class="p">,</span> <span class="s1">&#39;Countries most active in research&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[24]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Less 15 active countries</span>
<span class="n">top_active</span><span class="p">(</span><span class="n">country</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">country</span><span class="p">),</span> <span class="s1">&#39;Countries less active in research&#39;</span><span class="p">,</span> <span class="n">initial_pos</span> <span class="o">=</span> <span class="nb">len</span><span class="p">(</span><span class="n">country</span><span class="p">)</span> <span class="o">-</span> <span class="mi">15</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAABTYAAAHMCAYAAADvbPdUAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADl0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uIDIuMi4zLCBodHRwOi8vbWF0cGxvdGxpYi5vcmcvIxREBQAAIABJREFUeJzs3Xm4XVV9//H3J4lAECFICCUqxuCsXBACggOD4thapaiRWk0cQh1+xQmtbR1ALW0dahEcGq0m1nkWo61aIYLIGIYAiiNYRMSCRAUDkuT7+2Pvaw6He5N7D/fm5Ny8X89znrPP2muv/d3TfeCbtdZOVSFJkiRJkiRJg2RavwOQJEmSJEmSpPEysSlJkiRJkiRp4JjYlCRJkiRJkjRwTGxKkiRJkiRJGjgmNiVJkiRJkiQNHBObkiRJkiRJkgaOiU1JkiRtMUnmJakky7aCWE5oYzm837EMgiSHt+frhH7HAlvXvaSt7/6QJG0bTGxKkiRtIUkenOSUJJcn+U2SPyT5RZKvJnlRkh36HePmJFncJi8W9zsWTSwThZIkadDM6HcAkiRJ24IkbwLeTPMPy+cCy4GbgT2Aw4EPAS8FFvQpxC3lWuAhwG/6HYjG7Xyaa3dDvwNpeS9JkrSNM7EpSZI0yZL8PXAicA3wrKo6b4Q6fwa8ZkvHtqVV1e3Alf2OQ+NXVb9nK7p23kuSJMmh6JIkSZMoyTzgBOB24KkjJTUBqmoF8OQRtn92kjPboetrk1yW5O+SbD9C3UqycpQ4lrXr53XGNjz0uF3+VJIbktya5MI22drZxkrgI+3Pj7TbVme7nfNWJvnLJOcluTnJ1d37HCHGHdtjuyTJLe125yQ5ZoS6SbIoyXeT/F8b8zVJvp5k4UjnYDzaaQOWtW3eluT6JJ9I8qAR6u6R5J1JftDGvaZdXpZk/kTGnGRukjclOTvJLzumM/hEkodsYruDknw6ybXt8VyX5BtJnt2uPwG4qq2+qOvaLm7r3GkOxSRXtjHMHmW/r2+3eXlX+b2TnJrkp208NyY5LcmBYzkPbRsj3kud93qSv26fmVvba7g0yS7j2Mcm7+eOeo9M8rmOa3JNkn9PMneENue3cfw4zTP96zbGDyTZbYT6xyQ5I8lN7XF8P8kbMvLfgGck+ViSH3Y8Q6uSHJfkTv/v13Gu5if5mySr25hWdtV7YpKvJPlVe72uSfLlJEeOct72SzPFxpokv0/y7SSP2vwZlyRpfOyxKUmSNLleANwN+FRVXb6pilV1W+fvJCcBf0cz9PcTNEPXnwKcBDwpyRPaXmt31X1phhn/FPhP4J7AQuDLSY6sqjPaesuANcDTgS8Dl3S0saarzdcATwC+ApwBbDKZlGQWcDrwCOAi4MM0/wj/JOATSR5WVW/o2OQfac7NVcBnaIYj7wkcCDwL+PTYDn3EWJ4MfIHmun0F+DFwb+AvgD9NckRVXdTW3RE4G9gb+GZbPzTn9OnA52jO60TFfCjweppz+nmae+IBwDOBP0/y6Kq6tOt4lgDvB9YDpwE/AubQTHvwsjaWlcAs4BXApcCXOprovM7dltPcj8cAp4yw/vnAH4BPdcSzP/ANmvvs6zTnejbwDOA7SY6qqq9t+jSMydtp7p+vtPs7AlgC3B943DjbGvV+TvIC4IPAbTTn9xqaa/Ji4GlJDq6q/23r7glcAOwMfI3mGu4A3A94HnAqcGNH2/8BvBD4Oc15WgMcDLwVeHz7N2BdR5z/DGwAzqMZqr9Le6wn09xnzxvl+E4GHgt8tY1rfUcMJwJvornXvtQe31zgUcBfAf/T1dYC4HXAOTRTbOwFHA18K8l+VfWDUWKQJGn8qsqPHz9+/Pjx48fPJH2AbwEFvHic2x3Sbve/wJ90lM+gSa4U8Pdd2xSwcpT2lrXr53WUzWvLCnhzV/0nteVf6ypf3JYvHmU/J7TrbwEeMcL64X0uGyW+13WV7wD8N02yZr+O8htpkj07jrCP2WM8x8OxHt5RtitwE00y+aFd9R9Gk9y5qKPsaW0b7x6h/e2Ae0xwzHM62+wo37eN7b+6yh9K01v418DDRtju3pu7Nh3rD2/Xn9BRdi+aJNiFI9Q/sK3/+a7798fArcBhXfXn0iTjrgO2H8O52Ny99L/AXl37PrNdd9A475HR7ucH0iRufwzcq2vd49pz88WOsr9p23vFCG3dHZg5wrP2hc7yrrhe0VW+9wjtTqNJQBfwyFHO1bXA/UbY9ont+p92H98I98/w/XGnvw/AX7fl7xvLeffjx48fP37G+nEouiRJ0uTas/3++Ti3e2H7/baq+uVwYTW9s15Dk+h78V0PD4CfAW/rLKiqr9Mkhg7qsc2lVXXxWCq2w2//iiY59vauOG4F/pamF+Rfdm16Ox09yzq2uSsvt3k+Tc/FN1fV97ravYKmZ94jkjy0a7u1I8Txh6r63UTGXFW/GqFNqumleTpwRJK7dax6KU1C761t/N3bjfe+7N7+Wprk/QFJHta1elH7vbyj7E9pereeUlXf7mrrFzS9LP8EePxdiav1lmp7Srbtr2PjVArjva9Hu59fStOz9xXtufijqjqdpgfn05Lco2u7ke6XW6qqs/wVwDrghV3l0PTYvBF4blcbPxmh3Q00PTKh+QeLkby9qq4aofxv2u/XdB9f2/ZI98/ZVbWsq+zDNMfS698TSZJG5FB0SZKkyZX2u8a53f7t9+ndK6rqh0l+Dtwvyayq6h4GPl6XVNWdkm00Q04P6bHN88dR90BgOnCH+Rs7DCfqOueQ/DhN0uWKJJ8Fvg2cU1V39Q3Zw8e77yixPLAjlu+1+70WeH07xPprNEPTRzqnExJzkj8FXkIz5Hc2d/5v+tk0vR6hGbYM8F/j2cc4LaMZpr2IZggySbYDngP8H805GTZ8fu87yvl9QPv9kK7tenHhCGXXtN+7jrOt0e7n4eM5bJT5QefQ3NsPBFbRJDpPAt6b5Ek0Q/HPBr5XVX/8G9FOcbAvTc/hVybpbheaoe93mFe1/UeC1wJPBebT9ALtdK9xHt/BNH+7/nuU9SO503mvqtuTXM/4z7skSZtkYlOSJGly/QJ4MM0cjeMxPIffdaOsv45m7rpduPP8luM12vbr6P1lk7/cfJU/Gn5hyoHtZzQ7dSy/CvgJTc/W17efdUm+RtO77Mfj2P9IsSzZTL2dAKrqt0kOpnnr/Z+zsUfcDUneR9Pjdnge1Lscc5LjaHrf3UQzp+f/Ar+nST49gyYZ1vlSmVnt9516202gLwK/Bf4qyd+1Cd0/ozmX/1Z3nANy+Pw+azNt7rSZ9WMx0n09HMv0cbY12v08fDyv3cz2w/fLz5IcRDOU/Mk087YCXJPknVX1nvb3rjT/KLI78OaxBNjOU3sBzXyd5wMfpZmCYB0b50+90wuHWqMd3yzgphF6jG7Kpv6ejPe8S5K0SSY2JUmSJtd3aObaezzwH+PYbrgX35/QJMO67dlVD5rk1mj/fTdrlPLJMp4eqsPH8O6qevWYGm+SZycDJyeZAzyGpofgs4CHtS8bum1TbWwmln2ravUYY/k58KI03eoeSnO9X07zwpVpwBsnIuYkM2gSqL8E9q+q67rWj9S7djjJdC/gyrEcz3hV1dokn6GZGuEJNL37RhqGDhvP79Or6rTJiGeSjHY/Dx/PLlX12zE1VPV9YGF7PfcFjqTpyXtykluq6j862r24qvYfpaluL6ZJap5YVSd0rmjvjVdsKqxRytcAuyWZOc7kpiRJW4RzbEqSJE2uj9DMq3j0CPMy3kGSzt5Uw/P5HT5CvfvT9AC9qmsY+k3AfUaoPx3Yb3xhj2p4ePVE9rw6n2bO0Mf2snE77+QXqurZNEP39wYe3mMs57bf446lGldU1Sk0CT5oelGOVLeXmGfTJKi/O0JScyc2Tl/Qafh4njKGQ7gr13ZZ+70oyex2f6urqvuN6j2f363UXblf1lXVqqr6F5q3ykN7v1TVzcAVNAnve46xyfu3358fYd1h442vdS5Nz9En97i9JEmTysSmJEnSJKqqq2mGnW4HfDXJgpHqJXkyd5wH8cPt9xuS7N5RbzrwTpr/juvuAXo+sFeSJ3aVvwG4b4+H0O3G9nuvCWqPqvoVzfyTC5K8se3JdgdJ9k5yv3Z5+ySPT9fEg+1Lc4aTQL/vMZyP0PRSe3M7ZLg7jmlJDu/4/fAk80ZoZ4/OOCYo5l+1dQ5oE5mdbZxMk/js9n6aIcBvHCmxnqRzioSbaHrujfvaVtXZwI+Ap7PxhTrLRqj6ZZoeyC9P8tSR2kpySDvH5CA4leYfLt6d5IHdK5Nsl+SxHb8PSrJHdz267pfWv9L83fhwO8y8u+1d23ldh13dfh/eVe8RwN9t/lBGdEr7/a4kd5qfc6QySZK2JIeiS5IkTbKqOqlN1r0ZuCDJd2lesHEzTULjUJqXplzYsc13k7yd5mUslyf5HHALTU+4h9MMcX9H167eSTPH45eTfJpmfr1H0QxPXckIvT97cA5N8uWVbU+y69vyU+7ii3v+H805eAvwvCTfadueS/OClANperVdBcwE/ge4Osl5NG9134Gml+RDgNPa4b7jVlU3JnkmzbyR5yb5Fk3PuQ00Cb9DaOZV3KHd5EjgX9treiVN8vHeNAm+DWy8Rnc55qrakOQ9NHNzXpbkyzSJryNokqNntMud23wvycuADwAXt9v8qD2GBcDvhrepqpvb2B6b5OPAD2l6cZ42xmH5H6V5W/cbaZKpnxjhGG5P8hc0L835anveLqG5p+5Dc53n00y10GtyeoupqiuTvJDmHyKuSPLfNOftbjT3y2NpXqD04HaTv6RJ6n4b+DFNMnlv4Gk0LwP6t462P5zkAOBlwE+SfJ1mTtV70jzTh9Ik4l/SbvJRmrk+/y3JETTX+QE0851+AVjYw/F9I8nwNf1+ki/RvIBpD5qpFM4FFo+3XUmSJoqJTUmSpC2gqt7Svgn7ZTSJpBfQJLZupEns/Avwsa5t/jbJxTRJv+fTJEt+QtMD811V9Yeu+t9K8gyauR2fQ5MI/SZNQuPECTqOm5IcTZOkfQEb37r8Me443+d42/1tksOAY2mSP0fTnJ/raRI0r6I5FmiO629pzuOjaIbv/o7m3LyUjb1de43lW0mGgONpEsWPBf5A8yKo07njUN+v0ySjDqVJZu5M82KnbwL/WlXfneCY30iTKHsx8Nc05/ybNPfEiNe4qj6Y5PL2eA5v930DsBr4UFf15wHvphl6fAzNMOSft3U356NtDHcDVlTV9SNVqqrVSfYFXk2TdHsBTRL4OpopGN7cxjcQqupjSS4FXkNzfZ9Ic71/AXwO+HRH9U/SvMDnUTRTB8ykebHTp2ie6cu72n55kv+iSV4eSTMVwa9pEpzvoONvRlX9ou0d+s80Sccn0STbX0aTVB93YrNt901JzgWOo7led6dJ4F9Ic80lSeqbVI1nXndJkiRJkiRJ6j/n2JQkSZIkSZI0cExsSpIkSZIkSRo4JjYlSZIkSZIkDRwTm5IkSZIkSZIGjolNSZIkSZIkSQNnRr8DkAbVrvfYrfZ+0P36HYY0Zdx603p22HV6v8OQpgyfKWni+DxJE8tnSpo4U/F5WrVq1Q1VtftY6prYlHq05z3vw4UXXtjvMKQpY/XyNQwtmtXvMKQpw2dKmjg+T9LE8pmSJs5UfJ6S/GysdR2KLvUq6XcEkiRJkiRJ2ywTm1KPan31OwRJkiRJkqRtlolNSZIkSZIkSQPHxKbUK0eiS5IkSZIk9Y2JTalH06ab2ZQkSZIkSeoXE5tSjzasc45NSZIkSZKkfjGxKUmSJEmSJGngmNiUJEmSJEmSNHBMbEo9mjbDOTYlSZIkSZL6xcSm1KMN651jU5IkSZIkqV9MbEq9Mq8pSZIkSZLUNyY2JUmSJEmSJA0cE5tSjzLdOTYlSZIkSZL6xcSm1KtyLLokSZIkSVK/mNiUelQb+h2BJEmSJEnStsvEpiRJkiRJkqSBY2JT6lF8eiRJkiRJkvom5TyBUk/mzB2qhUtW9DsMSZIkSZK0jVoyf2eGFs3qdxgTKsmqqlowlrr2OZMkSZIkSZI0cExsSpIkSZIkSRo4JjYlSZIkSZIkDRwTm5IkSZIkSZIGjolNSZIkSZIkSQPHxKa2uCTrk1yS5PIkX0nSt9d3Jfluv/YtSZIkSZKk3pnYVD+srar9qurhwK+Bl/crkKp6VL/2LUmSJEmSpN6Z2FS/nQPcCyCNd7Q9OS9LsrAtPzzJt5N8JskPk/xzkucmOb+tt3db72lJzktycZL/SbJHW35Ckg8nWZnkp0mOG955kpvb752SfCvJRW2bT9/iZ0KSJEmSJEljNqPfAWjblWQ68HjgP9qivwD2A/YFZgMXJDmzXbcv8BCaHp4/BT5UVQcleQXwN8Arge8AB1dVJXkx8DrgNe32DwaOAO4B/CDJ+6vq9o5wbgWOqqrfJpkNnJvktKqqSTl4SZIkSZIk3SUmNtUPM5NcAswDVgHfbMsfA3yyqtYD1yf5NnAg8Fvggqq6DiDJT4BvtNtcRpOwBLg38OkkewLbAVd17POrVXUbcFuSXwF7AD/vWB/gpCSHAhtoepHuAfyyM/AkxwLHAuy+5z535RxIkiRJkiTdJWtvWMfq5Wv6HUbfmNhUP6ytqv2S7AKsoJlj8z00ycXR3NaxvKHj9wY23senAP9aVaclORw4YZTt13Pne/+5wO7AAVV1e5KrgR26g6iqpcBSgDlzh+zNKUmSJEmS+mbm7BkMLerbO5knx+KxV3WOTfVNVf0GOA44PsndgDOBhUmmJ9kdOBQ4fxxN7gJc2y4vGmc4uwC/apOaRwD3Hef2kiRJkiRJ2oJMbKqvqupi4FLgOcAXgdXt79OB11XVLzexebcTgM8mOQu4YZyhfBxYkORCmt6bV45ze0mSJEmSJG1B8d0oUm/mzB2qhUtW9DsMSZIkSZK0jVoyf+cpNxQ9yaqqWjCWuvbYlCRJkiRJkjRwTGxKkiRJkiRJGjgmNiVJkiRJkiQNHBObkiRJkiRJkgaOiU1JkiRJkiRJA2dGvwOQBtXsGdM45cS9+h2GNGWsXr5myr3NT+onnylp4vg8SRPLZ0qaOKuXr+l3CH1lj02pR5mWfocgSZIkSZK0zTKxKfVow/rqdwiSJEmSJEnbLBObkiRJkiRJkgaOiU1JkiRJkiRJAydVDqeVejFn7lAtXLKi32FIkiRJkqRt1JL5O0+5l3ElWVVVC8ZS1x6bkiRJkiRJkgaOiU1JkiRJkiRJA8fEpiRJkiRJkqSBY2JTkiRJkiRJ0sAxsSlJkiRJkiRp4JjY1JSTZF6Sy7vKTkhyfLs8I8kNSf6pq87KJD9Ickn7+dyWjFuSJEmSJEljN6PfAUh98ETgB8Czk/x9VVXHuudW1YV9ikuSJEmSJEljZI9NbYuOAU4G/hc4uM+xSJIkSZIkqQf22NQ2JclM4PHAXwOzaJKc53RU+XiSte3yN6vqtVs4REmSJEmSJI2BiU1NRbWJ8j8Dzqiq3yf5PPDGJK+qqvVtnU0ORU9yLHAswO577jORMUuSJEmSJI3L2hvWsXr5mn6H0TcmNjUV3Qjs2lV2T+Aqmh6aj05ydVu+G3AE8D9jabiqlgJLAebMHRotgSpJkiRJkjTpZs6ewdCiWf0OY2ItHntV59jUlFNVNwPXJXk8QJJ7Ak8GLgEeA+xVVfOqah7wcppkpyRJkiRJkgaIPTY1VT0feG+Sd7W/TwQeAZxeVbd11Psy8PYk27e/O+fYvKGqjtwy4UqSJEmSJGk8TGxqSqqq79EMMe+2rKver4Hd25+HT25UkiRJkiRJmigORZckSZIkSZI0cExsSpIkSZIkSRo4JjYlSZIkSZIkDRwTm5IkSZIkSZIGjolNSZIkSZIkSQPHt6JLPdpt+jROOXGvfochTRmrl69haNGsfochTRk+U9LE8XmSJpbPlDRxVi9f0+8Q+soem1KPpk1Pv0OQJEmSJEnaZpnYlHpUG6rfIUiSJEmSJG2zTGxKPSrzmpIkSZIkSX1jYlOSJEmSJEnSwEnZ7UzqyZy5Q7VwyYp+hyFJkiRJkrZRS+bvPOVexpVkVVUtGEtde2xKkiRJkiRJGjgmNiVJkiRJkiQNHBObkiRJkiRJkgaOiU1JkiRJkiRJA8fEpiRJkiRJkqSBY2JTfZNkXpLLu8pOSHJ8v2KSJEmSJEnSYDCxqa1ekhn9jkGSJEmSJElbFxOb2iolWZnkpCTfBl6RZFmSZ3asv7n9npbkfUmuSLIiydeG6yW5OsnsdnlBkpXt8kFJvpvk4vb7QW35WUn269jH2UmGttxRS5IkSZIkaaxMbGprNquqDquqd22izl8A84B9gBcDh4yh3SuBQ6vqEcCbgJPa8g8BiwGSPBDYvqpW9xa6JEmSJEmSJpNDfNVPtZnyT4+hjccAn62qDcAvk5wxhm12AZYneUC7r7u15Z8F3pjktcALgWXdGyY5FjgWYPc99xnDriRJkiRJkibH2hvWsXr5mn6H0TcmNtVPNwK7dpXdE7iqXb6lo3wdbQ/jJAG2a8uzifb/uA2wQ0f5W4EzquqoJPOAlQBV9fsk3wSeDjwbWNDdYFUtBZYCzJk7NFpiVpIkSZIkadLNnD2DoUWz+h3GxFo89qoORVffVNXNwHVJHg+Q5J7Ak4HvjFD9auCAdvnpbOxl+R3g6HauzT2Aw0fZ5uiO8l2Aa9vlxV37+RDwHuCCqvr1uA5IkiRJkiRJW4yJTfXb84E3JLkEOB04sap+MkK9DwKHJTkfeCQbe3N+Hvg5cDnw78B5wG/adScCJyc5C1jf0dbbgX9KcjYwvXMnVbUK+C3wkQk4NkmSJEmSJE0Sh6Krr6rqe8ARI5Qf3vX7euDgjqK/a8s3JDm+qm5OshtwPnBZu+4s4IEjtH1OV/kbhxeSzKVJ+H+jx0OSJEmSJEnSFmBiU1PBiiSzaObdfGtV/bKXRpI8H/hH4NXty4gkSZIkSZK0lTKxqYHX3bvzLrTzUeCjE9GWJEmSJEmSJpdzbEqSJEmSJEkaOCY2JUmSJEmSJA0cE5uSJEmSJEmSBo5zbEo92m36NE45ca9+hyFNGauXr2Fo0ax+hyFNGT5T0sTxeZImls+UNHFWL1/T7xD6yh6bUo/i0yNJkiRJktQ3pmakXiX9jkCSJEmSJGmbZWJT6lGtr36HIEmSJEmStM0ysSlJkiRJkiRp4KTKXmdSL+bMHaqFS1b0OwxJkiRJkrSNWjJ/5yn3Mq4kq6pqwVjq2mNTkiRJkiRJ0sAxsSlJkiRJkiRp4JjYlCRJkiRJkjRwTGxKkiRJkiRJGjgmNiVJkiRJkiQNHBObmjBJ9kjyiSQ/TbIqyTlJjuqxrVcm2XGiYxxhPzdP9j4kSZIkSZI08UxsakIkCfAl4Myqml9VBwDPAe7dY5OvBCY9sSlJkiRJkqTBZGJTE+VxwB+q6gPDBVX1s6o6JcniJKcOlydZkeTwdvn9SS5MckWSE9uy44C5wBlJzmjLntj2AL0oyWeT7NSWX53kpHbdhUn2T/L1JD9J8pK2zk5JvtVue1mSp3cHP5Y6kiRJkiRJ2nqY2NREeRhwUQ/b/UNVLQCGgMOSDFXVe4BfAEdU1RFJZgNvAI6sqv2BC4FXd7RxTVUdApwFLAOeCRwMvKVdfytwVLvtEcC72h6mncZSR5IkSZIkSVuJGf0OQFNTkvcCjwH+ALx3E1WfneRYmntxT+ChwOquOge35We3ucbtgHM61p/Wfl8G7FRVvwN+l+TWJLOAW4CTkhwKbADuBewB/LIz5DHUoY31WIDd99xnM2dBkiRJkiRp8qy9YR2rl6/pdxh9Y2JTE+UK4OjhH1X18ran5YXAOu7YO3gHgCT3A44HDqyqm5IsG17XJcA3q+qYUfZ9W/u9oWN5+PcM4LnA7sABVXV7kqtH2M9Y6lBVS4GlAHPmDtUo8UiSJEmSJE26mbNnMLRoVr/DmFiLx17VoeiaKKcDOyR5aUfZ8Mt/rgb2SzItyX2Ag9rynWl6U/4myR7AUzq2/R1wj3b5XODRSe4PkGTHJA8cR2y7AL9qE5ZHAPftsY4kSZIkSZK2EvbY1ISoqkryDODdSV4H/B9N0vJvgbOBq2iGil9OOxdnVV2a5GKa3p4/besNWwr8V5Lr2nk2FwOfTLJ9u/4NwA/HGN7Hga8kuRC4BLiyxzqSJEmSJEnaSqTK0bRSL+bMHaqFS1b0OwxJkiRJkrSNWjJ/5yk3FD3JqvZF05vlUHRJkiRJkiRJA8fEpiRJkiRJkqSBY2JTkiRJkiRJ0sAxsSlJkiRJkiRp4JjYlCRJkiRJkjRwZvQ7AGlQ7TZ9GqecuFe/w5CmjNXL10y5t/lJ/eQzJU0cnydpYvlMSRNn9fI1/Q6hr+yxKUmSJEmSJGngmNiUejRtRvodgiRJkiRJ0jbLxKbUow3rq98hSJIkSZIkbbNMbEq9Mq8pSZIkSZLUN6kyOyP1Ys7coVq4ZEW/w5AkSZIkSduoJfN3nnIv40qyqqoWjKWuPTYlSZIkSZIkDRwTm5IkSZIkSZIGjolNSZIkSZIkSQPHxKYkSZIkSZKkgWNiU5IkSZIkSdLAMbGpgZRkvyRP7WG7eUkub5cXJHnPxEcnSZIkSZKkyTaj3wFIPdoPWAB8rXtFkhlVtW5zDVTVhcCFkxCbJEmSJEmSJpk9NtUXSb6UZFWSK5Ic25bd3LH+mUmWtcvPSnJ5kkuTnJlkO+AtwMIklyRZmOSEJEuTfAP4aNsz86wkF7WfR40Qw+FJVrTLByX5bpKL2+8HbYnzIEmSJEmSpN7YY1P98sKq+nWSmcAFST6/ibpvAp5UVdcmmVVVf0jyJmBBVf0/gCQnAAcAj6mqtUl2BJ5QVbcmeQDwSZoenqO5Eji0qtYlORI4CTj6rh+mJEmSJEmSJoOJTfXLcUmOapfvAzxgE3XPBpYl+QzwhU3UO62q1rbLdwNOTbIfsB544Gbi2QVY3iZBq93+TtrepccC7L7nPptpUpIkSZIkafKsvWEdq5ev6XcYfWNiU1tcksOBI4FDqur3SVYCO9AkFIftMLxQVS9J8kjgT4FL2mTlSG7pWH4VcD2wL82UC7duJqy3AmdU1VFJ5gGFCIKjAAAgAElEQVQrR6pUVUuBpQBz5g7VSHUkSZIkSZK2hJmzZzC0aFa/w5hYi8de1Tk21Q+7ADe1Sc0HAwe35dcneUiSacBwb06S7F1V51XVm4AbaHp4/g64x2b2cV1VbQCeB0wfQ0zXtsuLx3tAkiRJkiRJ2rJMbKof/huYkWQ1TU/Jc9vy1wMrgNOB6zrqvyPJZUkuB84ELgXOAB46/PKgEfbxPmBRknNphqHfMkKdTm8H/inJ2Ww+CSpJkiRJkqQ+S5WjaaVezJk7VAuXrOh3GJIkSZIkaRu1ZP7OU24oepJVVbWpF0D/kT02JUmSJEmSJA0cE5uSJEmSJEmSBo6JTUmSJEmSJEkDx8SmJEmSJEmSpIFjYlOSJEmSJEnSwJnR7wCkQbXb9GmccuJe/Q5DmjJWL18z5d7mJ/WTz5Q0cXyepInlMyVNnNXL1/Q7hL6yx6YkSZIkSZKkgWNiU+pRfHokSZIkSZL6xtSMJEmSJEmSpIFjYlPqUW3odwSSJEmSJEnbrlRVv2OQBtKcuUO1cMmKfochSZIkSZK2UUvm7zzlXsaVZFVVLRhLXXtsSpIkSZIkSRo4JjYlSZIkSZIkDRwTm5IkSZIkSZIGjolNSZIkSZIkSQPHxKYkSZIkSZKkgWNiUxMmyfoklyS5PMlnk+yYZF6Sy0ep/5YkR7bLK5MsaJe/lqSnV3oleUmS5/d+FJIkSZIkSRoEM/odgKaUtVW1H0CSjwMvAb4wWuWqetMo5U/tNYCq+kCv20qSJEmSJGlw2GNTk+Us4P7t8vQkH0xyRZJvJJkJkGRZkmd2b5jk6iSz296eVyZZnmR1ks8l2bGjzr8kOb/93L8tPyHJ8e3yyo46P0zy2LZ8epJ3JLmgbfev2/I9k5zZ0ev0sZN/miRJkiRJktQLE5uacElmAE8BLmuLHgC8t6oeBqwBjh5Hcw8CllbVEPBb4GUd635bVQcBpwL/Nsr2M9o6rwTe3Ja9CPhNVR0IHAgsSXI/4C+Br7e9TvcFLhlHnJIkSZIkSdqCHIquiTQzyXAy8CzgP4C5wFVVNVy+Cpg3jjavqaqz2+WPAccB72x/f7Lj+92jbD88FL5zv08Ehjp6i+5Ck3y9APhwkrsBX+qI+Y+SHAscC7D7nvuM4zAkSZIkSZIm1tob1rF6+Zp+h9E3JjY1kf44x+awJAC3dRStB2aOo83axO/RljsN73s9G+/3AH9TVV/vrpzkUOBPgf9M8o6q+ugddl61FFgKMGfu0Gj7lCRJkiRJmnQzZ89gaFFP71/eei0ee1WHomtrt1eSQ9rlY4DvdKxb2PF9zjja/Drw0rZnJkkemOTuSe4L/KqqPkjT23T/uxa6JEmSJEmSJos9NrW1+z6wKMm/Az8C3t+xbvsk59Ek6I8ZR5sfohmWflGaLqX/BzwDOBx4bZLbgZuB59/l6CVJkiRJkjQpUuVoWm2dkswDVlTVw0dYdzWwoKpu2MJh/dGcuUO1cMmKfu1ekiRJkiRt45bM33nKDUVPsqqqFoylrkPRJUmSJEmSJA0ch6Jrq1VVVwN36q3Zrpu3RYORJEmSJEnSVsUem5IkSZIkSZIGjolNSZIkSZIkSQPHxKYkSZIkSZKkgeMcm1KPdps+jVNO3KvfYUhTxurla6bc2/ykfvKZkiaOz5M0sXympImzevmafofQV/bYlCRJkiRJkjRwTGxKvUq/A5AkSZIkSdp2mdiUejRtuplNSZIkSZKkfjGxKfVow7rqdwiSJEmSJEnbrFSZnJF6MWfuUC1csqLfYUiSJEmSpG3Ukvk7T7mXcSVZVVULxlLXHpuSJEmSJEmSBo6JTUmSJEmSJEkDx8SmJEmSJEmSpIFjYlOSJEmSJEnSwDGxKUmSJEmSJGngbDaxmeQfklyRZHWSS5I8ciJ2nGRlkgXt8teSjPgKpySPSFJJntTjfq5OMnuE8pckeX6PbR6eZEXH77cl+XqS7ZN8KMlDe2l3hP0sS/LMiWhrjPs7Lsn3k3y8q3zHJB9PclmSy5N8J8lOE7TPm9vvuUk+t4l6r0pya5JdetjHvCSXj7Juwq6XJEmSJEmStpwZm1qZ5BDgz4D9q+q2NkG43UQHUVVP3cTqY4DvtN9fHyHGAKmqDePc5wfGFeQokvwD8GjgqVV1G/DiiWi3T14GPKWqruoqfwVwfVXtA5DkQcDtE7njqvoFsKkk7jHABcBRwLLulUlmVNW6HvY7yNdLkiRJkiRpm7W5Hpt7Aje0CTuq6oY2AUWSNyW5oO3Bt7RNMHb3xJyd5Op2eWaST7U9Pz8NzBzeySZ6VYYm2bUYeGKSHdryeW3PwvcBFwH3SfL+JBe2vUtP7GrqtUnObz/3b9s4Icnx7fKS9lguTfL5JDuO5eQleQ3wVOBpVbV2hOO/Ock/tu2em2SPtnzv9vcFSd7S0WsxSU5N8r0kXwXmdOzr8UkubntNfjjJ9h3n7qQk57THv3/be/QnSV4yStyvbq/b5Ule2ZZ9AJgPnJbkVV2b7AlcO/yjqn4wfE8k+VKSVe15P7ZjHzd3LD8zybJ2+X5trBckeWtHnU31qtwb2Al4A02Cc7h8cZLPJvkK8I0kOyX5VpKL2vP09I5mZiRZ3t5/nxu+xl3Xa1P3kCRJkiRJkrYim0tsfoMmafjDJO9LcljHulOr6sCqejhNkvLPNtPWS4HfV9UQ8I/AAWOI79HAVVX1E2AlTRJx2IOAj1bVI6rqZ8A/VNUCYAg4LMlQR93fVtVBwKnAv42wny+0x7Iv8H3gRWOM7SU0PRxvHqXO3YFz23bPBJa05ScDJ1fVgcAvOuof1R7XPm3dRwG0Cd1lwMK21+QMmvM57JqqOgQ4q633TOBg4C3dASU5AHgB8Mi2zpIkj6iql7SxHFFV7+7a7MPA37YJybcleUDHuhdW1QHAAuC4JLuNci6GnQy8vz32X26m7rBjgE+2x/egJHM61h0CLKqqxwG3AkdV1f7AEcC7hhPuNOd1aXv//Zamd2q3Td1DkiRJkiRJ2opscih6Vd3cJsIeS5Mo+nSS11fVMuCIJK8DdgTuCVwBfGUTzR0KvKdtd3WS1WOI7xjgU+3yp4DnAV9of/+sqs7tqPvstsfgDJoehg8FhvfxyY7v7qQdwMOTvA2YRdMz8E5D3kfwY2BX4InAaHND/gEYnotzFfCEdvkQ4Bnt8ieAd7bLhwKfrKr1wC+SnN6WP4gmwfvD9vdy4OVsTNKe1n5fBuxUVb8DfpdmTspZVbWmI6bHAF+sqlsAknyB5vpePNqBVtUlSea3x3okcEGSQ6rq+zTJzKPaqvcBHgDcOFpbNAnho9vl/wT+ZRN1hz2HJmG5oY33WcB723XfrKpft8sBTkpyKLABuBewR7vumqo6u13+GHAcG8/7sE3dQ80OmvXHAuy+5z5jCF2SJEmSJGlyrL1hHauXr9l8xSlqk4lNgDbJthJYmeQyYFGSTwHvAxZU1TVJTgB2aDdZx8aeoDt0NzfWwJJMp0mA/XmaeSwD7JbkHm2VWzrq3g84Hjiwqm5qhz137rtGWR62DHhGVV2aZDFw+BhCvB54LvCtJDdW1Rkj1Lm9qob3t54xnO9R4ssIZZ1ua783dCwP/+7e5+baGjmoplfqF4AvJNkAPLUdWn8kcEhV/T7JSjae987juCv3wRBNsvSbbefL7YCfsjGxeUtH9ecCuwMHVNXtaaZBGCmeO/0ewz3UbFS1FFgKMGfu0JiPQ5IkSZIkaaLNnD2DoUUjvo97cC0ee9VNDkVP8qCuYcf7AT9jY8LnhjRvx+586cvVbBxm3ll+Jk3iiSQPpxnuuylHApdW1X2qal5V3Rf4PBt7OnbamSbB9Zs22faUrvULO77PGWH7ewDXJbnbcIxtnEcl+afRAmx7UP4F8LEk+23meDqdy8Zei8/pKD8TeE6S6Un2pOklC3AlMC/t/KA0PVe/PY79dToTeEaaN53fnWb4+1mb2iDJo5Ps2i5vR9OT8WfALsBNbVLzwTRD24ddn+QhSaa1+xh2NhuP+bls3jHACe09MK+q5gL3SnLfEeruAvyqTWoeAXTW2SvNy7CG2/xO17abu4ckSZIkSZK0FdlcD8KdgFOSzKLpiflj4NiqWpPkgzRDn6+meVv1sHcCn0nyPOD0jvL3Ax9ph6BfApy/mX0fA3yxq+zzNHNL3iER1/a0vJhmOPxPaZJnnbZPch5NIvcY7uyNwHk0ybrLaBKdAHvTzMc4qqq6IMkLaF66c8Sm6nZ4JU0y9DXAV4HftOVfBB7XxvBD2uRlVd3a7uOzSWbQnO+e3upeVRe1vRGHz/+HqmrUYeitvYH3t/NVTmtj/jxN78mXtNf0BzQJ22GvpxmGfw1wOc29BM0b1j+R5BVtG5vzHO6cZPxiW359V/nHga8kuZDmHruyY933aXob/zvwI5r78Y/GcA9JkiRJkiRpK5KNI6XVLcnHgFdV1f9NcLs7AmurqpI8Bzimqp6+ue20dZkzd6gWLlmx+YqSJEmSJEmTYMn8nafcUPQkq9qXO2/WWOZ83GZV1V9NUtMHAKe2PSDXAC+cpP1IkiRJkiRJU5KJzT6oqrOAffsdhyRJkiRJkjSoNvnyIEmSJEmSJEnaGpnYlCRJkiRJkjRwTGxKkiRJkiRJGjjOsSn1aLcZ0zjlxL36HYY0ZaxevmbKvc1P6iefKWni+DxJE8tnSpo4q5ev6XcIfWWPTalX1e8AJEmSJEmStl0mNiVJkiRJkiQNHBObUo8yPf0OQZIkSZIkaZtlYlPqVTkWXZIkSZIkqV9SJmeknsyZO1QLl6zodxiSJEmSJGkbtWT+zlPuZVxJVlXVgrHUtcemJEmSJEmSpIFjYlOSJEmSJEnSwDGxKUmSJEmSJGngmNiUJEmSJEmSNHBMbEqSJEmSJEkaOCY21VdJ1ie5JMmlSS5K8qgxbLMyyZjejjWGthYkec9EtCVJkiRJkqQtZ0a/A9A2b21V7QeQ5EnAPwGHbYkdJ5lRVRcCF26J/UmSJEmSJGni2GNTW5OdgZsAkhyeZMXwiiSnJlncvUGSFyX5YduL84NJTm3Ln5bkvCQXJ/mfJHu05SckWZrkG8BHO/eT5KAk3223+W6SB22BY5YkSZIkSVIP7LGpfpuZ5BJgB2BP4HFj3TDJXOCNwP7A74DTgUvb1d8BDq6qSvJi4HXAa9p1BwCPqaq1SQ7vaPJK4NCqWpfkSOAk4Oiej0ySJEmSJEmTxsSm+q1zKPohNL0oHz7GbQ8Cvl1Vv263/yzwwHbdvYFPJ9kT2A64qmO706pq7Qjt7QIsT/IAoIC7dVdIcixwLMDue+4zxjAlSZIkSZIm3tob1rF6+Zp+h9E3Jja11aiqc5LMBnYH1nHHqRJ2GGGTbKK5U4B/rarT2l6ZJ3Ssu2WUbd4KnFFVRyWZB6wcIcalwFKAOXOHahP7lyRJkiRJmlQzZ89gaNGsfocxsRaPvapzbGqrkeTBwHTgRuBnwEOTbJ9kF+DxI2xyPnBYkl2TzOCOw8Z3Aa5tlxeNMYTObRaPM3xJkiRJkiRtQfbYVL8Nz7EJTQ/MRVW1HrgmyWeA1cCPgIu7N6yqa5OcBJwH/AL4HvCbdvUJwGeTXAucC9xvDLG8nWYo+qtp5uuUJEmSJEnSVipVjqbV4EqyU1Xd3PbY/CLw4ar64pbY95y5Q7VwyYrNV5QkSZIkSZoES+bvPOWGoidZVVULxlLXoegadCe0PT4vp3lB0Jf6HI8kSZIkSZK2AIeia6BV1fH9jkGSJEmSJElbnj02JUmSJEmSJA0cE5uSJEmSJEmSBo6JTUmSJEmSJEkDxzk2pR7N3m46p5y4V7/DkKaM1cvXTLm3+Un95DMlTRyfJ2li+UxJE2f18jX9DqGv7LEp9ajWV79DkCRJkiRJ2maZ2JQkSZIkSZI0cExsSr1KvwOQJEmSJEnadpnYlHo0bbqZTUmSJEmSpH5JlfMESr2YM3eoFi5Z0e8wJEmSJEnSNmrJ/J2n3Mu4kqyqqgVjqWuPTUmSJEmSJEkDx8SmJEmSJEmSpIFjYlOSJEmSJEnSwDGxKUmSJEmSJGngmNiUJEmSJEmSNHBMbKrvkqxPckmSy5N8JckWe51Xkpu31L4kSZIkSZI0cUxsamuwtqr2q6qHA78GXt7vgCRJkiRJkrR1M7Gprc05wL0AkrwvyZ+3y19M8uF2+UVJ3tYufynJqiRXJDl2uJEkNyf5xySXJjk3yR5t+f2SnJPkgiRv7ai/U5JvJbkoyWVJnr4Fj1mSJEmSJEnjZGJTW40k04HHA6e1RWcCj22X7wU8tF1+DHBWu/zCqjoAWAAcl2S3tvzuwLlVtW/bzpK2/GTg/VV1IPDLjt3fChxVVfsDRwDvSpKJPD5JkiRJkiRNnBn9DkACZia5BJgHrAK+2ZafBbwyyUOB7wG7JtkTOAQ4rq1zXJKj2uX7AA8AbgT+AKxoy1cBT2iXHw0c3S7/J/Av7XKAk5IcCmygSaTuwR2Tn7S9Qo8F2H3Pfe7SQUuSJEmSJN0Va29Yx+rla/odRt+Y2NTWYG1V7ZdkF5pk5MuB91TVtUl2BZ5M0+vynsCzgZur6ndJDgeOBA6pqt8nWQns0LZ5e1VVu7yeO97rxZ09F9gdOKCqbk9ydUdbGzesWgosBZgzd2ikdiRJkiRJkraImbNnMLRoi72DectYPPaqDkXXVqOqfkPTE/P4JHdri88BXkmT2DwLOJ6Nw9B3AW5qk5oPBg4ew27OBp7TLj+3o3wX4FdtUvMI4L536WAkSZIkSZI0qUxsaqtSVRcDl7Ix+XgWMKOqfgxcRNNrczix+d/AjCSrgbcC545hF68AXp7kAppk5rCPAwuSXEiT8Lzyrh6LJEmSJEmSJk82jtaVNB5z5g7VwiUrNl9RkiRJkiRpEiyZv/OUG4qeZFVVLRhLXXtsSpIkSZIkSRo4JjYlSZIkSZIkDRwTm5IkSZIkSZIGjolNSZIkSZIkSQPHxKYkSZIkSZKkgTOj3wFIg2r37adzyol79TsMacpYvXzNlHubn9RPPlPSxPF5kiaWz5Q0cVYvX9PvEPrKHptSjzasr36HIEmSJEmStM0ysSn1yrymJEmSJElS35jYlCRJkiRJkjRwTGxKPcr09DsESZIkSZKkbVaqHE8r9WLO3KFauGRFv8OQJEmSJEnbqCXzd55yL+NKsqqqFoylrj02JUmSJEmSJA0cE5uSJEmSJEmSBo6JTUmSJEn/v737D/e0rOsE/v4wo8LGjykGDFRCyh+hnPyBhKaFq9sqqVyWl5NrNZQ7c21uGZvlZdkPsN3czDQlNWllnX4BaZuyZOpqkoAKiuBRXExTKrVdHXVQgtCBz/5xntlO42H48uU75zvPOa/XdZ3rPN/7uZ/n+TzD3JyZ99z38wAAjI5gEwAAAAAYHcEmAAAAADA6G+ddANwdVXVkkncNH781yW1JvjB8PqW7vzaXwgAAAADYrwSbjFp3fzHJw5Kkqs5OclN3v2yuRQEAAACw31mKzppVVS+oqo8OXz+9rP2cqrq+qv5XVV1UVWcN7Y+oqiurarGq/rSqjphf9QAAAADsi2CTNamqTkny7CSnJHl0kudW1UJVnZrkKUm+K8kPJXnUssP+MMnzu3shyceT/PLqVg0AAADApCxFZ616XJI/7e6bk6Sq3pzksUn+VZI3d/etSW6tqkuG/UcmObi7Lx+O35HkD/Y+aVVtT7I9SY465qT9fhMAAAAAd+SWnbuzuGPXvMuYG8Ema1XNqP1f6O7zkpyXJEcfu9BT1AUAAAAwE4ds3piFrZvmXcZsnTl5V0vRWavek+TpVXVIVR2a5IwklyW5PMnTqupeVXVYktOTpLt3Jrmlqh4zHP+jSf5qDnUDAAAAMAEzNlmTuvuqqrogyQeGptd290eSpKrelmQxyQ3D/huHPj+a5LVVdUiSTyb58VUtGgAAAICJCTZZM7r77L0+vzTJS1fo+hvd/ctV9U1ZmsH5kqH/h5J89/6uEwAAAIC7T7DJevT6qnpQkoOTnN/di/MuCAAAAIC7RrDJutPdW+ZdAwAAAAB3j5cHAQAAAACjI9gEAAAAAEZHsAkAAAAAjI5nbMKUNt/joJx7znHzLgPWjMUdu7KwddO8y4A1w5iC2TGeYLaMKZidxR275l3CXJmxCQAAAACMjmATptS3z7sCAAAAgPVLsAkAAAAAjI5gE6ZUNe8KAAAAANav6u551wCjdPSxC71l2yXzLgMAAABYp7adcPiaexlXVV3d3SdP0teMTQAAAABgdASbAAAAAMDoCDYBAAAAgNERbAIAAAAAoyPYBAAAAABGR7DJAa2qblq2fXpVfaKqjttP13prVW0avp67P64BAAAAwGwINhmFqnpCknOTPKm7/25/XKO7T+/uXUk2JRFsAgAAABzABJsc8KrqcUl+L8kPdPffDG1vqKpnLOtz0/D9NVX1tGH7z6rq/GH7OVX1n4ftN1fV1VV1XVVtX3aOG6pqc5L/muTbq+raqvrN1bpPAAAAACa3cd4FwJ24V5K3JDmtu6+foP97kjwuycVJ7pPkmKH9sUkuHLZ/oru/VFWHJPlAVf1pd39x2TlemOSh3f2wmdwBAAAAADMn2ORA9/Uk703ynCQ/M0H/y5KcVVUnJvlYkm+uqmOSPDrJ84Y+z6uqpw/b90vygCRf/IYzrWCY4bk9SY465qRJ7wEAAABg5m7ZuTuLO3bNu4y5EWxyoLs9yTOTvLOqfrG7f31o353hUQpVVUnumSTd/dmq+uYkT8rS7M1vGY6/qbu/WlWnJXlikkd3981VdWmSgyctprvPS3Jekhx97ELf/dsDAAAAmM4hmzdmYeumeZcxW2dO3tUzNjngdffNSZ6S5NlV9Zyh+YYkjxy2z0hyj2WHvC/JWVkKNi9L8nPD9yQ5IsmXh1DzwUlOXeGSX01y2CzvAQAAAIDZEmwyCt39pSzNwvylqjojSy8T+r6quirJdyf5x2XdL0uysbs/meRDWZq1uSfYfFuSjVW1mOTXkrx/hWt9MckVVfVRLw8CAAAAODBZis4BrbsPXbb990nuv2z38tmWv7Cs3+uTvH7Y/nqSb1q279YkT76Dax2/bPvf3c3SAQAAANiPzNgEAAAAAEZHsAkAAAAAjI5gEwAAAAAYHcEmAAAAADA6gk0AAAAAYHS8FR2mdOTGg3LuOcfNuwxYMxZ37MrC1k3zLgPWDGMKZsd4gtkypmB2FnfsmncJc2XGJkzpoA017xIAAAAA1i3BJkzp9t097xIAAAAA1i3BJgAAAAAwOoJNAAAAAGB0qttyWpjG0ccu9JZtl8y7DAAAAGCd2nbC4WvuZVxVdXV3nzxJXzM2AQAAAIDREWwCAAAAAKMj2AQAAAAARkewCQAAAACMjmATAAAAABgdwSZ3WVV1Vf3Bss8bq+oLVXWXXhFeVZdW1URvuQIAAACA5QSbTOMfkzy0qg4ZPv+bJJ+dYz37TVVtnHcNAAAAAHwjwSbT+oskPzBsPyvJBXt2VNUpVfXeqrpm+P6gof2Qqrqwqhar6qIkhyw75rVV9cGquq6qzlnWfnpVXV9Vl1fVq/bMCt3HNR5SVVdV1bXDdR4wtP/Y8PnDe2abVtVTq+rK4RzvrKp7D+1nV9V5VfWOJL+/H38NAQAAAJiS2WhM68IkvzIEjQtJzk/yuGHf9Um+t7t3V9UTk/x6kh9K8pNJbu7uhapaSPKhZed7UXd/qao2JHnXsP+vk7xuONenq+qCZf3v6Br/Ickru/uPquqeSTZU1UOSvCjJ93T3zqr6luEclyc5tbu7qv59khckef6w75FJHtvdt8zo1wsAAACAGRJsMpXuXqyq47M0W/Ote+0+IsmOYbZkJ7nH0P69SV617PjFZcc8s6q2Z+n35DFJTszSjOJPdfenhz4XJNl+J9d4X5IXVdV9k/yP7v5EVf3rJG/q7p3Dtb809L1vkouq6pgk90yy5zpJcvFKoeZQ4/YkOeqYk/b9iwQAAACwH92yc3cWd+yadxlzI9jk7rg4ycuSnJbkyGXtv5bk3d399CH8vHTZvt77JFV1/yQ/l+RR3f3lqnpDkoOT1D6uveI1uvuPq+rKLC2Tf/swE7NWum6Sc5O8vLsvrqrTkpy9bN8/rnTR7j4vyXlJcvSxCyudEwAAAGBVHLJ5Yxa2bpp3GbN15uRdPWOTu+P8JC/u7o/s1X5E/vllQmcua39PkmcnSVU9NEtL2JPk8CwFiTcOz7l88tB+fZIThuAySbbc2TWq6oQszfJ8VZaC14Uk78rSjNAjhz7fssI5tk5wvwAAAAAcIASbTK27P9Pdr1xh10uTvKSqrkiyYVn7a5McOixBf0GSq4bzfDjJNUmuy1JYesXQfkuS5yZ5W1VdnuT/JrnxTq6xJclHq+raJA9O8vvdfV2S/5Lkr6rqw0lePvQ9O8kbq+qyJDun/oUAAAAAYNVVt9W0HLiq6tDuvqmqKsmrk3yiu18x77qSpaXoW7ZdMu8yAAAAgHVq2wmHr7ml6FV1dXefPElfMzY50G0bZl9el6Wl46+bcz0AAAAAHAC8PIgD2jA784CYoQkAAADAgcOMTQAAAABgdASbAAAAAMDoCDYBAAAAgNHxjE2Y0pEbDsq55xw37zJgzVjcsWvNvc0P5smYgtkxnmC2jCmYncUdu+ZdwlyZsQlTqg017xIAAAAA1i3BJkyre94VAAAAAKxbgk2YUt8+7woAAAAA1i/BJgAAAAAwOtWW08JUjj52obdsu2TeZQAAAADr1LYTDl9zL+Oqqqu7++RJ+pqxCQAAAACMjmATAAAAABgdwSYAAAAAMDqCTQAAAABgdASbAAAAAMDoCDYZtar61qq6sKr+pqo+VlVvraoH7qP/DVW1eTVrBAAAAGD2BJuMVlVVkj9Lcml3f3t3n5jkF5Pce76VAQAAALC/CTYZs8cn+Xp3/+6ehu6+NsmGqrpkT1tV/U5VnbnsuLIuL00AAA8JSURBVJ+vqquGr+8Y+jy1qq6sqmuq6p1VJRwFAAAAOIAJNhmzhya5eorjvtLdpyT5nSS/PbRdnuTU7n54kguTvGA2JQIAAACwP2ycdwEwBxcs+/6KYfu+SS6qqmOS3DPJp1c6sKq2J9meJEcdc9J+LhMAAADgjt2yc3cWd+yadxlzI9hkzK5L8owV2nfnX85GPniv/b3C9rlJXt7dF1fVaUnOXumC3X1ekvOS5OhjF3qlPgAAAACr4ZDNG7OwddO8y5itMyfvaik6Y/aXSe5VVdv2NFTVo5JsSHJiVd2rqo5I8oS9jtuy7Pv7hu0jknx22N66/0oGAAAAYBbM2GS0urur6ulJfruqXpjkn5LckOSsJH+SZDHJJ5Jcs9eh96qqK7MU7D9raDs7yRur6rNJ3p/k/vv9BgAAAACYmmCTUevuzyV55gq7XpAVXgDU3ccPm+fs1f6WJG+ZdX0AAAAA7B+WogMAAAAAoyPYBAAAAABGR7AJAAAAAIyOYBMAAAAAGB3BJgAAAAAwOt6KDlM6csNBOfec4+ZdBqwZizt2ZWHrpnmXAWuGMQWzYzzBbBlTMDuLO3bNu4S5MmMTplQ17woAAAAA1i/BJkypDpJsAgAAAMyLYBOmdPttPe8SAAAAANYtwSYAAAAAMDrVbdYZTOPoYxd6y7ZL5l0GAAAAsE5tO+HwNfcyrqq6urtPnqSvGZsAAAAAwOgINgEAAACA0RFsAgAAAACjI9gEAAAAAEZHsAkAAAAAjI5gc8Sq6kVVdV1VLVbVtVX13VOc42FVdfqyz2dW1e/MqL6zq+rn7qTPmVX1haH+PV8nTnm9Va0dAAAAgPnZOO8CmE5VPTrJU5I8ortvrarNSe45xakeluTkJG+dZX130UXd/VNzvD4AAAAAI2PG5ngdk2Rnd9+aJN29s7s/lyRV9aiqem9Vfbiqrqqqw6rq4Kr671X1kaq6pqoeX1X3TPLiJFuGmZJbll+gqp5aVVcO/d9ZVfce2s+uqvOr6tKq+lRVPW/ZMS+qqo9X1TuTPGjam6uq04bzv6mqrq+qP6qqGvadPrRdXlWvqqpLVjh+brUDAAAAsP8JNsfrHUnuV1V/XVWvqarvS5IhrLwoyc9093cleWKSW5L8xyTp7pOSPCvJjiz99/+VLM2YfFh3X7TXNS5Pcmp3PzzJhUlesGzfg5P82ySnJPnVqrpHVT0yyQ8neXiSH0zyqAnvZU+wuufrkKH94UnOSnJikhOSfE9VHZzkdUme3N2PTXLUHZxztWoHAAAAYA4sRR+p7r5pCOMel+TxSS6qqhcmuTrJP3T3B4Z+X0mSqnpsknOHtuur6m+TPPBOLnPf4bzHZGmZ+6eX7fvzYbborVX1+ST3Hmr5s+6+ebjmxRPezjcsRR8mZ17V3Z8ZPl+b5PgkNyX5VHfvqeWCJNtXq/aq2r7nekcdc9KEtwcAAAAwe7fs3J3FHbvmXcbcCDZHrLtvS3Jpkkur6iNJtib5UJJeoXtNcYlzk7y8uy+uqtOSnL1s363Ltm/LP/9eWuna01rpGpPex36pvbvPS3Jekhx97MIs7xUAAADgLjlk88YsbN007zJm68zJu1qKPlJV9aCqesCypocl+dsk1yc5tqoeNfQ7rKo2JnlPkmcPbQ9MclySjyf5apLD7uAyRyT57LC9dYKy3pPk6VV1SFUdluSpy+r9qaqaxQuCrk9yQlUdP3zecgf9ZlY7AAAAAAceMzbH69Ak51bVpiS7k3wyyfbu/trwEqBzh2dV3pKl52y+JsnvDjM7dyc5c3ib+ruTvHBY6v2Sva5xdpI3VtVnk7w/yf33VVB3f6iqLkpybZZC1suW7X5wkivu4NAtw1L5PZ67j2vcUlXPTfK2qtqZ5Ko76DrL2gEAAAA4wFS31bTsf8Oby3+wu782g3MdOjxjtJK8OsknuvsVd7vIu+joYxd6y7ZveCE7AAAAwKrYdsLha24pelVd3d0nT9LXUnRWRXc/ZRah5mDbMMP0uiwtOX/djM4LAAAAwEhYis7oDLMzV32GJgAAAAAHDjM2AQAAAIDREWwCAAAAAKMj2AQAAAAARsczNmFKR244KOeec9y8y4A1Y3HHrjX3Nj+YJ2MKZsd4gtkypmB2FnfsmncJc2XGJgAAAAAwOoJNmNJBG2reJQAAAACsW4JNmFLf3vMuAQAAAGDdEmzClFquCQAAADA31dIZmMrRxy70lm2XzLsMAAAAYJ3adsLha+5lXFV1dXefPElfMzYBAAAAgNERbAIAAAAAoyPYBAAAAABGR7AJAAAAAIyOYBMAAAAAGB3BJqNRVa+oqrOWfX57Vf23ZZ9/q6p+dh/H37S/awQAAABgdQg2GZP3JnlMklTVQUk2J3nIsv2PSXLFHOoCAAAAYJUJNhmTKzIEm1kKND+a5KtV9c1Vda8k35nkf1fVu6rqQ1X1kao6Y6UTVdXPV9UHqmqxqs4Z2r6pqv68qj5cVR+tqi2rcVMAAAAA3HUb510ATKq7P1dVu6vquCwFnO9Lcp8kj05yY5LFJDcneXp3f6WqNid5f1Vd3N295zxV9f1JHpDklCSV5OKq+t4kRyX5XHf/wNDviFW8PQAAAADuAsEmY7Nn1uZjkrw8S8HmY7IUbL43S0Hlrw9B5e3D/nsn+T/LzvH9w9c1w+dDsxR0XpbkZVX1G0ku6e7L9r54VW1Psj1JjjrmpFnfGwAAAMDEbtm5O4s7ds27jLkRbDI2e56zeVKWlqL/fZLnJ/lKkvOTPDtLMy8f2d1fr6obkhy81zkqyUu6+3V7n7yqHpnk9CQvqap3dPeLl+/v7vOSnJckRx+70HsfDwAAALBaDtm8MQtbN827jNk6c/KunrHJ2FyR5ClJvtTdt3X3l5JsytJy9PclOSLJ54dQ8/FJvm2Fc7w9yU9U1aFJUlX3qaqjq+rYJDd39x8meVmSR6zC/QAAAAAwBTM2GZuPZOlt6H+8V9uh3b2zqv4oyf+sqg8muTbJ9XufoLvfUVXfmeR9VZUkNyX5kSTfkeQ3q+r2JF9P8pP79U4AAAAAmJpgk1Hp7tuSHL5X25nLtndmafbmSsceumz7lUleuVeXv8nSbE4AAAAADnCWogMAAAAAoyPYBAAAAABGR7AJAAAAAIyOYBMAAAAAGB3BJgAAAAAwOt6KDlM6csNBOfec4+ZdBqwZizt2ZWHrpnmXAWuGMQWzYzzBbBlTMDuLO3bNu4S5MmMTAAAAABgdwSZMqYweAAAAgLkRzcC0quZdAQAAAMC6JdiEKfVtPe8SAAAAANYtwSYAAAAAMDqCTZiWlegAAAAAcyPYhCkdtEGyCQAAADAvgk2Y0u27PWMTAAAAYF4EmwAAAADA6Ag2AQAAAIDREWzClA7a6BmbAAAAAPMi2IQp3X6bZ2wCAAAAzItgE6Yl1wQAAACYG8EmAAAAADA6gk2YUm3wjE0AAACAeRFswrTaWnQAAACAeRFswpT69nlXAAAAALB+CTYBAAAAgNGptpwWplJVtyS5bt51wBqyOcnOeRcBa4gxBbNjPMFsGVMwO2txPH1bdx81SUfBJkypqr4w6UAD7lxVfbC7T553HbBWGFMwO8YTzJYxBbOz3seTpegwvV3zLgAAAABgvRJswvRunHcBAAAAAOuVYBOmd968C4A1xpiC2TKmYHaMJ5gtYwpmZ12PJ8/YBAAAAABGx4xNAAAAAGB0BJtwJ6rqSVX18ar6ZFW9cIX996qqi4b9V1bV8atfJYzHBGPqZ6vqY1W1WFXvqqpvm0edMAZ3Np6W9XtGVXVVrds3ZsIkJhlTVfXM4efUdVX1x6tdI4zFBH/mO66q3l1V1wx/7jt9HnXCGFTV+VX1+ar66B3sr6p61TDeFqvqEatd47wINmEfqmpDklcneXKSE5M8q6pO3Kvbc5J8ubu/I8krkvzG6lYJ4zHhmLomycndvZDkTUleurpVwjhMOJ5SVYcleV6SK1e3QhiXScZUVT0gyS8k+Z7ufkiSs1a9UBiBCX9G/VKSP+nuhyf54SSvWd0qYVTekORJ+9j/5CQPGL62J3ntKtR0QBBswr6dkuST3f2p7v5akguTnLFXnzOS7Bi235TkCVVVq1gjjMmdjqnufnd33zx8fH+S+65yjTAWk/yMSpJfy9I/EPzTahYHIzTJmNqW5NXd/eUk6e7Pr3KNMBaTjKdOcviwfUSSz61ifTAq3f2eJF/aR5czkvx+L3l/kk1VdczqVDdfgk3Yt/sk+ftlnz8ztK3Yp7t3J7kxyZGrUh2MzyRjarnnJPmL/VoRjNedjqeqeniS+3X3JatZGIzUJD+jHpjkgVV1RVW9v6r2NXsG1rNJxtPZSX6kqj6T5K1Jfnp1SoM16a7+PWvN2DjvAuAAt9LMy56iD7Bk4vFSVT+S5OQk37dfK4Lx2ud4qqqDsvSIlDNXqyAYuUl+Rm3M0jK/07K0ouCyqnpod+/az7XB2Ewynp6V5A3d/VtV9egkfzCMp9v3f3mw5qzbXMKMTdi3zyS537LP9803LpH4/32qamOWllHsa4o4rGeTjKlU1ROTvCjJ07r71lWqDcbmzsbTYUkemuTSqrohyalJLvYCIbhDk/657y3d/fXu/nSSj2cp6AT+pUnG03OS/EmSdPf7khycZPOqVAdrz0R/z1qLBJuwbx9I8oCqun9V3TNLD7W+eK8+FyfZOmw/I8lfdve6+JcRmMKdjqlh6ezrshRqenYZ3LF9jqfuvrG7N3f38d19fJaeWfu07v7gfMqFA94kf+57c5LHJ0lVbc7S0vRPrWqVMA6TjKe/S/KEJKmq78xSsPmFVa0S1o6Lk/zY8Hb0U5Pc2N3/MO+iVoOl6LAP3b27qn4qyduTbEhyfndfV1UvTvLB7r44yeuztGzik1maqfnD86sYDmwTjqnfTHJokjcO7+H6u+5+2tyKhgPUhOMJmNCEY+rtSb6/qj6W5LYkP9/dX5xf1XBgmnA8PT/J71XVf8rSktkzTRCBlVXVBVl6DMrm4bm0v5rkHknS3b+bpefUnp7kk0luTvLj86l09ZX/bwAAAAAAY2MpOgAAAAAwOoJNAAAAAGB0BJsAAAAAwOgINgEAAACA0RFsAgAAAACjI9gEAAAAAEZHsAkAAAAAjI5gEwAAAAAYnf8HciZ63qyB0aIAAAAASUVORK5CYII=
"
>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="3.2-Universities-most-and-less-active-in-research">3.2 Universities most and less active in research<a class="anchor-link" href="#3.2-Universities-most-and-less-active-in-research">&#182;</a></h2><p>Same procedure as before. In this case we will:</p>
<ul>
<li><code>pluck</code> in 'metadata'</li>
<li><code>pluck</code> in 'authors'</li>
<li><code>flatten</code> the results in order to get rid of the list</li>
<li><code>pluck</code> in 'affiliation'</li>
<li><code>filter</code> None values in order to get rid of the empty <code>dict</code></li>
</ul>

</div>
</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[20]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">data_univ</span> <span class="o">=</span> <span class="p">(</span><span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;metadata&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;authors&#39;</span><span class="p">)</span><span class="o">.</span>
             <span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;affiliation&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="kc">None</span><span class="p">))</span>
<span class="n">data_univ</span> <span class="o">=</span> <span class="n">data_univ</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
<span class="n">data_univ</span><span class="o">.</span><span class="n">head</span><span class="p">(</span><span class="mi">10</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[20]:</div>



<div class="jp-RenderedHTMLCommon jp-RenderedHTML jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/html">
<div>
<style scoped>
    .dataframe tbody tr th:only-of-type {
        vertical-align: middle;
    }

    .dataframe tbody tr th {
        vertical-align: top;
    }

    .dataframe thead th {
        text-align: right;
    }
</style>
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>laboratory</th>
      <th>institution</th>
      <th>location</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td></td>
      <td>University of Illinois</td>
      <td>{'settlement': 'Chicago', 'region': 'IL', 'cou...</td>
    </tr>
    <tr>
      <th>1</th>
      <td></td>
      <td>University of Illinois</td>
      <td>{'settlement': 'Chicago', 'region': 'IL', 'cou...</td>
    </tr>
    <tr>
      <th>2</th>
      <td></td>
      <td>University of Illinois at Chicago College of M...</td>
      <td>{'settlement': 'Chicago', 'region': 'IL', 'cou...</td>
    </tr>
    <tr>
      <th>3</th>
      <td></td>
      <td>University of West Attica</td>
      <td>{'settlement': 'Athens', 'country': 'Greece'}</td>
    </tr>
    <tr>
      <th>4</th>
      <td></td>
      <td>Juntendo University Urayasu Hospital</td>
      <td>{'addrLine': '2-1-1 Tomioka', 'postCode': '279...</td>
    </tr>
    <tr>
      <th>5</th>
      <td></td>
      <td>Juntendo University Urayasu Hospital</td>
      <td>{'addrLine': '2-1-1 Tomioka', 'postCode': '279...</td>
    </tr>
    <tr>
      <th>6</th>
      <td></td>
      <td>Juntendo University Urayasu Hospital</td>
      <td>{'addrLine': '2-1-1 Tomioka', 'postCode': '279...</td>
    </tr>
    <tr>
      <th>7</th>
      <td></td>
      <td>Juntendo University Urayasu Hospital</td>
      <td>{'addrLine': '2-1-1 Tomioka', 'postCode': '279...</td>
    </tr>
    <tr>
      <th>8</th>
      <td></td>
      <td>Juntendo University Urayasu Hospital</td>
      <td>{'addrLine': '2-1-1 Tomioka', 'postCode': '279...</td>
    </tr>
    <tr>
      <th>9</th>
      <td></td>
      <td>Bu-Ali Sina University</td>
      <td>{'postCode': '65178-38683', 'settlement': 'Ham...</td>
    </tr>
  </tbody>
</table>
</div>
</div>

</div>

</div>

</div>

</div></div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[25]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">univ</span> <span class="o">=</span> <span class="n">data_univ</span><span class="o">.</span><span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;institution&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span><span class="o">.</span><span class="n">sort_values</span><span class="p">(</span><span class="n">ascending</span> <span class="o">=</span> <span class="kc">False</span><span class="p">)</span>

<span class="c1"># Top 15 active universities</span>
<span class="n">top_active</span><span class="p">(</span><span class="n">univ</span><span class="p">,</span> <span class="mi">15</span><span class="p">,</span> <span class="s1">&#39;Universities most active in research&#39;</span><span class="p">,</span><span class="n">initial_pos</span><span class="o">=</span><span class="mi">1</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[26]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Less 15 active universities</span>
<span class="n">top_active</span><span class="p">(</span><span class="n">univ</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">univ</span><span class="p">),</span> <span class="s1">&#39;Universities less active in research&#39;</span><span class="p">,</span> <span class="n">initial_pos</span> <span class="o">=</span> <span class="nb">len</span><span class="p">(</span><span class="n">univ</span><span class="p">)</span> <span class="o">-</span> <span class="mi">15</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="3.3-Grid-search-on-countries-and-universities-with-different-number-of-partititons-and-workers">3.3 Grid-search on countries and universities with different number of partititons and workers<a class="anchor-link" href="#3.3-Grid-search-on-countries-and-universities-with-different-number-of-partititons-and-workers">&#182;</a></h2><p>We have run the algorithm several times by changing the number of workers and the number of partitions in order to visualize the execution time.</p>
<p>We will consider:</p>
<ul>
<li>$[1, 2, 3, 4, 5, 6]$ workers</li>
<li>$[1, 10, 20, 50, 100, 500]$ number of partitions.</li>
</ul>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[49]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">grid_search_countries</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">):</span>
    
    <span class="n">start</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    
    <span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;./json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">)</span>
    <span class="n">data_country</span> <span class="o">=</span> <span class="p">(</span><span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;metadata&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;authors&#39;</span><span class="p">)</span>
                   <span class="o">.</span><span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;affiliation&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="kc">None</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;location&#39;</span><span class="p">))</span>
    <span class="n">data_country</span> <span class="o">=</span> <span class="n">data_country</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
    <span class="n">country</span> <span class="o">=</span> <span class="n">data_country</span><span class="o">.</span><span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;country&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
    
    <span class="n">end</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">diff</span> <span class="o">=</span> <span class="n">end</span> <span class="o">-</span> <span class="n">start</span>
    
    <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;For </span><span class="si">{}</span><span class="s2"> partitions, computational time: </span><span class="si">{}</span><span class="s2">&quot;</span><span class="o">.</span><span class="n">format</span><span class="p">(</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="n">diff</span><span class="p">))</span>
    <span class="k">return</span> <span class="n">diff</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[50]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_matrix_country</span> <span class="o">=</span> <span class="p">[]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[31]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">part</span> <span class="ow">in</span> <span class="n">n_partitions</span><span class="p">:</span>
    <span class="n">time_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">grid_search_countries</span><span class="p">(</span><span class="n">part</span><span class="p">))</span>
<span class="n">time_matrix_country</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">time_list</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>For 1 partitions, computational time: 12.846150875091553
For 10 partitions, computational time: 3.831408977508545
For 20 partitions, computational time: 3.243894577026367
For 50 partitions, computational time: 3.040823459625244
For 100 partitions, computational time: 2.961162567138672
For 500 partitions, computational time: 3.3865442276000977
</pre>
</div>
</div>

</div>

</div>

</div></div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[32]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df_cm</span> <span class="o">=</span> <span class="n">pd</span><span class="o">.</span><span class="n">DataFrame</span><span class="p">(</span><span class="n">time_matrix_country</span><span class="p">,</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span><span class="mi">2</span><span class="p">,</span><span class="mi">3</span><span class="p">,</span><span class="mi">4</span><span class="p">,</span><span class="mi">5</span><span class="p">,</span><span class="mi">6</span><span class="p">])</span>
<span class="n">plt</span><span class="o">.</span><span class="n">figure</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">16</span><span class="p">,</span><span class="mi">10</span><span class="p">))</span>
<span class="n">sn</span><span class="o">.</span><span class="n">set</span><span class="p">(</span><span class="n">font_scale</span><span class="o">=</span><span class="mf">1.7</span><span class="p">)</span> 
<span class="n">sn</span><span class="o">.</span><span class="n">heatmap</span><span class="p">(</span><span class="n">df_cm</span><span class="p">,</span> <span class="n">annot</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span> <span class="n">annot_kws</span><span class="o">=</span><span class="p">{</span><span class="s2">&quot;size&quot;</span><span class="p">:</span> <span class="mi">16</span><span class="p">},</span><span class="n">fmt</span><span class="o">=</span><span class="s2">&quot;.3f&quot;</span><span class="p">,</span>
               <span class="n">cbar_kws</span><span class="o">=</span><span class="p">{</span><span class="s1">&#39;label&#39;</span><span class="p">:</span><span class="s1">&#39;Execution time [s]&#39;</span><span class="p">},</span><span class="n">cmap</span><span class="o">=</span><span class="n">sn</span><span class="o">.</span><span class="n">color_palette</span><span class="p">(</span><span class="s2">&quot;inferno_r&quot;</span><span class="p">,</span><span class="mi">40</span><span class="p">))</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">&#39;workers&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">&#39;partitions&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">&quot;Computational time countries algorithm search&quot;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">20</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
<span class="n">plt</span><span class="o">.</span><span class="n">style</span><span class="o">.</span><span class="n">use</span><span class="p">(</span><span class="s1">&#39;default&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[28]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">grid_search_univ</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">):</span>

    <span class="n">start</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;./json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">)</span>
    
    <span class="n">data_univ</span> <span class="o">=</span> <span class="p">(</span><span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;metadata&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;authors&#39;</span><span class="p">)</span><span class="o">.</span>
                 <span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;affiliation&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="kc">None</span><span class="p">))</span>
    <span class="n">data_univ</span> <span class="o">=</span> <span class="n">data_univ</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
    <span class="n">univ</span> <span class="o">=</span> <span class="n">data_univ</span><span class="o">.</span><span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;institution&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
    
    <span class="n">end</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">diff</span> <span class="o">=</span> <span class="n">end</span> <span class="o">-</span> <span class="n">start</span>
    
    <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;For </span><span class="si">{}</span><span class="s2"> partitions, computational time: </span><span class="si">{}</span><span class="s2">&quot;</span><span class="o">.</span><span class="n">format</span><span class="p">(</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="n">diff</span><span class="p">))</span>
    
    <span class="k">return</span> <span class="n">diff</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div><div class="fragment"><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[31]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_matrix_univ</span><span class="o">=</span><span class="p">[]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[29]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">n_partitions</span> <span class="o">=</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span> <span class="mi">10</span><span class="p">,</span> <span class="mi">20</span><span class="p">,</span> <span class="mi">50</span><span class="p">,</span> <span class="mi">100</span><span class="p">,</span> <span class="mi">500</span><span class="p">]</span>
<span class="n">time_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">part</span> <span class="ow">in</span> <span class="n">n_partitions</span><span class="p">:</span>
    <span class="n">time_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">grid_search_univ</span><span class="p">(</span> <span class="n">part</span><span class="p">))</span>
<span class="n">time_matrix_univ</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">time_list</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>For 1 partitions, computational time: 13.863276243209839
For 20 partitions, computational time: 4.202592134475708
For 10 partitions, computational time: 4.373464822769165
For 50 partitions, computational time: 3.872154712677002
For 100 partitions, computational time: 3.624666929244995
For 500 partitions, computational time: 4.341679811477661
</pre>
</div>
</div>

</div>

</div>

</div></div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[5]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df_cm</span> <span class="o">=</span> <span class="n">pd</span><span class="o">.</span><span class="n">DataFrame</span><span class="p">(</span><span class="n">time_matrix_univ</span><span class="p">,</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span><span class="mi">2</span><span class="p">,</span><span class="mi">3</span><span class="p">,</span><span class="mi">4</span><span class="p">,</span><span class="mi">5</span><span class="p">,</span><span class="mi">6</span><span class="p">])</span>
<span class="n">plt</span><span class="o">.</span><span class="n">figure</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">16</span><span class="p">,</span><span class="mi">10</span><span class="p">))</span>
<span class="n">sn</span><span class="o">.</span><span class="n">set</span><span class="p">(</span><span class="n">font_scale</span><span class="o">=</span><span class="mf">1.7</span><span class="p">)</span> 
<span class="n">sn</span><span class="o">.</span><span class="n">heatmap</span><span class="p">(</span><span class="n">df_cm</span><span class="p">,</span> <span class="n">annot</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span> <span class="n">annot_kws</span><span class="o">=</span><span class="p">{</span><span class="s2">&quot;size&quot;</span><span class="p">:</span> <span class="mi">16</span><span class="p">},</span><span class="n">fmt</span><span class="o">=</span><span class="s2">&quot;.3f&quot;</span><span class="p">,</span>
               <span class="n">cbar_kws</span><span class="o">=</span><span class="p">{</span><span class="s1">&#39;label&#39;</span><span class="p">:</span><span class="s1">&#39;Execution time [s]&#39;</span><span class="p">},</span><span class="n">cmap</span><span class="o">=</span><span class="n">sn</span><span class="o">.</span><span class="n">color_palette</span><span class="p">(</span><span class="s2">&quot;inferno_r&quot;</span><span class="p">,</span><span class="mi">40</span><span class="p">))</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">&#39;workers&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">&#39;partitions&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">&quot;Computational time university algorithm search&quot;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">20</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
<span class="n">plt</span><span class="o">.</span><span class="n">style</span><span class="o">.</span><span class="n">use</span><span class="p">(</span><span class="s1">&#39;default&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="4-Embedding-the-title-of-the-papers">4 Embedding the title of the papers<a class="anchor-link" href="#4-Embedding-the-title-of-the-papers">&#182;</a></h1><p>In NLP a common technique to perform analysis over a set of texts is based on the idea to transform each of them into a set of vectors. In this scenario given a set of vectors each of them will represent a single word for the corresponding document. So at the end of the pre-processing a document will be mapped into a list of vectors or a matrix of $n \times m$ where $n$ is the number of words in the document and $m$ is the size of the vector that represents the word $n$.</p>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>In order to implement this technique we have downloaded a pre-trained model that can be found at this link: <a href="https://dl.fbaipublicfiles.com/fasttext/vectors-wiki/wiki.en.vec">https://dl.fbaipublicfiles.com/fasttext/vectors-wiki/wiki.en.vec</a>. This model is a huge dictionary in the following format: $key: vector$ where the different keys ($300$) will be the "available" words.
Basically, if we have a sentence made by $5$ words (according to the model), we will have a matrix $5 \times 300$ featuring the sentence.</p>
<p>We have used the map approach to create a DataFrame
that is composed by:</p>
<ul>
<li>paper-id</li>
<li>title-embedding</li>
</ul>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[13]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s1">&#39;./json_singleline/*.json&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span>
<span class="n">df</span> <span class="o">=</span> <span class="n">df</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">npartitions</span> <span class="o">=</span> <span class="mi">100</span><span class="p">)</span>
<span class="n">df</span><span class="o">.</span><span class="n">take</span><span class="p">(</span><span class="mi">1</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[13]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>({&#39;paper_id&#39;: &#39;00c75478b9f6b815f8b552a50fd5e20a6d10e9f4&#39;,
  &#39;metadata&#39;: {&#39;title&#39;: &#39;Journal Pre-proof Fighting COVID-19 Hypoxia with One Hand Tied Behind Our Back: Blanket Prohibition of High Flow Oxygen and Non-Invasive Positive End-Expiratory Pressure in United States Hospitals Fighting COVID-19 Hypoxia with One Hand Tied Behind Our Back: Blanket Prohibition of High Flow Oxygen and Non-Invasive Positive End-Expiratory Pressure in United States Hospitals Fighting COVID-19 Hypoxia with One Hand Tied Behind Our Back: Blanket Prohibition of High Flow Oxygen and Non-Invasive Positive End-Expiratory Pressure in United States Hospitals&#39;,
   &#39;authors&#39;: [{&#39;first&#39;: &#39;Joseph&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Colla&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {&#39;laboratory&#39;: &#39;&#39;,
      &#39;institution&#39;: &#39;University of Illinois&#39;,
      &#39;location&#39;: {&#39;settlement&#39;: &#39;Chicago&#39;, &#39;region&#39;: &#39;IL&#39;, &#39;country&#39;: &#39;USA&#39;}},
     &#39;email&#39;: &#39;&#39;},
    {&#39;first&#39;: &#39;Adam&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Rodos&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {&#39;laboratory&#39;: &#39;&#39;,
      &#39;institution&#39;: &#39;University of Illinois&#39;,
      &#39;location&#39;: {&#39;settlement&#39;: &#39;Chicago&#39;, &#39;region&#39;: &#39;IL&#39;, &#39;country&#39;: &#39;USA&#39;}},
     &#39;email&#39;: &#39;&#39;},
    {&#39;first&#39;: &#39;Hannah&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Seyller&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {&#39;laboratory&#39;: &#39;&#39;,
      &#39;institution&#39;: &#39;University of Illinois at Chicago College of Medicine&#39;,
      &#39;location&#39;: {&#39;settlement&#39;: &#39;Chicago&#39;, &#39;region&#39;: &#39;IL&#39;, &#39;country&#39;: &#39;USA&#39;}},
     &#39;email&#39;: &#39;&#39;},
    {&#39;first&#39;: &#39;Scott&#39;,
     &#39;middle&#39;: [],
     &#39;last&#39;: &#39;Weingart&#39;,
     &#39;suffix&#39;: &#39;&#39;,
     &#39;affiliation&#39;: {},
     &#39;email&#39;: &#39;&#39;}]},
  &#39;abstract&#39;: [],
  &#39;body_text&#39;: [{&#39;text&#39;: &#39;Before COVID-19 pandemic, patients with hypoxia failing low flow oxygen via nasal cannula were treated using non-invasive positive pressure ventilation (NIPPV) or high flow nasal cannula (HFNC) oxygen, aimed at delivering higher concentration and flow of oxygen to match patient demand, decreasing anatomical dead space by preventing rebreathing, and recruiting alveoli using positive end-expiratory pressure (PEEP). Many emergency medicine physicians began their fight against COVID-19 with both of these options off the table due to concerns of exposure to staff and other patients from virus aerosolization. Instead, early endotracheal intubation (ETI) has been the suggested option for a patient failing nasal cannula. Often this is the correct answer, but not always.&#39;,
    &#39;cite_spans&#39;: [],
    &#39;ref_spans&#39;: [],
    &#39;section&#39;: &#39;Dear Editor:&#39;},
   {&#39;text&#39;: &#39;There is a cost to staff and patients from over-utilization of ETI. ETI is an extremely high aerosol generating event. A systematic review of aerosol generating procedures and their risk of transmission of SARS transmission to health care workers found ETI to be an odds ratio of 6.6 compared to 2.2 for NIPPV 1 . Plus, many hospitals face the risk of running out of ventilators and ICU beds. Once intubated, COVID-19 patients tend to remain on mechanical ventilation for over one week with poor outcomes. In vitro studies have demonstrated less airflow dispersal from HFNC or CPAP using sealed masks than from nasal cannula 2 .&#39;,
    &#39;cite_spans&#39;: [],
    &#39;ref_spans&#39;: [],
    &#39;section&#39;: &#39;Dear Editor:&#39;},
   {&#39;text&#39;: &#34;Furthermore, data coming from overseas indicates an important role for NIPPV and HFNC in managing COVID-19 patients. Retrospective data from China demonstrates that approximately 21% of patients required HFNC and 14% of patients required NIPPV. 3 Among admitted patients in Italy, about 30% required ventilation support beyond oxygen therapy. Of those given ventilation support, 89% were assisted with NIPPV compared to 12% on invasive ventilation. 4 The Chinese Handbook on COVID-19 Prevention and Management recommends the use of HFNC for hypoxic patients not tolerating nasal cannula. 5 We advocate early planning with colleagues from critical care, respiratory therapy, and nursing to develop protocols that mitigate risk associated with HFNC and NIPPV rather than prohibiting the use of these critical alternatives to ETI. Ideally these interventions should be performed in negative airflow rooms, but most ED&#39;s have a limited number of these. We are recommending use of these interventions in closed isolation rooms with staff in full airborne PPE. HFNC should be performed with surgical mask over patients mouth or high flow oxygen could be provided using a non-vented sealed CPAP mask attached to self-inflating bag plus viral filter with dual oxygen source see https://emcrit.org/emcrit/covid-airway-management/ CPAP should be provided via helmeted set-up or non-vented CPAP masks with viral filter attached to expiratory port. Policies can be rapidly adapted as more data emerges regarding COVID-19, but it&#39;s already clear that we must find safe and creative ways to expand, not limit, our armamentarium during this pandemic.&#34;,
    &#39;cite_spans&#39;: [{&#39;start&#39;: 245,
      &#39;end&#39;: 246,
      &#39;text&#39;: &#39;3&#39;,
      &#39;ref_id&#39;: &#39;BIBREF2&#39;},
     {&#39;start&#39;: 449, &#39;end&#39;: 450, &#39;text&#39;: &#39;4&#39;, &#39;ref_id&#39;: &#39;BIBREF3&#39;},
     {&#39;start&#39;: 588, &#39;end&#39;: 589, &#39;text&#39;: &#39;5&#39;, &#39;ref_id&#39;: &#39;BIBREF4&#39;}],
    &#39;ref_spans&#39;: [],
    &#39;section&#39;: &#39;Dear Editor:&#39;}],
  &#39;bib_entries&#39;: {&#39;BIBREF0&#39;: {&#39;ref_id&#39;: &#39;b0&#39;,
    &#39;title&#39;: &#39;Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;K&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Tran&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;K&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Cimon&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;M&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Severn&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;C&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Pessoa-Silva&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;J&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Conly&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2012,
    &#39;venue&#39;: &#39;PLoS One&#39;,
    &#39;volume&#39;: &#39;7&#39;,
    &#39;issn&#39;: &#39;4&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF1&#39;: {&#39;ref_id&#39;: &#39;b1&#39;,
    &#39;title&#39;: &#39;Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;D&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Hui&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;B&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Chow&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;T&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Lo&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2019,
    &#39;venue&#39;: &#39;European Respiratory Journal&#39;,
    &#39;volume&#39;: &#39;53&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF2&#39;: {&#39;ref_id&#39;: &#39;b2&#39;,
    &#39;title&#39;: &#39;Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;F&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Zhou&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;T&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Yu&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;R&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Du&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;G&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Fan&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;Y&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Liu&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;Z&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Liu&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2020,
    &#39;venue&#39;: &#39;&#39;,
    &#39;volume&#39;: &#39;395&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;1054--1062&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF3&#39;: {&#39;ref_id&#39;: &#39;b3&#39;,
    &#39;title&#39;: &#39;Novel 2019 Coronavirus SARS-CoV-2 (COVID-19): An Updated Overview for Emergency Clinicians. EB Medicine&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;A&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Giwa&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;A&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Desai&#39;, &#39;suffix&#39;: &#39;&#39;},
     {&#39;first&#39;: &#39;A&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Duca&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: 2020,
    &#39;venue&#39;: &#39;&#39;,
    &#39;volume&#39;: &#39;&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}},
   &#39;BIBREF4&#39;: {&#39;ref_id&#39;: &#39;b4&#39;,
    &#39;title&#39;: &#39;Handbook of COVID-19 Prevention and Treatment&#39;,
    &#39;authors&#39;: [{&#39;first&#39;: &#39;T&#39;, &#39;middle&#39;: [], &#39;last&#39;: &#39;Liang&#39;, &#39;suffix&#39;: &#39;&#39;}],
    &#39;year&#39;: None,
    &#39;venue&#39;: &#39;&#39;,
    &#39;volume&#39;: &#39;&#39;,
    &#39;issn&#39;: &#39;&#39;,
    &#39;pages&#39;: &#39;&#39;,
    &#39;other_ids&#39;: {}}},
  &#39;ref_entries&#39;: {},
  &#39;back_matter&#39;: []},)</pre>
</div>

</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[4]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">flatten</span><span class="p">(</span><span class="n">record</span><span class="p">):</span>
    <span class="k">return</span> <span class="p">{</span>
        <span class="s1">&#39;id&#39;</span><span class="p">:</span> <span class="n">record</span><span class="p">[</span><span class="s1">&#39;paper_id&#39;</span><span class="p">],</span>
        <span class="s1">&#39;title&#39;</span><span class="p">:</span> <span class="n">record</span><span class="p">[</span><span class="s1">&#39;metadata&#39;</span><span class="p">][</span><span class="s1">&#39;title&#39;</span><span class="p">]</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>
    <span class="p">}</span>

<span class="n">df</span> <span class="o">=</span> <span class="n">df</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">flatten</span><span class="p">)</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
<span class="n">df</span> <span class="o">=</span> <span class="n">df</span><span class="o">.</span><span class="n">persist</span><span class="p">()</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[5]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df</span><span class="o">.</span><span class="n">head</span><span class="p">()</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[5]:</div>



<div class="jp-RenderedHTMLCommon jp-RenderedHTML jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/html">
<div>
<style scoped>
    .dataframe tbody tr th:only-of-type {
        vertical-align: middle;
    }

    .dataframe tbody tr th {
        vertical-align: top;
    }

    .dataframe thead th {
        text-align: right;
    }
</style>
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>id</th>
      <th>title</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>00c75478b9f6b815f8b552a50fd5e20a6d10e9f4</td>
      <td>journal pre-proof fighting covid-19 hypoxia wi...</td>
    </tr>
    <tr>
      <th>1</th>
      <td>00d785ead20c76504710e80ee07313c6f9c05a52</td>
      <td>a cross-sectional population-based study on th...</td>
    </tr>
    <tr>
      <th>2</th>
      <td>00de656e1c8f3b13afc0f491200e3b43b907945b</td>
      <td>the author's response</td>
    </tr>
    <tr>
      <th>3</th>
      <td>00f1ef126735474ccaf3a8d1cce9a4823d7f1228</td>
      <td>a green strategy for the synthesis of sulfone ...</td>
    </tr>
    <tr>
      <th>4</th>
      <td>012ae149fdd6c4bcc958aab78a29bf234a8f7d93</td>
      <td>selected approaches to the assessment of envir...</td>
    </tr>
  </tbody>
</table>
</div>
</div>

</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[6]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Read the model</span>
<span class="k">def</span> <span class="nf">load_vectors</span><span class="p">(</span><span class="n">fname</span><span class="p">):</span>
    <span class="n">fin</span> <span class="o">=</span> <span class="n">io</span><span class="o">.</span><span class="n">open</span><span class="p">(</span><span class="n">fname</span><span class="p">,</span> <span class="s2">&quot;r&quot;</span><span class="p">,</span> <span class="n">encoding</span><span class="o">=</span><span class="s2">&quot;utf-8&quot;</span><span class="p">,</span> <span class="n">newline</span><span class="o">=</span><span class="s2">&quot;</span><span class="se">\n</span><span class="s2">&quot;</span><span class="p">,</span> <span class="n">errors</span><span class="o">=</span><span class="s2">&quot;ignore&quot;</span><span class="p">)</span>
    <span class="n">n</span><span class="p">,</span> <span class="n">d</span> <span class="o">=</span> <span class="nb">map</span><span class="p">(</span><span class="nb">int</span><span class="p">,</span> <span class="n">fin</span><span class="o">.</span><span class="n">readline</span><span class="p">()</span><span class="o">.</span><span class="n">split</span><span class="p">())</span>
    <span class="n">data</span> <span class="o">=</span> <span class="p">{}</span>
    <span class="k">for</span> <span class="n">line</span> <span class="ow">in</span> <span class="n">fin</span><span class="p">:</span>
        <span class="n">tokens</span> <span class="o">=</span> <span class="n">line</span><span class="o">.</span><span class="n">rstrip</span><span class="p">()</span><span class="o">.</span><span class="n">split</span><span class="p">(</span><span class="s2">&quot; &quot;</span><span class="p">)</span>
        <span class="n">data</span><span class="p">[</span><span class="n">tokens</span><span class="p">[</span><span class="mi">0</span><span class="p">]]</span> <span class="o">=</span> <span class="nb">list</span><span class="p">(</span><span class="nb">map</span><span class="p">(</span><span class="nb">float</span><span class="p">,</span> <span class="n">tokens</span><span class="p">[</span><span class="mi">1</span><span class="p">:]))</span>
    <span class="k">return</span> <span class="n">data</span>

<span class="c1">#  This function finds the embedded title</span>
<span class="k">def</span> <span class="nf">embed</span><span class="p">(</span><span class="n">text</span><span class="p">,</span> <span class="n">model</span><span class="p">):</span>
    <span class="n">text</span> <span class="o">=</span> <span class="n">text</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>
    <span class="n">text_split</span> <span class="o">=</span> <span class="n">text</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    <span class="n">text_list</span> <span class="o">=</span> <span class="p">[</span><span class="n">model</span><span class="p">[</span><span class="n">t</span><span class="p">]</span> <span class="k">for</span> <span class="n">t</span> <span class="ow">in</span> <span class="n">text_split</span><span class="p">]</span>
    <span class="n">text_string</span> <span class="o">=</span> <span class="p">[[</span><span class="s2">&quot;</span><span class="si">%.8f</span><span class="s2">&quot;</span> <span class="o">%</span> <span class="n">n</span> <span class="k">for</span> <span class="n">n</span> <span class="ow">in</span> <span class="n">emb</span><span class="p">]</span> <span class="k">for</span> <span class="n">emb</span> <span class="ow">in</span> <span class="n">text_list</span><span class="p">]</span>       
    <span class="k">return</span> <span class="n">text_string</span>

<span class="c1"># This function formats properly the title and its &quot;embedding&quot;</span>
<span class="k">def</span> <span class="nf">dict_embed</span><span class="p">(</span><span class="n">text</span><span class="p">,</span> <span class="n">model</span><span class="p">):</span>
    
    <span class="k">return</span> <span class="p">{</span>
        <span class="s2">&quot;title&quot;</span><span class="p">:</span> <span class="n">text</span><span class="p">,</span>
        <span class="s2">&quot;emb_title&quot;</span><span class="p">:</span> <span class="n">embed</span><span class="p">(</span><span class="n">text</span><span class="p">,</span> <span class="n">model</span><span class="p">)</span>
    <span class="p">}</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[19]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Import data</span>
<span class="n">titles</span> <span class="o">=</span> <span class="p">(</span><span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s1">&#39;./kaggle/papers_in_json_singleline/*.json&#39;</span><span class="p">)</span>
          <span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;metadata&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;title&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">compute</span><span class="p">())</span>
<span class="n">model</span> <span class="o">=</span> <span class="n">load_vectors</span><span class="p">(</span><span class="s2">&quot;wiki.en.vec&quot;</span><span class="p">)</span>

<span class="c1"># Clean up the title from word not &quot;knowed&quot; by the model</span>
<span class="n">allow_words</span> <span class="o">=</span> <span class="nb">list</span><span class="p">(</span><span class="n">model</span><span class="o">.</span><span class="n">keys</span><span class="p">())</span>
<span class="n">clean_title</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">title</span> <span class="ow">in</span> <span class="n">titles</span><span class="p">:</span>
    <span class="n">dummy_list</span> <span class="o">=</span> <span class="n">title</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>
    <span class="n">dummy_list</span> <span class="o">=</span> <span class="n">dummy_list</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    <span class="n">dummy_list</span> <span class="o">=</span> <span class="p">[</span><span class="n">word</span> <span class="k">for</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">dummy_list</span> <span class="k">if</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">allow_words</span><span class="p">]</span>
    <span class="n">dummy_list</span> <span class="o">=</span> <span class="s1">&#39; &#39;</span><span class="o">.</span><span class="n">join</span><span class="p">(</span><span class="n">dummy_list</span><span class="p">)</span>
    <span class="n">clean_title</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">dummy_list</span><span class="p">)</span>

<span class="c1"># Get titles and embed them</span>
<span class="n">titles_emb</span> <span class="o">=</span> <span class="p">[</span><span class="n">dict_embed</span><span class="p">(</span><span class="n">d</span><span class="p">,</span> <span class="n">model</span><span class="p">)</span> <span class="k">for</span> <span class="n">d</span> <span class="ow">in</span> <span class="n">clean_title</span><span class="p">]</span>

<span class="c1"># Save embedded paper titles in files </span>
<span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="nb">len</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">)):</span>
    <span class="n">fname</span> <span class="o">=</span> <span class="s2">&quot;./new_emb/embeddings&quot;</span><span class="o">+</span><span class="nb">str</span><span class="p">(</span><span class="n">i</span><span class="p">)</span><span class="o">+</span><span class="s2">&quot;.json&quot;</span>
    <span class="k">with</span> <span class="nb">open</span> <span class="p">(</span><span class="n">fname</span><span class="p">,</span> <span class="s1">&#39;w+&#39;</span><span class="p">)</span> <span class="k">as</span> <span class="n">wf</span><span class="p">:</span>
        <span class="n">json</span><span class="o">.</span><span class="n">dump</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">[</span><span class="n">i</span><span class="p">],</span> <span class="n">wf</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[26]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Load embedded papers</span>
<span class="n">embedded_files</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s1">&#39;./new_emb/*.json&#39;</span><span class="p">)</span>
<span class="n">embedded_files</span><span class="o">.</span><span class="n">take</span><span class="p">(</span><span class="mi">1</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[26]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>(&#39;{&#34;title&#34;: &#34;journal fighting hypoxia with one hand tied behind our blanket prohibition of high flow oxygen and positive pressure in united states hospitals fighting hypoxia with one hand tied behind our blanket prohibition of high flow oxygen and positive pressure in united states hospitals fighting hypoxia with one hand tied behind our blanket prohibition of high flow oxygen and positive pressure in united states hospitals&#34;, &#34;emb_title&#34;: [[&#34;0.2325500000&#34;, &#34;-0.1198300000&#34;, &#34;-0.0346240000&#34;, &#34;0.4187700000&#34;, &#34;-0.4648700000&#34;, &#34;0.3026600000&#34;, &#34;0.1324000000&#34;, &#34;0.0944070000&#34;, &#34;0.5767400000&#34;, &#34;0.2616600000&#34;, &#34;0.2728700000&#34;, &#34;0.0657800000&#34;, &#34;-0.2101100000&#34;, &#34;-0.1671500000&#34;, &#34;-0.1821400000&#34;, &#34;-0.2185500000&#34;, &#34;0.1167800000&#34;, &#34;0.1720800000&#34;, &#34;0.1625000000&#34;, &#34;0.6169900000&#34;, &#34;-0.1489900000&#34;, &#34;0.2747800000&#34;, &#34;0.0220260000&#34;, &#34;-0.2643000000&#34;, &#34;-0.1748500000&#34;, &#34;-0.2324600000&#34;, &#34;0.3029700000&#34;, &#34;0.0398340000&#34;, &#34;0.3834900000&#34;, &#34;0.1121700000&#34;, &#34;0.1629700000&#34;, &#34;0.2079100000&#34;, &#34;-0.1091200000&#34;, &#34;0.5325500000&#34;, &#34;-0.4082000000&#34;, &#34;-0.2810000000&#34;, &#34;0.1589200000&#34;, &#34;-0.0594300000&#34;, &#34;-0.0345940000&#34;, &#34;-0.0331620000&#34;, &#34;0.0962850000&#34;, &#34;-0.2343400000&#34;, &#34;0.0697060000&#34;, &#34;-0.2512900000&#34;, &#34;-0.3990000000&#34;, &#34;0.1667600000&#34;, &#34;-0.2491700000&#34;, &#34;-0.1725000000&#34;, &#34;0.1576400000&#34;, &#34;-0.4181000000&#34;, &#34;-0.0246180000&#34;, &#34;-0.0277040000&#34;, &#34;-0.0551600000&#34;, &#34;-0.6570900000&#34;, &#34;-0.0879960000&#34;, &#34;-0.5395000000&#34;, &#34;-0.0431410000&#34;, &#34;0.0533090000&#34;, &#34;0.3769100000&#34;, &#34;0.3065500000&#34;, &#34;-0.0588650000&#34;, &#34;0.0099112000&#34;, &#34;0.2585700000&#34;, &#34;0.6052500000&#34;, &#34;0.2266600000&#34;, &#34;-0.5236200000&#34;, &#34;0.1917500000&#34;, &#34;-0.0030730000&#34;, &#34;-0.2627900000&#34;, &#34;-0.0254600000&#34;, &#34;-0.2325400000&#34;, &#34;-0.0894550000&#34;, &#34;0.4005500000&#34;, &#34;-0.0186700000&#34;, &#34;0.1880600000&#34;, &#34;-0.1841300000&#34;, &#34;0.3690300000&#34;, &#34;0.0589040000&#34;, &#34;0.3002700000&#34;, &#34;0.1274300000&#34;, &#34;0.0608570000&#34;, &#34;0.2792100000&#34;, &#34;-0.0673130000&#34;, &#34;-0.1364800000&#34;, &#34;-0.1228800000&#34;, &#34;-0.0182410000&#34;, &#34;-0.0246600000&#34;, &#34;-0.2414900000&#34;, &#34;0.0166320000&#34;, &#34;0.0833770000&#34;, &#34;0.1305500000&#34;, &#34;0.0827740000&#34;, &#34;0.2727400000&#34;, &#34;-0.5282200000&#34;, &#34;-0.0656650000&#34;, &#34;-0.2377800000&#34;, &#34;-0.0540560000&#34;, &#34;0.0602840000&#34;, &#34;-0.0141580000&#34;, &#34;0.1749800000&#34;, &#34;-0.1073200000&#34;, &#34;-0.2676700000&#34;, &#34;-0.0796090000&#34;, &#34;-0.3238000000&#34;, &#34;0.4705500000&#34;, &#34;0.3596700000&#34;, &#34;0.0558460000&#34;, &#34;0.0674810000&#34;, &#34;-0.1403900000&#34;, &#34;-0.2370300000&#34;, &#34;-0.2633600000&#34;, &#34;0.2374900000&#34;, &#34;-0.0995350000&#34;, &#34;-0.2161800000&#34;, &#34;-0.0381390000&#34;, &#34;0.2774200000&#34;, &#34;0.0205630000&#34;, &#34;0.3006800000&#34;, &#34;-0.4611700000&#34;, &#34;0.4256200000&#34;, &#34;0.4868300000&#34;, &#34;-0.0778130000&#34;, &#34;0.0185820000&#34;, &#34;0.3206100000&#34;, &#34;-0.1227800000&#34;, &#34;0.0019277000&#34;, &#34;-0.2072400000&#34;, &#34;0.0651750000&#34;, &#34;-0.1155100000&#34;, &#34;0.0243100000&#34;, &#34;0.0120690000&#34;, &#34;-0.1137100000&#34;, &#34;0.4220900000&#34;, &#34;-0.3268900000&#34;, &#34;-0.0241350000&#34;, &#34;0.0144480000&#34;, &#34;-0.2683000000&#34;, &#34;-0.0587420000&#34;, &#34;0.0060829000&#34;, &#34;0.3564900000&#34;, &#34;-0.1045300000&#34;, &#34;0.4135300000&#34;, &#34;0.6160200000&#34;, &#34;-0.1591400000&#34;, &#34;0.0313880000&#34;, &#34;0.0832180000&#34;, &#34;-0.0283770000&#34;, &#34;-0.1784300000&#34;, &#34;0.0556960000&#34;, &#34;0.1912700000&#34;, &#34;0.0740220000&#34;, &#34;-0.4047800000&#34;, &#34;-0.2823300000&#34;, &#34;0.2733500000&#34;, &#34;0.0339240000&#34;, &#34;0.0567150000&#34;, &#34;-0.2444600000&#34;, &#34;-0.4068900000&#34;, &#34;0.0459560000&#34;, &#34;0.2629600000&#34;, &#34;0.2576300000&#34;, &#34;0.6746900000&#34;, &#34;0.0281510000&#34;, &#34;0.0081265000&#34;, &#34;0.4454200000&#34;, &#34;0.2128500000&#34;, &#34;-0.2734700000&#34;, &#34;-0.0831930000&#34;, &#34;0.1306600000&#34;, &#34;-0.0483920000&#34;, &#34;0.1322700000&#34;, &#34;0.2896200000&#34;, &#34;0.0190820000&#34;, &#34;-0.2082100000&#34;, &#34;-0.4423700000&#34;, &#34;0.2508600000&#34;, &#34;-0.1767800000&#34;, &#34;0.0060190000&#34;, &#34;0.3338800000&#34;, &#34;0.0373870000&#34;, &#34;-0.1153200000&#34;, &#34;0.1329800000&#34;, &#34;0.3024400000&#34;, &#34;0.2930400000&#34;, &#34;-0.4676100000&#34;, &#34;0.1714200000&#34;, &#34;-0.0780520000&#34;, &#34;0.1030200000&#34;, &#34;0.0101750000&#34;, &#34;0.4464400000&#34;, &#34;0.2185700000&#34;, &#34;-0.2191600000&#34;, &#34;-0.2947300000&#34;, &#34;0.4087000000&#34;, &#34;-0.2936400000&#34;, &#34;0.1234500000&#34;, &#34;0.1293800000&#34;, &#34;0.1147200000&#34;, &#34;-0.6601700000&#34;, &#34;-0.3278800000&#34;, &#34;0.2939000000&#34;, &#34;0.1403000000&#34;, &#34;0.1115500000&#34;, &#34;0.0979390000&#34;, &#34;0.0571840000&#34;, &#34;-0.1047000000&#34;, &#34;0.0423450000&#34;, &#34;-0.2418300000&#34;, &#34;0.4192000000&#34;, &#34;-0.0249390000&#34;, &#34;0.0917150000&#34;, &#34;-0.1947000000&#34;, &#34;0.1924500000&#34;, &#34;-0.2284600000&#34;, &#34;0.0171290000&#34;, &#34;-0.1536300000&#34;, &#34;0.1825900000&#34;, &#34;-0.0796760000&#34;, &#34;0.0488900000&#34;, &#34;0.2171900000&#34;, &#34;-0.2441200000&#34;, &#34;-0.0425090000&#34;, &#34;-0.2345000000&#34;, &#34;-0.1046100000&#34;, &#34;-0.5679000000&#34;, &#34;-0.3093700000&#34;, &#34;0.1209200000&#34;, &#34;-0.5980600000&#34;, &#34;-0.0584390000&#34;, &#34;-0.1362900000&#34;, &#34;-0.2899600000&#34;, &#34;0.0328500000&#34;, &#34;-0.5671400000&#34;, &#34;-0.2200800000&#34;, &#34;-0.0119440000&#34;, &#34;0.0533000000&#34;, &#34;-0.2059900000&#34;, &#34;0.0723930000&#34;, &#34;0.1134800000&#34;, &#34;0.0598820000&#34;, &#34;-0.0492140000&#34;, &#34;-0.1585700000&#34;, &#34;0.0454550000&#34;, &#34;-0.3446100000&#34;, &#34;0.3533200000&#34;, &#34;0.5003200000&#34;, &#34;0.1284700000&#34;, &#34;-0.2855200000&#34;, &#34;-0.2271000000&#34;, &#34;-0.1767600000&#34;, &#34;-0.0043058000&#34;, &#34;0.2417900000&#34;, &#34;-0.0248330000&#34;, &#34;0.0964730000&#34;, &#34;0.1567600000&#34;, &#34;0.3724500000&#34;, &#34;-0.2321400000&#34;, &#34;-0.2403700000&#34;, &#34;-0.1832100000&#34;, &#34;-0.1963100000&#34;, &#34;0.1432400000&#34;, &#34;-0.2428500000&#34;, &#34;0.2755000000&#34;, &#34;-0.1942500000&#34;, &#34;-0.2787200000&#34;, &#34;0.3569600000&#34;, &#34;0.3475500000&#34;, &#34;-0.1100400000&#34;, &#34;0.1762600000&#34;, &#34;0.1738400000&#34;, &#34;0.0981900000&#34;, &#34;-0.1526000000&#34;, &#34;0.4337400000&#34;, &#34;-0.1748900000&#34;, &#34;0.0446420000&#34;, &#34;-0.2215000000&#34;, &#34;0.0644370000&#34;, &#34;0.2836500000&#34;, &#34;0.0368090000&#34;, &#34;0.0272200000&#34;, &#34;-0.2764200000&#34;, &#34;-0.3093300000&#34;, &#34;0.0471250000&#34;, &#34;0.2082500000&#34;, &#34;0.0620310000&#34;, &#34;-0.2775700000&#34;, &#34;0.3685000000&#34;, &#34;0.2201900000&#34;, &#34;0.3312600000&#34;, &#34;0.4280900000&#34;, &#34;-0.1035400000&#34;, &#34;0.2119600000&#34;, &#34;0.0548630000&#34;, &#34;-0.3269100000&#34;, &#34;-0.3808600000&#34;, &#34;-0.5626600000&#34;, &#34;0.4477800000&#34;, &#34;-0.1613900000&#34;, &#34;-0.0036914000&#34;, &#34;-0.2550800000&#34;], [&#34;-0.1736500000&#34;, &#34;-0.2836300000&#34;, &#34;-0.1809400000&#34;, &#34;0.4295200000&#34;, &#34;-0.4730500000&#34;, &#34;-0.1101200000&#34;, &#34;-0.3302000000&#34;, &#34;-0.2372000000&#34;, &#34;-0.0368550000&#34;, &#34;0.1094800000&#34;, &#34;-0.2674100000&#34;, &#34;0.1127600000&#34;, &#34;0.0421600000&#34;, &#34;-0.0596830000&#34;, &#34;0.0221990000&#34;, &#34;0.0161790000&#34;, &#34;-0.1255500000&#34;, &#34;-0.1879400000&#34;, &#34;0.3825400000&#34;, &#34;0.2012000000&#34;, &#34;-0.1902300000&#34;, &#34;0.0398530000&#34;, &#34;-0.5339500000&#34;, &#34;-0.3074600000&#34;, &#34;-0.0738130000&#34;, &#34;-0.3190500000&#34;, &#34;0.1111500000&#34;, &#34;-0.0914910000&#34;, &#34;-0.0852410000&#34;, &#34;0.0711860000&#34;, &#34;0.3237800000&#34;, &#34;0.2832100000&#34;, &#34;-0.1494500000&#34;, &#34;0.2852300000&#34;, &#34;0.0254060000&#34;, &#34;-0.3089800000&#34;, &#34;0.0609480000&#34;, &#34;0.0112770000&#34;, &#34;0.1611600000&#34;, &#34;0.1690200000&#34;, &#34;-0.1827800000&#34;, &#34;0.5029000000&#34;, &#34;-0.0581000000&#34;, &#34;0.2478800000&#34;, &#34;-0.1699600000&#34;, &#34;0.0835340000&#34;, &#34;0.2265800000&#34;, &#34;-0.2294700000&#34;, &#34;-0.0323500000&#34;, &#34;0.1080200000&#34;, &#34;-0.1090300000&#34;, &#34;0.0604570000&#34;, &#34;0.2522200000&#34;, &#34;0.2881300000&#34;, &#34;-0.2414500000&#34;, &#34;0.2326000000&#34;, &#34;0.0253100000&#34;, &#34;0.1817300000&#34;, &#34;-0.2879700000&#34;, &#34;0.1155900000&#34;, &#34;-0.2285900000&#34;, &#34;-0.0734400000&#34;, &#34;0.1111300000&#34;, &#34;0.0768120000&#34;, &#34;0.0783700000&#34;, &#34;0.6290300000&#34;, &#34;0.0804510000&#34;, &#34;0.2050600000&#34;, &#34;-0.0385150000&#34;, &#34;0.1185100000&#34;, &#34;0.1758900000&#34;, &#34;-0.0324720000&#34;, &#34;-0.2694300000&#34;, &#34;-0.0339290000&#34;, &#34;0.1621400000&#34;, &#34;0.3858600000&#34;, &#34;0.2558200000&#34;, &#34;0.4283000000&#34;, &#34;-0.2526000000&#34;, &#34;0.1252000000&#34;, &#34;-0.0549830000&#34;, &#34;0.0087438000&#34;, &#34;-0.2013700000&#34;, &#34;0.0608780000&#34;, &#34;-0.2458000000&#34;, &#34;0.0438840000&#34;, &#34;-0.2682600000&#34;, &#34;0.2361200000&#34;, &#34;-0.1442700000&#34;, &#34;-0.0306300000&#34;, &#34;-0.2719500000&#34;, &#34;-0.2093100000&#34;, &#34;-0.0815660000&#34;, &#34;-0.3089000000&#34;, &#34;0.0916080000&#34;, &#34;-0.3417200000&#34;, &#34;-0.1684600000&#34;, &#34;-0.1204900000&#34;, &#34;-0.1106400000&#34;, &#34;-0.2890400000&#34;, &#34;-0.0094841000&#34;, &#34;-0.0700150000&#34;, &#34;-0.1462600000&#34;, &#34;-0.1977800000&#34;, &#34;-0.4332300000&#34;, &#34;-0.3091900000&#34;, &#34;-0.0579740000&#34;, &#34;0.3495700000&#34;, &#34;-0.0845180000&#34;, &#34;0.1615400000&#34;, &#34;-0.2518100000&#34;, &#34;0.1614000000&#34;, &#34;-0.1739800000&#34;, &#34;-0.4145300000&#34;, &#34;0.0362110000&#34;, &#34;0.0645290000&#34;, &#34;0.5992300000&#34;, &#34;0.1707800000&#34;, &#34;-0.2215700000&#34;, &#34;0.0572800000&#34;, &#34;0.1832900000&#34;, &#34;-0.1033200000&#34;, &#34;-0.1942700000&#34;, &#34;0.0140610000&#34;, &#34;-0.0254520000&#34;, &#34;-0.1506100000&#34;, &#34;-0.3636800000&#34;, &#34;-0.0394820000&#34;, &#34;0.1226600000&#34;, &#34;-0.0769340000&#34;, &#34;-0.2435900000&#34;, &#34;0.0206100000&#34;, &#34;-0.1323000000&#34;, &#34;-0.3813600000&#34;, &#34;-0.0509760000&#34;, &#34;0.1678400000&#34;, &#34;0.0433760000&#34;, &#34;-0.0220620000&#34;, &#34;0.0261470000&#34;, &#34;-0.0752060000&#34;, &#34;0.1347700000&#34;, &#34;0.0381730000&#34;, &#34;0.0765570000&#34;, &#34;0.2803000000&#34;, &#34;-0.0060694000&#34;, &#34;-0.0622820000&#34;, &#34;-0.0593170000&#34;, &#34;-0.3559400000&#34;, &#34;0.0774780000&#34;, &#34;0.1479700000&#34;, &#34;0.1982700000&#34;, &#34;-0.0788700000&#34;, &#34;-0.4599400000&#34;, &#34;0.2981300000&#34;, &#34;-0.4199800000&#34;, &#34;-0.2579400000&#34;, &#34;-0.1823600000&#34;, &#34;0.0027135000&#34;, &#34;0.0696170000&#34;, &#34;0.0438040000&#34;, &#34;-0.0452570000&#34;, &#34;-0.3199400000&#34;, &#34;-0.0558440000&#34;, &#34;0.4669400000&#34;, &#34;0.2625200000&#34;, &#34;-0.0785060000&#34;, &#34;-0.0500560000&#34;, &#34;-0.0792630000&#34;, &#34;0.1339100000&#34;, &#34;-0.1054600000&#34;, &#34;0.0004455400&#34;, &#34;0.0617780000&#34;, &#34;-0.4249100000&#34;, &#34;-0.2486400000&#34;, &#34;0.4032100000&#34;, &#34;0.6722000000&#34;, &#34;-0.1047300000&#34;, &#34;0.1965700000&#34;, &#34;0.0338270000&#34;, &#34;0.1000800000&#34;, &#34;0.4372600000&#34;, &#34;-0.1265300000&#34;, &#34;0.4267600000&#34;, &#34;0.1379500000&#34;, &#34;-0.0211350000&#34;, &#34;0.2574800000&#34;, &#34;-0.2618700000&#34;, &#34;0.0452240000&#34;, &#34;0.0737280000&#34;, &#34;-0.1873500000&#34;, &#34;0.0567800000&#34;, &#34;-0.7268700000&#34;, &#34;-0.0364160000&#34;, &#34;0.3168400000&#34;, &#34;0.0526610000&#34;, &#34;-0.0535450000&#34;, &#34;-0.0554020000&#34;, &#34;0.0129660000&#34;, &#34;-0.3280700000&#34;, &#34;-0.0957510000&#34;, &#34;0.4189200000&#34;, &#34;-0.2883300000&#34;, &#34;0.0881070000&#34;, &#34;0.1209300000&#34;, &#34;0.0346670000&#34;, &#34;-0.2230400000&#34;, &#34;-0.0668240000&#34;, &#34;-0.5780500000&#34;, &#34;-0.0530530000&#34;, &#34;0.2087400000&#34;, &#34;0.4597700000&#34;, &#34;0.3749600000&#34;, &#34;-0.2387100000&#34;, &#34;-0.2213900000&#34;, &#34;0.0789210000&#34;, &#34;-0.1349400000&#34;, &#34;-0.2596700000&#34;, &#34;-0.1978100000&#34;, &#34;0.0547500000&#34;, &#34;0.3032200000&#34;, &#34;0.1851800000&#34;, &#34;0.0723950000&#34;, &#34;0.0476010000&#34;, &#34;0.1572600000&#34;, &#34;-0.2084900000&#34;, &#34;-0.0223590000&#34;, &#34;0.3760000000&#34;, &#34;0.2397500000&#34;, &#34;0.2781600000&#34;, &#34;-0.1934700000&#34;, &#34;0.7435700000&#34;, &#34;-0.2691700000&#34;, &#34;-0.1246200000&#34;, &#34;-0.5516800000&#34;, &#34;-0.0467160000&#34;, &#34;0.2924000000&#34;, &#34;0.2381000000&#34;, &#34;0.0339250000&#34;, &#34;0.1799400000&#34;, &#34;-0.2307800000&#34;, &#34;0.2560900000&#34;, &#34;0.0624750000&#34;, &#34;0.2686900000&#34;, &#34;0.3941800000&#34;, &#34;0.2299500000&#34;, &#34;0.0301630000&#34;, &#34;0.4480900000&#34;, &#34;0.0212780000&#34;, &#34;-0.1172500000&#34;, &#34;0.5232700000&#34;, &#34;0.0436650000&#34;, &#34;0.1992800000&#34;, &#34;-0.0273640000&#34;, &#34;0.0599610000&#34;, &#34;0.0189820000&#34;, &#34;-0.2465900000&#34;, &#34;-0.4179700000&#34;, &#34;-0.3634300000&#34;, &#34;0.2551900000&#34;, &#34;-0.0426970000&#34;, &#34;0.0747530000&#34;, &#34;0.0606080000&#34;, &#34;0.0752030000&#34;, &#34;-0.2680200000&#34;, &#34;-0.1723500000&#34;, &#34;-0.0697920000&#34;, &#34;-0.3474000000&#34;, &#34;-0.1707600000&#34;, &#34;0.3632000000&#34;, &#34;0.0960900000&#34;, &#34;-0.1171900000&#34;, &#34;-0.1351400000&#34;, &#34;-0.2400300000&#34;, &#34;0.0425490000&#34;, &#34;-0.0081243000&#34;, &#34;-0.1372900000&#34;, &#34;0.1335200000&#34;, &#34;0.2793400000&#34;, &#34;0.0591050000&#34;, &#34;0.0738470000&#34;, &#34;0.0990680000&#34;, &#34;-0.0383910000&#34;, &#34;0.0817850000&#34;, &#34;-0.2255000000&#34;, &#34;0.0856740000&#34;, &#34;0.0845380000&#34;, &#34;0.1462600000&#34;, &#34;0.2489100000&#34;, &#34;-0.1412400000&#34;, &#34;0.0157220000&#34;, &#34;0.2033300000&#34;, &#34;-0.0020506000&#34;, &#34;0.0713030000&#34;, &#34;0.2393500000&#34;, &#34;-0.2820000000&#34;, &#34;0.5960100000&#34;, &#34;0.1398000000&#34;, &#34;0.6361700000&#34;, &#34;0.0428380000&#34;, &#34;0.1769800000&#34;], [&#34;-0.0940560000&#34;, &#34;-0.2341300000&#34;, &#34;-0.7815000000&#34;, &#34;0.3331400000&#34;, &#34;-0.9646400000&#34;, &#34;-0.4424500000&#34;, &#34;0.2937900000&#34;, &#34;-0.4881200000&#34;, &#34;-0.2112100000&#34;, &#34;-0.1441400000&#34;, &#34;0.1277800000&#34;, &#34;0.2240100000&#34;, &#34;-0.2451700000&#34;, &#34;0.0298300000&#34;, &#34;0.1723700000&#34;, &#34;0.0541280000&#34;, &#34;0.1732100000&#34;, &#34;0.0191690000&#34;, &#34;-0.2644800000&#34;, &#34;0.3111200000&#34;, &#34;0.3086200000&#34;, &#34;0.1728800000&#34;, &#34;-0.4366200000&#34;, &#34;-0.1477400000&#34;, &#34;-0.0079717000&#34;, &#34;-0.0397720000&#34;, &#34;0.1221300000&#34;, &#34;0.0228840000&#34;, &#34;0.1682100000&#34;, &#34;0.4504400000&#34;, &#34;0.0662230000&#34;, &#34;0.1486900000&#34;, &#34;-0.1513700000&#34;, &#34;0.7382900000&#34;, &#34;0.3694800000&#34;, &#34;0.2051600000&#34;, &#34;0.0164620000&#34;, &#34;0.3338300000&#34;, &#34;0.0774790000&#34;, &#34;0.0245320000&#34;, &#34;0.5119500000&#34;, &#34;-0.0733730000&#34;, &#34;-0.2505200000&#34;, &#34;0.4430700000&#34;, &#34;0.5690100000&#34;, &#34;-0.0203540000&#34;, &#34;0.3633600000&#34;, &#34;0.0103310000&#34;, &#34;0.1395300000&#34;, &#34;0.2817500000&#34;, &#34;0.0104470000&#34;, &#34;-0.2372900000&#34;, &#34;-0.2085400000&#34;, &#34;-0.7273000000&#34;, &#34;0.1013200000&#34;, &#34;-0.3156300000&#34;, &#34;0.0874210000&#34;, &#34;0.0403650000&#34;, &#34;0.0070915000&#34;, &#34;0.0127760000&#34;, &#34;-0.4727200000&#34;, &#34;-0.0157890000&#34;, &#34;0.6688400000&#34;, &#34;0.0641250000&#34;, &#34;-0.2177100000&#34;, &#34;-0.1877100000&#34;, &#34;-0.2004400000&#34;, &#34;0.4396900000&#34;, &#34;-0.0370770000&#34;, &#34;-0.0892220000&#34;, &#34;-0.0224830000&#34;, &#34;-0.1147900000&#34;, &#34;0.4624200000&#34;, &#34;0.2170400000&#34;, &#34;0.0236440000&#34;, &#34;0.2547100000&#34;, &#34;0.5423300000&#34;, &#34;0.4597400000&#34;, &#34;-0.3465000000&#34;, &#34;0.2184400000&#34;, &#34;0.3804700000&#34;, &#34;-0.6449800000&#34;, &#34;-0.2697200000&#34;, &#34;-0.2471100000&#34;, &#34;-0.6309100000&#34;, &#34;-0.4259000000&#34;, &#34;0.2281100000&#34;, &#34;0.1789400000&#34;, &#34;-0.3821600000&#34;, &#34;-0.8804300000&#34;, &#34;0.2474400000&#34;, &#34;0.1223900000&#34;, &#34;0.3382700000&#34;, &#34;-0.0387880000&#34;, &#34;-0.0110770000&#34;, &#34;-0.1667700000&#34;, &#34;0.7326900000&#34;, &#34;0.3821200000&#34;, &#34;0.0092299000&#34;, &#34;0.6061500000&#34;, &#34;0.0900580000&#34;, &#34;0.1687900000&#34;, &#34;-0.0877870000&#34;, &#34;-0.1740800000&#34;, &#34;0.8485900000&#34;, &#34;-0.0940780000&#34;, &#34;-0.2738000000&#34;, &#34;0.3198900000&#34;, &#34;0.2378500000&#34;, &#34;-0.1227900000&#34;, &#34;-0.1228400000&#34;, &#34;0.0573790000&#34;, &#34;-0.4123100000&#34;, &#34;-0.1291900000&#34;, &#34;-0.2413700000&#34;, &#34;-0.2802200000&#34;, &#34;0.4231900000&#34;, &#34;-0.0138740000&#34;, &#34;-0.2164000000&#34;, &#34;0.1429200000&#34;, &#34;0.0470380000&#34;, &#34;-0.5769100000&#34;, &#34;-0.5420200000&#34;, &#34;0.1491800000&#34;, &#34;0.0592060000&#34;, &#34;-0.1560700000&#34;, &#34;-0.5935700000&#34;, &#34;0.2544100000&#34;, &#34;-0.1816900000&#34;, &#34;0.0987310000&#34;, &#34;0.0475060000&#34;, &#34;0.2991500000&#34;, &#34;-0.2161000000&#34;, &#34;-0.2621300000&#34;, &#34;0.4210100000&#34;, &#34;0.6068000000&#34;, &#34;-0.5335800000&#34;, &#34;0.4012100000&#34;, &#34;-0.3907000000&#34;, &#34;0.3023400000&#34;, &#34;0.1611000000&#34;, &#34;0.4221700000&#34;, &#34;-0.3133000000&#34;, &#34;-0.3994300000&#34;, &#34;-0.2859400000&#34;, &#34;0.0769700000&#34;, &#34;0.2766600000&#34;, &#34;0.3325000000&#34;, &#34;0.1954500000&#34;, &#34;-0.1239000000&#34;, &#34;0.4425100000&#34;, &#34;-0.3573100000&#34;, &#34;0.0787960000&#34;, &#34;-0.5777100000&#34;, &#34;0.0755430000&#34;, &#34;0.3752600000&#34;, &#34;0.0507340000&#34;, &#34;0.5712500000&#34;, &#34;-0.1927100000&#34;, &#34;-0.1453600000&#34;, &#34;0.3480300000&#34;, &#34;0.1611200000&#34;, &#34;0.3318900000&#34;, &#34;-0.0610160000&#34;, &#34;0.2535200000&#34;, &#34;0.1312900000&#34;, &#34;-0.3072300000&#34;, &#34;0.0801230000&#34;, &#34;-0.0359160000&#34;, &#34;0.4872900000&#34;, &#34;-0.1650900000&#34;, &#34;-0.5552100000&#34;, &#34;-0.2179900000&#34;, &#34;0.4273400000&#34;, &#34;0.3668400000&#34;, &#34;-0.1158200000&#34;, &#34;-0.2852000000&#34;, &#34;-0.3824700000&#34;, &#34;-0.2469800000&#34;, &#34;-0.2733100000&#34;, &#34;0.0711290000&#34;, &#34;0.0538940000&#34;, &#34;-0.0862870000&#34;, &#34;-0.1701200000&#34;, &#34;-0.0214950000&#34;, &#34;0.8117500000&#34;, &#34;-0.0426910000&#34;, &#34;-0.1251700000&#34;, &#34;0.3880400000&#34;, &#34;-0.2023700000&#34;, &#34;-0.3604800000&#34;, &#34;-0.2014100000&#34;, &#34;0.2776800000&#34;, &#34;0.1086400000&#34;, &#34;-0.2867400000&#34;, &#34;-0.1631100000&#34;, &#34;0.1961100000&#34;, &#34;0.1760700000&#34;, &#34;0.2110300000&#34;, &#34;-0.4506400000&#34;, &#34;-0.2389100000&#34;, &#34;-0.4081100000&#34;, &#34;-0.0780110000&#34;, &#34;-0.1285200000&#34;, &#34;0.0116200000&#34;, &#34;-0.4668500000&#34;, &#34;-0.1622300000&#34;, &#34;-0.0252250000&#34;, &#34;0.0742630000&#34;, &#34;0.1955900000&#34;, &#34;0.4233100000&#34;, &#34;0.0870680000&#34;, &#34;0.3864300000&#34;, &#34;0.5383200000&#34;, &#34;-0.3342600000&#34;, &#34;-0.1555900000&#34;, &#34;-0.2311000000&#34;, &#34;-0.9875800000&#34;, &#34;0.0156320000&#34;, &#34;-0.0275420000&#34;, &#34;-0.2044400000&#34;, &#34;-0.0552260000&#34;, &#34;0.2387600000&#34;, &#34;0.3003900000&#34;, &#34;0.2132100000&#34;, &#34;0.1191000000&#34;, &#34;-0.2594100000&#34;, &#34;-0.5998000000&#34;, &#34;-0.1533500000&#34;, &#34;-0.2843900000&#34;, &#34;-0.2871500000&#34;, &#34;0.2011700000&#34;, &#34;-0.6836100000&#34;, &#34;-0.2381600000&#34;, &#34;0.1618000000&#34;, &#34;0.2262800000&#34;, &#34;-0.1845800000&#34;, &#34;-0.1872700000&#34;, &#34;0.1174000000&#34;, &#34;0.3883500000&#34;, &#34;0.4897900000&#34;, &#34;-0.0361370000&#34;, &#34;0.2117100000&#34;, &#34;-0.3522000000&#34;, &#34;-0.4010800000&#34;, &#34;0.4712900000&#34;, &#34;-0.1911700000&#34;, &#34;-0.5298600000&#34;, &#34;-0.2798500000&#34;, &#34;-0.4583000000&#34;, &#34;0.1843500000&#34;, &#34;-0.0495520000&#34;, &#34;-0.3404600000&#34;, &#34;0.2670000000&#34;, &#34;-0.3084400000&#34;, &#34;-0.0552860000&#34;, &#34;0.1440900000&#34;, &#34;-0.3509400000&#34;, &#34;0.3253500000&#34;, &#34;0.0257070000&#34;, &#34;0.2786900000&#34;, &#34;0.4512400000&#34;, &#34;-0.3697500000&#34;, &#34;-0.1993600000&#34;, &#34;-0.4986700000&#34;, &#34;-0.1919100000&#34;, &#34;-0.2616000000&#34;, &#34;0.0510100000&#34;, &#34;-0.1762400000&#34;, &#34;-0.2776300000&#34;, &#34;0.0218740000&#34;, &#34;-0.2827000000&#34;, &#34;-0.0130810000&#34;, &#34;-0.0680520000&#34;, &#34;-0.1026300000&#34;, &#34;-0.3704300000&#34;, &#34;-0.2594500000&#34;, &#34;-0.2856000000&#34;, &#34;-0.0783220000&#34;, &#34;-0.0265240000&#34;, &#34;0.0177150000&#34;, &#34;0.1381300000&#34;, &#34;-0.7896800000&#34;, &#34;-0.0922000000&#34;, &#34;0.8370100000&#34;, &#34;-0.0994560000&#34;, &#34;0.3206500000&#34;, &#34;-0.1031800000&#34;, &#34;-0.3371900000&#34;, &#34;-0.0032685000&#34;, &#34;-0.8159700000&#34;, &#34;0.4399900000&#34;, &#34;0.0478600000&#34;, &#34;-0.1486100000&#34;, &#34;-0.4751400000&#34;, &#34;-0.1740700000&#34;, &#34;0.4617400000&#34;, &#34;0.6174300000&#34;, &#34;0.2242100000&#34;, &#34;-0.0501340000&#34;], [&#34;-0.0642060000&#34;, &#34;0.0917140000&#34;, &#34;0.1194200000&#34;, &#34;0.4186000000&#34;, &#34;0.1746500000&#34;, &#34;0.1194100000&#34;, &#34;0.3185900000&#34;, &#34;-0.1638000000&#34;, &#34;0.2056500000&#34;, &#34;0.0880940000&#34;, &#34;-0.0462130000&#34;, &#34;0.1533100000&#34;, &#34;0.1577500000&#34;, &#34;-0.0965040000&#34;, &#34;0.0227270000&#34;, &#34;-0.1413800000&#34;, &#34;0.0098457000&#34;, &#34;-0.0265880000&#34;, &#34;0.0211830000&#34;, &#34;0.2297200000&#34;, &#34;0.0425290000&#34;, &#34;0.0272430000&#34;, &#34;0.0231370000&#34;, &#34;-0.0798720000&#34;, &#34;0.0495000000&#34;, &#34;-0.0611290000&#34;, &#34;0.1054600000&#34;, &#34;0.0849050000&#34;, &#34;-0.1019000000&#34;, &#34;0.0254450000&#34;, &#34;-0.2259300000&#34;, &#34;-0.0094519000&#34;, &#34;-0.1131600000&#34;, &#34;-0.0454760000&#34;, &#34;-0.0991100000&#34;, &#34;0.0020657000&#34;, &#34;-0.2440000000&#34;, &#34;-0.2076200000&#34;, &#34;0.2789300000&#34;, &#34;-0.0306010000&#34;, &#34;0.2543800000&#34;, &#34;-0.0434000000&#34;, &#34;0.1410000000&#34;, &#34;0.0411700000&#34;, &#34;-0.0268320000&#34;, &#34;-0.0757660000&#34;, &#34;0.0998660000&#34;, &#34;-0.1085700000&#34;, &#34;0.0527440000&#34;, &#34;-0.0064439000&#34;, &#34;0.0146670000&#34;, &#34;0.0240910000&#34;, &#34;-0.1482300000&#34;, &#34;-0.0751400000&#34;, &#34;-0.1763900000&#34;, &#34;0.0059049000&#34;, &#34;0.0069194000&#34;, &#34;-0.0533160000&#34;, &#34;-0.1120600000&#34;, &#34;-0.0605830000&#34;, &#34;-0.0128220000&#34;, &#34;-0.3179900000&#34;, &#34;0.0878980000&#34;, &#34;-0.0624170000&#34;, &#34;0.0481660000&#34;, &#34;-0.0059139000&#34;, &#34;-0.0180730000&#34;, &#34;0.2366100000&#34;, &#34;-0.1531000000&#34;, &#34;0.0032921000&#34;, &#34;-0.1283700000&#34;, &#34;0.0754290000&#34;, &#34;-0.1972500000&#34;, &#34;-0.2471200000&#34;, &#34;-0.0508580000&#34;, &#34;0.1005800000&#34;, &#34;0.1284100000&#34;, &#34;0.2528200000&#34;, &#34;0.0972760000&#34;, &#34;0.0105210000&#34;, &#34;0.1836100000&#34;, &#34;-0.1974900000&#34;, &#34;-0.0404440000&#34;, &#34;-0.1118500000&#34;, &#34;-0.1269800000&#34;, &#34;-0.1015200000&#34;, &#34;0.0270530000&#34;, &#34;0.0955040000&#34;, &#34;0.1474600000&#34;, &#34;-0.1945200000&#34;, &#34;0.0551560000&#34;, &#34;-0.1500400000&#34;, &#34;-0.0396780000&#34;, &#34;-0.0397960000&#34;, &#34;0.3459200000&#34;, &#34;0.2937900000&#34;, &#34;0.2451900000&#34;, &#34;-0.0993540000&#34;, &#34;0.0608150000&#34;, &#34;-0.2600300000&#34;, &#34;-0.0617430000&#34;, &#34;-0.0552700000&#34;, &#34;0.1101400000&#34;, &#34;0.1176600000&#34;, &#34;-0.2154600000&#34;, &#34;-0.1546700000&#34;, &#34;-0.0919750000&#34;, &#34;0.1169700000&#34;, &#34;0.0128670000&#34;, &#34;0.0462720000&#34;, &#34;0.0333600000&#34;, &#34;0.0377810000&#34;, &#34;0.0198910000&#34;, &#34;-0.0641890000&#34;, &#34;0.0792300000&#34;, &#34;-0.1214700000&#34;, &#34;-0.0219640000&#34;, &#34;0.0589270000&#34;, &#34;0.0391170000&#34;, &#34;0.2828900000&#34;, &#34;0.2215200000&#34;, &#34;-0.0972440000&#34;, &#34;-0.2508400000&#34;, &#34;0.3571700000&#34;, &#34;0.1410300000&#34;, &#34;-0.0916740000&#34;, &#34;0.1179000000&#34;, &#34;-0.0172910000&#34;, &#34;0.0098494000&#34;, &#34;0.2756000000&#34;, &#34;0.1550400000&#34;, &#34;0.0081984000&#34;, &#34;-0.2442400000&#34;, &#34;0.1335100000&#34;, &#34;-0.0413200000&#34;, &#34;0.0407330000&#34;, &#34;0.1772700000&#34;, &#34;0.0697880000&#34;, &#34;0.1017800000&#34;, &#34;0.1053000000&#34;, &#34;-0.1472700000&#34;, &#34;0.2026300000&#34;, &#34;-0.0593920000&#34;, &#34;-0.0287660000&#34;, &#34;0.0634910000&#34;, &#34;0.1825200000&#34;, &#34;-0.0014041000&#34;, &#34;0.1027400000&#34;, &#34;-0.1648100000&#34;, &#34;-0.0667120000&#34;, &#34;0.1384200000&#34;, &#34;-0.2726500000&#34;, &#34;-0.1963400000&#34;, &#34;-0.1605000000&#34;, &#34;-0.0742050000&#34;, &#34;0.0018183000&#34;, &#34;0.1026000000&#34;, &#34;-0.0435470000&#34;, &#34;-0.0072141000&#34;, &#34;0.0553060000&#34;, &#34;-0.0146920000&#34;, &#34;0.2226900000&#34;, &#34;-0.0125140000&#34;, &#34;0.1923300000&#34;, &#34;0.0218660000&#34;, &#34;-0.1175500000&#34;, &#34;0.0409160000&#34;, &#34;-0.1911000000&#34;, &#34;0.0944860000&#34;, &#34;-0.1134700000&#34;, &#34;-0.0054213000&#34;, &#34;-0.1179000000&#34;, &#34;-0.1594700000&#34;, &#34;0.1532900000&#34;, &#34;-0.1529900000&#34;, &#34;0.0930030000&#34;, &#34;0.0057173000&#34;, &#34;0.2451700000&#34;, &#34;-0.2296100000&#34;, &#34;-0.1095900000&#34;, &#34;0.1722900000&#34;, &#34;-0.1835800000&#34;, &#34;-0.0126960000&#34;, &#34;0.0583180000&#34;, &#34;0.0402570000&#34;, &#34;0.3110400000&#34;, &#34;0.1012500000&#34;, &#34;-0.1034000000&#34;, &#34;0.0863980000&#34;, &#34;-0.0512790000&#34;, &#34;0.2368600000&#34;, &#34;-0.1796100000&#34;, &#34;0.2068100000&#34;, &#34;-0.0761070000&#34;, &#34;-0.0010114000&#34;, &#34;0.0556930000&#34;, &#34;-0.1500500000&#34;, &#34;0.1915500000&#34;, &#34;-0.2685200000&#34;, &#34;-0.0636000000&#34;, &#34;0.1467400000&#34;, &#34;-0.0845620000&#34;, &#34;0.1201000000&#34;, &#34;-0.0160690000&#34;, &#34;0.1558900000&#34;, &#34;0.0321520000&#34;, &#34;-0.1993900000&#34;, &#34;-0.1060500000&#34;, &#34;0.2882500000&#34;, &#34;0.2997600000&#34;, &#34;0.0800010000&#34;, &#34;-0.0288720000&#34;, &#34;-0.1506500000&#34;, &#34;-0.1427700000&#34;, &#34;-0.0809550000&#34;, &#34;-0.0731380000&#34;, &#34;-0.1102500000&#34;, &#34;-0.3209600000&#34;, &#34;-0.1666400000&#34;, &#34;-0.0242900000&#34;, &#34;-0.1598900000&#34;, &#34;-0.0932460000&#34;, &#34;-0.1067300000&#34;, &#34;0.2122700000&#34;, &#34;0.0588260000&#34;, &#34;-0.0403710000&#34;, &#34;-0.1516500000&#34;, &#34;0.1209200000&#34;, &#34;0.0257990000&#34;, &#34;0.1389600000&#34;, &#34;0.1410700000&#34;, &#34;-0.0347680000&#34;, &#34;-0.0987820000&#34;, &#34;-0.0370760000&#34;, &#34;-0.1742000000&#34;, &#34;0.1546800000&#34;, &#34;0.2027100000&#34;, &#34;-0.2016000000&#34;, &#34;0.0056756000&#34;, &#34;0.2220900000&#34;, &#34;0.0655690000&#34;, &#34;-0.0482300000&#34;, &#34;-0.0019982000&#34;, &#34;0.2774900000&#34;, &#34;0.0535130000&#34;, &#34;0.1678500000&#34;, &#34;-0.0729150000&#34;, &#34;-0.0250250000&#34;, &#34;-0.0304100000&#34;, &#34;0.1003700000&#34;, &#34;-0.0847070000&#34;, &#34;-0.1525100000&#34;, &#34;-0.0455380000&#34;, &#34;-0.0767320000&#34;, &#34;-0.1807600000&#34;, &#34;0.0195180000&#34;, &#34;-0.2908300000&#34;, &#34;-0.1805300000&#34;, &#34;-0.0532130000&#34;, &#34;0.0342540000&#34;, &#34;0.2854300000&#34;, &#34;0.1992200000&#34;, &#34;0.2406300000&#34;, &#34;-0.0177200000&#34;, &#34;-0.0176050000&#34;, &#34;0.2447400000&#34;, &#34;-0.0109690000&#34;, &#34;0.1430600000&#34;, &#34;0.0639200000&#34;, &#34;0.0740190000&#34;, &#34;-0.1269800000&#34;, &#34;-0.0677130000&#34;, &#34;0.0295590000&#34;, &#34;0.0251710000&#34;, &#34;-0.2451000000&#34;, &#34;-0.0466250000&#34;, &#34;0.1457600000&#34;, &#34;0.1901500000&#34;, &#34;0.2264700000&#34;, &#34;0.1861200000&#34;, &#34;0.0878830000&#34;, &#34;0.0278500000&#34;, &#34;0.2847700000&#34;, &#34;-0.0500630000&#34;, &#34;0.1608700000&#34;, &#34;-0.0434980000&#34;, &#34;0.0756410000&#34;, &#34;0.4027000000&#34;, &#34;-0.0384560000&#34;, &#34;0.1930400000&#34;, &#34;0.0637230000&#34;, &#34;-0.3561900000&#34;, &#34;0.1758700000&#34;, &#34;0.2216500000&#34;, &#34;0.0756050000&#34;, &#34;-0.0550850000&#34;, &#34;-0.0307070000&#34;, &#34;0.0883560000&#34;, &#34;-0.0159830000&#34;, &#34;-0.2573500000&#34;], [&#34;-0.1597500000&#34;, &#34;-0.1194700000&#34;, &#34;0.1206000000&#34;, &#34;-0.0586310000&#34;, &#34;0.0045518000&#34;, &#34;0.1651800000&#34;, &#34;0.0574410000&#34;, &#34;-0.1168400000&#34;, &#34;-0.0418270000&#34;, &#34;0.1201700000&#34;, &#34;0.1386900000&#34;, &#34;-0.1617900000&#34;, &#34;0.0125150000&#34;, &#34;-0.1079400000&#34;, &#34;-0.0967700000&#34;, &#34;-0.1275900000&#34;, &#34;-0.0109600000&#34;, &#34;0.0291510000&#34;, &#34;-0.0457370000&#34;, &#34;0.1919200000&#34;, &#34;-0.0029964000&#34;, &#34;0.1302900000&#34;, &#34;-0.1860300000&#34;, &#34;-0.2492000000&#34;, &#34;-0.0215030000&#34;, &#34;0.0389760000&#34;, &#34;0.0620910000&#34;, &#34;0.1815400000&#34;, &#34;0.0269740000&#34;, &#34;-0.0415060000&#34;, &#34;0.0685610000&#34;, &#34;0.0431210000&#34;, &#34;-0.1334000000&#34;, &#34;0.1992700000&#34;, &#34;-0.0827060000&#34;, &#34;-0.2060000000&#34;, &#34;-0.0110170000&#34;, &#34;-0.0153460000&#34;, &#34;0.0357090000&#34;, &#34;-0.0914670000&#34;, &#34;-0.0154540000&#34;, &#34;-0.1300200000&#34;, &#34;0.0134620000&#34;, &#34;-0.0747070000&#34;, &#34;0.1367200000&#34;, &#34;0.1145900000&#34;, &#34;-0.0004246400&#34;, &#34;0.0876710000&#34;, &#34;-0.0415940000&#34;, &#34;-0.2623600000&#34;, &#34;0.1172700000&#34;, &#34;-0.0325420000&#34;, &#34;0.1532700000&#34;, &#34;0.0840430000&#34;, &#34;-0.1532300000&#34;, &#34;0.1215100000&#34;, &#34;-0.0390980000&#34;, &#34;0.2143100000&#34;, &#34;-0.1707800000&#34;, &#34;0.0645370000&#34;, &#34;-0.0107080000&#34;, &#34;-0.2263500000&#34;, &#34;0.1976400000&#34;, &#34;-0.0792570000&#34;, &#34;-0.1739900000&#34;, &#34;-0.0743980000&#34;, &#34;-0.3009200000&#34;, &#34;-0.0766730000&#34;, &#34;0.1579800000&#34;, &#34;-0.0461830000&#34;, &#34;-0.0098803000&#34;, &#34;-0.1065000000&#34;, &#34;0.2280500000&#34;, &#34;-0.2408000000&#34;, &#34;0.0836460000&#34;, &#34;0.0782390000&#34;, &#34;0.3040300000&#34;, &#34;0.1921900000&#34;, &#34;0.0015495000&#34;, &#34;0.0924000000&#34;, &#34;0.2875100000&#34;, &#34;-0.0517050000&#34;, &#34;-0.0757220000&#34;, &#34;0.0472960000&#34;, &#34;-0.0550460000&#34;, &#34;0.0087570000&#34;, &#34;-0.1959000000&#34;, &#34;0.1436400000&#34;, &#34;-0.0743430000&#34;, &#34;-0.2349700000&#34;, &#34;0.0419860000&#34;, &#34;-0.0219020000&#34;, &#34;0.4202800000&#34;, &#34;-0.1275300000&#34;, &#34;0.0843030000&#34;, &#34;-0.0607250000&#34;, &#34;-0.0227560000&#34;, &#34;-0.0252230000&#34;, &#34;-0.1021300000&#34;, &#34;0.1290200000&#34;, &#34;0.0817980000&#34;, &#34;-0.0921100000&#34;, &#34;0.1935800000&#34;, &#34;0.1562200000&#34;, &#34;-0.0684930000&#34;, &#34;-0.1778800000&#34;, &#34;0.0110350000&#34;, &#34;0.0802360000&#34;, &#34;0.0198540000&#34;, &#34;0.0012992000&#34;, &#34;0.0332260000&#34;, &#34;0.0603570000&#34;, &#34;0.0045871000&#34;, &#34;-0.1168300000&#34;, &#34;-0.0023224000&#34;, &#34;-0.2202600000&#34;, &#34;0.2224100000&#34;, &#34;0.1059700000&#34;, &#34;-0.1074200000&#34;, &#34;0.2180400000&#34;, &#34;0.2407900000&#34;, &#34;0.1862700000&#34;, &#34;0.0587230000&#34;, &#34;0.3724000000&#34;, &#34;0.0586390000&#34;, &#34;0.1055600000&#34;, &#34;0.2468900000&#34;, &#34;0.3110700000&#34;, &#34;-0.0125390000&#34;, &#34;0.2088600000&#34;, &#34;0.0551650000&#34;, &#34;0.0844530000&#34;, &#34;-0.0449190000&#34;, &#34;0.0254860000&#34;, &#34;-0.1053300000&#34;, &#34;-0.1342300000&#34;, &#34;-0.0506190000&#34;, &#34;0.0748310000&#34;, &#34;0.0018074000&#34;, &#34;-0.0259520000&#34;, &#34;-0.0250490000&#34;, &#34;-0.0902310000&#34;, &#34;0.1810600000&#34;, &#34;0.0095015000&#34;, &#34;0.0883090000&#34;, &#34;0.1277100000&#34;, &#34;-0.0249920000&#34;, &#34;0.0124670000&#34;, &#34;-0.0730790000&#34;, &#34;-0.0306170000&#34;, &#34;0.0771760000&#34;, &#34;-0.2062700000&#34;, &#34;0.0168790000&#34;, &#34;-0.1694000000&#34;, &#34;-0.0982330000&#34;, &#34;0.0319440000&#34;, &#34;0.1321900000&#34;, &#34;-0.0246180000&#34;, &#34;0.3809400000&#34;, &#34;0.0490890000&#34;, &#34;-0.1460100000&#34;, &#34;0.2135400000&#34;, &#34;0.1295100000&#34;, &#34;-0.0123390000&#34;, &#34;0.2074100000&#34;, &#34;0.0846430000&#34;, &#34;0.0634560000&#34;, &#34;0.1395200000&#34;, &#34;-0.0125550000&#34;, &#34;-0.0757660000&#34;, &#34;0.0782540000&#34;, &#34;-0.1459400000&#34;, &#34;-0.1357600000&#34;, &#34;-0.0696200000&#34;, &#34;-0.1481000000&#34;, &#34;0.1095300000&#34;, &#34;0.1311500000&#34;, &#34;0.0912090000&#34;, &#34;0.2220300000&#34;, &#34;0.0241870000&#34;, &#34;0.0944250000&#34;, &#34;0.1066100000&#34;, &#34;-0.1266600000&#34;, &#34;0.1007800000&#34;, &#34;-0.2401300000&#34;, &#34;-0.0868480000&#34;, &#34;0.1612300000&#34;, &#34;-0.1649900000&#34;, &#34;0.1583400000&#34;, &#34;-0.1061300000&#34;, &#34;0.0256160000&#34;, &#34;-0.2481200000&#34;, &#34;0.0641940000&#34;, &#34;0.1494500000&#34;, &#34;-0.1171600000&#34;, &#34;-0.0231960000&#34;, &#34;0.0940800000&#34;, &#34;0.1758000000&#34;, &#34;-0.1441500000&#34;, &#34;0.0091053000&#34;, &#34;-0.0890350000&#34;, &#34;-0.1526900000&#34;, &#34;0.2028700000&#34;, &#34;-0.0486790000&#34;, &#34;0.1099900000&#34;, &#34;-0.1919900000&#34;, &#34;0.0169160000&#34;, &#34;0.1698700000&#34;, &#34;0.1340700000&#34;, &#34;0.1483200000&#34;, &#34;0.2556100000&#34;, &#34;-0.1148100000&#34;, &#34;0.0459760000&#34;, &#34;-0.1045300000&#34;, &#34;0.3047100000&#34;, &#34;-0.1565500000&#34;, &#34;-0.0612180000&#34;, &#34;-0.3080200000&#34;, &#34;-0.0268840000&#34;, &#34;0.1247300000&#34;, &#34;-0.0397910000&#34;, &#34;-0.0412340000&#34;, &#34;-0.2260000000&#34;, &#34;0.1589800000&#34;, &#34;0.0540950000&#34;, &#34;0.0610630000&#34;, &#34;-0.0739540000&#34;, &#34;0.1043000000&#34;, &#34;0.2258500000&#34;, &#34;0.0319390000&#34;, &#34;0.1291900000&#34;, &#34;-0.0964080000&#34;, &#34;0.0081266000&#34;, &#34;-0.1627600000&#34;, &#34;0.0072641000&#34;, &#34;0.0078385000&#34;, &#34;-0.0832850000&#34;, &#34;-0.0519330000&#34;, &#34;0.1072400000&#34;, &#34;-0.0990100000&#34;, &#34;0.0224090000&#34;, &#34;-0.1303900000&#34;, &#34;0.0988350000&#34;, &#34;0.1285800000&#34;, &#34;0.2241000000&#34;, &#34;0.3579100000&#34;, &#34;0.1492700000&#34;, &#34;-0.0027789000&#34;, &#34;-0.0121560000&#34;, &#34;-0.0523360000&#34;, &#34;-0.0280420000&#34;, &#34;-0.1270700000&#34;, &#34;-0.3056300000&#34;, &#34;-0.1310700000&#34;, &#34;-0.0346780000&#34;, &#34;0.0571560000&#34;, &#34;-0.1181700000&#34;, &#34;0.0539260000&#34;, &#34;-0.0309180000&#34;, &#34;-0.0819190000&#34;, &#34;0.0356900000&#34;, &#34;0.2039900000&#34;, &#34;-0.0580470000&#34;, &#34;0.0400650000&#34;, &#34;-0.2662500000&#34;, &#34;-0.1968400000&#34;, &#34;-0.1096200000&#34;, &#34;0.0073118000&#34;, &#34;-0.0426280000&#34;, &#34;-0.3038000000&#34;, &#34;-0.1309400000&#34;, &#34;0.0584870000&#34;, &#34;-0.0224660000&#34;, &#34;-0.0186820000&#34;, &#34;-0.0805460000&#34;, &#34;-0.1308800000&#34;, &#34;0.0833770000&#34;, &#34;0.1824400000&#34;, &#34;-0.0409670000&#34;, &#34;-0.0075252000&#34;, &#34;0.1743600000&#34;, &#34;0.0567890000&#34;, &#34;-0.0822560000&#34;, &#34;0.1022600000&#34;, &#34;0.0556980000&#34;, &#34;-0.1287700000&#34;, &#34;0.1435200000&#34;, &#34;0.0745990000&#34;, &#34;-0.1185500000&#34;, &#34;0.1364300000&#34;, &#34;0.0524580000&#34;, &#34;-0.0794700000&#34;, &#34;0.0478250000&#34;, &#34;0.0403550000&#34;, &#34;0.0064958000&#34;, &#34;-0.0176890000&#34;, &#34;-0.0607240000&#34;, &#34;0.1316800000&#34;, &#34;0.1987800000&#34;, &#34;-0.0295310000&#34;], [&#34;-0.0165320000&#34;, &#34;0.1710700000&#34;, &#34;-0.2611200000&#34;, &#34;0.3131800000&#34;, &#34;-0.0300940000&#34;, &#34;0.0464090000&#34;, &#34;-0.1599200000&#34;, &#34;-0.2636200000&#34;, &#34;0.3855300000&#34;, &#34;-0.0138240000&#34;, &#34;-0.0671340000&#34;, &#34;0.0051643000&#34;, &#34;-0.0134130000&#34;, &#34;0.2662200000&#34;, &#34;-0.0151940000&#34;, &#34;-0.3197300000&#34;, &#34;0.1838200000&#34;, &#34;-0.0234700000&#34;, &#34;0.2055500000&#34;, &#34;0.3097400000&#34;, &#34;-0.0542570000&#34;, &#34;0.0430070000&#34;, &#34;-0.1823400000&#34;, &#34;-0.3464400000&#34;, &#34;-0.0621450000&#34;, &#34;-0.1618300000&#34;, &#34;0.0231650000&#34;, &#34;-0.0907440000&#34;, &#34;-0.1432000000&#34;, &#34;0.0582580000&#34;, &#34;0.1875200000&#34;, &#34;0.2007400000&#34;, &#34;-0.1458300000&#34;, &#34;0.0534900000&#34;, &#34;-0.2232900000&#34;, &#34;-0.0658370000&#34;, &#34;-0.1516500000&#34;, &#34;-0.2026900000&#34;, &#34;0.1110800000&#34;, &#34;0.1248300000&#34;, &#34;0.3305400000&#34;, &#34;0.2732700000&#34;, &#34;0.0115370000&#34;, &#34;-0.3310600000&#34;, &#34;-0.0323800000&#34;, &#34;0.1640300000&#34;, &#34;-0.1057300000&#34;, &#34;-0.0050296000&#34;, &#34;0.1879600000&#34;, &#34;0.0627670000&#34;, &#34;-0.2218200000&#34;, &#34;0.0867750000&#34;, &#34;0.0144030000&#34;, &#34;0.0238900000&#34;, &#34;-0.2108000000&#34;, &#34;-0.0042702000&#34;, &#34;-0.2056200000&#34;, &#34;0.0363660000&#34;, &#34;-0.2174800000&#34;, &#34;0.1515900000&#34;, &#34;-0.2326600000&#34;, &#34;-0.0729230000&#34;, &#34;-0.0047179000&#34;, &#34;0.1584500000&#34;, &#34;-0.0359620000&#34;, &#34;0.2844600000&#34;, &#34;-0.1093700000&#34;, &#34;0.0645970000&#34;, &#34;0.0879210000&#34;, &#34;-0.0965370000&#34;, &#34;0.0725770000&#34;, &#34;0.1149000000&#34;, &#34;0.1410300000&#34;, &#34;-0.2644700000&#34;, &#34;-0.0886060000&#34;, &#34;-0.0104600000&#34;, &#34;0.2195800000&#34;, &#34;0.1105100000&#34;, &#34;-0.3139700000&#34;, &#34;0.1450200000&#34;, &#34;0.0480880000&#34;, &#34;-0.1294200000&#34;, &#34;-0.2285200000&#34;, &#34;-0.0982450000&#34;, &#34;-0.1304500000&#34;, &#34;0.1189500000&#34;, &#34;-0.1380800000&#34;, &#34;0.0120620000&#34;, &#34;0.0972600000&#34;, &#34;0.0412810000&#34;, &#34;0.2265400000&#34;, &#34;-0.0808980000&#34;, &#34;0.0880520000&#34;, &#34;-0.2776700000&#34;, &#34;0.0931530000&#34;, &#34;0.0084290000&#34;, &#34;-0.0882860000&#34;, &#34;0.0092110000&#34;, &#34;-0.1894500000&#34;, &#34;0.1061600000&#34;, &#34;0.0214470000&#34;, &#34;-0.1277200000&#34;, &#34;0.1409800000&#34;, &#34;-0.0396720000&#34;, &#34;0.1994000000&#34;, &#34;-0.1007800000&#34;, &#34;-0.3036000000&#34;, &#34;-0.0269100000&#34;, &#34;0.0540760000&#34;, &#34;-0.0132040000&#34;, &#34;0.0617560000&#34;, &#34;-0.1297600000&#34;, &#34;0.2317000000&#34;, &#34;0.0940240000&#34;, &#34;0.4020700000&#34;, &#34;-0.1462000000&#34;, &#34;0.1619100000&#34;, &#34;-0.1050000000&#34;, &#34;0.1837000000&#34;, &#34;-0.0301660000&#34;, &#34;0.0643160000&#34;, &#34;0.2298600000&#34;, &#34;-0.0838490000&#34;, &#34;0.2339900000&#34;, &#34;-0.0792380000&#34;, &#34;0.2700700000&#34;, &#34;0.2114200000&#34;, &#34;0.2335700000&#34;, &#34;-0.1425800000&#34;, &#34;0.1152100000&#34;, &#34;0.1539200000&#34;, &#34;0.1047000000&#34;, &#34;-0.0947090000&#34;, &#34;0.1386000000&#34;, &#34;-0.1446200000&#34;, &#34;0.0620510000&#34;, &#34;-0.0044305000&#34;, &#34;-0.1285400000&#34;, &#34;0.1382200000&#34;, &#34;-0.0316550000&#34;, &#34;-0.1695100000&#34;, &#34;-0.1367700000&#34;, &#34;0.1313600000&#34;, &#34;-0.2762700000&#34;, &#34;-0.1914000000&#34;, &#34;0.3059000000&#34;, &#34;0.0170790000&#34;, &#34;-0.2680300000&#34;, &#34;-0.3186400000&#34;, &#34;0.0304450000&#34;, &#34;0.3651800000&#34;, &#34;0.0184090000&#34;, &#34;-0.1012100000&#34;, &#34;-0.0467270000&#34;, &#34;-0.0126190000&#34;, &#34;0.0328800000&#34;, &#34;0.0154770000&#34;, &#34;-0.1274800000&#34;, &#34;0.0446920000&#34;, &#34;-0.0402220000&#34;, &#34;-0.0314990000&#34;, &#34;0.1505700000&#34;, &#34;0.0870170000&#34;, &#34;0.0133790000&#34;, &#34;0.2274500000&#34;, &#34;0.3145600000&#34;, &#34;0.1069700000&#34;, &#34;-0.3411300000&#34;, &#34;0.3150900000&#34;, &#34;-0.0411670000&#34;, &#34;-0.1916800000&#34;, &#34;-0.2439000000&#34;, &#34;-0.3271500000&#34;, &#34;-0.1050500000&#34;, &#34;-0.0576140000&#34;, &#34;0.2293500000&#34;, &#34;0.1768800000&#34;, &#34;0.1841800000&#34;, &#34;0.3173300000&#34;, &#34;-0.0790880000&#34;, &#34;0.0327750000&#34;, &#34;-0.2019400000&#34;, &#34;-0.0521350000&#34;, &#34;0.1306500000&#34;, &#34;0.1920100000&#34;, &#34;0.1734000000&#34;, &#34;-0.0450400000&#34;, &#34;-0.1040500000&#34;, &#34;0.3138500000&#34;, &#34;-0.0890620000&#34;, &#34;0.0906790000&#34;, &#34;-0.1320100000&#34;, &#34;0.1034400000&#34;, &#34;0.1291300000&#34;, &#34;-0.2005600000&#34;, &#34;-0.2201400000&#34;, &#34;-0.0510940000&#34;, &#34;0.1094400000&#34;, &#34;-0.3006300000&#34;, &#34;-0.0546590000&#34;, &#34;-0.0038813000&#34;, &#34;0.0434660000&#34;, &#34;-0.0010636000&#34;, &#34;-0.1885100000&#34;, &#34;0.0613900000&#34;, &#34;-0.2651000000&#34;, &#34;-0.1395100000&#34;, &#34;-0.0673480000&#34;, &#34;0.1648100000&#34;, &#34;-0.3510800000&#34;, &#34;0.3366100000&#34;, &#34;0.0811980000&#34;, &#34;-0.1135400000&#34;, &#34;-0.3476100000&#34;, &#34;0.3973400000&#34;, &#34;0.2814700000&#34;, &#34;-0.0305920000&#34;, &#34;-0.4129300000&#34;, &#34;-0.2356500000&#34;, &#34;0.2974600000&#34;, &#34;-0.2045200000&#34;, &#34;-0.0563990000&#34;, &#34;-0.0224850000&#34;, &#34;0.0748530000&#34;, &#34;-0.2839100000&#34;, &#34;0.2283300000&#34;, &#34;-0.1343000000&#34;, &#34;-0.0239020000&#34;, &#34;0.1862900000&#34;, &#34;0.0122100000&#34;, &#34;0.0787960000&#34;, &#34;-0.1795900000&#34;, &#34;0.2287400000&#34;, &#34;0.1065800000&#34;, &#34;-0.1156900000&#34;, &#34;0.1901700000&#34;, &#34;0.0894970000&#34;, &#34;-0.1611900000&#34;, &#34;0.1548800000&#34;, &#34;0.0765240000&#34;, &#34;0.0904400000&#34;, &#34;0.1095200000&#34;, &#34;0.1358200000&#34;, &#34;0.2498300000&#34;, &#34;-0.2086100000&#34;, &#34;0.2076900000&#34;, &#34;0.1985000000&#34;, &#34;-0.1046400000&#34;, &#34;-0.0172640000&#34;, &#34;0.3161100000&#34;, &#34;-0.1890000000&#34;, &#34;-0.1069600000&#34;, &#34;0.0014526000&#34;, &#34;-0.1325600000&#34;, &#34;-0.0744180000&#34;, &#34;0.2159500000&#34;, &#34;-0.1605800000&#34;, &#34;0.1070400000&#34;, &#34;-0.0234520000&#34;, &#34;0.0142380000&#34;, &#34;0.0703660000&#34;, &#34;0.2588800000&#34;, &#34;-0.0766330000&#34;, &#34;-0.0196120000&#34;, &#34;-0.0607880000&#34;, &#34;-0.2178000000&#34;, &#34;-0.3737300000&#34;, &#34;0.1071000000&#34;, &#34;0.2958200000&#34;, &#34;0.0749020000&#34;, &#34;-0.2108300000&#34;, &#34;-0.0646680000&#34;, &#34;0.0895320000&#34;, &#34;0.2278000000&#34;, &#34;-0.0836900000&#34;, &#34;-0.1296900000&#34;, &#34;0.0680520000&#34;, &#34;0.4146100000&#34;, &#34;-0.1122100000&#34;, &#34;-0.1895900000&#34;, &#34;0.3560200000&#34;, &#34;-0.0876930000&#34;, &#34;0.0240680000&#34;, &#34;0.0223130000&#34;, &#34;0.2179200000&#34;, &#34;-0.3211200000&#34;, &#34;0.1606100000&#34;, &#34;0.3766700000&#34;, &#34;-0.2078800000&#34;, &#34;-0.1647900000&#34;, &#34;0.0751510000&#34;, &#34;-0.0041485000&#34;, &#34;0.1091800000&#34;, &#34;0.0995230000&#34;, &#34;0.0720380000&#34;, &#34;-0.0709360000&#34;, &#34;-0.0753820000&#34;, &#34;0.0435620000&#34;, &#34;0.2280000000&#34;, &#34;0.3304800000&#34;], [&#34;0.0513240000&#34;, &#34;-0.0706180000&#34;, &#34;-0.0216120000&#34;, &#34;0.5856600000&#34;, &#34;0.1919200000&#34;, &#34;0.2800500000&#34;, &#34;0.0892610000&#34;, &#34;0.0098064000&#34;, &#34;-0.3134600000&#34;, &#34;-0.0616510000&#34;, &#34;0.3603000000&#34;, &#34;-0.1643700000&#34;, &#34;-0.0322600000&#34;, &#34;-0.2181800000&#34;, &#34;0.3228400000&#34;, &#34;-0.0107670000&#34;, &#34;0.0232250000&#34;, &#34;0.2576400000&#34;, &#34;0.0131400000&#34;, &#34;0.6553600000&#34;, &#34;-0.0747040000&#34;, &#34;-0.5633000000&#34;, &#34;-0.1134500000&#34;, &#34;0.0538770000&#34;, &#34;0.2335800000&#34;, &#34;0.0176880000&#34;, &#34;-0.0304740000&#34;, &#34;-0.1508400000&#34;, &#34;-0.2486100000&#34;, &#34;0.1206400000&#34;, &#34;-0.2654000000&#34;, &#34;0.2544000000&#34;, &#34;-0.3460100000&#34;, &#34;-0.0414720000&#34;, &#34;0.3663200000&#34;, &#34;-0.2086800000&#34;, &#34;0.0339750000&#34;, &#34;-0.1131600000&#34;, &#34;0.3747000000&#34;, &#34;0.1632300000&#34;, &#34;0.7036400000&#34;, &#34;0.0847610000&#34;, &#34;-0.2616400000&#34;, &#34;0.0527830000&#34;, &#34;-0.0889470000&#34;, &#34;0.2709700000&#34;, &#34;0.0937870000&#34;, &#34;0.3125600000&#34;, &#34;0.2093100000&#34;, &#34;-0.1148700000&#34;, &#34;0.1083700000&#34;, &#34;-0.2969900000&#34;, &#34;0.1621800000&#34;, &#34;0.0154810000&#34;, &#34;-0.1120100000&#34;, &#34;0.2092200000&#34;, &#34;0.0704070000&#34;, &#34;0.2809900000&#34;, &#34;-0.0788350000&#34;, &#34;0.0993810000&#34;, &#34;0.2130000000&#34;, &#34;-0.2676100000&#34;, &#34;0.1290000000&#34;, &#34;0.0404300000&#34;, &#34;-0.0245720000&#34;, &#34;0.1703200000&#34;, &#34;-0.0496790000&#34;, &#34;-0.5684900000&#34;, &#34;-0.0088404000&#34;, &#34;0.1870300000&#34;, &#34;0.0335670000&#34;, &#34;0.0234760000&#34;, &#34;0.1444200000&#34;, &#34;-0.2524900000&#34;, &#34;0.0129050000&#34;, &#34;-0.0846210000&#34;, &#34;0.3420200000&#34;, &#34;0.0260740000&#34;, &#34;-0.5733900000&#34;, &#34;-0.0584450000&#34;, &#34;0.0260860000&#34;, &#34;-0.0647970000&#34;, &#34;0.0757690000&#34;, &#34;0.2953000000&#34;, &#34;-0.3896800000&#34;, &#34;0.0375920000&#34;, &#34;-0.0896950000&#34;, &#34;-0.3790100000&#34;, &#34;0.2678800000&#34;, &#34;-0.5073400000&#34;, &#34;0.0343320000&#34;, &#34;-0.1170100000&#34;, &#34;0.2985100000&#34;, &#34;-0.2539900000&#34;, &#34;0.0146440000&#34;, &#34;-0.0041997000&#34;, &#34;0.1566400000&#34;, &#34;-0.1199500000&#34;, &#34;-0.0019714000&#34;, &#34;0.0973370000&#34;, &#34;0.0435290000&#34;, &#34;0.0090645000&#34;, &#34;-0.1124200000&#34;, &#34;-0.0575640000&#34;, &#34;-0.2087200000&#34;, &#34;0.2946300000&#34;, &#34;0.1898300000&#34;, &#34;0.4180600000&#34;, &#34;0.2139800000&#34;, &#34;-0.0914810000&#34;, &#34;-0.1177200000&#34;, &#34;0.0085325000&#34;, &#34;-0.0028863000&#34;, &#34;0.0629740000&#34;, &#34;0.2071000000&#34;, &#34;-0.5297100000&#34;, &#34;-0.0178240000&#34;, &#34;0.1106400000&#34;, &#34;0.1349100000&#34;, &#34;0.0285410000&#34;, &#34;-0.0795620000&#34;, &#34;0.0495980000&#34;, &#34;-0.2556500000&#34;, &#34;0.0645160000&#34;, &#34;-0.0310300000&#34;, &#34;0.2444500000&#34;, &#34;0.1085700000&#34;, &#34;0.4715200000&#34;, &#34;0.0416410000&#34;, &#34;-0.1023000000&#34;, &#34;-0.1178900000&#34;, &#34;-0.0843260000&#34;, &#34;0.0187060000&#34;, &#34;-0.0590420000&#34;, &#34;-0.0958200000&#34;, &#34;0.1088600000&#34;, &#34;0.0987560000&#34;, &#34;-0.1241400000&#34;, &#34;-0.0807060000&#34;, &#34;0.2369000000&#34;, &#34;-0.1612000000&#34;, &#34;0.2176800000&#34;, &#34;0.4958500000&#34;, &#34;-0.0116190000&#34;, &#34;0.0097915000&#34;, &#34;0.6407700000&#34;, &#34;-0.1111500000&#34;, &#34;-0.0939950000&#34;, &#34;-0.1427100000&#34;, &#34;0.1573400000&#34;, &#34;0.1143800000&#34;, &#34;-0.1520900000&#34;, &#34;-0.5125000000&#34;, &#34;0.1470700000&#34;, &#34;-0.2382900000&#34;, &#34;0.1973100000&#34;, &#34;-0.4134800000&#34;, &#34;0.0188450000&#34;, &#34;0.1175400000&#34;, &#34;-0.1826600000&#34;, &#34;0.0221760000&#34;, &#34;-0.0663910000&#34;, &#34;-0.1203300000&#34;, &#34;0.0800400000&#34;, &#34;-0.2650600000&#34;, &#34;0.1684900000&#34;, &#34;0.1821600000&#34;, &#34;0.1750000000&#34;, &#34;-0.2825200000&#34;, &#34;-0.1813900000&#34;, &#34;0.1902200000&#34;, &#34;-0.3249500000&#34;, &#34;-0.0502280000&#34;, &#34;0.0892980000&#34;, &#34;-0.2048100000&#34;, &#34;-0.1448400000&#34;, &#34;0.0368750000&#34;, &#34;0.0495450000&#34;, &#34;-0.1724000000&#34;, &#34;0.1092700000&#34;, &#34;0.3847700000&#34;, &#34;-0.2678900000&#34;, &#34;-0.0853380000&#34;, &#34;-0.2645000000&#34;, &#34;0.0387650000&#34;, &#34;0.2556600000&#34;, &#34;0.0359980000&#34;, &#34;0.3837500000&#34;, &#34;-0.0998950000&#34;, &#34;-0.1705500000&#34;, &#34;0.2840000000&#34;, &#34;-0.0212870000&#34;, &#34;0.2804200000&#34;, &#34;0.0322540000&#34;, &#34;-0.2825500000&#34;, &#34;0.0654640000&#34;, &#34;-0.1203800000&#34;, &#34;-0.0149070000&#34;, &#34;-0.0006525500&#34;, &#34;0.0689850000&#34;, &#34;0.3073000000&#34;, &#34;-0.0346560000&#34;, &#34;0.3533500000&#34;, &#34;-0.0960390000&#34;, &#34;0.3632900000&#34;, &#34;-0.1311700000&#34;, &#34;-0.0607550000&#34;, &#34;-0.0942790000&#34;, &#34;0.3221300000&#34;, &#34;-0.0789180000&#34;, &#34;0.4698700000&#34;, &#34;-0.3843200000&#34;, &#34;-0.2243300000&#34;, &#34;-0.1883900000&#34;, &#34;0.1916100000&#34;, &#34;0.1373600000&#34;, &#34;-0.2309900000&#34;, &#34;-0.4350000000&#34;, &#34;-0.3800400000&#34;, &#34;-0.1009300000&#34;, &#34;-0.1491000000&#34;, &#34;-0.2365500000&#34;, &#34;-0.2094400000&#34;, &#34;0.3091000000&#34;, &#34;-0.1917300000&#34;, &#34;0.3218600000&#34;, &#34;0.0055599000&#34;, &#34;-0.1206200000&#34;, &#34;-0.1460500000&#34;, &#34;-0.2416900000&#34;, &#34;-0.0649800000&#34;, &#34;0.2606000000&#34;, &#34;-0.0654100000&#34;, &#34;0.1320700000&#34;, &#34;-0.7516100000&#34;, &#34;-0.3307700000&#34;, &#34;0.3523600000&#34;, &#34;-0.0248020000&#34;, &#34;0.1542700000&#34;, &#34;0.4268500000&#34;, &#34;0.2129000000&#34;, &#34;0.3395900000&#34;, &#34;0.1042900000&#34;, &#34;0.2427500000&#34;, &#34;-0.1701100000&#34;, &#34;0.1601900000&#34;, &#34;0.2847300000&#34;, &#34;-0.0765880000&#34;, &#34;0.2018200000&#34;, &#34;0.2639700000&#34;, &#34;0.0782000000&#34;, &#34;-0.3502300000&#34;, &#34;-0.3503500000&#34;, &#34;-0.1307800000&#34;, &#34;-0.0330730000&#34;, &#34;0.2162000000&#34;, &#34;-0.0010383000&#34;, &#34;-0.3543800000&#34;, &#34;-0.0803670000&#34;, &#34;-0.0958300000&#34;, &#34;-0.0802800000&#34;, &#34;0.3350300000&#34;, &#34;0.2789600000&#34;, &#34;-0.0995590000&#34;, &#34;-0.0920350000&#34;, &#34;0.1171500000&#34;, &#34;0.0803270000&#34;, &#34;0.0449470000&#34;, &#34;-0.0167250000&#34;, &#34;0.1094200000&#34;, &#34;-0.2763900000&#34;, &#34;-0.0384650000&#34;, &#34;0.1456100000&#34;, &#34;-0.1062600000&#34;, &#34;-0.1602400000&#34;, &#34;-0.0417930000&#34;, &#34;-0.0073398000&#34;, &#34;0.3471000000&#34;, &#34;0.0676280000&#34;, &#34;-0.0707770000&#34;, &#34;-0.0941370000&#34;, &#34;0.2950600000&#34;, &#34;-0.0639280000&#34;, &#34;0.0929010000&#34;, &#34;0.2258700000&#34;, &#34;-0.0332070000&#34;, &#34;0.0270170000&#34;, &#34;0.2455600000&#34;, &#34;-0.0296220000&#34;, &#34;0.0488670000&#34;, &#34;0.2562300000&#34;, &#34;-0.1718800000&#34;, &#34;0.2008900000&#34;, &#34;0.2300800000&#34;, &#34;-0.1056900000&#34;, &#34;0.0341030000&#34;, &#34;-0.5088700000&#34;, &#34;0.0771760000&#34;, &#34;0.0981730000&#34;, &#34;-0.2371300000&#34;], [&#34;-0.1330000000&#34;, &#34;-0.1230500000&#34;, &#34;0.0654240000&#34;, &#34;0.5002100000&#34;, &#34;0.1878300000&#34;, &#34;0.0762630000&#34;, &#34;-0.2700200000&#34;, &#34;0.1340500000&#34;, &#34;-0.0301880000&#34;, &#34;0.2475800000&#34;, &#34;0.2231800000&#34;, &#34;-0.0309880000&#34;, &#34;0.0095239000&#34;, &#34;-0.0302910000&#34;, &#34;0.3365300000&#34;, &#34;-0.0819380000&#34;, &#34;-0.1014500000&#34;, &#34;0.0432690000&#34;, &#34;-0.1446000000&#34;, &#34;0.3872900000&#34;, &#34;0.1021000000&#34;, &#34;0.1189900000&#34;, &#34;-0.3871300000&#34;, &#34;0.0372040000&#34;, &#34;-0.0557930000&#34;, &#34;0.1880900000&#34;, &#34;0.1961200000&#34;, &#34;0.0721930000&#34;, &#34;-0.2545900000&#34;, &#34;0.0810470000&#34;, &#34;-0.1890300000&#34;, &#34;0.2529600000&#34;, &#34;-0.2818200000&#34;, &#34;0.0023962000&#34;, &#34;0.1639000000&#34;, &#34;-0.2247500000&#34;, &#34;-0.1622400000&#34;, &#34;-0.0056278000&#34;, &#34;0.2569500000&#34;, &#34;-0.1198800000&#34;, &#34;0.2859200000&#34;, &#34;0.0456000000&#34;, &#34;-0.2220400000&#34;, &#34;0.1559000000&#34;, &#34;0.1067800000&#34;, &#34;0.1666400000&#34;, &#34;-0.2087300000&#34;, &#34;0.0633790000&#34;, &#34;-0.0412220000&#34;, &#34;-0.1158200000&#34;, &#34;0.1115500000&#34;, &#34;-0.0557060000&#34;, &#34;0.1310700000&#34;, &#34;0.2168700000&#34;, &#34;-0.3144800000&#34;, &#34;0.2510100000&#34;, &#34;0.0207120000&#34;, &#34;0.3685400000&#34;, &#34;-0.2311400000&#34;, &#34;0.1430400000&#34;, &#34;0.2466500000&#34;, &#34;-0.2332600000&#34;, &#34;0.0571900000&#34;, &#34;-0.0043860000&#34;, &#34;-0.0813010000&#34;, &#34;-0.0132580000&#34;, &#34;0.2274700000&#34;, &#34;0.0333920000&#34;, &#34;0.1033800000&#34;, &#34;0.0598810000&#34;, &#34;-0.1073500000&#34;, &#34;-0.1365400000&#34;, &#34;0.1125400000&#34;, &#34;-0.0988680000&#34;, &#34;-0.0695260000&#34;, &#34;0.0383090000&#34;, &#34;0.1010900000&#34;, &#34;0.1770200000&#34;, &#34;0.1813900000&#34;, &#34;-0.0801690000&#34;, &#34;0.0391810000&#34;, &#34;-0.1440200000&#34;, &#34;-0.0917060000&#34;, &#34;0.0243660000&#34;, &#34;-0.3997300000&#34;, &#34;-0.1256800000&#34;, &#34;0.0566750000&#34;, &#34;-0.2665900000&#34;, &#34;-0.0073045000&#34;, &#34;-0.0512830000&#34;, &#34;-0.1976700000&#34;, &#34;0.0553250000&#34;, &#34;0.3101300000&#34;, &#34;0.3243800000&#34;, &#34;0.0448760000&#34;, &#34;0.0727180000&#34;, &#34;0.0532680000&#34;, &#34;-0.0671240000&#34;, &#34;-0.0368180000&#34;, &#34;0.2518600000&#34;, &#34;0.0771260000&#34;, &#34;-0.1968400000&#34;, &#34;-0.0358860000&#34;, &#34;0.1611700000&#34;, &#34;-0.0525660000&#34;, &#34;0.2913900000&#34;, &#34;-0.1062300000&#34;, &#34;0.1228600000&#34;, &#34;0.1760900000&#34;, &#34;0.1388100000&#34;, &#34;0.0378150000&#34;, &#34;0.3313000000&#34;, &#34;-0.0143720000&#34;, &#34;-0.0945050000&#34;, &#34;-0.0169190000&#34;, &#34;-0.2014500000&#34;, &#34;-0.1476400000&#34;, &#34;0.0538020000&#34;, &#34;0.0506930000&#34;, &#34;-0.0860970000&#34;, &#34;0.0839150000&#34;, &#34;0.2542600000&#34;, &#34;0.1766300000&#34;, &#34;0.2031000000&#34;, &#34;0.0682790000&#34;, &#34;-0.0075550000&#34;, &#34;0.1232600000&#34;, &#34;0.3478500000&#34;, &#34;0.3979500000&#34;, &#34;-0.0663870000&#34;, &#34;-0.1576400000&#34;, &#34;-0.1517600000&#34;, &#34;-0.1482700000&#34;, &#34;-0.1665300000&#34;, &#34;-0.2751600000&#34;, &#34;-0.0498440000&#34;, &#34;-0.1192200000&#34;, &#34;0.0160070000&#34;, &#34;0.0845950000&#34;, &#34;0.1670200000&#34;, &#34;0.0034598000&#34;, &#34;0.0776680000&#34;, &#34;0.2430300000&#34;, &#34;-0.1834800000&#34;, &#34;0.2450600000&#34;, &#34;0.3285500000&#34;, &#34;-0.1578500000&#34;, &#34;-0.0379420000&#34;, &#34;0.2383200000&#34;, &#34;0.1035800000&#34;, &#34;-0.0600190000&#34;, &#34;0.1622300000&#34;, &#34;-0.2943400000&#34;, &#34;0.0151640000&#34;, &#34;-0.0838050000&#34;, &#34;0.1340800000&#34;, &#34;-0.0835450000&#34;, &#34;-0.0512260000&#34;, &#34;0.0106080000&#34;, &#34;-0.0535620000&#34;, &#34;-0.2310200000&#34;, &#34;0.0384450000&#34;, &#34;-0.0385240000&#34;, &#34;0.1454600000&#34;, &#34;-0.0089040000&#34;, &#34;-0.0828960000&#34;, &#34;0.0380030000&#34;, &#34;-0.1197400000&#34;, &#34;-0.0201110000&#34;, &#34;-0.1256200000&#34;, &#34;0.0312790000&#34;, &#34;-0.3003500000&#34;, &#34;-0.2645600000&#34;, &#34;-0.0769120000&#34;, &#34;-0.2510900000&#34;, &#34;0.1448800000&#34;, &#34;-0.2009200000&#34;, &#34;0.2136200000&#34;, &#34;-0.3350700000&#34;, &#34;-0.3743400000&#34;, &#34;0.0916680000&#34;, &#34;-0.1699600000&#34;, &#34;-0.1231500000&#34;, &#34;-0.1837100000&#34;, &#34;0.0568870000&#34;, &#34;0.0411630000&#34;, &#34;-0.0808080000&#34;, &#34;0.0754920000&#34;, &#34;0.1289200000&#34;, &#34;-0.2601000000&#34;, &#34;0.3371800000&#34;, &#34;-0.1970400000&#34;, &#34;0.2350400000&#34;, &#34;0.0662160000&#34;, &#34;-0.1401000000&#34;, &#34;0.0089649000&#34;, &#34;-0.2438000000&#34;, &#34;0.3026500000&#34;, &#34;-0.0326670000&#34;, &#34;-0.1689700000&#34;, &#34;0.0310410000&#34;, &#34;-0.1047400000&#34;, &#34;-0.0372180000&#34;, &#34;0.0252550000&#34;, &#34;0.1253600000&#34;, &#34;-0.3567600000&#34;, &#34;-0.1074500000&#34;, &#34;0.0542280000&#34;, &#34;-0.1310300000&#34;, &#34;-0.0520740000&#34;, &#34;0.4642300000&#34;, &#34;-0.2344200000&#34;, &#34;-0.2835800000&#34;, &#34;-0.1800700000&#34;, &#34;0.1348400000&#34;, &#34;-0.1042700000&#34;, &#34;0.0451520000&#34;, &#34;-0.5176100000&#34;, &#34;-0.1776800000&#34;, &#34;0.0315960000&#34;, &#34;-0.1157300000&#34;, &#34;-0.1056100000&#34;, &#34;0.0301210000&#34;, &#34;0.3722900000&#34;, &#34;-0.2012800000&#34;, &#34;0.0172310000&#34;, &#34;-0.1889200000&#34;, &#34;0.1339200000&#34;, &#34;-0.0736580000&#34;, &#34;-0.0168030000&#34;, &#34;-0.3517800000&#34;, &#34;0.2472100000&#34;, &#34;-0.0885820000&#34;, &#34;0.0752250000&#34;, &#34;-0.1495000000&#34;, &#34;-0.0373050000&#34;, &#34;0.2970200000&#34;, &#34;0.3019300000&#34;, &#34;0.0611570000&#34;, &#34;0.0621070000&#34;, &#34;0.4233700000&#34;, &#34;0.0415200000&#34;, &#34;-0.1969800000&#34;, &#34;0.5872500000&#34;, &#34;0.1964900000&#34;, &#34;0.3078100000&#34;, &#34;-0.1176000000&#34;, &#34;0.0108470000&#34;, &#34;0.1316000000&#34;, &#34;0.1806600000&#34;, &#34;0.0603290000&#34;, &#34;0.0718290000&#34;, &#34;-0.1875600000&#34;, &#34;-0.2057400000&#34;, &#34;0.0515100000&#34;, &#34;0.4237400000&#34;, &#34;-0.1491000000&#34;, &#34;-0.1581500000&#34;, &#34;-0.1430600000&#34;, &#34;-0.0060690000&#34;, &#34;-0.0182760000&#34;, &#34;0.2150100000&#34;, &#34;0.2668500000&#34;, &#34;-0.1726200000&#34;, &#34;-0.2509100000&#34;, &#34;-0.2382200000&#34;, &#34;0.0631350000&#34;, &#34;0.0398520000&#34;, &#34;-0.2362200000&#34;, &#34;0.1117400000&#34;, &#34;-0.3647300000&#34;, &#34;-0.2024800000&#34;, &#34;0.3980300000&#34;, &#34;0.1648000000&#34;, &#34;-0.2356300000&#34;, &#34;-0.3245400000&#34;, &#34;0.0714630000&#34;, &#34;0.5656300000&#34;, &#34;-0.0298980000&#34;, &#34;-0.0705180000&#34;, &#34;0.1893500000&#34;, &#34;-0.1499200000&#34;, &#34;-0.0436140000&#34;, &#34;-0.0066567000&#34;, &#34;0.2131200000&#34;, &#34;0.1828500000&#34;, &#34;0.0206320000&#34;, &#34;0.0815120000&#34;, &#34;-0.0083290000&#34;, &#34;0.2550400000&#34;, &#34;0.1868700000&#34;, &#34;-0.1163700000&#34;, &#34;0.0272600000&#34;, &#34;-0.0971270000&#34;, &#34;0.0247740000&#34;, &#34;-0.0573220000&#34;, &#34;-0.1964500000&#34;, &#34;-0.0504570000&#34;, &#34;-0.0743630000&#34;, &#34;-0.1283500000&#34;], [&#34;0.0851800000&#34;, &#34;-0.0200700000&#34;, &#34;0.2141800000&#34;, &#34;0.2401300000&#34;, &#34;-0.1031900000&#34;, &#34;0.1685900000&#34;, &#34;0.1346500000&#34;, &#34;-0.1485100000&#34;, &#34;0.0937640000&#34;, &#34;0.4982400000&#34;, &#34;0.1612300000&#34;, &#34;-0.1684300000&#34;, &#34;0.1391500000&#34;, &#34;-0.0679850000&#34;, &#34;0.0001754800&#34;, &#34;-0.1974800000&#34;, &#34;0.1750700000&#34;, &#34;0.1355900000&#34;, &#34;0.0657920000&#34;, &#34;0.1310200000&#34;, &#34;-0.1790300000&#34;, &#34;-0.1134600000&#34;, &#34;-0.1238100000&#34;, &#34;-0.1578600000&#34;, &#34;0.1249200000&#34;, &#34;0.1280100000&#34;, &#34;0.1193200000&#34;, &#34;0.1261300000&#34;, &#34;0.0035274000&#34;, &#34;0.0521450000&#34;, &#34;-0.3986400000&#34;, &#34;0.3450500000&#34;, &#34;-0.5077400000&#34;, &#34;0.1172800000&#34;, &#34;-0.3182800000&#34;, &#34;-0.1933900000&#34;, &#34;0.0136420000&#34;, &#34;-0.0165740000&#34;, &#34;-0.1712100000&#34;, &#34;0.1095500000&#34;, &#34;0.1430500000&#34;, &#34;-0.1762400000&#34;, &#34;-0.0783430000&#34;, &#34;0.0913900000&#34;, &#34;0.3295400000&#34;, &#34;0.1202400000&#34;, &#34;0.1950600000&#34;, &#34;0.0386110000&#34;, &#34;-0.1520600000&#34;, &#34;-0.2076400000&#34;, &#34;-0.1730700000&#34;, &#34;-0.4215400000&#34;, &#34;0.0623800000&#34;, &#34;-0.1658300000&#34;, &#34;-0.0227580000&#34;, &#34;-0.0628160000&#34;, &#34;0.0971100000&#34;, &#34;-0.0493320000&#34;, &#34;-0.0646270000&#34;, &#34;0.1649700000&#34;, &#34;-0.2716200000&#34;, &#34;-0.0864980000&#34;, &#34;0.5714800000&#34;, &#34;0.0000320680&#34;, &#34;0.0071824000&#34;, &#34;-0.4222700000&#34;, &#34;0.2138000000&#34;, &#34;0.2210000000&#34;, &#34;0.0498440000&#34;, &#34;0.3391500000&#34;, &#34;-0.0719490000&#34;, &#34;0.0577400000&#34;, &#34;-0.0322730000&#34;, &#34;-0.2662000000&#34;, &#34;-0.1071800000&#34;, &#34;0.0652310000&#34;, &#34;0.0326830000&#34;, &#34;0.3165200000&#34;, &#34;-0.1916300000&#34;, &#34;-0.1756200000&#34;, &#34;0.0544100000&#34;, &#34;0.4661100000&#34;, &#34;-0.0094752000&#34;, &#34;-0.0645490000&#34;, &#34;0.1156200000&#34;, &#34;0.0370780000&#34;, &#34;0.1921800000&#34;, &#34;0.2274000000&#34;, &#34;-0.3620100000&#34;, &#34;-0.2009800000&#34;, &#34;0.1897100000&#34;, &#34;0.0505870000&#34;, &#34;0.1515400000&#34;, &#34;-0.2923900000&#34;, &#34;0.0855460000&#34;, &#34;0.0821190000&#34;, &#34;0.3057500000&#34;, &#34;-0.1839200000&#34;, &#34;0.1427500000&#34;, &#34;0.2597300000&#34;, &#34;-0.0573870000&#34;, &#34;-0.0809190000&#34;, &#34;0.0080007000&#34;, &#34;-0.4582200000&#34;, &#34;-0.3904500000&#34;, &#34;-0.0856770000&#34;, &#34;-0.0902180000&#34;, &#34;0.4028800000&#34;, &#34;0.0243540000&#34;, &#34;0.0220950000&#34;, &#34;-0.0229840000&#34;, &#34;0.0065696000&#34;, &#34;0.0370420000&#34;, &#34;-0.0625060000&#34;, &#34;-0.1645500000&#34;, &#34;-0.1022600000&#34;, &#34;0.1809200000&#34;, &#34;-0.0560690000&#34;, &#34;-0.3262800000&#34;, &#34;0.1441200000&#34;, &#34;0.1364300000&#34;, &#34;-0.0427510000&#34;, &#34;0.0834990000&#34;, &#34;-0.0559940000&#34;, &#34;-0.0408320000&#34;, &#34;0.0451580000&#34;, &#34;0.0601930000&#34;, &#34;0.0182640000&#34;, &#34;0.0222160000&#34;, &#34;0.1123300000&#34;, &#34;0.2150200000&#34;, &#34;0.1451800000&#34;, &#34;-0.2200500000&#34;, &#34;-0.1028100000&#34;, &#34;0.1120400000&#34;, &#34;-0.0683040000&#34;, &#34;-0.1594100000&#34;, &#34;0.1758900000&#34;, &#34;0.5128100000&#34;, &#34;0.0957280000&#34;, &#34;-0.0657770000&#34;, &#34;0.0451430000&#34;, &#34;0.1306800000&#34;, &#34;0.1293900000&#34;, &#34;-0.1016700000&#34;, &#34;-0.1396700000&#34;, &#34;0.0801730000&#34;, &#34;-0.4389300000&#34;, &#34;0.2679300000&#34;, &#34;-0.0700760000&#34;, &#34;0.3494700000&#34;, &#34;-0.2701300000&#34;, &#34;0.1588500000&#34;, &#34;0.0181890000&#34;, &#34;-0.0337430000&#34;, &#34;-0.0422830000&#34;, &#34;-0.2267500000&#34;, &#34;0.1944400000&#34;, &#34;0.0013730000&#34;, &#34;0.1136100000&#34;, &#34;-0.0624300000&#34;, &#34;0.0578810000&#34;, &#34;-0.0960000000&#34;, &#34;0.0473200000&#34;, &#34;-0.1566800000&#34;, &#34;-0.0202400000&#34;, &#34;0.0320620000&#34;, &#34;-0.0726230000&#34;, &#34;0.0689580000&#34;, &#34;0.1297000000&#34;, &#34;-0.2781000000&#34;, &#34;-0.3522000000&#34;, &#34;-0.2316600000&#34;, &#34;-0.0691740000&#34;, &#34;-0.1931800000&#34;, &#34;0.4989900000&#34;, &#34;0.0502420000&#34;, &#34;0.0172720000&#34;, &#34;-0.2182400000&#34;, &#34;-0.2038900000&#34;, &#34;0.2229000000&#34;, &#34;-0.1098600000&#34;, &#34;0.0989670000&#34;, &#34;0.2818500000&#34;, &#34;0.1975100000&#34;, &#34;0.0632280000&#34;, &#34;0.1905200000&#34;, &#34;-0.5237800000&#34;, &#34;0.3318100000&#34;, &#34;-0.0095121000&#34;, &#34;0.1064300000&#34;, &#34;-0.3345400000&#34;, &#34;-0.2359500000&#34;, &#34;0.2270900000&#34;, &#34;-0.2105800000&#34;, &#34;-0.0589760000&#34;, &#34;-0.1400700000&#34;, &#34;0.0427870000&#34;, &#34;-0.0528680000&#34;, &#34;-0.1844700000&#34;, &#34;0.1337400000&#34;, &#34;0.1705900000&#34;, &#34;0.0193090000&#34;, &#34;0.0379540000&#34;, &#34;0.0046226000&#34;, &#34;-0.1347800000&#34;, &#34;-0.0976870000&#34;, &#34;-0.2025300000&#34;, &#34;0.0447970000&#34;, &#34;0.0356180000&#34;, &#34;0.3508800000&#34;, &#34;0.1167700000&#34;, &#34;0.1158100000&#34;, &#34;-0.4729400000&#34;, &#34;0.2493100000&#34;, &#34;-0.1033000000&#34;, &#34;0.0524140000&#34;, &#34;-0.3493600000&#34;, &#34;-0.1720000000&#34;, &#34;0.3523500000&#34;, &#34;0.0313910000&#34;, &#34;-0.0075628000&#34;, &#34;-0.3449000000&#34;, &#34;0.1398400000&#34;, &#34;-0.0975960000&#34;, &#34;0.3973700000&#34;, &#34;-0.4213500000&#34;, &#34;-0.0734910000&#34;, &#34;0.0699600000&#34;, &#34;0.0249500000&#34;, &#34;-0.1186300000&#34;, &#34;0.0692330000&#34;, &#34;0.0318490000&#34;, &#34;-0.1868100000&#34;, &#34;0.0119780000&#34;, &#34;-0.1418200000&#34;, &#34;-0.0832710000&#34;, &#34;0.1002500000&#34;, &#34;0.2276000000&#34;, &#34;-0.2265800000&#34;, &#34;0.1252800000&#34;, &#34;-0.0507510000&#34;, &#34;0.0610840000&#34;, &#34;0.0515400000&#34;, &#34;-0.0228720000&#34;, &#34;0.0507840000&#34;, &#34;0.2249100000&#34;, &#34;-0.1222700000&#34;, &#34;0.2929300000&#34;, &#34;0.0299200000&#34;, &#34;-0.0748870000&#34;, &#34;0.2658300000&#34;, &#34;0.1934400000&#34;, &#34;0.3944700000&#34;, &#34;0.1033600000&#34;, &#34;0.2358800000&#34;, &#34;-0.2657700000&#34;, &#34;-0.1336100000&#34;, &#34;0.3426200000&#34;, &#34;-0.0096122000&#34;, &#34;0.1828100000&#34;, &#34;-0.3648300000&#34;, &#34;0.1314900000&#34;, &#34;0.0784400000&#34;, &#34;-0.2421400000&#34;, &#34;-0.3927000000&#34;, &#34;-0.0823610000&#34;, &#34;0.2368600000&#34;, &#34;0.0903440000&#34;, &#34;-0.2082100000&#34;, &#34;0.0654830000&#34;, &#34;-0.0429180000&#34;, &#34;0.5265200000&#34;, &#34;0.0523810000&#34;, &#34;-0.0753590000&#34;, &#34;0.1181200000&#34;, &#34;0.0941880000&#34;, &#34;0.0837270000&#34;, &#34;-0.2149000000&#34;, &#34;-0.0581420000&#34;, &#34;-0.1207800000&#34;, &#34;-0.1138000000&#34;, &#34;0.2055500000&#34;, &#34;0.0381250000&#34;, &#34;0.3186800000&#34;, &#34;-0.1447200000&#34;, &#34;-0.0084665000&#34;, &#34;0.2390900000&#34;, &#34;-0.2235700000&#34;, &#34;0.5528100000&#34;, &#34;0.0545930000&#34;, &#34;0.1377200000&#34;, &#34;0.0817060000&#34;, &#34;0.0724950000&#34;, &#34;0.2288000000&#34;, &#34;-0.0872900000&#34;, &#34;-0.0172320000&#34;, &#34;0.2579100000&#34;, &#34;0.1911700000&#34;, &#34;0.0124620000&#34;], [&#34;-0.1329400000&#34;, &#34;-0.0040341000&#34;, &#34;-0.2528700000&#34;, &#34;0.7473600000&#34;, &#34;-0.0522580000&#34;, &#34;-0.2666700000&#34;, &#34;0.2227600000&#34;, &#34;-0.3468700000&#34;, &#34;0.1293200000&#34;, &#34;0.0079318000&#34;, &#34;0.0466260000&#34;, &#34;0.1468700000&#34;, &#34;0.1007400000&#34;, &#34;-0.0792940000&#34;, &#34;0.2395000000&#34;, &#34;-0.3809500000&#34;, &#34;-0.2268300000&#34;, &#34;0.0759170000&#34;, &#34;-0.2820100000&#34;, &#34;0.1698100000&#34;, &#34;-0.0174520000&#34;, &#34;-0.1808300000&#34;, &#34;-0.1503000000&#34;, &#34;0.1868700000&#34;, &#34;0.1684800000&#34;, &#34;0.1996000000&#34;, &#34;-0.1113000000&#34;, &#34;-0.0648440000&#34;, &#34;0.2044500000&#34;, &#34;0.1401600000&#34;, &#34;0.1828900000&#34;, &#34;0.2726100000&#34;, &#34;-0.0857620000&#34;, &#34;-0.1995400000&#34;, &#34;-0.0166050000&#34;, &#34;0.0530080000&#34;, &#34;0.0587480000&#34;, &#34;-0.3078000000&#34;, &#34;-0.1012500000&#34;, &#34;-0.1944600000&#34;, &#34;0.3231300000&#34;, &#34;-0.3749200000&#34;, &#34;-0.3575800000&#34;, &#34;0.1566100000&#34;, &#34;0.1158300000&#34;, &#34;0.5502400000&#34;, &#34;0.2186600000&#34;, &#34;-0.2560100000&#34;, &#34;0.2414500000&#34;, &#34;0.1539600000&#34;, &#34;0.2189500000&#34;, &#34;-0.1320800000&#34;, &#34;0.4339600000&#34;, &#34;-0.2742000000&#34;, &#34;-0.1460400000&#34;, &#34;-0.1582100000&#34;, &#34;-0.0977820000&#34;, &#34;0.2375300000&#34;, &#34;-0.0138630000&#34;, &#34;0.1441300000&#34;, &#34;-0.3629500000&#34;, &#34;-0.0287050000&#34;, &#34;0.1719500000&#34;, &#34;-0.2894000000&#34;, &#34;-0.2306500000&#34;, &#34;-0.0192500000&#34;, &#34;-0.1589800000&#34;, &#34;0.1226600000&#34;, &#34;0.2047400000&#34;, &#34;-0.1476100000&#34;, &#34;-0.1721800000&#34;, &#34;0.2289100000&#34;, &#34;0.4538800000&#34;, &#34;-0.3794000000&#34;, &#34;-0.2612700000&#34;, &#34;-0.0750980000&#34;, &#34;0.0902550000&#34;, &#34;-0.1638600000&#34;, &#34;-0.2516900000&#34;, &#34;-0.1709500000&#34;, &#34;-0.3844600000&#34;, &#34;-0.1637900000&#34;, &#34;-0.0539090000&#34;, &#34;-0.0511950000&#34;, &#34;0.1601700000&#34;, &#34;0.0802550000&#34;, &#34;-0.1573500000&#34;, &#34;0.1084100000&#34;, &#34;0.1586400000&#34;, &#34;-0.0157300000&#34;, &#34;0.1188000000&#34;, &#34;-0.1445300000&#34;, &#34;0.2231300000&#34;, &#34;0.0243460000&#34;, &#34;-0.0180430000&#34;, &#34;0.2428600000&#34;, &#34;-0.0558100000&#34;, &#34;-0.0121520000&#34;, &#34;-0.0708120000&#34;, &#34;-0.1179600000&#34;, &#34;-0.4600300000&#34;, &#34;-0.0559390000&#34;, &#34;0.1673500000&#34;, &#34;-0.2604600000&#34;, &#34;-0.1724000000&#34;, &#34;-0.0828000000&#34;, &#34;-0.1188000000&#34;, &#34;-0.2305400000&#34;, &#34;-0.0129530000&#34;, &#34;-0.4526100000&#34;, &#34;-0.1724300000&#34;, &#34;0.1151200000&#34;, &#34;-0.3108400000&#34;, &#34;-0.1094800000&#34;, &#34;0.0415000000&#34;, &#34;0.1968200000&#34;, &#34;0.0401660000&#34;, &#34;-0.1161000000&#34;, &#34;0.0869520000&#34;, &#34;0.0416410000&#34;, &#34;0.4455300000&#34;, &#34;0.4731700000&#34;, &#34;0.0098619000&#34;, &#34;0.1431700000&#34;, &#34;0.2682600000&#34;, &#34;0.0569110000&#34;, &#34;0.2369800000&#34;, &#34;-0.0882120000&#34;, &#34;0.3660100000&#34;, &#34;0.3186500000&#34;, &#34;0.3223000000&#34;, &#34;0.2683000000&#34;, &#34;0.0467380000&#34;, &#34;-0.3218400000&#34;, &#34;0.3445700000&#34;, &#34;-0.1737700000&#34;, &#34;-0.1917200000&#34;, &#34;0.0660220000&#34;, &#34;0.1783900000&#34;, &#34;-0.1917900000&#34;, &#34;0.2302300000&#34;, &#34;0.3166100000&#34;, &#34;0.1722200000&#34;, &#34;0.0210510000&#34;, &#34;0.2011500000&#34;, &#34;-0.0726930000&#34;, &#34;-0.0139950000&#34;, &#34;0.0637070000&#34;, &#34;-0.1541700000&#34;, &#34;0.1900300000&#34;, &#34;-0.1488100000&#34;, &#34;-0.0864240000&#34;, &#34;-0.4749800000&#34;, &#34;0.0396390000&#34;, &#34;-0.1359100000&#34;, &#34;0.2262000000&#34;, &#34;-0.1297200000&#34;, &#34;-0.1611800000&#34;, &#34;0.2446800000&#34;, &#34;0.0166980000&#34;, &#34;-0.1117300000&#34;, &#34;0.1821600000&#34;, &#34;-0.4173200000&#34;, &#34;-0.3033800000&#34;, &#34;-0.1177300000&#34;, &#34;0.5779600000&#34;, &#34;-0.0655710000&#34;, &#34;-0.5637500000&#34;, &#34;0.3918000000&#34;, &#34;-0.0778960000&#34;, &#34;-0.3234600000&#34;, &#34;-0.3475600000&#34;, &#34;-0.3348200000&#34;, &#34;-0.1010500000&#34;, &#34;-0.0611140000&#34;, &#34;0.0550690000&#34;, &#34;-0.0905710000&#34;, &#34;-0.0815730000&#34;, &#34;-0.3094700000&#34;, &#34;-0.6805700000&#34;, &#34;0.0172680000&#34;, &#34;-0.2111600000&#34;, &#34;-0.1099300000&#34;, &#34;-0.0311870000&#34;, &#34;-0.3995600000&#34;, &#34;0.1094700000&#34;, &#34;-0.0548880000&#34;, &#34;0.1790500000&#34;, &#34;0.0158170000&#34;, &#34;0.1301700000&#34;, &#34;0.1595700000&#34;, &#34;-0.1519300000&#34;, &#34;-0.0928810000&#34;, &#34;0.0781060000&#34;, &#34;0.0519230000&#34;, &#34;-0.3589900000&#34;, &#34;0.0366990000&#34;, &#34;0.0662820000&#34;, &#34;-0.3750000000&#34;, &#34;0.0156820000&#34;, &#34;-0.3274300000&#34;, &#34;-0.1991800000&#34;, &#34;0.1159300000&#34;, &#34;-0.1478900000&#34;, &#34;-0.2842800000&#34;, &#34;-0.6705900000&#34;, &#34;-0.1556300000&#34;, &#34;-0.7228500000&#34;, &#34;-0.1450400000&#34;, &#34;-0.0868670000&#34;, &#34;0.1271600000&#34;, &#34;0.2324600000&#34;, &#34;0.0451520000&#34;, &#34;-0.0783510000&#34;, &#34;0.3321100000&#34;, &#34;-0.3912600000&#34;, &#34;-0.4054900000&#34;, &#34;-0.0341500000&#34;, &#34;-0.1628000000&#34;, &#34;0.3739500000&#34;, &#34;-0.3406000000&#34;, &#34;0.0241210000&#34;, &#34;-0.2131200000&#34;, &#34;0.1685600000&#34;, &#34;-0.1051900000&#34;, &#34;0.0422010000&#34;, &#34;-0.2304900000&#34;, &#34;0.2668200000&#34;, &#34;-0.2949800000&#34;, &#34;0.0866800000&#34;, &#34;0.1791200000&#34;, &#34;0.2326900000&#34;, &#34;0.0081227000&#34;, &#34;0.3044600000&#34;, &#34;-0.0068773000&#34;, &#34;-0.0314850000&#34;, &#34;-0.1289200000&#34;, &#34;-0.3601000000&#34;, &#34;0.2866800000&#34;, &#34;0.1896800000&#34;, &#34;0.1489800000&#34;, &#34;0.1840400000&#34;, &#34;0.0896390000&#34;, &#34;0.2711500000&#34;, &#34;-0.1706100000&#34;, &#34;0.2525000000&#34;, &#34;0.3225100000&#34;, &#34;-0.1207400000&#34;, &#34;0.1650200000&#34;, &#34;0.2747200000&#34;, &#34;0.1814400000&#34;, &#34;-0.1612200000&#34;, &#34;-0.2881100000&#34;, &#34;0.2643800000&#34;, &#34;-0.0423200000&#34;, &#34;0.4544400000&#34;, &#34;-0.3193500000&#34;, &#34;-0.4021500000&#34;, &#34;-0.0146670000&#34;, &#34;-0.0428330000&#34;, &#34;-0.0412490000&#34;, &#34;0.1641800000&#34;, &#34;0.1345000000&#34;, &#34;-0.2220100000&#34;, &#34;-0.1087600000&#34;, &#34;-0.5052200000&#34;, &#34;0.0882370000&#34;, &#34;0.2334200000&#34;, &#34;-0.1275600000&#34;, &#34;-0.1542900000&#34;, &#34;-0.0573300000&#34;, &#34;-0.2659200000&#34;, &#34;0.6617000000&#34;, &#34;-0.1194000000&#34;, &#34;0.0545380000&#34;, &#34;-0.1999100000&#34;, &#34;-0.0244130000&#34;, &#34;0.1016200000&#34;, &#34;-0.2644800000&#34;, &#34;0.2442800000&#34;, &#34;0.0035108000&#34;, &#34;-0.0334870000&#34;, &#34;-0.0689520000&#34;, &#34;-0.0041886000&#34;, &#34;0.5570600000&#34;, &#34;-0.0880990000&#34;, &#34;0.2995500000&#34;, &#34;0.1473100000&#34;, &#34;-0.2065700000&#34;, &#34;0.1496100000&#34;, &#34;0.2581300000&#34;, &#34;-0.0317330000&#34;, &#34;-0.1245700000&#34;, &#34;-0.0930970000&#34;, &#34;0.2215800000&#34;, &#34;-0.2244100000&#34;, &#34;0.2205600000&#34;, &#34;0.0828950000&#34;, &#34;0.3491200000&#34;, &#34;0.3267200000&#34;], [&#34;-0.0821570000&#34;, &#34;0.0551590000&#34;, &#34;-0.1657600000&#34;, &#34;0.3520600000&#34;, &#34;-0.0223220000&#34;, &#34;-0.0778630000&#34;, &#34;0.3862900000&#34;, &#34;-0.5446400000&#34;, &#34;0.1514000000&#34;, &#34;0.0972030000&#34;, &#34;-0.0744400000&#34;, &#34;0.2802400000&#34;, &#34;-0.0993530000&#34;, &#34;0.5928800000&#34;, &#34;-0.2579300000&#34;, &#34;-0.4403100000&#34;, &#34;-0.3942100000&#34;, &#34;0.1328900000&#34;, &#34;0.4262500000&#34;, &#34;0.1132500000&#34;, &#34;0.0027451000&#34;, &#34;0.1915600000&#34;, &#34;-0.0779630000&#34;, &#34;-0.3008900000&#34;, &#34;0.1516300000&#34;, &#34;0.2203600000&#34;, &#34;-0.3060000000&#34;, &#34;-0.3920400000&#34;, &#34;0.6744100000&#34;, &#34;-0.0266980000&#34;, &#34;-0.1476400000&#34;, &#34;0.0629660000&#34;, &#34;0.0200700000&#34;, &#34;0.2054200000&#34;, &#34;0.1375000000&#34;, &#34;-0.4318000000&#34;, &#34;0.3834700000&#34;, &#34;-0.5985100000&#34;, &#34;0.1957000000&#34;, &#34;-0.1516900000&#34;, &#34;-0.1199600000&#34;, &#34;-0.0382590000&#34;, &#34;0.2223900000&#34;, &#34;-0.0933100000&#34;, &#34;0.1947400000&#34;, &#34;0.4427000000&#34;, &#34;-0.0860080000&#34;, &#34;-0.3233300000&#34;, &#34;-0.0155910000&#34;, &#34;0.0335440000&#34;, &#34;0.3085100000&#34;, &#34;-0.5045400000&#34;, &#34;0.3970000000&#34;, &#34;-0.4759200000&#34;, &#34;-0.6172900000&#34;, &#34;0.0726510000&#34;, &#34;-0.2968100000&#34;, &#34;-0.0052561000&#34;, &#34;-0.3308900000&#34;, &#34;0.0097070000&#34;, &#34;-0.0155650000&#34;, &#34;-0.1932400000&#34;, &#34;0.6768100000&#34;, &#34;-0.4971600000&#34;, &#34;0.2152700000&#34;, &#34;0.1020500000&#34;, &#34;0.1463900000&#34;, &#34;0.0053264000&#34;, &#34;0.0847450000&#34;, &#34;0.0963660000&#34;, &#34;-0.0596670000&#34;, &#34;0.2078600000&#34;, &#34;0.2598500000&#34;, &#34;0.1488000000&#34;, &#34;-0.3508700000&#34;, &#34;-0.1753400000&#34;, &#34;-0.1306300000&#34;, &#34;-0.1562700000&#34;, &#34;0.1045500000&#34;, &#34;0.2493900000&#34;, &#34;0.2865200000&#34;, &#34;0.2166800000&#34;, &#34;-0.0218610000&#34;, &#34;0.0735370000&#34;, &#34;-0.1330200000&#34;, &#34;0.3135500000&#34;, &#34;-0.3336800000&#34;, &#34;0.5265100000&#34;, &#34;0.0995670000&#34;, &#34;0.4253800000&#34;, &#34;-0.1079600000&#34;, &#34;-0.0289250000&#34;, &#34;0.1756800000&#34;, &#34;-0.1813300000&#34;, &#34;-0.4076200000&#34;, &#34;0.2246200000&#34;, &#34;0.1657100000&#34;, &#34;-0.0463460000&#34;, &#34;-0.0763770000&#34;, &#34;-0.0573720000&#34;, &#34;-0.0857430000&#34;, &#34;-0.0299300000&#34;, &#34;0.0930800000&#34;, &#34;0.1665300000&#34;, &#34;0.1540500000&#34;, &#34;-0.1188400000&#34;, &#34;-0.2006600000&#34;, &#34;0.2996500000&#34;, &#34;0.1095100000&#34;, &#34;0.1393700000&#34;, &#34;-0.1359100000&#34;, &#34;0.0366770000&#34;, &#34;-0.4156400000&#34;, &#34;-0.1751100000&#34;, &#34;0.3539200000&#34;, &#34;0.3526300000&#34;, &#34;0.0637140000&#34;, &#34;0.0035714000&#34;, &#34;-0.2909300000&#34;, &#34;-0.0741830000&#34;, &#34;0.5216200000&#34;, &#34;-0.0087506000&#34;, &#34;-0.2356600000&#34;, &#34;0.2029100000&#34;, &#34;-0.1011300000&#34;, &#34;-0.2151200000&#34;, &#34;0.0304650000&#34;, &#34;0.4477600000&#34;, &#34;-0.0048431000&#34;, &#34;0.1511700000&#34;, &#34;-0.4036500000&#34;, &#34;-0.3351900000&#34;, &#34;-0.3376000000&#34;, &#34;-0.1276200000&#34;, &#34;-0.1516600000&#34;, &#34;0.1038000000&#34;, &#34;-0.0031190000&#34;, &#34;-0.1878700000&#34;, &#34;0.0217180000&#34;, &#34;-0.3423000000&#34;, &#34;0.1781300000&#34;, &#34;0.2007700000&#34;, &#34;-0.2571600000&#34;, &#34;-0.1021700000&#34;, &#34;-0.0583640000&#34;, &#34;0.4881100000&#34;, &#34;0.0753900000&#34;, &#34;0.2455000000&#34;, &#34;-0.1272200000&#34;, &#34;0.4704300000&#34;, &#34;0.2874000000&#34;, &#34;-0.3336200000&#34;, &#34;-0.1766600000&#34;, &#34;-0.4117600000&#34;, &#34;-0.2270500000&#34;, &#34;0.0977800000&#34;, &#34;-0.3651100000&#34;, &#34;0.0178340000&#34;, &#34;0.1581100000&#34;, &#34;-0.0377300000&#34;, &#34;-0.0450480000&#34;, &#34;0.1042400000&#34;, &#34;-0.4253300000&#34;, &#34;-0.2591700000&#34;, &#34;0.2554700000&#34;, &#34;0.1730600000&#34;, &#34;-0.0229010000&#34;, &#34;-0.3288000000&#34;, &#34;-0.1891700000&#34;, &#34;0.3146000000&#34;, &#34;0.0037259000&#34;, &#34;-0.0311420000&#34;, &#34;-0.0112230000&#34;, &#34;-0.0949450000&#34;, &#34;-0.3705100000&#34;, &#34;-0.1865700000&#34;, &#34;-0.0765260000&#34;, &#34;0.1120600000&#34;, &#34;-0.2587400000&#34;, &#34;-0.1570700000&#34;, &#34;0.0258250000&#34;, &#34;-0.1485100000&#34;, &#34;-0.0449910000&#34;, &#34;0.1428600000&#34;, &#34;-0.1632800000&#34;, &#34;0.3083000000&#34;, &#34;0.0136670000&#34;, &#34;-0.1186900000&#34;, &#34;-0.1623500000&#34;, &#34;-0.0047887000&#34;, &#34;0.0415350000&#34;, &#34;-0.4218700000&#34;, &#34;-0.2952500000&#34;, &#34;-0.2038600000&#34;, &#34;-0.2014100000&#34;, &#34;0.2563700000&#34;, &#34;0.1457700000&#34;, &#34;-0.0319150000&#34;, &#34;-0.2285200000&#34;, &#34;0.2501200000&#34;, &#34;-0.3111800000&#34;, &#34;-0.1793900000&#34;, &#34;-0.0982310000&#34;, &#34;-0.0381850000&#34;, &#34;-0.1336400000&#34;, &#34;0.0192960000&#34;, &#34;-0.2208900000&#34;, &#34;-0.1206300000&#34;, &#34;0.2097200000&#34;, &#34;0.2853500000&#34;, &#34;0.1813300000&#34;, &#34;0.0294660000&#34;, &#34;-0.0646010000&#34;, &#34;-0.1771300000&#34;, &#34;0.4132300000&#34;, &#34;-0.2959900000&#34;, &#34;-0.3212300000&#34;, &#34;-0.1448700000&#34;, &#34;-0.3139500000&#34;, &#34;0.1505100000&#34;, &#34;0.1628600000&#34;, &#34;-0.3218000000&#34;, &#34;-0.3945900000&#34;, &#34;-0.2566500000&#34;, &#34;-0.4434100000&#34;, &#34;0.3812200000&#34;, &#34;-0.0107890000&#34;, &#34;-0.4741300000&#34;, &#34;-0.4508600000&#34;, &#34;-0.0834800000&#34;, &#34;0.0299350000&#34;, &#34;-0.1000300000&#34;, &#34;0.3764500000&#34;, &#34;0.0001085700&#34;, &#34;0.0299450000&#34;, &#34;-0.0416520000&#34;, &#34;0.3458600000&#34;, &#34;-0.2455000000&#34;, &#34;-0.1765200000&#34;, &#34;-0.4379600000&#34;, &#34;-0.1578200000&#34;, &#34;0.1923100000&#34;, &#34;-0.4150300000&#34;, &#34;0.1487400000&#34;, &#34;-0.2540100000&#34;, &#34;-0.0940380000&#34;, &#34;0.3424200000&#34;, &#34;0.2924100000&#34;, &#34;-0.1216100000&#34;, &#34;-0.2287700000&#34;, &#34;-0.4925200000&#34;, &#34;-0.1334900000&#34;, &#34;0.2400900000&#34;, &#34;-0.0273510000&#34;, &#34;-0.1193900000&#34;, &#34;0.0464170000&#34;, &#34;-0.2726200000&#34;, &#34;-0.8609100000&#34;, &#34;0.0243370000&#34;, &#34;-0.0293280000&#34;, &#34;-0.2932100000&#34;, &#34;0.5959400000&#34;, &#34;-0.1634700000&#34;, &#34;-0.3189200000&#34;, &#34;-0.3741700000&#34;, &#34;-0.3039100000&#34;, &#34;0.3405600000&#34;, &#34;-0.2369400000&#34;, &#34;-0.1842700000&#34;, &#34;-0.1660400000&#34;, &#34;-0.2861000000&#34;, &#34;-0.1751800000&#34;, &#34;-0.0028950000&#34;, &#34;0.2197000000&#34;, &#34;-0.1751500000&#34;, &#34;-0.1430100000&#34;, &#34;0.1372400000&#34;, &#34;0.3685000000&#34;, &#34;0.1130900000&#34;, &#34;0.0589650000&#34;, &#34;-0.1478800000&#34;, &#34;0.0853980000&#34;, &#34;0.3102600000&#34;, &#34;0.1133000000&#34;, &#34;0.5054500000&#34;, &#34;0.3415200000&#34;, &#34;0.2930000000&#34;, &#34;0.3244900000&#34;, &#34;-0.0282710000&#34;, &#34;-0.0818050000&#34;, &#34;-0.0356940000&#34;, &#34;-0.2337500000&#34;, &#34;-0.0441030000&#34;, &#34;-0.0967910000&#34;, &#34;-0.1861400000&#34;, &#34;-0.3800900000&#34;, &#34;0.0523130000&#34;, &#34;0.0664720000&#34;, &#34;-0.1679500000&#34;, &#34;0.4734300000&#34;], [&#34;0.0488040000&#34;, &#34;-0.2852800000&#34;, &#34;0.0185570000&#34;, &#34;0.2057700000&#34;, &#34;0.0607040000&#34;, &#34;0.0854460000&#34;, &#34;-0.0362670000&#34;, &#34;-0.0683730000&#34;, &#34;0.1450700000&#34;, &#34;0.1785200000&#34;, &#34;0.1457900000&#34;, &#34;-0.1363000000&#34;, &#34;0.2334800000&#34;, &#34;0.0297580000&#34;, &#34;-0.2200100000&#34;, &#34;-0.0045515000&#34;, &#34;-0.1119700000&#34;, &#34;-0.0413670000&#34;, &#34;0.0842310000&#34;, &#34;0.0766730000&#34;, &#34;-0.2446100000&#34;, &#34;0.0535930000&#34;, &#34;-0.1093900000&#34;, &#34;-0.1246800000&#34;, &#34;-0.2029000000&#34;, &#34;0.0745650000&#34;, &#34;0.1066000000&#34;, &#34;0.0543390000&#34;, &#34;0.0882680000&#34;, &#34;0.2255700000&#34;, &#34;-0.0290810000&#34;, &#34;0.2980000000&#34;, &#34;-0.1612900000&#34;, &#34;0.3641900000&#34;, &#34;0.0739780000&#34;, &#34;-0.0895610000&#34;, &#34;-0.0411040000&#34;, &#34;-0.2427700000&#34;, &#34;-0.0058010000&#34;, &#34;-0.0628380000&#34;, &#34;0.0617660000&#34;, &#34;-0.0633800000&#34;, &#34;0.0648860000&#34;, &#34;0.0766810000&#34;, &#34;0.0547310000&#34;, &#34;-0.1214600000&#34;, &#34;-0.1090700000&#34;, &#34;-0.0927890000&#34;, &#34;0.0335690000&#34;, &#34;-0.1898400000&#34;, &#34;0.0891000000&#34;, &#34;0.0130160000&#34;, &#34;-0.0515710000&#34;, &#34;0.0280400000&#34;, &#34;0.1269700000&#34;, &#34;-0.0775540000&#34;, &#34;0.1572200000&#34;, &#34;0.0774760000&#34;, &#34;-0.1634300000&#34;, &#34;0.1654700000&#34;, &#34;-0.2609900000&#34;, &#34;-0.2912200000&#34;, &#34;0.3018200000&#34;, &#34;-0.1675900000&#34;, &#34;-0.0565190000&#34;, &#34;-0.1289800000&#34;, &#34;-0.1970200000&#34;, &#34;-0.1511800000&#34;, &#34;-0.1337400000&#34;, &#34;-0.1500300000&#34;, &#34;-0.2352500000&#34;, &#34;-0.1591500000&#34;, &#34;0.1304200000&#34;, &#34;-0.0273440000&#34;, &#34;-0.1242700000&#34;, &#34;-0.0436310000&#34;, &#34;0.1241400000&#34;, &#34;0.3488900000&#34;, &#34;0.0494370000&#34;, &#34;-0.0101120000&#34;, &#34;0.2024700000&#34;, &#34;0.0822940000&#34;, &#34;-0.1515700000&#34;, &#34;-0.2273700000&#34;, &#34;0.1206400000&#34;, &#34;-0.0613040000&#34;, &#34;-0.0777130000&#34;, &#34;0.1096000000&#34;, &#34;-0.0960960000&#34;, &#34;-0.2033800000&#34;, &#34;-0.0229400000&#34;, &#34;0.1594500000&#34;, &#34;0.2332500000&#34;, &#34;-0.2310700000&#34;, &#34;0.0526840000&#34;, &#34;-0.0969460000&#34;, &#34;0.0573730000&#34;, &#34;0.1414300000&#34;, &#34;0.0765470000&#34;, &#34;0.0182650000&#34;, &#34;0.0640910000&#34;, &#34;0.0448580000&#34;, &#34;0.0881280000&#34;, &#34;-0.1169400000&#34;, &#34;-0.2496000000&#34;, &#34;-0.1304900000&#34;, &#34;-0.0830170000&#34;, &#34;-0.0600820000&#34;, &#34;0.0240550000&#34;, &#34;-0.0207480000&#34;, &#34;0.0391350000&#34;, &#34;0.0435670000&#34;, &#34;-0.1020800000&#34;, &#34;-0.1546400000&#34;, &#34;0.1289200000&#34;, &#34;-0.0241900000&#34;, &#34;0.0453700000&#34;, &#34;0.1277800000&#34;, &#34;0.1321200000&#34;, &#34;0.1920800000&#34;, &#34;0.2473700000&#34;, &#34;0.1240600000&#34;, &#34;-0.2024600000&#34;, &#34;0.1376200000&#34;, &#34;-0.0231510000&#34;, &#34;0.0417360000&#34;, &#34;-0.0139670000&#34;, &#34;0.1819400000&#34;, &#34;0.1621000000&#34;, &#34;0.0625860000&#34;, &#34;-0.0799810000&#34;, &#34;0.1318400000&#34;, &#34;-0.0773880000&#34;, &#34;0.0203130000&#34;, &#34;-0.0414880000&#34;, &#34;0.0205240000&#34;, &#34;-0.1131000000&#34;, &#34;0.1463900000&#34;, &#34;0.0801130000&#34;, &#34;0.0368500000&#34;, &#34;0.1364000000&#34;, &#34;-0.0097955000&#34;, &#34;0.1177900000&#34;, &#34;0.1354700000&#34;, &#34;0.2289000000&#34;, &#34;0.2123100000&#34;, &#34;-0.0797790000&#34;, &#34;0.1383100000&#34;, &#34;-0.0761140000&#34;, &#34;0.0285630000&#34;, &#34;0.1144100000&#34;, &#34;-0.1545500000&#34;, &#34;-0.0832670000&#34;, &#34;-0.0571670000&#34;, &#34;-0.0993520000&#34;, &#34;-0.1706300000&#34;, &#34;-0.0717570000&#34;, &#34;-0.0514970000&#34;, &#34;0.2656800000&#34;, &#34;0.0187990000&#34;, &#34;-0.2722000000&#34;, &#34;0.1268000000&#34;, &#34;-0.0210450000&#34;, &#34;0.0588310000&#34;, &#34;0.3021300000&#34;, &#34;-0.0352550000&#34;, &#34;-0.0959520000&#34;, &#34;-0.0390820000&#34;, &#34;0.2036900000&#34;, &#34;-0.1786900000&#34;, &#34;-0.2618800000&#34;, &#34;-0.1100600000&#34;, &#34;-0.1569400000&#34;, &#34;-0.0288030000&#34;, &#34;-0.2387200000&#34;, &#34;0.1559400000&#34;, &#34;0.0087185000&#34;, &#34;0.2405300000&#34;, &#34;0.1213900000&#34;, &#34;0.1372800000&#34;, &#34;0.0159270000&#34;, &#34;-0.0133860000&#34;, &#34;-0.0690450000&#34;, &#34;0.1030300000&#34;, &#34;-0.0720710000&#34;, &#34;0.2796200000&#34;, &#34;0.1915700000&#34;, &#34;-0.1381000000&#34;, &#34;0.0713930000&#34;, &#34;-0.0315480000&#34;, &#34;-0.0352990000&#34;, &#34;-0.0746090000&#34;, &#34;0.2041500000&#34;, &#34;0.0718500000&#34;, &#34;-0.0686720000&#34;, &#34;-0.0412170000&#34;, &#34;-0.0870570000&#34;, &#34;-0.1166500000&#34;, &#34;-0.2025700000&#34;, &#34;0.0731880000&#34;, &#34;-0.0734970000&#34;, &#34;-0.2795100000&#34;, &#34;-0.1739300000&#34;, &#34;0.0640050000&#34;, &#34;-0.0503940000&#34;, &#34;-0.0444260000&#34;, &#34;0.0084868000&#34;, &#34;0.0651470000&#34;, &#34;0.0753810000&#34;, &#34;0.1112400000&#34;, &#34;0.2497100000&#34;, &#34;0.1669600000&#34;, &#34;0.0404720000&#34;, &#34;-0.1453300000&#34;, &#34;0.0167630000&#34;, &#34;-0.1127300000&#34;, &#34;0.0174350000&#34;, &#34;-0.1917700000&#34;, &#34;-0.0449610000&#34;, &#34;0.0856380000&#34;, &#34;0.0793410000&#34;, &#34;-0.0462130000&#34;, &#34;-0.2025500000&#34;, &#34;0.2627400000&#34;, &#34;-0.0910530000&#34;, &#34;0.0777210000&#34;, &#34;-0.1545400000&#34;, &#34;0.0423210000&#34;, &#34;0.1174200000&#34;, &#34;-0.0860410000&#34;, &#34;0.0876110000&#34;, &#34;0.2136500000&#34;, &#34;-0.1359700000&#34;, &#34;-0.0299870000&#34;, &#34;-0.0210530000&#34;, &#34;0.0262220000&#34;, &#34;-0.0637410000&#34;, &#34;-0.0836490000&#34;, &#34;0.0165660000&#34;, &#34;0.0435410000&#34;, &#34;-0.0390120000&#34;, &#34;-0.0099747000&#34;, &#34;0.1342700000&#34;, &#34;0.0632090000&#34;, &#34;0.2282500000&#34;, &#34;0.1484400000&#34;, &#34;0.0329260000&#34;, &#34;-0.1901200000&#34;, &#34;0.1983800000&#34;, &#34;-0.2236900000&#34;, &#34;0.0001884700&#34;, &#34;0.1740500000&#34;, &#34;-0.0379030000&#34;, &#34;0.0206610000&#34;, &#34;-0.0840530000&#34;, &#34;0.1841900000&#34;, &#34;0.0285170000&#34;, &#34;-0.0980060000&#34;, &#34;0.1993900000&#34;, &#34;0.0798100000&#34;, &#34;0.1241000000&#34;, &#34;0.0952500000&#34;, &#34;-0.0353410000&#34;, &#34;0.0841300000&#34;, &#34;-0.0823030000&#34;, &#34;-0.0757920000&#34;, &#34;0.1653500000&#34;, &#34;0.1158100000&#34;, &#34;0.0130190000&#34;, &#34;-0.0808940000&#34;, &#34;-0.0104000000&#34;, &#34;-0.0787360000&#34;, &#34;-0.1112200000&#34;, &#34;0.0289960000&#34;, &#34;-0.0633100000&#34;, &#34;-0.0339300000&#34;, &#34;0.0205720000&#34;, &#34;0.2645200000&#34;, &#34;0.0017304000&#34;, &#34;0.0190020000&#34;, &#34;0.1413200000&#34;, &#34;-0.0791100000&#34;, &#34;0.1535600000&#34;, &#34;0.0728730000&#34;, &#34;0.0871680000&#34;, &#34;-0.0055530000&#34;, &#34;-0.0200730000&#34;, &#34;0.1502200000&#34;, &#34;-0.0153510000&#34;, &#34;0.1674300000&#34;, &#34;0.1695600000&#34;, &#34;-0.3367700000&#34;, &#34;-0.0602860000&#34;, &#34;0.0860970000&#34;, &#34;-0.0650010000&#34;, &#34;0.0048331000&#34;, &#34;-0.1009600000&#34;, &#34;0.1391000000&#34;, &#34;-0.1371400000&#34;, &#34;-0.0397050000&#34;], [&#34;0.2576100000&#34;, &#34;0.0498830000&#34;, &#34;0.2522900000&#34;, &#34;0.4697300000&#34;, &#34;0.1034600000&#34;, &#34;-0.0240450000&#34;, &#34;0.0088398000&#34;, &#34;-0.2274800000&#34;, &#34;0.4485000000&#34;, &#34;-0.0707920000&#34;, &#34;0.4768700000&#34;, &#34;0.0553360000&#34;, &#34;-0.1565000000&#34;, &#34;-0.2308300000&#34;, &#34;0.4498700000&#34;, &#34;-0.0644760000&#34;, &#34;0.1669300000&#34;, &#34;-0.0715100000&#34;, &#34;0.3342400000&#34;, &#34;0.3535400000&#34;, &#34;-0.2725600000&#34;, &#34;0.1478900000&#34;, &#34;0.1803300000&#34;, &#34;-0.0472340000&#34;, &#34;-0.2308600000&#34;, &#34;0.3127800000&#34;, &#34;-0.0118420000&#34;, &#34;0.2047800000&#34;, &#34;-0.3107600000&#34;, &#34;0.2896700000&#34;, &#34;-0.2036400000&#34;, &#34;0.4134400000&#34;, &#34;-0.3138900000&#34;, &#34;-0.0244240000&#34;, &#34;0.1570300000&#34;, &#34;0.0415070000&#34;, &#34;0.1052000000&#34;, &#34;-0.0450440000&#34;, &#34;0.0137740000&#34;, &#34;-0.0611710000&#34;, &#34;0.4547900000&#34;, &#34;-0.0195840000&#34;, &#34;-0.3795500000&#34;, &#34;0.4757900000&#34;, &#34;0.0349800000&#34;, &#34;0.2764000000&#34;, &#34;-0.1168200000&#34;, &#34;0.1686200000&#34;, &#34;-0.0475000000&#34;, &#34;-0.0996640000&#34;, &#34;-0.0956250000&#34;, &#34;-0.1745400000&#34;, &#34;0.0430370000&#34;, &#34;-0.0571580000&#34;, &#34;0.0347470000&#34;, &#34;-0.1270000000&#34;, &#34;-0.1546000000&#34;, &#34;-0.1156300000&#34;, &#34;-0.4520600000&#34;, &#34;-0.0140030000&#34;, &#34;-0.2059100000&#34;, &#34;0.0766850000&#34;, &#34;0.3093800000&#34;, &#34;0.2549300000&#34;, &#34;-0.1845700000&#34;, &#34;-0.2392600000&#34;, &#34;-0.1454200000&#34;, &#34;0.2572800000&#34;, &#34;0.2311600000&#34;, &#34;-0.1269500000&#34;, &#34;-0.1668300000&#34;, &#34;0.1106600000&#34;, &#34;0.0136380000&#34;, &#34;0.1033000000&#34;, &#34;0.0856880000&#34;, &#34;-0.0219830000&#34;, &#34;0.5544900000&#34;, &#34;0.0224660000&#34;, &#34;0.0407880000&#34;, &#34;-0.2900500000&#34;, &#34;-0.0578260000&#34;, &#34;0.3924500000&#34;, &#34;-0.3068200000&#34;, &#34;-0.2656900000&#34;, &#34;0.0958790000&#34;, &#34;0.0431440000&#34;, &#34;-0.1065100000&#34;, &#34;0.1602600000&#34;, &#34;0.0078983000&#34;, &#34;0.0719570000&#34;, &#34;-0.0682610000&#34;, &#34;0.1889700000&#34;, &#34;0.4482300000&#34;, &#34;-0.4827000000&#34;, &#34;-0.0824450000&#34;, &#34;0.1179600000&#34;, &#34;0.3445000000&#34;, &#34;0.1846700000&#34;, &#34;-0.3836300000&#34;, &#34;-0.0253770000&#34;, &#34;0.1451000000&#34;, &#34;0.1030600000&#34;, &#34;0.2302700000&#34;, &#34;-0.1013100000&#34;, &#34;-0.1802600000&#34;, &#34;-0.1979700000&#34;, &#34;-0.1414100000&#34;, &#34;0.0243780000&#34;, &#34;-0.1174700000&#34;, &#34;0.0429810000&#34;, &#34;-0.3171400000&#34;, &#34;0.3114000000&#34;, &#34;-0.2077200000&#34;, &#34;-0.1691500000&#34;, &#34;-0.0474650000&#34;, &#34;-0.1797400000&#34;, &#34;0.0740380000&#34;, &#34;-0.2572700000&#34;, &#34;-0.0477410000&#34;, &#34;-0.0261270000&#34;, &#34;0.2260500000&#34;, &#34;-0.2186200000&#34;, &#34;-0.3768000000&#34;, &#34;0.1168700000&#34;, &#34;0.0878920000&#34;, &#34;0.0253730000&#34;, &#34;-0.1511300000&#34;, &#34;-0.3771800000&#34;, &#34;-0.0941650000&#34;, &#34;0.2612200000&#34;, &#34;-0.0948940000&#34;, &#34;0.0966500000&#34;, &#34;0.1221900000&#34;, &#34;0.3357000000&#34;, &#34;-0.4663500000&#34;, &#34;0.1240100000&#34;, &#34;-0.0280710000&#34;, &#34;-0.0353240000&#34;, &#34;-0.1160400000&#34;, &#34;0.1255900000&#34;, &#34;0.1294500000&#34;, &#34;0.3766500000&#34;, &#34;-0.0498470000&#34;, &#34;0.1566400000&#34;, &#34;0.1644400000&#34;, &#34;0.4491300000&#34;, &#34;0.3040100000&#34;, &#34;0.0566570000&#34;, &#34;-0.1629300000&#34;, &#34;0.0433950000&#34;, &#34;-0.1707100000&#34;, &#34;-0.2768000000&#34;, &#34;-0.5619900000&#34;, &#34;-0.1267300000&#34;, &#34;0.0284040000&#34;, &#34;-0.3314100000&#34;, &#34;-0.1353900000&#34;, &#34;-0.2051000000&#34;, &#34;0.1561200000&#34;, &#34;0.0321760000&#34;, &#34;0.0325120000&#34;, &#34;0.3252900000&#34;, &#34;-0.0204760000&#34;, &#34;-0.2660400000&#34;, &#34;0.2923800000&#34;, &#34;-0.0918760000&#34;, &#34;0.2176400000&#34;, &#34;0.3006700000&#34;, &#34;0.1130500000&#34;, &#34;0.0756780000&#34;, &#34;-0.2516200000&#34;, &#34;-0.1369600000&#34;, &#34;-0.2226500000&#34;, &#34;0.0929890000&#34;, &#34;-0.0540260000&#34;, &#34;-0.0310660000&#34;, &#34;-0.1757100000&#34;, &#34;0.0034190000&#34;, &#34;0.4077300000&#34;, &#34;-0.2868300000&#34;, &#34;0.0818900000&#34;, &#34;0.0356060000&#34;, &#34;-0.1427700000&#34;, &#34;0.0441420000&#34;, &#34;0.0596490000&#34;, &#34;0.3647200000&#34;, &#34;-0.2288400000&#34;, &#34;0.0157600000&#34;, &#34;0.1556600000&#34;, &#34;-0.2784400000&#34;, &#34;-0.4091900000&#34;, &#34;-0.1635800000&#34;, &#34;0.0723090000&#34;, &#34;0.2206900000&#34;, &#34;0.1242000000&#34;, &#34;0.0138220000&#34;, &#34;0.1920100000&#34;, &#34;0.2486900000&#34;, &#34;-0.1761000000&#34;, &#34;-0.2160900000&#34;, &#34;-0.2101800000&#34;, &#34;-0.3116400000&#34;, &#34;-0.1328500000&#34;, &#34;0.1315200000&#34;, &#34;-0.0828380000&#34;, &#34;-0.1720700000&#34;, &#34;0.0142350000&#34;, &#34;0.0000532270&#34;, &#34;0.6004800000&#34;, &#34;0.1395700000&#34;, &#34;0.6135400000&#34;, &#34;-0.1014600000&#34;, &#34;0.0895460000&#34;, &#34;-0.0718870000&#34;, &#34;-0.0797020000&#34;, &#34;-0.2143200000&#34;, &#34;-0.1823300000&#34;, &#34;0.1172300000&#34;, &#34;0.0926630000&#34;, &#34;0.1273800000&#34;, &#34;-0.2187700000&#34;, &#34;0.4550800000&#34;, &#34;-0.1949000000&#34;, &#34;0.1642300000&#34;, &#34;0.0079016000&#34;, &#34;0.0051538000&#34;, &#34;-0.3267000000&#34;, &#34;-0.0764360000&#34;, &#34;-0.2438000000&#34;, &#34;-0.2685200000&#34;, &#34;0.0193920000&#34;, &#34;-0.1682000000&#34;, &#34;-0.0994380000&#34;, &#34;-0.3137100000&#34;, &#34;-0.1200100000&#34;, &#34;0.0051944000&#34;, &#34;0.0029277000&#34;, &#34;0.2245500000&#34;, &#34;-0.3278500000&#34;, &#34;0.3743800000&#34;, &#34;0.1684900000&#34;, &#34;-0.1351700000&#34;, &#34;-0.0438710000&#34;, &#34;0.1709000000&#34;, &#34;0.0181980000&#34;, &#34;-0.4817400000&#34;, &#34;-0.0249240000&#34;, &#34;-0.3569000000&#34;, &#34;-0.2236400000&#34;, &#34;-0.1536800000&#34;, &#34;0.0366920000&#34;, &#34;0.0108350000&#34;, &#34;-0.1188100000&#34;, &#34;-0.0135090000&#34;, &#34;-0.3823800000&#34;, &#34;-0.0655870000&#34;, &#34;0.0649680000&#34;, &#34;-0.1670200000&#34;, &#34;0.0601880000&#34;, &#34;0.0726660000&#34;, &#34;-0.1894900000&#34;, &#34;-0.1669000000&#34;, &#34;0.1220200000&#34;, &#34;-0.6277000000&#34;, &#34;0.0577930000&#34;, &#34;0.0557220000&#34;, &#34;-0.1216900000&#34;, &#34;0.2617200000&#34;, &#34;-0.1390000000&#34;, &#34;-0.0465770000&#34;, &#34;-0.2551400000&#34;, &#34;0.2811700000&#34;, &#34;-0.3228100000&#34;, &#34;-0.2040800000&#34;, &#34;0.0238830000&#34;, &#34;-0.2731800000&#34;, &#34;0.2812600000&#34;, &#34;0.2255100000&#34;, &#34;-0.2777100000&#34;, &#34;0.1377300000&#34;, &#34;-0.1328300000&#34;, &#34;-0.1103800000&#34;, &#34;-0.0364880000&#34;, &#34;-0.1647500000&#34;, &#34;0.0441320000&#34;, &#34;-0.3204900000&#34;, &#34;-0.0297440000&#34;, &#34;-0.0134920000&#34;, &#34;0.0570560000&#34;, &#34;-0.0111380000&#34;, &#34;0.5766000000&#34;, &#34;-0.1950200000&#34;, &#34;0.3828600000&#34;, &#34;-0.0409440000&#34;, &#34;0.1138800000&#34;, &#34;-0.1461900000&#34;, &#34;-0.0389640000&#34;, &#34;0.1082000000&#34;, &#34;0.0137960000&#34;, &#34;-0.3645600000&#34;], [&#34;-0.1872000000&#34;, &#34;-0.0302420000&#34;, &#34;-0.2254600000&#34;, &#34;0.4859600000&#34;, &#34;-0.3529400000&#34;, &#34;-0.3825400000&#34;, &#34;0.0929030000&#34;, &#34;-0.3685200000&#34;, &#34;-0.1951600000&#34;, &#34;-0.0498530000&#34;, &#34;0.0908620000&#34;, &#34;0.0407990000&#34;, &#34;-0.3072100000&#34;, &#34;-0.0709640000&#34;, &#34;-0.0941560000&#34;, &#34;-0.0978660000&#34;, &#34;-0.1372500000&#34;, &#34;-0.0414930000&#34;, &#34;0.3032700000&#34;, &#34;0.1050900000&#34;, &#34;-0.0076578000&#34;, &#34;-0.1000700000&#34;, &#34;0.0800080000&#34;, &#34;-0.2233700000&#34;, &#34;0.0359090000&#34;, &#34;-0.0584450000&#34;, &#34;0.0244540000&#34;, &#34;-0.1193400000&#34;, &#34;0.1702500000&#34;, &#34;-0.3432500000&#34;, &#34;0.1077500000&#34;, &#34;0.5631200000&#34;, &#34;-0.5181200000&#34;, &#34;-0.1461600000&#34;, &#34;0.1113700000&#34;, &#34;-0.4206000000&#34;, &#34;0.0596090000&#34;, &#34;0.1471300000&#34;, &#34;0.2001500000&#34;, &#34;-0.1909500000&#34;, &#34;0.1685900000&#34;, &#34;0.0076862000&#34;, &#34;0.0351940000&#34;, &#34;-0.0800700000&#34;, &#34;-0.1226700000&#34;, &#34;0.1733700000&#34;, &#34;0.0905270000&#34;, &#34;0.0217220000&#34;, &#34;0.2671000000&#34;, &#34;-0.1678600000&#34;, &#34;0.3143600000&#34;, &#34;0.0912250000&#34;, &#34;-0.2971400000&#34;, &#34;-0.5219500000&#34;, &#34;0.1874100000&#34;, &#34;0.2489300000&#34;, &#34;0.2154500000&#34;, &#34;0.5061000000&#34;, &#34;0.0684540000&#34;, &#34;-0.5239000000&#34;, &#34;-0.2948300000&#34;, &#34;0.0606950000&#34;, &#34;0.1887500000&#34;, &#34;-0.0923290000&#34;, &#34;-0.0058402000&#34;, &#34;-0.0352760000&#34;, &#34;-0.4210000000&#34;, &#34;-0.1033500000&#34;, &#34;-0.1876500000&#34;, &#34;-0.4809900000&#34;, &#34;-0.5377500000&#34;, &#34;-0.1599100000&#34;, &#34;0.1835900000&#34;, &#34;0.0864560000&#34;, &#34;-0.1268000000&#34;, &#34;0.1318300000&#34;, &#34;0.3980000000&#34;, &#34;-0.2230200000&#34;, &#34;0.2135200000&#34;, &#34;-0.4014300000&#34;, &#34;-0.2573700000&#34;, &#34;-0.0931500000&#34;, &#34;-0.2693700000&#34;, &#34;-0.2378500000&#34;, &#34;-0.7180800000&#34;, &#34;0.0019796000&#34;, &#34;-0.1154700000&#34;, &#34;-0.0263870000&#34;, &#34;-0.1542000000&#34;, &#34;-0.0280980000&#34;, &#34;-0.0285050000&#34;, &#34;0.3491400000&#34;, &#34;0.4856400000&#34;, &#34;-0.1690300000&#34;, &#34;0.1436600000&#34;, &#34;0.0318030000&#34;, &#34;0.3217800000&#34;, &#34;0.1380500000&#34;, &#34;0.2728200000&#34;, &#34;0.5049100000&#34;, &#34;0.1664300000&#34;, &#34;-0.1448900000&#34;, &#34;0.2125200000&#34;, &#34;-0.1341200000&#34;, &#34;0.0838860000&#34;, &#34;-0.2328500000&#34;, &#34;-0.3145600000&#34;, &#34;0.3400200000&#34;, &#34;-0.3158500000&#34;, &#34;0.0759740000&#34;, &#34;0.1302700000&#34;, &#34;-0.0240090000&#34;, &#34;-0.0903000000&#34;, &#34;-0.1906600000&#34;, &#34;-0.3051900000&#34;, &#34;-0.1550300000&#34;, &#34;0.0072282000&#34;, &#34;0.3208200000&#34;, &#34;-0.1138600000&#34;, &#34;-0.0513200000&#34;, &#34;0.6661500000&#34;, &#34;-0.0855150000&#34;, &#34;-0.4434600000&#34;, &#34;0.1410600000&#34;, &#34;0.1760400000&#34;, &#34;0.4323200000&#34;, &#34;-0.4307000000&#34;, &#34;-0.0598750000&#34;, &#34;-0.1399500000&#34;, &#34;0.2492800000&#34;, &#34;0.0695550000&#34;, &#34;0.0965270000&#34;, &#34;0.0939160000&#34;, &#34;0.0617970000&#34;, &#34;0.0525190000&#34;, &#34;-0.0749970000&#34;, &#34;-0.0488870000&#34;, &#34;0.3896500000&#34;, &#34;-0.0437090000&#34;, &#34;0.6691200000&#34;, &#34;0.1628500000&#34;, &#34;0.0932350000&#34;, &#34;-0.0328160000&#34;, &#34;0.1839800000&#34;, &#34;-0.0754280000&#34;, &#34;-0.2968400000&#34;, &#34;0.1668600000&#34;, &#34;0.0593240000&#34;, &#34;0.0251530000&#34;, &#34;0.0512080000&#34;, &#34;0.5032000000&#34;, &#34;0.0594630000&#34;, &#34;-0.1619200000&#34;, &#34;-0.4913400000&#34;, &#34;-0.1015400000&#34;, &#34;-0.4073700000&#34;, &#34;0.4849100000&#34;, &#34;-0.1077600000&#34;, &#34;-0.2144100000&#34;, &#34;-0.5785900000&#34;, &#34;0.0542930000&#34;, &#34;0.0497600000&#34;, &#34;0.0423400000&#34;, &#34;0.2114500000&#34;, &#34;-0.0863330000&#34;, &#34;0.1085400000&#34;, &#34;-0.5758900000&#34;, &#34;-0.3975800000&#34;, &#34;0.1180800000&#34;, &#34;0.2298500000&#34;, &#34;-0.3438700000&#34;, &#34;-0.0920800000&#34;, &#34;-0.1144600000&#34;, &#34;0.0740170000&#34;, &#34;-0.4509900000&#34;, &#34;-0.0822830000&#34;, &#34;0.1899500000&#34;, &#34;-0.1227300000&#34;, &#34;-0.1095900000&#34;, &#34;-0.0005473000&#34;, &#34;0.6126900000&#34;, &#34;-0.2204800000&#34;, &#34;0.1407300000&#34;, &#34;-0.0395650000&#34;, &#34;0.1667500000&#34;, &#34;0.5801700000&#34;, &#34;-0.0584250000&#34;, &#34;-0.0619060000&#34;, &#34;0.6612200000&#34;, &#34;-0.0712260000&#34;, &#34;-0.2108400000&#34;, &#34;-0.1812200000&#34;, &#34;-0.0101210000&#34;, &#34;0.3141200000&#34;, &#34;-0.2826000000&#34;, &#34;-0.1921900000&#34;, &#34;-0.0458870000&#34;, &#34;0.3238600000&#34;, &#34;-0.4751300000&#34;, &#34;-0.0933170000&#34;, &#34;0.0754570000&#34;, &#34;-0.0080931000&#34;, &#34;0.0897010000&#34;, &#34;-0.2116200000&#34;, &#34;-0.2208200000&#34;, &#34;-0.2092000000&#34;, &#34;0.1851100000&#34;, &#34;-0.1653500000&#34;, &#34;0.0740850000&#34;, &#34;0.0266020000&#34;, &#34;-0.0974900000&#34;, &#34;0.3796400000&#34;, &#34;0.1468100000&#34;, &#34;-0.1682900000&#34;, &#34;0.2318900000&#34;, &#34;-0.1005200000&#34;, &#34;-0.1863400000&#34;, &#34;-0.4332400000&#34;, &#34;-0.0667370000&#34;, &#34;-0.1543900000&#34;, &#34;0.2330100000&#34;, &#34;-0.2363500000&#34;, &#34;0.1945700000&#34;, &#34;0.1350300000&#34;, &#34;0.1206200000&#34;, &#34;-0.1858500000&#34;, &#34;-0.2281400000&#34;, &#34;-0.8050500000&#34;, &#34;0.1976100000&#34;, &#34;-0.0441520000&#34;, &#34;-0.2157400000&#34;, &#34;0.2222600000&#34;, &#34;-0.0491980000&#34;, &#34;0.0587420000&#34;, &#34;0.1350500000&#34;, &#34;0.0905450000&#34;, &#34;0.2420800000&#34;, &#34;-0.0127400000&#34;, &#34;0.1750000000&#34;, &#34;0.1095600000&#34;, &#34;0.1612800000&#34;, &#34;-0.3499200000&#34;, &#34;0.1757300000&#34;, &#34;-0.2536300000&#34;, &#34;-0.3201500000&#34;, &#34;0.3218000000&#34;, &#34;0.0410470000&#34;, &#34;-0.0623210000&#34;, &#34;-0.2030900000&#34;, &#34;-0.0781820000&#34;, &#34;-0.0504510000&#34;, &#34;-0.1302900000&#34;, &#34;0.0445080000&#34;, &#34;0.2193600000&#34;, &#34;-0.0134300000&#34;, &#34;0.0377120000&#34;, &#34;0.0651670000&#34;, &#34;-0.0532490000&#34;, &#34;0.2846400000&#34;, &#34;0.0539880000&#34;, &#34;0.0781200000&#34;, &#34;0.2064800000&#34;, &#34;0.2330800000&#34;, &#34;0.2235400000&#34;, &#34;-0.3331700000&#34;, &#34;-0.3691800000&#34;, &#34;-0.2975400000&#34;, &#34;0.1137900000&#34;, &#34;0.3412900000&#34;, &#34;0.0204940000&#34;, &#34;-0.4146400000&#34;, &#34;0.2122200000&#34;, &#34;0.0533570000&#34;, &#34;-0.2561800000&#34;, &#34;0.0018763000&#34;, &#34;-0.1171700000&#34;, &#34;0.1756400000&#34;, &#34;0.2612300000&#34;, &#34;-0.1151800000&#34;, &#34;-0.1479800000&#34;, &#34;0.2521200000&#34;, &#34;-0.0550510000&#34;, &#34;-0.0555300000&#34;, &#34;-0.4026900000&#34;, &#34;0.1939700000&#34;, &#34;-0.0147990000&#34;, &#34;0.3273300000&#34;, &#34;-0.2912700000&#34;, &#34;-0.2635800000&#34;, &#34;0.0639000000&#34;, &#34;0.3415500000&#34;, &#34;0.2763000000&#34;, &#34;0.1275400000&#34;, &#34;0.1321700000&#34;, &#34;-0.0924440000&#34;, &#34;-0.2194800000&#34;, &#34;0.1008300000&#34;, &#34;0.3518600000&#34;, &#34;0.1284600000&#34;, &#34;0.1200900000&#34;], [&#34;-0.0483010000&#34;, &#34;0.1926000000&#34;, &#34;-0.6080700000&#34;, &#34;-0.1321700000&#34;, &#34;-0.7480600000&#34;, &#34;-0.1779300000&#34;, &#34;0.1883100000&#34;, &#34;-0.6710000000&#34;, &#34;-0.3516700000&#34;, &#34;0.4761700000&#34;, &#34;0.2126700000&#34;, &#34;0.1931800000&#34;, &#34;-0.0309560000&#34;, &#34;0.3532300000&#34;, &#34;0.1101600000&#34;, &#34;0.0179630000&#34;, &#34;-0.0054491000&#34;, &#34;-0.0927580000&#34;, &#34;-0.5833500000&#34;, &#34;0.2006100000&#34;, &#34;0.3485700000&#34;, &#34;-0.2006200000&#34;, &#34;-0.4491000000&#34;, &#34;-0.1015000000&#34;, &#34;-0.1915400000&#34;, &#34;-0.0624400000&#34;, &#34;-0.1961200000&#34;, &#34;0.1386100000&#34;, &#34;-0.3221000000&#34;, &#34;0.2511000000&#34;, &#34;-0.3066600000&#34;, &#34;0.2149300000&#34;, &#34;0.3389300000&#34;, &#34;0.3087800000&#34;, &#34;-0.0710470000&#34;, &#34;-0.0528590000&#34;, &#34;0.0813120000&#34;, &#34;0.0924810000&#34;, &#34;0.4397400000&#34;, &#34;0.1130700000&#34;, &#34;0.7637600000&#34;, &#34;0.1650700000&#34;, &#34;-0.4197200000&#34;, &#34;-0.2212400000&#34;, &#34;0.0775690000&#34;, &#34;-0.1602800000&#34;, &#34;0.1373400000&#34;, &#34;0.0908770000&#34;, &#34;-0.0427150000&#34;, &#34;-0.1802500000&#34;, &#34;-0.1432800000&#34;, &#34;0.0392000000&#34;, &#34;0.3309600000&#34;, &#34;-0.5582400000&#34;, &#34;0.2220600000&#34;, &#34;-0.0236850000&#34;, &#34;0.2582500000&#34;, &#34;0.2877900000&#34;, &#34;0.3834000000&#34;, &#34;-0.1787200000&#34;, &#34;-0.3949400000&#34;, &#34;0.1114700000&#34;, &#34;0.3441100000&#34;, &#34;0.1905500000&#34;, &#34;-0.0914810000&#34;, &#34;-0.2756000000&#34;, &#34;-0.3321300000&#34;, &#34;0.7403800000&#34;, &#34;-0.0275420000&#34;, &#34;-0.0581460000&#34;, &#34;-0.2213900000&#34;, &#34;0.0869770000&#34;, &#34;0.4184900000&#34;, &#34;-0.1886400000&#34;, &#34;0.4007800000&#34;, &#34;0.2311300000&#34;, &#34;0.1741300000&#34;, &#34;0.3344600000&#34;, &#34;-0.3010300000&#34;, &#34;-0.1821600000&#34;, &#34;0.7534000000&#34;, &#34;-0.3557000000&#34;, &#34;-0.2855800000&#34;, &#34;0.0095493000&#34;, &#34;-0.5681900000&#34;, &#34;0.1049900000&#34;, &#34;-0.1144700000&#34;, &#34;0.2515400000&#34;, &#34;-0.3135600000&#34;, &#34;-0.6600000000&#34;, &#34;0.1312800000&#34;, &#34;0.2128300000&#34;, &#34;-0.1066400000&#34;, &#34;0.1817900000&#34;, &#34;0.0611570000&#34;, &#34;0.4052800000&#34;, &#34;-0.0131620000&#34;, &#34;0.1683800000&#34;, &#34;-0.0057097000&#34;, &#34;0.2874300000&#34;, &#34;0.0248060000&#34;, &#34;-0.2986400000&#34;, &#34;0.0607920000&#34;, &#34;-0.1837400000&#34;, &#34;0.1848300000&#34;, &#34;0.0196420000&#34;, &#34;-0.3581200000&#34;, &#34;0.2625900000&#34;, &#34;0.1211600000&#34;, &#34;-0.3594200000&#34;, &#34;-0.1380800000&#34;, &#34;0.2121700000&#34;, &#34;-0.2607000000&#34;, &#34;-0.2744700000&#34;, &#34;-0.3924400000&#34;, &#34;0.1087600000&#34;, &#34;0.3051100000&#34;, &#34;0.1226900000&#34;, &#34;-0.4248500000&#34;, &#34;-0.0759340000&#34;, &#34;0.1010800000&#34;, &#34;-0.4214200000&#34;, &#34;-0.6684900000&#34;, &#34;0.1061700000&#34;, &#34;-0.0502350000&#34;, &#34;-0.0975560000&#34;, &#34;-0.1387000000&#34;, &#34;0.4019400000&#34;, &#34;-0.3693400000&#34;, &#34;0.2467500000&#34;, &#34;0.1400000000&#34;, &#34;0.2109000000&#34;, &#34;-0.2712700000&#34;, &#34;0.2194000000&#34;, &#34;-0.0493550000&#34;, &#34;0.3635500000&#34;, &#34;-0.2876200000&#34;, &#34;0.3838900000&#34;, &#34;-0.0655080000&#34;, &#34;0.7611400000&#34;, &#34;0.1918600000&#34;, &#34;0.4933100000&#34;, &#34;0.0512070000&#34;, &#34;-0.0441210000&#34;, &#34;-0.1881400000&#34;, &#34;0.0263140000&#34;, &#34;0.1479400000&#34;, &#34;0.4528900000&#34;, &#34;0.1681000000&#34;, &#34;-0.2359600000&#34;, &#34;0.4548100000&#34;, &#34;-0.1847000000&#34;, &#34;0.0072012000&#34;, &#34;-0.4249700000&#34;, &#34;0.2303500000&#34;, &#34;-0.0514900000&#34;, &#34;0.0759190000&#34;, &#34;0.2862200000&#34;, &#34;-0.2176900000&#34;, &#34;-0.2780600000&#34;, &#34;0.4701800000&#34;, &#34;0.0066373000&#34;, &#34;0.0284700000&#34;, &#34;-0.2938900000&#34;, &#34;0.2662000000&#34;, &#34;0.0508210000&#34;, &#34;-0.1260300000&#34;, &#34;-0.3013000000&#34;, &#34;-0.1193200000&#34;, &#34;0.2994300000&#34;, &#34;-0.4114900000&#34;, &#34;-0.2179900000&#34;, &#34;-0.3400100000&#34;, &#34;0.5519200000&#34;, &#34;-0.0458200000&#34;, &#34;-0.0102490000&#34;, &#34;-0.5164800000&#34;, &#34;-0.5789100000&#34;, &#34;0.0335170000&#34;, &#34;-0.1876100000&#34;, &#34;0.3194000000&#34;, &#34;0.1623900000&#34;, &#34;0.2697900000&#34;, &#34;-0.2737500000&#34;, &#34;0.0049825000&#34;, &#34;0.4875700000&#34;, &#34;0.5360200000&#34;, &#34;0.1312700000&#34;, &#34;0.1804500000&#34;, &#34;-0.6424600000&#34;, &#34;-0.3519600000&#34;, &#34;-0.2902300000&#34;, &#34;0.1350800000&#34;, &#34;-0.0327020000&#34;, &#34;-0.3141600000&#34;, &#34;0.1261500000&#34;, &#34;0.1984500000&#34;, &#34;0.2206800000&#34;, &#34;0.1732000000&#34;, &#34;-0.2917400000&#34;, &#34;-0.3712800000&#34;, &#34;-0.1567800000&#34;, &#34;-0.1238400000&#34;, &#34;0.0504430000&#34;, &#34;-0.0666780000&#34;, &#34;-0.5873100000&#34;, &#34;-0.2468000000&#34;, &#34;-0.0337500000&#34;, &#34;0.4086200000&#34;, &#34;-0.0480300000&#34;, &#34;0.5460400000&#34;, &#34;0.0845210000&#34;, &#34;0.2171700000&#34;, &#34;0.5037900000&#34;, &#34;0.3088900000&#34;, &#34;-0.4551900000&#34;, &#34;-0.3263000000&#34;, &#34;-0.5679400000&#34;, &#34;0.0633180000&#34;, &#34;0.0841560000&#34;, &#34;0.0090246000&#34;, &#34;0.1762800000&#34;, &#34;0.3983600000&#34;, &#34;0.6389500000&#34;, &#34;0.1402900000&#34;, &#34;-0.0057605000&#34;, &#34;-0.2321600000&#34;, &#34;-0.4368900000&#34;, &#34;0.0136430000&#34;, &#34;-0.1616300000&#34;, &#34;0.1766800000&#34;, &#34;-0.0056310000&#34;, &#34;-0.4336600000&#34;, &#34;-0.1409900000&#34;, &#34;0.4197400000&#34;, &#34;0.0091529000&#34;, &#34;-0.1334500000&#34;, &#34;-0.4143500000&#34;, &#34;-0.1956300000&#34;, &#34;0.3126700000&#34;, &#34;0.1455300000&#34;, &#34;0.0933600000&#34;, &#34;0.2726400000&#34;, &#34;-0.4169600000&#34;, &#34;-0.6605300000&#34;, &#34;0.4904700000&#34;, &#34;0.3367900000&#34;, &#34;-0.1244500000&#34;, &#34;-0.3173500000&#34;, &#34;-0.8259700000&#34;, &#34;-0.0970430000&#34;, &#34;0.0334070000&#34;, &#34;-0.2525100000&#34;, &#34;0.0437130000&#34;, &#34;-0.2893600000&#34;, &#34;0.1854300000&#34;, &#34;0.3990200000&#34;, &#34;-0.0563480000&#34;, &#34;-0.1447100000&#34;, &#34;0.1710800000&#34;, &#34;0.1277400000&#34;, &#34;0.3424800000&#34;, &#34;-0.3259100000&#34;, &#34;-0.2452800000&#34;, &#34;-0.7021700000&#34;, &#34;-0.1631100000&#34;, &#34;0.0105840000&#34;, &#34;-0.0852060000&#34;, &#34;-0.1944300000&#34;, &#34;-0.1338100000&#34;, &#34;-0.1362900000&#34;, &#34;-0.3097300000&#34;, &#34;0.3536200000&#34;, &#34;-0.1985100000&#34;, &#34;-0.4806200000&#34;, &#34;-0.1549700000&#34;, &#34;0.0440020000&#34;, &#34;-0.2656100000&#34;, &#34;-0.1193800000&#34;, &#34;0.2374200000&#34;, &#34;0.3663700000&#34;, &#34;0.2077800000&#34;, &#34;-0.5147400000&#34;, &#34;-0.0764550000&#34;, &#34;0.5292200000&#34;, &#34;-0.2214200000&#34;, &#34;0.3417900000&#34;, &#34;-0.1087000000&#34;, &#34;-0.7125100000&#34;, &#34;0.4339200000&#34;, &#34;-0.0127000000&#34;, &#34;0.1711800000&#34;, &#34;0.2068900000&#34;, &#34;0.1402600000&#34;, &#34;-0.1459300000&#34;, &#34;-0.2484100000&#34;, &#34;0.5119900000&#34;, &#34;0.5650100000&#34;, &#34;0.3061400000&#34;, &#34;0.3182900000&#34;], [&#34;-0.0315330000&#34;, &#34;0.0462780000&#34;, &#34;-0.1253400000&#34;, &#34;0.1916500000&#34;, &#34;-0.1266000000&#34;, &#34;-0.0128530000&#34;, &#34;0.1034200000&#34;, &#34;-0.0098085000&#34;, &#34;0.1518900000&#34;, &#34;0.2758200000&#34;, &#34;0.1369500000&#34;, &#34;0.0088799000&#34;, &#34;0.1413200000&#34;, &#34;-0.1200000000&#34;, &#34;-0.0634390000&#34;, &#34;-0.1517800000&#34;, &#34;0.0980900000&#34;, &#34;-0.1201000000&#34;, &#34;-0.0690860000&#34;, &#34;0.0146660000&#34;, &#34;-0.0230410000&#34;, &#34;0.0304300000&#34;, &#34;-0.1266400000&#34;, &#34;-0.0632820000&#34;, &#34;-0.0822460000&#34;, &#34;0.0367180000&#34;, &#34;0.2269800000&#34;, &#34;-0.0960250000&#34;, &#34;-0.0116990000&#34;, &#34;0.0661580000&#34;, &#34;-0.1854200000&#34;, &#34;0.1922300000&#34;, &#34;-0.0616850000&#34;, &#34;0.2704900000&#34;, &#34;0.0751160000&#34;, &#34;-0.0549280000&#34;, &#34;-0.0860270000&#34;, &#34;-0.1938700000&#34;, &#34;0.1467700000&#34;, &#34;-0.0601300000&#34;, &#34;0.0682690000&#34;, &#34;0.0716130000&#34;, &#34;-0.0944140000&#34;, &#34;0.0361580000&#34;, &#34;0.0027820000&#34;, &#34;-0.0817110000&#34;, &#34;-0.0133690000&#34;, &#34;-0.0530170000&#34;, &#34;0.0522270000&#34;, &#34;-0.0796820000&#34;, &#34;-0.0003176800&#34;, &#34;0.0303970000&#34;, &#34;-0.1684700000&#34;, &#34;0.0218280000&#34;, &#34;-0.1957700000&#34;, &#34;-0.0501090000&#34;, &#34;-0.0096879000&#34;, &#34;0.0855360000&#34;, &#34;-0.2813500000&#34;, &#34;0.1700100000&#34;, &#34;-0.0491940000&#34;, &#34;-0.1672100000&#34;, &#34;0.1901800000&#34;, &#34;-0.0474000000&#34;, &#34;-0.0003641200&#34;, &#34;0.0263160000&#34;, &#34;-0.2213500000&#34;, &#34;-0.0615830000&#34;, &#34;-0.2185400000&#34;, &#34;-0.0216690000&#34;, &#34;-0.2963000000&#34;, &#34;-0.0719490000&#34;, &#34;0.0106380000&#34;, &#34;-0.1905500000&#34;, &#34;-0.1129200000&#34;, &#34;-0.0990720000&#34;, &#34;0.1935700000&#34;, &#34;0.1411500000&#34;, &#34;0.0683460000&#34;, &#34;-0.0004594700&#34;, &#34;0.0726210000&#34;, &#34;-0.0211920000&#34;, &#34;-0.1242000000&#34;, &#34;-0.0419330000&#34;, &#34;-0.0283860000&#34;, &#34;0.0490830000&#34;, &#34;-0.0735740000&#34;, &#34;0.0735250000&#34;, &#34;0.0881350000&#34;, &#34;-0.0321840000&#34;, &#34;0.0299030000&#34;, &#34;-0.0700250000&#34;, &#34;0.1532300000&#34;, &#34;-0.1723600000&#34;, &#34;0.0735020000&#34;, &#34;0.1323200000&#34;, &#34;0.0901910000&#34;, &#34;0.0079023000&#34;, &#34;-0.0278870000&#34;, &#34;-0.0469710000&#34;, &#34;0.0391980000&#34;, &#34;-0.1256700000&#34;, &#34;0.1980300000&#34;, &#34;-0.0759950000&#34;, &#34;-0.2135300000&#34;, &#34;0.0319640000&#34;, &#34;-0.1734600000&#34;, &#34;0.0558840000&#34;, &#34;-0.0554040000&#34;, &#34;-0.0083924000&#34;, &#34;-0.0241040000&#34;, &#34;0.0023894000&#34;, &#34;-0.1057000000&#34;, &#34;-0.1060400000&#34;, &#34;-0.0613230000&#34;, &#34;-0.0414730000&#34;, &#34;0.0060497000&#34;, &#34;0.0558960000&#34;, &#34;-0.0713380000&#34;, &#34;0.1375000000&#34;, &#34;0.0947810000&#34;, &#34;0.0481210000&#34;, &#34;-0.0712360000&#34;, &#34;0.2626300000&#34;, &#34;0.0725700000&#34;, &#34;-0.0002034400&#34;, &#34;0.1864000000&#34;, &#34;0.0667030000&#34;, &#34;0.0552290000&#34;, &#34;0.1125800000&#34;, &#34;0.0476470000&#34;, &#34;0.0854820000&#34;, &#34;-0.1448900000&#34;, &#34;0.0098078000&#34;, &#34;0.0825850000&#34;, &#34;0.0392540000&#34;, &#34;-0.1004400000&#34;, &#34;0.1653200000&#34;, &#34;-0.0308410000&#34;, &#34;0.1031500000&#34;, &#34;-0.0465840000&#34;, &#34;0.1121100000&#34;, &#34;0.1541600000&#34;, &#34;-0.0503090000&#34;, &#34;0.1485300000&#34;, &#34;0.2287000000&#34;, &#34;-0.0560360000&#34;, &#34;-0.0729660000&#34;, &#34;0.0018167000&#34;, &#34;-0.0156940000&#34;, &#34;-0.0602200000&#34;, &#34;-0.1904400000&#34;, &#34;-0.0750730000&#34;, &#34;-0.0032815000&#34;, &#34;-0.0792560000&#34;, &#34;-0.0783240000&#34;, &#34;-0.1107300000&#34;, &#34;-0.0937050000&#34;, &#34;0.2628400000&#34;, &#34;0.0103400000&#34;, &#34;-0.0950000000&#34;, &#34;0.1729500000&#34;, &#34;-0.0539490000&#34;, &#34;0.1505600000&#34;, &#34;0.2281500000&#34;, &#34;-0.1658900000&#34;, &#34;-0.0800740000&#34;, &#34;-0.0762480000&#34;, &#34;0.1342300000&#34;, &#34;-0.0936260000&#34;, &#34;-0.0653840000&#34;, &#34;-0.0141810000&#34;, &#34;-0.0679370000&#34;, &#34;-0.0382830000&#34;, &#34;-0.0845140000&#34;, &#34;0.1108200000&#34;, &#34;0.0688040000&#34;, &#34;0.1940200000&#34;, &#34;-0.0693730000&#34;, &#34;-0.0433980000&#34;, &#34;0.1540200000&#34;, &#34;-0.1017200000&#34;, &#34;0.0497850000&#34;, &#34;-0.0100050000&#34;, &#34;-0.0337100000&#34;, &#34;0.2901800000&#34;, &#34;0.0254050000&#34;, &#34;-0.0949190000&#34;, &#34;0.0938760000&#34;, &#34;-0.0554230000&#34;, &#34;-0.0594190000&#34;, &#34;-0.0825420000&#34;, &#34;0.0940480000&#34;, &#34;0.0594220000&#34;, &#34;-0.0325640000&#34;, &#34;-0.0062017000&#34;, &#34;-0.0095274000&#34;, &#34;0.0924390000&#34;, &#34;-0.1699500000&#34;, &#34;0.0003890400&#34;, &#34;0.1918700000&#34;, &#34;-0.0250480000&#34;, &#34;-0.1184400000&#34;, &#34;0.0278790000&#34;, &#34;-0.0340240000&#34;, &#34;-0.0468660000&#34;, &#34;-0.0900900000&#34;, &#34;-0.0344170000&#34;, &#34;0.2553400000&#34;, &#34;0.0967780000&#34;, &#34;0.2084100000&#34;, &#34;0.0296930000&#34;, &#34;-0.0159430000&#34;, &#34;-0.0357790000&#34;, &#34;0.0021559000&#34;, &#34;0.0802460000&#34;, &#34;-0.0313550000&#34;, &#34;-0.2267600000&#34;, &#34;-0.1157900000&#34;, &#34;-0.0595790000&#34;, &#34;-0.0744200000&#34;, &#34;-0.1287100000&#34;, &#34;-0.1019900000&#34;, &#34;0.0649690000&#34;, &#34;-0.0703880000&#34;, &#34;-0.0401310000&#34;, &#34;-0.1474000000&#34;, &#34;-0.0988390000&#34;, &#34;0.1161400000&#34;, &#34;0.1587100000&#34;, &#34;0.0693000000&#34;, &#34;0.0318970000&#34;, &#34;-0.0287380000&#34;, &#34;-0.0846340000&#34;, &#34;-0.1486400000&#34;, &#34;0.1139800000&#34;, &#34;0.0726880000&#34;, &#34;-0.0657520000&#34;, &#34;-0.0132960000&#34;, &#34;0.0851640000&#34;, &#34;0.0250530000&#34;, &#34;0.0168670000&#34;, &#34;-0.0452570000&#34;, &#34;-0.0429250000&#34;, &#34;0.1232900000&#34;, &#34;0.1301200000&#34;, &#34;-0.0153200000&#34;, &#34;-0.1394300000&#34;, &#34;0.0897640000&#34;, &#34;0.0821720000&#34;, &#34;-0.0819180000&#34;, &#34;-0.0116880000&#34;, &#34;-0.1174200000&#34;, &#34;0.0292420000&#34;, &#34;-0.0658140000&#34;, &#34;0.0299590000&#34;, &#34;-0.0109410000&#34;, &#34;-0.0183000000&#34;, &#34;0.0571800000&#34;, &#34;0.0684360000&#34;, &#34;0.0072271000&#34;, &#34;0.0057584000&#34;, &#34;0.0714660000&#34;, &#34;-0.0831640000&#34;, &#34;-0.0150100000&#34;, &#34;-0.0780600000&#34;, &#34;0.0033293000&#34;, &#34;0.0991320000&#34;, &#34;0.0611880000&#34;, &#34;-0.0978150000&#34;, &#34;-0.1400800000&#34;, &#34;-0.0026304000&#34;, &#34;0.0022269000&#34;, &#34;0.0834960000&#34;, &#34;-0.1433400000&#34;, &#34;-0.0374470000&#34;, &#34;0.0615640000&#34;, &#34;0.2153600000&#34;, &#34;-0.0368360000&#34;, &#34;0.0386290000&#34;, &#34;0.1303100000&#34;, &#34;0.0459440000&#34;, &#34;0.0277010000&#34;, &#34;0.0616790000&#34;, &#34;0.0629210000&#34;, &#34;0.0684530000&#34;, &#34;-0.0262920000&#34;, &#34;0.1734200000&#34;, &#34;-0.1442100000&#34;, &#34;-0.0131240000&#34;, &#34;0.1549400000&#34;, &#34;-0.1078600000&#34;, &#34;0.1831400000&#34;, &#34;0.1388100000&#34;, &#34;0.0275700000&#34;, &#34;-0.0350730000&#34;, &#34;-0.0178290000&#34;, &#34;0.1116300000&#34;, &#34;-0.0582310000&#34;, &#34;0.0119770000&#34;], [&#34;-0.1587600000&#34;, &#34;-0.3227800000&#34;, &#34;-0.3359300000&#34;, &#34;0.3772600000&#34;, &#34;0.0181430000&#34;, &#34;-0.0432970000&#34;, &#34;0.1131200000&#34;, &#34;0.3340600000&#34;, &#34;0.0813920000&#34;, &#34;0.3173600000&#34;, &#34;-0.6511300000&#34;, &#34;0.3122200000&#34;, &#34;-0.3403500000&#34;, &#34;-0.0143110000&#34;, &#34;0.0947010000&#34;, &#34;0.1030300000&#34;, &#34;-0.0264650000&#34;, &#34;-0.2975800000&#34;, &#34;0.2857200000&#34;, &#34;0.1407000000&#34;, &#34;0.4714900000&#34;, &#34;-0.2468500000&#34;, &#34;0.0218830000&#34;, &#34;-0.2756400000&#34;, &#34;-0.2135600000&#34;, &#34;-0.1009600000&#34;, &#34;0.0781600000&#34;, &#34;-0.0266210000&#34;, &#34;-0.3624200000&#34;, &#34;0.1317900000&#34;, &#34;-0.0128400000&#34;, &#34;0.3227500000&#34;, &#34;-0.2141200000&#34;, &#34;0.5504600000&#34;, &#34;0.0096127000&#34;, &#34;-0.0289060000&#34;, &#34;0.0297310000&#34;, &#34;-0.1070000000&#34;, &#34;-0.0262920000&#34;, &#34;-0.2351100000&#34;, &#34;-0.2201000000&#34;, &#34;-0.3021400000&#34;, &#34;0.2727900000&#34;, &#34;-0.0970060000&#34;, &#34;0.1617500000&#34;, &#34;0.3892400000&#34;, &#34;0.1930100000&#34;, &#34;0.1013100000&#34;, &#34;0.2822700000&#34;, &#34;-0.0601160000&#34;, &#34;-0.2111700000&#34;, &#34;-0.0417050000&#34;, &#34;-0.2473800000&#34;, &#34;-0.2462600000&#34;, &#34;0.2009900000&#34;, &#34;0.2127100000&#34;, &#34;0.1202300000&#34;, &#34;0.4742100000&#34;, &#34;0.2738700000&#34;, &#34;-0.3520600000&#34;, &#34;-0.1265300000&#34;, &#34;0.1471700000&#34;, &#34;0.2083000000&#34;, &#34;0.0757050000&#34;, &#34;0.1981700000&#34;, &#34;-0.1608700000&#34;, &#34;-0.3880500000&#34;, &#34;0.1526500000&#34;, &#34;-0.0720210000&#34;, &#34;-0.1207400000&#34;, &#34;0.2680500000&#34;, &#34;0.0079369000&#34;, &#34;0.3982100000&#34;, &#34;0.0477760000&#34;, &#34;-0.2226300000&#34;, &#34;-0.2731800000&#34;, &#34;0.3082700000&#34;, &#34;-0.0780150000&#34;, &#34;0.6067500000&#34;, &#34;0.0958000000&#34;, &#34;-0.2810400000&#34;, &#34;0.0069502000&#34;, &#34;0.0300680000&#34;, &#34;0.1701500000&#34;, &#34;0.2536200000&#34;, &#34;-0.1601700000&#34;, &#34;0.1847200000&#34;, &#34;-0.1219200000&#34;, &#34;-0.2927000000&#34;, &#34;-0.2109100000&#34;, &#34;-0.0316770000&#34;, &#34;-0.0606560000&#34;, &#34;0.2542000000&#34;, &#34;-0.4263400000&#34;, &#34;0.3392500000&#34;, &#34;0.0381370000&#34;, &#34;0.2056600000&#34;, &#34;0.1665800000&#34;, &#34;0.2306600000&#34;, &#34;-0.3268600000&#34;, &#34;0.2220000000&#34;, &#34;0.0315130000&#34;, &#34;0.2612500000&#34;, &#34;-0.3222300000&#34;, &#34;-0.1175300000&#34;, &#34;-0.2433500000&#34;, &#34;-0.1013900000&#34;, &#34;0.2406800000&#34;, &#34;0.2898800000&#34;, &#34;0.0240570000&#34;, &#34;-0.2951700000&#34;, &#34;0.1695700000&#34;, &#34;0.4008100000&#34;, &#34;-0.0042294000&#34;, &#34;-0.0335240000&#34;, &#34;0.0333200000&#34;, &#34;0.0429930000&#34;, &#34;0.3818900000&#34;, &#34;0.0941170000&#34;, &#34;0.5117400000&#34;, &#34;0.1200700000&#34;, &#34;-0.2027800000&#34;, &#34;0.0749920000&#34;, &#34;0.3657700000&#34;, &#34;-0.6609300000&#34;, &#34;-0.3408200000&#34;, &#34;0.2731700000&#34;, &#34;0.1198500000&#34;, &#34;-0.1932600000&#34;, &#34;-0.0202370000&#34;, &#34;0.2031300000&#34;, &#34;0.1111300000&#34;, &#34;-0.1025100000&#34;, &#34;0.0484810000&#34;, &#34;0.1543400000&#34;, &#34;-0.0066719000&#34;, &#34;-0.1572600000&#34;, &#34;-0.1875100000&#34;, &#34;0.0743050000&#34;, &#34;0.2277600000&#34;, &#34;0.1359300000&#34;, &#34;0.3004500000&#34;, &#34;0.0681940000&#34;, &#34;-0.1956300000&#34;, &#34;-0.4441500000&#34;, &#34;0.1899800000&#34;, &#34;0.1851300000&#34;, &#34;0.1271800000&#34;, &#34;0.0233870000&#34;, &#34;-0.3482400000&#34;, &#34;0.2604500000&#34;, &#34;-0.0486800000&#34;, &#34;0.0026238000&#34;, &#34;-0.4195600000&#34;, &#34;-0.0549180000&#34;, &#34;-0.1955500000&#34;, &#34;-0.1820000000&#34;, &#34;-0.3471300000&#34;, &#34;0.2985400000&#34;, &#34;-0.0061094000&#34;, &#34;-0.1142100000&#34;, &#34;0.0122620000&#34;, &#34;-0.3194700000&#34;, &#34;-0.3279700000&#34;, &#34;0.0911590000&#34;, &#34;0.5112700000&#34;, &#34;0.2883100000&#34;, &#34;-0.3982400000&#34;, &#34;0.0116600000&#34;, &#34;-0.0952440000&#34;, &#34;-0.2137700000&#34;, &#34;-0.0727480000&#34;, &#34;-0.4034500000&#34;, &#34;0.3805100000&#34;, &#34;0.1486700000&#34;, &#34;-0.0929530000&#34;, &#34;-0.4091000000&#34;, &#34;0.2761400000&#34;, &#34;0.2208600000&#34;, &#34;0.0716520000&#34;, &#34;-0.1259000000&#34;, &#34;-0.2557700000&#34;, &#34;0.2259900000&#34;, &#34;0.2915500000&#34;, &#34;-0.3567100000&#34;, &#34;0.2179500000&#34;, &#34;0.0748660000&#34;, &#34;-0.2928200000&#34;, &#34;0.1110700000&#34;, &#34;-0.0321290000&#34;, &#34;-0.2541200000&#34;, &#34;-0.4156600000&#34;, &#34;0.3442900000&#34;, &#34;0.3934500000&#34;, &#34;-0.3489600000&#34;, &#34;-0.0745850000&#34;, &#34;0.1719800000&#34;, &#34;0.1018100000&#34;, &#34;-0.7027900000&#34;, &#34;-0.2589900000&#34;, &#34;0.2178400000&#34;, &#34;0.1526600000&#34;, &#34;0.3109000000&#34;, &#34;-0.3097300000&#34;, &#34;0.0234520000&#34;, &#34;-0.3409200000&#34;, &#34;-0.4034900000&#34;, &#34;-0.2364100000&#34;, &#34;-0.1380800000&#34;, &#34;-0.1189200000&#34;, &#34;0.4886600000&#34;, &#34;0.0729720000&#34;, &#34;0.4358600000&#34;, &#34;0.3096100000&#34;, &#34;-0.0931440000&#34;, &#34;-0.3680700000&#34;, &#34;0.1772000000&#34;, &#34;-0.3639400000&#34;, &#34;0.1151000000&#34;, &#34;-0.2219700000&#34;, &#34;-0.0662020000&#34;, &#34;0.0569440000&#34;, &#34;0.2996900000&#34;, &#34;0.2226600000&#34;, &#34;-0.4408000000&#34;, &#34;0.6536600000&#34;, &#34;-0.3059300000&#34;, &#34;-0.1836900000&#34;, &#34;0.1697000000&#34;, &#34;-0.0735740000&#34;, &#34;0.2771500000&#34;, &#34;0.1002600000&#34;, &#34;0.0886740000&#34;, &#34;-0.2617200000&#34;, &#34;-0.0674060000&#34;, &#34;0.1481900000&#34;, &#34;0.2398500000&#34;, &#34;-0.1801000000&#34;, &#34;0.2293500000&#34;, &#34;0.3916000000&#34;, &#34;-0.0148380000&#34;, &#34;-0.0284200000&#34;, &#34;-0.0851330000&#34;, &#34;0.1336000000&#34;, &#34;-0.0623770000&#34;, &#34;0.2805400000&#34;, &#34;-0.1503900000&#34;, &#34;-0.0478630000&#34;, &#34;0.2532000000&#34;, &#34;0.3712600000&#34;, &#34;-0.0988940000&#34;, &#34;0.0769980000&#34;, &#34;-0.0333030000&#34;, &#34;0.2335400000&#34;, &#34;-0.0862550000&#34;, &#34;0.1724700000&#34;, &#34;0.1407700000&#34;, &#34;0.0133260000&#34;, &#34;0.1846500000&#34;, &#34;0.1063000000&#34;, &#34;-0.0403180000&#34;, &#34;0.2216400000&#34;, &#34;0.5125000000&#34;, &#34;-0.0494960000&#34;, &#34;-0.3136200000&#34;, &#34;0.1578700000&#34;, &#34;0.1495300000&#34;, &#34;0.2847800000&#34;, &#34;-0.3695700000&#34;, &#34;-0.2211000000&#34;, &#34;-0.2212000000&#34;, &#34;0.1326000000&#34;, &#34;0.2133000000&#34;, &#34;0.3313100000&#34;, &#34;-0.5580700000&#34;, &#34;-0.2778400000&#34;, &#34;0.0173270000&#34;, &#34;-0.4024200000&#34;, &#34;-0.0102690000&#34;, &#34;-0.1359200000&#34;, &#34;-0.2050400000&#34;, &#34;-0.2245200000&#34;, &#34;-0.0172750000&#34;, &#34;0.1393200000&#34;, &#34;0.1057100000&#34;, &#34;-0.4470900000&#34;, &#34;0.4182100000&#34;, &#34;-0.1518400000&#34;, &#34;0.0130620000&#34;, &#34;0.0178030000&#34;, &#34;0.0209970000&#34;, &#34;0.0712130000&#34;, &#34;0.0926260000&#34;, &#34;0.0014617000&#34;, &#34;-0.1932800000&#34;, &#34;-0.2181800000&#34;, &#34;0.1399300000&#34;, &#34;0.2508200000&#34;, &#34;0.0280280000&#34;, &#34;-0.2789300000&#34;], [&#34;-0.0523090000&#34;, &#34;0.2665800000&#34;, &#34;-0.3307500000&#34;, &#34;0.1053000000&#34;, &#34;-0.3252100000&#34;, &#34;-0.3258600000&#34;, &#34;-0.2779200000&#34;, &#34;-0.2762400000&#34;, &#34;-0.0535120000&#34;, &#34;0.1969700000&#34;, &#34;-0.1683500000&#34;, &#34;-0.0741790000&#34;, &#34;-0.2795100000&#34;, &#34;0.1874800000&#34;, &#34;0.3636300000&#34;, &#34;-0.0343460000&#34;, &#34;0.0034359000&#34;, &#34;0.0694370000&#34;, &#34;0.2621400000&#34;, &#34;0.3995000000&#34;, &#34;-0.0571170000&#34;, &#34;0.1617900000&#34;, &#34;-0.2680600000&#34;, &#34;-0.1917100000&#34;, &#34;-0.4367500000&#34;, &#34;-0.0312640000&#34;, &#34;-0.1036400000&#34;, &#34;-0.0204780000&#34;, &#34;-0.1271200000&#34;, &#34;0.2809100000&#34;, &#34;0.0257580000&#34;, &#34;0.0885600000&#34;, &#34;-0.1328100000&#34;, &#34;-0.2613600000&#34;, &#34;-0.2562300000&#34;, &#34;-0.3481500000&#34;, &#34;0.2366100000&#34;, &#34;-0.1661100000&#34;, &#34;0.1263500000&#34;, &#34;-0.2177100000&#34;, &#34;0.5237100000&#34;, &#34;0.0348660000&#34;, &#34;-0.3854700000&#34;, &#34;-0.1805000000&#34;, &#34;0.1851300000&#34;, &#34;0.0513540000&#34;, &#34;0.0390160000&#34;, &#34;0.0303340000&#34;, &#34;0.1302200000&#34;, &#34;-0.2503400000&#34;, &#34;-0.1443400000&#34;, &#34;-0.0069149000&#34;, &#34;-0.0412930000&#34;, &#34;-0.0744350000&#34;, &#34;0.3769300000&#34;, &#34;0.0148660000&#34;, &#34;0.1352500000&#34;, &#34;-0.1433800000&#34;, &#34;-0.0192900000&#34;, &#34;-0.0956020000&#34;, &#34;-0.4735900000&#34;, &#34;-0.2745100000&#34;, &#34;0.1971700000&#34;, &#34;-0.2502800000&#34;, &#34;0.1090400000&#34;, &#34;-0.2183100000&#34;, &#34;-0.3640500000&#34;, &#34;-0.0252150000&#34;, &#34;0.0029815000&#34;, &#34;-0.1809100000&#34;, &#34;0.0151360000&#34;, &#34;-0.0723530000&#34;, &#34;-0.2393800000&#34;, &#34;0.0014383000&#34;, &#34;0.1144600000&#34;, &#34;0.1457600000&#34;, &#34;0.3139800000&#34;, &#34;0.2727300000&#34;, &#34;0.1515300000&#34;, &#34;-0.1210300000&#34;, &#34;0.1985700000&#34;, &#34;-0.0353030000&#34;, &#34;-0.3405400000&#34;, &#34;-0.2667000000&#34;, &#34;-0.1719400000&#34;, &#34;0.1369100000&#34;, &#34;0.2015100000&#34;, &#34;0.0296830000&#34;, &#34;0.3212700000&#34;, &#34;-0.1517900000&#34;, &#34;-0.4949500000&#34;, &#34;-0.2224600000&#34;, &#34;0.1629600000&#34;, &#34;-0.0825980000&#34;, &#34;0.1640500000&#34;, &#34;-0.0537130000&#34;, &#34;0.1062600000&#34;, &#34;0.0879090000&#34;, &#34;-0.0403420000&#34;, &#34;0.0248830000&#34;, &#34;-0.0331590000&#34;, &#34;-0.1199500000&#34;, &#34;0.0557670000&#34;, &#34;0.0614410000&#34;, &#34;0.1482100000&#34;, &#34;-0.2978200000&#34;, &#34;0.1739600000&#34;, &#34;0.2502600000&#34;, &#34;0.2588700000&#34;, &#34;-0.3141400000&#34;, &#34;-0.0317020000&#34;, &#34;0.4975700000&#34;, &#34;-0.1000300000&#34;, &#34;-0.1502300000&#34;, &#34;-0.1115500000&#34;, &#34;0.0118040000&#34;, &#34;0.1026300000&#34;, &#34;-0.1602800000&#34;, &#34;-0.1540300000&#34;, &#34;-0.0941530000&#34;, &#34;-0.0747390000&#34;, &#34;0.1678500000&#34;, &#34;-0.3977300000&#34;, &#34;0.1695800000&#34;, &#34;0.2269400000&#34;, &#34;0.1442100000&#34;, &#34;-0.0991110000&#34;, &#34;-0.0322830000&#34;, &#34;-0.4709700000&#34;, &#34;0.3251000000&#34;, &#34;-0.0434390000&#34;, &#34;-0.2292100000&#34;, &#34;0.0341340000&#34;, &#34;-0.1904500000&#34;, &#34;-0.0263260000&#34;, &#34;0.0424960000&#34;, &#34;-0.2934400000&#34;, &#34;0.0661140000&#34;, &#34;-0.0383760000&#34;, &#34;0.2520200000&#34;, &#34;-0.2320500000&#34;, &#34;0.3394200000&#34;, &#34;-0.0715850000&#34;, &#34;0.2545700000&#34;, &#34;0.0043527000&#34;, &#34;-0.2423400000&#34;, &#34;0.1613800000&#34;, &#34;0.1826500000&#34;, &#34;0.1417700000&#34;, &#34;0.0315390000&#34;, &#34;0.2728900000&#34;, &#34;-0.1275500000&#34;, &#34;-0.1180800000&#34;, &#34;-0.1475800000&#34;, &#34;0.1905000000&#34;, &#34;-0.2014400000&#34;, &#34;-0.1384200000&#34;, &#34;0.0865480000&#34;, &#34;-0.0022205000&#34;, &#34;-0.2578100000&#34;, &#34;0.0660550000&#34;, &#34;-0.0046081000&#34;, &#34;0.1155900000&#34;, &#34;0.1838300000&#34;, &#34;0.4447300000&#34;, &#34;0.2147300000&#34;, &#34;-0.3040000000&#34;, &#34;-0.1430200000&#34;, &#34;0.2544300000&#34;, &#34;0.1547000000&#34;, &#34;-0.5520200000&#34;, &#34;0.0660840000&#34;, &#34;-0.2717800000&#34;, &#34;0.3506900000&#34;, &#34;-0.0151610000&#34;, &#34;0.0985190000&#34;, &#34;-0.1620000000&#34;, &#34;-0.2963000000&#34;, &#34;-0.4363200000&#34;, &#34;-0.1256400000&#34;, &#34;0.1911800000&#34;, &#34;-0.0352810000&#34;, &#34;0.1363200000&#34;, &#34;0.3178500000&#34;, &#34;0.1294900000&#34;, &#34;0.6165000000&#34;, &#34;-0.3402400000&#34;, &#34;0.2943500000&#34;, &#34;-0.0869620000&#34;, &#34;-0.4286400000&#34;, &#34;-0.1893000000&#34;, &#34;-0.3347900000&#34;, &#34;0.0923770000&#34;, &#34;0.0800120000&#34;, &#34;-0.1322000000&#34;, &#34;-0.0549550000&#34;, &#34;0.1689600000&#34;, &#34;-0.0370430000&#34;, &#34;-0.4501700000&#34;, &#34;-0.3235400000&#34;, &#34;-0.1161100000&#34;, &#34;-0.3692300000&#34;, &#34;-0.0146730000&#34;, &#34;0.0314730000&#34;, &#34;-0.1917100000&#34;, &#34;-0.3675500000&#34;, &#34;-0.1943500000&#34;, &#34;0.1106700000&#34;, &#34;0.2250300000&#34;, &#34;-0.1847700000&#34;, &#34;0.6242600000&#34;, &#34;0.4363800000&#34;, &#34;0.0975350000&#34;, &#34;0.3124200000&#34;, &#34;0.3247100000&#34;, &#34;-0.3258600000&#34;, &#34;-0.2797100000&#34;, &#34;-0.6241900000&#34;, &#34;0.0450560000&#34;, &#34;0.4311600000&#34;, &#34;-0.3806500000&#34;, &#34;-0.2122000000&#34;, &#34;0.0478970000&#34;, &#34;0.1864700000&#34;, &#34;0.0286250000&#34;, &#34;-0.1867900000&#34;, &#34;-0.5833600000&#34;, &#34;-0.6953800000&#34;, &#34;-0.0776850000&#34;, &#34;0.2366500000&#34;, &#34;-0.2479400000&#34;, &#34;-0.0457940000&#34;, &#34;0.0851970000&#34;, &#34;0.0603540000&#34;, &#34;0.0143630000&#34;, &#34;-0.0620990000&#34;, &#34;0.2408800000&#34;, &#34;-0.3537800000&#34;, &#34;0.4175300000&#34;, &#34;0.2923900000&#34;, &#34;0.1785600000&#34;, &#34;-0.0163310000&#34;, &#34;-0.0095452000&#34;, &#34;-0.1880500000&#34;, &#34;-0.3723500000&#34;, &#34;0.2063400000&#34;, &#34;-0.1614900000&#34;, &#34;-0.4303400000&#34;, &#34;-0.2321500000&#34;, &#34;0.0587000000&#34;, &#34;-0.0318890000&#34;, &#34;-0.2462900000&#34;, &#34;-0.0038514000&#34;, &#34;0.1322600000&#34;, &#34;-0.4549300000&#34;, &#34;-0.0139040000&#34;, &#34;0.0713100000&#34;, &#34;-0.3762300000&#34;, &#34;-0.0745100000&#34;, &#34;-0.1904000000&#34;, &#34;-0.2019900000&#34;, &#34;0.1999300000&#34;, &#34;0.1617300000&#34;, &#34;-0.5173500000&#34;, &#34;-0.3040400000&#34;, &#34;-0.1386000000&#34;, &#34;-0.2150100000&#34;, &#34;-0.0667560000&#34;, &#34;-0.3111200000&#34;, &#34;-0.0036347000&#34;, &#34;-0.2470800000&#34;, &#34;-0.2344100000&#34;, &#34;-0.0708040000&#34;, &#34;0.2091300000&#34;, &#34;-0.0409730000&#34;, &#34;-0.0256060000&#34;, &#34;0.1770600000&#34;, &#34;0.2917000000&#34;, &#34;0.1914900000&#34;, &#34;-0.1772700000&#34;, &#34;-0.0403130000&#34;, &#34;-0.2448500000&#34;, &#34;-0.0863410000&#34;, &#34;-0.0036669000&#34;, &#34;0.3125200000&#34;, &#34;-0.0368460000&#34;, &#34;0.2402000000&#34;, &#34;-0.5649400000&#34;, &#34;-0.2658100000&#34;, &#34;0.2239800000&#34;, &#34;0.1460900000&#34;, &#34;0.3064000000&#34;, &#34;0.3317100000&#34;, &#34;0.1802400000&#34;, &#34;-0.4603000000&#34;, &#34;-0.2471800000&#34;, &#34;0.1571900000&#34;, &#34;0.2939100000&#34;, &#34;0.0876830000&#34;, &#34;-0.0864860000&#34;], [&#34;0.1236700000&#34;, &#34;-0.1396500000&#34;, &#34;0.0448770000&#34;, &#34;0.1891900000&#34;, &#34;-0.1099700000&#34;, &#34;-0.0064458000&#34;, &#34;0.0504990000&#34;, &#34;-0.2043900000&#34;, &#34;-0.0157610000&#34;, &#34;0.1504900000&#34;, &#34;0.1377400000&#34;, &#34;-0.0682410000&#34;, &#34;0.1707800000&#34;, &#34;-0.1352900000&#34;, &#34;-0.1832400000&#34;, &#34;-0.0003556700&#34;, &#34;-0.0995660000&#34;, &#34;-0.1454900000&#34;, &#34;0.0671830000&#34;, &#34;0.0282730000&#34;, &#34;-0.1008400000&#34;, &#34;0.1049800000&#34;, &#34;-0.2461300000&#34;, &#34;0.0088310000&#34;, &#34;-0.1843700000&#34;, &#34;0.0500110000&#34;, &#34;-0.0328390000&#34;, &#34;-0.0691290000&#34;, &#34;0.0043659000&#34;, &#34;0.1101100000&#34;, &#34;-0.3227200000&#34;, &#34;0.2662500000&#34;, &#34;-0.1246500000&#34;, &#34;0.3215700000&#34;, &#34;0.0679820000&#34;, &#34;-0.2267100000&#34;, &#34;0.0818430000&#34;, &#34;0.1143500000&#34;, &#34;0.0620670000&#34;, &#34;-0.0729730000&#34;, &#34;-0.0134150000&#34;, &#34;-0.0484930000&#34;, &#34;-0.1142600000&#34;, &#34;0.0697430000&#34;, &#34;-0.0709370000&#34;, &#34;-0.0628860000&#34;, &#34;-0.0156920000&#34;, &#34;-0.0336630000&#34;, &#34;0.1044100000&#34;, &#34;0.0050113000&#34;, &#34;-0.0017716000&#34;, &#34;0.0117200000&#34;, &#34;-0.0861680000&#34;, &#34;0.0122210000&#34;, &#34;-0.1481700000&#34;, &#34;0.0353730000&#34;, &#34;0.0398690000&#34;, &#34;0.2990400000&#34;, &#34;0.0246700000&#34;, &#34;0.1809600000&#34;, &#34;0.0708580000&#34;, &#34;-0.3536000000&#34;, &#34;0.0905180000&#34;, &#34;-0.1290500000&#34;, &#34;-0.0104430000&#34;, &#34;-0.1869700000&#34;, &#34;-0.2125800000&#34;, &#34;-0.0446440000&#34;, &#34;-0.2533300000&#34;, &#34;0.1003100000&#34;, &#34;-0.1736900000&#34;, &#34;-0.0373540000&#34;, &#34;-0.0309310000&#34;, &#34;-0.0919720000&#34;, &#34;-0.0682330000&#34;, &#34;0.0223660000&#34;, &#34;0.1256900000&#34;, &#34;0.1374900000&#34;, &#34;-0.0795470000&#34;, &#34;0.0071489000&#34;, &#34;-0.1511700000&#34;, &#34;0.2753800000&#34;, &#34;0.1396400000&#34;, &#34;0.0088001000&#34;, &#34;-0.0032892000&#34;, &#34;-0.2131300000&#34;, &#34;-0.0605430000&#34;, &#34;-0.1232100000&#34;, &#34;-0.1487500000&#34;, &#34;-0.2236200000&#34;, &#34;-0.2102400000&#34;, &#34;-0.0888030000&#34;, &#34;0.2922200000&#34;, &#34;-0.2596700000&#34;, &#34;0.2233100000&#34;, &#34;-0.0453370000&#34;, &#34;-0.0318100000&#34;, &#34;0.2028200000&#34;, &#34;-0.0727630000&#34;, &#34;0.0842300000&#34;, &#34;-0.1361900000&#34;, &#34;-0.0653910000&#34;, &#34;0.0456860000&#34;, &#34;0.1329200000&#34;, &#34;-0.1604500000&#34;, &#34;0.0683270000&#34;, &#34;-0.0858540000&#34;, &#34;0.1138000000&#34;, &#34;-0.0373010000&#34;, &#34;0.1485000000&#34;, &#34;0.1142900000&#34;, &#34;0.0751520000&#34;, &#34;-0.0826890000&#34;, &#34;-0.1272000000&#34;, &#34;-0.0255670000&#34;, &#34;0.0070075000&#34;, &#34;0.2604500000&#34;, &#34;-0.0658110000&#34;, &#34;0.0327150000&#34;, &#34;0.1979600000&#34;, &#34;0.1615400000&#34;, &#34;0.0461600000&#34;, &#34;-0.1811000000&#34;, &#34;0.2221000000&#34;, &#34;-0.0976020000&#34;, &#34;-0.1694600000&#34;, &#34;0.1414200000&#34;, &#34;0.0990350000&#34;, &#34;0.1553600000&#34;, &#34;0.1927700000&#34;, &#34;-0.0770730000&#34;, &#34;0.1304000000&#34;, &#34;0.0783040000&#34;, &#34;0.0732620000&#34;, &#34;-0.1485800000&#34;, &#34;0.1540000000&#34;, &#34;-0.1068800000&#34;, &#34;0.0550930000&#34;, &#34;0.0086387000&#34;, &#34;0.1932600000&#34;, &#34;-0.0268620000&#34;, &#34;0.2605700000&#34;, &#34;0.0527280000&#34;, &#34;-0.1146300000&#34;, &#34;0.1786900000&#34;, &#34;0.3908300000&#34;, &#34;0.2517200000&#34;, &#34;0.1414000000&#34;, &#34;-0.0663810000&#34;, &#34;0.0981100000&#34;, &#34;-0.1260400000&#34;, &#34;-0.0534040000&#34;, &#34;-0.1278300000&#34;, &#34;0.0151130000&#34;, &#34;-0.1591200000&#34;, &#34;-0.1964700000&#34;, &#34;0.1783100000&#34;, &#34;0.0119900000&#34;, &#34;0.0790110000&#34;, &#34;0.0381480000&#34;, &#34;-0.1492000000&#34;, &#34;0.3732400000&#34;, &#34;-0.2612100000&#34;, &#34;0.1281300000&#34;, &#34;0.1283600000&#34;, &#34;0.0535780000&#34;, &#34;-0.0765070000&#34;, &#34;0.0766710000&#34;, &#34;0.1352600000&#34;, &#34;-0.0133000000&#34;, &#34;-0.1612300000&#34;, &#34;-0.1084800000&#34;, &#34;-0.0253150000&#34;, &#34;-0.1773100000&#34;, &#34;0.0761610000&#34;, &#34;-0.0601740000&#34;, &#34;0.1403600000&#34;, &#34;0.2360600000&#34;, &#34;0.0130440000&#34;, &#34;-0.0038421000&#34;, &#34;0.1878900000&#34;, &#34;-0.0887220000&#34;, &#34;0.0325180000&#34;, &#34;0.2278100000&#34;, &#34;-0.0235590000&#34;, &#34;0.0846430000&#34;, &#34;0.1224200000&#34;, &#34;0.0088557000&#34;, &#34;0.0765080000&#34;, &#34;-0.0050585000&#34;, &#34;-0.0991940000&#34;, &#34;-0.0678060000&#34;, &#34;0.0599070000&#34;, &#34;0.0354040000&#34;, &#34;0.0187190000&#34;, &#34;-0.0268160000&#34;, &#34;-0.0043838000&#34;, &#34;0.0820260000&#34;, &#34;-0.1198600000&#34;, &#34;-0.2079700000&#34;, &#34;0.1857000000&#34;, &#34;-0.0937720000&#34;, &#34;-0.0162990000&#34;, &#34;0.1604400000&#34;, &#34;0.0333070000&#34;, &#34;-0.1544700000&#34;, &#34;-0.1299000000&#34;, &#34;0.1244600000&#34;, &#34;0.1037500000&#34;, &#34;0.1518600000&#34;, &#34;0.1791600000&#34;, &#34;-0.0392000000&#34;, &#34;-0.1754400000&#34;, &#34;0.0117540000&#34;, &#34;-0.0835660000&#34;, &#34;-0.0018136000&#34;, &#34;0.1267200000&#34;, &#34;-0.2011700000&#34;, &#34;-0.1697700000&#34;, &#34;-0.1478300000&#34;, &#34;0.0441560000&#34;, &#34;-0.1790700000&#34;, &#34;-0.0467720000&#34;, &#34;-0.0019811000&#34;, &#34;-0.0374120000&#34;, &#34;0.0013870000&#34;, &#34;-0.1056100000&#34;, &#34;-0.1542700000&#34;, &#34;0.1401600000&#34;, &#34;0.0411570000&#34;, &#34;0.1922200000&#34;, &#34;0.0120730000&#34;, &#34;-0.0667530000&#34;, &#34;-0.0252570000&#34;, &#34;-0.1564800000&#34;, &#34;0.0244270000&#34;, &#34;-0.0186740000&#34;, &#34;-0.1670500000&#34;, &#34;-0.0506200000&#34;, &#34;-0.0752870000&#34;, &#34;0.0430620000&#34;, &#34;0.0061818000&#34;, &#34;0.1057300000&#34;, &#34;-0.0029119000&#34;, &#34;0.0716430000&#34;, &#34;0.1332400000&#34;, &#34;0.2488900000&#34;, &#34;-0.0129980000&#34;, &#34;-0.0771420000&#34;, &#34;0.1755000000&#34;, &#34;0.1697100000&#34;, &#34;-0.0348750000&#34;, &#34;0.0849390000&#34;, &#34;-0.1958700000&#34;, &#34;-0.2611500000&#34;, &#34;-0.0529240000&#34;, &#34;-0.2303400000&#34;, &#34;-0.1347900000&#34;, &#34;0.1393300000&#34;, &#34;0.0411060000&#34;, &#34;0.0458160000&#34;, &#34;0.1111300000&#34;, &#34;-0.0703000000&#34;, &#34;0.0129250000&#34;, &#34;0.1397700000&#34;, &#34;-0.0636160000&#34;, &#34;0.0438910000&#34;, &#34;0.0278550000&#34;, &#34;-0.0396100000&#34;, &#34;-0.0957990000&#34;, &#34;-0.1258800000&#34;, &#34;-0.0847110000&#34;, &#34;-0.0042531000&#34;, &#34;-0.0590850000&#34;, &#34;-0.0933240000&#34;, &#34;-0.3395800000&#34;, &#34;0.0635250000&#34;, &#34;0.0822760000&#34;, &#34;0.0623950000&#34;, &#34;-0.0999550000&#34;, &#34;0.0143260000&#34;, &#34;0.0426450000&#34;, &#34;0.0802270000&#34;, &#34;0.0896460000&#34;, &#34;0.1758000000&#34;, &#34;0.0341530000&#34;, &#34;0.0005516700&#34;, &#34;0.1168700000&#34;, &#34;-0.0890060000&#34;, &#34;-0.0084893000&#34;, &#34;0.0251150000&#34;, &#34;-0.3180400000&#34;, &#34;0.1253300000&#34;, &#34;-0.0815070000&#34;, &#34;-0.1114000000&#34;, &#34;0.0175820000&#34;, &#34;-0.0373590000&#34;, &#34;0.0647400000&#34;, &#34;-0.1458100000&#34;, &#34;0.1617500000&#34;], [&#34;0.0463650000&#34;, &#34;-0.3176900000&#34;, &#34;0.3122200000&#34;, &#34;0.4272800000&#34;, &#34;-0.0520170000&#34;, &#34;-0.2056800000&#34;, &#34;-0.1305400000&#34;, &#34;-0.3554400000&#34;, &#34;-0.0454930000&#34;, &#34;0.1198300000&#34;, &#34;-0.1421300000&#34;, &#34;0.3160800000&#34;, &#34;-0.1794100000&#34;, &#34;-0.1854300000&#34;, &#34;0.1835900000&#34;, &#34;-0.1580800000&#34;, &#34;0.0726640000&#34;, &#34;-0.0014783000&#34;, &#34;0.1662200000&#34;, &#34;-0.1454300000&#34;, &#34;-0.2524000000&#34;, &#34;0.2721600000&#34;, &#34;-0.3226700000&#34;, &#34;-0.1066400000&#34;, &#34;-0.2970800000&#34;, &#34;0.1880700000&#34;, &#34;-0.0985250000&#34;, &#34;-0.1836500000&#34;, &#34;0.3127200000&#34;, &#34;0.2836100000&#34;, &#34;-0.1890300000&#34;, &#34;-0.0887010000&#34;, &#34;-0.3565200000&#34;, &#34;0.0357040000&#34;, &#34;-0.1088000000&#34;, &#34;-0.0503230000&#34;, &#34;0.0233360000&#34;, &#34;-0.2635200000&#34;, &#34;0.3081800000&#34;, &#34;-0.2282500000&#34;, &#34;0.0582360000&#34;, &#34;-0.4150600000&#34;, &#34;-0.0267630000&#34;, &#34;0.0463490000&#34;, &#34;0.1995900000&#34;, &#34;-0.3986100000&#34;, &#34;-0.1737500000&#34;, &#34;-0.3011900000&#34;, &#34;0.2229300000&#34;, &#34;-0.0381840000&#34;, &#34;0.0685010000&#34;, &#34;-0.0974790000&#34;, &#34;0.0158070000&#34;, &#34;-0.2198600000&#34;, &#34;-0.3758900000&#34;, &#34;0.1728500000&#34;, &#34;0.0040284000&#34;, &#34;0.3255200000&#34;, &#34;-0.0011404000&#34;, &#34;0.3276100000&#34;, &#34;-0.0131050000&#34;, &#34;0.0152470000&#34;, &#34;0.1571200000&#34;, &#34;-0.2604500000&#34;, &#34;-0.1249400000&#34;, &#34;0.2813600000&#34;, &#34;-0.2671600000&#34;, &#34;-0.4610200000&#34;, &#34;-0.4107300000&#34;, &#34;-0.3222800000&#34;, &#34;0.1654500000&#34;, &#34;-0.0149960000&#34;, &#34;0.3511800000&#34;, &#34;0.0614230000&#34;, &#34;-0.1164300000&#34;, &#34;0.4313700000&#34;, &#34;0.0923770000&#34;, &#34;0.0299480000&#34;, &#34;-0.0858560000&#34;, &#34;-0.4110400000&#34;, &#34;0.0688170000&#34;, &#34;0.2929700000&#34;, &#34;-0.2121200000&#34;, &#34;-0.1218000000&#34;, &#34;-0.2695500000&#34;, &#34;-0.2420700000&#34;, &#34;-0.1880200000&#34;, &#34;0.1836200000&#34;, &#34;0.1854900000&#34;, &#34;0.1858900000&#34;, &#34;-0.1702000000&#34;, &#34;-0.0390480000&#34;, &#34;0.1155100000&#34;, &#34;-0.1973600000&#34;, &#34;0.1412200000&#34;, &#34;-0.0578840000&#34;, &#34;0.2088100000&#34;, &#34;0.0725870000&#34;, &#34;-0.4841100000&#34;, &#34;0.2685600000&#34;, &#34;0.1630300000&#34;, &#34;-0.1606900000&#34;, &#34;0.2750200000&#34;, &#34;-0.0595090000&#34;, &#34;-0.1850700000&#34;, &#34;-0.1289800000&#34;, &#34;-0.3099100000&#34;, &#34;0.4653400000&#34;, &#34;0.2392700000&#34;, &#34;-0.1323200000&#34;, &#34;-0.1390900000&#34;, &#34;-0.1310800000&#34;, &#34;-0.2652500000&#34;, &#34;-0.1235600000&#34;, &#34;0.0591330000&#34;, &#34;0.2327500000&#34;, &#34;0.4766700000&#34;, &#34;0.1262600000&#34;, &#34;0.1188300000&#34;, &#34;-0.1736800000&#34;, &#34;-0.0639730000&#34;, &#34;0.0535020000&#34;, &#34;-0.2536000000&#34;, &#34;0.3104200000&#34;, &#34;0.0804350000&#34;, &#34;-0.3012800000&#34;, &#34;0.0892770000&#34;, &#34;0.3681700000&#34;, &#34;0.1285200000&#34;, &#34;-0.1420900000&#34;, &#34;-0.0198250000&#34;, &#34;0.2551800000&#34;, &#34;-0.1726500000&#34;, &#34;-0.3079200000&#34;, &#34;-0.4626300000&#34;, &#34;0.0240730000&#34;, &#34;-0.0807790000&#34;, &#34;-0.0355850000&#34;, &#34;-0.1450900000&#34;, &#34;0.0465280000&#34;, &#34;0.0910750000&#34;, &#34;0.2393300000&#34;, &#34;0.2534700000&#34;, &#34;0.3377400000&#34;, &#34;-0.2525400000&#34;, &#34;0.3782400000&#34;, &#34;0.4848000000&#34;, &#34;-0.0541820000&#34;, &#34;0.2947600000&#34;, &#34;0.0865240000&#34;, &#34;-0.0932760000&#34;, &#34;0.0558760000&#34;, &#34;-0.3779900000&#34;, &#34;-0.1854800000&#34;, &#34;-0.2925200000&#34;, &#34;-0.1958300000&#34;, &#34;-0.0990030000&#34;, &#34;-0.4394200000&#34;, &#34;0.0876350000&#34;, &#34;-0.0124590000&#34;, &#34;-0.2909800000&#34;, &#34;0.5147000000&#34;, &#34;-0.1854500000&#34;, &#34;0.1396500000&#34;, &#34;0.5051900000&#34;, &#34;-0.0987320000&#34;, &#34;0.2557500000&#34;, &#34;0.1304000000&#34;, &#34;0.5544500000&#34;, &#34;-0.0214270000&#34;, &#34;-0.0295070000&#34;, &#34;0.0211700000&#34;, &#34;-0.1621000000&#34;, &#34;0.0148080000&#34;, &#34;0.0497580000&#34;, &#34;0.0360560000&#34;, &#34;-0.0623040000&#34;, &#34;0.6364200000&#34;, &#34;-0.4364400000&#34;, &#34;-0.0767760000&#34;, &#34;-0.3918200000&#34;, &#34;-0.1376000000&#34;, &#34;-0.2439400000&#34;, &#34;-0.2273100000&#34;, &#34;0.0665700000&#34;, &#34;0.1443800000&#34;, &#34;0.3847800000&#34;, &#34;0.1537400000&#34;, &#34;-0.1217200000&#34;, &#34;-0.0908160000&#34;, &#34;0.0459150000&#34;, &#34;-0.1055400000&#34;, &#34;-0.0736280000&#34;, &#34;-0.1917500000&#34;, &#34;-0.2921800000&#34;, &#34;0.2679500000&#34;, &#34;0.5089700000&#34;, &#34;0.0507820000&#34;, &#34;-0.2165700000&#34;, &#34;-0.0859700000&#34;, &#34;-0.2622300000&#34;, &#34;0.0221730000&#34;, &#34;0.1312700000&#34;, &#34;0.2496800000&#34;, &#34;0.1859000000&#34;, &#34;-0.1064700000&#34;, &#34;-0.3341000000&#34;, &#34;-0.4195600000&#34;, &#34;0.4828700000&#34;, &#34;0.5315000000&#34;, &#34;0.4137700000&#34;, &#34;-0.1783900000&#34;, &#34;0.2191900000&#34;, &#34;-0.1759100000&#34;, &#34;0.2718100000&#34;, &#34;0.0696030000&#34;, &#34;0.1032600000&#34;, &#34;-0.3397300000&#34;, &#34;-0.0553010000&#34;, &#34;0.1900100000&#34;, &#34;0.1406000000&#34;, &#34;-0.1833600000&#34;, &#34;-0.2006000000&#34;, &#34;-0.1718700000&#34;, &#34;0.2891500000&#34;, &#34;0.1472300000&#34;, &#34;-0.1442000000&#34;, &#34;-0.1555900000&#34;, &#34;-0.2456900000&#34;, &#34;-0.2394000000&#34;, &#34;0.1255800000&#34;, &#34;0.0276060000&#34;, &#34;0.1091400000&#34;, &#34;-0.1685800000&#34;, &#34;-0.0104810000&#34;, &#34;0.0252680000&#34;, &#34;-0.4089600000&#34;, &#34;0.4035400000&#34;, &#34;0.2546200000&#34;, &#34;-0.1537700000&#34;, &#34;0.3820000000&#34;, &#34;0.3436200000&#34;, &#34;-0.1251400000&#34;, &#34;-0.0505150000&#34;, &#34;0.1468700000&#34;, &#34;-0.0349930000&#34;, &#34;0.0669180000&#34;, &#34;0.1820300000&#34;, &#34;-0.1824700000&#34;, &#34;-0.0515000000&#34;, &#34;0.4634800000&#34;, &#34;-0.0582060000&#34;, &#34;0.0171330000&#34;, &#34;-0.0897660000&#34;, &#34;-0.4300800000&#34;, &#34;0.2556600000&#34;, &#34;-0.0925030000&#34;, &#34;0.3139000000&#34;, &#34;0.2618700000&#34;, &#34;0.2952500000&#34;, &#34;0.1411200000&#34;, &#34;0.1121100000&#34;, &#34;0.0774650000&#34;, &#34;-0.0810540000&#34;, &#34;0.0272460000&#34;, &#34;-0.3590800000&#34;, &#34;0.2473100000&#34;, &#34;0.2364700000&#34;, &#34;0.0182670000&#34;, &#34;-0.0976000000&#34;, &#34;0.1849400000&#34;, &#34;-0.0737550000&#34;, &#34;-0.0809840000&#34;, &#34;-0.1399200000&#34;, &#34;-0.1203000000&#34;, &#34;-0.0248450000&#34;, &#34;0.1400100000&#34;, &#34;0.1134500000&#34;, &#34;0.3576000000&#34;, &#34;0.0182790000&#34;, &#34;-0.3489200000&#34;, &#34;0.1073600000&#34;, &#34;-0.1351200000&#34;, &#34;0.1727700000&#34;, &#34;0.6192000000&#34;, &#34;0.0788150000&#34;, &#34;-0.1206400000&#34;, &#34;0.0543810000&#34;, &#34;-0.2672600000&#34;, &#34;0.1541100000&#34;, &#34;0.1107000000&#34;, &#34;-0.1556500000&#34;, &#34;0.2000600000&#34;, &#34;0.0365320000&#34;, &#34;-0.0519310000&#34;, &#34;-0.1327000000&#34;, &#34;0.0648700000&#34;, &#34;0.0222260000&#34;, &#34;-0.0132770000&#34;, &#34;-0.2840300000&#34;], [&#34;-0.0242940000&#34;, &#34;-0.3239500000&#34;, &#34;0.0416820000&#34;, &#34;0.3595100000&#34;, &#34;-0.0633400000&#34;, &#34;-0.0187400000&#34;, &#34;0.0271570000&#34;, &#34;-0.2658200000&#34;, &#34;0.0790410000&#34;, &#34;0.0189980000&#34;, &#34;-0.2384500000&#34;, &#34;0.2018200000&#34;, &#34;-0.1744400000&#34;, &#34;-0.1616700000&#34;, &#34;0.0889900000&#34;, &#34;0.0446220000&#34;, &#34;0.2123800000&#34;, &#34;-0.0304880000&#34;, &#34;0.2676700000&#34;, &#34;0.0243910000&#34;, &#34;-0.0481600000&#34;, &#34;0.4059700000&#34;, &#34;-0.4106000000&#34;, &#34;0.0084117000&#34;, &#34;-0.1556800000&#34;, &#34;0.2261100000&#34;, &#34;-0.0949880000&#34;, &#34;-0.2961900000&#34;, &#34;0.2178500000&#34;, &#34;0.2087100000&#34;, &#34;-0.0634690000&#34;, &#34;0.1624800000&#34;, &#34;-0.3018100000&#34;, &#34;-0.0512650000&#34;, &#34;-0.0935090000&#34;, &#34;-0.0678830000&#34;, &#34;0.0773100000&#34;, &#34;-0.2619000000&#34;, &#34;0.2478900000&#34;, &#34;-0.1452600000&#34;, &#34;-0.0132880000&#34;, &#34;-0.2955800000&#34;, &#34;-0.0406290000&#34;, &#34;-0.0517810000&#34;, &#34;0.1531500000&#34;, &#34;-0.1170000000&#34;, &#34;-0.0388830000&#34;, &#34;-0.1496300000&#34;, &#34;0.1859600000&#34;, &#34;-0.1104100000&#34;, &#34;-0.0091632000&#34;, &#34;-0.0394350000&#34;, &#34;-0.0266110000&#34;, &#34;-0.2930500000&#34;, &#34;-0.4908600000&#34;, &#34;0.1894300000&#34;, &#34;0.1154400000&#34;, &#34;0.3440000000&#34;, &#34;0.0313070000&#34;, &#34;0.2795000000&#34;, &#34;-0.0004033100&#34;, &#34;-0.1001400000&#34;, &#34;0.1903000000&#34;, &#34;-0.2856300000&#34;, &#34;-0.2030600000&#34;, &#34;0.2616400000&#34;, &#34;-0.2483300000&#34;, &#34;-0.3037300000&#34;, &#34;-0.2997800000&#34;, &#34;-0.3423000000&#34;, &#34;0.0978230000&#34;, &#34;-0.0056031000&#34;, &#34;0.4326900000&#34;, &#34;0.0664090000&#34;, &#34;-0.0188520000&#34;, &#34;0.3497700000&#34;, &#34;0.0095120000&#34;, &#34;0.0777580000&#34;, &#34;-0.1161600000&#34;, &#34;-0.3649400000&#34;, &#34;-0.0357600000&#34;, &#34;0.2563500000&#34;, &#34;-0.1065300000&#34;, &#34;-0.1825100000&#34;, &#34;-0.4096400000&#34;, &#34;-0.0930490000&#34;, &#34;-0.2399500000&#34;, &#34;0.1830700000&#34;, &#34;0.0844960000&#34;, &#34;0.0113040000&#34;, &#34;-0.0908230000&#34;, &#34;0.0686370000&#34;, &#34;0.0907610000&#34;, &#34;-0.2092100000&#34;, &#34;0.1721200000&#34;, &#34;-0.1507400000&#34;, &#34;0.1721700000&#34;, &#34;0.0313720000&#34;, &#34;-0.3987500000&#34;, &#34;0.3512700000&#34;, &#34;0.1610700000&#34;, &#34;-0.1358800000&#34;, &#34;0.3285600000&#34;, &#34;-0.0740190000&#34;, &#34;-0.2131900000&#34;, &#34;-0.1929600000&#34;, &#34;-0.3076900000&#34;, &#34;0.2266200000&#34;, &#34;0.1220100000&#34;, &#34;0.0307650000&#34;, &#34;0.0034103000&#34;, &#34;-0.3236500000&#34;, &#34;-0.2254400000&#34;, &#34;-0.1614700000&#34;, &#34;0.0403000000&#34;, &#34;0.2501300000&#34;, &#34;0.3367500000&#34;, &#34;0.2089000000&#34;, &#34;0.2335300000&#34;, &#34;-0.2064400000&#34;, &#34;0.0054006000&#34;, &#34;0.1259600000&#34;, &#34;-0.2135800000&#34;, &#34;0.4612500000&#34;, &#34;-0.0974460000&#34;, &#34;-0.0833560000&#34;, &#34;-0.0047900000&#34;, &#34;0.2662200000&#34;, &#34;0.2942800000&#34;, &#34;-0.0036505000&#34;, &#34;0.1492400000&#34;, &#34;0.2285700000&#34;, &#34;0.0057792000&#34;, &#34;-0.4267300000&#34;, &#34;-0.3525300000&#34;, &#34;-0.0277540000&#34;, &#34;-0.0688070000&#34;, &#34;-0.0220590000&#34;, &#34;-0.1709600000&#34;, &#34;0.0075218000&#34;, &#34;0.2095600000&#34;, &#34;0.3758300000&#34;, &#34;0.1411700000&#34;, &#34;0.3974300000&#34;, &#34;-0.1308600000&#34;, &#34;0.3608300000&#34;, &#34;0.3766100000&#34;, &#34;0.0606630000&#34;, &#34;0.1532600000&#34;, &#34;0.0470050000&#34;, &#34;-0.1083200000&#34;, &#34;-0.1943300000&#34;, &#34;-0.2677700000&#34;, &#34;-0.0867870000&#34;, &#34;-0.1062400000&#34;, &#34;-0.1830500000&#34;, &#34;0.0123840000&#34;, &#34;-0.1651100000&#34;, &#34;0.1138500000&#34;, &#34;0.0624900000&#34;, &#34;-0.4335600000&#34;, &#34;0.5021500000&#34;, &#34;-0.1896400000&#34;, &#34;-0.0977140000&#34;, &#34;0.4413700000&#34;, &#34;0.0029150000&#34;, &#34;0.2110000000&#34;, &#34;-0.0178610000&#34;, &#34;0.4172900000&#34;, &#34;0.0891950000&#34;, &#34;-0.1889000000&#34;, &#34;0.0759990000&#34;, &#34;-0.0367490000&#34;, &#34;0.0236250000&#34;, &#34;0.1068000000&#34;, &#34;0.0021618000&#34;, &#34;0.0526030000&#34;, &#34;0.5860000000&#34;, &#34;-0.4146800000&#34;, &#34;-0.0426800000&#34;, &#34;-0.2409900000&#34;, &#34;-0.0980560000&#34;, &#34;-0.0600310000&#34;, &#34;-0.0472040000&#34;, &#34;-0.1209300000&#34;, &#34;0.0993520000&#34;, &#34;0.4296400000&#34;, &#34;0.0664360000&#34;, &#34;0.0525380000&#34;, &#34;-0.1083300000&#34;, &#34;-0.1364400000&#34;, &#34;-0.2545300000&#34;, &#34;-0.1385900000&#34;, &#34;-0.2049400000&#34;, &#34;-0.2140200000&#34;, &#34;0.1844600000&#34;, &#34;0.4171800000&#34;, &#34;0.0527950000&#34;, &#34;-0.3474500000&#34;, &#34;-0.0156120000&#34;, &#34;-0.0747160000&#34;, &#34;-0.0352120000&#34;, &#34;0.2024700000&#34;, &#34;0.2419400000&#34;, &#34;0.1586900000&#34;, &#34;-0.1130300000&#34;, &#34;-0.1961800000&#34;, &#34;-0.4176400000&#34;, &#34;0.4982800000&#34;, &#34;0.3397800000&#34;, &#34;0.2777000000&#34;, &#34;-0.2783800000&#34;, &#34;0.1916100000&#34;, &#34;-0.2289500000&#34;, &#34;0.2389400000&#34;, &#34;-0.1750900000&#34;, &#34;0.1791900000&#34;, &#34;-0.2655000000&#34;, &#34;-0.0676030000&#34;, &#34;0.1801900000&#34;, &#34;-0.0503290000&#34;, &#34;-0.2555900000&#34;, &#34;-0.1330600000&#34;, &#34;-0.0910780000&#34;, &#34;0.2350600000&#34;, &#34;0.1578500000&#34;, &#34;-0.0945700000&#34;, &#34;-0.1061400000&#34;, &#34;-0.2513600000&#34;, &#34;-0.3436200000&#34;, &#34;0.1153100000&#34;, &#34;0.0469850000&#34;, &#34;0.2516800000&#34;, &#34;-0.1805500000&#34;, &#34;0.0971710000&#34;, &#34;0.0339080000&#34;, &#34;-0.2471000000&#34;, &#34;0.1703900000&#34;, &#34;0.0776150000&#34;, &#34;-0.1344600000&#34;, &#34;0.2537800000&#34;, &#34;0.2486000000&#34;, &#34;-0.0134710000&#34;, &#34;-0.0874520000&#34;, &#34;0.2856200000&#34;, &#34;-0.0718710000&#34;, &#34;0.2150100000&#34;, &#34;0.0718500000&#34;, &#34;-0.0148210000&#34;, &#34;-0.1938600000&#34;, &#34;0.4450900000&#34;, &#34;0.0558750000&#34;, &#34;0.0086543000&#34;, &#34;-0.0832180000&#34;, &#34;-0.4327300000&#34;, &#34;0.3075600000&#34;, &#34;0.1733100000&#34;, &#34;0.1430000000&#34;, &#34;0.0318120000&#34;, &#34;0.0799010000&#34;, &#34;0.1654500000&#34;, &#34;-0.0156160000&#34;, &#34;0.2118800000&#34;, &#34;-0.0251020000&#34;, &#34;-0.1068600000&#34;, &#34;-0.4185400000&#34;, &#34;0.1659600000&#34;, &#34;0.3885500000&#34;, &#34;0.0883650000&#34;, &#34;-0.1181000000&#34;, &#34;0.2872300000&#34;, &#34;0.0783410000&#34;, &#34;0.1460700000&#34;, &#34;-0.0681060000&#34;, &#34;-0.1567200000&#34;, &#34;0.1383700000&#34;, &#34;0.1536700000&#34;, &#34;-0.0212600000&#34;, &#34;0.2712500000&#34;, &#34;-0.0975090000&#34;, &#34;-0.2976100000&#34;, &#34;0.1161900000&#34;, &#34;-0.0630370000&#34;, &#34;0.0590700000&#34;, &#34;0.4889300000&#34;, &#34;0.1329800000&#34;, &#34;-0.1882000000&#34;, &#34;0.0291000000&#34;, &#34;-0.3653800000&#34;, &#34;-0.0827490000&#34;, &#34;0.0793000000&#34;, &#34;0.1312200000&#34;, &#34;0.2543000000&#34;, &#34;0.1376000000&#34;, &#34;-0.1528000000&#34;, &#34;-0.0783560000&#34;, &#34;0.1339400000&#34;, &#34;0.1069800000&#34;, &#34;-0.2136600000&#34;, &#34;-0.1665700000&#34;], [&#34;0.3297300000&#34;, &#34;-0.3556600000&#34;, &#34;0.0912140000&#34;, &#34;0.4278000000&#34;, &#34;-0.1860500000&#34;, &#34;0.2286600000&#34;, &#34;0.2729500000&#34;, &#34;-0.3176300000&#34;, &#34;0.0654800000&#34;, &#34;0.0286500000&#34;, &#34;-0.1624800000&#34;, &#34;0.1392200000&#34;, &#34;-0.1724600000&#34;, &#34;0.1802800000&#34;, &#34;-0.0780540000&#34;, &#34;-0.6242900000&#34;, &#34;0.2703700000&#34;, &#34;-0.3544900000&#34;, &#34;-0.4743500000&#34;, &#34;0.5511700000&#34;, &#34;0.2268800000&#34;, &#34;0.5110300000&#34;, &#34;-0.5912900000&#34;, &#34;-0.0860950000&#34;, &#34;-0.0155720000&#34;, &#34;0.1994000000&#34;, &#34;-0.2632800000&#34;, &#34;-0.1392200000&#34;, &#34;-0.0088878000&#34;, &#34;0.7540400000&#34;, &#34;-0.4957700000&#34;, &#34;0.2192800000&#34;, &#34;-0.3889200000&#34;, &#34;0.1637100000&#34;, &#34;0.0973420000&#34;, &#34;-0.1469800000&#34;, &#34;0.3972400000&#34;, &#34;-0.2265700000&#34;, &#34;-0.3383700000&#34;, &#34;-0.1341700000&#34;, &#34;-0.1078600000&#34;, &#34;-0.1713200000&#34;, &#34;0.2618700000&#34;, &#34;0.2394700000&#34;, &#34;0.1195900000&#34;, &#34;0.3077000000&#34;, &#34;-0.0875170000&#34;, &#34;-0.3220600000&#34;, &#34;0.2539900000&#34;, &#34;0.3387200000&#34;, &#34;0.1478600000&#34;, &#34;0.2100300000&#34;, &#34;-0.0782010000&#34;, &#34;0.1231700000&#34;, &#34;-0.1766600000&#34;, &#34;-0.0825180000&#34;, &#34;-0.1440600000&#34;, &#34;0.0033585000&#34;, &#34;-0.1562800000&#34;, &#34;0.6561600000&#34;, &#34;-0.0779720000&#34;, &#34;-0.4151900000&#34;, &#34;0.3605700000&#34;, &#34;-0.0880550000&#34;, &#34;-0.0490930000&#34;, &#34;0.0161190000&#34;, &#34;-0.3492200000&#34;, &#34;-0.2678300000&#34;, &#34;0.1366100000&#34;, &#34;0.1236400000&#34;, &#34;-0.0977190000&#34;, &#34;0.0004395400&#34;, &#34;0.6962700000&#34;, &#34;-0.3196800000&#34;, &#34;0.2334100000&#34;, &#34;0.1828600000&#34;, &#34;0.6553300000&#34;, &#34;0.3765900000&#34;, &#34;0.0914660000&#34;, &#34;0.1528000000&#34;, &#34;0.4496700000&#34;, &#34;-0.0467210000&#34;, &#34;0.0271550000&#34;, &#34;-0.0621830000&#34;, &#34;0.0171210000&#34;, &#34;-0.1775300000&#34;, &#34;-0.4827000000&#34;, &#34;0.1631200000&#34;, &#34;-0.2930700000&#34;, &#34;-0.7393300000&#34;, &#34;-0.0642870000&#34;, &#34;-0.2645100000&#34;, &#34;0.4221100000&#34;, &#34;-0.3683600000&#34;, &#34;0.0013729000&#34;, &#34;0.0788040000&#34;, &#34;0.1658700000&#34;, &#34;0.1868300000&#34;, &#34;-0.1539700000&#34;, &#34;0.2405700000&#34;, &#34;-0.0749970000&#34;, &#34;0.0708060000&#34;, &#34;0.2169000000&#34;, &#34;-0.1030300000&#34;, &#34;0.0431140000&#34;, &#34;0.1311800000&#34;, &#34;-0.0639800000&#34;, &#34;-0.0705880000&#34;, &#34;0.1198600000&#34;, &#34;0.2962200000&#34;, &#34;-0.2221100000&#34;, &#34;0.3317500000&#34;, &#34;0.2680100000&#34;, &#34;0.0035323000&#34;, &#34;-0.1022900000&#34;, &#34;-0.1959800000&#34;, &#34;0.0703780000&#34;, &#34;0.0671080000&#34;, &#34;-0.3266900000&#34;, &#34;0.3488200000&#34;, &#34;0.6139600000&#34;, &#34;0.1418200000&#34;, &#34;-0.1403700000&#34;, &#34;-0.0634710000&#34;, &#34;-0.1017400000&#34;, &#34;-0.5554100000&#34;, &#34;0.0132580000&#34;, &#34;0.1860700000&#34;, &#34;0.1684200000&#34;, &#34;0.4018300000&#34;, &#34;0.2441500000&#34;, &#34;-0.0244280000&#34;, &#34;-0.2644000000&#34;, &#34;-0.0449790000&#34;, &#34;-0.0283060000&#34;, &#34;0.0975810000&#34;, &#34;-0.3063500000&#34;, &#34;0.1088500000&#34;, &#34;0.1134500000&#34;, &#34;0.6479700000&#34;, &#34;-0.3710300000&#34;, &#34;0.2057600000&#34;, &#34;-0.0468020000&#34;, &#34;-0.0519850000&#34;, &#34;0.5226500000&#34;, &#34;-0.3188600000&#34;, &#34;0.1780000000&#34;, &#34;-0.0346180000&#34;, &#34;-0.0927760000&#34;, &#34;0.1026700000&#34;, &#34;-0.1340200000&#34;, &#34;-0.0918360000&#34;, &#34;-0.4753000000&#34;, &#34;-0.2600600000&#34;, &#34;-0.0466660000&#34;, &#34;-0.0845210000&#34;, &#34;0.2354100000&#34;, &#34;-0.1613200000&#34;, &#34;0.2594500000&#34;, &#34;0.0589440000&#34;, &#34;0.0647540000&#34;, &#34;0.4094900000&#34;, &#34;-0.4049600000&#34;, &#34;0.0634170000&#34;, &#34;0.4876100000&#34;, &#34;0.0229780000&#34;, &#34;-0.1019100000&#34;, &#34;-0.0814310000&#34;, &#34;0.2847900000&#34;, &#34;0.2806300000&#34;, &#34;-0.1785800000&#34;, &#34;0.1011700000&#34;, &#34;0.2200400000&#34;, &#34;0.3961900000&#34;, &#34;-0.1020500000&#34;, &#34;0.0762120000&#34;, &#34;0.2872800000&#34;, &#34;-0.3623900000&#34;, &#34;-0.3962400000&#34;, &#34;0.1975200000&#34;, &#34;-0.0295920000&#34;, &#34;-0.2442900000&#34;, &#34;-0.3738800000&#34;, &#34;-0.0469790000&#34;, &#34;0.0491700000&#34;, &#34;-0.2483500000&#34;, &#34;0.2019400000&#34;, &#34;-0.3030500000&#34;, &#34;-0.0583790000&#34;, &#34;-0.2548900000&#34;, &#34;0.2768700000&#34;, &#34;-0.0083026000&#34;, &#34;-0.4150300000&#34;, &#34;0.1373800000&#34;, &#34;-0.3285000000&#34;, &#34;0.4835700000&#34;, &#34;0.1823800000&#34;, &#34;-0.2945300000&#34;, &#34;-0.4003500000&#34;, &#34;-0.1138200000&#34;, &#34;0.0240130000&#34;, &#34;-0.0401920000&#34;, &#34;0.2646200000&#34;, &#34;0.0060517000&#34;, &#34;0.2194500000&#34;, &#34;-0.3565600000&#34;, &#34;-0.3231100000&#34;, &#34;-0.0579250000&#34;, &#34;-0.1299200000&#34;, &#34;0.3791000000&#34;, &#34;0.4819200000&#34;, &#34;-0.0729980000&#34;, &#34;-0.0895620000&#34;, &#34;-0.4844800000&#34;, &#34;-0.0855470000&#34;, &#34;0.1216500000&#34;, &#34;0.0496070000&#34;, &#34;-0.1130200000&#34;, &#34;0.4998800000&#34;, &#34;-0.2149200000&#34;, &#34;0.1500100000&#34;, &#34;-0.0638330000&#34;, &#34;-0.4739700000&#34;, &#34;-0.1504800000&#34;, &#34;0.2040600000&#34;, &#34;-0.0246430000&#34;, &#34;0.0096142000&#34;, &#34;-0.1903900000&#34;, &#34;0.0763020000&#34;, &#34;0.1814500000&#34;, &#34;0.0858460000&#34;, &#34;-0.0666130000&#34;, &#34;-0.3796300000&#34;, &#34;0.0012397000&#34;, &#34;0.1106800000&#34;, &#34;-0.0316870000&#34;, &#34;-0.4972900000&#34;, &#34;-0.1197200000&#34;, &#34;-0.1223500000&#34;, &#34;-0.1565000000&#34;, &#34;0.6281700000&#34;, &#34;0.0407220000&#34;, &#34;-0.0801920000&#34;, &#34;-0.1377500000&#34;, &#34;-0.3523700000&#34;, &#34;0.1699700000&#34;, &#34;0.0486930000&#34;, &#34;-0.3552400000&#34;, &#34;-0.2106800000&#34;, &#34;0.1641000000&#34;, &#34;0.1320200000&#34;, &#34;0.2065300000&#34;, &#34;-0.1284700000&#34;, &#34;-0.1857700000&#34;, &#34;-0.0013799000&#34;, &#34;-0.0348540000&#34;, &#34;0.1900800000&#34;, &#34;-0.3504800000&#34;, &#34;0.4373600000&#34;, &#34;0.1438400000&#34;, &#34;0.0583970000&#34;, &#34;0.0675360000&#34;, &#34;-0.0274320000&#34;, &#34;0.0565660000&#34;, &#34;-0.5415500000&#34;, &#34;0.2420000000&#34;, &#34;0.0780820000&#34;, &#34;-0.0284790000&#34;, &#34;0.0015143000&#34;, &#34;0.6451000000&#34;, &#34;0.1003100000&#34;, &#34;0.0325710000&#34;, &#34;0.0715540000&#34;, &#34;-0.0721530000&#34;, &#34;-0.0347940000&#34;, &#34;0.4477600000&#34;, &#34;0.1405600000&#34;, &#34;0.1827600000&#34;, &#34;-0.1663900000&#34;, &#34;-0.0824300000&#34;, &#34;-0.1650300000&#34;, &#34;0.0987490000&#34;, &#34;0.0973930000&#34;, &#34;-0.0779960000&#34;, &#34;-0.0045350000&#34;, &#34;0.2438100000&#34;, &#34;-0.5503900000&#34;, &#34;-0.3891300000&#34;, &#34;-0.4439800000&#34;, &#34;-0.0767440000&#34;, &#34;0.3202500000&#34;, &#34;0.1939800000&#34;, &#34;0.2653600000&#34;, &#34;0.1206500000&#34;, &#34;-0.1673100000&#34;, &#34;0.0001194300&#34;, &#34;-0.1581400000&#34;, &#34;-0.0350040000&#34;, &#34;0.5433600000&#34;, &#34;0.1530000000&#34;], [&#34;-0.1736500000&#34;, &#34;-0.2836300000&#34;, &#34;-0.1809400000&#34;, &#34;0.4295200000&#34;, &#34;-0.4730500000&#34;, &#34;-0.1101200000&#34;, &#34;-0.3302000000&#34;, &#34;-0.2372000000&#34;, &#34;-0.0368550000&#34;, &#34;0.1094800000&#34;, &#34;-0.2674100000&#34;, &#34;0.1127600000&#34;, &#34;0.0421600000&#34;, &#34;-0.0596830000&#34;, &#34;0.0221990000&#34;, &#34;0.0161790000&#34;, &#34;-0.1255500000&#34;, &#34;-0.1879400000&#34;, &#34;0.3825400000&#34;, &#34;0.2012000000&#34;, &#34;-0.1902300000&#34;, &#34;0.0398530000&#34;, &#34;-0.5339500000&#34;, &#34;-0.3074600000&#34;, &#34;-0.0738130000&#34;, &#34;-0.3190500000&#34;, &#34;0.1111500000&#34;, &#34;-0.0914910000&#34;, &#34;-0.0852410000&#34;, &#34;0.0711860000&#34;, &#34;0.3237800000&#34;, &#34;0.2832100000&#34;, &#34;-0.1494500000&#34;, &#34;0.2852300000&#34;, &#34;0.0254060000&#34;, &#34;-0.3089800000&#34;, &#34;0.0609480000&#34;, &#34;0.0112770000&#34;, &#34;0.1611600000&#34;, &#34;0.1690200000&#34;, &#34;-0.1827800000&#34;, &#34;0.5029000000&#34;, &#34;-0.0581000000&#34;, &#34;0.2478800000&#34;, &#34;-0.1699600000&#34;, &#34;0.0835340000&#34;, &#34;0.2265800000&#34;, &#34;-0.2294700000&#34;, &#34;-0.0323500000&#34;, &#34;0.1080200000&#34;, &#34;-0.1090300000&#34;, &#34;0.0604570000&#34;, &#34;0.2522200000&#34;, &#34;0.2881300000&#34;, &#34;-0.2414500000&#34;, &#34;0.2326000000&#34;, &#34;0.0253100000&#34;, &#34;0.1817300000&#34;, &#34;-0.2879700000&#34;, &#34;0.1155900000&#34;, &#34;-0.2285900000&#34;, &#34;-0.0734400000&#34;, &#34;0.1111300000&#34;, &#34;0.0768120000&#34;, &#34;0.0783700000&#34;, &#34;0.6290300000&#34;, &#34;0.0804510000&#34;, &#34;0.2050600000&#34;, &#34;-0.0385150000&#34;, &#34;0.1185100000&#34;, &#34;0.1758900000&#34;, &#34;-0.0324720000&#34;, &#34;-0.2694300000&#34;, &#34;-0.0339290000&#34;, &#34;0.1621400000&#34;, &#34;0.3858600000&#34;, &#34;0.2558200000&#34;, &#34;0.4283000000&#34;, &#34;-0.2526000000&#34;, &#34;0.1252000000&#34;, &#34;-0.0549830000&#34;, &#34;0.0087438000&#34;, &#34;-0.2013700000&#34;, &#34;0.0608780000&#34;, &#34;-0.2458000000&#34;, &#34;0.0438840000&#34;, &#34;-0.2682600000&#34;, &#34;0.2361200000&#34;, &#34;-0.1442700000&#34;, &#34;-0.0306300000&#34;, &#34;-0.2719500000&#34;, &#34;-0.2093100000&#34;, &#34;-0.0815660000&#34;, &#34;-0.3089000000&#34;, &#34;0.0916080000&#34;, &#34;-0.3417200000&#34;, &#34;-0.1684600000&#34;, &#34;-0.1204900000&#34;, &#34;-0.1106400000&#34;, &#34;-0.2890400000&#34;, &#34;-0.0094841000&#34;, &#34;-0.0700150000&#34;, &#34;-0.1462600000&#34;, &#34;-0.1977800000&#34;, &#34;-0.4332300000&#34;, &#34;-0.3091900000&#34;, &#34;-0.0579740000&#34;, &#34;0.3495700000&#34;, &#34;-0.0845180000&#34;, &#34;0.1615400000&#34;, &#34;-0.2518100000&#34;, &#34;0.1614000000&#34;, &#34;-0.1739800000&#34;, &#34;-0.4145300000&#34;, &#34;0.0362110000&#34;, &#34;0.0645290000&#34;, &#34;0.5992300000&#34;, &#34;0.1707800000&#34;, &#34;-0.2215700000&#34;, &#34;0.0572800000&#34;, &#34;0.1832900000&#34;, &#34;-0.1033200000&#34;, &#34;-0.1942700000&#34;, &#34;0.0140610000&#34;, &#34;-0.0254520000&#34;, &#34;-0.1506100000&#34;, &#34;-0.3636800000&#34;, &#34;-0.0394820000&#34;, &#34;0.1226600000&#34;, &#34;-0.0769340000&#34;, &#34;-0.2435900000&#34;, &#34;0.0206100000&#34;, &#34;-0.1323000000&#34;, &#34;-0.3813600000&#34;, &#34;-0.0509760000&#34;, &#34;0.1678400000&#34;, &#34;0.0433760000&#34;, &#34;-0.0220620000&#34;, &#34;0.0261470000&#34;, &#34;-0.0752060000&#34;, &#34;0.1347700000&#34;, &#34;0.0381730000&#34;, &#34;0.0765570000&#34;, &#34;0.2803000000&#34;, &#34;-0.0060694000&#34;, &#34;-0.0622820000&#34;, &#34;-0.0593170000&#34;, &#34;-0.3559400000&#34;, &#34;0.0774780000&#34;, &#34;0.1479700000&#34;, &#34;0.1982700000&#34;, &#34;-0.0788700000&#34;, &#34;-0.4599400000&#34;, &#34;0.2981300000&#34;, &#34;-0.4199800000&#34;, &#34;-0.2579400000&#34;, &#34;-0.1823600000&#34;, &#34;0.0027135000&#34;, &#34;0.0696170000&#34;, &#34;0.0438040000&#34;, &#34;-0.0452570000&#34;, &#34;-0.3199400000&#34;, &#34;-0.0558440000&#34;, &#34;0.4669400000&#34;, &#34;0.2625200000&#34;, &#34;-0.0785060000&#34;, &#34;-0.0500560000&#34;, &#34;-0.0792630000&#34;, &#34;0.1339100000&#34;, &#34;-0.1054600000&#34;, &#34;0.0004455400&#34;, &#34;0.0617780000&#34;, &#34;-0.4249100000&#34;, &#34;-0.2486400000&#34;, &#34;0.4032100000&#34;, &#34;0.6722000000&#34;, &#34;-0.1047300000&#34;, &#34;0.1965700000&#34;, &#34;0.0338270000&#34;, &#34;0.1000800000&#34;, &#34;0.4372600000&#34;, &#34;-0.1265300000&#34;, &#34;0.4267600000&#34;, &#34;0.1379500000&#34;, &#34;-0.0211350000&#34;, &#34;0.2574800000&#34;, &#34;-0.2618700000&#34;, &#34;0.0452240000&#34;, &#34;0.0737280000&#34;, &#34;-0.1873500000&#34;, &#34;0.0567800000&#34;, &#34;-0.7268700000&#34;, &#34;-0.0364160000&#34;, &#34;0.3168400000&#34;, &#34;0.0526610000&#34;, &#34;-0.0535450000&#34;, &#34;-0.0554020000&#34;, &#34;0.0129660000&#34;, &#34;-0.3280700000&#34;, &#34;-0.0957510000&#34;, &#34;0.4189200000&#34;, &#34;-0.2883300000&#34;, &#34;0.0881070000&#34;, &#34;0.1209300000&#34;, &#34;0.0346670000&#34;, &#34;-0.2230400000&#34;, &#34;-0.0668240000&#34;, &#34;-0.5780500000&#34;, &#34;-0.0530530000&#34;, &#34;0.2087400000&#34;, &#34;0.4597700000&#34;, &#34;0.3749600000&#34;, &#34;-0.2387100000&#34;, &#34;-0.2213900000&#34;, &#34;0.0789210000&#34;, &#34;-0.1349400000&#34;, &#34;-0.2596700000&#34;, &#34;-0.1978100000&#34;, &#34;0.0547500000&#34;, &#34;0.3032200000&#34;, &#34;0.1851800000&#34;, &#34;0.0723950000&#34;, &#34;0.0476010000&#34;, &#34;0.1572600000&#34;, &#34;-0.2084900000&#34;, &#34;-0.0223590000&#34;, &#34;0.3760000000&#34;, &#34;0.2397500000&#34;, &#34;0.2781600000&#34;, &#34;-0.1934700000&#34;, &#34;0.7435700000&#34;, &#34;-0.2691700000&#34;, &#34;-0.1246200000&#34;, &#34;-0.5516800000&#34;, &#34;-0.0467160000&#34;, &#34;0.2924000000&#34;, &#34;0.2381000000&#34;, &#34;0.0339250000&#34;, &#34;0.1799400000&#34;, &#34;-0.2307800000&#34;, &#34;0.2560900000&#34;, &#34;0.0624750000&#34;, &#34;0.2686900000&#34;, &#34;0.3941800000&#34;, &#34;0.2299500000&#34;, &#34;0.0301630000&#34;, &#34;0.4480900000&#34;, &#34;0.0212780000&#34;, &#34;-0.1172500000&#34;, &#34;0.5232700000&#34;, &#34;0.0436650000&#34;, &#34;0.1992800000&#34;, &#34;-0.0273640000&#34;, &#34;0.0599610000&#34;, &#34;0.0189820000&#34;, &#34;-0.2465900000&#34;, &#34;-0.4179700000&#34;, &#34;-0.3634300000&#34;, &#34;0.2551900000&#34;, &#34;-0.0426970000&#34;, &#34;0.0747530000&#34;, &#34;0.0606080000&#34;, &#34;0.0752030000&#34;, &#34;-0.2680200000&#34;, &#34;-0.1723500000&#34;, &#34;-0.0697920000&#34;, &#34;-0.3474000000&#34;, &#34;-0.1707600000&#34;, &#34;0.3632000000&#34;, &#34;0.0960900000&#34;, &#34;-0.1171900000&#34;, &#34;-0.1351400000&#34;, &#34;-0.2400300000&#34;, &#34;0.0425490000&#34;, &#34;-0.0081243000&#34;, &#34;-0.1372900000&#34;, &#34;0.1335200000&#34;, &#34;0.2793400000&#34;, &#34;0.0591050000&#34;, &#34;0.0738470000&#34;, &#34;0.0990680000&#34;, &#34;-0.0383910000&#34;, &#34;0.0817850000&#34;, &#34;-0.2255000000&#34;, &#34;0.0856740000&#34;, &#34;0.0845380000&#34;, &#34;0.1462600000&#34;, &#34;0.2489100000&#34;, &#34;-0.1412400000&#34;, &#34;0.0157220000&#34;, &#34;0.2033300000&#34;, &#34;-0.0020506000&#34;, &#34;0.0713030000&#34;, &#34;0.2393500000&#34;, &#34;-0.2820000000&#34;, &#34;0.5960100000&#34;, &#34;0.1398000000&#34;, &#34;0.6361700000&#34;, &#34;0.0428380000&#34;, &#34;0.1769800000&#34;], [&#34;-0.0940560000&#34;, &#34;-0.2341300000&#34;, &#34;-0.7815000000&#34;, &#34;0.3331400000&#34;, &#34;-0.9646400000&#34;, &#34;-0.4424500000&#34;, &#34;0.2937900000&#34;, &#34;-0.4881200000&#34;, &#34;-0.2112100000&#34;, &#34;-0.1441400000&#34;, &#34;0.1277800000&#34;, &#34;0.2240100000&#34;, &#34;-0.2451700000&#34;, &#34;0.0298300000&#34;, &#34;0.1723700000&#34;, &#34;0.0541280000&#34;, &#34;0.1732100000&#34;, &#34;0.0191690000&#34;, &#34;-0.2644800000&#34;, &#34;0.3111200000&#34;, &#34;0.3086200000&#34;, &#34;0.1728800000&#34;, &#34;-0.4366200000&#34;, &#34;-0.1477400000&#34;, &#34;-0.0079717000&#34;, &#34;-0.0397720000&#34;, &#34;0.1221300000&#34;, &#34;0.0228840000&#34;, &#34;0.1682100000&#34;, &#34;0.4504400000&#34;, &#34;0.0662230000&#34;, &#34;0.1486900000&#34;, &#34;-0.1513700000&#34;, &#34;0.7382900000&#34;, &#34;0.3694800000&#34;, &#34;0.2051600000&#34;, &#34;0.0164620000&#34;, &#34;0.3338300000&#34;, &#34;0.0774790000&#34;, &#34;0.0245320000&#34;, &#34;0.5119500000&#34;, &#34;-0.0733730000&#34;, &#34;-0.2505200000&#34;, &#34;0.4430700000&#34;, &#34;0.5690100000&#34;, &#34;-0.0203540000&#34;, &#34;0.3633600000&#34;, &#34;0.0103310000&#34;, &#34;0.1395300000&#34;, &#34;0.2817500000&#34;, &#34;0.0104470000&#34;, &#34;-0.2372900000&#34;, &#34;-0.2085400000&#34;, &#34;-0.7273000000&#34;, &#34;0.1013200000&#34;, &#34;-0.3156300000&#34;, &#34;0.0874210000&#34;, &#34;0.0403650000&#34;, &#34;0.0070915000&#34;, &#34;0.0127760000&#34;, &#34;-0.4727200000&#34;, &#34;-0.0157890000&#34;, &#34;0.6688400000&#34;, &#34;0.0641250000&#34;, &#34;-0.2177100000&#34;, &#34;-0.1877100000&#34;, &#34;-0.2004400000&#34;, &#34;0.4396900000&#34;, &#34;-0.0370770000&#34;, &#34;-0.0892220000&#34;, &#34;-0.0224830000&#34;, &#34;-0.1147900000&#34;, &#34;0.4624200000&#34;, &#34;0.2170400000&#34;, &#34;0.0236440000&#34;, &#34;0.2547100000&#34;, &#34;0.5423300000&#34;, &#34;0.4597400000&#34;, &#34;-0.3465000000&#34;, &#34;0.2184400000&#34;, &#34;0.3804700000&#34;, &#34;-0.6449800000&#34;, &#34;-0.2697200000&#34;, &#34;-0.2471100000&#34;, &#34;-0.6309100000&#34;, &#34;-0.4259000000&#34;, &#34;0.2281100000&#34;, &#34;0.1789400000&#34;, &#34;-0.3821600000&#34;, &#34;-0.8804300000&#34;, &#34;0.2474400000&#34;, &#34;0.1223900000&#34;, &#34;0.3382700000&#34;, &#34;-0.0387880000&#34;, &#34;-0.0110770000&#34;, &#34;-0.1667700000&#34;, &#34;0.7326900000&#34;, &#34;0.3821200000&#34;, &#34;0.0092299000&#34;, &#34;0.6061500000&#34;, &#34;0.0900580000&#34;, &#34;0.1687900000&#34;, &#34;-0.0877870000&#34;, &#34;-0.1740800000&#34;, &#34;0.8485900000&#34;, &#34;-0.0940780000&#34;, &#34;-0.2738000000&#34;, &#34;0.3198900000&#34;, &#34;0.2378500000&#34;, &#34;-0.1227900000&#34;, &#34;-0.1228400000&#34;, &#34;0.0573790000&#34;, &#34;-0.4123100000&#34;, &#34;-0.1291900000&#34;, &#34;-0.2413700000&#34;, &#34;-0.2802200000&#34;, &#34;0.4231900000&#34;, &#34;-0.0138740000&#34;, &#34;-0.2164000000&#34;, &#34;0.1429200000&#34;, &#34;0.0470380000&#34;, &#34;-0.5769100000&#34;, &#34;-0.5420200000&#34;, &#34;0.1491800000&#34;, &#34;0.0592060000&#34;, &#34;-0.1560700000&#34;, &#34;-0.5935700000&#34;, &#34;0.2544100000&#34;, &#34;-0.1816900000&#34;, &#34;0.0987310000&#34;, &#34;0.0475060000&#34;, &#34;0.2991500000&#34;, &#34;-0.2161000000&#34;, &#34;-0.2621300000&#34;, &#34;0.4210100000&#34;, &#34;0.6068000000&#34;, &#34;-0.5335800000&#34;, &#34;0.4012100000&#34;, &#34;-0.3907000000&#34;, &#34;0.3023400000&#34;, &#34;0.1611000000&#34;, &#34;0.4221700000&#34;, &#34;-0.3133000000&#34;, &#34;-0.3994300000&#34;, &#34;-0.2859400000&#34;, &#34;0.0769700000&#34;, &#34;0.2766600000&#34;, &#34;0.3325000000&#34;, &#34;0.1954500000&#34;, &#34;-0.1239000000&#34;, &#34;0.4425100000&#34;, &#34;-0.3573100000&#34;, &#34;0.0787960000&#34;, &#34;-0.5777100000&#34;, &#34;0.0755430000&#34;, &#34;0.3752600000&#34;, &#34;0.0507340000&#34;, &#34;0.5712500000&#34;, &#34;-0.1927100000&#34;, &#34;-0.1453600000&#34;, &#34;0.3480300000&#34;, &#34;0.1611200000&#34;, &#34;0.3318900000&#34;, &#34;-0.0610160000&#34;, &#34;0.2535200000&#34;, &#34;0.1312900000&#34;, &#34;-0.3072300000&#34;, &#34;0.0801230000&#34;, &#34;-0.0359160000&#34;, &#34;0.4872900000&#34;, &#34;-0.1650900000&#34;, &#34;-0.5552100000&#34;, &#34;-0.2179900000&#34;, &#34;0.4273400000&#34;, &#34;0.3668400000&#34;, &#34;-0.1158200000&#34;, &#34;-0.2852000000&#34;, &#34;-0.3824700000&#34;, &#34;-0.2469800000&#34;, &#34;-0.2733100000&#34;, &#34;0.0711290000&#34;, &#34;0.0538940000&#34;, &#34;-0.0862870000&#34;, &#34;-0.1701200000&#34;, &#34;-0.0214950000&#34;, &#34;0.8117500000&#34;, &#34;-0.0426910000&#34;, &#34;-0.1251700000&#34;, &#34;0.3880400000&#34;, &#34;-0.2023700000&#34;, &#34;-0.3604800000&#34;, &#34;-0.2014100000&#34;, &#34;0.2776800000&#34;, &#34;0.1086400000&#34;, &#34;-0.2867400000&#34;, &#34;-0.1631100000&#34;, &#34;0.1961100000&#34;, &#34;0.1760700000&#34;, &#34;0.2110300000&#34;, &#34;-0.4506400000&#34;, &#34;-0.2389100000&#34;, &#34;-0.4081100000&#34;, &#34;-0.0780110000&#34;, &#34;-0.1285200000&#34;, &#34;0.0116200000&#34;, &#34;-0.4668500000&#34;, &#34;-0.1622300000&#34;, &#34;-0.0252250000&#34;, &#34;0.0742630000&#34;, &#34;0.1955900000&#34;, &#34;0.4233100000&#34;, &#34;0.0870680000&#34;, &#34;0.3864300000&#34;, &#34;0.5383200000&#34;, &#34;-0.3342600000&#34;, &#34;-0.1555900000&#34;, &#34;-0.2311000000&#34;, &#34;-0.9875800000&#34;, &#34;0.0156320000&#34;, &#34;-0.0275420000&#34;, &#34;-0.2044400000&#34;, &#34;-0.0552260000&#34;, &#34;0.2387600000&#34;, &#34;0.3003900000&#34;, &#34;0.2132100000&#34;, &#34;0.1191000000&#34;, &#34;-0.2594100000&#34;, &#34;-0.5998000000&#34;, &#34;-0.1533500000&#34;, &#34;-0.2843900000&#34;, &#34;-0.2871500000&#34;, &#34;0.2011700000&#34;, &#34;-0.6836100000&#34;, &#34;-0.2381600000&#34;, &#34;0.1618000000&#34;, &#34;0.2262800000&#34;, &#34;-0.1845800000&#34;, &#34;-0.1872700000&#34;, &#34;0.1174000000&#34;, &#34;0.3883500000&#34;, &#34;0.4897900000&#34;, &#34;-0.0361370000&#34;, &#34;0.2117100000&#34;, &#34;-0.3522000000&#34;, &#34;-0.4010800000&#34;, &#34;0.4712900000&#34;, &#34;-0.1911700000&#34;, &#34;-0.5298600000&#34;, &#34;-0.2798500000&#34;, &#34;-0.4583000000&#34;, &#34;0.1843500000&#34;, &#34;-0.0495520000&#34;, &#34;-0.3404600000&#34;, &#34;0.2670000000&#34;, &#34;-0.3084400000&#34;, &#34;-0.0552860000&#34;, &#34;0.1440900000&#34;, &#34;-0.3509400000&#34;, &#34;0.3253500000&#34;, &#34;0.0257070000&#34;, &#34;0.2786900000&#34;, &#34;0.4512400000&#34;, &#34;-0.3697500000&#34;, &#34;-0.1993600000&#34;, &#34;-0.4986700000&#34;, &#34;-0.1919100000&#34;, &#34;-0.2616000000&#34;, &#34;0.0510100000&#34;, &#34;-0.1762400000&#34;, &#34;-0.2776300000&#34;, &#34;0.0218740000&#34;, &#34;-0.2827000000&#34;, &#34;-0.0130810000&#34;, &#34;-0.0680520000&#34;, &#34;-0.1026300000&#34;, &#34;-0.3704300000&#34;, &#34;-0.2594500000&#34;, &#34;-0.2856000000&#34;, &#34;-0.0783220000&#34;, &#34;-0.0265240000&#34;, &#34;0.0177150000&#34;, &#34;0.1381300000&#34;, &#34;-0.7896800000&#34;, &#34;-0.0922000000&#34;, &#34;0.8370100000&#34;, &#34;-0.0994560000&#34;, &#34;0.3206500000&#34;, &#34;-0.1031800000&#34;, &#34;-0.3371900000&#34;, &#34;-0.0032685000&#34;, &#34;-0.8159700000&#34;, &#34;0.4399900000&#34;, &#34;0.0478600000&#34;, &#34;-0.1486100000&#34;, &#34;-0.4751400000&#34;, &#34;-0.1740700000&#34;, &#34;0.4617400000&#34;, &#34;0.6174300000&#34;, &#34;0.2242100000&#34;, &#34;-0.0501340000&#34;], [&#34;-0.0642060000&#34;, &#34;0.0917140000&#34;, &#34;0.1194200000&#34;, &#34;0.4186000000&#34;, &#34;0.1746500000&#34;, &#34;0.1194100000&#34;, &#34;0.3185900000&#34;, &#34;-0.1638000000&#34;, &#34;0.2056500000&#34;, &#34;0.0880940000&#34;, &#34;-0.0462130000&#34;, &#34;0.1533100000&#34;, &#34;0.1577500000&#34;, &#34;-0.0965040000&#34;, &#34;0.0227270000&#34;, &#34;-0.1413800000&#34;, &#34;0.0098457000&#34;, &#34;-0.0265880000&#34;, &#34;0.0211830000&#34;, &#34;0.2297200000&#34;, &#34;0.0425290000&#34;, &#34;0.0272430000&#34;, &#34;0.0231370000&#34;, &#34;-0.0798720000&#34;, &#34;0.0495000000&#34;, &#34;-0.0611290000&#34;, &#34;0.1054600000&#34;, &#34;0.0849050000&#34;, &#34;-0.1019000000&#34;, &#34;0.0254450000&#34;, &#34;-0.2259300000&#34;, &#34;-0.0094519000&#34;, &#34;-0.1131600000&#34;, &#34;-0.0454760000&#34;, &#34;-0.0991100000&#34;, &#34;0.0020657000&#34;, &#34;-0.2440000000&#34;, &#34;-0.2076200000&#34;, &#34;0.2789300000&#34;, &#34;-0.0306010000&#34;, &#34;0.2543800000&#34;, &#34;-0.0434000000&#34;, &#34;0.1410000000&#34;, &#34;0.0411700000&#34;, &#34;-0.0268320000&#34;, &#34;-0.0757660000&#34;, &#34;0.0998660000&#34;, &#34;-0.1085700000&#34;, &#34;0.0527440000&#34;, &#34;-0.0064439000&#34;, &#34;0.0146670000&#34;, &#34;0.0240910000&#34;, &#34;-0.1482300000&#34;, &#34;-0.0751400000&#34;, &#34;-0.1763900000&#34;, &#34;0.0059049000&#34;, &#34;0.0069194000&#34;, &#34;-0.0533160000&#34;, &#34;-0.1120600000&#34;, &#34;-0.0605830000&#34;, &#34;-0.0128220000&#34;, &#34;-0.3179900000&#34;, &#34;0.0878980000&#34;, &#34;-0.0624170000&#34;, &#34;0.0481660000&#34;, &#34;-0.0059139000&#34;, &#34;-0.0180730000&#34;, &#34;0.2366100000&#34;, &#34;-0.1531000000&#34;, &#34;0.0032921000&#34;, &#34;-0.1283700000&#34;, &#34;0.0754290000&#34;, &#34;-0.1972500000&#34;, &#34;-0.2471200000&#34;, &#34;-0.0508580000&#34;, &#34;0.1005800000&#34;, &#34;0.1284100000&#34;, &#34;0.2528200000&#34;, &#34;0.0972760000&#34;, &#34;0.0105210000&#34;, &#34;0.1836100000&#34;, &#34;-0.1974900000&#34;, &#34;-0.0404440000&#34;, &#34;-0.1118500000&#34;, &#34;-0.1269800000&#34;, &#34;-0.1015200000&#34;, &#34;0.0270530000&#34;, &#34;0.0955040000&#34;, &#34;0.1474600000&#34;, &#34;-0.1945200000&#34;, &#34;0.0551560000&#34;, &#34;-0.1500400000&#34;, &#34;-0.0396780000&#34;, &#34;-0.0397960000&#34;, &#34;0.3459200000&#34;, &#34;0.2937900000&#34;, &#34;0.2451900000&#34;, &#34;-0.0993540000&#34;, &#34;0.0608150000&#34;, &#34;-0.2600300000&#34;, &#34;-0.0617430000&#34;, &#34;-0.0552700000&#34;, &#34;0.1101400000&#34;, &#34;0.1176600000&#34;, &#34;-0.2154600000&#34;, &#34;-0.1546700000&#34;, &#34;-0.0919750000&#34;, &#34;0.1169700000&#34;, &#34;0.0128670000&#34;, &#34;0.0462720000&#34;, &#34;0.0333600000&#34;, &#34;0.0377810000&#34;, &#34;0.0198910000&#34;, &#34;-0.0641890000&#34;, &#34;0.0792300000&#34;, &#34;-0.1214700000&#34;, &#34;-0.0219640000&#34;, &#34;0.0589270000&#34;, &#34;0.0391170000&#34;, &#34;0.2828900000&#34;, &#34;0.2215200000&#34;, &#34;-0.0972440000&#34;, &#34;-0.2508400000&#34;, &#34;0.3571700000&#34;, &#34;0.1410300000&#34;, &#34;-0.0916740000&#34;, &#34;0.1179000000&#34;, &#34;-0.0172910000&#34;, &#34;0.0098494000&#34;, &#34;0.2756000000&#34;, &#34;0.1550400000&#34;, &#34;0.0081984000&#34;, &#34;-0.2442400000&#34;, &#34;0.1335100000&#34;, &#34;-0.0413200000&#34;, &#34;0.0407330000&#34;, &#34;0.1772700000&#34;, &#34;0.0697880000&#34;, &#34;0.1017800000&#34;, &#34;0.1053000000&#34;, &#34;-0.1472700000&#34;, &#34;0.2026300000&#34;, &#34;-0.0593920000&#34;, &#34;-0.0287660000&#34;, &#34;0.0634910000&#34;, &#34;0.1825200000&#34;, &#34;-0.0014041000&#34;, &#34;0.1027400000&#34;, &#34;-0.1648100000&#34;, &#34;-0.0667120000&#34;, &#34;0.1384200000&#34;, &#34;-0.2726500000&#34;, &#34;-0.1963400000&#34;, &#34;-0.1605000000&#34;, &#34;-0.0742050000&#34;, &#34;0.0018183000&#34;, &#34;0.1026000000&#34;, &#34;-0.0435470000&#34;, &#34;-0.0072141000&#34;, &#34;0.0553060000&#34;, &#34;-0.0146920000&#34;, &#34;0.2226900000&#34;, &#34;-0.0125140000&#34;, &#34;0.1923300000&#34;, &#34;0.0218660000&#34;, &#34;-0.1175500000&#34;, &#34;0.0409160000&#34;, &#34;-0.1911000000&#34;, &#34;0.0944860000&#34;, &#34;-0.1134700000&#34;, &#34;-0.0054213000&#34;, &#34;-0.1179000000&#34;, &#34;-0.1594700000&#34;, &#34;0.1532900000&#34;, &#34;-0.1529900000&#34;, &#34;0.0930030000&#34;, &#34;0.0057173000&#34;, &#34;0.2451700000&#34;, &#34;-0.2296100000&#34;, &#34;-0.1095900000&#34;, &#34;0.1722900000&#34;, &#34;-0.1835800000&#34;, &#34;-0.0126960000&#34;, &#34;0.0583180000&#34;, &#34;0.0402570000&#34;, &#34;0.3110400000&#34;, &#34;0.1012500000&#34;, &#34;-0.1034000000&#34;, &#34;0.0863980000&#34;, &#34;-0.0512790000&#34;, &#34;0.2368600000&#34;, &#34;-0.1796100000&#34;, &#34;0.2068100000&#34;, &#34;-0.0761070000&#34;, &#34;-0.0010114000&#34;, &#34;0.0556930000&#34;, &#34;-0.1500500000&#34;, &#34;0.1915500000&#34;, &#34;-0.2685200000&#34;, &#34;-0.0636000000&#34;, &#34;0.1467400000&#34;, &#34;-0.0845620000&#34;, &#34;0.1201000000&#34;, &#34;-0.0160690000&#34;, &#34;0.1558900000&#34;, &#34;0.0321520000&#34;, &#34;-0.1993900000&#34;, &#34;-0.1060500000&#34;, &#34;0.2882500000&#34;, &#34;0.2997600000&#34;, &#34;0.0800010000&#34;, &#34;-0.0288720000&#34;, &#34;-0.1506500000&#34;, &#34;-0.1427700000&#34;, &#34;-0.0809550000&#34;, &#34;-0.0731380000&#34;, &#34;-0.1102500000&#34;, &#34;-0.3209600000&#34;, &#34;-0.1666400000&#34;, &#34;-0.0242900000&#34;, &#34;-0.1598900000&#34;, &#34;-0.0932460000&#34;, &#34;-0.1067300000&#34;, &#34;0.2122700000&#34;, &#34;0.0588260000&#34;, &#34;-0.0403710000&#34;, &#34;-0.1516500000&#34;, &#34;0.1209200000&#34;, &#34;0.0257990000&#34;, &#34;0.1389600000&#34;, &#34;0.1410700000&#34;, &#34;-0.0347680000&#34;, &#34;-0.0987820000&#34;, &#34;-0.0370760000&#34;, &#34;-0.1742000000&#34;, &#34;0.1546800000&#34;, &#34;0.2027100000&#34;, &#34;-0.2016000000&#34;, &#34;0.0056756000&#34;, &#34;0.2220900000&#34;, &#34;0.0655690000&#34;, &#34;-0.0482300000&#34;, &#34;-0.0019982000&#34;, &#34;0.2774900000&#34;, &#34;0.0535130000&#34;, &#34;0.1678500000&#34;, &#34;-0.0729150000&#34;, &#34;-0.0250250000&#34;, &#34;-0.0304100000&#34;, &#34;0.1003700000&#34;, &#34;-0.0847070000&#34;, &#34;-0.1525100000&#34;, &#34;-0.0455380000&#34;, &#34;-0.0767320000&#34;, &#34;-0.1807600000&#34;, &#34;0.0195180000&#34;, &#34;-0.2908300000&#34;, &#34;-0.1805300000&#34;, &#34;-0.0532130000&#34;, &#34;0.0342540000&#34;, &#34;0.2854300000&#34;, &#34;0.1992200000&#34;, &#34;0.2406300000&#34;, &#34;-0.0177200000&#34;, &#34;-0.0176050000&#34;, &#34;0.2447400000&#34;, &#34;-0.0109690000&#34;, &#34;0.1430600000&#34;, &#34;0.0639200000&#34;, &#34;0.0740190000&#34;, &#34;-0.1269800000&#34;, &#34;-0.0677130000&#34;, &#34;0.0295590000&#34;, &#34;0.0251710000&#34;, &#34;-0.2451000000&#34;, &#34;-0.0466250000&#34;, &#34;0.1457600000&#34;, &#34;0.1901500000&#34;, &#34;0.2264700000&#34;, &#34;0.1861200000&#34;, &#34;0.0878830000&#34;, &#34;0.0278500000&#34;, &#34;0.2847700000&#34;, &#34;-0.0500630000&#34;, &#34;0.1608700000&#34;, &#34;-0.0434980000&#34;, &#34;0.0756410000&#34;, &#34;0.4027000000&#34;, &#34;-0.0384560000&#34;, &#34;0.1930400000&#34;, &#34;0.0637230000&#34;, &#34;-0.3561900000&#34;, &#34;0.1758700000&#34;, &#34;0.2216500000&#34;, &#34;0.0756050000&#34;, &#34;-0.0550850000&#34;, &#34;-0.0307070000&#34;, &#34;0.0883560000&#34;, &#34;-0.0159830000&#34;, &#34;-0.2573500000&#34;], [&#34;-0.1597500000&#34;, &#34;-0.1194700000&#34;, &#34;0.1206000000&#34;, &#34;-0.0586310000&#34;, &#34;0.0045518000&#34;, &#34;0.1651800000&#34;, &#34;0.0574410000&#34;, &#34;-0.1168400000&#34;, &#34;-0.0418270000&#34;, &#34;0.1201700000&#34;, &#34;0.1386900000&#34;, &#34;-0.1617900000&#34;, &#34;0.0125150000&#34;, &#34;-0.1079400000&#34;, &#34;-0.0967700000&#34;, &#34;-0.1275900000&#34;, &#34;-0.0109600000&#34;, &#34;0.0291510000&#34;, &#34;-0.0457370000&#34;, &#34;0.1919200000&#34;, &#34;-0.0029964000&#34;, &#34;0.1302900000&#34;, &#34;-0.1860300000&#34;, &#34;-0.2492000000&#34;, &#34;-0.0215030000&#34;, &#34;0.0389760000&#34;, &#34;0.0620910000&#34;, &#34;0.1815400000&#34;, &#34;0.0269740000&#34;, &#34;-0.0415060000&#34;, &#34;0.0685610000&#34;, &#34;0.0431210000&#34;, &#34;-0.1334000000&#34;, &#34;0.1992700000&#34;, &#34;-0.0827060000&#34;, &#34;-0.2060000000&#34;, &#34;-0.0110170000&#34;, &#34;-0.0153460000&#34;, &#34;0.0357090000&#34;, &#34;-0.0914670000&#34;, &#34;-0.0154540000&#34;, &#34;-0.1300200000&#34;, &#34;0.0134620000&#34;, &#34;-0.0747070000&#34;, &#34;0.1367200000&#34;, &#34;0.1145900000&#34;, &#34;-0.0004246400&#34;, &#34;0.0876710000&#34;, &#34;-0.0415940000&#34;, &#34;-0.2623600000&#34;, &#34;0.1172700000&#34;, &#34;-0.0325420000&#34;, &#34;0.1532700000&#34;, &#34;0.0840430000&#34;, &#34;-0.1532300000&#34;, &#34;0.1215100000&#34;, &#34;-0.0390980000&#34;, &#34;0.2143100000&#34;, &#34;-0.1707800000&#34;, &#34;0.0645370000&#34;, &#34;-0.0107080000&#34;, &#34;-0.2263500000&#34;, &#34;0.1976400000&#34;, &#34;-0.0792570000&#34;, &#34;-0.1739900000&#34;, &#34;-0.0743980000&#34;, &#34;-0.3009200000&#34;, &#34;-0.0766730000&#34;, &#34;0.1579800000&#34;, &#34;-0.0461830000&#34;, &#34;-0.0098803000&#34;, &#34;-0.1065000000&#34;, &#34;0.2280500000&#34;, &#34;-0.2408000000&#34;, &#34;0.0836460000&#34;, &#34;0.0782390000&#34;, &#34;0.3040300000&#34;, &#34;0.1921900000&#34;, &#34;0.0015495000&#34;, &#34;0.0924000000&#34;, &#34;0.2875100000&#34;, &#34;-0.0517050000&#34;, &#34;-0.0757220000&#34;, &#34;0.0472960000&#34;, &#34;-0.0550460000&#34;, &#34;0.0087570000&#34;, &#34;-0.1959000000&#34;, &#34;0.1436400000&#34;, &#34;-0.0743430000&#34;, &#34;-0.2349700000&#34;, &#34;0.0419860000&#34;, &#34;-0.0219020000&#34;, &#34;0.4202800000&#34;, &#34;-0.1275300000&#34;, &#34;0.0843030000&#34;, &#34;-0.0607250000&#34;, &#34;-0.0227560000&#34;, &#34;-0.0252230000&#34;, &#34;-0.1021300000&#34;, &#34;0.1290200000&#34;, &#34;0.0817980000&#34;, &#34;-0.0921100000&#34;, &#34;0.1935800000&#34;, &#34;0.1562200000&#34;, &#34;-0.0684930000&#34;, &#34;-0.1778800000&#34;, &#34;0.0110350000&#34;, &#34;0.0802360000&#34;, &#34;0.0198540000&#34;, &#34;0.0012992000&#34;, &#34;0.0332260000&#34;, &#34;0.0603570000&#34;, &#34;0.0045871000&#34;, &#34;-0.1168300000&#34;, &#34;-0.0023224000&#34;, &#34;-0.2202600000&#34;, &#34;0.2224100000&#34;, &#34;0.1059700000&#34;, &#34;-0.1074200000&#34;, &#34;0.2180400000&#34;, &#34;0.2407900000&#34;, &#34;0.1862700000&#34;, &#34;0.0587230000&#34;, &#34;0.3724000000&#34;, &#34;0.0586390000&#34;, &#34;0.1055600000&#34;, &#34;0.2468900000&#34;, &#34;0.3110700000&#34;, &#34;-0.0125390000&#34;, &#34;0.2088600000&#34;, &#34;0.0551650000&#34;, &#34;0.0844530000&#34;, &#34;-0.0449190000&#34;, &#34;0.0254860000&#34;, &#34;-0.1053300000&#34;, &#34;-0.1342300000&#34;, &#34;-0.0506190000&#34;, &#34;0.0748310000&#34;, &#34;0.0018074000&#34;, &#34;-0.0259520000&#34;, &#34;-0.0250490000&#34;, &#34;-0.0902310000&#34;, &#34;0.1810600000&#34;, &#34;0.0095015000&#34;, &#34;0.0883090000&#34;, &#34;0.1277100000&#34;, &#34;-0.0249920000&#34;, &#34;0.0124670000&#34;, &#34;-0.0730790000&#34;, &#34;-0.0306170000&#34;, &#34;0.0771760000&#34;, &#34;-0.2062700000&#34;, &#34;0.0168790000&#34;, &#34;-0.1694000000&#34;, &#34;-0.0982330000&#34;, &#34;0.0319440000&#34;, &#34;0.1321900000&#34;, &#34;-0.0246180000&#34;, &#34;0.3809400000&#34;, &#34;0.0490890000&#34;, &#34;-0.1460100000&#34;, &#34;0.2135400000&#34;, &#34;0.1295100000&#34;, &#34;-0.0123390000&#34;, &#34;0.2074100000&#34;, &#34;0.0846430000&#34;, &#34;0.0634560000&#34;, &#34;0.1395200000&#34;, &#34;-0.0125550000&#34;, &#34;-0.0757660000&#34;, &#34;0.0782540000&#34;, &#34;-0.1459400000&#34;, &#34;-0.1357600000&#34;, &#34;-0.0696200000&#34;, &#34;-0.1481000000&#34;, &#34;0.1095300000&#34;, &#34;0.1311500000&#34;, &#34;0.0912090000&#34;, &#34;0.2220300000&#34;, &#34;0.0241870000&#34;, &#34;0.0944250000&#34;, &#34;0.1066100000&#34;, &#34;-0.1266600000&#34;, &#34;0.1007800000&#34;, &#34;-0.2401300000&#34;, &#34;-0.0868480000&#34;, &#34;0.1612300000&#34;, &#34;-0.1649900000&#34;, &#34;0.1583400000&#34;, &#34;-0.1061300000&#34;, &#34;0.0256160000&#34;, &#34;-0.2481200000&#34;, &#34;0.0641940000&#34;, &#34;0.1494500000&#34;, &#34;-0.1171600000&#34;, &#34;-0.0231960000&#34;, &#34;0.0940800000&#34;, &#34;0.1758000000&#34;, &#34;-0.1441500000&#34;, &#34;0.0091053000&#34;, &#34;-0.0890350000&#34;, &#34;-0.1526900000&#34;, &#34;0.2028700000&#34;, &#34;-0.0486790000&#34;, &#34;0.1099900000&#34;, &#34;-0.1919900000&#34;, &#34;0.0169160000&#34;, &#34;0.1698700000&#34;, &#34;0.1340700000&#34;, &#34;0.1483200000&#34;, &#34;0.2556100000&#34;, &#34;-0.1148100000&#34;, &#34;0.0459760000&#34;, &#34;-0.1045300000&#34;, &#34;0.3047100000&#34;, &#34;-0.1565500000&#34;, &#34;-0.0612180000&#34;, &#34;-0.3080200000&#34;, &#34;-0.0268840000&#34;, &#34;0.1247300000&#34;, &#34;-0.0397910000&#34;, &#34;-0.0412340000&#34;, &#34;-0.2260000000&#34;, &#34;0.1589800000&#34;, &#34;0.0540950000&#34;, &#34;0.0610630000&#34;, &#34;-0.0739540000&#34;, &#34;0.1043000000&#34;, &#34;0.2258500000&#34;, &#34;0.0319390000&#34;, &#34;0.1291900000&#34;, &#34;-0.0964080000&#34;, &#34;0.0081266000&#34;, &#34;-0.1627600000&#34;, &#34;0.0072641000&#34;, &#34;0.0078385000&#34;, &#34;-0.0832850000&#34;, &#34;-0.0519330000&#34;, &#34;0.1072400000&#34;, &#34;-0.0990100000&#34;, &#34;0.0224090000&#34;, &#34;-0.1303900000&#34;, &#34;0.0988350000&#34;, &#34;0.1285800000&#34;, &#34;0.2241000000&#34;, &#34;0.3579100000&#34;, &#34;0.1492700000&#34;, &#34;-0.0027789000&#34;, &#34;-0.0121560000&#34;, &#34;-0.0523360000&#34;, &#34;-0.0280420000&#34;, &#34;-0.1270700000&#34;, &#34;-0.3056300000&#34;, &#34;-0.1310700000&#34;, &#34;-0.0346780000&#34;, &#34;0.0571560000&#34;, &#34;-0.1181700000&#34;, &#34;0.0539260000&#34;, &#34;-0.0309180000&#34;, &#34;-0.0819190000&#34;, &#34;0.0356900000&#34;, &#34;0.2039900000&#34;, &#34;-0.0580470000&#34;, &#34;0.0400650000&#34;, &#34;-0.2662500000&#34;, &#34;-0.1968400000&#34;, &#34;-0.1096200000&#34;, &#34;0.0073118000&#34;, &#34;-0.0426280000&#34;, &#34;-0.3038000000&#34;, &#34;-0.1309400000&#34;, &#34;0.0584870000&#34;, &#34;-0.0224660000&#34;, &#34;-0.0186820000&#34;, &#34;-0.0805460000&#34;, &#34;-0.1308800000&#34;, &#34;0.0833770000&#34;, &#34;0.1824400000&#34;, &#34;-0.0409670000&#34;, &#34;-0.0075252000&#34;, &#34;0.1743600000&#34;, &#34;0.0567890000&#34;, &#34;-0.0822560000&#34;, &#34;0.1022600000&#34;, &#34;0.0556980000&#34;, &#34;-0.1287700000&#34;, &#34;0.1435200000&#34;, &#34;0.0745990000&#34;, &#34;-0.1185500000&#34;, &#34;0.1364300000&#34;, &#34;0.0524580000&#34;, &#34;-0.0794700000&#34;, &#34;0.0478250000&#34;, &#34;0.0403550000&#34;, &#34;0.0064958000&#34;, &#34;-0.0176890000&#34;, &#34;-0.0607240000&#34;, &#34;0.1316800000&#34;, &#34;0.1987800000&#34;, &#34;-0.0295310000&#34;], [&#34;-0.0165320000&#34;, &#34;0.1710700000&#34;, &#34;-0.2611200000&#34;, &#34;0.3131800000&#34;, &#34;-0.0300940000&#34;, &#34;0.0464090000&#34;, &#34;-0.1599200000&#34;, &#34;-0.2636200000&#34;, &#34;0.3855300000&#34;, &#34;-0.0138240000&#34;, &#34;-0.0671340000&#34;, &#34;0.0051643000&#34;, &#34;-0.0134130000&#34;, &#34;0.2662200000&#34;, &#34;-0.0151940000&#34;, &#34;-0.3197300000&#34;, &#34;0.1838200000&#34;, &#34;-0.0234700000&#34;, &#34;0.2055500000&#34;, &#34;0.3097400000&#34;, &#34;-0.0542570000&#34;, &#34;0.0430070000&#34;, &#34;-0.1823400000&#34;, &#34;-0.3464400000&#34;, &#34;-0.0621450000&#34;, &#34;-0.1618300000&#34;, &#34;0.0231650000&#34;, &#34;-0.0907440000&#34;, &#34;-0.1432000000&#34;, &#34;0.0582580000&#34;, &#34;0.1875200000&#34;, &#34;0.2007400000&#34;, &#34;-0.1458300000&#34;, &#34;0.0534900000&#34;, &#34;-0.2232900000&#34;, &#34;-0.0658370000&#34;, &#34;-0.1516500000&#34;, &#34;-0.2026900000&#34;, &#34;0.1110800000&#34;, &#34;0.1248300000&#34;, &#34;0.3305400000&#34;, &#34;0.2732700000&#34;, &#34;0.0115370000&#34;, &#34;-0.3310600000&#34;, &#34;-0.0323800000&#34;, &#34;0.1640300000&#34;, &#34;-0.1057300000&#34;, &#34;-0.0050296000&#34;, &#34;0.1879600000&#34;, &#34;0.0627670000&#34;, &#34;-0.2218200000&#34;, &#34;0.0867750000&#34;, &#34;0.0144030000&#34;, &#34;0.0238900000&#34;, &#34;-0.2108000000&#34;, &#34;-0.0042702000&#34;, &#34;-0.2056200000&#34;, &#34;0.0363660000&#34;, &#34;-0.2174800000&#34;, &#34;0.1515900000&#34;, &#34;-0.2326600000&#34;, &#34;-0.0729230000&#34;, &#34;-0.0047179000&#34;, &#34;0.1584500000&#34;, &#34;-0.0359620000&#34;, &#34;0.2844600000&#34;, &#34;-0.1093700000&#34;, &#34;0.0645970000&#34;, &#34;0.0879210000&#34;, &#34;-0.0965370000&#34;, &#34;0.0725770000&#34;, &#34;0.1149000000&#34;, &#34;0.1410300000&#34;, &#34;-0.2644700000&#34;, &#34;-0.0886060000&#34;, &#34;-0.0104600000&#34;, &#34;0.2195800000&#34;, &#34;0.1105100000&#34;, &#34;-0.3139700000&#34;, &#34;0.1450200000&#34;, &#34;0.0480880000&#34;, &#34;-0.1294200000&#34;, &#34;-0.2285200000&#34;, &#34;-0.0982450000&#34;, &#34;-0.1304500000&#34;, &#34;0.1189500000&#34;, &#34;-0.1380800000&#34;, &#34;0.0120620000&#34;, &#34;0.0972600000&#34;, &#34;0.0412810000&#34;, &#34;0.2265400000&#34;, &#34;-0.0808980000&#34;, &#34;0.0880520000&#34;, &#34;-0.2776700000&#34;, &#34;0.0931530000&#34;, &#34;0.0084290000&#34;, &#34;-0.0882860000&#34;, &#34;0.0092110000&#34;, &#34;-0.1894500000&#34;, &#34;0.1061600000&#34;, &#34;0.0214470000&#34;, &#34;-0.1277200000&#34;, &#34;0.1409800000&#34;, &#34;-0.0396720000&#34;, &#34;0.1994000000&#34;, &#34;-0.1007800000&#34;, &#34;-0.3036000000&#34;, &#34;-0.0269100000&#34;, &#34;0.0540760000&#34;, &#34;-0.0132040000&#34;, &#34;0.0617560000&#34;, &#34;-0.1297600000&#34;, &#34;0.2317000000&#34;, &#34;0.0940240000&#34;, &#34;0.4020700000&#34;, &#34;-0.1462000000&#34;, &#34;0.1619100000&#34;, &#34;-0.1050000000&#34;, &#34;0.1837000000&#34;, &#34;-0.0301660000&#34;, &#34;0.0643160000&#34;, &#34;0.2298600000&#34;, &#34;-0.0838490000&#34;, &#34;0.2339900000&#34;, &#34;-0.0792380000&#34;, &#34;0.2700700000&#34;, &#34;0.2114200000&#34;, &#34;0.2335700000&#34;, &#34;-0.1425800000&#34;, &#34;0.1152100000&#34;, &#34;0.1539200000&#34;, &#34;0.1047000000&#34;, &#34;-0.0947090000&#34;, &#34;0.1386000000&#34;, &#34;-0.1446200000&#34;, &#34;0.0620510000&#34;, &#34;-0.0044305000&#34;, &#34;-0.1285400000&#34;, &#34;0.1382200000&#34;, &#34;-0.0316550000&#34;, &#34;-0.1695100000&#34;, &#34;-0.1367700000&#34;, &#34;0.1313600000&#34;, &#34;-0.2762700000&#34;, &#34;-0.1914000000&#34;, &#34;0.3059000000&#34;, &#34;0.0170790000&#34;, &#34;-0.2680300000&#34;, &#34;-0.3186400000&#34;, &#34;0.0304450000&#34;, &#34;0.3651800000&#34;, &#34;0.0184090000&#34;, &#34;-0.1012100000&#34;, &#34;-0.0467270000&#34;, &#34;-0.0126190000&#34;, &#34;0.0328800000&#34;, &#34;0.0154770000&#34;, &#34;-0.1274800000&#34;, &#34;0.0446920000&#34;, &#34;-0.0402220000&#34;, &#34;-0.0314990000&#34;, &#34;0.1505700000&#34;, &#34;0.0870170000&#34;, &#34;0.0133790000&#34;, &#34;0.2274500000&#34;, &#34;0.3145600000&#34;, &#34;0.1069700000&#34;, &#34;-0.3411300000&#34;, &#34;0.3150900000&#34;, &#34;-0.0411670000&#34;, &#34;-0.1916800000&#34;, &#34;-0.2439000000&#34;, &#34;-0.3271500000&#34;, &#34;-0.1050500000&#34;, &#34;-0.0576140000&#34;, &#34;0.2293500000&#34;, &#34;0.1768800000&#34;, &#34;0.1841800000&#34;, &#34;0.3173300000&#34;, &#34;-0.0790880000&#34;, &#34;0.0327750000&#34;, &#34;-0.2019400000&#34;, &#34;-0.0521350000&#34;, &#34;0.1306500000&#34;, &#34;0.1920100000&#34;, &#34;0.1734000000&#34;, &#34;-0.0450400000&#34;, &#34;-0.1040500000&#34;, &#34;0.3138500000&#34;, &#34;-0.0890620000&#34;, &#34;0.0906790000&#34;, &#34;-0.1320100000&#34;, &#34;0.1034400000&#34;, &#34;0.1291300000&#34;, &#34;-0.2005600000&#34;, &#34;-0.2201400000&#34;, &#34;-0.0510940000&#34;, &#34;0.1094400000&#34;, &#34;-0.3006300000&#34;, &#34;-0.0546590000&#34;, &#34;-0.0038813000&#34;, &#34;0.0434660000&#34;, &#34;-0.0010636000&#34;, &#34;-0.1885100000&#34;, &#34;0.0613900000&#34;, &#34;-0.2651000000&#34;, &#34;-0.1395100000&#34;, &#34;-0.0673480000&#34;, &#34;0.1648100000&#34;, &#34;-0.3510800000&#34;, &#34;0.3366100000&#34;, &#34;0.0811980000&#34;, &#34;-0.1135400000&#34;, &#34;-0.3476100000&#34;, &#34;0.3973400000&#34;, &#34;0.2814700000&#34;, &#34;-0.0305920000&#34;, &#34;-0.4129300000&#34;, &#34;-0.2356500000&#34;, &#34;0.2974600000&#34;, &#34;-0.2045200000&#34;, &#34;-0.0563990000&#34;, &#34;-0.0224850000&#34;, &#34;0.0748530000&#34;, &#34;-0.2839100000&#34;, &#34;0.2283300000&#34;, &#34;-0.1343000000&#34;, &#34;-0.0239020000&#34;, &#34;0.1862900000&#34;, &#34;0.0122100000&#34;, &#34;0.0787960000&#34;, &#34;-0.1795900000&#34;, &#34;0.2287400000&#34;, &#34;0.1065800000&#34;, &#34;-0.1156900000&#34;, &#34;0.1901700000&#34;, &#34;0.0894970000&#34;, &#34;-0.1611900000&#34;, &#34;0.1548800000&#34;, &#34;0.0765240000&#34;, &#34;0.0904400000&#34;, &#34;0.1095200000&#34;, &#34;0.1358200000&#34;, &#34;0.2498300000&#34;, &#34;-0.2086100000&#34;, &#34;0.2076900000&#34;, &#34;0.1985000000&#34;, &#34;-0.1046400000&#34;, &#34;-0.0172640000&#34;, &#34;0.3161100000&#34;, &#34;-0.1890000000&#34;, &#34;-0.1069600000&#34;, &#34;0.0014526000&#34;, &#34;-0.1325600000&#34;, &#34;-0.0744180000&#34;, &#34;0.2159500000&#34;, &#34;-0.1605800000&#34;, &#34;0.1070400000&#34;, &#34;-0.0234520000&#34;, &#34;0.0142380000&#34;, &#34;0.0703660000&#34;, &#34;0.2588800000&#34;, &#34;-0.0766330000&#34;, &#34;-0.0196120000&#34;, &#34;-0.0607880000&#34;, &#34;-0.2178000000&#34;, &#34;-0.3737300000&#34;, &#34;0.1071000000&#34;, &#34;0.2958200000&#34;, &#34;0.0749020000&#34;, &#34;-0.2108300000&#34;, &#34;-0.0646680000&#34;, &#34;0.0895320000&#34;, &#34;0.2278000000&#34;, &#34;-0.0836900000&#34;, &#34;-0.1296900000&#34;, &#34;0.0680520000&#34;, &#34;0.4146100000&#34;, &#34;-0.1122100000&#34;, &#34;-0.1895900000&#34;, &#34;0.3560200000&#34;, &#34;-0.0876930000&#34;, &#34;0.0240680000&#34;, &#34;0.0223130000&#34;, &#34;0.2179200000&#34;, &#34;-0.3211200000&#34;, &#34;0.1606100000&#34;, &#34;0.3766700000&#34;, &#34;-0.2078800000&#34;, &#34;-0.1647900000&#34;, &#34;0.0751510000&#34;, &#34;-0.0041485000&#34;, &#34;0.1091800000&#34;, &#34;0.0995230000&#34;, &#34;0.0720380000&#34;, &#34;-0.0709360000&#34;, &#34;-0.0753820000&#34;, &#34;0.0435620000&#34;, &#34;0.2280000000&#34;, &#34;0.3304800000&#34;], [&#34;0.0513240000&#34;, &#34;-0.0706180000&#34;, &#34;-0.0216120000&#34;, &#34;0.5856600000&#34;, &#34;0.1919200000&#34;, &#34;0.2800500000&#34;, &#34;0.0892610000&#34;, &#34;0.0098064000&#34;, &#34;-0.3134600000&#34;, &#34;-0.0616510000&#34;, &#34;0.3603000000&#34;, &#34;-0.1643700000&#34;, &#34;-0.0322600000&#34;, &#34;-0.2181800000&#34;, &#34;0.3228400000&#34;, &#34;-0.0107670000&#34;, &#34;0.0232250000&#34;, &#34;0.2576400000&#34;, &#34;0.0131400000&#34;, &#34;0.6553600000&#34;, &#34;-0.0747040000&#34;, &#34;-0.5633000000&#34;, &#34;-0.1134500000&#34;, &#34;0.0538770000&#34;, &#34;0.2335800000&#34;, &#34;0.0176880000&#34;, &#34;-0.0304740000&#34;, &#34;-0.1508400000&#34;, &#34;-0.2486100000&#34;, &#34;0.1206400000&#34;, &#34;-0.2654000000&#34;, &#34;0.2544000000&#34;, &#34;-0.3460100000&#34;, &#34;-0.0414720000&#34;, &#34;0.3663200000&#34;, &#34;-0.2086800000&#34;, &#34;0.0339750000&#34;, &#34;-0.1131600000&#34;, &#34;0.3747000000&#34;, &#34;0.1632300000&#34;, &#34;0.7036400000&#34;, &#34;0.0847610000&#34;, &#34;-0.2616400000&#34;, &#34;0.0527830000&#34;, &#34;-0.0889470000&#34;, &#34;0.2709700000&#34;, &#34;0.0937870000&#34;, &#34;0.3125600000&#34;, &#34;0.2093100000&#34;, &#34;-0.1148700000&#34;, &#34;0.1083700000&#34;, &#34;-0.2969900000&#34;, &#34;0.1621800000&#34;, &#34;0.0154810000&#34;, &#34;-0.1120100000&#34;, &#34;0.2092200000&#34;, &#34;0.0704070000&#34;, &#34;0.2809900000&#34;, &#34;-0.0788350000&#34;, &#34;0.0993810000&#34;, &#34;0.2130000000&#34;, &#34;-0.2676100000&#34;, &#34;0.1290000000&#34;, &#34;0.0404300000&#34;, &#34;-0.0245720000&#34;, &#34;0.1703200000&#34;, &#34;-0.0496790000&#34;, &#34;-0.5684900000&#34;, &#34;-0.0088404000&#34;, &#34;0.1870300000&#34;, &#34;0.0335670000&#34;, &#34;0.0234760000&#34;, &#34;0.1444200000&#34;, &#34;-0.2524900000&#34;, &#34;0.0129050000&#34;, &#34;-0.0846210000&#34;, &#34;0.3420200000&#34;, &#34;0.0260740000&#34;, &#34;-0.5733900000&#34;, &#34;-0.0584450000&#34;, &#34;0.0260860000&#34;, &#34;-0.0647970000&#34;, &#34;0.0757690000&#34;, &#34;0.2953000000&#34;, &#34;-0.3896800000&#34;, &#34;0.0375920000&#34;, &#34;-0.0896950000&#34;, &#34;-0.3790100000&#34;, &#34;0.2678800000&#34;, &#34;-0.5073400000&#34;, &#34;0.0343320000&#34;, &#34;-0.1170100000&#34;, &#34;0.2985100000&#34;, &#34;-0.2539900000&#34;, &#34;0.0146440000&#34;, &#34;-0.0041997000&#34;, &#34;0.1566400000&#34;, &#34;-0.1199500000&#34;, &#34;-0.0019714000&#34;, &#34;0.0973370000&#34;, &#34;0.0435290000&#34;, &#34;0.0090645000&#34;, &#34;-0.1124200000&#34;, &#34;-0.0575640000&#34;, &#34;-0.2087200000&#34;, &#34;0.2946300000&#34;, &#34;0.1898300000&#34;, &#34;0.4180600000&#34;, &#34;0.2139800000&#34;, &#34;-0.0914810000&#34;, &#34;-0.1177200000&#34;, &#34;0.0085325000&#34;, &#34;-0.0028863000&#34;, &#34;0.0629740000&#34;, &#34;0.2071000000&#34;, &#34;-0.5297100000&#34;, &#34;-0.0178240000&#34;, &#34;0.1106400000&#34;, &#34;0.1349100000&#34;, &#34;0.0285410000&#34;, &#34;-0.0795620000&#34;, &#34;0.0495980000&#34;, &#34;-0.2556500000&#34;, &#34;0.0645160000&#34;, &#34;-0.0310300000&#34;, &#34;0.2444500000&#34;, &#34;0.1085700000&#34;, &#34;0.4715200000&#34;, &#34;0.0416410000&#34;, &#34;-0.1023000000&#34;, &#34;-0.1178900000&#34;, &#34;-0.0843260000&#34;, &#34;0.0187060000&#34;, &#34;-0.0590420000&#34;, &#34;-0.0958200000&#34;, &#34;0.1088600000&#34;, &#34;0.0987560000&#34;, &#34;-0.1241400000&#34;, &#34;-0.0807060000&#34;, &#34;0.2369000000&#34;, &#34;-0.1612000000&#34;, &#34;0.2176800000&#34;, &#34;0.4958500000&#34;, &#34;-0.0116190000&#34;, &#34;0.0097915000&#34;, &#34;0.6407700000&#34;, &#34;-0.1111500000&#34;, &#34;-0.0939950000&#34;, &#34;-0.1427100000&#34;, &#34;0.1573400000&#34;, &#34;0.1143800000&#34;, &#34;-0.1520900000&#34;, &#34;-0.5125000000&#34;, &#34;0.1470700000&#34;, &#34;-0.2382900000&#34;, &#34;0.1973100000&#34;, &#34;-0.4134800000&#34;, &#34;0.0188450000&#34;, &#34;0.1175400000&#34;, &#34;-0.1826600000&#34;, &#34;0.0221760000&#34;, &#34;-0.0663910000&#34;, &#34;-0.1203300000&#34;, &#34;0.0800400000&#34;, &#34;-0.2650600000&#34;, &#34;0.1684900000&#34;, &#34;0.1821600000&#34;, &#34;0.1750000000&#34;, &#34;-0.2825200000&#34;, &#34;-0.1813900000&#34;, &#34;0.1902200000&#34;, &#34;-0.3249500000&#34;, &#34;-0.0502280000&#34;, &#34;0.0892980000&#34;, &#34;-0.2048100000&#34;, &#34;-0.1448400000&#34;, &#34;0.0368750000&#34;, &#34;0.0495450000&#34;, &#34;-0.1724000000&#34;, &#34;0.1092700000&#34;, &#34;0.3847700000&#34;, &#34;-0.2678900000&#34;, &#34;-0.0853380000&#34;, &#34;-0.2645000000&#34;, &#34;0.0387650000&#34;, &#34;0.2556600000&#34;, &#34;0.0359980000&#34;, &#34;0.3837500000&#34;, &#34;-0.0998950000&#34;, &#34;-0.1705500000&#34;, &#34;0.2840000000&#34;, &#34;-0.0212870000&#34;, &#34;0.2804200000&#34;, &#34;0.0322540000&#34;, &#34;-0.2825500000&#34;, &#34;0.0654640000&#34;, &#34;-0.1203800000&#34;, &#34;-0.0149070000&#34;, &#34;-0.0006525500&#34;, &#34;0.0689850000&#34;, &#34;0.3073000000&#34;, &#34;-0.0346560000&#34;, &#34;0.3533500000&#34;, &#34;-0.0960390000&#34;, &#34;0.3632900000&#34;, &#34;-0.1311700000&#34;, &#34;-0.0607550000&#34;, &#34;-0.0942790000&#34;, &#34;0.3221300000&#34;, &#34;-0.0789180000&#34;, &#34;0.4698700000&#34;, &#34;-0.3843200000&#34;, &#34;-0.2243300000&#34;, &#34;-0.1883900000&#34;, &#34;0.1916100000&#34;, &#34;0.1373600000&#34;, &#34;-0.2309900000&#34;, &#34;-0.4350000000&#34;, &#34;-0.3800400000&#34;, &#34;-0.1009300000&#34;, &#34;-0.1491000000&#34;, &#34;-0.2365500000&#34;, &#34;-0.2094400000&#34;, &#34;0.3091000000&#34;, &#34;-0.1917300000&#34;, &#34;0.3218600000&#34;, &#34;0.0055599000&#34;, &#34;-0.1206200000&#34;, &#34;-0.1460500000&#34;, &#34;-0.2416900000&#34;, &#34;-0.0649800000&#34;, &#34;0.2606000000&#34;, &#34;-0.0654100000&#34;, &#34;0.1320700000&#34;, &#34;-0.7516100000&#34;, &#34;-0.3307700000&#34;, &#34;0.3523600000&#34;, &#34;-0.0248020000&#34;, &#34;0.1542700000&#34;, &#34;0.4268500000&#34;, &#34;0.2129000000&#34;, &#34;0.3395900000&#34;, &#34;0.1042900000&#34;, &#34;0.2427500000&#34;, &#34;-0.1701100000&#34;, &#34;0.1601900000&#34;, &#34;0.2847300000&#34;, &#34;-0.0765880000&#34;, &#34;0.2018200000&#34;, &#34;0.2639700000&#34;, &#34;0.0782000000&#34;, &#34;-0.3502300000&#34;, &#34;-0.3503500000&#34;, &#34;-0.1307800000&#34;, &#34;-0.0330730000&#34;, &#34;0.2162000000&#34;, &#34;-0.0010383000&#34;, &#34;-0.3543800000&#34;, &#34;-0.0803670000&#34;, &#34;-0.0958300000&#34;, &#34;-0.0802800000&#34;, &#34;0.3350300000&#34;, &#34;0.2789600000&#34;, &#34;-0.0995590000&#34;, &#34;-0.0920350000&#34;, &#34;0.1171500000&#34;, &#34;0.0803270000&#34;, &#34;0.0449470000&#34;, &#34;-0.0167250000&#34;, &#34;0.1094200000&#34;, &#34;-0.2763900000&#34;, &#34;-0.0384650000&#34;, &#34;0.1456100000&#34;, &#34;-0.1062600000&#34;, &#34;-0.1602400000&#34;, &#34;-0.0417930000&#34;, &#34;-0.0073398000&#34;, &#34;0.3471000000&#34;, &#34;0.0676280000&#34;, &#34;-0.0707770000&#34;, &#34;-0.0941370000&#34;, &#34;0.2950600000&#34;, &#34;-0.0639280000&#34;, &#34;0.0929010000&#34;, &#34;0.2258700000&#34;, &#34;-0.0332070000&#34;, &#34;0.0270170000&#34;, &#34;0.2455600000&#34;, &#34;-0.0296220000&#34;, &#34;0.0488670000&#34;, &#34;0.2562300000&#34;, &#34;-0.1718800000&#34;, &#34;0.2008900000&#34;, &#34;0.2300800000&#34;, &#34;-0.1056900000&#34;, &#34;0.0341030000&#34;, &#34;-0.5088700000&#34;, &#34;0.0771760000&#34;, &#34;0.0981730000&#34;, &#34;-0.2371300000&#34;], [&#34;-0.1330000000&#34;, &#34;-0.1230500000&#34;, &#34;0.0654240000&#34;, &#34;0.5002100000&#34;, &#34;0.1878300000&#34;, &#34;0.0762630000&#34;, &#34;-0.2700200000&#34;, &#34;0.1340500000&#34;, &#34;-0.0301880000&#34;, &#34;0.2475800000&#34;, &#34;0.2231800000&#34;, &#34;-0.0309880000&#34;, &#34;0.0095239000&#34;, &#34;-0.0302910000&#34;, &#34;0.3365300000&#34;, &#34;-0.0819380000&#34;, &#34;-0.1014500000&#34;, &#34;0.0432690000&#34;, &#34;-0.1446000000&#34;, &#34;0.3872900000&#34;, &#34;0.1021000000&#34;, &#34;0.1189900000&#34;, &#34;-0.3871300000&#34;, &#34;0.0372040000&#34;, &#34;-0.0557930000&#34;, &#34;0.1880900000&#34;, &#34;0.1961200000&#34;, &#34;0.0721930000&#34;, &#34;-0.2545900000&#34;, &#34;0.0810470000&#34;, &#34;-0.1890300000&#34;, &#34;0.2529600000&#34;, &#34;-0.2818200000&#34;, &#34;0.0023962000&#34;, &#34;0.1639000000&#34;, &#34;-0.2247500000&#34;, &#34;-0.1622400000&#34;, &#34;-0.0056278000&#34;, &#34;0.2569500000&#34;, &#34;-0.1198800000&#34;, &#34;0.2859200000&#34;, &#34;0.0456000000&#34;, &#34;-0.2220400000&#34;, &#34;0.1559000000&#34;, &#34;0.1067800000&#34;, &#34;0.1666400000&#34;, &#34;-0.2087300000&#34;, &#34;0.0633790000&#34;, &#34;-0.0412220000&#34;, &#34;-0.1158200000&#34;, &#34;0.1115500000&#34;, &#34;-0.0557060000&#34;, &#34;0.1310700000&#34;, &#34;0.2168700000&#34;, &#34;-0.3144800000&#34;, &#34;0.2510100000&#34;, &#34;0.0207120000&#34;, &#34;0.3685400000&#34;, &#34;-0.2311400000&#34;, &#34;0.1430400000&#34;, &#34;0.2466500000&#34;, &#34;-0.2332600000&#34;, &#34;0.0571900000&#34;, &#34;-0.0043860000&#34;, &#34;-0.0813010000&#34;, &#34;-0.0132580000&#34;, &#34;0.2274700000&#34;, &#34;0.0333920000&#34;, &#34;0.1033800000&#34;, &#34;0.0598810000&#34;, &#34;-0.1073500000&#34;, &#34;-0.1365400000&#34;, &#34;0.1125400000&#34;, &#34;-0.0988680000&#34;, &#34;-0.0695260000&#34;, &#34;0.0383090000&#34;, &#34;0.1010900000&#34;, &#34;0.1770200000&#34;, &#34;0.1813900000&#34;, &#34;-0.0801690000&#34;, &#34;0.0391810000&#34;, &#34;-0.1440200000&#34;, &#34;-0.0917060000&#34;, &#34;0.0243660000&#34;, &#34;-0.3997300000&#34;, &#34;-0.1256800000&#34;, &#34;0.0566750000&#34;, &#34;-0.2665900000&#34;, &#34;-0.0073045000&#34;, &#34;-0.0512830000&#34;, &#34;-0.1976700000&#34;, &#34;0.0553250000&#34;, &#34;0.3101300000&#34;, &#34;0.3243800000&#34;, &#34;0.0448760000&#34;, &#34;0.0727180000&#34;, &#34;0.0532680000&#34;, &#34;-0.0671240000&#34;, &#34;-0.0368180000&#34;, &#34;0.2518600000&#34;, &#34;0.0771260000&#34;, &#34;-0.1968400000&#34;, &#34;-0.0358860000&#34;, &#34;0.1611700000&#34;, &#34;-0.0525660000&#34;, &#34;0.2913900000&#34;, &#34;-0.1062300000&#34;, &#34;0.1228600000&#34;, &#34;0.1760900000&#34;, &#34;0.1388100000&#34;, &#34;0.0378150000&#34;, &#34;0.3313000000&#34;, &#34;-0.0143720000&#34;, &#34;-0.0945050000&#34;, &#34;-0.0169190000&#34;, &#34;-0.2014500000&#34;, &#34;-0.1476400000&#34;, &#34;0.0538020000&#34;, &#34;0.0506930000&#34;, &#34;-0.0860970000&#34;, &#34;0.0839150000&#34;, &#34;0.2542600000&#34;, &#34;0.1766300000&#34;, &#34;0.2031000000&#34;, &#34;0.0682790000&#34;, &#34;-0.0075550000&#34;, &#34;0.1232600000&#34;, &#34;0.3478500000&#34;, &#34;0.3979500000&#34;, &#34;-0.0663870000&#34;, &#34;-0.1576400000&#34;, &#34;-0.1517600000&#34;, &#34;-0.1482700000&#34;, &#34;-0.1665300000&#34;, &#34;-0.2751600000&#34;, &#34;-0.0498440000&#34;, &#34;-0.1192200000&#34;, &#34;0.0160070000&#34;, &#34;0.0845950000&#34;, &#34;0.1670200000&#34;, &#34;0.0034598000&#34;, &#34;0.0776680000&#34;, &#34;0.2430300000&#34;, &#34;-0.1834800000&#34;, &#34;0.2450600000&#34;, &#34;0.3285500000&#34;, &#34;-0.1578500000&#34;, &#34;-0.0379420000&#34;, &#34;0.2383200000&#34;, &#34;0.1035800000&#34;, &#34;-0.0600190000&#34;, &#34;0.1622300000&#34;, &#34;-0.2943400000&#34;, &#34;0.0151640000&#34;, &#34;-0.0838050000&#34;, &#34;0.1340800000&#34;, &#34;-0.0835450000&#34;, &#34;-0.0512260000&#34;, &#34;0.0106080000&#34;, &#34;-0.0535620000&#34;, &#34;-0.2310200000&#34;, &#34;0.0384450000&#34;, &#34;-0.0385240000&#34;, &#34;0.1454600000&#34;, &#34;-0.0089040000&#34;, &#34;-0.0828960000&#34;, &#34;0.0380030000&#34;, &#34;-0.1197400000&#34;, &#34;-0.0201110000&#34;, &#34;-0.1256200000&#34;, &#34;0.0312790000&#34;, &#34;-0.3003500000&#34;, &#34;-0.2645600000&#34;, &#34;-0.0769120000&#34;, &#34;-0.2510900000&#34;, &#34;0.1448800000&#34;, &#34;-0.2009200000&#34;, &#34;0.2136200000&#34;, &#34;-0.3350700000&#34;, &#34;-0.3743400000&#34;, &#34;0.0916680000&#34;, &#34;-0.1699600000&#34;, &#34;-0.1231500000&#34;, &#34;-0.1837100000&#34;, &#34;0.0568870000&#34;, &#34;0.0411630000&#34;, &#34;-0.0808080000&#34;, &#34;0.0754920000&#34;, &#34;0.1289200000&#34;, &#34;-0.2601000000&#34;, &#34;0.3371800000&#34;, &#34;-0.1970400000&#34;, &#34;0.2350400000&#34;, &#34;0.0662160000&#34;, &#34;-0.1401000000&#34;, &#34;0.0089649000&#34;, &#34;-0.2438000000&#34;, &#34;0.3026500000&#34;, &#34;-0.0326670000&#34;, &#34;-0.1689700000&#34;, &#34;0.0310410000&#34;, &#34;-0.1047400000&#34;, &#34;-0.0372180000&#34;, &#34;0.0252550000&#34;, &#34;0.1253600000&#34;, &#34;-0.3567600000&#34;, &#34;-0.1074500000&#34;, &#34;0.0542280000&#34;, &#34;-0.1310300000&#34;, &#34;-0.0520740000&#34;, &#34;0.4642300000&#34;, &#34;-0.2344200000&#34;, &#34;-0.2835800000&#34;, &#34;-0.1800700000&#34;, &#34;0.1348400000&#34;, &#34;-0.1042700000&#34;, &#34;0.0451520000&#34;, &#34;-0.5176100000&#34;, &#34;-0.1776800000&#34;, &#34;0.0315960000&#34;, &#34;-0.1157300000&#34;, &#34;-0.1056100000&#34;, &#34;0.0301210000&#34;, &#34;0.3722900000&#34;, &#34;-0.2012800000&#34;, &#34;0.0172310000&#34;, &#34;-0.1889200000&#34;, &#34;0.1339200000&#34;, &#34;-0.0736580000&#34;, &#34;-0.0168030000&#34;, &#34;-0.3517800000&#34;, &#34;0.2472100000&#34;, &#34;-0.0885820000&#34;, &#34;0.0752250000&#34;, &#34;-0.1495000000&#34;, &#34;-0.0373050000&#34;, &#34;0.2970200000&#34;, &#34;0.3019300000&#34;, &#34;0.0611570000&#34;, &#34;0.0621070000&#34;, &#34;0.4233700000&#34;, &#34;0.0415200000&#34;, &#34;-0.1969800000&#34;, &#34;0.5872500000&#34;, &#34;0.1964900000&#34;, &#34;0.3078100000&#34;, &#34;-0.1176000000&#34;, &#34;0.0108470000&#34;, &#34;0.1316000000&#34;, &#34;0.1806600000&#34;, &#34;0.0603290000&#34;, &#34;0.0718290000&#34;, &#34;-0.1875600000&#34;, &#34;-0.2057400000&#34;, &#34;0.0515100000&#34;, &#34;0.4237400000&#34;, &#34;-0.1491000000&#34;, &#34;-0.1581500000&#34;, &#34;-0.1430600000&#34;, &#34;-0.0060690000&#34;, &#34;-0.0182760000&#34;, &#34;0.2150100000&#34;, &#34;0.2668500000&#34;, &#34;-0.1726200000&#34;, &#34;-0.2509100000&#34;, &#34;-0.2382200000&#34;, &#34;0.0631350000&#34;, &#34;0.0398520000&#34;, &#34;-0.2362200000&#34;, &#34;0.1117400000&#34;, &#34;-0.3647300000&#34;, &#34;-0.2024800000&#34;, &#34;0.3980300000&#34;, &#34;0.1648000000&#34;, &#34;-0.2356300000&#34;, &#34;-0.3245400000&#34;, &#34;0.0714630000&#34;, &#34;0.5656300000&#34;, &#34;-0.0298980000&#34;, &#34;-0.0705180000&#34;, &#34;0.1893500000&#34;, &#34;-0.1499200000&#34;, &#34;-0.0436140000&#34;, &#34;-0.0066567000&#34;, &#34;0.2131200000&#34;, &#34;0.1828500000&#34;, &#34;0.0206320000&#34;, &#34;0.0815120000&#34;, &#34;-0.0083290000&#34;, &#34;0.2550400000&#34;, &#34;0.1868700000&#34;, &#34;-0.1163700000&#34;, &#34;0.0272600000&#34;, &#34;-0.0971270000&#34;, &#34;0.0247740000&#34;, &#34;-0.0573220000&#34;, &#34;-0.1964500000&#34;, &#34;-0.0504570000&#34;, &#34;-0.0743630000&#34;, &#34;-0.1283500000&#34;], [&#34;0.0851800000&#34;, &#34;-0.0200700000&#34;, &#34;0.2141800000&#34;, &#34;0.2401300000&#34;, &#34;-0.1031900000&#34;, &#34;0.1685900000&#34;, &#34;0.1346500000&#34;, &#34;-0.1485100000&#34;, &#34;0.0937640000&#34;, &#34;0.4982400000&#34;, &#34;0.1612300000&#34;, &#34;-0.1684300000&#34;, &#34;0.1391500000&#34;, &#34;-0.0679850000&#34;, &#34;0.0001754800&#34;, &#34;-0.1974800000&#34;, &#34;0.1750700000&#34;, &#34;0.1355900000&#34;, &#34;0.0657920000&#34;, &#34;0.1310200000&#34;, &#34;-0.1790300000&#34;, &#34;-0.1134600000&#34;, &#34;-0.1238100000&#34;, &#34;-0.1578600000&#34;, &#34;0.1249200000&#34;, &#34;0.1280100000&#34;, &#34;0.1193200000&#34;, &#34;0.1261300000&#34;, &#34;0.0035274000&#34;, &#34;0.0521450000&#34;, &#34;-0.3986400000&#34;, &#34;0.3450500000&#34;, &#34;-0.5077400000&#34;, &#34;0.1172800000&#34;, &#34;-0.3182800000&#34;, &#34;-0.1933900000&#34;, &#34;0.0136420000&#34;, &#34;-0.0165740000&#34;, &#34;-0.1712100000&#34;, &#34;0.1095500000&#34;, &#34;0.1430500000&#34;, &#34;-0.1762400000&#34;, &#34;-0.0783430000&#34;, &#34;0.0913900000&#34;, &#34;0.3295400000&#34;, &#34;0.1202400000&#34;, &#34;0.1950600000&#34;, &#34;0.0386110000&#34;, &#34;-0.1520600000&#34;, &#34;-0.2076400000&#34;, &#34;-0.1730700000&#34;, &#34;-0.4215400000&#34;, &#34;0.0623800000&#34;, &#34;-0.1658300000&#34;, &#34;-0.0227580000&#34;, &#34;-0.0628160000&#34;, &#34;0.0971100000&#34;, &#34;-0.0493320000&#34;, &#34;-0.0646270000&#34;, &#34;0.1649700000&#34;, &#34;-0.2716200000&#34;, &#34;-0.0864980000&#34;, &#34;0.5714800000&#34;, &#34;0.0000320680&#34;, &#34;0.0071824000&#34;, &#34;-0.4222700000&#34;, &#34;0.2138000000&#34;, &#34;0.2210000000&#34;, &#34;0.0498440000&#34;, &#34;0.3391500000&#34;, &#34;-0.0719490000&#34;, &#34;0.0577400000&#34;, &#34;-0.0322730000&#34;, &#34;-0.2662000000&#34;, &#34;-0.1071800000&#34;, &#34;0.0652310000&#34;, &#34;0.0326830000&#34;, &#34;0.3165200000&#34;, &#34;-0.1916300000&#34;, &#34;-0.1756200000&#34;, &#34;0.0544100000&#34;, &#34;0.4661100000&#34;, &#34;-0.0094752000&#34;, &#34;-0.0645490000&#34;, &#34;0.1156200000&#34;, &#34;0.0370780000&#34;, &#34;0.1921800000&#34;, &#34;0.2274000000&#34;, &#34;-0.3620100000&#34;, &#34;-0.2009800000&#34;, &#34;0.1897100000&#34;, &#34;0.0505870000&#34;, &#34;0.1515400000&#34;, &#34;-0.2923900000&#34;, &#34;0.0855460000&#34;, &#34;0.0821190000&#34;, &#34;0.3057500000&#34;, &#34;-0.1839200000&#34;, &#34;0.1427500000&#34;, &#34;0.2597300000&#34;, &#34;-0.0573870000&#34;, &#34;-0.0809190000&#34;, &#34;0.0080007000&#34;, &#34;-0.4582200000&#34;, &#34;-0.3904500000&#34;, &#34;-0.0856770000&#34;, &#34;-0.0902180000&#34;, &#34;0.4028800000&#34;, &#34;0.0243540000&#34;, &#34;0.0220950000&#34;, &#34;-0.0229840000&#34;, &#34;0.0065696000&#34;, &#34;0.0370420000&#34;, &#34;-0.0625060000&#34;, &#34;-0.1645500000&#34;, &#34;-0.1022600000&#34;, &#34;0.1809200000&#34;, &#34;-0.0560690000&#34;, &#34;-0.3262800000&#34;, &#34;0.1441200000&#34;, &#34;0.1364300000&#34;, &#34;-0.0427510000&#34;, &#34;0.0834990000&#34;, &#34;-0.0559940000&#34;, &#34;-0.0408320000&#34;, &#34;0.0451580000&#34;, &#34;0.0601930000&#34;, &#34;0.0182640000&#34;, &#34;0.0222160000&#34;, &#34;0.1123300000&#34;, &#34;0.2150200000&#34;, &#34;0.1451800000&#34;, &#34;-0.2200500000&#34;, &#34;-0.1028100000&#34;, &#34;0.1120400000&#34;, &#34;-0.0683040000&#34;, &#34;-0.1594100000&#34;, &#34;0.1758900000&#34;, &#34;0.5128100000&#34;, &#34;0.0957280000&#34;, &#34;-0.0657770000&#34;, &#34;0.0451430000&#34;, &#34;0.1306800000&#34;, &#34;0.1293900000&#34;, &#34;-0.1016700000&#34;, &#34;-0.1396700000&#34;, &#34;0.0801730000&#34;, &#34;-0.4389300000&#34;, &#34;0.2679300000&#34;, &#34;-0.0700760000&#34;, &#34;0.3494700000&#34;, &#34;-0.2701300000&#34;, &#34;0.1588500000&#34;, &#34;0.0181890000&#34;, &#34;-0.0337430000&#34;, &#34;-0.0422830000&#34;, &#34;-0.2267500000&#34;, &#34;0.1944400000&#34;, &#34;0.0013730000&#34;, &#34;0.1136100000&#34;, &#34;-0.0624300000&#34;, &#34;0.0578810000&#34;, &#34;-0.0960000000&#34;, &#34;0.0473200000&#34;, &#34;-0.1566800000&#34;, &#34;-0.0202400000&#34;, &#34;0.0320620000&#34;, &#34;-0.0726230000&#34;, &#34;0.0689580000&#34;, &#34;0.1297000000&#34;, &#34;-0.2781000000&#34;, &#34;-0.3522000000&#34;, &#34;-0.2316600000&#34;, &#34;-0.0691740000&#34;, &#34;-0.1931800000&#34;, &#34;0.4989900000&#34;, &#34;0.0502420000&#34;, &#34;0.0172720000&#34;, &#34;-0.2182400000&#34;, &#34;-0.2038900000&#34;, &#34;0.2229000000&#34;, &#34;-0.1098600000&#34;, &#34;0.0989670000&#34;, &#34;0.2818500000&#34;, &#34;0.1975100000&#34;, &#34;0.0632280000&#34;, &#34;0.1905200000&#34;, &#34;-0.5237800000&#34;, &#34;0.3318100000&#34;, &#34;-0.0095121000&#34;, &#34;0.1064300000&#34;, &#34;-0.3345400000&#34;, &#34;-0.2359500000&#34;, &#34;0.2270900000&#34;, &#34;-0.2105800000&#34;, &#34;-0.0589760000&#34;, &#34;-0.1400700000&#34;, &#34;0.0427870000&#34;, &#34;-0.0528680000&#34;, &#34;-0.1844700000&#34;, &#34;0.1337400000&#34;, &#34;0.1705900000&#34;, &#34;0.0193090000&#34;, &#34;0.0379540000&#34;, &#34;0.0046226000&#34;, &#34;-0.1347800000&#34;, &#34;-0.0976870000&#34;, &#34;-0.2025300000&#34;, &#34;0.0447970000&#34;, &#34;0.0356180000&#34;, &#34;0.3508800000&#34;, &#34;0.1167700000&#34;, &#34;0.1158100000&#34;, &#34;-0.4729400000&#34;, &#34;0.2493100000&#34;, &#34;-0.1033000000&#34;, &#34;0.0524140000&#34;, &#34;-0.3493600000&#34;, &#34;-0.1720000000&#34;, &#34;0.3523500000&#34;, &#34;0.0313910000&#34;, &#34;-0.0075628000&#34;, &#34;-0.3449000000&#34;, &#34;0.1398400000&#34;, &#34;-0.0975960000&#34;, &#34;0.3973700000&#34;, &#34;-0.4213500000&#34;, &#34;-0.0734910000&#34;, &#34;0.0699600000&#34;, &#34;0.0249500000&#34;, &#34;-0.1186300000&#34;, &#34;0.0692330000&#34;, &#34;0.0318490000&#34;, &#34;-0.1868100000&#34;, &#34;0.0119780000&#34;, &#34;-0.1418200000&#34;, &#34;-0.0832710000&#34;, &#34;0.1002500000&#34;, &#34;0.2276000000&#34;, &#34;-0.2265800000&#34;, &#34;0.1252800000&#34;, &#34;-0.0507510000&#34;, &#34;0.0610840000&#34;, &#34;0.0515400000&#34;, &#34;-0.0228720000&#34;, &#34;0.0507840000&#34;, &#34;0.2249100000&#34;, &#34;-0.1222700000&#34;, &#34;0.2929300000&#34;, &#34;0.0299200000&#34;, &#34;-0.0748870000&#34;, &#34;0.2658300000&#34;, &#34;0.1934400000&#34;, &#34;0.3944700000&#34;, &#34;0.1033600000&#34;, &#34;0.2358800000&#34;, &#34;-0.2657700000&#34;, &#34;-0.1336100000&#34;, &#34;0.3426200000&#34;, &#34;-0.0096122000&#34;, &#34;0.1828100000&#34;, &#34;-0.3648300000&#34;, &#34;0.1314900000&#34;, &#34;0.0784400000&#34;, &#34;-0.2421400000&#34;, &#34;-0.3927000000&#34;, &#34;-0.0823610000&#34;, &#34;0.2368600000&#34;, &#34;0.0903440000&#34;, &#34;-0.2082100000&#34;, &#34;0.0654830000&#34;, &#34;-0.0429180000&#34;, &#34;0.5265200000&#34;, &#34;0.0523810000&#34;, &#34;-0.0753590000&#34;, &#34;0.1181200000&#34;, &#34;0.0941880000&#34;, &#34;0.0837270000&#34;, &#34;-0.2149000000&#34;, &#34;-0.0581420000&#34;, &#34;-0.1207800000&#34;, &#34;-0.1138000000&#34;, &#34;0.2055500000&#34;, &#34;0.0381250000&#34;, &#34;0.3186800000&#34;, &#34;-0.1447200000&#34;, &#34;-0.0084665000&#34;, &#34;0.2390900000&#34;, &#34;-0.2235700000&#34;, &#34;0.5528100000&#34;, &#34;0.0545930000&#34;, &#34;0.1377200000&#34;, &#34;0.0817060000&#34;, &#34;0.0724950000&#34;, &#34;0.2288000000&#34;, &#34;-0.0872900000&#34;, &#34;-0.0172320000&#34;, &#34;0.2579100000&#34;, &#34;0.1911700000&#34;, &#34;0.0124620000&#34;], [&#34;-0.1329400000&#34;, &#34;-0.0040341000&#34;, &#34;-0.2528700000&#34;, &#34;0.7473600000&#34;, &#34;-0.0522580000&#34;, &#34;-0.2666700000&#34;, &#34;0.2227600000&#34;, &#34;-0.3468700000&#34;, &#34;0.1293200000&#34;, &#34;0.0079318000&#34;, &#34;0.0466260000&#34;, &#34;0.1468700000&#34;, &#34;0.1007400000&#34;, &#34;-0.0792940000&#34;, &#34;0.2395000000&#34;, &#34;-0.3809500000&#34;, &#34;-0.2268300000&#34;, &#34;0.0759170000&#34;, &#34;-0.2820100000&#34;, &#34;0.1698100000&#34;, &#34;-0.0174520000&#34;, &#34;-0.1808300000&#34;, &#34;-0.1503000000&#34;, &#34;0.1868700000&#34;, &#34;0.1684800000&#34;, &#34;0.1996000000&#34;, &#34;-0.1113000000&#34;, &#34;-0.0648440000&#34;, &#34;0.2044500000&#34;, &#34;0.1401600000&#34;, &#34;0.1828900000&#34;, &#34;0.2726100000&#34;, &#34;-0.0857620000&#34;, &#34;-0.1995400000&#34;, &#34;-0.0166050000&#34;, &#34;0.0530080000&#34;, &#34;0.0587480000&#34;, &#34;-0.3078000000&#34;, &#34;-0.1012500000&#34;, &#34;-0.1944600000&#34;, &#34;0.3231300000&#34;, &#34;-0.3749200000&#34;, &#34;-0.3575800000&#34;, &#34;0.1566100000&#34;, &#34;0.1158300000&#34;, &#34;0.5502400000&#34;, &#34;0.2186600000&#34;, &#34;-0.2560100000&#34;, &#34;0.2414500000&#34;, &#34;0.1539600000&#34;, &#34;0.2189500000&#34;, &#34;-0.1320800000&#34;, &#34;0.4339600000&#34;, &#34;-0.2742000000&#34;, &#34;-0.1460400000&#34;, &#34;-0.1582100000&#34;, &#34;-0.0977820000&#34;, &#34;0.2375300000&#34;, &#34;-0.0138630000&#34;, &#34;0.1441300000&#34;, &#34;-0.3629500000&#34;, &#34;-0.0287050000&#34;, &#34;0.1719500000&#34;, &#34;-0.2894000000&#34;, &#34;-0.2306500000&#34;, &#34;-0.0192500000&#34;, &#34;-0.1589800000&#34;, &#34;0.1226600000&#34;, &#34;0.2047400000&#34;, &#34;-0.1476100000&#34;, &#34;-0.1721800000&#34;, &#34;0.2289100000&#34;, &#34;0.4538800000&#34;, &#34;-0.3794000000&#34;, &#34;-0.2612700000&#34;, &#34;-0.0750980000&#34;, &#34;0.0902550000&#34;, &#34;-0.1638600000&#34;, &#34;-0.2516900000&#34;, &#34;-0.1709500000&#34;, &#34;-0.3844600000&#34;, &#34;-0.1637900000&#34;, &#34;-0.0539090000&#34;, &#34;-0.0511950000&#34;, &#34;0.1601700000&#34;, &#34;0.0802550000&#34;, &#34;-0.1573500000&#34;, &#34;0.1084100000&#34;, &#34;0.1586400000&#34;, &#34;-0.0157300000&#34;, &#34;0.1188000000&#34;, &#34;-0.1445300000&#34;, &#34;0.2231300000&#34;, &#34;0.0243460000&#34;, &#34;-0.0180430000&#34;, &#34;0.2428600000&#34;, &#34;-0.0558100000&#34;, &#34;-0.0121520000&#34;, &#34;-0.0708120000&#34;, &#34;-0.1179600000&#34;, &#34;-0.4600300000&#34;, &#34;-0.0559390000&#34;, &#34;0.1673500000&#34;, &#34;-0.2604600000&#34;, &#34;-0.1724000000&#34;, &#34;-0.0828000000&#34;, &#34;-0.1188000000&#34;, &#34;-0.2305400000&#34;, &#34;-0.0129530000&#34;, &#34;-0.4526100000&#34;, &#34;-0.1724300000&#34;, &#34;0.1151200000&#34;, &#34;-0.3108400000&#34;, &#34;-0.1094800000&#34;, &#34;0.0415000000&#34;, &#34;0.1968200000&#34;, &#34;0.0401660000&#34;, &#34;-0.1161000000&#34;, &#34;0.0869520000&#34;, &#34;0.0416410000&#34;, &#34;0.4455300000&#34;, &#34;0.4731700000&#34;, &#34;0.0098619000&#34;, &#34;0.1431700000&#34;, &#34;0.2682600000&#34;, &#34;0.0569110000&#34;, &#34;0.2369800000&#34;, &#34;-0.0882120000&#34;, &#34;0.3660100000&#34;, &#34;0.3186500000&#34;, &#34;0.3223000000&#34;, &#34;0.2683000000&#34;, &#34;0.0467380000&#34;, &#34;-0.3218400000&#34;, &#34;0.3445700000&#34;, &#34;-0.1737700000&#34;, &#34;-0.1917200000&#34;, &#34;0.0660220000&#34;, &#34;0.1783900000&#34;, &#34;-0.1917900000&#34;, &#34;0.2302300000&#34;, &#34;0.3166100000&#34;, &#34;0.1722200000&#34;, &#34;0.0210510000&#34;, &#34;0.2011500000&#34;, &#34;-0.0726930000&#34;, &#34;-0.0139950000&#34;, &#34;0.0637070000&#34;, &#34;-0.1541700000&#34;, &#34;0.1900300000&#34;, &#34;-0.1488100000&#34;, &#34;-0.0864240000&#34;, &#34;-0.4749800000&#34;, &#34;0.0396390000&#34;, &#34;-0.1359100000&#34;, &#34;0.2262000000&#34;, &#34;-0.1297200000&#34;, &#34;-0.1611800000&#34;, &#34;0.2446800000&#34;, &#34;0.0166980000&#34;, &#34;-0.1117300000&#34;, &#34;0.1821600000&#34;, &#34;-0.4173200000&#34;, &#34;-0.3033800000&#34;, &#34;-0.1177300000&#34;, &#34;0.5779600000&#34;, &#34;-0.0655710000&#34;, &#34;-0.5637500000&#34;, &#34;0.3918000000&#34;, &#34;-0.0778960000&#34;, &#34;-0.3234600000&#34;, &#34;-0.3475600000&#34;, &#34;-0.3348200000&#34;, &#34;-0.1010500000&#34;, &#34;-0.0611140000&#34;, &#34;0.0550690000&#34;, &#34;-0.0905710000&#34;, &#34;-0.0815730000&#34;, &#34;-0.3094700000&#34;, &#34;-0.6805700000&#34;, &#34;0.0172680000&#34;, &#34;-0.2111600000&#34;, &#34;-0.1099300000&#34;, &#34;-0.0311870000&#34;, &#34;-0.3995600000&#34;, &#34;0.1094700000&#34;, &#34;-0.0548880000&#34;, &#34;0.1790500000&#34;, &#34;0.0158170000&#34;, &#34;0.1301700000&#34;, &#34;0.1595700000&#34;, &#34;-0.1519300000&#34;, &#34;-0.0928810000&#34;, &#34;0.0781060000&#34;, &#34;0.0519230000&#34;, &#34;-0.3589900000&#34;, &#34;0.0366990000&#34;, &#34;0.0662820000&#34;, &#34;-0.3750000000&#34;, &#34;0.0156820000&#34;, &#34;-0.3274300000&#34;, &#34;-0.1991800000&#34;, &#34;0.1159300000&#34;, &#34;-0.1478900000&#34;, &#34;-0.2842800000&#34;, &#34;-0.6705900000&#34;, &#34;-0.1556300000&#34;, &#34;-0.7228500000&#34;, &#34;-0.1450400000&#34;, &#34;-0.0868670000&#34;, &#34;0.1271600000&#34;, &#34;0.2324600000&#34;, &#34;0.0451520000&#34;, &#34;-0.0783510000&#34;, &#34;0.3321100000&#34;, &#34;-0.3912600000&#34;, &#34;-0.4054900000&#34;, &#34;-0.0341500000&#34;, &#34;-0.1628000000&#34;, &#34;0.3739500000&#34;, &#34;-0.3406000000&#34;, &#34;0.0241210000&#34;, &#34;-0.2131200000&#34;, &#34;0.1685600000&#34;, &#34;-0.1051900000&#34;, &#34;0.0422010000&#34;, &#34;-0.2304900000&#34;, &#34;0.2668200000&#34;, &#34;-0.2949800000&#34;, &#34;0.0866800000&#34;, &#34;0.1791200000&#34;, &#34;0.2326900000&#34;, &#34;0.0081227000&#34;, &#34;0.3044600000&#34;, &#34;-0.0068773000&#34;, &#34;-0.0314850000&#34;, &#34;-0.1289200000&#34;, &#34;-0.3601000000&#34;, &#34;0.2866800000&#34;, &#34;0.1896800000&#34;, &#34;0.1489800000&#34;, &#34;0.1840400000&#34;, &#34;0.0896390000&#34;, &#34;0.2711500000&#34;, &#34;-0.1706100000&#34;, &#34;0.2525000000&#34;, &#34;0.3225100000&#34;, &#34;-0.1207400000&#34;, &#34;0.1650200000&#34;, &#34;0.2747200000&#34;, &#34;0.1814400000&#34;, &#34;-0.1612200000&#34;, &#34;-0.2881100000&#34;, &#34;0.2643800000&#34;, &#34;-0.0423200000&#34;, &#34;0.4544400000&#34;, &#34;-0.3193500000&#34;, &#34;-0.4021500000&#34;, &#34;-0.0146670000&#34;, &#34;-0.0428330000&#34;, &#34;-0.0412490000&#34;, &#34;0.1641800000&#34;, &#34;0.1345000000&#34;, &#34;-0.2220100000&#34;, &#34;-0.1087600000&#34;, &#34;-0.5052200000&#34;, &#34;0.0882370000&#34;, &#34;0.2334200000&#34;, &#34;-0.1275600000&#34;, &#34;-0.1542900000&#34;, &#34;-0.0573300000&#34;, &#34;-0.2659200000&#34;, &#34;0.6617000000&#34;, &#34;-0.1194000000&#34;, &#34;0.0545380000&#34;, &#34;-0.1999100000&#34;, &#34;-0.0244130000&#34;, &#34;0.1016200000&#34;, &#34;-0.2644800000&#34;, &#34;0.2442800000&#34;, &#34;0.0035108000&#34;, &#34;-0.0334870000&#34;, &#34;-0.0689520000&#34;, &#34;-0.0041886000&#34;, &#34;0.5570600000&#34;, &#34;-0.0880990000&#34;, &#34;0.2995500000&#34;, &#34;0.1473100000&#34;, &#34;-0.2065700000&#34;, &#34;0.1496100000&#34;, &#34;0.2581300000&#34;, &#34;-0.0317330000&#34;, &#34;-0.1245700000&#34;, &#34;-0.0930970000&#34;, &#34;0.2215800000&#34;, &#34;-0.2244100000&#34;, &#34;0.2205600000&#34;, &#34;0.0828950000&#34;, &#34;0.3491200000&#34;, &#34;0.3267200000&#34;], [&#34;-0.0821570000&#34;, &#34;0.0551590000&#34;, &#34;-0.1657600000&#34;, &#34;0.3520600000&#34;, &#34;-0.0223220000&#34;, &#34;-0.0778630000&#34;, &#34;0.3862900000&#34;, &#34;-0.5446400000&#34;, &#34;0.1514000000&#34;, &#34;0.0972030000&#34;, &#34;-0.0744400000&#34;, &#34;0.2802400000&#34;, &#34;-0.0993530000&#34;, &#34;0.5928800000&#34;, &#34;-0.2579300000&#34;, &#34;-0.4403100000&#34;, &#34;-0.3942100000&#34;, &#34;0.1328900000&#34;, &#34;0.4262500000&#34;, &#34;0.1132500000&#34;, &#34;0.0027451000&#34;, &#34;0.1915600000&#34;, &#34;-0.0779630000&#34;, &#34;-0.3008900000&#34;, &#34;0.1516300000&#34;, &#34;0.2203600000&#34;, &#34;-0.3060000000&#34;, &#34;-0.3920400000&#34;, &#34;0.6744100000&#34;, &#34;-0.0266980000&#34;, &#34;-0.1476400000&#34;, &#34;0.0629660000&#34;, &#34;0.0200700000&#34;, &#34;0.2054200000&#34;, &#34;0.1375000000&#34;, &#34;-0.4318000000&#34;, &#34;0.3834700000&#34;, &#34;-0.5985100000&#34;, &#34;0.1957000000&#34;, &#34;-0.1516900000&#34;, &#34;-0.1199600000&#34;, &#34;-0.0382590000&#34;, &#34;0.2223900000&#34;, &#34;-0.0933100000&#34;, &#34;0.1947400000&#34;, &#34;0.4427000000&#34;, &#34;-0.0860080000&#34;, &#34;-0.3233300000&#34;, &#34;-0.0155910000&#34;, &#34;0.0335440000&#34;, &#34;0.3085100000&#34;, &#34;-0.5045400000&#34;, &#34;0.3970000000&#34;, &#34;-0.4759200000&#34;, &#34;-0.6172900000&#34;, &#34;0.0726510000&#34;, &#34;-0.2968100000&#34;, &#34;-0.0052561000&#34;, &#34;-0.3308900000&#34;, &#34;0.0097070000&#34;, &#34;-0.0155650000&#34;, &#34;-0.1932400000&#34;, &#34;0.6768100000&#34;, &#34;-0.4971600000&#34;, &#34;0.2152700000&#34;, &#34;0.1020500000&#34;, &#34;0.1463900000&#34;, &#34;0.0053264000&#34;, &#34;0.0847450000&#34;, &#34;0.0963660000&#34;, &#34;-0.0596670000&#34;, &#34;0.2078600000&#34;, &#34;0.2598500000&#34;, &#34;0.1488000000&#34;, &#34;-0.3508700000&#34;, &#34;-0.1753400000&#34;, &#34;-0.1306300000&#34;, &#34;-0.1562700000&#34;, &#34;0.1045500000&#34;, &#34;0.2493900000&#34;, &#34;0.2865200000&#34;, &#34;0.2166800000&#34;, &#34;-0.0218610000&#34;, &#34;0.0735370000&#34;, &#34;-0.1330200000&#34;, &#34;0.3135500000&#34;, &#34;-0.3336800000&#34;, &#34;0.5265100000&#34;, &#34;0.0995670000&#34;, &#34;0.4253800000&#34;, &#34;-0.1079600000&#34;, &#34;-0.0289250000&#34;, &#34;0.1756800000&#34;, &#34;-0.1813300000&#34;, &#34;-0.4076200000&#34;, &#34;0.2246200000&#34;, &#34;0.1657100000&#34;, &#34;-0.0463460000&#34;, &#34;-0.0763770000&#34;, &#34;-0.0573720000&#34;, &#34;-0.0857430000&#34;, &#34;-0.0299300000&#34;, &#34;0.0930800000&#34;, &#34;0.1665300000&#34;, &#34;0.1540500000&#34;, &#34;-0.1188400000&#34;, &#34;-0.2006600000&#34;, &#34;0.2996500000&#34;, &#34;0.1095100000&#34;, &#34;0.1393700000&#34;, &#34;-0.1359100000&#34;, &#34;0.0366770000&#34;, &#34;-0.4156400000&#34;, &#34;-0.1751100000&#34;, &#34;0.3539200000&#34;, &#34;0.3526300000&#34;, &#34;0.0637140000&#34;, &#34;0.0035714000&#34;, &#34;-0.2909300000&#34;, &#34;-0.0741830000&#34;, &#34;0.5216200000&#34;, &#34;-0.0087506000&#34;, &#34;-0.2356600000&#34;, &#34;0.2029100000&#34;, &#34;-0.1011300000&#34;, &#34;-0.2151200000&#34;, &#34;0.0304650000&#34;, &#34;0.4477600000&#34;, &#34;-0.0048431000&#34;, &#34;0.1511700000&#34;, &#34;-0.4036500000&#34;, &#34;-0.3351900000&#34;, &#34;-0.3376000000&#34;, &#34;-0.1276200000&#34;, &#34;-0.1516600000&#34;, &#34;0.1038000000&#34;, &#34;-0.0031190000&#34;, &#34;-0.1878700000&#34;, &#34;0.0217180000&#34;, &#34;-0.3423000000&#34;, &#34;0.1781300000&#34;, &#34;0.2007700000&#34;, &#34;-0.2571600000&#34;, &#34;-0.1021700000&#34;, &#34;-0.0583640000&#34;, &#34;0.4881100000&#34;, &#34;0.0753900000&#34;, &#34;0.2455000000&#34;, &#34;-0.1272200000&#34;, &#34;0.4704300000&#34;, &#34;0.2874000000&#34;, &#34;-0.3336200000&#34;, &#34;-0.1766600000&#34;, &#34;-0.4117600000&#34;, &#34;-0.2270500000&#34;, &#34;0.0977800000&#34;, &#34;-0.3651100000&#34;, &#34;0.0178340000&#34;, &#34;0.1581100000&#34;, &#34;-0.0377300000&#34;, &#34;-0.0450480000&#34;, &#34;0.1042400000&#34;, &#34;-0.4253300000&#34;, &#34;-0.2591700000&#34;, &#34;0.2554700000&#34;, &#34;0.1730600000&#34;, &#34;-0.0229010000&#34;, &#34;-0.3288000000&#34;, &#34;-0.1891700000&#34;, &#34;0.3146000000&#34;, &#34;0.0037259000&#34;, &#34;-0.0311420000&#34;, &#34;-0.0112230000&#34;, &#34;-0.0949450000&#34;, &#34;-0.3705100000&#34;, &#34;-0.1865700000&#34;, &#34;-0.0765260000&#34;, &#34;0.1120600000&#34;, &#34;-0.2587400000&#34;, &#34;-0.1570700000&#34;, &#34;0.0258250000&#34;, &#34;-0.1485100000&#34;, &#34;-0.0449910000&#34;, &#34;0.1428600000&#34;, &#34;-0.1632800000&#34;, &#34;0.3083000000&#34;, &#34;0.0136670000&#34;, &#34;-0.1186900000&#34;, &#34;-0.1623500000&#34;, &#34;-0.0047887000&#34;, &#34;0.0415350000&#34;, &#34;-0.4218700000&#34;, &#34;-0.2952500000&#34;, &#34;-0.2038600000&#34;, &#34;-0.2014100000&#34;, &#34;0.2563700000&#34;, &#34;0.1457700000&#34;, &#34;-0.0319150000&#34;, &#34;-0.2285200000&#34;, &#34;0.2501200000&#34;, &#34;-0.3111800000&#34;, &#34;-0.1793900000&#34;, &#34;-0.0982310000&#34;, &#34;-0.0381850000&#34;, &#34;-0.1336400000&#34;, &#34;0.0192960000&#34;, &#34;-0.2208900000&#34;, &#34;-0.1206300000&#34;, &#34;0.2097200000&#34;, &#34;0.2853500000&#34;, &#34;0.1813300000&#34;, &#34;0.0294660000&#34;, &#34;-0.0646010000&#34;, &#34;-0.1771300000&#34;, &#34;0.4132300000&#34;, &#34;-0.2959900000&#34;, &#34;-0.3212300000&#34;, &#34;-0.1448700000&#34;, &#34;-0.3139500000&#34;, &#34;0.1505100000&#34;, &#34;0.1628600000&#34;, &#34;-0.3218000000&#34;, &#34;-0.3945900000&#34;, &#34;-0.2566500000&#34;, &#34;-0.4434100000&#34;, &#34;0.3812200000&#34;, &#34;-0.0107890000&#34;, &#34;-0.4741300000&#34;, &#34;-0.4508600000&#34;, &#34;-0.0834800000&#34;, &#34;0.0299350000&#34;, &#34;-0.1000300000&#34;, &#34;0.3764500000&#34;, &#34;0.0001085700&#34;, &#34;0.0299450000&#34;, &#34;-0.0416520000&#34;, &#34;0.3458600000&#34;, &#34;-0.2455000000&#34;, &#34;-0.1765200000&#34;, &#34;-0.4379600000&#34;, &#34;-0.1578200000&#34;, &#34;0.1923100000&#34;, &#34;-0.4150300000&#34;, &#34;0.1487400000&#34;, &#34;-0.2540100000&#34;, &#34;-0.0940380000&#34;, &#34;0.3424200000&#34;, &#34;0.2924100000&#34;, &#34;-0.1216100000&#34;, &#34;-0.2287700000&#34;, &#34;-0.4925200000&#34;, &#34;-0.1334900000&#34;, &#34;0.2400900000&#34;, &#34;-0.0273510000&#34;, &#34;-0.1193900000&#34;, &#34;0.0464170000&#34;, &#34;-0.2726200000&#34;, &#34;-0.8609100000&#34;, &#34;0.0243370000&#34;, &#34;-0.0293280000&#34;, &#34;-0.2932100000&#34;, &#34;0.5959400000&#34;, &#34;-0.1634700000&#34;, &#34;-0.3189200000&#34;, &#34;-0.3741700000&#34;, &#34;-0.3039100000&#34;, &#34;0.3405600000&#34;, &#34;-0.2369400000&#34;, &#34;-0.1842700000&#34;, &#34;-0.1660400000&#34;, &#34;-0.2861000000&#34;, &#34;-0.1751800000&#34;, &#34;-0.0028950000&#34;, &#34;0.2197000000&#34;, &#34;-0.1751500000&#34;, &#34;-0.1430100000&#34;, &#34;0.1372400000&#34;, &#34;0.3685000000&#34;, &#34;0.1130900000&#34;, &#34;0.0589650000&#34;, &#34;-0.1478800000&#34;, &#34;0.0853980000&#34;, &#34;0.3102600000&#34;, &#34;0.1133000000&#34;, &#34;0.5054500000&#34;, &#34;0.3415200000&#34;, &#34;0.2930000000&#34;, &#34;0.3244900000&#34;, &#34;-0.0282710000&#34;, &#34;-0.0818050000&#34;, &#34;-0.0356940000&#34;, &#34;-0.2337500000&#34;, &#34;-0.0441030000&#34;, &#34;-0.0967910000&#34;, &#34;-0.1861400000&#34;, &#34;-0.3800900000&#34;, &#34;0.0523130000&#34;, &#34;0.0664720000&#34;, &#34;-0.1679500000&#34;, &#34;0.4734300000&#34;], [&#34;0.0488040000&#34;, &#34;-0.2852800000&#34;, &#34;0.0185570000&#34;, &#34;0.2057700000&#34;, &#34;0.0607040000&#34;, &#34;0.0854460000&#34;, &#34;-0.0362670000&#34;, &#34;-0.0683730000&#34;, &#34;0.1450700000&#34;, &#34;0.1785200000&#34;, &#34;0.1457900000&#34;, &#34;-0.1363000000&#34;, &#34;0.2334800000&#34;, &#34;0.0297580000&#34;, &#34;-0.2200100000&#34;, &#34;-0.0045515000&#34;, &#34;-0.1119700000&#34;, &#34;-0.0413670000&#34;, &#34;0.0842310000&#34;, &#34;0.0766730000&#34;, &#34;-0.2446100000&#34;, &#34;0.0535930000&#34;, &#34;-0.1093900000&#34;, &#34;-0.1246800000&#34;, &#34;-0.2029000000&#34;, &#34;0.0745650000&#34;, &#34;0.1066000000&#34;, &#34;0.0543390000&#34;, &#34;0.0882680000&#34;, &#34;0.2255700000&#34;, &#34;-0.0290810000&#34;, &#34;0.2980000000&#34;, &#34;-0.1612900000&#34;, &#34;0.3641900000&#34;, &#34;0.0739780000&#34;, &#34;-0.0895610000&#34;, &#34;-0.0411040000&#34;, &#34;-0.2427700000&#34;, &#34;-0.0058010000&#34;, &#34;-0.0628380000&#34;, &#34;0.0617660000&#34;, &#34;-0.0633800000&#34;, &#34;0.0648860000&#34;, &#34;0.0766810000&#34;, &#34;0.0547310000&#34;, &#34;-0.1214600000&#34;, &#34;-0.1090700000&#34;, &#34;-0.0927890000&#34;, &#34;0.0335690000&#34;, &#34;-0.1898400000&#34;, &#34;0.0891000000&#34;, &#34;0.0130160000&#34;, &#34;-0.0515710000&#34;, &#34;0.0280400000&#34;, &#34;0.1269700000&#34;, &#34;-0.0775540000&#34;, &#34;0.1572200000&#34;, &#34;0.0774760000&#34;, &#34;-0.1634300000&#34;, &#34;0.1654700000&#34;, &#34;-0.2609900000&#34;, &#34;-0.2912200000&#34;, &#34;0.3018200000&#34;, &#34;-0.1675900000&#34;, &#34;-0.0565190000&#34;, &#34;-0.1289800000&#34;, &#34;-0.1970200000&#34;, &#34;-0.1511800000&#34;, &#34;-0.1337400000&#34;, &#34;-0.1500300000&#34;, &#34;-0.2352500000&#34;, &#34;-0.1591500000&#34;, &#34;0.1304200000&#34;, &#34;-0.0273440000&#34;, &#34;-0.1242700000&#34;, &#34;-0.0436310000&#34;, &#34;0.1241400000&#34;, &#34;0.3488900000&#34;, &#34;0.0494370000&#34;, &#34;-0.0101120000&#34;, &#34;0.2024700000&#34;, &#34;0.0822940000&#34;, &#34;-0.1515700000&#34;, &#34;-0.2273700000&#34;, &#34;0.1206400000&#34;, &#34;-0.0613040000&#34;, &#34;-0.0777130000&#34;, &#34;0.1096000000&#34;, &#34;-0.0960960000&#34;, &#34;-0.2033800000&#34;, &#34;-0.0229400000&#34;, &#34;0.1594500000&#34;, &#34;0.2332500000&#34;, &#34;-0.2310700000&#34;, &#34;0.0526840000&#34;, &#34;-0.0969460000&#34;, &#34;0.0573730000&#34;, &#34;0.1414300000&#34;, &#34;0.0765470000&#34;, &#34;0.0182650000&#34;, &#34;0.0640910000&#34;, &#34;0.0448580000&#34;, &#34;0.0881280000&#34;, &#34;-0.1169400000&#34;, &#34;-0.2496000000&#34;, &#34;-0.1304900000&#34;, &#34;-0.0830170000&#34;, &#34;-0.0600820000&#34;, &#34;0.0240550000&#34;, &#34;-0.0207480000&#34;, &#34;0.0391350000&#34;, &#34;0.0435670000&#34;, &#34;-0.1020800000&#34;, &#34;-0.1546400000&#34;, &#34;0.1289200000&#34;, &#34;-0.0241900000&#34;, &#34;0.0453700000&#34;, &#34;0.1277800000&#34;, &#34;0.1321200000&#34;, &#34;0.1920800000&#34;, &#34;0.2473700000&#34;, &#34;0.1240600000&#34;, &#34;-0.2024600000&#34;, &#34;0.1376200000&#34;, &#34;-0.0231510000&#34;, &#34;0.0417360000&#34;, &#34;-0.0139670000&#34;, &#34;0.1819400000&#34;, &#34;0.1621000000&#34;, &#34;0.0625860000&#34;, &#34;-0.0799810000&#34;, &#34;0.1318400000&#34;, &#34;-0.0773880000&#34;, &#34;0.0203130000&#34;, &#34;-0.0414880000&#34;, &#34;0.0205240000&#34;, &#34;-0.1131000000&#34;, &#34;0.1463900000&#34;, &#34;0.0801130000&#34;, &#34;0.0368500000&#34;, &#34;0.1364000000&#34;, &#34;-0.0097955000&#34;, &#34;0.1177900000&#34;, &#34;0.1354700000&#34;, &#34;0.2289000000&#34;, &#34;0.2123100000&#34;, &#34;-0.0797790000&#34;, &#34;0.1383100000&#34;, &#34;-0.0761140000&#34;, &#34;0.0285630000&#34;, &#34;0.1144100000&#34;, &#34;-0.1545500000&#34;, &#34;-0.0832670000&#34;, &#34;-0.0571670000&#34;, &#34;-0.0993520000&#34;, &#34;-0.1706300000&#34;, &#34;-0.0717570000&#34;, &#34;-0.0514970000&#34;, &#34;0.2656800000&#34;, &#34;0.0187990000&#34;, &#34;-0.2722000000&#34;, &#34;0.1268000000&#34;, &#34;-0.0210450000&#34;, &#34;0.0588310000&#34;, &#34;0.3021300000&#34;, &#34;-0.0352550000&#34;, &#34;-0.0959520000&#34;, &#34;-0.0390820000&#34;, &#34;0.2036900000&#34;, &#34;-0.1786900000&#34;, &#34;-0.2618800000&#34;, &#34;-0.1100600000&#34;, &#34;-0.1569400000&#34;, &#34;-0.0288030000&#34;, &#34;-0.2387200000&#34;, &#34;0.1559400000&#34;, &#34;0.0087185000&#34;, &#34;0.2405300000&#34;, &#34;0.1213900000&#34;, &#34;0.1372800000&#34;, &#34;0.0159270000&#34;, &#34;-0.0133860000&#34;, &#34;-0.0690450000&#34;, &#34;0.1030300000&#34;, &#34;-0.0720710000&#34;, &#34;0.2796200000&#34;, &#34;0.1915700000&#34;, &#34;-0.1381000000&#34;, &#34;0.0713930000&#34;, &#34;-0.0315480000&#34;, &#34;-0.0352990000&#34;, &#34;-0.0746090000&#34;, &#34;0.2041500000&#34;, &#34;0.0718500000&#34;, &#34;-0.0686720000&#34;, &#34;-0.0412170000&#34;, &#34;-0.0870570000&#34;, &#34;-0.1166500000&#34;, &#34;-0.2025700000&#34;, &#34;0.0731880000&#34;, &#34;-0.0734970000&#34;, &#34;-0.2795100000&#34;, &#34;-0.1739300000&#34;, &#34;0.0640050000&#34;, &#34;-0.0503940000&#34;, &#34;-0.0444260000&#34;, &#34;0.0084868000&#34;, &#34;0.0651470000&#34;, &#34;0.0753810000&#34;, &#34;0.1112400000&#34;, &#34;0.2497100000&#34;, &#34;0.1669600000&#34;, &#34;0.0404720000&#34;, &#34;-0.1453300000&#34;, &#34;0.0167630000&#34;, &#34;-0.1127300000&#34;, &#34;0.0174350000&#34;, &#34;-0.1917700000&#34;, &#34;-0.0449610000&#34;, &#34;0.0856380000&#34;, &#34;0.0793410000&#34;, &#34;-0.0462130000&#34;, &#34;-0.2025500000&#34;, &#34;0.2627400000&#34;, &#34;-0.0910530000&#34;, &#34;0.0777210000&#34;, &#34;-0.1545400000&#34;, &#34;0.0423210000&#34;, &#34;0.1174200000&#34;, &#34;-0.0860410000&#34;, &#34;0.0876110000&#34;, &#34;0.2136500000&#34;, &#34;-0.1359700000&#34;, &#34;-0.0299870000&#34;, &#34;-0.0210530000&#34;, &#34;0.0262220000&#34;, &#34;-0.0637410000&#34;, &#34;-0.0836490000&#34;, &#34;0.0165660000&#34;, &#34;0.0435410000&#34;, &#34;-0.0390120000&#34;, &#34;-0.0099747000&#34;, &#34;0.1342700000&#34;, &#34;0.0632090000&#34;, &#34;0.2282500000&#34;, &#34;0.1484400000&#34;, &#34;0.0329260000&#34;, &#34;-0.1901200000&#34;, &#34;0.1983800000&#34;, &#34;-0.2236900000&#34;, &#34;0.0001884700&#34;, &#34;0.1740500000&#34;, &#34;-0.0379030000&#34;, &#34;0.0206610000&#34;, &#34;-0.0840530000&#34;, &#34;0.1841900000&#34;, &#34;0.0285170000&#34;, &#34;-0.0980060000&#34;, &#34;0.1993900000&#34;, &#34;0.0798100000&#34;, &#34;0.1241000000&#34;, &#34;0.0952500000&#34;, &#34;-0.0353410000&#34;, &#34;0.0841300000&#34;, &#34;-0.0823030000&#34;, &#34;-0.0757920000&#34;, &#34;0.1653500000&#34;, &#34;0.1158100000&#34;, &#34;0.0130190000&#34;, &#34;-0.0808940000&#34;, &#34;-0.0104000000&#34;, &#34;-0.0787360000&#34;, &#34;-0.1112200000&#34;, &#34;0.0289960000&#34;, &#34;-0.0633100000&#34;, &#34;-0.0339300000&#34;, &#34;0.0205720000&#34;, &#34;0.2645200000&#34;, &#34;0.0017304000&#34;, &#34;0.0190020000&#34;, &#34;0.1413200000&#34;, &#34;-0.0791100000&#34;, &#34;0.1535600000&#34;, &#34;0.0728730000&#34;, &#34;0.0871680000&#34;, &#34;-0.0055530000&#34;, &#34;-0.0200730000&#34;, &#34;0.1502200000&#34;, &#34;-0.0153510000&#34;, &#34;0.1674300000&#34;, &#34;0.1695600000&#34;, &#34;-0.3367700000&#34;, &#34;-0.0602860000&#34;, &#34;0.0860970000&#34;, &#34;-0.0650010000&#34;, &#34;0.0048331000&#34;, &#34;-0.1009600000&#34;, &#34;0.1391000000&#34;, &#34;-0.1371400000&#34;, &#34;-0.0397050000&#34;], [&#34;0.2576100000&#34;, &#34;0.0498830000&#34;, &#34;0.2522900000&#34;, &#34;0.4697300000&#34;, &#34;0.1034600000&#34;, &#34;-0.0240450000&#34;, &#34;0.0088398000&#34;, &#34;-0.2274800000&#34;, &#34;0.4485000000&#34;, &#34;-0.0707920000&#34;, &#34;0.4768700000&#34;, &#34;0.0553360000&#34;, &#34;-0.1565000000&#34;, &#34;-0.2308300000&#34;, &#34;0.4498700000&#34;, &#34;-0.0644760000&#34;, &#34;0.1669300000&#34;, &#34;-0.0715100000&#34;, &#34;0.3342400000&#34;, &#34;0.3535400000&#34;, &#34;-0.2725600000&#34;, &#34;0.1478900000&#34;, &#34;0.1803300000&#34;, &#34;-0.0472340000&#34;, &#34;-0.2308600000&#34;, &#34;0.3127800000&#34;, &#34;-0.0118420000&#34;, &#34;0.2047800000&#34;, &#34;-0.3107600000&#34;, &#34;0.2896700000&#34;, &#34;-0.2036400000&#34;, &#34;0.4134400000&#34;, &#34;-0.3138900000&#34;, &#34;-0.0244240000&#34;, &#34;0.1570300000&#34;, &#34;0.0415070000&#34;, &#34;0.1052000000&#34;, &#34;-0.0450440000&#34;, &#34;0.0137740000&#34;, &#34;-0.0611710000&#34;, &#34;0.4547900000&#34;, &#34;-0.0195840000&#34;, &#34;-0.3795500000&#34;, &#34;0.4757900000&#34;, &#34;0.0349800000&#34;, &#34;0.2764000000&#34;, &#34;-0.1168200000&#34;, &#34;0.1686200000&#34;, &#34;-0.0475000000&#34;, &#34;-0.0996640000&#34;, &#34;-0.0956250000&#34;, &#34;-0.1745400000&#34;, &#34;0.0430370000&#34;, &#34;-0.0571580000&#34;, &#34;0.0347470000&#34;, &#34;-0.1270000000&#34;, &#34;-0.1546000000&#34;, &#34;-0.1156300000&#34;, &#34;-0.4520600000&#34;, &#34;-0.0140030000&#34;, &#34;-0.2059100000&#34;, &#34;0.0766850000&#34;, &#34;0.3093800000&#34;, &#34;0.2549300000&#34;, &#34;-0.1845700000&#34;, &#34;-0.2392600000&#34;, &#34;-0.1454200000&#34;, &#34;0.2572800000&#34;, &#34;0.2311600000&#34;, &#34;-0.1269500000&#34;, &#34;-0.1668300000&#34;, &#34;0.1106600000&#34;, &#34;0.0136380000&#34;, &#34;0.1033000000&#34;, &#34;0.0856880000&#34;, &#34;-0.0219830000&#34;, &#34;0.5544900000&#34;, &#34;0.0224660000&#34;, &#34;0.0407880000&#34;, &#34;-0.2900500000&#34;, &#34;-0.0578260000&#34;, &#34;0.3924500000&#34;, &#34;-0.3068200000&#34;, &#34;-0.2656900000&#34;, &#34;0.0958790000&#34;, &#34;0.0431440000&#34;, &#34;-0.1065100000&#34;, &#34;0.1602600000&#34;, &#34;0.0078983000&#34;, &#34;0.0719570000&#34;, &#34;-0.0682610000&#34;, &#34;0.1889700000&#34;, &#34;0.4482300000&#34;, &#34;-0.4827000000&#34;, &#34;-0.0824450000&#34;, &#34;0.1179600000&#34;, &#34;0.3445000000&#34;, &#34;0.1846700000&#34;, &#34;-0.3836300000&#34;, &#34;-0.0253770000&#34;, &#34;0.1451000000&#34;, &#34;0.1030600000&#34;, &#34;0.2302700000&#34;, &#34;-0.1013100000&#34;, &#34;-0.1802600000&#34;, &#34;-0.1979700000&#34;, &#34;-0.1414100000&#34;, &#34;0.0243780000&#34;, &#34;-0.1174700000&#34;, &#34;0.0429810000&#34;, &#34;-0.3171400000&#34;, &#34;0.3114000000&#34;, &#34;-0.2077200000&#34;, &#34;-0.1691500000&#34;, &#34;-0.0474650000&#34;, &#34;-0.1797400000&#34;, &#34;0.0740380000&#34;, &#34;-0.2572700000&#34;, &#34;-0.0477410000&#34;, &#34;-0.0261270000&#34;, &#34;0.2260500000&#34;, &#34;-0.2186200000&#34;, &#34;-0.3768000000&#34;, &#34;0.1168700000&#34;, &#34;0.0878920000&#34;, &#34;0.0253730000&#34;, &#34;-0.1511300000&#34;, &#34;-0.3771800000&#34;, &#34;-0.0941650000&#34;, &#34;0.2612200000&#34;, &#34;-0.0948940000&#34;, &#34;0.0966500000&#34;, &#34;0.1221900000&#34;, &#34;0.3357000000&#34;, &#34;-0.4663500000&#34;, &#34;0.1240100000&#34;, &#34;-0.0280710000&#34;, &#34;-0.0353240000&#34;, &#34;-0.1160400000&#34;, &#34;0.1255900000&#34;, &#34;0.1294500000&#34;, &#34;0.3766500000&#34;, &#34;-0.0498470000&#34;, &#34;0.1566400000&#34;, &#34;0.1644400000&#34;, &#34;0.4491300000&#34;, &#34;0.3040100000&#34;, &#34;0.0566570000&#34;, &#34;-0.1629300000&#34;, &#34;0.0433950000&#34;, &#34;-0.1707100000&#34;, &#34;-0.2768000000&#34;, &#34;-0.5619900000&#34;, &#34;-0.1267300000&#34;, &#34;0.0284040000&#34;, &#34;-0.3314100000&#34;, &#34;-0.1353900000&#34;, &#34;-0.2051000000&#34;, &#34;0.1561200000&#34;, &#34;0.0321760000&#34;, &#34;0.0325120000&#34;, &#34;0.3252900000&#34;, &#34;-0.0204760000&#34;, &#34;-0.2660400000&#34;, &#34;0.2923800000&#34;, &#34;-0.0918760000&#34;, &#34;0.2176400000&#34;, &#34;0.3006700000&#34;, &#34;0.1130500000&#34;, &#34;0.0756780000&#34;, &#34;-0.2516200000&#34;, &#34;-0.1369600000&#34;, &#34;-0.2226500000&#34;, &#34;0.0929890000&#34;, &#34;-0.0540260000&#34;, &#34;-0.0310660000&#34;, &#34;-0.1757100000&#34;, &#34;0.0034190000&#34;, &#34;0.4077300000&#34;, &#34;-0.2868300000&#34;, &#34;0.0818900000&#34;, &#34;0.0356060000&#34;, &#34;-0.1427700000&#34;, &#34;0.0441420000&#34;, &#34;0.0596490000&#34;, &#34;0.3647200000&#34;, &#34;-0.2288400000&#34;, &#34;0.0157600000&#34;, &#34;0.1556600000&#34;, &#34;-0.2784400000&#34;, &#34;-0.4091900000&#34;, &#34;-0.1635800000&#34;, &#34;0.0723090000&#34;, &#34;0.2206900000&#34;, &#34;0.1242000000&#34;, &#34;0.0138220000&#34;, &#34;0.1920100000&#34;, &#34;0.2486900000&#34;, &#34;-0.1761000000&#34;, &#34;-0.2160900000&#34;, &#34;-0.2101800000&#34;, &#34;-0.3116400000&#34;, &#34;-0.1328500000&#34;, &#34;0.1315200000&#34;, &#34;-0.0828380000&#34;, &#34;-0.1720700000&#34;, &#34;0.0142350000&#34;, &#34;0.0000532270&#34;, &#34;0.6004800000&#34;, &#34;0.1395700000&#34;, &#34;0.6135400000&#34;, &#34;-0.1014600000&#34;, &#34;0.0895460000&#34;, &#34;-0.0718870000&#34;, &#34;-0.0797020000&#34;, &#34;-0.2143200000&#34;, &#34;-0.1823300000&#34;, &#34;0.1172300000&#34;, &#34;0.0926630000&#34;, &#34;0.1273800000&#34;, &#34;-0.2187700000&#34;, &#34;0.4550800000&#34;, &#34;-0.1949000000&#34;, &#34;0.1642300000&#34;, &#34;0.0079016000&#34;, &#34;0.0051538000&#34;, &#34;-0.3267000000&#34;, &#34;-0.0764360000&#34;, &#34;-0.2438000000&#34;, &#34;-0.2685200000&#34;, &#34;0.0193920000&#34;, &#34;-0.1682000000&#34;, &#34;-0.0994380000&#34;, &#34;-0.3137100000&#34;, &#34;-0.1200100000&#34;, &#34;0.0051944000&#34;, &#34;0.0029277000&#34;, &#34;0.2245500000&#34;, &#34;-0.3278500000&#34;, &#34;0.3743800000&#34;, &#34;0.1684900000&#34;, &#34;-0.1351700000&#34;, &#34;-0.0438710000&#34;, &#34;0.1709000000&#34;, &#34;0.0181980000&#34;, &#34;-0.4817400000&#34;, &#34;-0.0249240000&#34;, &#34;-0.3569000000&#34;, &#34;-0.2236400000&#34;, &#34;-0.1536800000&#34;, &#34;0.0366920000&#34;, &#34;0.0108350000&#34;, &#34;-0.1188100000&#34;, &#34;-0.0135090000&#34;, &#34;-0.3823800000&#34;, &#34;-0.0655870000&#34;, &#34;0.0649680000&#34;, &#34;-0.1670200000&#34;, &#34;0.0601880000&#34;, &#34;0.0726660000&#34;, &#34;-0.1894900000&#34;, &#34;-0.1669000000&#34;, &#34;0.1220200000&#34;, &#34;-0.6277000000&#34;, &#34;0.0577930000&#34;, &#34;0.0557220000&#34;, &#34;-0.1216900000&#34;, &#34;0.2617200000&#34;, &#34;-0.1390000000&#34;, &#34;-0.0465770000&#34;, &#34;-0.2551400000&#34;, &#34;0.2811700000&#34;, &#34;-0.3228100000&#34;, &#34;-0.2040800000&#34;, &#34;0.0238830000&#34;, &#34;-0.2731800000&#34;, &#34;0.2812600000&#34;, &#34;0.2255100000&#34;, &#34;-0.2777100000&#34;, &#34;0.1377300000&#34;, &#34;-0.1328300000&#34;, &#34;-0.1103800000&#34;, &#34;-0.0364880000&#34;, &#34;-0.1647500000&#34;, &#34;0.0441320000&#34;, &#34;-0.3204900000&#34;, &#34;-0.0297440000&#34;, &#34;-0.0134920000&#34;, &#34;0.0570560000&#34;, &#34;-0.0111380000&#34;, &#34;0.5766000000&#34;, &#34;-0.1950200000&#34;, &#34;0.3828600000&#34;, &#34;-0.0409440000&#34;, &#34;0.1138800000&#34;, &#34;-0.1461900000&#34;, &#34;-0.0389640000&#34;, &#34;0.1082000000&#34;, &#34;0.0137960000&#34;, &#34;-0.3645600000&#34;], [&#34;-0.1872000000&#34;, &#34;-0.0302420000&#34;, &#34;-0.2254600000&#34;, &#34;0.4859600000&#34;, &#34;-0.3529400000&#34;, &#34;-0.3825400000&#34;, &#34;0.0929030000&#34;, &#34;-0.3685200000&#34;, &#34;-0.1951600000&#34;, &#34;-0.0498530000&#34;, &#34;0.0908620000&#34;, &#34;0.0407990000&#34;, &#34;-0.3072100000&#34;, &#34;-0.0709640000&#34;, &#34;-0.0941560000&#34;, &#34;-0.0978660000&#34;, &#34;-0.1372500000&#34;, &#34;-0.0414930000&#34;, &#34;0.3032700000&#34;, &#34;0.1050900000&#34;, &#34;-0.0076578000&#34;, &#34;-0.1000700000&#34;, &#34;0.0800080000&#34;, &#34;-0.2233700000&#34;, &#34;0.0359090000&#34;, &#34;-0.0584450000&#34;, &#34;0.0244540000&#34;, &#34;-0.1193400000&#34;, &#34;0.1702500000&#34;, &#34;-0.3432500000&#34;, &#34;0.1077500000&#34;, &#34;0.5631200000&#34;, &#34;-0.5181200000&#34;, &#34;-0.1461600000&#34;, &#34;0.1113700000&#34;, &#34;-0.4206000000&#34;, &#34;0.0596090000&#34;, &#34;0.1471300000&#34;, &#34;0.2001500000&#34;, &#34;-0.1909500000&#34;, &#34;0.1685900000&#34;, &#34;0.0076862000&#34;, &#34;0.0351940000&#34;, &#34;-0.0800700000&#34;, &#34;-0.1226700000&#34;, &#34;0.1733700000&#34;, &#34;0.0905270000&#34;, &#34;0.0217220000&#34;, &#34;0.2671000000&#34;, &#34;-0.1678600000&#34;, &#34;0.3143600000&#34;, &#34;0.0912250000&#34;, &#34;-0.2971400000&#34;, &#34;-0.5219500000&#34;, &#34;0.1874100000&#34;, &#34;0.2489300000&#34;, &#34;0.2154500000&#34;, &#34;0.5061000000&#34;, &#34;0.0684540000&#34;, &#34;-0.5239000000&#34;, &#34;-0.2948300000&#34;, &#34;0.0606950000&#34;, &#34;0.1887500000&#34;, &#34;-0.0923290000&#34;, &#34;-0.0058402000&#34;, &#34;-0.0352760000&#34;, &#34;-0.4210000000&#34;, &#34;-0.1033500000&#34;, &#34;-0.1876500000&#34;, &#34;-0.4809900000&#34;, &#34;-0.5377500000&#34;, &#34;-0.1599100000&#34;, &#34;0.1835900000&#34;, &#34;0.0864560000&#34;, &#34;-0.1268000000&#34;, &#34;0.1318300000&#34;, &#34;0.3980000000&#34;, &#34;-0.2230200000&#34;, &#34;0.2135200000&#34;, &#34;-0.4014300000&#34;, &#34;-0.2573700000&#34;, &#34;-0.0931500000&#34;, &#34;-0.2693700000&#34;, &#34;-0.2378500000&#34;, &#34;-0.7180800000&#34;, &#34;0.0019796000&#34;, &#34;-0.1154700000&#34;, &#34;-0.0263870000&#34;, &#34;-0.1542000000&#34;, &#34;-0.0280980000&#34;, &#34;-0.0285050000&#34;, &#34;0.3491400000&#34;, &#34;0.4856400000&#34;, &#34;-0.1690300000&#34;, &#34;0.1436600000&#34;, &#34;0.0318030000&#34;, &#34;0.3217800000&#34;, &#34;0.1380500000&#34;, &#34;0.2728200000&#34;, &#34;0.5049100000&#34;, &#34;0.1664300000&#34;, &#34;-0.1448900000&#34;, &#34;0.2125200000&#34;, &#34;-0.1341200000&#34;, &#34;0.0838860000&#34;, &#34;-0.2328500000&#34;, &#34;-0.3145600000&#34;, &#34;0.3400200000&#34;, &#34;-0.3158500000&#34;, &#34;0.0759740000&#34;, &#34;0.1302700000&#34;, &#34;-0.0240090000&#34;, &#34;-0.0903000000&#34;, &#34;-0.1906600000&#34;, &#34;-0.3051900000&#34;, &#34;-0.1550300000&#34;, &#34;0.0072282000&#34;, &#34;0.3208200000&#34;, &#34;-0.1138600000&#34;, &#34;-0.0513200000&#34;, &#34;0.6661500000&#34;, &#34;-0.0855150000&#34;, &#34;-0.4434600000&#34;, &#34;0.1410600000&#34;, &#34;0.1760400000&#34;, &#34;0.4323200000&#34;, &#34;-0.4307000000&#34;, &#34;-0.0598750000&#34;, &#34;-0.1399500000&#34;, &#34;0.2492800000&#34;, &#34;0.0695550000&#34;, &#34;0.0965270000&#34;, &#34;0.0939160000&#34;, &#34;0.0617970000&#34;, &#34;0.0525190000&#34;, &#34;-0.0749970000&#34;, &#34;-0.0488870000&#34;, &#34;0.3896500000&#34;, &#34;-0.0437090000&#34;, &#34;0.6691200000&#34;, &#34;0.1628500000&#34;, &#34;0.0932350000&#34;, &#34;-0.0328160000&#34;, &#34;0.1839800000&#34;, &#34;-0.0754280000&#34;, &#34;-0.2968400000&#34;, &#34;0.1668600000&#34;, &#34;0.0593240000&#34;, &#34;0.0251530000&#34;, &#34;0.0512080000&#34;, &#34;0.5032000000&#34;, &#34;0.0594630000&#34;, &#34;-0.1619200000&#34;, &#34;-0.4913400000&#34;, &#34;-0.1015400000&#34;, &#34;-0.4073700000&#34;, &#34;0.4849100000&#34;, &#34;-0.1077600000&#34;, &#34;-0.2144100000&#34;, &#34;-0.5785900000&#34;, &#34;0.0542930000&#34;, &#34;0.0497600000&#34;, &#34;0.0423400000&#34;, &#34;0.2114500000&#34;, &#34;-0.0863330000&#34;, &#34;0.1085400000&#34;, &#34;-0.5758900000&#34;, &#34;-0.3975800000&#34;, &#34;0.1180800000&#34;, &#34;0.2298500000&#34;, &#34;-0.3438700000&#34;, &#34;-0.0920800000&#34;, &#34;-0.1144600000&#34;, &#34;0.0740170000&#34;, &#34;-0.4509900000&#34;, &#34;-0.0822830000&#34;, &#34;0.1899500000&#34;, &#34;-0.1227300000&#34;, &#34;-0.1095900000&#34;, &#34;-0.0005473000&#34;, &#34;0.6126900000&#34;, &#34;-0.2204800000&#34;, &#34;0.1407300000&#34;, &#34;-0.0395650000&#34;, &#34;0.1667500000&#34;, &#34;0.5801700000&#34;, &#34;-0.0584250000&#34;, &#34;-0.0619060000&#34;, &#34;0.6612200000&#34;, &#34;-0.0712260000&#34;, &#34;-0.2108400000&#34;, &#34;-0.1812200000&#34;, &#34;-0.0101210000&#34;, &#34;0.3141200000&#34;, &#34;-0.2826000000&#34;, &#34;-0.1921900000&#34;, &#34;-0.0458870000&#34;, &#34;0.3238600000&#34;, &#34;-0.4751300000&#34;, &#34;-0.0933170000&#34;, &#34;0.0754570000&#34;, &#34;-0.0080931000&#34;, &#34;0.0897010000&#34;, &#34;-0.2116200000&#34;, &#34;-0.2208200000&#34;, &#34;-0.2092000000&#34;, &#34;0.1851100000&#34;, &#34;-0.1653500000&#34;, &#34;0.0740850000&#34;, &#34;0.0266020000&#34;, &#34;-0.0974900000&#34;, &#34;0.3796400000&#34;, &#34;0.1468100000&#34;, &#34;-0.1682900000&#34;, &#34;0.2318900000&#34;, &#34;-0.1005200000&#34;, &#34;-0.1863400000&#34;, &#34;-0.4332400000&#34;, &#34;-0.0667370000&#34;, &#34;-0.1543900000&#34;, &#34;0.2330100000&#34;, &#34;-0.2363500000&#34;, &#34;0.1945700000&#34;, &#34;0.1350300000&#34;, &#34;0.1206200000&#34;, &#34;-0.1858500000&#34;, &#34;-0.2281400000&#34;, &#34;-0.8050500000&#34;, &#34;0.1976100000&#34;, &#34;-0.0441520000&#34;, &#34;-0.2157400000&#34;, &#34;0.2222600000&#34;, &#34;-0.0491980000&#34;, &#34;0.0587420000&#34;, &#34;0.1350500000&#34;, &#34;0.0905450000&#34;, &#34;0.2420800000&#34;, &#34;-0.0127400000&#34;, &#34;0.1750000000&#34;, &#34;0.1095600000&#34;, &#34;0.1612800000&#34;, &#34;-0.3499200000&#34;, &#34;0.1757300000&#34;, &#34;-0.2536300000&#34;, &#34;-0.3201500000&#34;, &#34;0.3218000000&#34;, &#34;0.0410470000&#34;, &#34;-0.0623210000&#34;, &#34;-0.2030900000&#34;, &#34;-0.0781820000&#34;, &#34;-0.0504510000&#34;, &#34;-0.1302900000&#34;, &#34;0.0445080000&#34;, &#34;0.2193600000&#34;, &#34;-0.0134300000&#34;, &#34;0.0377120000&#34;, &#34;0.0651670000&#34;, &#34;-0.0532490000&#34;, &#34;0.2846400000&#34;, &#34;0.0539880000&#34;, &#34;0.0781200000&#34;, &#34;0.2064800000&#34;, &#34;0.2330800000&#34;, &#34;0.2235400000&#34;, &#34;-0.3331700000&#34;, &#34;-0.3691800000&#34;, &#34;-0.2975400000&#34;, &#34;0.1137900000&#34;, &#34;0.3412900000&#34;, &#34;0.0204940000&#34;, &#34;-0.4146400000&#34;, &#34;0.2122200000&#34;, &#34;0.0533570000&#34;, &#34;-0.2561800000&#34;, &#34;0.0018763000&#34;, &#34;-0.1171700000&#34;, &#34;0.1756400000&#34;, &#34;0.2612300000&#34;, &#34;-0.1151800000&#34;, &#34;-0.1479800000&#34;, &#34;0.2521200000&#34;, &#34;-0.0550510000&#34;, &#34;-0.0555300000&#34;, &#34;-0.4026900000&#34;, &#34;0.1939700000&#34;, &#34;-0.0147990000&#34;, &#34;0.3273300000&#34;, &#34;-0.2912700000&#34;, &#34;-0.2635800000&#34;, &#34;0.0639000000&#34;, &#34;0.3415500000&#34;, &#34;0.2763000000&#34;, &#34;0.1275400000&#34;, &#34;0.1321700000&#34;, &#34;-0.0924440000&#34;, &#34;-0.2194800000&#34;, &#34;0.1008300000&#34;, &#34;0.3518600000&#34;, &#34;0.1284600000&#34;, &#34;0.1200900000&#34;], [&#34;-0.0483010000&#34;, &#34;0.1926000000&#34;, &#34;-0.6080700000&#34;, &#34;-0.1321700000&#34;, &#34;-0.7480600000&#34;, &#34;-0.1779300000&#34;, &#34;0.1883100000&#34;, &#34;-0.6710000000&#34;, &#34;-0.3516700000&#34;, &#34;0.4761700000&#34;, &#34;0.2126700000&#34;, &#34;0.1931800000&#34;, &#34;-0.0309560000&#34;, &#34;0.3532300000&#34;, &#34;0.1101600000&#34;, &#34;0.0179630000&#34;, &#34;-0.0054491000&#34;, &#34;-0.0927580000&#34;, &#34;-0.5833500000&#34;, &#34;0.2006100000&#34;, &#34;0.3485700000&#34;, &#34;-0.2006200000&#34;, &#34;-0.4491000000&#34;, &#34;-0.1015000000&#34;, &#34;-0.1915400000&#34;, &#34;-0.0624400000&#34;, &#34;-0.1961200000&#34;, &#34;0.1386100000&#34;, &#34;-0.3221000000&#34;, &#34;0.2511000000&#34;, &#34;-0.3066600000&#34;, &#34;0.2149300000&#34;, &#34;0.3389300000&#34;, &#34;0.3087800000&#34;, &#34;-0.0710470000&#34;, &#34;-0.0528590000&#34;, &#34;0.0813120000&#34;, &#34;0.0924810000&#34;, &#34;0.4397400000&#34;, &#34;0.1130700000&#34;, &#34;0.7637600000&#34;, &#34;0.1650700000&#34;, &#34;-0.4197200000&#34;, &#34;-0.2212400000&#34;, &#34;0.0775690000&#34;, &#34;-0.1602800000&#34;, &#34;0.1373400000&#34;, &#34;0.0908770000&#34;, &#34;-0.0427150000&#34;, &#34;-0.1802500000&#34;, &#34;-0.1432800000&#34;, &#34;0.0392000000&#34;, &#34;0.3309600000&#34;, &#34;-0.5582400000&#34;, &#34;0.2220600000&#34;, &#34;-0.0236850000&#34;, &#34;0.2582500000&#34;, &#34;0.2877900000&#34;, &#34;0.3834000000&#34;, &#34;-0.1787200000&#34;, &#34;-0.3949400000&#34;, &#34;0.1114700000&#34;, &#34;0.3441100000&#34;, &#34;0.1905500000&#34;, &#34;-0.0914810000&#34;, &#34;-0.2756000000&#34;, &#34;-0.3321300000&#34;, &#34;0.7403800000&#34;, &#34;-0.0275420000&#34;, &#34;-0.0581460000&#34;, &#34;-0.2213900000&#34;, &#34;0.0869770000&#34;, &#34;0.4184900000&#34;, &#34;-0.1886400000&#34;, &#34;0.4007800000&#34;, &#34;0.2311300000&#34;, &#34;0.1741300000&#34;, &#34;0.3344600000&#34;, &#34;-0.3010300000&#34;, &#34;-0.1821600000&#34;, &#34;0.7534000000&#34;, &#34;-0.3557000000&#34;, &#34;-0.2855800000&#34;, &#34;0.0095493000&#34;, &#34;-0.5681900000&#34;, &#34;0.1049900000&#34;, &#34;-0.1144700000&#34;, &#34;0.2515400000&#34;, &#34;-0.3135600000&#34;, &#34;-0.6600000000&#34;, &#34;0.1312800000&#34;, &#34;0.2128300000&#34;, &#34;-0.1066400000&#34;, &#34;0.1817900000&#34;, &#34;0.0611570000&#34;, &#34;0.4052800000&#34;, &#34;-0.0131620000&#34;, &#34;0.1683800000&#34;, &#34;-0.0057097000&#34;, &#34;0.2874300000&#34;, &#34;0.0248060000&#34;, &#34;-0.2986400000&#34;, &#34;0.0607920000&#34;, &#34;-0.1837400000&#34;, &#34;0.1848300000&#34;, &#34;0.0196420000&#34;, &#34;-0.3581200000&#34;, &#34;0.2625900000&#34;, &#34;0.1211600000&#34;, &#34;-0.3594200000&#34;, &#34;-0.1380800000&#34;, &#34;0.2121700000&#34;, &#34;-0.2607000000&#34;, &#34;-0.2744700000&#34;, &#34;-0.3924400000&#34;, &#34;0.1087600000&#34;, &#34;0.3051100000&#34;, &#34;0.1226900000&#34;, &#34;-0.4248500000&#34;, &#34;-0.0759340000&#34;, &#34;0.1010800000&#34;, &#34;-0.4214200000&#34;, &#34;-0.6684900000&#34;, &#34;0.1061700000&#34;, &#34;-0.0502350000&#34;, &#34;-0.0975560000&#34;, &#34;-0.1387000000&#34;, &#34;0.4019400000&#34;, &#34;-0.3693400000&#34;, &#34;0.2467500000&#34;, &#34;0.1400000000&#34;, &#34;0.2109000000&#34;, &#34;-0.2712700000&#34;, &#34;0.2194000000&#34;, &#34;-0.0493550000&#34;, &#34;0.3635500000&#34;, &#34;-0.2876200000&#34;, &#34;0.3838900000&#34;, &#34;-0.0655080000&#34;, &#34;0.7611400000&#34;, &#34;0.1918600000&#34;, &#34;0.4933100000&#34;, &#34;0.0512070000&#34;, &#34;-0.0441210000&#34;, &#34;-0.1881400000&#34;, &#34;0.0263140000&#34;, &#34;0.1479400000&#34;, &#34;0.4528900000&#34;, &#34;0.1681000000&#34;, &#34;-0.2359600000&#34;, &#34;0.4548100000&#34;, &#34;-0.1847000000&#34;, &#34;0.0072012000&#34;, &#34;-0.4249700000&#34;, &#34;0.2303500000&#34;, &#34;-0.0514900000&#34;, &#34;0.0759190000&#34;, &#34;0.2862200000&#34;, &#34;-0.2176900000&#34;, &#34;-0.2780600000&#34;, &#34;0.4701800000&#34;, &#34;0.0066373000&#34;, &#34;0.0284700000&#34;, &#34;-0.2938900000&#34;, &#34;0.2662000000&#34;, &#34;0.0508210000&#34;, &#34;-0.1260300000&#34;, &#34;-0.3013000000&#34;, &#34;-0.1193200000&#34;, &#34;0.2994300000&#34;, &#34;-0.4114900000&#34;, &#34;-0.2179900000&#34;, &#34;-0.3400100000&#34;, &#34;0.5519200000&#34;, &#34;-0.0458200000&#34;, &#34;-0.0102490000&#34;, &#34;-0.5164800000&#34;, &#34;-0.5789100000&#34;, &#34;0.0335170000&#34;, &#34;-0.1876100000&#34;, &#34;0.3194000000&#34;, &#34;0.1623900000&#34;, &#34;0.2697900000&#34;, &#34;-0.2737500000&#34;, &#34;0.0049825000&#34;, &#34;0.4875700000&#34;, &#34;0.5360200000&#34;, &#34;0.1312700000&#34;, &#34;0.1804500000&#34;, &#34;-0.6424600000&#34;, &#34;-0.3519600000&#34;, &#34;-0.2902300000&#34;, &#34;0.1350800000&#34;, &#34;-0.0327020000&#34;, &#34;-0.3141600000&#34;, &#34;0.1261500000&#34;, &#34;0.1984500000&#34;, &#34;0.2206800000&#34;, &#34;0.1732000000&#34;, &#34;-0.2917400000&#34;, &#34;-0.3712800000&#34;, &#34;-0.1567800000&#34;, &#34;-0.1238400000&#34;, &#34;0.0504430000&#34;, &#34;-0.0666780000&#34;, &#34;-0.5873100000&#34;, &#34;-0.2468000000&#34;, &#34;-0.0337500000&#34;, &#34;0.4086200000&#34;, &#34;-0.0480300000&#34;, &#34;0.5460400000&#34;, &#34;0.0845210000&#34;, &#34;0.2171700000&#34;, &#34;0.5037900000&#34;, &#34;0.3088900000&#34;, &#34;-0.4551900000&#34;, &#34;-0.3263000000&#34;, &#34;-0.5679400000&#34;, &#34;0.0633180000&#34;, &#34;0.0841560000&#34;, &#34;0.0090246000&#34;, &#34;0.1762800000&#34;, &#34;0.3983600000&#34;, &#34;0.6389500000&#34;, &#34;0.1402900000&#34;, &#34;-0.0057605000&#34;, &#34;-0.2321600000&#34;, &#34;-0.4368900000&#34;, &#34;0.0136430000&#34;, &#34;-0.1616300000&#34;, &#34;0.1766800000&#34;, &#34;-0.0056310000&#34;, &#34;-0.4336600000&#34;, &#34;-0.1409900000&#34;, &#34;0.4197400000&#34;, &#34;0.0091529000&#34;, &#34;-0.1334500000&#34;, &#34;-0.4143500000&#34;, &#34;-0.1956300000&#34;, &#34;0.3126700000&#34;, &#34;0.1455300000&#34;, &#34;0.0933600000&#34;, &#34;0.2726400000&#34;, &#34;-0.4169600000&#34;, &#34;-0.6605300000&#34;, &#34;0.4904700000&#34;, &#34;0.3367900000&#34;, &#34;-0.1244500000&#34;, &#34;-0.3173500000&#34;, &#34;-0.8259700000&#34;, &#34;-0.0970430000&#34;, &#34;0.0334070000&#34;, &#34;-0.2525100000&#34;, &#34;0.0437130000&#34;, &#34;-0.2893600000&#34;, &#34;0.1854300000&#34;, &#34;0.3990200000&#34;, &#34;-0.0563480000&#34;, &#34;-0.1447100000&#34;, &#34;0.1710800000&#34;, &#34;0.1277400000&#34;, &#34;0.3424800000&#34;, &#34;-0.3259100000&#34;, &#34;-0.2452800000&#34;, &#34;-0.7021700000&#34;, &#34;-0.1631100000&#34;, &#34;0.0105840000&#34;, &#34;-0.0852060000&#34;, &#34;-0.1944300000&#34;, &#34;-0.1338100000&#34;, &#34;-0.1362900000&#34;, &#34;-0.3097300000&#34;, &#34;0.3536200000&#34;, &#34;-0.1985100000&#34;, &#34;-0.4806200000&#34;, &#34;-0.1549700000&#34;, &#34;0.0440020000&#34;, &#34;-0.2656100000&#34;, &#34;-0.1193800000&#34;, &#34;0.2374200000&#34;, &#34;0.3663700000&#34;, &#34;0.2077800000&#34;, &#34;-0.5147400000&#34;, &#34;-0.0764550000&#34;, &#34;0.5292200000&#34;, &#34;-0.2214200000&#34;, &#34;0.3417900000&#34;, &#34;-0.1087000000&#34;, &#34;-0.7125100000&#34;, &#34;0.4339200000&#34;, &#34;-0.0127000000&#34;, &#34;0.1711800000&#34;, &#34;0.2068900000&#34;, &#34;0.1402600000&#34;, &#34;-0.1459300000&#34;, &#34;-0.2484100000&#34;, &#34;0.5119900000&#34;, &#34;0.5650100000&#34;, &#34;0.3061400000&#34;, &#34;0.3182900000&#34;], [&#34;-0.0315330000&#34;, &#34;0.0462780000&#34;, &#34;-0.1253400000&#34;, &#34;0.1916500000&#34;, &#34;-0.1266000000&#34;, &#34;-0.0128530000&#34;, &#34;0.1034200000&#34;, &#34;-0.0098085000&#34;, &#34;0.1518900000&#34;, &#34;0.2758200000&#34;, &#34;0.1369500000&#34;, &#34;0.0088799000&#34;, &#34;0.1413200000&#34;, &#34;-0.1200000000&#34;, &#34;-0.0634390000&#34;, &#34;-0.1517800000&#34;, &#34;0.0980900000&#34;, &#34;-0.1201000000&#34;, &#34;-0.0690860000&#34;, &#34;0.0146660000&#34;, &#34;-0.0230410000&#34;, &#34;0.0304300000&#34;, &#34;-0.1266400000&#34;, &#34;-0.0632820000&#34;, &#34;-0.0822460000&#34;, &#34;0.0367180000&#34;, &#34;0.2269800000&#34;, &#34;-0.0960250000&#34;, &#34;-0.0116990000&#34;, &#34;0.0661580000&#34;, &#34;-0.1854200000&#34;, &#34;0.1922300000&#34;, &#34;-0.0616850000&#34;, &#34;0.2704900000&#34;, &#34;0.0751160000&#34;, &#34;-0.0549280000&#34;, &#34;-0.0860270000&#34;, &#34;-0.1938700000&#34;, &#34;0.1467700000&#34;, &#34;-0.0601300000&#34;, &#34;0.0682690000&#34;, &#34;0.0716130000&#34;, &#34;-0.0944140000&#34;, &#34;0.0361580000&#34;, &#34;0.0027820000&#34;, &#34;-0.0817110000&#34;, &#34;-0.0133690000&#34;, &#34;-0.0530170000&#34;, &#34;0.0522270000&#34;, &#34;-0.0796820000&#34;, &#34;-0.0003176800&#34;, &#34;0.0303970000&#34;, &#34;-0.1684700000&#34;, &#34;0.0218280000&#34;, &#34;-0.1957700000&#34;, &#34;-0.0501090000&#34;, &#34;-0.0096879000&#34;, &#34;0.0855360000&#34;, &#34;-0.2813500000&#34;, &#34;0.1700100000&#34;, &#34;-0.0491940000&#34;, &#34;-0.1672100000&#34;, &#34;0.1901800000&#34;, &#34;-0.0474000000&#34;, &#34;-0.0003641200&#34;, &#34;0.0263160000&#34;, &#34;-0.2213500000&#34;, &#34;-0.0615830000&#34;, &#34;-0.2185400000&#34;, &#34;-0.0216690000&#34;, &#34;-0.2963000000&#34;, &#34;-0.0719490000&#34;, &#34;0.0106380000&#34;, &#34;-0.1905500000&#34;, &#34;-0.1129200000&#34;, &#34;-0.0990720000&#34;, &#34;0.1935700000&#34;, &#34;0.1411500000&#34;, &#34;0.0683460000&#34;, &#34;-0.0004594700&#34;, &#34;0.0726210000&#34;, &#34;-0.0211920000&#34;, &#34;-0.1242000000&#34;, &#34;-0.0419330000&#34;, &#34;-0.0283860000&#34;, &#34;0.0490830000&#34;, &#34;-0.0735740000&#34;, &#34;0.0735250000&#34;, &#34;0.0881350000&#34;, &#34;-0.0321840000&#34;, &#34;0.0299030000&#34;, &#34;-0.0700250000&#34;, &#34;0.1532300000&#34;, &#34;-0.1723600000&#34;, &#34;0.0735020000&#34;, &#34;0.1323200000&#34;, &#34;0.0901910000&#34;, &#34;0.0079023000&#34;, &#34;-0.0278870000&#34;, &#34;-0.0469710000&#34;, &#34;0.0391980000&#34;, &#34;-0.1256700000&#34;, &#34;0.1980300000&#34;, &#34;-0.0759950000&#34;, &#34;-0.2135300000&#34;, &#34;0.0319640000&#34;, &#34;-0.1734600000&#34;, &#34;0.0558840000&#34;, &#34;-0.0554040000&#34;, &#34;-0.0083924000&#34;, &#34;-0.0241040000&#34;, &#34;0.0023894000&#34;, &#34;-0.1057000000&#34;, &#34;-0.1060400000&#34;, &#34;-0.0613230000&#34;, &#34;-0.0414730000&#34;, &#34;0.0060497000&#34;, &#34;0.0558960000&#34;, &#34;-0.0713380000&#34;, &#34;0.1375000000&#34;, &#34;0.0947810000&#34;, &#34;0.0481210000&#34;, &#34;-0.0712360000&#34;, &#34;0.2626300000&#34;, &#34;0.0725700000&#34;, &#34;-0.0002034400&#34;, &#34;0.1864000000&#34;, &#34;0.0667030000&#34;, &#34;0.0552290000&#34;, &#34;0.1125800000&#34;, &#34;0.0476470000&#34;, &#34;0.0854820000&#34;, &#34;-0.1448900000&#34;, &#34;0.0098078000&#34;, &#34;0.0825850000&#34;, &#34;0.0392540000&#34;, &#34;-0.1004400000&#34;, &#34;0.1653200000&#34;, &#34;-0.0308410000&#34;, &#34;0.1031500000&#34;, &#34;-0.0465840000&#34;, &#34;0.1121100000&#34;, &#34;0.1541600000&#34;, &#34;-0.0503090000&#34;, &#34;0.1485300000&#34;, &#34;0.2287000000&#34;, &#34;-0.0560360000&#34;, &#34;-0.0729660000&#34;, &#34;0.0018167000&#34;, &#34;-0.0156940000&#34;, &#34;-0.0602200000&#34;, &#34;-0.1904400000&#34;, &#34;-0.0750730000&#34;, &#34;-0.0032815000&#34;, &#34;-0.0792560000&#34;, &#34;-0.0783240000&#34;, &#34;-0.1107300000&#34;, &#34;-0.0937050000&#34;, &#34;0.2628400000&#34;, &#34;0.0103400000&#34;, &#34;-0.0950000000&#34;, &#34;0.1729500000&#34;, &#34;-0.0539490000&#34;, &#34;0.1505600000&#34;, &#34;0.2281500000&#34;, &#34;-0.1658900000&#34;, &#34;-0.0800740000&#34;, &#34;-0.0762480000&#34;, &#34;0.1342300000&#34;, &#34;-0.0936260000&#34;, &#34;-0.0653840000&#34;, &#34;-0.0141810000&#34;, &#34;-0.0679370000&#34;, &#34;-0.0382830000&#34;, &#34;-0.0845140000&#34;, &#34;0.1108200000&#34;, &#34;0.0688040000&#34;, &#34;0.1940200000&#34;, &#34;-0.0693730000&#34;, &#34;-0.0433980000&#34;, &#34;0.1540200000&#34;, &#34;-0.1017200000&#34;, &#34;0.0497850000&#34;, &#34;-0.0100050000&#34;, &#34;-0.0337100000&#34;, &#34;0.2901800000&#34;, &#34;0.0254050000&#34;, &#34;-0.0949190000&#34;, &#34;0.0938760000&#34;, &#34;-0.0554230000&#34;, &#34;-0.0594190000&#34;, &#34;-0.0825420000&#34;, &#34;0.0940480000&#34;, &#34;0.0594220000&#34;, &#34;-0.0325640000&#34;, &#34;-0.0062017000&#34;, &#34;-0.0095274000&#34;, &#34;0.0924390000&#34;, &#34;-0.1699500000&#34;, &#34;0.0003890400&#34;, &#34;0.1918700000&#34;, &#34;-0.0250480000&#34;, &#34;-0.1184400000&#34;, &#34;0.0278790000&#34;, &#34;-0.0340240000&#34;, &#34;-0.0468660000&#34;, &#34;-0.0900900000&#34;, &#34;-0.0344170000&#34;, &#34;0.2553400000&#34;, &#34;0.0967780000&#34;, &#34;0.2084100000&#34;, &#34;0.0296930000&#34;, &#34;-0.0159430000&#34;, &#34;-0.0357790000&#34;, &#34;0.0021559000&#34;, &#34;0.0802460000&#34;, &#34;-0.0313550000&#34;, &#34;-0.2267600000&#34;, &#34;-0.1157900000&#34;, &#34;-0.0595790000&#34;, &#34;-0.0744200000&#34;, &#34;-0.1287100000&#34;, &#34;-0.1019900000&#34;, &#34;0.0649690000&#34;, &#34;-0.0703880000&#34;, &#34;-0.0401310000&#34;, &#34;-0.1474000000&#34;, &#34;-0.0988390000&#34;, &#34;0.1161400000&#34;, &#34;0.1587100000&#34;, &#34;0.0693000000&#34;, &#34;0.0318970000&#34;, &#34;-0.0287380000&#34;, &#34;-0.0846340000&#34;, &#34;-0.1486400000&#34;, &#34;0.1139800000&#34;, &#34;0.0726880000&#34;, &#34;-0.0657520000&#34;, &#34;-0.0132960000&#34;, &#34;0.0851640000&#34;, &#34;0.0250530000&#34;, &#34;0.0168670000&#34;, &#34;-0.0452570000&#34;, &#34;-0.0429250000&#34;, &#34;0.1232900000&#34;, &#34;0.1301200000&#34;, &#34;-0.0153200000&#34;, &#34;-0.1394300000&#34;, &#34;0.0897640000&#34;, &#34;0.0821720000&#34;, &#34;-0.0819180000&#34;, &#34;-0.0116880000&#34;, &#34;-0.1174200000&#34;, &#34;0.0292420000&#34;, &#34;-0.0658140000&#34;, &#34;0.0299590000&#34;, &#34;-0.0109410000&#34;, &#34;-0.0183000000&#34;, &#34;0.0571800000&#34;, &#34;0.0684360000&#34;, &#34;0.0072271000&#34;, &#34;0.0057584000&#34;, &#34;0.0714660000&#34;, &#34;-0.0831640000&#34;, &#34;-0.0150100000&#34;, &#34;-0.0780600000&#34;, &#34;0.0033293000&#34;, &#34;0.0991320000&#34;, &#34;0.0611880000&#34;, &#34;-0.0978150000&#34;, &#34;-0.1400800000&#34;, &#34;-0.0026304000&#34;, &#34;0.0022269000&#34;, &#34;0.0834960000&#34;, &#34;-0.1433400000&#34;, &#34;-0.0374470000&#34;, &#34;0.0615640000&#34;, &#34;0.2153600000&#34;, &#34;-0.0368360000&#34;, &#34;0.0386290000&#34;, &#34;0.1303100000&#34;, &#34;0.0459440000&#34;, &#34;0.0277010000&#34;, &#34;0.0616790000&#34;, &#34;0.0629210000&#34;, &#34;0.0684530000&#34;, &#34;-0.0262920000&#34;, &#34;0.1734200000&#34;, &#34;-0.1442100000&#34;, &#34;-0.0131240000&#34;, &#34;0.1549400000&#34;, &#34;-0.1078600000&#34;, &#34;0.1831400000&#34;, &#34;0.1388100000&#34;, &#34;0.0275700000&#34;, &#34;-0.0350730000&#34;, &#34;-0.0178290000&#34;, &#34;0.1116300000&#34;, &#34;-0.0582310000&#34;, &#34;0.0119770000&#34;], [&#34;-0.1587600000&#34;, &#34;-0.3227800000&#34;, &#34;-0.3359300000&#34;, &#34;0.3772600000&#34;, &#34;0.0181430000&#34;, &#34;-0.0432970000&#34;, &#34;0.1131200000&#34;, &#34;0.3340600000&#34;, &#34;0.0813920000&#34;, &#34;0.3173600000&#34;, &#34;-0.6511300000&#34;, &#34;0.3122200000&#34;, &#34;-0.3403500000&#34;, &#34;-0.0143110000&#34;, &#34;0.0947010000&#34;, &#34;0.1030300000&#34;, &#34;-0.0264650000&#34;, &#34;-0.2975800000&#34;, &#34;0.2857200000&#34;, &#34;0.1407000000&#34;, &#34;0.4714900000&#34;, &#34;-0.2468500000&#34;, &#34;0.0218830000&#34;, &#34;-0.2756400000&#34;, &#34;-0.2135600000&#34;, &#34;-0.1009600000&#34;, &#34;0.0781600000&#34;, &#34;-0.0266210000&#34;, &#34;-0.3624200000&#34;, &#34;0.1317900000&#34;, &#34;-0.0128400000&#34;, &#34;0.3227500000&#34;, &#34;-0.2141200000&#34;, &#34;0.5504600000&#34;, &#34;0.0096127000&#34;, &#34;-0.0289060000&#34;, &#34;0.0297310000&#34;, &#34;-0.1070000000&#34;, &#34;-0.0262920000&#34;, &#34;-0.2351100000&#34;, &#34;-0.2201000000&#34;, &#34;-0.3021400000&#34;, &#34;0.2727900000&#34;, &#34;-0.0970060000&#34;, &#34;0.1617500000&#34;, &#34;0.3892400000&#34;, &#34;0.1930100000&#34;, &#34;0.1013100000&#34;, &#34;0.2822700000&#34;, &#34;-0.0601160000&#34;, &#34;-0.2111700000&#34;, &#34;-0.0417050000&#34;, &#34;-0.2473800000&#34;, &#34;-0.2462600000&#34;, &#34;0.2009900000&#34;, &#34;0.2127100000&#34;, &#34;0.1202300000&#34;, &#34;0.4742100000&#34;, &#34;0.2738700000&#34;, &#34;-0.3520600000&#34;, &#34;-0.1265300000&#34;, &#34;0.1471700000&#34;, &#34;0.2083000000&#34;, &#34;0.0757050000&#34;, &#34;0.1981700000&#34;, &#34;-0.1608700000&#34;, &#34;-0.3880500000&#34;, &#34;0.1526500000&#34;, &#34;-0.0720210000&#34;, &#34;-0.1207400000&#34;, &#34;0.2680500000&#34;, &#34;0.0079369000&#34;, &#34;0.3982100000&#34;, &#34;0.0477760000&#34;, &#34;-0.2226300000&#34;, &#34;-0.2731800000&#34;, &#34;0.3082700000&#34;, &#34;-0.0780150000&#34;, &#34;0.6067500000&#34;, &#34;0.0958000000&#34;, &#34;-0.2810400000&#34;, &#34;0.0069502000&#34;, &#34;0.0300680000&#34;, &#34;0.1701500000&#34;, &#34;0.2536200000&#34;, &#34;-0.1601700000&#34;, &#34;0.1847200000&#34;, &#34;-0.1219200000&#34;, &#34;-0.2927000000&#34;, &#34;-0.2109100000&#34;, &#34;-0.0316770000&#34;, &#34;-0.0606560000&#34;, &#34;0.2542000000&#34;, &#34;-0.4263400000&#34;, &#34;0.3392500000&#34;, &#34;0.0381370000&#34;, &#34;0.2056600000&#34;, &#34;0.1665800000&#34;, &#34;0.2306600000&#34;, &#34;-0.3268600000&#34;, &#34;0.2220000000&#34;, &#34;0.0315130000&#34;, &#34;0.2612500000&#34;, &#34;-0.3222300000&#34;, &#34;-0.1175300000&#34;, &#34;-0.2433500000&#34;, &#34;-0.1013900000&#34;, &#34;0.2406800000&#34;, &#34;0.2898800000&#34;, &#34;0.0240570000&#34;, &#34;-0.2951700000&#34;, &#34;0.1695700000&#34;, &#34;0.4008100000&#34;, &#34;-0.0042294000&#34;, &#34;-0.0335240000&#34;, &#34;0.0333200000&#34;, &#34;0.0429930000&#34;, &#34;0.3818900000&#34;, &#34;0.0941170000&#34;, &#34;0.5117400000&#34;, &#34;0.1200700000&#34;, &#34;-0.2027800000&#34;, &#34;0.0749920000&#34;, &#34;0.3657700000&#34;, &#34;-0.6609300000&#34;, &#34;-0.3408200000&#34;, &#34;0.2731700000&#34;, &#34;0.1198500000&#34;, &#34;-0.1932600000&#34;, &#34;-0.0202370000&#34;, &#34;0.2031300000&#34;, &#34;0.1111300000&#34;, &#34;-0.1025100000&#34;, &#34;0.0484810000&#34;, &#34;0.1543400000&#34;, &#34;-0.0066719000&#34;, &#34;-0.1572600000&#34;, &#34;-0.1875100000&#34;, &#34;0.0743050000&#34;, &#34;0.2277600000&#34;, &#34;0.1359300000&#34;, &#34;0.3004500000&#34;, &#34;0.0681940000&#34;, &#34;-0.1956300000&#34;, &#34;-0.4441500000&#34;, &#34;0.1899800000&#34;, &#34;0.1851300000&#34;, &#34;0.1271800000&#34;, &#34;0.0233870000&#34;, &#34;-0.3482400000&#34;, &#34;0.2604500000&#34;, &#34;-0.0486800000&#34;, &#34;0.0026238000&#34;, &#34;-0.4195600000&#34;, &#34;-0.0549180000&#34;, &#34;-0.1955500000&#34;, &#34;-0.1820000000&#34;, &#34;-0.3471300000&#34;, &#34;0.2985400000&#34;, &#34;-0.0061094000&#34;, &#34;-0.1142100000&#34;, &#34;0.0122620000&#34;, &#34;-0.3194700000&#34;, &#34;-0.3279700000&#34;, &#34;0.0911590000&#34;, &#34;0.5112700000&#34;, &#34;0.2883100000&#34;, &#34;-0.3982400000&#34;, &#34;0.0116600000&#34;, &#34;-0.0952440000&#34;, &#34;-0.2137700000&#34;, &#34;-0.0727480000&#34;, &#34;-0.4034500000&#34;, &#34;0.3805100000&#34;, &#34;0.1486700000&#34;, &#34;-0.0929530000&#34;, &#34;-0.4091000000&#34;, &#34;0.2761400000&#34;, &#34;0.2208600000&#34;, &#34;0.0716520000&#34;, &#34;-0.1259000000&#34;, &#34;-0.2557700000&#34;, &#34;0.2259900000&#34;, &#34;0.2915500000&#34;, &#34;-0.3567100000&#34;, &#34;0.2179500000&#34;, &#34;0.0748660000&#34;, &#34;-0.2928200000&#34;, &#34;0.1110700000&#34;, &#34;-0.0321290000&#34;, &#34;-0.2541200000&#34;, &#34;-0.4156600000&#34;, &#34;0.3442900000&#34;, &#34;0.3934500000&#34;, &#34;-0.3489600000&#34;, &#34;-0.0745850000&#34;, &#34;0.1719800000&#34;, &#34;0.1018100000&#34;, &#34;-0.7027900000&#34;, &#34;-0.2589900000&#34;, &#34;0.2178400000&#34;, &#34;0.1526600000&#34;, &#34;0.3109000000&#34;, &#34;-0.3097300000&#34;, &#34;0.0234520000&#34;, &#34;-0.3409200000&#34;, &#34;-0.4034900000&#34;, &#34;-0.2364100000&#34;, &#34;-0.1380800000&#34;, &#34;-0.1189200000&#34;, &#34;0.4886600000&#34;, &#34;0.0729720000&#34;, &#34;0.4358600000&#34;, &#34;0.3096100000&#34;, &#34;-0.0931440000&#34;, &#34;-0.3680700000&#34;, &#34;0.1772000000&#34;, &#34;-0.3639400000&#34;, &#34;0.1151000000&#34;, &#34;-0.2219700000&#34;, &#34;-0.0662020000&#34;, &#34;0.0569440000&#34;, &#34;0.2996900000&#34;, &#34;0.2226600000&#34;, &#34;-0.4408000000&#34;, &#34;0.6536600000&#34;, &#34;-0.3059300000&#34;, &#34;-0.1836900000&#34;, &#34;0.1697000000&#34;, &#34;-0.0735740000&#34;, &#34;0.2771500000&#34;, &#34;0.1002600000&#34;, &#34;0.0886740000&#34;, &#34;-0.2617200000&#34;, &#34;-0.0674060000&#34;, &#34;0.1481900000&#34;, &#34;0.2398500000&#34;, &#34;-0.1801000000&#34;, &#34;0.2293500000&#34;, &#34;0.3916000000&#34;, &#34;-0.0148380000&#34;, &#34;-0.0284200000&#34;, &#34;-0.0851330000&#34;, &#34;0.1336000000&#34;, &#34;-0.0623770000&#34;, &#34;0.2805400000&#34;, &#34;-0.1503900000&#34;, &#34;-0.0478630000&#34;, &#34;0.2532000000&#34;, &#34;0.3712600000&#34;, &#34;-0.0988940000&#34;, &#34;0.0769980000&#34;, &#34;-0.0333030000&#34;, &#34;0.2335400000&#34;, &#34;-0.0862550000&#34;, &#34;0.1724700000&#34;, &#34;0.1407700000&#34;, &#34;0.0133260000&#34;, &#34;0.1846500000&#34;, &#34;0.1063000000&#34;, &#34;-0.0403180000&#34;, &#34;0.2216400000&#34;, &#34;0.5125000000&#34;, &#34;-0.0494960000&#34;, &#34;-0.3136200000&#34;, &#34;0.1578700000&#34;, &#34;0.1495300000&#34;, &#34;0.2847800000&#34;, &#34;-0.3695700000&#34;, &#34;-0.2211000000&#34;, &#34;-0.2212000000&#34;, &#34;0.1326000000&#34;, &#34;0.2133000000&#34;, &#34;0.3313100000&#34;, &#34;-0.5580700000&#34;, &#34;-0.2778400000&#34;, &#34;0.0173270000&#34;, &#34;-0.4024200000&#34;, &#34;-0.0102690000&#34;, &#34;-0.1359200000&#34;, &#34;-0.2050400000&#34;, &#34;-0.2245200000&#34;, &#34;-0.0172750000&#34;, &#34;0.1393200000&#34;, &#34;0.1057100000&#34;, &#34;-0.4470900000&#34;, &#34;0.4182100000&#34;, &#34;-0.1518400000&#34;, &#34;0.0130620000&#34;, &#34;0.0178030000&#34;, &#34;0.0209970000&#34;, &#34;0.0712130000&#34;, &#34;0.0926260000&#34;, &#34;0.0014617000&#34;, &#34;-0.1932800000&#34;, &#34;-0.2181800000&#34;, &#34;0.1399300000&#34;, &#34;0.2508200000&#34;, &#34;0.0280280000&#34;, &#34;-0.2789300000&#34;], [&#34;-0.0523090000&#34;, &#34;0.2665800000&#34;, &#34;-0.3307500000&#34;, &#34;0.1053000000&#34;, &#34;-0.3252100000&#34;, &#34;-0.3258600000&#34;, &#34;-0.2779200000&#34;, &#34;-0.2762400000&#34;, &#34;-0.0535120000&#34;, &#34;0.1969700000&#34;, &#34;-0.1683500000&#34;, &#34;-0.0741790000&#34;, &#34;-0.2795100000&#34;, &#34;0.1874800000&#34;, &#34;0.3636300000&#34;, &#34;-0.0343460000&#34;, &#34;0.0034359000&#34;, &#34;0.0694370000&#34;, &#34;0.2621400000&#34;, &#34;0.3995000000&#34;, &#34;-0.0571170000&#34;, &#34;0.1617900000&#34;, &#34;-0.2680600000&#34;, &#34;-0.1917100000&#34;, &#34;-0.4367500000&#34;, &#34;-0.0312640000&#34;, &#34;-0.1036400000&#34;, &#34;-0.0204780000&#34;, &#34;-0.1271200000&#34;, &#34;0.2809100000&#34;, &#34;0.0257580000&#34;, &#34;0.0885600000&#34;, &#34;-0.1328100000&#34;, &#34;-0.2613600000&#34;, &#34;-0.2562300000&#34;, &#34;-0.3481500000&#34;, &#34;0.2366100000&#34;, &#34;-0.1661100000&#34;, &#34;0.1263500000&#34;, &#34;-0.2177100000&#34;, &#34;0.5237100000&#34;, &#34;0.0348660000&#34;, &#34;-0.3854700000&#34;, &#34;-0.1805000000&#34;, &#34;0.1851300000&#34;, &#34;0.0513540000&#34;, &#34;0.0390160000&#34;, &#34;0.0303340000&#34;, &#34;0.1302200000&#34;, &#34;-0.2503400000&#34;, &#34;-0.1443400000&#34;, &#34;-0.0069149000&#34;, &#34;-0.0412930000&#34;, &#34;-0.0744350000&#34;, &#34;0.3769300000&#34;, &#34;0.0148660000&#34;, &#34;0.1352500000&#34;, &#34;-0.1433800000&#34;, &#34;-0.0192900000&#34;, &#34;-0.0956020000&#34;, &#34;-0.4735900000&#34;, &#34;-0.2745100000&#34;, &#34;0.1971700000&#34;, &#34;-0.2502800000&#34;, &#34;0.1090400000&#34;, &#34;-0.2183100000&#34;, &#34;-0.3640500000&#34;, &#34;-0.0252150000&#34;, &#34;0.0029815000&#34;, &#34;-0.1809100000&#34;, &#34;0.0151360000&#34;, &#34;-0.0723530000&#34;, &#34;-0.2393800000&#34;, &#34;0.0014383000&#34;, &#34;0.1144600000&#34;, &#34;0.1457600000&#34;, &#34;0.3139800000&#34;, &#34;0.2727300000&#34;, &#34;0.1515300000&#34;, &#34;-0.1210300000&#34;, &#34;0.1985700000&#34;, &#34;-0.0353030000&#34;, &#34;-0.3405400000&#34;, &#34;-0.2667000000&#34;, &#34;-0.1719400000&#34;, &#34;0.1369100000&#34;, &#34;0.2015100000&#34;, &#34;0.0296830000&#34;, &#34;0.3212700000&#34;, &#34;-0.1517900000&#34;, &#34;-0.4949500000&#34;, &#34;-0.2224600000&#34;, &#34;0.1629600000&#34;, &#34;-0.0825980000&#34;, &#34;0.1640500000&#34;, &#34;-0.0537130000&#34;, &#34;0.1062600000&#34;, &#34;0.0879090000&#34;, &#34;-0.0403420000&#34;, &#34;0.0248830000&#34;, &#34;-0.0331590000&#34;, &#34;-0.1199500000&#34;, &#34;0.0557670000&#34;, &#34;0.0614410000&#34;, &#34;0.1482100000&#34;, &#34;-0.2978200000&#34;, &#34;0.1739600000&#34;, &#34;0.2502600000&#34;, &#34;0.2588700000&#34;, &#34;-0.3141400000&#34;, &#34;-0.0317020000&#34;, &#34;0.4975700000&#34;, &#34;-0.1000300000&#34;, &#34;-0.1502300000&#34;, &#34;-0.1115500000&#34;, &#34;0.0118040000&#34;, &#34;0.1026300000&#34;, &#34;-0.1602800000&#34;, &#34;-0.1540300000&#34;, &#34;-0.0941530000&#34;, &#34;-0.0747390000&#34;, &#34;0.1678500000&#34;, &#34;-0.3977300000&#34;, &#34;0.1695800000&#34;, &#34;0.2269400000&#34;, &#34;0.1442100000&#34;, &#34;-0.0991110000&#34;, &#34;-0.0322830000&#34;, &#34;-0.4709700000&#34;, &#34;0.3251000000&#34;, &#34;-0.0434390000&#34;, &#34;-0.2292100000&#34;, &#34;0.0341340000&#34;, &#34;-0.1904500000&#34;, &#34;-0.0263260000&#34;, &#34;0.0424960000&#34;, &#34;-0.2934400000&#34;, &#34;0.0661140000&#34;, &#34;-0.0383760000&#34;, &#34;0.2520200000&#34;, &#34;-0.2320500000&#34;, &#34;0.3394200000&#34;, &#34;-0.0715850000&#34;, &#34;0.2545700000&#34;, &#34;0.0043527000&#34;, &#34;-0.2423400000&#34;, &#34;0.1613800000&#34;, &#34;0.1826500000&#34;, &#34;0.1417700000&#34;, &#34;0.0315390000&#34;, &#34;0.2728900000&#34;, &#34;-0.1275500000&#34;, &#34;-0.1180800000&#34;, &#34;-0.1475800000&#34;, &#34;0.1905000000&#34;, &#34;-0.2014400000&#34;, &#34;-0.1384200000&#34;, &#34;0.0865480000&#34;, &#34;-0.0022205000&#34;, &#34;-0.2578100000&#34;, &#34;0.0660550000&#34;, &#34;-0.0046081000&#34;, &#34;0.1155900000&#34;, &#34;0.1838300000&#34;, &#34;0.4447300000&#34;, &#34;0.2147300000&#34;, &#34;-0.3040000000&#34;, &#34;-0.1430200000&#34;, &#34;0.2544300000&#34;, &#34;0.1547000000&#34;, &#34;-0.5520200000&#34;, &#34;0.0660840000&#34;, &#34;-0.2717800000&#34;, &#34;0.3506900000&#34;, &#34;-0.0151610000&#34;, &#34;0.0985190000&#34;, &#34;-0.1620000000&#34;, &#34;-0.2963000000&#34;, &#34;-0.4363200000&#34;, &#34;-0.1256400000&#34;, &#34;0.1911800000&#34;, &#34;-0.0352810000&#34;, &#34;0.1363200000&#34;, &#34;0.3178500000&#34;, &#34;0.1294900000&#34;, &#34;0.6165000000&#34;, &#34;-0.3402400000&#34;, &#34;0.2943500000&#34;, &#34;-0.0869620000&#34;, &#34;-0.4286400000&#34;, &#34;-0.1893000000&#34;, &#34;-0.3347900000&#34;, &#34;0.0923770000&#34;, &#34;0.0800120000&#34;, &#34;-0.1322000000&#34;, &#34;-0.0549550000&#34;, &#34;0.1689600000&#34;, &#34;-0.0370430000&#34;, &#34;-0.4501700000&#34;, &#34;-0.3235400000&#34;, &#34;-0.1161100000&#34;, &#34;-0.3692300000&#34;, &#34;-0.0146730000&#34;, &#34;0.0314730000&#34;, &#34;-0.1917100000&#34;, &#34;-0.3675500000&#34;, &#34;-0.1943500000&#34;, &#34;0.1106700000&#34;, &#34;0.2250300000&#34;, &#34;-0.1847700000&#34;, &#34;0.6242600000&#34;, &#34;0.4363800000&#34;, &#34;0.0975350000&#34;, &#34;0.3124200000&#34;, &#34;0.3247100000&#34;, &#34;-0.3258600000&#34;, &#34;-0.2797100000&#34;, &#34;-0.6241900000&#34;, &#34;0.0450560000&#34;, &#34;0.4311600000&#34;, &#34;-0.3806500000&#34;, &#34;-0.2122000000&#34;, &#34;0.0478970000&#34;, &#34;0.1864700000&#34;, &#34;0.0286250000&#34;, &#34;-0.1867900000&#34;, &#34;-0.5833600000&#34;, &#34;-0.6953800000&#34;, &#34;-0.0776850000&#34;, &#34;0.2366500000&#34;, &#34;-0.2479400000&#34;, &#34;-0.0457940000&#34;, &#34;0.0851970000&#34;, &#34;0.0603540000&#34;, &#34;0.0143630000&#34;, &#34;-0.0620990000&#34;, &#34;0.2408800000&#34;, &#34;-0.3537800000&#34;, &#34;0.4175300000&#34;, &#34;0.2923900000&#34;, &#34;0.1785600000&#34;, &#34;-0.0163310000&#34;, &#34;-0.0095452000&#34;, &#34;-0.1880500000&#34;, &#34;-0.3723500000&#34;, &#34;0.2063400000&#34;, &#34;-0.1614900000&#34;, &#34;-0.4303400000&#34;, &#34;-0.2321500000&#34;, &#34;0.0587000000&#34;, &#34;-0.0318890000&#34;, &#34;-0.2462900000&#34;, &#34;-0.0038514000&#34;, &#34;0.1322600000&#34;, &#34;-0.4549300000&#34;, &#34;-0.0139040000&#34;, &#34;0.0713100000&#34;, &#34;-0.3762300000&#34;, &#34;-0.0745100000&#34;, &#34;-0.1904000000&#34;, &#34;-0.2019900000&#34;, &#34;0.1999300000&#34;, &#34;0.1617300000&#34;, &#34;-0.5173500000&#34;, &#34;-0.3040400000&#34;, &#34;-0.1386000000&#34;, &#34;-0.2150100000&#34;, &#34;-0.0667560000&#34;, &#34;-0.3111200000&#34;, &#34;-0.0036347000&#34;, &#34;-0.2470800000&#34;, &#34;-0.2344100000&#34;, &#34;-0.0708040000&#34;, &#34;0.2091300000&#34;, &#34;-0.0409730000&#34;, &#34;-0.0256060000&#34;, &#34;0.1770600000&#34;, &#34;0.2917000000&#34;, &#34;0.1914900000&#34;, &#34;-0.1772700000&#34;, &#34;-0.0403130000&#34;, &#34;-0.2448500000&#34;, &#34;-0.0863410000&#34;, &#34;-0.0036669000&#34;, &#34;0.3125200000&#34;, &#34;-0.0368460000&#34;, &#34;0.2402000000&#34;, &#34;-0.5649400000&#34;, &#34;-0.2658100000&#34;, &#34;0.2239800000&#34;, &#34;0.1460900000&#34;, &#34;0.3064000000&#34;, &#34;0.3317100000&#34;, &#34;0.1802400000&#34;, &#34;-0.4603000000&#34;, &#34;-0.2471800000&#34;, &#34;0.1571900000&#34;, &#34;0.2939100000&#34;, &#34;0.0876830000&#34;, &#34;-0.0864860000&#34;], [&#34;0.1236700000&#34;, &#34;-0.1396500000&#34;, &#34;0.0448770000&#34;, &#34;0.1891900000&#34;, &#34;-0.1099700000&#34;, &#34;-0.0064458000&#34;, &#34;0.0504990000&#34;, &#34;-0.2043900000&#34;, &#34;-0.0157610000&#34;, &#34;0.1504900000&#34;, &#34;0.1377400000&#34;, &#34;-0.0682410000&#34;, &#34;0.1707800000&#34;, &#34;-0.1352900000&#34;, &#34;-0.1832400000&#34;, &#34;-0.0003556700&#34;, &#34;-0.0995660000&#34;, &#34;-0.1454900000&#34;, &#34;0.0671830000&#34;, &#34;0.0282730000&#34;, &#34;-0.1008400000&#34;, &#34;0.1049800000&#34;, &#34;-0.2461300000&#34;, &#34;0.0088310000&#34;, &#34;-0.1843700000&#34;, &#34;0.0500110000&#34;, &#34;-0.0328390000&#34;, &#34;-0.0691290000&#34;, &#34;0.0043659000&#34;, &#34;0.1101100000&#34;, &#34;-0.3227200000&#34;, &#34;0.2662500000&#34;, &#34;-0.1246500000&#34;, &#34;0.3215700000&#34;, &#34;0.0679820000&#34;, &#34;-0.2267100000&#34;, &#34;0.0818430000&#34;, &#34;0.1143500000&#34;, &#34;0.0620670000&#34;, &#34;-0.0729730000&#34;, &#34;-0.0134150000&#34;, &#34;-0.0484930000&#34;, &#34;-0.1142600000&#34;, &#34;0.0697430000&#34;, &#34;-0.0709370000&#34;, &#34;-0.0628860000&#34;, &#34;-0.0156920000&#34;, &#34;-0.0336630000&#34;, &#34;0.1044100000&#34;, &#34;0.0050113000&#34;, &#34;-0.0017716000&#34;, &#34;0.0117200000&#34;, &#34;-0.0861680000&#34;, &#34;0.0122210000&#34;, &#34;-0.1481700000&#34;, &#34;0.0353730000&#34;, &#34;0.0398690000&#34;, &#34;0.2990400000&#34;, &#34;0.0246700000&#34;, &#34;0.1809600000&#34;, &#34;0.0708580000&#34;, &#34;-0.3536000000&#34;, &#34;0.0905180000&#34;, &#34;-0.1290500000&#34;, &#34;-0.0104430000&#34;, &#34;-0.1869700000&#34;, &#34;-0.2125800000&#34;, &#34;-0.0446440000&#34;, &#34;-0.2533300000&#34;, &#34;0.1003100000&#34;, &#34;-0.1736900000&#34;, &#34;-0.0373540000&#34;, &#34;-0.0309310000&#34;, &#34;-0.0919720000&#34;, &#34;-0.0682330000&#34;, &#34;0.0223660000&#34;, &#34;0.1256900000&#34;, &#34;0.1374900000&#34;, &#34;-0.0795470000&#34;, &#34;0.0071489000&#34;, &#34;-0.1511700000&#34;, &#34;0.2753800000&#34;, &#34;0.1396400000&#34;, &#34;0.0088001000&#34;, &#34;-0.0032892000&#34;, &#34;-0.2131300000&#34;, &#34;-0.0605430000&#34;, &#34;-0.1232100000&#34;, &#34;-0.1487500000&#34;, &#34;-0.2236200000&#34;, &#34;-0.2102400000&#34;, &#34;-0.0888030000&#34;, &#34;0.2922200000&#34;, &#34;-0.2596700000&#34;, &#34;0.2233100000&#34;, &#34;-0.0453370000&#34;, &#34;-0.0318100000&#34;, &#34;0.2028200000&#34;, &#34;-0.0727630000&#34;, &#34;0.0842300000&#34;, &#34;-0.1361900000&#34;, &#34;-0.0653910000&#34;, &#34;0.0456860000&#34;, &#34;0.1329200000&#34;, &#34;-0.1604500000&#34;, &#34;0.0683270000&#34;, &#34;-0.0858540000&#34;, &#34;0.1138000000&#34;, &#34;-0.0373010000&#34;, &#34;0.1485000000&#34;, &#34;0.1142900000&#34;, &#34;0.0751520000&#34;, &#34;-0.0826890000&#34;, &#34;-0.1272000000&#34;, &#34;-0.0255670000&#34;, &#34;0.0070075000&#34;, &#34;0.2604500000&#34;, &#34;-0.0658110000&#34;, &#34;0.0327150000&#34;, &#34;0.1979600000&#34;, &#34;0.1615400000&#34;, &#34;0.0461600000&#34;, &#34;-0.1811000000&#34;, &#34;0.2221000000&#34;, &#34;-0.0976020000&#34;, &#34;-0.1694600000&#34;, &#34;0.1414200000&#34;, &#34;0.0990350000&#34;, &#34;0.1553600000&#34;, &#34;0.1927700000&#34;, &#34;-0.0770730000&#34;, &#34;0.1304000000&#34;, &#34;0.0783040000&#34;, &#34;0.0732620000&#34;, &#34;-0.1485800000&#34;, &#34;0.1540000000&#34;, &#34;-0.1068800000&#34;, &#34;0.0550930000&#34;, &#34;0.0086387000&#34;, &#34;0.1932600000&#34;, &#34;-0.0268620000&#34;, &#34;0.2605700000&#34;, &#34;0.0527280000&#34;, &#34;-0.1146300000&#34;, &#34;0.1786900000&#34;, &#34;0.3908300000&#34;, &#34;0.2517200000&#34;, &#34;0.1414000000&#34;, &#34;-0.0663810000&#34;, &#34;0.0981100000&#34;, &#34;-0.1260400000&#34;, &#34;-0.0534040000&#34;, &#34;-0.1278300000&#34;, &#34;0.0151130000&#34;, &#34;-0.1591200000&#34;, &#34;-0.1964700000&#34;, &#34;0.1783100000&#34;, &#34;0.0119900000&#34;, &#34;0.0790110000&#34;, &#34;0.0381480000&#34;, &#34;-0.1492000000&#34;, &#34;0.3732400000&#34;, &#34;-0.2612100000&#34;, &#34;0.1281300000&#34;, &#34;0.1283600000&#34;, &#34;0.0535780000&#34;, &#34;-0.0765070000&#34;, &#34;0.0766710000&#34;, &#34;0.1352600000&#34;, &#34;-0.0133000000&#34;, &#34;-0.1612300000&#34;, &#34;-0.1084800000&#34;, &#34;-0.0253150000&#34;, &#34;-0.1773100000&#34;, &#34;0.0761610000&#34;, &#34;-0.0601740000&#34;, &#34;0.1403600000&#34;, &#34;0.2360600000&#34;, &#34;0.0130440000&#34;, &#34;-0.0038421000&#34;, &#34;0.1878900000&#34;, &#34;-0.0887220000&#34;, &#34;0.0325180000&#34;, &#34;0.2278100000&#34;, &#34;-0.0235590000&#34;, &#34;0.0846430000&#34;, &#34;0.1224200000&#34;, &#34;0.0088557000&#34;, &#34;0.0765080000&#34;, &#34;-0.0050585000&#34;, &#34;-0.0991940000&#34;, &#34;-0.0678060000&#34;, &#34;0.0599070000&#34;, &#34;0.0354040000&#34;, &#34;0.0187190000&#34;, &#34;-0.0268160000&#34;, &#34;-0.0043838000&#34;, &#34;0.0820260000&#34;, &#34;-0.1198600000&#34;, &#34;-0.2079700000&#34;, &#34;0.1857000000&#34;, &#34;-0.0937720000&#34;, &#34;-0.0162990000&#34;, &#34;0.1604400000&#34;, &#34;0.0333070000&#34;, &#34;-0.1544700000&#34;, &#34;-0.1299000000&#34;, &#34;0.1244600000&#34;, &#34;0.1037500000&#34;, &#34;0.1518600000&#34;, &#34;0.1791600000&#34;, &#34;-0.0392000000&#34;, &#34;-0.1754400000&#34;, &#34;0.0117540000&#34;, &#34;-0.0835660000&#34;, &#34;-0.0018136000&#34;, &#34;0.1267200000&#34;, &#34;-0.2011700000&#34;, &#34;-0.1697700000&#34;, &#34;-0.1478300000&#34;, &#34;0.0441560000&#34;, &#34;-0.1790700000&#34;, &#34;-0.0467720000&#34;, &#34;-0.0019811000&#34;, &#34;-0.0374120000&#34;, &#34;0.0013870000&#34;, &#34;-0.1056100000&#34;, &#34;-0.1542700000&#34;, &#34;0.1401600000&#34;, &#34;0.0411570000&#34;, &#34;0.1922200000&#34;, &#34;0.0120730000&#34;, &#34;-0.0667530000&#34;, &#34;-0.0252570000&#34;, &#34;-0.1564800000&#34;, &#34;0.0244270000&#34;, &#34;-0.0186740000&#34;, &#34;-0.1670500000&#34;, &#34;-0.0506200000&#34;, &#34;-0.0752870000&#34;, &#34;0.0430620000&#34;, &#34;0.0061818000&#34;, &#34;0.1057300000&#34;, &#34;-0.0029119000&#34;, &#34;0.0716430000&#34;, &#34;0.1332400000&#34;, &#34;0.2488900000&#34;, &#34;-0.0129980000&#34;, &#34;-0.0771420000&#34;, &#34;0.1755000000&#34;, &#34;0.1697100000&#34;, &#34;-0.0348750000&#34;, &#34;0.0849390000&#34;, &#34;-0.1958700000&#34;, &#34;-0.2611500000&#34;, &#34;-0.0529240000&#34;, &#34;-0.2303400000&#34;, &#34;-0.1347900000&#34;, &#34;0.1393300000&#34;, &#34;0.0411060000&#34;, &#34;0.0458160000&#34;, &#34;0.1111300000&#34;, &#34;-0.0703000000&#34;, &#34;0.0129250000&#34;, &#34;0.1397700000&#34;, &#34;-0.0636160000&#34;, &#34;0.0438910000&#34;, &#34;0.0278550000&#34;, &#34;-0.0396100000&#34;, &#34;-0.0957990000&#34;, &#34;-0.1258800000&#34;, &#34;-0.0847110000&#34;, &#34;-0.0042531000&#34;, &#34;-0.0590850000&#34;, &#34;-0.0933240000&#34;, &#34;-0.3395800000&#34;, &#34;0.0635250000&#34;, &#34;0.0822760000&#34;, &#34;0.0623950000&#34;, &#34;-0.0999550000&#34;, &#34;0.0143260000&#34;, &#34;0.0426450000&#34;, &#34;0.0802270000&#34;, &#34;0.0896460000&#34;, &#34;0.1758000000&#34;, &#34;0.0341530000&#34;, &#34;0.0005516700&#34;, &#34;0.1168700000&#34;, &#34;-0.0890060000&#34;, &#34;-0.0084893000&#34;, &#34;0.0251150000&#34;, &#34;-0.3180400000&#34;, &#34;0.1253300000&#34;, &#34;-0.0815070000&#34;, &#34;-0.1114000000&#34;, &#34;0.0175820000&#34;, &#34;-0.0373590000&#34;, &#34;0.0647400000&#34;, &#34;-0.1458100000&#34;, &#34;0.1617500000&#34;], [&#34;0.0463650000&#34;, &#34;-0.3176900000&#34;, &#34;0.3122200000&#34;, &#34;0.4272800000&#34;, &#34;-0.0520170000&#34;, &#34;-0.2056800000&#34;, &#34;-0.1305400000&#34;, &#34;-0.3554400000&#34;, &#34;-0.0454930000&#34;, &#34;0.1198300000&#34;, &#34;-0.1421300000&#34;, &#34;0.3160800000&#34;, &#34;-0.1794100000&#34;, &#34;-0.1854300000&#34;, &#34;0.1835900000&#34;, &#34;-0.1580800000&#34;, &#34;0.0726640000&#34;, &#34;-0.0014783000&#34;, &#34;0.1662200000&#34;, &#34;-0.1454300000&#34;, &#34;-0.2524000000&#34;, &#34;0.2721600000&#34;, &#34;-0.3226700000&#34;, &#34;-0.1066400000&#34;, &#34;-0.2970800000&#34;, &#34;0.1880700000&#34;, &#34;-0.0985250000&#34;, &#34;-0.1836500000&#34;, &#34;0.3127200000&#34;, &#34;0.2836100000&#34;, &#34;-0.1890300000&#34;, &#34;-0.0887010000&#34;, &#34;-0.3565200000&#34;, &#34;0.0357040000&#34;, &#34;-0.1088000000&#34;, &#34;-0.0503230000&#34;, &#34;0.0233360000&#34;, &#34;-0.2635200000&#34;, &#34;0.3081800000&#34;, &#34;-0.2282500000&#34;, &#34;0.0582360000&#34;, &#34;-0.4150600000&#34;, &#34;-0.0267630000&#34;, &#34;0.0463490000&#34;, &#34;0.1995900000&#34;, &#34;-0.3986100000&#34;, &#34;-0.1737500000&#34;, &#34;-0.3011900000&#34;, &#34;0.2229300000&#34;, &#34;-0.0381840000&#34;, &#34;0.0685010000&#34;, &#34;-0.0974790000&#34;, &#34;0.0158070000&#34;, &#34;-0.2198600000&#34;, &#34;-0.3758900000&#34;, &#34;0.1728500000&#34;, &#34;0.0040284000&#34;, &#34;0.3255200000&#34;, &#34;-0.0011404000&#34;, &#34;0.3276100000&#34;, &#34;-0.0131050000&#34;, &#34;0.0152470000&#34;, &#34;0.1571200000&#34;, &#34;-0.2604500000&#34;, &#34;-0.1249400000&#34;, &#34;0.2813600000&#34;, &#34;-0.2671600000&#34;, &#34;-0.4610200000&#34;, &#34;-0.4107300000&#34;, &#34;-0.3222800000&#34;, &#34;0.1654500000&#34;, &#34;-0.0149960000&#34;, &#34;0.3511800000&#34;, &#34;0.0614230000&#34;, &#34;-0.1164300000&#34;, &#34;0.4313700000&#34;, &#34;0.0923770000&#34;, &#34;0.0299480000&#34;, &#34;-0.0858560000&#34;, &#34;-0.4110400000&#34;, &#34;0.0688170000&#34;, &#34;0.2929700000&#34;, &#34;-0.2121200000&#34;, &#34;-0.1218000000&#34;, &#34;-0.2695500000&#34;, &#34;-0.2420700000&#34;, &#34;-0.1880200000&#34;, &#34;0.1836200000&#34;, &#34;0.1854900000&#34;, &#34;0.1858900000&#34;, &#34;-0.1702000000&#34;, &#34;-0.0390480000&#34;, &#34;0.1155100000&#34;, &#34;-0.1973600000&#34;, &#34;0.1412200000&#34;, &#34;-0.0578840000&#34;, &#34;0.2088100000&#34;, &#34;0.0725870000&#34;, &#34;-0.4841100000&#34;, &#34;0.2685600000&#34;, &#34;0.1630300000&#34;, &#34;-0.1606900000&#34;, &#34;0.2750200000&#34;, &#34;-0.0595090000&#34;, &#34;-0.1850700000&#34;, &#34;-0.1289800000&#34;, &#34;-0.3099100000&#34;, &#34;0.4653400000&#34;, &#34;0.2392700000&#34;, &#34;-0.1323200000&#34;, &#34;-0.1390900000&#34;, &#34;-0.1310800000&#34;, &#34;-0.2652500000&#34;, &#34;-0.1235600000&#34;, &#34;0.0591330000&#34;, &#34;0.2327500000&#34;, &#34;0.4766700000&#34;, &#34;0.1262600000&#34;, &#34;0.1188300000&#34;, &#34;-0.1736800000&#34;, &#34;-0.0639730000&#34;, &#34;0.0535020000&#34;, &#34;-0.2536000000&#34;, &#34;0.3104200000&#34;, &#34;0.0804350000&#34;, &#34;-0.3012800000&#34;, &#34;0.0892770000&#34;, &#34;0.3681700000&#34;, &#34;0.1285200000&#34;, &#34;-0.1420900000&#34;, &#34;-0.0198250000&#34;, &#34;0.2551800000&#34;, &#34;-0.1726500000&#34;, &#34;-0.3079200000&#34;, &#34;-0.4626300000&#34;, &#34;0.0240730000&#34;, &#34;-0.0807790000&#34;, &#34;-0.0355850000&#34;, &#34;-0.1450900000&#34;, &#34;0.0465280000&#34;, &#34;0.0910750000&#34;, &#34;0.2393300000&#34;, &#34;0.2534700000&#34;, &#34;0.3377400000&#34;, &#34;-0.2525400000&#34;, &#34;0.3782400000&#34;, &#34;0.4848000000&#34;, &#34;-0.0541820000&#34;, &#34;0.2947600000&#34;, &#34;0.0865240000&#34;, &#34;-0.0932760000&#34;, &#34;0.0558760000&#34;, &#34;-0.3779900000&#34;, &#34;-0.1854800000&#34;, &#34;-0.2925200000&#34;, &#34;-0.1958300000&#34;, &#34;-0.0990030000&#34;, &#34;-0.4394200000&#34;, &#34;0.0876350000&#34;, &#34;-0.0124590000&#34;, &#34;-0.2909800000&#34;, &#34;0.5147000000&#34;, &#34;-0.1854500000&#34;, &#34;0.1396500000&#34;, &#34;0.5051900000&#34;, &#34;-0.0987320000&#34;, &#34;0.2557500000&#34;, &#34;0.1304000000&#34;, &#34;0.5544500000&#34;, &#34;-0.0214270000&#34;, &#34;-0.0295070000&#34;, &#34;0.0211700000&#34;, &#34;-0.1621000000&#34;, &#34;0.0148080000&#34;, &#34;0.0497580000&#34;, &#34;0.0360560000&#34;, &#34;-0.0623040000&#34;, &#34;0.6364200000&#34;, &#34;-0.4364400000&#34;, &#34;-0.0767760000&#34;, &#34;-0.3918200000&#34;, &#34;-0.1376000000&#34;, &#34;-0.2439400000&#34;, &#34;-0.2273100000&#34;, &#34;0.0665700000&#34;, &#34;0.1443800000&#34;, &#34;0.3847800000&#34;, &#34;0.1537400000&#34;, &#34;-0.1217200000&#34;, &#34;-0.0908160000&#34;, &#34;0.0459150000&#34;, &#34;-0.1055400000&#34;, &#34;-0.0736280000&#34;, &#34;-0.1917500000&#34;, &#34;-0.2921800000&#34;, &#34;0.2679500000&#34;, &#34;0.5089700000&#34;, &#34;0.0507820000&#34;, &#34;-0.2165700000&#34;, &#34;-0.0859700000&#34;, &#34;-0.2622300000&#34;, &#34;0.0221730000&#34;, &#34;0.1312700000&#34;, &#34;0.2496800000&#34;, &#34;0.1859000000&#34;, &#34;-0.1064700000&#34;, &#34;-0.3341000000&#34;, &#34;-0.4195600000&#34;, &#34;0.4828700000&#34;, &#34;0.5315000000&#34;, &#34;0.4137700000&#34;, &#34;-0.1783900000&#34;, &#34;0.2191900000&#34;, &#34;-0.1759100000&#34;, &#34;0.2718100000&#34;, &#34;0.0696030000&#34;, &#34;0.1032600000&#34;, &#34;-0.3397300000&#34;, &#34;-0.0553010000&#34;, &#34;0.1900100000&#34;, &#34;0.1406000000&#34;, &#34;-0.1833600000&#34;, &#34;-0.2006000000&#34;, &#34;-0.1718700000&#34;, &#34;0.2891500000&#34;, &#34;0.1472300000&#34;, &#34;-0.1442000000&#34;, &#34;-0.1555900000&#34;, &#34;-0.2456900000&#34;, &#34;-0.2394000000&#34;, &#34;0.1255800000&#34;, &#34;0.0276060000&#34;, &#34;0.1091400000&#34;, &#34;-0.1685800000&#34;, &#34;-0.0104810000&#34;, &#34;0.0252680000&#34;, &#34;-0.4089600000&#34;, &#34;0.4035400000&#34;, &#34;0.2546200000&#34;, &#34;-0.1537700000&#34;, &#34;0.3820000000&#34;, &#34;0.3436200000&#34;, &#34;-0.1251400000&#34;, &#34;-0.0505150000&#34;, &#34;0.1468700000&#34;, &#34;-0.0349930000&#34;, &#34;0.0669180000&#34;, &#34;0.1820300000&#34;, &#34;-0.1824700000&#34;, &#34;-0.0515000000&#34;, &#34;0.4634800000&#34;, &#34;-0.0582060000&#34;, &#34;0.0171330000&#34;, &#34;-0.0897660000&#34;, &#34;-0.4300800000&#34;, &#34;0.2556600000&#34;, &#34;-0.0925030000&#34;, &#34;0.3139000000&#34;, &#34;0.2618700000&#34;, &#34;0.2952500000&#34;, &#34;0.1411200000&#34;, &#34;0.1121100000&#34;, &#34;0.0774650000&#34;, &#34;-0.0810540000&#34;, &#34;0.0272460000&#34;, &#34;-0.3590800000&#34;, &#34;0.2473100000&#34;, &#34;0.2364700000&#34;, &#34;0.0182670000&#34;, &#34;-0.0976000000&#34;, &#34;0.1849400000&#34;, &#34;-0.0737550000&#34;, &#34;-0.0809840000&#34;, &#34;-0.1399200000&#34;, &#34;-0.1203000000&#34;, &#34;-0.0248450000&#34;, &#34;0.1400100000&#34;, &#34;0.1134500000&#34;, &#34;0.3576000000&#34;, &#34;0.0182790000&#34;, &#34;-0.3489200000&#34;, &#34;0.1073600000&#34;, &#34;-0.1351200000&#34;, &#34;0.1727700000&#34;, &#34;0.6192000000&#34;, &#34;0.0788150000&#34;, &#34;-0.1206400000&#34;, &#34;0.0543810000&#34;, &#34;-0.2672600000&#34;, &#34;0.1541100000&#34;, &#34;0.1107000000&#34;, &#34;-0.1556500000&#34;, &#34;0.2000600000&#34;, &#34;0.0365320000&#34;, &#34;-0.0519310000&#34;, &#34;-0.1327000000&#34;, &#34;0.0648700000&#34;, &#34;0.0222260000&#34;, &#34;-0.0132770000&#34;, &#34;-0.2840300000&#34;], [&#34;-0.0242940000&#34;, &#34;-0.3239500000&#34;, &#34;0.0416820000&#34;, &#34;0.3595100000&#34;, &#34;-0.0633400000&#34;, &#34;-0.0187400000&#34;, &#34;0.0271570000&#34;, &#34;-0.2658200000&#34;, &#34;0.0790410000&#34;, &#34;0.0189980000&#34;, &#34;-0.2384500000&#34;, &#34;0.2018200000&#34;, &#34;-0.1744400000&#34;, &#34;-0.1616700000&#34;, &#34;0.0889900000&#34;, &#34;0.0446220000&#34;, &#34;0.2123800000&#34;, &#34;-0.0304880000&#34;, &#34;0.2676700000&#34;, &#34;0.0243910000&#34;, &#34;-0.0481600000&#34;, &#34;0.4059700000&#34;, &#34;-0.4106000000&#34;, &#34;0.0084117000&#34;, &#34;-0.1556800000&#34;, &#34;0.2261100000&#34;, &#34;-0.0949880000&#34;, &#34;-0.2961900000&#34;, &#34;0.2178500000&#34;, &#34;0.2087100000&#34;, &#34;-0.0634690000&#34;, &#34;0.1624800000&#34;, &#34;-0.3018100000&#34;, &#34;-0.0512650000&#34;, &#34;-0.0935090000&#34;, &#34;-0.0678830000&#34;, &#34;0.0773100000&#34;, &#34;-0.2619000000&#34;, &#34;0.2478900000&#34;, &#34;-0.1452600000&#34;, &#34;-0.0132880000&#34;, &#34;-0.2955800000&#34;, &#34;-0.0406290000&#34;, &#34;-0.0517810000&#34;, &#34;0.1531500000&#34;, &#34;-0.1170000000&#34;, &#34;-0.0388830000&#34;, &#34;-0.1496300000&#34;, &#34;0.1859600000&#34;, &#34;-0.1104100000&#34;, &#34;-0.0091632000&#34;, &#34;-0.0394350000&#34;, &#34;-0.0266110000&#34;, &#34;-0.2930500000&#34;, &#34;-0.4908600000&#34;, &#34;0.1894300000&#34;, &#34;0.1154400000&#34;, &#34;0.3440000000&#34;, &#34;0.0313070000&#34;, &#34;0.2795000000&#34;, &#34;-0.0004033100&#34;, &#34;-0.1001400000&#34;, &#34;0.1903000000&#34;, &#34;-0.2856300000&#34;, &#34;-0.2030600000&#34;, &#34;0.2616400000&#34;, &#34;-0.2483300000&#34;, &#34;-0.3037300000&#34;, &#34;-0.2997800000&#34;, &#34;-0.3423000000&#34;, &#34;0.0978230000&#34;, &#34;-0.0056031000&#34;, &#34;0.4326900000&#34;, &#34;0.0664090000&#34;, &#34;-0.0188520000&#34;, &#34;0.3497700000&#34;, &#34;0.0095120000&#34;, &#34;0.0777580000&#34;, &#34;-0.1161600000&#34;, &#34;-0.3649400000&#34;, &#34;-0.0357600000&#34;, &#34;0.2563500000&#34;, &#34;-0.1065300000&#34;, &#34;-0.1825100000&#34;, &#34;-0.4096400000&#34;, &#34;-0.0930490000&#34;, &#34;-0.2399500000&#34;, &#34;0.1830700000&#34;, &#34;0.0844960000&#34;, &#34;0.0113040000&#34;, &#34;-0.0908230000&#34;, &#34;0.0686370000&#34;, &#34;0.0907610000&#34;, &#34;-0.2092100000&#34;, &#34;0.1721200000&#34;, &#34;-0.1507400000&#34;, &#34;0.1721700000&#34;, &#34;0.0313720000&#34;, &#34;-0.3987500000&#34;, &#34;0.3512700000&#34;, &#34;0.1610700000&#34;, &#34;-0.1358800000&#34;, &#34;0.3285600000&#34;, &#34;-0.0740190000&#34;, &#34;-0.2131900000&#34;, &#34;-0.1929600000&#34;, &#34;-0.3076900000&#34;, &#34;0.2266200000&#34;, &#34;0.1220100000&#34;, &#34;0.0307650000&#34;, &#34;0.0034103000&#34;, &#34;-0.3236500000&#34;, &#34;-0.2254400000&#34;, &#34;-0.1614700000&#34;, &#34;0.0403000000&#34;, &#34;0.2501300000&#34;, &#34;0.3367500000&#34;, &#34;0.2089000000&#34;, &#34;0.2335300000&#34;, &#34;-0.2064400000&#34;, &#34;0.0054006000&#34;, &#34;0.1259600000&#34;, &#34;-0.2135800000&#34;, &#34;0.4612500000&#34;, &#34;-0.0974460000&#34;, &#34;-0.0833560000&#34;, &#34;-0.0047900000&#34;, &#34;0.2662200000&#34;, &#34;0.2942800000&#34;, &#34;-0.0036505000&#34;, &#34;0.1492400000&#34;, &#34;0.2285700000&#34;, &#34;0.0057792000&#34;, &#34;-0.4267300000&#34;, &#34;-0.3525300000&#34;, &#34;-0.0277540000&#34;, &#34;-0.0688070000&#34;, &#34;-0.0220590000&#34;, &#34;-0.1709600000&#34;, &#34;0.0075218000&#34;, &#34;0.2095600000&#34;, &#34;0.3758300000&#34;, &#34;0.1411700000&#34;, &#34;0.3974300000&#34;, &#34;-0.1308600000&#34;, &#34;0.3608300000&#34;, &#34;0.3766100000&#34;, &#34;0.0606630000&#34;, &#34;0.1532600000&#34;, &#34;0.0470050000&#34;, &#34;-0.1083200000&#34;, &#34;-0.1943300000&#34;, &#34;-0.2677700000&#34;, &#34;-0.0867870000&#34;, &#34;-0.1062400000&#34;, &#34;-0.1830500000&#34;, &#34;0.0123840000&#34;, &#34;-0.1651100000&#34;, &#34;0.1138500000&#34;, &#34;0.0624900000&#34;, &#34;-0.4335600000&#34;, &#34;0.5021500000&#34;, &#34;-0.1896400000&#34;, &#34;-0.0977140000&#34;, &#34;0.4413700000&#34;, &#34;0.0029150000&#34;, &#34;0.2110000000&#34;, &#34;-0.0178610000&#34;, &#34;0.4172900000&#34;, &#34;0.0891950000&#34;, &#34;-0.1889000000&#34;, &#34;0.0759990000&#34;, &#34;-0.0367490000&#34;, &#34;0.0236250000&#34;, &#34;0.1068000000&#34;, &#34;0.0021618000&#34;, &#34;0.0526030000&#34;, &#34;0.5860000000&#34;, &#34;-0.4146800000&#34;, &#34;-0.0426800000&#34;, &#34;-0.2409900000&#34;, &#34;-0.0980560000&#34;, &#34;-0.0600310000&#34;, &#34;-0.0472040000&#34;, &#34;-0.1209300000&#34;, &#34;0.0993520000&#34;, &#34;0.4296400000&#34;, &#34;0.0664360000&#34;, &#34;0.0525380000&#34;, &#34;-0.1083300000&#34;, &#34;-0.1364400000&#34;, &#34;-0.2545300000&#34;, &#34;-0.1385900000&#34;, &#34;-0.2049400000&#34;, &#34;-0.2140200000&#34;, &#34;0.1844600000&#34;, &#34;0.4171800000&#34;, &#34;0.0527950000&#34;, &#34;-0.3474500000&#34;, &#34;-0.0156120000&#34;, &#34;-0.0747160000&#34;, &#34;-0.0352120000&#34;, &#34;0.2024700000&#34;, &#34;0.2419400000&#34;, &#34;0.1586900000&#34;, &#34;-0.1130300000&#34;, &#34;-0.1961800000&#34;, &#34;-0.4176400000&#34;, &#34;0.4982800000&#34;, &#34;0.3397800000&#34;, &#34;0.2777000000&#34;, &#34;-0.2783800000&#34;, &#34;0.1916100000&#34;, &#34;-0.2289500000&#34;, &#34;0.2389400000&#34;, &#34;-0.1750900000&#34;, &#34;0.1791900000&#34;, &#34;-0.2655000000&#34;, &#34;-0.0676030000&#34;, &#34;0.1801900000&#34;, &#34;-0.0503290000&#34;, &#34;-0.2555900000&#34;, &#34;-0.1330600000&#34;, &#34;-0.0910780000&#34;, &#34;0.2350600000&#34;, &#34;0.1578500000&#34;, &#34;-0.0945700000&#34;, &#34;-0.1061400000&#34;, &#34;-0.2513600000&#34;, &#34;-0.3436200000&#34;, &#34;0.1153100000&#34;, &#34;0.0469850000&#34;, &#34;0.2516800000&#34;, &#34;-0.1805500000&#34;, &#34;0.0971710000&#34;, &#34;0.0339080000&#34;, &#34;-0.2471000000&#34;, &#34;0.1703900000&#34;, &#34;0.0776150000&#34;, &#34;-0.1344600000&#34;, &#34;0.2537800000&#34;, &#34;0.2486000000&#34;, &#34;-0.0134710000&#34;, &#34;-0.0874520000&#34;, &#34;0.2856200000&#34;, &#34;-0.0718710000&#34;, &#34;0.2150100000&#34;, &#34;0.0718500000&#34;, &#34;-0.0148210000&#34;, &#34;-0.1938600000&#34;, &#34;0.4450900000&#34;, &#34;0.0558750000&#34;, &#34;0.0086543000&#34;, &#34;-0.0832180000&#34;, &#34;-0.4327300000&#34;, &#34;0.3075600000&#34;, &#34;0.1733100000&#34;, &#34;0.1430000000&#34;, &#34;0.0318120000&#34;, &#34;0.0799010000&#34;, &#34;0.1654500000&#34;, &#34;-0.0156160000&#34;, &#34;0.2118800000&#34;, &#34;-0.0251020000&#34;, &#34;-0.1068600000&#34;, &#34;-0.4185400000&#34;, &#34;0.1659600000&#34;, &#34;0.3885500000&#34;, &#34;0.0883650000&#34;, &#34;-0.1181000000&#34;, &#34;0.2872300000&#34;, &#34;0.0783410000&#34;, &#34;0.1460700000&#34;, &#34;-0.0681060000&#34;, &#34;-0.1567200000&#34;, &#34;0.1383700000&#34;, &#34;0.1536700000&#34;, &#34;-0.0212600000&#34;, &#34;0.2712500000&#34;, &#34;-0.0975090000&#34;, &#34;-0.2976100000&#34;, &#34;0.1161900000&#34;, &#34;-0.0630370000&#34;, &#34;0.0590700000&#34;, &#34;0.4889300000&#34;, &#34;0.1329800000&#34;, &#34;-0.1882000000&#34;, &#34;0.0291000000&#34;, &#34;-0.3653800000&#34;, &#34;-0.0827490000&#34;, &#34;0.0793000000&#34;, &#34;0.1312200000&#34;, &#34;0.2543000000&#34;, &#34;0.1376000000&#34;, &#34;-0.1528000000&#34;, &#34;-0.0783560000&#34;, &#34;0.1339400000&#34;, &#34;0.1069800000&#34;, &#34;-0.2136600000&#34;, &#34;-0.1665700000&#34;], [&#34;0.3297300000&#34;, &#34;-0.3556600000&#34;, &#34;0.0912140000&#34;, &#34;0.4278000000&#34;, &#34;-0.1860500000&#34;, &#34;0.2286600000&#34;, &#34;0.2729500000&#34;, &#34;-0.3176300000&#34;, &#34;0.0654800000&#34;, &#34;0.0286500000&#34;, &#34;-0.1624800000&#34;, &#34;0.1392200000&#34;, &#34;-0.1724600000&#34;, &#34;0.1802800000&#34;, &#34;-0.0780540000&#34;, &#34;-0.6242900000&#34;, &#34;0.2703700000&#34;, &#34;-0.3544900000&#34;, &#34;-0.4743500000&#34;, &#34;0.5511700000&#34;, &#34;0.2268800000&#34;, &#34;0.5110300000&#34;, &#34;-0.5912900000&#34;, &#34;-0.0860950000&#34;, &#34;-0.0155720000&#34;, &#34;0.1994000000&#34;, &#34;-0.2632800000&#34;, &#34;-0.1392200000&#34;, &#34;-0.0088878000&#34;, &#34;0.7540400000&#34;, &#34;-0.4957700000&#34;, &#34;0.2192800000&#34;, &#34;-0.3889200000&#34;, &#34;0.1637100000&#34;, &#34;0.0973420000&#34;, &#34;-0.1469800000&#34;, &#34;0.3972400000&#34;, &#34;-0.2265700000&#34;, &#34;-0.3383700000&#34;, &#34;-0.1341700000&#34;, &#34;-0.1078600000&#34;, &#34;-0.1713200000&#34;, &#34;0.2618700000&#34;, &#34;0.2394700000&#34;, &#34;0.1195900000&#34;, &#34;0.3077000000&#34;, &#34;-0.0875170000&#34;, &#34;-0.3220600000&#34;, &#34;0.2539900000&#34;, &#34;0.3387200000&#34;, &#34;0.1478600000&#34;, &#34;0.2100300000&#34;, &#34;-0.0782010000&#34;, &#34;0.1231700000&#34;, &#34;-0.1766600000&#34;, &#34;-0.0825180000&#34;, &#34;-0.1440600000&#34;, &#34;0.0033585000&#34;, &#34;-0.1562800000&#34;, &#34;0.6561600000&#34;, &#34;-0.0779720000&#34;, &#34;-0.4151900000&#34;, &#34;0.3605700000&#34;, &#34;-0.0880550000&#34;, &#34;-0.0490930000&#34;, &#34;0.0161190000&#34;, &#34;-0.3492200000&#34;, &#34;-0.2678300000&#34;, &#34;0.1366100000&#34;, &#34;0.1236400000&#34;, &#34;-0.0977190000&#34;, &#34;0.0004395400&#34;, &#34;0.6962700000&#34;, &#34;-0.3196800000&#34;, &#34;0.2334100000&#34;, &#34;0.1828600000&#34;, &#34;0.6553300000&#34;, &#34;0.3765900000&#34;, &#34;0.0914660000&#34;, &#34;0.1528000000&#34;, &#34;0.4496700000&#34;, &#34;-0.0467210000&#34;, &#34;0.0271550000&#34;, &#34;-0.0621830000&#34;, &#34;0.0171210000&#34;, &#34;-0.1775300000&#34;, &#34;-0.4827000000&#34;, &#34;0.1631200000&#34;, &#34;-0.2930700000&#34;, &#34;-0.7393300000&#34;, &#34;-0.0642870000&#34;, &#34;-0.2645100000&#34;, &#34;0.4221100000&#34;, &#34;-0.3683600000&#34;, &#34;0.0013729000&#34;, &#34;0.0788040000&#34;, &#34;0.1658700000&#34;, &#34;0.1868300000&#34;, &#34;-0.1539700000&#34;, &#34;0.2405700000&#34;, &#34;-0.0749970000&#34;, &#34;0.0708060000&#34;, &#34;0.2169000000&#34;, &#34;-0.1030300000&#34;, &#34;0.0431140000&#34;, &#34;0.1311800000&#34;, &#34;-0.0639800000&#34;, &#34;-0.0705880000&#34;, &#34;0.1198600000&#34;, &#34;0.2962200000&#34;, &#34;-0.2221100000&#34;, &#34;0.3317500000&#34;, &#34;0.2680100000&#34;, &#34;0.0035323000&#34;, &#34;-0.1022900000&#34;, &#34;-0.1959800000&#34;, &#34;0.0703780000&#34;, &#34;0.0671080000&#34;, &#34;-0.3266900000&#34;, &#34;0.3488200000&#34;, &#34;0.6139600000&#34;, &#34;0.1418200000&#34;, &#34;-0.1403700000&#34;, &#34;-0.0634710000&#34;, &#34;-0.1017400000&#34;, &#34;-0.5554100000&#34;, &#34;0.0132580000&#34;, &#34;0.1860700000&#34;, &#34;0.1684200000&#34;, &#34;0.4018300000&#34;, &#34;0.2441500000&#34;, &#34;-0.0244280000&#34;, &#34;-0.2644000000&#34;, &#34;-0.0449790000&#34;, &#34;-0.0283060000&#34;, &#34;0.0975810000&#34;, &#34;-0.3063500000&#34;, &#34;0.1088500000&#34;, &#34;0.1134500000&#34;, &#34;0.6479700000&#34;, &#34;-0.3710300000&#34;, &#34;0.2057600000&#34;, &#34;-0.0468020000&#34;, &#34;-0.0519850000&#34;, &#34;0.5226500000&#34;, &#34;-0.3188600000&#34;, &#34;0.1780000000&#34;, &#34;-0.0346180000&#34;, &#34;-0.0927760000&#34;, &#34;0.1026700000&#34;, &#34;-0.1340200000&#34;, &#34;-0.0918360000&#34;, &#34;-0.4753000000&#34;, &#34;-0.2600600000&#34;, &#34;-0.0466660000&#34;, &#34;-0.0845210000&#34;, &#34;0.2354100000&#34;, &#34;-0.1613200000&#34;, &#34;0.2594500000&#34;, &#34;0.0589440000&#34;, &#34;0.0647540000&#34;, &#34;0.4094900000&#34;, &#34;-0.4049600000&#34;, &#34;0.0634170000&#34;, &#34;0.4876100000&#34;, &#34;0.0229780000&#34;, &#34;-0.1019100000&#34;, &#34;-0.0814310000&#34;, &#34;0.2847900000&#34;, &#34;0.2806300000&#34;, &#34;-0.1785800000&#34;, &#34;0.1011700000&#34;, &#34;0.2200400000&#34;, &#34;0.3961900000&#34;, &#34;-0.1020500000&#34;, &#34;0.0762120000&#34;, &#34;0.2872800000&#34;, &#34;-0.3623900000&#34;, &#34;-0.3962400000&#34;, &#34;0.1975200000&#34;, &#34;-0.0295920000&#34;, &#34;-0.2442900000&#34;, &#34;-0.3738800000&#34;, &#34;-0.0469790000&#34;, &#34;0.0491700000&#34;, &#34;-0.2483500000&#34;, &#34;0.2019400000&#34;, &#34;-0.3030500000&#34;, &#34;-0.0583790000&#34;, &#34;-0.2548900000&#34;, &#34;0.2768700000&#34;, &#34;-0.0083026000&#34;, &#34;-0.4150300000&#34;, &#34;0.1373800000&#34;, &#34;-0.3285000000&#34;, &#34;0.4835700000&#34;, &#34;0.1823800000&#34;, &#34;-0.2945300000&#34;, &#34;-0.4003500000&#34;, &#34;-0.1138200000&#34;, &#34;0.0240130000&#34;, &#34;-0.0401920000&#34;, &#34;0.2646200000&#34;, &#34;0.0060517000&#34;, &#34;0.2194500000&#34;, &#34;-0.3565600000&#34;, &#34;-0.3231100000&#34;, &#34;-0.0579250000&#34;, &#34;-0.1299200000&#34;, &#34;0.3791000000&#34;, &#34;0.4819200000&#34;, &#34;-0.0729980000&#34;, &#34;-0.0895620000&#34;, &#34;-0.4844800000&#34;, &#34;-0.0855470000&#34;, &#34;0.1216500000&#34;, &#34;0.0496070000&#34;, &#34;-0.1130200000&#34;, &#34;0.4998800000&#34;, &#34;-0.2149200000&#34;, &#34;0.1500100000&#34;, &#34;-0.0638330000&#34;, &#34;-0.4739700000&#34;, &#34;-0.1504800000&#34;, &#34;0.2040600000&#34;, &#34;-0.0246430000&#34;, &#34;0.0096142000&#34;, &#34;-0.1903900000&#34;, &#34;0.0763020000&#34;, &#34;0.1814500000&#34;, &#34;0.0858460000&#34;, &#34;-0.0666130000&#34;, &#34;-0.3796300000&#34;, &#34;0.0012397000&#34;, &#34;0.1106800000&#34;, &#34;-0.0316870000&#34;, &#34;-0.4972900000&#34;, &#34;-0.1197200000&#34;, &#34;-0.1223500000&#34;, &#34;-0.1565000000&#34;, &#34;0.6281700000&#34;, &#34;0.0407220000&#34;, &#34;-0.0801920000&#34;, &#34;-0.1377500000&#34;, &#34;-0.3523700000&#34;, &#34;0.1699700000&#34;, &#34;0.0486930000&#34;, &#34;-0.3552400000&#34;, &#34;-0.2106800000&#34;, &#34;0.1641000000&#34;, &#34;0.1320200000&#34;, &#34;0.2065300000&#34;, &#34;-0.1284700000&#34;, &#34;-0.1857700000&#34;, &#34;-0.0013799000&#34;, &#34;-0.0348540000&#34;, &#34;0.1900800000&#34;, &#34;-0.3504800000&#34;, &#34;0.4373600000&#34;, &#34;0.1438400000&#34;, &#34;0.0583970000&#34;, &#34;0.0675360000&#34;, &#34;-0.0274320000&#34;, &#34;0.0565660000&#34;, &#34;-0.5415500000&#34;, &#34;0.2420000000&#34;, &#34;0.0780820000&#34;, &#34;-0.0284790000&#34;, &#34;0.0015143000&#34;, &#34;0.6451000000&#34;, &#34;0.1003100000&#34;, &#34;0.0325710000&#34;, &#34;0.0715540000&#34;, &#34;-0.0721530000&#34;, &#34;-0.0347940000&#34;, &#34;0.4477600000&#34;, &#34;0.1405600000&#34;, &#34;0.1827600000&#34;, &#34;-0.1663900000&#34;, &#34;-0.0824300000&#34;, &#34;-0.1650300000&#34;, &#34;0.0987490000&#34;, &#34;0.0973930000&#34;, &#34;-0.0779960000&#34;, &#34;-0.0045350000&#34;, &#34;0.2438100000&#34;, &#34;-0.5503900000&#34;, &#34;-0.3891300000&#34;, &#34;-0.4439800000&#34;, &#34;-0.0767440000&#34;, &#34;0.3202500000&#34;, &#34;0.1939800000&#34;, &#34;0.2653600000&#34;, &#34;0.1206500000&#34;, &#34;-0.1673100000&#34;, &#34;0.0001194300&#34;, &#34;-0.1581400000&#34;, &#34;-0.0350040000&#34;, &#34;0.5433600000&#34;, &#34;0.1530000000&#34;], [&#34;-0.1736500000&#34;, &#34;-0.2836300000&#34;, &#34;-0.1809400000&#34;, &#34;0.4295200000&#34;, &#34;-0.4730500000&#34;, &#34;-0.1101200000&#34;, &#34;-0.3302000000&#34;, &#34;-0.2372000000&#34;, &#34;-0.0368550000&#34;, &#34;0.1094800000&#34;, &#34;-0.2674100000&#34;, &#34;0.1127600000&#34;, &#34;0.0421600000&#34;, &#34;-0.0596830000&#34;, &#34;0.0221990000&#34;, &#34;0.0161790000&#34;, &#34;-0.1255500000&#34;, &#34;-0.1879400000&#34;, &#34;0.3825400000&#34;, &#34;0.2012000000&#34;, &#34;-0.1902300000&#34;, &#34;0.0398530000&#34;, &#34;-0.5339500000&#34;, &#34;-0.3074600000&#34;, &#34;-0.0738130000&#34;, &#34;-0.3190500000&#34;, &#34;0.1111500000&#34;, &#34;-0.0914910000&#34;, &#34;-0.0852410000&#34;, &#34;0.0711860000&#34;, &#34;0.3237800000&#34;, &#34;0.2832100000&#34;, &#34;-0.1494500000&#34;, &#34;0.2852300000&#34;, &#34;0.0254060000&#34;, &#34;-0.3089800000&#34;, &#34;0.0609480000&#34;, &#34;0.0112770000&#34;, &#34;0.1611600000&#34;, &#34;0.1690200000&#34;, &#34;-0.1827800000&#34;, &#34;0.5029000000&#34;, &#34;-0.0581000000&#34;, &#34;0.2478800000&#34;, &#34;-0.1699600000&#34;, &#34;0.0835340000&#34;, &#34;0.2265800000&#34;, &#34;-0.2294700000&#34;, &#34;-0.0323500000&#34;, &#34;0.1080200000&#34;, &#34;-0.1090300000&#34;, &#34;0.0604570000&#34;, &#34;0.2522200000&#34;, &#34;0.2881300000&#34;, &#34;-0.2414500000&#34;, &#34;0.2326000000&#34;, &#34;0.0253100000&#34;, &#34;0.1817300000&#34;, &#34;-0.2879700000&#34;, &#34;0.1155900000&#34;, &#34;-0.2285900000&#34;, &#34;-0.0734400000&#34;, &#34;0.1111300000&#34;, &#34;0.0768120000&#34;, &#34;0.0783700000&#34;, &#34;0.6290300000&#34;, &#34;0.0804510000&#34;, &#34;0.2050600000&#34;, &#34;-0.0385150000&#34;, &#34;0.1185100000&#34;, &#34;0.1758900000&#34;, &#34;-0.0324720000&#34;, &#34;-0.2694300000&#34;, &#34;-0.0339290000&#34;, &#34;0.1621400000&#34;, &#34;0.3858600000&#34;, &#34;0.2558200000&#34;, &#34;0.4283000000&#34;, &#34;-0.2526000000&#34;, &#34;0.1252000000&#34;, &#34;-0.0549830000&#34;, &#34;0.0087438000&#34;, &#34;-0.2013700000&#34;, &#34;0.0608780000&#34;, &#34;-0.2458000000&#34;, &#34;0.0438840000&#34;, &#34;-0.2682600000&#34;, &#34;0.2361200000&#34;, &#34;-0.1442700000&#34;, &#34;-0.0306300000&#34;, &#34;-0.2719500000&#34;, &#34;-0.2093100000&#34;, &#34;-0.0815660000&#34;, &#34;-0.3089000000&#34;, &#34;0.0916080000&#34;, &#34;-0.3417200000&#34;, &#34;-0.1684600000&#34;, &#34;-0.1204900000&#34;, &#34;-0.1106400000&#34;, &#34;-0.2890400000&#34;, &#34;-0.0094841000&#34;, &#34;-0.0700150000&#34;, &#34;-0.1462600000&#34;, &#34;-0.1977800000&#34;, &#34;-0.4332300000&#34;, &#34;-0.3091900000&#34;, &#34;-0.0579740000&#34;, &#34;0.3495700000&#34;, &#34;-0.0845180000&#34;, &#34;0.1615400000&#34;, &#34;-0.2518100000&#34;, &#34;0.1614000000&#34;, &#34;-0.1739800000&#34;, &#34;-0.4145300000&#34;, &#34;0.0362110000&#34;, &#34;0.0645290000&#34;, &#34;0.5992300000&#34;, &#34;0.1707800000&#34;, &#34;-0.2215700000&#34;, &#34;0.0572800000&#34;, &#34;0.1832900000&#34;, &#34;-0.1033200000&#34;, &#34;-0.1942700000&#34;, &#34;0.0140610000&#34;, &#34;-0.0254520000&#34;, &#34;-0.1506100000&#34;, &#34;-0.3636800000&#34;, &#34;-0.0394820000&#34;, &#34;0.1226600000&#34;, &#34;-0.0769340000&#34;, &#34;-0.2435900000&#34;, &#34;0.0206100000&#34;, &#34;-0.1323000000&#34;, &#34;-0.3813600000&#34;, &#34;-0.0509760000&#34;, &#34;0.1678400000&#34;, &#34;0.0433760000&#34;, &#34;-0.0220620000&#34;, &#34;0.0261470000&#34;, &#34;-0.0752060000&#34;, &#34;0.1347700000&#34;, &#34;0.0381730000&#34;, &#34;0.0765570000&#34;, &#34;0.2803000000&#34;, &#34;-0.0060694000&#34;, &#34;-0.0622820000&#34;, &#34;-0.0593170000&#34;, &#34;-0.3559400000&#34;, &#34;0.0774780000&#34;, &#34;0.1479700000&#34;, &#34;0.1982700000&#34;, &#34;-0.0788700000&#34;, &#34;-0.4599400000&#34;, &#34;0.2981300000&#34;, &#34;-0.4199800000&#34;, &#34;-0.2579400000&#34;, &#34;-0.1823600000&#34;, &#34;0.0027135000&#34;, &#34;0.0696170000&#34;, &#34;0.0438040000&#34;, &#34;-0.0452570000&#34;, &#34;-0.3199400000&#34;, &#34;-0.0558440000&#34;, &#34;0.4669400000&#34;, &#34;0.2625200000&#34;, &#34;-0.0785060000&#34;, &#34;-0.0500560000&#34;, &#34;-0.0792630000&#34;, &#34;0.1339100000&#34;, &#34;-0.1054600000&#34;, &#34;0.0004455400&#34;, &#34;0.0617780000&#34;, &#34;-0.4249100000&#34;, &#34;-0.2486400000&#34;, &#34;0.4032100000&#34;, &#34;0.6722000000&#34;, &#34;-0.1047300000&#34;, &#34;0.1965700000&#34;, &#34;0.0338270000&#34;, &#34;0.1000800000&#34;, &#34;0.4372600000&#34;, &#34;-0.1265300000&#34;, &#34;0.4267600000&#34;, &#34;0.1379500000&#34;, &#34;-0.0211350000&#34;, &#34;0.2574800000&#34;, &#34;-0.2618700000&#34;, &#34;0.0452240000&#34;, &#34;0.0737280000&#34;, &#34;-0.1873500000&#34;, &#34;0.0567800000&#34;, &#34;-0.7268700000&#34;, &#34;-0.0364160000&#34;, &#34;0.3168400000&#34;, &#34;0.0526610000&#34;, &#34;-0.0535450000&#34;, &#34;-0.0554020000&#34;, &#34;0.0129660000&#34;, &#34;-0.3280700000&#34;, &#34;-0.0957510000&#34;, &#34;0.4189200000&#34;, &#34;-0.2883300000&#34;, &#34;0.0881070000&#34;, &#34;0.1209300000&#34;, &#34;0.0346670000&#34;, &#34;-0.2230400000&#34;, &#34;-0.0668240000&#34;, &#34;-0.5780500000&#34;, &#34;-0.0530530000&#34;, &#34;0.2087400000&#34;, &#34;0.4597700000&#34;, &#34;0.3749600000&#34;, &#34;-0.2387100000&#34;, &#34;-0.2213900000&#34;, &#34;0.0789210000&#34;, &#34;-0.1349400000&#34;, &#34;-0.2596700000&#34;, &#34;-0.1978100000&#34;, &#34;0.0547500000&#34;, &#34;0.3032200000&#34;, &#34;0.1851800000&#34;, &#34;0.0723950000&#34;, &#34;0.0476010000&#34;, &#34;0.1572600000&#34;, &#34;-0.2084900000&#34;, &#34;-0.0223590000&#34;, &#34;0.3760000000&#34;, &#34;0.2397500000&#34;, &#34;0.2781600000&#34;, &#34;-0.1934700000&#34;, &#34;0.7435700000&#34;, &#34;-0.2691700000&#34;, &#34;-0.1246200000&#34;, &#34;-0.5516800000&#34;, &#34;-0.0467160000&#34;, &#34;0.2924000000&#34;, &#34;0.2381000000&#34;, &#34;0.0339250000&#34;, &#34;0.1799400000&#34;, &#34;-0.2307800000&#34;, &#34;0.2560900000&#34;, &#34;0.0624750000&#34;, &#34;0.2686900000&#34;, &#34;0.3941800000&#34;, &#34;0.2299500000&#34;, &#34;0.0301630000&#34;, &#34;0.4480900000&#34;, &#34;0.0212780000&#34;, &#34;-0.1172500000&#34;, &#34;0.5232700000&#34;, &#34;0.0436650000&#34;, &#34;0.1992800000&#34;, &#34;-0.0273640000&#34;, &#34;0.0599610000&#34;, &#34;0.0189820000&#34;, &#34;-0.2465900000&#34;, &#34;-0.4179700000&#34;, &#34;-0.3634300000&#34;, &#34;0.2551900000&#34;, &#34;-0.0426970000&#34;, &#34;0.0747530000&#34;, &#34;0.0606080000&#34;, &#34;0.0752030000&#34;, &#34;-0.2680200000&#34;, &#34;-0.1723500000&#34;, &#34;-0.0697920000&#34;, &#34;-0.3474000000&#34;, &#34;-0.1707600000&#34;, &#34;0.3632000000&#34;, &#34;0.0960900000&#34;, &#34;-0.1171900000&#34;, &#34;-0.1351400000&#34;, &#34;-0.2400300000&#34;, &#34;0.0425490000&#34;, &#34;-0.0081243000&#34;, &#34;-0.1372900000&#34;, &#34;0.1335200000&#34;, &#34;0.2793400000&#34;, &#34;0.0591050000&#34;, &#34;0.0738470000&#34;, &#34;0.0990680000&#34;, &#34;-0.0383910000&#34;, &#34;0.0817850000&#34;, &#34;-0.2255000000&#34;, &#34;0.0856740000&#34;, &#34;0.0845380000&#34;, &#34;0.1462600000&#34;, &#34;0.2489100000&#34;, &#34;-0.1412400000&#34;, &#34;0.0157220000&#34;, &#34;0.2033300000&#34;, &#34;-0.0020506000&#34;, &#34;0.0713030000&#34;, &#34;0.2393500000&#34;, &#34;-0.2820000000&#34;, &#34;0.5960100000&#34;, &#34;0.1398000000&#34;, &#34;0.6361700000&#34;, &#34;0.0428380000&#34;, &#34;0.1769800000&#34;], [&#34;-0.0940560000&#34;, &#34;-0.2341300000&#34;, &#34;-0.7815000000&#34;, &#34;0.3331400000&#34;, &#34;-0.9646400000&#34;, &#34;-0.4424500000&#34;, &#34;0.2937900000&#34;, &#34;-0.4881200000&#34;, &#34;-0.2112100000&#34;, &#34;-0.1441400000&#34;, &#34;0.1277800000&#34;, &#34;0.2240100000&#34;, &#34;-0.2451700000&#34;, &#34;0.0298300000&#34;, &#34;0.1723700000&#34;, &#34;0.0541280000&#34;, &#34;0.1732100000&#34;, &#34;0.0191690000&#34;, &#34;-0.2644800000&#34;, &#34;0.3111200000&#34;, &#34;0.3086200000&#34;, &#34;0.1728800000&#34;, &#34;-0.4366200000&#34;, &#34;-0.1477400000&#34;, &#34;-0.0079717000&#34;, &#34;-0.0397720000&#34;, &#34;0.1221300000&#34;, &#34;0.0228840000&#34;, &#34;0.1682100000&#34;, &#34;0.4504400000&#34;, &#34;0.0662230000&#34;, &#34;0.1486900000&#34;, &#34;-0.1513700000&#34;, &#34;0.7382900000&#34;, &#34;0.3694800000&#34;, &#34;0.2051600000&#34;, &#34;0.0164620000&#34;, &#34;0.3338300000&#34;, &#34;0.0774790000&#34;, &#34;0.0245320000&#34;, &#34;0.5119500000&#34;, &#34;-0.0733730000&#34;, &#34;-0.2505200000&#34;, &#34;0.4430700000&#34;, &#34;0.5690100000&#34;, &#34;-0.0203540000&#34;, &#34;0.3633600000&#34;, &#34;0.0103310000&#34;, &#34;0.1395300000&#34;, &#34;0.2817500000&#34;, &#34;0.0104470000&#34;, &#34;-0.2372900000&#34;, &#34;-0.2085400000&#34;, &#34;-0.7273000000&#34;, &#34;0.1013200000&#34;, &#34;-0.3156300000&#34;, &#34;0.0874210000&#34;, &#34;0.0403650000&#34;, &#34;0.0070915000&#34;, &#34;0.0127760000&#34;, &#34;-0.4727200000&#34;, &#34;-0.0157890000&#34;, &#34;0.6688400000&#34;, &#34;0.0641250000&#34;, &#34;-0.2177100000&#34;, &#34;-0.1877100000&#34;, &#34;-0.2004400000&#34;, &#34;0.4396900000&#34;, &#34;-0.0370770000&#34;, &#34;-0.0892220000&#34;, &#34;-0.0224830000&#34;, &#34;-0.1147900000&#34;, &#34;0.4624200000&#34;, &#34;0.2170400000&#34;, &#34;0.0236440000&#34;, &#34;0.2547100000&#34;, &#34;0.5423300000&#34;, &#34;0.4597400000&#34;, &#34;-0.3465000000&#34;, &#34;0.2184400000&#34;, &#34;0.3804700000&#34;, &#34;-0.6449800000&#34;, &#34;-0.2697200000&#34;, &#34;-0.2471100000&#34;, &#34;-0.6309100000&#34;, &#34;-0.4259000000&#34;, &#34;0.2281100000&#34;, &#34;0.1789400000&#34;, &#34;-0.3821600000&#34;, &#34;-0.8804300000&#34;, &#34;0.2474400000&#34;, &#34;0.1223900000&#34;, &#34;0.3382700000&#34;, &#34;-0.0387880000&#34;, &#34;-0.0110770000&#34;, &#34;-0.1667700000&#34;, &#34;0.7326900000&#34;, &#34;0.3821200000&#34;, &#34;0.0092299000&#34;, &#34;0.6061500000&#34;, &#34;0.0900580000&#34;, &#34;0.1687900000&#34;, &#34;-0.0877870000&#34;, &#34;-0.1740800000&#34;, &#34;0.8485900000&#34;, &#34;-0.0940780000&#34;, &#34;-0.2738000000&#34;, &#34;0.3198900000&#34;, &#34;0.2378500000&#34;, &#34;-0.1227900000&#34;, &#34;-0.1228400000&#34;, &#34;0.0573790000&#34;, &#34;-0.4123100000&#34;, &#34;-0.1291900000&#34;, &#34;-0.2413700000&#34;, &#34;-0.2802200000&#34;, &#34;0.4231900000&#34;, &#34;-0.0138740000&#34;, &#34;-0.2164000000&#34;, &#34;0.1429200000&#34;, &#34;0.0470380000&#34;, &#34;-0.5769100000&#34;, &#34;-0.5420200000&#34;, &#34;0.1491800000&#34;, &#34;0.0592060000&#34;, &#34;-0.1560700000&#34;, &#34;-0.5935700000&#34;, &#34;0.2544100000&#34;, &#34;-0.1816900000&#34;, &#34;0.0987310000&#34;, &#34;0.0475060000&#34;, &#34;0.2991500000&#34;, &#34;-0.2161000000&#34;, &#34;-0.2621300000&#34;, &#34;0.4210100000&#34;, &#34;0.6068000000&#34;, &#34;-0.5335800000&#34;, &#34;0.4012100000&#34;, &#34;-0.3907000000&#34;, &#34;0.3023400000&#34;, &#34;0.1611000000&#34;, &#34;0.4221700000&#34;, &#34;-0.3133000000&#34;, &#34;-0.3994300000&#34;, &#34;-0.2859400000&#34;, &#34;0.0769700000&#34;, &#34;0.2766600000&#34;, &#34;0.3325000000&#34;, &#34;0.1954500000&#34;, &#34;-0.1239000000&#34;, &#34;0.4425100000&#34;, &#34;-0.3573100000&#34;, &#34;0.0787960000&#34;, &#34;-0.5777100000&#34;, &#34;0.0755430000&#34;, &#34;0.3752600000&#34;, &#34;0.0507340000&#34;, &#34;0.5712500000&#34;, &#34;-0.1927100000&#34;, &#34;-0.1453600000&#34;, &#34;0.3480300000&#34;, &#34;0.1611200000&#34;, &#34;0.3318900000&#34;, &#34;-0.0610160000&#34;, &#34;0.2535200000&#34;, &#34;0.1312900000&#34;, &#34;-0.3072300000&#34;, &#34;0.0801230000&#34;, &#34;-0.0359160000&#34;, &#34;0.4872900000&#34;, &#34;-0.1650900000&#34;, &#34;-0.5552100000&#34;, &#34;-0.2179900000&#34;, &#34;0.4273400000&#34;, &#34;0.3668400000&#34;, &#34;-0.1158200000&#34;, &#34;-0.2852000000&#34;, &#34;-0.3824700000&#34;, &#34;-0.2469800000&#34;, &#34;-0.2733100000&#34;, &#34;0.0711290000&#34;, &#34;0.0538940000&#34;, &#34;-0.0862870000&#34;, &#34;-0.1701200000&#34;, &#34;-0.0214950000&#34;, &#34;0.8117500000&#34;, &#34;-0.0426910000&#34;, &#34;-0.1251700000&#34;, &#34;0.3880400000&#34;, &#34;-0.2023700000&#34;, &#34;-0.3604800000&#34;, &#34;-0.2014100000&#34;, &#34;0.2776800000&#34;, &#34;0.1086400000&#34;, &#34;-0.2867400000&#34;, &#34;-0.1631100000&#34;, &#34;0.1961100000&#34;, &#34;0.1760700000&#34;, &#34;0.2110300000&#34;, &#34;-0.4506400000&#34;, &#34;-0.2389100000&#34;, &#34;-0.4081100000&#34;, &#34;-0.0780110000&#34;, &#34;-0.1285200000&#34;, &#34;0.0116200000&#34;, &#34;-0.4668500000&#34;, &#34;-0.1622300000&#34;, &#34;-0.0252250000&#34;, &#34;0.0742630000&#34;, &#34;0.1955900000&#34;, &#34;0.4233100000&#34;, &#34;0.0870680000&#34;, &#34;0.3864300000&#34;, &#34;0.5383200000&#34;, &#34;-0.3342600000&#34;, &#34;-0.1555900000&#34;, &#34;-0.2311000000&#34;, &#34;-0.9875800000&#34;, &#34;0.0156320000&#34;, &#34;-0.0275420000&#34;, &#34;-0.2044400000&#34;, &#34;-0.0552260000&#34;, &#34;0.2387600000&#34;, &#34;0.3003900000&#34;, &#34;0.2132100000&#34;, &#34;0.1191000000&#34;, &#34;-0.2594100000&#34;, &#34;-0.5998000000&#34;, &#34;-0.1533500000&#34;, &#34;-0.2843900000&#34;, &#34;-0.2871500000&#34;, &#34;0.2011700000&#34;, &#34;-0.6836100000&#34;, &#34;-0.2381600000&#34;, &#34;0.1618000000&#34;, &#34;0.2262800000&#34;, &#34;-0.1845800000&#34;, &#34;-0.1872700000&#34;, &#34;0.1174000000&#34;, &#34;0.3883500000&#34;, &#34;0.4897900000&#34;, &#34;-0.0361370000&#34;, &#34;0.2117100000&#34;, &#34;-0.3522000000&#34;, &#34;-0.4010800000&#34;, &#34;0.4712900000&#34;, &#34;-0.1911700000&#34;, &#34;-0.5298600000&#34;, &#34;-0.2798500000&#34;, &#34;-0.4583000000&#34;, &#34;0.1843500000&#34;, &#34;-0.0495520000&#34;, &#34;-0.3404600000&#34;, &#34;0.2670000000&#34;, &#34;-0.3084400000&#34;, &#34;-0.0552860000&#34;, &#34;0.1440900000&#34;, &#34;-0.3509400000&#34;, &#34;0.3253500000&#34;, &#34;0.0257070000&#34;, &#34;0.2786900000&#34;, &#34;0.4512400000&#34;, &#34;-0.3697500000&#34;, &#34;-0.1993600000&#34;, &#34;-0.4986700000&#34;, &#34;-0.1919100000&#34;, &#34;-0.2616000000&#34;, &#34;0.0510100000&#34;, &#34;-0.1762400000&#34;, &#34;-0.2776300000&#34;, &#34;0.0218740000&#34;, &#34;-0.2827000000&#34;, &#34;-0.0130810000&#34;, &#34;-0.0680520000&#34;, &#34;-0.1026300000&#34;, &#34;-0.3704300000&#34;, &#34;-0.2594500000&#34;, &#34;-0.2856000000&#34;, &#34;-0.0783220000&#34;, &#34;-0.0265240000&#34;, &#34;0.0177150000&#34;, &#34;0.1381300000&#34;, &#34;-0.7896800000&#34;, &#34;-0.0922000000&#34;, &#34;0.8370100000&#34;, &#34;-0.0994560000&#34;, &#34;0.3206500000&#34;, &#34;-0.1031800000&#34;, &#34;-0.3371900000&#34;, &#34;-0.0032685000&#34;, &#34;-0.8159700000&#34;, &#34;0.4399900000&#34;, &#34;0.0478600000&#34;, &#34;-0.1486100000&#34;, &#34;-0.4751400000&#34;, &#34;-0.1740700000&#34;, &#34;0.4617400000&#34;, &#34;0.6174300000&#34;, &#34;0.2242100000&#34;, &#34;-0.0501340000&#34;], [&#34;-0.0642060000&#34;, &#34;0.0917140000&#34;, &#34;0.1194200000&#34;, &#34;0.4186000000&#34;, &#34;0.1746500000&#34;, &#34;0.1194100000&#34;, &#34;0.3185900000&#34;, &#34;-0.1638000000&#34;, &#34;0.2056500000&#34;, &#34;0.0880940000&#34;, &#34;-0.0462130000&#34;, &#34;0.1533100000&#34;, &#34;0.1577500000&#34;, &#34;-0.0965040000&#34;, &#34;0.0227270000&#34;, &#34;-0.1413800000&#34;, &#34;0.0098457000&#34;, &#34;-0.0265880000&#34;, &#34;0.0211830000&#34;, &#34;0.2297200000&#34;, &#34;0.0425290000&#34;, &#34;0.0272430000&#34;, &#34;0.0231370000&#34;, &#34;-0.0798720000&#34;, &#34;0.0495000000&#34;, &#34;-0.0611290000&#34;, &#34;0.1054600000&#34;, &#34;0.0849050000&#34;, &#34;-0.1019000000&#34;, &#34;0.0254450000&#34;, &#34;-0.2259300000&#34;, &#34;-0.0094519000&#34;, &#34;-0.1131600000&#34;, &#34;-0.0454760000&#34;, &#34;-0.0991100000&#34;, &#34;0.0020657000&#34;, &#34;-0.2440000000&#34;, &#34;-0.2076200000&#34;, &#34;0.2789300000&#34;, &#34;-0.0306010000&#34;, &#34;0.2543800000&#34;, &#34;-0.0434000000&#34;, &#34;0.1410000000&#34;, &#34;0.0411700000&#34;, &#34;-0.0268320000&#34;, &#34;-0.0757660000&#34;, &#34;0.0998660000&#34;, &#34;-0.1085700000&#34;, &#34;0.0527440000&#34;, &#34;-0.0064439000&#34;, &#34;0.0146670000&#34;, &#34;0.0240910000&#34;, &#34;-0.1482300000&#34;, &#34;-0.0751400000&#34;, &#34;-0.1763900000&#34;, &#34;0.0059049000&#34;, &#34;0.0069194000&#34;, &#34;-0.0533160000&#34;, &#34;-0.1120600000&#34;, &#34;-0.0605830000&#34;, &#34;-0.0128220000&#34;, &#34;-0.3179900000&#34;, &#34;0.0878980000&#34;, &#34;-0.0624170000&#34;, &#34;0.0481660000&#34;, &#34;-0.0059139000&#34;, &#34;-0.0180730000&#34;, &#34;0.2366100000&#34;, &#34;-0.1531000000&#34;, &#34;0.0032921000&#34;, &#34;-0.1283700000&#34;, &#34;0.0754290000&#34;, &#34;-0.1972500000&#34;, &#34;-0.2471200000&#34;, &#34;-0.0508580000&#34;, &#34;0.1005800000&#34;, &#34;0.1284100000&#34;, &#34;0.2528200000&#34;, &#34;0.0972760000&#34;, &#34;0.0105210000&#34;, &#34;0.1836100000&#34;, &#34;-0.1974900000&#34;, &#34;-0.0404440000&#34;, &#34;-0.1118500000&#34;, &#34;-0.1269800000&#34;, &#34;-0.1015200000&#34;, &#34;0.0270530000&#34;, &#34;0.0955040000&#34;, &#34;0.1474600000&#34;, &#34;-0.1945200000&#34;, &#34;0.0551560000&#34;, &#34;-0.1500400000&#34;, &#34;-0.0396780000&#34;, &#34;-0.0397960000&#34;, &#34;0.3459200000&#34;, &#34;0.2937900000&#34;, &#34;0.2451900000&#34;, &#34;-0.0993540000&#34;, &#34;0.0608150000&#34;, &#34;-0.2600300000&#34;, &#34;-0.0617430000&#34;, &#34;-0.0552700000&#34;, &#34;0.1101400000&#34;, &#34;0.1176600000&#34;, &#34;-0.2154600000&#34;, &#34;-0.1546700000&#34;, &#34;-0.0919750000&#34;, &#34;0.1169700000&#34;, &#34;0.0128670000&#34;, &#34;0.0462720000&#34;, &#34;0.0333600000&#34;, &#34;0.0377810000&#34;, &#34;0.0198910000&#34;, &#34;-0.0641890000&#34;, &#34;0.0792300000&#34;, &#34;-0.1214700000&#34;, &#34;-0.0219640000&#34;, &#34;0.0589270000&#34;, &#34;0.0391170000&#34;, &#34;0.2828900000&#34;, &#34;0.2215200000&#34;, &#34;-0.0972440000&#34;, &#34;-0.2508400000&#34;, &#34;0.3571700000&#34;, &#34;0.1410300000&#34;, &#34;-0.0916740000&#34;, &#34;0.1179000000&#34;, &#34;-0.0172910000&#34;, &#34;0.0098494000&#34;, &#34;0.2756000000&#34;, &#34;0.1550400000&#34;, &#34;0.0081984000&#34;, &#34;-0.2442400000&#34;, &#34;0.1335100000&#34;, &#34;-0.0413200000&#34;, &#34;0.0407330000&#34;, &#34;0.1772700000&#34;, &#34;0.0697880000&#34;, &#34;0.1017800000&#34;, &#34;0.1053000000&#34;, &#34;-0.1472700000&#34;, &#34;0.2026300000&#34;, &#34;-0.0593920000&#34;, &#34;-0.0287660000&#34;, &#34;0.0634910000&#34;, &#34;0.1825200000&#34;, &#34;-0.0014041000&#34;, &#34;0.1027400000&#34;, &#34;-0.1648100000&#34;, &#34;-0.0667120000&#34;, &#34;0.1384200000&#34;, &#34;-0.2726500000&#34;, &#34;-0.1963400000&#34;, &#34;-0.1605000000&#34;, &#34;-0.0742050000&#34;, &#34;0.0018183000&#34;, &#34;0.1026000000&#34;, &#34;-0.0435470000&#34;, &#34;-0.0072141000&#34;, &#34;0.0553060000&#34;, &#34;-0.0146920000&#34;, &#34;0.2226900000&#34;, &#34;-0.0125140000&#34;, &#34;0.1923300000&#34;, &#34;0.0218660000&#34;, &#34;-0.1175500000&#34;, &#34;0.0409160000&#34;, &#34;-0.1911000000&#34;, &#34;0.0944860000&#34;, &#34;-0.1134700000&#34;, &#34;-0.0054213000&#34;, &#34;-0.1179000000&#34;, &#34;-0.1594700000&#34;, &#34;0.1532900000&#34;, &#34;-0.1529900000&#34;, &#34;0.0930030000&#34;, &#34;0.0057173000&#34;, &#34;0.2451700000&#34;, &#34;-0.2296100000&#34;, &#34;-0.1095900000&#34;, &#34;0.1722900000&#34;, &#34;-0.1835800000&#34;, &#34;-0.0126960000&#34;, &#34;0.0583180000&#34;, &#34;0.0402570000&#34;, &#34;0.3110400000&#34;, &#34;0.1012500000&#34;, &#34;-0.1034000000&#34;, &#34;0.0863980000&#34;, &#34;-0.0512790000&#34;, &#34;0.2368600000&#34;, &#34;-0.1796100000&#34;, &#34;0.2068100000&#34;, &#34;-0.0761070000&#34;, &#34;-0.0010114000&#34;, &#34;0.0556930000&#34;, &#34;-0.1500500000&#34;, &#34;0.1915500000&#34;, &#34;-0.2685200000&#34;, &#34;-0.0636000000&#34;, &#34;0.1467400000&#34;, &#34;-0.0845620000&#34;, &#34;0.1201000000&#34;, &#34;-0.0160690000&#34;, &#34;0.1558900000&#34;, &#34;0.0321520000&#34;, &#34;-0.1993900000&#34;, &#34;-0.1060500000&#34;, &#34;0.2882500000&#34;, &#34;0.2997600000&#34;, &#34;0.0800010000&#34;, &#34;-0.0288720000&#34;, &#34;-0.1506500000&#34;, &#34;-0.1427700000&#34;, &#34;-0.0809550000&#34;, &#34;-0.0731380000&#34;, &#34;-0.1102500000&#34;, &#34;-0.3209600000&#34;, &#34;-0.1666400000&#34;, &#34;-0.0242900000&#34;, &#34;-0.1598900000&#34;, &#34;-0.0932460000&#34;, &#34;-0.1067300000&#34;, &#34;0.2122700000&#34;, &#34;0.0588260000&#34;, &#34;-0.0403710000&#34;, &#34;-0.1516500000&#34;, &#34;0.1209200000&#34;, &#34;0.0257990000&#34;, &#34;0.1389600000&#34;, &#34;0.1410700000&#34;, &#34;-0.0347680000&#34;, &#34;-0.0987820000&#34;, &#34;-0.0370760000&#34;, &#34;-0.1742000000&#34;, &#34;0.1546800000&#34;, &#34;0.2027100000&#34;, &#34;-0.2016000000&#34;, &#34;0.0056756000&#34;, &#34;0.2220900000&#34;, &#34;0.0655690000&#34;, &#34;-0.0482300000&#34;, &#34;-0.0019982000&#34;, &#34;0.2774900000&#34;, &#34;0.0535130000&#34;, &#34;0.1678500000&#34;, &#34;-0.0729150000&#34;, &#34;-0.0250250000&#34;, &#34;-0.0304100000&#34;, &#34;0.1003700000&#34;, &#34;-0.0847070000&#34;, &#34;-0.1525100000&#34;, &#34;-0.0455380000&#34;, &#34;-0.0767320000&#34;, &#34;-0.1807600000&#34;, &#34;0.0195180000&#34;, &#34;-0.2908300000&#34;, &#34;-0.1805300000&#34;, &#34;-0.0532130000&#34;, &#34;0.0342540000&#34;, &#34;0.2854300000&#34;, &#34;0.1992200000&#34;, &#34;0.2406300000&#34;, &#34;-0.0177200000&#34;, &#34;-0.0176050000&#34;, &#34;0.2447400000&#34;, &#34;-0.0109690000&#34;, &#34;0.1430600000&#34;, &#34;0.0639200000&#34;, &#34;0.0740190000&#34;, &#34;-0.1269800000&#34;, &#34;-0.0677130000&#34;, &#34;0.0295590000&#34;, &#34;0.0251710000&#34;, &#34;-0.2451000000&#34;, &#34;-0.0466250000&#34;, &#34;0.1457600000&#34;, &#34;0.1901500000&#34;, &#34;0.2264700000&#34;, &#34;0.1861200000&#34;, &#34;0.0878830000&#34;, &#34;0.0278500000&#34;, &#34;0.2847700000&#34;, &#34;-0.0500630000&#34;, &#34;0.1608700000&#34;, &#34;-0.0434980000&#34;, &#34;0.0756410000&#34;, &#34;0.4027000000&#34;, &#34;-0.0384560000&#34;, &#34;0.1930400000&#34;, &#34;0.0637230000&#34;, &#34;-0.3561900000&#34;, &#34;0.1758700000&#34;, &#34;0.2216500000&#34;, &#34;0.0756050000&#34;, &#34;-0.0550850000&#34;, &#34;-0.0307070000&#34;, &#34;0.0883560000&#34;, &#34;-0.0159830000&#34;, &#34;-0.2573500000&#34;], [&#34;-0.1597500000&#34;, &#34;-0.1194700000&#34;, &#34;0.1206000000&#34;, &#34;-0.0586310000&#34;, &#34;0.0045518000&#34;, &#34;0.1651800000&#34;, &#34;0.0574410000&#34;, &#34;-0.1168400000&#34;, &#34;-0.0418270000&#34;, &#34;0.1201700000&#34;, &#34;0.1386900000&#34;, &#34;-0.1617900000&#34;, &#34;0.0125150000&#34;, &#34;-0.1079400000&#34;, &#34;-0.0967700000&#34;, &#34;-0.1275900000&#34;, &#34;-0.0109600000&#34;, &#34;0.0291510000&#34;, &#34;-0.0457370000&#34;, &#34;0.1919200000&#34;, &#34;-0.0029964000&#34;, &#34;0.1302900000&#34;, &#34;-0.1860300000&#34;, &#34;-0.2492000000&#34;, &#34;-0.0215030000&#34;, &#34;0.0389760000&#34;, &#34;0.0620910000&#34;, &#34;0.1815400000&#34;, &#34;0.0269740000&#34;, &#34;-0.0415060000&#34;, &#34;0.0685610000&#34;, &#34;0.0431210000&#34;, &#34;-0.1334000000&#34;, &#34;0.1992700000&#34;, &#34;-0.0827060000&#34;, &#34;-0.2060000000&#34;, &#34;-0.0110170000&#34;, &#34;-0.0153460000&#34;, &#34;0.0357090000&#34;, &#34;-0.0914670000&#34;, &#34;-0.0154540000&#34;, &#34;-0.1300200000&#34;, &#34;0.0134620000&#34;, &#34;-0.0747070000&#34;, &#34;0.1367200000&#34;, &#34;0.1145900000&#34;, &#34;-0.0004246400&#34;, &#34;0.0876710000&#34;, &#34;-0.0415940000&#34;, &#34;-0.2623600000&#34;, &#34;0.1172700000&#34;, &#34;-0.0325420000&#34;, &#34;0.1532700000&#34;, &#34;0.0840430000&#34;, &#34;-0.1532300000&#34;, &#34;0.1215100000&#34;, &#34;-0.0390980000&#34;, &#34;0.2143100000&#34;, &#34;-0.1707800000&#34;, &#34;0.0645370000&#34;, &#34;-0.0107080000&#34;, &#34;-0.2263500000&#34;, &#34;0.1976400000&#34;, &#34;-0.0792570000&#34;, &#34;-0.1739900000&#34;, &#34;-0.0743980000&#34;, &#34;-0.3009200000&#34;, &#34;-0.0766730000&#34;, &#34;0.1579800000&#34;, &#34;-0.0461830000&#34;, &#34;-0.0098803000&#34;, &#34;-0.1065000000&#34;, &#34;0.2280500000&#34;, &#34;-0.2408000000&#34;, &#34;0.0836460000&#34;, &#34;0.0782390000&#34;, &#34;0.3040300000&#34;, &#34;0.1921900000&#34;, &#34;0.0015495000&#34;, &#34;0.0924000000&#34;, &#34;0.2875100000&#34;, &#34;-0.0517050000&#34;, &#34;-0.0757220000&#34;, &#34;0.0472960000&#34;, &#34;-0.0550460000&#34;, &#34;0.0087570000&#34;, &#34;-0.1959000000&#34;, &#34;0.1436400000&#34;, &#34;-0.0743430000&#34;, &#34;-0.2349700000&#34;, &#34;0.0419860000&#34;, &#34;-0.0219020000&#34;, &#34;0.4202800000&#34;, &#34;-0.1275300000&#34;, &#34;0.0843030000&#34;, &#34;-0.0607250000&#34;, &#34;-0.0227560000&#34;, &#34;-0.0252230000&#34;, &#34;-0.1021300000&#34;, &#34;0.1290200000&#34;, &#34;0.0817980000&#34;, &#34;-0.0921100000&#34;, &#34;0.1935800000&#34;, &#34;0.1562200000&#34;, &#34;-0.0684930000&#34;, &#34;-0.1778800000&#34;, &#34;0.0110350000&#34;, &#34;0.0802360000&#34;, &#34;0.0198540000&#34;, &#34;0.0012992000&#34;, &#34;0.0332260000&#34;, &#34;0.0603570000&#34;, &#34;0.0045871000&#34;, &#34;-0.1168300000&#34;, &#34;-0.0023224000&#34;, &#34;-0.2202600000&#34;, &#34;0.2224100000&#34;, &#34;0.1059700000&#34;, &#34;-0.1074200000&#34;, &#34;0.2180400000&#34;, &#34;0.2407900000&#34;, &#34;0.1862700000&#34;, &#34;0.0587230000&#34;, &#34;0.3724000000&#34;, &#34;0.0586390000&#34;, &#34;0.1055600000&#34;, &#34;0.2468900000&#34;, &#34;0.3110700000&#34;, &#34;-0.0125390000&#34;, &#34;0.2088600000&#34;, &#34;0.0551650000&#34;, &#34;0.0844530000&#34;, &#34;-0.0449190000&#34;, &#34;0.0254860000&#34;, &#34;-0.1053300000&#34;, &#34;-0.1342300000&#34;, &#34;-0.0506190000&#34;, &#34;0.0748310000&#34;, &#34;0.0018074000&#34;, &#34;-0.0259520000&#34;, &#34;-0.0250490000&#34;, &#34;-0.0902310000&#34;, &#34;0.1810600000&#34;, &#34;0.0095015000&#34;, &#34;0.0883090000&#34;, &#34;0.1277100000&#34;, &#34;-0.0249920000&#34;, &#34;0.0124670000&#34;, &#34;-0.0730790000&#34;, &#34;-0.0306170000&#34;, &#34;0.0771760000&#34;, &#34;-0.2062700000&#34;, &#34;0.0168790000&#34;, &#34;-0.1694000000&#34;, &#34;-0.0982330000&#34;, &#34;0.0319440000&#34;, &#34;0.1321900000&#34;, &#34;-0.0246180000&#34;, &#34;0.3809400000&#34;, &#34;0.0490890000&#34;, &#34;-0.1460100000&#34;, &#34;0.2135400000&#34;, &#34;0.1295100000&#34;, &#34;-0.0123390000&#34;, &#34;0.2074100000&#34;, &#34;0.0846430000&#34;, &#34;0.0634560000&#34;, &#34;0.1395200000&#34;, &#34;-0.0125550000&#34;, &#34;-0.0757660000&#34;, &#34;0.0782540000&#34;, &#34;-0.1459400000&#34;, &#34;-0.1357600000&#34;, &#34;-0.0696200000&#34;, &#34;-0.1481000000&#34;, &#34;0.1095300000&#34;, &#34;0.1311500000&#34;, &#34;0.0912090000&#34;, &#34;0.2220300000&#34;, &#34;0.0241870000&#34;, &#34;0.0944250000&#34;, &#34;0.1066100000&#34;, &#34;-0.1266600000&#34;, &#34;0.1007800000&#34;, &#34;-0.2401300000&#34;, &#34;-0.0868480000&#34;, &#34;0.1612300000&#34;, &#34;-0.1649900000&#34;, &#34;0.1583400000&#34;, &#34;-0.1061300000&#34;, &#34;0.0256160000&#34;, &#34;-0.2481200000&#34;, &#34;0.0641940000&#34;, &#34;0.1494500000&#34;, &#34;-0.1171600000&#34;, &#34;-0.0231960000&#34;, &#34;0.0940800000&#34;, &#34;0.1758000000&#34;, &#34;-0.1441500000&#34;, &#34;0.0091053000&#34;, &#34;-0.0890350000&#34;, &#34;-0.1526900000&#34;, &#34;0.2028700000&#34;, &#34;-0.0486790000&#34;, &#34;0.1099900000&#34;, &#34;-0.1919900000&#34;, &#34;0.0169160000&#34;, &#34;0.1698700000&#34;, &#34;0.1340700000&#34;, &#34;0.1483200000&#34;, &#34;0.2556100000&#34;, &#34;-0.1148100000&#34;, &#34;0.0459760000&#34;, &#34;-0.1045300000&#34;, &#34;0.3047100000&#34;, &#34;-0.1565500000&#34;, &#34;-0.0612180000&#34;, &#34;-0.3080200000&#34;, &#34;-0.0268840000&#34;, &#34;0.1247300000&#34;, &#34;-0.0397910000&#34;, &#34;-0.0412340000&#34;, &#34;-0.2260000000&#34;, &#34;0.1589800000&#34;, &#34;0.0540950000&#34;, &#34;0.0610630000&#34;, &#34;-0.0739540000&#34;, &#34;0.1043000000&#34;, &#34;0.2258500000&#34;, &#34;0.0319390000&#34;, &#34;0.1291900000&#34;, &#34;-0.0964080000&#34;, &#34;0.0081266000&#34;, &#34;-0.1627600000&#34;, &#34;0.0072641000&#34;, &#34;0.0078385000&#34;, &#34;-0.0832850000&#34;, &#34;-0.0519330000&#34;, &#34;0.1072400000&#34;, &#34;-0.0990100000&#34;, &#34;0.0224090000&#34;, &#34;-0.1303900000&#34;, &#34;0.0988350000&#34;, &#34;0.1285800000&#34;, &#34;0.2241000000&#34;, &#34;0.3579100000&#34;, &#34;0.1492700000&#34;, &#34;-0.0027789000&#34;, &#34;-0.0121560000&#34;, &#34;-0.0523360000&#34;, &#34;-0.0280420000&#34;, &#34;-0.1270700000&#34;, &#34;-0.3056300000&#34;, &#34;-0.1310700000&#34;, &#34;-0.0346780000&#34;, &#34;0.0571560000&#34;, &#34;-0.1181700000&#34;, &#34;0.0539260000&#34;, &#34;-0.0309180000&#34;, &#34;-0.0819190000&#34;, &#34;0.0356900000&#34;, &#34;0.2039900000&#34;, &#34;-0.0580470000&#34;, &#34;0.0400650000&#34;, &#34;-0.2662500000&#34;, &#34;-0.1968400000&#34;, &#34;-0.1096200000&#34;, &#34;0.0073118000&#34;, &#34;-0.0426280000&#34;, &#34;-0.3038000000&#34;, &#34;-0.1309400000&#34;, &#34;0.0584870000&#34;, &#34;-0.0224660000&#34;, &#34;-0.0186820000&#34;, &#34;-0.0805460000&#34;, &#34;-0.1308800000&#34;, &#34;0.0833770000&#34;, &#34;0.1824400000&#34;, &#34;-0.0409670000&#34;, &#34;-0.0075252000&#34;, &#34;0.1743600000&#34;, &#34;0.0567890000&#34;, &#34;-0.0822560000&#34;, &#34;0.1022600000&#34;, &#34;0.0556980000&#34;, &#34;-0.1287700000&#34;, &#34;0.1435200000&#34;, &#34;0.0745990000&#34;, &#34;-0.1185500000&#34;, &#34;0.1364300000&#34;, &#34;0.0524580000&#34;, &#34;-0.0794700000&#34;, &#34;0.0478250000&#34;, &#34;0.0403550000&#34;, &#34;0.0064958000&#34;, &#34;-0.0176890000&#34;, &#34;-0.0607240000&#34;, &#34;0.1316800000&#34;, &#34;0.1987800000&#34;, &#34;-0.0295310000&#34;], [&#34;-0.0165320000&#34;, &#34;0.1710700000&#34;, &#34;-0.2611200000&#34;, &#34;0.3131800000&#34;, &#34;-0.0300940000&#34;, &#34;0.0464090000&#34;, &#34;-0.1599200000&#34;, &#34;-0.2636200000&#34;, &#34;0.3855300000&#34;, &#34;-0.0138240000&#34;, &#34;-0.0671340000&#34;, &#34;0.0051643000&#34;, &#34;-0.0134130000&#34;, &#34;0.2662200000&#34;, &#34;-0.0151940000&#34;, &#34;-0.3197300000&#34;, &#34;0.1838200000&#34;, &#34;-0.0234700000&#34;, &#34;0.2055500000&#34;, &#34;0.3097400000&#34;, &#34;-0.0542570000&#34;, &#34;0.0430070000&#34;, &#34;-0.1823400000&#34;, &#34;-0.3464400000&#34;, &#34;-0.0621450000&#34;, &#34;-0.1618300000&#34;, &#34;0.0231650000&#34;, &#34;-0.0907440000&#34;, &#34;-0.1432000000&#34;, &#34;0.0582580000&#34;, &#34;0.1875200000&#34;, &#34;0.2007400000&#34;, &#34;-0.1458300000&#34;, &#34;0.0534900000&#34;, &#34;-0.2232900000&#34;, &#34;-0.0658370000&#34;, &#34;-0.1516500000&#34;, &#34;-0.2026900000&#34;, &#34;0.1110800000&#34;, &#34;0.1248300000&#34;, &#34;0.3305400000&#34;, &#34;0.2732700000&#34;, &#34;0.0115370000&#34;, &#34;-0.3310600000&#34;, &#34;-0.0323800000&#34;, &#34;0.1640300000&#34;, &#34;-0.1057300000&#34;, &#34;-0.0050296000&#34;, &#34;0.1879600000&#34;, &#34;0.0627670000&#34;, &#34;-0.2218200000&#34;, &#34;0.0867750000&#34;, &#34;0.0144030000&#34;, &#34;0.0238900000&#34;, &#34;-0.2108000000&#34;, &#34;-0.0042702000&#34;, &#34;-0.2056200000&#34;, &#34;0.0363660000&#34;, &#34;-0.2174800000&#34;, &#34;0.1515900000&#34;, &#34;-0.2326600000&#34;, &#34;-0.0729230000&#34;, &#34;-0.0047179000&#34;, &#34;0.1584500000&#34;, &#34;-0.0359620000&#34;, &#34;0.2844600000&#34;, &#34;-0.1093700000&#34;, &#34;0.0645970000&#34;, &#34;0.0879210000&#34;, &#34;-0.0965370000&#34;, &#34;0.0725770000&#34;, &#34;0.1149000000&#34;, &#34;0.1410300000&#34;, &#34;-0.2644700000&#34;, &#34;-0.0886060000&#34;, &#34;-0.0104600000&#34;, &#34;0.2195800000&#34;, &#34;0.1105100000&#34;, &#34;-0.3139700000&#34;, &#34;0.1450200000&#34;, &#34;0.0480880000&#34;, &#34;-0.1294200000&#34;, &#34;-0.2285200000&#34;, &#34;-0.0982450000&#34;, &#34;-0.1304500000&#34;, &#34;0.1189500000&#34;, &#34;-0.1380800000&#34;, &#34;0.0120620000&#34;, &#34;0.0972600000&#34;, &#34;0.0412810000&#34;, &#34;0.2265400000&#34;, &#34;-0.0808980000&#34;, &#34;0.0880520000&#34;, &#34;-0.2776700000&#34;, &#34;0.0931530000&#34;, &#34;0.0084290000&#34;, &#34;-0.0882860000&#34;, &#34;0.0092110000&#34;, &#34;-0.1894500000&#34;, &#34;0.1061600000&#34;, &#34;0.0214470000&#34;, &#34;-0.1277200000&#34;, &#34;0.1409800000&#34;, &#34;-0.0396720000&#34;, &#34;0.1994000000&#34;, &#34;-0.1007800000&#34;, &#34;-0.3036000000&#34;, &#34;-0.0269100000&#34;, &#34;0.0540760000&#34;, &#34;-0.0132040000&#34;, &#34;0.0617560000&#34;, &#34;-0.1297600000&#34;, &#34;0.2317000000&#34;, &#34;0.0940240000&#34;, &#34;0.4020700000&#34;, &#34;-0.1462000000&#34;, &#34;0.1619100000&#34;, &#34;-0.1050000000&#34;, &#34;0.1837000000&#34;, &#34;-0.0301660000&#34;, &#34;0.0643160000&#34;, &#34;0.2298600000&#34;, &#34;-0.0838490000&#34;, &#34;0.2339900000&#34;, &#34;-0.0792380000&#34;, &#34;0.2700700000&#34;, &#34;0.2114200000&#34;, &#34;0.2335700000&#34;, &#34;-0.1425800000&#34;, &#34;0.1152100000&#34;, &#34;0.1539200000&#34;, &#34;0.1047000000&#34;, &#34;-0.0947090000&#34;, &#34;0.1386000000&#34;, &#34;-0.1446200000&#34;, &#34;0.0620510000&#34;, &#34;-0.0044305000&#34;, &#34;-0.1285400000&#34;, &#34;0.1382200000&#34;, &#34;-0.0316550000&#34;, &#34;-0.1695100000&#34;, &#34;-0.1367700000&#34;, &#34;0.1313600000&#34;, &#34;-0.2762700000&#34;, &#34;-0.1914000000&#34;, &#34;0.3059000000&#34;, &#34;0.0170790000&#34;, &#34;-0.2680300000&#34;, &#34;-0.3186400000&#34;, &#34;0.0304450000&#34;, &#34;0.3651800000&#34;, &#34;0.0184090000&#34;, &#34;-0.1012100000&#34;, &#34;-0.0467270000&#34;, &#34;-0.0126190000&#34;, &#34;0.0328800000&#34;, &#34;0.0154770000&#34;, &#34;-0.1274800000&#34;, &#34;0.0446920000&#34;, &#34;-0.0402220000&#34;, &#34;-0.0314990000&#34;, &#34;0.1505700000&#34;, &#34;0.0870170000&#34;, &#34;0.0133790000&#34;, &#34;0.2274500000&#34;, &#34;0.3145600000&#34;, &#34;0.1069700000&#34;, &#34;-0.3411300000&#34;, &#34;0.3150900000&#34;, &#34;-0.0411670000&#34;, &#34;-0.1916800000&#34;, &#34;-0.2439000000&#34;, &#34;-0.3271500000&#34;, &#34;-0.1050500000&#34;, &#34;-0.0576140000&#34;, &#34;0.2293500000&#34;, &#34;0.1768800000&#34;, &#34;0.1841800000&#34;, &#34;0.3173300000&#34;, &#34;-0.0790880000&#34;, &#34;0.0327750000&#34;, &#34;-0.2019400000&#34;, &#34;-0.0521350000&#34;, &#34;0.1306500000&#34;, &#34;0.1920100000&#34;, &#34;0.1734000000&#34;, &#34;-0.0450400000&#34;, &#34;-0.1040500000&#34;, &#34;0.3138500000&#34;, &#34;-0.0890620000&#34;, &#34;0.0906790000&#34;, &#34;-0.1320100000&#34;, &#34;0.1034400000&#34;, &#34;0.1291300000&#34;, &#34;-0.2005600000&#34;, &#34;-0.2201400000&#34;, &#34;-0.0510940000&#34;, &#34;0.1094400000&#34;, &#34;-0.3006300000&#34;, &#34;-0.0546590000&#34;, &#34;-0.0038813000&#34;, &#34;0.0434660000&#34;, &#34;-0.0010636000&#34;, &#34;-0.1885100000&#34;, &#34;0.0613900000&#34;, &#34;-0.2651000000&#34;, &#34;-0.1395100000&#34;, &#34;-0.0673480000&#34;, &#34;0.1648100000&#34;, &#34;-0.3510800000&#34;, &#34;0.3366100000&#34;, &#34;0.0811980000&#34;, &#34;-0.1135400000&#34;, &#34;-0.3476100000&#34;, &#34;0.3973400000&#34;, &#34;0.2814700000&#34;, &#34;-0.0305920000&#34;, &#34;-0.4129300000&#34;, &#34;-0.2356500000&#34;, &#34;0.2974600000&#34;, &#34;-0.2045200000&#34;, &#34;-0.0563990000&#34;, &#34;-0.0224850000&#34;, &#34;0.0748530000&#34;, &#34;-0.2839100000&#34;, &#34;0.2283300000&#34;, &#34;-0.1343000000&#34;, &#34;-0.0239020000&#34;, &#34;0.1862900000&#34;, &#34;0.0122100000&#34;, &#34;0.0787960000&#34;, &#34;-0.1795900000&#34;, &#34;0.2287400000&#34;, &#34;0.1065800000&#34;, &#34;-0.1156900000&#34;, &#34;0.1901700000&#34;, &#34;0.0894970000&#34;, &#34;-0.1611900000&#34;, &#34;0.1548800000&#34;, &#34;0.0765240000&#34;, &#34;0.0904400000&#34;, &#34;0.1095200000&#34;, &#34;0.1358200000&#34;, &#34;0.2498300000&#34;, &#34;-0.2086100000&#34;, &#34;0.2076900000&#34;, &#34;0.1985000000&#34;, &#34;-0.1046400000&#34;, &#34;-0.0172640000&#34;, &#34;0.3161100000&#34;, &#34;-0.1890000000&#34;, &#34;-0.1069600000&#34;, &#34;0.0014526000&#34;, &#34;-0.1325600000&#34;, &#34;-0.0744180000&#34;, &#34;0.2159500000&#34;, &#34;-0.1605800000&#34;, &#34;0.1070400000&#34;, &#34;-0.0234520000&#34;, &#34;0.0142380000&#34;, &#34;0.0703660000&#34;, &#34;0.2588800000&#34;, &#34;-0.0766330000&#34;, &#34;-0.0196120000&#34;, &#34;-0.0607880000&#34;, &#34;-0.2178000000&#34;, &#34;-0.3737300000&#34;, &#34;0.1071000000&#34;, &#34;0.2958200000&#34;, &#34;0.0749020000&#34;, &#34;-0.2108300000&#34;, &#34;-0.0646680000&#34;, &#34;0.0895320000&#34;, &#34;0.2278000000&#34;, &#34;-0.0836900000&#34;, &#34;-0.1296900000&#34;, &#34;0.0680520000&#34;, &#34;0.4146100000&#34;, &#34;-0.1122100000&#34;, &#34;-0.1895900000&#34;, &#34;0.3560200000&#34;, &#34;-0.0876930000&#34;, &#34;0.0240680000&#34;, &#34;0.0223130000&#34;, &#34;0.2179200000&#34;, &#34;-0.3211200000&#34;, &#34;0.1606100000&#34;, &#34;0.3766700000&#34;, &#34;-0.2078800000&#34;, &#34;-0.1647900000&#34;, &#34;0.0751510000&#34;, &#34;-0.0041485000&#34;, &#34;0.1091800000&#34;, &#34;0.0995230000&#34;, &#34;0.0720380000&#34;, &#34;-0.0709360000&#34;, &#34;-0.0753820000&#34;, &#34;0.0435620000&#34;, &#34;0.2280000000&#34;, &#34;0.3304800000&#34;], [&#34;0.0513240000&#34;, &#34;-0.0706180000&#34;, &#34;-0.0216120000&#34;, &#34;0.5856600000&#34;, &#34;0.1919200000&#34;, &#34;0.2800500000&#34;, &#34;0.0892610000&#34;, &#34;0.0098064000&#34;, &#34;-0.3134600000&#34;, &#34;-0.0616510000&#34;, &#34;0.3603000000&#34;, &#34;-0.1643700000&#34;, &#34;-0.0322600000&#34;, &#34;-0.2181800000&#34;, &#34;0.3228400000&#34;, &#34;-0.0107670000&#34;, &#34;0.0232250000&#34;, &#34;0.2576400000&#34;, &#34;0.0131400000&#34;, &#34;0.6553600000&#34;, &#34;-0.0747040000&#34;, &#34;-0.5633000000&#34;, &#34;-0.1134500000&#34;, &#34;0.0538770000&#34;, &#34;0.2335800000&#34;, &#34;0.0176880000&#34;, &#34;-0.0304740000&#34;, &#34;-0.1508400000&#34;, &#34;-0.2486100000&#34;, &#34;0.1206400000&#34;, &#34;-0.2654000000&#34;, &#34;0.2544000000&#34;, &#34;-0.3460100000&#34;, &#34;-0.0414720000&#34;, &#34;0.3663200000&#34;, &#34;-0.2086800000&#34;, &#34;0.0339750000&#34;, &#34;-0.1131600000&#34;, &#34;0.3747000000&#34;, &#34;0.1632300000&#34;, &#34;0.7036400000&#34;, &#34;0.0847610000&#34;, &#34;-0.2616400000&#34;, &#34;0.0527830000&#34;, &#34;-0.0889470000&#34;, &#34;0.2709700000&#34;, &#34;0.0937870000&#34;, &#34;0.3125600000&#34;, &#34;0.2093100000&#34;, &#34;-0.1148700000&#34;, &#34;0.1083700000&#34;, &#34;-0.2969900000&#34;, &#34;0.1621800000&#34;, &#34;0.0154810000&#34;, &#34;-0.1120100000&#34;, &#34;0.2092200000&#34;, &#34;0.0704070000&#34;, &#34;0.2809900000&#34;, &#34;-0.0788350000&#34;, &#34;0.0993810000&#34;, &#34;0.2130000000&#34;, &#34;-0.2676100000&#34;, &#34;0.1290000000&#34;, &#34;0.0404300000&#34;, &#34;-0.0245720000&#34;, &#34;0.1703200000&#34;, &#34;-0.0496790000&#34;, &#34;-0.5684900000&#34;, &#34;-0.0088404000&#34;, &#34;0.1870300000&#34;, &#34;0.0335670000&#34;, &#34;0.0234760000&#34;, &#34;0.1444200000&#34;, &#34;-0.2524900000&#34;, &#34;0.0129050000&#34;, &#34;-0.0846210000&#34;, &#34;0.3420200000&#34;, &#34;0.0260740000&#34;, &#34;-0.5733900000&#34;, &#34;-0.0584450000&#34;, &#34;0.0260860000&#34;, &#34;-0.0647970000&#34;, &#34;0.0757690000&#34;, &#34;0.2953000000&#34;, &#34;-0.3896800000&#34;, &#34;0.0375920000&#34;, &#34;-0.0896950000&#34;, &#34;-0.3790100000&#34;, &#34;0.2678800000&#34;, &#34;-0.5073400000&#34;, &#34;0.0343320000&#34;, &#34;-0.1170100000&#34;, &#34;0.2985100000&#34;, &#34;-0.2539900000&#34;, &#34;0.0146440000&#34;, &#34;-0.0041997000&#34;, &#34;0.1566400000&#34;, &#34;-0.1199500000&#34;, &#34;-0.0019714000&#34;, &#34;0.0973370000&#34;, &#34;0.0435290000&#34;, &#34;0.0090645000&#34;, &#34;-0.1124200000&#34;, &#34;-0.0575640000&#34;, &#34;-0.2087200000&#34;, &#34;0.2946300000&#34;, &#34;0.1898300000&#34;, &#34;0.4180600000&#34;, &#34;0.2139800000&#34;, &#34;-0.0914810000&#34;, &#34;-0.1177200000&#34;, &#34;0.0085325000&#34;, &#34;-0.0028863000&#34;, &#34;0.0629740000&#34;, &#34;0.2071000000&#34;, &#34;-0.5297100000&#34;, &#34;-0.0178240000&#34;, &#34;0.1106400000&#34;, &#34;0.1349100000&#34;, &#34;0.0285410000&#34;, &#34;-0.0795620000&#34;, &#34;0.0495980000&#34;, &#34;-0.2556500000&#34;, &#34;0.0645160000&#34;, &#34;-0.0310300000&#34;, &#34;0.2444500000&#34;, &#34;0.1085700000&#34;, &#34;0.4715200000&#34;, &#34;0.0416410000&#34;, &#34;-0.1023000000&#34;, &#34;-0.1178900000&#34;, &#34;-0.0843260000&#34;, &#34;0.0187060000&#34;, &#34;-0.0590420000&#34;, &#34;-0.0958200000&#34;, &#34;0.1088600000&#34;, &#34;0.0987560000&#34;, &#34;-0.1241400000&#34;, &#34;-0.0807060000&#34;, &#34;0.2369000000&#34;, &#34;-0.1612000000&#34;, &#34;0.2176800000&#34;, &#34;0.4958500000&#34;, &#34;-0.0116190000&#34;, &#34;0.0097915000&#34;, &#34;0.6407700000&#34;, &#34;-0.1111500000&#34;, &#34;-0.0939950000&#34;, &#34;-0.1427100000&#34;, &#34;0.1573400000&#34;, &#34;0.1143800000&#34;, &#34;-0.1520900000&#34;, &#34;-0.5125000000&#34;, &#34;0.1470700000&#34;, &#34;-0.2382900000&#34;, &#34;0.1973100000&#34;, &#34;-0.4134800000&#34;, &#34;0.0188450000&#34;, &#34;0.1175400000&#34;, &#34;-0.1826600000&#34;, &#34;0.0221760000&#34;, &#34;-0.0663910000&#34;, &#34;-0.1203300000&#34;, &#34;0.0800400000&#34;, &#34;-0.2650600000&#34;, &#34;0.1684900000&#34;, &#34;0.1821600000&#34;, &#34;0.1750000000&#34;, &#34;-0.2825200000&#34;, &#34;-0.1813900000&#34;, &#34;0.1902200000&#34;, &#34;-0.3249500000&#34;, &#34;-0.0502280000&#34;, &#34;0.0892980000&#34;, &#34;-0.2048100000&#34;, &#34;-0.1448400000&#34;, &#34;0.0368750000&#34;, &#34;0.0495450000&#34;, &#34;-0.1724000000&#34;, &#34;0.1092700000&#34;, &#34;0.3847700000&#34;, &#34;-0.2678900000&#34;, &#34;-0.0853380000&#34;, &#34;-0.2645000000&#34;, &#34;0.0387650000&#34;, &#34;0.2556600000&#34;, &#34;0.0359980000&#34;, &#34;0.3837500000&#34;, &#34;-0.0998950000&#34;, &#34;-0.1705500000&#34;, &#34;0.2840000000&#34;, &#34;-0.0212870000&#34;, &#34;0.2804200000&#34;, &#34;0.0322540000&#34;, &#34;-0.2825500000&#34;, &#34;0.0654640000&#34;, &#34;-0.1203800000&#34;, &#34;-0.0149070000&#34;, &#34;-0.0006525500&#34;, &#34;0.0689850000&#34;, &#34;0.3073000000&#34;, &#34;-0.0346560000&#34;, &#34;0.3533500000&#34;, &#34;-0.0960390000&#34;, &#34;0.3632900000&#34;, &#34;-0.1311700000&#34;, &#34;-0.0607550000&#34;, &#34;-0.0942790000&#34;, &#34;0.3221300000&#34;, &#34;-0.0789180000&#34;, &#34;0.4698700000&#34;, &#34;-0.3843200000&#34;, &#34;-0.2243300000&#34;, &#34;-0.1883900000&#34;, &#34;0.1916100000&#34;, &#34;0.1373600000&#34;, &#34;-0.2309900000&#34;, &#34;-0.4350000000&#34;, &#34;-0.3800400000&#34;, &#34;-0.1009300000&#34;, &#34;-0.1491000000&#34;, &#34;-0.2365500000&#34;, &#34;-0.2094400000&#34;, &#34;0.3091000000&#34;, &#34;-0.1917300000&#34;, &#34;0.3218600000&#34;, &#34;0.0055599000&#34;, &#34;-0.1206200000&#34;, &#34;-0.1460500000&#34;, &#34;-0.2416900000&#34;, &#34;-0.0649800000&#34;, &#34;0.2606000000&#34;, &#34;-0.0654100000&#34;, &#34;0.1320700000&#34;, &#34;-0.7516100000&#34;, &#34;-0.3307700000&#34;, &#34;0.3523600000&#34;, &#34;-0.0248020000&#34;, &#34;0.1542700000&#34;, &#34;0.4268500000&#34;, &#34;0.2129000000&#34;, &#34;0.3395900000&#34;, &#34;0.1042900000&#34;, &#34;0.2427500000&#34;, &#34;-0.1701100000&#34;, &#34;0.1601900000&#34;, &#34;0.2847300000&#34;, &#34;-0.0765880000&#34;, &#34;0.2018200000&#34;, &#34;0.2639700000&#34;, &#34;0.0782000000&#34;, &#34;-0.3502300000&#34;, &#34;-0.3503500000&#34;, &#34;-0.1307800000&#34;, &#34;-0.0330730000&#34;, &#34;0.2162000000&#34;, &#34;-0.0010383000&#34;, &#34;-0.3543800000&#34;, &#34;-0.0803670000&#34;, &#34;-0.0958300000&#34;, &#34;-0.0802800000&#34;, &#34;0.3350300000&#34;, &#34;0.2789600000&#34;, &#34;-0.0995590000&#34;, &#34;-0.0920350000&#34;, &#34;0.1171500000&#34;, &#34;0.0803270000&#34;, &#34;0.0449470000&#34;, &#34;-0.0167250000&#34;, &#34;0.1094200000&#34;, &#34;-0.2763900000&#34;, &#34;-0.0384650000&#34;, &#34;0.1456100000&#34;, &#34;-0.1062600000&#34;, &#34;-0.1602400000&#34;, &#34;-0.0417930000&#34;, &#34;-0.0073398000&#34;, &#34;0.3471000000&#34;, &#34;0.0676280000&#34;, &#34;-0.0707770000&#34;, &#34;-0.0941370000&#34;, &#34;0.2950600000&#34;, &#34;-0.0639280000&#34;, &#34;0.0929010000&#34;, &#34;0.2258700000&#34;, &#34;-0.0332070000&#34;, &#34;0.0270170000&#34;, &#34;0.2455600000&#34;, &#34;-0.0296220000&#34;, &#34;0.0488670000&#34;, &#34;0.2562300000&#34;, &#34;-0.1718800000&#34;, &#34;0.2008900000&#34;, &#34;0.2300800000&#34;, &#34;-0.1056900000&#34;, &#34;0.0341030000&#34;, &#34;-0.5088700000&#34;, &#34;0.0771760000&#34;, &#34;0.0981730000&#34;, &#34;-0.2371300000&#34;], [&#34;-0.1330000000&#34;, &#34;-0.1230500000&#34;, &#34;0.0654240000&#34;, &#34;0.5002100000&#34;, &#34;0.1878300000&#34;, &#34;0.0762630000&#34;, &#34;-0.2700200000&#34;, &#34;0.1340500000&#34;, &#34;-0.0301880000&#34;, &#34;0.2475800000&#34;, &#34;0.2231800000&#34;, &#34;-0.0309880000&#34;, &#34;0.0095239000&#34;, &#34;-0.0302910000&#34;, &#34;0.3365300000&#34;, &#34;-0.0819380000&#34;, &#34;-0.1014500000&#34;, &#34;0.0432690000&#34;, &#34;-0.1446000000&#34;, &#34;0.3872900000&#34;, &#34;0.1021000000&#34;, &#34;0.1189900000&#34;, &#34;-0.3871300000&#34;, &#34;0.0372040000&#34;, &#34;-0.0557930000&#34;, &#34;0.1880900000&#34;, &#34;0.1961200000&#34;, &#34;0.0721930000&#34;, &#34;-0.2545900000&#34;, &#34;0.0810470000&#34;, &#34;-0.1890300000&#34;, &#34;0.2529600000&#34;, &#34;-0.2818200000&#34;, &#34;0.0023962000&#34;, &#34;0.1639000000&#34;, &#34;-0.2247500000&#34;, &#34;-0.1622400000&#34;, &#34;-0.0056278000&#34;, &#34;0.2569500000&#34;, &#34;-0.1198800000&#34;, &#34;0.2859200000&#34;, &#34;0.0456000000&#34;, &#34;-0.2220400000&#34;, &#34;0.1559000000&#34;, &#34;0.1067800000&#34;, &#34;0.1666400000&#34;, &#34;-0.2087300000&#34;, &#34;0.0633790000&#34;, &#34;-0.0412220000&#34;, &#34;-0.1158200000&#34;, &#34;0.1115500000&#34;, &#34;-0.0557060000&#34;, &#34;0.1310700000&#34;, &#34;0.2168700000&#34;, &#34;-0.3144800000&#34;, &#34;0.2510100000&#34;, &#34;0.0207120000&#34;, &#34;0.3685400000&#34;, &#34;-0.2311400000&#34;, &#34;0.1430400000&#34;, &#34;0.2466500000&#34;, &#34;-0.2332600000&#34;, &#34;0.0571900000&#34;, &#34;-0.0043860000&#34;, &#34;-0.0813010000&#34;, &#34;-0.0132580000&#34;, &#34;0.2274700000&#34;, &#34;0.0333920000&#34;, &#34;0.1033800000&#34;, &#34;0.0598810000&#34;, &#34;-0.1073500000&#34;, &#34;-0.1365400000&#34;, &#34;0.1125400000&#34;, &#34;-0.0988680000&#34;, &#34;-0.0695260000&#34;, &#34;0.0383090000&#34;, &#34;0.1010900000&#34;, &#34;0.1770200000&#34;, &#34;0.1813900000&#34;, &#34;-0.0801690000&#34;, &#34;0.0391810000&#34;, &#34;-0.1440200000&#34;, &#34;-0.0917060000&#34;, &#34;0.0243660000&#34;, &#34;-0.3997300000&#34;, &#34;-0.1256800000&#34;, &#34;0.0566750000&#34;, &#34;-0.2665900000&#34;, &#34;-0.0073045000&#34;, &#34;-0.0512830000&#34;, &#34;-0.1976700000&#34;, &#34;0.0553250000&#34;, &#34;0.3101300000&#34;, &#34;0.3243800000&#34;, &#34;0.0448760000&#34;, &#34;0.0727180000&#34;, &#34;0.0532680000&#34;, &#34;-0.0671240000&#34;, &#34;-0.0368180000&#34;, &#34;0.2518600000&#34;, &#34;0.0771260000&#34;, &#34;-0.1968400000&#34;, &#34;-0.0358860000&#34;, &#34;0.1611700000&#34;, &#34;-0.0525660000&#34;, &#34;0.2913900000&#34;, &#34;-0.1062300000&#34;, &#34;0.1228600000&#34;, &#34;0.1760900000&#34;, &#34;0.1388100000&#34;, &#34;0.0378150000&#34;, &#34;0.3313000000&#34;, &#34;-0.0143720000&#34;, &#34;-0.0945050000&#34;, &#34;-0.0169190000&#34;, &#34;-0.2014500000&#34;, &#34;-0.1476400000&#34;, &#34;0.0538020000&#34;, &#34;0.0506930000&#34;, &#34;-0.0860970000&#34;, &#34;0.0839150000&#34;, &#34;0.2542600000&#34;, &#34;0.1766300000&#34;, &#34;0.2031000000&#34;, &#34;0.0682790000&#34;, &#34;-0.0075550000&#34;, &#34;0.1232600000&#34;, &#34;0.3478500000&#34;, &#34;0.3979500000&#34;, &#34;-0.0663870000&#34;, &#34;-0.1576400000&#34;, &#34;-0.1517600000&#34;, &#34;-0.1482700000&#34;, &#34;-0.1665300000&#34;, &#34;-0.2751600000&#34;, &#34;-0.0498440000&#34;, &#34;-0.1192200000&#34;, &#34;0.0160070000&#34;, &#34;0.0845950000&#34;, &#34;0.1670200000&#34;, &#34;0.0034598000&#34;, &#34;0.0776680000&#34;, &#34;0.2430300000&#34;, &#34;-0.1834800000&#34;, &#34;0.2450600000&#34;, &#34;0.3285500000&#34;, &#34;-0.1578500000&#34;, &#34;-0.0379420000&#34;, &#34;0.2383200000&#34;, &#34;0.1035800000&#34;, &#34;-0.0600190000&#34;, &#34;0.1622300000&#34;, &#34;-0.2943400000&#34;, &#34;0.0151640000&#34;, &#34;-0.0838050000&#34;, &#34;0.1340800000&#34;, &#34;-0.0835450000&#34;, &#34;-0.0512260000&#34;, &#34;0.0106080000&#34;, &#34;-0.0535620000&#34;, &#34;-0.2310200000&#34;, &#34;0.0384450000&#34;, &#34;-0.0385240000&#34;, &#34;0.1454600000&#34;, &#34;-0.0089040000&#34;, &#34;-0.0828960000&#34;, &#34;0.0380030000&#34;, &#34;-0.1197400000&#34;, &#34;-0.0201110000&#34;, &#34;-0.1256200000&#34;, &#34;0.0312790000&#34;, &#34;-0.3003500000&#34;, &#34;-0.2645600000&#34;, &#34;-0.0769120000&#34;, &#34;-0.2510900000&#34;, &#34;0.1448800000&#34;, &#34;-0.2009200000&#34;, &#34;0.2136200000&#34;, &#34;-0.3350700000&#34;, &#34;-0.3743400000&#34;, &#34;0.0916680000&#34;, &#34;-0.1699600000&#34;, &#34;-0.1231500000&#34;, &#34;-0.1837100000&#34;, &#34;0.0568870000&#34;, &#34;0.0411630000&#34;, &#34;-0.0808080000&#34;, &#34;0.0754920000&#34;, &#34;0.1289200000&#34;, &#34;-0.2601000000&#34;, &#34;0.3371800000&#34;, &#34;-0.1970400000&#34;, &#34;0.2350400000&#34;, &#34;0.0662160000&#34;, &#34;-0.1401000000&#34;, &#34;0.0089649000&#34;, &#34;-0.2438000000&#34;, &#34;0.3026500000&#34;, &#34;-0.0326670000&#34;, &#34;-0.1689700000&#34;, &#34;0.0310410000&#34;, &#34;-0.1047400000&#34;, &#34;-0.0372180000&#34;, &#34;0.0252550000&#34;, &#34;0.1253600000&#34;, &#34;-0.3567600000&#34;, &#34;-0.1074500000&#34;, &#34;0.0542280000&#34;, &#34;-0.1310300000&#34;, &#34;-0.0520740000&#34;, &#34;0.4642300000&#34;, &#34;-0.2344200000&#34;, &#34;-0.2835800000&#34;, &#34;-0.1800700000&#34;, &#34;0.1348400000&#34;, &#34;-0.1042700000&#34;, &#34;0.0451520000&#34;, &#34;-0.5176100000&#34;, &#34;-0.1776800000&#34;, &#34;0.0315960000&#34;, &#34;-0.1157300000&#34;, &#34;-0.1056100000&#34;, &#34;0.0301210000&#34;, &#34;0.3722900000&#34;, &#34;-0.2012800000&#34;, &#34;0.0172310000&#34;, &#34;-0.1889200000&#34;, &#34;0.1339200000&#34;, &#34;-0.0736580000&#34;, &#34;-0.0168030000&#34;, &#34;-0.3517800000&#34;, &#34;0.2472100000&#34;, &#34;-0.0885820000&#34;, &#34;0.0752250000&#34;, &#34;-0.1495000000&#34;, &#34;-0.0373050000&#34;, &#34;0.2970200000&#34;, &#34;0.3019300000&#34;, &#34;0.0611570000&#34;, &#34;0.0621070000&#34;, &#34;0.4233700000&#34;, &#34;0.0415200000&#34;, &#34;-0.1969800000&#34;, &#34;0.5872500000&#34;, &#34;0.1964900000&#34;, &#34;0.3078100000&#34;, &#34;-0.1176000000&#34;, &#34;0.0108470000&#34;, &#34;0.1316000000&#34;, &#34;0.1806600000&#34;, &#34;0.0603290000&#34;, &#34;0.0718290000&#34;, &#34;-0.1875600000&#34;, &#34;-0.2057400000&#34;, &#34;0.0515100000&#34;, &#34;0.4237400000&#34;, &#34;-0.1491000000&#34;, &#34;-0.1581500000&#34;, &#34;-0.1430600000&#34;, &#34;-0.0060690000&#34;, &#34;-0.0182760000&#34;, &#34;0.2150100000&#34;, &#34;0.2668500000&#34;, &#34;-0.1726200000&#34;, &#34;-0.2509100000&#34;, &#34;-0.2382200000&#34;, &#34;0.0631350000&#34;, &#34;0.0398520000&#34;, &#34;-0.2362200000&#34;, &#34;0.1117400000&#34;, &#34;-0.3647300000&#34;, &#34;-0.2024800000&#34;, &#34;0.3980300000&#34;, &#34;0.1648000000&#34;, &#34;-0.2356300000&#34;, &#34;-0.3245400000&#34;, &#34;0.0714630000&#34;, &#34;0.5656300000&#34;, &#34;-0.0298980000&#34;, &#34;-0.0705180000&#34;, &#34;0.1893500000&#34;, &#34;-0.1499200000&#34;, &#34;-0.0436140000&#34;, &#34;-0.0066567000&#34;, &#34;0.2131200000&#34;, &#34;0.1828500000&#34;, &#34;0.0206320000&#34;, &#34;0.0815120000&#34;, &#34;-0.0083290000&#34;, &#34;0.2550400000&#34;, &#34;0.1868700000&#34;, &#34;-0.1163700000&#34;, &#34;0.0272600000&#34;, &#34;-0.0971270000&#34;, &#34;0.0247740000&#34;, &#34;-0.0573220000&#34;, &#34;-0.1964500000&#34;, &#34;-0.0504570000&#34;, &#34;-0.0743630000&#34;, &#34;-0.1283500000&#34;], [&#34;0.0851800000&#34;, &#34;-0.0200700000&#34;, &#34;0.2141800000&#34;, &#34;0.2401300000&#34;, &#34;-0.1031900000&#34;, &#34;0.1685900000&#34;, &#34;0.1346500000&#34;, &#34;-0.1485100000&#34;, &#34;0.0937640000&#34;, &#34;0.4982400000&#34;, &#34;0.1612300000&#34;, &#34;-0.1684300000&#34;, &#34;0.1391500000&#34;, &#34;-0.0679850000&#34;, &#34;0.0001754800&#34;, &#34;-0.1974800000&#34;, &#34;0.1750700000&#34;, &#34;0.1355900000&#34;, &#34;0.0657920000&#34;, &#34;0.1310200000&#34;, &#34;-0.1790300000&#34;, &#34;-0.1134600000&#34;, &#34;-0.1238100000&#34;, &#34;-0.1578600000&#34;, &#34;0.1249200000&#34;, &#34;0.1280100000&#34;, &#34;0.1193200000&#34;, &#34;0.1261300000&#34;, &#34;0.0035274000&#34;, &#34;0.0521450000&#34;, &#34;-0.3986400000&#34;, &#34;0.3450500000&#34;, &#34;-0.5077400000&#34;, &#34;0.1172800000&#34;, &#34;-0.3182800000&#34;, &#34;-0.1933900000&#34;, &#34;0.0136420000&#34;, &#34;-0.0165740000&#34;, &#34;-0.1712100000&#34;, &#34;0.1095500000&#34;, &#34;0.1430500000&#34;, &#34;-0.1762400000&#34;, &#34;-0.0783430000&#34;, &#34;0.0913900000&#34;, &#34;0.3295400000&#34;, &#34;0.1202400000&#34;, &#34;0.1950600000&#34;, &#34;0.0386110000&#34;, &#34;-0.1520600000&#34;, &#34;-0.2076400000&#34;, &#34;-0.1730700000&#34;, &#34;-0.4215400000&#34;, &#34;0.0623800000&#34;, &#34;-0.1658300000&#34;, &#34;-0.0227580000&#34;, &#34;-0.0628160000&#34;, &#34;0.0971100000&#34;, &#34;-0.0493320000&#34;, &#34;-0.0646270000&#34;, &#34;0.1649700000&#34;, &#34;-0.2716200000&#34;, &#34;-0.0864980000&#34;, &#34;0.5714800000&#34;, &#34;0.0000320680&#34;, &#34;0.0071824000&#34;, &#34;-0.4222700000&#34;, &#34;0.2138000000&#34;, &#34;0.2210000000&#34;, &#34;0.0498440000&#34;, &#34;0.3391500000&#34;, &#34;-0.0719490000&#34;, &#34;0.0577400000&#34;, &#34;-0.0322730000&#34;, &#34;-0.2662000000&#34;, &#34;-0.1071800000&#34;, &#34;0.0652310000&#34;, &#34;0.0326830000&#34;, &#34;0.3165200000&#34;, &#34;-0.1916300000&#34;, &#34;-0.1756200000&#34;, &#34;0.0544100000&#34;, &#34;0.4661100000&#34;, &#34;-0.0094752000&#34;, &#34;-0.0645490000&#34;, &#34;0.1156200000&#34;, &#34;0.0370780000&#34;, &#34;0.1921800000&#34;, &#34;0.2274000000&#34;, &#34;-0.3620100000&#34;, &#34;-0.2009800000&#34;, &#34;0.1897100000&#34;, &#34;0.0505870000&#34;, &#34;0.1515400000&#34;, &#34;-0.2923900000&#34;, &#34;0.0855460000&#34;, &#34;0.0821190000&#34;, &#34;0.3057500000&#34;, &#34;-0.1839200000&#34;, &#34;0.1427500000&#34;, &#34;0.2597300000&#34;, &#34;-0.0573870000&#34;, &#34;-0.0809190000&#34;, &#34;0.0080007000&#34;, &#34;-0.4582200000&#34;, &#34;-0.3904500000&#34;, &#34;-0.0856770000&#34;, &#34;-0.0902180000&#34;, &#34;0.4028800000&#34;, &#34;0.0243540000&#34;, &#34;0.0220950000&#34;, &#34;-0.0229840000&#34;, &#34;0.0065696000&#34;, &#34;0.0370420000&#34;, &#34;-0.0625060000&#34;, &#34;-0.1645500000&#34;, &#34;-0.1022600000&#34;, &#34;0.1809200000&#34;, &#34;-0.0560690000&#34;, &#34;-0.3262800000&#34;, &#34;0.1441200000&#34;, &#34;0.1364300000&#34;, &#34;-0.0427510000&#34;, &#34;0.0834990000&#34;, &#34;-0.0559940000&#34;, &#34;-0.0408320000&#34;, &#34;0.0451580000&#34;, &#34;0.0601930000&#34;, &#34;0.0182640000&#34;, &#34;0.0222160000&#34;, &#34;0.1123300000&#34;, &#34;0.2150200000&#34;, &#34;0.1451800000&#34;, &#34;-0.2200500000&#34;, &#34;-0.1028100000&#34;, &#34;0.1120400000&#34;, &#34;-0.0683040000&#34;, &#34;-0.1594100000&#34;, &#34;0.1758900000&#34;, &#34;0.5128100000&#34;, &#34;0.0957280000&#34;, &#34;-0.0657770000&#34;, &#34;0.0451430000&#34;, &#34;0.1306800000&#34;, &#34;0.1293900000&#34;, &#34;-0.1016700000&#34;, &#34;-0.1396700000&#34;, &#34;0.0801730000&#34;, &#34;-0.4389300000&#34;, &#34;0.2679300000&#34;, &#34;-0.0700760000&#34;, &#34;0.3494700000&#34;, &#34;-0.2701300000&#34;, &#34;0.1588500000&#34;, &#34;0.0181890000&#34;, &#34;-0.0337430000&#34;, &#34;-0.0422830000&#34;, &#34;-0.2267500000&#34;, &#34;0.1944400000&#34;, &#34;0.0013730000&#34;, &#34;0.1136100000&#34;, &#34;-0.0624300000&#34;, &#34;0.0578810000&#34;, &#34;-0.0960000000&#34;, &#34;0.0473200000&#34;, &#34;-0.1566800000&#34;, &#34;-0.0202400000&#34;, &#34;0.0320620000&#34;, &#34;-0.0726230000&#34;, &#34;0.0689580000&#34;, &#34;0.1297000000&#34;, &#34;-0.2781000000&#34;, &#34;-0.3522000000&#34;, &#34;-0.2316600000&#34;, &#34;-0.0691740000&#34;, &#34;-0.1931800000&#34;, &#34;0.4989900000&#34;, &#34;0.0502420000&#34;, &#34;0.0172720000&#34;, &#34;-0.2182400000&#34;, &#34;-0.2038900000&#34;, &#34;0.2229000000&#34;, &#34;-0.1098600000&#34;, &#34;0.0989670000&#34;, &#34;0.2818500000&#34;, &#34;0.1975100000&#34;, &#34;0.0632280000&#34;, &#34;0.1905200000&#34;, &#34;-0.5237800000&#34;, &#34;0.3318100000&#34;, &#34;-0.0095121000&#34;, &#34;0.1064300000&#34;, &#34;-0.3345400000&#34;, &#34;-0.2359500000&#34;, &#34;0.2270900000&#34;, &#34;-0.2105800000&#34;, &#34;-0.0589760000&#34;, &#34;-0.1400700000&#34;, &#34;0.0427870000&#34;, &#34;-0.0528680000&#34;, &#34;-0.1844700000&#34;, &#34;0.1337400000&#34;, &#34;0.1705900000&#34;, &#34;0.0193090000&#34;, &#34;0.0379540000&#34;, &#34;0.0046226000&#34;, &#34;-0.1347800000&#34;, &#34;-0.0976870000&#34;, &#34;-0.2025300000&#34;, &#34;0.0447970000&#34;, &#34;0.0356180000&#34;, &#34;0.3508800000&#34;, &#34;0.1167700000&#34;, &#34;0.1158100000&#34;, &#34;-0.4729400000&#34;, &#34;0.2493100000&#34;, &#34;-0.1033000000&#34;, &#34;0.0524140000&#34;, &#34;-0.3493600000&#34;, &#34;-0.1720000000&#34;, &#34;0.3523500000&#34;, &#34;0.0313910000&#34;, &#34;-0.0075628000&#34;, &#34;-0.3449000000&#34;, &#34;0.1398400000&#34;, &#34;-0.0975960000&#34;, &#34;0.3973700000&#34;, &#34;-0.4213500000&#34;, &#34;-0.0734910000&#34;, &#34;0.0699600000&#34;, &#34;0.0249500000&#34;, &#34;-0.1186300000&#34;, &#34;0.0692330000&#34;, &#34;0.0318490000&#34;, &#34;-0.1868100000&#34;, &#34;0.0119780000&#34;, &#34;-0.1418200000&#34;, &#34;-0.0832710000&#34;, &#34;0.1002500000&#34;, &#34;0.2276000000&#34;, &#34;-0.2265800000&#34;, &#34;0.1252800000&#34;, &#34;-0.0507510000&#34;, &#34;0.0610840000&#34;, &#34;0.0515400000&#34;, &#34;-0.0228720000&#34;, &#34;0.0507840000&#34;, &#34;0.2249100000&#34;, &#34;-0.1222700000&#34;, &#34;0.2929300000&#34;, &#34;0.0299200000&#34;, &#34;-0.0748870000&#34;, &#34;0.2658300000&#34;, &#34;0.1934400000&#34;, &#34;0.3944700000&#34;, &#34;0.1033600000&#34;, &#34;0.2358800000&#34;, &#34;-0.2657700000&#34;, &#34;-0.1336100000&#34;, &#34;0.3426200000&#34;, &#34;-0.0096122000&#34;, &#34;0.1828100000&#34;, &#34;-0.3648300000&#34;, &#34;0.1314900000&#34;, &#34;0.0784400000&#34;, &#34;-0.2421400000&#34;, &#34;-0.3927000000&#34;, &#34;-0.0823610000&#34;, &#34;0.2368600000&#34;, &#34;0.0903440000&#34;, &#34;-0.2082100000&#34;, &#34;0.0654830000&#34;, &#34;-0.0429180000&#34;, &#34;0.5265200000&#34;, &#34;0.0523810000&#34;, &#34;-0.0753590000&#34;, &#34;0.1181200000&#34;, &#34;0.0941880000&#34;, &#34;0.0837270000&#34;, &#34;-0.2149000000&#34;, &#34;-0.0581420000&#34;, &#34;-0.1207800000&#34;, &#34;-0.1138000000&#34;, &#34;0.2055500000&#34;, &#34;0.0381250000&#34;, &#34;0.3186800000&#34;, &#34;-0.1447200000&#34;, &#34;-0.0084665000&#34;, &#34;0.2390900000&#34;, &#34;-0.2235700000&#34;, &#34;0.5528100000&#34;, &#34;0.0545930000&#34;, &#34;0.1377200000&#34;, &#34;0.0817060000&#34;, &#34;0.0724950000&#34;, &#34;0.2288000000&#34;, &#34;-0.0872900000&#34;, &#34;-0.0172320000&#34;, &#34;0.2579100000&#34;, &#34;0.1911700000&#34;, &#34;0.0124620000&#34;], [&#34;-0.1329400000&#34;, &#34;-0.0040341000&#34;, &#34;-0.2528700000&#34;, &#34;0.7473600000&#34;, &#34;-0.0522580000&#34;, &#34;-0.2666700000&#34;, &#34;0.2227600000&#34;, &#34;-0.3468700000&#34;, &#34;0.1293200000&#34;, &#34;0.0079318000&#34;, &#34;0.0466260000&#34;, &#34;0.1468700000&#34;, &#34;0.1007400000&#34;, &#34;-0.0792940000&#34;, &#34;0.2395000000&#34;, &#34;-0.3809500000&#34;, &#34;-0.2268300000&#34;, &#34;0.0759170000&#34;, &#34;-0.2820100000&#34;, &#34;0.1698100000&#34;, &#34;-0.0174520000&#34;, &#34;-0.1808300000&#34;, &#34;-0.1503000000&#34;, &#34;0.1868700000&#34;, &#34;0.1684800000&#34;, &#34;0.1996000000&#34;, &#34;-0.1113000000&#34;, &#34;-0.0648440000&#34;, &#34;0.2044500000&#34;, &#34;0.1401600000&#34;, &#34;0.1828900000&#34;, &#34;0.2726100000&#34;, &#34;-0.0857620000&#34;, &#34;-0.1995400000&#34;, &#34;-0.0166050000&#34;, &#34;0.0530080000&#34;, &#34;0.0587480000&#34;, &#34;-0.3078000000&#34;, &#34;-0.1012500000&#34;, &#34;-0.1944600000&#34;, &#34;0.3231300000&#34;, &#34;-0.3749200000&#34;, &#34;-0.3575800000&#34;, &#34;0.1566100000&#34;, &#34;0.1158300000&#34;, &#34;0.5502400000&#34;, &#34;0.2186600000&#34;, &#34;-0.2560100000&#34;, &#34;0.2414500000&#34;, &#34;0.1539600000&#34;, &#34;0.2189500000&#34;, &#34;-0.1320800000&#34;, &#34;0.4339600000&#34;, &#34;-0.2742000000&#34;, &#34;-0.1460400000&#34;, &#34;-0.1582100000&#34;, &#34;-0.0977820000&#34;, &#34;0.2375300000&#34;, &#34;-0.0138630000&#34;, &#34;0.1441300000&#34;, &#34;-0.3629500000&#34;, &#34;-0.0287050000&#34;, &#34;0.1719500000&#34;, &#34;-0.2894000000&#34;, &#34;-0.2306500000&#34;, &#34;-0.0192500000&#34;, &#34;-0.1589800000&#34;, &#34;0.1226600000&#34;, &#34;0.2047400000&#34;, &#34;-0.1476100000&#34;, &#34;-0.1721800000&#34;, &#34;0.2289100000&#34;, &#34;0.4538800000&#34;, &#34;-0.3794000000&#34;, &#34;-0.2612700000&#34;, &#34;-0.0750980000&#34;, &#34;0.0902550000&#34;, &#34;-0.1638600000&#34;, &#34;-0.2516900000&#34;, &#34;-0.1709500000&#34;, &#34;-0.3844600000&#34;, &#34;-0.1637900000&#34;, &#34;-0.0539090000&#34;, &#34;-0.0511950000&#34;, &#34;0.1601700000&#34;, &#34;0.0802550000&#34;, &#34;-0.1573500000&#34;, &#34;0.1084100000&#34;, &#34;0.1586400000&#34;, &#34;-0.0157300000&#34;, &#34;0.1188000000&#34;, &#34;-0.1445300000&#34;, &#34;0.2231300000&#34;, &#34;0.0243460000&#34;, &#34;-0.0180430000&#34;, &#34;0.2428600000&#34;, &#34;-0.0558100000&#34;, &#34;-0.0121520000&#34;, &#34;-0.0708120000&#34;, &#34;-0.1179600000&#34;, &#34;-0.4600300000&#34;, &#34;-0.0559390000&#34;, &#34;0.1673500000&#34;, &#34;-0.2604600000&#34;, &#34;-0.1724000000&#34;, &#34;-0.0828000000&#34;, &#34;-0.1188000000&#34;, &#34;-0.2305400000&#34;, &#34;-0.0129530000&#34;, &#34;-0.4526100000&#34;, &#34;-0.1724300000&#34;, &#34;0.1151200000&#34;, &#34;-0.3108400000&#34;, &#34;-0.1094800000&#34;, &#34;0.0415000000&#34;, &#34;0.1968200000&#34;, &#34;0.0401660000&#34;, &#34;-0.1161000000&#34;, &#34;0.0869520000&#34;, &#34;0.0416410000&#34;, &#34;0.4455300000&#34;, &#34;0.4731700000&#34;, &#34;0.0098619000&#34;, &#34;0.1431700000&#34;, &#34;0.2682600000&#34;, &#34;0.0569110000&#34;, &#34;0.2369800000&#34;, &#34;-0.0882120000&#34;, &#34;0.3660100000&#34;, &#34;0.3186500000&#34;, &#34;0.3223000000&#34;, &#34;0.2683000000&#34;, &#34;0.0467380000&#34;, &#34;-0.3218400000&#34;, &#34;0.3445700000&#34;, &#34;-0.1737700000&#34;, &#34;-0.1917200000&#34;, &#34;0.0660220000&#34;, &#34;0.1783900000&#34;, &#34;-0.1917900000&#34;, &#34;0.2302300000&#34;, &#34;0.3166100000&#34;, &#34;0.1722200000&#34;, &#34;0.0210510000&#34;, &#34;0.2011500000&#34;, &#34;-0.0726930000&#34;, &#34;-0.0139950000&#34;, &#34;0.0637070000&#34;, &#34;-0.1541700000&#34;, &#34;0.1900300000&#34;, &#34;-0.1488100000&#34;, &#34;-0.0864240000&#34;, &#34;-0.4749800000&#34;, &#34;0.0396390000&#34;, &#34;-0.1359100000&#34;, &#34;0.2262000000&#34;, &#34;-0.1297200000&#34;, &#34;-0.1611800000&#34;, &#34;0.2446800000&#34;, &#34;0.0166980000&#34;, &#34;-0.1117300000&#34;, &#34;0.1821600000&#34;, &#34;-0.4173200000&#34;, &#34;-0.3033800000&#34;, &#34;-0.1177300000&#34;, &#34;0.5779600000&#34;, &#34;-0.0655710000&#34;, &#34;-0.5637500000&#34;, &#34;0.3918000000&#34;, &#34;-0.0778960000&#34;, &#34;-0.3234600000&#34;, &#34;-0.3475600000&#34;, &#34;-0.3348200000&#34;, &#34;-0.1010500000&#34;, &#34;-0.0611140000&#34;, &#34;0.0550690000&#34;, &#34;-0.0905710000&#34;, &#34;-0.0815730000&#34;, &#34;-0.3094700000&#34;, &#34;-0.6805700000&#34;, &#34;0.0172680000&#34;, &#34;-0.2111600000&#34;, &#34;-0.1099300000&#34;, &#34;-0.0311870000&#34;, &#34;-0.3995600000&#34;, &#34;0.1094700000&#34;, &#34;-0.0548880000&#34;, &#34;0.1790500000&#34;, &#34;0.0158170000&#34;, &#34;0.1301700000&#34;, &#34;0.1595700000&#34;, &#34;-0.1519300000&#34;, &#34;-0.0928810000&#34;, &#34;0.0781060000&#34;, &#34;0.0519230000&#34;, &#34;-0.3589900000&#34;, &#34;0.0366990000&#34;, &#34;0.0662820000&#34;, &#34;-0.3750000000&#34;, &#34;0.0156820000&#34;, &#34;-0.3274300000&#34;, &#34;-0.1991800000&#34;, &#34;0.1159300000&#34;, &#34;-0.1478900000&#34;, &#34;-0.2842800000&#34;, &#34;-0.6705900000&#34;, &#34;-0.1556300000&#34;, &#34;-0.7228500000&#34;, &#34;-0.1450400000&#34;, &#34;-0.0868670000&#34;, &#34;0.1271600000&#34;, &#34;0.2324600000&#34;, &#34;0.0451520000&#34;, &#34;-0.0783510000&#34;, &#34;0.3321100000&#34;, &#34;-0.3912600000&#34;, &#34;-0.4054900000&#34;, &#34;-0.0341500000&#34;, &#34;-0.1628000000&#34;, &#34;0.3739500000&#34;, &#34;-0.3406000000&#34;, &#34;0.0241210000&#34;, &#34;-0.2131200000&#34;, &#34;0.1685600000&#34;, &#34;-0.1051900000&#34;, &#34;0.0422010000&#34;, &#34;-0.2304900000&#34;, &#34;0.2668200000&#34;, &#34;-0.2949800000&#34;, &#34;0.0866800000&#34;, &#34;0.1791200000&#34;, &#34;0.2326900000&#34;, &#34;0.0081227000&#34;, &#34;0.3044600000&#34;, &#34;-0.0068773000&#34;, &#34;-0.0314850000&#34;, &#34;-0.1289200000&#34;, &#34;-0.3601000000&#34;, &#34;0.2866800000&#34;, &#34;0.1896800000&#34;, &#34;0.1489800000&#34;, &#34;0.1840400000&#34;, &#34;0.0896390000&#34;, &#34;0.2711500000&#34;, &#34;-0.1706100000&#34;, &#34;0.2525000000&#34;, &#34;0.3225100000&#34;, &#34;-0.1207400000&#34;, &#34;0.1650200000&#34;, &#34;0.2747200000&#34;, &#34;0.1814400000&#34;, &#34;-0.1612200000&#34;, &#34;-0.2881100000&#34;, &#34;0.2643800000&#34;, &#34;-0.0423200000&#34;, &#34;0.4544400000&#34;, &#34;-0.3193500000&#34;, &#34;-0.4021500000&#34;, &#34;-0.0146670000&#34;, &#34;-0.0428330000&#34;, &#34;-0.0412490000&#34;, &#34;0.1641800000&#34;, &#34;0.1345000000&#34;, &#34;-0.2220100000&#34;, &#34;-0.1087600000&#34;, &#34;-0.5052200000&#34;, &#34;0.0882370000&#34;, &#34;0.2334200000&#34;, &#34;-0.1275600000&#34;, &#34;-0.1542900000&#34;, &#34;-0.0573300000&#34;, &#34;-0.2659200000&#34;, &#34;0.6617000000&#34;, &#34;-0.1194000000&#34;, &#34;0.0545380000&#34;, &#34;-0.1999100000&#34;, &#34;-0.0244130000&#34;, &#34;0.1016200000&#34;, &#34;-0.2644800000&#34;, &#34;0.2442800000&#34;, &#34;0.0035108000&#34;, &#34;-0.0334870000&#34;, &#34;-0.0689520000&#34;, &#34;-0.0041886000&#34;, &#34;0.5570600000&#34;, &#34;-0.0880990000&#34;, &#34;0.2995500000&#34;, &#34;0.1473100000&#34;, &#34;-0.2065700000&#34;, &#34;0.1496100000&#34;, &#34;0.2581300000&#34;, &#34;-0.0317330000&#34;, &#34;-0.1245700000&#34;, &#34;-0.0930970000&#34;, &#34;0.2215800000&#34;, &#34;-0.2244100000&#34;, &#34;0.2205600000&#34;, &#34;0.0828950000&#34;, &#34;0.3491200000&#34;, &#34;0.3267200000&#34;], [&#34;-0.0821570000&#34;, &#34;0.0551590000&#34;, &#34;-0.1657600000&#34;, &#34;0.3520600000&#34;, &#34;-0.0223220000&#34;, &#34;-0.0778630000&#34;, &#34;0.3862900000&#34;, &#34;-0.5446400000&#34;, &#34;0.1514000000&#34;, &#34;0.0972030000&#34;, &#34;-0.0744400000&#34;, &#34;0.2802400000&#34;, &#34;-0.0993530000&#34;, &#34;0.5928800000&#34;, &#34;-0.2579300000&#34;, &#34;-0.4403100000&#34;, &#34;-0.3942100000&#34;, &#34;0.1328900000&#34;, &#34;0.4262500000&#34;, &#34;0.1132500000&#34;, &#34;0.0027451000&#34;, &#34;0.1915600000&#34;, &#34;-0.0779630000&#34;, &#34;-0.3008900000&#34;, &#34;0.1516300000&#34;, &#34;0.2203600000&#34;, &#34;-0.3060000000&#34;, &#34;-0.3920400000&#34;, &#34;0.6744100000&#34;, &#34;-0.0266980000&#34;, &#34;-0.1476400000&#34;, &#34;0.0629660000&#34;, &#34;0.0200700000&#34;, &#34;0.2054200000&#34;, &#34;0.1375000000&#34;, &#34;-0.4318000000&#34;, &#34;0.3834700000&#34;, &#34;-0.5985100000&#34;, &#34;0.1957000000&#34;, &#34;-0.1516900000&#34;, &#34;-0.1199600000&#34;, &#34;-0.0382590000&#34;, &#34;0.2223900000&#34;, &#34;-0.0933100000&#34;, &#34;0.1947400000&#34;, &#34;0.4427000000&#34;, &#34;-0.0860080000&#34;, &#34;-0.3233300000&#34;, &#34;-0.0155910000&#34;, &#34;0.0335440000&#34;, &#34;0.3085100000&#34;, &#34;-0.5045400000&#34;, &#34;0.3970000000&#34;, &#34;-0.4759200000&#34;, &#34;-0.6172900000&#34;, &#34;0.0726510000&#34;, &#34;-0.2968100000&#34;, &#34;-0.0052561000&#34;, &#34;-0.3308900000&#34;, &#34;0.0097070000&#34;, &#34;-0.0155650000&#34;, &#34;-0.1932400000&#34;, &#34;0.6768100000&#34;, &#34;-0.4971600000&#34;, &#34;0.2152700000&#34;, &#34;0.1020500000&#34;, &#34;0.1463900000&#34;, &#34;0.0053264000&#34;, &#34;0.0847450000&#34;, &#34;0.0963660000&#34;, &#34;-0.0596670000&#34;, &#34;0.2078600000&#34;, &#34;0.2598500000&#34;, &#34;0.1488000000&#34;, &#34;-0.3508700000&#34;, &#34;-0.1753400000&#34;, &#34;-0.1306300000&#34;, &#34;-0.1562700000&#34;, &#34;0.1045500000&#34;, &#34;0.2493900000&#34;, &#34;0.2865200000&#34;, &#34;0.2166800000&#34;, &#34;-0.0218610000&#34;, &#34;0.0735370000&#34;, &#34;-0.1330200000&#34;, &#34;0.3135500000&#34;, &#34;-0.3336800000&#34;, &#34;0.5265100000&#34;, &#34;0.0995670000&#34;, &#34;0.4253800000&#34;, &#34;-0.1079600000&#34;, &#34;-0.0289250000&#34;, &#34;0.1756800000&#34;, &#34;-0.1813300000&#34;, &#34;-0.4076200000&#34;, &#34;0.2246200000&#34;, &#34;0.1657100000&#34;, &#34;-0.0463460000&#34;, &#34;-0.0763770000&#34;, &#34;-0.0573720000&#34;, &#34;-0.0857430000&#34;, &#34;-0.0299300000&#34;, &#34;0.0930800000&#34;, &#34;0.1665300000&#34;, &#34;0.1540500000&#34;, &#34;-0.1188400000&#34;, &#34;-0.2006600000&#34;, &#34;0.2996500000&#34;, &#34;0.1095100000&#34;, &#34;0.1393700000&#34;, &#34;-0.1359100000&#34;, &#34;0.0366770000&#34;, &#34;-0.4156400000&#34;, &#34;-0.1751100000&#34;, &#34;0.3539200000&#34;, &#34;0.3526300000&#34;, &#34;0.0637140000&#34;, &#34;0.0035714000&#34;, &#34;-0.2909300000&#34;, &#34;-0.0741830000&#34;, &#34;0.5216200000&#34;, &#34;-0.0087506000&#34;, &#34;-0.2356600000&#34;, &#34;0.2029100000&#34;, &#34;-0.1011300000&#34;, &#34;-0.2151200000&#34;, &#34;0.0304650000&#34;, &#34;0.4477600000&#34;, &#34;-0.0048431000&#34;, &#34;0.1511700000&#34;, &#34;-0.4036500000&#34;, &#34;-0.3351900000&#34;, &#34;-0.3376000000&#34;, &#34;-0.1276200000&#34;, &#34;-0.1516600000&#34;, &#34;0.1038000000&#34;, &#34;-0.0031190000&#34;, &#34;-0.1878700000&#34;, &#34;0.0217180000&#34;, &#34;-0.3423000000&#34;, &#34;0.1781300000&#34;, &#34;0.2007700000&#34;, &#34;-0.2571600000&#34;, &#34;-0.1021700000&#34;, &#34;-0.0583640000&#34;, &#34;0.4881100000&#34;, &#34;0.0753900000&#34;, &#34;0.2455000000&#34;, &#34;-0.1272200000&#34;, &#34;0.4704300000&#34;, &#34;0.2874000000&#34;, &#34;-0.3336200000&#34;, &#34;-0.1766600000&#34;, &#34;-0.4117600000&#34;, &#34;-0.2270500000&#34;, &#34;0.0977800000&#34;, &#34;-0.3651100000&#34;, &#34;0.0178340000&#34;, &#34;0.1581100000&#34;, &#34;-0.0377300000&#34;, &#34;-0.0450480000&#34;, &#34;0.1042400000&#34;, &#34;-0.4253300000&#34;, &#34;-0.2591700000&#34;, &#34;0.2554700000&#34;, &#34;0.1730600000&#34;, &#34;-0.0229010000&#34;, &#34;-0.3288000000&#34;, &#34;-0.1891700000&#34;, &#34;0.3146000000&#34;, &#34;0.0037259000&#34;, &#34;-0.0311420000&#34;, &#34;-0.0112230000&#34;, &#34;-0.0949450000&#34;, &#34;-0.3705100000&#34;, &#34;-0.1865700000&#34;, &#34;-0.0765260000&#34;, &#34;0.1120600000&#34;, &#34;-0.2587400000&#34;, &#34;-0.1570700000&#34;, &#34;0.0258250000&#34;, &#34;-0.1485100000&#34;, &#34;-0.0449910000&#34;, &#34;0.1428600000&#34;, &#34;-0.1632800000&#34;, &#34;0.3083000000&#34;, &#34;0.0136670000&#34;, &#34;-0.1186900000&#34;, &#34;-0.1623500000&#34;, &#34;-0.0047887000&#34;, &#34;0.0415350000&#34;, &#34;-0.4218700000&#34;, &#34;-0.2952500000&#34;, &#34;-0.2038600000&#34;, &#34;-0.2014100000&#34;, &#34;0.2563700000&#34;, &#34;0.1457700000&#34;, &#34;-0.0319150000&#34;, &#34;-0.2285200000&#34;, &#34;0.2501200000&#34;, &#34;-0.3111800000&#34;, &#34;-0.1793900000&#34;, &#34;-0.0982310000&#34;, &#34;-0.0381850000&#34;, &#34;-0.1336400000&#34;, &#34;0.0192960000&#34;, &#34;-0.2208900000&#34;, &#34;-0.1206300000&#34;, &#34;0.2097200000&#34;, &#34;0.2853500000&#34;, &#34;0.1813300000&#34;, &#34;0.0294660000&#34;, &#34;-0.0646010000&#34;, &#34;-0.1771300000&#34;, &#34;0.4132300000&#34;, &#34;-0.2959900000&#34;, &#34;-0.3212300000&#34;, &#34;-0.1448700000&#34;, &#34;-0.3139500000&#34;, &#34;0.1505100000&#34;, &#34;0.1628600000&#34;, &#34;-0.3218000000&#34;, &#34;-0.3945900000&#34;, &#34;-0.2566500000&#34;, &#34;-0.4434100000&#34;, &#34;0.3812200000&#34;, &#34;-0.0107890000&#34;, &#34;-0.4741300000&#34;, &#34;-0.4508600000&#34;, &#34;-0.0834800000&#34;, &#34;0.0299350000&#34;, &#34;-0.1000300000&#34;, &#34;0.3764500000&#34;, &#34;0.0001085700&#34;, &#34;0.0299450000&#34;, &#34;-0.0416520000&#34;, &#34;0.3458600000&#34;, &#34;-0.2455000000&#34;, &#34;-0.1765200000&#34;, &#34;-0.4379600000&#34;, &#34;-0.1578200000&#34;, &#34;0.1923100000&#34;, &#34;-0.4150300000&#34;, &#34;0.1487400000&#34;, &#34;-0.2540100000&#34;, &#34;-0.0940380000&#34;, &#34;0.3424200000&#34;, &#34;0.2924100000&#34;, &#34;-0.1216100000&#34;, &#34;-0.2287700000&#34;, &#34;-0.4925200000&#34;, &#34;-0.1334900000&#34;, &#34;0.2400900000&#34;, &#34;-0.0273510000&#34;, &#34;-0.1193900000&#34;, &#34;0.0464170000&#34;, &#34;-0.2726200000&#34;, &#34;-0.8609100000&#34;, &#34;0.0243370000&#34;, &#34;-0.0293280000&#34;, &#34;-0.2932100000&#34;, &#34;0.5959400000&#34;, &#34;-0.1634700000&#34;, &#34;-0.3189200000&#34;, &#34;-0.3741700000&#34;, &#34;-0.3039100000&#34;, &#34;0.3405600000&#34;, &#34;-0.2369400000&#34;, &#34;-0.1842700000&#34;, &#34;-0.1660400000&#34;, &#34;-0.2861000000&#34;, &#34;-0.1751800000&#34;, &#34;-0.0028950000&#34;, &#34;0.2197000000&#34;, &#34;-0.1751500000&#34;, &#34;-0.1430100000&#34;, &#34;0.1372400000&#34;, &#34;0.3685000000&#34;, &#34;0.1130900000&#34;, &#34;0.0589650000&#34;, &#34;-0.1478800000&#34;, &#34;0.0853980000&#34;, &#34;0.3102600000&#34;, &#34;0.1133000000&#34;, &#34;0.5054500000&#34;, &#34;0.3415200000&#34;, &#34;0.2930000000&#34;, &#34;0.3244900000&#34;, &#34;-0.0282710000&#34;, &#34;-0.0818050000&#34;, &#34;-0.0356940000&#34;, &#34;-0.2337500000&#34;, &#34;-0.0441030000&#34;, &#34;-0.0967910000&#34;, &#34;-0.1861400000&#34;, &#34;-0.3800900000&#34;, &#34;0.0523130000&#34;, &#34;0.0664720000&#34;, &#34;-0.1679500000&#34;, &#34;0.4734300000&#34;], [&#34;0.0488040000&#34;, &#34;-0.2852800000&#34;, &#34;0.0185570000&#34;, &#34;0.2057700000&#34;, &#34;0.0607040000&#34;, &#34;0.0854460000&#34;, &#34;-0.0362670000&#34;, &#34;-0.0683730000&#34;, &#34;0.1450700000&#34;, &#34;0.1785200000&#34;, &#34;0.1457900000&#34;, &#34;-0.1363000000&#34;, &#34;0.2334800000&#34;, &#34;0.0297580000&#34;, &#34;-0.2200100000&#34;, &#34;-0.0045515000&#34;, &#34;-0.1119700000&#34;, &#34;-0.0413670000&#34;, &#34;0.0842310000&#34;, &#34;0.0766730000&#34;, &#34;-0.2446100000&#34;, &#34;0.0535930000&#34;, &#34;-0.1093900000&#34;, &#34;-0.1246800000&#34;, &#34;-0.2029000000&#34;, &#34;0.0745650000&#34;, &#34;0.1066000000&#34;, &#34;0.0543390000&#34;, &#34;0.0882680000&#34;, &#34;0.2255700000&#34;, &#34;-0.0290810000&#34;, &#34;0.2980000000&#34;, &#34;-0.1612900000&#34;, &#34;0.3641900000&#34;, &#34;0.0739780000&#34;, &#34;-0.0895610000&#34;, &#34;-0.0411040000&#34;, &#34;-0.2427700000&#34;, &#34;-0.0058010000&#34;, &#34;-0.0628380000&#34;, &#34;0.0617660000&#34;, &#34;-0.0633800000&#34;, &#34;0.0648860000&#34;, &#34;0.0766810000&#34;, &#34;0.0547310000&#34;, &#34;-0.1214600000&#34;, &#34;-0.1090700000&#34;, &#34;-0.0927890000&#34;, &#34;0.0335690000&#34;, &#34;-0.1898400000&#34;, &#34;0.0891000000&#34;, &#34;0.0130160000&#34;, &#34;-0.0515710000&#34;, &#34;0.0280400000&#34;, &#34;0.1269700000&#34;, &#34;-0.0775540000&#34;, &#34;0.1572200000&#34;, &#34;0.0774760000&#34;, &#34;-0.1634300000&#34;, &#34;0.1654700000&#34;, &#34;-0.2609900000&#34;, &#34;-0.2912200000&#34;, &#34;0.3018200000&#34;, &#34;-0.1675900000&#34;, &#34;-0.0565190000&#34;, &#34;-0.1289800000&#34;, &#34;-0.1970200000&#34;, &#34;-0.1511800000&#34;, &#34;-0.1337400000&#34;, &#34;-0.1500300000&#34;, &#34;-0.2352500000&#34;, &#34;-0.1591500000&#34;, &#34;0.1304200000&#34;, &#34;-0.0273440000&#34;, &#34;-0.1242700000&#34;, &#34;-0.0436310000&#34;, &#34;0.1241400000&#34;, &#34;0.3488900000&#34;, &#34;0.0494370000&#34;, &#34;-0.0101120000&#34;, &#34;0.2024700000&#34;, &#34;0.0822940000&#34;, &#34;-0.1515700000&#34;, &#34;-0.2273700000&#34;, &#34;0.1206400000&#34;, &#34;-0.0613040000&#34;, &#34;-0.0777130000&#34;, &#34;0.1096000000&#34;, &#34;-0.0960960000&#34;, &#34;-0.2033800000&#34;, &#34;-0.0229400000&#34;, &#34;0.1594500000&#34;, &#34;0.2332500000&#34;, &#34;-0.2310700000&#34;, &#34;0.0526840000&#34;, &#34;-0.0969460000&#34;, &#34;0.0573730000&#34;, &#34;0.1414300000&#34;, &#34;0.0765470000&#34;, &#34;0.0182650000&#34;, &#34;0.0640910000&#34;, &#34;0.0448580000&#34;, &#34;0.0881280000&#34;, &#34;-0.1169400000&#34;, &#34;-0.2496000000&#34;, &#34;-0.1304900000&#34;, &#34;-0.0830170000&#34;, &#34;-0.0600820000&#34;, &#34;0.0240550000&#34;, &#34;-0.0207480000&#34;, &#34;0.0391350000&#34;, &#34;0.0435670000&#34;, &#34;-0.1020800000&#34;, &#34;-0.1546400000&#34;, &#34;0.1289200000&#34;, &#34;-0.0241900000&#34;, &#34;0.0453700000&#34;, &#34;0.1277800000&#34;, &#34;0.1321200000&#34;, &#34;0.1920800000&#34;, &#34;0.2473700000&#34;, &#34;0.1240600000&#34;, &#34;-0.2024600000&#34;, &#34;0.1376200000&#34;, &#34;-0.0231510000&#34;, &#34;0.0417360000&#34;, &#34;-0.0139670000&#34;, &#34;0.1819400000&#34;, &#34;0.1621000000&#34;, &#34;0.0625860000&#34;, &#34;-0.0799810000&#34;, &#34;0.1318400000&#34;, &#34;-0.0773880000&#34;, &#34;0.0203130000&#34;, &#34;-0.0414880000&#34;, &#34;0.0205240000&#34;, &#34;-0.1131000000&#34;, &#34;0.1463900000&#34;, &#34;0.0801130000&#34;, &#34;0.0368500000&#34;, &#34;0.1364000000&#34;, &#34;-0.0097955000&#34;, &#34;0.1177900000&#34;, &#34;0.1354700000&#34;, &#34;0.2289000000&#34;, &#34;0.2123100000&#34;, &#34;-0.0797790000&#34;, &#34;0.1383100000&#34;, &#34;-0.0761140000&#34;, &#34;0.0285630000&#34;, &#34;0.1144100000&#34;, &#34;-0.1545500000&#34;, &#34;-0.0832670000&#34;, &#34;-0.0571670000&#34;, &#34;-0.0993520000&#34;, &#34;-0.1706300000&#34;, &#34;-0.0717570000&#34;, &#34;-0.0514970000&#34;, &#34;0.2656800000&#34;, &#34;0.0187990000&#34;, &#34;-0.2722000000&#34;, &#34;0.1268000000&#34;, &#34;-0.0210450000&#34;, &#34;0.0588310000&#34;, &#34;0.3021300000&#34;, &#34;-0.0352550000&#34;, &#34;-0.0959520000&#34;, &#34;-0.0390820000&#34;, &#34;0.2036900000&#34;, &#34;-0.1786900000&#34;, &#34;-0.2618800000&#34;, &#34;-0.1100600000&#34;, &#34;-0.1569400000&#34;, &#34;-0.0288030000&#34;, &#34;-0.2387200000&#34;, &#34;0.1559400000&#34;, &#34;0.0087185000&#34;, &#34;0.2405300000&#34;, &#34;0.1213900000&#34;, &#34;0.1372800000&#34;, &#34;0.0159270000&#34;, &#34;-0.0133860000&#34;, &#34;-0.0690450000&#34;, &#34;0.1030300000&#34;, &#34;-0.0720710000&#34;, &#34;0.2796200000&#34;, &#34;0.1915700000&#34;, &#34;-0.1381000000&#34;, &#34;0.0713930000&#34;, &#34;-0.0315480000&#34;, &#34;-0.0352990000&#34;, &#34;-0.0746090000&#34;, &#34;0.2041500000&#34;, &#34;0.0718500000&#34;, &#34;-0.0686720000&#34;, &#34;-0.0412170000&#34;, &#34;-0.0870570000&#34;, &#34;-0.1166500000&#34;, &#34;-0.2025700000&#34;, &#34;0.0731880000&#34;, &#34;-0.0734970000&#34;, &#34;-0.2795100000&#34;, &#34;-0.1739300000&#34;, &#34;0.0640050000&#34;, &#34;-0.0503940000&#34;, &#34;-0.0444260000&#34;, &#34;0.0084868000&#34;, &#34;0.0651470000&#34;, &#34;0.0753810000&#34;, &#34;0.1112400000&#34;, &#34;0.2497100000&#34;, &#34;0.1669600000&#34;, &#34;0.0404720000&#34;, &#34;-0.1453300000&#34;, &#34;0.0167630000&#34;, &#34;-0.1127300000&#34;, &#34;0.0174350000&#34;, &#34;-0.1917700000&#34;, &#34;-0.0449610000&#34;, &#34;0.0856380000&#34;, &#34;0.0793410000&#34;, &#34;-0.0462130000&#34;, &#34;-0.2025500000&#34;, &#34;0.2627400000&#34;, &#34;-0.0910530000&#34;, &#34;0.0777210000&#34;, &#34;-0.1545400000&#34;, &#34;0.0423210000&#34;, &#34;0.1174200000&#34;, &#34;-0.0860410000&#34;, &#34;0.0876110000&#34;, &#34;0.2136500000&#34;, &#34;-0.1359700000&#34;, &#34;-0.0299870000&#34;, &#34;-0.0210530000&#34;, &#34;0.0262220000&#34;, &#34;-0.0637410000&#34;, &#34;-0.0836490000&#34;, &#34;0.0165660000&#34;, &#34;0.0435410000&#34;, &#34;-0.0390120000&#34;, &#34;-0.0099747000&#34;, &#34;0.1342700000&#34;, &#34;0.0632090000&#34;, &#34;0.2282500000&#34;, &#34;0.1484400000&#34;, &#34;0.0329260000&#34;, &#34;-0.1901200000&#34;, &#34;0.1983800000&#34;, &#34;-0.2236900000&#34;, &#34;0.0001884700&#34;, &#34;0.1740500000&#34;, &#34;-0.0379030000&#34;, &#34;0.0206610000&#34;, &#34;-0.0840530000&#34;, &#34;0.1841900000&#34;, &#34;0.0285170000&#34;, &#34;-0.0980060000&#34;, &#34;0.1993900000&#34;, &#34;0.0798100000&#34;, &#34;0.1241000000&#34;, &#34;0.0952500000&#34;, &#34;-0.0353410000&#34;, &#34;0.0841300000&#34;, &#34;-0.0823030000&#34;, &#34;-0.0757920000&#34;, &#34;0.1653500000&#34;, &#34;0.1158100000&#34;, &#34;0.0130190000&#34;, &#34;-0.0808940000&#34;, &#34;-0.0104000000&#34;, &#34;-0.0787360000&#34;, &#34;-0.1112200000&#34;, &#34;0.0289960000&#34;, &#34;-0.0633100000&#34;, &#34;-0.0339300000&#34;, &#34;0.0205720000&#34;, &#34;0.2645200000&#34;, &#34;0.0017304000&#34;, &#34;0.0190020000&#34;, &#34;0.1413200000&#34;, &#34;-0.0791100000&#34;, &#34;0.1535600000&#34;, &#34;0.0728730000&#34;, &#34;0.0871680000&#34;, &#34;-0.0055530000&#34;, &#34;-0.0200730000&#34;, &#34;0.1502200000&#34;, &#34;-0.0153510000&#34;, &#34;0.1674300000&#34;, &#34;0.1695600000&#34;, &#34;-0.3367700000&#34;, &#34;-0.0602860000&#34;, &#34;0.0860970000&#34;, &#34;-0.0650010000&#34;, &#34;0.0048331000&#34;, &#34;-0.1009600000&#34;, &#34;0.1391000000&#34;, &#34;-0.1371400000&#34;, &#34;-0.0397050000&#34;], [&#34;0.2576100000&#34;, &#34;0.0498830000&#34;, &#34;0.2522900000&#34;, &#34;0.4697300000&#34;, &#34;0.1034600000&#34;, &#34;-0.0240450000&#34;, &#34;0.0088398000&#34;, &#34;-0.2274800000&#34;, &#34;0.4485000000&#34;, &#34;-0.0707920000&#34;, &#34;0.4768700000&#34;, &#34;0.0553360000&#34;, &#34;-0.1565000000&#34;, &#34;-0.2308300000&#34;, &#34;0.4498700000&#34;, &#34;-0.0644760000&#34;, &#34;0.1669300000&#34;, &#34;-0.0715100000&#34;, &#34;0.3342400000&#34;, &#34;0.3535400000&#34;, &#34;-0.2725600000&#34;, &#34;0.1478900000&#34;, &#34;0.1803300000&#34;, &#34;-0.0472340000&#34;, &#34;-0.2308600000&#34;, &#34;0.3127800000&#34;, &#34;-0.0118420000&#34;, &#34;0.2047800000&#34;, &#34;-0.3107600000&#34;, &#34;0.2896700000&#34;, &#34;-0.2036400000&#34;, &#34;0.4134400000&#34;, &#34;-0.3138900000&#34;, &#34;-0.0244240000&#34;, &#34;0.1570300000&#34;, &#34;0.0415070000&#34;, &#34;0.1052000000&#34;, &#34;-0.0450440000&#34;, &#34;0.0137740000&#34;, &#34;-0.0611710000&#34;, &#34;0.4547900000&#34;, &#34;-0.0195840000&#34;, &#34;-0.3795500000&#34;, &#34;0.4757900000&#34;, &#34;0.0349800000&#34;, &#34;0.2764000000&#34;, &#34;-0.1168200000&#34;, &#34;0.1686200000&#34;, &#34;-0.0475000000&#34;, &#34;-0.0996640000&#34;, &#34;-0.0956250000&#34;, &#34;-0.1745400000&#34;, &#34;0.0430370000&#34;, &#34;-0.0571580000&#34;, &#34;0.0347470000&#34;, &#34;-0.1270000000&#34;, &#34;-0.1546000000&#34;, &#34;-0.1156300000&#34;, &#34;-0.4520600000&#34;, &#34;-0.0140030000&#34;, &#34;-0.2059100000&#34;, &#34;0.0766850000&#34;, &#34;0.3093800000&#34;, &#34;0.2549300000&#34;, &#34;-0.1845700000&#34;, &#34;-0.2392600000&#34;, &#34;-0.1454200000&#34;, &#34;0.2572800000&#34;, &#34;0.2311600000&#34;, &#34;-0.1269500000&#34;, &#34;-0.1668300000&#34;, &#34;0.1106600000&#34;, &#34;0.0136380000&#34;, &#34;0.1033000000&#34;, &#34;0.0856880000&#34;, &#34;-0.0219830000&#34;, &#34;0.5544900000&#34;, &#34;0.0224660000&#34;, &#34;0.0407880000&#34;, &#34;-0.2900500000&#34;, &#34;-0.0578260000&#34;, &#34;0.3924500000&#34;, &#34;-0.3068200000&#34;, &#34;-0.2656900000&#34;, &#34;0.0958790000&#34;, &#34;0.0431440000&#34;, &#34;-0.1065100000&#34;, &#34;0.1602600000&#34;, &#34;0.0078983000&#34;, &#34;0.0719570000&#34;, &#34;-0.0682610000&#34;, &#34;0.1889700000&#34;, &#34;0.4482300000&#34;, &#34;-0.4827000000&#34;, &#34;-0.0824450000&#34;, &#34;0.1179600000&#34;, &#34;0.3445000000&#34;, &#34;0.1846700000&#34;, &#34;-0.3836300000&#34;, &#34;-0.0253770000&#34;, &#34;0.1451000000&#34;, &#34;0.1030600000&#34;, &#34;0.2302700000&#34;, &#34;-0.1013100000&#34;, &#34;-0.1802600000&#34;, &#34;-0.1979700000&#34;, &#34;-0.1414100000&#34;, &#34;0.0243780000&#34;, &#34;-0.1174700000&#34;, &#34;0.0429810000&#34;, &#34;-0.3171400000&#34;, &#34;0.3114000000&#34;, &#34;-0.2077200000&#34;, &#34;-0.1691500000&#34;, &#34;-0.0474650000&#34;, &#34;-0.1797400000&#34;, &#34;0.0740380000&#34;, &#34;-0.2572700000&#34;, &#34;-0.0477410000&#34;, &#34;-0.0261270000&#34;, &#34;0.2260500000&#34;, &#34;-0.2186200000&#34;, &#34;-0.3768000000&#34;, &#34;0.1168700000&#34;, &#34;0.0878920000&#34;, &#34;0.0253730000&#34;, &#34;-0.1511300000&#34;, &#34;-0.3771800000&#34;, &#34;-0.0941650000&#34;, &#34;0.2612200000&#34;, &#34;-0.0948940000&#34;, &#34;0.0966500000&#34;, &#34;0.1221900000&#34;, &#34;0.3357000000&#34;, &#34;-0.4663500000&#34;, &#34;0.1240100000&#34;, &#34;-0.0280710000&#34;, &#34;-0.0353240000&#34;, &#34;-0.1160400000&#34;, &#34;0.1255900000&#34;, &#34;0.1294500000&#34;, &#34;0.3766500000&#34;, &#34;-0.0498470000&#34;, &#34;0.1566400000&#34;, &#34;0.1644400000&#34;, &#34;0.4491300000&#34;, &#34;0.3040100000&#34;, &#34;0.0566570000&#34;, &#34;-0.1629300000&#34;, &#34;0.0433950000&#34;, &#34;-0.1707100000&#34;, &#34;-0.2768000000&#34;, &#34;-0.5619900000&#34;, &#34;-0.1267300000&#34;, &#34;0.0284040000&#34;, &#34;-0.3314100000&#34;, &#34;-0.1353900000&#34;, &#34;-0.2051000000&#34;, &#34;0.1561200000&#34;, &#34;0.0321760000&#34;, &#34;0.0325120000&#34;, &#34;0.3252900000&#34;, &#34;-0.0204760000&#34;, &#34;-0.2660400000&#34;, &#34;0.2923800000&#34;, &#34;-0.0918760000&#34;, &#34;0.2176400000&#34;, &#34;0.3006700000&#34;, &#34;0.1130500000&#34;, &#34;0.0756780000&#34;, &#34;-0.2516200000&#34;, &#34;-0.1369600000&#34;, &#34;-0.2226500000&#34;, &#34;0.0929890000&#34;, &#34;-0.0540260000&#34;, &#34;-0.0310660000&#34;, &#34;-0.1757100000&#34;, &#34;0.0034190000&#34;, &#34;0.4077300000&#34;, &#34;-0.2868300000&#34;, &#34;0.0818900000&#34;, &#34;0.0356060000&#34;, &#34;-0.1427700000&#34;, &#34;0.0441420000&#34;, &#34;0.0596490000&#34;, &#34;0.3647200000&#34;, &#34;-0.2288400000&#34;, &#34;0.0157600000&#34;, &#34;0.1556600000&#34;, &#34;-0.2784400000&#34;, &#34;-0.4091900000&#34;, &#34;-0.1635800000&#34;, &#34;0.0723090000&#34;, &#34;0.2206900000&#34;, &#34;0.1242000000&#34;, &#34;0.0138220000&#34;, &#34;0.1920100000&#34;, &#34;0.2486900000&#34;, &#34;-0.1761000000&#34;, &#34;-0.2160900000&#34;, &#34;-0.2101800000&#34;, &#34;-0.3116400000&#34;, &#34;-0.1328500000&#34;, &#34;0.1315200000&#34;, &#34;-0.0828380000&#34;, &#34;-0.1720700000&#34;, &#34;0.0142350000&#34;, &#34;0.0000532270&#34;, &#34;0.6004800000&#34;, &#34;0.1395700000&#34;, &#34;0.6135400000&#34;, &#34;-0.1014600000&#34;, &#34;0.0895460000&#34;, &#34;-0.0718870000&#34;, &#34;-0.0797020000&#34;, &#34;-0.2143200000&#34;, &#34;-0.1823300000&#34;, &#34;0.1172300000&#34;, &#34;0.0926630000&#34;, &#34;0.1273800000&#34;, &#34;-0.2187700000&#34;, &#34;0.4550800000&#34;, &#34;-0.1949000000&#34;, &#34;0.1642300000&#34;, &#34;0.0079016000&#34;, &#34;0.0051538000&#34;, &#34;-0.3267000000&#34;, &#34;-0.0764360000&#34;, &#34;-0.2438000000&#34;, &#34;-0.2685200000&#34;, &#34;0.0193920000&#34;, &#34;-0.1682000000&#34;, &#34;-0.0994380000&#34;, &#34;-0.3137100000&#34;, &#34;-0.1200100000&#34;, &#34;0.0051944000&#34;, &#34;0.0029277000&#34;, &#34;0.2245500000&#34;, &#34;-0.3278500000&#34;, &#34;0.3743800000&#34;, &#34;0.1684900000&#34;, &#34;-0.1351700000&#34;, &#34;-0.0438710000&#34;, &#34;0.1709000000&#34;, &#34;0.0181980000&#34;, &#34;-0.4817400000&#34;, &#34;-0.0249240000&#34;, &#34;-0.3569000000&#34;, &#34;-0.2236400000&#34;, &#34;-0.1536800000&#34;, &#34;0.0366920000&#34;, &#34;0.0108350000&#34;, &#34;-0.1188100000&#34;, &#34;-0.0135090000&#34;, &#34;-0.3823800000&#34;, &#34;-0.0655870000&#34;, &#34;0.0649680000&#34;, &#34;-0.1670200000&#34;, &#34;0.0601880000&#34;, &#34;0.0726660000&#34;, &#34;-0.1894900000&#34;, &#34;-0.1669000000&#34;, &#34;0.1220200000&#34;, &#34;-0.6277000000&#34;, &#34;0.0577930000&#34;, &#34;0.0557220000&#34;, &#34;-0.1216900000&#34;, &#34;0.2617200000&#34;, &#34;-0.1390000000&#34;, &#34;-0.0465770000&#34;, &#34;-0.2551400000&#34;, &#34;0.2811700000&#34;, &#34;-0.3228100000&#34;, &#34;-0.2040800000&#34;, &#34;0.0238830000&#34;, &#34;-0.2731800000&#34;, &#34;0.2812600000&#34;, &#34;0.2255100000&#34;, &#34;-0.2777100000&#34;, &#34;0.1377300000&#34;, &#34;-0.1328300000&#34;, &#34;-0.1103800000&#34;, &#34;-0.0364880000&#34;, &#34;-0.1647500000&#34;, &#34;0.0441320000&#34;, &#34;-0.3204900000&#34;, &#34;-0.0297440000&#34;, &#34;-0.0134920000&#34;, &#34;0.0570560000&#34;, &#34;-0.0111380000&#34;, &#34;0.5766000000&#34;, &#34;-0.1950200000&#34;, &#34;0.3828600000&#34;, &#34;-0.0409440000&#34;, &#34;0.1138800000&#34;, &#34;-0.1461900000&#34;, &#34;-0.0389640000&#34;, &#34;0.1082000000&#34;, &#34;0.0137960000&#34;, &#34;-0.3645600000&#34;], [&#34;-0.1872000000&#34;, &#34;-0.0302420000&#34;, &#34;-0.2254600000&#34;, &#34;0.4859600000&#34;, &#34;-0.3529400000&#34;, &#34;-0.3825400000&#34;, &#34;0.0929030000&#34;, &#34;-0.3685200000&#34;, &#34;-0.1951600000&#34;, &#34;-0.0498530000&#34;, &#34;0.0908620000&#34;, &#34;0.0407990000&#34;, &#34;-0.3072100000&#34;, &#34;-0.0709640000&#34;, &#34;-0.0941560000&#34;, &#34;-0.0978660000&#34;, &#34;-0.1372500000&#34;, &#34;-0.0414930000&#34;, &#34;0.3032700000&#34;, &#34;0.1050900000&#34;, &#34;-0.0076578000&#34;, &#34;-0.1000700000&#34;, &#34;0.0800080000&#34;, &#34;-0.2233700000&#34;, &#34;0.0359090000&#34;, &#34;-0.0584450000&#34;, &#34;0.0244540000&#34;, &#34;-0.1193400000&#34;, &#34;0.1702500000&#34;, &#34;-0.3432500000&#34;, &#34;0.1077500000&#34;, &#34;0.5631200000&#34;, &#34;-0.5181200000&#34;, &#34;-0.1461600000&#34;, &#34;0.1113700000&#34;, &#34;-0.4206000000&#34;, &#34;0.0596090000&#34;, &#34;0.1471300000&#34;, &#34;0.2001500000&#34;, &#34;-0.1909500000&#34;, &#34;0.1685900000&#34;, &#34;0.0076862000&#34;, &#34;0.0351940000&#34;, &#34;-0.0800700000&#34;, &#34;-0.1226700000&#34;, &#34;0.1733700000&#34;, &#34;0.0905270000&#34;, &#34;0.0217220000&#34;, &#34;0.2671000000&#34;, &#34;-0.1678600000&#34;, &#34;0.3143600000&#34;, &#34;0.0912250000&#34;, &#34;-0.2971400000&#34;, &#34;-0.5219500000&#34;, &#34;0.1874100000&#34;, &#34;0.2489300000&#34;, &#34;0.2154500000&#34;, &#34;0.5061000000&#34;, &#34;0.0684540000&#34;, &#34;-0.5239000000&#34;, &#34;-0.2948300000&#34;, &#34;0.0606950000&#34;, &#34;0.1887500000&#34;, &#34;-0.0923290000&#34;, &#34;-0.0058402000&#34;, &#34;-0.0352760000&#34;, &#34;-0.4210000000&#34;, &#34;-0.1033500000&#34;, &#34;-0.1876500000&#34;, &#34;-0.4809900000&#34;, &#34;-0.5377500000&#34;, &#34;-0.1599100000&#34;, &#34;0.1835900000&#34;, &#34;0.0864560000&#34;, &#34;-0.1268000000&#34;, &#34;0.1318300000&#34;, &#34;0.3980000000&#34;, &#34;-0.2230200000&#34;, &#34;0.2135200000&#34;, &#34;-0.4014300000&#34;, &#34;-0.2573700000&#34;, &#34;-0.0931500000&#34;, &#34;-0.2693700000&#34;, &#34;-0.2378500000&#34;, &#34;-0.7180800000&#34;, &#34;0.0019796000&#34;, &#34;-0.1154700000&#34;, &#34;-0.0263870000&#34;, &#34;-0.1542000000&#34;, &#34;-0.0280980000&#34;, &#34;-0.0285050000&#34;, &#34;0.3491400000&#34;, &#34;0.4856400000&#34;, &#34;-0.1690300000&#34;, &#34;0.1436600000&#34;, &#34;0.0318030000&#34;, &#34;0.3217800000&#34;, &#34;0.1380500000&#34;, &#34;0.2728200000&#34;, &#34;0.5049100000&#34;, &#34;0.1664300000&#34;, &#34;-0.1448900000&#34;, &#34;0.2125200000&#34;, &#34;-0.1341200000&#34;, &#34;0.0838860000&#34;, &#34;-0.2328500000&#34;, &#34;-0.3145600000&#34;, &#34;0.3400200000&#34;, &#34;-0.3158500000&#34;, &#34;0.0759740000&#34;, &#34;0.1302700000&#34;, &#34;-0.0240090000&#34;, &#34;-0.0903000000&#34;, &#34;-0.1906600000&#34;, &#34;-0.3051900000&#34;, &#34;-0.1550300000&#34;, &#34;0.0072282000&#34;, &#34;0.3208200000&#34;, &#34;-0.1138600000&#34;, &#34;-0.0513200000&#34;, &#34;0.6661500000&#34;, &#34;-0.0855150000&#34;, &#34;-0.4434600000&#34;, &#34;0.1410600000&#34;, &#34;0.1760400000&#34;, &#34;0.4323200000&#34;, &#34;-0.4307000000&#34;, &#34;-0.0598750000&#34;, &#34;-0.1399500000&#34;, &#34;0.2492800000&#34;, &#34;0.0695550000&#34;, &#34;0.0965270000&#34;, &#34;0.0939160000&#34;, &#34;0.0617970000&#34;, &#34;0.0525190000&#34;, &#34;-0.0749970000&#34;, &#34;-0.0488870000&#34;, &#34;0.3896500000&#34;, &#34;-0.0437090000&#34;, &#34;0.6691200000&#34;, &#34;0.1628500000&#34;, &#34;0.0932350000&#34;, &#34;-0.0328160000&#34;, &#34;0.1839800000&#34;, &#34;-0.0754280000&#34;, &#34;-0.2968400000&#34;, &#34;0.1668600000&#34;, &#34;0.0593240000&#34;, &#34;0.0251530000&#34;, &#34;0.0512080000&#34;, &#34;0.5032000000&#34;, &#34;0.0594630000&#34;, &#34;-0.1619200000&#34;, &#34;-0.4913400000&#34;, &#34;-0.1015400000&#34;, &#34;-0.4073700000&#34;, &#34;0.4849100000&#34;, &#34;-0.1077600000&#34;, &#34;-0.2144100000&#34;, &#34;-0.5785900000&#34;, &#34;0.0542930000&#34;, &#34;0.0497600000&#34;, &#34;0.0423400000&#34;, &#34;0.2114500000&#34;, &#34;-0.0863330000&#34;, &#34;0.1085400000&#34;, &#34;-0.5758900000&#34;, &#34;-0.3975800000&#34;, &#34;0.1180800000&#34;, &#34;0.2298500000&#34;, &#34;-0.3438700000&#34;, &#34;-0.0920800000&#34;, &#34;-0.1144600000&#34;, &#34;0.0740170000&#34;, &#34;-0.4509900000&#34;, &#34;-0.0822830000&#34;, &#34;0.1899500000&#34;, &#34;-0.1227300000&#34;, &#34;-0.1095900000&#34;, &#34;-0.0005473000&#34;, &#34;0.6126900000&#34;, &#34;-0.2204800000&#34;, &#34;0.1407300000&#34;, &#34;-0.0395650000&#34;, &#34;0.1667500000&#34;, &#34;0.5801700000&#34;, &#34;-0.0584250000&#34;, &#34;-0.0619060000&#34;, &#34;0.6612200000&#34;, &#34;-0.0712260000&#34;, &#34;-0.2108400000&#34;, &#34;-0.1812200000&#34;, &#34;-0.0101210000&#34;, &#34;0.3141200000&#34;, &#34;-0.2826000000&#34;, &#34;-0.1921900000&#34;, &#34;-0.0458870000&#34;, &#34;0.3238600000&#34;, &#34;-0.4751300000&#34;, &#34;-0.0933170000&#34;, &#34;0.0754570000&#34;, &#34;-0.0080931000&#34;, &#34;0.0897010000&#34;, &#34;-0.2116200000&#34;, &#34;-0.2208200000&#34;, &#34;-0.2092000000&#34;, &#34;0.1851100000&#34;, &#34;-0.1653500000&#34;, &#34;0.0740850000&#34;, &#34;0.0266020000&#34;, &#34;-0.0974900000&#34;, &#34;0.3796400000&#34;, &#34;0.1468100000&#34;, &#34;-0.1682900000&#34;, &#34;0.2318900000&#34;, &#34;-0.1005200000&#34;, &#34;-0.1863400000&#34;, &#34;-0.4332400000&#34;, &#34;-0.0667370000&#34;, &#34;-0.1543900000&#34;, &#34;0.2330100000&#34;, &#34;-0.2363500000&#34;, &#34;0.1945700000&#34;, &#34;0.1350300000&#34;, &#34;0.1206200000&#34;, &#34;-0.1858500000&#34;, &#34;-0.2281400000&#34;, &#34;-0.8050500000&#34;, &#34;0.1976100000&#34;, &#34;-0.0441520000&#34;, &#34;-0.2157400000&#34;, &#34;0.2222600000&#34;, &#34;-0.0491980000&#34;, &#34;0.0587420000&#34;, &#34;0.1350500000&#34;, &#34;0.0905450000&#34;, &#34;0.2420800000&#34;, &#34;-0.0127400000&#34;, &#34;0.1750000000&#34;, &#34;0.1095600000&#34;, &#34;0.1612800000&#34;, &#34;-0.3499200000&#34;, &#34;0.1757300000&#34;, &#34;-0.2536300000&#34;, &#34;-0.3201500000&#34;, &#34;0.3218000000&#34;, &#34;0.0410470000&#34;, &#34;-0.0623210000&#34;, &#34;-0.2030900000&#34;, &#34;-0.0781820000&#34;, &#34;-0.0504510000&#34;, &#34;-0.1302900000&#34;, &#34;0.0445080000&#34;, &#34;0.2193600000&#34;, &#34;-0.0134300000&#34;, &#34;0.0377120000&#34;, &#34;0.0651670000&#34;, &#34;-0.0532490000&#34;, &#34;0.2846400000&#34;, &#34;0.0539880000&#34;, &#34;0.0781200000&#34;, &#34;0.2064800000&#34;, &#34;0.2330800000&#34;, &#34;0.2235400000&#34;, &#34;-0.3331700000&#34;, &#34;-0.3691800000&#34;, &#34;-0.2975400000&#34;, &#34;0.1137900000&#34;, &#34;0.3412900000&#34;, &#34;0.0204940000&#34;, &#34;-0.4146400000&#34;, &#34;0.2122200000&#34;, &#34;0.0533570000&#34;, &#34;-0.2561800000&#34;, &#34;0.0018763000&#34;, &#34;-0.1171700000&#34;, &#34;0.1756400000&#34;, &#34;0.2612300000&#34;, &#34;-0.1151800000&#34;, &#34;-0.1479800000&#34;, &#34;0.2521200000&#34;, &#34;-0.0550510000&#34;, &#34;-0.0555300000&#34;, &#34;-0.4026900000&#34;, &#34;0.1939700000&#34;, &#34;-0.0147990000&#34;, &#34;0.3273300000&#34;, &#34;-0.2912700000&#34;, &#34;-0.2635800000&#34;, &#34;0.0639000000&#34;, &#34;0.3415500000&#34;, &#34;0.2763000000&#34;, &#34;0.1275400000&#34;, &#34;0.1321700000&#34;, &#34;-0.0924440000&#34;, &#34;-0.2194800000&#34;, &#34;0.1008300000&#34;, &#34;0.3518600000&#34;, &#34;0.1284600000&#34;, &#34;0.1200900000&#34;], [&#34;-0.0483010000&#34;, &#34;0.1926000000&#34;, &#34;-0.6080700000&#34;, &#34;-0.1321700000&#34;, &#34;-0.7480600000&#34;, &#34;-0.1779300000&#34;, &#34;0.1883100000&#34;, &#34;-0.6710000000&#34;, &#34;-0.3516700000&#34;, &#34;0.4761700000&#34;, &#34;0.2126700000&#34;, &#34;0.1931800000&#34;, &#34;-0.0309560000&#34;, &#34;0.3532300000&#34;, &#34;0.1101600000&#34;, &#34;0.0179630000&#34;, &#34;-0.0054491000&#34;, &#34;-0.0927580000&#34;, &#34;-0.5833500000&#34;, &#34;0.2006100000&#34;, &#34;0.3485700000&#34;, &#34;-0.2006200000&#34;, &#34;-0.4491000000&#34;, &#34;-0.1015000000&#34;, &#34;-0.1915400000&#34;, &#34;-0.0624400000&#34;, &#34;-0.1961200000&#34;, &#34;0.1386100000&#34;, &#34;-0.3221000000&#34;, &#34;0.2511000000&#34;, &#34;-0.3066600000&#34;, &#34;0.2149300000&#34;, &#34;0.3389300000&#34;, &#34;0.3087800000&#34;, &#34;-0.0710470000&#34;, &#34;-0.0528590000&#34;, &#34;0.0813120000&#34;, &#34;0.0924810000&#34;, &#34;0.4397400000&#34;, &#34;0.1130700000&#34;, &#34;0.7637600000&#34;, &#34;0.1650700000&#34;, &#34;-0.4197200000&#34;, &#34;-0.2212400000&#34;, &#34;0.0775690000&#34;, &#34;-0.1602800000&#34;, &#34;0.1373400000&#34;, &#34;0.0908770000&#34;, &#34;-0.0427150000&#34;, &#34;-0.1802500000&#34;, &#34;-0.1432800000&#34;, &#34;0.0392000000&#34;, &#34;0.3309600000&#34;, &#34;-0.5582400000&#34;, &#34;0.2220600000&#34;, &#34;-0.0236850000&#34;, &#34;0.2582500000&#34;, &#34;0.2877900000&#34;, &#34;0.3834000000&#34;, &#34;-0.1787200000&#34;, &#34;-0.3949400000&#34;, &#34;0.1114700000&#34;, &#34;0.3441100000&#34;, &#34;0.1905500000&#34;, &#34;-0.0914810000&#34;, &#34;-0.2756000000&#34;, &#34;-0.3321300000&#34;, &#34;0.7403800000&#34;, &#34;-0.0275420000&#34;, &#34;-0.0581460000&#34;, &#34;-0.2213900000&#34;, &#34;0.0869770000&#34;, &#34;0.4184900000&#34;, &#34;-0.1886400000&#34;, &#34;0.4007800000&#34;, &#34;0.2311300000&#34;, &#34;0.1741300000&#34;, &#34;0.3344600000&#34;, &#34;-0.3010300000&#34;, &#34;-0.1821600000&#34;, &#34;0.7534000000&#34;, &#34;-0.3557000000&#34;, &#34;-0.2855800000&#34;, &#34;0.0095493000&#34;, &#34;-0.5681900000&#34;, &#34;0.1049900000&#34;, &#34;-0.1144700000&#34;, &#34;0.2515400000&#34;, &#34;-0.3135600000&#34;, &#34;-0.6600000000&#34;, &#34;0.1312800000&#34;, &#34;0.2128300000&#34;, &#34;-0.1066400000&#34;, &#34;0.1817900000&#34;, &#34;0.0611570000&#34;, &#34;0.4052800000&#34;, &#34;-0.0131620000&#34;, &#34;0.1683800000&#34;, &#34;-0.0057097000&#34;, &#34;0.2874300000&#34;, &#34;0.0248060000&#34;, &#34;-0.2986400000&#34;, &#34;0.0607920000&#34;, &#34;-0.1837400000&#34;, &#34;0.1848300000&#34;, &#34;0.0196420000&#34;, &#34;-0.3581200000&#34;, &#34;0.2625900000&#34;, &#34;0.1211600000&#34;, &#34;-0.3594200000&#34;, &#34;-0.1380800000&#34;, &#34;0.2121700000&#34;, &#34;-0.2607000000&#34;, &#34;-0.2744700000&#34;, &#34;-0.3924400000&#34;, &#34;0.1087600000&#34;, &#34;0.3051100000&#34;, &#34;0.1226900000&#34;, &#34;-0.4248500000&#34;, &#34;-0.0759340000&#34;, &#34;0.1010800000&#34;, &#34;-0.4214200000&#34;, &#34;-0.6684900000&#34;, &#34;0.1061700000&#34;, &#34;-0.0502350000&#34;, &#34;-0.0975560000&#34;, &#34;-0.1387000000&#34;, &#34;0.4019400000&#34;, &#34;-0.3693400000&#34;, &#34;0.2467500000&#34;, &#34;0.1400000000&#34;, &#34;0.2109000000&#34;, &#34;-0.2712700000&#34;, &#34;0.2194000000&#34;, &#34;-0.0493550000&#34;, &#34;0.3635500000&#34;, &#34;-0.2876200000&#34;, &#34;0.3838900000&#34;, &#34;-0.0655080000&#34;, &#34;0.7611400000&#34;, &#34;0.1918600000&#34;, &#34;0.4933100000&#34;, &#34;0.0512070000&#34;, &#34;-0.0441210000&#34;, &#34;-0.1881400000&#34;, &#34;0.0263140000&#34;, &#34;0.1479400000&#34;, &#34;0.4528900000&#34;, &#34;0.1681000000&#34;, &#34;-0.2359600000&#34;, &#34;0.4548100000&#34;, &#34;-0.1847000000&#34;, &#34;0.0072012000&#34;, &#34;-0.4249700000&#34;, &#34;0.2303500000&#34;, &#34;-0.0514900000&#34;, &#34;0.0759190000&#34;, &#34;0.2862200000&#34;, &#34;-0.2176900000&#34;, &#34;-0.2780600000&#34;, &#34;0.4701800000&#34;, &#34;0.0066373000&#34;, &#34;0.0284700000&#34;, &#34;-0.2938900000&#34;, &#34;0.2662000000&#34;, &#34;0.0508210000&#34;, &#34;-0.1260300000&#34;, &#34;-0.3013000000&#34;, &#34;-0.1193200000&#34;, &#34;0.2994300000&#34;, &#34;-0.4114900000&#34;, &#34;-0.2179900000&#34;, &#34;-0.3400100000&#34;, &#34;0.5519200000&#34;, &#34;-0.0458200000&#34;, &#34;-0.0102490000&#34;, &#34;-0.5164800000&#34;, &#34;-0.5789100000&#34;, &#34;0.0335170000&#34;, &#34;-0.1876100000&#34;, &#34;0.3194000000&#34;, &#34;0.1623900000&#34;, &#34;0.2697900000&#34;, &#34;-0.2737500000&#34;, &#34;0.0049825000&#34;, &#34;0.4875700000&#34;, &#34;0.5360200000&#34;, &#34;0.1312700000&#34;, &#34;0.1804500000&#34;, &#34;-0.6424600000&#34;, &#34;-0.3519600000&#34;, &#34;-0.2902300000&#34;, &#34;0.1350800000&#34;, &#34;-0.0327020000&#34;, &#34;-0.3141600000&#34;, &#34;0.1261500000&#34;, &#34;0.1984500000&#34;, &#34;0.2206800000&#34;, &#34;0.1732000000&#34;, &#34;-0.2917400000&#34;, &#34;-0.3712800000&#34;, &#34;-0.1567800000&#34;, &#34;-0.1238400000&#34;, &#34;0.0504430000&#34;, &#34;-0.0666780000&#34;, &#34;-0.5873100000&#34;, &#34;-0.2468000000&#34;, &#34;-0.0337500000&#34;, &#34;0.4086200000&#34;, &#34;-0.0480300000&#34;, &#34;0.5460400000&#34;, &#34;0.0845210000&#34;, &#34;0.2171700000&#34;, &#34;0.5037900000&#34;, &#34;0.3088900000&#34;, &#34;-0.4551900000&#34;, &#34;-0.3263000000&#34;, &#34;-0.5679400000&#34;, &#34;0.0633180000&#34;, &#34;0.0841560000&#34;, &#34;0.0090246000&#34;, &#34;0.1762800000&#34;, &#34;0.3983600000&#34;, &#34;0.6389500000&#34;, &#34;0.1402900000&#34;, &#34;-0.0057605000&#34;, &#34;-0.2321600000&#34;, &#34;-0.4368900000&#34;, &#34;0.0136430000&#34;, &#34;-0.1616300000&#34;, &#34;0.1766800000&#34;, &#34;-0.0056310000&#34;, &#34;-0.4336600000&#34;, &#34;-0.1409900000&#34;, &#34;0.4197400000&#34;, &#34;0.0091529000&#34;, &#34;-0.1334500000&#34;, &#34;-0.4143500000&#34;, &#34;-0.1956300000&#34;, &#34;0.3126700000&#34;, &#34;0.1455300000&#34;, &#34;0.0933600000&#34;, &#34;0.2726400000&#34;, &#34;-0.4169600000&#34;, &#34;-0.6605300000&#34;, &#34;0.4904700000&#34;, &#34;0.3367900000&#34;, &#34;-0.1244500000&#34;, &#34;-0.3173500000&#34;, &#34;-0.8259700000&#34;, &#34;-0.0970430000&#34;, &#34;0.0334070000&#34;, &#34;-0.2525100000&#34;, &#34;0.0437130000&#34;, &#34;-0.2893600000&#34;, &#34;0.1854300000&#34;, &#34;0.3990200000&#34;, &#34;-0.0563480000&#34;, &#34;-0.1447100000&#34;, &#34;0.1710800000&#34;, &#34;0.1277400000&#34;, &#34;0.3424800000&#34;, &#34;-0.3259100000&#34;, &#34;-0.2452800000&#34;, &#34;-0.7021700000&#34;, &#34;-0.1631100000&#34;, &#34;0.0105840000&#34;, &#34;-0.0852060000&#34;, &#34;-0.1944300000&#34;, &#34;-0.1338100000&#34;, &#34;-0.1362900000&#34;, &#34;-0.3097300000&#34;, &#34;0.3536200000&#34;, &#34;-0.1985100000&#34;, &#34;-0.4806200000&#34;, &#34;-0.1549700000&#34;, &#34;0.0440020000&#34;, &#34;-0.2656100000&#34;, &#34;-0.1193800000&#34;, &#34;0.2374200000&#34;, &#34;0.3663700000&#34;, &#34;0.2077800000&#34;, &#34;-0.5147400000&#34;, &#34;-0.0764550000&#34;, &#34;0.5292200000&#34;, &#34;-0.2214200000&#34;, &#34;0.3417900000&#34;, &#34;-0.1087000000&#34;, &#34;-0.7125100000&#34;, &#34;0.4339200000&#34;, &#34;-0.0127000000&#34;, &#34;0.1711800000&#34;, &#34;0.2068900000&#34;, &#34;0.1402600000&#34;, &#34;-0.1459300000&#34;, &#34;-0.2484100000&#34;, &#34;0.5119900000&#34;, &#34;0.5650100000&#34;, &#34;0.3061400000&#34;, &#34;0.3182900000&#34;], [&#34;-0.0315330000&#34;, &#34;0.0462780000&#34;, &#34;-0.1253400000&#34;, &#34;0.1916500000&#34;, &#34;-0.1266000000&#34;, &#34;-0.0128530000&#34;, &#34;0.1034200000&#34;, &#34;-0.0098085000&#34;, &#34;0.1518900000&#34;, &#34;0.2758200000&#34;, &#34;0.1369500000&#34;, &#34;0.0088799000&#34;, &#34;0.1413200000&#34;, &#34;-0.1200000000&#34;, &#34;-0.0634390000&#34;, &#34;-0.1517800000&#34;, &#34;0.0980900000&#34;, &#34;-0.1201000000&#34;, &#34;-0.0690860000&#34;, &#34;0.0146660000&#34;, &#34;-0.0230410000&#34;, &#34;0.0304300000&#34;, &#34;-0.1266400000&#34;, &#34;-0.0632820000&#34;, &#34;-0.0822460000&#34;, &#34;0.0367180000&#34;, &#34;0.2269800000&#34;, &#34;-0.0960250000&#34;, &#34;-0.0116990000&#34;, &#34;0.0661580000&#34;, &#34;-0.1854200000&#34;, &#34;0.1922300000&#34;, &#34;-0.0616850000&#34;, &#34;0.2704900000&#34;, &#34;0.0751160000&#34;, &#34;-0.0549280000&#34;, &#34;-0.0860270000&#34;, &#34;-0.1938700000&#34;, &#34;0.1467700000&#34;, &#34;-0.0601300000&#34;, &#34;0.0682690000&#34;, &#34;0.0716130000&#34;, &#34;-0.0944140000&#34;, &#34;0.0361580000&#34;, &#34;0.0027820000&#34;, &#34;-0.0817110000&#34;, &#34;-0.0133690000&#34;, &#34;-0.0530170000&#34;, &#34;0.0522270000&#34;, &#34;-0.0796820000&#34;, &#34;-0.0003176800&#34;, &#34;0.0303970000&#34;, &#34;-0.1684700000&#34;, &#34;0.0218280000&#34;, &#34;-0.1957700000&#34;, &#34;-0.0501090000&#34;, &#34;-0.0096879000&#34;, &#34;0.0855360000&#34;, &#34;-0.2813500000&#34;, &#34;0.1700100000&#34;, &#34;-0.0491940000&#34;, &#34;-0.1672100000&#34;, &#34;0.1901800000&#34;, &#34;-0.0474000000&#34;, &#34;-0.0003641200&#34;, &#34;0.0263160000&#34;, &#34;-0.2213500000&#34;, &#34;-0.0615830000&#34;, &#34;-0.2185400000&#34;, &#34;-0.0216690000&#34;, &#34;-0.2963000000&#34;, &#34;-0.0719490000&#34;, &#34;0.0106380000&#34;, &#34;-0.1905500000&#34;, &#34;-0.1129200000&#34;, &#34;-0.0990720000&#34;, &#34;0.1935700000&#34;, &#34;0.1411500000&#34;, &#34;0.0683460000&#34;, &#34;-0.0004594700&#34;, &#34;0.0726210000&#34;, &#34;-0.0211920000&#34;, &#34;-0.1242000000&#34;, &#34;-0.0419330000&#34;, &#34;-0.0283860000&#34;, &#34;0.0490830000&#34;, &#34;-0.0735740000&#34;, &#34;0.0735250000&#34;, &#34;0.0881350000&#34;, &#34;-0.0321840000&#34;, &#34;0.0299030000&#34;, &#34;-0.0700250000&#34;, &#34;0.1532300000&#34;, &#34;-0.1723600000&#34;, &#34;0.0735020000&#34;, &#34;0.1323200000&#34;, &#34;0.0901910000&#34;, &#34;0.0079023000&#34;, &#34;-0.0278870000&#34;, &#34;-0.0469710000&#34;, &#34;0.0391980000&#34;, &#34;-0.1256700000&#34;, &#34;0.1980300000&#34;, &#34;-0.0759950000&#34;, &#34;-0.2135300000&#34;, &#34;0.0319640000&#34;, &#34;-0.1734600000&#34;, &#34;0.0558840000&#34;, &#34;-0.0554040000&#34;, &#34;-0.0083924000&#34;, &#34;-0.0241040000&#34;, &#34;0.0023894000&#34;, &#34;-0.1057000000&#34;, &#34;-0.1060400000&#34;, &#34;-0.0613230000&#34;, &#34;-0.0414730000&#34;, &#34;0.0060497000&#34;, &#34;0.0558960000&#34;, &#34;-0.0713380000&#34;, &#34;0.1375000000&#34;, &#34;0.0947810000&#34;, &#34;0.0481210000&#34;, &#34;-0.0712360000&#34;, &#34;0.2626300000&#34;, &#34;0.0725700000&#34;, &#34;-0.0002034400&#34;, &#34;0.1864000000&#34;, &#34;0.0667030000&#34;, &#34;0.0552290000&#34;, &#34;0.1125800000&#34;, &#34;0.0476470000&#34;, &#34;0.0854820000&#34;, &#34;-0.1448900000&#34;, &#34;0.0098078000&#34;, &#34;0.0825850000&#34;, &#34;0.0392540000&#34;, &#34;-0.1004400000&#34;, &#34;0.1653200000&#34;, &#34;-0.0308410000&#34;, &#34;0.1031500000&#34;, &#34;-0.0465840000&#34;, &#34;0.1121100000&#34;, &#34;0.1541600000&#34;, &#34;-0.0503090000&#34;, &#34;0.1485300000&#34;, &#34;0.2287000000&#34;, &#34;-0.0560360000&#34;, &#34;-0.0729660000&#34;, &#34;0.0018167000&#34;, &#34;-0.0156940000&#34;, &#34;-0.0602200000&#34;, &#34;-0.1904400000&#34;, &#34;-0.0750730000&#34;, &#34;-0.0032815000&#34;, &#34;-0.0792560000&#34;, &#34;-0.0783240000&#34;, &#34;-0.1107300000&#34;, &#34;-0.0937050000&#34;, &#34;0.2628400000&#34;, &#34;0.0103400000&#34;, &#34;-0.0950000000&#34;, &#34;0.1729500000&#34;, &#34;-0.0539490000&#34;, &#34;0.1505600000&#34;, &#34;0.2281500000&#34;, &#34;-0.1658900000&#34;, &#34;-0.0800740000&#34;, &#34;-0.0762480000&#34;, &#34;0.1342300000&#34;, &#34;-0.0936260000&#34;, &#34;-0.0653840000&#34;, &#34;-0.0141810000&#34;, &#34;-0.0679370000&#34;, &#34;-0.0382830000&#34;, &#34;-0.0845140000&#34;, &#34;0.1108200000&#34;, &#34;0.0688040000&#34;, &#34;0.1940200000&#34;, &#34;-0.0693730000&#34;, &#34;-0.0433980000&#34;, &#34;0.1540200000&#34;, &#34;-0.1017200000&#34;, &#34;0.0497850000&#34;, &#34;-0.0100050000&#34;, &#34;-0.0337100000&#34;, &#34;0.2901800000&#34;, &#34;0.0254050000&#34;, &#34;-0.0949190000&#34;, &#34;0.0938760000&#34;, &#34;-0.0554230000&#34;, &#34;-0.0594190000&#34;, &#34;-0.0825420000&#34;, &#34;0.0940480000&#34;, &#34;0.0594220000&#34;, &#34;-0.0325640000&#34;, &#34;-0.0062017000&#34;, &#34;-0.0095274000&#34;, &#34;0.0924390000&#34;, &#34;-0.1699500000&#34;, &#34;0.0003890400&#34;, &#34;0.1918700000&#34;, &#34;-0.0250480000&#34;, &#34;-0.1184400000&#34;, &#34;0.0278790000&#34;, &#34;-0.0340240000&#34;, &#34;-0.0468660000&#34;, &#34;-0.0900900000&#34;, &#34;-0.0344170000&#34;, &#34;0.2553400000&#34;, &#34;0.0967780000&#34;, &#34;0.2084100000&#34;, &#34;0.0296930000&#34;, &#34;-0.0159430000&#34;, &#34;-0.0357790000&#34;, &#34;0.0021559000&#34;, &#34;0.0802460000&#34;, &#34;-0.0313550000&#34;, &#34;-0.2267600000&#34;, &#34;-0.1157900000&#34;, &#34;-0.0595790000&#34;, &#34;-0.0744200000&#34;, &#34;-0.1287100000&#34;, &#34;-0.1019900000&#34;, &#34;0.0649690000&#34;, &#34;-0.0703880000&#34;, &#34;-0.0401310000&#34;, &#34;-0.1474000000&#34;, &#34;-0.0988390000&#34;, &#34;0.1161400000&#34;, &#34;0.1587100000&#34;, &#34;0.0693000000&#34;, &#34;0.0318970000&#34;, &#34;-0.0287380000&#34;, &#34;-0.0846340000&#34;, &#34;-0.1486400000&#34;, &#34;0.1139800000&#34;, &#34;0.0726880000&#34;, &#34;-0.0657520000&#34;, &#34;-0.0132960000&#34;, &#34;0.0851640000&#34;, &#34;0.0250530000&#34;, &#34;0.0168670000&#34;, &#34;-0.0452570000&#34;, &#34;-0.0429250000&#34;, &#34;0.1232900000&#34;, &#34;0.1301200000&#34;, &#34;-0.0153200000&#34;, &#34;-0.1394300000&#34;, &#34;0.0897640000&#34;, &#34;0.0821720000&#34;, &#34;-0.0819180000&#34;, &#34;-0.0116880000&#34;, &#34;-0.1174200000&#34;, &#34;0.0292420000&#34;, &#34;-0.0658140000&#34;, &#34;0.0299590000&#34;, &#34;-0.0109410000&#34;, &#34;-0.0183000000&#34;, &#34;0.0571800000&#34;, &#34;0.0684360000&#34;, &#34;0.0072271000&#34;, &#34;0.0057584000&#34;, &#34;0.0714660000&#34;, &#34;-0.0831640000&#34;, &#34;-0.0150100000&#34;, &#34;-0.0780600000&#34;, &#34;0.0033293000&#34;, &#34;0.0991320000&#34;, &#34;0.0611880000&#34;, &#34;-0.0978150000&#34;, &#34;-0.1400800000&#34;, &#34;-0.0026304000&#34;, &#34;0.0022269000&#34;, &#34;0.0834960000&#34;, &#34;-0.1433400000&#34;, &#34;-0.0374470000&#34;, &#34;0.0615640000&#34;, &#34;0.2153600000&#34;, &#34;-0.0368360000&#34;, &#34;0.0386290000&#34;, &#34;0.1303100000&#34;, &#34;0.0459440000&#34;, &#34;0.0277010000&#34;, &#34;0.0616790000&#34;, &#34;0.0629210000&#34;, &#34;0.0684530000&#34;, &#34;-0.0262920000&#34;, &#34;0.1734200000&#34;, &#34;-0.1442100000&#34;, &#34;-0.0131240000&#34;, &#34;0.1549400000&#34;, &#34;-0.1078600000&#34;, &#34;0.1831400000&#34;, &#34;0.1388100000&#34;, &#34;0.0275700000&#34;, &#34;-0.0350730000&#34;, &#34;-0.0178290000&#34;, &#34;0.1116300000&#34;, &#34;-0.0582310000&#34;, &#34;0.0119770000&#34;], [&#34;-0.1587600000&#34;, &#34;-0.3227800000&#34;, &#34;-0.3359300000&#34;, &#34;0.3772600000&#34;, &#34;0.0181430000&#34;, &#34;-0.0432970000&#34;, &#34;0.1131200000&#34;, &#34;0.3340600000&#34;, &#34;0.0813920000&#34;, &#34;0.3173600000&#34;, &#34;-0.6511300000&#34;, &#34;0.3122200000&#34;, &#34;-0.3403500000&#34;, &#34;-0.0143110000&#34;, &#34;0.0947010000&#34;, &#34;0.1030300000&#34;, &#34;-0.0264650000&#34;, &#34;-0.2975800000&#34;, &#34;0.2857200000&#34;, &#34;0.1407000000&#34;, &#34;0.4714900000&#34;, &#34;-0.2468500000&#34;, &#34;0.0218830000&#34;, &#34;-0.2756400000&#34;, &#34;-0.2135600000&#34;, &#34;-0.1009600000&#34;, &#34;0.0781600000&#34;, &#34;-0.0266210000&#34;, &#34;-0.3624200000&#34;, &#34;0.1317900000&#34;, &#34;-0.0128400000&#34;, &#34;0.3227500000&#34;, &#34;-0.2141200000&#34;, &#34;0.5504600000&#34;, &#34;0.0096127000&#34;, &#34;-0.0289060000&#34;, &#34;0.0297310000&#34;, &#34;-0.1070000000&#34;, &#34;-0.0262920000&#34;, &#34;-0.2351100000&#34;, &#34;-0.2201000000&#34;, &#34;-0.3021400000&#34;, &#34;0.2727900000&#34;, &#34;-0.0970060000&#34;, &#34;0.1617500000&#34;, &#34;0.3892400000&#34;, &#34;0.1930100000&#34;, &#34;0.1013100000&#34;, &#34;0.2822700000&#34;, &#34;-0.0601160000&#34;, &#34;-0.2111700000&#34;, &#34;-0.0417050000&#34;, &#34;-0.2473800000&#34;, &#34;-0.2462600000&#34;, &#34;0.2009900000&#34;, &#34;0.2127100000&#34;, &#34;0.1202300000&#34;, &#34;0.4742100000&#34;, &#34;0.2738700000&#34;, &#34;-0.3520600000&#34;, &#34;-0.1265300000&#34;, &#34;0.1471700000&#34;, &#34;0.2083000000&#34;, &#34;0.0757050000&#34;, &#34;0.1981700000&#34;, &#34;-0.1608700000&#34;, &#34;-0.3880500000&#34;, &#34;0.1526500000&#34;, &#34;-0.0720210000&#34;, &#34;-0.1207400000&#34;, &#34;0.2680500000&#34;, &#34;0.0079369000&#34;, &#34;0.3982100000&#34;, &#34;0.0477760000&#34;, &#34;-0.2226300000&#34;, &#34;-0.2731800000&#34;, &#34;0.3082700000&#34;, &#34;-0.0780150000&#34;, &#34;0.6067500000&#34;, &#34;0.0958000000&#34;, &#34;-0.2810400000&#34;, &#34;0.0069502000&#34;, &#34;0.0300680000&#34;, &#34;0.1701500000&#34;, &#34;0.2536200000&#34;, &#34;-0.1601700000&#34;, &#34;0.1847200000&#34;, &#34;-0.1219200000&#34;, &#34;-0.2927000000&#34;, &#34;-0.2109100000&#34;, &#34;-0.0316770000&#34;, &#34;-0.0606560000&#34;, &#34;0.2542000000&#34;, &#34;-0.4263400000&#34;, &#34;0.3392500000&#34;, &#34;0.0381370000&#34;, &#34;0.2056600000&#34;, &#34;0.1665800000&#34;, &#34;0.2306600000&#34;, &#34;-0.3268600000&#34;, &#34;0.2220000000&#34;, &#34;0.0315130000&#34;, &#34;0.2612500000&#34;, &#34;-0.3222300000&#34;, &#34;-0.1175300000&#34;, &#34;-0.2433500000&#34;, &#34;-0.1013900000&#34;, &#34;0.2406800000&#34;, &#34;0.2898800000&#34;, &#34;0.0240570000&#34;, &#34;-0.2951700000&#34;, &#34;0.1695700000&#34;, &#34;0.4008100000&#34;, &#34;-0.0042294000&#34;, &#34;-0.0335240000&#34;, &#34;0.0333200000&#34;, &#34;0.0429930000&#34;, &#34;0.3818900000&#34;, &#34;0.0941170000&#34;, &#34;0.5117400000&#34;, &#34;0.1200700000&#34;, &#34;-0.2027800000&#34;, &#34;0.0749920000&#34;, &#34;0.3657700000&#34;, &#34;-0.6609300000&#34;, &#34;-0.3408200000&#34;, &#34;0.2731700000&#34;, &#34;0.1198500000&#34;, &#34;-0.1932600000&#34;, &#34;-0.0202370000&#34;, &#34;0.2031300000&#34;, &#34;0.1111300000&#34;, &#34;-0.1025100000&#34;, &#34;0.0484810000&#34;, &#34;0.1543400000&#34;, &#34;-0.0066719000&#34;, &#34;-0.1572600000&#34;, &#34;-0.1875100000&#34;, &#34;0.0743050000&#34;, &#34;0.2277600000&#34;, &#34;0.1359300000&#34;, &#34;0.3004500000&#34;, &#34;0.0681940000&#34;, &#34;-0.1956300000&#34;, &#34;-0.4441500000&#34;, &#34;0.1899800000&#34;, &#34;0.1851300000&#34;, &#34;0.1271800000&#34;, &#34;0.0233870000&#34;, &#34;-0.3482400000&#34;, &#34;0.2604500000&#34;, &#34;-0.0486800000&#34;, &#34;0.0026238000&#34;, &#34;-0.4195600000&#34;, &#34;-0.0549180000&#34;, &#34;-0.1955500000&#34;, &#34;-0.1820000000&#34;, &#34;-0.3471300000&#34;, &#34;0.2985400000&#34;, &#34;-0.0061094000&#34;, &#34;-0.1142100000&#34;, &#34;0.0122620000&#34;, &#34;-0.3194700000&#34;, &#34;-0.3279700000&#34;, &#34;0.0911590000&#34;, &#34;0.5112700000&#34;, &#34;0.2883100000&#34;, &#34;-0.3982400000&#34;, &#34;0.0116600000&#34;, &#34;-0.0952440000&#34;, &#34;-0.2137700000&#34;, &#34;-0.0727480000&#34;, &#34;-0.4034500000&#34;, &#34;0.3805100000&#34;, &#34;0.1486700000&#34;, &#34;-0.0929530000&#34;, &#34;-0.4091000000&#34;, &#34;0.2761400000&#34;, &#34;0.2208600000&#34;, &#34;0.0716520000&#34;, &#34;-0.1259000000&#34;, &#34;-0.2557700000&#34;, &#34;0.2259900000&#34;, &#34;0.2915500000&#34;, &#34;-0.3567100000&#34;, &#34;0.2179500000&#34;, &#34;0.0748660000&#34;, &#34;-0.2928200000&#34;, &#34;0.1110700000&#34;, &#34;-0.0321290000&#34;, &#34;-0.2541200000&#34;, &#34;-0.4156600000&#34;, &#34;0.3442900000&#34;, &#34;0.3934500000&#34;, &#34;-0.3489600000&#34;, &#34;-0.0745850000&#34;, &#34;0.1719800000&#34;, &#34;0.1018100000&#34;, &#34;-0.7027900000&#34;, &#34;-0.2589900000&#34;, &#34;0.2178400000&#34;, &#34;0.1526600000&#34;, &#34;0.3109000000&#34;, &#34;-0.3097300000&#34;, &#34;0.0234520000&#34;, &#34;-0.3409200000&#34;, &#34;-0.4034900000&#34;, &#34;-0.2364100000&#34;, &#34;-0.1380800000&#34;, &#34;-0.1189200000&#34;, &#34;0.4886600000&#34;, &#34;0.0729720000&#34;, &#34;0.4358600000&#34;, &#34;0.3096100000&#34;, &#34;-0.0931440000&#34;, &#34;-0.3680700000&#34;, &#34;0.1772000000&#34;, &#34;-0.3639400000&#34;, &#34;0.1151000000&#34;, &#34;-0.2219700000&#34;, &#34;-0.0662020000&#34;, &#34;0.0569440000&#34;, &#34;0.2996900000&#34;, &#34;0.2226600000&#34;, &#34;-0.4408000000&#34;, &#34;0.6536600000&#34;, &#34;-0.3059300000&#34;, &#34;-0.1836900000&#34;, &#34;0.1697000000&#34;, &#34;-0.0735740000&#34;, &#34;0.2771500000&#34;, &#34;0.1002600000&#34;, &#34;0.0886740000&#34;, &#34;-0.2617200000&#34;, &#34;-0.0674060000&#34;, &#34;0.1481900000&#34;, &#34;0.2398500000&#34;, &#34;-0.1801000000&#34;, &#34;0.2293500000&#34;, &#34;0.3916000000&#34;, &#34;-0.0148380000&#34;, &#34;-0.0284200000&#34;, &#34;-0.0851330000&#34;, &#34;0.1336000000&#34;, &#34;-0.0623770000&#34;, &#34;0.2805400000&#34;, &#34;-0.1503900000&#34;, &#34;-0.0478630000&#34;, &#34;0.2532000000&#34;, &#34;0.3712600000&#34;, &#34;-0.0988940000&#34;, &#34;0.0769980000&#34;, &#34;-0.0333030000&#34;, &#34;0.2335400000&#34;, &#34;-0.0862550000&#34;, &#34;0.1724700000&#34;, &#34;0.1407700000&#34;, &#34;0.0133260000&#34;, &#34;0.1846500000&#34;, &#34;0.1063000000&#34;, &#34;-0.0403180000&#34;, &#34;0.2216400000&#34;, &#34;0.5125000000&#34;, &#34;-0.0494960000&#34;, &#34;-0.3136200000&#34;, &#34;0.1578700000&#34;, &#34;0.1495300000&#34;, &#34;0.2847800000&#34;, &#34;-0.3695700000&#34;, &#34;-0.2211000000&#34;, &#34;-0.2212000000&#34;, &#34;0.1326000000&#34;, &#34;0.2133000000&#34;, &#34;0.3313100000&#34;, &#34;-0.5580700000&#34;, &#34;-0.2778400000&#34;, &#34;0.0173270000&#34;, &#34;-0.4024200000&#34;, &#34;-0.0102690000&#34;, &#34;-0.1359200000&#34;, &#34;-0.2050400000&#34;, &#34;-0.2245200000&#34;, &#34;-0.0172750000&#34;, &#34;0.1393200000&#34;, &#34;0.1057100000&#34;, &#34;-0.4470900000&#34;, &#34;0.4182100000&#34;, &#34;-0.1518400000&#34;, &#34;0.0130620000&#34;, &#34;0.0178030000&#34;, &#34;0.0209970000&#34;, &#34;0.0712130000&#34;, &#34;0.0926260000&#34;, &#34;0.0014617000&#34;, &#34;-0.1932800000&#34;, &#34;-0.2181800000&#34;, &#34;0.1399300000&#34;, &#34;0.2508200000&#34;, &#34;0.0280280000&#34;, &#34;-0.2789300000&#34;], [&#34;-0.0523090000&#34;, &#34;0.2665800000&#34;, &#34;-0.3307500000&#34;, &#34;0.1053000000&#34;, &#34;-0.3252100000&#34;, &#34;-0.3258600000&#34;, &#34;-0.2779200000&#34;, &#34;-0.2762400000&#34;, &#34;-0.0535120000&#34;, &#34;0.1969700000&#34;, &#34;-0.1683500000&#34;, &#34;-0.0741790000&#34;, &#34;-0.2795100000&#34;, &#34;0.1874800000&#34;, &#34;0.3636300000&#34;, &#34;-0.0343460000&#34;, &#34;0.0034359000&#34;, &#34;0.0694370000&#34;, &#34;0.2621400000&#34;, &#34;0.3995000000&#34;, &#34;-0.0571170000&#34;, &#34;0.1617900000&#34;, &#34;-0.2680600000&#34;, &#34;-0.1917100000&#34;, &#34;-0.4367500000&#34;, &#34;-0.0312640000&#34;, &#34;-0.1036400000&#34;, &#34;-0.0204780000&#34;, &#34;-0.1271200000&#34;, &#34;0.2809100000&#34;, &#34;0.0257580000&#34;, &#34;0.0885600000&#34;, &#34;-0.1328100000&#34;, &#34;-0.2613600000&#34;, &#34;-0.2562300000&#34;, &#34;-0.3481500000&#34;, &#34;0.2366100000&#34;, &#34;-0.1661100000&#34;, &#34;0.1263500000&#34;, &#34;-0.2177100000&#34;, &#34;0.5237100000&#34;, &#34;0.0348660000&#34;, &#34;-0.3854700000&#34;, &#34;-0.1805000000&#34;, &#34;0.1851300000&#34;, &#34;0.0513540000&#34;, &#34;0.0390160000&#34;, &#34;0.0303340000&#34;, &#34;0.1302200000&#34;, &#34;-0.2503400000&#34;, &#34;-0.1443400000&#34;, &#34;-0.0069149000&#34;, &#34;-0.0412930000&#34;, &#34;-0.0744350000&#34;, &#34;0.3769300000&#34;, &#34;0.0148660000&#34;, &#34;0.1352500000&#34;, &#34;-0.1433800000&#34;, &#34;-0.0192900000&#34;, &#34;-0.0956020000&#34;, &#34;-0.4735900000&#34;, &#34;-0.2745100000&#34;, &#34;0.1971700000&#34;, &#34;-0.2502800000&#34;, &#34;0.1090400000&#34;, &#34;-0.2183100000&#34;, &#34;-0.3640500000&#34;, &#34;-0.0252150000&#34;, &#34;0.0029815000&#34;, &#34;-0.1809100000&#34;, &#34;0.0151360000&#34;, &#34;-0.0723530000&#34;, &#34;-0.2393800000&#34;, &#34;0.0014383000&#34;, &#34;0.1144600000&#34;, &#34;0.1457600000&#34;, &#34;0.3139800000&#34;, &#34;0.2727300000&#34;, &#34;0.1515300000&#34;, &#34;-0.1210300000&#34;, &#34;0.1985700000&#34;, &#34;-0.0353030000&#34;, &#34;-0.3405400000&#34;, &#34;-0.2667000000&#34;, &#34;-0.1719400000&#34;, &#34;0.1369100000&#34;, &#34;0.2015100000&#34;, &#34;0.0296830000&#34;, &#34;0.3212700000&#34;, &#34;-0.1517900000&#34;, &#34;-0.4949500000&#34;, &#34;-0.2224600000&#34;, &#34;0.1629600000&#34;, &#34;-0.0825980000&#34;, &#34;0.1640500000&#34;, &#34;-0.0537130000&#34;, &#34;0.1062600000&#34;, &#34;0.0879090000&#34;, &#34;-0.0403420000&#34;, &#34;0.0248830000&#34;, &#34;-0.0331590000&#34;, &#34;-0.1199500000&#34;, &#34;0.0557670000&#34;, &#34;0.0614410000&#34;, &#34;0.1482100000&#34;, &#34;-0.2978200000&#34;, &#34;0.1739600000&#34;, &#34;0.2502600000&#34;, &#34;0.2588700000&#34;, &#34;-0.3141400000&#34;, &#34;-0.0317020000&#34;, &#34;0.4975700000&#34;, &#34;-0.1000300000&#34;, &#34;-0.1502300000&#34;, &#34;-0.1115500000&#34;, &#34;0.0118040000&#34;, &#34;0.1026300000&#34;, &#34;-0.1602800000&#34;, &#34;-0.1540300000&#34;, &#34;-0.0941530000&#34;, &#34;-0.0747390000&#34;, &#34;0.1678500000&#34;, &#34;-0.3977300000&#34;, &#34;0.1695800000&#34;, &#34;0.2269400000&#34;, &#34;0.1442100000&#34;, &#34;-0.0991110000&#34;, &#34;-0.0322830000&#34;, &#34;-0.4709700000&#34;, &#34;0.3251000000&#34;, &#34;-0.0434390000&#34;, &#34;-0.2292100000&#34;, &#34;0.0341340000&#34;, &#34;-0.1904500000&#34;, &#34;-0.0263260000&#34;, &#34;0.0424960000&#34;, &#34;-0.2934400000&#34;, &#34;0.0661140000&#34;, &#34;-0.0383760000&#34;, &#34;0.2520200000&#34;, &#34;-0.2320500000&#34;, &#34;0.3394200000&#34;, &#34;-0.0715850000&#34;, &#34;0.2545700000&#34;, &#34;0.0043527000&#34;, &#34;-0.2423400000&#34;, &#34;0.1613800000&#34;, &#34;0.1826500000&#34;, &#34;0.1417700000&#34;, &#34;0.0315390000&#34;, &#34;0.2728900000&#34;, &#34;-0.1275500000&#34;, &#34;-0.1180800000&#34;, &#34;-0.1475800000&#34;, &#34;0.1905000000&#34;, &#34;-0.2014400000&#34;, &#34;-0.1384200000&#34;, &#34;0.0865480000&#34;, &#34;-0.0022205000&#34;, &#34;-0.2578100000&#34;, &#34;0.0660550000&#34;, &#34;-0.0046081000&#34;, &#34;0.1155900000&#34;, &#34;0.1838300000&#34;, &#34;0.4447300000&#34;, &#34;0.2147300000&#34;, &#34;-0.3040000000&#34;, &#34;-0.1430200000&#34;, &#34;0.2544300000&#34;, &#34;0.1547000000&#34;, &#34;-0.5520200000&#34;, &#34;0.0660840000&#34;, &#34;-0.2717800000&#34;, &#34;0.3506900000&#34;, &#34;-0.0151610000&#34;, &#34;0.0985190000&#34;, &#34;-0.1620000000&#34;, &#34;-0.2963000000&#34;, &#34;-0.4363200000&#34;, &#34;-0.1256400000&#34;, &#34;0.1911800000&#34;, &#34;-0.0352810000&#34;, &#34;0.1363200000&#34;, &#34;0.3178500000&#34;, &#34;0.1294900000&#34;, &#34;0.6165000000&#34;, &#34;-0.3402400000&#34;, &#34;0.2943500000&#34;, &#34;-0.0869620000&#34;, &#34;-0.4286400000&#34;, &#34;-0.1893000000&#34;, &#34;-0.3347900000&#34;, &#34;0.0923770000&#34;, &#34;0.0800120000&#34;, &#34;-0.1322000000&#34;, &#34;-0.0549550000&#34;, &#34;0.1689600000&#34;, &#34;-0.0370430000&#34;, &#34;-0.4501700000&#34;, &#34;-0.3235400000&#34;, &#34;-0.1161100000&#34;, &#34;-0.3692300000&#34;, &#34;-0.0146730000&#34;, &#34;0.0314730000&#34;, &#34;-0.1917100000&#34;, &#34;-0.3675500000&#34;, &#34;-0.1943500000&#34;, &#34;0.1106700000&#34;, &#34;0.2250300000&#34;, &#34;-0.1847700000&#34;, &#34;0.6242600000&#34;, &#34;0.4363800000&#34;, &#34;0.0975350000&#34;, &#34;0.3124200000&#34;, &#34;0.3247100000&#34;, &#34;-0.3258600000&#34;, &#34;-0.2797100000&#34;, &#34;-0.6241900000&#34;, &#34;0.0450560000&#34;, &#34;0.4311600000&#34;, &#34;-0.3806500000&#34;, &#34;-0.2122000000&#34;, &#34;0.0478970000&#34;, &#34;0.1864700000&#34;, &#34;0.0286250000&#34;, &#34;-0.1867900000&#34;, &#34;-0.5833600000&#34;, &#34;-0.6953800000&#34;, &#34;-0.0776850000&#34;, &#34;0.2366500000&#34;, &#34;-0.2479400000&#34;, &#34;-0.0457940000&#34;, &#34;0.0851970000&#34;, &#34;0.0603540000&#34;, &#34;0.0143630000&#34;, &#34;-0.0620990000&#34;, &#34;0.2408800000&#34;, &#34;-0.3537800000&#34;, &#34;0.4175300000&#34;, &#34;0.2923900000&#34;, &#34;0.1785600000&#34;, &#34;-0.0163310000&#34;, &#34;-0.0095452000&#34;, &#34;-0.1880500000&#34;, &#34;-0.3723500000&#34;, &#34;0.2063400000&#34;, &#34;-0.1614900000&#34;, &#34;-0.4303400000&#34;, &#34;-0.2321500000&#34;, &#34;0.0587000000&#34;, &#34;-0.0318890000&#34;, &#34;-0.2462900000&#34;, &#34;-0.0038514000&#34;, &#34;0.1322600000&#34;, &#34;-0.4549300000&#34;, &#34;-0.0139040000&#34;, &#34;0.0713100000&#34;, &#34;-0.3762300000&#34;, &#34;-0.0745100000&#34;, &#34;-0.1904000000&#34;, &#34;-0.2019900000&#34;, &#34;0.1999300000&#34;, &#34;0.1617300000&#34;, &#34;-0.5173500000&#34;, &#34;-0.3040400000&#34;, &#34;-0.1386000000&#34;, &#34;-0.2150100000&#34;, &#34;-0.0667560000&#34;, &#34;-0.3111200000&#34;, &#34;-0.0036347000&#34;, &#34;-0.2470800000&#34;, &#34;-0.2344100000&#34;, &#34;-0.0708040000&#34;, &#34;0.2091300000&#34;, &#34;-0.0409730000&#34;, &#34;-0.0256060000&#34;, &#34;0.1770600000&#34;, &#34;0.2917000000&#34;, &#34;0.1914900000&#34;, &#34;-0.1772700000&#34;, &#34;-0.0403130000&#34;, &#34;-0.2448500000&#34;, &#34;-0.0863410000&#34;, &#34;-0.0036669000&#34;, &#34;0.3125200000&#34;, &#34;-0.0368460000&#34;, &#34;0.2402000000&#34;, &#34;-0.5649400000&#34;, &#34;-0.2658100000&#34;, &#34;0.2239800000&#34;, &#34;0.1460900000&#34;, &#34;0.3064000000&#34;, &#34;0.3317100000&#34;, &#34;0.1802400000&#34;, &#34;-0.4603000000&#34;, &#34;-0.2471800000&#34;, &#34;0.1571900000&#34;, &#34;0.2939100000&#34;, &#34;0.0876830000&#34;, &#34;-0.0864860000&#34;], [&#34;0.1236700000&#34;, &#34;-0.1396500000&#34;, &#34;0.0448770000&#34;, &#34;0.1891900000&#34;, &#34;-0.1099700000&#34;, &#34;-0.0064458000&#34;, &#34;0.0504990000&#34;, &#34;-0.2043900000&#34;, &#34;-0.0157610000&#34;, &#34;0.1504900000&#34;, &#34;0.1377400000&#34;, &#34;-0.0682410000&#34;, &#34;0.1707800000&#34;, &#34;-0.1352900000&#34;, &#34;-0.1832400000&#34;, &#34;-0.0003556700&#34;, &#34;-0.0995660000&#34;, &#34;-0.1454900000&#34;, &#34;0.0671830000&#34;, &#34;0.0282730000&#34;, &#34;-0.1008400000&#34;, &#34;0.1049800000&#34;, &#34;-0.2461300000&#34;, &#34;0.0088310000&#34;, &#34;-0.1843700000&#34;, &#34;0.0500110000&#34;, &#34;-0.0328390000&#34;, &#34;-0.0691290000&#34;, &#34;0.0043659000&#34;, &#34;0.1101100000&#34;, &#34;-0.3227200000&#34;, &#34;0.2662500000&#34;, &#34;-0.1246500000&#34;, &#34;0.3215700000&#34;, &#34;0.0679820000&#34;, &#34;-0.2267100000&#34;, &#34;0.0818430000&#34;, &#34;0.1143500000&#34;, &#34;0.0620670000&#34;, &#34;-0.0729730000&#34;, &#34;-0.0134150000&#34;, &#34;-0.0484930000&#34;, &#34;-0.1142600000&#34;, &#34;0.0697430000&#34;, &#34;-0.0709370000&#34;, &#34;-0.0628860000&#34;, &#34;-0.0156920000&#34;, &#34;-0.0336630000&#34;, &#34;0.1044100000&#34;, &#34;0.0050113000&#34;, &#34;-0.0017716000&#34;, &#34;0.0117200000&#34;, &#34;-0.0861680000&#34;, &#34;0.0122210000&#34;, &#34;-0.1481700000&#34;, &#34;0.0353730000&#34;, &#34;0.0398690000&#34;, &#34;0.2990400000&#34;, &#34;0.0246700000&#34;, &#34;0.1809600000&#34;, &#34;0.0708580000&#34;, &#34;-0.3536000000&#34;, &#34;0.0905180000&#34;, &#34;-0.1290500000&#34;, &#34;-0.0104430000&#34;, &#34;-0.1869700000&#34;, &#34;-0.2125800000&#34;, &#34;-0.0446440000&#34;, &#34;-0.2533300000&#34;, &#34;0.1003100000&#34;, &#34;-0.1736900000&#34;, &#34;-0.0373540000&#34;, &#34;-0.0309310000&#34;, &#34;-0.0919720000&#34;, &#34;-0.0682330000&#34;, &#34;0.0223660000&#34;, &#34;0.1256900000&#34;, &#34;0.1374900000&#34;, &#34;-0.0795470000&#34;, &#34;0.0071489000&#34;, &#34;-0.1511700000&#34;, &#34;0.2753800000&#34;, &#34;0.1396400000&#34;, &#34;0.0088001000&#34;, &#34;-0.0032892000&#34;, &#34;-0.2131300000&#34;, &#34;-0.0605430000&#34;, &#34;-0.1232100000&#34;, &#34;-0.1487500000&#34;, &#34;-0.2236200000&#34;, &#34;-0.2102400000&#34;, &#34;-0.0888030000&#34;, &#34;0.2922200000&#34;, &#34;-0.2596700000&#34;, &#34;0.2233100000&#34;, &#34;-0.0453370000&#34;, &#34;-0.0318100000&#34;, &#34;0.2028200000&#34;, &#34;-0.0727630000&#34;, &#34;0.0842300000&#34;, &#34;-0.1361900000&#34;, &#34;-0.0653910000&#34;, &#34;0.0456860000&#34;, &#34;0.1329200000&#34;, &#34;-0.1604500000&#34;, &#34;0.0683270000&#34;, &#34;-0.0858540000&#34;, &#34;0.1138000000&#34;, &#34;-0.0373010000&#34;, &#34;0.1485000000&#34;, &#34;0.1142900000&#34;, &#34;0.0751520000&#34;, &#34;-0.0826890000&#34;, &#34;-0.1272000000&#34;, &#34;-0.0255670000&#34;, &#34;0.0070075000&#34;, &#34;0.2604500000&#34;, &#34;-0.0658110000&#34;, &#34;0.0327150000&#34;, &#34;0.1979600000&#34;, &#34;0.1615400000&#34;, &#34;0.0461600000&#34;, &#34;-0.1811000000&#34;, &#34;0.2221000000&#34;, &#34;-0.0976020000&#34;, &#34;-0.1694600000&#34;, &#34;0.1414200000&#34;, &#34;0.0990350000&#34;, &#34;0.1553600000&#34;, &#34;0.1927700000&#34;, &#34;-0.0770730000&#34;, &#34;0.1304000000&#34;, &#34;0.0783040000&#34;, &#34;0.0732620000&#34;, &#34;-0.1485800000&#34;, &#34;0.1540000000&#34;, &#34;-0.1068800000&#34;, &#34;0.0550930000&#34;, &#34;0.0086387000&#34;, &#34;0.1932600000&#34;, &#34;-0.0268620000&#34;, &#34;0.2605700000&#34;, &#34;0.0527280000&#34;, &#34;-0.1146300000&#34;, &#34;0.1786900000&#34;, &#34;0.3908300000&#34;, &#34;0.2517200000&#34;, &#34;0.1414000000&#34;, &#34;-0.0663810000&#34;, &#34;0.0981100000&#34;, &#34;-0.1260400000&#34;, &#34;-0.0534040000&#34;, &#34;-0.1278300000&#34;, &#34;0.0151130000&#34;, &#34;-0.1591200000&#34;, &#34;-0.1964700000&#34;, &#34;0.1783100000&#34;, &#34;0.0119900000&#34;, &#34;0.0790110000&#34;, &#34;0.0381480000&#34;, &#34;-0.1492000000&#34;, &#34;0.3732400000&#34;, &#34;-0.2612100000&#34;, &#34;0.1281300000&#34;, &#34;0.1283600000&#34;, &#34;0.0535780000&#34;, &#34;-0.0765070000&#34;, &#34;0.0766710000&#34;, &#34;0.1352600000&#34;, &#34;-0.0133000000&#34;, &#34;-0.1612300000&#34;, &#34;-0.1084800000&#34;, &#34;-0.0253150000&#34;, &#34;-0.1773100000&#34;, &#34;0.0761610000&#34;, &#34;-0.0601740000&#34;, &#34;0.1403600000&#34;, &#34;0.2360600000&#34;, &#34;0.0130440000&#34;, &#34;-0.0038421000&#34;, &#34;0.1878900000&#34;, &#34;-0.0887220000&#34;, &#34;0.0325180000&#34;, &#34;0.2278100000&#34;, &#34;-0.0235590000&#34;, &#34;0.0846430000&#34;, &#34;0.1224200000&#34;, &#34;0.0088557000&#34;, &#34;0.0765080000&#34;, &#34;-0.0050585000&#34;, &#34;-0.0991940000&#34;, &#34;-0.0678060000&#34;, &#34;0.0599070000&#34;, &#34;0.0354040000&#34;, &#34;0.0187190000&#34;, &#34;-0.0268160000&#34;, &#34;-0.0043838000&#34;, &#34;0.0820260000&#34;, &#34;-0.1198600000&#34;, &#34;-0.2079700000&#34;, &#34;0.1857000000&#34;, &#34;-0.0937720000&#34;, &#34;-0.0162990000&#34;, &#34;0.1604400000&#34;, &#34;0.0333070000&#34;, &#34;-0.1544700000&#34;, &#34;-0.1299000000&#34;, &#34;0.1244600000&#34;, &#34;0.1037500000&#34;, &#34;0.1518600000&#34;, &#34;0.1791600000&#34;, &#34;-0.0392000000&#34;, &#34;-0.1754400000&#34;, &#34;0.0117540000&#34;, &#34;-0.0835660000&#34;, &#34;-0.0018136000&#34;, &#34;0.1267200000&#34;, &#34;-0.2011700000&#34;, &#34;-0.1697700000&#34;, &#34;-0.1478300000&#34;, &#34;0.0441560000&#34;, &#34;-0.1790700000&#34;, &#34;-0.0467720000&#34;, &#34;-0.0019811000&#34;, &#34;-0.0374120000&#34;, &#34;0.0013870000&#34;, &#34;-0.1056100000&#34;, &#34;-0.1542700000&#34;, &#34;0.1401600000&#34;, &#34;0.0411570000&#34;, &#34;0.1922200000&#34;, &#34;0.0120730000&#34;, &#34;-0.0667530000&#34;, &#34;-0.0252570000&#34;, &#34;-0.1564800000&#34;, &#34;0.0244270000&#34;, &#34;-0.0186740000&#34;, &#34;-0.1670500000&#34;, &#34;-0.0506200000&#34;, &#34;-0.0752870000&#34;, &#34;0.0430620000&#34;, &#34;0.0061818000&#34;, &#34;0.1057300000&#34;, &#34;-0.0029119000&#34;, &#34;0.0716430000&#34;, &#34;0.1332400000&#34;, &#34;0.2488900000&#34;, &#34;-0.0129980000&#34;, &#34;-0.0771420000&#34;, &#34;0.1755000000&#34;, &#34;0.1697100000&#34;, &#34;-0.0348750000&#34;, &#34;0.0849390000&#34;, &#34;-0.1958700000&#34;, &#34;-0.2611500000&#34;, &#34;-0.0529240000&#34;, &#34;-0.2303400000&#34;, &#34;-0.1347900000&#34;, &#34;0.1393300000&#34;, &#34;0.0411060000&#34;, &#34;0.0458160000&#34;, &#34;0.1111300000&#34;, &#34;-0.0703000000&#34;, &#34;0.0129250000&#34;, &#34;0.1397700000&#34;, &#34;-0.0636160000&#34;, &#34;0.0438910000&#34;, &#34;0.0278550000&#34;, &#34;-0.0396100000&#34;, &#34;-0.0957990000&#34;, &#34;-0.1258800000&#34;, &#34;-0.0847110000&#34;, &#34;-0.0042531000&#34;, &#34;-0.0590850000&#34;, &#34;-0.0933240000&#34;, &#34;-0.3395800000&#34;, &#34;0.0635250000&#34;, &#34;0.0822760000&#34;, &#34;0.0623950000&#34;, &#34;-0.0999550000&#34;, &#34;0.0143260000&#34;, &#34;0.0426450000&#34;, &#34;0.0802270000&#34;, &#34;0.0896460000&#34;, &#34;0.1758000000&#34;, &#34;0.0341530000&#34;, &#34;0.0005516700&#34;, &#34;0.1168700000&#34;, &#34;-0.0890060000&#34;, &#34;-0.0084893000&#34;, &#34;0.0251150000&#34;, &#34;-0.3180400000&#34;, &#34;0.1253300000&#34;, &#34;-0.0815070000&#34;, &#34;-0.1114000000&#34;, &#34;0.0175820000&#34;, &#34;-0.0373590000&#34;, &#34;0.0647400000&#34;, &#34;-0.1458100000&#34;, &#34;0.1617500000&#34;], [&#34;0.0463650000&#34;, &#34;-0.3176900000&#34;, &#34;0.3122200000&#34;, &#34;0.4272800000&#34;, &#34;-0.0520170000&#34;, &#34;-0.2056800000&#34;, &#34;-0.1305400000&#34;, &#34;-0.3554400000&#34;, &#34;-0.0454930000&#34;, &#34;0.1198300000&#34;, &#34;-0.1421300000&#34;, &#34;0.3160800000&#34;, &#34;-0.1794100000&#34;, &#34;-0.1854300000&#34;, &#34;0.1835900000&#34;, &#34;-0.1580800000&#34;, &#34;0.0726640000&#34;, &#34;-0.0014783000&#34;, &#34;0.1662200000&#34;, &#34;-0.1454300000&#34;, &#34;-0.2524000000&#34;, &#34;0.2721600000&#34;, &#34;-0.3226700000&#34;, &#34;-0.1066400000&#34;, &#34;-0.2970800000&#34;, &#34;0.1880700000&#34;, &#34;-0.0985250000&#34;, &#34;-0.1836500000&#34;, &#34;0.3127200000&#34;, &#34;0.2836100000&#34;, &#34;-0.1890300000&#34;, &#34;-0.0887010000&#34;, &#34;-0.3565200000&#34;, &#34;0.0357040000&#34;, &#34;-0.1088000000&#34;, &#34;-0.0503230000&#34;, &#34;0.0233360000&#34;, &#34;-0.2635200000&#34;, &#34;0.3081800000&#34;, &#34;-0.2282500000&#34;, &#34;0.0582360000&#34;, &#34;-0.4150600000&#34;, &#34;-0.0267630000&#34;, &#34;0.0463490000&#34;, &#34;0.1995900000&#34;, &#34;-0.3986100000&#34;, &#34;-0.1737500000&#34;, &#34;-0.3011900000&#34;, &#34;0.2229300000&#34;, &#34;-0.0381840000&#34;, &#34;0.0685010000&#34;, &#34;-0.0974790000&#34;, &#34;0.0158070000&#34;, &#34;-0.2198600000&#34;, &#34;-0.3758900000&#34;, &#34;0.1728500000&#34;, &#34;0.0040284000&#34;, &#34;0.3255200000&#34;, &#34;-0.0011404000&#34;, &#34;0.3276100000&#34;, &#34;-0.0131050000&#34;, &#34;0.0152470000&#34;, &#34;0.1571200000&#34;, &#34;-0.2604500000&#34;, &#34;-0.1249400000&#34;, &#34;0.2813600000&#34;, &#34;-0.2671600000&#34;, &#34;-0.4610200000&#34;, &#34;-0.4107300000&#34;, &#34;-0.3222800000&#34;, &#34;0.1654500000&#34;, &#34;-0.0149960000&#34;, &#34;0.3511800000&#34;, &#34;0.0614230000&#34;, &#34;-0.1164300000&#34;, &#34;0.4313700000&#34;, &#34;0.0923770000&#34;, &#34;0.0299480000&#34;, &#34;-0.0858560000&#34;, &#34;-0.4110400000&#34;, &#34;0.0688170000&#34;, &#34;0.2929700000&#34;, &#34;-0.2121200000&#34;, &#34;-0.1218000000&#34;, &#34;-0.2695500000&#34;, &#34;-0.2420700000&#34;, &#34;-0.1880200000&#34;, &#34;0.1836200000&#34;, &#34;0.1854900000&#34;, &#34;0.1858900000&#34;, &#34;-0.1702000000&#34;, &#34;-0.0390480000&#34;, &#34;0.1155100000&#34;, &#34;-0.1973600000&#34;, &#34;0.1412200000&#34;, &#34;-0.0578840000&#34;, &#34;0.2088100000&#34;, &#34;0.0725870000&#34;, &#34;-0.4841100000&#34;, &#34;0.2685600000&#34;, &#34;0.1630300000&#34;, &#34;-0.1606900000&#34;, &#34;0.2750200000&#34;, &#34;-0.0595090000&#34;, &#34;-0.1850700000&#34;, &#34;-0.1289800000&#34;, &#34;-0.3099100000&#34;, &#34;0.4653400000&#34;, &#34;0.2392700000&#34;, &#34;-0.1323200000&#34;, &#34;-0.1390900000&#34;, &#34;-0.1310800000&#34;, &#34;-0.2652500000&#34;, &#34;-0.1235600000&#34;, &#34;0.0591330000&#34;, &#34;0.2327500000&#34;, &#34;0.4766700000&#34;, &#34;0.1262600000&#34;, &#34;0.1188300000&#34;, &#34;-0.1736800000&#34;, &#34;-0.0639730000&#34;, &#34;0.0535020000&#34;, &#34;-0.2536000000&#34;, &#34;0.3104200000&#34;, &#34;0.0804350000&#34;, &#34;-0.3012800000&#34;, &#34;0.0892770000&#34;, &#34;0.3681700000&#34;, &#34;0.1285200000&#34;, &#34;-0.1420900000&#34;, &#34;-0.0198250000&#34;, &#34;0.2551800000&#34;, &#34;-0.1726500000&#34;, &#34;-0.3079200000&#34;, &#34;-0.4626300000&#34;, &#34;0.0240730000&#34;, &#34;-0.0807790000&#34;, &#34;-0.0355850000&#34;, &#34;-0.1450900000&#34;, &#34;0.0465280000&#34;, &#34;0.0910750000&#34;, &#34;0.2393300000&#34;, &#34;0.2534700000&#34;, &#34;0.3377400000&#34;, &#34;-0.2525400000&#34;, &#34;0.3782400000&#34;, &#34;0.4848000000&#34;, &#34;-0.0541820000&#34;, &#34;0.2947600000&#34;, &#34;0.0865240000&#34;, &#34;-0.0932760000&#34;, &#34;0.0558760000&#34;, &#34;-0.3779900000&#34;, &#34;-0.1854800000&#34;, &#34;-0.2925200000&#34;, &#34;-0.1958300000&#34;, &#34;-0.0990030000&#34;, &#34;-0.4394200000&#34;, &#34;0.0876350000&#34;, &#34;-0.0124590000&#34;, &#34;-0.2909800000&#34;, &#34;0.5147000000&#34;, &#34;-0.1854500000&#34;, &#34;0.1396500000&#34;, &#34;0.5051900000&#34;, &#34;-0.0987320000&#34;, &#34;0.2557500000&#34;, &#34;0.1304000000&#34;, &#34;0.5544500000&#34;, &#34;-0.0214270000&#34;, &#34;-0.0295070000&#34;, &#34;0.0211700000&#34;, &#34;-0.1621000000&#34;, &#34;0.0148080000&#34;, &#34;0.0497580000&#34;, &#34;0.0360560000&#34;, &#34;-0.0623040000&#34;, &#34;0.6364200000&#34;, &#34;-0.4364400000&#34;, &#34;-0.0767760000&#34;, &#34;-0.3918200000&#34;, &#34;-0.1376000000&#34;, &#34;-0.2439400000&#34;, &#34;-0.2273100000&#34;, &#34;0.0665700000&#34;, &#34;0.1443800000&#34;, &#34;0.3847800000&#34;, &#34;0.1537400000&#34;, &#34;-0.1217200000&#34;, &#34;-0.0908160000&#34;, &#34;0.0459150000&#34;, &#34;-0.1055400000&#34;, &#34;-0.0736280000&#34;, &#34;-0.1917500000&#34;, &#34;-0.2921800000&#34;, &#34;0.2679500000&#34;, &#34;0.5089700000&#34;, &#34;0.0507820000&#34;, &#34;-0.2165700000&#34;, &#34;-0.0859700000&#34;, &#34;-0.2622300000&#34;, &#34;0.0221730000&#34;, &#34;0.1312700000&#34;, &#34;0.2496800000&#34;, &#34;0.1859000000&#34;, &#34;-0.1064700000&#34;, &#34;-0.3341000000&#34;, &#34;-0.4195600000&#34;, &#34;0.4828700000&#34;, &#34;0.5315000000&#34;, &#34;0.4137700000&#34;, &#34;-0.1783900000&#34;, &#34;0.2191900000&#34;, &#34;-0.1759100000&#34;, &#34;0.2718100000&#34;, &#34;0.0696030000&#34;, &#34;0.1032600000&#34;, &#34;-0.3397300000&#34;, &#34;-0.0553010000&#34;, &#34;0.1900100000&#34;, &#34;0.1406000000&#34;, &#34;-0.1833600000&#34;, &#34;-0.2006000000&#34;, &#34;-0.1718700000&#34;, &#34;0.2891500000&#34;, &#34;0.1472300000&#34;, &#34;-0.1442000000&#34;, &#34;-0.1555900000&#34;, &#34;-0.2456900000&#34;, &#34;-0.2394000000&#34;, &#34;0.1255800000&#34;, &#34;0.0276060000&#34;, &#34;0.1091400000&#34;, &#34;-0.1685800000&#34;, &#34;-0.0104810000&#34;, &#34;0.0252680000&#34;, &#34;-0.4089600000&#34;, &#34;0.4035400000&#34;, &#34;0.2546200000&#34;, &#34;-0.1537700000&#34;, &#34;0.3820000000&#34;, &#34;0.3436200000&#34;, &#34;-0.1251400000&#34;, &#34;-0.0505150000&#34;, &#34;0.1468700000&#34;, &#34;-0.0349930000&#34;, &#34;0.0669180000&#34;, &#34;0.1820300000&#34;, &#34;-0.1824700000&#34;, &#34;-0.0515000000&#34;, &#34;0.4634800000&#34;, &#34;-0.0582060000&#34;, &#34;0.0171330000&#34;, &#34;-0.0897660000&#34;, &#34;-0.4300800000&#34;, &#34;0.2556600000&#34;, &#34;-0.0925030000&#34;, &#34;0.3139000000&#34;, &#34;0.2618700000&#34;, &#34;0.2952500000&#34;, &#34;0.1411200000&#34;, &#34;0.1121100000&#34;, &#34;0.0774650000&#34;, &#34;-0.0810540000&#34;, &#34;0.0272460000&#34;, &#34;-0.3590800000&#34;, &#34;0.2473100000&#34;, &#34;0.2364700000&#34;, &#34;0.0182670000&#34;, &#34;-0.0976000000&#34;, &#34;0.1849400000&#34;, &#34;-0.0737550000&#34;, &#34;-0.0809840000&#34;, &#34;-0.1399200000&#34;, &#34;-0.1203000000&#34;, &#34;-0.0248450000&#34;, &#34;0.1400100000&#34;, &#34;0.1134500000&#34;, &#34;0.3576000000&#34;, &#34;0.0182790000&#34;, &#34;-0.3489200000&#34;, &#34;0.1073600000&#34;, &#34;-0.1351200000&#34;, &#34;0.1727700000&#34;, &#34;0.6192000000&#34;, &#34;0.0788150000&#34;, &#34;-0.1206400000&#34;, &#34;0.0543810000&#34;, &#34;-0.2672600000&#34;, &#34;0.1541100000&#34;, &#34;0.1107000000&#34;, &#34;-0.1556500000&#34;, &#34;0.2000600000&#34;, &#34;0.0365320000&#34;, &#34;-0.0519310000&#34;, &#34;-0.1327000000&#34;, &#34;0.0648700000&#34;, &#34;0.0222260000&#34;, &#34;-0.0132770000&#34;, &#34;-0.2840300000&#34;], [&#34;-0.0242940000&#34;, &#34;-0.3239500000&#34;, &#34;0.0416820000&#34;, &#34;0.3595100000&#34;, &#34;-0.0633400000&#34;, &#34;-0.0187400000&#34;, &#34;0.0271570000&#34;, &#34;-0.2658200000&#34;, &#34;0.0790410000&#34;, &#34;0.0189980000&#34;, &#34;-0.2384500000&#34;, &#34;0.2018200000&#34;, &#34;-0.1744400000&#34;, &#34;-0.1616700000&#34;, &#34;0.0889900000&#34;, &#34;0.0446220000&#34;, &#34;0.2123800000&#34;, &#34;-0.0304880000&#34;, &#34;0.2676700000&#34;, &#34;0.0243910000&#34;, &#34;-0.0481600000&#34;, &#34;0.4059700000&#34;, &#34;-0.4106000000&#34;, &#34;0.0084117000&#34;, &#34;-0.1556800000&#34;, &#34;0.2261100000&#34;, &#34;-0.0949880000&#34;, &#34;-0.2961900000&#34;, &#34;0.2178500000&#34;, &#34;0.2087100000&#34;, &#34;-0.0634690000&#34;, &#34;0.1624800000&#34;, &#34;-0.3018100000&#34;, &#34;-0.0512650000&#34;, &#34;-0.0935090000&#34;, &#34;-0.0678830000&#34;, &#34;0.0773100000&#34;, &#34;-0.2619000000&#34;, &#34;0.2478900000&#34;, &#34;-0.1452600000&#34;, &#34;-0.0132880000&#34;, &#34;-0.2955800000&#34;, &#34;-0.0406290000&#34;, &#34;-0.0517810000&#34;, &#34;0.1531500000&#34;, &#34;-0.1170000000&#34;, &#34;-0.0388830000&#34;, &#34;-0.1496300000&#34;, &#34;0.1859600000&#34;, &#34;-0.1104100000&#34;, &#34;-0.0091632000&#34;, &#34;-0.0394350000&#34;, &#34;-0.0266110000&#34;, &#34;-0.2930500000&#34;, &#34;-0.4908600000&#34;, &#34;0.1894300000&#34;, &#34;0.1154400000&#34;, &#34;0.3440000000&#34;, &#34;0.0313070000&#34;, &#34;0.2795000000&#34;, &#34;-0.0004033100&#34;, &#34;-0.1001400000&#34;, &#34;0.1903000000&#34;, &#34;-0.2856300000&#34;, &#34;-0.2030600000&#34;, &#34;0.2616400000&#34;, &#34;-0.2483300000&#34;, &#34;-0.3037300000&#34;, &#34;-0.2997800000&#34;, &#34;-0.3423000000&#34;, &#34;0.0978230000&#34;, &#34;-0.0056031000&#34;, &#34;0.4326900000&#34;, &#34;0.0664090000&#34;, &#34;-0.0188520000&#34;, &#34;0.3497700000&#34;, &#34;0.0095120000&#34;, &#34;0.0777580000&#34;, &#34;-0.1161600000&#34;, &#34;-0.3649400000&#34;, &#34;-0.0357600000&#34;, &#34;0.2563500000&#34;, &#34;-0.1065300000&#34;, &#34;-0.1825100000&#34;, &#34;-0.4096400000&#34;, &#34;-0.0930490000&#34;, &#34;-0.2399500000&#34;, &#34;0.1830700000&#34;, &#34;0.0844960000&#34;, &#34;0.0113040000&#34;, &#34;-0.0908230000&#34;, &#34;0.0686370000&#34;, &#34;0.0907610000&#34;, &#34;-0.2092100000&#34;, &#34;0.1721200000&#34;, &#34;-0.1507400000&#34;, &#34;0.1721700000&#34;, &#34;0.0313720000&#34;, &#34;-0.3987500000&#34;, &#34;0.3512700000&#34;, &#34;0.1610700000&#34;, &#34;-0.1358800000&#34;, &#34;0.3285600000&#34;, &#34;-0.0740190000&#34;, &#34;-0.2131900000&#34;, &#34;-0.1929600000&#34;, &#34;-0.3076900000&#34;, &#34;0.2266200000&#34;, &#34;0.1220100000&#34;, &#34;0.0307650000&#34;, &#34;0.0034103000&#34;, &#34;-0.3236500000&#34;, &#34;-0.2254400000&#34;, &#34;-0.1614700000&#34;, &#34;0.0403000000&#34;, &#34;0.2501300000&#34;, &#34;0.3367500000&#34;, &#34;0.2089000000&#34;, &#34;0.2335300000&#34;, &#34;-0.2064400000&#34;, &#34;0.0054006000&#34;, &#34;0.1259600000&#34;, &#34;-0.2135800000&#34;, &#34;0.4612500000&#34;, &#34;-0.0974460000&#34;, &#34;-0.0833560000&#34;, &#34;-0.0047900000&#34;, &#34;0.2662200000&#34;, &#34;0.2942800000&#34;, &#34;-0.0036505000&#34;, &#34;0.1492400000&#34;, &#34;0.2285700000&#34;, &#34;0.0057792000&#34;, &#34;-0.4267300000&#34;, &#34;-0.3525300000&#34;, &#34;-0.0277540000&#34;, &#34;-0.0688070000&#34;, &#34;-0.0220590000&#34;, &#34;-0.1709600000&#34;, &#34;0.0075218000&#34;, &#34;0.2095600000&#34;, &#34;0.3758300000&#34;, &#34;0.1411700000&#34;, &#34;0.3974300000&#34;, &#34;-0.1308600000&#34;, &#34;0.3608300000&#34;, &#34;0.3766100000&#34;, &#34;0.0606630000&#34;, &#34;0.1532600000&#34;, &#34;0.0470050000&#34;, &#34;-0.1083200000&#34;, &#34;-0.1943300000&#34;, &#34;-0.2677700000&#34;, &#34;-0.0867870000&#34;, &#34;-0.1062400000&#34;, &#34;-0.1830500000&#34;, &#34;0.0123840000&#34;, &#34;-0.1651100000&#34;, &#34;0.1138500000&#34;, &#34;0.0624900000&#34;, &#34;-0.4335600000&#34;, &#34;0.5021500000&#34;, &#34;-0.1896400000&#34;, &#34;-0.0977140000&#34;, &#34;0.4413700000&#34;, &#34;0.0029150000&#34;, &#34;0.2110000000&#34;, &#34;-0.0178610000&#34;, &#34;0.4172900000&#34;, &#34;0.0891950000&#34;, &#34;-0.1889000000&#34;, &#34;0.0759990000&#34;, &#34;-0.0367490000&#34;, &#34;0.0236250000&#34;, &#34;0.1068000000&#34;, &#34;0.0021618000&#34;, &#34;0.0526030000&#34;, &#34;0.5860000000&#34;, &#34;-0.4146800000&#34;, &#34;-0.0426800000&#34;, &#34;-0.2409900000&#34;, &#34;-0.0980560000&#34;, &#34;-0.0600310000&#34;, &#34;-0.0472040000&#34;, &#34;-0.1209300000&#34;, &#34;0.0993520000&#34;, &#34;0.4296400000&#34;, &#34;0.0664360000&#34;, &#34;0.0525380000&#34;, &#34;-0.1083300000&#34;, &#34;-0.1364400000&#34;, &#34;-0.2545300000&#34;, &#34;-0.1385900000&#34;, &#34;-0.2049400000&#34;, &#34;-0.2140200000&#34;, &#34;0.1844600000&#34;, &#34;0.4171800000&#34;, &#34;0.0527950000&#34;, &#34;-0.3474500000&#34;, &#34;-0.0156120000&#34;, &#34;-0.0747160000&#34;, &#34;-0.0352120000&#34;, &#34;0.2024700000&#34;, &#34;0.2419400000&#34;, &#34;0.1586900000&#34;, &#34;-0.1130300000&#34;, &#34;-0.1961800000&#34;, &#34;-0.4176400000&#34;, &#34;0.4982800000&#34;, &#34;0.3397800000&#34;, &#34;0.2777000000&#34;, &#34;-0.2783800000&#34;, &#34;0.1916100000&#34;, &#34;-0.2289500000&#34;, &#34;0.2389400000&#34;, &#34;-0.1750900000&#34;, &#34;0.1791900000&#34;, &#34;-0.2655000000&#34;, &#34;-0.0676030000&#34;, &#34;0.1801900000&#34;, &#34;-0.0503290000&#34;, &#34;-0.2555900000&#34;, &#34;-0.1330600000&#34;, &#34;-0.0910780000&#34;, &#34;0.2350600000&#34;, &#34;0.1578500000&#34;, &#34;-0.0945700000&#34;, &#34;-0.1061400000&#34;, &#34;-0.2513600000&#34;, &#34;-0.3436200000&#34;, &#34;0.1153100000&#34;, &#34;0.0469850000&#34;, &#34;0.2516800000&#34;, &#34;-0.1805500000&#34;, &#34;0.0971710000&#34;, &#34;0.0339080000&#34;, &#34;-0.2471000000&#34;, &#34;0.1703900000&#34;, &#34;0.0776150000&#34;, &#34;-0.1344600000&#34;, &#34;0.2537800000&#34;, &#34;0.2486000000&#34;, &#34;-0.0134710000&#34;, &#34;-0.0874520000&#34;, &#34;0.2856200000&#34;, &#34;-0.0718710000&#34;, &#34;0.2150100000&#34;, &#34;0.0718500000&#34;, &#34;-0.0148210000&#34;, &#34;-0.1938600000&#34;, &#34;0.4450900000&#34;, &#34;0.0558750000&#34;, &#34;0.0086543000&#34;, &#34;-0.0832180000&#34;, &#34;-0.4327300000&#34;, &#34;0.3075600000&#34;, &#34;0.1733100000&#34;, &#34;0.1430000000&#34;, &#34;0.0318120000&#34;, &#34;0.0799010000&#34;, &#34;0.1654500000&#34;, &#34;-0.0156160000&#34;, &#34;0.2118800000&#34;, &#34;-0.0251020000&#34;, &#34;-0.1068600000&#34;, &#34;-0.4185400000&#34;, &#34;0.1659600000&#34;, &#34;0.3885500000&#34;, &#34;0.0883650000&#34;, &#34;-0.1181000000&#34;, &#34;0.2872300000&#34;, &#34;0.0783410000&#34;, &#34;0.1460700000&#34;, &#34;-0.0681060000&#34;, &#34;-0.1567200000&#34;, &#34;0.1383700000&#34;, &#34;0.1536700000&#34;, &#34;-0.0212600000&#34;, &#34;0.2712500000&#34;, &#34;-0.0975090000&#34;, &#34;-0.2976100000&#34;, &#34;0.1161900000&#34;, &#34;-0.0630370000&#34;, &#34;0.0590700000&#34;, &#34;0.4889300000&#34;, &#34;0.1329800000&#34;, &#34;-0.1882000000&#34;, &#34;0.0291000000&#34;, &#34;-0.3653800000&#34;, &#34;-0.0827490000&#34;, &#34;0.0793000000&#34;, &#34;0.1312200000&#34;, &#34;0.2543000000&#34;, &#34;0.1376000000&#34;, &#34;-0.1528000000&#34;, &#34;-0.0783560000&#34;, &#34;0.1339400000&#34;, &#34;0.1069800000&#34;, &#34;-0.2136600000&#34;, &#34;-0.1665700000&#34;], [&#34;0.3297300000&#34;, &#34;-0.3556600000&#34;, &#34;0.0912140000&#34;, &#34;0.4278000000&#34;, &#34;-0.1860500000&#34;, &#34;0.2286600000&#34;, &#34;0.2729500000&#34;, &#34;-0.3176300000&#34;, &#34;0.0654800000&#34;, &#34;0.0286500000&#34;, &#34;-0.1624800000&#34;, &#34;0.1392200000&#34;, &#34;-0.1724600000&#34;, &#34;0.1802800000&#34;, &#34;-0.0780540000&#34;, &#34;-0.6242900000&#34;, &#34;0.2703700000&#34;, &#34;-0.3544900000&#34;, &#34;-0.4743500000&#34;, &#34;0.5511700000&#34;, &#34;0.2268800000&#34;, &#34;0.5110300000&#34;, &#34;-0.5912900000&#34;, &#34;-0.0860950000&#34;, &#34;-0.0155720000&#34;, &#34;0.1994000000&#34;, &#34;-0.2632800000&#34;, &#34;-0.1392200000&#34;, &#34;-0.0088878000&#34;, &#34;0.7540400000&#34;, &#34;-0.4957700000&#34;, &#34;0.2192800000&#34;, &#34;-0.3889200000&#34;, &#34;0.1637100000&#34;, &#34;0.0973420000&#34;, &#34;-0.1469800000&#34;, &#34;0.3972400000&#34;, &#34;-0.2265700000&#34;, &#34;-0.3383700000&#34;, &#34;-0.1341700000&#34;, &#34;-0.1078600000&#34;, &#34;-0.1713200000&#34;, &#34;0.2618700000&#34;, &#34;0.2394700000&#34;, &#34;0.1195900000&#34;, &#34;0.3077000000&#34;, &#34;-0.0875170000&#34;, &#34;-0.3220600000&#34;, &#34;0.2539900000&#34;, &#34;0.3387200000&#34;, &#34;0.1478600000&#34;, &#34;0.2100300000&#34;, &#34;-0.0782010000&#34;, &#34;0.1231700000&#34;, &#34;-0.1766600000&#34;, &#34;-0.0825180000&#34;, &#34;-0.1440600000&#34;, &#34;0.0033585000&#34;, &#34;-0.1562800000&#34;, &#34;0.6561600000&#34;, &#34;-0.0779720000&#34;, &#34;-0.4151900000&#34;, &#34;0.3605700000&#34;, &#34;-0.0880550000&#34;, &#34;-0.0490930000&#34;, &#34;0.0161190000&#34;, &#34;-0.3492200000&#34;, &#34;-0.2678300000&#34;, &#34;0.1366100000&#34;, &#34;0.1236400000&#34;, &#34;-0.0977190000&#34;, &#34;0.0004395400&#34;, &#34;0.6962700000&#34;, &#34;-0.3196800000&#34;, &#34;0.2334100000&#34;, &#34;0.1828600000&#34;, &#34;0.6553300000&#34;, &#34;0.3765900000&#34;, &#34;0.0914660000&#34;, &#34;0.1528000000&#34;, &#34;0.4496700000&#34;, &#34;-0.0467210000&#34;, &#34;0.0271550000&#34;, &#34;-0.0621830000&#34;, &#34;0.0171210000&#34;, &#34;-0.1775300000&#34;, &#34;-0.4827000000&#34;, &#34;0.1631200000&#34;, &#34;-0.2930700000&#34;, &#34;-0.7393300000&#34;, &#34;-0.0642870000&#34;, &#34;-0.2645100000&#34;, &#34;0.4221100000&#34;, &#34;-0.3683600000&#34;, &#34;0.0013729000&#34;, &#34;0.0788040000&#34;, &#34;0.1658700000&#34;, &#34;0.1868300000&#34;, &#34;-0.1539700000&#34;, &#34;0.2405700000&#34;, &#34;-0.0749970000&#34;, &#34;0.0708060000&#34;, &#34;0.2169000000&#34;, &#34;-0.1030300000&#34;, &#34;0.0431140000&#34;, &#34;0.1311800000&#34;, &#34;-0.0639800000&#34;, &#34;-0.0705880000&#34;, &#34;0.1198600000&#34;, &#34;0.2962200000&#34;, &#34;-0.2221100000&#34;, &#34;0.3317500000&#34;, &#34;0.2680100000&#34;, &#34;0.0035323000&#34;, &#34;-0.1022900000&#34;, &#34;-0.1959800000&#34;, &#34;0.0703780000&#34;, &#34;0.0671080000&#34;, &#34;-0.3266900000&#34;, &#34;0.3488200000&#34;, &#34;0.6139600000&#34;, &#34;0.1418200000&#34;, &#34;-0.1403700000&#34;, &#34;-0.0634710000&#34;, &#34;-0.1017400000&#34;, &#34;-0.5554100000&#34;, &#34;0.0132580000&#34;, &#34;0.1860700000&#34;, &#34;0.1684200000&#34;, &#34;0.4018300000&#34;, &#34;0.2441500000&#34;, &#34;-0.0244280000&#34;, &#34;-0.2644000000&#34;, &#34;-0.0449790000&#34;, &#34;-0.0283060000&#34;, &#34;0.0975810000&#34;, &#34;-0.3063500000&#34;, &#34;0.1088500000&#34;, &#34;0.1134500000&#34;, &#34;0.6479700000&#34;, &#34;-0.3710300000&#34;, &#34;0.2057600000&#34;, &#34;-0.0468020000&#34;, &#34;-0.0519850000&#34;, &#34;0.5226500000&#34;, &#34;-0.3188600000&#34;, &#34;0.1780000000&#34;, &#34;-0.0346180000&#34;, &#34;-0.0927760000&#34;, &#34;0.1026700000&#34;, &#34;-0.1340200000&#34;, &#34;-0.0918360000&#34;, &#34;-0.4753000000&#34;, &#34;-0.2600600000&#34;, &#34;-0.0466660000&#34;, &#34;-0.0845210000&#34;, &#34;0.2354100000&#34;, &#34;-0.1613200000&#34;, &#34;0.2594500000&#34;, &#34;0.0589440000&#34;, &#34;0.0647540000&#34;, &#34;0.4094900000&#34;, &#34;-0.4049600000&#34;, &#34;0.0634170000&#34;, &#34;0.4876100000&#34;, &#34;0.0229780000&#34;, &#34;-0.1019100000&#34;, &#34;-0.0814310000&#34;, &#34;0.2847900000&#34;, &#34;0.2806300000&#34;, &#34;-0.1785800000&#34;, &#34;0.1011700000&#34;, &#34;0.2200400000&#34;, &#34;0.3961900000&#34;, &#34;-0.1020500000&#34;, &#34;0.0762120000&#34;, &#34;0.2872800000&#34;, &#34;-0.3623900000&#34;, &#34;-0.3962400000&#34;, &#34;0.1975200000&#34;, &#34;-0.0295920000&#34;, &#34;-0.2442900000&#34;, &#34;-0.3738800000&#34;, &#34;-0.0469790000&#34;, &#34;0.0491700000&#34;, &#34;-0.2483500000&#34;, &#34;0.2019400000&#34;, &#34;-0.3030500000&#34;, &#34;-0.0583790000&#34;, &#34;-0.2548900000&#34;, &#34;0.2768700000&#34;, &#34;-0.0083026000&#34;, &#34;-0.4150300000&#34;, &#34;0.1373800000&#34;, &#34;-0.3285000000&#34;, &#34;0.4835700000&#34;, &#34;0.1823800000&#34;, &#34;-0.2945300000&#34;, &#34;-0.4003500000&#34;, &#34;-0.1138200000&#34;, &#34;0.0240130000&#34;, &#34;-0.0401920000&#34;, &#34;0.2646200000&#34;, &#34;0.0060517000&#34;, &#34;0.2194500000&#34;, &#34;-0.3565600000&#34;, &#34;-0.3231100000&#34;, &#34;-0.0579250000&#34;, &#34;-0.1299200000&#34;, &#34;0.3791000000&#34;, &#34;0.4819200000&#34;, &#34;-0.0729980000&#34;, &#34;-0.0895620000&#34;, &#34;-0.4844800000&#34;, &#34;-0.0855470000&#34;, &#34;0.1216500000&#34;, &#34;0.0496070000&#34;, &#34;-0.1130200000&#34;, &#34;0.4998800000&#34;, &#34;-0.2149200000&#34;, &#34;0.1500100000&#34;, &#34;-0.0638330000&#34;, &#34;-0.4739700000&#34;, &#34;-0.1504800000&#34;, &#34;0.2040600000&#34;, &#34;-0.0246430000&#34;, &#34;0.0096142000&#34;, &#34;-0.1903900000&#34;, &#34;0.0763020000&#34;, &#34;0.1814500000&#34;, &#34;0.0858460000&#34;, &#34;-0.0666130000&#34;, &#34;-0.3796300000&#34;, &#34;0.0012397000&#34;, &#34;0.1106800000&#34;, &#34;-0.0316870000&#34;, &#34;-0.4972900000&#34;, &#34;-0.1197200000&#34;, &#34;-0.1223500000&#34;, &#34;-0.1565000000&#34;, &#34;0.6281700000&#34;, &#34;0.0407220000&#34;, &#34;-0.0801920000&#34;, &#34;-0.1377500000&#34;, &#34;-0.3523700000&#34;, &#34;0.1699700000&#34;, &#34;0.0486930000&#34;, &#34;-0.3552400000&#34;, &#34;-0.2106800000&#34;, &#34;0.1641000000&#34;, &#34;0.1320200000&#34;, &#34;0.2065300000&#34;, &#34;-0.1284700000&#34;, &#34;-0.1857700000&#34;, &#34;-0.0013799000&#34;, &#34;-0.0348540000&#34;, &#34;0.1900800000&#34;, &#34;-0.3504800000&#34;, &#34;0.4373600000&#34;, &#34;0.1438400000&#34;, &#34;0.0583970000&#34;, &#34;0.0675360000&#34;, &#34;-0.0274320000&#34;, &#34;0.0565660000&#34;, &#34;-0.5415500000&#34;, &#34;0.2420000000&#34;, &#34;0.0780820000&#34;, &#34;-0.0284790000&#34;, &#34;0.0015143000&#34;, &#34;0.6451000000&#34;, &#34;0.1003100000&#34;, &#34;0.0325710000&#34;, &#34;0.0715540000&#34;, &#34;-0.0721530000&#34;, &#34;-0.0347940000&#34;, &#34;0.4477600000&#34;, &#34;0.1405600000&#34;, &#34;0.1827600000&#34;, &#34;-0.1663900000&#34;, &#34;-0.0824300000&#34;, &#34;-0.1650300000&#34;, &#34;0.0987490000&#34;, &#34;0.0973930000&#34;, &#34;-0.0779960000&#34;, &#34;-0.0045350000&#34;, &#34;0.2438100000&#34;, &#34;-0.5503900000&#34;, &#34;-0.3891300000&#34;, &#34;-0.4439800000&#34;, &#34;-0.0767440000&#34;, &#34;0.3202500000&#34;, &#34;0.1939800000&#34;, &#34;0.2653600000&#34;, &#34;0.1206500000&#34;, &#34;-0.1673100000&#34;, &#34;0.0001194300&#34;, &#34;-0.1581400000&#34;, &#34;-0.0350040000&#34;, &#34;0.5433600000&#34;, &#34;0.1530000000&#34;]]}&#39;,)</pre>
</div>

</div>

</div>

</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="3.2-Bonus-Point--Cosine-Similarity">3.2 Bonus Point- Cosine Similarity<a class="anchor-link" href="#3.2-Bonus-Point--Cosine-Similarity">&#182;</a></h2><p>Cosine similarity is a metric which measures the similarity between two vectors.
We can try to use this tool in order to explore the realized framework based on the idea of words mappend in vectors. In particular similar words will have similar numerical representation.</p>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>According to this we will implement an algorithm that can detect if two sentences are similar (we will do it in sequential and parallel case).
We can define the cosine similarity ($\varphi(\textbf{x},\textbf{y})$) of two different vectors $\textbf{x},\textbf{y}$  in the following way: 
$$
\varphi(\textbf{x},\textbf{y}) = \dfrac{ \textbf{x} \cdot \textbf{y} }{ \sqrt{ \textbf{x} \cdot \textbf{x} \, \textbf{y} \cdot \textbf{y} } }
$$</p>

</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>In this cell we take in input the files saved in the previus point. They are still in <code>.json</code> format to make our work in this section easier.</p>
<p>Now we have to save the input file in a format which make easy the computation of $\varphi$ (i.e. numpy arrays):</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[5]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">input_emb_titles</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s1">&#39;./new_emb/*.json&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span>
 
<span class="k">def</span> <span class="nf">string_to_float</span><span class="p">(</span><span class="n">title</span><span class="p">):</span>
    <span class="k">return</span> <span class="n">np</span><span class="o">.</span><span class="n">array</span><span class="p">([[</span><span class="nb">float</span><span class="p">(</span><span class="n">w</span><span class="p">)</span> <span class="k">for</span> <span class="n">w</span> <span class="ow">in</span> <span class="n">word</span><span class="p">]</span> <span class="k">for</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">title</span><span class="p">])</span>

<span class="k">def</span> <span class="nf">float_db</span><span class="p">(</span><span class="n">record</span><span class="p">):</span>
    <span class="k">return</span> <span class="p">{</span>
        <span class="s2">&quot;title&quot;</span><span class="p">:</span> <span class="n">record</span><span class="p">[</span><span class="s1">&#39;title&#39;</span><span class="p">],</span>
        <span class="s2">&quot;embedding&quot;</span><span class="p">:</span> <span class="n">string_to_float</span><span class="p">(</span><span class="n">record</span><span class="p">[</span><span class="s1">&#39;emb_title&#39;</span><span class="p">])</span>
    <span class="p">}</span>

<span class="n">titles_emb</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">from_sequence</span><span class="p">(</span><span class="n">input_emb_titles</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">float_db</span><span class="p">))</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span> 
<span class="nb">print</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">[</span><span class="mi">1</span><span class="p">])</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>{&#39;title&#39;: &#39;a study on the influence of the pandemic on incomes in greece&#39;, &#39;embedding&#39;: array([[ 1.1559e-01,  3.0192e-01, -1.1465e-01, ...,  1.1048e-01,
         1.3074e-01,  4.1164e-02],
       [ 1.5190e-01, -1.0733e-04, -6.2792e-02, ...,  8.7667e-02,
         2.8810e-02, -2.7188e-01],
       [-2.9945e-02,  8.3080e-02, -4.1043e-02, ...,  3.6366e-02,
        -4.8136e-02,  1.4706e-03],
       ...,
       [-6.6420e-02,  3.0969e-01, -8.6885e-02, ...,  2.7098e-01,
         4.1447e-01, -2.5261e-01],
       [ 1.2367e-01, -1.3965e-01,  4.4877e-02, ...,  6.4740e-02,
        -1.4581e-01,  1.6175e-01],
       [-2.9095e-01, -2.0288e-01, -8.1345e-02, ..., -4.3330e-01,
         1.4470e-01,  2.3747e-01]])}
</pre>
</div>
</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[6]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="c1"># Original length of the considered list</span>
<span class="nb">len</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">)</span> 
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[6]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>998</pre>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>Discard empty entries in the titles list.</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[7]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">count</span> <span class="o">=</span> <span class="mi">0</span>
<span class="n">new_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">)):</span>
    <span class="k">if</span> <span class="p">(</span><span class="nb">len</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">[</span><span class="n">i</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">])</span> <span class="o">&gt;</span> <span class="mi">0</span><span class="p">):</span>
        <span class="n">new_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">titles_emb</span><span class="p">[</span><span class="n">i</span><span class="p">])</span>
        <span class="n">count</span> <span class="o">=</span> <span class="n">count</span> <span class="o">+</span> <span class="mi">1</span>
<span class="n">count</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[7]:</div>




<div class="jp-RenderedText jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/plain">
<pre>892</pre>
</div>

</div>

</div>

</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h3 id="3.2.1-Serial-approach">3.2.1 Serial approach<a class="anchor-link" href="#3.2.1-Serial-approach">&#182;</a></h3><p>First we implement the algorithm using a serial approach.</p>
<p>We have $2$ indexes ($k$, $l$) running over the papers. Then we will have $2$ others indexes ($i$, $j$) running over the words/vectors in each title.</p>
<p>The matrix <code>m_3</code> is a matrix containing all the cosine results for $2$ titles. After the computation of <code>m_3</code>, we mean all these values and we put the mean in <code>final_matrix</code>, which is a $892x892$ matrix in our case.</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[4]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">cosine</span><span class="p">(</span><span class="n">a</span><span class="p">,</span> <span class="n">b</span><span class="p">):</span>
    <span class="n">dot_prod</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">dot</span><span class="p">(</span><span class="n">a</span><span class="o">.</span><span class="n">T</span><span class="p">,</span> <span class="n">b</span><span class="o">.</span><span class="n">T</span><span class="p">)</span>
    <span class="n">normalization</span> <span class="o">=</span> <span class="p">(</span><span class="n">np</span><span class="o">.</span><span class="n">dot</span><span class="p">(</span><span class="n">a</span><span class="o">.</span><span class="n">T</span><span class="p">,</span> <span class="n">a</span><span class="o">.</span><span class="n">T</span><span class="p">)</span> <span class="o">*</span> <span class="n">np</span><span class="o">.</span><span class="n">dot</span><span class="p">(</span><span class="n">b</span><span class="o">.</span><span class="n">T</span><span class="p">,</span> <span class="n">b</span><span class="o">.</span><span class="n">T</span><span class="p">))</span><span class="o">**</span><span class="mf">0.5</span>
    <span class="k">return</span> <span class="n">dot_prod</span> <span class="o">/</span> <span class="n">normalization</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[71]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">n_papers</span> <span class="o">=</span> <span class="nb">len</span><span class="p">(</span><span class="n">new_list</span><span class="p">)</span>
<span class="n">final_matrix</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">zeros</span><span class="p">((</span><span class="n">n_papers</span><span class="p">,</span> <span class="n">n_papers</span><span class="p">))</span>

<span class="k">for</span> <span class="n">k</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">n_papers</span><span class="p">):</span>
    <span class="k">for</span> <span class="n">l</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">k</span><span class="p">):</span>
        
        <span class="n">first_index</span> <span class="o">=</span> <span class="n">k</span>
        <span class="n">second_index</span> <span class="o">=</span> <span class="n">l</span>
        
        <span class="n">m_1</span> <span class="o">=</span> <span class="n">new_list</span><span class="p">[</span><span class="n">first_index</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">]</span>
        <span class="n">m_2</span> <span class="o">=</span> <span class="n">new_list</span><span class="p">[</span><span class="n">second_index</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">]</span>
        <span class="n">m_3</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">zeros</span><span class="p">((</span><span class="n">m_1</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">0</span><span class="p">],</span> <span class="n">m_2</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">0</span><span class="p">]))</span>
        
        <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">m_3</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">0</span><span class="p">]):</span>
            <span class="k">for</span> <span class="n">j</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">m_3</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">1</span><span class="p">]):</span>
                
                <span class="n">m_3</span><span class="p">[</span><span class="n">i</span><span class="p">][</span><span class="n">j</span><span class="p">]</span> <span class="o">=</span> <span class="n">cosine</span><span class="p">(</span><span class="n">m_1</span><span class="p">[</span><span class="n">i</span><span class="p">][:]</span><span class="o">.</span><span class="n">T</span><span class="p">,</span> <span class="n">m_2</span><span class="p">[</span><span class="n">j</span><span class="p">][:]</span><span class="o">.</span><span class="n">T</span><span class="p">)</span>
                
        <span class="n">final_matrix</span><span class="p">[</span><span class="n">k</span><span class="p">][</span><span class="n">l</span><span class="p">]</span> <span class="o">=</span> <span class="n">m_3</span><span class="o">.</span><span class="n">mean</span><span class="p">()</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p><code>final_matrix</code> is a lower triangular matrix. The diagonal is the similarity between same title but it is not equals to $1$ because of the mean done on <code>m_3</code>.</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[24]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="nb">print</span><span class="p">(</span><span class="n">final_matrix</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>[[0.25998096 0.         0.         ... 0.         0.         0.        ]
 [0.25136145 0.38174239 0.         ... 0.         0.         0.        ]
 [0.21692805 0.24009    0.35371286 ... 0.         0.         0.        ]
 ...
 [0.20141433 0.22207867 0.23670566 ... 0.26207461 0.         0.        ]
 [0.21284151 0.23783449 0.24229411 ... 0.21006182 0.32498415 0.        ]
 [0.22180615 0.27085309 0.23744156 ... 0.21697991 0.24709101 0.31103645]]
</pre>
</div>
</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>List of the best results in terms of compatibility:</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[60]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">result</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">where</span><span class="p">(</span><span class="n">np</span><span class="o">.</span><span class="n">logical_and</span><span class="p">(</span><span class="n">final_matrix</span> <span class="o">&gt;</span> <span class="mf">0.30</span><span class="p">,</span> <span class="n">final_matrix</span> <span class="o">&lt;</span> <span class="mf">0.99</span><span class="p">))</span>
<span class="n">listOfIndices</span><span class="o">=</span> <span class="nb">list</span><span class="p">(</span><span class="nb">zip</span><span class="p">(</span><span class="n">result</span><span class="p">[</span><span class="mi">0</span><span class="p">],</span> <span class="n">result</span><span class="p">[</span><span class="mi">1</span><span class="p">]))</span>

<span class="k">for</span> <span class="n">index</span> <span class="ow">in</span> <span class="n">listOfIndices</span><span class="p">:</span>
    <span class="nb">print</span><span class="p">(</span><span class="n">index</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>(4, 1)
(8, 1)
(8, 4)
(15, 1)
(15, 4)
(17, 4)
(18, 1)
(18, 4)
(18, 17)
(19, 1)
(22, 1)
(25, 4)
(25, 10)
(25, 17)
(25, 18)
(27, 1)
(27, 4)
(28, 1)
(28, 4)
(28, 15)
(28, 22)
(28, 25)
(28, 27)
(30, 4)
(32, 1)
(32, 22)
(36, 4)
(37, 1)
(37, 4)
(37, 15)
(37, 22)
(37, 27)
(37, 28)
(39, 1)
(39, 27)
(39, 28)
(39, 37)
(42, 1)
(42, 28)
(42, 37)
(46, 1)
(46, 4)
(46, 25)
(46, 28)
(50, 4)
(50, 15)
(50, 25)
(50, 28)
(51, 1)
(51, 4)
(51, 10)
(51, 15)
(51, 17)
(51, 18)
(51, 19)
(51, 22)
(51, 27)
(51, 28)
(51, 32)
(51, 36)
(51, 37)
(51, 39)
(51, 46)
(51, 50)
(53, 51)
(60, 4)
(60, 12)
(60, 33)
(60, 36)
(61, 60)
(63, 51)
(66, 1)
(66, 4)
(66, 15)
(66, 18)
(66, 25)
(66, 28)
(66, 37)
(66, 51)
(67, 4)
(67, 15)
(67, 28)
(67, 51)
(69, 4)
(69, 60)
(71, 1)
(71, 4)
(71, 8)
(71, 10)
(71, 15)
(71, 17)
(71, 18)
(71, 22)
(71, 25)
(71, 27)
(71, 28)
(71, 30)
(71, 32)
(71, 37)
(71, 39)
(71, 42)
(71, 46)
(71, 51)
(71, 53)
(71, 66)
(71, 67)
(74, 51)
(80, 37)
(80, 39)
(80, 71)
(82, 4)
(82, 17)
(82, 18)
(82, 25)
(82, 36)
(82, 51)
(82, 63)
(82, 68)
(82, 76)
(85, 1)
(85, 4)
(85, 15)
(85, 22)
(85, 27)
(85, 28)
(85, 37)
(85, 50)
(85, 51)
(85, 71)
(87, 1)
(87, 37)
(87, 51)
(87, 71)
(88, 1)
(88, 4)
(88, 28)
(88, 37)
(88, 42)
(88, 51)
(88, 71)
(89, 36)
(90, 1)
(90, 4)
(90, 8)
(90, 15)
(90, 18)
(90, 22)
(90, 27)
(90, 28)
(90, 32)
(90, 37)
(90, 39)
(90, 42)
(90, 46)
(90, 51)
(90, 66)
(90, 71)
(92, 60)
(93, 1)
(93, 37)
(93, 71)
(93, 90)
(96, 1)
(96, 4)
(96, 18)
(96, 37)
(96, 51)
(96, 71)
(96, 82)
(96, 85)
(96, 90)
(102, 60)
(103, 4)
(103, 82)
(103, 90)
(104, 1)
(104, 3)
(104, 4)
(104, 8)
(104, 10)
(104, 11)
(104, 15)
(104, 17)
(104, 18)
(104, 19)
(104, 21)
(104, 22)
(104, 24)
(104, 27)
(104, 28)
(104, 30)
(104, 32)
(104, 34)
(104, 37)
(104, 38)
(104, 39)
(104, 42)
(104, 45)
(104, 46)
(104, 48)
(104, 49)
(104, 50)
(104, 51)
(104, 53)
(104, 55)
(104, 62)
(104, 63)
(104, 66)
(104, 67)
(104, 71)
(104, 72)
(104, 74)
(104, 75)
(104, 76)
(104, 80)
(104, 85)
(104, 87)
(104, 88)
(104, 90)
(104, 93)
(104, 94)
(104, 95)
(104, 96)
(104, 99)
(104, 103)
(105, 104)
(106, 104)
(107, 4)
(107, 36)
(107, 60)
(107, 82)
(107, 104)
(108, 25)
(109, 4)
(109, 104)
(110, 4)
(110, 15)
(110, 18)
(110, 25)
(110, 28)
(110, 51)
(110, 66)
(110, 67)
(110, 71)
(110, 82)
(110, 85)
(110, 96)
(110, 103)
(110, 104)
(111, 1)
(111, 4)
(111, 18)
(111, 27)
(111, 28)
(111, 37)
(111, 39)
(111, 51)
(111, 71)
(111, 85)
(111, 90)
(111, 96)
(111, 104)
(114, 1)
(114, 15)
(114, 37)
(114, 39)
(114, 51)
(114, 71)
(114, 90)
(114, 104)
(115, 37)
(115, 87)
(115, 104)
(117, 25)
(117, 82)
(117, 104)
(118, 4)
(118, 12)
(118, 33)
(118, 60)
(118, 85)
(118, 104)
(119, 4)
(119, 36)
(120, 71)
(120, 104)
(123, 104)
(124, 10)
(124, 18)
(124, 25)
(126, 1)
(126, 4)
(126, 17)
(126, 18)
(126, 25)
(126, 27)
(126, 28)
(126, 37)
(126, 46)
(126, 51)
(126, 66)
(126, 71)
(126, 90)
(126, 104)
(126, 111)
(127, 18)
(127, 82)
(128, 39)
(128, 80)
(128, 90)
(128, 104)
(128, 105)
(129, 4)
(129, 7)
(129, 10)
(129, 11)
(129, 15)
(129, 17)
(129, 18)
(129, 25)
(129, 28)
(129, 46)
(129, 50)
(129, 51)
(129, 60)
(129, 66)
(129, 69)
(129, 71)
(129, 77)
(129, 82)
(129, 85)
(129, 96)
(129, 103)
(129, 110)
(129, 124)
(129, 126)
(129, 127)
(131, 104)
(132, 36)
(133, 1)
(133, 37)
(133, 39)
(133, 46)
(133, 51)
(133, 71)
(133, 104)
(133, 111)
(133, 126)
(134, 1)
(134, 4)
(134, 18)
(134, 27)
(134, 28)
(134, 37)
(134, 51)
(134, 71)
(134, 85)
(134, 96)
(134, 104)
(134, 110)
(134, 111)
(136, 4)
(136, 8)
(136, 18)
(136, 25)
(136, 28)
(136, 36)
(136, 60)
(136, 67)
(136, 71)
(136, 81)
(136, 82)
(136, 85)
(136, 90)
(136, 92)
(136, 96)
(136, 103)
(136, 104)
(136, 107)
(136, 110)
(136, 118)
(136, 129)
(136, 134)
(137, 4)
(137, 25)
(137, 28)
(137, 71)
(137, 104)
(139, 104)
(140, 104)
(141, 1)
(141, 37)
(141, 71)
(141, 104)
(143, 104)
(144, 51)
(144, 82)
(144, 127)
(144, 129)
(148, 37)
(148, 51)
(148, 71)
(148, 104)
(150, 82)
(150, 129)
(151, 60)
(151, 119)
(152, 1)
(152, 37)
(152, 51)
(152, 71)
(152, 90)
(152, 104)
(152, 126)
(153, 104)
(155, 33)
(155, 118)
(156, 1)
(156, 4)
(156, 15)
(156, 18)
(156, 22)
(156, 28)
(156, 37)
(156, 51)
(156, 66)
(156, 67)
(156, 71)
(156, 85)
(156, 90)
(156, 104)
(156, 110)
(156, 129)
(156, 134)
(156, 136)
(158, 4)
(158, 28)
(158, 104)
(161, 104)
(162, 1)
(162, 4)
(162, 15)
(162, 27)
(162, 37)
(162, 39)
(162, 51)
(162, 71)
(162, 90)
(162, 103)
(162, 104)
(162, 111)
(165, 4)
(165, 15)
(165, 28)
(165, 37)
(165, 51)
(165, 67)
(165, 71)
(165, 90)
(165, 104)
(165, 118)
(165, 136)
(165, 156)
(168, 4)
(168, 25)
(168, 129)
(169, 4)
(169, 18)
(169, 19)
(169, 22)
(169, 36)
(169, 82)
(169, 104)
(169, 118)
(169, 119)
(169, 137)
(170, 4)
(170, 25)
(170, 50)
(172, 1)
(172, 15)
(172, 28)
(172, 37)
(172, 39)
(172, 51)
(172, 71)
(172, 90)
(172, 104)
(173, 4)
(173, 51)
(173, 71)
(173, 82)
(173, 104)
(173, 129)
(173, 144)
(175, 4)
(175, 8)
(175, 10)
(175, 15)
(175, 19)
(175, 25)
(175, 28)
(175, 51)
(175, 53)
(175, 66)
(175, 71)
(175, 85)
(175, 90)
(175, 96)
(175, 103)
(175, 104)
(175, 110)
(175, 118)
(175, 129)
(175, 136)
(175, 156)
(175, 169)
(175, 173)
(176, 4)
(176, 71)
(176, 104)
(177, 51)
(177, 82)
(177, 104)
(177, 129)
(178, 169)
(178, 175)
(179, 4)
(179, 60)
(179, 104)
(179, 118)
(180, 74)
(182, 1)
(182, 4)
(182, 8)
(182, 10)
(182, 15)
(182, 18)
(182, 22)
(182, 25)
(182, 27)
(182, 28)
(182, 32)
(182, 37)
(182, 39)
(182, 42)
(182, 46)
(182, 51)
(182, 66)
(182, 71)
(182, 85)
(182, 87)
(182, 88)
(182, 90)
(182, 93)
(182, 96)
(182, 104)
(182, 110)
(182, 111)
(182, 114)
(182, 126)
(182, 129)
(182, 133)
(182, 134)
(182, 136)
(182, 141)
(182, 148)
(182, 152)
(182, 156)
(182, 160)
(182, 162)
(182, 172)
(182, 175)
(184, 1)
(184, 4)
(184, 15)
(184, 18)
(184, 27)
(184, 28)
(184, 37)
(184, 39)
(184, 51)
(184, 66)
(184, 71)
(184, 80)
(184, 82)
(184, 85)
(184, 87)
(184, 88)
(184, 90)
(184, 96)
(184, 103)
(184, 104)
(184, 110)
(184, 111)
(184, 114)
(184, 126)
(184, 133)
(184, 134)
(184, 156)
(184, 162)
(184, 172)
(184, 173)
(184, 182)
(188, 4)
(188, 104)
(189, 4)
(189, 36)
(189, 82)
(189, 104)
(190, 4)
(190, 36)
(190, 51)
(190, 60)
(190, 67)
(190, 69)
(190, 71)
(190, 82)
(190, 104)
(190, 107)
(190, 110)
(190, 127)
(190, 129)
(190, 136)
(190, 144)
(190, 173)
(190, 175)
(190, 179)
(190, 184)
(190, 189)
(191, 4)
(191, 60)
(191, 71)
(191, 104)
(191, 190)
(192, 1)
(192, 4)
(192, 8)
(192, 10)
(192, 12)
(192, 15)
(192, 17)
(192, 18)
(192, 21)
(192, 22)
(192, 25)
(192, 27)
(192, 28)
(192, 30)
(192, 32)
(192, 33)
(192, 36)
(192, 37)
(192, 39)
(192, 42)
(192, 46)
(192, 50)
(192, 51)
(192, 60)
(192, 61)
(192, 66)
(192, 67)
(192, 69)
(192, 71)
(192, 82)
(192, 84)
(192, 85)
(192, 87)
(192, 88)
(192, 90)
(192, 95)
(192, 96)
(192, 103)
(192, 104)
(192, 107)
(192, 109)
(192, 110)
(192, 111)
(192, 118)
(192, 126)
(192, 129)
(192, 134)
(192, 136)
(192, 137)
(192, 141)
(192, 147)
(192, 152)
(192, 155)
(192, 156)
(192, 158)
(192, 160)
(192, 161)
(192, 162)
(192, 165)
(192, 168)
(192, 169)
(192, 170)
(192, 172)
(192, 173)
(192, 175)
(192, 176)
(192, 179)
(192, 182)
(192, 184)
(192, 188)
(192, 191)
(194, 1)
(194, 4)
(194, 15)
(194, 18)
(194, 22)
(194, 25)
(194, 27)
(194, 28)
(194, 37)
(194, 51)
(194, 66)
(194, 71)
(194, 85)
(194, 90)
(194, 96)
(194, 104)
(194, 129)
(194, 156)
(194, 162)
(194, 165)
(194, 169)
(194, 172)
(194, 175)
(194, 182)
(194, 192)
(195, 51)
(195, 71)
(195, 104)
(195, 182)
(196, 104)
(199, 1)
(199, 4)
(199, 15)
(199, 19)
(199, 22)
(199, 27)
(199, 28)
(199, 36)
(199, 37)
(199, 39)
(199, 50)
(199, 51)
(199, 66)
(199, 67)
(199, 71)
(199, 82)
(199, 85)
(199, 87)
(199, 90)
(199, 96)
(199, 104)
(199, 107)
(199, 110)
(199, 114)
(199, 134)
(199, 137)
(199, 156)
(199, 160)
(199, 162)
(199, 165)
(199, 169)
(199, 172)
(199, 182)
(199, 184)
(199, 192)
(199, 194)
(200, 104)
(202, 18)
(202, 124)
(203, 4)
(203, 28)
(203, 71)
(203, 104)
(203, 118)
(203, 136)
(203, 165)
(203, 175)
(203, 192)
(204, 4)
(204, 28)
(204, 67)
(204, 71)
(204, 104)
(204, 136)
(204, 156)
(204, 158)
(204, 165)
(204, 170)
(204, 192)
(205, 4)
(205, 15)
(205, 51)
(205, 71)
(205, 90)
(205, 104)
(205, 136)
(205, 184)
(205, 192)
(207, 6)
(207, 90)
(208, 1)
(208, 4)
(208, 15)
(208, 22)
(208, 28)
(208, 37)
(208, 39)
(208, 51)
(208, 71)
(208, 90)
(208, 104)
(208, 123)
(208, 126)
(208, 182)
(208, 184)
(208, 192)
(208, 194)
(208, 199)
(210, 25)
(210, 56)
(210, 124)
(210, 159)
(210, 170)
(211, 104)
(214, 82)
(218, 1)
(218, 4)
(218, 27)
(218, 28)
(218, 37)
(218, 39)
(218, 51)
(218, 71)
(218, 90)
(218, 104)
(218, 111)
(218, 134)
(218, 156)
(218, 182)
(218, 184)
(218, 192)
(218, 199)
(218, 208)
(221, 4)
(221, 28)
(221, 37)
(221, 71)
(221, 90)
(221, 104)
(221, 182)
(221, 192)
(222, 104)
(222, 175)
(224, 1)
(224, 4)
(224, 7)
(224, 8)
(224, 15)
(224, 17)
(224, 18)
(224, 21)
(224, 22)
(224, 25)
(224, 27)
(224, 28)
(224, 36)
(224, 37)
(224, 39)
(224, 42)
(224, 46)
(224, 50)
(224, 51)
(224, 66)
(224, 71)
(224, 82)
(224, 85)
(224, 87)
(224, 90)
(224, 96)
(224, 103)
(224, 104)
(224, 110)
(224, 111)
(224, 114)
(224, 115)
(224, 117)
(224, 126)
(224, 133)
(224, 134)
(224, 136)
(224, 152)
(224, 156)
(224, 160)
(224, 162)
(224, 165)
(224, 169)
(224, 172)
(224, 175)
(224, 182)
(224, 184)
(224, 192)
(224, 194)
(224, 199)
(224, 208)
(224, 218)
(224, 221)
(225, 104)
(227, 104)
(228, 1)
(228, 18)
(228, 22)
(228, 37)
(228, 51)
(228, 71)
(228, 85)
(228, 90)
(228, 104)
(228, 124)
(228, 182)
(228, 192)
(228, 224)
(229, 60)
(229, 151)
(230, 1)
(230, 4)
(230, 8)
(230, 15)
(230, 18)
(230, 22)
(230, 27)
(230, 28)
(230, 37)
(230, 39)
(230, 51)
(230, 66)
(230, 71)
(230, 85)
(230, 90)
(230, 104)
(230, 110)
(230, 111)
(230, 134)
(230, 136)
(230, 156)
(230, 162)
(230, 165)
(230, 172)
(230, 175)
(230, 182)
(230, 184)
(230, 191)
(230, 192)
(230, 194)
(230, 199)
(230, 203)
(230, 204)
(230, 218)
(230, 222)
(230, 224)
(235, 192)
(236, 4)
(236, 12)
(236, 33)
(236, 36)
(236, 60)
(236, 61)
(236, 69)
(236, 94)
(236, 104)
(236, 107)
(236, 110)
(236, 118)
(236, 136)
(236, 151)
(236, 155)
(236, 175)
(236, 179)
(236, 189)
(236, 190)
(236, 191)
(236, 192)
(236, 204)
(236, 229)
(238, 4)
(238, 33)
(238, 36)
(238, 60)
(238, 82)
(238, 97)
(238, 104)
(238, 107)
(238, 110)
(238, 118)
(238, 119)
(238, 129)
(238, 136)
(238, 169)
(238, 175)
(238, 189)
(238, 192)
(238, 204)
(238, 236)
(239, 4)
(239, 25)
(239, 36)
(239, 60)
(239, 110)
(239, 129)
(239, 175)
(239, 192)
(239, 236)
(239, 238)
(240, 1)
(240, 4)
(240, 7)
(240, 8)
(240, 10)
(240, 15)
(240, 17)
(240, 18)
(240, 22)
(240, 25)
(240, 27)
(240, 28)
(240, 32)
(240, 37)
(240, 39)
(240, 46)
(240, 51)
(240, 57)
(240, 66)
(240, 71)
(240, 74)
(240, 82)
(240, 85)
(240, 90)
(240, 96)
(240, 103)
(240, 104)
(240, 110)
(240, 111)
(240, 126)
(240, 129)
(240, 133)
(240, 134)
(240, 136)
(240, 148)
(240, 152)
(240, 156)
(240, 160)
(240, 162)
(240, 165)
(240, 172)
(240, 175)
(240, 177)
(240, 182)
(240, 184)
(240, 192)
(240, 194)
(240, 195)
(240, 199)
(240, 205)
(240, 208)
(240, 218)
(240, 221)
(240, 224)
(240, 228)
(240, 230)
(240, 239)
(242, 1)
(242, 37)
(242, 39)
(242, 71)
(242, 104)
(242, 184)
(243, 15)
(243, 71)
(243, 104)
(244, 4)
(244, 15)
(244, 28)
(244, 50)
(244, 51)
(244, 60)
(244, 67)
(244, 71)
(244, 85)
(244, 103)
(244, 104)
(244, 110)
(244, 118)
(244, 129)
(244, 136)
(244, 155)
(244, 156)
(244, 161)
(244, 165)
(244, 175)
(244, 192)
(244, 194)
(244, 199)
(244, 203)
(244, 205)
(244, 230)
(244, 236)
(244, 243)
(246, 28)
(246, 71)
(246, 104)
(246, 192)
(248, 1)
(248, 4)
(248, 10)
(248, 18)
(248, 37)
(248, 39)
(248, 51)
(248, 71)
(248, 90)
(248, 96)
(248, 104)
(248, 110)
(248, 129)
(248, 173)
(248, 175)
(248, 182)
(248, 184)
(248, 192)
(248, 218)
(248, 224)
(248, 228)
(248, 230)
(248, 240)
(249, 1)
(249, 4)
(249, 18)
(249, 37)
(249, 71)
(249, 90)
(249, 104)
(249, 182)
(249, 192)
(249, 224)
(249, 240)
(250, 192)
(251, 104)
(253, 1)
(253, 4)
(253, 10)
(253, 15)
(253, 18)
(253, 22)
(253, 25)
(253, 27)
(253, 28)
(253, 37)
(253, 39)
(253, 50)
(253, 51)
(253, 66)
(253, 67)
(253, 71)
(253, 85)
(253, 88)
(253, 90)
(253, 96)
(253, 103)
(253, 104)
(253, 107)
(253, 110)
(253, 111)
(253, 114)
(253, 118)
(253, 129)
(253, 134)
(253, 137)
(253, 156)
(253, 158)
(253, 160)
(253, 162)
(253, 165)
(253, 172)
(253, 175)
(253, 182)
(253, 184)
(253, 192)
(253, 194)
(253, 199)
(253, 203)
(253, 205)
(253, 208)
(253, 218)
(253, 224)
(253, 228)
(253, 230)
(253, 239)
(253, 240)
(253, 244)
(253, 248)
(254, 1)
(254, 37)
(254, 71)
(254, 90)
(254, 104)
(254, 192)
(254, 253)
(255, 4)
(255, 19)
(255, 51)
(255, 104)
(255, 118)
(255, 124)
(255, 134)
(255, 169)
(255, 175)
(255, 192)
(255, 199)
(255, 238)
(255, 253)
(256, 1)
(256, 28)
(256, 37)
(256, 39)
(256, 51)
(256, 66)
(256, 71)
(256, 90)
(256, 104)
(256, 182)
(256, 184)
(256, 192)
(256, 208)
(256, 218)
(257, 4)
(257, 12)
(257, 18)
(257, 23)
(257, 25)
(257, 30)
(257, 33)
(257, 36)
(257, 52)
(257, 60)
(257, 64)
(257, 68)
(257, 69)
(257, 76)
(257, 81)
(257, 82)
(257, 83)
(257, 89)
(257, 92)
(257, 94)
(257, 97)
(257, 101)
(257, 103)
(257, 107)
(257, 109)
(257, 117)
(257, 119)
(257, 127)
(257, 129)
(257, 132)
(257, 136)
(257, 144)
(257, 146)
(257, 150)
(257, 151)
(257, 154)
(257, 169)
(257, 171)
(257, 173)
(257, 178)
(257, 179)
(257, 184)
(257, 185)
(257, 189)
(257, 190)
(257, 197)
(257, 214)
(257, 216)
(257, 219)
(257, 229)
(257, 233)
(257, 235)
(257, 236)
(257, 238)
(257, 239)
(257, 248)
(257, 250)
(257, 255)
(259, 1)
(259, 4)
(259, 27)
(259, 28)
(259, 37)
(259, 39)
(259, 51)
(259, 71)
(259, 90)
(259, 104)
(259, 111)
(259, 126)
(259, 133)
(259, 182)
(259, 184)
(259, 199)
(259, 208)
(259, 224)
(259, 230)
(259, 240)
(261, 175)
(261, 244)
(262, 104)
(262, 182)
(262, 240)
(264, 59)
(266, 1)
(266, 4)
(266, 15)
(266, 18)
(266, 27)
(266, 28)
(266, 37)
(266, 39)
(266, 51)
(266, 53)
(266, 66)
(266, 67)
(266, 71)
(266, 85)
(266, 88)
(266, 90)
(266, 96)
(266, 104)
(266, 110)
(266, 111)
(266, 126)
(266, 134)
(266, 136)
(266, 137)
(266, 156)
(266, 158)
(266, 162)
(266, 165)
(266, 175)
(266, 182)
(266, 184)
(266, 191)
(266, 192)
(266, 194)
(266, 199)
(266, 204)
(266, 208)
(266, 218)
(266, 224)
(266, 230)
(266, 240)
(266, 244)
(266, 253)
(266, 256)
(266, 259)
(267, 1)
(267, 4)
(267, 7)
(267, 8)
(267, 10)
(267, 11)
(267, 15)
(267, 17)
(267, 18)
(267, 19)
(267, 21)
(267, 22)
(267, 25)
(267, 27)
(267, 28)
(267, 32)
(267, 37)
(267, 40)
(267, 46)
(267, 50)
(267, 51)
(267, 62)
(267, 65)
(267, 66)
(267, 67)
(267, 70)
(267, 71)
(267, 77)
(267, 82)
(267, 85)
(267, 87)
(267, 88)
(267, 90)
(267, 96)
(267, 104)
(267, 110)
(267, 111)
(267, 114)
(267, 126)
(267, 129)
(267, 134)
(267, 137)
(267, 150)
(267, 152)
(267, 156)
(267, 160)
(267, 162)
(267, 165)
(267, 169)
(267, 172)
(267, 175)
(267, 177)
(267, 182)
(267, 184)
(267, 192)
(267, 194)
(267, 199)
(267, 200)
(267, 205)
(267, 208)
(267, 211)
(267, 218)
(267, 220)
(267, 224)
(267, 228)
(267, 230)
(267, 235)
(267, 239)
(267, 240)
(267, 243)
(267, 244)
(267, 248)
(267, 249)
(267, 253)
(267, 255)
(267, 256)
(267, 261)
(267, 266)
(268, 28)
(268, 37)
(268, 71)
(268, 90)
(268, 104)
(268, 182)
(268, 240)
(269, 104)
(270, 37)
(270, 51)
(270, 71)
(270, 104)
(270, 184)
(270, 192)
(271, 82)
(271, 257)
(274, 170)
(274, 210)
(276, 129)
(278, 104)
(278, 257)
(279, 4)
(279, 25)
(279, 82)
(279, 129)
(279, 169)
(279, 192)
(279, 240)
(279, 257)
(281, 257)
(282, 1)
(282, 4)
(282, 7)
(282, 8)
(282, 10)
(282, 11)
(282, 15)
(282, 17)
(282, 18)
(282, 19)
(282, 21)
(282, 22)
(282, 25)
(282, 27)
(282, 28)
(282, 30)
(282, 32)
(282, 36)
(282, 37)
(282, 39)
(282, 42)
(282, 44)
(282, 45)
(282, 46)
(282, 50)
(282, 51)
(282, 53)
(282, 55)
(282, 57)
(282, 62)
(282, 63)
(282, 65)
(282, 66)
(282, 67)
(282, 71)
(282, 74)
(282, 75)
(282, 76)
(282, 80)
(282, 82)
(282, 85)
(282, 87)
(282, 88)
(282, 90)
(282, 93)
(282, 95)
(282, 96)
(282, 99)
(282, 103)
(282, 104)
(282, 107)
(282, 109)
(282, 110)
(282, 111)
(282, 114)
(282, 115)
(282, 117)
(282, 118)
(282, 123)
(282, 126)
(282, 128)
(282, 129)
(282, 130)
(282, 131)
(282, 133)
(282, 134)
(282, 136)
(282, 137)
(282, 138)
(282, 141)
(282, 143)
(282, 144)
(282, 148)
(282, 152)
(282, 156)
(282, 158)
(282, 160)
(282, 162)
(282, 165)
(282, 168)
(282, 169)
(282, 172)
(282, 173)
(282, 175)
(282, 176)
(282, 177)
(282, 178)
(282, 179)
(282, 182)
(282, 184)
(282, 188)
(282, 190)
(282, 191)
(282, 192)
(282, 194)
(282, 195)
(282, 199)
(282, 200)
(282, 203)
(282, 204)
(282, 205)
(282, 208)
(282, 209)
(282, 211)
(282, 218)
(282, 220)
(282, 221)
(282, 222)
(282, 224)
(282, 225)
(282, 228)
(282, 230)
(282, 235)
(282, 239)
(282, 240)
(282, 242)
(282, 243)
(282, 244)
(282, 246)
(282, 248)
(282, 249)
(282, 253)
(282, 254)
(282, 255)
(282, 256)
(282, 259)
(282, 262)
(282, 266)
(282, 267)
(282, 268)
(282, 269)
(282, 270)
(282, 271)
(282, 279)
(287, 1)
(287, 15)
(287, 37)
(287, 39)
(287, 51)
(287, 90)
(287, 104)
(287, 128)
(287, 182)
(287, 192)
(287, 199)
(287, 224)
(287, 253)
(287, 266)
(287, 267)
(287, 282)
(288, 257)
(289, 4)
(289, 28)
(289, 71)
(289, 82)
(289, 104)
(289, 136)
(289, 175)
(289, 192)
(289, 240)
(289, 257)
(289, 282)
(290, 37)
(290, 104)
(290, 282)
(292, 25)
(292, 28)
(292, 71)
(292, 90)
(292, 104)
(292, 240)
(292, 282)
(294, 4)
(294, 60)
(294, 69)
(294, 94)
(294, 151)
(294, 179)
(294, 190)
(294, 191)
(294, 192)
(294, 236)
(294, 257)
(295, 124)
(295, 267)
(295, 282)
(297, 1)
(297, 46)
(297, 104)
(297, 126)
(297, 240)
(297, 282)
(298, 192)
(299, 1)
(299, 4)
(299, 8)
(299, 15)
(299, 17)
(299, 18)
(299, 19)
(299, 22)
(299, 27)
(299, 28)
(299, 30)
(299, 32)
(299, 37)
(299, 39)
(299, 45)
(299, 49)
(299, 51)
(299, 53)
(299, 55)
(299, 63)
(299, 66)
(299, 67)
(299, 71)
(299, 80)
(299, 82)
(299, 85)
(299, 87)
(299, 88)
(299, 90)
(299, 93)
(299, 96)
(299, 103)
(299, 104)
(299, 110)
(299, 111)
(299, 114)
(299, 115)
(299, 126)
(299, 128)
(299, 133)
(299, 134)
(299, 136)
(299, 139)
(299, 148)
(299, 152)
(299, 156)
(299, 158)
(299, 162)
(299, 165)
(299, 172)
(299, 173)
(299, 175)
(299, 176)
(299, 177)
(299, 182)
(299, 184)
(299, 188)
(299, 191)
(299, 192)
(299, 194)
(299, 195)
(299, 199)
(299, 203)
(299, 204)
(299, 208)
(299, 218)
(299, 221)
(299, 224)
(299, 228)
(299, 230)
(299, 240)
(299, 242)
(299, 244)
(299, 248)
(299, 249)
(299, 253)
(299, 254)
(299, 255)
(299, 256)
(299, 259)
(299, 266)
(299, 267)
(299, 268)
(299, 269)
(299, 270)
(299, 282)
(299, 287)
(299, 290)
(299, 297)
(300, 4)
(300, 18)
(300, 25)
(300, 28)
(300, 36)
(300, 46)
(300, 50)
(300, 51)
(300, 68)
(300, 74)
(300, 82)
(300, 97)
(300, 103)
(300, 117)
(300, 126)
(300, 129)
(300, 144)
(300, 169)
(300, 173)
(300, 177)
(300, 182)
(300, 184)
(300, 190)
(300, 199)
(300, 214)
(300, 224)
(300, 240)
(300, 248)
(300, 257)
(300, 267)
(300, 282)
(301, 257)
(302, 71)
(302, 104)
(302, 182)
(302, 240)
(302, 282)
(302, 299)
(303, 28)
(303, 104)
(303, 282)
(306, 104)
(306, 257)
(306, 282)
(307, 104)
(307, 282)
(308, 1)
(308, 37)
(308, 39)
(308, 71)
(308, 80)
(308, 90)
(308, 104)
(308, 128)
(308, 182)
(308, 184)
(308, 192)
(308, 208)
(308, 218)
(308, 224)
(308, 282)
(310, 1)
(310, 4)
(310, 18)
(310, 28)
(310, 37)
(310, 39)
(310, 51)
(310, 71)
(310, 104)
(310, 182)
(310, 184)
(310, 192)
(310, 224)
(310, 230)
(310, 253)
(310, 266)
(310, 267)
(310, 282)
(310, 299)
(311, 104)
(311, 257)
(312, 19)
(312, 257)
(313, 4)
(313, 60)
(313, 94)
(313, 104)
(313, 118)
(313, 136)
(313, 179)
(313, 192)
(313, 236)
(313, 244)
(313, 266)
(313, 282)
(314, 4)
(314, 36)
(314, 82)
(314, 104)
(314, 192)
(314, 238)
(314, 257)
(314, 282)
(315, 1)
(315, 4)
(315, 15)
(315, 22)
(315, 28)
(315, 37)
(315, 39)
(315, 46)
(315, 51)
(315, 71)
(315, 85)
(315, 90)
(315, 93)
(315, 104)
(315, 111)
(315, 126)
(315, 134)
(315, 136)
(315, 152)
(315, 156)
(315, 162)
(315, 165)
(315, 172)
(315, 182)
(315, 184)
(315, 192)
(315, 194)
(315, 199)
(315, 208)
(315, 218)
(315, 224)
(315, 230)
(315, 240)
(315, 244)
(315, 253)
(315, 266)
(315, 267)
(315, 268)
(315, 282)
(315, 299)
(316, 60)
(316, 69)
(316, 82)
(316, 151)
(316, 190)
(316, 236)
(316, 257)
(316, 294)
(317, 192)
(318, 104)
(319, 4)
(319, 15)
(319, 25)
(319, 28)
(319, 33)
(319, 60)
(319, 61)
(319, 67)
(319, 71)
(319, 77)
(319, 85)
(319, 92)
(319, 97)
(319, 102)
(319, 104)
(319, 107)
(319, 110)
(319, 118)
(319, 129)
(319, 136)
(319, 155)
(319, 156)
(319, 158)
(319, 161)
(319, 165)
(319, 170)
(319, 175)
(319, 176)
(319, 191)
(319, 192)
(319, 203)
(319, 204)
(319, 230)
(319, 236)
(319, 238)
(319, 240)
(319, 244)
(319, 249)
(319, 253)
(319, 267)
(319, 274)
(319, 282)
(319, 292)
(319, 299)
(319, 315)
(320, 39)
(320, 80)
(320, 90)
(320, 104)
(320, 128)
(320, 282)
(320, 287)
(320, 299)
(320, 308)
(321, 4)
(321, 10)
(321, 15)
(321, 17)
(321, 18)
(321, 25)
(321, 28)
(321, 30)
(321, 36)
(321, 46)
(321, 50)
(321, 51)
(321, 52)
(321, 57)
(321, 60)
(321, 64)
(321, 66)
(321, 67)
(321, 68)
(321, 69)
(321, 71)
(321, 74)
(321, 76)
(321, 82)
(321, 85)
(321, 89)
(321, 92)
(321, 95)
(321, 96)
(321, 97)
(321, 101)
(321, 103)
(321, 107)
(321, 108)
(321, 109)
(321, 110)
(321, 117)
(321, 118)
(321, 119)
(321, 124)
(321, 126)
(321, 127)
(321, 129)
(321, 130)
(321, 132)
(321, 134)
(321, 136)
(321, 137)
(321, 144)
(321, 150)
(321, 151)
(321, 168)
(321, 169)
(321, 170)
(321, 171)
(321, 173)
(321, 175)
(321, 177)
(321, 178)
(321, 179)
(321, 182)
(321, 184)
(321, 189)
(321, 190)
(321, 192)
(321, 197)
(321, 199)
(321, 200)
(321, 205)
(321, 210)
(321, 211)
(321, 214)
(321, 219)
(321, 224)
(321, 229)
(321, 233)
(321, 235)
(321, 236)
(321, 238)
(321, 239)
(321, 240)
(321, 248)
(321, 249)
(321, 250)
(321, 253)
(321, 255)
(321, 257)
(321, 261)
(321, 266)
(321, 267)
(321, 271)
(321, 278)
(321, 279)
(321, 282)
(321, 289)
(321, 294)
(321, 295)
(321, 300)
(321, 301)
(321, 304)
(321, 306)
(321, 311)
(321, 313)
(321, 314)
(321, 316)
(321, 317)
(321, 319)
(322, 4)
(322, 18)
(322, 25)
(322, 36)
(322, 51)
(322, 82)
(322, 104)
(322, 129)
(322, 144)
(322, 162)
(322, 169)
(322, 192)
(322, 224)
(322, 240)
(322, 257)
(322, 282)
(322, 300)
(322, 321)
(323, 257)
(324, 104)
(324, 282)
(325, 36)
(325, 257)
(325, 321)
(326, 15)
(326, 92)
(326, 192)
(326, 244)
(326, 319)
(327, 71)
(327, 104)
(327, 282)
(329, 60)
(329, 104)
(329, 192)
(329, 236)
(329, 257)
(329, 313)
(329, 319)
(331, 4)
(331, 37)
(331, 39)
(331, 51)
(331, 82)
(331, 104)
(331, 126)
(331, 182)
(331, 184)
(331, 199)
(331, 224)
(331, 240)
(331, 257)
(331, 282)
(331, 299)
(331, 300)
(331, 321)
(331, 322)
(332, 257)
(332, 294)
(332, 321)
(335, 8)
(335, 10)
(335, 19)
(335, 22)
(335, 66)
(335, 90)
(335, 104)
(335, 118)
(335, 169)
(335, 175)
(335, 178)
(335, 182)
(335, 194)
(335, 222)
(335, 230)
(335, 244)
(335, 267)
(335, 282)
(336, 1)
(336, 4)
(336, 8)
(336, 10)
(336, 15)
(336, 17)
(336, 18)
(336, 22)
(336, 27)
(336, 28)
(336, 32)
(336, 37)
(336, 39)
(336, 42)
(336, 51)
(336, 55)
(336, 66)
(336, 67)
(336, 71)
(336, 80)
(336, 85)
(336, 87)
(336, 88)
(336, 90)
(336, 93)
(336, 96)
(336, 104)
(336, 110)
(336, 111)
(336, 114)
(336, 126)
(336, 129)
(336, 133)
(336, 134)
(336, 136)
(336, 137)
(336, 141)
(336, 148)
(336, 152)
(336, 156)
(336, 158)
(336, 162)
(336, 165)
(336, 172)
(336, 173)
(336, 175)
(336, 176)
(336, 182)
(336, 184)
(336, 190)
(336, 191)
(336, 192)
(336, 194)
(336, 195)
(336, 199)
(336, 203)
(336, 205)
(336, 208)
(336, 218)
(336, 221)
(336, 224)
(336, 228)
(336, 230)
(336, 240)
(336, 242)
(336, 244)
(336, 248)
(336, 249)
(336, 253)
(336, 254)
(336, 256)
(336, 259)
(336, 266)
(336, 267)
(336, 268)
(336, 270)
(336, 282)
(336, 287)
(336, 289)
(336, 292)
(336, 299)
(336, 303)
(336, 308)
(336, 310)
(336, 315)
(336, 319)
(336, 327)
(336, 331)
(337, 4)
(337, 60)
(337, 192)
(337, 236)
(337, 257)
(337, 282)
(337, 321)
(338, 257)
(338, 321)
(339, 4)
(339, 15)
(339, 28)
(339, 36)
(339, 50)
(339, 51)
(339, 60)
(339, 67)
(339, 71)
(339, 85)
(339, 104)
(339, 107)
(339, 110)
(339, 118)
(339, 129)
(339, 136)
(339, 156)
(339, 169)
(339, 182)
(339, 184)
(339, 192)
(339, 199)
(339, 205)
(339, 224)
(339, 236)
(339, 238)
(339, 239)
(339, 240)
(339, 244)
(339, 253)
(339, 257)
(339, 266)
(339, 267)
(339, 282)
(339, 300)
(339, 313)
(339, 321)
(339, 329)
(339, 336)
(339, 337)
(340, 1)
(340, 28)
(340, 37)
(340, 46)
(340, 51)
(340, 66)
(340, 71)
(340, 90)
(340, 104)
(340, 126)
(340, 136)
(340, 182)
(340, 224)
(340, 230)
(340, 240)
(340, 259)
(340, 282)
(340, 299)
(340, 315)
(340, 336)
(341, 8)
(341, 10)
(341, 18)
(341, 25)
(341, 71)
(341, 104)
(341, 108)
(341, 124)
(341, 129)
(341, 136)
(341, 169)
(341, 175)
(341, 178)
(341, 182)
(341, 192)
(341, 222)
(341, 228)
(341, 230)
(341, 240)
(341, 248)
(341, 321)
(341, 335)
(342, 326)
(343, 257)
(343, 321)
(344, 1)
(344, 4)
(344, 27)
(344, 28)
(344, 37)
(344, 39)
(344, 51)
(344, 71)
(344, 90)
(344, 104)
(344, 134)
(344, 136)
(344, 156)
(344, 165)
(344, 182)
(344, 184)
(344, 192)
(344, 204)
(344, 218)
(344, 224)
(344, 230)
(344, 240)
(344, 253)
(344, 266)
(344, 282)
(344, 299)
(344, 315)
(344, 319)
(344, 336)
(346, 257)
(346, 321)
(347, 104)
(347, 192)
(348, 1)
(348, 4)
(348, 15)
(348, 25)
(348, 28)
(348, 46)
(348, 51)
(348, 66)
(348, 71)
(348, 104)
(348, 129)
(348, 175)
(348, 182)
(348, 192)
(348, 194)
(348, 240)
(348, 244)
(348, 248)
(348, 253)
(348, 267)
(348, 282)
(348, 299)
(348, 300)
(348, 315)
(348, 321)
(348, 336)
(348, 341)
(349, 339)
(352, 82)
(352, 257)
(352, 321)
(353, 25)
(353, 300)
(354, 257)
(355, 104)
(355, 267)
(355, 282)
(356, 104)
(357, 104)
(358, 104)
(359, 104)
(359, 124)
(359, 282)
(359, 321)
(359, 341)
(360, 1)
(360, 37)
(360, 71)
(360, 104)
(360, 182)
(360, 282)
(360, 299)
(360, 336)
(361, 4)
(361, 25)
(361, 82)
(361, 129)
(361, 136)
(361, 190)
(361, 192)
(361, 236)
(361, 239)
(361, 240)
(361, 257)
(361, 282)
(361, 321)
(362, 82)
(362, 104)
(362, 190)
(362, 257)
(362, 282)
(362, 321)
(363, 1)
(363, 37)
(363, 51)
(363, 71)
(363, 90)
(363, 104)
(363, 182)
(363, 184)
(363, 192)
(363, 199)
(363, 240)
(363, 248)
(363, 267)
(363, 282)
(363, 299)
(363, 300)
(363, 321)
(363, 336)
(363, 348)
(364, 124)
(365, 257)
(365, 321)
(366, 15)
(366, 20)
(366, 28)
(366, 66)
(366, 71)
(366, 90)
(366, 192)
(366, 207)
(366, 208)
(366, 240)
(366, 267)
(366, 282)
(366, 290)
(366, 308)
(366, 336)
(366, 353)
(369, 4)
(369, 28)
(369, 71)
(369, 104)
(369, 192)
(369, 230)
(369, 266)
(369, 282)
(369, 299)
(369, 321)
(370, 104)
(370, 267)
(370, 282)
(370, 299)
(372, 104)
(373, 82)
(373, 144)
(373, 190)
(373, 257)
(373, 300)
(373, 321)
(374, 4)
(374, 18)
(374, 25)
(374, 36)
(374, 51)
(374, 82)
(374, 127)
(374, 129)
(374, 144)
(374, 169)
(374, 173)
(374, 190)
(374, 192)
(374, 257)
(374, 267)
(374, 282)
(374, 299)
(374, 300)
(374, 321)
(374, 322)
(374, 373)
(376, 25)
(376, 46)
(376, 51)
(376, 129)
(376, 240)
(376, 267)
(376, 282)
(376, 300)
(376, 321)
(377, 4)
(377, 36)
(377, 82)
(377, 144)
(377, 169)
(377, 192)
(377, 224)
(377, 238)
(377, 240)
(377, 257)
(377, 267)
(377, 282)
(377, 300)
(377, 321)
(377, 322)
(377, 374)
(379, 15)
(379, 28)
(379, 51)
(379, 90)
(379, 104)
(379, 253)
(379, 267)
(379, 282)
(379, 299)
(379, 315)
(379, 336)
(380, 28)
(380, 51)
(380, 71)
(380, 90)
(380, 104)
(380, 182)
(380, 192)
(380, 224)
(380, 253)
(380, 267)
(380, 282)
(380, 321)
(380, 336)
(381, 25)
(381, 129)
(381, 321)
(382, 25)
(382, 28)
(382, 71)
(382, 104)
(382, 170)
(382, 182)
(382, 282)
(382, 292)
(382, 315)
(382, 319)
(382, 336)
(383, 18)
(383, 124)
(383, 202)
(383, 257)
(384, 28)
(384, 71)
(384, 90)
(384, 104)
(384, 124)
(384, 182)
(384, 192)
(384, 282)
(384, 319)
(384, 336)
(384, 341)
(385, 25)
(385, 129)
(385, 175)
(385, 257)
(385, 321)
(385, 341)
(387, 4)
(387, 15)
(387, 18)
(387, 25)
(387, 46)
(387, 51)
(387, 71)
(387, 82)
(387, 96)
(387, 110)
(387, 126)
(387, 127)
(387, 129)
(387, 144)
(387, 175)
(387, 182)
(387, 192)
(387, 224)
(387, 240)
(387, 257)
(387, 267)
(387, 282)
(387, 300)
(387, 321)
(387, 322)
(387, 348)
(387, 374)
(388, 104)
(388, 182)
(388, 240)
(388, 282)
(389, 28)
(389, 71)
(389, 104)
(389, 175)
(389, 182)
(389, 282)
(389, 299)
(389, 335)
(390, 1)
(390, 37)
(390, 39)
(390, 51)
(390, 71)
(390, 104)
(390, 182)
(390, 184)
(390, 192)
(390, 199)
(390, 224)
(390, 267)
(390, 282)
(390, 299)
(390, 300)
(390, 308)
(390, 336)
(390, 363)
(392, 104)
(392, 192)
(392, 282)
(394, 104)
(394, 192)
(394, 257)
(394, 282)
(394, 321)
(395, 1)
(395, 18)
(395, 71)
(395, 104)
(395, 124)
(395, 192)
(395, 282)
(395, 299)
(395, 336)
(396, 25)
(397, 341)
(398, 4)
(398, 17)
(398, 18)
(398, 25)
(398, 36)
(398, 51)
(398, 71)
(398, 82)
(398, 85)
(398, 96)
(398, 110)
(398, 129)
(398, 144)
(398, 169)
(398, 175)
(398, 182)
(398, 190)
(398, 192)
(398, 224)
(398, 238)
(398, 240)
(398, 257)
(398, 267)
(398, 282)
(398, 300)
(398, 321)
(398, 322)
(398, 374)
(398, 377)
(398, 387)
(399, 104)
(399, 244)
(399, 282)
(399, 321)
(400, 104)
(400, 136)
(400, 169)
(400, 175)
(400, 192)
(400, 238)
(400, 257)
(400, 282)
(400, 321)
(400, 341)
(401, 1)
(401, 28)
(401, 37)
(401, 46)
(401, 51)
(401, 71)
(401, 90)
(401, 104)
(401, 126)
(401, 152)
(401, 182)
(401, 184)
(401, 192)
(401, 208)
(401, 224)
(401, 240)
(401, 259)
(401, 267)
(401, 282)
(401, 299)
(401, 315)
(401, 336)
(401, 340)
(402, 36)
(402, 238)
(402, 257)
(402, 321)
(404, 51)
(404, 82)
(404, 129)
(404, 144)
(404, 240)
(404, 267)
(404, 282)
(404, 300)
(404, 321)
(404, 387)
(405, 74)
(405, 282)
(406, 4)
(406, 60)
(406, 71)
(406, 104)
(406, 118)
(406, 136)
(406, 192)
(406, 236)
(406, 244)
(406, 282)
(406, 299)
(406, 313)
(406, 319)
(406, 339)
(408, 25)
(408, 210)
(408, 257)
(408, 321)
(409, 104)
(410, 104)
(410, 240)
(410, 282)
(411, 13)
(411, 104)
(411, 113)
(411, 210)
(411, 212)
(412, 104)
(412, 253)
(412, 282)
(412, 299)
(413, 1)
(413, 71)
(413, 104)
(413, 182)
(413, 282)
(413, 299)
(413, 336)
(415, 15)
(415, 51)
(415, 71)
(415, 85)
(415, 90)
(415, 104)
(415, 175)
(415, 182)
(415, 192)
(415, 194)
(415, 253)
(415, 267)
(415, 282)
(415, 308)
(415, 335)
(415, 336)
(415, 341)
(415, 359)
(415, 366)
(416, 104)
(416, 267)
(416, 282)
(416, 299)
(417, 199)
(417, 244)
(417, 321)
(418, 23)
(419, 1)
(419, 4)
(419, 8)
(419, 10)
(419, 15)
(419, 19)
(419, 22)
(419, 27)
(419, 28)
(419, 30)
(419, 32)
(419, 37)
(419, 39)
(419, 51)
(419, 53)
(419, 55)
(419, 66)
(419, 67)
(419, 71)
(419, 85)
(419, 87)
(419, 88)
(419, 90)
(419, 93)
(419, 96)
(419, 104)
(419, 110)
(419, 111)
(419, 114)
(419, 118)
(419, 120)
(419, 123)
(419, 126)
(419, 129)
(419, 134)
(419, 136)
(419, 143)
(419, 148)
(419, 156)
(419, 162)
(419, 165)
(419, 172)
(419, 175)
(419, 182)
(419, 184)
(419, 191)
(419, 192)
(419, 194)
(419, 199)
(419, 203)
(419, 205)
(419, 208)
(419, 218)
(419, 221)
(419, 222)
(419, 224)
(419, 230)
(419, 240)
(419, 242)
(419, 243)
(419, 244)
(419, 248)
(419, 249)
(419, 253)
(419, 256)
(419, 259)
(419, 266)
(419, 267)
(419, 268)
(419, 269)
(419, 282)
(419, 287)
(419, 299)
(419, 302)
(419, 310)
(419, 315)
(419, 319)
(419, 327)
(419, 335)
(419, 336)
(419, 340)
(419, 344)
(419, 348)
(419, 360)
(419, 363)
(419, 379)
(419, 382)
(419, 389)
(419, 398)
(419, 401)
(419, 413)
(419, 415)
(420, 4)
(420, 25)
(420, 36)
(420, 68)
(420, 69)
(420, 82)
(420, 103)
(420, 107)
(420, 110)
(420, 127)
(420, 129)
(420, 144)
(420, 150)
(420, 151)
(420, 169)
(420, 173)
(420, 189)
(420, 190)
(420, 236)
(420, 238)
(420, 239)
(420, 240)
(420, 257)
(420, 271)
(420, 279)
(420, 282)
(420, 294)
(420, 300)
(420, 314)
(420, 316)
(420, 321)
(420, 322)
(420, 361)
(420, 373)
(420, 374)
(420, 377)
(420, 385)
(420, 387)
(420, 398)
(421, 1)
(421, 28)
(421, 37)
(421, 39)
(421, 71)
(421, 90)
(421, 104)
(421, 114)
(421, 182)
(421, 184)
(421, 218)
(421, 224)
(421, 259)
(421, 266)
(421, 282)
(421, 299)
(421, 308)
(421, 336)
(422, 104)
(422, 282)
(423, 104)
(424, 1)
(424, 4)
(424, 15)
(424, 19)
(424, 22)
(424, 28)
(424, 37)
(424, 39)
(424, 51)
(424, 71)
(424, 80)
(424, 85)
(424, 88)
(424, 90)
(424, 104)
(424, 111)
(424, 114)
(424, 124)
(424, 134)
(424, 136)
(424, 156)
(424, 175)
(424, 182)
(424, 184)
(424, 191)
(424, 192)
(424, 194)
(424, 208)
(424, 218)
(424, 230)
(424, 240)
(424, 244)
(424, 253)
(424, 256)
(424, 266)
(424, 267)
(424, 282)
(424, 299)
(424, 315)
(424, 319)
(424, 335)
(424, 336)
(424, 341)
(424, 389)
(424, 419)
(425, 192)
(425, 282)
(426, 321)
(427, 124)
(428, 104)
(429, 4)
(429, 33)
(429, 60)
(429, 192)
(429, 204)
(429, 236)
(429, 238)
(429, 257)
(429, 319)
(429, 321)
(429, 329)
(429, 339)
(430, 124)
(431, 282)
(432, 1)
(432, 4)
(432, 8)
(432, 15)
(432, 18)
(432, 22)
(432, 27)
(432, 28)
(432, 37)
(432, 39)
(432, 51)
(432, 66)
(432, 71)
(432, 85)
(432, 90)
(432, 96)
(432, 104)
(432, 111)
(432, 126)
(432, 175)
(432, 182)
(432, 184)
(432, 192)
(432, 194)
(432, 208)
(432, 218)
(432, 224)
(432, 228)
(432, 230)
(432, 240)
(432, 248)
(432, 253)
(432, 266)
(432, 267)
(432, 282)
(432, 299)
(432, 315)
(432, 336)
(432, 340)
(432, 341)
(432, 348)
(432, 401)
(432, 419)
(432, 421)
(432, 424)
(433, 104)
(433, 192)
(433, 282)
(433, 321)
(434, 22)
(434, 25)
(434, 66)
(434, 90)
(434, 104)
(434, 240)
(434, 292)
(434, 319)
(434, 336)
(434, 366)
(435, 104)
(435, 321)
(436, 104)
(436, 182)
(436, 282)
(439, 1)
(439, 28)
(439, 37)
(439, 71)
(439, 104)
(439, 182)
(439, 192)
(439, 240)
(439, 267)
(439, 282)
(439, 299)
(439, 315)
(439, 336)
(439, 419)
(440, 1)
(440, 71)
(440, 104)
(440, 192)
(440, 224)
(440, 240)
(440, 282)
(440, 299)
(440, 336)
(441, 4)
(441, 18)
(441, 36)
(441, 60)
(441, 82)
(441, 97)
(441, 107)
(441, 110)
(441, 119)
(441, 132)
(441, 136)
(441, 169)
(441, 190)
(441, 192)
(441, 199)
(441, 224)
(441, 236)
(441, 238)
(441, 239)
(441, 257)
(441, 282)
(441, 294)
(441, 300)
(441, 314)
(441, 321)
(441, 322)
(441, 332)
(441, 339)
(441, 374)
(441, 377)
(441, 398)
(441, 420)
(441, 429)
(443, 104)
(444, 59)
(445, 104)
(445, 282)
(446, 4)
(446, 18)
(446, 25)
(446, 28)
(446, 71)
(446, 90)
(446, 104)
(446, 129)
(446, 175)
(446, 182)
(446, 192)
(446, 194)
(446, 230)
(446, 240)
(446, 267)
(446, 282)
(446, 299)
(446, 315)
(446, 319)
(446, 336)
(446, 419)
(446, 424)
(447, 36)
(447, 60)
(447, 82)
(447, 107)
(447, 169)
(447, 192)
(447, 236)
(447, 238)
(447, 257)
(447, 294)
(447, 321)
(447, 329)
(447, 339)
(447, 420)
(447, 429)
(447, 441)
(450, 82)
(450, 144)
(450, 257)
(450, 321)
(450, 374)
(450, 377)
(450, 420)
(451, 59)
(451, 264)
(451, 334)
(451, 444)
(452, 39)
(452, 80)
(452, 90)
(452, 104)
(452, 128)
(452, 282)
(452, 287)
(452, 299)
(452, 308)
(452, 320)
(454, 321)
(455, 104)
(455, 282)
(455, 321)
(456, 170)
(457, 18)
(457, 25)
(457, 82)
(457, 104)
(457, 182)
(457, 184)
(457, 224)
(457, 240)
(457, 257)
(457, 282)
(457, 300)
(457, 321)
(457, 420)
(458, 1)
(458, 4)
(458, 15)
(458, 22)
(458, 27)
(458, 28)
(458, 37)
(458, 39)
(458, 42)
(458, 51)
(458, 66)
(458, 71)
(458, 85)
(458, 87)
(458, 90)
(458, 93)
(458, 104)
(458, 111)
(458, 114)
(458, 123)
(458, 126)
(458, 128)
(458, 134)
(458, 152)
(458, 156)
(458, 162)
(458, 172)
(458, 182)
(458, 184)
(458, 192)
(458, 194)
(458, 199)
(458, 208)
(458, 218)
(458, 221)
(458, 224)
(458, 228)
(458, 230)
(458, 240)
(458, 253)
(458, 254)
(458, 256)
(458, 259)
(458, 266)
(458, 267)
(458, 268)
(458, 282)
(458, 287)
(458, 290)
(458, 298)
(458, 299)
(458, 308)
(458, 315)
(458, 320)
(458, 336)
(458, 340)
(458, 363)
(458, 366)
(458, 379)
(458, 380)
(458, 382)
(458, 389)
(458, 401)
(458, 419)
(458, 421)
(458, 424)
(458, 432)
(458, 434)
(458, 439)
(458, 452)
(459, 104)
(460, 25)
(460, 82)
(460, 129)
(460, 190)
(460, 257)
(460, 282)
(460, 321)
(460, 374)
(460, 398)
(460, 420)
(461, 104)
(461, 257)
(462, 1)
(462, 4)
(462, 28)
(462, 36)
(462, 37)
(462, 71)
(462, 104)
(462, 134)
(462, 136)
(462, 175)
(462, 182)
(462, 191)
(462, 192)
(462, 224)
(462, 230)
(462, 238)
(462, 253)
(462, 257)
(462, 282)
(462, 299)
(462, 321)
(462, 336)
(462, 344)
(462, 419)
(463, 71)
(463, 192)
(463, 244)
(463, 253)
(463, 267)
(463, 282)
(463, 339)
(464, 25)
(464, 82)
(464, 169)
(464, 257)
(464, 282)
(464, 321)
(465, 25)
(465, 104)
(465, 267)
(465, 282)
(465, 299)
(466, 51)
(466, 104)
(466, 182)
(466, 267)
(466, 282)
(467, 1)
(467, 18)
(467, 25)
(467, 46)
(467, 51)
(467, 71)
(467, 82)
(467, 85)
(467, 90)
(467, 96)
(467, 104)
(467, 126)
(467, 129)
(467, 182)
(467, 192)
(467, 194)
(467, 224)
(467, 228)
(467, 240)
(467, 253)
(467, 267)
(467, 282)
(467, 300)
(467, 321)
(467, 336)
(467, 387)
(467, 398)
(467, 419)
(468, 4)
(468, 85)
(468, 104)
(468, 118)
(468, 192)
(468, 236)
(468, 244)
(468, 257)
(468, 282)
(468, 319)
(468, 321)
(468, 336)
(468, 339)
(469, 82)
(469, 190)
(469, 257)
(469, 321)
(469, 361)
(469, 385)
(469, 420)
(470, 82)
(470, 257)
(470, 282)
(470, 299)
(471, 1)
(471, 4)
(471, 15)
(471, 28)
(471, 37)
(471, 39)
(471, 51)
(471, 66)
(471, 71)
(471, 90)
(471, 104)
(471, 136)
(471, 172)
(471, 182)
(471, 184)
(471, 192)
(471, 199)
(471, 208)
(471, 218)
(471, 224)
(471, 230)
(471, 240)
(471, 242)
(471, 253)
(471, 256)
(471, 259)
(471, 266)
(471, 267)
(471, 282)
(471, 287)
(471, 299)
(471, 315)
(471, 336)
(471, 340)
(471, 366)
(471, 419)
(471, 432)
(471, 458)
(472, 104)
(472, 191)
(472, 257)
(472, 282)
(472, 321)
(473, 1)
(473, 51)
(473, 104)
(473, 182)
(473, 240)
(473, 282)
(473, 321)
(474, 321)
(475, 1)
(475, 4)
(475, 15)
(475, 27)
(475, 28)
(475, 37)
(475, 39)
(475, 51)
(475, 66)
(475, 67)
(475, 71)
(475, 80)
(475, 85)
(475, 88)
(475, 90)
(475, 96)
(475, 103)
(475, 104)
(475, 109)
(475, 110)
(475, 111)
(475, 114)
(475, 118)
(475, 126)
(475, 128)
(475, 134)
(475, 136)
(475, 148)
(475, 156)
(475, 158)
(475, 162)
(475, 165)
(475, 172)
(475, 175)
(475, 182)
(475, 184)
(475, 192)
(475, 194)
(475, 199)
(475, 203)
(475, 204)
(475, 205)
(475, 208)
(475, 218)
(475, 224)
(475, 230)
(475, 240)
(475, 242)
(475, 244)
(475, 253)
(475, 255)
(475, 256)
(475, 259)
(475, 266)
(475, 267)
(475, 268)
(475, 282)
(475, 287)
(475, 299)
(475, 310)
(475, 315)
(475, 319)
(475, 320)
(475, 331)
(475, 335)
(475, 336)
(475, 339)
(475, 340)
(475, 344)
(475, 348)
(475, 395)
(475, 401)
(475, 419)
(475, 421)
(475, 424)
(475, 432)
(475, 446)
(475, 452)
(475, 458)
(475, 462)
(475, 471)
(476, 1)
(476, 37)
(476, 39)
(476, 51)
(476, 71)
(476, 90)
(476, 104)
(476, 182)
(476, 184)
(476, 192)
(476, 218)
(476, 224)
(476, 230)
(476, 240)
(476, 266)
(476, 282)
(476, 287)
(476, 299)
(476, 336)
(476, 419)
(476, 458)
(476, 471)
(476, 475)
(477, 104)
(477, 282)
(479, 23)
(479, 290)
(482, 51)
(482, 82)
(482, 104)
(482, 129)
(482, 144)
(482, 173)
(482, 240)
(482, 257)
(482, 282)
(482, 299)
(482, 300)
(482, 321)
(482, 373)
(482, 374)
(482, 398)
(482, 420)
(484, 1)
(484, 4)
(484, 15)
(484, 27)
(484, 28)
(484, 37)
(484, 39)
(484, 50)
(484, 51)
(484, 71)
(484, 90)
(484, 104)
(484, 111)
(484, 114)
(484, 128)
(484, 143)
(484, 162)
(484, 165)
(484, 172)
(484, 182)
(484, 184)
(484, 192)
(484, 194)
(484, 199)
(484, 208)
(484, 218)
(484, 224)
(484, 230)
(484, 242)
(484, 244)
(484, 253)
(484, 256)
(484, 259)
(484, 266)
(484, 267)
(484, 282)
(484, 287)
(484, 299)
(484, 315)
(484, 320)
(484, 336)
(484, 379)
(484, 419)
(484, 421)
(484, 452)
(484, 458)
(484, 471)
(484, 475)
(484, 476)
(485, 4)
(485, 18)
(485, 25)
(485, 36)
(485, 51)
(485, 68)
(485, 69)
(485, 82)
(485, 107)
(485, 110)
(485, 127)
(485, 129)
(485, 144)
(485, 150)
(485, 151)
(485, 169)
(485, 173)
(485, 189)
(485, 190)
(485, 214)
(485, 238)
(485, 240)
(485, 257)
(485, 271)
(485, 279)
(485, 282)
(485, 294)
(485, 300)
(485, 306)
(485, 314)
(485, 316)
(485, 321)
(485, 322)
(485, 325)
(485, 352)
(485, 373)
(485, 374)
(485, 377)
(485, 387)
(485, 398)
(485, 404)
(485, 420)
(485, 441)
(485, 447)
(485, 450)
(485, 460)
(485, 464)
(485, 469)
(485, 472)
(485, 482)
(486, 2)
(487, 104)
(487, 282)
(488, 1)
(488, 4)
(488, 15)
(488, 17)
(488, 25)
(488, 28)
(488, 37)
(488, 46)
(488, 51)
(488, 66)
(488, 71)
(488, 90)
(488, 96)
(488, 104)
(488, 111)
(488, 126)
(488, 129)
(488, 133)
(488, 136)
(488, 152)
(488, 165)
(488, 175)
(488, 182)
(488, 184)
(488, 192)
(488, 194)
(488, 208)
(488, 224)
(488, 230)
(488, 240)
(488, 248)
(488, 253)
(488, 256)
(488, 259)
(488, 266)
(488, 267)
(488, 282)
(488, 292)
(488, 299)
(488, 315)
(488, 321)
(488, 336)
(488, 340)
(488, 348)
(488, 366)
(488, 382)
(488, 401)
(488, 419)
(488, 421)
(488, 424)
(488, 432)
(488, 458)
(488, 467)
(488, 471)
(488, 475)
(489, 1)
(489, 4)
(489, 15)
(489, 22)
(489, 28)
(489, 37)
(489, 39)
(489, 51)
(489, 66)
(489, 71)
(489, 85)
(489, 88)
(489, 90)
(489, 104)
(489, 111)
(489, 126)
(489, 129)
(489, 156)
(489, 182)
(489, 184)
(489, 192)
(489, 199)
(489, 208)
(489, 218)
(489, 224)
(489, 228)
(489, 240)
(489, 253)
(489, 256)
(489, 266)
(489, 267)
(489, 282)
(489, 299)
(489, 310)
(489, 321)
(489, 336)
(489, 363)
(489, 390)
(489, 415)
(489, 419)
(489, 424)
(489, 432)
(489, 458)
(489, 471)
(489, 475)
(489, 488)
(490, 25)
(490, 28)
(490, 46)
(490, 71)
(490, 90)
(490, 126)
(490, 152)
(490, 207)
(490, 240)
(490, 267)
(490, 282)
(490, 292)
(490, 315)
(490, 321)
(490, 353)
(490, 366)
(490, 434)
(490, 458)
(490, 488)
(491, 1)
(491, 4)
(491, 10)
(491, 15)
(491, 25)
(491, 28)
(491, 32)
(491, 36)
(491, 37)
(491, 46)
(491, 50)
(491, 51)
(491, 67)
(491, 71)
(491, 74)
(491, 75)
(491, 82)
(491, 85)
(491, 90)
(491, 96)
(491, 97)
(491, 104)
(491, 110)
(491, 114)
(491, 117)
(491, 124)
(491, 129)
(491, 131)
(491, 133)
(491, 137)
(491, 168)
(491, 170)
(491, 173)
(491, 175)
(491, 177)
(491, 182)
(491, 184)
(491, 187)
(491, 190)
(491, 192)
(491, 194)
(491, 199)
(491, 200)
(491, 205)
(491, 207)
(491, 208)
(491, 210)
(491, 211)
(491, 224)
(491, 238)
(491, 239)
(491, 240)
(491, 244)
(491, 248)
(491, 253)
(491, 257)
(491, 267)
(491, 271)
(491, 282)
(491, 295)
(491, 300)
(491, 302)
(491, 304)
(491, 308)
(491, 315)
(491, 319)
(491, 321)
(491, 336)
(491, 339)
(491, 341)
(491, 348)
(491, 353)
(491, 363)
(491, 366)
(491, 376)
(491, 379)
(491, 380)
(491, 381)
(491, 382)
(491, 384)
(491, 385)
(491, 387)
(491, 390)
(491, 398)
(491, 399)
(491, 405)
(491, 415)
(491, 417)
(491, 419)
(491, 420)
(491, 421)
(491, 424)
(491, 432)
(491, 441)
(491, 454)
(491, 456)
(491, 457)
(491, 458)
(491, 467)
(491, 474)
(491, 484)
(491, 485)
(491, 488)
(491, 489)
(491, 490)
(495, 15)
(495, 29)
(495, 104)
(495, 212)
(495, 227)
(495, 256)
(495, 267)
(495, 282)
(495, 389)
(495, 411)
(495, 419)
(495, 475)
(495, 491)
(496, 4)
(496, 82)
(496, 104)
(496, 118)
(496, 190)
(496, 192)
(496, 236)
(496, 244)
(496, 257)
(496, 282)
(496, 321)
(496, 361)
(496, 485)
(497, 1)
(497, 37)
(497, 39)
(497, 51)
(497, 71)
(497, 90)
(497, 104)
(497, 114)
(497, 182)
(497, 184)
(497, 192)
(497, 199)
(497, 218)
(497, 224)
(497, 253)
(497, 256)
(497, 266)
(497, 267)
(497, 282)
(497, 299)
(497, 336)
(497, 419)
(497, 421)
(497, 458)
(497, 471)
(497, 475)
(497, 484)
(497, 489)
(497, 495)
(498, 4)
(498, 25)
(498, 50)
(498, 267)
(498, 282)
(498, 300)
(498, 321)
(499, 1)
(499, 4)
(499, 17)
(499, 18)
(499, 22)
(499, 27)
(499, 28)
(499, 37)
(499, 39)
(499, 42)
(499, 46)
(499, 51)
(499, 66)
(499, 71)
(499, 85)
(499, 87)
(499, 88)
(499, 90)
(499, 93)
(499, 96)
(499, 104)
(499, 111)
(499, 114)
(499, 126)
(499, 133)
(499, 134)
(499, 152)
(499, 156)
(499, 162)
(499, 172)
(499, 182)
(499, 184)
(499, 192)
(499, 194)
(499, 199)
(499, 208)
(499, 218)
(499, 224)
(499, 228)
(499, 230)
(499, 240)
(499, 248)
(499, 249)
(499, 253)
(499, 259)
(499, 266)
(499, 267)
(499, 282)
(499, 299)
(499, 300)
(499, 315)
(499, 336)
(499, 344)
(499, 390)
(499, 401)
(499, 419)
(499, 421)
(499, 432)
(499, 458)
(499, 471)
(499, 475)
(499, 476)
(499, 484)
(499, 488)
(499, 489)
(499, 491)
(500, 104)
(500, 190)
(500, 192)
(500, 257)
(500, 321)
(501, 1)
(501, 27)
(501, 37)
(501, 51)
(501, 71)
(501, 104)
(501, 182)
(501, 184)
(501, 192)
(501, 199)
(501, 224)
(501, 240)
(501, 253)
(501, 267)
(501, 282)
(501, 299)
(501, 300)
(501, 336)
(501, 390)
(501, 419)
(501, 458)
(501, 475)
(501, 484)
(501, 499)
(503, 4)
(503, 25)
(503, 71)
(503, 104)
(503, 192)
(503, 282)
(503, 299)
(503, 319)
(503, 321)
(504, 104)
(504, 267)
(504, 282)
(504, 321)
(506, 204)
(508, 4)
(508, 25)
(508, 104)
(508, 192)
(508, 224)
(508, 240)
(508, 257)
(508, 282)
(508, 321)
(508, 491)
(509, 1)
(509, 37)
(509, 39)
(509, 71)
(509, 90)
(509, 104)
(509, 182)
(509, 184)
(509, 192)
(509, 218)
(509, 224)
(509, 267)
(509, 282)
(509, 299)
(509, 336)
(509, 475)
(510, 1)
(510, 4)
(510, 27)
(510, 28)
(510, 37)
(510, 39)
(510, 51)
(510, 67)
(510, 71)
(510, 85)
(510, 88)
(510, 90)
(510, 96)
(510, 104)
(510, 111)
(510, 117)
(510, 126)
(510, 134)
(510, 136)
(510, 156)
(510, 165)
(510, 182)
(510, 184)
(510, 192)
(510, 199)
(510, 218)
(510, 224)
(510, 230)
(510, 240)
(510, 242)
(510, 249)
(510, 253)
(510, 259)
(510, 266)
(510, 267)
(510, 282)
(510, 299)
(510, 310)
(510, 315)
(510, 319)
(510, 321)
(510, 331)
(510, 336)
(510, 344)
(510, 401)
(510, 419)
(510, 421)
(510, 424)
(510, 432)
(510, 458)
(510, 462)
(510, 475)
(510, 484)
(510, 488)
(510, 489)
(510, 491)
(510, 499)
(511, 321)
(511, 491)
(512, 25)
(512, 82)
(512, 129)
(512, 257)
(512, 282)
(512, 300)
(512, 321)
(512, 387)
(512, 398)
(512, 420)
(512, 485)
(513, 15)
(513, 51)
(513, 104)
(513, 129)
(513, 182)
(513, 240)
(513, 267)
(513, 282)
(513, 300)
(513, 321)
(513, 491)
(514, 1)
(514, 4)
(514, 7)
(514, 8)
(514, 10)
(514, 15)
(514, 17)
(514, 18)
(514, 22)
(514, 25)
(514, 27)
(514, 28)
(514, 30)
(514, 32)
(514, 37)
(514, 39)
(514, 42)
(514, 46)
(514, 50)
(514, 51)
(514, 53)
(514, 66)
(514, 67)
(514, 71)
(514, 74)
(514, 75)
(514, 82)
(514, 85)
(514, 87)
(514, 88)
(514, 90)
(514, 93)
(514, 96)
(514, 103)
(514, 104)
(514, 110)
(514, 111)
(514, 114)
(514, 115)
(514, 118)
(514, 126)
(514, 129)
(514, 133)
(514, 134)
(514, 136)
(514, 137)
(514, 148)
(514, 152)
(514, 156)
(514, 158)
(514, 160)
(514, 162)
(514, 165)
(514, 172)
(514, 175)
(514, 177)
(514, 182)
(514, 184)
(514, 192)
(514, 194)
(514, 195)
(514, 199)
(514, 203)
(514, 205)
(514, 208)
(514, 218)
(514, 221)
(514, 224)
(514, 228)
(514, 230)
(514, 239)
(514, 240)
(514, 243)
(514, 244)
(514, 246)
(514, 248)
(514, 249)
(514, 253)
(514, 254)
(514, 256)
(514, 259)
(514, 266)
(514, 267)
(514, 268)
(514, 282)
(514, 287)
(514, 289)
(514, 299)
(514, 300)
(514, 302)
(514, 308)
(514, 310)
(514, 315)
(514, 319)
(514, 321)
(514, 322)
(514, 327)
(514, 335)
(514, 336)
(514, 339)
(514, 340)
(514, 341)
(514, 344)
(514, 348)
(514, 359)
(514, 360)
(514, 361)
(514, 363)
(514, 366)
(514, 369)
(514, 376)
(514, 379)
(514, 380)
(514, 382)
(514, 384)
(514, 387)
(514, 389)
(514, 390)
(514, 395)
(514, 398)
(514, 401)
(514, 404)
(514, 413)
(514, 415)
(514, 419)
(514, 421)
(514, 422)
(514, 424)
(514, 432)
(514, 436)
(514, 446)
(514, 457)
(514, 458)
(514, 462)
(514, 463)
(514, 465)
(514, 466)
(514, 467)
(514, 468)
(514, 471)
(514, 473)
(514, 475)
(514, 476)
(514, 477)
(514, 484)
(514, 488)
(514, 489)
(514, 490)
(514, 491)
(514, 496)
(514, 497)
(514, 498)
(514, 499)
(514, 501)
(514, 503)
(514, 504)
(514, 509)
(514, 510)
(514, 513)
(515, 1)
(515, 22)
(515, 28)
(515, 37)
(515, 39)
(515, 51)
(515, 71)
(515, 90)
(515, 104)
(515, 134)
(515, 182)
(515, 184)
(515, 192)
(515, 218)
(515, 224)
(515, 240)
(515, 253)
(515, 267)
(515, 282)
(515, 299)
(515, 315)
(515, 336)
(515, 419)
(515, 458)
(515, 475)
(515, 489)
(515, 499)
(515, 510)
(515, 514)
(516, 25)
(516, 36)
(516, 49)
(516, 52)
(516, 64)
(516, 68)
(516, 69)
(516, 82)
(516, 89)
(516, 94)
(516, 97)
(516, 101)
(516, 107)
(516, 117)
(516, 119)
(516, 127)
(516, 132)
(516, 144)
(516, 146)
(516, 151)
(516, 154)
(516, 169)
(516, 173)
(516, 184)
(516, 185)
(516, 189)
(516, 190)
(516, 197)
(516, 210)
(516, 214)
(516, 216)
(516, 219)
(516, 224)
(516, 233)
(516, 236)
(516, 238)
(516, 239)
(516, 257)
(516, 271)
(516, 281)
(516, 289)
(516, 294)
(516, 300)
(516, 301)
(516, 304)
(516, 306)
(516, 308)
(516, 314)
(516, 316)
(516, 321)
(516, 322)
(516, 331)
(516, 332)
(516, 339)
(516, 352)
(516, 361)
(516, 373)
(516, 374)
(516, 377)
(516, 390)
(516, 398)
(516, 400)
(516, 402)
(516, 408)
(516, 420)
(516, 429)
(516, 441)
(516, 447)
(516, 450)
(516, 457)
(516, 464)
(516, 469)
(516, 472)
(516, 482)
(516, 485)
(516, 491)
(516, 508)
(516, 510)
(516, 511)
(517, 321)
(519, 104)
(520, 257)
(520, 300)
(520, 321)
(520, 420)
(520, 485)
(520, 491)
(520, 516)
(521, 113)
(522, 257)
(522, 321)
(522, 516)
(523, 25)
(523, 82)
(523, 110)
(523, 129)
(523, 144)
(523, 173)
(523, 190)
(523, 240)
(523, 257)
(523, 267)
(523, 282)
(523, 300)
(523, 321)
(523, 420)
(523, 485)
(523, 491)
(523, 516)
(523, 520)
(524, 4)
(524, 17)
(524, 18)
(524, 25)
(524, 46)
(524, 82)
(524, 126)
(524, 129)
(524, 192)
(524, 224)
(524, 240)
(524, 257)
(524, 267)
(524, 282)
(524, 300)
(524, 321)
(524, 361)
(524, 374)
(524, 387)
(524, 420)
(524, 485)
(524, 491)
(524, 498)
(524, 514)
(525, 104)
(526, 104)
(526, 257)
(526, 282)
(526, 321)
(527, 1)
(527, 4)
(527, 8)
(527, 10)
(527, 15)
(527, 18)
(527, 25)
(527, 28)
(527, 30)
(527, 36)
(527, 37)
(527, 39)
(527, 50)
(527, 51)
(527, 66)
(527, 67)
(527, 71)
(527, 80)
(527, 82)
(527, 85)
(527, 88)
(527, 90)
(527, 96)
(527, 103)
(527, 104)
(527, 107)
(527, 110)
(527, 111)
(527, 114)
(527, 117)
(527, 124)
(527, 126)
(527, 129)
(527, 134)
(527, 136)
(527, 169)
(527, 172)
(527, 173)
(527, 175)
(527, 177)
(527, 178)
(527, 182)
(527, 184)
(527, 190)
(527, 191)
(527, 192)
(527, 194)
(527, 199)
(527, 205)
(527, 218)
(527, 224)
(527, 228)
(527, 230)
(527, 240)
(527, 244)
(527, 248)
(527, 249)
(527, 253)
(527, 255)
(527, 256)
(527, 257)
(527, 259)
(527, 266)
(527, 267)
(527, 271)
(527, 282)
(527, 289)
(527, 295)
(527, 299)
(527, 300)
(527, 307)
(527, 321)
(527, 335)
(527, 336)
(527, 339)
(527, 340)
(527, 341)
(527, 348)
(527, 362)
(527, 363)
(527, 380)
(527, 395)
(527, 398)
(527, 400)
(527, 405)
(527, 419)
(527, 420)
(527, 421)
(527, 424)
(527, 432)
(527, 441)
(527, 457)
(527, 458)
(527, 471)
(527, 475)
(527, 476)
(527, 485)
(527, 488)
(527, 489)
(527, 491)
(527, 495)
(527, 497)
(527, 499)
(527, 508)
(527, 510)
(527, 511)
(527, 513)
(527, 514)
(527, 516)
(527, 523)
(527, 524)
(528, 18)
(528, 36)
(528, 68)
(528, 69)
(528, 82)
(528, 127)
(528, 129)
(528, 144)
(528, 150)
(528, 151)
(528, 169)
(528, 173)
(528, 190)
(528, 214)
(528, 240)
(528, 257)
(528, 279)
(528, 282)
(528, 300)
(528, 316)
(528, 321)
(528, 322)
(528, 361)
(528, 373)
(528, 374)
(528, 377)
(528, 387)
(528, 398)
(528, 404)
(528, 420)
(528, 441)
(528, 450)
(528, 460)
(528, 469)
(528, 472)
(528, 482)
(528, 485)
(528, 496)
(528, 500)
(528, 512)
(528, 516)
(528, 523)
(528, 524)
(529, 236)
(529, 257)
(529, 321)
(529, 516)
(532, 104)
(532, 282)
(533, 18)
(533, 25)
(533, 82)
(533, 129)
(533, 257)
(533, 300)
(533, 321)
(533, 374)
(533, 420)
(533, 485)
(533, 516)
(533, 528)
(534, 1)
(534, 51)
(534, 71)
(534, 182)
(534, 192)
(534, 228)
(534, 253)
(534, 267)
(534, 282)
(534, 321)
(534, 491)
(534, 514)
(535, 1)
(535, 37)
(535, 51)
(535, 71)
(535, 104)
(535, 182)
(535, 192)
(535, 208)
(535, 224)
(535, 240)
(535, 253)
(535, 267)
(535, 282)
(535, 299)
(535, 336)
(535, 419)
(535, 458)
(535, 475)
(535, 499)
(535, 514)
(536, 282)
(537, 92)
(537, 104)
(537, 136)
(537, 156)
(537, 175)
(537, 192)
(537, 230)
(537, 267)
(537, 282)
(537, 319)
(538, 4)
(538, 15)
(538, 25)
(538, 28)
(538, 51)
(538, 71)
(538, 90)
(538, 104)
(538, 165)
(538, 192)
(538, 240)
(538, 244)
(538, 253)
(538, 267)
(538, 282)
(538, 292)
(538, 299)
(538, 315)
(538, 319)
(538, 336)
(538, 348)
(538, 419)
(538, 434)
(538, 458)
(538, 475)
(538, 484)
(538, 488)
(538, 491)
(538, 514)
(539, 82)
(539, 124)
(539, 257)
(539, 321)
(539, 430)
(539, 485)
(539, 516)
(539, 528)
(540, 104)
(540, 257)
(540, 282)
(540, 321)
(541, 36)
(541, 257)
(541, 294)
(541, 321)
(541, 441)
(541, 447)
(541, 485)
(541, 516)
(542, 104)
(542, 192)
(543, 257)
(543, 282)
(543, 321)
(543, 516)
(545, 1)
(545, 4)
(545, 12)
(545, 18)
(545, 28)
(545, 33)
(545, 36)
(545, 37)
(545, 49)
(545, 51)
(545, 67)
(545, 71)
(545, 82)
(545, 85)
(545, 97)
(545, 104)
(545, 107)
(545, 110)
(545, 118)
(545, 134)
(545, 136)
(545, 156)
(545, 158)
(545, 169)
(545, 182)
(545, 184)
(545, 192)
(545, 199)
(545, 204)
(545, 218)
(545, 224)
(545, 230)
(545, 236)
(545, 238)
(545, 239)
(545, 240)
(545, 253)
(545, 255)
(545, 257)
(545, 266)
(545, 267)
(545, 279)
(545, 282)
(545, 299)
(545, 314)
(545, 319)
(545, 321)
(545, 322)
(545, 331)
(545, 336)
(545, 339)
(545, 344)
(545, 374)
(545, 377)
(545, 398)
(545, 406)
(545, 420)
(545, 429)
(545, 441)
(545, 447)
(545, 462)
(545, 468)
(545, 475)
(545, 485)
(545, 499)
(545, 510)
(545, 514)
(545, 516)
(545, 527)
(545, 541)
(546, 4)
(546, 8)
(546, 10)
(546, 11)
(546, 18)
(546, 25)
(546, 28)
(546, 40)
(546, 53)
(546, 60)
(546, 66)
(546, 71)
(546, 77)
(546, 85)
(546, 90)
(546, 92)
(546, 96)
(546, 104)
(546, 108)
(546, 110)
(546, 111)
(546, 120)
(546, 124)
(546, 129)
(546, 136)
(546, 156)
(546, 170)
(546, 173)
(546, 175)
(546, 182)
(546, 190)
(546, 191)
(546, 192)
(546, 194)
(546, 200)
(546, 203)
(546, 205)
(546, 230)
(546, 238)
(546, 239)
(546, 240)
(546, 244)
(546, 248)
(546, 253)
(546, 267)
(546, 282)
(546, 289)
(546, 292)
(546, 317)
(546, 319)
(546, 321)
(546, 335)
(546, 336)
(546, 340)
(546, 341)
(546, 348)
(546, 353)
(546, 361)
(546, 381)
(546, 382)
(546, 384)
(546, 385)
(546, 387)
(546, 389)
(546, 398)
(546, 400)
(546, 413)
(546, 414)
(546, 415)
(546, 419)
(546, 420)
(546, 424)
(546, 427)
(546, 432)
(546, 434)
(546, 446)
(546, 457)
(546, 468)
(546, 469)
(546, 488)
(546, 489)
(546, 490)
(546, 491)
(546, 510)
(546, 514)
(546, 523)
(546, 527)
(546, 537)
(546, 538)
(547, 1)
(547, 19)
(547, 37)
(547, 39)
(547, 51)
(547, 66)
(547, 71)
(547, 90)
(547, 104)
(547, 126)
(547, 182)
(547, 184)
(547, 192)
(547, 199)
(547, 224)
(547, 230)
(547, 240)
(547, 267)
(547, 282)
(547, 299)
(547, 335)
(547, 336)
(547, 419)
(547, 432)
(547, 458)
(547, 471)
(547, 475)
(547, 497)
(547, 499)
(547, 514)
(548, 257)
(548, 321)
(548, 516)
(549, 1)
(549, 42)
(549, 141)
(549, 160)
(549, 169)
(549, 182)
(549, 184)
(549, 192)
(549, 199)
(549, 224)
(549, 228)
(549, 257)
(549, 267)
(549, 282)
(549, 298)
(549, 300)
(549, 308)
(549, 321)
(549, 377)
(549, 390)
(549, 466)
(549, 491)
(549, 501)
(549, 515)
(549, 516)
(550, 1)
(550, 4)
(550, 15)
(550, 27)
(550, 28)
(550, 37)
(550, 39)
(550, 46)
(550, 51)
(550, 71)
(550, 88)
(550, 90)
(550, 104)
(550, 111)
(550, 114)
(550, 126)
(550, 165)
(550, 172)
(550, 182)
(550, 184)
(550, 192)
(550, 194)
(550, 199)
(550, 208)
(550, 224)
(550, 230)
(550, 240)
(550, 244)
(550, 248)
(550, 253)
(550, 256)
(550, 259)
(550, 266)
(550, 267)
(550, 282)
(550, 299)
(550, 315)
(550, 336)
(550, 340)
(550, 348)
(550, 389)
(550, 401)
(550, 419)
(550, 421)
(550, 424)
(550, 432)
(550, 458)
(550, 471)
(550, 475)
(550, 484)
(550, 488)
(550, 489)
(550, 491)
(550, 499)
(550, 510)
(550, 514)
(550, 527)
(550, 535)
(551, 90)
(551, 104)
(551, 282)
(551, 336)
(551, 366)
(551, 419)
(551, 458)
(551, 514)
(552, 104)
(552, 282)
(553, 1)
(553, 51)
(553, 71)
(553, 104)
(553, 182)
(553, 184)
(553, 192)
(553, 224)
(553, 240)
(553, 253)
(553, 267)
(553, 282)
(553, 299)
(553, 336)
(553, 419)
(553, 475)
(553, 514)
(554, 4)
(554, 36)
(554, 51)
(554, 71)
(554, 82)
(554, 104)
(554, 129)
(554, 182)
(554, 192)
(554, 199)
(554, 224)
(554, 240)
(554, 253)
(554, 257)
(554, 267)
(554, 282)
(554, 299)
(554, 300)
(554, 321)
(554, 336)
(554, 398)
(554, 482)
(554, 485)
(554, 514)
(555, 4)
(555, 12)
(555, 33)
(555, 36)
(555, 50)
(555, 60)
(555, 104)
(555, 107)
(555, 118)
(555, 136)
(555, 153)
(555, 179)
(555, 191)
(555, 192)
(555, 204)
(555, 230)
(555, 236)
(555, 257)
(555, 266)
(555, 282)
(555, 294)
(555, 299)
(555, 313)
(555, 316)
(555, 319)
(555, 321)
(555, 336)
(555, 406)
(555, 429)
(555, 475)
(555, 514)
(555, 545)
(555, 554)
(556, 4)
(556, 17)
(556, 18)
(556, 25)
(556, 51)
(556, 71)
(556, 82)
(556, 103)
(556, 110)
(556, 124)
(556, 129)
(556, 134)
(556, 175)
(556, 190)
(556, 192)
(556, 240)
(556, 267)
(556, 282)
(556, 299)
(556, 319)
(556, 321)
(556, 387)
(556, 398)
(556, 419)
(556, 420)
(556, 446)
(556, 460)
(556, 485)
(556, 512)
(556, 514)
(556, 523)
(556, 527)
(556, 528)
(556, 546)
(557, 25)
(557, 36)
(557, 82)
(557, 129)
(557, 169)
(557, 190)
(557, 238)
(557, 257)
(557, 282)
(557, 300)
(557, 321)
(557, 398)
(557, 420)
(557, 485)
(557, 516)
(557, 527)
(557, 528)
(557, 546)
(558, 257)
(558, 321)
(558, 516)
(561, 1)
(561, 28)
(561, 37)
(561, 42)
(561, 51)
(561, 71)
(561, 90)
(561, 104)
(561, 182)
(561, 192)
(561, 208)
(561, 224)
(561, 240)
(561, 253)
(561, 282)
(561, 299)
(561, 315)
(561, 336)
(561, 366)
(561, 419)
(561, 458)
(561, 475)
(561, 488)
(561, 499)
(561, 514)
(563, 4)
(563, 51)
(563, 71)
(563, 104)
(563, 129)
(563, 182)
(563, 192)
(563, 240)
(563, 253)
(563, 267)
(563, 282)
(563, 299)
(563, 319)
(563, 321)
(563, 336)
(563, 419)
(563, 514)
(563, 527)
(563, 546)
(565, 104)
(566, 36)
(566, 82)
(566, 107)
(566, 119)
(566, 169)
(566, 189)
(566, 190)
(566, 238)
(566, 257)
(566, 300)
(566, 316)
(566, 321)
(566, 373)
(566, 420)
(566, 441)
(566, 447)
(566, 485)
(566, 516)
(566, 523)
(566, 528)
(566, 541)
(567, 104)
(567, 299)
(568, 104)
(568, 282)
(569, 104)
(569, 136)
(569, 192)
(569, 238)
(569, 257)
(569, 319)
(569, 321)
(569, 516)
(570, 36)
(570, 257)
(570, 321)
(570, 441)
(570, 485)
(570, 516)
(571, 82)
(571, 257)
(571, 321)
(571, 322)
(571, 377)
(571, 420)
(571, 485)
(571, 516)
(571, 528)
(572, 1)
(572, 4)
(572, 15)
(572, 19)
(572, 22)
(572, 27)
(572, 28)
(572, 37)
(572, 39)
(572, 51)
(572, 71)
(572, 85)
(572, 90)
(572, 104)
(572, 111)
(572, 114)
(572, 124)
(572, 134)
(572, 156)
(572, 165)
(572, 175)
(572, 182)
(572, 184)
(572, 192)
(572, 194)
(572, 199)
(572, 218)
(572, 224)
(572, 230)
(572, 240)
(572, 242)
(572, 253)
(572, 256)
(572, 266)
(572, 267)
(572, 282)
(572, 287)
(572, 299)
(572, 310)
(572, 315)
(572, 319)
(572, 335)
(572, 336)
(572, 389)
(572, 395)
(572, 415)
(572, 419)
(572, 424)
(572, 432)
(572, 446)
(572, 458)
(572, 471)
(572, 475)
(572, 476)
(572, 484)
(572, 488)
(572, 489)
(572, 495)
(572, 497)
(572, 499)
(572, 510)
(572, 514)
(572, 527)
(572, 546)
(572, 547)
(572, 550)
(573, 257)
(576, 192)
(577, 36)
(577, 79)
(577, 82)
(577, 119)
(577, 151)
(577, 169)
(577, 173)
(577, 180)
(577, 190)
(577, 236)
(577, 257)
(577, 288)
(577, 294)
(577, 300)
(577, 316)
(577, 321)
(577, 361)
(577, 385)
(577, 420)
(577, 441)
(577, 447)
(577, 469)
(577, 485)
(577, 491)
(577, 516)
(577, 523)
(577, 528)
(577, 566)
(577, 570)
(578, 257)
(578, 321)
(578, 516)
(579, 4)
(579, 136)
(579, 192)
(579, 244)
(579, 282)
(579, 321)
(579, 339)
(580, 495)
(581, 104)
(581, 124)
(581, 282)
(581, 321)
(582, 4)
(582, 18)
(582, 25)
(582, 36)
(582, 68)
(582, 69)
(582, 82)
(582, 97)
(582, 101)
(582, 107)
(582, 119)
(582, 127)
(582, 129)
(582, 144)
(582, 151)
(582, 160)
(582, 169)
(582, 190)
(582, 192)
(582, 214)
(582, 238)
(582, 239)
(582, 240)
(582, 257)
(582, 279)
(582, 300)
(582, 301)
(582, 306)
(582, 314)
(582, 321)
(582, 322)
(582, 339)
(582, 361)
(582, 373)
(582, 374)
(582, 377)
(582, 385)
(582, 387)
(582, 398)
(582, 404)
(582, 408)
(582, 420)
(582, 441)
(582, 447)
(582, 450)
(582, 460)
(582, 469)
(582, 472)
(582, 485)
(582, 491)
(582, 516)
(582, 520)
(582, 523)
(582, 524)
(582, 528)
(582, 533)
(582, 541)
(582, 545)
(582, 554)
(582, 557)
(582, 566)
(582, 570)
(582, 571)
(582, 577)
(585, 82)
(585, 129)
(585, 144)
(585, 190)
(585, 257)
(585, 282)
(585, 300)
(585, 321)
(585, 373)
(585, 374)
(585, 387)
(585, 420)
(585, 460)
(585, 469)
(585, 485)
(585, 491)
(585, 516)
(585, 523)
(585, 527)
(585, 528)
(585, 533)
(585, 582)
(586, 1)
(586, 37)
(586, 39)
(586, 71)
(586, 90)
(586, 104)
(586, 182)
(586, 224)
(586, 282)
(586, 299)
(586, 336)
(586, 458)
(586, 499)
(587, 537)
(587, 546)
(588, 82)
(588, 257)
(588, 321)
(588, 373)
(588, 420)
(588, 485)
(588, 516)
(588, 528)
(588, 566)
(588, 582)
(589, 1)
(589, 4)
(589, 7)
(589, 8)
(589, 10)
(589, 15)
(589, 17)
(589, 18)
(589, 19)
(589, 21)
(589, 22)
(589, 25)
(589, 27)
(589, 28)
(589, 30)
(589, 32)
(589, 36)
(589, 37)
(589, 39)
(589, 42)
(589, 46)
(589, 50)
(589, 51)
(589, 53)
(589, 57)
(589, 63)
(589, 66)
(589, 67)
(589, 68)
(589, 69)
(589, 71)
(589, 76)
(589, 80)
(589, 82)
(589, 85)
(589, 87)
(589, 88)
(589, 90)
(589, 93)
(589, 96)
(589, 97)
(589, 103)
(589, 104)
(589, 107)
(589, 109)
(589, 110)
(589, 111)
(589, 114)
(589, 115)
(589, 117)
(589, 118)
(589, 126)
(589, 127)
(589, 129)
(589, 130)
(589, 133)
(589, 134)
(589, 136)
(589, 137)
(589, 141)
(589, 144)
(589, 148)
(589, 152)
(589, 156)
(589, 158)
(589, 160)
(589, 162)
(589, 165)
(589, 168)
(589, 169)
(589, 172)
(589, 173)
(589, 175)
(589, 176)
(589, 177)
(589, 182)
(589, 184)
(589, 188)
(589, 189)
(589, 190)
(589, 191)
(589, 192)
(589, 194)
(589, 195)
(589, 199)
(589, 203)
(589, 204)
(589, 205)
(589, 208)
(589, 214)
(589, 218)
(589, 221)
(589, 224)
(589, 228)
(589, 230)
(589, 235)
(589, 236)
(589, 238)
(589, 239)
(589, 240)
(589, 242)
(589, 244)
(589, 248)
(589, 249)
(589, 253)
(589, 255)
(589, 256)
(589, 257)
(589, 259)
(589, 266)
(589, 267)
(589, 268)
(589, 269)
(589, 270)
(589, 279)
(589, 282)
(589, 287)
(589, 289)
(589, 297)
(589, 299)
(589, 300)
(589, 302)
(589, 306)
(589, 308)
(589, 310)
(589, 314)
(589, 315)
(589, 319)
(589, 321)
(589, 322)
(589, 331)
(589, 336)
(589, 337)
(589, 339)
(589, 340)
(589, 343)
(589, 344)
(589, 348)
(589, 359)
(589, 360)
(589, 361)
(589, 362)
(589, 363)
(589, 369)
(589, 374)
(589, 376)
(589, 377)
(589, 379)
(589, 380)
(589, 387)
(589, 390)
(589, 392)
(589, 394)
(589, 395)
(589, 398)
(589, 399)
(589, 400)
(589, 401)
(589, 404)
(589, 406)
(589, 410)
(589, 415)
(589, 419)
(589, 420)
(589, 422)
(589, 424)
(589, 426)
(589, 431)
(589, 432)
(589, 433)
(589, 436)
(589, 439)
(589, 440)
(589, 441)
(589, 446)
(589, 450)
(589, 455)
(589, 457)
(589, 458)
(589, 460)
(589, 462)
(589, 463)
(589, 464)
(589, 465)
(589, 466)
(589, 467)
(589, 468)
(589, 470)
(589, 471)
(589, 473)
(589, 475)
(589, 476)
(589, 482)
(589, 484)
(589, 485)
(589, 488)
(589, 489)
(589, 490)
(589, 491)
(589, 496)
(589, 497)
(589, 498)
(589, 499)
(589, 500)
(589, 501)
(589, 503)
(589, 508)
(589, 509)
(589, 510)
(589, 512)
(589, 513)
(589, 514)
(589, 515)
(589, 516)
(589, 523)
(589, 524)
(589, 526)
(589, 527)
(589, 528)
(589, 533)
(589, 534)
(589, 535)
(589, 538)
(589, 539)
(589, 540)
(589, 543)
(589, 545)
(589, 546)
(589, 547)
(589, 549)
(589, 550)
(589, 553)
(589, 554)
(589, 555)
(589, 556)
(589, 557)
(589, 561)
(589, 563)
(589, 570)
(589, 571)
(589, 572)
(589, 579)
(589, 581)
(589, 582)
(589, 585)
(589, 586)
(590, 1)
(590, 4)
(590, 7)
(590, 8)
(590, 10)
(590, 15)
(590, 17)
(590, 18)
(590, 21)
(590, 22)
(590, 25)
(590, 27)
(590, 28)
(590, 30)
(590, 32)
(590, 36)
(590, 37)
(590, 39)
(590, 42)
(590, 46)
(590, 49)
(590, 50)
(590, 51)
(590, 53)
(590, 63)
(590, 66)
(590, 67)
(590, 71)
(590, 80)
(590, 82)
(590, 85)
(590, 87)
(590, 88)
(590, 90)
(590, 93)
(590, 95)
(590, 96)
(590, 97)
(590, 103)
(590, 104)
(590, 107)
(590, 109)
(590, 110)
(590, 111)
(590, 114)
(590, 115)
(590, 117)
(590, 118)
(590, 126)
(590, 128)
(590, 129)
(590, 133)
(590, 134)
(590, 136)
(590, 137)
(590, 141)
(590, 148)
(590, 152)
(590, 156)
(590, 158)
(590, 160)
(590, 162)
(590, 165)
(590, 168)
(590, 169)
(590, 170)
(590, 172)
(590, 173)
(590, 175)
(590, 176)
(590, 177)
(590, 182)
(590, 184)
(590, 188)
(590, 189)
(590, 190)
(590, 191)
(590, 192)
(590, 194)
(590, 195)
(590, 199)
(590, 203)
(590, 204)
(590, 205)
(590, 208)
(590, 218)
(590, 221)
(590, 224)
(590, 228)
(590, 230)
(590, 236)
(590, 238)
(590, 239)
(590, 240)
(590, 242)
(590, 244)
(590, 246)
(590, 248)
(590, 249)
(590, 253)
(590, 255)
(590, 256)
(590, 257)
(590, 259)
(590, 266)
(590, 267)
(590, 268)
(590, 269)
(590, 270)
(590, 279)
(590, 282)
(590, 287)
(590, 289)
(590, 292)
(590, 297)
(590, 299)
(590, 300)
(590, 302)
(590, 308)
(590, 310)
(590, 313)
(590, 314)
(590, 315)
(590, 319)
(590, 320)
(590, 321)
(590, 322)
(590, 331)
(590, 336)
(590, 339)
(590, 340)
(590, 344)
(590, 348)
(590, 361)
(590, 363)
(590, 369)
(590, 374)
(590, 377)
(590, 380)
(590, 382)
(590, 384)
(590, 387)
(590, 390)
(590, 394)
(590, 395)
(590, 398)
(590, 400)
(590, 401)
(590, 406)
(590, 410)
(590, 412)
(590, 413)
(590, 416)
(590, 419)
(590, 420)
(590, 421)
(590, 424)
(590, 426)
(590, 429)
(590, 432)
(590, 433)
(590, 434)
(590, 436)
(590, 439)
(590, 440)
(590, 441)
(590, 446)
(590, 450)
(590, 452)
(590, 457)
(590, 458)
(590, 460)
(590, 462)
(590, 465)
(590, 467)
(590, 468)
(590, 471)
(590, 473)
(590, 475)
(590, 476)
(590, 482)
(590, 484)
(590, 485)
(590, 488)
(590, 489)
(590, 490)
(590, 491)
(590, 496)
(590, 497)
(590, 498)
(590, 499)
(590, 501)
(590, 503)
(590, 508)
(590, 509)
(590, 510)
(590, 512)
(590, 513)
(590, 514)
(590, 515)
(590, 524)
(590, 527)
(590, 533)
(590, 535)
(590, 537)
(590, 538)
(590, 540)
(590, 543)
(590, 545)
(590, 546)
(590, 547)
(590, 549)
(590, 550)
(590, 553)
(590, 554)
(590, 555)
(590, 556)
(590, 557)
(590, 561)
(590, 563)
(590, 569)
(590, 572)
(590, 581)
(590, 582)
(590, 586)
(590, 589)
(593, 1)
(593, 4)
(593, 15)
(593, 22)
(593, 25)
(593, 27)
(593, 28)
(593, 32)
(593, 37)
(593, 46)
(593, 50)
(593, 51)
(593, 66)
(593, 67)
(593, 71)
(593, 85)
(593, 90)
(593, 96)
(593, 104)
(593, 110)
(593, 111)
(593, 114)
(593, 126)
(593, 129)
(593, 134)
(593, 137)
(593, 156)
(593, 162)
(593, 165)
(593, 170)
(593, 182)
(593, 184)
(593, 192)
(593, 194)
(593, 199)
(593, 208)
(593, 224)
(593, 230)
(593, 240)
(593, 244)
(593, 248)
(593, 249)
(593, 253)
(593, 256)
(593, 259)
(593, 266)
(593, 267)
(593, 282)
(593, 299)
(593, 300)
(593, 302)
(593, 315)
(593, 319)
(593, 321)
(593, 336)
(593, 344)
(593, 348)
(593, 382)
(593, 419)
(593, 421)
(593, 424)
(593, 432)
(593, 446)
(593, 456)
(593, 458)
(593, 475)
(593, 484)
(593, 488)
(593, 489)
(593, 490)
(593, 491)
(593, 499)
(593, 510)
(593, 514)
(593, 515)
(593, 527)
(593, 535)
(593, 538)
(593, 545)
(593, 546)
(593, 550)
(593, 572)
(593, 589)
(593, 590)
(594, 257)
(594, 516)
(595, 25)
(595, 129)
(595, 257)
(595, 321)
(595, 420)
(595, 582)
(596, 240)
(596, 282)
(596, 589)
(597, 1)
(597, 104)
(597, 282)
(597, 299)
(597, 336)
(597, 589)
(597, 590)
(598, 51)
(598, 104)
(598, 282)
(598, 299)
(598, 419)
(598, 589)
(600, 71)
(600, 104)
(600, 192)
(600, 282)
(600, 589)
(600, 590)
(601, 4)
(601, 15)
(601, 39)
(601, 51)
(601, 71)
(601, 104)
(601, 175)
(601, 182)
(601, 184)
(601, 192)
(601, 199)
(601, 224)
(601, 253)
(601, 266)
(601, 267)
(601, 282)
(601, 299)
(601, 321)
(601, 336)
(601, 419)
(601, 475)
(601, 514)
(601, 527)
(601, 589)
(601, 590)
(603, 90)
(603, 104)
(603, 182)
(603, 240)
(603, 282)
(603, 340)
(603, 514)
(604, 4)
(604, 12)
(604, 23)
(604, 33)
(604, 36)
(604, 60)
(604, 67)
(604, 69)
(604, 71)
(604, 82)
(604, 104)
(604, 107)
(604, 110)
(604, 118)
(604, 129)
(604, 136)
(604, 151)
(604, 173)
(604, 179)
(604, 189)
(604, 190)
(604, 191)
(604, 192)
(604, 229)
(604, 236)
(604, 239)
(604, 244)
(604, 257)
(604, 266)
(604, 282)
(604, 294)
(604, 313)
(604, 316)
(604, 321)
(604, 329)
(604, 337)
(604, 339)
(604, 361)
(604, 374)
(604, 406)
(604, 420)
(604, 429)
(604, 441)
(604, 447)
(604, 469)
(604, 485)
(604, 496)
(604, 500)
(604, 514)
(604, 527)
(604, 528)
(604, 541)
(604, 545)
(604, 555)
(604, 563)
(604, 577)
(604, 589)
(604, 590)
(605, 104)
(605, 182)
(605, 300)
(605, 491)
(605, 516)
(606, 1)
(606, 28)
(606, 37)
(606, 46)
(606, 51)
(606, 71)
(606, 90)
(606, 104)
(606, 126)
(606, 133)
(606, 182)
(606, 224)
(606, 240)
(606, 267)
(606, 282)
(606, 299)
(606, 300)
(606, 315)
(606, 321)
(606, 336)
(606, 458)
(606, 488)
(606, 491)
(606, 499)
(606, 514)
(606, 550)
(606, 589)
(606, 590)
(606, 593)
(608, 1)
(608, 4)
(608, 7)
(608, 10)
(608, 15)
(608, 25)
(608, 28)
(608, 36)
(608, 37)
(608, 46)
(608, 50)
(608, 51)
(608, 66)
(608, 71)
(608, 82)
(608, 85)
(608, 90)
(608, 96)
(608, 103)
(608, 104)
(608, 110)
(608, 126)
(608, 129)
(608, 134)
(608, 156)
(608, 165)
(608, 172)
(608, 175)
(608, 182)
(608, 184)
(608, 190)
(608, 192)
(608, 194)
(608, 199)
(608, 205)
(608, 224)
(608, 239)
(608, 240)
(608, 244)
(608, 248)
(608, 253)
(608, 257)
(608, 266)
(608, 267)
(608, 282)
(608, 299)
(608, 300)
(608, 315)
(608, 321)
(608, 322)
(608, 336)
(608, 339)
(608, 348)
(608, 387)
(608, 398)
(608, 419)
(608, 420)
(608, 458)
(608, 467)
(608, 475)
(608, 482)
(608, 485)
(608, 488)
(608, 489)
(608, 490)
(608, 491)
(608, 499)
(608, 510)
(608, 513)
(608, 514)
(608, 516)
(608, 523)
(608, 527)
(608, 534)
(608, 545)
(608, 546)
(608, 550)
(608, 554)
(608, 556)
(608, 582)
(608, 585)
(608, 589)
(608, 590)
(608, 593)
(609, 212)
(609, 277)
(609, 495)
(610, 1)
(610, 4)
(610, 15)
(610, 17)
(610, 18)
(610, 25)
(610, 27)
(610, 28)
(610, 37)
(610, 39)
(610, 46)
(610, 51)
(610, 66)
(610, 71)
(610, 82)
(610, 85)
(610, 90)
(610, 96)
(610, 103)
(610, 104)
(610, 110)
(610, 126)
(610, 129)
(610, 134)
(610, 136)
(610, 162)
(610, 165)
(610, 182)
(610, 184)
(610, 190)
(610, 192)
(610, 194)
(610, 199)
(610, 205)
(610, 218)
(610, 224)
(610, 240)
(610, 248)
(610, 253)
(610, 259)
(610, 266)
(610, 267)
(610, 282)
(610, 299)
(610, 300)
(610, 315)
(610, 321)
(610, 336)
(610, 339)
(610, 348)
(610, 387)
(610, 390)
(610, 398)
(610, 419)
(610, 432)
(610, 457)
(610, 458)
(610, 467)
(610, 471)
(610, 475)
(610, 484)
(610, 488)
(610, 489)
(610, 491)
(610, 499)
(610, 501)
(610, 510)
(610, 514)
(610, 516)
(610, 527)
(610, 545)
(610, 550)
(610, 589)
(610, 590)
(610, 593)
(610, 608)
(611, 1)
(611, 28)
(611, 51)
(611, 71)
(611, 90)
(611, 104)
(611, 182)
(611, 240)
(611, 266)
(611, 267)
(611, 282)
(611, 299)
(611, 315)
(611, 336)
(611, 389)
(611, 419)
(611, 432)
(611, 475)
(611, 484)
(611, 488)
(611, 514)
(611, 550)
(611, 572)
(611, 589)
(611, 590)
(613, 1)
(613, 51)
(613, 71)
(613, 104)
(613, 192)
(613, 253)
(613, 267)
(613, 282)
(613, 299)
(613, 336)
(613, 419)
(613, 514)
(613, 589)
(616, 104)
(616, 267)
(616, 282)
(616, 589)
(617, 549)
(617, 589)
(618, 1)
(618, 4)
(618, 15)
(618, 28)
(618, 37)
(618, 39)
(618, 51)
(618, 66)
(618, 67)
(618, 71)
(618, 85)
(618, 88)
(618, 90)
(618, 104)
(618, 110)
(618, 118)
(618, 134)
(618, 136)
(618, 156)
(618, 158)
(618, 165)
(618, 175)
(618, 179)
(618, 182)
(618, 184)
(618, 191)
(618, 192)
(618, 199)
(618, 204)
(618, 218)
(618, 224)
(618, 230)
(618, 236)
(618, 240)
(618, 244)
(618, 253)
(618, 256)
(618, 266)
(618, 267)
(618, 282)
(618, 299)
(618, 313)
(618, 315)
(618, 319)
(618, 321)
(618, 336)
(618, 339)
(618, 344)
(618, 406)
(618, 419)
(618, 424)
(618, 429)
(618, 458)
(618, 462)
(618, 471)
(618, 475)
(618, 484)
(618, 489)
(618, 499)
(618, 510)
(618, 514)
(618, 527)
(618, 545)
(618, 550)
(618, 555)
(618, 572)
(618, 589)
(618, 590)
(618, 593)
(618, 604)
(618, 610)
(619, 104)
(619, 257)
(620, 4)
(620, 25)
(620, 33)
(620, 36)
(620, 60)
(620, 107)
(620, 118)
(620, 136)
(620, 155)
(620, 170)
(620, 192)
(620, 204)
(620, 236)
(620, 238)
(620, 257)
(620, 319)
(620, 321)
(620, 429)
(620, 441)
(620, 447)
(620, 516)
(620, 545)
(620, 546)
(620, 555)
(620, 589)
(620, 590)
(620, 604)
(622, 124)
(622, 207)
(622, 267)
(622, 335)
(622, 341)
(622, 419)
(622, 491)
(623, 36)
(623, 68)
(623, 82)
(623, 129)
(623, 144)
(623, 169)
(623, 190)
(623, 238)
(623, 257)
(623, 282)
(623, 300)
(623, 321)
(623, 373)
(623, 374)
(623, 377)
(623, 398)
(623, 420)
(623, 441)
(623, 460)
(623, 485)
(623, 516)
(623, 528)
(623, 533)
(623, 557)
(623, 566)
(623, 582)
(623, 585)
(623, 589)
(623, 590)
(624, 4)
(624, 18)
(624, 25)
(624, 28)
(624, 36)
(624, 46)
(624, 50)
(624, 60)
(624, 66)
(624, 82)
(624, 92)
(624, 108)
(624, 110)
(624, 127)
(624, 129)
(624, 136)
(624, 144)
(624, 168)
(624, 170)
(624, 173)
(624, 175)
(624, 189)
(624, 190)
(624, 192)
(624, 236)
(624, 238)
(624, 239)
(624, 240)
(624, 257)
(624, 267)
(624, 282)
(624, 300)
(624, 317)
(624, 319)
(624, 321)
(624, 322)
(624, 341)
(624, 348)
(624, 361)
(624, 373)
(624, 374)
(624, 385)
(624, 387)
(624, 398)
(624, 408)
(624, 420)
(624, 441)
(624, 450)
(624, 464)
(624, 469)
(624, 482)
(624, 485)
(624, 490)
(624, 491)
(624, 503)
(624, 512)
(624, 514)
(624, 516)
(624, 523)
(624, 524)
(624, 527)
(624, 528)
(624, 533)
(624, 546)
(624, 556)
(624, 557)
(624, 563)
(624, 566)
(624, 577)
(624, 582)
(624, 585)
(624, 589)
(624, 590)
(624, 595)
(624, 604)
(624, 608)
(624, 620)
(624, 623)
(625, 4)
(625, 50)
(625, 85)
(625, 104)
(625, 169)
(625, 192)
(625, 199)
(625, 224)
(625, 238)
(625, 244)
(625, 253)
(625, 257)
(625, 267)
(625, 282)
(625, 321)
(625, 339)
(625, 441)
(625, 475)
(625, 491)
(625, 514)
(625, 516)
(625, 545)
(625, 589)
(625, 590)
(626, 4)
(626, 36)
(626, 51)
(626, 71)
(626, 82)
(626, 96)
(626, 104)
(626, 129)
(626, 136)
(626, 144)
(626, 173)
(626, 190)
(626, 192)
(626, 236)
(626, 240)
(626, 257)
(626, 282)
(626, 299)
(626, 300)
(626, 321)
(626, 322)
(626, 361)
(626, 373)
(626, 374)
(626, 387)
(626, 398)
(626, 404)
(626, 420)
(626, 460)
(626, 469)
(626, 482)
(626, 485)
(626, 496)
(626, 514)
(626, 516)
(626, 523)
(626, 528)
(626, 577)
(626, 582)
(626, 585)
(626, 589)
(626, 590)
(626, 604)
(626, 608)
(626, 624)
(627, 22)
(627, 104)
(627, 267)
(628, 192)
(628, 238)
(628, 257)
(628, 321)
(628, 339)
(628, 441)
(628, 516)
(628, 545)
(628, 582)
(628, 589)
(628, 590)
(629, 4)
(629, 36)
(629, 51)
(629, 71)
(629, 82)
(629, 104)
(629, 107)
(629, 110)
(629, 129)
(629, 144)
(629, 169)
(629, 173)
(629, 184)
(629, 190)
(629, 192)
(629, 236)
(629, 238)
(629, 240)
(629, 257)
(629, 282)
(629, 300)
(629, 321)
(629, 322)
(629, 361)
(629, 373)
(629, 374)
(629, 377)
(629, 398)
(629, 420)
(629, 441)
(629, 450)
(629, 469)
(629, 482)
(629, 485)
(629, 491)
(629, 496)
(629, 516)
(629, 523)
(629, 527)
(629, 528)
(629, 545)
(629, 557)
(629, 566)
(629, 577)
(629, 582)
(629, 585)
(629, 589)
(629, 590)
(629, 604)
(629, 608)
(629, 623)
(629, 624)
(629, 626)
(630, 1)
(630, 10)
(630, 15)
(630, 25)
(630, 28)
(630, 71)
(630, 85)
(630, 104)
(630, 124)
(630, 129)
(630, 175)
(630, 182)
(630, 192)
(630, 253)
(630, 267)
(630, 282)
(630, 319)
(630, 321)
(630, 336)
(630, 341)
(630, 348)
(630, 384)
(630, 419)
(630, 424)
(630, 462)
(630, 491)
(630, 510)
(630, 514)
(630, 527)
(630, 546)
(630, 572)
(630, 589)
(630, 590)
(630, 593)
(630, 622)
(632, 1)
(632, 4)
(632, 18)
(632, 27)
(632, 28)
(632, 37)
(632, 39)
(632, 51)
(632, 53)
(632, 66)
(632, 71)
(632, 85)
(632, 90)
(632, 96)
(632, 104)
(632, 111)
(632, 126)
(632, 133)
(632, 134)
(632, 156)
(632, 173)
(632, 175)
(632, 182)
(632, 184)
(632, 192)
(632, 218)
(632, 224)
(632, 230)
(632, 240)
(632, 242)
(632, 248)
(632, 253)
(632, 259)
(632, 266)
(632, 267)
(632, 282)
(632, 299)
(632, 310)
(632, 315)
(632, 327)
(632, 336)
(632, 344)
(632, 348)
(632, 401)
(632, 415)
(632, 419)
(632, 421)
(632, 424)
(632, 432)
(632, 439)
(632, 458)
(632, 471)
(632, 475)
(632, 476)
(632, 488)
(632, 489)
(632, 491)
(632, 497)
(632, 499)
(632, 510)
(632, 514)
(632, 527)
(632, 546)
(632, 547)
(632, 550)
(632, 572)
(632, 589)
(632, 590)
(632, 593)
(632, 608)
(632, 610)
(632, 618)
(633, 4)
(633, 50)
(633, 151)
(633, 192)
(633, 236)
(633, 257)
(633, 267)
(633, 282)
(633, 313)
(633, 321)
(633, 339)
(633, 374)
(633, 485)
(633, 516)
(633, 528)
(633, 582)
(633, 589)
(633, 604)
(633, 624)
(634, 25)
(634, 36)
(634, 51)
(634, 82)
(634, 129)
(634, 169)
(634, 192)
(634, 199)
(634, 224)
(634, 240)
(634, 257)
(634, 267)
(634, 282)
(634, 300)
(634, 321)
(634, 322)
(634, 377)
(634, 420)
(634, 485)
(634, 491)
(634, 514)
(634, 516)
(634, 523)
(634, 527)
(634, 528)
(634, 582)
(634, 585)
(634, 589)
(634, 590)
(634, 608)
(634, 610)
(634, 626)
(634, 629)
(635, 257)
(635, 528)
(636, 82)
(636, 129)
(636, 175)
(636, 182)
(636, 192)
(636, 240)
(636, 248)
(636, 257)
(636, 282)
(636, 321)
(636, 341)
(636, 485)
(636, 514)
(636, 527)
(636, 528)
(636, 546)
(636, 589)
(636, 590)
(637, 192)
(637, 236)
(637, 257)
(637, 321)
(637, 516)
(638, 25)
(638, 44)
(638, 46)
(638, 57)
(638, 74)
(638, 82)
(638, 101)
(638, 144)
(638, 240)
(638, 257)
(638, 263)
(638, 300)
(638, 321)
(638, 373)
(638, 387)
(638, 404)
(638, 408)
(638, 491)
(638, 492)
(638, 528)
(638, 582)
(638, 585)
(638, 596)
(638, 603)
(638, 624)
(639, 36)
(639, 82)
(639, 173)
(639, 190)
(639, 257)
(639, 282)
(639, 321)
(639, 420)
(639, 441)
(639, 485)
(639, 516)
(639, 528)
(639, 582)
(639, 589)
(640, 1)
(640, 4)
(640, 15)
(640, 18)
(640, 25)
(640, 27)
(640, 28)
(640, 36)
(640, 37)
(640, 39)
(640, 46)
(640, 50)
(640, 51)
(640, 66)
(640, 67)
(640, 71)
(640, 82)
(640, 85)
(640, 90)
(640, 96)
(640, 104)
(640, 107)
(640, 110)
(640, 111)
(640, 117)
(640, 126)
(640, 129)
(640, 133)
(640, 134)
(640, 136)
(640, 137)
(640, 162)
(640, 169)
(640, 172)
(640, 182)
(640, 184)
(640, 190)
(640, 192)
(640, 194)
(640, 199)
(640, 218)
(640, 224)
(640, 240)
(640, 242)
(640, 248)
(640, 249)
(640, 253)
(640, 257)
(640, 259)
(640, 266)
(640, 267)
(640, 282)
(640, 287)
(640, 299)
(640, 300)
(640, 315)
(640, 321)
(640, 322)
(640, 331)
(640, 336)
(640, 339)
(640, 348)
(640, 380)
(640, 387)
(640, 398)
(640, 419)
(640, 420)
(640, 432)
(640, 441)
(640, 458)
(640, 462)
(640, 467)
(640, 468)
(640, 471)
(640, 475)
(640, 484)
(640, 485)
(640, 488)
(640, 489)
(640, 490)
(640, 491)
(640, 498)
(640, 499)
(640, 501)
(640, 508)
(640, 510)
(640, 514)
(640, 516)
(640, 524)
(640, 527)
(640, 534)
(640, 545)
(640, 550)
(640, 554)
(640, 566)
(640, 572)
(640, 582)
(640, 589)
(640, 590)
(640, 593)
(640, 606)
(640, 608)
(640, 610)
(640, 618)
(640, 624)
(640, 625)
(640, 629)
(640, 630)
(640, 632)
(640, 634)
(641, 104)
(641, 199)
(641, 257)
(641, 282)
(641, 300)
(641, 321)
(641, 491)
(641, 516)
(641, 549)
(641, 589)
(643, 22)
(643, 25)
(643, 56)
(643, 124)
(643, 210)
(643, 292)
(643, 295)
(643, 408)
(643, 427)
(643, 434)
(643, 479)
(646, 104)
(646, 282)
(646, 495)
(649, 4)
(649, 10)
(649, 17)
(649, 18)
(649, 25)
(649, 28)
(649, 36)
(649, 51)
(649, 60)
(649, 66)
(649, 67)
(649, 69)
(649, 71)
(649, 82)
(649, 85)
(649, 96)
(649, 103)
(649, 104)
(649, 107)
(649, 110)
(649, 118)
(649, 124)
(649, 127)
(649, 129)
(649, 134)
(649, 136)
(649, 144)
(649, 156)
(649, 162)
(649, 165)
(649, 173)
(649, 175)
(649, 177)
(649, 182)
(649, 184)
(649, 190)
(649, 191)
(649, 192)
(649, 194)
(649, 224)
(649, 230)
(649, 236)
(649, 238)
(649, 239)
(649, 240)
(649, 244)
(649, 248)
(649, 253)
(649, 255)
(649, 257)
(649, 266)
(649, 267)
(649, 282)
(649, 289)
(649, 299)
(649, 300)
(649, 319)
(649, 321)
(649, 322)
(649, 336)
(649, 339)
(649, 348)
(649, 361)
(649, 374)
(649, 377)
(649, 387)
(649, 398)
(649, 419)
(649, 420)
(649, 441)
(649, 446)
(649, 450)
(649, 457)
(649, 460)
(649, 467)
(649, 475)
(649, 482)
(649, 485)
(649, 491)
(649, 496)
(649, 510)
(649, 512)
(649, 514)
(649, 523)
(649, 524)
(649, 527)
(649, 528)
(649, 537)
(649, 545)
(649, 546)
(649, 554)
(649, 555)
(649, 556)
(649, 557)
(649, 563)
(649, 582)
(649, 585)
(649, 589)
(649, 590)
(649, 593)
(649, 604)
(649, 608)
(649, 610)
(649, 618)
(649, 620)
(649, 623)
(649, 624)
(649, 626)
(649, 629)
(649, 630)
(649, 634)
(649, 639)
(649, 640)
(650, 210)
(650, 277)
(651, 25)
(651, 129)
(651, 257)
(651, 321)
(651, 420)
(651, 516)
(651, 546)
(651, 582)
(651, 624)
(652, 257)
(652, 516)
(654, 129)
(654, 175)
(654, 267)
(654, 321)
(655, 341)
(655, 546)
(655, 638)
(656, 321)
(657, 4)
(657, 33)
(657, 36)
(657, 60)
(657, 69)
(657, 94)
(657, 107)
(657, 118)
(657, 119)
(657, 136)
(657, 151)
(657, 169)
(657, 192)
(657, 236)
(657, 238)
(657, 239)
(657, 244)
(657, 257)
(657, 294)
(657, 313)
(657, 316)
(657, 321)
(657, 329)
(657, 339)
(657, 361)
(657, 406)
(657, 420)
(657, 429)
(657, 441)
(657, 447)
(657, 468)
(657, 516)
(657, 529)
(657, 541)
(657, 545)
(657, 555)
(657, 577)
(657, 582)
(657, 589)
(657, 590)
(657, 604)
(657, 620)
(657, 633)
(657, 637)
(658, 15)
(658, 28)
(658, 50)
(658, 51)
(658, 74)
(658, 180)
(658, 182)
(658, 184)
(658, 192)
(658, 199)
(658, 207)
(658, 240)
(658, 257)
(658, 267)
(658, 282)
(658, 300)
(658, 321)
(658, 339)
(658, 348)
(658, 366)
(658, 399)
(658, 405)
(658, 420)
(658, 454)
(658, 471)
(658, 490)
(658, 491)
(658, 514)
(658, 516)
(658, 523)
(658, 527)
(658, 550)
(658, 577)
(658, 589)
(658, 593)
(658, 605)
(658, 608)
(658, 610)
(658, 624)
(658, 634)
(658, 640)
(659, 4)
(659, 104)
(659, 192)
(659, 282)
(659, 555)
(659, 589)
(659, 590)
(662, 192)
(662, 267)
(662, 282)
(664, 104)
(664, 240)
(664, 282)
(665, 4)
(665, 18)
(665, 25)
(665, 28)
(665, 37)
(665, 39)
(665, 51)
(665, 71)
(665, 82)
(665, 90)
(665, 96)
(665, 104)
(665, 110)
(665, 126)
(665, 129)
(665, 134)
(665, 136)
(665, 156)
(665, 182)
(665, 184)
(665, 192)
(665, 195)
(665, 218)
(665, 224)
(665, 230)
(665, 240)
(665, 248)
(665, 257)
(665, 259)
(665, 267)
(665, 282)
(665, 289)
(665, 299)
(665, 300)
(665, 321)
(665, 331)
(665, 336)
(665, 363)
(665, 387)
(665, 390)
(665, 398)
(665, 419)
(665, 457)
(665, 482)
(665, 485)
(665, 499)
(665, 501)
(665, 510)
(665, 514)
(665, 516)
(665, 527)
(665, 528)
(665, 545)
(665, 546)
(665, 554)
(665, 582)
(665, 589)
(665, 590)
(665, 608)
(665, 610)
(665, 624)
(665, 626)
(665, 632)
(665, 640)
(665, 649)
(667, 1)
(667, 27)
(667, 37)
(667, 51)
(667, 71)
(667, 104)
(667, 134)
(667, 182)
(667, 184)
(667, 192)
(667, 199)
(667, 224)
(667, 240)
(667, 253)
(667, 267)
(667, 282)
(667, 299)
(667, 336)
(667, 419)
(667, 458)
(667, 475)
(667, 484)
(667, 499)
(667, 514)
(667, 572)
(667, 589)
(667, 590)
(667, 632)
(668, 37)
(668, 51)
(668, 71)
(668, 104)
(668, 182)
(668, 192)
(668, 224)
(668, 240)
(668, 282)
(668, 299)
(668, 336)
(668, 499)
(668, 514)
(668, 589)
(668, 590)
(670, 82)
(670, 144)
(670, 190)
(670, 257)
(670, 321)
(670, 374)
(670, 485)
(670, 516)
(670, 528)
(670, 589)
(670, 624)
(670, 629)
(670, 649)
(671, 33)
(671, 36)
(671, 52)
(671, 60)
(671, 69)
(671, 79)
(671, 94)
(671, 151)
(671, 154)
(671, 185)
(671, 189)
(671, 192)
(671, 229)
(671, 236)
(671, 257)
(671, 288)
(671, 293)
(671, 294)
(671, 313)
(671, 316)
(671, 321)
(671, 329)
(671, 332)
(671, 339)
(671, 361)
(671, 385)
(671, 406)
(671, 420)
(671, 429)
(671, 441)
(671, 447)
(671, 469)
(671, 485)
(671, 516)
(671, 522)
(671, 529)
(671, 541)
(671, 566)
(671, 577)
(671, 582)
(671, 588)
(671, 604)
(671, 637)
(671, 652)
(671, 657)
(673, 15)
(673, 28)
(673, 90)
(673, 104)
(673, 124)
(673, 182)
(673, 207)
(673, 282)
(673, 366)
(673, 389)
(673, 419)
(673, 458)
(673, 491)
(673, 514)
(673, 658)
(674, 15)
(674, 28)
(674, 71)
(674, 90)
(674, 104)
(674, 129)
(674, 175)
(674, 182)
(674, 194)
(674, 230)
(674, 253)
(674, 267)
(674, 282)
(674, 299)
(674, 319)
(674, 327)
(674, 335)
(674, 336)
(674, 415)
(674, 419)
(674, 424)
(674, 446)
(674, 475)
(674, 488)
(674, 491)
(674, 514)
(674, 546)
(674, 572)
(674, 590)
(674, 593)
(674, 630)
(674, 632)
(675, 257)
(675, 516)
(676, 257)
(676, 321)
(677, 257)
(678, 51)
(678, 71)
(678, 104)
(678, 182)
(678, 253)
(678, 267)
(678, 282)
(678, 299)
(678, 419)
(678, 491)
(678, 514)
(678, 589)
(679, 151)
(679, 236)
(679, 257)
(679, 294)
(679, 313)
(679, 321)
(679, 555)
(679, 604)
(679, 633)
(679, 657)
(679, 671)
(680, 257)
(680, 300)
(680, 321)
(680, 441)
(680, 491)
(680, 516)
(680, 527)
(680, 658)
(681, 1)
(681, 4)
(681, 8)
(681, 15)
(681, 17)
(681, 18)
(681, 22)
(681, 27)
(681, 28)
(681, 37)
(681, 39)
(681, 46)
(681, 51)
(681, 53)
(681, 63)
(681, 66)
(681, 67)
(681, 71)
(681, 82)
(681, 85)
(681, 87)
(681, 88)
(681, 90)
(681, 96)
(681, 103)
(681, 104)
(681, 110)
(681, 111)
(681, 126)
(681, 129)
(681, 134)
(681, 136)
(681, 156)
(681, 162)
(681, 165)
(681, 172)
(681, 175)
(681, 182)
(681, 184)
(681, 190)
(681, 192)
(681, 194)
(681, 195)
(681, 199)
(681, 208)
(681, 218)
(681, 221)
(681, 224)
(681, 228)
(681, 230)
(681, 236)
(681, 240)
(681, 244)
(681, 248)
(681, 249)
(681, 253)
(681, 255)
(681, 259)
(681, 266)
(681, 267)
(681, 279)
(681, 282)
(681, 289)
(681, 297)
(681, 299)
(681, 310)
(681, 314)
(681, 315)
(681, 321)
(681, 322)
(681, 331)
(681, 336)
(681, 339)
(681, 340)
(681, 344)
(681, 348)
(681, 363)
(681, 374)
(681, 387)
(681, 390)
(681, 395)
(681, 398)
(681, 401)
(681, 419)
(681, 424)
(681, 432)
(681, 446)
(681, 457)
(681, 458)
(681, 460)
(681, 462)
(681, 467)
(681, 471)
(681, 475)
(681, 476)
(681, 482)
(681, 484)
(681, 485)
(681, 488)
(681, 489)
(681, 496)
(681, 497)
(681, 499)
(681, 501)
(681, 503)
(681, 510)
(681, 514)
(681, 515)
(681, 526)
(681, 527)
(681, 528)
(681, 535)
(681, 545)
(681, 547)
(681, 550)
(681, 553)
(681, 554)
(681, 555)
(681, 556)
(681, 561)
(681, 563)
(681, 572)
(681, 589)
(681, 590)
(681, 593)
(681, 601)
(681, 604)
(681, 608)
(681, 610)
(681, 618)
(681, 626)
(681, 629)
(681, 632)
(681, 640)
(681, 649)
(681, 665)
(681, 667)
(681, 668)
(682, 86)
(683, 366)
(684, 82)
(684, 104)
(684, 282)
(684, 321)
(684, 485)
(684, 589)
(685, 25)
(685, 257)
(685, 282)
(685, 300)
(685, 321)
(685, 420)
(685, 491)
(685, 516)
(685, 527)
(685, 582)
(685, 590)
(685, 624)
(685, 640)
(686, 104)
(686, 192)
(686, 253)
(686, 267)
(686, 282)
(686, 299)
(686, 589)
(686, 590)
(687, 1)
(687, 4)
(687, 15)
(687, 17)
(687, 18)
(687, 22)
(687, 27)
(687, 28)
(687, 32)
(687, 37)
(687, 39)
(687, 46)
(687, 51)
(687, 53)
(687, 55)
(687, 66)
(687, 67)
(687, 71)
(687, 75)
(687, 80)
(687, 85)
(687, 87)
(687, 88)
(687, 90)
(687, 93)
(687, 96)
(687, 99)
(687, 104)
(687, 110)
(687, 111)
(687, 114)
(687, 117)
(687, 123)
(687, 126)
(687, 129)
(687, 133)
(687, 134)
(687, 136)
(687, 143)
(687, 148)
(687, 152)
(687, 156)
(687, 160)
(687, 162)
(687, 165)
(687, 172)
(687, 175)
(687, 182)
(687, 184)
(687, 192)
(687, 194)
(687, 195)
(687, 199)
(687, 205)
(687, 208)
(687, 218)
(687, 221)
(687, 224)
(687, 228)
(687, 230)
(687, 240)
(687, 242)
(687, 244)
(687, 246)
(687, 248)
(687, 249)
(687, 253)
(687, 254)
(687, 256)
(687, 259)
(687, 262)
(687, 266)
(687, 267)
(687, 268)
(687, 270)
(687, 282)
(687, 297)
(687, 299)
(687, 302)
(687, 303)
(687, 310)
(687, 315)
(687, 331)
(687, 336)
(687, 340)
(687, 344)
(687, 348)
(687, 360)
(687, 363)
(687, 379)
(687, 380)
(687, 382)
(687, 390)
(687, 395)
(687, 401)
(687, 413)
(687, 416)
(687, 419)
(687, 421)
(687, 424)
(687, 432)
(687, 436)
(687, 439)
(687, 440)
(687, 446)
(687, 458)
(687, 462)
(687, 467)
(687, 471)
(687, 475)
(687, 476)
(687, 484)
(687, 488)
(687, 489)
(687, 490)
(687, 491)
(687, 497)
(687, 499)
(687, 501)
(687, 510)
(687, 514)
(687, 515)
(687, 524)
(687, 527)
(687, 532)
(687, 535)
(687, 538)
(687, 545)
(687, 547)
(687, 550)
(687, 553)
(687, 554)
(687, 561)
(687, 567)
(687, 572)
(687, 586)
(687, 589)
(687, 590)
(687, 593)
(687, 597)
(687, 600)
(687, 601)
(687, 606)
(687, 608)
(687, 610)
(687, 611)
(687, 618)
(687, 632)
(687, 640)
(687, 649)
(687, 665)
(687, 667)
(687, 668)
(687, 674)
(687, 681)
(688, 74)
(688, 180)
(688, 287)
(688, 341)
(688, 397)
(688, 546)
(688, 577)
(689, 1)
(689, 19)
(689, 104)
(689, 124)
(689, 182)
(689, 282)
(689, 299)
(689, 335)
(689, 389)
(689, 419)
(689, 424)
(689, 572)
(690, 104)
(690, 282)
(690, 321)
(690, 589)
(690, 590)
(691, 1)
(691, 4)
(691, 18)
(691, 19)
(691, 27)
(691, 37)
(691, 39)
(691, 51)
(691, 71)
(691, 90)
(691, 96)
(691, 104)
(691, 110)
(691, 129)
(691, 134)
(691, 169)
(691, 175)
(691, 182)
(691, 184)
(691, 192)
(691, 199)
(691, 218)
(691, 224)
(691, 228)
(691, 240)
(691, 248)
(691, 253)
(691, 267)
(691, 282)
(691, 299)
(691, 310)
(691, 321)
(691, 322)
(691, 336)
(691, 374)
(691, 419)
(691, 432)
(691, 475)
(691, 476)
(691, 489)
(691, 497)
(691, 499)
(691, 514)
(691, 527)
(691, 528)
(691, 547)
(691, 572)
(691, 582)
(691, 589)
(691, 590)
(691, 608)
(691, 610)
(691, 632)
(691, 640)
(691, 649)
(691, 681)
(691, 687)
(692, 71)
(692, 90)
(692, 104)
(692, 282)
(692, 315)
(692, 336)
(692, 458)
(692, 687)
(693, 1)
(693, 4)
(693, 18)
(693, 22)
(693, 27)
(693, 28)
(693, 37)
(693, 51)
(693, 71)
(693, 85)
(693, 96)
(693, 104)
(693, 110)
(693, 111)
(693, 124)
(693, 129)
(693, 134)
(693, 156)
(693, 175)
(693, 182)
(693, 184)
(693, 192)
(693, 224)
(693, 228)
(693, 230)
(693, 240)
(693, 248)
(693, 253)
(693, 267)
(693, 282)
(693, 299)
(693, 315)
(693, 321)
(693, 336)
(693, 341)
(693, 419)
(693, 424)
(693, 432)
(693, 488)
(693, 489)
(693, 499)
(693, 510)
(693, 514)
(693, 534)
(693, 546)
(693, 572)
(693, 589)
(693, 590)
(693, 608)
(693, 630)
(693, 632)
(693, 640)
(693, 649)
(693, 681)
(693, 687)
(693, 691)
(694, 1)
(694, 28)
(694, 37)
(694, 71)
(694, 90)
(694, 104)
(694, 111)
(694, 156)
(694, 182)
(694, 192)
(694, 230)
(694, 240)
(694, 266)
(694, 267)
(694, 282)
(694, 299)
(694, 315)
(694, 327)
(694, 335)
(694, 336)
(694, 419)
(694, 424)
(694, 432)
(694, 488)
(694, 499)
(694, 514)
(694, 550)
(694, 572)
(694, 589)
(694, 590)
(694, 632)
(694, 674)
(694, 681)
(694, 687)
(695, 104)
(695, 282)
(696, 15)
(696, 104)
(696, 282)
(696, 419)
(696, 475)
(696, 495)
(696, 527)
(696, 572)
(697, 257)
(697, 321)
(697, 516)
(698, 1)
(698, 28)
(698, 37)
(698, 51)
(698, 71)
(698, 90)
(698, 104)
(698, 134)
(698, 165)
(698, 182)
(698, 192)
(698, 205)
(698, 208)
(698, 240)
(698, 244)
(698, 254)
(698, 282)
(698, 299)
(698, 315)
(698, 336)
(698, 389)
(698, 419)
(698, 424)
(698, 458)
(698, 475)
(698, 510)
(698, 514)
(698, 550)
(698, 589)
(698, 590)
(698, 687)
(698, 696)
(699, 82)
(699, 257)
(699, 282)
(699, 321)
(699, 516)
(699, 589)
(700, 60)
(700, 82)
(700, 119)
(700, 129)
(700, 144)
(700, 151)
(700, 169)
(700, 190)
(700, 192)
(700, 236)
(700, 257)
(700, 321)
(700, 322)
(700, 339)
(700, 361)
(700, 374)
(700, 377)
(700, 387)
(700, 398)
(700, 404)
(700, 420)
(700, 441)
(700, 447)
(700, 460)
(700, 469)
(700, 485)
(700, 500)
(700, 516)
(700, 528)
(700, 533)
(700, 577)
(700, 582)
(700, 585)
(700, 588)
(700, 589)
(700, 604)
(700, 623)
(700, 624)
(700, 626)
(700, 629)
(700, 649)
(700, 657)
(700, 665)
(700, 671)
(700, 681)
(700, 691)
(701, 4)
(701, 18)
(701, 23)
(701, 25)
(701, 36)
(701, 52)
(701, 60)
(701, 64)
(701, 68)
(701, 69)
(701, 82)
(701, 101)
(701, 107)
(701, 119)
(701, 127)
(701, 129)
(701, 144)
(701, 151)
(701, 169)
(701, 173)
(701, 189)
(701, 190)
(701, 210)
(701, 214)
(701, 233)
(701, 238)
(701, 257)
(701, 279)
(701, 294)
(701, 300)
(701, 301)
(701, 306)
(701, 314)
(701, 316)
(701, 321)
(701, 322)
(701, 331)
(701, 332)
(701, 352)
(701, 361)
(701, 373)
(701, 374)
(701, 377)
(701, 385)
(701, 387)
(701, 398)
(701, 408)
(701, 420)
(701, 441)
(701, 447)
(701, 450)
(701, 464)
(701, 469)
(701, 482)
(701, 485)
(701, 491)
(701, 498)
(701, 500)
(701, 508)
(701, 512)
(701, 516)
(701, 520)
(701, 522)
(701, 523)
(701, 524)
(701, 528)
(701, 533)
(701, 541)
(701, 557)
(701, 558)
(701, 566)
(701, 570)
(701, 571)
(701, 577)
(701, 578)
(701, 582)
(701, 585)
(701, 588)
(701, 589)
(701, 590)
(701, 595)
(701, 604)
(701, 623)
(701, 624)
(701, 626)
(701, 628)
(701, 629)
(701, 633)
(701, 634)
(701, 638)
(701, 639)
(701, 640)
(701, 649)
(701, 651)
(701, 657)
(701, 670)
(701, 671)
(701, 677)
(701, 680)
(701, 685)
(701, 699)
(701, 700)
(702, 1)
(702, 4)
(702, 8)
(702, 10)
(702, 11)
(702, 15)
(702, 17)
(702, 18)
(702, 22)
(702, 25)
(702, 27)
(702, 28)
(702, 30)
(702, 37)
(702, 39)
(702, 46)
(702, 51)
(702, 53)
(702, 63)
(702, 66)
(702, 67)
(702, 69)
(702, 71)
(702, 76)
(702, 82)
(702, 85)
(702, 90)
(702, 96)
(702, 103)
(702, 104)
(702, 107)
(702, 109)
(702, 110)
(702, 111)
(702, 114)
(702, 126)
(702, 127)
(702, 129)
(702, 134)
(702, 136)
(702, 156)
(702, 162)
(702, 165)
(702, 169)
(702, 172)
(702, 175)
(702, 177)
(702, 182)
(702, 184)
(702, 190)
(702, 191)
(702, 192)
(702, 194)
(702, 195)
(702, 199)
(702, 203)
(702, 204)
(702, 218)
(702, 222)
(702, 224)
(702, 228)
(702, 230)
(702, 236)
(702, 238)
(702, 239)
(702, 240)
(702, 244)
(702, 248)
(702, 249)
(702, 253)
(702, 255)
(702, 259)
(702, 266)
(702, 267)
(702, 279)
(702, 282)
(702, 289)
(702, 299)
(702, 300)
(702, 310)
(702, 314)
(702, 315)
(702, 319)
(702, 321)
(702, 322)
(702, 331)
(702, 336)
(702, 339)
(702, 340)
(702, 341)
(702, 344)
(702, 348)
(702, 363)
(702, 369)
(702, 374)
(702, 387)
(702, 394)
(702, 395)
(702, 398)
(702, 401)
(702, 410)
(702, 415)
(702, 419)
(702, 420)
(702, 424)
(702, 432)
(702, 441)
(702, 446)
(702, 457)
(702, 458)
(702, 460)
(702, 462)
(702, 467)
(702, 471)
(702, 475)
(702, 476)
(702, 482)
(702, 484)
(702, 485)
(702, 488)
(702, 489)
(702, 498)
(702, 499)
(702, 501)
(702, 503)
(702, 510)
(702, 512)
(702, 513)
(702, 514)
(702, 524)
(702, 526)
(702, 527)
(702, 528)
(702, 533)
(702, 535)
(702, 537)
(702, 539)
(702, 545)
(702, 546)
(702, 547)
(702, 550)
(702, 553)
(702, 554)
(702, 555)
(702, 556)
(702, 563)
(702, 572)
(702, 582)
(702, 585)
(702, 589)
(702, 590)
(702, 593)
(702, 598)
(702, 601)
(702, 604)
(702, 608)
(702, 610)
(702, 618)
(702, 623)
(702, 624)
(702, 626)
(702, 629)
(702, 630)
(702, 632)
(702, 636)
(702, 640)
(702, 649)
(702, 665)
(702, 667)
(702, 674)
(702, 681)
(702, 684)
(702, 686)
(702, 687)
(702, 691)
(702, 693)
(702, 694)
(702, 700)
(703, 267)
(703, 282)
(703, 335)
(703, 546)
(703, 674)
(704, 36)
(704, 238)
(704, 257)
(704, 321)
(704, 441)
(704, 485)
(704, 516)
(704, 582)
(704, 701)
(705, 104)
(705, 299)
(706, 104)
(706, 282)
(707, 521)
(708, 18)
(708, 25)
(708, 46)
(708, 104)
(708, 126)
(708, 129)
(708, 182)
(708, 240)
(708, 257)
(708, 282)
(708, 300)
(708, 321)
(708, 408)
(708, 491)
(708, 516)
(708, 524)
(708, 582)
(708, 589)
(708, 590)
(708, 624)
(708, 640)
(708, 643)
(708, 665)
(708, 701)
(709, 210)
(711, 546)
(713, 104)
(713, 192)
(714, 257)
(715, 18)
(715, 82)
(715, 104)
(715, 129)
(715, 257)
(715, 282)
(715, 300)
(715, 321)
(715, 485)
(715, 528)
(715, 589)
(715, 590)
(715, 681)
(715, 701)
(715, 702)
(717, 4)
(717, 129)
(717, 257)
(717, 321)
(717, 420)
(717, 589)
(717, 701)
(718, 82)
(718, 144)
(718, 190)
(718, 257)
(718, 321)
(718, 373)
(718, 420)
(718, 485)
(718, 516)
(718, 528)
(718, 582)
(718, 624)
(718, 701)
(719, 1)
(719, 4)
(719, 15)
(719, 25)
(719, 28)
(719, 37)
(719, 50)
(719, 51)
(719, 71)
(719, 85)
(719, 90)
(719, 96)
(719, 104)
(719, 110)
(719, 129)
(719, 134)
(719, 152)
(719, 160)
(719, 165)
(719, 172)
(719, 177)
(719, 182)
(719, 184)
(719, 192)
(719, 194)
(719, 199)
(719, 205)
(719, 208)
(719, 224)
(719, 228)
(719, 240)
(719, 244)
(719, 248)
(719, 253)
(719, 266)
(719, 267)
(719, 282)
(719, 299)
(719, 300)
(719, 315)
(719, 321)
(719, 336)
(719, 339)
(719, 348)
(719, 355)
(719, 366)
(719, 376)
(719, 379)
(719, 380)
(719, 387)
(719, 419)
(719, 432)
(719, 436)
(719, 439)
(719, 458)
(719, 467)
(719, 473)
(719, 475)
(719, 484)
(719, 488)
(719, 489)
(719, 490)
(719, 491)
(719, 499)
(719, 501)
(719, 513)
(719, 514)
(719, 515)
(719, 523)
(719, 527)
(719, 534)
(719, 535)
(719, 550)
(719, 561)
(719, 589)
(719, 590)
(719, 593)
(719, 608)
(719, 610)
(719, 613)
(719, 618)
(719, 632)
(719, 640)
(719, 649)
(719, 658)
(719, 667)
(719, 678)
(719, 681)
(719, 687)
(719, 691)
(719, 693)
(719, 702)
(720, 86)
(720, 682)
(721, 104)
(721, 192)
(721, 282)
(724, 104)
(724, 192)
(726, 4)
(726, 18)
(726, 25)
(726, 27)
(726, 28)
(726, 36)
(726, 37)
(726, 39)
(726, 49)
(726, 51)
(726, 67)
(726, 71)
(726, 82)
(726, 85)
(726, 96)
(726, 103)
(726, 104)
(726, 107)
(726, 110)
(726, 117)
(726, 118)
(726, 119)
(726, 134)
(726, 136)
(726, 137)
(726, 156)
(726, 165)
(726, 169)
(726, 182)
(726, 184)
(726, 189)
(726, 190)
(726, 191)
(726, 192)
(726, 199)
(726, 204)
(726, 218)
(726, 224)
(726, 230)
(726, 236)
(726, 238)
(726, 240)
(726, 244)
(726, 249)
(726, 253)
(726, 255)
(726, 257)
(726, 266)
(726, 267)
(726, 279)
(726, 282)
(726, 299)
(726, 310)
(726, 314)
(726, 315)
(726, 319)
(726, 321)
(726, 322)
(726, 331)
(726, 336)
(726, 339)
(726, 344)
(726, 374)
(726, 377)
(726, 398)
(726, 406)
(726, 419)
(726, 420)
(726, 424)
(726, 429)
(726, 441)
(726, 446)
(726, 447)
(726, 462)
(726, 468)
(726, 475)
(726, 499)
(726, 508)
(726, 510)
(726, 514)
(726, 516)
(726, 527)
(726, 545)
(726, 554)
(726, 555)
(726, 556)
(726, 557)
(726, 566)
(726, 589)
(726, 590)
(726, 593)
(726, 604)
(726, 608)
(726, 610)
(726, 618)
(726, 620)
(726, 625)
(726, 626)
(726, 629)
(726, 640)
(726, 649)
(726, 657)
(726, 665)
(726, 681)
(726, 687)
(726, 691)
(726, 693)
(726, 701)
(726, 702)
(726, 717)
(727, 257)
(727, 321)
(728, 4)
(728, 36)
(728, 104)
(728, 107)
(728, 169)
(728, 192)
(728, 199)
(728, 238)
(728, 257)
(728, 282)
(728, 299)
(728, 321)
(728, 441)
(728, 516)
(728, 545)
(728, 589)
(728, 590)
(728, 681)
(728, 726)
(729, 192)
(729, 257)
(729, 300)
(729, 321)
(729, 385)
(729, 420)
(729, 491)
(729, 514)
(729, 516)
(729, 523)
(729, 549)
(729, 576)
(729, 577)
(729, 582)
(729, 637)
(729, 658)
(730, 1)
(730, 28)
(730, 37)
(730, 42)
(730, 51)
(730, 71)
(730, 88)
(730, 90)
(730, 104)
(730, 134)
(730, 156)
(730, 182)
(730, 192)
(730, 224)
(730, 230)
(730, 253)
(730, 267)
(730, 282)
(730, 299)
(730, 315)
(730, 336)
(730, 419)
(730, 424)
(730, 458)
(730, 475)
(730, 499)
(730, 510)
(730, 514)
(730, 572)
(730, 589)
(730, 590)
(730, 632)
(730, 681)
(730, 687)
(730, 702)
(731, 257)
(731, 321)
(731, 516)
(732, 1)
(732, 4)
(732, 17)
(732, 18)
(732, 25)
(732, 27)
(732, 28)
(732, 37)
(732, 51)
(732, 71)
(732, 82)
(732, 85)
(732, 96)
(732, 104)
(732, 110)
(732, 111)
(732, 126)
(732, 129)
(732, 134)
(732, 162)
(732, 173)
(732, 175)
(732, 177)
(732, 182)
(732, 184)
(732, 190)
(732, 192)
(732, 199)
(732, 218)
(732, 224)
(732, 228)
(732, 240)
(732, 248)
(732, 253)
(732, 257)
(732, 266)
(732, 267)
(732, 282)
(732, 299)
(732, 300)
(732, 321)
(732, 322)
(732, 336)
(732, 348)
(732, 374)
(732, 387)
(732, 398)
(732, 419)
(732, 420)
(732, 432)
(732, 460)
(732, 467)
(732, 475)
(732, 482)
(732, 485)
(732, 489)
(732, 491)
(732, 499)
(732, 510)
(732, 514)
(732, 523)
(732, 527)
(732, 528)
(732, 545)
(732, 546)
(732, 554)
(732, 556)
(732, 582)
(732, 589)
(732, 590)
(732, 593)
(732, 608)
(732, 610)
(732, 624)
(732, 626)
(732, 629)
(732, 632)
(732, 636)
(732, 640)
(732, 649)
(732, 665)
(732, 681)
(732, 687)
(732, 691)
(732, 693)
(732, 702)
(732, 719)
(732, 726)
(733, 25)
(733, 36)
(733, 50)
(733, 129)
(733, 257)
(733, 300)
(733, 321)
(733, 387)
(733, 420)
(733, 491)
(733, 516)
(733, 608)
(733, 624)
(733, 701)
(734, 13)
(734, 104)
(734, 113)
(734, 210)
(734, 212)
(734, 495)
(735, 1)
(735, 28)
(735, 51)
(735, 71)
(735, 90)
(735, 104)
(735, 182)
(735, 224)
(735, 240)
(735, 267)
(735, 282)
(735, 336)
(735, 366)
(735, 458)
(735, 514)
(735, 589)
(735, 590)
(735, 687)
(736, 104)
(736, 282)
(737, 1)
(737, 4)
(737, 8)
(737, 18)
(737, 22)
(737, 27)
(737, 28)
(737, 32)
(737, 37)
(737, 39)
(737, 51)
(737, 71)
(737, 80)
(737, 85)
(737, 87)
(737, 88)
(737, 90)
(737, 96)
(737, 104)
(737, 111)
(737, 114)
(737, 124)
(737, 126)
(737, 128)
(737, 134)
(737, 156)
(737, 162)
(737, 172)
(737, 182)
(737, 184)
(737, 192)
(737, 194)
(737, 199)
(737, 202)
(737, 208)
(737, 218)
(737, 224)
(737, 228)
(737, 230)
(737, 240)
(737, 249)
(737, 253)
(737, 255)
(737, 259)
(737, 266)
(737, 267)
(737, 268)
(737, 270)
(737, 282)
(737, 287)
(737, 299)
(737, 308)
(737, 310)
(737, 315)
(737, 336)
(737, 340)
(737, 344)
(737, 363)
(737, 383)
(737, 390)
(737, 395)
(737, 401)
(737, 419)
(737, 421)
(737, 422)
(737, 424)
(737, 432)
(737, 446)
(737, 458)
(737, 467)
(737, 471)
(737, 475)
(737, 476)
(737, 484)
(737, 488)
(737, 489)
(737, 497)
(737, 499)
(737, 501)
(737, 510)
(737, 514)
(737, 515)
(737, 527)
(737, 535)
(737, 547)
(737, 550)
(737, 553)
(737, 556)
(737, 561)
(737, 572)
(737, 586)
(737, 589)
(737, 590)
(737, 593)
(737, 610)
(737, 618)
(737, 632)
(737, 640)
(737, 649)
(737, 665)
(737, 667)
(737, 681)
(737, 687)
(737, 691)
(737, 693)
(737, 694)
(737, 698)
(737, 702)
(737, 726)
(737, 730)
(737, 732)
(738, 104)
(739, 4)
(739, 104)
(739, 192)
(739, 238)
(739, 282)
(739, 299)
(739, 475)
(739, 545)
(739, 589)
(739, 590)
(739, 687)
(739, 726)
(740, 4)
(740, 15)
(740, 18)
(740, 25)
(740, 28)
(740, 37)
(740, 50)
(740, 51)
(740, 71)
(740, 85)
(740, 90)
(740, 104)
(740, 110)
(740, 129)
(740, 134)
(740, 156)
(740, 182)
(740, 192)
(740, 199)
(740, 224)
(740, 240)
(740, 253)
(740, 266)
(740, 267)
(740, 282)
(740, 299)
(740, 321)
(740, 336)
(740, 339)
(740, 387)
(740, 398)
(740, 419)
(740, 489)
(740, 491)
(740, 514)
(740, 527)
(740, 546)
(740, 589)
(740, 590)
(740, 593)
(740, 608)
(740, 624)
(740, 640)
(740, 649)
(740, 681)
(740, 687)
(740, 702)
(740, 719)
(740, 732)
(740, 737)
(741, 82)
(741, 169)
(741, 175)
(741, 190)
(741, 192)
(741, 257)
(741, 267)
(741, 282)
(741, 321)
(741, 485)
(741, 516)
(741, 582)
(741, 589)
(741, 590)
(741, 649)
(741, 681)
(742, 335)
(743, 192)
(743, 671)
(744, 257)
(745, 257)
(745, 321)
(746, 15)
(746, 28)
(746, 37)
(746, 104)
(746, 224)
(746, 253)
(746, 282)
(746, 299)
(746, 300)
(746, 321)
(746, 484)
(746, 491)
(746, 589)
(746, 593)
(746, 640)
(747, 4)
(747, 15)
(747, 25)
(747, 28)
(747, 51)
(747, 66)
(747, 71)
(747, 90)
(747, 104)
(747, 165)
(747, 182)
(747, 192)
(747, 194)
(747, 230)
(747, 240)
(747, 244)
(747, 253)
(747, 266)
(747, 267)
(747, 282)
(747, 292)
(747, 299)
(747, 315)
(747, 319)
(747, 336)
(747, 366)
(747, 415)
(747, 419)
(747, 424)
(747, 434)
(747, 458)
(747, 488)
(747, 490)
(747, 491)
(747, 514)
(747, 538)
(747, 546)
(747, 550)
(747, 589)
(747, 590)
(747, 593)
(747, 681)
(747, 687)
(747, 702)
(747, 719)
(748, 1)
(748, 4)
(748, 8)
(748, 15)
(748, 28)
(748, 37)
(748, 39)
(748, 51)
(748, 66)
(748, 71)
(748, 85)
(748, 90)
(748, 104)
(748, 111)
(748, 114)
(748, 124)
(748, 128)
(748, 156)
(748, 165)
(748, 176)
(748, 182)
(748, 184)
(748, 192)
(748, 194)
(748, 218)
(748, 224)
(748, 230)
(748, 244)
(748, 253)
(748, 256)
(748, 266)
(748, 267)
(748, 282)
(748, 287)
(748, 299)
(748, 310)
(748, 315)
(748, 320)
(748, 327)
(748, 335)
(748, 336)
(748, 344)
(748, 415)
(748, 419)
(748, 424)
(748, 432)
(748, 452)
(748, 458)
(748, 471)
(748, 475)
(748, 476)
(748, 484)
(748, 488)
(748, 489)
(748, 497)
(748, 499)
(748, 510)
(748, 514)
(748, 527)
(748, 547)
(748, 550)
(748, 572)
(748, 589)
(748, 590)
(748, 593)
(748, 618)
(748, 630)
(748, 632)
(748, 640)
(748, 674)
(748, 681)
(748, 687)
(748, 694)
(748, 702)
(748, 730)
(748, 737)
(748, 747)
(749, 257)
(749, 321)
(749, 516)
(749, 701)
(750, 25)
(750, 321)
(750, 638)
(750, 701)
(751, 257)
(751, 321)
(751, 516)
(751, 671)
(752, 23)
(752, 82)
(752, 119)
(752, 129)
(752, 144)
(752, 151)
(752, 169)
(752, 190)
(752, 257)
(752, 300)
(752, 316)
(752, 321)
(752, 322)
(752, 361)
(752, 373)
(752, 374)
(752, 377)
(752, 420)
(752, 441)
(752, 469)
(752, 485)
(752, 516)
(752, 528)
(752, 533)
(752, 566)
(752, 570)
(752, 577)
(752, 582)
(752, 585)
(752, 588)
(752, 589)
(752, 604)
(752, 623)
(752, 624)
(752, 626)
(752, 629)
(752, 633)
(752, 657)
(752, 671)
(752, 700)
(752, 701)
(753, 15)
(753, 104)
(753, 282)
(755, 129)
(755, 267)
(755, 282)
(755, 491)
(755, 514)
(755, 719)
(757, 60)
(757, 79)
(757, 94)
(757, 104)
(757, 192)
(757, 236)
(757, 257)
(757, 294)
(757, 313)
(757, 321)
(757, 339)
(757, 385)
(757, 420)
(757, 447)
(757, 469)
(757, 516)
(757, 577)
(757, 604)
(757, 657)
(757, 671)
(757, 701)
(758, 104)
(758, 192)
(758, 299)
(758, 698)
(759, 192)
(759, 321)
(759, 491)
(759, 546)
(760, 60)
(760, 604)
(760, 671)
(763, 282)
(763, 491)
(763, 658)
(764, 104)
(765, 1)
(765, 28)
(765, 37)
(765, 51)
(765, 71)
(765, 90)
(765, 104)
(765, 182)
(765, 240)
(765, 253)
(765, 267)
(765, 282)
(765, 299)
(765, 315)
(765, 336)
(765, 366)
(765, 419)
(765, 458)
(765, 488)
(765, 491)
(765, 514)
(765, 550)
(765, 589)
(765, 593)
(765, 687)
(766, 104)
(766, 282)
(769, 1)
(769, 4)
(769, 18)
(769, 25)
(769, 36)
(769, 51)
(769, 71)
(769, 82)
(769, 96)
(769, 104)
(769, 110)
(769, 117)
(769, 129)
(769, 134)
(769, 173)
(769, 182)
(769, 184)
(769, 190)
(769, 192)
(769, 218)
(769, 224)
(769, 238)
(769, 239)
(769, 240)
(769, 248)
(769, 257)
(769, 282)
(769, 289)
(769, 300)
(769, 314)
(769, 321)
(769, 322)
(769, 331)
(769, 336)
(769, 339)
(769, 377)
(769, 390)
(769, 398)
(769, 420)
(769, 441)
(769, 447)
(769, 457)
(769, 482)
(769, 485)
(769, 491)
(769, 499)
(769, 510)
(769, 514)
(769, 516)
(769, 523)
(769, 527)
(769, 528)
(769, 545)
(769, 549)
(769, 577)
(769, 582)
(769, 589)
(769, 590)
(769, 608)
(769, 610)
(769, 626)
(769, 629)
(769, 634)
(769, 640)
(769, 649)
(769, 657)
(769, 658)
(769, 665)
(769, 681)
(769, 687)
(769, 691)
(769, 700)
(769, 701)
(769, 702)
(769, 726)
(769, 729)
(769, 732)
(770, 104)
(771, 25)
(771, 321)
(772, 4)
(772, 28)
(772, 71)
(772, 104)
(772, 136)
(772, 192)
(772, 240)
(772, 244)
(772, 267)
(772, 282)
(772, 299)
(772, 321)
(772, 336)
(772, 339)
(772, 419)
(772, 491)
(772, 514)
(772, 527)
(772, 546)
(772, 589)
(772, 590)
(772, 593)
(772, 608)
(772, 658)
(773, 638)
(774, 104)
(775, 282)
(776, 1)
(776, 4)
(776, 37)
(776, 39)
(776, 51)
(776, 71)
(776, 85)
(776, 104)
(776, 118)
(776, 134)
(776, 136)
(776, 156)
(776, 165)
(776, 182)
(776, 184)
(776, 192)
(776, 199)
(776, 204)
(776, 218)
(776, 224)
(776, 230)
(776, 236)
(776, 240)
(776, 244)
(776, 253)
(776, 266)
(776, 267)
(776, 282)
(776, 299)
(776, 310)
(776, 336)
(776, 339)
(776, 406)
(776, 475)
(776, 489)
(776, 496)
(776, 499)
(776, 514)
(776, 545)
(776, 555)
(776, 572)
(776, 589)
(776, 590)
(776, 604)
(776, 618)
(776, 633)
(776, 657)
(776, 681)
(776, 687)
(776, 691)
(776, 702)
(776, 726)
(776, 737)
(778, 59)
(778, 264)
(778, 451)
(779, 25)
(779, 82)
(779, 129)
(779, 257)
(779, 300)
(779, 321)
(779, 420)
(779, 485)
(779, 491)
(779, 516)
(779, 582)
(779, 624)
(779, 701)
(780, 4)
(780, 15)
(780, 28)
(780, 37)
(780, 51)
(780, 66)
(780, 71)
(780, 90)
(780, 104)
(780, 129)
(780, 136)
(780, 156)
(780, 165)
(780, 182)
(780, 192)
(780, 194)
(780, 230)
(780, 240)
(780, 244)
(780, 253)
(780, 266)
(780, 267)
(780, 282)
(780, 292)
(780, 299)
(780, 315)
(780, 319)
(780, 336)
(780, 340)
(780, 382)
(780, 415)
(780, 419)
(780, 424)
(780, 434)
(780, 458)
(780, 488)
(780, 491)
(780, 514)
(780, 538)
(780, 546)
(780, 550)
(780, 589)
(780, 590)
(780, 593)
(780, 630)
(780, 632)
(780, 649)
(780, 674)
(780, 687)
(780, 698)
(780, 702)
(780, 747)
(780, 748)
(780, 772)
(781, 1)
(781, 4)
(781, 15)
(781, 28)
(781, 37)
(781, 51)
(781, 71)
(781, 85)
(781, 96)
(781, 104)
(781, 129)
(781, 134)
(781, 182)
(781, 184)
(781, 192)
(781, 199)
(781, 224)
(781, 240)
(781, 253)
(781, 266)
(781, 267)
(781, 282)
(781, 299)
(781, 321)
(781, 336)
(781, 419)
(781, 458)
(781, 475)
(781, 484)
(781, 489)
(781, 491)
(781, 499)
(781, 514)
(781, 527)
(781, 550)
(781, 572)
(781, 589)
(781, 590)
(781, 593)
(781, 608)
(781, 610)
(781, 632)
(781, 640)
(781, 649)
(781, 667)
(781, 681)
(781, 687)
(781, 702)
(781, 719)
(781, 732)
(782, 23)
(782, 36)
(782, 60)
(782, 69)
(782, 82)
(782, 119)
(782, 151)
(782, 190)
(782, 229)
(782, 236)
(782, 238)
(782, 257)
(782, 294)
(782, 316)
(782, 321)
(782, 420)
(782, 441)
(782, 447)
(782, 485)
(782, 516)
(782, 522)
(782, 528)
(782, 566)
(782, 577)
(782, 582)
(782, 588)
(782, 604)
(782, 620)
(782, 623)
(782, 624)
(782, 657)
(782, 671)
(782, 700)
(782, 701)
(782, 752)
(783, 104)
(783, 124)
(783, 282)
(783, 491)
(783, 514)
(783, 546)
(784, 4)
(784, 51)
(784, 71)
(784, 104)
(784, 192)
(784, 199)
(784, 282)
(784, 299)
(784, 336)
(784, 419)
(784, 475)
(784, 514)
(784, 589)
(784, 590)
(784, 681)
(784, 687)
(784, 702)
(784, 726)
(785, 82)
(785, 129)
(785, 144)
(785, 257)
(785, 300)
(785, 321)
(785, 374)
(785, 485)
(785, 528)
(785, 582)
(785, 623)
(785, 701)
(785, 702)
(786, 104)
(786, 175)
(786, 180)
(786, 192)
(786, 282)
(786, 321)
(786, 335)
(786, 341)
(786, 372)
(786, 424)
(786, 577)
(786, 729)
(786, 757)
(786, 769)
(787, 282)
(788, 15)
(788, 90)
(788, 207)
(788, 267)
(788, 282)
(788, 458)
(788, 514)
(789, 22)
(789, 104)
(789, 124)
(789, 491)
(789, 643)
(790, 82)
(790, 257)
(790, 321)
(790, 373)
(790, 485)
(790, 516)
(790, 582)
(790, 701)
(791, 257)
(793, 25)
(793, 28)
(793, 66)
(793, 71)
(793, 90)
(793, 104)
(793, 124)
(793, 129)
(793, 170)
(793, 175)
(793, 182)
(793, 240)
(793, 267)
(793, 282)
(793, 292)
(793, 315)
(793, 319)
(793, 321)
(793, 335)
(793, 336)
(793, 341)
(793, 348)
(793, 382)
(793, 419)
(793, 424)
(793, 432)
(793, 488)
(793, 489)
(793, 490)
(793, 491)
(793, 514)
(793, 546)
(793, 590)
(793, 593)
(793, 624)
(793, 630)
(793, 674)
(793, 703)
(793, 780)
(794, 257)
(794, 300)
(794, 321)
(794, 491)
(794, 516)
(795, 321)
(796, 36)
(796, 82)
(796, 129)
(796, 190)
(796, 257)
(796, 300)
(796, 321)
(796, 420)
(796, 485)
(796, 516)
(796, 523)
(796, 528)
(796, 566)
(796, 582)
(796, 589)
(796, 649)
(796, 701)
(797, 175)
(797, 341)
(798, 4)
(798, 36)
(798, 60)
(798, 192)
(798, 257)
(798, 321)
(798, 555)
(798, 589)
(798, 604)
(799, 25)
(799, 104)
(799, 192)
(799, 240)
(799, 257)
(799, 267)
(799, 282)
(799, 321)
(799, 514)
(799, 589)
(799, 590)
(800, 4)
(800, 25)
(800, 36)
(800, 51)
(800, 71)
(800, 82)
(800, 104)
(800, 118)
(800, 129)
(800, 169)
(800, 175)
(800, 192)
(800, 199)
(800, 236)
(800, 240)
(800, 244)
(800, 253)
(800, 257)
(800, 267)
(800, 282)
(800, 300)
(800, 321)
(800, 339)
(800, 361)
(800, 374)
(800, 398)
(800, 420)
(800, 485)
(800, 491)
(800, 514)
(800, 516)
(800, 527)
(800, 528)
(800, 545)
(800, 557)
(800, 582)
(800, 589)
(800, 590)
(800, 604)
(800, 608)
(800, 624)
(800, 626)
(800, 649)
(800, 657)
(800, 681)
(800, 702)
(801, 104)
(801, 124)
(801, 282)
(801, 321)
(802, 1)
(802, 4)
(802, 36)
(802, 39)
(802, 104)
(802, 107)
(802, 169)
(802, 178)
(802, 184)
(802, 192)
(802, 199)
(802, 224)
(802, 238)
(802, 257)
(802, 267)
(802, 282)
(802, 299)
(802, 321)
(802, 339)
(802, 441)
(802, 516)
(802, 527)
(802, 545)
(802, 582)
(802, 589)
(802, 590)
(802, 640)
(802, 681)
(802, 691)
(802, 702)
(802, 726)
(802, 728)
(802, 769)
(802, 776)
(803, 51)
(803, 104)
(803, 182)
(803, 253)
(803, 267)
(803, 282)
(803, 299)
(803, 336)
(803, 484)
(803, 514)
(803, 589)
(804, 4)
(804, 51)
(804, 71)
(804, 82)
(804, 104)
(804, 182)
(804, 184)
(804, 192)
(804, 199)
(804, 224)
(804, 240)
(804, 253)
(804, 257)
(804, 267)
(804, 282)
(804, 299)
(804, 321)
(804, 336)
(804, 339)
(804, 514)
(804, 545)
(804, 589)
(804, 590)
(804, 608)
(804, 681)
(804, 702)
(804, 719)
(804, 776)
(805, 13)
(805, 56)
(805, 210)
(805, 212)
(805, 277)
(805, 411)
(805, 627)
(805, 643)
(805, 650)
(805, 734)
(806, 82)
(806, 257)
(806, 321)
(806, 485)
(806, 528)
(806, 582)
(806, 589)
(806, 700)
(806, 701)
(806, 702)
(807, 257)
(808, 4)
(808, 28)
(808, 37)
(808, 39)
(808, 51)
(808, 71)
(808, 104)
(808, 134)
(808, 136)
(808, 173)
(808, 175)
(808, 182)
(808, 184)
(808, 192)
(808, 199)
(808, 224)
(808, 240)
(808, 248)
(808, 253)
(808, 257)
(808, 267)
(808, 282)
(808, 299)
(808, 300)
(808, 321)
(808, 336)
(808, 339)
(808, 441)
(808, 475)
(808, 491)
(808, 510)
(808, 514)
(808, 516)
(808, 527)
(808, 545)
(808, 589)
(808, 590)
(808, 608)
(808, 610)
(808, 640)
(808, 649)
(808, 665)
(808, 681)
(808, 687)
(808, 726)
(808, 769)
(808, 772)
(809, 1)
(809, 28)
(809, 37)
(809, 51)
(809, 71)
(809, 90)
(809, 104)
(809, 182)
(809, 224)
(809, 230)
(809, 240)
(809, 282)
(809, 292)
(809, 299)
(809, 336)
(809, 419)
(809, 499)
(809, 510)
(809, 514)
(809, 589)
(809, 590)
(809, 681)
(809, 687)
(810, 104)
(810, 257)
(810, 282)
(810, 321)
(810, 516)
(811, 71)
(811, 104)
(811, 192)
(811, 230)
(811, 240)
(811, 282)
(811, 299)
(811, 419)
(811, 514)
(811, 546)
(811, 589)
(811, 590)
(811, 687)
(812, 4)
(812, 28)
(812, 46)
(812, 51)
(812, 90)
(812, 104)
(812, 182)
(812, 184)
(812, 192)
(812, 199)
(812, 224)
(812, 240)
(812, 257)
(812, 267)
(812, 282)
(812, 300)
(812, 308)
(812, 321)
(812, 339)
(812, 390)
(812, 441)
(812, 489)
(812, 490)
(812, 491)
(812, 514)
(812, 516)
(812, 527)
(812, 549)
(812, 582)
(812, 589)
(812, 590)
(812, 608)
(812, 610)
(812, 640)
(812, 658)
(812, 719)
(812, 729)
(812, 769)
(813, 104)
(813, 192)
(813, 257)
(813, 321)
(813, 577)
(813, 671)
(813, 757)
(813, 786)
(814, 4)
(814, 28)
(814, 104)
(814, 136)
(814, 175)
(814, 192)
(814, 199)
(814, 224)
(814, 257)
(814, 282)
(814, 299)
(814, 321)
(814, 514)
(814, 527)
(814, 545)
(814, 589)
(814, 590)
(814, 640)
(814, 649)
(814, 726)
(815, 4)
(815, 104)
(815, 192)
(815, 555)
(816, 25)
(816, 129)
(816, 267)
(816, 282)
(816, 300)
(816, 321)
(816, 387)
(816, 514)
(816, 589)
(816, 590)
(816, 702)
(818, 25)
(818, 170)
(818, 210)
(818, 292)
(818, 319)
(818, 434)
(818, 546)
(818, 643)
(819, 13)
(819, 277)
(819, 411)
(819, 627)
(819, 734)
(819, 805)
(820, 37)
(820, 39)
(820, 71)
(820, 104)
(820, 184)
(820, 282)
(820, 299)
(820, 336)
(820, 419)
(820, 475)
(820, 590)
(820, 687)
(821, 104)
(821, 282)
(822, 25)
(822, 46)
(822, 66)
(822, 124)
(822, 129)
(822, 169)
(822, 170)
(822, 175)
(822, 192)
(822, 240)
(822, 319)
(822, 321)
(822, 335)
(822, 341)
(822, 387)
(822, 398)
(822, 446)
(822, 491)
(822, 514)
(822, 546)
(822, 590)
(822, 624)
(822, 649)
(822, 651)
(822, 701)
(822, 702)
(822, 708)
(822, 793)
(823, 4)
(823, 10)
(823, 17)
(823, 18)
(823, 25)
(823, 28)
(823, 51)
(823, 66)
(823, 71)
(823, 82)
(823, 90)
(823, 96)
(823, 104)
(823, 129)
(823, 165)
(823, 169)
(823, 175)
(823, 182)
(823, 194)
(823, 224)
(823, 230)
(823, 240)
(823, 267)
(823, 282)
(823, 292)
(823, 299)
(823, 319)
(823, 321)
(823, 335)
(823, 336)
(823, 341)
(823, 348)
(823, 387)
(823, 398)
(823, 415)
(823, 419)
(823, 446)
(823, 467)
(823, 488)
(823, 491)
(823, 514)
(823, 527)
(823, 546)
(823, 589)
(823, 590)
(823, 593)
(823, 608)
(823, 624)
(823, 640)
(823, 649)
(823, 674)
(823, 681)
(823, 687)
(823, 702)
(823, 732)
(823, 747)
(823, 793)
(823, 822)
(824, 1)
(824, 4)
(824, 15)
(824, 27)
(824, 28)
(824, 37)
(824, 39)
(824, 51)
(824, 71)
(824, 90)
(824, 104)
(824, 172)
(824, 182)
(824, 184)
(824, 192)
(824, 199)
(824, 224)
(824, 253)
(824, 266)
(824, 267)
(824, 282)
(824, 299)
(824, 315)
(824, 336)
(824, 419)
(824, 458)
(824, 475)
(824, 484)
(824, 499)
(824, 514)
(824, 550)
(824, 589)
(824, 590)
(824, 593)
(824, 608)
(824, 610)
(824, 618)
(824, 640)
(824, 681)
(824, 687)
(824, 702)
(824, 719)
(827, 4)
(827, 51)
(827, 104)
(827, 192)
(827, 199)
(827, 257)
(827, 267)
(827, 282)
(827, 300)
(827, 321)
(827, 339)
(827, 514)
(827, 589)
(827, 590)
(827, 640)
(827, 681)
(827, 702)
(828, 1)
(828, 4)
(828, 10)
(828, 15)
(828, 25)
(828, 28)
(828, 37)
(828, 40)
(828, 46)
(828, 50)
(828, 51)
(828, 66)
(828, 67)
(828, 71)
(828, 77)
(828, 85)
(828, 88)
(828, 90)
(828, 104)
(828, 110)
(828, 120)
(828, 129)
(828, 156)
(828, 165)
(828, 170)
(828, 175)
(828, 182)
(828, 192)
(828, 194)
(828, 199)
(828, 200)
(828, 207)
(828, 211)
(828, 224)
(828, 240)
(828, 243)
(828, 244)
(828, 253)
(828, 266)
(828, 267)
(828, 282)
(828, 292)
(828, 303)
(828, 315)
(828, 319)
(828, 321)
(828, 336)
(828, 348)
(828, 363)
(828, 366)
(828, 369)
(828, 376)
(828, 380)
(828, 382)
(828, 384)
(828, 387)
(828, 414)
(828, 415)
(828, 419)
(828, 424)
(828, 432)
(828, 439)
(828, 458)
(828, 467)
(828, 471)
(828, 488)
(828, 489)
(828, 490)
(828, 491)
(828, 499)
(828, 514)
(828, 527)
(828, 534)
(828, 538)
(828, 546)
(828, 550)
(828, 563)
(828, 572)
(828, 576)
(828, 589)
(828, 590)
(828, 593)
(828, 608)
(828, 610)
(828, 613)
(828, 618)
(828, 622)
(828, 624)
(828, 630)
(828, 632)
(828, 640)
(828, 649)
(828, 658)
(828, 673)
(828, 674)
(828, 678)
(828, 681)
(828, 687)
(828, 693)
(828, 694)
(828, 702)
(828, 703)
(828, 719)
(828, 730)
(828, 732)
(828, 740)
(828, 747)
(828, 748)
(828, 765)
(828, 780)
(828, 781)
(828, 793)
(828, 812)
(828, 823)
(828, 824)
(829, 59)
(829, 264)
(829, 334)
(829, 444)
(829, 451)
(829, 707)
(829, 778)
(830, 257)
(830, 294)
(830, 316)
(830, 671)
(832, 1)
(832, 4)
(832, 15)
(832, 22)
(832, 27)
(832, 28)
(832, 32)
(832, 37)
(832, 39)
(832, 51)
(832, 66)
(832, 71)
(832, 80)
(832, 87)
(832, 90)
(832, 93)
(832, 96)
(832, 104)
(832, 111)
(832, 114)
(832, 123)
(832, 126)
(832, 128)
(832, 133)
(832, 134)
(832, 156)
(832, 162)
(832, 165)
(832, 172)
(832, 182)
(832, 184)
(832, 191)
(832, 192)
(832, 194)
(832, 199)
(832, 208)
(832, 218)
(832, 224)
(832, 230)
(832, 240)
(832, 242)
(832, 249)
(832, 253)
(832, 254)
(832, 256)
(832, 259)
(832, 266)
(832, 267)
(832, 268)
(832, 270)
(832, 282)
(832, 287)
(832, 290)
(832, 299)
(832, 308)
(832, 310)
(832, 315)
(832, 320)
(832, 335)
(832, 336)
(832, 340)
(832, 344)
(832, 363)
(832, 382)
(832, 389)
(832, 395)
(832, 401)
(832, 413)
(832, 416)
(832, 419)
(832, 421)
(832, 424)
(832, 432)
(832, 446)
(832, 452)
(832, 458)
(832, 471)
(832, 475)
(832, 476)
(832, 484)
(832, 488)
(832, 489)
(832, 497)
(832, 499)
(832, 501)
(832, 510)
(832, 514)
(832, 515)
(832, 527)
(832, 535)
(832, 538)
(832, 547)
(832, 550)
(832, 553)
(832, 561)
(832, 572)
(832, 586)
(832, 589)
(832, 590)
(832, 593)
(832, 610)
(832, 611)
(832, 618)
(832, 632)
(832, 665)
(832, 667)
(832, 674)
(832, 681)
(832, 687)
(832, 689)
(832, 691)
(832, 692)
(832, 694)
(832, 698)
(832, 702)
(832, 726)
(832, 730)
(832, 737)
(832, 747)
(832, 748)
(832, 765)
(832, 776)
(832, 780)
(832, 809)
(832, 820)
(832, 823)
(834, 1)
(834, 4)
(834, 15)
(834, 19)
(834, 21)
(834, 22)
(834, 27)
(834, 28)
(834, 32)
(834, 37)
(834, 39)
(834, 51)
(834, 66)
(834, 71)
(834, 80)
(834, 85)
(834, 88)
(834, 90)
(834, 93)
(834, 96)
(834, 104)
(834, 111)
(834, 114)
(834, 126)
(834, 128)
(834, 133)
(834, 134)
(834, 152)
(834, 156)
(834, 162)
(834, 172)
(834, 175)
(834, 182)
(834, 184)
(834, 192)
(834, 194)
(834, 199)
(834, 208)
(834, 218)
(834, 224)
(834, 228)
(834, 230)
(834, 240)
(834, 242)
(834, 248)
(834, 253)
(834, 256)
(834, 259)
(834, 266)
(834, 267)
(834, 268)
(834, 282)
(834, 287)
(834, 299)
(834, 310)
(834, 315)
(834, 320)
(834, 335)
(834, 336)
(834, 340)
(834, 344)
(834, 348)
(834, 360)
(834, 363)
(834, 379)
(834, 401)
(834, 413)
(834, 415)
(834, 419)
(834, 421)
(834, 424)
(834, 432)
(834, 452)
(834, 458)
(834, 467)
(834, 471)
(834, 475)
(834, 476)
(834, 477)
(834, 484)
(834, 488)
(834, 489)
(834, 497)
(834, 499)
(834, 501)
(834, 509)
(834, 510)
(834, 514)
(834, 515)
(834, 527)
(834, 532)
(834, 534)
(834, 535)
(834, 547)
(834, 550)
(834, 553)
(834, 561)
(834, 572)
(834, 586)
(834, 589)
(834, 590)
(834, 593)
(834, 601)
(834, 608)
(834, 610)
(834, 611)
(834, 618)
(834, 630)
(834, 632)
(834, 640)
(834, 667)
(834, 674)
(834, 678)
(834, 681)
(834, 687)
(834, 691)
(834, 693)
(834, 694)
(834, 698)
(834, 702)
(834, 719)
(834, 730)
(834, 732)
(834, 735)
(834, 737)
(834, 748)
(834, 765)
(834, 780)
(834, 781)
(834, 824)
(834, 828)
(834, 832)
(835, 319)
(835, 389)
(835, 491)
(836, 1)
(836, 4)
(836, 15)
(836, 28)
(836, 37)
(836, 39)
(836, 51)
(836, 66)
(836, 71)
(836, 90)
(836, 104)
(836, 129)
(836, 182)
(836, 184)
(836, 192)
(836, 199)
(836, 224)
(836, 240)
(836, 248)
(836, 253)
(836, 259)
(836, 266)
(836, 267)
(836, 282)
(836, 299)
(836, 300)
(836, 321)
(836, 336)
(836, 348)
(836, 363)
(836, 390)
(836, 419)
(836, 458)
(836, 471)
(836, 475)
(836, 484)
(836, 488)
(836, 489)
(836, 491)
(836, 499)
(836, 510)
(836, 514)
(836, 527)
(836, 550)
(836, 589)
(836, 590)
(836, 593)
(836, 608)
(836, 610)
(836, 632)
(836, 640)
(836, 658)
(836, 665)
(836, 681)
(836, 687)
(836, 702)
(836, 719)
(836, 732)
(836, 781)
(836, 812)
(836, 828)
(836, 834)
(837, 1)
(837, 4)
(837, 27)
(837, 28)
(837, 37)
(837, 39)
(837, 46)
(837, 51)
(837, 71)
(837, 82)
(837, 96)
(837, 104)
(837, 126)
(837, 129)
(837, 182)
(837, 184)
(837, 192)
(837, 199)
(837, 224)
(837, 240)
(837, 253)
(837, 267)
(837, 282)
(837, 299)
(837, 300)
(837, 315)
(837, 321)
(837, 336)
(837, 401)
(837, 419)
(837, 458)
(837, 475)
(837, 488)
(837, 491)
(837, 499)
(837, 510)
(837, 514)
(837, 527)
(837, 550)
(837, 589)
(837, 590)
(837, 593)
(837, 606)
(837, 608)
(837, 610)
(837, 632)
(837, 640)
(837, 649)
(837, 665)
(837, 681)
(837, 687)
(837, 702)
(837, 719)
(837, 732)
(837, 769)
(837, 832)
(837, 834)
(838, 257)
(839, 104)
(839, 495)
(840, 4)
(840, 104)
(840, 257)
(840, 282)
(840, 299)
(840, 589)
(840, 590)
(840, 726)
(841, 4)
(841, 18)
(841, 25)
(841, 36)
(841, 46)
(841, 71)
(841, 82)
(841, 129)
(841, 192)
(841, 224)
(841, 240)
(841, 257)
(841, 282)
(841, 300)
(841, 321)
(841, 322)
(841, 331)
(841, 374)
(841, 377)
(841, 387)
(841, 398)
(841, 420)
(841, 441)
(841, 485)
(841, 491)
(841, 514)
(841, 516)
(841, 524)
(841, 528)
(841, 545)
(841, 546)
(841, 582)
(841, 589)
(841, 590)
(841, 608)
(841, 624)
(841, 629)
(841, 640)
(841, 649)
(841, 665)
(841, 681)
(841, 701)
(841, 702)
(841, 708)
(841, 726)
(841, 769)
(841, 822)
(842, 4)
(842, 10)
(842, 15)
(842, 17)
(842, 18)
(842, 25)
(842, 28)
(842, 30)
(842, 36)
(842, 46)
(842, 50)
(842, 51)
(842, 57)
(842, 60)
(842, 66)
(842, 67)
(842, 68)
(842, 71)
(842, 74)
(842, 75)
(842, 82)
(842, 85)
(842, 90)
(842, 92)
(842, 96)
(842, 97)
(842, 103)
(842, 104)
(842, 107)
(842, 108)
(842, 110)
(842, 117)
(842, 126)
(842, 129)
(842, 130)
(842, 132)
(842, 136)
(842, 137)
(842, 144)
(842, 165)
(842, 168)
(842, 169)
(842, 173)
(842, 175)
(842, 177)
(842, 179)
(842, 182)
(842, 184)
(842, 189)
(842, 190)
(842, 191)
(842, 192)
(842, 194)
(842, 195)
(842, 199)
(842, 205)
(842, 214)
(842, 224)
(842, 236)
(842, 238)
(842, 239)
(842, 240)
(842, 244)
(842, 248)
(842, 249)
(842, 253)
(842, 257)
(842, 266)
(842, 267)
(842, 271)
(842, 278)
(842, 279)
(842, 282)
(842, 289)
(842, 292)
(842, 295)
(842, 300)
(842, 304)
(842, 306)
(842, 313)
(842, 314)
(842, 319)
(842, 321)
(842, 322)
(842, 331)
(842, 336)
(842, 337)
(842, 338)
(842, 339)
(842, 340)
(842, 348)
(842, 353)
(842, 359)
(842, 361)
(842, 362)
(842, 366)
(842, 369)
(842, 373)
(842, 374)
(842, 376)
(842, 377)
(842, 379)
(842, 380)
(842, 381)
(842, 385)
(842, 387)
(842, 398)
(842, 399)
(842, 400)
(842, 402)
(842, 404)
(842, 405)
(842, 417)
(842, 420)
(842, 441)
(842, 447)
(842, 454)
(842, 455)
(842, 457)
(842, 460)
(842, 462)
(842, 464)
(842, 467)
(842, 469)
(842, 471)
(842, 472)
(842, 473)
(842, 474)
(842, 485)
(842, 488)
(842, 489)
(842, 490)
(842, 491)
(842, 496)
(842, 498)
(842, 503)
(842, 504)
(842, 508)
(842, 510)
(842, 511)
(842, 512)
(842, 513)
(842, 514)
(842, 516)
(842, 520)
(842, 523)
(842, 524)
(842, 527)
(842, 528)
(842, 538)
(842, 540)
(842, 541)
(842, 545)
(842, 546)
(842, 550)
(842, 554)
(842, 556)
(842, 557)
(842, 563)
(842, 566)
(842, 570)
(842, 571)
(842, 577)
(842, 579)
(842, 582)
(842, 585)
(842, 588)
(842, 589)
(842, 590)
(842, 593)
(842, 601)
(842, 603)
(842, 604)
(842, 606)
(842, 608)
(842, 610)
(842, 623)
(842, 624)
(842, 625)
(842, 626)
(842, 628)
(842, 629)
(842, 630)
(842, 632)
(842, 633)
(842, 634)
(842, 636)
(842, 638)
(842, 639)
(842, 640)
(842, 641)
(842, 649)
(842, 651)
(842, 657)
(842, 658)
(842, 665)
(842, 670)
(842, 671)
(842, 673)
(842, 680)
(842, 681)
(842, 684)
(842, 685)
(842, 687)
(842, 699)
(842, 701)
(842, 702)
(842, 706)
(842, 708)
(842, 715)
(842, 719)
(842, 726)
(842, 728)
(842, 729)
(842, 731)
(842, 732)
(842, 733)
(842, 740)
(842, 746)
(842, 747)
(842, 752)
(842, 757)
(842, 759)
(842, 769)
(842, 772)
(842, 779)
(842, 780)
(842, 781)
(842, 786)
(842, 793)
(842, 794)
(842, 796)
(842, 799)
(842, 800)
(842, 802)
(842, 804)
(842, 808)
(842, 812)
(842, 814)
(842, 816)
(842, 822)
(842, 823)
(842, 827)
(842, 828)
(842, 836)
(842, 837)
(842, 841)
(843, 4)
(843, 28)
(843, 33)
(843, 71)
(843, 104)
(843, 110)
(843, 118)
(843, 136)
(843, 156)
(843, 192)
(843, 204)
(843, 230)
(843, 236)
(843, 238)
(843, 244)
(843, 253)
(843, 266)
(843, 267)
(843, 282)
(843, 299)
(843, 319)
(843, 321)
(843, 336)
(843, 339)
(843, 406)
(843, 475)
(843, 514)
(843, 545)
(843, 546)
(843, 555)
(843, 589)
(843, 590)
(843, 604)
(843, 618)
(843, 620)
(843, 649)
(843, 681)
(843, 702)
(843, 726)
(844, 257)
(844, 701)
(845, 4)
(845, 25)
(845, 28)
(845, 104)
(845, 192)
(845, 224)
(845, 240)
(845, 282)
(845, 299)
(845, 300)
(845, 321)
(845, 491)
(845, 514)
(845, 589)
(845, 590)
(845, 608)
(845, 640)
(845, 649)
(845, 687)
(845, 726)
(845, 842)
(846, 321)
(847, 25)
(847, 240)
(847, 321)
(847, 490)
(847, 491)
(847, 638)
(847, 643)
(847, 842)
(848, 4)
(848, 10)
(848, 11)
(848, 15)
(848, 17)
(848, 18)
(848, 25)
(848, 36)
(848, 46)
(848, 50)
(848, 51)
(848, 68)
(848, 69)
(848, 71)
(848, 76)
(848, 82)
(848, 85)
(848, 96)
(848, 103)
(848, 104)
(848, 110)
(848, 124)
(848, 127)
(848, 129)
(848, 144)
(848, 150)
(848, 169)
(848, 173)
(848, 175)
(848, 177)
(848, 182)
(848, 184)
(848, 190)
(848, 192)
(848, 199)
(848, 224)
(848, 228)
(848, 239)
(848, 240)
(848, 248)
(848, 253)
(848, 257)
(848, 267)
(848, 271)
(848, 282)
(848, 300)
(848, 306)
(848, 321)
(848, 322)
(848, 336)
(848, 339)
(848, 341)
(848, 348)
(848, 359)
(848, 361)
(848, 362)
(848, 373)
(848, 374)
(848, 376)
(848, 377)
(848, 385)
(848, 387)
(848, 398)
(848, 404)
(848, 419)
(848, 420)
(848, 457)
(848, 460)
(848, 467)
(848, 469)
(848, 482)
(848, 485)
(848, 491)
(848, 512)
(848, 513)
(848, 514)
(848, 516)
(848, 520)
(848, 523)
(848, 524)
(848, 527)
(848, 528)
(848, 533)
(848, 534)
(848, 539)
(848, 546)
(848, 554)
(848, 556)
(848, 557)
(848, 582)
(848, 585)
(848, 589)
(848, 590)
(848, 604)
(848, 608)
(848, 610)
(848, 623)
(848, 624)
(848, 626)
(848, 629)
(848, 630)
(848, 634)
(848, 636)
(848, 638)
(848, 639)
(848, 640)
(848, 649)
(848, 654)
(848, 658)
(848, 665)
(848, 681)
(848, 684)
(848, 691)
(848, 693)
(848, 700)
(848, 701)
(848, 702)
(848, 718)
(848, 719)
(848, 732)
(848, 740)
(848, 741)
(848, 752)
(848, 769)
(848, 779)
(848, 781)
(848, 785)
(848, 796)
(848, 800)
(848, 804)
(848, 808)
(848, 812)
(848, 823)
(848, 827)
(848, 828)
(848, 836)
(848, 837)
(848, 841)
(848, 842)
(851, 1)
(851, 4)
(851, 15)
(851, 28)
(851, 36)
(851, 37)
(851, 51)
(851, 67)
(851, 71)
(851, 85)
(851, 90)
(851, 96)
(851, 103)
(851, 104)
(851, 107)
(851, 110)
(851, 111)
(851, 118)
(851, 126)
(851, 129)
(851, 134)
(851, 136)
(851, 137)
(851, 156)
(851, 158)
(851, 165)
(851, 170)
(851, 172)
(851, 175)
(851, 182)
(851, 184)
(851, 191)
(851, 192)
(851, 194)
(851, 199)
(851, 203)
(851, 204)
(851, 218)
(851, 224)
(851, 230)
(851, 240)
(851, 244)
(851, 253)
(851, 266)
(851, 267)
(851, 282)
(851, 299)
(851, 310)
(851, 315)
(851, 319)
(851, 321)
(851, 336)
(851, 339)
(851, 344)
(851, 382)
(851, 406)
(851, 419)
(851, 424)
(851, 432)
(851, 446)
(851, 458)
(851, 462)
(851, 471)
(851, 475)
(851, 484)
(851, 488)
(851, 489)
(851, 491)
(851, 499)
(851, 510)
(851, 514)
(851, 527)
(851, 538)
(851, 545)
(851, 546)
(851, 550)
(851, 555)
(851, 563)
(851, 572)
(851, 589)
(851, 590)
(851, 593)
(851, 608)
(851, 610)
(851, 618)
(851, 620)
(851, 630)
(851, 632)
(851, 640)
(851, 649)
(851, 681)
(851, 687)
(851, 698)
(851, 702)
(851, 719)
(851, 726)
(851, 737)
(851, 739)
(851, 740)
(851, 747)
(851, 748)
(851, 772)
(851, 776)
(851, 780)
(851, 824)
(851, 828)
(851, 832)
(851, 834)
(851, 842)
(851, 843)
(853, 22)
(853, 25)
(853, 335)
(853, 546)
(853, 643)
(853, 793)
(854, 4)
(854, 36)
(854, 82)
(854, 169)
(854, 238)
(854, 257)
(854, 282)
(854, 300)
(854, 321)
(854, 377)
(854, 420)
(854, 441)
(854, 485)
(854, 491)
(854, 516)
(854, 523)
(854, 527)
(854, 545)
(854, 566)
(854, 582)
(854, 589)
(854, 590)
(854, 634)
(854, 640)
(854, 649)
(854, 701)
(854, 726)
(854, 769)
(854, 808)
(854, 812)
(854, 842)
(854, 848)
(855, 240)
(855, 257)
(855, 282)
(855, 299)
(855, 321)
(855, 589)
(855, 590)
(855, 640)
(855, 649)
(855, 842)
(856, 39)
(856, 104)
(856, 192)
(856, 218)
(856, 282)
(856, 299)
(856, 475)
(856, 589)
(856, 590)
(857, 257)
(857, 321)
(857, 516)
(857, 701)
(858, 4)
(858, 10)
(858, 17)
(858, 25)
(858, 28)
(858, 36)
(858, 50)
(858, 51)
(858, 63)
(858, 68)
(858, 82)
(858, 85)
(858, 96)
(858, 103)
(858, 107)
(858, 110)
(858, 117)
(858, 129)
(858, 130)
(858, 132)
(858, 144)
(858, 165)
(858, 169)
(858, 173)
(858, 175)
(858, 177)
(858, 184)
(858, 189)
(858, 190)
(858, 199)
(858, 219)
(858, 224)
(858, 238)
(858, 240)
(858, 248)
(858, 253)
(858, 255)
(858, 257)
(858, 267)
(858, 271)
(858, 279)
(858, 282)
(858, 299)
(858, 300)
(858, 306)
(858, 321)
(858, 322)
(858, 325)
(858, 339)
(858, 362)
(858, 373)
(858, 374)
(858, 377)
(858, 387)
(858, 398)
(858, 404)
(858, 405)
(858, 417)
(858, 420)
(858, 441)
(858, 450)
(858, 457)
(858, 460)
(858, 464)
(858, 470)
(858, 482)
(858, 485)
(858, 490)
(858, 491)
(858, 498)
(858, 508)
(858, 512)
(858, 514)
(858, 516)
(858, 520)
(858, 523)
(858, 524)
(858, 527)
(858, 528)
(858, 533)
(858, 545)
(858, 554)
(858, 556)
(858, 557)
(858, 563)
(858, 566)
(858, 570)
(858, 579)
(858, 582)
(858, 585)
(858, 588)
(858, 589)
(858, 590)
(858, 593)
(858, 604)
(858, 608)
(858, 610)
(858, 623)
(858, 624)
(858, 625)
(858, 626)
(858, 629)
(858, 633)
(858, 634)
(858, 639)
(858, 640)
(858, 649)
(858, 658)
(858, 670)
(858, 685)
(858, 699)
(858, 701)
(858, 702)
(858, 719)
(858, 726)
(858, 732)
(858, 733)
(858, 740)
(858, 751)
(858, 752)
(858, 779)
(858, 781)
(858, 782)
(858, 785)
(858, 794)
(858, 795)
(858, 796)
(858, 800)
(858, 803)
(858, 804)
(858, 808)
(858, 812)
(858, 814)
(858, 823)
(858, 841)
(858, 842)
(858, 845)
(858, 848)
(858, 854)
(859, 4)
(859, 28)
(859, 36)
(859, 51)
(859, 60)
(859, 67)
(859, 71)
(859, 85)
(859, 104)
(859, 107)
(859, 110)
(859, 118)
(859, 129)
(859, 134)
(859, 136)
(859, 137)
(859, 156)
(859, 169)
(859, 175)
(859, 179)
(859, 182)
(859, 190)
(859, 191)
(859, 192)
(859, 199)
(859, 224)
(859, 230)
(859, 236)
(859, 238)
(859, 239)
(859, 240)
(859, 244)
(859, 253)
(859, 257)
(859, 266)
(859, 267)
(859, 282)
(859, 299)
(859, 319)
(859, 321)
(859, 336)
(859, 339)
(859, 374)
(859, 406)
(859, 419)
(859, 424)
(859, 429)
(859, 441)
(859, 462)
(859, 475)
(859, 489)
(859, 514)
(859, 527)
(859, 545)
(859, 546)
(859, 555)
(859, 563)
(859, 589)
(859, 590)
(859, 604)
(859, 618)
(859, 620)
(859, 624)
(859, 640)
(859, 649)
(859, 657)
(859, 681)
(859, 691)
(859, 702)
(859, 726)
(859, 776)
(859, 800)
(859, 802)
(859, 828)
(859, 842)
(859, 843)
(859, 851)
(859, 858)
(860, 25)
(860, 321)
(861, 687)
(862, 1)
(862, 4)
(862, 8)
(862, 10)
(862, 17)
(862, 18)
(862, 19)
(862, 22)
(862, 27)
(862, 28)
(862, 37)
(862, 39)
(862, 51)
(862, 53)
(862, 66)
(862, 67)
(862, 71)
(862, 82)
(862, 85)
(862, 88)
(862, 90)
(862, 96)
(862, 104)
(862, 110)
(862, 111)
(862, 118)
(862, 126)
(862, 129)
(862, 133)
(862, 134)
(862, 136)
(862, 156)
(862, 162)
(862, 165)
(862, 173)
(862, 175)
(862, 182)
(862, 184)
(862, 190)
(862, 191)
(862, 192)
(862, 194)
(862, 199)
(862, 203)
(862, 218)
(862, 224)
(862, 230)
(862, 236)
(862, 240)
(862, 242)
(862, 244)
(862, 248)
(862, 253)
(862, 255)
(862, 256)
(862, 259)
(862, 266)
(862, 267)
(862, 282)
(862, 289)
(862, 297)
(862, 299)
(862, 310)
(862, 315)
(862, 319)
(862, 321)
(862, 335)
(862, 336)
(862, 339)
(862, 340)
(862, 344)
(862, 348)
(862, 361)
(862, 363)
(862, 374)
(862, 389)
(862, 398)
(862, 401)
(862, 406)
(862, 419)
(862, 424)
(862, 432)
(862, 446)
(862, 462)
(862, 467)
(862, 471)
(862, 475)
(862, 484)
(862, 488)
(862, 489)
(862, 496)
(862, 499)
(862, 510)
(862, 514)
(862, 524)
(862, 527)
(862, 535)
(862, 545)
(862, 546)
(862, 547)
(862, 550)
(862, 553)
(862, 554)
(862, 555)
(862, 556)
(862, 563)
(862, 572)
(862, 589)
(862, 590)
(862, 593)
(862, 604)
(862, 608)
(862, 610)
(862, 611)
(862, 618)
(862, 625)
(862, 626)
(862, 629)
(862, 630)
(862, 632)
(862, 640)
(862, 649)
(862, 665)
(862, 667)
(862, 681)
(862, 687)
(862, 691)
(862, 693)
(862, 694)
(862, 698)
(862, 702)
(862, 719)
(862, 726)
(862, 730)
(862, 732)
(862, 737)
(862, 740)
(862, 741)
(862, 747)
(862, 748)
(862, 776)
(862, 780)
(862, 781)
(862, 793)
(862, 800)
(862, 804)
(862, 809)
(862, 811)
(862, 823)
(862, 828)
(862, 832)
(862, 834)
(862, 836)
(862, 837)
(862, 842)
(862, 843)
(862, 848)
(862, 851)
(862, 858)
(862, 859)
(863, 19)
(863, 66)
(863, 90)
(863, 104)
(863, 129)
(863, 169)
(863, 175)
(863, 267)
(863, 282)
(863, 321)
(863, 335)
(863, 341)
(863, 419)
(863, 514)
(863, 589)
(863, 590)
(863, 649)
(863, 702)
(863, 786)
(863, 793)
(863, 823)
(863, 842)
(863, 848)
(863, 862)
(865, 104)
(865, 257)
(865, 282)
(865, 589)
(865, 590)
(867, 70)
(867, 92)
(867, 170)
(867, 274)
(867, 277)
(867, 326)
(867, 342)
(867, 828)
(868, 25)
(868, 71)
(868, 129)
(868, 192)
(868, 240)
(868, 267)
(868, 282)
(868, 319)
(868, 321)
(868, 514)
(868, 546)
(868, 589)
(868, 590)
(868, 828)
(869, 4)
(869, 36)
(869, 136)
(869, 192)
(869, 236)
(869, 238)
(869, 257)
(869, 321)
(869, 441)
(869, 516)
(869, 582)
(869, 589)
(869, 590)
(869, 620)
(869, 624)
(869, 701)
(869, 726)
(869, 842)
(870, 4)
(870, 36)
(870, 51)
(870, 82)
(870, 104)
(870, 144)
(870, 169)
(870, 173)
(870, 189)
(870, 190)
(870, 238)
(870, 257)
(870, 282)
(870, 294)
(870, 300)
(870, 321)
(870, 322)
(870, 373)
(870, 374)
(870, 377)
(870, 398)
(870, 420)
(870, 441)
(870, 450)
(870, 482)
(870, 485)
(870, 516)
(870, 523)
(870, 527)
(870, 528)
(870, 557)
(870, 566)
(870, 570)
(870, 577)
(870, 582)
(870, 585)
(870, 588)
(870, 589)
(870, 590)
(870, 604)
(870, 623)
(870, 624)
(870, 626)
(870, 629)
(870, 639)
(870, 649)
(870, 670)
(870, 671)
(870, 700)
(870, 701)
(870, 718)
(870, 726)
(870, 752)
(870, 785)
(870, 796)
(870, 800)
(870, 842)
(870, 848)
(870, 858)
(870, 862)
(871, 74)
(871, 104)
(871, 128)
(871, 186)
(871, 257)
(871, 320)
(871, 452)
(871, 498)
(871, 626)
(871, 688)
(871, 701)
(871, 794)
(873, 4)
(873, 28)
(873, 37)
(873, 39)
(873, 67)
(873, 71)
(873, 104)
(873, 136)
(873, 156)
(873, 165)
(873, 176)
(873, 182)
(873, 184)
(873, 191)
(873, 192)
(873, 204)
(873, 218)
(873, 230)
(873, 253)
(873, 266)
(873, 282)
(873, 299)
(873, 315)
(873, 336)
(873, 344)
(873, 419)
(873, 424)
(873, 462)
(873, 475)
(873, 510)
(873, 514)
(873, 589)
(873, 590)
(873, 618)
(873, 632)
(873, 681)
(873, 687)
(873, 702)
(873, 726)
(873, 748)
(873, 832)
(873, 851)
(873, 862)
(874, 82)
(874, 129)
(874, 257)
(874, 321)
(874, 485)
(874, 528)
(874, 589)
(874, 702)
(874, 848)
(874, 858)
(875, 257)
(875, 300)
(875, 321)
(875, 701)
(877, 1)
(877, 4)
(877, 18)
(877, 25)
(877, 28)
(877, 37)
(877, 51)
(877, 71)
(877, 90)
(877, 96)
(877, 104)
(877, 110)
(877, 111)
(877, 126)
(877, 129)
(877, 134)
(877, 136)
(877, 156)
(877, 175)
(877, 182)
(877, 184)
(877, 192)
(877, 199)
(877, 224)
(877, 230)
(877, 240)
(877, 253)
(877, 266)
(877, 267)
(877, 282)
(877, 299)
(877, 315)
(877, 319)
(877, 321)
(877, 336)
(877, 340)
(877, 419)
(877, 432)
(877, 458)
(877, 475)
(877, 488)
(877, 491)
(877, 499)
(877, 510)
(877, 514)
(877, 527)
(877, 546)
(877, 556)
(877, 589)
(877, 590)
(877, 593)
(877, 608)
(877, 632)
(877, 640)
(877, 649)
(877, 665)
(877, 681)
(877, 687)
(877, 702)
(877, 726)
(877, 732)
(877, 737)
(877, 740)
(877, 780)
(877, 832)
(877, 842)
(877, 851)
(877, 862)
(878, 4)
(878, 28)
(878, 66)
(878, 71)
(878, 90)
(878, 104)
(878, 129)
(878, 136)
(878, 175)
(878, 182)
(878, 192)
(878, 230)
(878, 240)
(878, 244)
(878, 253)
(878, 266)
(878, 267)
(878, 282)
(878, 299)
(878, 319)
(878, 321)
(878, 336)
(878, 419)
(878, 475)
(878, 514)
(878, 527)
(878, 546)
(878, 589)
(878, 590)
(878, 618)
(878, 632)
(878, 649)
(878, 681)
(878, 687)
(878, 702)
(878, 726)
(878, 780)
(878, 828)
(878, 842)
(878, 851)
(878, 862)
(879, 1)
(879, 4)
(879, 18)
(879, 22)
(879, 27)
(879, 37)
(879, 51)
(879, 71)
(879, 82)
(879, 90)
(879, 96)
(879, 104)
(879, 124)
(879, 172)
(879, 175)
(879, 182)
(879, 184)
(879, 192)
(879, 194)
(879, 199)
(879, 224)
(879, 230)
(879, 240)
(879, 253)
(879, 267)
(879, 282)
(879, 299)
(879, 321)
(879, 335)
(879, 336)
(879, 363)
(879, 419)
(879, 424)
(879, 432)
(879, 458)
(879, 475)
(879, 484)
(879, 499)
(879, 514)
(879, 527)
(879, 572)
(879, 589)
(879, 590)
(879, 610)
(879, 640)
(879, 649)
(879, 681)
(879, 687)
(879, 702)
(879, 732)
(879, 737)
(879, 823)
(879, 832)
(879, 834)
(879, 842)
(879, 848)
(879, 862)
(879, 877)
(880, 4)
(880, 25)
(880, 36)
(880, 50)
(880, 60)
(880, 82)
(880, 92)
(880, 107)
(880, 118)
(880, 119)
(880, 129)
(880, 136)
(880, 151)
(880, 169)
(880, 175)
(880, 178)
(880, 179)
(880, 185)
(880, 189)
(880, 190)
(880, 192)
(880, 199)
(880, 224)
(880, 229)
(880, 236)
(880, 238)
(880, 239)
(880, 257)
(880, 261)
(880, 271)
(880, 278)
(880, 282)
(880, 289)
(880, 294)
(880, 300)
(880, 304)
(880, 313)
(880, 316)
(880, 321)
(880, 329)
(880, 339)
(880, 385)
(880, 387)
(880, 398)
(880, 400)
(880, 420)
(880, 429)
(880, 441)
(880, 447)
(880, 468)
(880, 469)
(880, 485)
(880, 491)
(880, 508)
(880, 511)
(880, 514)
(880, 516)
(880, 522)
(880, 523)
(880, 527)
(880, 528)
(880, 541)
(880, 545)
(880, 546)
(880, 557)
(880, 566)
(880, 577)
(880, 582)
(880, 588)
(880, 589)
(880, 590)
(880, 604)
(880, 608)
(880, 618)
(880, 620)
(880, 623)
(880, 624)
(880, 629)
(880, 633)
(880, 634)
(880, 637)
(880, 640)
(880, 649)
(880, 657)
(880, 658)
(880, 671)
(880, 672)
(880, 680)
(880, 685)
(880, 701)
(880, 726)
(880, 729)
(880, 733)
(880, 749)
(880, 752)
(880, 757)
(880, 772)
(880, 782)
(880, 786)
(880, 800)
(880, 808)
(880, 812)
(880, 813)
(880, 814)
(880, 842)
(880, 843)
(880, 848)
(880, 854)
(880, 858)
(880, 859)
(880, 869)
(882, 71)
(882, 104)
(882, 129)
(882, 175)
(882, 192)
(882, 253)
(882, 267)
(882, 282)
(882, 321)
(882, 419)
(882, 514)
(882, 546)
(882, 589)
(882, 590)
(882, 702)
(882, 828)
(882, 842)
(886, 282)
(886, 495)
(887, 136)
(887, 546)
(888, 51)
(888, 129)
(888, 240)
(888, 267)
(888, 282)
(888, 321)
(888, 514)
(888, 589)
(888, 608)
(888, 719)
(888, 842)
(889, 257)
(890, 104)
(891, 104)
</pre>
</div>
</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[21]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">for</span> <span class="n">index_1</span><span class="p">,</span><span class="n">index_2</span> <span class="ow">in</span> <span class="n">listOfIndices</span><span class="p">:</span>
    <span class="k">if</span> <span class="p">(</span><span class="nb">len</span><span class="p">(</span><span class="n">new_list</span><span class="p">[</span><span class="n">index_1</span><span class="p">][</span><span class="s2">&quot;title&quot;</span><span class="p">]</span><span class="o">.</span><span class="n">split</span><span class="p">())</span><span class="o">&gt;</span><span class="mi">3</span> <span class="ow">and</span> <span class="nb">len</span><span class="p">(</span><span class="n">new_list</span><span class="p">[</span><span class="n">index_2</span><span class="p">][</span><span class="s2">&quot;title&quot;</span><span class="p">]</span><span class="o">.</span><span class="n">split</span><span class="p">())</span> <span class="o">&gt;</span><span class="mi">3</span> <span class="p">)</span> <span class="p">:</span>
        
        <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;First: &quot;</span><span class="p">,</span><span class="n">new_list</span><span class="p">[</span><span class="n">index_1</span><span class="p">][</span><span class="s2">&quot;title&quot;</span><span class="p">])</span>
        <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;Second: &quot;</span><span class="p">,</span><span class="n">new_list</span><span class="p">[</span><span class="n">index_2</span><span class="p">][</span><span class="s2">&quot;title&quot;</span><span class="p">],</span><span class="s1">&#39;</span><span class="se">\n</span><span class="s1">&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>First:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  fabrication of nanostructures with approach and their utility in and others
Second:  a study on the influence of the pandemic on incomes in greece 

First:  fabrication of nanostructures with approach and their utility in and others
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  impact of on patients with rheumatic complications of cancer results of a registry survey
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  case report mammography in the diagnosis of breast
Second:  a study on the influence of the pandemic on incomes in greece 

First:  case report mammography in the diagnosis of breast
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  case report mammography in the diagnosis of breast
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  a remedy or a ripple in severe
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal innovations in in the age of a systematic literature review
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal of cancer research and clinical oncology
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal of cancer research and clinical oncology
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  journal of cancer research and clinical oncology
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  journal of cancer research and clinical oncology
Second:  case report mammography in the diagnosis of breast 

First:  disease in the era of an observation on a series of six patients with
Second:  a study on the influence of the pandemic on incomes in greece 

First:  disease in the era of an observation on a series of six patients with
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  mapping the technological landscape of and vaccines
Second:  a study on the influence of the pandemic on incomes in greece 

First:  mapping the technological landscape of and vaccines
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  mapping the technological landscape of and vaccines
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  mapping the technological landscape of and vaccines
Second:  journal innovations in in the age of a systematic literature review 

First:  mapping the technological landscape of and vaccines
Second:  journal of cancer research and clinical oncology 

First:  mapping the technological landscape of and vaccines
Second:  disease in the era of an observation on a series of six patients with 

First:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  suicide in the context of diagnosis in insights and implications from online print media reports
Second:  a study on the influence of the pandemic on incomes in greece 

First:  suicide in the context of diagnosis in insights and implications from online print media reports
Second:  journal innovations in in the age of a systematic literature review 

First:  viral intestinal infections of animals and man
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil
Second:  a study on the influence of the pandemic on incomes in greece 

First:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil
Second:  journal innovations in in the age of a systematic literature review 

First:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil
Second:  disease in the era of an observation on a series of six patients with 

First:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil
Second:  mapping the technological landscape of and vaccines 

First:  does the pandemic spell the end for the direct
Second:  a study on the influence of the pandemic on incomes in greece 

First:  does the pandemic spell the end for the direct
Second:  disease in the era of an observation on a series of six patients with 

First:  does the pandemic spell the end for the direct
Second:  mapping the technological landscape of and vaccines 

First:  does the pandemic spell the end for the direct
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  coordinating genomic surveillance in the united states
Second:  a study on the influence of the pandemic on incomes in greece 

First:  coordinating genomic surveillance in the united states
Second:  mapping the technological landscape of and vaccines 

First:  coordinating genomic surveillance in the united states
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology
Second:  a study on the influence of the pandemic on incomes in greece 

First:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology
Second:  journal of cancer research and clinical oncology 

First:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology
Second:  mapping the technological landscape of and vaccines 

First:  and cell biology lung advances in generation and
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and cell biology lung advances in generation and
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and cell biology lung advances in generation and
Second:  journal of cancer research and clinical oncology 

First:  and cell biology lung advances in generation and
Second:  mapping the technological landscape of and vaccines 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  a study on the influence of the pandemic on incomes in greece 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  case report mammography in the diagnosis of breast 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  a remedy or a ripple in severe 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  journal innovations in in the age of a systematic literature review 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  disease in the era of an observation on a series of six patients with 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  mapping the technological landscape of and vaccines 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  viral intestinal infections of animals and man 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  does the pandemic spell the end for the direct 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected
Second:  and cell biology lung advances in generation and 

First:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  using conjugated antibodies allows profiling of human and murine tissues
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  using conjugated antibodies allows profiling of human and murine tissues
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  using conjugated antibodies allows profiling of human and murine tissues
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  using conjugated antibodies allows profiling of human and murine tissues
Second:  viral intestinal infections of animals and man 

First:  biomarker detection based on amplified of magnetite nanoparticles
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  a study on the influence of the pandemic on incomes in greece 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  case report mammography in the diagnosis of breast 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  journal of cancer research and clinical oncology 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  mapping the technological landscape of and vaccines 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses
Second:  mapping the technological landscape of and vaccines 

First:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  a study on the influence of the pandemic on incomes in greece 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  case report mammography in the diagnosis of breast 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  journal innovations in in the age of a systematic literature review 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  journal of cancer research and clinical oncology 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  disease in the era of an observation on a series of six patients with 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  mapping the technological landscape of and vaccines 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  does the pandemic spell the end for the direct 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  coordinating genomic surveillance in the united states 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  sensitivity analysis of the effects of interventions on in europe
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  responding to healthcare disparities and challenges with access to care during
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  reply to against the risk of airborne
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  reply to against the risk of airborne
Second:  does the pandemic spell the end for the direct 

First:  reply to against the risk of airborne
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  case report mammography in the diagnosis of breast 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  journal of cancer research and clinical oncology 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  viral intestinal infections of animals and man 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  in ckd lessons from ckd patients with kidney disease 

First:  effective treatment of severe acute pancreatitis and pneumonia with
Second:  invasive strategy for patients presenting with acute coronary the first italian experience 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  a study on the influence of the pandemic on incomes in greece 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  journal innovations in in the age of a systematic literature review 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  disease in the era of an observation on a series of six patients with 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  mapping the technological landscape of and vaccines 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  and cell biology lung advances in generation and 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and correlates of neutralizing antibodies from a study in germany
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  excess neurological death in new york city after the emergence of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  excess neurological death in new york city after the emergence of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  excess neurological death in new york city after the emergence of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  excess neurological death in new york city after the emergence of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  mapping the technological landscape of and vaccines 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  coordinating genomic surveillance in the united states 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  viral and bacterial infections associated with camel calf diarrhea in north saudi arabia
Second:  viral intestinal infections of animals and man 

First:  editorial recommendations for the management of in countries
Second:  a study on the influence of the pandemic on incomes in greece 

First:  editorial recommendations for the management of in countries
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  editorial recommendations for the management of in countries
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  editorial recommendations for the management of in countries
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  editorial recommendations for the management of in countries
Second:  case report mammography in the diagnosis of breast 

First:  editorial recommendations for the management of in countries
Second:  journal innovations in in the age of a systematic literature review 

First:  editorial recommendations for the management of in countries
Second:  disease in the era of an observation on a series of six patients with 

First:  editorial recommendations for the management of in countries
Second:  mapping the technological landscape of and vaccines 

First:  editorial recommendations for the management of in countries
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  editorial recommendations for the management of in countries
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  editorial recommendations for the management of in countries
Second:  does the pandemic spell the end for the direct 

First:  editorial recommendations for the management of in countries
Second:  coordinating genomic surveillance in the united states 

First:  editorial recommendations for the management of in countries
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  editorial recommendations for the management of in countries
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  editorial recommendations for the management of in countries
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  editorial recommendations for the management of in countries
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  solid and suspension microarrays for microbial diagnostics
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  the perceptions of anatomy teachers for different majors during the a national chinese survey
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the perceptions of anatomy teachers for different majors during the a national chinese survey
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the perceptions of anatomy teachers for different majors during the a national chinese survey
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the perceptions of anatomy teachers for different majors during the a national chinese survey
Second:  editorial recommendations for the management of in countries 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  case report mammography in the diagnosis of breast 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study
Second:  editorial recommendations for the management of in countries 

First:  molecular beacons allow specific detection of variant
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  prophylaxis of with and chloroquine accepted article
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  prophylaxis of with and chloroquine accepted article
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  prophylaxis of with and chloroquine accepted article
Second:  editorial recommendations for the management of in countries 

First:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization
Second:  viral intestinal infections of animals and man 

First:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  quercetin as a potential treatment for acute kidney based on network pharmacology and molecular docking study
Second:  journal of cancer research and clinical oncology 

First:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  case report mammography in the diagnosis of breast 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  journal of cancer research and clinical oncology 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  mapping the technological landscape of and vaccines 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients
Second:  prophylaxis of with and chloroquine accepted article 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  case report mammography in the diagnosis of breast 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  disease in the era of an observation on a series of six patients with 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  mapping the technological landscape of and vaccines 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  does the pandemic spell the end for the direct 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  editorial recommendations for the management of in countries 

First:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  a study on the influence of the pandemic on incomes in greece 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  does the pandemic spell the end for the direct 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have
Second:  editorial recommendations for the management of in countries 

First:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york
Second:  excess neurological death in new york city after the emergence of 

First:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview
Second:  journal of cancer research and clinical oncology 

First:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  and inhibitors of farnesyl pyrophosphate a perspective
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and inhibitors of farnesyl pyrophosphate a perspective
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  and inhibitors of farnesyl pyrophosphate a perspective
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  and inhibitors of farnesyl pyrophosphate a perspective
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  and inhibitors of farnesyl pyrophosphate a perspective
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  microorganisms nasal microbiota in rsv
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  microorganisms nasal microbiota in rsv
Second:  viral intestinal infections of animals and man 

First:  a comparative analysis on risk communication between international and chinese literature from the perspective of knowledge domain visualization
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the impact on surgical departments of hospitals
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the impact on surgical departments of hospitals
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the impact on surgical departments of hospitals
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  the impact on surgical departments of hospitals
Second:  case report mammography in the diagnosis of breast 

First:  the impact on surgical departments of hospitals
Second:  journal of cancer research and clinical oncology 

First:  the impact on surgical departments of hospitals
Second:  disease in the era of an observation on a series of six patients with 

First:  the impact on surgical departments of hospitals
Second:  mapping the technological landscape of and vaccines 

First:  the impact on surgical departments of hospitals
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the impact on surgical departments of hospitals
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  the impact on surgical departments of hospitals
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the impact on surgical departments of hospitals
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the impact on surgical departments of hospitals
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the impact on surgical departments of hospitals
Second:  editorial recommendations for the management of in countries 

First:  the impact on surgical departments of hospitals
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  chest computed tomographic findings of patients with pneumonia
Second:  case report mammography in the diagnosis of breast 

First:  chest computed tomographic findings of patients with pneumonia
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  letter to the editor
Second:  does the pandemic spell the end for the direct 

First:  letter to the editor
Second:  reply to against the risk of airborne 

First:  letter to the editor
Second:  editorial recommendations for the management of in countries 

First:  letter to the editor
Second:  journal letter to the editor rapid implementation of extreme protocols in prostate cer using in response to 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  case report mammography in the diagnosis of breast 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  journal of cancer research and clinical oncology 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  mapping the technological landscape of and vaccines 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  and cell biology lung advances in generation and 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  analysis of computed tomography helps predict poor prognostic outcome in 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  prophylaxis of with and chloroquine accepted article 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  the impact on surgical departments of hospitals 

First:  in adult patients with hematological analysis of clinical characteristics and outcomes
Second:  chest computed tomographic findings of patients with pneumonia 

First:  human infections associated with wild birds
Second:  viral intestinal infections of animals and man 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  a study on the influence of the pandemic on incomes in greece 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  does the pandemic spell the end for the direct 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  from cardiology to the impact of a pandemic on fellowship training
Second:  the impact on surgical departments of hospitals 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  case report mammography in the diagnosis of breast 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  disease in the era of an observation on a series of six patients with 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  mapping the technological landscape of and vaccines 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  predictors of incident viral symptoms ascertained in the era of
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  spectrum of antimicrobial activity for disinfection of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  spectrum of antimicrobial activity for disinfection of
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  spectrum of antimicrobial activity for disinfection of
Second:  case report mammography in the diagnosis of breast 

First:  spectrum of antimicrobial activity for disinfection of
Second:  journal of cancer research and clinical oncology 

First:  spectrum of antimicrobial activity for disinfection of
Second:  mapping the technological landscape of and vaccines 

First:  spectrum of antimicrobial activity for disinfection of
Second:  viral intestinal infections of animals and man 

First:  spectrum of antimicrobial activity for disinfection of
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  spectrum of antimicrobial activity for disinfection of
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  spectrum of antimicrobial activity for disinfection of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  spectrum of antimicrobial activity for disinfection of
Second:  spray drying of nanoparticles intended for inhalation 

First:  spectrum of antimicrobial activity for disinfection of
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  spectrum of antimicrobial activity for disinfection of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  spectrum of antimicrobial activity for disinfection of
Second:  editorial recommendations for the management of in countries 

First:  spectrum of antimicrobial activity for disinfection of
Second:  solid and suspension microarrays for microbial diagnostics 

First:  spectrum of antimicrobial activity for disinfection of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  spectrum of antimicrobial activity for disinfection of
Second:  prophylaxis of with and chloroquine accepted article 

First:  spectrum of antimicrobial activity for disinfection of
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  spectrum of antimicrobial activity for disinfection of
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  spectrum of antimicrobial activity for disinfection of
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  spectrum of antimicrobial activity for disinfection of
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  spectrum of antimicrobial activity for disinfection of
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens
Second:  journal of cancer research and clinical oncology 

First:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens
Second:  mapping the technological landscape of and vaccines 

First:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a model of pandemic evolution in african countries
Second:  a study on the influence of the pandemic on incomes in greece 

First:  a model of pandemic evolution in african countries
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  a model of pandemic evolution in african countries
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients
Second:  chest computed tomographic findings of patients with pneumonia 

First:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  healthcare application of the weathering intersection of and as a stressful life event among african americans
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  healthcare application of the weathering intersection of and as a stressful life event among african americans
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  healthcare application of the weathering intersection of and as a stressful life event among african americans
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  nutritional parameters associated with prognosis in ill
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  nutritional parameters associated with prognosis in ill
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis
Second:  microorganisms nasal microbiota in rsv 

First:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia
Second:  a study on the influence of the pandemic on incomes in greece 

First:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia
Second:  editorial recommendations for the management of in countries 

First:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia
Second:  the impact on surgical departments of hospitals 

First:  molecular cloning and characterization of an reductase gene from liquorice
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  molecular cloning and characterization of an reductase gene from liquorice
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  a study on the influence of the pandemic on incomes in greece 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  case report mammography in the diagnosis of breast 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  journal innovations in in the age of a systematic literature review 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  mapping the technological landscape of and vaccines 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  editorial recommendations for the management of in countries 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  analysis of the positive rate of cases of nucleic acid tests in different in china
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies
Second:  mapping the technological landscape of and vaccines 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  disease in the era of an observation on a series of six patients with 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  does the pandemic spell the end for the direct 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  editorial recommendations for the management of in countries 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  prophylaxis of with and chloroquine accepted article 

First:  combined with the chinese medicine capsule versus alone in the treatment of
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  toxic and properties of an coordination complex of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  toxic and properties of an coordination complex of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  toxic and properties of an coordination complex of
Second:  mapping the technological landscape of and vaccines 

First:  toxic and properties of an coordination complex of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  toxic and properties of an coordination complex of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  toxic and properties of an coordination complex of
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  toxic and properties of an coordination complex of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  toxic and properties of an coordination complex of
Second:  editorial recommendations for the management of in countries 

First:  toxic and properties of an coordination complex of
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  toxic and properties of an coordination complex of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  toxic and properties of an coordination complex of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma
Second:  journal of cancer research and clinical oncology 

First:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  a review in bacterial infections
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a review in bacterial infections
Second:  case report mammography in the diagnosis of breast 

First:  a review in bacterial infections
Second:  a remedy or a ripple in severe 

First:  a review in bacterial infections
Second:  journal innovations in in the age of a systematic literature review 

First:  a review in bacterial infections
Second:  viral intestinal infections of animals and man 

First:  a review in bacterial infections
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  a review in bacterial infections
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  a review in bacterial infections
Second:  microorganisms nasal microbiota in rsv 

First:  a review in bacterial infections
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  basics of molecular biology
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  basics of molecular biology
Second:  journal of cancer research and clinical oncology 

First:  basics of molecular biology
Second:  and cell biology lung advances in generation and 

First:  the common missed instances and areas after years of education
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the common missed instances and areas after years of education
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the common missed instances and areas after years of education
Second:  mapping the technological landscape of and vaccines 

First:  the common missed instances and areas after years of education
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the common missed instances and areas after years of education
Second:  does the pandemic spell the end for the direct 

First:  the common missed instances and areas after years of education
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the common missed instances and areas after years of education
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the common missed instances and areas after years of education
Second:  editorial recommendations for the management of in countries 

First:  predicting risk of transition to severe infection
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  predicting risk of transition to severe infection
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  predicting risk of transition to severe infection
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  predicting risk of transition to severe infection
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  predicting risk of transition to severe infection
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  predicting risk of transition to severe infection
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  a remedy or a ripple in severe 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  journal of cancer research and clinical oncology 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  mapping the technological landscape of and vaccines 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  editorial recommendations for the management of in countries 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  prophylaxis of with and chloroquine accepted article 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  a review in bacterial infections 

First:  article a combining a biomarker and clinical factors for predicting survival of
Second:  predicting risk of transition to severe infection 

First:  physics of fluids article aerosol persistence in relation to possible transmission of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  physics of fluids article aerosol persistence in relation to possible transmission of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  is a host factor for infection
Second:  a review in bacterial infections 

First:  is a host factor for infection
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  proactive strategy to improve staff engagement
Second:  responding to healthcare disparities and challenges with access to care during 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  case report mammography in the diagnosis of breast 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  journal innovations in in the age of a systematic literature review 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  journal of cancer research and clinical oncology 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  disease in the era of an observation on a series of six patients with 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  mapping the technological landscape of and vaccines 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  does the pandemic spell the end for the direct 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  coordinating genomic surveillance in the united states 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  excess neurological death in new york city after the emergence of 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  editorial recommendations for the management of in countries 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  the impact on surgical departments of hospitals 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  spectrum of antimicrobial activity for disinfection of 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  a model of pandemic evolution in african countries 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  prevalence of antibodies in young children in tennessee 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  the common missed instances and areas after years of education 

First:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  case report mammography in the diagnosis of breast 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  disease in the era of an observation on a series of six patients with 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  mapping the technological landscape of and vaccines 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  does the pandemic spell the end for the direct 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  reply to against the risk of airborne 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  excess neurological death in new york city after the emergence of 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  editorial recommendations for the management of in countries 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  prophylaxis of with and chloroquine accepted article 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  the impact on surgical departments of hospitals 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  the common missed instances and areas after years of education 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  predicting risk of transition to severe infection 

First:  the pandemic in avoiding of anaphylaxis risk while safely the world
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  functional contribution and targeted migration of innate lymphoid cells in inflammatory lung being at the right place at the right time
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection
Second:  viral intestinal infections of animals and man 

First:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  viral intestinal infections of animals and man 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  chest computed tomographic findings of patients with pneumonia 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  spectrum of antimicrobial activity for disinfection of 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  predicting risk of transition to severe infection 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  exhaled aerosol increases with and risk factors of disease symptom severity
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  concept of immune response
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  concept of immune response
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  concept of immune response
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  concept of immune response
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  potential of in vitro
Second:  a study on the influence of the pandemic on incomes in greece 

First:  potential of in vitro
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  potential of in vitro
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  potential of in vitro
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  potential of in vitro
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  potential of in vitro
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  potential of in vitro
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  potential of in vitro
Second:  case report mammography in the diagnosis of breast 

First:  potential of in vitro
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  potential of in vitro
Second:  journal innovations in in the age of a systematic literature review 

First:  potential of in vitro
Second:  journal of cancer research and clinical oncology 

First:  potential of in vitro
Second:  disease in the era of an observation on a series of six patients with 

First:  potential of in vitro
Second:  mapping the technological landscape of and vaccines 

First:  potential of in vitro
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  potential of in vitro
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  potential of in vitro
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  potential of in vitro
Second:  viral intestinal infections of animals and man 

First:  potential of in vitro
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  potential of in vitro
Second:  does the pandemic spell the end for the direct 

First:  potential of in vitro
Second:  coordinating genomic surveillance in the united states 

First:  potential of in vitro
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  potential of in vitro
Second:  and cell biology lung advances in generation and 

First:  potential of in vitro
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  potential of in vitro
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  potential of in vitro
Second:  biomarker detection based on amplified of magnetite nanoparticles 

First:  potential of in vitro
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  potential of in vitro
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  potential of in vitro
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  potential of in vitro
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  potential of in vitro
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  potential of in vitro
Second:  cronica measurement of barrier permeability in multiple sclerosis 

First:  potential of in vitro
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  potential of in vitro
Second:  excess neurological death in new york city after the emergence of 

First:  potential of in vitro
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  potential of in vitro
Second:  editorial recommendations for the management of in countries 

First:  potential of in vitro
Second:  a section of the journal frontiers in immunology t rm cells following infection and implications for more effective vaccine design 

First:  potential of in vitro
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  potential of in vitro
Second:  prophylaxis of with and chloroquine accepted article 

First:  potential of in vitro
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  potential of in vitro
Second:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies 

First:  potential of in vitro
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  potential of in vitro
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  potential of in vitro
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  potential of in vitro
Second:  the impact on surgical departments of hospitals 

First:  potential of in vitro
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  potential of in vitro
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  potential of in vitro
Second:  spectrum of antimicrobial activity for disinfection of 

First:  potential of in vitro
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  potential of in vitro
Second:  a model of pandemic evolution in african countries 

First:  potential of in vitro
Second:  unique evolution of antiviral in bats corresponding author 

First:  potential of in vitro
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  potential of in vitro
Second:  molecular cloning and characterization of an reductase gene from liquorice 

First:  potential of in vitro
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  potential of in vitro
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  potential of in vitro
Second:  prevalence of antibodies in young children in tennessee 

First:  potential of in vitro
Second:  structural studies of the agonist complexed human reveals novel structural rearrangements resulting in an 

First:  potential of in vitro
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  potential of in vitro
Second:  toxic and properties of an coordination complex of 

First:  potential of in vitro
Second:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma 

First:  potential of in vitro
Second:  a review in bacterial infections 

First:  potential of in vitro
Second:  basics of molecular biology 

First:  potential of in vitro
Second:  the common missed instances and areas after years of education 

First:  potential of in vitro
Second:  predicting risk of transition to severe infection 

First:  potential of in vitro
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  potential of in vitro
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  potential of in vitro
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  potential of in vitro
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  potential of in vitro
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  potential of in vitro
Second:  functional contribution and targeted migration of innate lymphoid cells in inflammatory lung being at the right place at the right time 

First:  potential of in vitro
Second:  concept of immune response 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  a study on the influence of the pandemic on incomes in greece 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  case report mammography in the diagnosis of breast 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  journal innovations in in the age of a systematic literature review 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  journal of cancer research and clinical oncology 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  disease in the era of an observation on a series of six patients with 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  mapping the technological landscape of and vaccines 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  editorial recommendations for the management of in countries 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  toxic and properties of an coordination complex of 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  a review in bacterial infections 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  the common missed instances and areas after years of education 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  state of the art review kidney outcomes in and a and systematic review
Second:  potential of in vitro 

First:  remote monitoring empowerment of patients with during the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  remote monitoring empowerment of patients with during the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  remote monitoring empowerment of patients with during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  bacterial and the deadly trio in
Second:  a study on the influence of the pandemic on incomes in greece 

First:  bacterial and the deadly trio in
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  bacterial and the deadly trio in
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  bacterial and the deadly trio in
Second:  a remedy or a ripple in severe 

First:  bacterial and the deadly trio in
Second:  journal innovations in in the age of a systematic literature review 

First:  bacterial and the deadly trio in
Second:  disease in the era of an observation on a series of six patients with 

First:  bacterial and the deadly trio in
Second:  mapping the technological landscape of and vaccines 

First:  bacterial and the deadly trio in
Second:  viral intestinal infections of animals and man 

First:  bacterial and the deadly trio in
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  bacterial and the deadly trio in
Second:  does the pandemic spell the end for the direct 

First:  bacterial and the deadly trio in
Second:  and cell biology lung advances in generation and 

First:  bacterial and the deadly trio in
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  bacterial and the deadly trio in
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  bacterial and the deadly trio in
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  bacterial and the deadly trio in
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  bacterial and the deadly trio in
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  bacterial and the deadly trio in
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  bacterial and the deadly trio in
Second:  excess neurological death in new york city after the emergence of 

First:  bacterial and the deadly trio in
Second:  editorial recommendations for the management of in countries 

First:  bacterial and the deadly trio in
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  bacterial and the deadly trio in
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  bacterial and the deadly trio in
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  bacterial and the deadly trio in
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  bacterial and the deadly trio in
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  bacterial and the deadly trio in
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  bacterial and the deadly trio in
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  bacterial and the deadly trio in
Second:  prevalence of antibodies in young children in tennessee 

First:  bacterial and the deadly trio in
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  bacterial and the deadly trio in
Second:  toxic and properties of an coordination complex of 

First:  bacterial and the deadly trio in
Second:  a review in bacterial infections 

First:  bacterial and the deadly trio in
Second:  the common missed instances and areas after years of education 

First:  bacterial and the deadly trio in
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  bacterial and the deadly trio in
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  bacterial and the deadly trio in
Second:  potential of in vitro 

First:  bacterial and the deadly trio in
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  syndrome in case report
Second:  case report mammography in the diagnosis of breast 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  mapping the technological landscape of and vaccines 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  spectrum of antimicrobial activity for disinfection of 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  toxic and properties of an coordination complex of 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open
Second:  potential of in vitro 

First:  supramolecular architecture of the coronavirus particle
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  supramolecular architecture of the coronavirus particle
Second:  mapping the technological landscape of and vaccines 

First:  supramolecular architecture of the coronavirus particle
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  supramolecular architecture of the coronavirus particle
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  supramolecular architecture of the coronavirus particle
Second:  spectrum of antimicrobial activity for disinfection of 

First:  supramolecular architecture of the coronavirus particle
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  supramolecular architecture of the coronavirus particle
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  supramolecular architecture of the coronavirus particle
Second:  toxic and properties of an coordination complex of 

First:  supramolecular architecture of the coronavirus particle
Second:  basics of molecular biology 

First:  supramolecular architecture of the coronavirus particle
Second:  potential of in vitro 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  editorial recommendations for the management of in countries 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  spectrum of antimicrobial activity for disinfection of 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  potential use of ivermectin and drugs in fighting scope and relevance
Second:  potential of in vitro 

First:  regular international perspectives and initiatives
Second:  editorial recommendations for the management of in countries 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  a study on the influence of the pandemic on incomes in greece 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  journal innovations in in the age of a systematic literature review 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  mapping the technological landscape of and vaccines 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  does the pandemic spell the end for the direct 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  editorial recommendations for the management of in countries 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  policymaking and the wicked problem of sdg gender equality 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  the impact on surgical departments of hospitals 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  potential of in vitro 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  protecting the health in reflections on policy deliberation and the role of civil society in democracy
Second:  bacterial and the deadly trio in 

First:  journal incidence of pulmonary embolism in patients with respiratory support during outbreak credit author statement incidence of pulmonary embolism in patients with invasive respiratory support during outbreak
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  a study on the influence of the pandemic on incomes in greece 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  disease in the era of an observation on a series of six patients with 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  mapping the technological landscape of and vaccines 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  does the pandemic spell the end for the direct 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  editorial recommendations for the management of in countries 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  potential of in vitro 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  bacterial and the deadly trio in 

First:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  mapping the technological landscape of and vaccines 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  editorial recommendations for the management of in countries 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists
Second:  potential of in vitro 

First:  a integrated with heater for visual testing of
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  a study on the influence of the pandemic on incomes in greece 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  case report mammography in the diagnosis of breast 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  journal innovations in in the age of a systematic literature review 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  journal of cancer research and clinical oncology 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  disease in the era of an observation on a series of six patients with 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  mapping the technological landscape of and vaccines 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  viral intestinal infections of animals and man 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  does the pandemic spell the end for the direct 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  coordinating genomic surveillance in the united states 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  and cell biology lung advances in generation and 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  excess neurological death in new york city after the emergence of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  editorial recommendations for the management of in countries 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  prophylaxis of with and chloroquine accepted article 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  the impact on surgical departments of hospitals 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  spectrum of antimicrobial activity for disinfection of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  prevalence of antibodies in young children in tennessee 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  toxic and properties of an coordination complex of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  a review in bacterial infections 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  the common missed instances and areas after years of education 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  potential of in vitro 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  bacterial and the deadly trio in 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  coronavirus disease emergency and cancer in the south of new for the
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  a study on the influence of the pandemic on incomes in greece 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  case report mammography in the diagnosis of breast 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  journal innovations in in the age of a systematic literature review 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  editorial recommendations for the management of in countries 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  potential of in vitro 

First:  ethnic disparities in hospitalization for a cohort study in the uk
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  molecular and cellular biochemistry derived peptides with mhc binding motifs from canine mammary tumor tissue elicit strong responses in mice
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  molecular and cellular biochemistry derived peptides with mhc binding motifs from canine mammary tumor tissue elicit strong responses in mice
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  establishment of a reference panel for the detection of antibodies
Second:  a study on the influence of the pandemic on incomes in greece 

First:  establishment of a reference panel for the detection of antibodies
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  establishment of a reference panel for the detection of antibodies
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  establishment of a reference panel for the detection of antibodies
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  establishment of a reference panel for the detection of antibodies
Second:  case report mammography in the diagnosis of breast 

First:  establishment of a reference panel for the detection of antibodies
Second:  journal innovations in in the age of a systematic literature review 

First:  establishment of a reference panel for the detection of antibodies
Second:  disease in the era of an observation on a series of six patients with 

First:  establishment of a reference panel for the detection of antibodies
Second:  mapping the technological landscape of and vaccines 

First:  establishment of a reference panel for the detection of antibodies
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  establishment of a reference panel for the detection of antibodies
Second:  does the pandemic spell the end for the direct 

First:  establishment of a reference panel for the detection of antibodies
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  establishment of a reference panel for the detection of antibodies
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  establishment of a reference panel for the detection of antibodies
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  establishment of a reference panel for the detection of antibodies
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  establishment of a reference panel for the detection of antibodies
Second:  editorial recommendations for the management of in countries 

First:  establishment of a reference panel for the detection of antibodies
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  establishment of a reference panel for the detection of antibodies
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  establishment of a reference panel for the detection of antibodies
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  establishment of a reference panel for the detection of antibodies
Second:  spectrum of antimicrobial activity for disinfection of 

First:  establishment of a reference panel for the detection of antibodies
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  establishment of a reference panel for the detection of antibodies
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  establishment of a reference panel for the detection of antibodies
Second:  toxic and properties of an coordination complex of 

First:  establishment of a reference panel for the detection of antibodies
Second:  the common missed instances and areas after years of education 

First:  establishment of a reference panel for the detection of antibodies
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  establishment of a reference panel for the detection of antibodies
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  establishment of a reference panel for the detection of antibodies
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  establishment of a reference panel for the detection of antibodies
Second:  concept of immune response 

First:  establishment of a reference panel for the detection of antibodies
Second:  potential of in vitro 

First:  establishment of a reference panel for the detection of antibodies
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  establishment of a reference panel for the detection of antibodies
Second:  bacterial and the deadly trio in 

First:  establishment of a reference panel for the detection of antibodies
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  establishment of a reference panel for the detection of antibodies
Second:  supramolecular architecture of the coronavirus particle 

First:  establishment of a reference panel for the detection of antibodies
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  establishment of a reference panel for the detection of antibodies
Second:  a integrated with heater for visual testing of 

First:  establishment of a reference panel for the detection of antibodies
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  bifurcated monocyte states are predictive of mortality in severe
Second:  potential of in vitro 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  viral intestinal infections of animals and man 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  biomarker detection based on amplified of magnetite nanoparticles 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  potent neutralizing antibodies elicited by vaccine candidate by the cell agonist 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  spectrum of antimicrobial activity for disinfection of 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  molecular cloning and characterization of an reductase gene from liquorice 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  concept of immune response 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  potential of in vitro 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  supramolecular architecture of the coronavirus particle 

First:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism
Second:  molecular and cellular biochemistry derived peptides with mhc binding motifs from canine mammary tumor tissue elicit strong responses in mice 

First:  a serological comparison of bovine coronavirus strains
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a serological comparison of bovine coronavirus strains
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  a serological comparison of bovine coronavirus strains
Second:  viral intestinal infections of animals and man 

First:  a serological comparison of bovine coronavirus strains
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  a serological comparison of bovine coronavirus strains
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  a serological comparison of bovine coronavirus strains
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  a serological comparison of bovine coronavirus strains
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  a serological comparison of bovine coronavirus strains
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  a serological comparison of bovine coronavirus strains
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  a serological comparison of bovine coronavirus strains
Second:  microorganisms nasal microbiota in rsv 

First:  a serological comparison of bovine coronavirus strains
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  a serological comparison of bovine coronavirus strains
Second:  spectrum of antimicrobial activity for disinfection of 

First:  a serological comparison of bovine coronavirus strains
Second:  a review in bacterial infections 

First:  a serological comparison of bovine coronavirus strains
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a serological comparison of bovine coronavirus strains
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  a serological comparison of bovine coronavirus strains
Second:  potential of in vitro 

First:  a serological comparison of bovine coronavirus strains
Second:  supramolecular architecture of the coronavirus particle 

First:  a serological comparison of bovine coronavirus strains
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  journal of cancer research and clinical oncology 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  viral intestinal infections of animals and man 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  potential of in vitro 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  article and efficacy of mrna vaccine in preclinical animal models
Second:  a serological comparison of bovine coronavirus strains 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  case report mammography in the diagnosis of breast 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  journal innovations in in the age of a systematic literature review 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  journal of cancer research and clinical oncology 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  disease in the era of an observation on a series of six patients with 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  mapping the technological landscape of and vaccines 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  does the pandemic spell the end for the direct 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  journal evaluation of internal and external surfaces used by health care workers and patients in wards 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  responding to healthcare disparities and challenges with access to care during 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  editorial recommendations for the management of in countries 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  prophylaxis of with and chloroquine accepted article 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  the impact on surgical departments of hospitals 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  spectrum of antimicrobial activity for disinfection of 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  prevalence of antibodies in young children in tennessee 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  toxic and properties of an coordination complex of 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  the common missed instances and areas after years of education 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  potential of in vitro 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  bacterial and the deadly trio in 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  establishment of a reference panel for the detection of antibodies 

First:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  predicting the trajectory of any epidemic from the best straight line
Second:  a study on the influence of the pandemic on incomes in greece 

First:  predicting the trajectory of any epidemic from the best straight line
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  predicting the trajectory of any epidemic from the best straight line
Second:  does the pandemic spell the end for the direct 

First:  predicting the trajectory of any epidemic from the best straight line
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  predicting the trajectory of any epidemic from the best straight line
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  task detection of persuasion techniques in texts and images
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  task detection of persuasion techniques in texts and images
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  synthesis and activity of derivatives and analogues thereof
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  synthesis and activity of derivatives and analogues thereof
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  synthesis and activity of derivatives and analogues thereof
Second:  mapping the technological landscape of and vaccines 

First:  synthesis and activity of derivatives and analogues thereof
Second:  and cell biology lung advances in generation and 

First:  synthesis and activity of derivatives and analogues thereof
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  synthesis and activity of derivatives and analogues thereof
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  synthesis and activity of derivatives and analogues thereof
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  synthesis and activity of derivatives and analogues thereof
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  synthesis and activity of derivatives and analogues thereof
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  synthesis and activity of derivatives and analogues thereof
Second:  prophylaxis of with and chloroquine accepted article 

First:  synthesis and activity of derivatives and analogues thereof
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  synthesis and activity of derivatives and analogues thereof
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  synthesis and activity of derivatives and analogues thereof
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  synthesis and activity of derivatives and analogues thereof
Second:  spectrum of antimicrobial activity for disinfection of 

First:  synthesis and activity of derivatives and analogues thereof
Second:  molecular cloning and characterization of an reductase gene from liquorice 

First:  synthesis and activity of derivatives and analogues thereof
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  synthesis and activity of derivatives and analogues thereof
Second:  structural studies of the agonist complexed human reveals novel structural rearrangements resulting in an 

First:  synthesis and activity of derivatives and analogues thereof
Second:  toxic and properties of an coordination complex of 

First:  synthesis and activity of derivatives and analogues thereof
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  synthesis and activity of derivatives and analogues thereof
Second:  potential of in vitro 

First:  synthesis and activity of derivatives and analogues thereof
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  synthesis and activity of derivatives and analogues thereof
Second:  bacterial and the deadly trio in 

First:  synthesis and activity of derivatives and analogues thereof
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  synthesis and activity of derivatives and analogues thereof
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  synthesis and activity of derivatives and analogues thereof
Second:  establishment of a reference panel for the detection of antibodies 

First:  synthesis and activity of derivatives and analogues thereof
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  synthesis and activity of derivatives and analogues thereof
Second:  task detection of persuasion techniques in texts and images 

First:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium
Second:  mapping the technological landscape of and vaccines 

First:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium
Second:  potential of in vitro 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  case report mammography in the diagnosis of breast 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  does the pandemic spell the end for the direct 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  editorial recommendations for the management of in countries 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  predicting risk of transition to severe infection 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  potential of in vitro 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  establishment of a reference panel for the detection of antibodies 

First:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  case report mammography in the diagnosis of breast 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  editorial recommendations for the management of in countries 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  potential of in vitro 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  potential therapeutic effects of on the differentiation of nave t cells into helios + + in clinical and experimental acute respiratory distress syndrome
Second:  potential of in vitro 

First:  genetic hypothesis and side of in
Second:  a study on the influence of the pandemic on incomes in greece 

First:  genetic hypothesis and side of in
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  genetic hypothesis and side of in
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  genetic hypothesis and side of in
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  genetic hypothesis and side of in
Second:  case report mammography in the diagnosis of breast 

First:  genetic hypothesis and side of in
Second:  journal innovations in in the age of a systematic literature review 

First:  genetic hypothesis and side of in
Second:  journal of cancer research and clinical oncology 

First:  genetic hypothesis and side of in
Second:  disease in the era of an observation on a series of six patients with 

First:  genetic hypothesis and side of in
Second:  mapping the technological landscape of and vaccines 

First:  genetic hypothesis and side of in
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  genetic hypothesis and side of in
Second:  does the pandemic spell the end for the direct 

First:  genetic hypothesis and side of in
Second:  and cell biology lung advances in generation and 

First:  genetic hypothesis and side of in
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  genetic hypothesis and side of in
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  genetic hypothesis and side of in
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  genetic hypothesis and side of in
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  genetic hypothesis and side of in
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  genetic hypothesis and side of in
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  genetic hypothesis and side of in
Second:  editorial recommendations for the management of in countries 

First:  genetic hypothesis and side of in
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  genetic hypothesis and side of in
Second:  prophylaxis of with and chloroquine accepted article 

First:  genetic hypothesis and side of in
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  genetic hypothesis and side of in
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  genetic hypothesis and side of in
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  genetic hypothesis and side of in
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  genetic hypothesis and side of in
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  genetic hypothesis and side of in
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  genetic hypothesis and side of in
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  genetic hypothesis and side of in
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  genetic hypothesis and side of in
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  genetic hypothesis and side of in
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  genetic hypothesis and side of in
Second:  prevalence of antibodies in young children in tennessee 

First:  genetic hypothesis and side of in
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  genetic hypothesis and side of in
Second:  toxic and properties of an coordination complex of 

First:  genetic hypothesis and side of in
Second:  the common missed instances and areas after years of education 

First:  genetic hypothesis and side of in
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  genetic hypothesis and side of in
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  genetic hypothesis and side of in
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  genetic hypothesis and side of in
Second:  potential of in vitro 

First:  genetic hypothesis and side of in
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  genetic hypothesis and side of in
Second:  bacterial and the deadly trio in 

First:  genetic hypothesis and side of in
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  genetic hypothesis and side of in
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  genetic hypothesis and side of in
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  genetic hypothesis and side of in
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  genetic hypothesis and side of in
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  genetic hypothesis and side of in
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  genetic hypothesis and side of in
Second:  establishment of a reference panel for the detection of antibodies 

First:  genetic hypothesis and side of in
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  genetic hypothesis and side of in
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  genetic hypothesis and side of in
Second:  synthesis and activity of derivatives and analogues thereof 

First:  genetic hypothesis and side of in
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  tactics in support of migrations
Second:  a study on the influence of the pandemic on incomes in greece 

First:  tactics in support of migrations
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  tactics in support of migrations
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  tactics in support of migrations
Second:  editorial recommendations for the management of in countries 

First:  tactics in support of migrations
Second:  potential of in vitro 

First:  tactics in support of migrations
Second:  genetic hypothesis and side of in 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  a remedy or a ripple in severe 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  a review in bacterial infections 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  potential of in vitro 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  bacterial and the deadly trio in 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  a serological comparison of bovine coronavirus strains 

First:  and probable varicella in a novel case of homozygous deficiency
Second:  genetic hypothesis and side of in 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  a study on the influence of the pandemic on incomes in greece 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  mapping the technological landscape of and vaccines 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  does the pandemic spell the end for the direct 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  editorial recommendations for the management of in countries 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  potential of in vitro 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  how the response is altering the legal and regulatory landscape on abortion
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  disease in the era of an observation on a series of six patients with 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  mapping the technological landscape of and vaccines 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  does the pandemic spell the end for the direct 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  editorial recommendations for the management of in countries 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  the impact on surgical departments of hospitals 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  bacterial and the deadly trio in 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  establishment of a reference panel for the detection of antibodies 

First:  recommendations from the taskforce on performance of tracheotomy during the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  viral otu a structural and functional comparison
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  viral otu a structural and functional comparison
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the need of health policy perspective to protect healthcare workers during a grade rapid review on the respirators effectiveness
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the need of health policy perspective to protect healthcare workers during a grade rapid review on the respirators effectiveness
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  medizinische klinik einfhrung zum thema
Second:  von bei und lichen in der a des deutscher a , der deutschen gesellschaft fr und b , der gesellschaft fr und c , der sterreichischen gesellschaft fr und d , der gesellschaft fr und e , der sterreichischen gesellschaft fr f in mit der und g und der europischen akademie fr und h 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  a study on the influence of the pandemic on incomes in greece 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  case report mammography in the diagnosis of breast 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  disease in the era of an observation on a series of six patients with 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  mapping the technological landscape of and vaccines 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  does the pandemic spell the end for the direct 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  editorial recommendations for the management of in countries 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  the impact on surgical departments of hospitals 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  spectrum of antimicrobial activity for disinfection of 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  toxic and properties of an coordination complex of 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  concept of immune response 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  potential of in vitro 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  bacterial and the deadly trio in 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  supramolecular architecture of the coronavirus particle 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  establishment of a reference panel for the detection of antibodies 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  synthesis and activity of derivatives and analogues thereof 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  genetic hypothesis and side of in 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  and prognostic significance in
Second:  a study on the influence of the pandemic on incomes in greece 

First:  and prognostic significance in
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and prognostic significance in
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  and prognostic significance in
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  and prognostic significance in
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  and prognostic significance in
Second:  risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review 

First:  and prognostic significance in
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and prognostic significance in
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  and prognostic significance in
Second:  case report mammography in the diagnosis of breast 

First:  and prognostic significance in
Second:  a remedy or a ripple in severe 

First:  and prognostic significance in
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  and prognostic significance in
Second:  journal innovations in in the age of a systematic literature review 

First:  and prognostic significance in
Second:  journal of cancer research and clinical oncology 

First:  and prognostic significance in
Second:  disease in the era of an observation on a series of six patients with 

First:  and prognostic significance in
Second:  mapping the technological landscape of and vaccines 

First:  and prognostic significance in
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  and prognostic significance in
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  and prognostic significance in
Second:  linguistic methods in healthcare application and variants classification 

First:  and prognostic significance in
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  and prognostic significance in
Second:  and cell biology lung advances in generation and 

First:  and prognostic significance in
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and prognostic significance in
Second:  july zinc and in a common connection involving recognition 

First:  and prognostic significance in
Second:  chronic lymphocytic is new and notable in with a special focus on 

First:  and prognostic significance in
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  and prognostic significance in
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  and prognostic significance in
Second:  composite in medical applications 

First:  and prognostic significance in
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  and prognostic significance in
Second:  analysis of computed tomography helps predict poor prognostic outcome in 

First:  and prognostic significance in
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  and prognostic significance in
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  and prognostic significance in
Second:  excess neurological death in new york city after the emergence of 

First:  and prognostic significance in
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  and prognostic significance in
Second:  editorial recommendations for the management of in countries 

First:  and prognostic significance in
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  and prognostic significance in
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  and prognostic significance in
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  and prognostic significance in
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  and prognostic significance in
Second:  the impact on surgical departments of hospitals 

First:  and prognostic significance in
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  and prognostic significance in
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  and prognostic significance in
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  and prognostic significance in
Second:  nutritional parameters associated with prognosis in ill 

First:  and prognostic significance in
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  and prognostic significance in
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  and prognostic significance in
Second:  prevalence of antibodies in young children in tennessee 

First:  and prognostic significance in
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  and prognostic significance in
Second:  toxic and properties of an coordination complex of 

First:  and prognostic significance in
Second:  a review in bacterial infections 

First:  and prognostic significance in
Second:  the common missed instances and areas after years of education 

First:  and prognostic significance in
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  and prognostic significance in
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  and prognostic significance in
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  and prognostic significance in
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  and prognostic significance in
Second:  potential of in vitro 

First:  and prognostic significance in
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  and prognostic significance in
Second:  bacterial and the deadly trio in 

First:  and prognostic significance in
Second:  an epidemic model for in mathematical analysis and forecast 

First:  and prognostic significance in
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  and prognostic significance in
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  and prognostic significance in
Second:  correlation between weather and pandemic in an empirical investigation 

First:  and prognostic significance in
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  and prognostic significance in
Second:  international part of springer nature j health vitamin d and mortality in in turkey 

First:  and prognostic significance in
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  and prognostic significance in
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  and prognostic significance in
Second:  establishment of a reference panel for the detection of antibodies 

First:  and prognostic significance in
Second:  bifurcated monocyte states are predictive of mortality in severe 

First:  and prognostic significance in
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  and prognostic significance in
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  and prognostic significance in
Second:  task detection of persuasion techniques in texts and images 

First:  and prognostic significance in
Second:  synthesis and activity of derivatives and analogues thereof 

First:  and prognostic significance in
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  and prognostic significance in
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  and prognostic significance in
Second:  genetic hypothesis and side of in 

First:  and prognostic significance in
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  and prognostic significance in
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  and prognostic significance in
Second:  viral otu a structural and functional comparison 

First:  and prognostic significance in
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the future of medical scribes documenting in the electronic health results of an expert consensus conference
Second:  mapping the technological landscape of and vaccines 

First:  the future of medical scribes documenting in the electronic health results of an expert consensus conference
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the future of medical scribes documenting in the electronic health results of an expert consensus conference
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the future of medical scribes documenting in the electronic health results of an expert consensus conference
Second:  editorial recommendations for the management of in countries 

First:  the future of medical scribes documenting in the electronic health results of an expert consensus conference
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the future of medical scribes documenting in the electronic health results of an expert consensus conference
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  rapid communication case fatality risk of the variant of concern in november to february
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  rapid communication case fatality risk of the variant of concern in november to february
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  rapid communication case fatality risk of the variant of concern in november to february
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  rapid communication case fatality risk of the variant of concern in november to february
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  rapid communication case fatality risk of the variant of concern in november to february
Second:  potential of in vitro 

First:  implications for people with chagas disease
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  molecular sciences legume proteins with diverse applications
Second:  basics of molecular biology 

First:  impact of computed emphysema score on clinical outcome in patients with
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal fungal in patients with role of antifungal
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal fungal in patients with role of antifungal
Second:  journal of cancer research and clinical oncology 

First:  journal fungal in patients with role of antifungal
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal fungal in patients with role of antifungal
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal fungal in patients with role of antifungal
Second:  a review in bacterial infections 

First:  journal fungal in patients with role of antifungal
Second:  potential of in vitro 

First:  journal fungal in patients with role of antifungal
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a study on the influence of the pandemic on incomes in greece 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  case report mammography in the diagnosis of breast 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a remedy or a ripple in severe 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal innovations in in the age of a systematic literature review 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal of cancer research and clinical oncology 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  disease in the era of an observation on a series of six patients with 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  mapping the technological landscape of and vaccines 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  viral intestinal infections of animals and man 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  does the pandemic spell the end for the direct 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  coordinating genomic surveillance in the united states 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  design and implementation of a skilled nursing facility unit 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  drink bleach or do what a dataset for health decision making in the presence of misinformation 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  and cell biology lung advances in generation and 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  overall quality of sporting events and emotions as predictors of future intentions of duathlon participants 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal evaluation of internal and external surfaces used by health care workers and patients in wards 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  july zinc and in a common connection involving recognition 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  chronic lymphocytic is new and notable in with a special focus on 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  responding to healthcare disparities and challenges with access to care during 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  second wave of global pandemic and recommendations to better manage and optimize the modified lifestyle 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  invasive strategy for patients presenting with acute coronary the first italian experience 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  reply to against the risk of airborne 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  excess neurological death in new york city after the emergence of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  editorial recommendations for the management of in countries 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a section of the journal frontiers in immunology t rm cells following infection and implications for more effective vaccine design 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  an official learning resource of review impact of response on hepatitis prevention care and results from global survey of providers and program managers 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  prophylaxis of with and chloroquine accepted article 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  policymaking and the wicked problem of sdg gender equality 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the impact on surgical departments of hospitals 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  letter to the editor 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  open forum infectious diseases comparison of rates of hospitalization between single and dual virus detection in a mexican cohort of children and adults with illness 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal hydrogen peroxide and viral a literature review with research definition in relation to the current pandemic hydrogen peroxide and viral a literature review with research hypothesis definition in relation to the current pandemic 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  spectrum of antimicrobial activity for disinfection of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  porcine type disease on pig farms and associated knowledge of key players in the pig industry in central uganda 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a model of pandemic evolution in african countries 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  international forum on the collection and use of convalescent challenges and lessons summary 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  prevalence of antibodies in young children in tennessee 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  toxic and properties of an coordination complex of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a review in bacterial infections 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the common missed instances and areas after years of education 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  predicting risk of transition to severe infection 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  is a host factor for infection 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  functional contribution and targeted migration of innate lymphoid cells in inflammatory lung being at the right place at the right time 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  concept of immune response 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  potential of in vitro 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  bacterial and the deadly trio in 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  an epidemic model for in mathematical analysis and forecast 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  supramolecular architecture of the coronavirus particle 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  medical mistrust and stigma associated with among people living with hiv in south africa 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  correlation between weather and pandemic in an empirical investigation 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  international part of springer nature j health vitamin d and mortality in in turkey 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  a integrated with heater for visual testing of 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  consensus recommendations on dosing and administration of medical cannabis to treat chronic results of a modified delphi process 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  establishment of a reference panel for the detection of antibodies 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  bifurcated monocyte states are predictive of mortality in severe 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  task detection of persuasion techniques in texts and images 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  synthesis and activity of derivatives and analogues thereof 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  genetic hypothesis and side of in 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  tactics in support of migrations 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the need of health policy perspective to protect healthcare workers during a grade rapid review on the respirators effectiveness 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  and prognostic significance in 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  of period between onset of symptoms for a cohort study short title aggressiveness of corresponding author 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  implications for people with chagas disease 

First:  and chronic the impact now and in the future the problem of and chronic disease
Second:  journal fungal in patients with role of antifungal 

First:  from ego to for ontology in the
Second:  a study on the influence of the pandemic on incomes in greece 

First:  from ego to for ontology in the
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  from ego to for ontology in the
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  from ego to for ontology in the
Second:  does the pandemic spell the end for the direct 

First:  from ego to for ontology in the
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  from ego to for ontology in the
Second:  editorial recommendations for the management of in countries 

First:  from ego to for ontology in the
Second:  letter to the editor 

First:  from ego to for ontology in the
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  from ego to for ontology in the
Second:  potential of in vitro 

First:  from ego to for ontology in the
Second:  bacterial and the deadly trio in 

First:  from ego to for ontology in the
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  from ego to for ontology in the
Second:  genetic hypothesis and side of in 

First:  from ego to for ontology in the
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  from ego to for ontology in the
Second:  and prognostic significance in 

First:  from ego to for ontology in the
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  mapping the technological landscape of and vaccines 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  spectrum of antimicrobial activity for disinfection of 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  potential of in vitro 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  chapter from boom to the economic crisis
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  chapter from boom to the economic crisis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal of management control
Second:  journal of cancer research and clinical oncology 

First:  journal of management control
Second:  mapping the technological landscape of and vaccines 

First:  journal of management control
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal of management control
Second:  editorial recommendations for the management of in countries 

First:  journal of management control
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal of management control
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  potent neutralizing antibodies elicited by vaccine candidate by the cell agonist 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  concept of immune response 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  potential of in vitro 

First:  cancers tumor immune evasion induced by dysregulation of progenitor cells development
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  journal and bleeding risk in unsolved question
Second:  and prognostic significance in 

First:  journal and bleeding risk in unsolved question
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  influence of pharmaceutical on emergency hospital a
Second:  a study on the influence of the pandemic on incomes in greece 

First:  influence of pharmaceutical on emergency hospital a
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  influence of pharmaceutical on emergency hospital a
Second:  the impact on surgical departments of hospitals 

First:  influence of pharmaceutical on emergency hospital a
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  influence of pharmaceutical on emergency hospital a
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  soft law governance in times of coronavirus in spain
Second:  potential of in vitro 

First:  the sudden appearance of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the sudden appearance of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the sudden appearance of
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  the sudden appearance of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the sudden appearance of
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  the sudden appearance of
Second:  case report mammography in the diagnosis of breast 

First:  the sudden appearance of
Second:  a remedy or a ripple in severe 

First:  the sudden appearance of
Second:  journal innovations in in the age of a systematic literature review 

First:  the sudden appearance of
Second:  disease in the era of an observation on a series of six patients with 

First:  the sudden appearance of
Second:  mapping the technological landscape of and vaccines 

First:  the sudden appearance of
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  the sudden appearance of
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  the sudden appearance of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the sudden appearance of
Second:  does the pandemic spell the end for the direct 

First:  the sudden appearance of
Second:  drink bleach or do what a dataset for health decision making in the presence of misinformation 

First:  the sudden appearance of
Second:  flying under the the stealth pandemic of escherichia coli sequence type 

First:  the sudden appearance of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the sudden appearance of
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  the sudden appearance of
Second:  overall quality of sporting events and emotions as predictors of future intentions of duathlon participants 

First:  the sudden appearance of
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  the sudden appearance of
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the sudden appearance of
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  the sudden appearance of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the sudden appearance of
Second:  reply to against the risk of airborne 

First:  the sudden appearance of
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the sudden appearance of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the sudden appearance of
Second:  excess neurological death in new york city after the emergence of 

First:  the sudden appearance of
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the sudden appearance of
Second:  editorial recommendations for the management of in countries 

First:  the sudden appearance of
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  the sudden appearance of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the sudden appearance of
Second:  prophylaxis of with and chloroquine accepted article 

First:  the sudden appearance of
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the sudden appearance of
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the sudden appearance of
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the sudden appearance of
Second:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york 

First:  the sudden appearance of
Second:  the impact on surgical departments of hospitals 

First:  the sudden appearance of
Second:  letter to the editor 

First:  the sudden appearance of
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  the sudden appearance of
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the sudden appearance of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the sudden appearance of
Second:  estimation of case fatality rate during an an example from pandemic 

First:  the sudden appearance of
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  the sudden appearance of
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  the sudden appearance of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the sudden appearance of
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  the sudden appearance of
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the sudden appearance of
Second:  toxic and properties of an coordination complex of 

First:  the sudden appearance of
Second:  the common missed instances and areas after years of education 

First:  the sudden appearance of
Second:  predicting risk of transition to severe infection 

First:  the sudden appearance of
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the sudden appearance of
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  the sudden appearance of
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  the sudden appearance of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the sudden appearance of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the sudden appearance of
Second:  functional contribution and targeted migration of innate lymphoid cells in inflammatory lung being at the right place at the right time 

First:  the sudden appearance of
Second:  concept of immune response 

First:  the sudden appearance of
Second:  potential of in vitro 

First:  the sudden appearance of
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the sudden appearance of
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  the sudden appearance of
Second:  bacterial and the deadly trio in 

First:  the sudden appearance of
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  the sudden appearance of
Second:  supramolecular architecture of the coronavirus particle 

First:  the sudden appearance of
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the sudden appearance of
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the sudden appearance of
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  the sudden appearance of
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the sudden appearance of
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  the sudden appearance of
Second:  establishment of a reference panel for the detection of antibodies 

First:  the sudden appearance of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the sudden appearance of
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  the sudden appearance of
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the sudden appearance of
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the sudden appearance of
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  the sudden appearance of
Second:  genetic hypothesis and side of in 

First:  the sudden appearance of
Second:  tactics in support of migrations 

First:  the sudden appearance of
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  the sudden appearance of
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  the sudden appearance of
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the sudden appearance of
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the sudden appearance of
Second:  and prognostic significance in 

First:  the sudden appearance of
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  the sudden appearance of
Second:  of period between onset of symptoms for a cohort study short title aggressiveness of corresponding author 

First:  the sudden appearance of
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  the sudden appearance of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the sudden appearance of
Second:  from ego to for ontology in the 

First:  the sudden appearance of
Second:  chapter from boom to the economic crisis 

First:  the sudden appearance of
Second:  influence of pharmaceutical on emergency hospital a 

First:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors
Second:  the sudden appearance of 

First:  selected approaches to the assessment of environmental noise from railways in urban areas
Second:  mapping the technological landscape of and vaccines 

First:  selected approaches to the assessment of environmental noise from railways in urban areas
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  mortality rates due to respiratory tract diseases in iran during a study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and indigenous an imperative for action
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  policy responses to the pandemic in vietnam
Second:  a study on the influence of the pandemic on incomes in greece 

First:  policy responses to the pandemic in vietnam
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  policy responses to the pandemic in vietnam
Second:  does the pandemic spell the end for the direct 

First:  policy responses to the pandemic in vietnam
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  policy responses to the pandemic in vietnam
Second:  reply to against the risk of airborne 

First:  policy responses to the pandemic in vietnam
Second:  editorial recommendations for the management of in countries 

First:  policy responses to the pandemic in vietnam
Second:  letter to the editor 

First:  policy responses to the pandemic in vietnam
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  policy responses to the pandemic in vietnam
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  policy responses to the pandemic in vietnam
Second:  potential of in vitro 

First:  policy responses to the pandemic in vietnam
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  policy responses to the pandemic in vietnam
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  policy responses to the pandemic in vietnam
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  policy responses to the pandemic in vietnam
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  a study on the influence of the pandemic on incomes in greece 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  case report mammography in the diagnosis of breast 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  mapping the technological landscape of and vaccines 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  does the pandemic spell the end for the direct 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  potential of in vitro 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  establishment of a reference panel for the detection of antibodies 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  genetic hypothesis and side of in 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  and prognostic significance in 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  initial introduction of minimally invasive using the concept in the upper mediastinum
Second:  the sudden appearance of 

First:  gastric diffuse large a experience
Second:  a remedy or a ripple in severe 

First:  the function and inhibition by designed antiviral compounds
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the function and inhibition by designed antiviral compounds
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  the function and inhibition by designed antiviral compounds
Second:  potent neutralizing antibodies elicited by vaccine candidate by the cell agonist 

First:  the function and inhibition by designed antiviral compounds
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  the function and inhibition by designed antiviral compounds
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the function and inhibition by designed antiviral compounds
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  the function and inhibition by designed antiviral compounds
Second:  potential of in vitro 

First:  the function and inhibition by designed antiviral compounds
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  the function and inhibition by designed antiviral compounds
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the function and inhibition by designed antiviral compounds
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the function and inhibition by designed antiviral compounds
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine
Second:  viral intestinal infections of animals and man 

First:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine
Second:  potential of in vitro 

First:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine
Second:  a serological comparison of bovine coronavirus strains 

First:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  school of population and global the university of evidence
Second:  a study on the influence of the pandemic on incomes in greece 

First:  school of population and global the university of evidence
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  school of population and global the university of evidence
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  school of population and global the university of evidence
Second:  journal innovations in in the age of a systematic literature review 

First:  school of population and global the university of evidence
Second:  mapping the technological landscape of and vaccines 

First:  school of population and global the university of evidence
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  school of population and global the university of evidence
Second:  does the pandemic spell the end for the direct 

First:  school of population and global the university of evidence
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  school of population and global the university of evidence
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  school of population and global the university of evidence
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  school of population and global the university of evidence
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  school of population and global the university of evidence
Second:  editorial recommendations for the management of in countries 

First:  school of population and global the university of evidence
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  school of population and global the university of evidence
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  school of population and global the university of evidence
Second:  the impact on surgical departments of hospitals 

First:  school of population and global the university of evidence
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  school of population and global the university of evidence
Second:  spectrum of antimicrobial activity for disinfection of 

First:  school of population and global the university of evidence
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  school of population and global the university of evidence
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  school of population and global the university of evidence
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  school of population and global the university of evidence
Second:  toxic and properties of an coordination complex of 

First:  school of population and global the university of evidence
Second:  the common missed instances and areas after years of education 

First:  school of population and global the university of evidence
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  school of population and global the university of evidence
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  school of population and global the university of evidence
Second:  potential of in vitro 

First:  school of population and global the university of evidence
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  school of population and global the university of evidence
Second:  bacterial and the deadly trio in 

First:  school of population and global the university of evidence
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  school of population and global the university of evidence
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  school of population and global the university of evidence
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  school of population and global the university of evidence
Second:  establishment of a reference panel for the detection of antibodies 

First:  school of population and global the university of evidence
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  school of population and global the university of evidence
Second:  synthesis and activity of derivatives and analogues thereof 

First:  school of population and global the university of evidence
Second:  genetic hypothesis and side of in 

First:  school of population and global the university of evidence
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  school of population and global the university of evidence
Second:  and prognostic significance in 

First:  school of population and global the university of evidence
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  school of population and global the university of evidence
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  school of population and global the university of evidence
Second:  the sudden appearance of 

First:  combination kills bladder cancer cells synergistically
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  combination kills bladder cancer cells synergistically
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  combination kills bladder cancer cells synergistically
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  combination kills bladder cancer cells synergistically
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  combination kills bladder cancer cells synergistically
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  combination kills bladder cancer cells synergistically
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  combination kills bladder cancer cells synergistically
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  pharmaceutics pharmacokinetic estimation approach to predict clinical implications for cyp induction by in human hepatocytes and cells estimation approach to predict clinical implications for cyp induction by in human hepatocytes and pharmaceutics
Second:  potential of in vitro 

First:  letters to the editor letters to the editor
Second:  does the pandemic spell the end for the direct 

First:  letters to the editor letters to the editor
Second:  reply to against the risk of airborne 

First:  letters to the editor letters to the editor
Second:  editorial recommendations for the management of in countries 

First:  letters to the editor letters to the editor
Second:  letter to the editor 

First:  letters to the editor letters to the editor
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  letters to the editor letters to the editor
Second:  from ego to for ontology in the 

First:  letters to the editor letters to the editor
Second:  the sudden appearance of 

First:  letters to the editor letters to the editor
Second:  policy responses to the pandemic in vietnam 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  case report mammography in the diagnosis of breast 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  journal of cancer research and clinical oncology 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  viral intestinal infections of animals and man 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  a review in bacterial infections 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  potential of in vitro 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  traditional chinese medicine in the treatment of acute respiratory tract infections
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  life beyond alternative target amplification technologies for the diagnosis of infectious part i
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  reversible and feline skin fragility syndrome in three cats
Second:  viral intestinal infections of animals and man 

First:  polymers additive manufacturing of polymer promise and challenges
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  polymers additive manufacturing of polymer promise and challenges
Second:  solid and suspension microarrays for microbial diagnostics 

First:  polymers additive manufacturing of polymer promise and challenges
Second:  potential of in vitro 

First:  polymers additive manufacturing of polymer promise and challenges
Second:  synthesis and activity of derivatives and analogues thereof 

First:  a visual analytics approach to facilitate the of online exams
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a visual analytics approach to facilitate the of online exams
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  restriction of replication by targeting programmed ribosomal in vitro
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  restriction of replication by targeting programmed ribosomal in vitro
Second:  potential of in vitro 

First:  restriction of replication by targeting programmed ribosomal in vitro
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  restriction of replication by targeting programmed ribosomal in vitro
Second:  the function and inhibition by designed antiviral compounds 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  does the pandemic spell the end for the direct 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  the impact on surgical departments of hospitals 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  bacterial and the deadly trio in 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  the sudden appearance of 

First:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  protects human alveolar epithelial cells against injury induced by influenza a virus
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  a protocol for a systematic review and
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  a protocol for a systematic review and
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  a protocol for a systematic review and
Second:  a remedy or a ripple in severe 

First:  a protocol for a systematic review and
Second:  journal innovations in in the age of a systematic literature review 

First:  a protocol for a systematic review and
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  a protocol for a systematic review and
Second:  editorial recommendations for the management of in countries 

First:  a protocol for a systematic review and
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  a protocol for a systematic review and
Second:  a review in bacterial infections 

First:  a protocol for a systematic review and
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a protocol for a systematic review and
Second:  is a host factor for infection 

First:  a protocol for a systematic review and
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  a protocol for a systematic review and
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  a protocol for a systematic review and
Second:  a integrated with heater for visual testing of 

First:  a protocol for a systematic review and
Second:  establishment of a reference panel for the detection of antibodies 

First:  a protocol for a systematic review and
Second:  synthesis and activity of derivatives and analogues thereof 

First:  a protocol for a systematic review and
Second:  and prognostic significance in 

First:  a protocol for a systematic review and
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  early forecasting of the potential risk zones of in
Second:  a study on the influence of the pandemic on incomes in greece 

First:  early forecasting of the potential risk zones of in
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  early forecasting of the potential risk zones of in
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  early forecasting of the potential risk zones of in
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  early forecasting of the potential risk zones of in
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  early forecasting of the potential risk zones of in
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  early forecasting of the potential risk zones of in
Second:  case report mammography in the diagnosis of breast 

First:  early forecasting of the potential risk zones of in
Second:  journal innovations in in the age of a systematic literature review 

First:  early forecasting of the potential risk zones of in
Second:  disease in the era of an observation on a series of six patients with 

First:  early forecasting of the potential risk zones of in
Second:  mapping the technological landscape of and vaccines 

First:  early forecasting of the potential risk zones of in
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  early forecasting of the potential risk zones of in
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  early forecasting of the potential risk zones of in
Second:  does the pandemic spell the end for the direct 

First:  early forecasting of the potential risk zones of in
Second:  coordinating genomic surveillance in the united states 

First:  early forecasting of the potential risk zones of in
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  early forecasting of the potential risk zones of in
Second:  overall quality of sporting events and emotions as predictors of future intentions of duathlon participants 

First:  early forecasting of the potential risk zones of in
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  early forecasting of the potential risk zones of in
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  early forecasting of the potential risk zones of in
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  early forecasting of the potential risk zones of in
Second:  reply to against the risk of airborne 

First:  early forecasting of the potential risk zones of in
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  early forecasting of the potential risk zones of in
Second:  excess neurological death in new york city after the emergence of 

First:  early forecasting of the potential risk zones of in
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  early forecasting of the potential risk zones of in
Second:  editorial recommendations for the management of in countries 

First:  early forecasting of the potential risk zones of in
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  early forecasting of the potential risk zones of in
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  early forecasting of the potential risk zones of in
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  early forecasting of the potential risk zones of in
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  early forecasting of the potential risk zones of in
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  early forecasting of the potential risk zones of in
Second:  the impact on surgical departments of hospitals 

First:  early forecasting of the potential risk zones of in
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  early forecasting of the potential risk zones of in
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  early forecasting of the potential risk zones of in
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  early forecasting of the potential risk zones of in
Second:  spectrum of antimicrobial activity for disinfection of 

First:  early forecasting of the potential risk zones of in
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  early forecasting of the potential risk zones of in
Second:  a model of pandemic evolution in african countries 

First:  early forecasting of the potential risk zones of in
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  early forecasting of the potential risk zones of in
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  early forecasting of the potential risk zones of in
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  early forecasting of the potential risk zones of in
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  early forecasting of the potential risk zones of in
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  early forecasting of the potential risk zones of in
Second:  toxic and properties of an coordination complex of 

First:  early forecasting of the potential risk zones of in
Second:  the common missed instances and areas after years of education 

First:  early forecasting of the potential risk zones of in
Second:  predicting risk of transition to severe infection 

First:  early forecasting of the potential risk zones of in
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  early forecasting of the potential risk zones of in
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  early forecasting of the potential risk zones of in
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  early forecasting of the potential risk zones of in
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  early forecasting of the potential risk zones of in
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  early forecasting of the potential risk zones of in
Second:  concept of immune response 

First:  early forecasting of the potential risk zones of in
Second:  potential of in vitro 

First:  early forecasting of the potential risk zones of in
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  early forecasting of the potential risk zones of in
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  early forecasting of the potential risk zones of in
Second:  bacterial and the deadly trio in 

First:  early forecasting of the potential risk zones of in
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  early forecasting of the potential risk zones of in
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  early forecasting of the potential risk zones of in
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  early forecasting of the potential risk zones of in
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  early forecasting of the potential risk zones of in
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  early forecasting of the potential risk zones of in
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  early forecasting of the potential risk zones of in
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  early forecasting of the potential risk zones of in
Second:  establishment of a reference panel for the detection of antibodies 

First:  early forecasting of the potential risk zones of in
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  early forecasting of the potential risk zones of in
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  early forecasting of the potential risk zones of in
Second:  synthesis and activity of derivatives and analogues thereof 

First:  early forecasting of the potential risk zones of in
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  early forecasting of the potential risk zones of in
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  early forecasting of the potential risk zones of in
Second:  genetic hypothesis and side of in 

First:  early forecasting of the potential risk zones of in
Second:  tactics in support of migrations 

First:  early forecasting of the potential risk zones of in
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  early forecasting of the potential risk zones of in
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  early forecasting of the potential risk zones of in
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  early forecasting of the potential risk zones of in
Second:  and prognostic significance in 

First:  early forecasting of the potential risk zones of in
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  early forecasting of the potential risk zones of in
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  early forecasting of the potential risk zones of in
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  early forecasting of the potential risk zones of in
Second:  from ego to for ontology in the 

First:  early forecasting of the potential risk zones of in
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  early forecasting of the potential risk zones of in
Second:  journal of management control 

First:  early forecasting of the potential risk zones of in
Second:  the sudden appearance of 

First:  early forecasting of the potential risk zones of in
Second:  selected approaches to the assessment of environmental noise from railways in urban areas 

First:  early forecasting of the potential risk zones of in
Second:  policy responses to the pandemic in vietnam 

First:  early forecasting of the potential risk zones of in
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  early forecasting of the potential risk zones of in
Second:  school of population and global the university of evidence 

First:  early forecasting of the potential risk zones of in
Second:  a visual analytics approach to facilitate the of online exams 

First:  early forecasting of the potential risk zones of in
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes
Second:  potential of in vitro 

First:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  mapping the technological landscape of and vaccines 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  viral intestinal infections of animals and man 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  and cell biology lung advances in generation and 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  spectrum of antimicrobial activity for disinfection of 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  a review in bacterial infections 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  potential of in vitro 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  bacterial and the deadly trio in 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  a serological comparison of bovine coronavirus strains 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  synthesis and activity of derivatives and analogues thereof 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  genetic hypothesis and side of in 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  and prognostic significance in 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  the function and inhibition by designed antiviral compounds 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  restriction of replication by targeting programmed ribosomal in vitro 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  early forecasting of the potential risk zones of in 

First:  antiviral activity of against virus both in vitro and in vivo
Second:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  a study on the influence of the pandemic on incomes in greece 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  mapping the technological landscape of and vaccines 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  editorial recommendations for the management of in countries 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  the impact on surgical departments of hospitals 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  spectrum of antimicrobial activity for disinfection of 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  establishment of a reference panel for the detection of antibodies 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  the sudden appearance of 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  school of population and global the university of evidence 

First:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for
Second:  early forecasting of the potential risk zones of in 

First:  therapy for a feasibility study
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  therapy for a feasibility study
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  therapy for a feasibility study
Second:  case report mammography in the diagnosis of breast 

First:  therapy for a feasibility study
Second:  journal of cancer research and clinical oncology 

First:  therapy for a feasibility study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  therapy for a feasibility study
Second:  quercetin as a potential treatment for acute kidney based on network pharmacology and molecular docking study 

First:  therapy for a feasibility study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  therapy for a feasibility study
Second:  spectrum of antimicrobial activity for disinfection of 

First:  therapy for a feasibility study
Second:  a review in bacterial infections 

First:  therapy for a feasibility study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  therapy for a feasibility study
Second:  is a host factor for infection 

First:  therapy for a feasibility study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  therapy for a feasibility study
Second:  potential of in vitro 

First:  therapy for a feasibility study
Second:  a integrated with heater for visual testing of 

First:  therapy for a feasibility study
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  therapy for a feasibility study
Second:  establishment of a reference panel for the detection of antibodies 

First:  therapy for a feasibility study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  therapy for a feasibility study
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  therapy for a feasibility study
Second:  a protocol for a systematic review and 

First:  materials nanoparticles functionalized viscose fabrics as potentially durable antibacterial medical textiles
Second:  polymers additive manufacturing of polymer promise and challenges 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  a study on the influence of the pandemic on incomes in greece 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  disease in the era of an observation on a series of six patients with 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  mapping the technological landscape of and vaccines 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  does the pandemic spell the end for the direct 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  editorial recommendations for the management of in countries 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  spectrum of antimicrobial activity for disinfection of 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  toxic and properties of an coordination complex of 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  potential of in vitro 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  supramolecular architecture of the coronavirus particle 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  establishment of a reference panel for the detection of antibodies 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  genetic hypothesis and side of in 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  the sudden appearance of 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  school of population and global the university of evidence 

First:  an updated estimation of the risk of transmission of the novel coronavirus license
Second:  early forecasting of the potential risk zones of in 

First:  effect of chemically modified short interfering rna on development of airway in mice
Second:  potential of in vitro 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  journal of cancer research and clinical oncology 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  mapping the technological landscape of and vaccines 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  potential of in vitro 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  synthesis and activity of derivatives and analogues thereof 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  genetic hypothesis and side of in 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  and prognostic significance in 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  the sudden appearance of 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  school of population and global the university of evidence 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic
Second:  therapy for a feasibility study 

First:  journal new and antiviral properties against new and antiviral properties against
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  verification of negative pressure box for preventing severe acute respiratory syndrome coronavirus transmission during upper gastrointestinal endoscopy
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery
Second:  journal of cancer research and clinical oncology 

First:  socioeconomic position over the and subjective social status in relation to nutritional status and mental health among guatemalan adults
Second:  and prognostic significance in 

First:  socioeconomic position over the and subjective social status in relation to nutritional status and mental health among guatemalan adults
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  in a comprehensive investigation from exposure to treatment outcomes
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  in a comprehensive investigation from exposure to treatment outcomes
Second:  therapy for a feasibility study 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  a study on the influence of the pandemic on incomes in greece 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  the sudden appearance of 

First:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults
Second:  early forecasting of the potential risk zones of in 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  journal of cancer research and clinical oncology 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  spectrum of antimicrobial activity for disinfection of 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  potential of in vitro 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  letter to the editor are patients with autoimmune disease at greater risk of developing severe
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  letter to the editor are patients with autoimmune disease at greater risk of developing severe
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  letter to the editor are patients with autoimmune disease at greater risk of developing severe
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  editorial recommendations for the management of in countries 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  potential of in vitro 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  bacterial and the deadly trio in 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  and prognostic significance in 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  the sudden appearance of 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  investment and economic policy options in
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  investment and economic policy options in
Second:  article c social value and urban sustainability in food markets 

First:  investment and economic policy options in
Second:  mapping the technological landscape of and vaccines 

First:  investment and economic policy options in
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  investment and economic policy options in
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  investment and economic policy options in
Second:  editorial recommendations for the management of in countries 

First:  investment and economic policy options in
Second:  potential of in vitro 

First:  investment and economic policy options in
Second:  regular international perspectives and initiatives 

First:  investment and economic policy options in
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  investment and economic policy options in
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  investment and economic policy options in
Second:  and prognostic significance in 

First:  investment and economic policy options in
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  investment and economic policy options in
Second:  chapter from boom to the economic crisis 

First:  investment and economic policy options in
Second:  policy responses to the pandemic in vietnam 

First:  investment and economic policy options in
Second:  early forecasting of the potential risk zones of in 

First:  investment and economic policy options in
Second:  journal radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery 

First:  edema assessment by means of the and laser scanning microscopy
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  edema assessment by means of the and laser scanning microscopy
Second:  mapping the technological landscape of and vaccines 

First:  edema assessment by means of the and laser scanning microscopy
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  edema assessment by means of the and laser scanning microscopy
Second:  potential of in vitro 

First:  edema assessment by means of the and laser scanning microscopy
Second:  establishment of a reference panel for the detection of antibodies 

First:  edema assessment by means of the and laser scanning microscopy
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  edema assessment by means of the and laser scanning microscopy
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  edema assessment by means of the and laser scanning microscopy
Second:  the sudden appearance of 

First:  journal does there exist an obesity paradox in insights of the international short obesity and
Second:  and prognostic significance in 

First:  journal does there exist an obesity paradox in insights of the international short obesity and
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal does there exist an obesity paradox in insights of the international short obesity and
Second:  the sudden appearance of 

First:  respiratory management for critically ill patients with acute respiratory distress syndrome
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  respiratory management for critically ill patients with acute respiratory distress syndrome
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  respiratory management for critically ill patients with acute respiratory distress syndrome
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  case report mammography in the diagnosis of breast 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  journal of cancer research and clinical oncology 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  viral intestinal infections of animals and man 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  chest computed tomographic findings of patients with pneumonia 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  a review in bacterial infections 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  predicting risk of transition to severe infection 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  potential of in vitro 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  and prognostic significance in 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  the sudden appearance of 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  liver histopathology in severe respiratory failure is suggestive of vascular alterations
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  journal of cancer research and clinical oncology 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  and prognostic significance in 

First:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  viral intestinal infections of animals and man 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  a review in bacterial infections 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  potential of in vitro 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  a serological comparison of bovine coronavirus strains 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  and prognostic significance in 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  etiology of acute respiratory disease in fattening pigs in finland
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  mapping the technological landscape of and vaccines 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  editorial recommendations for the management of in countries 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  genetic hypothesis and side of in 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  and prognostic significance in 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  the sudden appearance of 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  school of population and global the university of evidence 

First:  knowledge and attitude towards and its prevention in selected ten towns of survey
Second:  early forecasting of the potential risk zones of in 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  mapping the technological landscape of and vaccines 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  editorial recommendations for the management of in countries 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  potential of in vitro 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  genetic hypothesis and side of in 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  and prognostic significance in 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control
Second:  early forecasting of the potential risk zones of in 

First:  conducting focus groups in neurodegenerative disease ethical and methodological considerations
Second:  journal of cancer research and clinical oncology 

First:  conducting focus groups in neurodegenerative disease ethical and methodological considerations
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  integrating research integrity into the history of science
Second:  journal of cancer research and clinical oncology 

First:  integrating research integrity into the history of science
Second:  mapping the technological landscape of and vaccines 

First:  integrating research integrity into the history of science
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  integrating research integrity into the history of science
Second:  basics of molecular biology 

First:  integrating research integrity into the history of science
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  integrating research integrity into the history of science
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  integrating research integrity into the history of science
Second:  journal of management control 

First:  integrating research integrity into the history of science
Second:  school of population and global the university of evidence 

First:  integrating research integrity into the history of science
Second:  early forecasting of the potential risk zones of in 

First:  hemophilia a case report
Second:  case report mammography in the diagnosis of breast 

First:  hemophilia a case report
Second:  syndrome in case report 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  mapping the technological landscape of and vaccines 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  editorial recommendations for the management of in countries 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  potential of in vitro 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  early forecasting of the potential risk zones of in 

First:  scenario modelling for the mitigation of deaths in intensive computer simulation study
Second:  therapy for a feasibility study 

First:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy
Second:  journal of cancer research and clinical oncology 

First:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy
Second:  therapy for a feasibility study 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  case report mammography in the diagnosis of breast 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  journal of cancer research and clinical oncology 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  the impact on surgical departments of hospitals 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  chest computed tomographic findings of patients with pneumonia 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  potential of in vitro 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  and prognostic significance in 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  pathology trainee redeployment and education during the an institutional experience
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  pathology trainee redeployment and education during the an institutional experience
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  pathology trainee redeployment and education during the an institutional experience
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a better understanding of social distancing
Second:  mapping the technological landscape of and vaccines 

First:  a better understanding of social distancing
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a better understanding of social distancing
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a better understanding of social distancing
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  a better understanding of social distancing
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a better understanding of social distancing
Second:  the sudden appearance of 

First:  a better understanding of social distancing
Second:  a protocol for a systematic review and 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  does the pandemic spell the end for the direct 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  potential of in vitro 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  bacterial and the deadly trio in 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  and prognostic significance in 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  the sudden appearance of 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  policy responses to the pandemic in vietnam 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  early forecasting of the potential risk zones of in 

First:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  marine drugs caged formed of the morphogenetic active inorganic are strong of
Second:  potential of in vitro 

First:  marine drugs caged formed of the morphogenetic active inorganic are strong of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the expression in human heart indicates new potential mechanism of heart injury among patients infected with
Second:  potential of in vitro 

First:  the expression in human heart indicates new potential mechanism of heart injury among patients infected with
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  a study on the influence of the pandemic on incomes in greece 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  case report mammography in the diagnosis of breast 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  potential of in vitro 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  the sudden appearance of 

First:  case report as a cause of unfavorable outcome in the twin pregnancy
Second:  early forecasting of the potential risk zones of in 

First:  cancer inpatient with a report from the brazilian national cancer institute brief cancer inpatient with
Second:  journal of cancer research and clinical oncology 

First:  minimum costs to manufacture new treatments for
Second:  therapy for a feasibility study 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  case report mammography in the diagnosis of breast 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  journal of cancer research and clinical oncology 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  viral intestinal infections of animals and man 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  a review in bacterial infections 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  potential of in vitro 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  a serological comparison of bovine coronavirus strains 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  and prognostic significance in 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  activity of world health formulations against enveloped including and emerging
Second:  synthesis and activity of derivatives and analogues thereof 

First:  activity of world health formulations against enveloped including and emerging
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  spectrum of antimicrobial activity for disinfection of 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  a review in bacterial infections 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  potential of in vitro 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  a serological comparison of bovine coronavirus strains 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase
Second:  therapy for a feasibility study 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  a study on the influence of the pandemic on incomes in greece 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  mapping the technological landscape of and vaccines 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  editorial recommendations for the management of in countries 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  the impact on surgical departments of hospitals 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  potential of in vitro 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  and prognostic significance in 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  the sudden appearance of 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  school of population and global the university of evidence 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  early forecasting of the potential risk zones of in 

First:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  and rapid nucleic acid detection of african swine fever
Second:  viral intestinal infections of animals and man 

First:  and rapid nucleic acid detection of african swine fever
Second:  a serological comparison of bovine coronavirus strains 

First:  depression and sleep quality in patients undergoing
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  depression and sleep quality in patients undergoing
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  depression and sleep quality in patients undergoing
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  depression and sleep quality in patients undergoing
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  depression and sleep quality in patients undergoing
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  depression and sleep quality in patients undergoing
Second:  and prognostic significance in 

First:  depression and sleep quality in patients undergoing
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  depression and sleep quality in patients undergoing
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  care for people with disease and related during from challenges to solutions
Second:  responding to healthcare disparities and challenges with access to care during 

First:  care for people with disease and related during from challenges to solutions
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  enhances the peroxidase activity of myoglobin against
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  enhances the peroxidase activity of myoglobin against
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  enhances the peroxidase activity of myoglobin against
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  enhances the peroxidase activity of myoglobin against
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  enhances the peroxidase activity of myoglobin against
Second:  spectrum of antimicrobial activity for disinfection of 

First:  enhances the peroxidase activity of myoglobin against
Second:  potential of in vitro 

First:  enhances the peroxidase activity of myoglobin against
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  enhances the peroxidase activity of myoglobin against
Second:  synthesis and activity of derivatives and analogues thereof 

First:  enhances the peroxidase activity of myoglobin against
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  enhances the peroxidase activity of myoglobin against
Second:  the sudden appearance of 

First:  enhances the peroxidase activity of myoglobin against
Second:  the function and inhibition by designed antiviral compounds 

First:  enhances the peroxidase activity of myoglobin against
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  isolation of aspergillus in respiratory samples of patients with in a spanish tertiary care hospital acknowledgments and funding conflicts of interest statement
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  isolation of aspergillus in respiratory samples of patients with in a spanish tertiary care hospital acknowledgments and funding conflicts of interest statement
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  genetic diversity in the yellow head complex
Second:  genetic hypothesis and side of in 

First:  genetic diversity in the yellow head complex
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  genetic diversity in the yellow head complex
Second:  the sudden appearance of 

First:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods
Second:  a study on the influence of the pandemic on incomes in greece 

First:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods
Second:  the sudden appearance of 

First:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods
Second:  early forecasting of the potential risk zones of in 

First:  and responses to in south a rapid qualitative assessment
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and responses to in south a rapid qualitative assessment
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and responses to in south a rapid qualitative assessment
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  and responses to in south a rapid qualitative assessment
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  and responses to in south a rapid qualitative assessment
Second:  editorial recommendations for the management of in countries 

First:  and responses to in south a rapid qualitative assessment
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  and responses to in south a rapid qualitative assessment
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  and responses to in south a rapid qualitative assessment
Second:  potential of in vitro 

First:  and responses to in south a rapid qualitative assessment
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  and responses to in south a rapid qualitative assessment
Second:  genetic hypothesis and side of in 

First:  and responses to in south a rapid qualitative assessment
Second:  and prognostic significance in 

First:  and responses to in south a rapid qualitative assessment
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and responses to in south a rapid qualitative assessment
Second:  policy responses to the pandemic in vietnam 

First:  and responses to in south a rapid qualitative assessment
Second:  a protocol for a systematic review and 

First:  and responses to in south a rapid qualitative assessment
Second:  early forecasting of the potential risk zones of in 

First:  and responses to in south a rapid qualitative assessment
Second:  therapy for a feasibility study 

First:  and responses to in south a rapid qualitative assessment
Second:  in a comprehensive investigation from exposure to treatment outcomes 

First:  and responses to in south a rapid qualitative assessment
Second:  investment and economic policy options in 

First:  eines in einer im der implementation of an operational concept in an ent clinic in the context of the pandemic
Second:  and prognostic significance in 

First:  eines in einer im der implementation of an operational concept in an ent clinic in the context of the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  eines in einer im der implementation of an operational concept in an ent clinic in the context of the pandemic
Second:  the sudden appearance of 

First:  and molecular hybrids of and acids as novel b virus agents
Second:  bacterial and the deadly trio in 

First:  and molecular hybrids of and acids as novel b virus agents
Second:  synthesis and activity of derivatives and analogues thereof 

First:  older experience of the a analysis of stresses and joys
Second:  a study on the influence of the pandemic on incomes in greece 

First:  older experience of the a analysis of stresses and joys
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  older experience of the a analysis of stresses and joys
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  older experience of the a analysis of stresses and joys
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  older experience of the a analysis of stresses and joys
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  older experience of the a analysis of stresses and joys
Second:  a remedy or a ripple in severe 

First:  older experience of the a analysis of stresses and joys
Second:  journal innovations in in the age of a systematic literature review 

First:  older experience of the a analysis of stresses and joys
Second:  disease in the era of an observation on a series of six patients with 

First:  older experience of the a analysis of stresses and joys
Second:  mapping the technological landscape of and vaccines 

First:  older experience of the a analysis of stresses and joys
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  older experience of the a analysis of stresses and joys
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  older experience of the a analysis of stresses and joys
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  older experience of the a analysis of stresses and joys
Second:  does the pandemic spell the end for the direct 

First:  older experience of the a analysis of stresses and joys
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  older experience of the a analysis of stresses and joys
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  older experience of the a analysis of stresses and joys
Second:  overall quality of sporting events and emotions as predictors of future intentions of duathlon participants 

First:  older experience of the a analysis of stresses and joys
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  older experience of the a analysis of stresses and joys
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  older experience of the a analysis of stresses and joys
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  older experience of the a analysis of stresses and joys
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  older experience of the a analysis of stresses and joys
Second:  excess neurological death in new york city after the emergence of 

First:  older experience of the a analysis of stresses and joys
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  older experience of the a analysis of stresses and joys
Second:  editorial recommendations for the management of in countries 

First:  older experience of the a analysis of stresses and joys
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  older experience of the a analysis of stresses and joys
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  older experience of the a analysis of stresses and joys
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  older experience of the a analysis of stresses and joys
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  older experience of the a analysis of stresses and joys
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  older experience of the a analysis of stresses and joys
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  older experience of the a analysis of stresses and joys
Second:  a comparative analysis on risk communication between international and chinese literature from the perspective of knowledge domain visualization 

First:  older experience of the a analysis of stresses and joys
Second:  policymaking and the wicked problem of sdg gender equality 

First:  older experience of the a analysis of stresses and joys
Second:  the impact on surgical departments of hospitals 

First:  older experience of the a analysis of stresses and joys
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  older experience of the a analysis of stresses and joys
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  older experience of the a analysis of stresses and joys
Second:  spectrum of antimicrobial activity for disinfection of 

First:  older experience of the a analysis of stresses and joys
Second:  international forum on the collection and use of convalescent challenges and lessons summary 

First:  older experience of the a analysis of stresses and joys
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  older experience of the a analysis of stresses and joys
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  older experience of the a analysis of stresses and joys
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  older experience of the a analysis of stresses and joys
Second:  toxic and properties of an coordination complex of 

First:  older experience of the a analysis of stresses and joys
Second:  the common missed instances and areas after years of education 

First:  older experience of the a analysis of stresses and joys
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  older experience of the a analysis of stresses and joys
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  older experience of the a analysis of stresses and joys
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  older experience of the a analysis of stresses and joys
Second:  concept of immune response 

First:  older experience of the a analysis of stresses and joys
Second:  potential of in vitro 

First:  older experience of the a analysis of stresses and joys
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  older experience of the a analysis of stresses and joys
Second:  bacterial and the deadly trio in 

First:  older experience of the a analysis of stresses and joys
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  older experience of the a analysis of stresses and joys
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  older experience of the a analysis of stresses and joys
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  older experience of the a analysis of stresses and joys
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  older experience of the a analysis of stresses and joys
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  older experience of the a analysis of stresses and joys
Second:  a integrated with heater for visual testing of 

First:  older experience of the a analysis of stresses and joys
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  older experience of the a analysis of stresses and joys
Second:  establishment of a reference panel for the detection of antibodies 

First:  older experience of the a analysis of stresses and joys
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  older experience of the a analysis of stresses and joys
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  older experience of the a analysis of stresses and joys
Second:  task detection of persuasion techniques in texts and images 

First:  older experience of the a analysis of stresses and joys
Second:  synthesis and activity of derivatives and analogues thereof 

First:  older experience of the a analysis of stresses and joys
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  older experience of the a analysis of stresses and joys
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  older experience of the a analysis of stresses and joys
Second:  genetic hypothesis and side of in 

First:  older experience of the a analysis of stresses and joys
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  older experience of the a analysis of stresses and joys
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  older experience of the a analysis of stresses and joys
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  older experience of the a analysis of stresses and joys
Second:  and prognostic significance in 

First:  older experience of the a analysis of stresses and joys
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  older experience of the a analysis of stresses and joys
Second:  of period between onset of symptoms for a cohort study short title aggressiveness of corresponding author 

First:  older experience of the a analysis of stresses and joys
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  older experience of the a analysis of stresses and joys
Second:  from ego to for ontology in the 

First:  older experience of the a analysis of stresses and joys
Second:  the sudden appearance of 

First:  older experience of the a analysis of stresses and joys
Second:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors 

First:  older experience of the a analysis of stresses and joys
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  older experience of the a analysis of stresses and joys
Second:  school of population and global the university of evidence 

First:  older experience of the a analysis of stresses and joys
Second:  a visual analytics approach to facilitate the of online exams 

First:  older experience of the a analysis of stresses and joys
Second:  a protocol for a systematic review and 

First:  older experience of the a analysis of stresses and joys
Second:  early forecasting of the potential risk zones of in 

First:  older experience of the a analysis of stresses and joys
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  older experience of the a analysis of stresses and joys
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  older experience of the a analysis of stresses and joys
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  older experience of the a analysis of stresses and joys
Second:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults 

First:  older experience of the a analysis of stresses and joys
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  older experience of the a analysis of stresses and joys
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  older experience of the a analysis of stresses and joys
Second:  integrating research integrity into the history of science 

First:  older experience of the a analysis of stresses and joys
Second:  a better understanding of social distancing 

First:  older experience of the a analysis of stresses and joys
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  older experience of the a analysis of stresses and joys
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  older experience of the a analysis of stresses and joys
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  older experience of the a analysis of stresses and joys
Second:  and responses to in south a rapid qualitative assessment 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  journal of cancer research and clinical oncology 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  viral intestinal infections of animals and man 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  in ckd lessons from ckd patients with kidney disease 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  prophylaxis of with and chloroquine accepted article 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  chest computed tomographic findings of patients with pneumonia 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  nutritional parameters associated with prognosis in ill 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  a review in bacterial infections 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  predicting risk of transition to severe infection 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  a serological comparison of bovine coronavirus strains 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  implications for people with chagas disease 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  journal fungal in patients with role of antifungal 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  combination kills bladder cancer cells synergistically 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  mapping the technological landscape of and vaccines 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  does the pandemic spell the end for the direct 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  editorial recommendations for the management of in countries 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  the sudden appearance of 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  policy responses to the pandemic in vietnam 

First:  tracking the twitter attention around the research efforts on the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  journal case report rapid development of seizures and pres in a patient
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  a remedy or a ripple in severe 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  journal innovations in in the age of a systematic literature review 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  mapping the technological landscape of and vaccines 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  does the pandemic spell the end for the direct 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  reply to against the risk of airborne 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  editorial recommendations for the management of in countries 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  spectrum of antimicrobial activity for disinfection of 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  concept of immune response 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  potential of in vitro 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  establishment of a reference panel for the detection of antibodies 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  synthesis and activity of derivatives and analogues thereof 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  genetic hypothesis and side of in 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  and prognostic significance in 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  the sudden appearance of 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  school of population and global the university of evidence 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  a protocol for a systematic review and 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  early forecasting of the potential risk zones of in 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  therapy for a feasibility study 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  a better understanding of social distancing 

First:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study
Second:  older experience of the a analysis of stresses and joys 

First:  molecular sciences challenges and pitfalls of using as an adjuvant drug in 
Second:  potential of in vitro 

First:  molecular sciences challenges and pitfalls of using as an adjuvant drug in 
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  potential of in vitro 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  supramolecular architecture of the coronavirus particle 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  a serological comparison of bovine coronavirus strains 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  restriction of replication by targeting programmed ribosomal in vitro 

First:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  surveillance of pathogens in dairy and beef cows in yamagata japan from to
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  a study on the influence of the pandemic on incomes in greece 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  case report mammography in the diagnosis of breast 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  journal innovations in in the age of a systematic literature review 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  disease in the era of an observation on a series of six patients with 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  mapping the technological landscape of and vaccines 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  does the pandemic spell the end for the direct 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  editorial recommendations for the management of in countries 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  the impact on surgical departments of hospitals 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  potential of in vitro 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  establishment of a reference panel for the detection of antibodies 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  genetic hypothesis and side of in 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  and prognostic significance in 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  the sudden appearance of 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  school of population and global the university of evidence 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  early forecasting of the potential risk zones of in 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  therapy for a feasibility study 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  older experience of the a analysis of stresses and joys 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  effectiveness of a fluid chart in outpatient management of suspected dengue a pilot study
Second:  potential of in vitro 

First:  effectiveness of a fluid chart in outpatient management of suspected dengue a pilot study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal of banking regulation
Second:  journal innovations in in the age of a systematic literature review 

First:  journal of banking regulation
Second:  journal of cancer research and clinical oncology 

First:  journal of banking regulation
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  journal of banking regulation
Second:  editorial recommendations for the management of in countries 

First:  journal of banking regulation
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal of banking regulation
Second:  journal of management control 

First:  journal of banking regulation
Second:  early forecasting of the potential risk zones of in 

First:  journal of banking regulation
Second:  investment and economic policy options in 

First:  mask social and gender correlates of vaccine intentions among adults in the us
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  mask social and gender correlates of vaccine intentions among adults in the us
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  social determinants of mortality at the county level
Second:  a study on the influence of the pandemic on incomes in greece 

First:  social determinants of mortality at the county level
Second:  mapping the technological landscape of and vaccines 

First:  social determinants of mortality at the county level
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  social determinants of mortality at the county level
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  social determinants of mortality at the county level
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  social determinants of mortality at the county level
Second:  potential of in vitro 

First:  social determinants of mortality at the county level
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  social determinants of mortality at the county level
Second:  and prognostic significance in 

First:  social determinants of mortality at the county level
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  social determinants of mortality at the county level
Second:  the sudden appearance of 

First:  social determinants of mortality at the county level
Second:  school of population and global the university of evidence 

First:  social determinants of mortality at the county level
Second:  early forecasting of the potential risk zones of in 

First:  social determinants of mortality at the county level
Second:  older experience of the a analysis of stresses and joys 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  a study on the influence of the pandemic on incomes in greece 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  potential of in vitro 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  the sudden appearance of 

First:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece
Second:  early forecasting of the potential risk zones of in 

First:  use of in human immunodeficiency virus infection
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  use of in human immunodeficiency virus infection
Second:  case report mammography in the diagnosis of breast 

First:  use of in human immunodeficiency virus infection
Second:  viral intestinal infections of animals and man 

First:  use of in human immunodeficiency virus infection
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  use of in human immunodeficiency virus infection
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  use of in human immunodeficiency virus infection
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  use of in human immunodeficiency virus infection
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  use of in human immunodeficiency virus infection
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  use of in human immunodeficiency virus infection
Second:  microorganisms nasal microbiota in rsv 

First:  use of in human immunodeficiency virus infection
Second:  human infections associated with wild birds 

First:  use of in human immunodeficiency virus infection
Second:  spectrum of antimicrobial activity for disinfection of 

First:  use of in human immunodeficiency virus infection
Second:  a review in bacterial infections 

First:  use of in human immunodeficiency virus infection
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  use of in human immunodeficiency virus infection
Second:  potential of in vitro 

First:  use of in human immunodeficiency virus infection
Second:  bacterial and the deadly trio in 

First:  use of in human immunodeficiency virus infection
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  use of in human immunodeficiency virus infection
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  use of in human immunodeficiency virus infection
Second:  a serological comparison of bovine coronavirus strains 

First:  use of in human immunodeficiency virus infection
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  use of in human immunodeficiency virus infection
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  use of in human immunodeficiency virus infection
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  use of in human immunodeficiency virus infection
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  use of in human immunodeficiency virus infection
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  use of in human immunodeficiency virus infection
Second:  protects human alveolar epithelial cells against injury induced by influenza a virus 

First:  use of in human immunodeficiency virus infection
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  use of in human immunodeficiency virus infection
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  use of in human immunodeficiency virus infection
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  use of in human immunodeficiency virus infection
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  use of in human immunodeficiency virus infection
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  use of in human immunodeficiency virus infection
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  of population groups with the most interactions for vaccination can substantially reduce total fatalities
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  case report mammography in the diagnosis of breast 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  journal of cancer research and clinical oncology 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  mapping the technological landscape of and vaccines 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  editorial recommendations for the management of in countries 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  potential of in vitro 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  establishment of a reference panel for the detection of antibodies 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  and prognostic significance in 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  the sudden appearance of 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  school of population and global the university of evidence 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  early forecasting of the potential risk zones of in 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  older experience of the a analysis of stresses and joys 

First:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  viral intestinal infections of animals and man 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  a review in bacterial infections 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  potential of in vitro 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  a serological comparison of bovine coronavirus strains 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  restriction of replication by targeting programmed ribosomal in vitro 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro
Second:  use of in human immunodeficiency virus infection 

First:  divergence of severe acute respiratory syndrome in primate models
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  divergence of severe acute respiratory syndrome in primate models
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  divergence of severe acute respiratory syndrome in primate models
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  divergence of severe acute respiratory syndrome in primate models
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  divergence of severe acute respiratory syndrome in primate models
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  letters to the editor
Second:  does the pandemic spell the end for the direct 

First:  letters to the editor
Second:  reply to against the risk of airborne 

First:  letters to the editor
Second:  editorial recommendations for the management of in countries 

First:  letters to the editor
Second:  letter to the editor 

First:  letters to the editor
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  letters to the editor
Second:  from ego to for ontology in the 

First:  letters to the editor
Second:  the sudden appearance of 

First:  letters to the editor
Second:  policy responses to the pandemic in vietnam 

First:  letters to the editor
Second:  letters to the editor letters to the editor 

First:  effects of interval training and training on and resilience in healthy adults during coronavirus disease a randomized controlled trial
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  danish modern ecology and core studies
Second:  basics of molecular biology 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  case report mammography in the diagnosis of breast 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  journal of cancer research and clinical oncology 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  expert consensus for treating cancer patients during the pandemic of
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  immigration policy and justice in the era of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  immigration policy and justice in the era of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  immigration policy and justice in the era of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  immigration policy and justice in the era of
Second:  journal innovations in in the age of a systematic literature review 

First:  immigration policy and justice in the era of
Second:  disease in the era of an observation on a series of six patients with 

First:  immigration policy and justice in the era of
Second:  mapping the technological landscape of and vaccines 

First:  immigration policy and justice in the era of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  immigration policy and justice in the era of
Second:  does the pandemic spell the end for the direct 

First:  immigration policy and justice in the era of
Second:  coordinating genomic surveillance in the united states 

First:  immigration policy and justice in the era of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  immigration policy and justice in the era of
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  immigration policy and justice in the era of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  immigration policy and justice in the era of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  immigration policy and justice in the era of
Second:  excess neurological death in new york city after the emergence of 

First:  immigration policy and justice in the era of
Second:  editorial recommendations for the management of in countries 

First:  immigration policy and justice in the era of
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  immigration policy and justice in the era of
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  immigration policy and justice in the era of
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  immigration policy and justice in the era of
Second:  policymaking and the wicked problem of sdg gender equality 

First:  immigration policy and justice in the era of
Second:  the impact on surgical departments of hospitals 

First:  immigration policy and justice in the era of
Second:  letter to the editor 

First:  immigration policy and justice in the era of
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  immigration policy and justice in the era of
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  immigration policy and justice in the era of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  immigration policy and justice in the era of
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  immigration policy and justice in the era of
Second:  the common missed instances and areas after years of education 

First:  immigration policy and justice in the era of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  immigration policy and justice in the era of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  immigration policy and justice in the era of
Second:  potential of in vitro 

First:  immigration policy and justice in the era of
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  immigration policy and justice in the era of
Second:  bacterial and the deadly trio in 

First:  immigration policy and justice in the era of
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  immigration policy and justice in the era of
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  immigration policy and justice in the era of
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  immigration policy and justice in the era of
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  immigration policy and justice in the era of
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  immigration policy and justice in the era of
Second:  establishment of a reference panel for the detection of antibodies 

First:  immigration policy and justice in the era of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  immigration policy and justice in the era of
Second:  genetic hypothesis and side of in 

First:  immigration policy and justice in the era of
Second:  tactics in support of migrations 

First:  immigration policy and justice in the era of
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  immigration policy and justice in the era of
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  immigration policy and justice in the era of
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  immigration policy and justice in the era of
Second:  and prognostic significance in 

First:  immigration policy and justice in the era of
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  immigration policy and justice in the era of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  immigration policy and justice in the era of
Second:  from ego to for ontology in the 

First:  immigration policy and justice in the era of
Second:  chapter from boom to the economic crisis 

First:  immigration policy and justice in the era of
Second:  soft law governance in times of coronavirus in spain 

First:  immigration policy and justice in the era of
Second:  the sudden appearance of 

First:  immigration policy and justice in the era of
Second:  policy responses to the pandemic in vietnam 

First:  immigration policy and justice in the era of
Second:  school of population and global the university of evidence 

First:  immigration policy and justice in the era of
Second:  letters to the editor letters to the editor 

First:  immigration policy and justice in the era of
Second:  early forecasting of the potential risk zones of in 

First:  immigration policy and justice in the era of
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  immigration policy and justice in the era of
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  immigration policy and justice in the era of
Second:  investment and economic policy options in 

First:  immigration policy and justice in the era of
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  immigration policy and justice in the era of
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  immigration policy and justice in the era of
Second:  integrating research integrity into the history of science 

First:  immigration policy and justice in the era of
Second:  a better understanding of social distancing 

First:  immigration policy and justice in the era of
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  immigration policy and justice in the era of
Second:  older experience of the a analysis of stresses and joys 

First:  immigration policy and justice in the era of
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  immigration policy and justice in the era of
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  immigration policy and justice in the era of
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  immigration policy and justice in the era of
Second:  journal of banking regulation 

First:  immigration policy and justice in the era of
Second:  social determinants of mortality at the county level 

First:  immigration policy and justice in the era of
Second:  letters to the editor 

First:  regression of infantile glioblastoma after treatment with
Second:  journal of cancer research and clinical oncology 

First:  regression of infantile glioblastoma after treatment with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  regression of infantile glioblastoma after treatment with
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  regression of infantile glioblastoma after treatment with
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  regression of infantile glioblastoma after treatment with
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  regression of infantile glioblastoma after treatment with
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  regression of infantile glioblastoma after treatment with
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  regression of infantile glioblastoma after treatment with
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  diffusion as a first model of spread of viral infection
Second:  a study on the influence of the pandemic on incomes in greece 

First:  diffusion as a first model of spread of viral infection
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  diffusion as a first model of spread of viral infection
Second:  mapping the technological landscape of and vaccines 

First:  diffusion as a first model of spread of viral infection
Second:  viral intestinal infections of animals and man 

First:  diffusion as a first model of spread of viral infection
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  diffusion as a first model of spread of viral infection
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  diffusion as a first model of spread of viral infection
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  diffusion as a first model of spread of viral infection
Second:  spectrum of antimicrobial activity for disinfection of 

First:  diffusion as a first model of spread of viral infection
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  diffusion as a first model of spread of viral infection
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  diffusion as a first model of spread of viral infection
Second:  concept of immune response 

First:  diffusion as a first model of spread of viral infection
Second:  potential of in vitro 

First:  diffusion as a first model of spread of viral infection
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  diffusion as a first model of spread of viral infection
Second:  establishment of a reference panel for the detection of antibodies 

First:  diffusion as a first model of spread of viral infection
Second:  a serological comparison of bovine coronavirus strains 

First:  diffusion as a first model of spread of viral infection
Second:  genetic hypothesis and side of in 

First:  diffusion as a first model of spread of viral infection
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  diffusion as a first model of spread of viral infection
Second:  the sudden appearance of 

First:  diffusion as a first model of spread of viral infection
Second:  early forecasting of the potential risk zones of in 

First:  diffusion as a first model of spread of viral infection
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  diffusion as a first model of spread of viral infection
Second:  older experience of the a analysis of stresses and joys 

First:  properties of on human ex vivo and in vitro observations
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  properties of on human ex vivo and in vitro observations
Second:  potential of in vitro 

First:  properties of on human ex vivo and in vitro observations
Second:  synthesis and activity of derivatives and analogues thereof 

First:  properties of on human ex vivo and in vitro observations
Second:  genetic hypothesis and side of in 

First:  properties of on human ex vivo and in vitro observations
Second:  and prognostic significance in 

First:  properties of on human ex vivo and in vitro observations
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  properties of on human ex vivo and in vitro observations
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation
Second:  journal of cancer research and clinical oncology 

First:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation
Second:  a review in bacterial infections 

First:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  digitalized adaptation of oncology trials during and after
Second:  journal of cancer research and clinical oncology 

First:  digitalized adaptation of oncology trials during and after
Second:  and prognostic significance in 

First:  digitalized adaptation of oncology trials during and after
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  digitalized adaptation of oncology trials during and after
Second:  the sudden appearance of 

First:  outbreak situation and its psychological impact among surgeon in training in france
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  outbreak situation and its psychological impact among surgeon in training in france
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  outbreak situation and its psychological impact among surgeon in training in france
Second:  and prognostic significance in 

First:  outbreak situation and its psychological impact among surgeon in training in france
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  a study on the influence of the pandemic on incomes in greece 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  case report mammography in the diagnosis of breast 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  journal of cancer research and clinical oncology 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  editorial recommendations for the management of in countries 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  the impact on surgical departments of hospitals 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  potential of in vitro 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  genetic hypothesis and side of in 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  and prognostic significance in 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  early forecasting of the potential risk zones of in 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california
Second:  older experience of the a analysis of stresses and joys 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  potential of in vitro 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  synthesis and activity of derivatives and analogues thereof 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  early forecasting of the potential risk zones of in 

First:  alkaloids from as potential inhibitors of viral an in silico study
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  a rare complication of spontaneous pneumothorax following case report running associated pneumothorax and
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  a rare complication of spontaneous pneumothorax following case report running associated pneumothorax and
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a rare complication of spontaneous pneumothorax following case report running associated pneumothorax and
Second:  the sudden appearance of 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  mapping the technological landscape of and vaccines 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  does the pandemic spell the end for the direct 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  editorial recommendations for the management of in countries 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  spectrum of antimicrobial activity for disinfection of 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  the common missed instances and areas after years of education 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  potential of in vitro 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  bacterial and the deadly trio in 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  establishment of a reference panel for the detection of antibodies 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  genetic hypothesis and side of in 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  and prognostic significance in 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  from ego to for ontology in the 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  the sudden appearance of 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  school of population and global the university of evidence 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  investment and economic policy options in 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  older experience of the a analysis of stresses and joys 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  routing choices for safe and efficient transportation in the face of the pandemic
Second:  immigration policy and justice in the era of 

First:  vaccination in patients with multiple focus on immune response vaccination and immune response in mm
Second:  concept of immune response 

First:  vaccination in patients with multiple focus on immune response vaccination and immune response in mm
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the and ends of rnas is not
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the and ends of rnas is not
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the and ends of rnas is not
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the and ends of rnas is not
Second:  disease in the era of an observation on a series of six patients with 

First:  the and ends of rnas is not
Second:  mapping the technological landscape of and vaccines 

First:  the and ends of rnas is not
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the and ends of rnas is not
Second:  does the pandemic spell the end for the direct 

First:  the and ends of rnas is not
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the and ends of rnas is not
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the and ends of rnas is not
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  the and ends of rnas is not
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the and ends of rnas is not
Second:  reply to against the risk of airborne 

First:  the and ends of rnas is not
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the and ends of rnas is not
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the and ends of rnas is not
Second:  editorial recommendations for the management of in countries 

First:  the and ends of rnas is not
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the and ends of rnas is not
Second:  prophylaxis of with and chloroquine accepted article 

First:  the and ends of rnas is not
Second:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies 

First:  the and ends of rnas is not
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the and ends of rnas is not
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the and ends of rnas is not
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the and ends of rnas is not
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  the and ends of rnas is not
Second:  the impact on surgical departments of hospitals 

First:  the and ends of rnas is not
Second:  letter to the editor 

First:  the and ends of rnas is not
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the and ends of rnas is not
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the and ends of rnas is not
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  the and ends of rnas is not
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the and ends of rnas is not
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  the and ends of rnas is not
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the and ends of rnas is not
Second:  toxic and properties of an coordination complex of 

First:  the and ends of rnas is not
Second:  the common missed instances and areas after years of education 

First:  the and ends of rnas is not
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the and ends of rnas is not
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the and ends of rnas is not
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the and ends of rnas is not
Second:  potential of in vitro 

First:  the and ends of rnas is not
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the and ends of rnas is not
Second:  bacterial and the deadly trio in 

First:  the and ends of rnas is not
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  the and ends of rnas is not
Second:  supramolecular architecture of the coronavirus particle 

First:  the and ends of rnas is not
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  the and ends of rnas is not
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the and ends of rnas is not
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the and ends of rnas is not
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the and ends of rnas is not
Second:  establishment of a reference panel for the detection of antibodies 

First:  the and ends of rnas is not
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the and ends of rnas is not
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  the and ends of rnas is not
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the and ends of rnas is not
Second:  genetic hypothesis and side of in 

First:  the and ends of rnas is not
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  the and ends of rnas is not
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  the and ends of rnas is not
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the and ends of rnas is not
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the and ends of rnas is not
Second:  and prognostic significance in 

First:  the and ends of rnas is not
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  the and ends of rnas is not
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the and ends of rnas is not
Second:  from ego to for ontology in the 

First:  the and ends of rnas is not
Second:  the sudden appearance of 

First:  the and ends of rnas is not
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the and ends of rnas is not
Second:  school of population and global the university of evidence 

First:  the and ends of rnas is not
Second:  letters to the editor letters to the editor 

First:  the and ends of rnas is not
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  the and ends of rnas is not
Second:  a protocol for a systematic review and 

First:  the and ends of rnas is not
Second:  early forecasting of the potential risk zones of in 

First:  the and ends of rnas is not
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  the and ends of rnas is not
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  the and ends of rnas is not
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the and ends of rnas is not
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  the and ends of rnas is not
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  the and ends of rnas is not
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the and ends of rnas is not
Second:  older experience of the a analysis of stresses and joys 

First:  the and ends of rnas is not
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  the and ends of rnas is not
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the and ends of rnas is not
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the and ends of rnas is not
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  the and ends of rnas is not
Second:  letters to the editor 

First:  the and ends of rnas is not
Second:  immigration policy and justice in the era of 

First:  the and ends of rnas is not
Second:  diffusion as a first model of spread of viral infection 

First:  the and ends of rnas is not
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  does the pandemic spell the end for the direct 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  editorial recommendations for the management of in countries 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  potential of in vitro 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  establishment of a reference panel for the detection of antibodies 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  from ego to for ontology in the 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  the sudden appearance of 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  early forecasting of the potential risk zones of in 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  older experience of the a analysis of stresses and joys 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  immigration policy and justice in the era of 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the cost of getting is it time for change in the adult reconstruction fellowship application
Second:  the and ends of rnas is not 

First:  is the mother of specialist palliative care service innovation and practice change in response to results from a multinational survey
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  more severe presentations of acute appendicitis during
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  more severe presentations of acute appendicitis during
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  more severe presentations of acute appendicitis during
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  more severe presentations of acute appendicitis during
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  more severe presentations of acute appendicitis during
Second:  predicting risk of transition to severe infection 

First:  more severe presentations of acute appendicitis during
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  more severe presentations of acute appendicitis during
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  more severe presentations of acute appendicitis during
Second:  the sudden appearance of 

First:  more severe presentations of acute appendicitis during
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  more severe presentations of acute appendicitis during
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  more severe presentations of acute appendicitis during
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  more severe presentations of acute appendicitis during
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  and the saga continues
Second:  a study on the influence of the pandemic on incomes in greece 

First:  and the saga continues
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and the saga continues
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and the saga continues
Second:  disease in the era of an observation on a series of six patients with 

First:  and the saga continues
Second:  mapping the technological landscape of and vaccines 

First:  and the saga continues
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  and the saga continues
Second:  does the pandemic spell the end for the direct 

First:  and the saga continues
Second:  and cell biology lung advances in generation and 

First:  and the saga continues
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and the saga continues
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  and the saga continues
Second:  editorial recommendations for the management of in countries 

First:  and the saga continues
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  and the saga continues
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  and the saga continues
Second:  letter to the editor 

First:  and the saga continues
Second:  international forum on the collection and use of convalescent challenges and lessons summary 

First:  and the saga continues
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  and the saga continues
Second:  toxic and properties of an coordination complex of 

First:  and the saga continues
Second:  the common missed instances and areas after years of education 

First:  and the saga continues
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  and the saga continues
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  and the saga continues
Second:  potential of in vitro 

First:  and the saga continues
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  and the saga continues
Second:  bacterial and the deadly trio in 

First:  and the saga continues
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  and the saga continues
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  and the saga continues
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  and the saga continues
Second:  establishment of a reference panel for the detection of antibodies 

First:  and the saga continues
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  and the saga continues
Second:  synthesis and activity of derivatives and analogues thereof 

First:  and the saga continues
Second:  genetic hypothesis and side of in 

First:  and the saga continues
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  and the saga continues
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  and the saga continues
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  and the saga continues
Second:  and prognostic significance in 

First:  and the saga continues
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and the saga continues
Second:  from ego to for ontology in the 

First:  and the saga continues
Second:  the sudden appearance of 

First:  and the saga continues
Second:  school of population and global the university of evidence 

First:  and the saga continues
Second:  letters to the editor letters to the editor 

First:  and the saga continues
Second:  early forecasting of the potential risk zones of in 

First:  and the saga continues
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  and the saga continues
Second:  older experience of the a analysis of stresses and joys 

First:  and the saga continues
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  and the saga continues
Second:  letters to the editor 

First:  and the saga continues
Second:  immigration policy and justice in the era of 

First:  and the saga continues
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  and the saga continues
Second:  the and ends of rnas is not 

First:  and the saga continues
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  case report mammography in the diagnosis of breast 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  journal of cancer research and clinical oncology 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  viral intestinal infections of animals and man 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  in ckd lessons from ckd patients with kidney disease 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  chest computed tomographic findings of patients with pneumonia 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  nutritional parameters associated with prognosis in ill 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  a review in bacterial infections 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  predicting risk of transition to severe infection 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  journal incidence of pulmonary embolism in patients with respiratory support during outbreak credit author statement incidence of pulmonary embolism in patients with invasive respiratory support during outbreak 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  a serological comparison of bovine coronavirus strains 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  implications for people with chagas disease 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  journal fungal in patients with role of antifungal 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  mortality rates due to respiratory tract diseases in iran during a study 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  combination kills bladder cancer cells synergistically 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  reversible and feline skin fragility syndrome in three cats 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  verification of negative pressure box for preventing severe acute respiratory syndrome coronavirus transmission during upper gastrointestinal endoscopy 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  depression and sleep quality in patients undergoing 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  use of in human immunodeficiency virus infection 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  regression of infantile glioblastoma after treatment with 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  vaccination in patients with multiple focus on immune response vaccination and immune response in mm 

First:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome
Second:  more severe presentations of acute appendicitis during 

First:  use and content of primary care vs telemedicine care visits during the pandemic in the us key points
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  environmental research and public health the impact of on food results of a survey
Second:  a study on the influence of the pandemic on incomes in greece 

First:  environmental research and public health the impact of on food results of a survey
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  environmental research and public health the impact of on food results of a survey
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  environmental research and public health the impact of on food results of a survey
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  environmental research and public health the impact of on food results of a survey
Second:  journal of cancer research and clinical oncology 

First:  environmental research and public health the impact of on food results of a survey
Second:  mapping the technological landscape of and vaccines 

First:  environmental research and public health the impact of on food results of a survey
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  environmental research and public health the impact of on food results of a survey
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  environmental research and public health the impact of on food results of a survey
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  environmental research and public health the impact of on food results of a survey
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  environmental research and public health the impact of on food results of a survey
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  environmental research and public health the impact of on food results of a survey
Second:  editorial recommendations for the management of in countries 

First:  environmental research and public health the impact of on food results of a survey
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  environmental research and public health the impact of on food results of a survey
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  environmental research and public health the impact of on food results of a survey
Second:  the impact on surgical departments of hospitals 

First:  environmental research and public health the impact of on food results of a survey
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  environmental research and public health the impact of on food results of a survey
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  environmental research and public health the impact of on food results of a survey
Second:  spectrum of antimicrobial activity for disinfection of 

First:  environmental research and public health the impact of on food results of a survey
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  environmental research and public health the impact of on food results of a survey
Second:  toxic and properties of an coordination complex of 

First:  environmental research and public health the impact of on food results of a survey
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  environmental research and public health the impact of on food results of a survey
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  environmental research and public health the impact of on food results of a survey
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  environmental research and public health the impact of on food results of a survey
Second:  potential of in vitro 

First:  environmental research and public health the impact of on food results of a survey
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  environmental research and public health the impact of on food results of a survey
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  environmental research and public health the impact of on food results of a survey
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  environmental research and public health the impact of on food results of a survey
Second:  establishment of a reference panel for the detection of antibodies 

First:  environmental research and public health the impact of on food results of a survey
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  environmental research and public health the impact of on food results of a survey
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  environmental research and public health the impact of on food results of a survey
Second:  genetic hypothesis and side of in 

First:  environmental research and public health the impact of on food results of a survey
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  environmental research and public health the impact of on food results of a survey
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  environmental research and public health the impact of on food results of a survey
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  environmental research and public health the impact of on food results of a survey
Second:  and prognostic significance in 

First:  environmental research and public health the impact of on food results of a survey
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  environmental research and public health the impact of on food results of a survey
Second:  journal of management control 

First:  environmental research and public health the impact of on food results of a survey
Second:  the sudden appearance of 

First:  environmental research and public health the impact of on food results of a survey
Second:  school of population and global the university of evidence 

First:  environmental research and public health the impact of on food results of a survey
Second:  early forecasting of the potential risk zones of in 

First:  environmental research and public health the impact of on food results of a survey
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  environmental research and public health the impact of on food results of a survey
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  environmental research and public health the impact of on food results of a survey
Second:  investment and economic policy options in 

First:  environmental research and public health the impact of on food results of a survey
Second:  integrating research integrity into the history of science 

First:  environmental research and public health the impact of on food results of a survey
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  environmental research and public health the impact of on food results of a survey
Second:  older experience of the a analysis of stresses and joys 

First:  environmental research and public health the impact of on food results of a survey
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  environmental research and public health the impact of on food results of a survey
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  environmental research and public health the impact of on food results of a survey
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  environmental research and public health the impact of on food results of a survey
Second:  immigration policy and justice in the era of 

First:  environmental research and public health the impact of on food results of a survey
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  environmental research and public health the impact of on food results of a survey
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  environmental research and public health the impact of on food results of a survey
Second:  the and ends of rnas is not 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  journal innovations in in the age of a systematic literature review 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  mapping the technological landscape of and vaccines 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  does the pandemic spell the end for the direct 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  editorial recommendations for the management of in countries 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  the impact on surgical departments of hospitals 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  potential of in vitro 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  bacterial and the deadly trio in 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  genetic hypothesis and side of in 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  and prognostic significance in 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  the sudden appearance of 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  early forecasting of the potential risk zones of in 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  and responses to in south a rapid qualitative assessment 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  older experience of the a analysis of stresses and joys 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  immigration policy and justice in the era of 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  the and ends of rnas is not 

First:  result in changes in human mobility which may impact the epidemiologic dynamics of
Second:  environmental research and public health the impact of on food results of a survey 

First:  international archives of occupational and environmental health
Second:  journal of cancer research and clinical oncology 

First:  international archives of occupational and environmental health
Second:  mapping the technological landscape of and vaccines 

First:  international archives of occupational and environmental health
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  international archives of occupational and environmental health
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  international archives of occupational and environmental health
Second:  editorial recommendations for the management of in countries 

First:  international archives of occupational and environmental health
Second:  the impact on surgical departments of hospitals 

First:  international archives of occupational and environmental health
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  international archives of occupational and environmental health
Second:  regular international perspectives and initiatives 

First:  international archives of occupational and environmental health
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  international archives of occupational and environmental health
Second:  and prognostic significance in 

First:  international archives of occupational and environmental health
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  international archives of occupational and environmental health
Second:  journal of management control 

First:  international archives of occupational and environmental health
Second:  school of population and global the university of evidence 

First:  international archives of occupational and environmental health
Second:  journal radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery 

First:  international archives of occupational and environmental health
Second:  investment and economic policy options in 

First:  international archives of occupational and environmental health
Second:  journal of banking regulation 

First:  international archives of occupational and environmental health
Second:  immigration policy and justice in the era of 

First:  international archives of occupational and environmental health
Second:  environmental research and public health the impact of on food results of a survey 

First:  and what evidence needs our
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and what evidence needs our
Second:  what can we learn from military nursing and 

First:  and what evidence needs our
Second:  then tell me what you think about a freedom of expression perspective on the decision in ju hte 

First:  and what evidence needs our
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  and what evidence needs our
Second:  and prognostic significance in 

First:  and what evidence needs our
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and what evidence needs our
Second:  a better understanding of social distancing 

First:  and what evidence needs our
Second:  older experience of the a analysis of stresses and joys 

First:  and what evidence needs our
Second:  the and ends of rnas is not 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  potential of in vitro 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  synthesis and activity of derivatives and analogues thereof 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  how can blockchain help people in the event of pandemics such as the
Second:  a study on the influence of the pandemic on incomes in greece 

First:  how can blockchain help people in the event of pandemics such as the
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  how can blockchain help people in the event of pandemics such as the
Second:  does the pandemic spell the end for the direct 

First:  how can blockchain help people in the event of pandemics such as the
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  how can blockchain help people in the event of pandemics such as the
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  how can blockchain help people in the event of pandemics such as the
Second:  editorial recommendations for the management of in countries 

First:  how can blockchain help people in the event of pandemics such as the
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  how can blockchain help people in the event of pandemics such as the
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  how can blockchain help people in the event of pandemics such as the
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  how can blockchain help people in the event of pandemics such as the
Second:  potential of in vitro 

First:  how can blockchain help people in the event of pandemics such as the
Second:  bacterial and the deadly trio in 

First:  how can blockchain help people in the event of pandemics such as the
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  how can blockchain help people in the event of pandemics such as the
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  how can blockchain help people in the event of pandemics such as the
Second:  genetic hypothesis and side of in 

First:  how can blockchain help people in the event of pandemics such as the
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  how can blockchain help people in the event of pandemics such as the
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  how can blockchain help people in the event of pandemics such as the
Second:  and prognostic significance in 

First:  how can blockchain help people in the event of pandemics such as the
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  how can blockchain help people in the event of pandemics such as the
Second:  the sudden appearance of 

First:  how can blockchain help people in the event of pandemics such as the
Second:  early forecasting of the potential risk zones of in 

First:  how can blockchain help people in the event of pandemics such as the
Second:  older experience of the a analysis of stresses and joys 

First:  how can blockchain help people in the event of pandemics such as the
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  how can blockchain help people in the event of pandemics such as the
Second:  immigration policy and justice in the era of 

First:  how can blockchain help people in the event of pandemics such as the
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  how can blockchain help people in the event of pandemics such as the
Second:  the and ends of rnas is not 

First:  how can blockchain help people in the event of pandemics such as the
Second:  and the saga continues 

First:  how can blockchain help people in the event of pandemics such as the
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  how can blockchain help people in the event of pandemics such as the
Second:  and what evidence needs our 

First:  to appear advances in oral and maxillofacial surgery
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  to appear advances in oral and maxillofacial surgery
Second:  journal of cancer research and clinical oncology 

First:  to appear advances in oral and maxillofacial surgery
Second:  and cell biology lung advances in generation and 

First:  to appear advances in oral and maxillofacial surgery
Second:  and prognostic significance in 

First:  to appear advances in oral and maxillofacial surgery
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  case report mammography in the diagnosis of breast 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  journal innovations in in the age of a systematic literature review 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  disease in the era of an observation on a series of six patients with 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  mapping the technological landscape of and vaccines 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  does the pandemic spell the end for the direct 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  coordinating genomic surveillance in the united states 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  excess neurological death in new york city after the emergence of 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  editorial recommendations for the management of in countries 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the impact on surgical departments of hospitals 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the common missed instances and areas after years of education 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  potential of in vitro 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  bacterial and the deadly trio in 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  establishment of a reference panel for the detection of antibodies 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  genetic hypothesis and side of in 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  and prognostic significance in 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the sudden appearance of 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  school of population and global the university of evidence 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  early forecasting of the potential risk zones of in 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  older experience of the a analysis of stresses and joys 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  immigration policy and justice in the era of 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the and ends of rnas is not 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  and the saga continues 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  environmental research and public health the impact of on food results of a survey 

First:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  journal inhaled corticosteroids the receptor in copd through suppression of type i interferon increased severity from severity attenuation of expression by inhaled corticosteroid use in copd
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  journal inhaled corticosteroids the receptor in copd through suppression of type i interferon increased severity from severity attenuation of expression by inhaled corticosteroid use in copd
Second:  potential of in vitro 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  a study on the influence of the pandemic on incomes in greece 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  disease in the era of an observation on a series of six patients with 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  potential of in vitro 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  bacterial and the deadly trio in 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  genetic hypothesis and side of in 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  and prognostic significance in 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  the sudden appearance of 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  early forecasting of the potential risk zones of in 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  older experience of the a analysis of stresses and joys 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  immigration policy and justice in the era of 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  the and ends of rnas is not 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  and the saga continues 

First:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis
Second:  journal of cancer research and clinical oncology 

First:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis
Second:  potential of in vitro 

First:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis
Second:  the sudden appearance of 

First:  journal entry in host targets for treatment and prevention
Second:  and prognostic significance in 

First:  journal entry in host targets for treatment and prevention
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  sculpting the proteome with small molecules
Second:  supramolecular architecture of the coronavirus particle 

First:  modelling the transmission of infectious diseases inside hospital implications for
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  modelling the transmission of infectious diseases inside hospital implications for
Second:  journal of cancer research and clinical oncology 

First:  modelling the transmission of infectious diseases inside hospital implications for
Second:  potential of in vitro 

First:  modelling the transmission of infectious diseases inside hospital implications for
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  modelling the transmission of infectious diseases inside hospital implications for
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  modelling the transmission of infectious diseases inside hospital implications for
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  a study on the influence of the pandemic on incomes in greece 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  does the pandemic spell the end for the direct 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  editorial recommendations for the management of in countries 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  potential of in vitro 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  and prognostic significance in 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  the sudden appearance of 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  early forecasting of the potential risk zones of in 

First:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its
Second:  the and ends of rnas is not 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  disease in the era of an observation on a series of six patients with 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  mapping the technological landscape of and vaccines 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  does the pandemic spell the end for the direct 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  editorial recommendations for the management of in countries 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the impact on surgical departments of hospitals 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  toxic and properties of an coordination complex of 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  potential of in vitro 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  bacterial and the deadly trio in 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  establishment of a reference panel for the detection of antibodies 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  genetic hypothesis and side of in 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  and prognostic significance in 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the sudden appearance of 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  school of population and global the university of evidence 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  early forecasting of the potential risk zones of in 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  older experience of the a analysis of stresses and joys 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  immigration policy and justice in the era of 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  diffusion as a first model of spread of viral infection 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the and ends of rnas is not 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  and the saga continues 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  environmental research and public health the impact of on food results of a survey 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  journal of cancer research and clinical oncology 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  and prognostic significance in 

First:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  recent advancements in the and prospective drug therapy of
Second:  a study on the influence of the pandemic on incomes in greece 

First:  recent advancements in the and prospective drug therapy of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  recent advancements in the and prospective drug therapy of
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  recent advancements in the and prospective drug therapy of
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  recent advancements in the and prospective drug therapy of
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  recent advancements in the and prospective drug therapy of
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  recent advancements in the and prospective drug therapy of
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  recent advancements in the and prospective drug therapy of
Second:  case report mammography in the diagnosis of breast 

First:  recent advancements in the and prospective drug therapy of
Second:  journal innovations in in the age of a systematic literature review 

First:  recent advancements in the and prospective drug therapy of
Second:  journal of cancer research and clinical oncology 

First:  recent advancements in the and prospective drug therapy of
Second:  disease in the era of an observation on a series of six patients with 

First:  recent advancements in the and prospective drug therapy of
Second:  mapping the technological landscape of and vaccines 

First:  recent advancements in the and prospective drug therapy of
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  recent advancements in the and prospective drug therapy of
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  recent advancements in the and prospective drug therapy of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  recent advancements in the and prospective drug therapy of
Second:  does the pandemic spell the end for the direct 

First:  recent advancements in the and prospective drug therapy of
Second:  coordinating genomic surveillance in the united states 

First:  recent advancements in the and prospective drug therapy of
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  recent advancements in the and prospective drug therapy of
Second:  and cell biology lung advances in generation and 

First:  recent advancements in the and prospective drug therapy of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  recent advancements in the and prospective drug therapy of
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  recent advancements in the and prospective drug therapy of
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  recent advancements in the and prospective drug therapy of
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  recent advancements in the and prospective drug therapy of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  recent advancements in the and prospective drug therapy of
Second:  responding to healthcare disparities and challenges with access to care during 

First:  recent advancements in the and prospective drug therapy of
Second:  second wave of global pandemic and recommendations to better manage and optimize the modified lifestyle 

First:  recent advancements in the and prospective drug therapy of
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  recent advancements in the and prospective drug therapy of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  recent advancements in the and prospective drug therapy of
Second:  excess neurological death in new york city after the emergence of 

First:  recent advancements in the and prospective drug therapy of
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  recent advancements in the and prospective drug therapy of
Second:  editorial recommendations for the management of in countries 

First:  recent advancements in the and prospective drug therapy of
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  recent advancements in the and prospective drug therapy of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  recent advancements in the and prospective drug therapy of
Second:  prophylaxis of with and chloroquine accepted article 

First:  recent advancements in the and prospective drug therapy of
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  recent advancements in the and prospective drug therapy of
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  recent advancements in the and prospective drug therapy of
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  recent advancements in the and prospective drug therapy of
Second:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york 

First:  recent advancements in the and prospective drug therapy of
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  recent advancements in the and prospective drug therapy of
Second:  the impact on surgical departments of hospitals 

First:  recent advancements in the and prospective drug therapy of
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  recent advancements in the and prospective drug therapy of
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  recent advancements in the and prospective drug therapy of
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  recent advancements in the and prospective drug therapy of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  recent advancements in the and prospective drug therapy of
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  recent advancements in the and prospective drug therapy of
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  recent advancements in the and prospective drug therapy of
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  recent advancements in the and prospective drug therapy of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  recent advancements in the and prospective drug therapy of
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  recent advancements in the and prospective drug therapy of
Second:  prevalence of antibodies in young children in tennessee 

First:  recent advancements in the and prospective drug therapy of
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  recent advancements in the and prospective drug therapy of
Second:  toxic and properties of an coordination complex of 

First:  recent advancements in the and prospective drug therapy of
Second:  the common missed instances and areas after years of education 

First:  recent advancements in the and prospective drug therapy of
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  recent advancements in the and prospective drug therapy of
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  recent advancements in the and prospective drug therapy of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  recent advancements in the and prospective drug therapy of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  recent advancements in the and prospective drug therapy of
Second:  potential of in vitro 

First:  recent advancements in the and prospective drug therapy of
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  recent advancements in the and prospective drug therapy of
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  recent advancements in the and prospective drug therapy of
Second:  bacterial and the deadly trio in 

First:  recent advancements in the and prospective drug therapy of
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  recent advancements in the and prospective drug therapy of
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  recent advancements in the and prospective drug therapy of
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  recent advancements in the and prospective drug therapy of
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  recent advancements in the and prospective drug therapy of
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  recent advancements in the and prospective drug therapy of
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  recent advancements in the and prospective drug therapy of
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  recent advancements in the and prospective drug therapy of
Second:  establishment of a reference panel for the detection of antibodies 

First:  recent advancements in the and prospective drug therapy of
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  recent advancements in the and prospective drug therapy of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  recent advancements in the and prospective drug therapy of
Second:  task detection of persuasion techniques in texts and images 

First:  recent advancements in the and prospective drug therapy of
Second:  synthesis and activity of derivatives and analogues thereof 

First:  recent advancements in the and prospective drug therapy of
Second:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium 

First:  recent advancements in the and prospective drug therapy of
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  recent advancements in the and prospective drug therapy of
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  recent advancements in the and prospective drug therapy of
Second:  genetic hypothesis and side of in 

First:  recent advancements in the and prospective drug therapy of
Second:  tactics in support of migrations 

First:  recent advancements in the and prospective drug therapy of
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  recent advancements in the and prospective drug therapy of
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  recent advancements in the and prospective drug therapy of
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  recent advancements in the and prospective drug therapy of
Second:  and prognostic significance in 

First:  recent advancements in the and prospective drug therapy of
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  recent advancements in the and prospective drug therapy of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  recent advancements in the and prospective drug therapy of
Second:  from ego to for ontology in the 

First:  recent advancements in the and prospective drug therapy of
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  recent advancements in the and prospective drug therapy of
Second:  the sudden appearance of 

First:  recent advancements in the and prospective drug therapy of
Second:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors 

First:  recent advancements in the and prospective drug therapy of
Second:  policy responses to the pandemic in vietnam 

First:  recent advancements in the and prospective drug therapy of
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  recent advancements in the and prospective drug therapy of
Second:  school of population and global the university of evidence 

First:  recent advancements in the and prospective drug therapy of
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  recent advancements in the and prospective drug therapy of
Second:  a visual analytics approach to facilitate the of online exams 

First:  recent advancements in the and prospective drug therapy of
Second:  a protocol for a systematic review and 

First:  recent advancements in the and prospective drug therapy of
Second:  early forecasting of the potential risk zones of in 

First:  recent advancements in the and prospective drug therapy of
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  recent advancements in the and prospective drug therapy of
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  recent advancements in the and prospective drug therapy of
Second:  therapy for a feasibility study 

First:  recent advancements in the and prospective drug therapy of
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  recent advancements in the and prospective drug therapy of
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  recent advancements in the and prospective drug therapy of
Second:  in a comprehensive investigation from exposure to treatment outcomes 

First:  recent advancements in the and prospective drug therapy of
Second:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults 

First:  recent advancements in the and prospective drug therapy of
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  recent advancements in the and prospective drug therapy of
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  recent advancements in the and prospective drug therapy of
Second:  investment and economic policy options in 

First:  recent advancements in the and prospective drug therapy of
Second:  edema assessment by means of the and laser scanning microscopy 

First:  recent advancements in the and prospective drug therapy of
Second:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education 

First:  recent advancements in the and prospective drug therapy of
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  recent advancements in the and prospective drug therapy of
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  recent advancements in the and prospective drug therapy of
Second:  integrating research integrity into the history of science 

First:  recent advancements in the and prospective drug therapy of
Second:  scenario modelling for the mitigation of deaths in intensive computer simulation study 

First:  recent advancements in the and prospective drug therapy of
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  recent advancements in the and prospective drug therapy of
Second:  a better understanding of social distancing 

First:  recent advancements in the and prospective drug therapy of
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  recent advancements in the and prospective drug therapy of
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  recent advancements in the and prospective drug therapy of
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  recent advancements in the and prospective drug therapy of
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  recent advancements in the and prospective drug therapy of
Second:  depression and sleep quality in patients undergoing 

First:  recent advancements in the and prospective drug therapy of
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  recent advancements in the and prospective drug therapy of
Second:  and responses to in south a rapid qualitative assessment 

First:  recent advancements in the and prospective drug therapy of
Second:  older experience of the a analysis of stresses and joys 

First:  recent advancements in the and prospective drug therapy of
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  recent advancements in the and prospective drug therapy of
Second:  journal case report rapid development of seizures and pres in a patient 

First:  recent advancements in the and prospective drug therapy of
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  recent advancements in the and prospective drug therapy of
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  recent advancements in the and prospective drug therapy of
Second:  mask social and gender correlates of vaccine intentions among adults in the us 

First:  recent advancements in the and prospective drug therapy of
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  recent advancements in the and prospective drug therapy of
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  recent advancements in the and prospective drug therapy of
Second:  immigration policy and justice in the era of 

First:  recent advancements in the and prospective drug therapy of
Second:  diffusion as a first model of spread of viral infection 

First:  recent advancements in the and prospective drug therapy of
Second:  properties of on human ex vivo and in vitro observations 

First:  recent advancements in the and prospective drug therapy of
Second:  digitalized adaptation of oncology trials during and after 

First:  recent advancements in the and prospective drug therapy of
Second:  outbreak situation and its psychological impact among surgeon in training in france 

First:  recent advancements in the and prospective drug therapy of
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  recent advancements in the and prospective drug therapy of
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  recent advancements in the and prospective drug therapy of
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  recent advancements in the and prospective drug therapy of
Second:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study 

First:  recent advancements in the and prospective drug therapy of
Second:  the and ends of rnas is not 

First:  recent advancements in the and prospective drug therapy of
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  recent advancements in the and prospective drug therapy of
Second:  is the mother of specialist palliative care service innovation and practice change in response to results from a multinational survey 

First:  recent advancements in the and prospective drug therapy of
Second:  and the saga continues 

First:  recent advancements in the and prospective drug therapy of
Second:  environmental research and public health the impact of on food results of a survey 

First:  recent advancements in the and prospective drug therapy of
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  recent advancements in the and prospective drug therapy of
Second:  international archives of occupational and environmental health 

First:  recent advancements in the and prospective drug therapy of
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  recent advancements in the and prospective drug therapy of
Second:  how can blockchain help people in the event of pandemics such as the 

First:  recent advancements in the and prospective drug therapy of
Second:  to appear advances in oral and maxillofacial surgery 

First:  recent advancements in the and prospective drug therapy of
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  recent advancements in the and prospective drug therapy of
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  recent advancements in the and prospective drug therapy of
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  recent advancements in the and prospective drug therapy of
Second:  journal entry in host targets for treatment and prevention 

First:  recent advancements in the and prospective drug therapy of
Second:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its 

First:  recent advancements in the and prospective drug therapy of
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  recent advancements in the and prospective drug therapy of
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  journal the psychological status of people affected by the outbreak in china
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal the psychological status of people affected by the outbreak in china
Second:  journal innovations in in the age of a systematic literature review 

First:  journal the psychological status of people affected by the outbreak in china
Second:  mapping the technological landscape of and vaccines 

First:  journal the psychological status of people affected by the outbreak in china
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal the psychological status of people affected by the outbreak in china
Second:  does the pandemic spell the end for the direct 

First:  journal the psychological status of people affected by the outbreak in china
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal the psychological status of people affected by the outbreak in china
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal the psychological status of people affected by the outbreak in china
Second:  editorial recommendations for the management of in countries 

First:  journal the psychological status of people affected by the outbreak in china
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  journal the psychological status of people affected by the outbreak in china
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal the psychological status of people affected by the outbreak in china
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  journal the psychological status of people affected by the outbreak in china
Second:  potential of in vitro 

First:  journal the psychological status of people affected by the outbreak in china
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  journal the psychological status of people affected by the outbreak in china
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal the psychological status of people affected by the outbreak in china
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal the psychological status of people affected by the outbreak in china
Second:  genetic hypothesis and side of in 

First:  journal the psychological status of people affected by the outbreak in china
Second:  and prognostic significance in 

First:  journal the psychological status of people affected by the outbreak in china
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal the psychological status of people affected by the outbreak in china
Second:  the sudden appearance of 

First:  journal the psychological status of people affected by the outbreak in china
Second:  school of population and global the university of evidence 

First:  journal the psychological status of people affected by the outbreak in china
Second:  early forecasting of the potential risk zones of in 

First:  journal the psychological status of people affected by the outbreak in china
Second:  older experience of the a analysis of stresses and joys 

First:  journal the psychological status of people affected by the outbreak in china
Second:  immigration policy and justice in the era of 

First:  journal the psychological status of people affected by the outbreak in china
Second:  the and ends of rnas is not 

First:  journal the psychological status of people affected by the outbreak in china
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  journal the psychological status of people affected by the outbreak in china
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  journal the psychological status of people affected by the outbreak in china
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  journal the psychological status of people affected by the outbreak in china
Second:  recent advancements in the and prospective drug therapy of 

First:  morbidity and mortality weekly report
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  morbidity and mortality weekly report
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  journal of cancer research and clinical oncology 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  predicting risk of transition to severe infection 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  and prognostic significance in 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  vaccine hesitancy among paediatric prevalence and associated factors
Second:  morbidity and mortality weekly report 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  case report mammography in the diagnosis of breast 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  journal of cancer research and clinical oncology 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  the impact on surgical departments of hospitals 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  potential of in vitro 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  and prognostic significance in 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  to appear advances in oral and maxillofacial surgery 

First:  impact of on thyroid cancer surgery and adjunct therapy
Second:  recent advancements in the and prospective drug therapy of 

First:  higher glycemic variability within the first day of icu admission is associated with increased mortality in icu patients with sepsis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  infectious disease and the case for considering impacts
Second:  a study on the influence of the pandemic on incomes in greece 

First:  infectious disease and the case for considering impacts
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  infectious disease and the case for considering impacts
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  infectious disease and the case for considering impacts
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  infectious disease and the case for considering impacts
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  infectious disease and the case for considering impacts
Second:  case report mammography in the diagnosis of breast 

First:  infectious disease and the case for considering impacts
Second:  journal of cancer research and clinical oncology 

First:  infectious disease and the case for considering impacts
Second:  mapping the technological landscape of and vaccines 

First:  infectious disease and the case for considering impacts
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  infectious disease and the case for considering impacts
Second:  viral intestinal infections of animals and man 

First:  infectious disease and the case for considering impacts
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  infectious disease and the case for considering impacts
Second:  does the pandemic spell the end for the direct 

First:  infectious disease and the case for considering impacts
Second:  and cell biology lung advances in generation and 

First:  infectious disease and the case for considering impacts
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  infectious disease and the case for considering impacts
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  infectious disease and the case for considering impacts
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  infectious disease and the case for considering impacts
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  infectious disease and the case for considering impacts
Second:  reply to against the risk of airborne 

First:  infectious disease and the case for considering impacts
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  infectious disease and the case for considering impacts
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  infectious disease and the case for considering impacts
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  infectious disease and the case for considering impacts
Second:  editorial recommendations for the management of in countries 

First:  infectious disease and the case for considering impacts
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  infectious disease and the case for considering impacts
Second:  prophylaxis of with and chloroquine accepted article 

First:  infectious disease and the case for considering impacts
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  infectious disease and the case for considering impacts
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  infectious disease and the case for considering impacts
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  infectious disease and the case for considering impacts
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  infectious disease and the case for considering impacts
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  infectious disease and the case for considering impacts
Second:  the impact on surgical departments of hospitals 

First:  infectious disease and the case for considering impacts
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  infectious disease and the case for considering impacts
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  infectious disease and the case for considering impacts
Second:  spectrum of antimicrobial activity for disinfection of 

First:  infectious disease and the case for considering impacts
Second:  a review in bacterial infections 

First:  infectious disease and the case for considering impacts
Second:  the common missed instances and areas after years of education 

First:  infectious disease and the case for considering impacts
Second:  predicting risk of transition to severe infection 

First:  infectious disease and the case for considering impacts
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  infectious disease and the case for considering impacts
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  infectious disease and the case for considering impacts
Second:  is a host factor for infection 

First:  infectious disease and the case for considering impacts
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  infectious disease and the case for considering impacts
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  infectious disease and the case for considering impacts
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  infectious disease and the case for considering impacts
Second:  concept of immune response 

First:  infectious disease and the case for considering impacts
Second:  potential of in vitro 

First:  infectious disease and the case for considering impacts
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  infectious disease and the case for considering impacts
Second:  bacterial and the deadly trio in 

First:  infectious disease and the case for considering impacts
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  infectious disease and the case for considering impacts
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  infectious disease and the case for considering impacts
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  infectious disease and the case for considering impacts
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  infectious disease and the case for considering impacts
Second:  establishment of a reference panel for the detection of antibodies 

First:  infectious disease and the case for considering impacts
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  infectious disease and the case for considering impacts
Second:  synthesis and activity of derivatives and analogues thereof 

First:  infectious disease and the case for considering impacts
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  infectious disease and the case for considering impacts
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  infectious disease and the case for considering impacts
Second:  genetic hypothesis and side of in 

First:  infectious disease and the case for considering impacts
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  infectious disease and the case for considering impacts
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  infectious disease and the case for considering impacts
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  infectious disease and the case for considering impacts
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  infectious disease and the case for considering impacts
Second:  and prognostic significance in 

First:  infectious disease and the case for considering impacts
Second:  implications for people with chagas disease 

First:  infectious disease and the case for considering impacts
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  infectious disease and the case for considering impacts
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  infectious disease and the case for considering impacts
Second:  journal and bleeding risk in unsolved question 

First:  infectious disease and the case for considering impacts
Second:  the sudden appearance of 

First:  infectious disease and the case for considering impacts
Second:  and indigenous an imperative for action 

First:  infectious disease and the case for considering impacts
Second:  a protocol for a systematic review and 

First:  infectious disease and the case for considering impacts
Second:  early forecasting of the potential risk zones of in 

First:  infectious disease and the case for considering impacts
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  infectious disease and the case for considering impacts
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  infectious disease and the case for considering impacts
Second:  therapy for a feasibility study 

First:  infectious disease and the case for considering impacts
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  infectious disease and the case for considering impacts
Second:  letter to the editor are patients with autoimmune disease at greater risk of developing severe 

First:  infectious disease and the case for considering impacts
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  infectious disease and the case for considering impacts
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  infectious disease and the case for considering impacts
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  infectious disease and the case for considering impacts
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  infectious disease and the case for considering impacts
Second:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase 

First:  infectious disease and the case for considering impacts
Second:  care for people with disease and related during from challenges to solutions 

First:  infectious disease and the case for considering impacts
Second:  older experience of the a analysis of stresses and joys 

First:  infectious disease and the case for considering impacts
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  infectious disease and the case for considering impacts
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  infectious disease and the case for considering impacts
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  infectious disease and the case for considering impacts
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  infectious disease and the case for considering impacts
Second:  use of in human immunodeficiency virus infection 

First:  infectious disease and the case for considering impacts
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  infectious disease and the case for considering impacts
Second:  immigration policy and justice in the era of 

First:  infectious disease and the case for considering impacts
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  infectious disease and the case for considering impacts
Second:  the and ends of rnas is not 

First:  infectious disease and the case for considering impacts
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  infectious disease and the case for considering impacts
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  infectious disease and the case for considering impacts
Second:  environmental research and public health the impact of on food results of a survey 

First:  infectious disease and the case for considering impacts
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  infectious disease and the case for considering impacts
Second:  and what evidence needs our 

First:  infectious disease and the case for considering impacts
Second:  how can blockchain help people in the event of pandemics such as the 

First:  infectious disease and the case for considering impacts
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  infectious disease and the case for considering impacts
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  infectious disease and the case for considering impacts
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  infectious disease and the case for considering impacts
Second:  building momentum for malaria vaccine research and key considerations 

First:  infectious disease and the case for considering impacts
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  infectious disease and the case for considering impacts
Second:  recent advancements in the and prospective drug therapy of 

First:  infectious disease and the case for considering impacts
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  infectious disease and the case for considering impacts
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  stress symptoms in hemodialysis patients with exposure
Second:  case report mammography in the diagnosis of breast 

First:  stress symptoms in hemodialysis patients with exposure
Second:  viral intestinal infections of animals and man 

First:  stress symptoms in hemodialysis patients with exposure
Second:  in ckd lessons from ckd patients with kidney disease 

First:  stress symptoms in hemodialysis patients with exposure
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  stress symptoms in hemodialysis patients with exposure
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  stress symptoms in hemodialysis patients with exposure
Second:  chest computed tomographic findings of patients with pneumonia 

First:  stress symptoms in hemodialysis patients with exposure
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  stress symptoms in hemodialysis patients with exposure
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  stress symptoms in hemodialysis patients with exposure
Second:  nutritional parameters associated with prognosis in ill 

First:  stress symptoms in hemodialysis patients with exposure
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  stress symptoms in hemodialysis patients with exposure
Second:  a review in bacterial infections 

First:  stress symptoms in hemodialysis patients with exposure
Second:  predicting risk of transition to severe infection 

First:  stress symptoms in hemodialysis patients with exposure
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  stress symptoms in hemodialysis patients with exposure
Second:  journal incidence of pulmonary embolism in patients with respiratory support during outbreak credit author statement incidence of pulmonary embolism in patients with invasive respiratory support during outbreak 

First:  stress symptoms in hemodialysis patients with exposure
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  stress symptoms in hemodialysis patients with exposure
Second:  journal fungal in patients with role of antifungal 

First:  stress symptoms in hemodialysis patients with exposure
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  stress symptoms in hemodialysis patients with exposure
Second:  combination kills bladder cancer cells synergistically 

First:  stress symptoms in hemodialysis patients with exposure
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  stress symptoms in hemodialysis patients with exposure
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  stress symptoms in hemodialysis patients with exposure
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  stress symptoms in hemodialysis patients with exposure
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  stress symptoms in hemodialysis patients with exposure
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  stress symptoms in hemodialysis patients with exposure
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  stress symptoms in hemodialysis patients with exposure
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  stress symptoms in hemodialysis patients with exposure
Second:  depression and sleep quality in patients undergoing 

First:  stress symptoms in hemodialysis patients with exposure
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  stress symptoms in hemodialysis patients with exposure
Second:  use of in human immunodeficiency virus infection 

First:  stress symptoms in hemodialysis patients with exposure
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  stress symptoms in hemodialysis patients with exposure
Second:  regression of infantile glioblastoma after treatment with 

First:  stress symptoms in hemodialysis patients with exposure
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  stress symptoms in hemodialysis patients with exposure
Second:  vaccination in patients with multiple focus on immune response vaccination and immune response in mm 

First:  stress symptoms in hemodialysis patients with exposure
Second:  more severe presentations of acute appendicitis during 

First:  stress symptoms in hemodialysis patients with exposure
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  stress symptoms in hemodialysis patients with exposure
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  stress symptoms in hemodialysis patients with exposure
Second:  journal inhaled corticosteroids the receptor in copd through suppression of type i interferon increased severity from severity attenuation of expression by inhaled corticosteroid use in copd 

First:  stress symptoms in hemodialysis patients with exposure
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  stress symptoms in hemodialysis patients with exposure
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  stress symptoms in hemodialysis patients with exposure
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  personal view antiviral effects of chloroquine
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  human rights and a comment on the bath protocol
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  case report mammography in the diagnosis of breast 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  journal of cancer research and clinical oncology 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus
Second:  stress symptoms in hemodialysis patients with exposure 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  potential of in vitro 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  genetic hypothesis and side of in 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  and prognostic significance in 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  ethnic and regional variations in hospital mortality from in a observational study
Second:  recent advancements in the and prospective drug therapy of 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  a study on the influence of the pandemic on incomes in greece 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  potential of in vitro 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  genetic hypothesis and side of in 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  and prognostic significance in 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  the sudden appearance of 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  early forecasting of the potential risk zones of in 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  older experience of the a analysis of stresses and joys 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  immigration policy and justice in the era of 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  the and ends of rnas is not 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation
Second:  recent advancements in the and prospective drug therapy of 

First:  interspecies transmission and emergence of novel lessons from bats and birds
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  solid and suspension microarrays for microbial diagnostics 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  spectrum of antimicrobial activity for disinfection of 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  potential of in vitro 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  establishment of a reference panel for the detection of antibodies 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  and prognostic significance in 

First:  reliability of serological tests for comparison of three test kits for antibodies
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  journal of cancer research and clinical oncology 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  mapping the technological landscape of and vaccines 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  editorial recommendations for the management of in countries 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  toxic and properties of an coordination complex of 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  potential of in vitro 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  synthesis and activity of derivatives and analogues thereof 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  genetic hypothesis and side of in 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  and prognostic significance in 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  journal of management control 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  the sudden appearance of 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  school of population and global the university of evidence 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  early forecasting of the potential risk zones of in 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  older experience of the a analysis of stresses and joys 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  journal of banking regulation 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  immigration policy and justice in the era of 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  the and ends of rnas is not 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  and the saga continues 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  environmental research and public health the impact of on food results of a survey 

First:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work
Second:  recent advancements in the and prospective drug therapy of 

First:  suspected myocarditis in patients with a case series
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  suspected myocarditis in patients with a case series
Second:  single case neurology ischemic stroke in a patient with a case report et ischemic stroke in a young patient with 

First:  suspected myocarditis in patients with a case series
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  suspected myocarditis in patients with a case series
Second:  stress symptoms in hemodialysis patients with exposure 

First:  distinct cellular immune profiles in the airways and blood of critically ill patients with consortium and the amsterdam umc study group respiratory infection
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection
Second:  viral intestinal infections of animals and man 

First:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection
Second:  use of in human immunodeficiency virus infection 

First:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  understanding the binding affinity of with protease of for using md simulations at different temperatures
Second:  potential of in vitro 

First:  journal lack of rna environmental contamination in a tertiary referral hospital for infectious diseases in northern lack of rna environmental contamination in a tertiary referral hospital for infectious diseases in northern italy
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  a study on the influence of the pandemic on incomes in greece 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  case report mammography in the diagnosis of breast 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  mapping the technological landscape of and vaccines 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  viral intestinal infections of animals and man 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  flying under the the stealth pandemic of escherichia coli sequence type 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  spectrum of antimicrobial activity for disinfection of 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  a review in bacterial infections 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  potential of in vitro 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  bacterial and the deadly trio in 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  supramolecular architecture of the coronavirus particle 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  establishment of a reference panel for the detection of antibodies 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  a serological comparison of bovine coronavirus strains 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  genetic hypothesis and side of in 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  and prognostic significance in 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  journal fungal in patients with role of antifungal 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the sudden appearance of 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  early forecasting of the potential risk zones of in 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  enhances the peroxidase activity of myoglobin against 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  use of in human immunodeficiency virus infection 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  diffusion as a first model of spread of viral infection 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the and ends of rnas is not 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  recent advancements in the and prospective drug therapy of 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  infectious disease and the case for considering impacts 

First:  role of the gene of murine coronavirus strain in hepatitis
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  clinical potential of for assessing comparative analysis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical potential of for assessing comparative analysis
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  clinical potential of for assessing comparative analysis
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  clinical potential of for assessing comparative analysis
Second:  risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review 

First:  clinical potential of for assessing comparative analysis
Second:  case report mammography in the diagnosis of breast 

First:  clinical potential of for assessing comparative analysis
Second:  journal of cancer research and clinical oncology 

First:  clinical potential of for assessing comparative analysis
Second:  mapping the technological landscape of and vaccines 

First:  clinical potential of for assessing comparative analysis
Second:  linguistic methods in healthcare application and variants classification 

First:  clinical potential of for assessing comparative analysis
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  clinical potential of for assessing comparative analysis
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  clinical potential of for assessing comparative analysis
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  clinical potential of for assessing comparative analysis
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  clinical potential of for assessing comparative analysis
Second:  analysis of computed tomography helps predict poor prognostic outcome in 

First:  clinical potential of for assessing comparative analysis
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  clinical potential of for assessing comparative analysis
Second:  editorial recommendations for the management of in countries 

First:  clinical potential of for assessing comparative analysis
Second:  solid and suspension microarrays for microbial diagnostics 

First:  clinical potential of for assessing comparative analysis
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  clinical potential of for assessing comparative analysis
Second:  quercetin as a potential treatment for acute kidney based on network pharmacology and molecular docking study 

First:  clinical potential of for assessing comparative analysis
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  clinical potential of for assessing comparative analysis
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  clinical potential of for assessing comparative analysis
Second:  a comparative analysis on risk communication between international and chinese literature from the perspective of knowledge domain visualization 

First:  clinical potential of for assessing comparative analysis
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical potential of for assessing comparative analysis
Second:  spectrum of antimicrobial activity for disinfection of 

First:  clinical potential of for assessing comparative analysis
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  clinical potential of for assessing comparative analysis
Second:  basics of molecular biology 

First:  clinical potential of for assessing comparative analysis
Second:  predicting risk of transition to severe infection 

First:  clinical potential of for assessing comparative analysis
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  clinical potential of for assessing comparative analysis
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  clinical potential of for assessing comparative analysis
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical potential of for assessing comparative analysis
Second:  concept of immune response 

First:  clinical potential of for assessing comparative analysis
Second:  potential of in vitro 

First:  clinical potential of for assessing comparative analysis
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  clinical potential of for assessing comparative analysis
Second:  an epidemic model for in mathematical analysis and forecast 

First:  clinical potential of for assessing comparative analysis
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  clinical potential of for assessing comparative analysis
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  clinical potential of for assessing comparative analysis
Second:  establishment of a reference panel for the detection of antibodies 

First:  clinical potential of for assessing comparative analysis
Second:  a serological comparison of bovine coronavirus strains 

First:  clinical potential of for assessing comparative analysis
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  clinical potential of for assessing comparative analysis
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical potential of for assessing comparative analysis
Second:  synthesis and activity of derivatives and analogues thereof 

First:  clinical potential of for assessing comparative analysis
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  clinical potential of for assessing comparative analysis
Second:  genetic hypothesis and side of in 

First:  clinical potential of for assessing comparative analysis
Second:  and prognostic significance in 

First:  clinical potential of for assessing comparative analysis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical potential of for assessing comparative analysis
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  clinical potential of for assessing comparative analysis
Second:  journal of management control 

First:  clinical potential of for assessing comparative analysis
Second:  pharmaceutics pharmacokinetic estimation approach to predict clinical implications for cyp induction by in human hepatocytes and cells estimation approach to predict clinical implications for cyp induction by in human hepatocytes and pharmaceutics 

First:  clinical potential of for assessing comparative analysis
Second:  a protocol for a systematic review and 

First:  clinical potential of for assessing comparative analysis
Second:  early forecasting of the potential risk zones of in 

First:  clinical potential of for assessing comparative analysis
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  clinical potential of for assessing comparative analysis
Second:  therapy for a feasibility study 

First:  clinical potential of for assessing comparative analysis
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  clinical potential of for assessing comparative analysis
Second:  journal radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery 

First:  clinical potential of for assessing comparative analysis
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  clinical potential of for assessing comparative analysis
Second:  conducting focus groups in neurodegenerative disease ethical and methodological considerations 

First:  clinical potential of for assessing comparative analysis
Second:  integrating research integrity into the history of science 

First:  clinical potential of for assessing comparative analysis
Second:  scenario modelling for the mitigation of deaths in intensive computer simulation study 

First:  clinical potential of for assessing comparative analysis
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  clinical potential of for assessing comparative analysis
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical potential of for assessing comparative analysis
Second:  a better understanding of social distancing 

First:  clinical potential of for assessing comparative analysis
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  clinical potential of for assessing comparative analysis
Second:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase 

First:  clinical potential of for assessing comparative analysis
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  clinical potential of for assessing comparative analysis
Second:  multivariate analysis to assist making in engineering optimization problems 

First:  clinical potential of for assessing comparative analysis
Second:  and responses to in south a rapid qualitative assessment 

First:  clinical potential of for assessing comparative analysis
Second:  older experience of the a analysis of stresses and joys 

First:  clinical potential of for assessing comparative analysis
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical potential of for assessing comparative analysis
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  clinical potential of for assessing comparative analysis
Second:  journal systematically comparing with 

First:  clinical potential of for assessing comparative analysis
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  clinical potential of for assessing comparative analysis
Second:  journal of banking regulation 

First:  clinical potential of for assessing comparative analysis
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  clinical potential of for assessing comparative analysis
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  clinical potential of for assessing comparative analysis
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  clinical potential of for assessing comparative analysis
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  clinical potential of for assessing comparative analysis
Second:  environmental research and public health the impact of on food results of a survey 

First:  clinical potential of for assessing comparative analysis
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  clinical potential of for assessing comparative analysis
Second:  international archives of occupational and environmental health 

First:  clinical potential of for assessing comparative analysis
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  clinical potential of for assessing comparative analysis
Second:  recent advancements in the and prospective drug therapy of 

First:  clinical potential of for assessing comparative analysis
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  clinical potential of for assessing comparative analysis
Second:  infectious disease and the case for considering impacts 

First:  clinical potential of for assessing comparative analysis
Second:  reliability of serological tests for comparison of three test kits for antibodies 

First:  clinical potential of for assessing comparative analysis
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  a remedy or a ripple in severe 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  does the pandemic spell the end for the direct 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  editorial recommendations for the management of in countries 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  the impact on surgical departments of hospitals 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  potential of in vitro 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  bacterial and the deadly trio in 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  establishment of a reference panel for the detection of antibodies 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  and prognostic significance in 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  the sudden appearance of 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  a protocol for a systematic review and 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  older experience of the a analysis of stresses and joys 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  immigration policy and justice in the era of 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  the and ends of rnas is not 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  how can blockchain help people in the event of pandemics such as the 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic
Second:  recent advancements in the and prospective drug therapy of 

First:  the impact of and homeschooling on engagement with physical activity
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the impact of and homeschooling on engagement with physical activity
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the impact of and homeschooling on engagement with physical activity
Second:  disease in the era of an observation on a series of six patients with 

First:  the impact of and homeschooling on engagement with physical activity
Second:  mapping the technological landscape of and vaccines 

First:  the impact of and homeschooling on engagement with physical activity
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the impact of and homeschooling on engagement with physical activity
Second:  does the pandemic spell the end for the direct 

First:  the impact of and homeschooling on engagement with physical activity
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  the impact of and homeschooling on engagement with physical activity
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the impact of and homeschooling on engagement with physical activity
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the impact of and homeschooling on engagement with physical activity
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the impact of and homeschooling on engagement with physical activity
Second:  editorial recommendations for the management of in countries 

First:  the impact of and homeschooling on engagement with physical activity
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the impact of and homeschooling on engagement with physical activity
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the impact on surgical departments of hospitals 

First:  the impact of and homeschooling on engagement with physical activity
Second:  toxic and properties of an coordination complex of 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the common missed instances and areas after years of education 

First:  the impact of and homeschooling on engagement with physical activity
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the impact of and homeschooling on engagement with physical activity
Second:  potential of in vitro 

First:  the impact of and homeschooling on engagement with physical activity
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the impact of and homeschooling on engagement with physical activity
Second:  bacterial and the deadly trio in 

First:  the impact of and homeschooling on engagement with physical activity
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the impact of and homeschooling on engagement with physical activity
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the impact of and homeschooling on engagement with physical activity
Second:  establishment of a reference panel for the detection of antibodies 

First:  the impact of and homeschooling on engagement with physical activity
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the impact of and homeschooling on engagement with physical activity
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the impact of and homeschooling on engagement with physical activity
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the impact of and homeschooling on engagement with physical activity
Second:  genetic hypothesis and side of in 

First:  the impact of and homeschooling on engagement with physical activity
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  the impact of and homeschooling on engagement with physical activity
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the impact of and homeschooling on engagement with physical activity
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the impact of and homeschooling on engagement with physical activity
Second:  and prognostic significance in 

First:  the impact of and homeschooling on engagement with physical activity
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the sudden appearance of 

First:  the impact of and homeschooling on engagement with physical activity
Second:  school of population and global the university of evidence 

First:  the impact of and homeschooling on engagement with physical activity
Second:  early forecasting of the potential risk zones of in 

First:  the impact of and homeschooling on engagement with physical activity
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  the impact of and homeschooling on engagement with physical activity
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  the impact of and homeschooling on engagement with physical activity
Second:  a better understanding of social distancing 

First:  the impact of and homeschooling on engagement with physical activity
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the impact of and homeschooling on engagement with physical activity
Second:  older experience of the a analysis of stresses and joys 

First:  the impact of and homeschooling on engagement with physical activity
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  the impact of and homeschooling on engagement with physical activity
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the impact of and homeschooling on engagement with physical activity
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the impact of and homeschooling on engagement with physical activity
Second:  immigration policy and justice in the era of 

First:  the impact of and homeschooling on engagement with physical activity
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the and ends of rnas is not 

First:  the impact of and homeschooling on engagement with physical activity
Second:  and the saga continues 

First:  the impact of and homeschooling on engagement with physical activity
Second:  environmental research and public health the impact of on food results of a survey 

First:  the impact of and homeschooling on engagement with physical activity
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the impact of and homeschooling on engagement with physical activity
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the impact of and homeschooling on engagement with physical activity
Second:  recent advancements in the and prospective drug therapy of 

First:  the impact of and homeschooling on engagement with physical activity
Second:  infectious disease and the case for considering impacts 

First:  the impact of and homeschooling on engagement with physical activity
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  editorial recommendations for the management of in countries 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  early forecasting of the potential risk zones of in 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  investment and economic policy options in 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  older experience of the a analysis of stresses and joys 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  immigration policy and justice in the era of 

First:  the joint influences of resource and time bases in management earnings guidance disclosure
Second:  recent advancements in the and prospective drug therapy of 

First:  article when it is will we take social media perception of hypothetical vaccine in nigeria when it is will we take social media perception of hypothetical vaccine in nigeria
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  potential of in vitro 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  genetic hypothesis and side of in 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  and prognostic significance in 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  the sudden appearance of 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  early forecasting of the potential risk zones of in 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  older experience of the a analysis of stresses and joys 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  the and ends of rnas is not 

First:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent
Second:  recent advancements in the and prospective drug therapy of 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  viral intestinal infections of animals and man 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  potential of in vitro 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  bacterial and the deadly trio in 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  genetic hypothesis and side of in 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  and prognostic significance in 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  the sudden appearance of 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  early forecasting of the potential risk zones of in 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  more severe presentations of acute appendicitis during 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  innate cell profiles during the acute and convalescent phase of infection in children
Second:  recent advancements in the and prospective drug therapy of 

First:  cells the aging of t cells
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  cells the aging of t cells
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  cells the aging of t cells
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  cells the aging of t cells
Second:  viral intestinal infections of animals and man 

First:  cells the aging of t cells
Second:  and cell biology lung advances in generation and 

First:  cells the aging of t cells
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  cells the aging of t cells
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  cells the aging of t cells
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  cells the aging of t cells
Second:  spectrum of antimicrobial activity for disinfection of 

First:  cells the aging of t cells
Second:  modulating the quantity of hiv t cell help promotes rare b cell responses in germinal centers 

First:  cells the aging of t cells
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  cells the aging of t cells
Second:  concept of immune response 

First:  cells the aging of t cells
Second:  potential of in vitro 

First:  cells the aging of t cells
Second:  supramolecular architecture of the coronavirus particle 

First:  cells the aging of t cells
Second:  establishment of a reference panel for the detection of antibodies 

First:  cells the aging of t cells
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  cells the aging of t cells
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  cells the aging of t cells
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  cells the aging of t cells
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  cells the aging of t cells
Second:  the sudden appearance of 

First:  cells the aging of t cells
Second:  the function and inhibition by designed antiviral compounds 

First:  cells the aging of t cells
Second:  combination kills bladder cancer cells synergistically 

First:  cells the aging of t cells
Second:  early forecasting of the potential risk zones of in 

First:  cells the aging of t cells
Second:  enhances the peroxidase activity of myoglobin against 

First:  cells the aging of t cells
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  cells the aging of t cells
Second:  the and ends of rnas is not 

First:  cells the aging of t cells
Second:  recent advancements in the and prospective drug therapy of 

First:  cells the aging of t cells
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  cells the aging of t cells
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  clinical characteristics of death cases with
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical characteristics of death cases with
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  clinical characteristics of death cases with
Second:  case report mammography in the diagnosis of breast 

First:  clinical characteristics of death cases with
Second:  journal of cancer research and clinical oncology 

First:  clinical characteristics of death cases with
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  clinical characteristics of death cases with
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  clinical characteristics of death cases with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical characteristics of death cases with
Second:  prophylaxis of with and chloroquine accepted article 

First:  clinical characteristics of death cases with
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  clinical characteristics of death cases with
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical characteristics of death cases with
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  clinical characteristics of death cases with
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  clinical characteristics of death cases with
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical characteristics of death cases with
Second:  potential of in vitro 

First:  clinical characteristics of death cases with
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical characteristics of death cases with
Second:  and prognostic significance in 

First:  clinical characteristics of death cases with
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical characteristics of death cases with
Second:  the sudden appearance of 

First:  clinical characteristics of death cases with
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical characteristics of death cases with
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  clinical characteristics of death cases with
Second:  older experience of the a analysis of stresses and joys 

First:  clinical characteristics of death cases with
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical characteristics of death cases with
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  clinical characteristics of death cases with
Second:  regression of infantile glioblastoma after treatment with 

First:  clinical characteristics of death cases with
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical characteristics of death cases with
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  clinical characteristics of death cases with
Second:  recent advancements in the and prospective drug therapy of 

First:  clinical characteristics of death cases with
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  clinical characteristics of death cases with
Second:  infectious disease and the case for considering impacts 

First:  clinical characteristics of death cases with
Second:  stress symptoms in hemodialysis patients with exposure 

First:  clinical characteristics of death cases with
Second:  clinical potential of for assessing comparative analysis 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  journal of cancer research and clinical oncology 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  viral intestinal infections of animals and man 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  a review in bacterial infections 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  a serological comparison of bovine coronavirus strains 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  infectious disease and the case for considering impacts 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  stress symptoms in hemodialysis patients with exposure 

First:  clinical disease severity of respiratory viral versus single viral a systematic review and
Second:  clinical potential of for assessing comparative analysis 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  a study on the influence of the pandemic on incomes in greece 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  mapping the technological landscape of and vaccines 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  coordinating genomic surveillance in the united states 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  editorial recommendations for the management of in countries 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  potential of in vitro 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  genetic hypothesis and side of in 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  the sudden appearance of 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  school of population and global the university of evidence 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  early forecasting of the potential risk zones of in 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  investment and economic policy options in 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  older experience of the a analysis of stresses and joys 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  immigration policy and justice in the era of 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  the and ends of rnas is not 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  environmental research and public health the impact of on food results of a survey 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia
Second:  recent advancements in the and prospective drug therapy of 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  potential of in vitro 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  genetic hypothesis and side of in 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  and prognostic significance in 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  the sudden appearance of 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  early forecasting of the potential risk zones of in 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  older experience of the a analysis of stresses and joys 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  recent advancements in the and prospective drug therapy of 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  infectious disease and the case for considering impacts 

First:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases
Second:  clinical potential of for assessing comparative analysis 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  viral intestinal infections of animals and man 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  microorganisms nasal microbiota in rsv 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  a review in bacterial infections 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  a serological comparison of bovine coronavirus strains 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  combination kills bladder cancer cells synergistically 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  use of in human immunodeficiency virus infection 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  stress symptoms in hemodialysis patients with exposure 

First:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  evaluation of the effect of border closure on incidence rates across nine african an interrupted time series study
Second:  the sudden appearance of 

First:  has countrywide lockdown worked as a feasible measure in bending the curve in developing
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical validation of two isothermal amplification assays for the rapid detection of african swine fever virus
Second:  spectrum of antimicrobial activity for disinfection of 

First:  clinical validation of two isothermal amplification assays for the rapid detection of african swine fever virus
Second:  potential of in vitro 

First:  clinical validation of two isothermal amplification assays for the rapid detection of african swine fever virus
Second:  a serological comparison of bovine coronavirus strains 

First:  innate immunity to respiratory infection in early life
Second:  viral intestinal infections of animals and man 

First:  innate immunity to respiratory infection in early life
Second:  use of in human immunodeficiency virus infection 

First:  innate immunity to respiratory infection in early life
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china
Second:  stress symptoms in hemodialysis patients with exposure 

First:  a look in the how the field of behavior analysis can become
Second:  a study on the influence of the pandemic on incomes in greece 

First:  a look in the how the field of behavior analysis can become
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a look in the how the field of behavior analysis can become
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  a look in the how the field of behavior analysis can become
Second:  a remedy or a ripple in severe 

First:  a look in the how the field of behavior analysis can become
Second:  journal innovations in in the age of a systematic literature review 

First:  a look in the how the field of behavior analysis can become
Second:  disease in the era of an observation on a series of six patients with 

First:  a look in the how the field of behavior analysis can become
Second:  mapping the technological landscape of and vaccines 

First:  a look in the how the field of behavior analysis can become
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  a look in the how the field of behavior analysis can become
Second:  does the pandemic spell the end for the direct 

First:  a look in the how the field of behavior analysis can become
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  a look in the how the field of behavior analysis can become
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a look in the how the field of behavior analysis can become
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  a look in the how the field of behavior analysis can become
Second:  editorial recommendations for the management of in countries 

First:  a look in the how the field of behavior analysis can become
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  a look in the how the field of behavior analysis can become
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  a look in the how the field of behavior analysis can become
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  a look in the how the field of behavior analysis can become
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  a look in the how the field of behavior analysis can become
Second:  toxic and properties of an coordination complex of 

First:  a look in the how the field of behavior analysis can become
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a look in the how the field of behavior analysis can become
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  a look in the how the field of behavior analysis can become
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  a look in the how the field of behavior analysis can become
Second:  potential of in vitro 

First:  a look in the how the field of behavior analysis can become
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  a look in the how the field of behavior analysis can become
Second:  bacterial and the deadly trio in 

First:  a look in the how the field of behavior analysis can become
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  a look in the how the field of behavior analysis can become
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  a look in the how the field of behavior analysis can become
Second:  establishment of a reference panel for the detection of antibodies 

First:  a look in the how the field of behavior analysis can become
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  a look in the how the field of behavior analysis can become
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  a look in the how the field of behavior analysis can become
Second:  genetic hypothesis and side of in 

First:  a look in the how the field of behavior analysis can become
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  a look in the how the field of behavior analysis can become
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  a look in the how the field of behavior analysis can become
Second:  and prognostic significance in 

First:  a look in the how the field of behavior analysis can become
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a look in the how the field of behavior analysis can become
Second:  from ego to for ontology in the 

First:  a look in the how the field of behavior analysis can become
Second:  the sudden appearance of 

First:  a look in the how the field of behavior analysis can become
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  a look in the how the field of behavior analysis can become
Second:  school of population and global the university of evidence 

First:  a look in the how the field of behavior analysis can become
Second:  a protocol for a systematic review and 

First:  a look in the how the field of behavior analysis can become
Second:  early forecasting of the potential risk zones of in 

First:  a look in the how the field of behavior analysis can become
Second:  a better understanding of social distancing 

First:  a look in the how the field of behavior analysis can become
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  a look in the how the field of behavior analysis can become
Second:  and responses to in south a rapid qualitative assessment 

First:  a look in the how the field of behavior analysis can become
Second:  older experience of the a analysis of stresses and joys 

First:  a look in the how the field of behavior analysis can become
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  a look in the how the field of behavior analysis can become
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  a look in the how the field of behavior analysis can become
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  a look in the how the field of behavior analysis can become
Second:  immigration policy and justice in the era of 

First:  a look in the how the field of behavior analysis can become
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  a look in the how the field of behavior analysis can become
Second:  the and ends of rnas is not 

First:  a look in the how the field of behavior analysis can become
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  a look in the how the field of behavior analysis can become
Second:  and the saga continues 

First:  a look in the how the field of behavior analysis can become
Second:  environmental research and public health the impact of on food results of a survey 

First:  a look in the how the field of behavior analysis can become
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  a look in the how the field of behavior analysis can become
Second:  and what evidence needs our 

First:  a look in the how the field of behavior analysis can become
Second:  how can blockchain help people in the event of pandemics such as the 

First:  a look in the how the field of behavior analysis can become
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  a look in the how the field of behavior analysis can become
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  a look in the how the field of behavior analysis can become
Second:  recent advancements in the and prospective drug therapy of 

First:  a look in the how the field of behavior analysis can become
Second:  infectious disease and the case for considering impacts 

First:  a look in the how the field of behavior analysis can become
Second:  clinical potential of for assessing comparative analysis 

First:  a look in the how the field of behavior analysis can become
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  a look in the how the field of behavior analysis can become
Second:  the impact of and homeschooling on engagement with physical activity 

First:  optimality in vaccination strategies determined by heterogeneity in interaction networks
Second:  potential of in vitro 

First:  antiviral strategies to control infections
Second:  viral intestinal infections of animals and man 

First:  antiviral strategies to control infections
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  antiviral strategies to control infections
Second:  microorganisms nasal microbiota in rsv 

First:  antiviral strategies to control infections
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  antiviral strategies to control infections
Second:  a review in bacterial infections 

First:  antiviral strategies to control infections
Second:  predicting risk of transition to severe infection 

First:  antiviral strategies to control infections
Second:  proactive strategy to improve staff engagement 

First:  antiviral strategies to control infections
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  antiviral strategies to control infections
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  antiviral strategies to control infections
Second:  do viruses subvert cholesterol homeostasis to induce host cubic 

First:  antiviral strategies to control infections
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  antiviral strategies to control infections
Second:  combination kills bladder cancer cells synergistically 

First:  antiviral strategies to control infections
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  antiviral strategies to control infections
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  antiviral strategies to control infections
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  antiviral strategies to control infections
Second:  use of in human immunodeficiency virus infection 

First:  antiviral strategies to control infections
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  antiviral strategies to control infections
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  antiviral strategies to control infections
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  antiviral strategies to control infections
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  antiviral strategies to control infections
Second:  stress symptoms in hemodialysis patients with exposure 

First:  antiviral strategies to control infections
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  antiviral strategies to control infections
Second:  innate immunity to respiratory infection in early life 

First:  antimicrobial and cytotoxic activities of some novel clubbed
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  antimicrobial and cytotoxic activities of some novel clubbed
Second:  spectrum of antimicrobial activity for disinfection of 

First:  antimicrobial and cytotoxic activities of some novel clubbed
Second:  potential of in vitro 

First:  antimicrobial and cytotoxic activities of some novel clubbed
Second:  synthesis and activity of derivatives and analogues thereof 

First:  antimicrobial and cytotoxic activities of some novel clubbed
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  antimicrobial and cytotoxic activities of some novel clubbed
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  what is so complicated about prenatal testing for down a personal view
Second:  and what evidence needs our 

First:  world journal of clinical cases healthy neonate born to a infected a case report and review of literature informed consent the
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  case report mammography in the diagnosis of breast 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  journal of cancer research and clinical oncology 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  viral intestinal infections of animals and man 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  in ckd lessons from ckd patients with kidney disease 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  sciencedirect intensive care admission for coronavirus respiratory tract infections admissions en pour infection  coronavirus 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  microorganisms nasal microbiota in rsv 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  chest computed tomographic findings of patients with pneumonia 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  prevalence of antibodies in young children in tennessee 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  a review in bacterial infections 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  potential of in vitro 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  journal incidence of pulmonary embolism in patients with respiratory support during outbreak credit author statement incidence of pulmonary embolism in patients with invasive respiratory support during outbreak 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  a serological comparison of bovine coronavirus strains 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  journal fungal in patients with role of antifungal 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  course in coronavirus patients who are asymptomatic at admission 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  mortality rates due to respiratory tract diseases in iran during a study 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  depression and sleep quality in patients undergoing 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  use of in human immunodeficiency virus infection 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  regression of infantile glioblastoma after treatment with 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  vaccination in patients with multiple focus on immune response vaccination and immune response in mm 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  morbidity and mortality weekly report 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  stress symptoms in hemodialysis patients with exposure 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  innate immunity to respiratory infection in early life 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china 

First:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children
Second:  antiviral strategies to control infections 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  regression of infantile glioblastoma after treatment with 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  infectious disease and the case for considering impacts 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  stress symptoms in hemodialysis patients with exposure 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  risk worries and preventive behaviors in patients with previous pulmonary embolism
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  does the pandemic spell the end for the direct 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  editorial recommendations for the management of in countries 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  the sudden appearance of 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  immigration policy and justice in the era of 

First:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  supplementary information for generation of reporter for high throughput antiviral screening and testing
Second:  reliability of serological tests for comparison of three test kits for antibodies 

First:  supplementary information for generation of reporter for high throughput antiviral screening and testing
Second:  clinical potential of for assessing comparative analysis 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  stress symptoms in hemodialysis patients with exposure 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  levels of and in the lungs of pneumonia patients
Second:  a study on the influence of the pandemic on incomes in greece 

First:  levels of and in the lungs of pneumonia patients
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  levels of and in the lungs of pneumonia patients
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  levels of and in the lungs of pneumonia patients
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  levels of and in the lungs of pneumonia patients
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  levels of and in the lungs of pneumonia patients
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  levels of and in the lungs of pneumonia patients
Second:  case report mammography in the diagnosis of breast 

First:  levels of and in the lungs of pneumonia patients
Second:  a remedy or a ripple in severe 

First:  levels of and in the lungs of pneumonia patients
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  levels of and in the lungs of pneumonia patients
Second:  journal innovations in in the age of a systematic literature review 

First:  levels of and in the lungs of pneumonia patients
Second:  journal of cancer research and clinical oncology 

First:  levels of and in the lungs of pneumonia patients
Second:  disease in the era of an observation on a series of six patients with 

First:  levels of and in the lungs of pneumonia patients
Second:  mapping the technological landscape of and vaccines 

First:  levels of and in the lungs of pneumonia patients
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  levels of and in the lungs of pneumonia patients
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  levels of and in the lungs of pneumonia patients
Second:  viral intestinal infections of animals and man 

First:  levels of and in the lungs of pneumonia patients
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  levels of and in the lungs of pneumonia patients
Second:  does the pandemic spell the end for the direct 

First:  levels of and in the lungs of pneumonia patients
Second:  coordinating genomic surveillance in the united states 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  levels of and in the lungs of pneumonia patients
Second:  and cell biology lung advances in generation and 

First:  levels of and in the lungs of pneumonia patients
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  levels of and in the lungs of pneumonia patients
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  levels of and in the lungs of pneumonia patients
Second:  journal evaluation of internal and external surfaces used by health care workers and patients in wards 

First:  levels of and in the lungs of pneumonia patients
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  levels of and in the lungs of pneumonia patients
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  levels of and in the lungs of pneumonia patients
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  levels of and in the lungs of pneumonia patients
Second:  in ckd lessons from ckd patients with kidney disease 

First:  levels of and in the lungs of pneumonia patients
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  levels of and in the lungs of pneumonia patients
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  levels of and in the lungs of pneumonia patients
Second:  invasive strategy for patients presenting with acute coronary the first italian experience 

First:  levels of and in the lungs of pneumonia patients
Second:  reply to against the risk of airborne 

First:  levels of and in the lungs of pneumonia patients
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  levels of and in the lungs of pneumonia patients
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  levels of and in the lungs of pneumonia patients
Second:  excess neurological death in new york city after the emergence of 

First:  levels of and in the lungs of pneumonia patients
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  levels of and in the lungs of pneumonia patients
Second:  editorial recommendations for the management of in countries 

First:  levels of and in the lungs of pneumonia patients
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  levels of and in the lungs of pneumonia patients
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  levels of and in the lungs of pneumonia patients
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  levels of and in the lungs of pneumonia patients
Second:  prophylaxis of with and chloroquine accepted article 

First:  levels of and in the lungs of pneumonia patients
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  levels of and in the lungs of pneumonia patients
Second:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies 

First:  levels of and in the lungs of pneumonia patients
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  levels of and in the lungs of pneumonia patients
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  levels of and in the lungs of pneumonia patients
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  levels of and in the lungs of pneumonia patients
Second:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york 

First:  levels of and in the lungs of pneumonia patients
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  levels of and in the lungs of pneumonia patients
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  levels of and in the lungs of pneumonia patients
Second:  the impact on surgical departments of hospitals 

First:  levels of and in the lungs of pneumonia patients
Second:  chest computed tomographic findings of patients with pneumonia 

First:  levels of and in the lungs of pneumonia patients
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  levels of and in the lungs of pneumonia patients
Second:  open forum infectious diseases comparison of rates of hospitalization between single and dual virus detection in a mexican cohort of children and adults with illness 

First:  levels of and in the lungs of pneumonia patients
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  levels of and in the lungs of pneumonia patients
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  levels of and in the lungs of pneumonia patients
Second:  spectrum of antimicrobial activity for disinfection of 

First:  levels of and in the lungs of pneumonia patients
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  levels of and in the lungs of pneumonia patients
Second:  a model of pandemic evolution in african countries 

First:  levels of and in the lungs of pneumonia patients
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  levels of and in the lungs of pneumonia patients
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  levels of and in the lungs of pneumonia patients
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  levels of and in the lungs of pneumonia patients
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  levels of and in the lungs of pneumonia patients
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  levels of and in the lungs of pneumonia patients
Second:  prevalence of antibodies in young children in tennessee 

First:  levels of and in the lungs of pneumonia patients
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  levels of and in the lungs of pneumonia patients
Second:  toxic and properties of an coordination complex of 

First:  levels of and in the lungs of pneumonia patients
Second:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma 

First:  levels of and in the lungs of pneumonia patients
Second:  a review in bacterial infections 

First:  levels of and in the lungs of pneumonia patients
Second:  the common missed instances and areas after years of education 

First:  levels of and in the lungs of pneumonia patients
Second:  predicting risk of transition to severe infection 

First:  levels of and in the lungs of pneumonia patients
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  levels of and in the lungs of pneumonia patients
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  levels of and in the lungs of pneumonia patients
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  levels of and in the lungs of pneumonia patients
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  levels of and in the lungs of pneumonia patients
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  levels of and in the lungs of pneumonia patients
Second:  functional contribution and targeted migration of innate lymphoid cells in inflammatory lung being at the right place at the right time 

First:  levels of and in the lungs of pneumonia patients
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  levels of and in the lungs of pneumonia patients
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  levels of and in the lungs of pneumonia patients
Second:  concept of immune response 

First:  levels of and in the lungs of pneumonia patients
Second:  potential of in vitro 

First:  levels of and in the lungs of pneumonia patients
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  levels of and in the lungs of pneumonia patients
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  levels of and in the lungs of pneumonia patients
Second:  bacterial and the deadly trio in 

First:  levels of and in the lungs of pneumonia patients
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  levels of and in the lungs of pneumonia patients
Second:  supramolecular architecture of the coronavirus particle 

First:  levels of and in the lungs of pneumonia patients
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  levels of and in the lungs of pneumonia patients
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  levels of and in the lungs of pneumonia patients
Second:  journal incidence of pulmonary embolism in patients with respiratory support during outbreak credit author statement incidence of pulmonary embolism in patients with invasive respiratory support during outbreak 

First:  levels of and in the lungs of pneumonia patients
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  levels of and in the lungs of pneumonia patients
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  levels of and in the lungs of pneumonia patients
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  levels of and in the lungs of pneumonia patients
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  levels of and in the lungs of pneumonia patients
Second:  establishment of a reference panel for the detection of antibodies 

First:  levels of and in the lungs of pneumonia patients
Second:  bifurcated monocyte states are predictive of mortality in severe 

First:  levels of and in the lungs of pneumonia patients
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  levels of and in the lungs of pneumonia patients
Second:  a serological comparison of bovine coronavirus strains 

First:  levels of and in the lungs of pneumonia patients
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  levels of and in the lungs of pneumonia patients
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  levels of and in the lungs of pneumonia patients
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  levels of and in the lungs of pneumonia patients
Second:  synthesis and activity of derivatives and analogues thereof 

First:  levels of and in the lungs of pneumonia patients
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  levels of and in the lungs of pneumonia patients
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  levels of and in the lungs of pneumonia patients
Second:  genetic hypothesis and side of in 

First:  levels of and in the lungs of pneumonia patients
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  levels of and in the lungs of pneumonia patients
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  levels of and in the lungs of pneumonia patients
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  levels of and in the lungs of pneumonia patients
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  levels of and in the lungs of pneumonia patients
Second:  and prognostic significance in 

First:  levels of and in the lungs of pneumonia patients
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  levels of and in the lungs of pneumonia patients
Second:  of period between onset of symptoms for a cohort study short title aggressiveness of corresponding author 

First:  levels of and in the lungs of pneumonia patients
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  levels of and in the lungs of pneumonia patients
Second:  journal fungal in patients with role of antifungal 

First:  levels of and in the lungs of pneumonia patients
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  levels of and in the lungs of pneumonia patients
Second:  from ego to for ontology in the 

First:  levels of and in the lungs of pneumonia patients
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  levels of and in the lungs of pneumonia patients
Second:  influence of pharmaceutical on emergency hospital a 

First:  levels of and in the lungs of pneumonia patients
Second:  the sudden appearance of 

First:  levels of and in the lungs of pneumonia patients
Second:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors 

First:  levels of and in the lungs of pneumonia patients
Second:  mortality rates due to respiratory tract diseases in iran during a study 

First:  levels of and in the lungs of pneumonia patients
Second:  policy responses to the pandemic in vietnam 

First:  levels of and in the lungs of pneumonia patients
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  levels of and in the lungs of pneumonia patients
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  levels of and in the lungs of pneumonia patients
Second:  school of population and global the university of evidence 

First:  levels of and in the lungs of pneumonia patients
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  levels of and in the lungs of pneumonia patients
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  levels of and in the lungs of pneumonia patients
Second:  early forecasting of the potential risk zones of in 

First:  levels of and in the lungs of pneumonia patients
Second:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes 

First:  levels of and in the lungs of pneumonia patients
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  levels of and in the lungs of pneumonia patients
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  levels of and in the lungs of pneumonia patients
Second:  therapeutic advances in infectious disease benefits of viral screening of formerly incarcerated individuals during community reentry 

First:  levels of and in the lungs of pneumonia patients
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  levels of and in the lungs of pneumonia patients
Second:  in a comprehensive investigation from exposure to treatment outcomes 

First:  levels of and in the lungs of pneumonia patients
Second:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults 

First:  levels of and in the lungs of pneumonia patients
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  levels of and in the lungs of pneumonia patients
Second:  letter to the editor are patients with autoimmune disease at greater risk of developing severe 

First:  levels of and in the lungs of pneumonia patients
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  levels of and in the lungs of pneumonia patients
Second:  edema assessment by means of the and laser scanning microscopy 

First:  levels of and in the lungs of pneumonia patients
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  levels of and in the lungs of pneumonia patients
Second:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education 

First:  levels of and in the lungs of pneumonia patients
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  levels of and in the lungs of pneumonia patients
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  levels of and in the lungs of pneumonia patients
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  levels of and in the lungs of pneumonia patients
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  levels of and in the lungs of pneumonia patients
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  levels of and in the lungs of pneumonia patients
Second:  marine drugs caged formed of the morphogenetic active inorganic are strong of 

First:  levels of and in the lungs of pneumonia patients
Second:  the expression in human heart indicates new potential mechanism of heart injury among patients infected with 

First:  levels of and in the lungs of pneumonia patients
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  levels of and in the lungs of pneumonia patients
Second:  activity of world health formulations against enveloped including and emerging 

First:  levels of and in the lungs of pneumonia patients
Second:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase 

First:  levels of and in the lungs of pneumonia patients
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  levels of and in the lungs of pneumonia patients
Second:  depression and sleep quality in patients undergoing 

First:  levels of and in the lungs of pneumonia patients
Second:  enhances the peroxidase activity of myoglobin against 

First:  levels of and in the lungs of pneumonia patients
Second:  isolation of aspergillus in respiratory samples of patients with in a spanish tertiary care hospital acknowledgments and funding conflicts of interest statement 

First:  levels of and in the lungs of pneumonia patients
Second:  and responses to in south a rapid qualitative assessment 

First:  levels of and in the lungs of pneumonia patients
Second:  older experience of the a analysis of stresses and joys 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  levels of and in the lungs of pneumonia patients
Second:  journal case report rapid development of seizures and pres in a patient 

First:  levels of and in the lungs of pneumonia patients
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  levels of and in the lungs of pneumonia patients
Second:  systematic review of the prognostic utility of disseminated intravascular and anticoagulant therapy in critically ill patients palabras clave 

First:  levels of and in the lungs of pneumonia patients
Second:  surveillance of pathogens in dairy and beef cows in yamagata japan from to 

First:  levels of and in the lungs of pneumonia patients
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  levels of and in the lungs of pneumonia patients
Second:  effectiveness of a fluid chart in outpatient management of suspected dengue a pilot study 

First:  levels of and in the lungs of pneumonia patients
Second:  mask social and gender correlates of vaccine intentions among adults in the us 

First:  levels of and in the lungs of pneumonia patients
Second:  social determinants of mortality at the county level 

First:  levels of and in the lungs of pneumonia patients
Second:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece 

First:  levels of and in the lungs of pneumonia patients
Second:  use of in human immunodeficiency virus infection 

First:  levels of and in the lungs of pneumonia patients
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  levels of and in the lungs of pneumonia patients
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  levels of and in the lungs of pneumonia patients
Second:  effects of interval training and training on and resilience in healthy adults during coronavirus disease a randomized controlled trial 

First:  levels of and in the lungs of pneumonia patients
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  levels of and in the lungs of pneumonia patients
Second:  immigration policy and justice in the era of 

First:  levels of and in the lungs of pneumonia patients
Second:  regression of infantile glioblastoma after treatment with 

First:  levels of and in the lungs of pneumonia patients
Second:  diffusion as a first model of spread of viral infection 

First:  levels of and in the lungs of pneumonia patients
Second:  properties of on human ex vivo and in vitro observations 

First:  levels of and in the lungs of pneumonia patients
Second:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation 

First:  levels of and in the lungs of pneumonia patients
Second:  digitalized adaptation of oncology trials during and after 

First:  levels of and in the lungs of pneumonia patients
Second:  outbreak situation and its psychological impact among surgeon in training in france 

First:  levels of and in the lungs of pneumonia patients
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  levels of and in the lungs of pneumonia patients
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  levels of and in the lungs of pneumonia patients
Second:  a rare complication of spontaneous pneumothorax following case report running associated pneumothorax and 

First:  levels of and in the lungs of pneumonia patients
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  levels of and in the lungs of pneumonia patients
Second:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study 

First:  levels of and in the lungs of pneumonia patients
Second:  the and ends of rnas is not 

First:  levels of and in the lungs of pneumonia patients
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  levels of and in the lungs of pneumonia patients
Second:  more severe presentations of acute appendicitis during 

First:  levels of and in the lungs of pneumonia patients
Second:  and the saga continues 

First:  levels of and in the lungs of pneumonia patients
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  levels of and in the lungs of pneumonia patients
Second:  environmental research and public health the impact of on food results of a survey 

First:  levels of and in the lungs of pneumonia patients
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  levels of and in the lungs of pneumonia patients
Second:  international archives of occupational and environmental health 

First:  levels of and in the lungs of pneumonia patients
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  levels of and in the lungs of pneumonia patients
Second:  how can blockchain help people in the event of pandemics such as the 

First:  levels of and in the lungs of pneumonia patients
Second:  to appear advances in oral and maxillofacial surgery 

First:  levels of and in the lungs of pneumonia patients
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  levels of and in the lungs of pneumonia patients
Second:  journal inhaled corticosteroids the receptor in copd through suppression of type i interferon increased severity from severity attenuation of expression by inhaled corticosteroid use in copd 

First:  levels of and in the lungs of pneumonia patients
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  levels of and in the lungs of pneumonia patients
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  levels of and in the lungs of pneumonia patients
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  levels of and in the lungs of pneumonia patients
Second:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its 

First:  levels of and in the lungs of pneumonia patients
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  levels of and in the lungs of pneumonia patients
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  levels of and in the lungs of pneumonia patients
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  levels of and in the lungs of pneumonia patients
Second:  recent advancements in the and prospective drug therapy of 

First:  levels of and in the lungs of pneumonia patients
Second:  journal the psychological status of people affected by the outbreak in china 

First:  levels of and in the lungs of pneumonia patients
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  levels of and in the lungs of pneumonia patients
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  levels of and in the lungs of pneumonia patients
Second:  higher glycemic variability within the first day of icu admission is associated with increased mortality in icu patients with sepsis 

First:  levels of and in the lungs of pneumonia patients
Second:  infectious disease and the case for considering impacts 

First:  levels of and in the lungs of pneumonia patients
Second:  stress symptoms in hemodialysis patients with exposure 

First:  levels of and in the lungs of pneumonia patients
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  levels of and in the lungs of pneumonia patients
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  levels of and in the lungs of pneumonia patients
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  levels of and in the lungs of pneumonia patients
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  levels of and in the lungs of pneumonia patients
Second:  suspected myocarditis in patients with a case series 

First:  levels of and in the lungs of pneumonia patients
Second:  distinct cellular immune profiles in the airways and blood of critically ill patients with consortium and the amsterdam umc study group respiratory infection 

First:  levels of and in the lungs of pneumonia patients
Second:  journal lack of rna environmental contamination in a tertiary referral hospital for infectious diseases in northern lack of rna environmental contamination in a tertiary referral hospital for infectious diseases in northern italy 

First:  levels of and in the lungs of pneumonia patients
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical potential of for assessing comparative analysis 

First:  levels of and in the lungs of pneumonia patients
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  levels of and in the lungs of pneumonia patients
Second:  the impact of and homeschooling on engagement with physical activity 

First:  levels of and in the lungs of pneumonia patients
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  levels of and in the lungs of pneumonia patients
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  levels of and in the lungs of pneumonia patients
Second:  cells the aging of t cells 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical characteristics of death cases with 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  levels of and in the lungs of pneumonia patients
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  levels of and in the lungs of pneumonia patients
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  levels of and in the lungs of pneumonia patients
Second:  innate immunity to respiratory infection in early life 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china 

First:  levels of and in the lungs of pneumonia patients
Second:  a look in the how the field of behavior analysis can become 

First:  levels of and in the lungs of pneumonia patients
Second:  antimicrobial and cytotoxic activities of some novel clubbed 

First:  levels of and in the lungs of pneumonia patients
Second:  world journal of clinical cases healthy neonate born to a infected a case report and review of literature informed consent the 

First:  levels of and in the lungs of pneumonia patients
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  levels of and in the lungs of pneumonia patients
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  levels of and in the lungs of pneumonia patients
Second:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a study on the influence of the pandemic on incomes in greece 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  case report mammography in the diagnosis of breast 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal innovations in in the age of a systematic literature review 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal of cancer research and clinical oncology 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  disease in the era of an observation on a series of six patients with 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  mapping the technological landscape of and vaccines 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  viral intestinal infections of animals and man 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  does the pandemic spell the end for the direct 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  coordinating genomic surveillance in the united states 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  flying under the the stealth pandemic of escherichia coli sequence type 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and cell biology lung advances in generation and 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  reply to against the risk of airborne 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  excess neurological death in new york city after the emergence of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  editorial recommendations for the management of in countries 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a section of the journal frontiers in immunology t rm cells following infection and implications for more effective vaccine design 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  prophylaxis of with and chloroquine accepted article 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal pregnant versus and hospital the first weeks in new york pregnant versus and hospital the first weeks in new york 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the impact on surgical departments of hospitals 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  letter to the editor 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  spectrum of antimicrobial activity for disinfection of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a model of pandemic evolution in african countries 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  prevalence of antibodies in young children in tennessee 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  toxic and properties of an coordination complex of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a review in bacterial infections 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  basics of molecular biology 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the common missed instances and areas after years of education 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  predicting risk of transition to severe infection 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  functional contribution and targeted migration of innate lymphoid cells in inflammatory lung being at the right place at the right time 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  concept of immune response 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  potential of in vitro 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  bacterial and the deadly trio in 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  supramolecular architecture of the coronavirus particle 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  establishment of a reference panel for the detection of antibodies 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a serological comparison of bovine coronavirus strains 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  synthesis and activity of derivatives and analogues thereof 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  genetic hypothesis and side of in 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and prognostic significance in 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  of period between onset of symptoms for a cohort study short title aggressiveness of corresponding author 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal fungal in patients with role of antifungal 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  from ego to for ontology in the 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal of management control 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  influence of pharmaceutical on emergency hospital a 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the sudden appearance of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  policy responses to the pandemic in vietnam 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the function and inhibition by designed antiviral compounds 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  school of population and global the university of evidence 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  letters to the editor letters to the editor 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  early forecasting of the potential risk zones of in 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  edema assessment by means of the and laser scanning microscopy 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  integrating research integrity into the history of science 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  scenario modelling for the mitigation of deaths in intensive computer simulation study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the expression in human heart indicates new potential mechanism of heart injury among patients infected with 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  enhances the peroxidase activity of myoglobin against 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  isolation of aspergillus in respiratory samples of patients with in a spanish tertiary care hospital acknowledgments and funding conflicts of interest statement 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  genetic diversity in the yellow head complex 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  eines in einer im der implementation of an operational concept in an ent clinic in the context of the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  older experience of the a analysis of stresses and joys 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  systematic review of the prognostic utility of disseminated intravascular and anticoagulant therapy in critically ill patients palabras clave 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  effectiveness of a fluid chart in outpatient management of suspected dengue a pilot study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal of banking regulation 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  mask social and gender correlates of vaccine intentions among adults in the us 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  social determinants of mortality at the county level 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  use of in human immunodeficiency virus infection 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  letters to the editor 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  immigration policy and justice in the era of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  regression of infantile glioblastoma after treatment with 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  diffusion as a first model of spread of viral infection 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  digitalized adaptation of oncology trials during and after 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the and ends of rnas is not 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  more severe presentations of acute appendicitis during 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  and the saga continues 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  environmental research and public health the impact of on food results of a survey 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  international archives of occupational and environmental health 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  how can blockchain help people in the event of pandemics such as the 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  to appear advances in oral and maxillofacial surgery 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  recent advancements in the and prospective drug therapy of 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal the psychological status of people affected by the outbreak in china 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  infectious disease and the case for considering impacts 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  reliability of serological tests for comparison of three test kits for antibodies 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  distinct cellular immune profiles in the airways and blood of critically ill patients with consortium and the amsterdam umc study group respiratory infection 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal lack of rna environmental contamination in a tertiary referral hospital for infectious diseases in northern lack of rna environmental contamination in a tertiary referral hospital for infectious diseases in northern italy 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical potential of for assessing comparative analysis 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  the impact of and homeschooling on engagement with physical activity 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  cells the aging of t cells 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical characteristics of death cases with 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical validation of two isothermal amplification assays for the rapid detection of african swine fever virus 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  a look in the how the field of behavior analysis can become 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  world journal of clinical cases healthy neonate born to a infected a case report and review of literature informed consent the 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic 

First:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections
Second:  levels of and in the lungs of pneumonia patients 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  a study on the influence of the pandemic on incomes in greece 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  journal innovations in in the age of a systematic literature review 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  journal of cancer research and clinical oncology 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  disease in the era of an observation on a series of six patients with 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  mapping the technological landscape of and vaccines 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  and cell biology lung advances in generation and 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  editorial recommendations for the management of in countries 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the impact on surgical departments of hospitals 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  toxic and properties of an coordination complex of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  basics of molecular biology 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  potential of in vitro 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  bacterial and the deadly trio in 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  establishment of a reference panel for the detection of antibodies 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  synthesis and activity of derivatives and analogues thereof 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  genetic hypothesis and side of in 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  and prognostic significance in 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the sudden appearance of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  school of population and global the university of evidence 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  early forecasting of the potential risk zones of in 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  integrating research integrity into the history of science 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  older experience of the a analysis of stresses and joys 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  danish modern ecology and core studies 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  immigration policy and justice in the era of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the and ends of rnas is not 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  and the saga continues 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  environmental research and public health the impact of on food results of a survey 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  international archives of occupational and environmental health 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  recent advancements in the and prospective drug therapy of 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  journal the psychological status of people affected by the outbreak in china 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  infectious disease and the case for considering impacts 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  clinical potential of for assessing comparative analysis 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  the impact of and homeschooling on engagement with physical activity 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  a look in the how the field of behavior analysis can become 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  levels of and in the lungs of pneumonia patients 

First:  phylogenetic perspectives on the epidemiology and origins of sars and
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  clinical medicine review involvement in beyond pulmonary manifestations
Second:  journal of cancer research and clinical oncology 

First:  clinical medicine review involvement in beyond pulmonary manifestations
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical medicine review involvement in beyond pulmonary manifestations
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical medicine review involvement in beyond pulmonary manifestations
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  management of very old patients in intensive care units
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  management of very old patients in intensive care units
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  management of very old patients in intensive care units
Second:  levels of and in the lungs of pneumonia patients 

First:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea
Second:  the sudden appearance of 

First:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea
Second:  early forecasting of the potential risk zones of in 

First:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea
Second:  levels of and in the lungs of pneumonia patients 

First:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  response to have got dry macular end of a qualitative study into the experience of living with macular
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  response to have got dry macular end of a qualitative study into the experience of living with macular
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  response to have got dry macular end of a qualitative study into the experience of living with macular
Second:  the sudden appearance of 

First:  response to have got dry macular end of a qualitative study into the experience of living with macular
Second:  older experience of the a analysis of stresses and joys 

First:  response to have got dry macular end of a qualitative study into the experience of living with macular
Second:  levels of and in the lungs of pneumonia patients 

First:  estimation of the effective reproduction number of influenza based on weekly reports in miyazaki prefecture
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  estimation of the effective reproduction number of influenza based on weekly reports in miyazaki prefecture
Second:  potential of in vitro 

First:  estimation of the effective reproduction number of influenza based on weekly reports in miyazaki prefecture
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  estimation of the effective reproduction number of influenza based on weekly reports in miyazaki prefecture
Second:  levels of and in the lungs of pneumonia patients 

First:  estimation of the effective reproduction number of influenza based on weekly reports in miyazaki prefecture
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  does the pandemic spell the end for the direct 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  potential of in vitro 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  bacterial and the deadly trio in 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  genetic hypothesis and side of in 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  and prognostic significance in 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  the sudden appearance of 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  early forecasting of the potential risk zones of in 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  older experience of the a analysis of stresses and joys 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  the and ends of rnas is not 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  recent advancements in the and prospective drug therapy of 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  infectious disease and the case for considering impacts 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  levels of and in the lungs of pneumonia patients 

First:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  optimizing medication management during the an implementation guide for and care
Second:  editorial recommendations for the management of in countries 

First:  optimizing medication management during the an implementation guide for and care
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  optimizing medication management during the an implementation guide for and care
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  optimizing medication management during the an implementation guide for and care
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  optimizing medication management during the an implementation guide for and care
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  optimizing medication management during the an implementation guide for and care
Second:  recent advancements in the and prospective drug therapy of 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  ribonuclease l mediates the phenotype of rna editing enzyme deficiency in a human cell line 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  viral intestinal infections of animals and man 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  spectrum of antimicrobial activity for disinfection of 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  predicting risk of transition to severe infection 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  concept of immune response 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  potential of in vitro 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  molecular and cellular biochemistry derived peptides with mhc binding motifs from canine mammary tumor tissue elicit strong responses in mice 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  synthesis and activity of derivatives and analogues thereof 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  the function and inhibition by designed antiviral compounds 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  combination kills bladder cancer cells synergistically 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  restriction of replication by targeting programmed ribosomal in vitro 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  enhances the peroxidase activity of myoglobin against 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  use of in human immunodeficiency virus infection 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  journal inhaled corticosteroids the receptor in copd through suppression of type i interferon increased severity from severity attenuation of expression by inhaled corticosteroid use in copd 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  recent advancements in the and prospective drug therapy of 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  infectious disease and the case for considering impacts 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  stress symptoms in hemodialysis patients with exposure 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  cells the aging of t cells 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  antiviral strategies to control infections 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  levels of and in the lungs of pneumonia patients 

First:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  global challenges to urology practice during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  a study on the influence of the pandemic on incomes in greece 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  mapping the technological landscape of and vaccines 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  editorial recommendations for the management of in countries 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  the impact on surgical departments of hospitals 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  and prognostic significance in 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  the sudden appearance of 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  school of population and global the university of evidence 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  early forecasting of the potential risk zones of in 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  immigration policy and justice in the era of 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  environmental research and public health the impact of on food results of a survey 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  recent advancements in the and prospective drug therapy of 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  the impact of and homeschooling on engagement with physical activity 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  levels of and in the lungs of pneumonia patients 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  impact of the pandemic on emergency medicine insights from faculty and residents
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  a study on the influence of the pandemic on incomes in greece 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical and outcomes of patients from a large healthcare system in northern new jersey 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  journal of cancer research and clinical oncology 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  mapping the technological landscape of and vaccines 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  viral intestinal infections of animals and man 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  and cell biology lung advances in generation and 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  editorial recommendations for the management of in countries 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  prophylaxis of with and chloroquine accepted article 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the impact on surgical departments of hospitals 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  toxic and properties of an coordination complex of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the common missed instances and areas after years of education 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  potential of in vitro 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  bacterial and the deadly trio in 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  synthesis and activity of derivatives and analogues thereof 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  genetic hypothesis and side of in 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  and prognostic significance in 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the sudden appearance of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  school of population and global the university of evidence 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  early forecasting of the potential risk zones of in 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  older experience of the a analysis of stresses and joys 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  immigration policy and justice in the era of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the and ends of rnas is not 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  more severe presentations of acute appendicitis during 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  environmental research and public health the impact of on food results of a survey 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  international archives of occupational and environmental health 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  recent advancements in the and prospective drug therapy of 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  infectious disease and the case for considering impacts 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical potential of for assessing comparative analysis 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  the impact of and homeschooling on engagement with physical activity 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical characteristics of death cases with 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  levels of and in the lungs of pneumonia patients 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  clinical characteristics and outcomes of influenza and other illnesses in mexico city
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  case report mammography in the diagnosis of breast 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  journal of cancer research and clinical oncology 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  disease in the era of an observation on a series of six patients with 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  mapping the technological landscape of and vaccines 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  does the pandemic spell the end for the direct 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  editorial recommendations for the management of in countries 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  prophylaxis of with and chloroquine accepted article 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the impact on surgical departments of hospitals 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  spectrum of antimicrobial activity for disinfection of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  toxic and properties of an coordination complex of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  potential of in vitro 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  bacterial and the deadly trio in 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  genetic hypothesis and side of in 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  and prognostic significance in 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the sudden appearance of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  school of population and global the university of evidence 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  early forecasting of the potential risk zones of in 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  older experience of the a analysis of stresses and joys 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  immigration policy and justice in the era of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the and ends of rnas is not 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  and the saga continues 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  environmental research and public health the impact of on food results of a survey 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  recent advancements in the and prospective drug therapy of 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  infectious disease and the case for considering impacts 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  the impact of and homeschooling on engagement with physical activity 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  levels of and in the lungs of pneumonia patients 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  a study on the influence of the pandemic on incomes in greece 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  mapping the technological landscape of and vaccines 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  editorial recommendations for the management of in countries 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  and prognostic significance in 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  the sudden appearance of 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  school of population and global the university of evidence 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  early forecasting of the potential risk zones of in 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  a better understanding of social distancing 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  older experience of the a analysis of stresses and joys 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  the and ends of rnas is not 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  and the saga continues 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  environmental research and public health the impact of on food results of a survey 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  recent advancements in the and prospective drug therapy of 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  the impact of and homeschooling on engagement with physical activity 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  a look in the how the field of behavior analysis can become 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  levels of and in the lungs of pneumonia patients 

First:  identifying the needs of prekindergarten a focus on and family environment
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  potential of in vitro 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  genetic hypothesis and side of in 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  and prognostic significance in 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  the sudden appearance of 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  early forecasting of the potential risk zones of in 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  older experience of the a analysis of stresses and joys 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  recent advancements in the and prospective drug therapy of 

First:  temporal trends in rates of in hong kong people with and without a retrospective study
Second:  levels of and in the lungs of pneumonia patients 

First:  journal the experience on and cancer from an oncology hub institution in lombardy region the experience on and cancer from an oncology hub institution in lombardy region
Second:  and prognostic significance in 

First:  journal the experience on and cancer from an oncology hub institution in lombardy region the experience on and cancer from an oncology hub institution in lombardy region
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal the experience on and cancer from an oncology hub institution in lombardy region the experience on and cancer from an oncology hub institution in lombardy region
Second:  levels of and in the lungs of pneumonia patients 

First:  district level correlates of pandemic in india
Second:  levels of and in the lungs of pneumonia patients 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  a study on the influence of the pandemic on incomes in greece 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  mapping the technological landscape of and vaccines 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  does the pandemic spell the end for the direct 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  editorial recommendations for the management of in countries 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  spectrum of antimicrobial activity for disinfection of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  toxic and properties of an coordination complex of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  concept of immune response 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  potential of in vitro 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  bacterial and the deadly trio in 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  supramolecular architecture of the coronavirus particle 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  establishment of a reference panel for the detection of antibodies 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  synthesis and activity of derivatives and analogues thereof 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  genetic hypothesis and side of in 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  and prognostic significance in 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the sudden appearance of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the function and inhibition by designed antiviral compounds 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  school of population and global the university of evidence 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  early forecasting of the potential risk zones of in 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  enhances the peroxidase activity of myoglobin against 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  older experience of the a analysis of stresses and joys 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  immigration policy and justice in the era of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  diffusion as a first model of spread of viral infection 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the and ends of rnas is not 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  and the saga continues 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  recent advancements in the and prospective drug therapy of 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  infectious disease and the case for considering impacts 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  the impact of and homeschooling on engagement with physical activity 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  cells the aging of t cells 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  a look in the how the field of behavior analysis can become 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  levels of and in the lungs of pneumonia patients 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  compartmentalized replication organelle of at the er and the factors involved
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  journal of cancer research and clinical oncology 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  viral intestinal infections of animals and man 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  spectrum of antimicrobial activity for disinfection of 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  molecular cloning and characterization of an reductase gene from liquorice 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  basics of molecular biology 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  potential of in vitro 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  supramolecular architecture of the coronavirus particle 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  a serological comparison of bovine coronavirus strains 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  use of in human immunodeficiency virus infection 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  clinical potential of for assessing comparative analysis 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  cells the aging of t cells 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  levels of and in the lungs of pneumonia patients 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  bioinformatics analysis of spike proteins of porcine enteric
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  international mass gatherings and a observational study
Second:  regular international perspectives and initiatives 

First:  international mass gatherings and a observational study
Second:  and prognostic significance in 

First:  international mass gatherings and a observational study
Second:  a protocol for a systematic review and 

First:  international mass gatherings and a observational study
Second:  therapy for a feasibility study 

First:  international mass gatherings and a observational study
Second:  older experience of the a analysis of stresses and joys 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  viral intestinal infections of animals and man 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  in ckd lessons from ckd patients with kidney disease 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  a review in bacterial infections 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  a serological comparison of bovine coronavirus strains 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  use of in human immunodeficiency virus infection 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  regression of infantile glioblastoma after treatment with 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  stress symptoms in hemodialysis patients with exposure 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  levels of and in the lungs of pneumonia patients 

First:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  case report mammography in the diagnosis of breast 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  journal of cancer research and clinical oncology 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  mapping the technological landscape of and vaccines 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  viral intestinal infections of animals and man 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  and cell biology lung advances in generation and 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  solid and suspension microarrays for microbial diagnostics 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  quercetin as a potential treatment for acute kidney based on network pharmacology and molecular docking study 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  chest computed tomographic findings of patients with pneumonia 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  spectrum of antimicrobial activity for disinfection of 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  basics of molecular biology 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  predicting risk of transition to severe infection 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  potential of in vitro 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  a serological comparison of bovine coronavirus strains 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  and prognostic significance in 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  pharmaceutics pharmacokinetic estimation approach to predict clinical implications for cyp induction by in human hepatocytes and cells estimation approach to predict clinical implications for cyp induction by in human hepatocytes and pharmaceutics 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  therapy for a feasibility study 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  use of in human immunodeficiency virus infection 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  more severe presentations of acute appendicitis during 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  international archives of occupational and environmental health 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  recent advancements in the and prospective drug therapy of 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  infectious disease and the case for considering impacts 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  stress symptoms in hemodialysis patients with exposure 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical potential of for assessing comparative analysis 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical characteristics of death cases with 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  antiviral strategies to control infections 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  levels of and in the lungs of pneumonia patients 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical medicine review involvement in beyond pulmonary manifestations 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  proteomics of acute respiratory distress clinical and research applications
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  in vitro b and sars virus activities of a
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  in vitro b and sars virus activities of a
Second:  and cell biology lung advances in generation and 

First:  in vitro b and sars virus activities of a
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  in vitro b and sars virus activities of a
Second:  a review in bacterial infections 

First:  in vitro b and sars virus activities of a
Second:  potential of in vitro 

First:  in vitro b and sars virus activities of a
Second:  bacterial and the deadly trio in 

First:  in vitro b and sars virus activities of a
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  in vitro b and sars virus activities of a
Second:  a serological comparison of bovine coronavirus strains 

First:  in vitro b and sars virus activities of a
Second:  synthesis and activity of derivatives and analogues thereof 

First:  in vitro b and sars virus activities of a
Second:  genetic hypothesis and side of in 

First:  in vitro b and sars virus activities of a
Second:  and prognostic significance in 

First:  in vitro b and sars virus activities of a
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  in vitro b and sars virus activities of a
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  in vitro b and sars virus activities of a
Second:  use of in human immunodeficiency virus infection 

First:  in vitro b and sars virus activities of a
Second:  the and ends of rnas is not 

First:  in vitro b and sars virus activities of a
Second:  recent advancements in the and prospective drug therapy of 

First:  in vitro b and sars virus activities of a
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  in vitro b and sars virus activities of a
Second:  levels of and in the lungs of pneumonia patients 

First:  in vitro b and sars virus activities of a
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  hallucinations due to therapeutic doses of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  hallucinations due to therapeutic doses of
Second:  viral intestinal infections of animals and man 

First:  hallucinations due to therapeutic doses of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  hallucinations due to therapeutic doses of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  hallucinations due to therapeutic doses of
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  hallucinations due to therapeutic doses of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  hallucinations due to therapeutic doses of
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  hallucinations due to therapeutic doses of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  hallucinations due to therapeutic doses of
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  hallucinations due to therapeutic doses of
Second:  predicting risk of transition to severe infection 

First:  hallucinations due to therapeutic doses of
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  hallucinations due to therapeutic doses of
Second:  potential of in vitro 

First:  hallucinations due to therapeutic doses of
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  hallucinations due to therapeutic doses of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  hallucinations due to therapeutic doses of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  hallucinations due to therapeutic doses of
Second:  the sudden appearance of 

First:  hallucinations due to therapeutic doses of
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  hallucinations due to therapeutic doses of
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  hallucinations due to therapeutic doses of
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  hallucinations due to therapeutic doses of
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  hallucinations due to therapeutic doses of
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  hallucinations due to therapeutic doses of
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  hallucinations due to therapeutic doses of
Second:  depression and sleep quality in patients undergoing 

First:  hallucinations due to therapeutic doses of
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  hallucinations due to therapeutic doses of
Second:  regression of infantile glioblastoma after treatment with 

First:  hallucinations due to therapeutic doses of
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  hallucinations due to therapeutic doses of
Second:  more severe presentations of acute appendicitis during 

First:  hallucinations due to therapeutic doses of
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  hallucinations due to therapeutic doses of
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  hallucinations due to therapeutic doses of
Second:  recent advancements in the and prospective drug therapy of 

First:  hallucinations due to therapeutic doses of
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  hallucinations due to therapeutic doses of
Second:  stress symptoms in hemodialysis patients with exposure 

First:  hallucinations due to therapeutic doses of
Second:  antiviral strategies to control infections 

First:  hallucinations due to therapeutic doses of
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  hallucinations due to therapeutic doses of
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  hallucinations due to therapeutic doses of
Second:  levels of and in the lungs of pneumonia patients 

First:  hallucinations due to therapeutic doses of
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  hallucinations due to therapeutic doses of
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  hallucinations due to therapeutic doses of
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  hallucinations due to therapeutic doses of
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  potential of in vitro 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  a serological comparison of bovine coronavirus strains 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  use of in human immunodeficiency virus infection 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  levels of and in the lungs of pneumonia patients 

First:  high resolution analysis of respiratory virus infection in vivo
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  viral intestinal infections of animals and man 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  a review in bacterial infections 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  predicting risk of transition to severe infection 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  potential of in vitro 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  a serological comparison of bovine coronavirus strains 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  use of in human immunodeficiency virus infection 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  more severe presentations of acute appendicitis during 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  infectious disease and the case for considering impacts 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  stress symptoms in hemodialysis patients with exposure 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  antiviral strategies to control infections 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  levels of and in the lungs of pneumonia patients 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes
Second:  hallucinations due to therapeutic doses of 

First:  tracing and analysis of early infections outside a modeling study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  tracing and analysis of early infections outside a modeling study
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  tracing and analysis of early infections outside a modeling study
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  tracing and analysis of early infections outside a modeling study
Second:  journal of cancer research and clinical oncology 

First:  tracing and analysis of early infections outside a modeling study
Second:  mapping the technological landscape of and vaccines 

First:  tracing and analysis of early infections outside a modeling study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  tracing and analysis of early infections outside a modeling study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  tracing and analysis of early infections outside a modeling study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  tracing and analysis of early infections outside a modeling study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  tracing and analysis of early infections outside a modeling study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  tracing and analysis of early infections outside a modeling study
Second:  potential of in vitro 

First:  tracing and analysis of early infections outside a modeling study
Second:  genetic hypothesis and side of in 

First:  tracing and analysis of early infections outside a modeling study
Second:  and prognostic significance in 

First:  tracing and analysis of early infections outside a modeling study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  tracing and analysis of early infections outside a modeling study
Second:  early forecasting of the potential risk zones of in 

First:  tracing and analysis of early infections outside a modeling study
Second:  therapy for a feasibility study 

First:  tracing and analysis of early infections outside a modeling study
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  tracing and analysis of early infections outside a modeling study
Second:  scenario modelling for the mitigation of deaths in intensive computer simulation study 

First:  tracing and analysis of early infections outside a modeling study
Second:  older experience of the a analysis of stresses and joys 

First:  tracing and analysis of early infections outside a modeling study
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  tracing and analysis of early infections outside a modeling study
Second:  diffusion as a first model of spread of viral infection 

First:  tracing and analysis of early infections outside a modeling study
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  tracing and analysis of early infections outside a modeling study
Second:  recent advancements in the and prospective drug therapy of 

First:  tracing and analysis of early infections outside a modeling study
Second:  infectious disease and the case for considering impacts 

First:  tracing and analysis of early infections outside a modeling study
Second:  clinical potential of for assessing comparative analysis 

First:  tracing and analysis of early infections outside a modeling study
Second:  a look in the how the field of behavior analysis can become 

First:  tracing and analysis of early infections outside a modeling study
Second:  levels of and in the lungs of pneumonia patients 

First:  tracing and analysis of early infections outside a modeling study
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  tracing and analysis of early infections outside a modeling study
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  tracing and analysis of early infections outside a modeling study
Second:  international mass gatherings and a observational study 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  case report mammography in the diagnosis of breast 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  disease in the era of an observation on a series of six patients with 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  mapping the technological landscape of and vaccines 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  does the pandemic spell the end for the direct 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  editorial recommendations for the management of in countries 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the impact on surgical departments of hospitals 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  predicting risk of transition to severe infection 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  potential of in vitro 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  establishment of a reference panel for the detection of antibodies 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  genetic hypothesis and side of in 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  and prognostic significance in 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the sudden appearance of 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  school of population and global the university of evidence 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  a visual analytics approach to facilitate the of online exams 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  and responses to in south a rapid qualitative assessment 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  older experience of the a analysis of stresses and joys 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  social determinants of mortality at the county level 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  immigration policy and justice in the era of 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the and ends of rnas is not 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  environmental research and public health the impact of on food results of a survey 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  how can blockchain help people in the event of pandemics such as the 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  recent advancements in the and prospective drug therapy of 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  infectious disease and the case for considering impacts 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  clinical potential of for assessing comparative analysis 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  the impact of and homeschooling on engagement with physical activity 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  a look in the how the field of behavior analysis can become 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  levels of and in the lungs of pneumonia patients 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  nitric oxide signalling in kidney regulation and health
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  nitric oxide signalling in kidney regulation and health
Second:  and cell biology lung advances in generation and 

First:  nitric oxide signalling in kidney regulation and health
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  nitric oxide signalling in kidney regulation and health
Second:  potential of in vitro 

First:  nitric oxide signalling in kidney regulation and health
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  nitric oxide signalling in kidney regulation and health
Second:  and prognostic significance in 

First:  nitric oxide signalling in kidney regulation and health
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  nitric oxide signalling in kidney regulation and health
Second:  the function and inhibition by designed antiviral compounds 

First:  nitric oxide signalling in kidney regulation and health
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  nitric oxide signalling in kidney regulation and health
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  nitric oxide signalling in kidney regulation and health
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  nitric oxide signalling in kidney regulation and health
Second:  stress symptoms in hemodialysis patients with exposure 

First:  nitric oxide signalling in kidney regulation and health
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  nitric oxide signalling in kidney regulation and health
Second:  levels of and in the lungs of pneumonia patients 

First:  nitric oxide signalling in kidney regulation and health
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  nitric oxide signalling in kidney regulation and health
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  new causes and treatments for infectious diarrhea in children
Second:  journal of cancer research and clinical oncology 

First:  new causes and treatments for infectious diarrhea in children
Second:  viral intestinal infections of animals and man 

First:  new causes and treatments for infectious diarrhea in children
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  new causes and treatments for infectious diarrhea in children
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  new causes and treatments for infectious diarrhea in children
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  new causes and treatments for infectious diarrhea in children
Second:  a review in bacterial infections 

First:  new causes and treatments for infectious diarrhea in children
Second:  potential of in vitro 

First:  new causes and treatments for infectious diarrhea in children
Second:  bacterial and the deadly trio in 

First:  new causes and treatments for infectious diarrhea in children
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  new causes and treatments for infectious diarrhea in children
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  new causes and treatments for infectious diarrhea in children
Second:  and prognostic significance in 

First:  new causes and treatments for infectious diarrhea in children
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  new causes and treatments for infectious diarrhea in children
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  new causes and treatments for infectious diarrhea in children
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  new causes and treatments for infectious diarrhea in children
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  new causes and treatments for infectious diarrhea in children
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  new causes and treatments for infectious diarrhea in children
Second:  recent advancements in the and prospective drug therapy of 

First:  new causes and treatments for infectious diarrhea in children
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  new causes and treatments for infectious diarrhea in children
Second:  infectious disease and the case for considering impacts 

First:  new causes and treatments for infectious diarrhea in children
Second:  stress symptoms in hemodialysis patients with exposure 

First:  new causes and treatments for infectious diarrhea in children
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  new causes and treatments for infectious diarrhea in children
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  new causes and treatments for infectious diarrhea in children
Second:  levels of and in the lungs of pneumonia patients 

First:  new causes and treatments for infectious diarrhea in children
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  new causes and treatments for infectious diarrhea in children
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  new causes and treatments for infectious diarrhea in children
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  new causes and treatments for infectious diarrhea in children
Second:  hallucinations due to therapeutic doses of 

First:  new causes and treatments for infectious diarrhea in children
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  factors associated with current posttraumatic stress disorder among vaccinated older adults in israel
Second:  stress symptoms in hemodialysis patients with exposure 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  potential of in vitro 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  therapy for a feasibility study 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  recent advancements in the and prospective drug therapy of 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  infectious disease and the case for considering impacts 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  stress symptoms in hemodialysis patients with exposure 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  clinical potential of for assessing comparative analysis 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  levels of and in the lungs of pneumonia patients 

First:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  technological advances improving recombinant protein production in bacteria
Second:  potential of in vitro 

First:  technological advances improving recombinant protein production in bacteria
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  viral intestinal infections of animals and man 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  predicting risk of transition to severe infection 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  use of in human immunodeficiency virus infection 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  stress symptoms in hemodialysis patients with exposure 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia
Second:  levels of and in the lungs of pneumonia patients 

First:  epidemiology and infection from the field
Second:  a study on the influence of the pandemic on incomes in greece 

First:  epidemiology and infection from the field
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  epidemiology and infection from the field
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  epidemiology and infection from the field
Second:  case report mammography in the diagnosis of breast 

First:  epidemiology and infection from the field
Second:  journal of cancer research and clinical oncology 

First:  epidemiology and infection from the field
Second:  disease in the era of an observation on a series of six patients with 

First:  epidemiology and infection from the field
Second:  mapping the technological landscape of and vaccines 

First:  epidemiology and infection from the field
Second:  viral intestinal infections of animals and man 

First:  epidemiology and infection from the field
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  epidemiology and infection from the field
Second:  does the pandemic spell the end for the direct 

First:  epidemiology and infection from the field
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  epidemiology and infection from the field
Second:  and cell biology lung advances in generation and 

First:  epidemiology and infection from the field
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  epidemiology and infection from the field
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  epidemiology and infection from the field
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  epidemiology and infection from the field
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  epidemiology and infection from the field
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  epidemiology and infection from the field
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  epidemiology and infection from the field
Second:  editorial recommendations for the management of in countries 

First:  epidemiology and infection from the field
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  epidemiology and infection from the field
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  epidemiology and infection from the field
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  epidemiology and infection from the field
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  epidemiology and infection from the field
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  epidemiology and infection from the field
Second:  the impact on surgical departments of hospitals 

First:  epidemiology and infection from the field
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  epidemiology and infection from the field
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  epidemiology and infection from the field
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  epidemiology and infection from the field
Second:  spectrum of antimicrobial activity for disinfection of 

First:  epidemiology and infection from the field
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  epidemiology and infection from the field
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  epidemiology and infection from the field
Second:  a review in bacterial infections 

First:  epidemiology and infection from the field
Second:  the common missed instances and areas after years of education 

First:  epidemiology and infection from the field
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  epidemiology and infection from the field
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  epidemiology and infection from the field
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  epidemiology and infection from the field
Second:  potential of in vitro 

First:  epidemiology and infection from the field
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  epidemiology and infection from the field
Second:  bacterial and the deadly trio in 

First:  epidemiology and infection from the field
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  epidemiology and infection from the field
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  epidemiology and infection from the field
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  epidemiology and infection from the field
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  epidemiology and infection from the field
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  epidemiology and infection from the field
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  epidemiology and infection from the field
Second:  genetic hypothesis and side of in 

First:  epidemiology and infection from the field
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  epidemiology and infection from the field
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  epidemiology and infection from the field
Second:  and prognostic significance in 

First:  epidemiology and infection from the field
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  epidemiology and infection from the field
Second:  from ego to for ontology in the 

First:  epidemiology and infection from the field
Second:  the sudden appearance of 

First:  epidemiology and infection from the field
Second:  school of population and global the university of evidence 

First:  epidemiology and infection from the field
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  epidemiology and infection from the field
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  epidemiology and infection from the field
Second:  early forecasting of the potential risk zones of in 

First:  epidemiology and infection from the field
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  epidemiology and infection from the field
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  epidemiology and infection from the field
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  epidemiology and infection from the field
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  epidemiology and infection from the field
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  epidemiology and infection from the field
Second:  older experience of the a analysis of stresses and joys 

First:  epidemiology and infection from the field
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  epidemiology and infection from the field
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  epidemiology and infection from the field
Second:  use of in human immunodeficiency virus infection 

First:  epidemiology and infection from the field
Second:  immigration policy and justice in the era of 

First:  epidemiology and infection from the field
Second:  diffusion as a first model of spread of viral infection 

First:  epidemiology and infection from the field
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  epidemiology and infection from the field
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  epidemiology and infection from the field
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  epidemiology and infection from the field
Second:  the and ends of rnas is not 

First:  epidemiology and infection from the field
Second:  and the saga continues 

First:  epidemiology and infection from the field
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  epidemiology and infection from the field
Second:  environmental research and public health the impact of on food results of a survey 

First:  epidemiology and infection from the field
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  epidemiology and infection from the field
Second:  international archives of occupational and environmental health 

First:  epidemiology and infection from the field
Second:  to appear advances in oral and maxillofacial surgery 

First:  epidemiology and infection from the field
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  epidemiology and infection from the field
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  epidemiology and infection from the field
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  epidemiology and infection from the field
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  epidemiology and infection from the field
Second:  recent advancements in the and prospective drug therapy of 

First:  epidemiology and infection from the field
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  epidemiology and infection from the field
Second:  infectious disease and the case for considering impacts 

First:  epidemiology and infection from the field
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  epidemiology and infection from the field
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  epidemiology and infection from the field
Second:  the impact of and homeschooling on engagement with physical activity 

First:  epidemiology and infection from the field
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  epidemiology and infection from the field
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  epidemiology and infection from the field
Second:  a look in the how the field of behavior analysis can become 

First:  epidemiology and infection from the field
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  epidemiology and infection from the field
Second:  levels of and in the lungs of pneumonia patients 

First:  epidemiology and infection from the field
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  epidemiology and infection from the field
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  epidemiology and infection from the field
Second:  impact of the pandemic on emergency medicine insights from faculty and residents 

First:  epidemiology and infection from the field
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  epidemiology and infection from the field
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  epidemiology and infection from the field
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  epidemiology and infection from the field
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  epidemiology and infection from the field
Second:  in vitro b and sars virus activities of a 

First:  epidemiology and infection from the field
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  epidemiology and infection from the field
Second:  tracing and analysis of early infections outside a modeling study 

First:  epidemiology and infection from the field
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  epidemiology and infection from the field
Second:  new causes and treatments for infectious diarrhea in children 

First:  coronavirus outbreak and stress in iranians
Second:  bacterial and the deadly trio in 

First:  coronavirus outbreak and stress in iranians
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  coronavirus outbreak and stress in iranians
Second:  levels of and in the lungs of pneumonia patients 

First:  mitigating asian american bias and xenophobia in response to the coronavirus how you can be an
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  mitigating asian american bias and xenophobia in response to the coronavirus how you can be an
Second:  and what evidence needs our 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  case report mammography in the diagnosis of breast 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  journal of cancer research and clinical oncology 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  mapping the technological landscape of and vaccines 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  viral intestinal infections of animals and man 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  prophylaxis of with and chloroquine accepted article 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  chest computed tomographic findings of patients with pneumonia 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  toxic and properties of an coordination complex of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  predicting risk of transition to severe infection 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  concept of immune response 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  potential of in vitro 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  establishment of a reference panel for the detection of antibodies 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  a serological comparison of bovine coronavirus strains 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  synthesis and activity of derivatives and analogues thereof 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  genetic hypothesis and side of in 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  and prognostic significance in 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the sudden appearance of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  early forecasting of the potential risk zones of in 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  older experience of the a analysis of stresses and joys 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  use of in human immunodeficiency virus infection 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  regression of infantile glioblastoma after treatment with 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the and ends of rnas is not 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  more severe presentations of acute appendicitis during 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  recent advancements in the and prospective drug therapy of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  infectious disease and the case for considering impacts 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  stress symptoms in hemodialysis patients with exposure 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  reliability of serological tests for comparison of three test kits for antibodies 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical potential of for assessing comparative analysis 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  cells the aging of t cells 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical characteristics of death cases with 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  levels of and in the lungs of pneumonia patients 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  hallucinations due to therapeutic doses of 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  tracing and analysis of early infections outside a modeling study 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  new causes and treatments for infectious diarrhea in children 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia 

First:  mutation treatment and prenatal diagnosis of chinese cases of
Second:  epidemiology and infection from the field 

First:  article cardiac troponin testing in patients with a strategy for testing and reporting results
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  article cardiac troponin testing in patients with a strategy for testing and reporting results
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  article cardiac troponin testing in patients with a strategy for testing and reporting results
Second:  and prognostic significance in 

First:  health facility preparedness for protecting healthcare designing a tool for rapid assessment
Second:  therapy for a feasibility study 

First:  health facility preparedness for protecting healthcare designing a tool for rapid assessment
Second:  clinical potential of for assessing comparative analysis 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  viral intestinal infections of animals and man 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  potent neutralizing antibodies elicited by vaccine candidate by the cell agonist 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  microorganisms nasal microbiota in rsv 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  spectrum of antimicrobial activity for disinfection of 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  a review in bacterial infections 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  potential of in vitro 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  a serological comparison of bovine coronavirus strains 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  synthesis and activity of derivatives and analogues thereof 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  the function and inhibition by designed antiviral compounds 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  combination kills bladder cancer cells synergistically 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  restriction of replication by targeting programmed ribosomal in vitro 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  enhances the peroxidase activity of myoglobin against 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  use of in human immunodeficiency virus infection 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  personal view antiviral effects of chloroquine 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  cells the aging of t cells 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  antiviral strategies to control infections 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  levels of and in the lungs of pneumonia patients 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  nitric oxide signalling in kidney regulation and health 

First:  molecules in vitro antiviral activity of doxycycline against
Second:  technological advances improving recombinant protein production in bacteria 

First:  influenza opportunities and challenges
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  influenza opportunities and challenges
Second:  mapping the technological landscape of and vaccines 

First:  influenza opportunities and challenges
Second:  and cell biology lung advances in generation and 

First:  influenza opportunities and challenges
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  influenza opportunities and challenges
Second:  responding to healthcare disparities and challenges with access to care during 

First:  influenza opportunities and challenges
Second:  proactive strategy to improve staff engagement 

First:  influenza opportunities and challenges
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  influenza opportunities and challenges
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  influenza opportunities and challenges
Second:  potential of in vitro 

First:  influenza opportunities and challenges
Second:  bacterial and the deadly trio in 

First:  influenza opportunities and challenges
Second:  regular international perspectives and initiatives 

First:  influenza opportunities and challenges
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  influenza opportunities and challenges
Second:  and prognostic significance in 

First:  influenza opportunities and challenges
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  influenza opportunities and challenges
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  influenza opportunities and challenges
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  influenza opportunities and challenges
Second:  investment and economic policy options in 

First:  influenza opportunities and challenges
Second:  activity of world health formulations against enveloped including and emerging 

First:  influenza opportunities and challenges
Second:  care for people with disease and related during from challenges to solutions 

First:  influenza opportunities and challenges
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  influenza opportunities and challenges
Second:  journal hiv and impact on vulnerable population and harnessing lessons learnt from hiv programs hiv and impact on vulnerable population and harnessing lessons learnt from hiv programs hiv and impact on vulnerable population and harnessing lessons learnt from hiv programs 

First:  influenza opportunities and challenges
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  influenza opportunities and challenges
Second:  international archives of occupational and environmental health 

First:  influenza opportunities and challenges
Second:  recent advancements in the and prospective drug therapy of 

First:  influenza opportunities and challenges
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  influenza opportunities and challenges
Second:  infectious disease and the case for considering impacts 

First:  influenza opportunities and challenges
Second:  the impact of and homeschooling on engagement with physical activity 

First:  influenza opportunities and challenges
Second:  antiviral strategies to control infections 

First:  influenza opportunities and challenges
Second:  levels of and in the lungs of pneumonia patients 

First:  influenza opportunities and challenges
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  influenza opportunities and challenges
Second:  global challenges to urology practice during the pandemic 

First:  influenza opportunities and challenges
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  influenza opportunities and challenges
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  influenza opportunities and challenges
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  influenza opportunities and challenges
Second:  new causes and treatments for infectious diarrhea in children 

First:  influenza opportunities and challenges
Second:  epidemiology and infection from the field 

First:  the role of transmembrane protein in islet physiology and its potential use as a beta cell mass biomarker
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the role of transmembrane protein in islet physiology and its potential use as a beta cell mass biomarker
Second:  potential of in vitro 

First:  the role of transmembrane protein in islet physiology and its potential use as a beta cell mass biomarker
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the role of transmembrane protein in islet physiology and its potential use as a beta cell mass biomarker
Second:  cells the aging of t cells 

First:  the role of transmembrane protein in islet physiology and its potential use as a beta cell mass biomarker
Second:  levels of and in the lungs of pneumonia patients 

First:  the role of transmembrane protein in islet physiology and its potential use as a beta cell mass biomarker
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  influence of on prp sc formation using in vitro and systems
Second:  potential of in vitro 

First:  influence of on prp sc formation using in vitro and systems
Second:  and prognostic significance in 

First:  influence of on prp sc formation using in vitro and systems
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a street psychiatry rotation for medical humanizing the care of people experiencing homelessness
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  a street psychiatry rotation for medical humanizing the care of people experiencing homelessness
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  case report mammography in the diagnosis of breast 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  journal of cancer research and clinical oncology 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  mapping the technological landscape of and vaccines 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  does the pandemic spell the end for the direct 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  editorial recommendations for the management of in countries 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the impact on surgical departments of hospitals 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  spectrum of antimicrobial activity for disinfection of 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  potential of in vitro 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  establishment of a reference panel for the detection of antibodies 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  and prognostic significance in 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the sudden appearance of 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  early forecasting of the potential risk zones of in 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  older experience of the a analysis of stresses and joys 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  more severe presentations of acute appendicitis during 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  recent advancements in the and prospective drug therapy of 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  infectious disease and the case for considering impacts 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  stress symptoms in hemodialysis patients with exposure 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  clinical potential of for assessing comparative analysis 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  levels of and in the lungs of pneumonia patients 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  hallucinations due to therapeutic doses of 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  epidemiology and infection from the field 

First:  usefulness of pcr screening in the initial triage of trauma patients during pandemic
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  a study on the influence of the pandemic on incomes in greece 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  disease in the era of an observation on a series of six patients with 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  potential of in vitro 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  bacterial and the deadly trio in 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  genetic hypothesis and side of in 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  and prognostic significance in 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  the sudden appearance of 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  early forecasting of the potential risk zones of in 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  older experience of the a analysis of stresses and joys 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  immigration policy and justice in the era of 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  the and ends of rnas is not 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  and the saga continues 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  recent advancements in the and prospective drug therapy of 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  a look in the how the field of behavior analysis can become 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  levels of and in the lungs of pneumonia patients 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  potential of in vitro 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  the sudden appearance of 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  early forecasting of the potential risk zones of in 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  recent advancements in the and prospective drug therapy of 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  levels of and in the lungs of pneumonia patients 

First:  journal cardiovascular care delivery during the second wave of in canada
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  stress symptoms in hemodialysis patients with exposure 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  levels of and in the lungs of pneumonia patients 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  mapping the technological landscape of and vaccines 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  editorial recommendations for the management of in countries 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  regular international perspectives and initiatives 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  investment and economic policy options in 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  a better understanding of social distancing 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  older experience of the a analysis of stresses and joys 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  immigration policy and justice in the era of 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  recent advancements in the and prospective drug therapy of 

First:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories
Second:  influenza opportunities and challenges 

First:  design and analysis of a tweets dataset
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  design and analysis of a tweets dataset
Second:  mapping the technological landscape of and vaccines 

First:  design and analysis of a tweets dataset
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  design and analysis of a tweets dataset
Second:  editorial recommendations for the management of in countries 

First:  design and analysis of a tweets dataset
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  design and analysis of a tweets dataset
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  design and analysis of a tweets dataset
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  design and analysis of a tweets dataset
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  design and analysis of a tweets dataset
Second:  establishment of a reference panel for the detection of antibodies 

First:  design and analysis of a tweets dataset
Second:  genetic hypothesis and side of in 

First:  design and analysis of a tweets dataset
Second:  and prognostic significance in 

First:  design and analysis of a tweets dataset
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  design and analysis of a tweets dataset
Second:  the sudden appearance of 

First:  design and analysis of a tweets dataset
Second:  a visual analytics approach to facilitate the of online exams 

First:  design and analysis of a tweets dataset
Second:  a protocol for a systematic review and 

First:  design and analysis of a tweets dataset
Second:  early forecasting of the potential risk zones of in 

First:  design and analysis of a tweets dataset
Second:  and responses to in south a rapid qualitative assessment 

First:  design and analysis of a tweets dataset
Second:  older experience of the a analysis of stresses and joys 

First:  design and analysis of a tweets dataset
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  design and analysis of a tweets dataset
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  design and analysis of a tweets dataset
Second:  the and ends of rnas is not 

First:  design and analysis of a tweets dataset
Second:  environmental research and public health the impact of on food results of a survey 

First:  design and analysis of a tweets dataset
Second:  recent advancements in the and prospective drug therapy of 

First:  design and analysis of a tweets dataset
Second:  clinical potential of for assessing comparative analysis 

First:  design and analysis of a tweets dataset
Second:  a look in the how the field of behavior analysis can become 

First:  design and analysis of a tweets dataset
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  design and analysis of a tweets dataset
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  design and analysis of a tweets dataset
Second:  tracing and analysis of early infections outside a modeling study 

First:  design and analysis of a tweets dataset
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  genetic hypothesis and side of in 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  and prognostic significance in 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  the sudden appearance of 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  older experience of the a analysis of stresses and joys 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  recent advancements in the and prospective drug therapy of 

First:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study
Second:  levels of and in the lungs of pneumonia patients 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  the function and inhibition by designed antiviral compounds 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  cells the aging of t cells 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  nitric oxide signalling in kidney regulation and health 

First:  + t cell inflammatory activation and atherosclerosis in mice by metabolic suppression
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  lassa virus diversity and feasibility for universal prophylactic vaccine
Second:  use of in human immunodeficiency virus infection 

First:  lassa virus diversity and feasibility for universal prophylactic vaccine
Second:  infectious disease and the case for considering impacts 

First:  lassa virus diversity and feasibility for universal prophylactic vaccine
Second:  influenza opportunities and challenges 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  case report mammography in the diagnosis of breast 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal innovations in in the age of a systematic literature review 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  disease in the era of an observation on a series of six patients with 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  mapping the technological landscape of and vaccines 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  does the pandemic spell the end for the direct 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  excess neurological death in new york city after the emergence of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  editorial recommendations for the management of in countries 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  prophylaxis of with and chloroquine accepted article 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the impact on surgical departments of hospitals 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  toxic and properties of an coordination complex of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the common missed instances and areas after years of education 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  potential of in vitro 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  bacterial and the deadly trio in 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  establishment of a reference panel for the detection of antibodies 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  genetic hypothesis and side of in 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  and prognostic significance in 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal fungal in patients with role of antifungal 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  influence of pharmaceutical on emergency hospital a 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the sudden appearance of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  school of population and global the university of evidence 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  early forecasting of the potential risk zones of in 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  older experience of the a analysis of stresses and joys 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  immigration policy and justice in the era of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  regression of infantile glioblastoma after treatment with 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  diffusion as a first model of spread of viral infection 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the and ends of rnas is not 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  more severe presentations of acute appendicitis during 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  and the saga continues 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  environmental research and public health the impact of on food results of a survey 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  how can blockchain help people in the event of pandemics such as the 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  recent advancements in the and prospective drug therapy of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal the psychological status of people affected by the outbreak in china 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  higher glycemic variability within the first day of icu admission is associated with increased mortality in icu patients with sepsis 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  infectious disease and the case for considering impacts 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  stress symptoms in hemodialysis patients with exposure 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the impact of and homeschooling on engagement with physical activity 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  cells the aging of t cells 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  clinical characteristics of death cases with 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  a look in the how the field of behavior analysis can become 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  levels of and in the lungs of pneumonia patients 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  hallucinations due to therapeutic doses of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  epidemiology and infection from the field 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  the effect of the timing of dexamethasone administration in patients with pneumonia
Second:  journal cardiovascular care delivery during the second wave of in canada 

First:  artificial intelligence applied to bailout decisions in financial systemic risk management
Second:  investment and economic policy options in 

First:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism
Second:  levels of and in the lungs of pneumonia patients 

First:  epidemiology and infection original paper
Second:  journal of cancer research and clinical oncology 

First:  epidemiology and infection original paper
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  epidemiology and infection original paper
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  epidemiology and infection original paper
Second:  infectious disease and the case for considering impacts 

First:  epidemiology and infection original paper
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  epidemiology and infection original paper
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  epidemiology and infection original paper
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  epidemiology and infection original paper
Second:  epidemiology and infection from the field 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  potential of in vitro 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  genetic hypothesis and side of in 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  and prognostic significance in 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  the sudden appearance of 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  levels of and in the lungs of pneumonia patients 

First:  performance of a rapid serology test in whole blood and separated plasma
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the impacts of on children
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the impacts of on children
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the impacts of on children
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the impacts of on children
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  the impacts of on children
Second:  case report mammography in the diagnosis of breast 

First:  the impacts of on children
Second:  journal innovations in in the age of a systematic literature review 

First:  the impacts of on children
Second:  disease in the era of an observation on a series of six patients with 

First:  the impacts of on children
Second:  mapping the technological landscape of and vaccines 

First:  the impacts of on children
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  the impacts of on children
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the impacts of on children
Second:  does the pandemic spell the end for the direct 

First:  the impacts of on children
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  the impacts of on children
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the impacts of on children
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  the impacts of on children
Second:  overall quality of sporting events and emotions as predictors of future intentions of duathlon participants 

First:  the impacts of on children
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the impacts of on children
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  the impacts of on children
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the impacts of on children
Second:  second wave of global pandemic and recommendations to better manage and optimize the modified lifestyle 

First:  the impacts of on children
Second:  reply to against the risk of airborne 

First:  the impacts of on children
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the impacts of on children
Second:  excess neurological death in new york city after the emergence of 

First:  the impacts of on children
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the impacts of on children
Second:  editorial recommendations for the management of in countries 

First:  the impacts of on children
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  the impacts of on children
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the impacts of on children
Second:  an official learning resource of review impact of response on hepatitis prevention care and results from global survey of providers and program managers 

First:  the impacts of on children
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the impacts of on children
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the impacts of on children
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the impacts of on children
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  the impacts of on children
Second:  policymaking and the wicked problem of sdg gender equality 

First:  the impacts of on children
Second:  the impact on surgical departments of hospitals 

First:  the impacts of on children
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  the impacts of on children
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  the impacts of on children
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the impacts of on children
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the impacts of on children
Second:  international forum on the collection and use of convalescent challenges and lessons summary 

First:  the impacts of on children
Second:  healthcare application of the weathering intersection of and as a stressful life event among african americans 

First:  the impacts of on children
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  the impacts of on children
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the impacts of on children
Second:  prevalence of antibodies in young children in tennessee 

First:  the impacts of on children
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the impacts of on children
Second:  toxic and properties of an coordination complex of 

First:  the impacts of on children
Second:  the common missed instances and areas after years of education 

First:  the impacts of on children
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the impacts of on children
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the impacts of on children
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the impacts of on children
Second:  potential of in vitro 

First:  the impacts of on children
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the impacts of on children
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  the impacts of on children
Second:  bacterial and the deadly trio in 

First:  the impacts of on children
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  the impacts of on children
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the impacts of on children
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the impacts of on children
Second:  electroencephalography during practical recommendations from the task force of the italian society of neurophysiology the italian league against epilepsy and the italian association of neurophysiology technologists 

First:  the impacts of on children
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the impacts of on children
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  the impacts of on children
Second:  establishment of a reference panel for the detection of antibodies 

First:  the impacts of on children
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the impacts of on children
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  the impacts of on children
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the impacts of on children
Second:  microorganisms microbiome open communication microbiome applications in the future on behalf of the circles consortium 

First:  the impacts of on children
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the impacts of on children
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  the impacts of on children
Second:  genetic hypothesis and side of in 

First:  the impacts of on children
Second:  tactics in support of migrations 

First:  the impacts of on children
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  the impacts of on children
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the impacts of on children
Second:  the need of health policy perspective to protect healthcare workers during a grade rapid review on the respirators effectiveness 

First:  the impacts of on children
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the impacts of on children
Second:  and prognostic significance in 

First:  the impacts of on children
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  the impacts of on children
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  the impacts of on children
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the impacts of on children
Second:  influence of pharmaceutical on emergency hospital a 

First:  the impacts of on children
Second:  the sudden appearance of 

First:  the impacts of on children
Second:  title the impact of pandemic on mental health of young people and a systematic review protocol of observational studies authors 

First:  the impacts of on children
Second:  selected approaches to the assessment of environmental noise from railways in urban areas 

First:  the impacts of on children
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the impacts of on children
Second:  school of population and global the university of evidence 

First:  the impacts of on children
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  the impacts of on children
Second:  early forecasting of the potential risk zones of in 

First:  the impacts of on children
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  the impacts of on children
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the impacts of on children
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  the impacts of on children
Second:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults 

First:  the impacts of on children
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  the impacts of on children
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  the impacts of on children
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  the impacts of on children
Second:  integrating research integrity into the history of science 

First:  the impacts of on children
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  the impacts of on children
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  the impacts of on children
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the impacts of on children
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  the impacts of on children
Second:  eines in einer im der implementation of an operational concept in an ent clinic in the context of the pandemic 

First:  the impacts of on children
Second:  older experience of the a analysis of stresses and joys 

First:  the impacts of on children
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  the impacts of on children
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the impacts of on children
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the impacts of on children
Second:  mask social and gender correlates of vaccine intentions among adults in the us 

First:  the impacts of on children
Second:  social determinants of mortality at the county level 

First:  the impacts of on children
Second:  surveillance of community outbreaks of respiratory tract infections based on visits in the metropolitan area of greece 

First:  the impacts of on children
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  the impacts of on children
Second:  immigration policy and justice in the era of 

First:  the impacts of on children
Second:  diffusion as a first model of spread of viral infection 

First:  the impacts of on children
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  the impacts of on children
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the impacts of on children
Second:  the and ends of rnas is not 

First:  the impacts of on children
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  the impacts of on children
Second:  and the saga continues 

First:  the impacts of on children
Second:  environmental research and public health the impact of on food results of a survey 

First:  the impacts of on children
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the impacts of on children
Second:  international archives of occupational and environmental health 

First:  the impacts of on children
Second:  how can blockchain help people in the event of pandemics such as the 

First:  the impacts of on children
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the impacts of on children
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  the impacts of on children
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the impacts of on children
Second:  recent advancements in the and prospective drug therapy of 

First:  the impacts of on children
Second:  journal the psychological status of people affected by the outbreak in china 

First:  the impacts of on children
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  the impacts of on children
Second:  infectious disease and the case for considering impacts 

First:  the impacts of on children
Second:  human rights and a comment on the bath protocol 

First:  the impacts of on children
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  the impacts of on children
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  the impacts of on children
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the impacts of on children
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  the impacts of on children
Second:  the impact of and homeschooling on engagement with physical activity 

First:  the impacts of on children
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  the impacts of on children
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  the impacts of on children
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  the impacts of on children
Second:  evaluation of the effect of border closure on incidence rates across nine african an interrupted time series study 

First:  the impacts of on children
Second:  a look in the how the field of behavior analysis can become 

First:  the impacts of on children
Second:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic 

First:  the impacts of on children
Second:  levels of and in the lungs of pneumonia patients 

First:  the impacts of on children
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the impacts of on children
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the impacts of on children
Second:  journal implications of in marine fisheries from the northwestern mediterranean sea implications of in marine fisheries from the northwestern mediterranean sea 

First:  the impacts of on children
Second:  estimation of the effective reproduction number of influenza based on weekly reports in miyazaki prefecture 

First:  the impacts of on children
Second:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the 

First:  the impacts of on children
Second:  impact of the pandemic on emergency medicine insights from faculty and residents 

First:  the impacts of on children
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the impacts of on children
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  the impacts of on children
Second:  identifying the needs of prekindergarten a focus on and family environment 

First:  the impacts of on children
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  the impacts of on children
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  the impacts of on children
Second:  epidemiology and infection from the field 

First:  the impacts of on children
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  the impacts of on children
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  the impacts of on children
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  the impacts of on children
Second:  journal cardiovascular care delivery during the second wave of in canada 

First:  the impacts of on children
Second:  design and analysis of a tweets dataset 

First:  the impacts of on children
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  to perchance to practical strategies for testing
Second:  responding to healthcare disparities and challenges with access to care during 

First:  to perchance to practical strategies for testing
Second:  proactive strategy to improve staff engagement 

First:  to perchance to practical strategies for testing
Second:  from ego to for ontology in the 

First:  to perchance to practical strategies for testing
Second:  therapy for a feasibility study 

First:  to perchance to practical strategies for testing
Second:  minimum costs to manufacture new treatments for 

First:  to perchance to practical strategies for testing
Second:  clinical potential of for assessing comparative analysis 

First:  to perchance to practical strategies for testing
Second:  antiviral strategies to control infections 

First:  understanding during a a case of universitas indonesia
Second:  a study on the influence of the pandemic on incomes in greece 

First:  understanding during a a case of universitas indonesia
Second:  a remedy or a ripple in severe 

First:  understanding during a a case of universitas indonesia
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  understanding during a a case of universitas indonesia
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  understanding during a a case of universitas indonesia
Second:  the sudden appearance of 

First:  understanding during a a case of universitas indonesia
Second:  a protocol for a systematic review and 

First:  understanding during a a case of universitas indonesia
Second:  a better understanding of social distancing 

First:  understanding during a a case of universitas indonesia
Second:  older experience of the a analysis of stresses and joys 

First:  understanding during a a case of universitas indonesia
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  understanding during a a case of universitas indonesia
Second:  a look in the how the field of behavior analysis can become 

First:  letter to the editor phase of the coronavirus pandemic in ramping up surgical caseload and resident training while infections decrease
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  letter to the editor phase of the coronavirus pandemic in ramping up surgical caseload and resident training while infections decrease
Second:  levels of and in the lungs of pneumonia patients 

First:  letter to the editor phase of the coronavirus pandemic in ramping up surgical caseload and resident training while infections decrease
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  patients in is obesity or the real
Second:  a study on the influence of the pandemic on incomes in greece 

First:  patients in is obesity or the real
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  patients in is obesity or the real
Second:  case report mammography in the diagnosis of breast 

First:  patients in is obesity or the real
Second:  a remedy or a ripple in severe 

First:  patients in is obesity or the real
Second:  disease in the era of an observation on a series of six patients with 

First:  patients in is obesity or the real
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  patients in is obesity or the real
Second:  does the pandemic spell the end for the direct 

First:  patients in is obesity or the real
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  patients in is obesity or the real
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  patients in is obesity or the real
Second:  editorial recommendations for the management of in countries 

First:  patients in is obesity or the real
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  patients in is obesity or the real
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  patients in is obesity or the real
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  patients in is obesity or the real
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  patients in is obesity or the real
Second:  a review in bacterial infections 

First:  patients in is obesity or the real
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  patients in is obesity or the real
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  patients in is obesity or the real
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  patients in is obesity or the real
Second:  potential of in vitro 

First:  patients in is obesity or the real
Second:  bacterial and the deadly trio in 

First:  patients in is obesity or the real
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  patients in is obesity or the real
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  patients in is obesity or the real
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  patients in is obesity or the real
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  patients in is obesity or the real
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  patients in is obesity or the real
Second:  genetic hypothesis and side of in 

First:  patients in is obesity or the real
Second:  and prognostic significance in 

First:  patients in is obesity or the real
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  patients in is obesity or the real
Second:  the sudden appearance of 

First:  patients in is obesity or the real
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  patients in is obesity or the real
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  patients in is obesity or the real
Second:  early forecasting of the potential risk zones of in 

First:  patients in is obesity or the real
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  patients in is obesity or the real
Second:  older experience of the a analysis of stresses and joys 

First:  patients in is obesity or the real
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  patients in is obesity or the real
Second:  the and ends of rnas is not 

First:  patients in is obesity or the real
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  patients in is obesity or the real
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  patients in is obesity or the real
Second:  how can blockchain help people in the event of pandemics such as the 

First:  patients in is obesity or the real
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  patients in is obesity or the real
Second:  recent advancements in the and prospective drug therapy of 

First:  patients in is obesity or the real
Second:  infectious disease and the case for considering impacts 

First:  patients in is obesity or the real
Second:  stress symptoms in hemodialysis patients with exposure 

First:  patients in is obesity or the real
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  patients in is obesity or the real
Second:  a look in the how the field of behavior analysis can become 

First:  patients in is obesity or the real
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  patients in is obesity or the real
Second:  levels of and in the lungs of pneumonia patients 

First:  patients in is obesity or the real
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  patients in is obesity or the real
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  patients in is obesity or the real
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  patients in is obesity or the real
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  patients in is obesity or the real
Second:  epidemiology and infection from the field 

First:  patients in is obesity or the real
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  patients in is obesity or the real
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  patients in is obesity or the real
Second:  the impacts of on children 

First:  policy forum implications of an international consortium project of the european commission
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  policy forum implications of an international consortium project of the european commission
Second:  editorial recommendations for the management of in countries 

First:  policy forum implications of an international consortium project of the european commission
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  policy forum implications of an international consortium project of the european commission
Second:  school of population and global the university of evidence 

First:  policy forum implications of an international consortium project of the european commission
Second:  early forecasting of the potential risk zones of in 

First:  policy forum implications of an international consortium project of the european commission
Second:  immigration policy and justice in the era of 

First:  policy forum implications of an international consortium project of the european commission
Second:  the impacts of on children 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  a study on the influence of the pandemic on incomes in greece 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  case report mammography in the diagnosis of breast 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  journal innovations in in the age of a systematic literature review 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  disease in the era of an observation on a series of six patients with 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  mapping the technological landscape of and vaccines 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  potential of in vitro 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  establishment of a reference panel for the detection of antibodies 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  genetic hypothesis and side of in 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  and prognostic significance in 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the sudden appearance of 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  school of population and global the university of evidence 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  early forecasting of the potential risk zones of in 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  therapy for a feasibility study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  older experience of the a analysis of stresses and joys 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  environmental research and public health the impact of on food results of a survey 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  recent advancements in the and prospective drug therapy of 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  clinical potential of for assessing comparative analysis 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  a look in the how the field of behavior analysis can become 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  levels of and in the lungs of pneumonia patients 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  tracing and analysis of early infections outside a modeling study 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  epidemiology and infection from the field 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  the impacts of on children 

First:  a observational study of asymptomatic prevalence in the greater indianapolis area
Second:  patients in is obesity or the real 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  a study on the influence of the pandemic on incomes in greece 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  mapping the technological landscape of and vaccines 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  editorial recommendations for the management of in countries 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  potential of in vitro 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  establishment of a reference panel for the detection of antibodies 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  and prognostic significance in 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  the sudden appearance of 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  school of population and global the university of evidence 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  a visual analytics approach to facilitate the of online exams 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  a protocol for a systematic review and 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  early forecasting of the potential risk zones of in 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  older experience of the a analysis of stresses and joys 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  environmental research and public health the impact of on food results of a survey 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  recent advancements in the and prospective drug therapy of 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  the impact of and homeschooling on engagement with physical activity 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  a look in the how the field of behavior analysis can become 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  levels of and in the lungs of pneumonia patients 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  design and analysis of a tweets dataset 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  validation of a questionnaire on the use of interactive response system in higher education
Second:  the impacts of on children 

First:  building a of exotic diseases for the pig industry in australia using decision analysis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  older experience of the a analysis of stresses and joys 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  the and ends of rnas is not 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  and what evidence needs our 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  infectious disease and the case for considering impacts 

First:  and how and why we implemented a tobacco treatment and how and why we implemented a tobacco treatment conflict of interest neither author has any conflicts of interest
Second:  a look in the how the field of behavior analysis can become 

First:  journal viral etiology and outcome of severe lower respiratory tract infections among critically ill children admitted to the
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal viral etiology and outcome of severe lower respiratory tract infections among critically ill children admitted to the
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal viral etiology and outcome of severe lower respiratory tract infections among critically ill children admitted to the
Second:  levels of and in the lungs of pneumonia patients 

First:  prolongation in patients using chloroquine
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  prolongation in patients using chloroquine
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  prolongation in patients using chloroquine
Second:  microorganisms nasal microbiota in rsv 

First:  prolongation in patients using chloroquine
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  prolongation in patients using chloroquine
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  prolongation in patients using chloroquine
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  prolongation in patients using chloroquine
Second:  a review in bacterial infections 

First:  prolongation in patients using chloroquine
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  prolongation in patients using chloroquine
Second:  potential of in vitro 

First:  prolongation in patients using chloroquine
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  prolongation in patients using chloroquine
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  prolongation in patients using chloroquine
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  prolongation in patients using chloroquine
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  prolongation in patients using chloroquine
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  prolongation in patients using chloroquine
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  prolongation in patients using chloroquine
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  prolongation in patients using chloroquine
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  prolongation in patients using chloroquine
Second:  depression and sleep quality in patients undergoing 

First:  prolongation in patients using chloroquine
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  prolongation in patients using chloroquine
Second:  use of in human immunodeficiency virus infection 

First:  prolongation in patients using chloroquine
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  prolongation in patients using chloroquine
Second:  regression of infantile glioblastoma after treatment with 

First:  prolongation in patients using chloroquine
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  prolongation in patients using chloroquine
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  prolongation in patients using chloroquine
Second:  journal inhaled corticosteroids the receptor in copd through suppression of type i interferon increased severity from severity attenuation of expression by inhaled corticosteroid use in copd 

First:  prolongation in patients using chloroquine
Second:  stress symptoms in hemodialysis patients with exposure 

First:  prolongation in patients using chloroquine
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  prolongation in patients using chloroquine
Second:  antiviral strategies to control infections 

First:  prolongation in patients using chloroquine
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  prolongation in patients using chloroquine
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  prolongation in patients using chloroquine
Second:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia 

First:  prolongation in patients using chloroquine
Second:  levels of and in the lungs of pneumonia patients 

First:  prolongation in patients using chloroquine
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  prolongation in patients using chloroquine
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  prolongation in patients using chloroquine
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  prolongation in patients using chloroquine
Second:  hallucinations due to therapeutic doses of 

First:  prolongation in patients using chloroquine
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  prolongation in patients using chloroquine
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  prolongation in patients using chloroquine
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  prolongation in patients using chloroquine
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  prolongation in patients using chloroquine
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  prolongation in patients using chloroquine
Second:  patients in is obesity or the real 

First:  ultrasonography in the initial characterization of patients with
Second:  a study on the influence of the pandemic on incomes in greece 

First:  ultrasonography in the initial characterization of patients with
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  ultrasonography in the initial characterization of patients with
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  ultrasonography in the initial characterization of patients with
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  ultrasonography in the initial characterization of patients with
Second:  risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review 

First:  ultrasonography in the initial characterization of patients with
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  ultrasonography in the initial characterization of patients with
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  ultrasonography in the initial characterization of patients with
Second:  case report mammography in the diagnosis of breast 

First:  ultrasonography in the initial characterization of patients with
Second:  journal innovations in in the age of a systematic literature review 

First:  ultrasonography in the initial characterization of patients with
Second:  journal of cancer research and clinical oncology 

First:  ultrasonography in the initial characterization of patients with
Second:  disease in the era of an observation on a series of six patients with 

First:  ultrasonography in the initial characterization of patients with
Second:  mapping the technological landscape of and vaccines 

First:  ultrasonography in the initial characterization of patients with
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  ultrasonography in the initial characterization of patients with
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  ultrasonography in the initial characterization of patients with
Second:  does the pandemic spell the end for the direct 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  ultrasonography in the initial characterization of patients with
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  ultrasonography in the initial characterization of patients with
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  ultrasonography in the initial characterization of patients with
Second:  rhabdomyolysis as an initial presentation in a patient diagnosed with unusual association of 

First:  ultrasonography in the initial characterization of patients with
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  ultrasonography in the initial characterization of patients with
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  ultrasonography in the initial characterization of patients with
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  ultrasonography in the initial characterization of patients with
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  ultrasonography in the initial characterization of patients with
Second:  invasive strategy for patients presenting with acute coronary the first italian experience 

First:  ultrasonography in the initial characterization of patients with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  ultrasonography in the initial characterization of patients with
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  ultrasonography in the initial characterization of patients with
Second:  editorial recommendations for the management of in countries 

First:  ultrasonography in the initial characterization of patients with
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  ultrasonography in the initial characterization of patients with
Second:  prophylaxis of with and chloroquine accepted article 

First:  ultrasonography in the initial characterization of patients with
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  ultrasonography in the initial characterization of patients with
Second:  of vsv with ebola virus glycoprotein is superior to for the assessment of neutralising antibodies 

First:  ultrasonography in the initial characterization of patients with
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  ultrasonography in the initial characterization of patients with
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  ultrasonography in the initial characterization of patients with
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  ultrasonography in the initial characterization of patients with
Second:  the impact on surgical departments of hospitals 

First:  ultrasonography in the initial characterization of patients with
Second:  chest computed tomographic findings of patients with pneumonia 

First:  ultrasonography in the initial characterization of patients with
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  ultrasonography in the initial characterization of patients with
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  ultrasonography in the initial characterization of patients with
Second:  spectrum of antimicrobial activity for disinfection of 

First:  ultrasonography in the initial characterization of patients with
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  ultrasonography in the initial characterization of patients with
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  ultrasonography in the initial characterization of patients with
Second:  toxic and properties of an coordination complex of 

First:  ultrasonography in the initial characterization of patients with
Second:  a review in bacterial infections 

First:  ultrasonography in the initial characterization of patients with
Second:  the common missed instances and areas after years of education 

First:  ultrasonography in the initial characterization of patients with
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  ultrasonography in the initial characterization of patients with
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  ultrasonography in the initial characterization of patients with
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  ultrasonography in the initial characterization of patients with
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  ultrasonography in the initial characterization of patients with
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  ultrasonography in the initial characterization of patients with
Second:  concept of immune response 

First:  ultrasonography in the initial characterization of patients with
Second:  potential of in vitro 

First:  ultrasonography in the initial characterization of patients with
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  ultrasonography in the initial characterization of patients with
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  bacterial and the deadly trio in 

First:  ultrasonography in the initial characterization of patients with
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  ultrasonography in the initial characterization of patients with
Second:  supramolecular architecture of the coronavirus particle 

First:  ultrasonography in the initial characterization of patients with
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  ultrasonography in the initial characterization of patients with
Second:  a integrated with heater for visual testing of 

First:  ultrasonography in the initial characterization of patients with
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  ultrasonography in the initial characterization of patients with
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  ultrasonography in the initial characterization of patients with
Second:  establishment of a reference panel for the detection of antibodies 

First:  ultrasonography in the initial characterization of patients with
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  ultrasonography in the initial characterization of patients with
Second:  a serological comparison of bovine coronavirus strains 

First:  ultrasonography in the initial characterization of patients with
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  ultrasonography in the initial characterization of patients with
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  ultrasonography in the initial characterization of patients with
Second:  synthesis and activity of derivatives and analogues thereof 

First:  ultrasonography in the initial characterization of patients with
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  ultrasonography in the initial characterization of patients with
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  ultrasonography in the initial characterization of patients with
Second:  genetic hypothesis and side of in 

First:  ultrasonography in the initial characterization of patients with
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  ultrasonography in the initial characterization of patients with
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  ultrasonography in the initial characterization of patients with
Second:  and prognostic significance in 

First:  ultrasonography in the initial characterization of patients with
Second:  journal fungal in patients with role of antifungal 

First:  ultrasonography in the initial characterization of patients with
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  ultrasonography in the initial characterization of patients with
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  ultrasonography in the initial characterization of patients with
Second:  the sudden appearance of 

First:  ultrasonography in the initial characterization of patients with
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  ultrasonography in the initial characterization of patients with
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  ultrasonography in the initial characterization of patients with
Second:  school of population and global the university of evidence 

First:  ultrasonography in the initial characterization of patients with
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  ultrasonography in the initial characterization of patients with
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  ultrasonography in the initial characterization of patients with
Second:  early forecasting of the potential risk zones of in 

First:  ultrasonography in the initial characterization of patients with
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  ultrasonography in the initial characterization of patients with
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  ultrasonography in the initial characterization of patients with
Second:  therapy for a feasibility study 

First:  ultrasonography in the initial characterization of patients with
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  edema assessment by means of the and laser scanning microscopy 

First:  ultrasonography in the initial characterization of patients with
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  ultrasonography in the initial characterization of patients with
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  ultrasonography in the initial characterization of patients with
Second:  the expression in human heart indicates new potential mechanism of heart injury among patients infected with 

First:  ultrasonography in the initial characterization of patients with
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  ultrasonography in the initial characterization of patients with
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  ultrasonography in the initial characterization of patients with
Second:  isolation of aspergillus in respiratory samples of patients with in a spanish tertiary care hospital acknowledgments and funding conflicts of interest statement 

First:  ultrasonography in the initial characterization of patients with
Second:  and responses to in south a rapid qualitative assessment 

First:  ultrasonography in the initial characterization of patients with
Second:  older experience of the a analysis of stresses and joys 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  ultrasonography in the initial characterization of patients with
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  ultrasonography in the initial characterization of patients with
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  ultrasonography in the initial characterization of patients with
Second:  use of in human immunodeficiency virus infection 

First:  ultrasonography in the initial characterization of patients with
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  ultrasonography in the initial characterization of patients with
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  ultrasonography in the initial characterization of patients with
Second:  immigration policy and justice in the era of 

First:  ultrasonography in the initial characterization of patients with
Second:  regression of infantile glioblastoma after treatment with 

First:  ultrasonography in the initial characterization of patients with
Second:  diffusion as a first model of spread of viral infection 

First:  ultrasonography in the initial characterization of patients with
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  ultrasonography in the initial characterization of patients with
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  the and ends of rnas is not 

First:  ultrasonography in the initial characterization of patients with
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  ultrasonography in the initial characterization of patients with
Second:  more severe presentations of acute appendicitis during 

First:  ultrasonography in the initial characterization of patients with
Second:  and the saga continues 

First:  ultrasonography in the initial characterization of patients with
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  ultrasonography in the initial characterization of patients with
Second:  environmental research and public health the impact of on food results of a survey 

First:  ultrasonography in the initial characterization of patients with
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  ultrasonography in the initial characterization of patients with
Second:  to appear advances in oral and maxillofacial surgery 

First:  ultrasonography in the initial characterization of patients with
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  ultrasonography in the initial characterization of patients with
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  ultrasonography in the initial characterization of patients with
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  ultrasonography in the initial characterization of patients with
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  ultrasonography in the initial characterization of patients with
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  ultrasonography in the initial characterization of patients with
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  ultrasonography in the initial characterization of patients with
Second:  recent advancements in the and prospective drug therapy of 

First:  ultrasonography in the initial characterization of patients with
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  ultrasonography in the initial characterization of patients with
Second:  higher glycemic variability within the first day of icu admission is associated with increased mortality in icu patients with sepsis 

First:  ultrasonography in the initial characterization of patients with
Second:  infectious disease and the case for considering impacts 

First:  ultrasonography in the initial characterization of patients with
Second:  stress symptoms in hemodialysis patients with exposure 

First:  ultrasonography in the initial characterization of patients with
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  ultrasonography in the initial characterization of patients with
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  ultrasonography in the initial characterization of patients with
Second:  reliability of serological tests for comparison of three test kits for antibodies 

First:  ultrasonography in the initial characterization of patients with
Second:  suspected myocarditis in patients with a case series 

First:  ultrasonography in the initial characterization of patients with
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical potential of for assessing comparative analysis 

First:  ultrasonography in the initial characterization of patients with
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  the impact of and homeschooling on engagement with physical activity 

First:  ultrasonography in the initial characterization of patients with
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  ultrasonography in the initial characterization of patients with
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  ultrasonography in the initial characterization of patients with
Second:  cells the aging of t cells 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical characteristics of death cases with 

First:  ultrasonography in the initial characterization of patients with
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  ultrasonography in the initial characterization of patients with
Second:  a look in the how the field of behavior analysis can become 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  ultrasonography in the initial characterization of patients with
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  ultrasonography in the initial characterization of patients with
Second:  levels of and in the lungs of pneumonia patients 

First:  ultrasonography in the initial characterization of patients with
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  ultrasonography in the initial characterization of patients with
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  ultrasonography in the initial characterization of patients with
Second:  response to have got dry macular end of a qualitative study into the experience of living with macular 

First:  ultrasonography in the initial characterization of patients with
Second:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the 

First:  ultrasonography in the initial characterization of patients with
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  ultrasonography in the initial characterization of patients with
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  ultrasonography in the initial characterization of patients with
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  ultrasonography in the initial characterization of patients with
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  ultrasonography in the initial characterization of patients with
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  ultrasonography in the initial characterization of patients with
Second:  hallucinations due to therapeutic doses of 

First:  ultrasonography in the initial characterization of patients with
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  ultrasonography in the initial characterization of patients with
Second:  tracing and analysis of early infections outside a modeling study 

First:  ultrasonography in the initial characterization of patients with
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study 

First:  ultrasonography in the initial characterization of patients with
Second:  epidemiology and infection from the field 

First:  ultrasonography in the initial characterization of patients with
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  ultrasonography in the initial characterization of patients with
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  ultrasonography in the initial characterization of patients with
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  ultrasonography in the initial characterization of patients with
Second:  design and analysis of a tweets dataset 

First:  ultrasonography in the initial characterization of patients with
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  ultrasonography in the initial characterization of patients with
Second:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism 

First:  ultrasonography in the initial characterization of patients with
Second:  performance of a rapid serology test in whole blood and separated plasma 

First:  ultrasonography in the initial characterization of patients with
Second:  the impacts of on children 

First:  ultrasonography in the initial characterization of patients with
Second:  patients in is obesity or the real 

First:  ultrasonography in the initial characterization of patients with
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  ultrasonography in the initial characterization of patients with
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  ultrasonography in the initial characterization of patients with
Second:  prolongation in patients using chloroquine 

First:  a database resource and online analysis tools for on a historical and global scale
Second:  and prognostic significance in 

First:  a database resource and online analysis tools for on a historical and global scale
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a database resource and online analysis tools for on a historical and global scale
Second:  a protocol for a systematic review and 

First:  a database resource and online analysis tools for on a historical and global scale
Second:  clinical potential of for assessing comparative analysis 

First:  a database resource and online analysis tools for on a historical and global scale
Second:  design and analysis of a tweets dataset 

First:  animal models of middle east respiratory syndrome coronavirus infection
Second:  viral intestinal infections of animals and man 

First:  animal models of middle east respiratory syndrome coronavirus infection
Second:  a serological comparison of bovine coronavirus strains 

First:  animal models of middle east respiratory syndrome coronavirus infection
Second:  use of in human immunodeficiency virus infection 

First:  animal models of middle east respiratory syndrome coronavirus infection
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  animal models of middle east respiratory syndrome coronavirus infection
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  coronavirus a brief perspective from the front line
Second:  the sudden appearance of 

First:  design and implementation of an acute trauma and orthopaedic referral system utilising existing secure technology during the pandemic introduction
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  case report mammography in the diagnosis of breast 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  journal of cancer research and clinical oncology 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  the impact on surgical departments of hospitals 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  levels of and in the lungs of pneumonia patients 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  epidemiology and infection from the field 

First:  world journal of clinical pediatrics pediatric surgery during the pandemic statement
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  identification of heterogeneous drug candidates for treatment of via a rational drug repurposing approach
Second:  clinical potential of for assessing comparative analysis 

First:  rescues via stimulating pathway in promoting the export of accumulated bile
Second:  potential of in vitro 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  case report mammography in the diagnosis of breast 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  stress symptoms in hemodialysis patients with exposure 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  levels of and in the lungs of pneumonia patients 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report
Second:  ultrasonography in the initial characterization of patients with 

First:  comparative analyses of the microbiome in chronic periodontitis patients with and without gingival erosive oral lichen planus based on rrna gene sequencing
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  comparative analyses of the microbiome in chronic periodontitis patients with and without gingival erosive oral lichen planus based on rrna gene sequencing
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  comparative analyses of the microbiome in chronic periodontitis patients with and without gingival erosive oral lichen planus based on rrna gene sequencing
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  comparative analyses of the microbiome in chronic periodontitis patients with and without gingival erosive oral lichen planus based on rrna gene sequencing
Second:  levels of and in the lungs of pneumonia patients 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  stress symptoms in hemodialysis patients with exposure 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  socioeconomic correlates of obesity in and men and women
Second:  a study on the influence of the pandemic on incomes in greece 

First:  socioeconomic correlates of obesity in and men and women
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  socioeconomic correlates of obesity in and men and women
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  socioeconomic correlates of obesity in and men and women
Second:  journal of cancer research and clinical oncology 

First:  socioeconomic correlates of obesity in and men and women
Second:  mapping the technological landscape of and vaccines 

First:  socioeconomic correlates of obesity in and men and women
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  socioeconomic correlates of obesity in and men and women
Second:  and cell biology lung advances in generation and 

First:  socioeconomic correlates of obesity in and men and women
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  socioeconomic correlates of obesity in and men and women
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  socioeconomic correlates of obesity in and men and women
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  socioeconomic correlates of obesity in and men and women
Second:  editorial recommendations for the management of in countries 

First:  socioeconomic correlates of obesity in and men and women
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  socioeconomic correlates of obesity in and men and women
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  socioeconomic correlates of obesity in and men and women
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  socioeconomic correlates of obesity in and men and women
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  socioeconomic correlates of obesity in and men and women
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  socioeconomic correlates of obesity in and men and women
Second:  prevalence of antibodies in young children in tennessee 

First:  socioeconomic correlates of obesity in and men and women
Second:  toxic and properties of an coordination complex of 

First:  socioeconomic correlates of obesity in and men and women
Second:  the common missed instances and areas after years of education 

First:  socioeconomic correlates of obesity in and men and women
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  socioeconomic correlates of obesity in and men and women
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  socioeconomic correlates of obesity in and men and women
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  socioeconomic correlates of obesity in and men and women
Second:  potential of in vitro 

First:  socioeconomic correlates of obesity in and men and women
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  socioeconomic correlates of obesity in and men and women
Second:  bacterial and the deadly trio in 

First:  socioeconomic correlates of obesity in and men and women
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  socioeconomic correlates of obesity in and men and women
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  socioeconomic correlates of obesity in and men and women
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  socioeconomic correlates of obesity in and men and women
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  socioeconomic correlates of obesity in and men and women
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  socioeconomic correlates of obesity in and men and women
Second:  synthesis and activity of derivatives and analogues thereof 

First:  socioeconomic correlates of obesity in and men and women
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  socioeconomic correlates of obesity in and men and women
Second:  genetic hypothesis and side of in 

First:  socioeconomic correlates of obesity in and men and women
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  socioeconomic correlates of obesity in and men and women
Second:  and prognostic significance in 

First:  socioeconomic correlates of obesity in and men and women
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  socioeconomic correlates of obesity in and men and women
Second:  the sudden appearance of 

First:  socioeconomic correlates of obesity in and men and women
Second:  school of population and global the university of evidence 

First:  socioeconomic correlates of obesity in and men and women
Second:  early forecasting of the potential risk zones of in 

First:  socioeconomic correlates of obesity in and men and women
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  socioeconomic correlates of obesity in and men and women
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  socioeconomic correlates of obesity in and men and women
Second:  socioeconomic position over the and subjective social status in relation to nutritional status and mental health among guatemalan adults 

First:  socioeconomic correlates of obesity in and men and women
Second:  investment and economic policy options in 

First:  socioeconomic correlates of obesity in and men and women
Second:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education 

First:  socioeconomic correlates of obesity in and men and women
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  socioeconomic correlates of obesity in and men and women
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  socioeconomic correlates of obesity in and men and women
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  socioeconomic correlates of obesity in and men and women
Second:  older experience of the a analysis of stresses and joys 

First:  socioeconomic correlates of obesity in and men and women
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  socioeconomic correlates of obesity in and men and women
Second:  mask social and gender correlates of vaccine intentions among adults in the us 

First:  socioeconomic correlates of obesity in and men and women
Second:  social determinants of mortality at the county level 

First:  socioeconomic correlates of obesity in and men and women
Second:  immigration policy and justice in the era of 

First:  socioeconomic correlates of obesity in and men and women
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  socioeconomic correlates of obesity in and men and women
Second:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study 

First:  socioeconomic correlates of obesity in and men and women
Second:  the and ends of rnas is not 

First:  socioeconomic correlates of obesity in and men and women
Second:  and the saga continues 

First:  socioeconomic correlates of obesity in and men and women
Second:  environmental research and public health the impact of on food results of a survey 

First:  socioeconomic correlates of obesity in and men and women
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  socioeconomic correlates of obesity in and men and women
Second:  international archives of occupational and environmental health 

First:  socioeconomic correlates of obesity in and men and women
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  socioeconomic correlates of obesity in and men and women
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  socioeconomic correlates of obesity in and men and women
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  socioeconomic correlates of obesity in and men and women
Second:  recent advancements in the and prospective drug therapy of 

First:  socioeconomic correlates of obesity in and men and women
Second:  journal the psychological status of people affected by the outbreak in china 

First:  socioeconomic correlates of obesity in and men and women
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  socioeconomic correlates of obesity in and men and women
Second:  infectious disease and the case for considering impacts 

First:  socioeconomic correlates of obesity in and men and women
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  socioeconomic correlates of obesity in and men and women
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  socioeconomic correlates of obesity in and men and women
Second:  the impact of and homeschooling on engagement with physical activity 

First:  socioeconomic correlates of obesity in and men and women
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  socioeconomic correlates of obesity in and men and women
Second:  levels of and in the lungs of pneumonia patients 

First:  socioeconomic correlates of obesity in and men and women
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  socioeconomic correlates of obesity in and men and women
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  socioeconomic correlates of obesity in and men and women
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  socioeconomic correlates of obesity in and men and women
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  socioeconomic correlates of obesity in and men and women
Second:  temporal trends in rates of in hong kong people with and without a retrospective study 

First:  socioeconomic correlates of obesity in and men and women
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  socioeconomic correlates of obesity in and men and women
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  socioeconomic correlates of obesity in and men and women
Second:  epidemiology and infection from the field 

First:  socioeconomic correlates of obesity in and men and women
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  socioeconomic correlates of obesity in and men and women
Second:  influenza opportunities and challenges 

First:  socioeconomic correlates of obesity in and men and women
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  socioeconomic correlates of obesity in and men and women
Second:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study 

First:  socioeconomic correlates of obesity in and men and women
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  socioeconomic correlates of obesity in and men and women
Second:  the impacts of on children 

First:  socioeconomic correlates of obesity in and men and women
Second:  patients in is obesity or the real 

First:  socioeconomic correlates of obesity in and men and women
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  socioeconomic correlates of obesity in and men and women
Second:  ultrasonography in the initial characterization of patients with 

First:  prediction of interaction with host proteins during lung aging reveals a potential role for in
Second:  potential of in vitro 

First:  prediction of interaction with host proteins during lung aging reveals a potential role for in
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  identification of residues on human receptor critical for binding and entry
Second:  potential of in vitro 

First:  the fungal nature of pneumocystis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the fungal nature of pneumocystis
Second:  case report mammography in the diagnosis of breast 

First:  the fungal nature of pneumocystis
Second:  journal of cancer research and clinical oncology 

First:  the fungal nature of pneumocystis
Second:  disease in the era of an observation on a series of six patients with 

First:  the fungal nature of pneumocystis
Second:  mapping the technological landscape of and vaccines 

First:  the fungal nature of pneumocystis
Second:  viral intestinal infections of animals and man 

First:  the fungal nature of pneumocystis
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the fungal nature of pneumocystis
Second:  does the pandemic spell the end for the direct 

First:  the fungal nature of pneumocystis
Second:  flying under the the stealth pandemic of escherichia coli sequence type 

First:  the fungal nature of pneumocystis
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the fungal nature of pneumocystis
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  the fungal nature of pneumocystis
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the fungal nature of pneumocystis
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the fungal nature of pneumocystis
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the fungal nature of pneumocystis
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the fungal nature of pneumocystis
Second:  prophylaxis of with and chloroquine accepted article 

First:  the fungal nature of pneumocystis
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  the fungal nature of pneumocystis
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the fungal nature of pneumocystis
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  the fungal nature of pneumocystis
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  the fungal nature of pneumocystis
Second:  microorganisms nasal microbiota in rsv 

First:  the fungal nature of pneumocystis
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the fungal nature of pneumocystis
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the fungal nature of pneumocystis
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  the fungal nature of pneumocystis
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the fungal nature of pneumocystis
Second:  toxic and properties of an coordination complex of 

First:  the fungal nature of pneumocystis
Second:  a review in bacterial infections 

First:  the fungal nature of pneumocystis
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the fungal nature of pneumocystis
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the fungal nature of pneumocystis
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  the fungal nature of pneumocystis
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  the fungal nature of pneumocystis
Second:  concept of immune response 

First:  the fungal nature of pneumocystis
Second:  potential of in vitro 

First:  the fungal nature of pneumocystis
Second:  bacterial and the deadly trio in 

First:  the fungal nature of pneumocystis
Second:  supramolecular architecture of the coronavirus particle 

First:  the fungal nature of pneumocystis
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the fungal nature of pneumocystis
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the fungal nature of pneumocystis
Second:  establishment of a reference panel for the detection of antibodies 

First:  the fungal nature of pneumocystis
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  the fungal nature of pneumocystis
Second:  a serological comparison of bovine coronavirus strains 

First:  the fungal nature of pneumocystis
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the fungal nature of pneumocystis
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the fungal nature of pneumocystis
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  the fungal nature of pneumocystis
Second:  genetic hypothesis and side of in 

First:  the fungal nature of pneumocystis
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  the fungal nature of pneumocystis
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the fungal nature of pneumocystis
Second:  and prognostic significance in 

First:  the fungal nature of pneumocystis
Second:  journal fungal in patients with role of antifungal 

First:  the fungal nature of pneumocystis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the fungal nature of pneumocystis
Second:  the sudden appearance of 

First:  the fungal nature of pneumocystis
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the fungal nature of pneumocystis
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  the fungal nature of pneumocystis
Second:  school of population and global the university of evidence 

First:  the fungal nature of pneumocystis
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  the fungal nature of pneumocystis
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  the fungal nature of pneumocystis
Second:  early forecasting of the potential risk zones of in 

First:  the fungal nature of pneumocystis
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  the fungal nature of pneumocystis
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the fungal nature of pneumocystis
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  the fungal nature of pneumocystis
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  the fungal nature of pneumocystis
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  the fungal nature of pneumocystis
Second:  enhances the peroxidase activity of myoglobin against 

First:  the fungal nature of pneumocystis
Second:  older experience of the a analysis of stresses and joys 

First:  the fungal nature of pneumocystis
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  the fungal nature of pneumocystis
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the fungal nature of pneumocystis
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  the fungal nature of pneumocystis
Second:  use of in human immunodeficiency virus infection 

First:  the fungal nature of pneumocystis
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  the fungal nature of pneumocystis
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  the fungal nature of pneumocystis
Second:  diffusion as a first model of spread of viral infection 

First:  the fungal nature of pneumocystis
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  the fungal nature of pneumocystis
Second:  the and ends of rnas is not 

First:  the fungal nature of pneumocystis
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the fungal nature of pneumocystis
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  the fungal nature of pneumocystis
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the fungal nature of pneumocystis
Second:  recent advancements in the and prospective drug therapy of 

First:  the fungal nature of pneumocystis
Second:  infectious disease and the case for considering impacts 

First:  the fungal nature of pneumocystis
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the fungal nature of pneumocystis
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  the fungal nature of pneumocystis
Second:  cells the aging of t cells 

First:  the fungal nature of pneumocystis
Second:  clinical characteristics of death cases with 

First:  the fungal nature of pneumocystis
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  the fungal nature of pneumocystis
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  the fungal nature of pneumocystis
Second:  levels of and in the lungs of pneumonia patients 

First:  the fungal nature of pneumocystis
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the fungal nature of pneumocystis
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the fungal nature of pneumocystis
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  the fungal nature of pneumocystis
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the fungal nature of pneumocystis
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  the fungal nature of pneumocystis
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  the fungal nature of pneumocystis
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  the fungal nature of pneumocystis
Second:  in vitro b and sars virus activities of a 

First:  the fungal nature of pneumocystis
Second:  hallucinations due to therapeutic doses of 

First:  the fungal nature of pneumocystis
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  the fungal nature of pneumocystis
Second:  epidemiology and infection from the field 

First:  the fungal nature of pneumocystis
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  the fungal nature of pneumocystis
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  the fungal nature of pneumocystis
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  the fungal nature of pneumocystis
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the fungal nature of pneumocystis
Second:  the impacts of on children 

First:  the fungal nature of pneumocystis
Second:  patients in is obesity or the real 

First:  the fungal nature of pneumocystis
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  the fungal nature of pneumocystis
Second:  ultrasonography in the initial characterization of patients with 

First:  the fungal nature of pneumocystis
Second:  comparative analyses of the microbiome in chronic periodontitis patients with and without gingival erosive oral lichen planus based on rrna gene sequencing 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  viral intestinal infections of animals and man 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  a review in bacterial infections 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  potential of in vitro 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  bacterial and the deadly trio in 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  a serological comparison of bovine coronavirus strains 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  the sudden appearance of 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  use of in human immunodeficiency virus infection 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  levels of and in the lungs of pneumonia patients 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine
Second:  the fungal nature of pneumocystis 

First:  viral emerging challenges in developing vaccination strategies
Second:  potential of in vitro 

First:  viral emerging challenges in developing vaccination strategies
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  viral emerging challenges in developing vaccination strategies
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  viral emerging challenges in developing vaccination strategies
Second:  recent advancements in the and prospective drug therapy of 

First:  viral emerging challenges in developing vaccination strategies
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  viral emerging challenges in developing vaccination strategies
Second:  optimality in vaccination strategies determined by heterogeneity in interaction networks 

First:  viral emerging challenges in developing vaccination strategies
Second:  antiviral strategies to control infections 

First:  viral emerging challenges in developing vaccination strategies
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  viral emerging challenges in developing vaccination strategies
Second:  technological advances improving recombinant protein production in bacteria 

First:  viral emerging challenges in developing vaccination strategies
Second:  influenza opportunities and challenges 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  a study on the influence of the pandemic on incomes in greece 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  mapping the technological landscape of and vaccines 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  coordinating genomic surveillance in the united states 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  editorial recommendations for the management of in countries 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  potential of in vitro 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  establishment of a reference panel for the detection of antibodies 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  genetic hypothesis and side of in 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  and prognostic significance in 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  the sudden appearance of 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  school of population and global the university of evidence 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  early forecasting of the potential risk zones of in 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  older experience of the a analysis of stresses and joys 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  immigration policy and justice in the era of 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  the and ends of rnas is not 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  recent advancements in the and prospective drug therapy of 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  a look in the how the field of behavior analysis can become 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  levels of and in the lungs of pneumonia patients 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  the impacts of on children 

First:  forecast analysis of the epidemics trend of in the united states by a generalized seir model
Second:  ultrasonography in the initial characterization of patients with 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  case report mammography in the diagnosis of breast 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  journal of cancer research and clinical oncology 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  disease in the era of an observation on a series of six patients with 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  mapping the technological landscape of and vaccines 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the impact on surgical departments of hospitals 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  predicting risk of transition to severe infection 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  potential of in vitro 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  bacterial and the deadly trio in 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  genetic hypothesis and side of in 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  and prognostic significance in 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the sudden appearance of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  early forecasting of the potential risk zones of in 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  older experience of the a analysis of stresses and joys 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  regression of infantile glioblastoma after treatment with 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the and ends of rnas is not 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  more severe presentations of acute appendicitis during 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  recent advancements in the and prospective drug therapy of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  infectious disease and the case for considering impacts 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  stress symptoms in hemodialysis patients with exposure 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical potential of for assessing comparative analysis 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical characteristics of death cases with 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  levels of and in the lungs of pneumonia patients 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  hallucinations due to therapeutic doses of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  epidemiology and infection from the field 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the impacts of on children 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  patients in is obesity or the real 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  ultrasonography in the initial characterization of patients with 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  socioeconomic correlates of obesity in and men and women 

First:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study
Second:  the fungal nature of pneumocystis 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  a study on the influence of the pandemic on incomes in greece 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  mapping the technological landscape of and vaccines 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  editorial recommendations for the management of in countries 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  and prognostic significance in 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  early forecasting of the potential risk zones of in 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  investment and economic policy options in 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  immigration policy and justice in the era of 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  recent advancements in the and prospective drug therapy of 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  levels of and in the lungs of pneumonia patients 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access
Second:  the impacts of on children 

First:  the effectiveness of full and partial travel bans against spread in australia for travellers from china
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  autopsy in the time of case report
Second:  a study on the influence of the pandemic on incomes in greece 

First:  autopsy in the time of case report
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  autopsy in the time of case report
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  autopsy in the time of case report
Second:  case report mammography in the diagnosis of breast 

First:  autopsy in the time of case report
Second:  journal innovations in in the age of a systematic literature review 

First:  autopsy in the time of case report
Second:  disease in the era of an observation on a series of six patients with 

First:  autopsy in the time of case report
Second:  mapping the technological landscape of and vaccines 

First:  autopsy in the time of case report
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  autopsy in the time of case report
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  autopsy in the time of case report
Second:  does the pandemic spell the end for the direct 

First:  autopsy in the time of case report
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  autopsy in the time of case report
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  autopsy in the time of case report
Second:  reply to against the risk of airborne 

First:  autopsy in the time of case report
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  autopsy in the time of case report
Second:  excess neurological death in new york city after the emergence of 

First:  autopsy in the time of case report
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  autopsy in the time of case report
Second:  editorial recommendations for the management of in countries 

First:  autopsy in the time of case report
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  autopsy in the time of case report
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  autopsy in the time of case report
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  autopsy in the time of case report
Second:  the impact on surgical departments of hospitals 

First:  autopsy in the time of case report
Second:  letter to the editor 

First:  autopsy in the time of case report
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  autopsy in the time of case report
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  autopsy in the time of case report
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  autopsy in the time of case report
Second:  the common missed instances and areas after years of education 

First:  autopsy in the time of case report
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  autopsy in the time of case report
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  autopsy in the time of case report
Second:  potential of in vitro 

First:  autopsy in the time of case report
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  autopsy in the time of case report
Second:  bacterial and the deadly trio in 

First:  autopsy in the time of case report
Second:  syndrome in case report 

First:  autopsy in the time of case report
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  autopsy in the time of case report
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  autopsy in the time of case report
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  autopsy in the time of case report
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  autopsy in the time of case report
Second:  establishment of a reference panel for the detection of antibodies 

First:  autopsy in the time of case report
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  autopsy in the time of case report
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  autopsy in the time of case report
Second:  genetic hypothesis and side of in 

First:  autopsy in the time of case report
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  autopsy in the time of case report
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  autopsy in the time of case report
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  autopsy in the time of case report
Second:  and prognostic significance in 

First:  autopsy in the time of case report
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  autopsy in the time of case report
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  autopsy in the time of case report
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  autopsy in the time of case report
Second:  from ego to for ontology in the 

First:  autopsy in the time of case report
Second:  the sudden appearance of 

First:  autopsy in the time of case report
Second:  policy responses to the pandemic in vietnam 

First:  autopsy in the time of case report
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  autopsy in the time of case report
Second:  school of population and global the university of evidence 

First:  autopsy in the time of case report
Second:  early forecasting of the potential risk zones of in 

First:  autopsy in the time of case report
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  autopsy in the time of case report
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  autopsy in the time of case report
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  autopsy in the time of case report
Second:  hemophilia a case report 

First:  autopsy in the time of case report
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  autopsy in the time of case report
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  autopsy in the time of case report
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  autopsy in the time of case report
Second:  older experience of the a analysis of stresses and joys 

First:  autopsy in the time of case report
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  autopsy in the time of case report
Second:  journal case report rapid development of seizures and pres in a patient 

First:  autopsy in the time of case report
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  autopsy in the time of case report
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  autopsy in the time of case report
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  autopsy in the time of case report
Second:  immigration policy and justice in the era of 

First:  autopsy in the time of case report
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  autopsy in the time of case report
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  autopsy in the time of case report
Second:  the and ends of rnas is not 

First:  autopsy in the time of case report
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  autopsy in the time of case report
Second:  and the saga continues 

First:  autopsy in the time of case report
Second:  environmental research and public health the impact of on food results of a survey 

First:  autopsy in the time of case report
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  autopsy in the time of case report
Second:  how can blockchain help people in the event of pandemics such as the 

First:  autopsy in the time of case report
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  autopsy in the time of case report
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  autopsy in the time of case report
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  autopsy in the time of case report
Second:  recent advancements in the and prospective drug therapy of 

First:  autopsy in the time of case report
Second:  journal the psychological status of people affected by the outbreak in china 

First:  autopsy in the time of case report
Second:  infectious disease and the case for considering impacts 

First:  autopsy in the time of case report
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  autopsy in the time of case report
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  autopsy in the time of case report
Second:  the impact of and homeschooling on engagement with physical activity 

First:  autopsy in the time of case report
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  autopsy in the time of case report
Second:  clinical characteristics of death cases with 

First:  autopsy in the time of case report
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  autopsy in the time of case report
Second:  a look in the how the field of behavior analysis can become 

First:  autopsy in the time of case report
Second:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic 

First:  autopsy in the time of case report
Second:  levels of and in the lungs of pneumonia patients 

First:  autopsy in the time of case report
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  autopsy in the time of case report
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  autopsy in the time of case report
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  autopsy in the time of case report
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  autopsy in the time of case report
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  autopsy in the time of case report
Second:  epidemiology and infection from the field 

First:  autopsy in the time of case report
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  autopsy in the time of case report
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  autopsy in the time of case report
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  autopsy in the time of case report
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  autopsy in the time of case report
Second:  the impacts of on children 

First:  autopsy in the time of case report
Second:  patients in is obesity or the real 

First:  autopsy in the time of case report
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  autopsy in the time of case report
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  autopsy in the time of case report
Second:  ultrasonography in the initial characterization of patients with 

First:  autopsy in the time of case report
Second:  the fungal nature of pneumocystis 

First:  autopsy in the time of case report
Second:  forecast analysis of the epidemics trend of in the united states by a generalized seir model 

First:  autopsy in the time of case report
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  coronavirus genomes carry the signatures of their habitats
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  coronavirus genomes carry the signatures of their habitats
Second:  potential of in vitro 

First:  coronavirus genomes carry the signatures of their habitats
Second:  a serological comparison of bovine coronavirus strains 

First:  coronavirus genomes carry the signatures of their habitats
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  coronavirus genomes carry the signatures of their habitats
Second:  the sudden appearance of 

First:  coronavirus genomes carry the signatures of their habitats
Second:  the and ends of rnas is not 

First:  coronavirus genomes carry the signatures of their habitats
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  coronavirus genomes carry the signatures of their habitats
Second:  levels of and in the lungs of pneumonia patients 

First:  coronavirus genomes carry the signatures of their habitats
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  coronavirus genomes carry the signatures of their habitats
Second:  the impacts of on children 

First:  coronavirus genomes carry the signatures of their habitats
Second:  the fungal nature of pneumocystis 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  case report mammography in the diagnosis of breast 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  journal of cancer research and clinical oncology 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  mapping the technological landscape of and vaccines 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  and cell biology lung advances in generation and 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  editorial recommendations for the management of in countries 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  potential of in vitro 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  bacterial and the deadly trio in 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  genetic hypothesis and side of in 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  and prognostic significance in 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  the sudden appearance of 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  early forecasting of the potential risk zones of in 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  older experience of the a analysis of stresses and joys 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  recent advancements in the and prospective drug therapy of 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  infectious disease and the case for considering impacts 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  clinical potential of for assessing comparative analysis 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  levels of and in the lungs of pneumonia patients 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  epidemiology and infection from the field 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  the impacts of on children 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  ultrasonography in the initial characterization of patients with 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  socioeconomic correlates of obesity in and men and women 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  differences of clinical and imaging findings in multiple generations of secondary infection in china
Second:  autopsy in the time of case report 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  a review in bacterial infections 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  potential of in vitro 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  and prognostic significance in 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  levels of and in the lungs of pneumonia patients 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  surfactant protein a predictor for severity of pneumonia in children
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  common data elements for a proposal
Second:  a protocol for a systematic review and 

First:  marine drugs antiviral potential of algal comprehensive review
Second:  potential of in vitro 

First:  transmission route and introduction of pandemic between and spain
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  transmission route and introduction of pandemic between and spain
Second:  mapping the technological landscape of and vaccines 

First:  transmission route and introduction of pandemic between and spain
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  transmission route and introduction of pandemic between and spain
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  transmission route and introduction of pandemic between and spain
Second:  genetic hypothesis and side of in 

First:  transmission route and introduction of pandemic between and spain
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  transmission route and introduction of pandemic between and spain
Second:  the sudden appearance of 

First:  transmission route and introduction of pandemic between and spain
Second:  and the saga continues 

First:  transmission route and introduction of pandemic between and spain
Second:  levels of and in the lungs of pneumonia patients 

First:  transmission route and introduction of pandemic between and spain
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  transmission route and introduction of pandemic between and spain
Second:  epidemiology and infection from the field 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  journal of cancer research and clinical oncology 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  mapping the technological landscape of and vaccines 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  editorial recommendations for the management of in countries 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  toxic and properties of an coordination complex of 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  potential of in vitro 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  establishment of a reference panel for the detection of antibodies 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  synthesis and activity of derivatives and analogues thereof 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  genetic hypothesis and side of in 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  and prognostic significance in 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  journal of management control 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  the sudden appearance of 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  school of population and global the university of evidence 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  early forecasting of the potential risk zones of in 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  investment and economic policy options in 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  and responses to in south a rapid qualitative assessment 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  older experience of the a analysis of stresses and joys 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  journal of banking regulation 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  immigration policy and justice in the era of 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  environmental research and public health the impact of on food results of a survey 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  international archives of occupational and environmental health 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  recent advancements in the and prospective drug therapy of 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  clinical potential of for assessing comparative analysis 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  the impact of and homeschooling on engagement with physical activity 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  levels of and in the lungs of pneumonia patients 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  the impacts of on children 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  ultrasonography in the initial characterization of patients with 

First:  journal and timing of administration assessment and timing of administration assessment
Second:  socioeconomic correlates of obesity in and men and women 

First:  modeling the evolution of via and application to the cyprus case
Second:  a study on the influence of the pandemic on incomes in greece 

First:  modeling the evolution of via and application to the cyprus case
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  modeling the evolution of via and application to the cyprus case
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  modeling the evolution of via and application to the cyprus case
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  modeling the evolution of via and application to the cyprus case
Second:  mapping the technological landscape of and vaccines 

First:  modeling the evolution of via and application to the cyprus case
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  modeling the evolution of via and application to the cyprus case
Second:  does the pandemic spell the end for the direct 

First:  modeling the evolution of via and application to the cyprus case
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  modeling the evolution of via and application to the cyprus case
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  modeling the evolution of via and application to the cyprus case
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  modeling the evolution of via and application to the cyprus case
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  modeling the evolution of via and application to the cyprus case
Second:  editorial recommendations for the management of in countries 

First:  modeling the evolution of via and application to the cyprus case
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  modeling the evolution of via and application to the cyprus case
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  modeling the evolution of via and application to the cyprus case
Second:  letter to the editor 

First:  modeling the evolution of via and application to the cyprus case
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  modeling the evolution of via and application to the cyprus case
Second:  toxic and properties of an coordination complex of 

First:  modeling the evolution of via and application to the cyprus case
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  modeling the evolution of via and application to the cyprus case
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  modeling the evolution of via and application to the cyprus case
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  modeling the evolution of via and application to the cyprus case
Second:  potential of in vitro 

First:  modeling the evolution of via and application to the cyprus case
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  modeling the evolution of via and application to the cyprus case
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  modeling the evolution of via and application to the cyprus case
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  modeling the evolution of via and application to the cyprus case
Second:  establishment of a reference panel for the detection of antibodies 

First:  modeling the evolution of via and application to the cyprus case
Second:  synthesis and activity of derivatives and analogues thereof 

First:  modeling the evolution of via and application to the cyprus case
Second:  genetic hypothesis and side of in 

First:  modeling the evolution of via and application to the cyprus case
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  modeling the evolution of via and application to the cyprus case
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  modeling the evolution of via and application to the cyprus case
Second:  and prognostic significance in 

First:  modeling the evolution of via and application to the cyprus case
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  modeling the evolution of via and application to the cyprus case
Second:  from ego to for ontology in the 

First:  modeling the evolution of via and application to the cyprus case
Second:  the sudden appearance of 

First:  modeling the evolution of via and application to the cyprus case
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  modeling the evolution of via and application to the cyprus case
Second:  school of population and global the university of evidence 

First:  modeling the evolution of via and application to the cyprus case
Second:  letters to the editor letters to the editor 

First:  modeling the evolution of via and application to the cyprus case
Second:  a visual analytics approach to facilitate the of online exams 

First:  modeling the evolution of via and application to the cyprus case
Second:  a protocol for a systematic review and 

First:  modeling the evolution of via and application to the cyprus case
Second:  early forecasting of the potential risk zones of in 

First:  modeling the evolution of via and application to the cyprus case
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  modeling the evolution of via and application to the cyprus case
Second:  and responses to in south a rapid qualitative assessment 

First:  modeling the evolution of via and application to the cyprus case
Second:  older experience of the a analysis of stresses and joys 

First:  modeling the evolution of via and application to the cyprus case
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  modeling the evolution of via and application to the cyprus case
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  modeling the evolution of via and application to the cyprus case
Second:  letters to the editor 

First:  modeling the evolution of via and application to the cyprus case
Second:  immigration policy and justice in the era of 

First:  modeling the evolution of via and application to the cyprus case
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  modeling the evolution of via and application to the cyprus case
Second:  the and ends of rnas is not 

First:  modeling the evolution of via and application to the cyprus case
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  modeling the evolution of via and application to the cyprus case
Second:  and the saga continues 

First:  modeling the evolution of via and application to the cyprus case
Second:  environmental research and public health the impact of on food results of a survey 

First:  modeling the evolution of via and application to the cyprus case
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  modeling the evolution of via and application to the cyprus case
Second:  how can blockchain help people in the event of pandemics such as the 

First:  modeling the evolution of via and application to the cyprus case
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  modeling the evolution of via and application to the cyprus case
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  modeling the evolution of via and application to the cyprus case
Second:  recent advancements in the and prospective drug therapy of 

First:  modeling the evolution of via and application to the cyprus case
Second:  infectious disease and the case for considering impacts 

First:  modeling the evolution of via and application to the cyprus case
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  modeling the evolution of via and application to the cyprus case
Second:  the impact of and homeschooling on engagement with physical activity 

First:  modeling the evolution of via and application to the cyprus case
Second:  a look in the how the field of behavior analysis can become 

First:  modeling the evolution of via and application to the cyprus case
Second:  levels of and in the lungs of pneumonia patients 

First:  modeling the evolution of via and application to the cyprus case
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  modeling the evolution of via and application to the cyprus case
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  modeling the evolution of via and application to the cyprus case
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  modeling the evolution of via and application to the cyprus case
Second:  tracing and analysis of early infections outside a modeling study 

First:  modeling the evolution of via and application to the cyprus case
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  modeling the evolution of via and application to the cyprus case
Second:  epidemiology and infection from the field 

First:  modeling the evolution of via and application to the cyprus case
Second:  design and analysis of a tweets dataset 

First:  modeling the evolution of via and application to the cyprus case
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  modeling the evolution of via and application to the cyprus case
Second:  the impacts of on children 

First:  modeling the evolution of via and application to the cyprus case
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  modeling the evolution of via and application to the cyprus case
Second:  ultrasonography in the initial characterization of patients with 

First:  modeling the evolution of via and application to the cyprus case
Second:  forecast analysis of the epidemics trend of in the united states by a generalized seir model 

First:  modeling the evolution of via and application to the cyprus case
Second:  autopsy in the time of case report 

First:  modeling the evolution of via and application to the cyprus case
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  european geriatric medicine geriatric care in european countries where geriatric medicine is still emerging
Second:  journal of cancer research and clinical oncology 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  microorganisms nasal microbiota in rsv 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  a review in bacterial infections 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  combination kills bladder cancer cells synergistically 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  use of in human immunodeficiency virus infection 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  stress symptoms in hemodialysis patients with exposure 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  innate immunity to respiratory infection in early life 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  antiviral strategies to control infections 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  levels of and in the lungs of pneumonia patients 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  hallucinations due to therapeutic doses of 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  nitric oxide signalling in kidney regulation and health 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients
Second:  prolongation in patients using chloroquine 

First:  a new way to deal with relational problems associated with the epidemic
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  a new way to deal with relational problems associated with the epidemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  articles and trends among people with schizophrenia in a longitudinal cohort study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  articles and trends among people with schizophrenia in a longitudinal cohort study
Second:  and prognostic significance in 

First:  articles and trends among people with schizophrenia in a longitudinal cohort study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  articles and trends among people with schizophrenia in a longitudinal cohort study
Second:  recent advancements in the and prospective drug therapy of 

First:  articles and trends among people with schizophrenia in a longitudinal cohort study
Second:  socioeconomic correlates of obesity in and men and women 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  potent neutralizing antibodies elicited by vaccine candidate by the cell agonist 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  potential of in vitro 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  the function and inhibition by designed antiviral compounds 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  antiviral strategies to control infections 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  viral proteases as targets for chemotherapeutic intervention
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  declaration of competing interest
Second:  potential of in vitro 

First:  declaration of competing interest
Second:  the sudden appearance of 

First:  molecular docking and studies of allium indica and aethiopica isolates as potential drugs for
Second:  potential of in vitro 

First:  molecular docking and studies of allium indica and aethiopica isolates as potential drugs for
Second:  clinical potential of for assessing comparative analysis 

First:  reprogrammed suppresses replication and circumvents its mutational escape through mismatch tolerance
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  reprogrammed suppresses replication and circumvents its mutational escape through mismatch tolerance
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  emerging challenges and threats for dental health care sector attributable to tale of a developing country
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  emerging challenges and threats for dental health care sector attributable to tale of a developing country
Second:  influenza opportunities and challenges 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  mapping the technological landscape of and vaccines 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  editorial recommendations for the management of in countries 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  genetic hypothesis and side of in 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  and prognostic significance in 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  the sudden appearance of 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  school of population and global the university of evidence 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  early forecasting of the potential risk zones of in 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  investment and economic policy options in 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  older experience of the a analysis of stresses and joys 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  immigration policy and justice in the era of 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  environmental research and public health the impact of on food results of a survey 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  recent advancements in the and prospective drug therapy of 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  the impact of and homeschooling on engagement with physical activity 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  levels of and in the lungs of pneumonia patients 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values
Second:  the impacts of on children 

First:  building from the towards a approach for social work intervention facing social conflicts in vulnerable neighbourhoods
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  a study on the influence of the pandemic on incomes in greece 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  case report mammography in the diagnosis of breast 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  journal of cancer research and clinical oncology 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  viral intestinal infections of animals and man 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  predicting risk of transition to severe infection 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  potential of in vitro 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  a serological comparison of bovine coronavirus strains 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  early forecasting of the potential risk zones of in 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  use of in human immunodeficiency virus infection 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  more severe presentations of acute appendicitis during 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  recent advancements in the and prospective drug therapy of 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  infectious disease and the case for considering impacts 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  stress symptoms in hemodialysis patients with exposure 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  antiviral strategies to control infections 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  levels of and in the lungs of pneumonia patients 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  hallucinations due to therapeutic doses of 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  new causes and treatments for infectious diarrhea in children 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  epidemiology and infection from the field 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  influenza opportunities and challenges 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the impacts of on children 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  patients in is obesity or the real 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  prolongation in patients using chloroquine 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  ultrasonography in the initial characterization of patients with 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the fungal nature of pneumocystis 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  viral emerging challenges in developing vaccination strategies 

First:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  sites journal to appear current problems in diagnostic radiology current problems in diagnostic radiology
Second:  journal of cancer research and clinical oncology 

First:  inhibitors of virus recent developments and prospects
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  inhibitors of virus recent developments and prospects
Second:  mapping the technological landscape of and vaccines 

First:  inhibitors of virus recent developments and prospects
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  inhibitors of virus recent developments and prospects
Second:  spectrum of antimicrobial activity for disinfection of 

First:  inhibitors of virus recent developments and prospects
Second:  potential of in vitro 

First:  inhibitors of virus recent developments and prospects
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  inhibitors of virus recent developments and prospects
Second:  synthesis and activity of derivatives and analogues thereof 

First:  inhibitors of virus recent developments and prospects
Second:  and prognostic significance in 

First:  inhibitors of virus recent developments and prospects
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  inhibitors of virus recent developments and prospects
Second:  the sudden appearance of 

First:  inhibitors of virus recent developments and prospects
Second:  early forecasting of the potential risk zones of in 

First:  inhibitors of virus recent developments and prospects
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  inhibitors of virus recent developments and prospects
Second:  older experience of the a analysis of stresses and joys 

First:  inhibitors of virus recent developments and prospects
Second:  recent advancements in the and prospective drug therapy of 

First:  inhibitors of virus recent developments and prospects
Second:  infectious disease and the case for considering impacts 

First:  inhibitors of virus recent developments and prospects
Second:  clinical potential of for assessing comparative analysis 

First:  inhibitors of virus recent developments and prospects
Second:  levels of and in the lungs of pneumonia patients 

First:  inhibitors of virus recent developments and prospects
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  inhibitors of virus recent developments and prospects
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  inhibitors of virus recent developments and prospects
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  inhibitors of virus recent developments and prospects
Second:  influenza opportunities and challenges 

First:  governance challenges in many ples of involving programmes for mentally ill and individuals with substance government contracting
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  does the pandemic spell the end for the direct 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  toxic and properties of an coordination complex of 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  potential of in vitro 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  bacterial and the deadly trio in 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  supramolecular architecture of the coronavirus particle 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  establishment of a reference panel for the detection of antibodies 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  synthesis and activity of derivatives and analogues thereof 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  genetic hypothesis and side of in 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  and prognostic significance in 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the sudden appearance of 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  early forecasting of the potential risk zones of in 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  enhances the peroxidase activity of myoglobin against 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the and ends of rnas is not 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  recent advancements in the and prospective drug therapy of 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  cells the aging of t cells 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  a look in the how the field of behavior analysis can become 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  levels of and in the lungs of pneumonia patients 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  nitric oxide signalling in kidney regulation and health 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the impacts of on children 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  patients in is obesity or the real 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  ultrasonography in the initial characterization of patients with 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  the fungal nature of pneumocystis 

First:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla
Second:  autopsy in the time of case report 

First:  cme in deutschland nicht der lunge
Second:  von bei und lichen in der a des deutscher a , der deutschen gesellschaft fr und b , der gesellschaft fr und c , der sterreichischen gesellschaft fr und d , der gesellschaft fr und e , der sterreichischen gesellschaft fr f in mit der und g und der europischen akademie fr und h 

First:  cme in deutschland nicht der lunge
Second:  medizinische klinik einfhrung zum thema 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  journal of cancer research and clinical oncology 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  baseline chest in coronavirus disease association with clinical and laboratory data
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  development of rapid systematic survey of current practices and methods
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  development of rapid systematic survey of current practices and methods
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  development of rapid systematic survey of current practices and methods
Second:  mapping the technological landscape of and vaccines 

First:  development of rapid systematic survey of current practices and methods
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  development of rapid systematic survey of current practices and methods
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  development of rapid systematic survey of current practices and methods
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  development of rapid systematic survey of current practices and methods
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  development of rapid systematic survey of current practices and methods
Second:  editorial recommendations for the management of in countries 

First:  development of rapid systematic survey of current practices and methods
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  development of rapid systematic survey of current practices and methods
Second:  spectrum of antimicrobial activity for disinfection of 

First:  development of rapid systematic survey of current practices and methods
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  development of rapid systematic survey of current practices and methods
Second:  toxic and properties of an coordination complex of 

First:  development of rapid systematic survey of current practices and methods
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  development of rapid systematic survey of current practices and methods
Second:  potential of in vitro 

First:  development of rapid systematic survey of current practices and methods
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  development of rapid systematic survey of current practices and methods
Second:  establishment of a reference panel for the detection of antibodies 

First:  development of rapid systematic survey of current practices and methods
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  development of rapid systematic survey of current practices and methods
Second:  synthesis and activity of derivatives and analogues thereof 

First:  development of rapid systematic survey of current practices and methods
Second:  genetic hypothesis and side of in 

First:  development of rapid systematic survey of current practices and methods
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  development of rapid systematic survey of current practices and methods
Second:  and prognostic significance in 

First:  development of rapid systematic survey of current practices and methods
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  development of rapid systematic survey of current practices and methods
Second:  journal of management control 

First:  development of rapid systematic survey of current practices and methods
Second:  the sudden appearance of 

First:  development of rapid systematic survey of current practices and methods
Second:  school of population and global the university of evidence 

First:  development of rapid systematic survey of current practices and methods
Second:  early forecasting of the potential risk zones of in 

First:  development of rapid systematic survey of current practices and methods
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  development of rapid systematic survey of current practices and methods
Second:  integrating research integrity into the history of science 

First:  development of rapid systematic survey of current practices and methods
Second:  and responses to in south a rapid qualitative assessment 

First:  development of rapid systematic survey of current practices and methods
Second:  older experience of the a analysis of stresses and joys 

First:  development of rapid systematic survey of current practices and methods
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  development of rapid systematic survey of current practices and methods
Second:  journal of banking regulation 

First:  development of rapid systematic survey of current practices and methods
Second:  immigration policy and justice in the era of 

First:  development of rapid systematic survey of current practices and methods
Second:  environmental research and public health the impact of on food results of a survey 

First:  development of rapid systematic survey of current practices and methods
Second:  recent advancements in the and prospective drug therapy of 

First:  development of rapid systematic survey of current practices and methods
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  development of rapid systematic survey of current practices and methods
Second:  clinical potential of for assessing comparative analysis 

First:  development of rapid systematic survey of current practices and methods
Second:  the impact of and homeschooling on engagement with physical activity 

First:  development of rapid systematic survey of current practices and methods
Second:  levels of and in the lungs of pneumonia patients 

First:  development of rapid systematic survey of current practices and methods
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  development of rapid systematic survey of current practices and methods
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  development of rapid systematic survey of current practices and methods
Second:  tracing and analysis of early infections outside a modeling study 

First:  development of rapid systematic survey of current practices and methods
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  development of rapid systematic survey of current practices and methods
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  development of rapid systematic survey of current practices and methods
Second:  design and analysis of a tweets dataset 

First:  development of rapid systematic survey of current practices and methods
Second:  the impacts of on children 

First:  development of rapid systematic survey of current practices and methods
Second:  ultrasonography in the initial characterization of patients with 

First:  development of rapid systematic survey of current practices and methods
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  development of rapid systematic survey of current practices and methods
Second:  modeling the evolution of via and application to the cyprus case 

First:  development of rapid systematic survey of current practices and methods
Second:  inhibitors of virus recent developments and prospects 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  a study on the influence of the pandemic on incomes in greece 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  mapping the technological landscape of and vaccines 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  potential of in vitro 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  bacterial and the deadly trio in 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  genetic hypothesis and side of in 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  and prognostic significance in 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the sudden appearance of 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  early forecasting of the potential risk zones of in 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  older experience of the a analysis of stresses and joys 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  immigration policy and justice in the era of 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the and ends of rnas is not 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  and the saga continues 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  recent advancements in the and prospective drug therapy of 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  infectious disease and the case for considering impacts 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the impact of and homeschooling on engagement with physical activity 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  a look in the how the field of behavior analysis can become 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  levels of and in the lungs of pneumonia patients 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  epidemiology and infection from the field 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the impacts of on children 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  ultrasonography in the initial characterization of patients with 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  socioeconomic correlates of obesity in and men and women 

First:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  viral intestinal infections of animals and man 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  microorganisms nasal microbiota in rsv 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  molecular and cellular biochemistry derived peptides with mhc binding motifs from canine mammary tumor tissue elicit strong responses in mice 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  a serological comparison of bovine coronavirus strains 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  combination kills bladder cancer cells synergistically 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  use of in human immunodeficiency virus infection 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  an mrna vaccine protects mice against multiple infections 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  stress symptoms in hemodialysis patients with exposure 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  antiviral strategies to control infections 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  prolongation in patients using chloroquine 

First:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria
Second:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients 

First:  radiation therapy considerations during the literature review and expert opinions
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  radiation therapy considerations during the literature review and expert opinions
Second:  recent advancements in the and prospective drug therapy of 

First:  radiation therapy considerations during the literature review and expert opinions
Second:  clinical potential of for assessing comparative analysis 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  potential of in vitro 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  bacterial and the deadly trio in 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  the sudden appearance of 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  early forecasting of the potential risk zones of in 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  older experience of the a analysis of stresses and joys 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  the and ends of rnas is not 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  recent advancements in the and prospective drug therapy of 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  levels of and in the lungs of pneumonia patients 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  the impacts of on children 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  ultrasonography in the initial characterization of patients with 

First:  presented moderately during two episodes of the infection with lack of antibody responses
Second:  the fungal nature of pneumocystis 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  stress symptoms in hemodialysis patients with exposure 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury
Second:  ultrasonography in the initial characterization of patients with 

First:  as a targeted immunization strategy
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  as a targeted immunization strategy
Second:  proactive strategy to improve staff engagement 

First:  as a targeted immunization strategy
Second:  potential of in vitro 

First:  as a targeted immunization strategy
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  as a targeted immunization strategy
Second:  a protocol for a systematic review and 

First:  as a targeted immunization strategy
Second:  therapy for a feasibility study 

First:  as a targeted immunization strategy
Second:  no time to repurposing of generic drugs as a multifaceted strategy against 

First:  as a targeted immunization strategy
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  as a targeted immunization strategy
Second:  antiviral strategies to control infections 

First:  as a targeted immunization strategy
Second:  viral emerging challenges in developing vaccination strategies 

First:  as a targeted immunization strategy
Second:  viral proteases as targets for chemotherapeutic intervention 

First:  as a targeted immunization strategy
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  performance of beef cows and their progeny to slaughter on intensive and extensive grassland management systems
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  principles for and professional ethical guidance in england and wales
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  principles for and professional ethical guidance in england and wales
Second:  editorial recommendations for the management of in countries 

First:  principles for and professional ethical guidance in england and wales
Second:  regular international perspectives and initiatives 

First:  principles for and professional ethical guidance in england and wales
Second:  and prognostic significance in 

First:  principles for and professional ethical guidance in england and wales
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  principles for and professional ethical guidance in england and wales
Second:  immigration policy and justice in the era of 

First:  principles for and professional ethical guidance in england and wales
Second:  recent advancements in the and prospective drug therapy of 

First:  in pandemic context systematic literature review
Second:  journal innovations in in the age of a systematic literature review 

First:  preparing for severe acute respiratory syndrome coronavirus lessons learned from hiv
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  preparing for severe acute respiratory syndrome coronavirus lessons learned from hiv
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  preparing for severe acute respiratory syndrome coronavirus lessons learned from hiv
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  preparing for severe acute respiratory syndrome coronavirus lessons learned from hiv
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  a analysis of global health research
Second:  journal of cancer research and clinical oncology 

First:  a analysis of global health research
Second:  mapping the technological landscape of and vaccines 

First:  a analysis of global health research
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  a analysis of global health research
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  a analysis of global health research
Second:  editorial recommendations for the management of in countries 

First:  a analysis of global health research
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  a analysis of global health research
Second:  basics of molecular biology 

First:  a analysis of global health research
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  a analysis of global health research
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  a analysis of global health research
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  a analysis of global health research
Second:  and prognostic significance in 

First:  a analysis of global health research
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  a analysis of global health research
Second:  journal of management control 

First:  a analysis of global health research
Second:  school of population and global the university of evidence 

First:  a analysis of global health research
Second:  a protocol for a systematic review and 

First:  a analysis of global health research
Second:  early forecasting of the potential risk zones of in 

First:  a analysis of global health research
Second:  therapy for a feasibility study 

First:  a analysis of global health research
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  a analysis of global health research
Second:  integrating research integrity into the history of science 

First:  a analysis of global health research
Second:  older experience of the a analysis of stresses and joys 

First:  a analysis of global health research
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  a analysis of global health research
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  a analysis of global health research
Second:  environmental research and public health the impact of on food results of a survey 

First:  a analysis of global health research
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  a analysis of global health research
Second:  international archives of occupational and environmental health 

First:  a analysis of global health research
Second:  recent advancements in the and prospective drug therapy of 

First:  a analysis of global health research
Second:  clinical potential of for assessing comparative analysis 

First:  a analysis of global health research
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  a analysis of global health research
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  a analysis of global health research
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  a analysis of global health research
Second:  tracing and analysis of early infections outside a modeling study 

First:  a analysis of global health research
Second:  design and analysis of a tweets dataset 

First:  a analysis of global health research
Second:  a database resource and online analysis tools for on a historical and global scale 

First:  a analysis of global health research
Second:  development of rapid systematic survey of current practices and methods 

First:  abo blood types and sepsis mortality
Second:  viral intestinal infections of animals and man 

First:  abo blood types and sepsis mortality
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  abo blood types and sepsis mortality
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  abo blood types and sepsis mortality
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  abo blood types and sepsis mortality
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  abo blood types and sepsis mortality
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  abo blood types and sepsis mortality
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  abo blood types and sepsis mortality
Second:  stress symptoms in hemodialysis patients with exposure 

First:  abo blood types and sepsis mortality
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  abo blood types and sepsis mortality
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  abo blood types and sepsis mortality
Second:  levels of and in the lungs of pneumonia patients 

First:  abo blood types and sepsis mortality
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  development of a vaccine candidate using a synthetic platform
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  development of a vaccine candidate using a synthetic platform
Second:  therapy for a feasibility study 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  viral intestinal infections of animals and man 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  potential of in vitro 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  cells the aging of t cells 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  levels of and in the lungs of pneumonia patients 

First:  the effects of polystyrene on human kidney proximal tubular epithelial cells and male mice
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  journal of cancer research and clinical oncology 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  potential of in vitro 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  and prognostic significance in 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  recent advancements in the and prospective drug therapy of 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  levels of and in the lungs of pneumonia patients 

First:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  journal of cancer research and clinical oncology 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  viral intestinal infections of animals and man 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  a review in bacterial infections 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  potential of in vitro 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  bacterial and the deadly trio in 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  synthesis and activity of derivatives and analogues thereof 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  genetic hypothesis and side of in 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  and prognostic significance in 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  recent advancements in the and prospective drug therapy of 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  infectious disease and the case for considering impacts 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  stress symptoms in hemodialysis patients with exposure 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  levels of and in the lungs of pneumonia patients 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  hallucinations due to therapeutic doses of 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  journal cardiac arrhythmias in a combination of viral and drug interactions
Second:  ultrasonography in the initial characterization of patients with 

First:  headache attributed to vaccination against with the a observational cohort study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  viral intestinal infections of animals and man 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  does the pandemic spell the end for the direct 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  a review in bacterial infections 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  is a host factor for infection 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  potential of in vitro 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  bacterial and the deadly trio in 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  a serological comparison of bovine coronavirus strains 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  and prognostic significance in 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the sudden appearance of 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  use of in human immunodeficiency virus infection 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  infectious disease and the case for considering impacts 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  levels of and in the lungs of pneumonia patients 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  epidemiology and infection from the field 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  patients in is obesity or the real 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  ultrasonography in the initial characterization of patients with 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the fungal nature of pneumocystis 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open
Second:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  genetic hypothesis and side of in 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  and prognostic significance in 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  the sudden appearance of 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  early forecasting of the potential risk zones of in 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  and the saga continues 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  recent advancements in the and prospective drug therapy of 

First:  has mortality due to other causes increased during the early evidence from england and wales
Second:  levels of and in the lungs of pneumonia patients 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  potential of in vitro 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  bacterial and the deadly trio in 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  genetic hypothesis and side of in 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  and prognostic significance in 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  the sudden appearance of 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  early forecasting of the potential risk zones of in 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  recent advancements in the and prospective drug therapy of 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  levels of and in the lungs of pneumonia patients 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  ultrasonography in the initial characterization of patients with 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  socioeconomic correlates of obesity in and men and women 

First:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality
Second:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  stress symptoms in hemodialysis patients with exposure 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  levels of and in the lungs of pneumonia patients 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  prolongation in patients using chloroquine 

First:  dexamethasone following in pediatric inflammatory syndrome in temporal association with
Second:  ultrasonography in the initial characterization of patients with 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  mapping the technological landscape of and vaccines 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  does the pandemic spell the end for the direct 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  spectrum of antimicrobial activity for disinfection of 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  predicting risk of transition to severe infection 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  potential of in vitro 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  bacterial and the deadly trio in 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  genetic hypothesis and side of in 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  and prognostic significance in 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the sudden appearance of 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  early forecasting of the potential risk zones of in 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  use of in human immunodeficiency virus infection 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the and ends of rnas is not 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  recent advancements in the and prospective drug therapy of 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  infectious disease and the case for considering impacts 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  levels of and in the lungs of pneumonia patients 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  epidemiology and infection from the field 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the impacts of on children 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  the fungal nature of pneumocystis 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  prediction of the incubation period for and future virus disease outbreaks
Second:  inhibitors of virus recent developments and prospects 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  mapping the technological landscape of and vaccines 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  editorial recommendations for the management of in countries 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  establishment of a reference panel for the detection of antibodies 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  journal of management control 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  the sudden appearance of 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  early forecasting of the potential risk zones of in 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  older experience of the a analysis of stresses and joys 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  recent advancements in the and prospective drug therapy of 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  levels of and in the lungs of pneumonia patients 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic
Second:  the impacts of on children 

First:  journal change in outdoor walking behavior during the coronavirus disease pandemic in a longitudinal study change in outdoor walking behavior during the coronavirus disease pandemic in a longitudinal study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  potential of in vitro 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  establishment of a reference panel for the detection of antibodies 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  the sudden appearance of 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  older experience of the a analysis of stresses and joys 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  recent advancements in the and prospective drug therapy of 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  clinical potential of for assessing comparative analysis 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  levels of and in the lungs of pneumonia patients 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors
Second:  the impacts of on children 

First:  avian influenza in human in timely management and preparedness
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  avian influenza in human in timely management and preparedness
Second:  mapping the technological landscape of and vaccines 

First:  avian influenza in human in timely management and preparedness
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  avian influenza in human in timely management and preparedness
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  avian influenza in human in timely management and preparedness
Second:  editorial recommendations for the management of in countries 

First:  avian influenza in human in timely management and preparedness
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  avian influenza in human in timely management and preparedness
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  avian influenza in human in timely management and preparedness
Second:  potential of in vitro 

First:  avian influenza in human in timely management and preparedness
Second:  bacterial and the deadly trio in 

First:  avian influenza in human in timely management and preparedness
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  avian influenza in human in timely management and preparedness
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  avian influenza in human in timely management and preparedness
Second:  and prognostic significance in 

First:  avian influenza in human in timely management and preparedness
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  avian influenza in human in timely management and preparedness
Second:  policy responses to the pandemic in vietnam 

First:  avian influenza in human in timely management and preparedness
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  avian influenza in human in timely management and preparedness
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  avian influenza in human in timely management and preparedness
Second:  use of in human immunodeficiency virus infection 

First:  avian influenza in human in timely management and preparedness
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  avian influenza in human in timely management and preparedness
Second:  international archives of occupational and environmental health 

First:  avian influenza in human in timely management and preparedness
Second:  recent advancements in the and prospective drug therapy of 

First:  avian influenza in human in timely management and preparedness
Second:  infectious disease and the case for considering impacts 

First:  avian influenza in human in timely management and preparedness
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  avian influenza in human in timely management and preparedness
Second:  levels of and in the lungs of pneumonia patients 

First:  avian influenza in human in timely management and preparedness
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  avian influenza in human in timely management and preparedness
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  avian influenza in human in timely management and preparedness
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  avian influenza in human in timely management and preparedness
Second:  epidemiology and infection from the field 

First:  avian influenza in human in timely management and preparedness
Second:  influenza opportunities and challenges 

First:  avian influenza in human in timely management and preparedness
Second:  socioeconomic correlates of obesity in and men and women 

First:  avian influenza in human in timely management and preparedness
Second:  viral emerging challenges in developing vaccination strategies 

First:  avian influenza in human in timely management and preparedness
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  targeting of host genes as an antiviral strategy
Second:  potential of in vitro 

First:  targeting of host genes as an antiviral strategy
Second:  antiviral strategies to control infections 

First:  targeting of host genes as an antiviral strategy
Second:  viral proteases as targets for chemotherapeutic intervention 

First:  targeting of host genes as an antiviral strategy
Second:  as a targeted immunization strategy 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  mapping the technological landscape of and vaccines 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  spectrum of antimicrobial activity for disinfection of 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  potential of in vitro 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  bacterial and the deadly trio in 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  the sudden appearance of 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  recent advancements in the and prospective drug therapy of 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  infectious disease and the case for considering impacts 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  levels of and in the lungs of pneumonia patients 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  epidemiology and infection from the field 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  transient dominant selection for the modification and generation of recombinant infectious bronchitis
Second:  the fungal nature of pneumocystis 

First:  engineered niches support the development of human dendritic cells in humanized mice
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  engineered niches support the development of human dendritic cells in humanized mice
Second:  potential of in vitro 

First:  engineered niches support the development of human dendritic cells in humanized mice
Second:  cells the aging of t cells 

First:  clinical features and management of rhino orbital in post patients
Second:  journal of cancer research and clinical oncology 

First:  clinical features and management of rhino orbital in post patients
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical features and management of rhino orbital in post patients
Second:  and prognostic significance in 

First:  clinical features and management of rhino orbital in post patients
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical features and management of rhino orbital in post patients
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical features and management of rhino orbital in post patients
Second:  recent advancements in the and prospective drug therapy of 

First:  clinical features and management of rhino orbital in post patients
Second:  levels of and in the lungs of pneumonia patients 

First:  clinical features and management of rhino orbital in post patients
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  clinical features and management of rhino orbital in post patients
Second:  ultrasonography in the initial characterization of patients with 

First:  chinese journal of academic radiology
Second:  journal of cancer research and clinical oncology 

First:  chinese journal of academic radiology
Second:  basics of molecular biology 

First:  chinese journal of academic radiology
Second:  journal of management control 

First:  chinese journal of academic radiology
Second:  journal of banking regulation 

First:  chinese journal of academic radiology
Second:  clinical potential of for assessing comparative analysis 

First:  journal airborne transmission of the world should face the reality
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  journal airborne transmission of the world should face the reality
Second:  does the pandemic spell the end for the direct 

First:  journal airborne transmission of the world should face the reality
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal airborne transmission of the world should face the reality
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  journal airborne transmission of the world should face the reality
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal airborne transmission of the world should face the reality
Second:  the sudden appearance of 

First:  journal airborne transmission of the world should face the reality
Second:  early forecasting of the potential risk zones of in 

First:  journal airborne transmission of the world should face the reality
Second:  older experience of the a analysis of stresses and joys 

First:  journal airborne transmission of the world should face the reality
Second:  the and ends of rnas is not 

First:  journal airborne transmission of the world should face the reality
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  journal airborne transmission of the world should face the reality
Second:  the impacts of on children 

First:  journal disaster management digitally exploring the impact and key determinants from the uk national disaster management experience disaster management digitally exploring the impact and key determinants from the uk national disaster management experience
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  laboratory techniques of veterinary clinical a review
Second:  journal of cancer research and clinical oncology 

First:  laboratory techniques of veterinary clinical a review
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  laboratory techniques of veterinary clinical a review
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  laboratory techniques of veterinary clinical a review
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  laboratory techniques of veterinary clinical a review
Second:  a review in bacterial infections 

First:  laboratory techniques of veterinary clinical a review
Second:  basics of molecular biology 

First:  laboratory techniques of veterinary clinical a review
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  laboratory techniques of veterinary clinical a review
Second:  potential of in vitro 

First:  laboratory techniques of veterinary clinical a review
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  laboratory techniques of veterinary clinical a review
Second:  a protocol for a systematic review and 

First:  laboratory techniques of veterinary clinical a review
Second:  therapy for a feasibility study 

First:  laboratory techniques of veterinary clinical a review
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  laboratory techniques of veterinary clinical a review
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  laboratory techniques of veterinary clinical a review
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  laboratory techniques of veterinary clinical a review
Second:  recent advancements in the and prospective drug therapy of 

First:  laboratory techniques of veterinary clinical a review
Second:  clinical potential of for assessing comparative analysis 

First:  laboratory techniques of veterinary clinical a review
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  laboratory techniques of veterinary clinical a review
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  laboratory techniques of veterinary clinical a review
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  laboratory techniques of veterinary clinical a review
Second:  ultrasonography in the initial characterization of patients with 

First:  laboratory techniques of veterinary clinical a review
Second:  world journal of clinical pediatrics pediatric surgery during the pandemic statement 

First:  laboratory techniques of veterinary clinical a review
Second:  a analysis of global health research 

First:  acute a review of diagnosis and based management
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  acute a review of diagnosis and based management
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  acute a review of diagnosis and based management
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  acute a review of diagnosis and based management
Second:  case report mammography in the diagnosis of breast 

First:  acute a review of diagnosis and based management
Second:  journal of cancer research and clinical oncology 

First:  acute a review of diagnosis and based management
Second:  mapping the technological landscape of and vaccines 

First:  acute a review of diagnosis and based management
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  acute a review of diagnosis and based management
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  acute a review of diagnosis and based management
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  acute a review of diagnosis and based management
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  acute a review of diagnosis and based management
Second:  editorial recommendations for the management of in countries 

First:  acute a review of diagnosis and based management
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  acute a review of diagnosis and based management
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  acute a review of diagnosis and based management
Second:  toxic and properties of an coordination complex of 

First:  acute a review of diagnosis and based management
Second:  a review in bacterial infections 

First:  acute a review of diagnosis and based management
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  acute a review of diagnosis and based management
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  acute a review of diagnosis and based management
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  acute a review of diagnosis and based management
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  acute a review of diagnosis and based management
Second:  establishment of a reference panel for the detection of antibodies 

First:  acute a review of diagnosis and based management
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  acute a review of diagnosis and based management
Second:  and prognostic significance in 

First:  acute a review of diagnosis and based management
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  acute a review of diagnosis and based management
Second:  journal of management control 

First:  acute a review of diagnosis and based management
Second:  the sudden appearance of 

First:  acute a review of diagnosis and based management
Second:  a protocol for a systematic review and 

First:  acute a review of diagnosis and based management
Second:  early forecasting of the potential risk zones of in 

First:  acute a review of diagnosis and based management
Second:  therapy for a feasibility study 

First:  acute a review of diagnosis and based management
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  acute a review of diagnosis and based management
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  acute a review of diagnosis and based management
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  acute a review of diagnosis and based management
Second:  and responses to in south a rapid qualitative assessment 

First:  acute a review of diagnosis and based management
Second:  older experience of the a analysis of stresses and joys 

First:  acute a review of diagnosis and based management
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  acute a review of diagnosis and based management
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  acute a review of diagnosis and based management
Second:  environmental research and public health the impact of on food results of a survey 

First:  acute a review of diagnosis and based management
Second:  recent advancements in the and prospective drug therapy of 

First:  acute a review of diagnosis and based management
Second:  infectious disease and the case for considering impacts 

First:  acute a review of diagnosis and based management
Second:  clinical potential of for assessing comparative analysis 

First:  acute a review of diagnosis and based management
Second:  levels of and in the lungs of pneumonia patients 

First:  acute a review of diagnosis and based management
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  acute a review of diagnosis and based management
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  acute a review of diagnosis and based management
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  acute a review of diagnosis and based management
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  acute a review of diagnosis and based management
Second:  epidemiology and infection from the field 

First:  acute a review of diagnosis and based management
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  acute a review of diagnosis and based management
Second:  design and analysis of a tweets dataset 

First:  acute a review of diagnosis and based management
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  acute a review of diagnosis and based management
Second:  the impacts of on children 

First:  acute a review of diagnosis and based management
Second:  ultrasonography in the initial characterization of patients with 

First:  acute a review of diagnosis and based management
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  acute a review of diagnosis and based management
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  acute a review of diagnosis and based management
Second:  a analysis of global health research 

First:  acute a review of diagnosis and based management
Second:  laboratory techniques of veterinary clinical a review 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  a study on the influence of the pandemic on incomes in greece 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  disease in the era of an observation on a series of six patients with 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  mapping the technological landscape of and vaccines 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  does the pandemic spell the end for the direct 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  editorial recommendations for the management of in countries 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the common missed instances and areas after years of education 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  potential of in vitro 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  bacterial and the deadly trio in 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  genetic hypothesis and side of in 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  and prognostic significance in 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the sudden appearance of 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  school of population and global the university of evidence 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  early forecasting of the potential risk zones of in 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  older experience of the a analysis of stresses and joys 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  immigration policy and justice in the era of 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the and ends of rnas is not 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  and the saga continues 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  recent advancements in the and prospective drug therapy of 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the impact of and homeschooling on engagement with physical activity 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  levels of and in the lungs of pneumonia patients 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  epidemiology and infection from the field 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  the impacts of on children 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  ultrasonography in the initial characterization of patients with 

First:  of coronavirus and with their bat hosts in the same geographical areas
Second:  socioeconomic correlates of obesity in and men and women 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  potential of in vitro 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  bacterial and the deadly trio in 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  and prognostic significance in 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  recent advancements in the and prospective drug therapy of 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  levels of and in the lungs of pneumonia patients 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  epidemiology and infection from the field 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung
Second:  ultrasonography in the initial characterization of patients with 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a study on the influence of the pandemic on incomes in greece 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal of cancer research and clinical oncology 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  mapping the technological landscape of and vaccines 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  linguistic methods in healthcare application and variants classification 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  and cell biology lung advances in generation and 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  analysis of computed tomography helps predict poor prognostic outcome in 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  editorial recommendations for the management of in countries 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a comparative analysis on risk communication between international and chinese literature from the perspective of knowledge domain visualization 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  toxic and properties of an coordination complex of 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  basics of molecular biology 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  potential of in vitro 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  bacterial and the deadly trio in 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  an epidemic model for in mathematical analysis and forecast 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  regular international perspectives and initiatives 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  correlation between weather and pandemic in an empirical investigation 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  task detection of persuasion techniques in texts and images 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  synthesis and activity of derivatives and analogues thereof 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  genetic hypothesis and side of in 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  and prognostic significance in 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal of management control 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  selected approaches to the assessment of environmental noise from railways in urban areas 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  school of population and global the university of evidence 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  early forecasting of the potential risk zones of in 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  investment and economic policy options in 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  edema assessment by means of the and laser scanning microscopy 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  integrating research integrity into the history of science 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  scenario modelling for the mitigation of deaths in intensive computer simulation study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  multivariate analysis to assist making in engineering optimization problems 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  and responses to in south a rapid qualitative assessment 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  older experience of the a analysis of stresses and joys 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  social determinants of mortality at the county level 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  immigration policy and justice in the era of 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  environmental research and public health the impact of on food results of a survey 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  international archives of occupational and environmental health 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  recent advancements in the and prospective drug therapy of 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  infectious disease and the case for considering impacts 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  clinical potential of for assessing comparative analysis 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  the impact of and homeschooling on engagement with physical activity 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a look in the how the field of behavior analysis can become 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  optimality in vaccination strategies determined by heterogeneity in interaction networks 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  levels of and in the lungs of pneumonia patients 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  temporal trends in rates of in hong kong people with and without a retrospective study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  international mass gatherings and a observational study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  tracing and analysis of early infections outside a modeling study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  epidemiology and infection from the field 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  influenza opportunities and challenges 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  design and analysis of a tweets dataset 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  the impacts of on children 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  ultrasonography in the initial characterization of patients with 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a database resource and online analysis tools for on a historical and global scale 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  socioeconomic correlates of obesity in and men and women 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  forecast analysis of the epidemics trend of in the united states by a generalized seir model 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  differences of clinical and imaging findings in multiple generations of secondary infection in china 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  modeling the evolution of via and application to the cyprus case 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  development of rapid systematic survey of current practices and methods 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  a analysis of global health research 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  avian influenza in human in timely management and preparedness 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  acute a review of diagnosis and based management 

First:  spatial and epidemiology modelling in the spatial and statistical assessments
Second:  of coronavirus and with their bat hosts in the same geographical areas 

First:  die der und ihre folgen einleitung
Second:  von bei und lichen in der a des deutscher a , der deutschen gesellschaft fr und b , der gesellschaft fr und c , der sterreichischen gesellschaft fr und d , der gesellschaft fr und e , der sterreichischen gesellschaft fr f in mit der und g und der europischen akademie fr und h 

First:  die der und ihre folgen einleitung
Second:  medizinische klinik einfhrung zum thema 

First:  die der und ihre folgen einleitung
Second:  cme in deutschland nicht der lunge 

First:  tap expression reduces expressing tumor infiltrating lymphocytes and restores against melanoma
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  tap expression reduces expressing tumor infiltrating lymphocytes and restores against melanoma
Second:  combination kills bladder cancer cells synergistically 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  a study on the influence of the pandemic on incomes in greece 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal innovations in in the age of a systematic literature review 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  disease in the era of an observation on a series of six patients with 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  mapping the technological landscape of and vaccines 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  does the pandemic spell the end for the direct 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  reply to against the risk of airborne 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  excess neurological death in new york city after the emergence of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  editorial recommendations for the management of in countries 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  policymaking and the wicked problem of sdg gender equality 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the impact on surgical departments of hospitals 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  letter to the editor 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  toxic and properties of an coordination complex of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the common missed instances and areas after years of education 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  concept of immune response 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  potential of in vitro 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  bacterial and the deadly trio in 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  establishment of a reference panel for the detection of antibodies 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  genetic hypothesis and side of in 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  tactics in support of migrations 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  and prognostic significance in 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  rapid communication case fatality risk of the variant of concern in november to february 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  from ego to for ontology in the 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  chapter from boom to the economic crisis 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the sudden appearance of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  policy responses to the pandemic in vietnam 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  school of population and global the university of evidence 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  letters to the editor letters to the editor 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  a protocol for a systematic review and 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  early forecasting of the potential risk zones of in 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  integrating research integrity into the history of science 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  a better understanding of social distancing 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  case report as a cause of unfavorable outcome in the twin pregnancy 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  eines in einer im der implementation of an operational concept in an ent clinic in the context of the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  older experience of the a analysis of stresses and joys 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  letters to the editor 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  immigration policy and justice in the era of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the and ends of rnas is not 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  and the saga continues 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  environmental research and public health the impact of on food results of a survey 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  how can blockchain help people in the event of pandemics such as the 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  recent advancements in the and prospective drug therapy of 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal the psychological status of people affected by the outbreak in china 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  infectious disease and the case for considering impacts 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the impact of and homeschooling on engagement with physical activity 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  a look in the how the field of behavior analysis can become 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  levels of and in the lungs of pneumonia patients 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  identifying the needs of prekindergarten a focus on and family environment 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  design and analysis of a tweets dataset 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the impacts of on children 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  understanding during a a case of universitas indonesia 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  patients in is obesity or the real 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  policy forum implications of an international consortium project of the european commission 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  ultrasonography in the initial characterization of patients with 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the fungal nature of pneumocystis 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  forecast analysis of the epidemics trend of in the united states by a generalized seir model 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  autopsy in the time of case report 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  modeling the evolution of via and application to the cyprus case 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  development of rapid systematic survey of current practices and methods 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  journal airborne transmission of the world should face the reality 

First:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis
Second:  acute a review of diagnosis and based management 

First:  the home bias and the local a survey
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the home bias and the local a survey
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the home bias and the local a survey
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  the home bias and the local a survey
Second:  a remedy or a ripple in severe 

First:  the home bias and the local a survey
Second:  journal of antibodies against in a large national hospital and affiliated facility in japan of antibodies against in a large national hospital and affiliated facility in japan 

First:  the home bias and the local a survey
Second:  journal innovations in in the age of a systematic literature review 

First:  the home bias and the local a survey
Second:  disease in the era of an observation on a series of six patients with 

First:  the home bias and the local a survey
Second:  mapping the technological landscape of and vaccines 

First:  the home bias and the local a survey
Second:  suicide in the context of diagnosis in insights and implications from online print media reports 

First:  the home bias and the local a survey
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the home bias and the local a survey
Second:  does the pandemic spell the end for the direct 

First:  the home bias and the local a survey
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the home bias and the local a survey
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  the home bias and the local a survey
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the home bias and the local a survey
Second:  reply to against the risk of airborne 

First:  the home bias and the local a survey
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  the home bias and the local a survey
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  the home bias and the local a survey
Second:  editorial recommendations for the management of in countries 

First:  the home bias and the local a survey
Second:  the perceptions of anatomy teachers for different majors during the a national chinese survey 

First:  the home bias and the local a survey
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the home bias and the local a survey
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the home bias and the local a survey
Second:  behaviour during the pandemic among saudi a study what were the main where and on whom will the research have 

First:  the home bias and the local a survey
Second:  the impact on surgical departments of hospitals 

First:  the home bias and the local a survey
Second:  letter to the editor 

First:  the home bias and the local a survey
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  the home bias and the local a survey
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the home bias and the local a survey
Second:  article availability of and training status of health professionals on in southern ethiopia availability of and training status of health professionals on in southern ethiopia 

First:  the home bias and the local a survey
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the home bias and the local a survey
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  the home bias and the local a survey
Second:  the common missed instances and areas after years of education 

First:  the home bias and the local a survey
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the home bias and the local a survey
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the home bias and the local a survey
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the home bias and the local a survey
Second:  potential of in vitro 

First:  the home bias and the local a survey
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  the home bias and the local a survey
Second:  bacterial and the deadly trio in 

First:  the home bias and the local a survey
Second:  protecting the health in reflections on policy deliberation and the role of civil society in democracy 

First:  the home bias and the local a survey
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  the home bias and the local a survey
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the home bias and the local a survey
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  the home bias and the local a survey
Second:  establishment of a reference panel for the detection of antibodies 

First:  the home bias and the local a survey
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the home bias and the local a survey
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  the home bias and the local a survey
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  the home bias and the local a survey
Second:  genetic hypothesis and side of in 

First:  the home bias and the local a survey
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  the home bias and the local a survey
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  the home bias and the local a survey
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the home bias and the local a survey
Second:  and prognostic significance in 

First:  the home bias and the local a survey
Second:  the future of medical scribes documenting in the electronic health results of an expert consensus conference 

First:  the home bias and the local a survey
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the home bias and the local a survey
Second:  from ego to for ontology in the 

First:  the home bias and the local a survey
Second:  the sudden appearance of 

First:  the home bias and the local a survey
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  the home bias and the local a survey
Second:  school of population and global the university of evidence 

First:  the home bias and the local a survey
Second:  letters to the editor letters to the editor 

First:  the home bias and the local a survey
Second:  a protocol for a systematic review and 

First:  the home bias and the local a survey
Second:  early forecasting of the potential risk zones of in 

First:  the home bias and the local a survey
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  the home bias and the local a survey
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  the home bias and the local a survey
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  the home bias and the local a survey
Second:  changes in the frequency and experiences of visits to green space following restrictions on movement during the a nationally representative sectional study of uk adults 

First:  the home bias and the local a survey
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  the home bias and the local a survey
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  the home bias and the local a survey
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the home bias and the local a survey
Second:  does twitter affect stock market financial sentiment analysis during a comparative study of the and the periods 

First:  the home bias and the local a survey
Second:  and responses to in south a rapid qualitative assessment 

First:  the home bias and the local a survey
Second:  older experience of the a analysis of stresses and joys 

First:  the home bias and the local a survey
Second:  tracking the twitter attention around the research efforts on the pandemic 

First:  the home bias and the local a survey
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  the home bias and the local a survey
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the home bias and the local a survey
Second:  letters to the editor 

First:  the home bias and the local a survey
Second:  immigration policy and justice in the era of 

First:  the home bias and the local a survey
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  the home bias and the local a survey
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  the home bias and the local a survey
Second:  the and ends of rnas is not 

First:  the home bias and the local a survey
Second:  the cost of getting is it time for change in the adult reconstruction fellowship application 

First:  the home bias and the local a survey
Second:  is the mother of specialist palliative care service innovation and practice change in response to results from a multinational survey 

First:  the home bias and the local a survey
Second:  and the saga continues 

First:  the home bias and the local a survey
Second:  environmental research and public health the impact of on food results of a survey 

First:  the home bias and the local a survey
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  the home bias and the local a survey
Second:  how can blockchain help people in the event of pandemics such as the 

First:  the home bias and the local a survey
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the home bias and the local a survey
Second:  of infection among children in hospital zagreb during the initial and second wave of pandemic in croatia 

First:  the home bias and the local a survey
Second:  morocco achieves the highest vaccine rates in africa in the first what are reasons for its 

First:  the home bias and the local a survey
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the home bias and the local a survey
Second:  recent advancements in the and prospective drug therapy of 

First:  the home bias and the local a survey
Second:  journal the psychological status of people affected by the outbreak in china 

First:  the home bias and the local a survey
Second:  infectious disease and the case for considering impacts 

First:  the home bias and the local a survey
Second:  human rights and a comment on the bath protocol 

First:  the home bias and the local a survey
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  the home bias and the local a survey
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  the home bias and the local a survey
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  the home bias and the local a survey
Second:  the impact of and homeschooling on engagement with physical activity 

First:  the home bias and the local a survey
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  the home bias and the local a survey
Second:  foreign ministry of social services and equality of spain in delegation of the spanish government in catalonia 

First:  the home bias and the local a survey
Second:  a look in the how the field of behavior analysis can become 

First:  the home bias and the local a survey
Second:  journal independent restaurant operator perspectives in the wake of the pandemic independent restaurant operator perspectives in the wake of the pandemic 

First:  the home bias and the local a survey
Second:  levels of and in the lungs of pneumonia patients 

First:  the home bias and the local a survey
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the home bias and the local a survey
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the home bias and the local a survey
Second:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the 

First:  the home bias and the local a survey
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the home bias and the local a survey
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  the home bias and the local a survey
Second:  identifying the needs of prekindergarten a focus on and family environment 

First:  the home bias and the local a survey
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  the home bias and the local a survey
Second:  tracing and analysis of early infections outside a modeling study 

First:  the home bias and the local a survey
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  the home bias and the local a survey
Second:  epidemiology and infection from the field 

First:  the home bias and the local a survey
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  the home bias and the local a survey
Second:  design and analysis of a tweets dataset 

First:  the home bias and the local a survey
Second:  trends and geographical variation in population struggling and suffering across the a retrospective repeated sectional study 

First:  the home bias and the local a survey
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the home bias and the local a survey
Second:  the impacts of on children 

First:  the home bias and the local a survey
Second:  patients in is obesity or the real 

First:  the home bias and the local a survey
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  the home bias and the local a survey
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  the home bias and the local a survey
Second:  ultrasonography in the initial characterization of patients with 

First:  the home bias and the local a survey
Second:  socioeconomic correlates of obesity in and men and women 

First:  the home bias and the local a survey
Second:  forecast analysis of the epidemics trend of in the united states by a generalized seir model 

First:  the home bias and the local a survey
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  the home bias and the local a survey
Second:  mapping the burden of diabetes in five small countries in europe and setting the agenda for health policy and strategic action open access 

First:  the home bias and the local a survey
Second:  autopsy in the time of case report 

First:  the home bias and the local a survey
Second:  modeling the evolution of via and application to the cyprus case 

First:  the home bias and the local a survey
Second:  journal economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values economic diversification and the resiliency evidence from the impact of natural disasters on regional housing values 

First:  the home bias and the local a survey
Second:  development of rapid systematic survey of current practices and methods 

First:  the home bias and the local a survey
Second:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland 

First:  the home bias and the local a survey
Second:  of coronavirus and with their bat hosts in the same geographical areas 

First:  the home bias and the local a survey
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  the home bias and the local a survey
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  and analysis of crime dynamics amidst social distancing protocols supporting information
Second:  a better understanding of social distancing 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  a study on the influence of the pandemic on incomes in greece 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  mapping the technological landscape of and vaccines 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  does the pandemic spell the end for the direct 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  editorial recommendations for the management of in countries 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  potential of in vitro 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  bacterial and the deadly trio in 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  genetic hypothesis and side of in 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  and prognostic significance in 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the sudden appearance of 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  early forecasting of the potential risk zones of in 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  journal changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide changes in poisoning during the pandemic worldwide 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  older experience of the a analysis of stresses and joys 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  immigration policy and justice in the era of 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the and ends of rnas is not 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  and the saga continues 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  environmental research and public health the impact of on food results of a survey 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  recent advancements in the and prospective drug therapy of 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  infectious disease and the case for considering impacts 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the impact of and homeschooling on engagement with physical activity 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  levels of and in the lungs of pneumonia patients 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  epidemiology and infection from the field 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  influenza opportunities and challenges 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the impacts of on children 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  ultrasonography in the initial characterization of patients with 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  socioeconomic correlates of obesity in and men and women 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  avian influenza in human in timely management and preparedness 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic
Second:  the home bias and the local a survey 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  disease in the era of an observation on a series of six patients with 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  mapping the technological landscape of and vaccines 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  does the pandemic spell the end for the direct 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the impact on surgical departments of hospitals 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  potential of in vitro 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  bacterial and the deadly trio in 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  genetic hypothesis and side of in 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  and prognostic significance in 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the sudden appearance of 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  school of population and global the university of evidence 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  early forecasting of the potential risk zones of in 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  older experience of the a analysis of stresses and joys 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  immigration policy and justice in the era of 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the and ends of rnas is not 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  environmental research and public health the impact of on food results of a survey 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  recent advancements in the and prospective drug therapy of 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  infectious disease and the case for considering impacts 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the impact of and homeschooling on engagement with physical activity 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  levels of and in the lungs of pneumonia patients 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  impact of the pandemic on emergency medicine insights from faculty and residents 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  epidemiology and infection from the field 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the impacts of on children 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  ultrasonography in the initial characterization of patients with 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  socioeconomic correlates of obesity in and men and women 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia
Second:  the home bias and the local a survey 

First:  hey what should i comparing the use of social and algorithmic recommendations for different reading genres
Second:  and what evidence needs our 

First:  porcine type enteric an independent condition or part of the systemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  porcine type enteric an independent condition or part of the systemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  porcine type enteric an independent condition or part of the systemic
Second:  the sudden appearance of 

First:  porcine type enteric an independent condition or part of the systemic
Second:  levels of and in the lungs of pneumonia patients 

First:  porcine type enteric an independent condition or part of the systemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  porcine type enteric an independent condition or part of the systemic
Second:  the fungal nature of pneumocystis 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  case report mammography in the diagnosis of breast 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  journal of cancer research and clinical oncology 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  viral intestinal infections of animals and man 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  potential of in vitro 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  use of in human immunodeficiency virus infection 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  recent advancements in the and prospective drug therapy of 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  stress symptoms in hemodialysis patients with exposure 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  clinical potential of for assessing comparative analysis 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  levels of and in the lungs of pneumonia patients 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  epidemiology and infection from the field 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  ultrasonography in the initial characterization of patients with 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  world journal of clinical pediatrics pediatric surgery during the pandemic statement 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  the fungal nature of pneumocystis 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic
Second:  laboratory techniques of veterinary clinical a review 

First:  epidemiology and infection prevention and control
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  epidemiology and infection prevention and control
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  epidemiology and infection prevention and control
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  epidemiology and infection prevention and control
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  epidemiology and infection prevention and control
Second:  case report mammography in the diagnosis of breast 

First:  epidemiology and infection prevention and control
Second:  journal of cancer research and clinical oncology 

First:  epidemiology and infection prevention and control
Second:  mapping the technological landscape of and vaccines 

First:  epidemiology and infection prevention and control
Second:  evaluation of the igg antibody response to sars infection and performance of a lateral flow and longitudinal analysis over months 

First:  epidemiology and infection prevention and control
Second:  viral intestinal infections of animals and man 

First:  epidemiology and infection prevention and control
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  epidemiology and infection prevention and control
Second:  and cell biology lung advances in generation and 

First:  epidemiology and infection prevention and control
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  epidemiology and infection prevention and control
Second:  journal evaluation of internal and external surfaces used by health care workers and patients in wards 

First:  epidemiology and infection prevention and control
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  epidemiology and infection prevention and control
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  epidemiology and infection prevention and control
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  epidemiology and infection prevention and control
Second:  in ckd lessons from ckd patients with kidney disease 

First:  epidemiology and infection prevention and control
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  epidemiology and infection prevention and control
Second:  responding to healthcare disparities and challenges with access to care during 

First:  epidemiology and infection prevention and control
Second:  second wave of global pandemic and recommendations to better manage and optimize the modified lifestyle 

First:  epidemiology and infection prevention and control
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  epidemiology and infection prevention and control
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  epidemiology and infection prevention and control
Second:  editorial recommendations for the management of in countries 

First:  epidemiology and infection prevention and control
Second:  solid and suspension microarrays for microbial diagnostics 

First:  epidemiology and infection prevention and control
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  epidemiology and infection prevention and control
Second:  first clinical presentation and phylogenetic characterization of porcine epidemic diarrhea virus in austria 

First:  epidemiology and infection prevention and control
Second:  prophylaxis of with and chloroquine accepted article 

First:  epidemiology and infection prevention and control
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  epidemiology and infection prevention and control
Second:  quercetin as a potential treatment for acute kidney based on network pharmacology and molecular docking study 

First:  epidemiology and infection prevention and control
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  epidemiology and infection prevention and control
Second:  tropical medicine and infectious disease impact of the pandemic on tuberculosis an overview 

First:  epidemiology and infection prevention and control
Second:  the impact on surgical departments of hospitals 

First:  epidemiology and infection prevention and control
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  epidemiology and infection prevention and control
Second:  open forum infectious diseases comparison of rates of hospitalization between single and dual virus detection in a mexican cohort of children and adults with illness 

First:  epidemiology and infection prevention and control
Second:  human infections associated with wild birds 

First:  epidemiology and infection prevention and control
Second:  spectrum of antimicrobial activity for disinfection of 

First:  epidemiology and infection prevention and control
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  epidemiology and infection prevention and control
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  epidemiology and infection prevention and control
Second:  toxic and properties of an coordination complex of 

First:  epidemiology and infection prevention and control
Second:  laboratory mice driving force in and immunotherapy studies of human multiple myeloma 

First:  epidemiology and infection prevention and control
Second:  a review in bacterial infections 

First:  epidemiology and infection prevention and control
Second:  predicting risk of transition to severe infection 

First:  epidemiology and infection prevention and control
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  epidemiology and infection prevention and control
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  epidemiology and infection prevention and control
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  epidemiology and infection prevention and control
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  epidemiology and infection prevention and control
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  epidemiology and infection prevention and control
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  epidemiology and infection prevention and control
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  epidemiology and infection prevention and control
Second:  concept of immune response 

First:  epidemiology and infection prevention and control
Second:  potential of in vitro 

First:  epidemiology and infection prevention and control
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  epidemiology and infection prevention and control
Second:  remote monitoring empowerment of patients with during the pandemic 

First:  epidemiology and infection prevention and control
Second:  bacterial and the deadly trio in 

First:  epidemiology and infection prevention and control
Second:  potential use of ivermectin and drugs in fighting scope and relevance 

First:  epidemiology and infection prevention and control
Second:  journal incidence of pulmonary embolism in patients with respiratory support during outbreak credit author statement incidence of pulmonary embolism in patients with invasive respiratory support during outbreak 

First:  epidemiology and infection prevention and control
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  epidemiology and infection prevention and control
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  epidemiology and infection prevention and control
Second:  a serological comparison of bovine coronavirus strains 

First:  epidemiology and infection prevention and control
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  epidemiology and infection prevention and control
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  epidemiology and infection prevention and control
Second:  synthesis and activity of derivatives and analogues thereof 

First:  epidemiology and infection prevention and control
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  epidemiology and infection prevention and control
Second:  the epidemiology of invasive meningococcal disease in the kingdom of saudi a narrative review with updated analysis 

First:  epidemiology and infection prevention and control
Second:  genetic hypothesis and side of in 

First:  epidemiology and infection prevention and control
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  epidemiology and infection prevention and control
Second:  and prognostic significance in 

First:  epidemiology and infection prevention and control
Second:  implications for people with chagas disease 

First:  epidemiology and infection prevention and control
Second:  langerhans cells and play redundant roles in induced protective influenza and responses 

First:  epidemiology and infection prevention and control
Second:  journal fungal in patients with role of antifungal 

First:  epidemiology and infection prevention and control
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  epidemiology and infection prevention and control
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  epidemiology and infection prevention and control
Second:  journal of management control 

First:  epidemiology and infection prevention and control
Second:  journal and bleeding risk in unsolved question 

First:  epidemiology and infection prevention and control
Second:  animal models for sars and mers 

First:  epidemiology and infection prevention and control
Second:  mortality rates due to respiratory tract diseases in iran during a study 

First:  epidemiology and infection prevention and control
Second:  the function and inhibition by designed antiviral compounds 

First:  epidemiology and infection prevention and control
Second:  evaluation of enhancement of infection in rhesus macaques immunized with an inactivated vaccine 

First:  epidemiology and infection prevention and control
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  epidemiology and infection prevention and control
Second:  the cutting edge of thoracic anesthesia during the coronavirus disease outbreak 

First:  epidemiology and infection prevention and control
Second:  early forecasting of the potential risk zones of in 

First:  epidemiology and infection prevention and control
Second:  supporting information induced by combination therapy of chloroquine and in human embryonic stem cardiomyocytes 

First:  epidemiology and infection prevention and control
Second:  controlling epidemics through optimal allocation of test kits and vaccine doses across networks 

First:  epidemiology and infection prevention and control
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  epidemiology and infection prevention and control
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  epidemiology and infection prevention and control
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  epidemiology and infection prevention and control
Second:  journal radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery radiology department financial impact and planning for recovery 

First:  epidemiology and infection prevention and control
Second:  in a comprehensive investigation from exposure to treatment outcomes 

First:  epidemiology and infection prevention and control
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  epidemiology and infection prevention and control
Second:  letter to the editor are patients with autoimmune disease at greater risk of developing severe 

First:  epidemiology and infection prevention and control
Second:  investment and economic policy options in 

First:  epidemiology and infection prevention and control
Second:  edema assessment by means of the and laser scanning microscopy 

First:  epidemiology and infection prevention and control
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  epidemiology and infection prevention and control
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  epidemiology and infection prevention and control
Second:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education 

First:  epidemiology and infection prevention and control
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  epidemiology and infection prevention and control
Second:  knowledge and attitude towards and its prevention in selected ten towns of survey 

First:  epidemiology and infection prevention and control
Second:  epidemiological transition of in india from higher to lower hdi states and implications for prevention and control 

First:  epidemiology and infection prevention and control
Second:  conducting focus groups in neurodegenerative disease ethical and methodological considerations 

First:  epidemiology and infection prevention and control
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  epidemiology and infection prevention and control
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  epidemiology and infection prevention and control
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  epidemiology and infection prevention and control
Second:  activity of world health formulations against enveloped including and emerging 

First:  epidemiology and infection prevention and control
Second:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase 

First:  epidemiology and infection prevention and control
Second:  and rapid nucleic acid detection of african swine fever 

First:  epidemiology and infection prevention and control
Second:  depression and sleep quality in patients undergoing 

First:  epidemiology and infection prevention and control
Second:  care for people with disease and related during from challenges to solutions 

First:  epidemiology and infection prevention and control
Second:  and molecular hybrids of and acids as novel b virus agents 

First:  epidemiology and infection prevention and control
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  epidemiology and infection prevention and control
Second:  use of in human immunodeficiency virus infection 

First:  epidemiology and infection prevention and control
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  epidemiology and infection prevention and control
Second:  journal hiv and impact on vulnerable population and harnessing lessons learnt from hiv programs hiv and impact on vulnerable population and harnessing lessons learnt from hiv programs hiv and impact on vulnerable population and harnessing lessons learnt from hiv programs 

First:  epidemiology and infection prevention and control
Second:  effects of interval training and training on and resilience in healthy adults during coronavirus disease a randomized controlled trial 

First:  epidemiology and infection prevention and control
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  epidemiology and infection prevention and control
Second:  regression of infantile glioblastoma after treatment with 

First:  epidemiology and infection prevention and control
Second:  diffusion as a first model of spread of viral infection 

First:  epidemiology and infection prevention and control
Second:  journal long rna review and implications in acute lung inflammation long rna review and implications in acute lung inflammation 

First:  epidemiology and infection prevention and control
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  epidemiology and infection prevention and control
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  epidemiology and infection prevention and control
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  epidemiology and infection prevention and control
Second:  vaccination in patients with multiple focus on immune response vaccination and immune response in mm 

First:  epidemiology and infection prevention and control
Second:  psychological symptoms in spanish and portuguese youth during the health a longitudinal study 

First:  epidemiology and infection prevention and control
Second:  using gps technology to quantify human dynamic contacts and infectious disease dynamics in a urban environment 

First:  epidemiology and infection prevention and control
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  epidemiology and infection prevention and control
Second:  environmental research and public health the impact of on food results of a survey 

First:  epidemiology and infection prevention and control
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  epidemiology and infection prevention and control
Second:  international archives of occupational and environmental health 

First:  epidemiology and infection prevention and control
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  epidemiology and infection prevention and control
Second:  to appear advances in oral and maxillofacial surgery 

First:  epidemiology and infection prevention and control
Second:  integrated molecular docking with network pharmacology to reveal the molecular mechanism of powder in the treatment of acute arthritis 

First:  epidemiology and infection prevention and control
Second:  journal entry in host targets for treatment and prevention 

First:  epidemiology and infection prevention and control
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  epidemiology and infection prevention and control
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  epidemiology and infection prevention and control
Second:  building momentum for malaria vaccine research and key considerations 

First:  epidemiology and infection prevention and control
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  epidemiology and infection prevention and control
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  epidemiology and infection prevention and control
Second:  recent advancements in the and prospective drug therapy of 

First:  epidemiology and infection prevention and control
Second:  morbidity and mortality weekly report 

First:  epidemiology and infection prevention and control
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  epidemiology and infection prevention and control
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  epidemiology and infection prevention and control
Second:  infectious disease and the case for considering impacts 

First:  epidemiology and infection prevention and control
Second:  stress symptoms in hemodialysis patients with exposure 

First:  epidemiology and infection prevention and control
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  epidemiology and infection prevention and control
Second:  distinct cellular immune profiles in the airways and blood of critically ill patients with consortium and the amsterdam umc study group respiratory infection 

First:  epidemiology and infection prevention and control
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  epidemiology and infection prevention and control
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  epidemiology and infection prevention and control
Second:  clinical potential of for assessing comparative analysis 

First:  epidemiology and infection prevention and control
Second:  the impact of and homeschooling on engagement with physical activity 

First:  epidemiology and infection prevention and control
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  epidemiology and infection prevention and control
Second:  clinical characteristics of death cases with 

First:  epidemiology and infection prevention and control
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  epidemiology and infection prevention and control
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  epidemiology and infection prevention and control
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  epidemiology and infection prevention and control
Second:  innate immunity to respiratory infection in early life 

First:  epidemiology and infection prevention and control
Second:  clinical study viral aetiology in adults with acute upper respiratory tract infection in northern china 

First:  epidemiology and infection prevention and control
Second:  antiviral strategies to control infections 

First:  epidemiology and infection prevention and control
Second:  antimicrobial and cytotoxic activities of some novel clubbed 

First:  epidemiology and infection prevention and control
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  epidemiology and infection prevention and control
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  epidemiology and infection prevention and control
Second:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia 

First:  epidemiology and infection prevention and control
Second:  levels of and in the lungs of pneumonia patients 

First:  epidemiology and infection prevention and control
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  epidemiology and infection prevention and control
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  epidemiology and infection prevention and control
Second:  scientific rationale for a approach to target the host response in order to try and reduce the numbers presenting with adult respiratory distress syndrome associated with is there a role for statins and inhibitors in the prevention and early treatment of the 

First:  epidemiology and infection prevention and control
Second:  optimizing medication management during the an implementation guide for and care 

First:  epidemiology and infection prevention and control
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  epidemiology and infection prevention and control
Second:  impact of the pandemic on emergency medicine insights from faculty and residents 

First:  epidemiology and infection prevention and control
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  epidemiology and infection prevention and control
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  epidemiology and infection prevention and control
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  epidemiology and infection prevention and control
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  epidemiology and infection prevention and control
Second:  in vitro b and sars virus activities of a 

First:  epidemiology and infection prevention and control
Second:  hallucinations due to therapeutic doses of 

First:  epidemiology and infection prevention and control
Second:  high resolution analysis of respiratory virus infection in vivo 

First:  epidemiology and infection prevention and control
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  epidemiology and infection prevention and control
Second:  tracing and analysis of early infections outside a modeling study 

First:  epidemiology and infection prevention and control
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  epidemiology and infection prevention and control
Second:  nitric oxide signalling in kidney regulation and health 

First:  epidemiology and infection prevention and control
Second:  new causes and treatments for infectious diarrhea in children 

First:  epidemiology and infection prevention and control
Second:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study 

First:  epidemiology and infection prevention and control
Second:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia 

First:  epidemiology and infection prevention and control
Second:  epidemiology and infection from the field 

First:  epidemiology and infection prevention and control
Second:  coronavirus outbreak and stress in iranians 

First:  epidemiology and infection prevention and control
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  epidemiology and infection prevention and control
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  epidemiology and infection prevention and control
Second:  influenza opportunities and challenges 

First:  epidemiology and infection prevention and control
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  epidemiology and infection prevention and control
Second:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus 

First:  epidemiology and infection prevention and control
Second:  encouraging communication and cooperation in solving and creating new interdisciplinary case histories 

First:  epidemiology and infection prevention and control
Second:  lassa virus diversity and feasibility for universal prophylactic vaccine 

First:  epidemiology and infection prevention and control
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  epidemiology and infection prevention and control
Second:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism 

First:  epidemiology and infection prevention and control
Second:  epidemiology and infection original paper 

First:  epidemiology and infection prevention and control
Second:  the impacts of on children 

First:  epidemiology and infection prevention and control
Second:  journal viral etiology and outcome of severe lower respiratory tract infections among critically ill children admitted to the 

First:  epidemiology and infection prevention and control
Second:  ultrasonography in the initial characterization of patients with 

First:  epidemiology and infection prevention and control
Second:  design and implementation of an acute trauma and orthopaedic referral system utilising existing secure technology during the pandemic introduction 

First:  epidemiology and infection prevention and control
Second:  world journal of clinical pediatrics pediatric surgery during the pandemic statement 

First:  epidemiology and infection prevention and control
Second:  emergency presentation of iatrogenic airway stenosis following intubation in a patient with and its management case report 

First:  epidemiology and infection prevention and control
Second:  socioeconomic correlates of obesity in and men and women 

First:  epidemiology and infection prevention and control
Second:  the fungal nature of pneumocystis 

First:  epidemiology and infection prevention and control
Second:  the control of necrotic enteritis in sucking piglets by means of a clostridium vaccine 

First:  epidemiology and infection prevention and control
Second:  viral emerging challenges in developing vaccination strategies 

First:  epidemiology and infection prevention and control
Second:  controlling infectious disease lessons from mathematical modelling 

First:  epidemiology and infection prevention and control
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  epidemiology and infection prevention and control
Second:  differences of clinical and imaging findings in multiple generations of secondary infection in china 

First:  epidemiology and infection prevention and control
Second:  transmission route and introduction of pandemic between and spain 

First:  epidemiology and infection prevention and control
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  epidemiology and infection prevention and control
Second:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients 

First:  epidemiology and infection prevention and control
Second:  viral proteases as targets for chemotherapeutic intervention 

First:  epidemiology and infection prevention and control
Second:  molecular docking and studies of allium indica and aethiopica isolates as potential drugs for 

First:  epidemiology and infection prevention and control
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  epidemiology and infection prevention and control
Second:  inhibitors of virus recent developments and prospects 

First:  epidemiology and infection prevention and control
Second:  baseline chest in coronavirus disease association with clinical and laboratory data 

First:  epidemiology and infection prevention and control
Second:  development of rapid systematic survey of current practices and methods 

First:  epidemiology and infection prevention and control
Second:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland 

First:  epidemiology and infection prevention and control
Second:  as a targeted immunization strategy 

First:  epidemiology and infection prevention and control
Second:  a analysis of global health research 

First:  epidemiology and infection prevention and control
Second:  to appear disease &amp; health 

First:  epidemiology and infection prevention and control
Second:  abo blood types and sepsis mortality 

First:  epidemiology and infection prevention and control
Second:  journal update of the guideline on management of in cancer patients regarding viral vaccination and therapy excellence cluster on cellular stress responses in associated diseases 

First:  epidemiology and infection prevention and control
Second:  journal cardiac arrhythmias in a combination of viral and drug interactions 

First:  epidemiology and infection prevention and control
Second:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open 

First:  epidemiology and infection prevention and control
Second:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality 

First:  epidemiology and infection prevention and control
Second:  prediction of the incubation period for and future virus disease outbreaks 

First:  epidemiology and infection prevention and control
Second:  avian influenza in human in timely management and preparedness 

First:  epidemiology and infection prevention and control
Second:  transient dominant selection for the modification and generation of recombinant infectious bronchitis 

First:  epidemiology and infection prevention and control
Second:  clinical features and management of rhino orbital in post patients 

First:  epidemiology and infection prevention and control
Second:  laboratory techniques of veterinary clinical a review 

First:  epidemiology and infection prevention and control
Second:  acute a review of diagnosis and based management 

First:  epidemiology and infection prevention and control
Second:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung 

First:  epidemiology and infection prevention and control
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  epidemiology and infection prevention and control
Second:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic 

First:  epidemiology and infection prevention and control
Second:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia 

First:  epidemiology and infection prevention and control
Second:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  mapping the technological landscape of and vaccines 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  journal characterization of recombinant spike proteins characterization of recombinant spike proteins 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  spectrum of antimicrobial activity for disinfection of 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  potential of in vitro 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  supramolecular architecture of the coronavirus particle 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  establishment of a reference panel for the detection of antibodies 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  a serological comparison of bovine coronavirus strains 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  synthesis and activity of derivatives and analogues thereof 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  genetic hypothesis and side of in 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  and prognostic significance in 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  the sudden appearance of 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  early forecasting of the potential risk zones of in 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  enhances the peroxidase activity of myoglobin against 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  the and ends of rnas is not 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  recent advancements in the and prospective drug therapy of 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  clinical potential of for assessing comparative analysis 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  cells the aging of t cells 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  levels of and in the lungs of pneumonia patients 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  ultrasonography in the initial characterization of patients with 

First:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q
Second:  the fungal nature of pneumocystis 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  journal of cancer research and clinical oncology 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  mapping the technological landscape of and vaccines 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  potential of in vitro 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  the sudden appearance of 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  recent advancements in the and prospective drug therapy of 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  levels of and in the lungs of pneumonia patients 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  epidemiology and infection from the field 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  the impacts of on children 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  the fungal nature of pneumocystis 

First:  veterinary professional development series diseases of the dog and cat iii . diseases of the endocrine and vascular systems
Second:  epidemiology and infection prevention and control 

First:  african journal of primary health care &amp; family medicine public health and health faculty of health sciences
Second:  journal of cancer research and clinical oncology 

First:  african journal of primary health care &amp; family medicine public health and health faculty of health sciences
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  african journal of primary health care &amp; family medicine public health and health faculty of health sciences
Second:  international archives of occupational and environmental health 

First:  african journal of primary health care &amp; family medicine public health and health faculty of health sciences
Second:  epidemiology and infection prevention and control 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review risk and prognostic effect of imaging right ventricular involvement in patients with a analysis protocol for systematic review 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  case report mammography in the diagnosis of breast 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal of cancer research and clinical oncology 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  viral intestinal infections of animals and man 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical medicine impact of the pandemic on student and resident teaching and training in surgical oncology 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  and cell biology lung advances in generation and 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  in ckd lessons from ckd patients with kidney disease 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  integrity of plasma dna is inversely correlated with antitumor immunity in ovarian cancer patients 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  invasive strategy for patients presenting with acute coronary the first italian experience 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  prophylaxis of with and chloroquine accepted article 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  chest computed tomographic findings of patients with pneumonia 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  nutritional parameters associated with prognosis in ill 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  a review in bacterial infections 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  predicting risk of transition to severe infection 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  smoking prevalence among hospitalized patients and its association with disease severity and an expanded of a recent publication 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  potential of in vitro 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  bacterial and the deadly trio in 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  ethnic disparities in hospitalization for a cohort study in the uk 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  genetic hypothesis and side of in 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  and prognostic significance in 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  implications for people with chagas disease 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  mortality rates due to respiratory tract diseases in iran during a study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  early forecasting of the potential risk zones of in 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  therapy for a feasibility study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  in a comprehensive investigation from exposure to treatment outcomes 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  letter to the editor are patients with autoimmune disease at greater risk of developing severe 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal medical education in pediatric and congenital heart a focus on generational learning and technology in education medical education in pediatric and congenital heart a focus on generational learning and technology in education 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  depression and sleep quality in patients undergoing 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  older experience of the a analysis of stresses and joys 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  expert consensus for treating cancer patients during the pandemic of 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  regression of infantile glioblastoma after treatment with 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  more severe presentations of acute appendicitis during 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal chest ct features and clinical characteristics of patients infected with in china chest ct features and clinical characteristics of patients infected with 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic title comment on to psychological wellbeing for patients with bladder cancer and their and contextualization in the pandemic authors 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  recent advancements in the and prospective drug therapy of 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  morbidity and mortality weekly report 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  infectious disease and the case for considering impacts 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  stress symptoms in hemodialysis patients with exposure 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal letter to the editor retinal findings in patients with diabetes mellitus retinal findings in patients with diabetes mellitus 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  ethnic and regional variations in hospital mortality from in a observational study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  suspected myocarditis in patients with a case series 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical potential of for assessing comparative analysis 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical characteristics of death cases with 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  levels of and in the lungs of pneumonia patients 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  hallucinations due to therapeutic doses of 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  tracing and analysis of early infections outside a modeling study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  new causes and treatments for infectious diarrhea in children 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  risk factors for mortality of adult patients with hospitalised in an emerging a cohort study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  epidemiology and infection from the field 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  article cardiac troponin testing in patients with a strategy for testing and reporting results 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  influenza opportunities and challenges 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal catatonia in a hospitalized patient with and proposed mediated mechanism catatonia in a hospitalized patient with and proposed mechanism 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  patients in is obesity or the real 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  prolongation in patients using chloroquine 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  ultrasonography in the initial characterization of patients with 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  socioeconomic correlates of obesity in and men and women 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  differences of clinical and imaging findings in multiple generations of secondary infection in china 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  surfactant protein a predictor for severity of pneumonia in children 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  baseline chest in coronavirus disease association with clinical and laboratory data 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  abo blood types and sepsis mortality 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal cardiac arrhythmias in a combination of viral and drug interactions 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  prediction of the incubation period for and future virus disease outbreaks 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  avian influenza in human in timely management and preparedness 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  acute a review of diagnosis and based management 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  intensive care medicine enzyme activity in serum and lavage fluid after damage to the barrier in the human lung 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  journal of cardiothoracic and vascular anesthesia of ultrasound guided evaluation of dyspnea in coronavirus disease pandemic 

First:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study
Second:  epidemiology and infection prevention and control 

First:  and the importance of complete characterization of enteric microbial communities
Second:  a study on the influence of the pandemic on incomes in greece 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  and the importance of complete characterization of enteric microbial communities
Second:  fabrication of nanostructures with approach and their utility in and others 

First:  and the importance of complete characterization of enteric microbial communities
Second:  mapping the technological landscape of and vaccines 

First:  and the importance of complete characterization of enteric microbial communities
Second:  viral intestinal infections of animals and man 

First:  and the importance of complete characterization of enteric microbial communities
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  and the importance of complete characterization of enteric microbial communities
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  and the importance of complete characterization of enteric microbial communities
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  and the importance of complete characterization of enteric microbial communities
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  and the importance of complete characterization of enteric microbial communities
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  and the importance of complete characterization of enteric microbial communities
Second:  editorial recommendations for the management of in countries 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  and the importance of complete characterization of enteric microbial communities
Second:  prophylaxis of with and chloroquine accepted article 

First:  and the importance of complete characterization of enteric microbial communities
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  and the importance of complete characterization of enteric microbial communities
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  and the importance of complete characterization of enteric microbial communities
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  and the importance of complete characterization of enteric microbial communities
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the impact on surgical departments of hospitals 

First:  and the importance of complete characterization of enteric microbial communities
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  and the importance of complete characterization of enteric microbial communities
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  spectrum of antimicrobial activity for disinfection of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  and the importance of complete characterization of enteric microbial communities
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the role of the untranslated region of eukaryotic messenger rnas in translation and its investigation using antisense technologies 

First:  and the importance of complete characterization of enteric microbial communities
Second:  toxic and properties of an coordination complex of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  basics of molecular biology 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the common missed instances and areas after years of education 

First:  and the importance of complete characterization of enteric microbial communities
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  and the importance of complete characterization of enteric microbial communities
Second:  concept of immune response 

First:  and the importance of complete characterization of enteric microbial communities
Second:  potential of in vitro 

First:  and the importance of complete characterization of enteric microbial communities
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  and the importance of complete characterization of enteric microbial communities
Second:  bacterial and the deadly trio in 

First:  and the importance of complete characterization of enteric microbial communities
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  and the importance of complete characterization of enteric microbial communities
Second:  supramolecular architecture of the coronavirus particle 

First:  and the importance of complete characterization of enteric microbial communities
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  and the importance of complete characterization of enteric microbial communities
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  and the importance of complete characterization of enteric microbial communities
Second:  establishment of a reference panel for the detection of antibodies 

First:  and the importance of complete characterization of enteric microbial communities
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  and the importance of complete characterization of enteric microbial communities
Second:  synthesis and activity of derivatives and analogues thereof 

First:  and the importance of complete characterization of enteric microbial communities
Second:  genetic hypothesis and side of in 

First:  and the importance of complete characterization of enteric microbial communities
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  and the importance of complete characterization of enteric microbial communities
Second:  and prognostic significance in 

First:  and the importance of complete characterization of enteric microbial communities
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the sudden appearance of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  and the importance of complete characterization of enteric microbial communities
Second:  school of population and global the university of evidence 

First:  and the importance of complete characterization of enteric microbial communities
Second:  early forecasting of the potential risk zones of in 

First:  and the importance of complete characterization of enteric microbial communities
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  and the importance of complete characterization of enteric microbial communities
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  and the importance of complete characterization of enteric microbial communities
Second:  integrating research integrity into the history of science 

First:  and the importance of complete characterization of enteric microbial communities
Second:  enhances the peroxidase activity of myoglobin against 

First:  and the importance of complete characterization of enteric microbial communities
Second:  older experience of the a analysis of stresses and joys 

First:  and the importance of complete characterization of enteric microbial communities
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  and the importance of complete characterization of enteric microbial communities
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  and the importance of complete characterization of enteric microbial communities
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  and the importance of complete characterization of enteric microbial communities
Second:  immigration policy and justice in the era of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  diffusion as a first model of spread of viral infection 

First:  and the importance of complete characterization of enteric microbial communities
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the and ends of rnas is not 

First:  and the importance of complete characterization of enteric microbial communities
Second:  and the saga continues 

First:  and the importance of complete characterization of enteric microbial communities
Second:  environmental research and public health the impact of on food results of a survey 

First:  and the importance of complete characterization of enteric microbial communities
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  and the importance of complete characterization of enteric microbial communities
Second:  recent advancements in the and prospective drug therapy of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  infectious disease and the case for considering impacts 

First:  and the importance of complete characterization of enteric microbial communities
Second:  journal elucidating reasons of and its management strategies elucidating reasons of and its management strategies running title and institute of work 

First:  and the importance of complete characterization of enteric microbial communities
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  and the importance of complete characterization of enteric microbial communities
Second:  clinical potential of for assessing comparative analysis 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the impact of and homeschooling on engagement with physical activity 

First:  and the importance of complete characterization of enteric microbial communities
Second:  cells the aging of t cells 

First:  and the importance of complete characterization of enteric microbial communities
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  and the importance of complete characterization of enteric microbial communities
Second:  a look in the how the field of behavior analysis can become 

First:  and the importance of complete characterization of enteric microbial communities
Second:  levels of and in the lungs of pneumonia patients 

First:  and the importance of complete characterization of enteric microbial communities
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  and the importance of complete characterization of enteric microbial communities
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  and the importance of complete characterization of enteric microbial communities
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  and the importance of complete characterization of enteric microbial communities
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  and the importance of complete characterization of enteric microbial communities
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  and the importance of complete characterization of enteric microbial communities
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  and the importance of complete characterization of enteric microbial communities
Second:  tracing and analysis of early infections outside a modeling study 

First:  and the importance of complete characterization of enteric microbial communities
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  and the importance of complete characterization of enteric microbial communities
Second:  epidemiology and infection from the field 

First:  and the importance of complete characterization of enteric microbial communities
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the impacts of on children 

First:  and the importance of complete characterization of enteric microbial communities
Second:  ultrasonography in the initial characterization of patients with 

First:  and the importance of complete characterization of enteric microbial communities
Second:  socioeconomic correlates of obesity in and men and women 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the fungal nature of pneumocystis 

First:  and the importance of complete characterization of enteric microbial communities
Second:  autopsy in the time of case report 

First:  and the importance of complete characterization of enteric microbial communities
Second:  coronavirus genomes carry the signatures of their habitats 

First:  and the importance of complete characterization of enteric microbial communities
Second:  differences of clinical and imaging findings in multiple generations of secondary infection in china 

First:  and the importance of complete characterization of enteric microbial communities
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  and the importance of complete characterization of enteric microbial communities
Second:  modeling the evolution of via and application to the cyprus case 

First:  and the importance of complete characterization of enteric microbial communities
Second:  inhibitors of virus recent developments and prospects 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla 

First:  and the importance of complete characterization of enteric microbial communities
Second:  development of rapid systematic survey of current practices and methods 

First:  and the importance of complete characterization of enteric microbial communities
Second:  of coronavirus and with their bat hosts in the same geographical areas 

First:  and the importance of complete characterization of enteric microbial communities
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  and the importance of complete characterization of enteric microbial communities
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  and the importance of complete characterization of enteric microbial communities
Second:  the home bias and the local a survey 

First:  and the importance of complete characterization of enteric microbial communities
Second:  epidemiology and infection prevention and control 

First:  and the importance of complete characterization of enteric microbial communities
Second:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q 

First:  journal from a pharmacological perspective
Second:  journal innovations in in the age of a systematic literature review 

First:  journal from a pharmacological perspective
Second:  journal of cancer research and clinical oncology 

First:  journal from a pharmacological perspective
Second:  a protocol for a systematic review and 

First:  journal from a pharmacological perspective
Second:  clinical potential of for assessing comparative analysis 

First:  journal from a pharmacological perspective
Second:  a analysis of global health research 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  viral intestinal infections of animals and man 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  a review in bacterial infections 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  a serological comparison of bovine coronavirus strains 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  use of in human immunodeficiency virus infection 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  infectious disease and the case for considering impacts 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  levels of and in the lungs of pneumonia patients 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  new causes and treatments for infectious diarrhea in children 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  epidemiology and infection from the field 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  the fungal nature of pneumocystis 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  estimates of influenza vaccine effectiveness against influenza hospitalization in the elderly 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  prediction of the incubation period for and future virus disease outbreaks 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  avian influenza in human in timely management and preparedness 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  epidemiology and infection prevention and control 

First:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  evolution of a cohort of infection suspects from primary health care
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  evolution of a cohort of infection suspects from primary health care
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  evolution of a cohort of infection suspects from primary health care
Second:  the sudden appearance of 

First:  evolution of a cohort of infection suspects from primary health care
Second:  levels of and in the lungs of pneumonia patients 

First:  evolution of a cohort of infection suspects from primary health care
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  evolution of a cohort of infection suspects from primary health care
Second:  epidemiology and infection from the field 

First:  evolution of a cohort of infection suspects from primary health care
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  evolution of a cohort of infection suspects from primary health care
Second:  epidemiology and infection prevention and control 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  does the pandemic spell the end for the direct 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  potential of in vitro 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  the sudden appearance of 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  the and ends of rnas is not 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  levels of and in the lungs of pneumonia patients 

First:  population homogeneity for the antibody response to vaccine is only reached after the second dose
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  mapping the technological landscape of and vaccines 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  viral intestinal infections of animals and man 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  spectrum of antimicrobial activity for disinfection of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  a section of the journal frontiers in immunology crosstalk between platelets and microbial pathogens 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  a review in bacterial infections 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  concept of immune response 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  potential of in vitro 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  bacterial and the deadly trio in 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  establishment of a reference panel for the detection of antibodies 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  a serological comparison of bovine coronavirus strains 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  synthesis and activity of derivatives and analogues thereof 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  genetic hypothesis and side of in 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  and prognostic significance in 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the sudden appearance of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  early forecasting of the potential risk zones of in 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  enhances the peroxidase activity of myoglobin against 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  older experience of the a analysis of stresses and joys 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  use of in human immunodeficiency virus infection 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  diffusion as a first model of spread of viral infection 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the and ends of rnas is not 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  recent advancements in the and prospective drug therapy of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  infectious disease and the case for considering impacts 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  clinical potential of for assessing comparative analysis 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  cells the aging of t cells 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  levels of and in the lungs of pneumonia patients 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  epidemiology and infection from the field 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  patients in is obesity or the real 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  ultrasonography in the initial characterization of patients with 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the fungal nature of pneumocystis 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  journal cardiac arrhythmias in a combination of viral and drug interactions 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  the influenza a virus infection results in lethal inflammation in the mammalian host via the open 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  epidemiology and infection prevention and control 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q 

First:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model
Second:  and the importance of complete characterization of enteric microbial communities 

First:  journal guideline for training cardiology and radiology trainees as independent practitioners and advanced practitioners in cardiovascular computed a statement from the society of cardiovascular computed tomography guideline for training cardiology and radiology trainees as independent practitioners and advanced practitioners in cardiovascular computed a statement from the society of cardiovascular computed tomography
Second:  journal of cancer research and clinical oncology 

First:  mortality in california based on death disproportionate impacts across groups and nativity
Second:  the impacts of on children 

First:  effects of physical activity on the progression of diabetic a
Second:  a study on the influence of the pandemic on incomes in greece 

First:  effects of physical activity on the progression of diabetic a
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  effects of physical activity on the progression of diabetic a
Second:  journal a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in a novel method for determination of the potential antiviral candidate for the emergency treatment of virus in human application to a study in egyptian human volunteers 

First:  effects of physical activity on the progression of diabetic a
Second:  validation of reported risk factors for disease classification and prognosis in a descriptive and retrospective study 

First:  effects of physical activity on the progression of diabetic a
Second:  impact of on patients with rheumatic complications of cancer results of a registry survey 

First:  effects of physical activity on the progression of diabetic a
Second:  case report mammography in the diagnosis of breast 

First:  effects of physical activity on the progression of diabetic a
Second:  a remedy or a ripple in severe 

First:  effects of physical activity on the progression of diabetic a
Second:  journal innovations in in the age of a systematic literature review 

First:  effects of physical activity on the progression of diabetic a
Second:  disease in the era of an observation on a series of six patients with 

First:  effects of physical activity on the progression of diabetic a
Second:  mapping the technological landscape of and vaccines 

First:  effects of physical activity on the progression of diabetic a
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  effects of physical activity on the progression of diabetic a
Second:  does the pandemic spell the end for the direct 

First:  effects of physical activity on the progression of diabetic a
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  effects of physical activity on the progression of diabetic a
Second:  using a outcome to improve detection of cognitive impairment and the patient version of the quick dementia rating system 

First:  effects of physical activity on the progression of diabetic a
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  effects of physical activity on the progression of diabetic a
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  effects of physical activity on the progression of diabetic a
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  effects of physical activity on the progression of diabetic a
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  effects of physical activity on the progression of diabetic a
Second:  and correlates of neutralizing antibodies from a study in germany 

First:  effects of physical activity on the progression of diabetic a
Second:  journal exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states exploring spatiotemporal effects of the driving factors on incidences in the contiguous united states 

First:  effects of physical activity on the progression of diabetic a
Second:  editorial recommendations for the management of in countries 

First:  effects of physical activity on the progression of diabetic a
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  effects of physical activity on the progression of diabetic a
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  effects of physical activity on the progression of diabetic a
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  effects of physical activity on the progression of diabetic a
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  effects of physical activity on the progression of diabetic a
Second:  the impact on surgical departments of hospitals 

First:  effects of physical activity on the progression of diabetic a
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  effects of physical activity on the progression of diabetic a
Second:  from cardiology to the impact of a pandemic on fellowship training 

First:  effects of physical activity on the progression of diabetic a
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  effects of physical activity on the progression of diabetic a
Second:  spectrum of antimicrobial activity for disinfection of 

First:  effects of physical activity on the progression of diabetic a
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  effects of physical activity on the progression of diabetic a
Second:  combined with the chinese medicine capsule versus alone in the treatment of 

First:  effects of physical activity on the progression of diabetic a
Second:  toxic and properties of an coordination complex of 

First:  effects of physical activity on the progression of diabetic a
Second:  predicting risk of transition to severe infection 

First:  effects of physical activity on the progression of diabetic a
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  effects of physical activity on the progression of diabetic a
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  effects of physical activity on the progression of diabetic a
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  effects of physical activity on the progression of diabetic a
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  effects of physical activity on the progression of diabetic a
Second:  concept of immune response 

First:  effects of physical activity on the progression of diabetic a
Second:  potential of in vitro 

First:  effects of physical activity on the progression of diabetic a
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  effects of physical activity on the progression of diabetic a
Second:  bacterial and the deadly trio in 

First:  effects of physical activity on the progression of diabetic a
Second:  a green strategy for the synthesis of derivatives of kinetic evaluation and antibacterial susceptibility open 

First:  effects of physical activity on the progression of diabetic a
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  effects of physical activity on the progression of diabetic a
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  effects of physical activity on the progression of diabetic a
Second:  establishment of a reference panel for the detection of antibodies 

First:  effects of physical activity on the progression of diabetic a
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  effects of physical activity on the progression of diabetic a
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  effects of physical activity on the progression of diabetic a
Second:  predicting the trajectory of any epidemic from the best straight line 

First:  effects of physical activity on the progression of diabetic a
Second:  synthesis and activity of derivatives and analogues thereof 

First:  effects of physical activity on the progression of diabetic a
Second:  association between the pandemic and the risk for adverse pregnancy a cohort study association between the pandemic and the risk for adverse pregnancy a cohort study 

First:  effects of physical activity on the progression of diabetic a
Second:  genetic hypothesis and side of in 

First:  effects of physical activity on the progression of diabetic a
Second:  and probable varicella in a novel case of homozygous deficiency 

First:  effects of physical activity on the progression of diabetic a
Second:  how the response is altering the legal and regulatory landscape on abortion 

First:  effects of physical activity on the progression of diabetic a
Second:  recommendations from the taskforce on performance of tracheotomy during the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  effects of physical activity on the progression of diabetic a
Second:  and prognostic significance in 

First:  effects of physical activity on the progression of diabetic a
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  effects of physical activity on the progression of diabetic a
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  effects of physical activity on the progression of diabetic a
Second:  influence of pharmaceutical on emergency hospital a 

First:  effects of physical activity on the progression of diabetic a
Second:  the sudden appearance of 

First:  effects of physical activity on the progression of diabetic a
Second:  initial introduction of minimally invasive using the concept in the upper mediastinum 

First:  effects of physical activity on the progression of diabetic a
Second:  school of population and global the university of evidence 

First:  effects of physical activity on the progression of diabetic a
Second:  a protocol for a systematic review and 

First:  effects of physical activity on the progression of diabetic a
Second:  early forecasting of the potential risk zones of in 

First:  effects of physical activity on the progression of diabetic a
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  effects of physical activity on the progression of diabetic a
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  effects of physical activity on the progression of diabetic a
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  effects of physical activity on the progression of diabetic a
Second:  clinical medicine a predictive study of resilience and its relationship with academic and work dimensions during the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  pharmaceuticals therapeutic drug monitoring of antipsychotic of smoking behavior and inflammation on pharmacokinetics 

First:  effects of physical activity on the progression of diabetic a
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  effects of physical activity on the progression of diabetic a
Second:  a better understanding of social distancing 

First:  effects of physical activity on the progression of diabetic a
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  effects of physical activity on the progression of diabetic a
Second:  impact of job engagement on the quality of nursing the effect of nursing in south korean nurses 

First:  effects of physical activity on the progression of diabetic a
Second:  enhances the peroxidase activity of myoglobin against 

First:  effects of physical activity on the progression of diabetic a
Second:  older experience of the a analysis of stresses and joys 

First:  effects of physical activity on the progression of diabetic a
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  effects of physical activity on the progression of diabetic a
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  effects of physical activity on the progression of diabetic a
Second:  journal clinical description of the broad range of neurological presentations of a retrospective case series clinical description of the broad range of neurological presentations of a retrospective case series 

First:  effects of physical activity on the progression of diabetic a
Second:  diffusion as a first model of spread of viral infection 

First:  effects of physical activity on the progression of diabetic a
Second:  safety of and arb medications in a retrospective cohort study of inpatients and outpatients in california 

First:  effects of physical activity on the progression of diabetic a
Second:  routing choices for safe and efficient transportation in the face of the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  the and ends of rnas is not 

First:  effects of physical activity on the progression of diabetic a
Second:  and the saga continues 

First:  effects of physical activity on the progression of diabetic a
Second:  environmental research and public health the impact of on food results of a survey 

First:  effects of physical activity on the progression of diabetic a
Second:  result in changes in human mobility which may impact the epidemiologic dynamics of 

First:  effects of physical activity on the progression of diabetic a
Second:  mechanism of dopaminergic nerve transmission in different doses of morphine addiction and depression 

First:  effects of physical activity on the progression of diabetic a
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  effects of physical activity on the progression of diabetic a
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  effects of physical activity on the progression of diabetic a
Second:  recent advancements in the and prospective drug therapy of 

First:  effects of physical activity on the progression of diabetic a
Second:  impact of on thyroid cancer surgery and adjunct therapy 

First:  effects of physical activity on the progression of diabetic a
Second:  infectious disease and the case for considering impacts 

First:  effects of physical activity on the progression of diabetic a
Second:  survey on physician burnout during the pandemic in the role of ethnicity and sexual orientation 

First:  effects of physical activity on the progression of diabetic a
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  effects of physical activity on the progression of diabetic a
Second:  clinical potential of for assessing comparative analysis 

First:  effects of physical activity on the progression of diabetic a
Second:  the icf classification as a simple tool to aid in the assessment of healthcare services in a hospital during the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  the impact of and homeschooling on engagement with physical activity 

First:  effects of physical activity on the progression of diabetic a
Second:  journal in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent letter to the editor in reply perfusion defects and worsening oxygenation in a word of caution on the use of convalescent 

First:  effects of physical activity on the progression of diabetic a
Second:  innate cell profiles during the acute and convalescent phase of infection in children 

First:  effects of physical activity on the progression of diabetic a
Second:  cells the aging of t cells 

First:  effects of physical activity on the progression of diabetic a
Second:  clinical characteristics of death cases with 

First:  effects of physical activity on the progression of diabetic a
Second:  multidimensional assessment of emotion processing and the role of early life stress in inflammatory bowel diseases 

First:  effects of physical activity on the progression of diabetic a
Second:  a look in the how the field of behavior analysis can become 

First:  effects of physical activity on the progression of diabetic a
Second:  levels of and in the lungs of pneumonia patients 

First:  effects of physical activity on the progression of diabetic a
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  effects of physical activity on the progression of diabetic a
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  effects of physical activity on the progression of diabetic a
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  effects of physical activity on the progression of diabetic a
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  effects of physical activity on the progression of diabetic a
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  identifying the needs of prekindergarten a focus on and family environment 

First:  effects of physical activity on the progression of diabetic a
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  effects of physical activity on the progression of diabetic a
Second:  in vitro b and sars virus activities of a 

First:  effects of physical activity on the progression of diabetic a
Second:  hallucinations due to therapeutic doses of 

First:  effects of physical activity on the progression of diabetic a
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  effects of physical activity on the progression of diabetic a
Second:  tracing and analysis of early infections outside a modeling study 

First:  effects of physical activity on the progression of diabetic a
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  epidemiology and infection from the field 

First:  effects of physical activity on the progression of diabetic a
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  effects of physical activity on the progression of diabetic a
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  symptoms of anxiety and depression in relation to work patterns during the first wave of the epidemic in philadelphia pa a survey 

First:  effects of physical activity on the progression of diabetic a
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  effects of physical activity on the progression of diabetic a
Second:  the impacts of on children 

First:  effects of physical activity on the progression of diabetic a
Second:  patients in is obesity or the real 

First:  effects of physical activity on the progression of diabetic a
Second:  a observational study of asymptomatic prevalence in the greater indianapolis area 

First:  effects of physical activity on the progression of diabetic a
Second:  validation of a questionnaire on the use of interactive response system in higher education 

First:  effects of physical activity on the progression of diabetic a
Second:  ultrasonography in the initial characterization of patients with 

First:  effects of physical activity on the progression of diabetic a
Second:  socioeconomic correlates of obesity in and men and women 

First:  effects of physical activity on the progression of diabetic a
Second:  the fungal nature of pneumocystis 

First:  effects of physical activity on the progression of diabetic a
Second:  forecast analysis of the epidemics trend of in the united states by a generalized seir model 

First:  effects of physical activity on the progression of diabetic a
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  effects of physical activity on the progression of diabetic a
Second:  autopsy in the time of case report 

First:  effects of physical activity on the progression of diabetic a
Second:  differences of clinical and imaging findings in multiple generations of secondary infection in china 

First:  effects of physical activity on the progression of diabetic a
Second:  surfactant protein a predictor for severity of pneumonia in children 

First:  effects of physical activity on the progression of diabetic a
Second:  journal and timing of administration assessment and timing of administration assessment 

First:  effects of physical activity on the progression of diabetic a
Second:  modeling the evolution of via and application to the cyprus case 

First:  effects of physical activity on the progression of diabetic a
Second:  the release of nitric oxide is involved in the antihypertensive effect in the rostral medulla 

First:  effects of physical activity on the progression of diabetic a
Second:  development of rapid systematic survey of current practices and methods 

First:  effects of physical activity on the progression of diabetic a
Second:  personality traits and changes in health behaviors and depressive symptoms during the a longitudinal analysis from to onset and end of the initial emergency conditions in finland 

First:  effects of physical activity on the progression of diabetic a
Second:  a analysis of global health research 

First:  effects of physical activity on the progression of diabetic a
Second:  journal cardiac arrhythmias in a combination of viral and drug interactions 

First:  effects of physical activity on the progression of diabetic a
Second:  the role of vitamin d in suppressing cytokine storm in patients and associated mortality 

First:  effects of physical activity on the progression of diabetic a
Second:  journal management of a delivery suite during the epidemic management of a delivery suite during the epidemic 

First:  effects of physical activity on the progression of diabetic a
Second:  protocol of a network on the comparative efficacy of family interventions for psychotic disorders complete list of authors 

First:  effects of physical activity on the progression of diabetic a
Second:  acute a review of diagnosis and based management 

First:  effects of physical activity on the progression of diabetic a
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  effects of physical activity on the progression of diabetic a
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  effects of physical activity on the progression of diabetic a
Second:  the home bias and the local a survey 

First:  effects of physical activity on the progression of diabetic a
Second:  air environment and respiratory outcomes in the cohort design and adaptation during the pandemic 

First:  effects of physical activity on the progression of diabetic a
Second:  the psychological impact of pandemic and lockdown on caregivers of people with dementia the psychological impact of pandemic and lockdown on caregivers of people with dementia 

First:  effects of physical activity on the progression of diabetic a
Second:  epidemiology and infection prevention and control 

First:  effects of physical activity on the progression of diabetic a
Second:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q 

First:  effects of physical activity on the progression of diabetic a
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  effects of physical activity on the progression of diabetic a
Second:  and the importance of complete characterization of enteric microbial communities 

First:  effects of physical activity on the progression of diabetic a
Second:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  a remedy or a ripple in severe 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  editorial recommendations for the management of in countries 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  a review in bacterial infections 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  and prognostic significance in 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  a protocol for a systematic review and 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  therapy for a feasibility study 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  older experience of the a analysis of stresses and joys 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  recent advancements in the and prospective drug therapy of 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  levels of and in the lungs of pneumonia patients 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  ultrasonography in the initial characterization of patients with 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  as a targeted immunization strategy 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  a analysis of global health research 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  acute a review of diagnosis and based management 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  epidemiology and infection prevention and control 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  diagnosis and management of group a streptococcal a practice guideline
Second:  effects of physical activity on the progression of diabetic a 

First:  article rath d impaired myocardial function is prognostic for severe respiratory failure in the course of infection
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  article rath d impaired myocardial function is prognostic for severe respiratory failure in the course of infection
Second:  levels of and in the lungs of pneumonia patients 

First:  article rath d impaired myocardial function is prognostic for severe respiratory failure in the course of infection
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  composite in medical applications 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  solid and suspension microarrays for microbial diagnostics 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  basics of molecular biology 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  molecular sciences legume proteins with diverse applications 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  polymers additive manufacturing of polymer promise and challenges 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  materials nanoparticles functionalized viscose fabrics as potentially durable antibacterial medical textiles 

First:  supplementary materials insulator based and molecular scale biological applications
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  journal of cancer research and clinical oncology 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  potential of in vitro 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  and prognostic significance in 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  recent advancements in the and prospective drug therapy of 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  clinical potential of for assessing comparative analysis 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  levels of and in the lungs of pneumonia patients 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  quantitative and qualitative assessment of microbial aerosols in different indoor environments of a dental school clinic
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  viral intestinal infections of animals and man 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  potential of in vitro 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  a serological comparison of bovine coronavirus strains 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  use of in human immunodeficiency virus infection 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  levels of and in the lungs of pneumonia patients 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  the fungal nature of pneumocystis 

First:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of
Second:  epidemiology and infection prevention and control 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  viral intestinal infections of animals and man 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  a review in bacterial infections 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  predicting risk of transition to severe infection 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  a serological comparison of bovine coronavirus strains 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  traditional chinese medicine in the treatment of acute respiratory tract infections 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  respiratory management for critically ill patients with acute respiratory distress syndrome 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  liver histopathology in severe respiratory failure is suggestive of vascular alterations 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  etiology of acute respiratory disease in fattening pigs in finland 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  use of in human immunodeficiency virus infection 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  divergence of severe acute respiratory syndrome in primate models 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  more severe presentations of acute appendicitis during 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  infectious disease and the case for considering impacts 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  stress symptoms in hemodialysis patients with exposure 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  innate immunity to respiratory infection in early life 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  antiviral strategies to control infections 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  risk worries and preventive behaviors in patients with previous pulmonary embolism 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  levels of and in the lungs of pneumonia patients 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  hallucinations due to therapeutic doses of 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  low prevalence of human and human in adult immunocompromised high risk patients suspected to suffer from pneumocystis pneumonia 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  absence of contamination of personal protective equipment by severe acute respiratory syndrome coronavirus 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  prolongation in patients using chloroquine 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  vs cmv for neonates with perinatal onset acute respiratory distress syndrome a propensity score analysis 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  the fungal nature of pneumocystis 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  diagnostic imaging in a patient with an isolated blunt traumatic gallbladder injury 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  abo blood types and sepsis mortality 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  journal cardiac arrhythmias in a combination of viral and drug interactions 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  epidemiology and infection prevention and control 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  acute respiratory distress a life threatening associated complication of infection inducing
Second:  effects of physical activity on the progression of diabetic a 

First:  understanding the indoor transmission mechanism of
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  understanding the indoor transmission mechanism of
Second:  mapping the technological landscape of and vaccines 

First:  understanding the indoor transmission mechanism of
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  understanding the indoor transmission mechanism of
Second:  does the pandemic spell the end for the direct 

First:  understanding the indoor transmission mechanism of
Second:  mechanistic theory predicts the effects of temperature and humidity on inactivation of and other enveloped viruses 

First:  understanding the indoor transmission mechanism of
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  understanding the indoor transmission mechanism of
Second:  spectrum of antimicrobial activity for disinfection of 

First:  understanding the indoor transmission mechanism of
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  understanding the indoor transmission mechanism of
Second:  toxic and properties of an coordination complex of 

First:  understanding the indoor transmission mechanism of
Second:  physics of fluids article aerosol persistence in relation to possible transmission of 

First:  understanding the indoor transmission mechanism of
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  understanding the indoor transmission mechanism of
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  understanding the indoor transmission mechanism of
Second:  concept of immune response 

First:  understanding the indoor transmission mechanism of
Second:  potential of in vitro 

First:  understanding the indoor transmission mechanism of
Second:  supramolecular architecture of the coronavirus particle 

First:  understanding the indoor transmission mechanism of
Second:  overcoming vaccine preferential bias in is the end of the pandemic still overcoming vaccine preferential bias in is the end of the pandemic still 

First:  understanding the indoor transmission mechanism of
Second:  establishment of a reference panel for the detection of antibodies 

First:  understanding the indoor transmission mechanism of
Second:  genetic hypothesis and side of in 

First:  understanding the indoor transmission mechanism of
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  understanding the indoor transmission mechanism of
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  understanding the indoor transmission mechanism of
Second:  the sudden appearance of 

First:  understanding the indoor transmission mechanism of
Second:  school of population and global the university of evidence 

First:  understanding the indoor transmission mechanism of
Second:  early forecasting of the potential risk zones of in 

First:  understanding the indoor transmission mechanism of
Second:  an updated estimation of the risk of transmission of the novel coronavirus license 

First:  understanding the indoor transmission mechanism of
Second:  older experience of the a analysis of stresses and joys 

First:  understanding the indoor transmission mechanism of
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  understanding the indoor transmission mechanism of
Second:  diffusion as a first model of spread of viral infection 

First:  understanding the indoor transmission mechanism of
Second:  the and ends of rnas is not 

First:  understanding the indoor transmission mechanism of
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  understanding the indoor transmission mechanism of
Second:  recent advancements in the and prospective drug therapy of 

First:  understanding the indoor transmission mechanism of
Second:  levels of and in the lungs of pneumonia patients 

First:  understanding the indoor transmission mechanism of
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  understanding the indoor transmission mechanism of
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  understanding the indoor transmission mechanism of
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  understanding the indoor transmission mechanism of
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  understanding the indoor transmission mechanism of
Second:  the impacts of on children 

First:  understanding the indoor transmission mechanism of
Second:  ultrasonography in the initial characterization of patients with 

First:  understanding the indoor transmission mechanism of
Second:  the fungal nature of pneumocystis 

First:  understanding the indoor transmission mechanism of
Second:  modeling the evolution of via and application to the cyprus case 

First:  understanding the indoor transmission mechanism of
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  understanding the indoor transmission mechanism of
Second:  and the importance of complete characterization of enteric microbial communities 

First:  understanding the indoor transmission mechanism of
Second:  effects of physical activity on the progression of diabetic a 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  stress symptoms in hemodialysis patients with exposure 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  levels of and in the lungs of pneumonia patients 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  ultrasonography in the initial characterization of patients with 

First:  normal chest ct in symptomatic patients with confirmed characteristics and outcome
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  a study on the influence of the pandemic on incomes in greece 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  case report mammography in the diagnosis of breast 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  journal of cancer research and clinical oncology 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  mapping the technological landscape of and vaccines 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  editorial recommendations for the management of in countries 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  predictive association of genetic polymorphism with the efficacy or safety of and in coronavirus patients 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  impact of the lockdown on the adherence of stroke patients to direct oral a secondary analysis from the study 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the impact on surgical departments of hospitals 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  predictors of incident viral symptoms ascertained in the era of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  spectrum of antimicrobial activity for disinfection of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  analysis of the positive rate of cases of nucleic acid tests in different in china 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  potential of in vitro 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  bacterial and the deadly trio in 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  establishment of a reference panel for the detection of antibodies 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  genetic hypothesis and side of in 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  and prognostic significance in 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the sudden appearance of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  school of population and global the university of evidence 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  early forecasting of the potential risk zones of in 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  evaluation of the knowledge of operating room nurses on preventive practices for evaluation of the knowledge of operating room nurses on preventive practices for 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  older experience of the a analysis of stresses and joys 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  immigration policy and justice in the era of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the and ends of rnas is not 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  environmental research and public health the impact of on food results of a survey 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the influence of meteorology on the spread of survival analysis of an equine influenza outbreak 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  recent advancements in the and prospective drug therapy of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  infectious disease and the case for considering impacts 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  clinical potential of for assessing comparative analysis 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  clinical characteristics of death cases with 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  levels of and in the lungs of pneumonia patients 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  phylogenetic perspectives on the epidemiology and origins of sars and 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  epidemiology and infection from the field 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  usefulness of pcr screening in the initial triage of trauma patients during pandemic 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the impacts of on children 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  ultrasonography in the initial characterization of patients with 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the fungal nature of pneumocystis 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  autopsy in the time of case report 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  differences of clinical and imaging findings in multiple generations of secondary infection in china 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  development of rapid systematic survey of current practices and methods 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  epidemiology and infection prevention and control 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  and the importance of complete characterization of enteric microbial communities 

First:  the importance of microbiological testing for establishing cause of death in forensic autopsies
Second:  effects of physical activity on the progression of diabetic a 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  mapping the technological landscape of and vaccines 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  design of a regulatory strategy in compliance with the international and the regulation vitro diagnostic medical device 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  editorial recommendations for the management of in countries 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  spectrum of antimicrobial activity for disinfection of 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  potential of in vitro 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  establishment of a reference panel for the detection of antibodies 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  synthesis and activity of derivatives and analogues thereof 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  genetic hypothesis and side of in 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  modulation of olfactory signal detection in the olfactory focus on the internal and external and the emerging role of the immune system 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  and prognostic significance in 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  the sudden appearance of 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  early forecasting of the potential risk zones of in 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  older experience of the a analysis of stresses and joys 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  the and ends of rnas is not 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  recent advancements in the and prospective drug therapy of 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  infectious disease and the case for considering impacts 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  clinical potential of for assessing comparative analysis 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  levels of and in the lungs of pneumonia patients 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  a demographic adjustment to improve measurement of severity at the developing stage of the pandemic 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  the impacts of on children 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  ultrasonography in the initial characterization of patients with 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  the fungal nature of pneumocystis 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  development of rapid systematic survey of current practices and methods 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  epidemiology and infection prevention and control 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  and the importance of complete characterization of enteric microbial communities 

First:  performance and health economic evaluation of the mount sinai serological assay identifies modification of as necessary to maximise specificity of the assay
Second:  effects of physical activity on the progression of diabetic a 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  a study on the influence of the pandemic on incomes in greece 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  case report mammography in the diagnosis of breast 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  journal innovations in in the age of a systematic literature review 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  disease in the era of an observation on a series of six patients with 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  collapse of the public health system and the emergence of new variants during the second wave of the pandemic in brazil 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  editorial recommendations for the management of in countries 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the efficacy and safety of in feeding intolerance of critically ill patients receiving a study 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the common missed instances and areas after years of education 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  caring for the caregivers during the pandemic research the experiences and perceptions of workers during the pandemic in a qualitative study 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the pandemic in avoiding of anaphylaxis risk while safely the world 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  potential of in vitro 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  state of the art review kidney outcomes in and a and systematic review 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  bacterial and the deadly trio in 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  establishment of a reference panel for the detection of antibodies 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  genetic hypothesis and side of in 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  and prognostic significance in 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the sudden appearance of 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  a protocol for a systematic review and 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  early forecasting of the potential risk zones of in 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  prolonged lockdown and academic uncertainties in a qualitative investigation during the pandemic 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  older experience of the a analysis of stresses and joys 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  characterizing the patterns of policies against a study characterizing the patterns of policies against a study 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  evaluating the motivation of red cross health volunteers in the a study evaluating the motivation of red cross health volunteers in the a study ethics and dissemination 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  immigration policy and justice in the era of 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the and ends of rnas is not 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  and the saga continues 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the impact of the first peak of the pandemic on colorectal cancer services in england and a national survey 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  recent advancements in the and prospective drug therapy of 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  infectious disease and the case for considering impacts 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  a look in the how the field of behavior analysis can become 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  levels of and in the lungs of pneumonia patients 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  properties of in patients with risks and benefits at the time of pandemic running diabetes and pandemic 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  epidemiology and infection from the field 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the effect of the timing of dexamethasone administration in patients with pneumonia 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the impacts of on children 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  ultrasonography in the initial characterization of patients with 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the clinical frailty estimating the prevalence of frailty in older patients hospitalised with the cope study 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  autopsy in the time of case report 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  acute a review of diagnosis and based management 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  what is critical about the crisis of a review of gil the crisis of expertise polity the critical in the crisis 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the home bias and the local a survey 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  epidemiology and infection prevention and control 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  effects of physical activity on the progression of diabetic a 

First:  life after acute and organizing a case report of a patient months after diagnosis and review of the literature
Second:  the importance of microbiological testing for establishing cause of death in forensic autopsies 

First:  strategies for viral infections and organelles
Second:  the role of mucosal microbiota in the and pathologies of the mucosal immune system mucosal development and physiology of mucosal defense 

First:  strategies for viral infections and organelles
Second:  journal of cancer research and clinical oncology 

First:  strategies for viral infections and organelles
Second:  viral intestinal infections of animals and man 

First:  strategies for viral infections and organelles
Second:  and cell biology lung advances in generation and 

First:  strategies for viral infections and organelles
Second:  using conjugated antibodies allows profiling of human and murine tissues 

First:  strategies for viral infections and organelles
Second:  effective treatment of severe acute pancreatitis and pneumonia with 

First:  strategies for viral infections and organelles
Second:  solid and suspension microarrays for microbial diagnostics 

First:  strategies for viral infections and organelles
Second:  detection of nucleic acids of porcine reproductive and respiratory syndrome virus in the lungs of naturally infected piglets as determined by hybridization 

First:  strategies for viral infections and organelles
Second:  and inhibitors of farnesyl pyrophosphate a perspective 

First:  strategies for viral infections and organelles
Second:  microorganisms nasal microbiota in rsv 

First:  strategies for viral infections and organelles
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  strategies for viral infections and organelles
Second:  spectrum of antimicrobial activity for disinfection of 

First:  strategies for viral infections and organelles
Second:  metabolically engineered stem to regulate macrophage heterogeneity in rheumatoid arthritis 

First:  strategies for viral infections and organelles
Second:  a review in bacterial infections 

First:  strategies for viral infections and organelles
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  strategies for viral infections and organelles
Second:  is a host factor for infection 

First:  strategies for viral infections and organelles
Second:  genetic and epigenetic regulation of the myosin light chain kinase isoform by lung inflammatory factors and mechanical stress 

First:  strategies for viral infections and organelles
Second:  viral a regulatory molecule for controlling virus life cycle 

First:  strategies for viral infections and organelles
Second:  impact of rapid detection of viral and atypical bacterial pathogens by polymerase chain reaction for patients with lower respiratory tract infection 

First:  strategies for viral infections and organelles
Second:  exhaled aerosol increases with and risk factors of disease symptom severity 

First:  strategies for viral infections and organelles
Second:  potential of in vitro 

First:  strategies for viral infections and organelles
Second:  bacterial and the deadly trio in 

First:  strategies for viral infections and organelles
Second:  coronavirus disease emergency and cancer in the south of new for the 

First:  strategies for viral infections and organelles
Second:  molecular and cellular biochemistry derived peptides with mhc binding motifs from canine mammary tumor tissue elicit strong responses in mice 

First:  strategies for viral infections and organelles
Second:  enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism enhancing the antiviral efficacy of rna polymerase inhibition by combination with modulators of pyrimidine metabolism 

First:  strategies for viral infections and organelles
Second:  a serological comparison of bovine coronavirus strains 

First:  strategies for viral infections and organelles
Second:  article and efficacy of mrna vaccine in preclinical animal models 

First:  strategies for viral infections and organelles
Second:  viral otu a structural and functional comparison 

First:  strategies for viral infections and organelles
Second:  implications for people with chagas disease 

First:  strategies for viral infections and organelles
Second:  langerhans cells and play redundant roles in induced protective influenza and responses 

First:  strategies for viral infections and organelles
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  strategies for viral infections and organelles
Second:  safety and effectiveness of strategies for seasonal influenza vaccine a rapid scoping review of fractional dosing of the intramuscular influenza vaccine 

First:  strategies for viral infections and organelles
Second:  cancers tumor immune evasion induced by dysregulation of progenitor cells development 

First:  strategies for viral infections and organelles
Second:  animal models for sars and mers 

First:  strategies for viral infections and organelles
Second:  the function and inhibition by designed antiviral compounds 

First:  strategies for viral infections and organelles
Second:  combination kills bladder cancer cells synergistically 

First:  strategies for viral infections and organelles
Second:  restriction of replication by targeting programmed ribosomal in vitro 

First:  strategies for viral infections and organelles
Second:  antiviral activity of against virus both in vitro and in vivo 

First:  strategies for viral infections and organelles
Second:  molecular factors mediating infection to gain clinical insights for developing effective targeted therapy 

First:  strategies for viral infections and organelles
Second:  analytical and clinical evaluation of four commercial serological in hospitalized patients and ambulatory individuals 

First:  strategies for viral infections and organelles
Second:  clinical characteristics and viral of outpatients with acute respiratory infections in huzhou of a retrospective study 

First:  strategies for viral infections and organelles
Second:  evaluation of a rapid molecular algorithm for detection of pandemic influenza a virus and screening for a key oseltamivir resistance substitution in neuraminidase 

First:  strategies for viral infections and organelles
Second:  clinical characteristics and outcomes of breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases 

First:  strategies for viral infections and organelles
Second:  supplemental information escaping host factor enterovirus genomic rna replication in the absence of replication organelles 

First:  strategies for viral infections and organelles
Second:  use of in human immunodeficiency virus infection 

First:  strategies for viral infections and organelles
Second:  effective inhibition of porcine epidemic diarrhea virus by rna interference in vitro 

First:  strategies for viral infections and organelles
Second:  alkaloids from as potential inhibitors of viral an in silico study 

First:  strategies for viral infections and organelles
Second:  investigational treatments for may increase ventricular arrhythmia risk through drug interactions 

First:  strategies for viral infections and organelles
Second:  cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome 

First:  strategies for viral infections and organelles
Second:  modelling the transmission of infectious diseases inside hospital implications for 

First:  strategies for viral infections and organelles
Second:  building momentum for malaria vaccine research and key considerations 

First:  strategies for viral infections and organelles
Second:  recent advancements in the and prospective drug therapy of 

First:  strategies for viral infections and organelles
Second:  an mrna vaccine protects mice against multiple infections 

First:  strategies for viral infections and organelles
Second:  vaccine hesitancy among paediatric prevalence and associated factors 

First:  strategies for viral infections and organelles
Second:  infectious disease and the case for considering impacts 

First:  strategies for viral infections and organelles
Second:  stress symptoms in hemodialysis patients with exposure 

First:  strategies for viral infections and organelles
Second:  article high expression of in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection 

First:  strategies for viral infections and organelles
Second:  role of the gene of murine coronavirus strain in hepatitis 

First:  strategies for viral infections and organelles
Second:  clinical potential of for assessing comparative analysis 

First:  strategies for viral infections and organelles
Second:  clinical disease severity of respiratory viral versus single viral a systematic review and 

First:  strategies for viral infections and organelles
Second:  journal respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients short communication respiratory bacterial pathogen spectrum among infected and virus infected pneumonia patients running bacterial pathogens with 

First:  strategies for viral infections and organelles
Second:  antiviral strategies to control infections 

First:  strategies for viral infections and organelles
Second:  clinical outcomes in outpatient respiratory virus infection in immunocompromised children 

First:  strategies for viral infections and organelles
Second:  extracorporeal life support for immune reconstitution inflammatory syndrome in hiv patients with pneumocystis pneumonia 

First:  strategies for viral infections and organelles
Second:  levels of and in the lungs of pneumonia patients 

First:  strategies for viral infections and organelles
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  strategies for viral infections and organelles
Second:  depletion of enzyme reduces brain serotonin and impairs the neurogenic response 

First:  strategies for viral infections and organelles
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  strategies for viral infections and organelles
Second:  compartmentalized replication organelle of at the er and the factors involved 

First:  strategies for viral infections and organelles
Second:  bioinformatics analysis of spike proteins of porcine enteric 

First:  strategies for viral infections and organelles
Second:  digestive symptoms and liver injury in patients with coronavirus disease a systematic review with 

First:  strategies for viral infections and organelles
Second:  proteomics of acute respiratory distress clinical and research applications 

First:  strategies for viral infections and organelles
Second:  the effects of substance use on severe acute respiratory syndrome coronavirus infection risks and outcomes 

First:  strategies for viral infections and organelles
Second:  nitric oxide signalling in kidney regulation and health 

First:  strategies for viral infections and organelles
Second:  new causes and treatments for infectious diarrhea in children 

First:  strategies for viral infections and organelles
Second:  technological advances improving recombinant protein production in bacteria 

First:  strategies for viral infections and organelles
Second:  epidemiology and infection from the field 

First:  strategies for viral infections and organelles
Second:  mutation treatment and prenatal diagnosis of chinese cases of 

First:  strategies for viral infections and organelles
Second:  molecules in vitro antiviral activity of doxycycline against 

First:  strategies for viral infections and organelles
Second:  influenza opportunities and challenges 

First:  strategies for viral infections and organelles
Second:  online supplemental materials and methods for persistent infection and promiscuous recombination of multiple genotypes of an rna virus within a single host generate extensive diversity 

First:  strategies for viral infections and organelles
Second:  lassa virus diversity and feasibility for universal prophylactic vaccine 

First:  strategies for viral infections and organelles
Second:  epidemiology and infection original paper 

First:  strategies for viral infections and organelles
Second:  the fungal nature of pneumocystis 

First:  strategies for viral infections and organelles
Second:  viral emerging challenges in developing vaccination strategies 

First:  strategies for viral infections and organelles
Second:  oral presentations new aspects of emerging clostridium difficile infections pros and cons of molecular fingerprinting for clostridium difficile infections 

First:  strategies for viral infections and organelles
Second:  therapeutic advances in respiratory disease inhaled nitric oxide treatment in spontaneously breathing patients 

First:  strategies for viral infections and organelles
Second:  viral proteases as targets for chemotherapeutic intervention 

First:  strategies for viral infections and organelles
Second:  inhibitors of virus recent developments and prospects 

First:  strategies for viral infections and organelles
Second:  spinal fluid igg antibodies from patients with demyelinating diseases bind multiple bacteria 

First:  strategies for viral infections and organelles
Second:  as a targeted immunization strategy 

First:  strategies for viral infections and organelles
Second:  journal cardiac arrhythmias in a combination of viral and drug interactions 

First:  strategies for viral infections and organelles
Second:  prediction of the incubation period for and future virus disease outbreaks 

First:  strategies for viral infections and organelles
Second:  avian influenza in human in timely management and preparedness 

First:  strategies for viral infections and organelles
Second:  targeting of host genes as an antiviral strategy 

First:  strategies for viral infections and organelles
Second:  transient dominant selection for the modification and generation of recombinant infectious bronchitis 

First:  strategies for viral infections and organelles
Second:  epidemiology and infection prevention and control 

First:  strategies for viral infections and organelles
Second:  quantitative comparison of the efficiency of antibodies against and subunit of sars coronavirus spike protein in virus neutralization and blocking of receptor implications for the functional roles of subunit q 

First:  strategies for viral infections and organelles
Second:  clinical and risk factors for mortality in hospitalized patients with and cancer a propensity study 

First:  strategies for viral infections and organelles
Second:  factor influences for diagnosis and vaccination of avian infectious bronchitis virus in chickens 

First:  strategies for viral infections and organelles
Second:  transcriptional profiling of immune and inflammatory responses in the context of fungal in a human airway epithelial model 

First:  strategies for viral infections and organelles
Second:  bacteriophage inhibition of pseudomonas aeruginosa biofilm on endotracheal tube surface human and infectious diseases school of nursing of 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  sensitivity analysis of the effects of interventions on in europe 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  article a combining a biomarker and clinical factors for predicting survival of 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  potential of in vitro 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  genetic hypothesis and side of in 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  and prognostic significance in 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  older experience of the a analysis of stresses and joys 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  recent advancements in the and prospective drug therapy of 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  clinical potential of for assessing comparative analysis 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  levels of and in the lungs of pneumonia patients 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  editorial the role of the laboratory in the diagnosis of gastrointestinal infections 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  ultrasonography in the initial characterization of patients with 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  spatial and epidemiology modelling in the spatial and statistical assessments 

First:  improves and markers in males and an exploratory analysis of a trial early therapy with biochemical running the biochemical trial
Second:  epidemiology and infection prevention and control 

First:  when species and data meet
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  when species and data meet
Second:  and what evidence needs our 

First:  modern tools for rapid diagnostics of antimicrobial resistance
Second:  spectrum of antimicrobial activity for disinfection of 

First:  modern tools for rapid diagnostics of antimicrobial resistance
Second:  clinical potential of for assessing comparative analysis 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  healthcare elements of suffering in fatigue the experience of and trauma in the severely and very severely affected 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  in adult patients with hematological analysis of clinical characteristics and outcomes 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  journal prospects of nutritional interventions in the care of patients prospects of nutritional interventions in the care of patients 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  and prognostic significance in 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  and chronic the impact now and in the future the problem of and chronic disease 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  recent advancements in the and prospective drug therapy of 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  levels of and in the lungs of pneumonia patients 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  clinical characteristics and outcomes of influenza and other illnesses in mexico city 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  socioeconomic correlates of obesity in and men and women 

First:  journal risk of and major adverse clinical outcomes among people with disabilities in south korea risk of and major adverse clinical outcomes among people with disabilities in south korea
Second:  epidemiology and infection prevention and control 

</pre>
</div>
</div>

</div>

</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h3 id="3.2.2-Parallel-approach">3.2.2 Parallel approach<a class="anchor-link" href="#3.2.2-Parallel-approach">&#182;</a></h3>
</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[54]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">results</span> <span class="o">=</span> <span class="p">[]</span>
<span class="n">start_parallel</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
<span class="n">n_papers</span> <span class="o">=</span> <span class="mi">20</span>

<span class="k">for</span> <span class="n">k</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">n_papers</span><span class="p">):</span>
    <span class="k">for</span> <span class="n">l</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">k</span> <span class="o">+</span> <span class="mi">1</span><span class="p">):</span>
        
        <span class="n">first_index</span> <span class="o">=</span> <span class="n">k</span>
        <span class="n">second_index</span> <span class="o">=</span> <span class="n">l</span>

        <span class="n">m_1</span> <span class="o">=</span> <span class="n">new_list</span><span class="p">[</span><span class="n">first_index</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">]</span>
        <span class="n">m_2</span> <span class="o">=</span> <span class="n">new_list</span><span class="p">[</span><span class="n">second_index</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">]</span>
        
        <span class="n">m_3</span> <span class="o">=</span> <span class="p">[]</span>
        
        <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">m_2</span><span class="p">)):</span>
            <span class="k">for</span> <span class="n">j</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="nb">len</span><span class="p">(</span><span class="n">m_1</span><span class="p">)):</span>
                
                <span class="n">res</span> <span class="o">=</span> <span class="n">client</span><span class="o">.</span><span class="n">submit</span><span class="p">(</span><span class="n">cosine</span><span class="p">,</span> <span class="n">m_1</span><span class="p">[</span><span class="n">j</span><span class="p">],</span> <span class="n">m_2</span><span class="p">[</span><span class="n">i</span><span class="p">])</span>
                <span class="n">m_3</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">res</span><span class="p">)</span>
        <span class="n">m</span> <span class="o">=</span> <span class="n">client</span><span class="o">.</span><span class="n">submit</span><span class="p">(</span><span class="n">np</span><span class="o">.</span><span class="n">mean</span><span class="p">,</span> <span class="n">m_3</span><span class="p">)</span>
        <span class="n">results</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">m</span><span class="p">)</span>
        
<span class="n">final_matrix_parallel</span> <span class="o">=</span> <span class="n">client</span><span class="o">.</span><span class="n">gather</span><span class="p">(</span><span class="n">results</span><span class="p">)</span>
<span class="n">end_parallel</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
<span class="n">diff_parallel</span> <span class="o">=</span> <span class="n">end_parallel</span> <span class="o">-</span> <span class="n">start_parallel</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h3 id="3.3.3-Comparison-between-serial-and-parallel-approach">3.3.3 Comparison between serial and parallel approach<a class="anchor-link" href="#3.3.3-Comparison-between-serial-and-parallel-approach">&#182;</a></h3><p>Comparison between serial and parallel approach using only $20$ papers.</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[60]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">n_papers</span> <span class="o">=</span> <span class="mi">20</span>
<span class="n">final_matrix</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">zeros</span><span class="p">((</span><span class="n">n_papers</span><span class="p">,</span> <span class="n">n_papers</span><span class="p">))</span>
<span class="n">start_serial</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>

<span class="k">for</span> <span class="n">k</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span><span class="n">n_papers</span><span class="p">):</span>
    <span class="k">for</span> <span class="n">l</span> <span class="ow">in</span> <span class="nb">range</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span><span class="n">k</span><span class="o">+</span><span class="mi">1</span><span class="p">):</span>
        
        <span class="n">first_index</span> <span class="o">=</span> <span class="n">k</span>
        <span class="n">second_index</span> <span class="o">=</span> <span class="n">l</span>
        
        <span class="n">m_1</span> <span class="o">=</span> <span class="n">new_list</span><span class="p">[</span><span class="n">first_index</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">]</span>
        <span class="n">m_2</span> <span class="o">=</span> <span class="n">new_list</span><span class="p">[</span><span class="n">second_index</span><span class="p">][</span><span class="s2">&quot;embedding&quot;</span><span class="p">]</span>
        <span class="n">m_3</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">zeros</span><span class="p">((</span><span class="n">m_1</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">0</span><span class="p">],</span> <span class="n">m_2</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">0</span><span class="p">]))</span>
        
        <span class="k">for</span> <span class="n">i</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">m_3</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">0</span><span class="p">]):</span>
            <span class="k">for</span> <span class="n">j</span> <span class="ow">in</span> <span class="nb">range</span> <span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="n">m_3</span><span class="o">.</span><span class="n">shape</span><span class="p">[</span><span class="mi">1</span><span class="p">]):</span>
                
                <span class="n">m_3</span><span class="p">[</span><span class="n">i</span><span class="p">][</span><span class="n">j</span><span class="p">]</span> <span class="o">=</span> <span class="n">cosine</span><span class="p">(</span><span class="n">m_1</span><span class="p">[</span><span class="n">i</span><span class="p">][:]</span><span class="o">.</span><span class="n">T</span><span class="p">,</span> <span class="n">m_2</span><span class="p">[</span><span class="n">j</span><span class="p">][:]</span><span class="o">.</span><span class="n">T</span><span class="p">)</span>               
        <span class="n">final_matrix</span><span class="p">[</span><span class="n">k</span><span class="p">][</span><span class="n">l</span><span class="p">]</span> <span class="o">=</span> <span class="n">m_3</span><span class="o">.</span><span class="n">mean</span><span class="p">()</span>
        
<span class="n">end_serial</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
<span class="n">diff_serial</span> <span class="o">=</span> <span class="n">end_serial</span> <span class="o">-</span> <span class="n">start_serial</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[70]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s1">&#39;Computational time using parallel approach: </span><span class="si">{</span><span class="n">diff_parallel</span><span class="si">}</span><span class="s1">&#39;</span><span class="p">)</span>
<span class="nb">print</span><span class="p">(</span><span class="sa">f</span><span class="s1">&#39;Computational time using serial approach: </span><span class="si">{</span><span class="n">diff_serial</span><span class="si">}</span><span class="s1">&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>Computational time using parallel approach: 122.61365675926208
Computational time using serial approach: 0.49546051025390625
</pre>
</div>
</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>Parallel approach is considerably slower than serial approach.</p>

</div>
</div></section></section><section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h1 id="Appendix">Appendix<a class="anchor-link" href="#Appendix">&#182;</a></h1>
</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Performance-in-the-string-splitting">Performance in the string splitting<a class="anchor-link" href="#Performance-in-the-string-splitting">&#182;</a></h2>
</div>
</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<p>To split <code>string</code> we can use two different functions:</p>
<ul>
<li><code>string.split()</code> (this is an attribute of the string class).</li>
<li><code>word_tokenize(string)</code> from the <code>nltk</code> library.</li>
</ul>
<p>in the two cells below we study the performance with one document.</p>

</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[33]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;./json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="mi">20</span><span class="p">)</span>

<span class="k">def</span> <span class="nf">body_merge</span><span class="p">(</span><span class="n">record</span><span class="p">):</span>
    <span class="n">txt</span><span class="o">=</span><span class="s1">&#39;&#39;</span>
    <span class="k">for</span> <span class="n">reco</span> <span class="ow">in</span> <span class="n">record</span><span class="p">:</span>
        <span class="n">txt</span><span class="o">+=</span><span class="n">reco</span><span class="p">[</span><span class="s1">&#39;text&#39;</span><span class="p">]</span>
    <span class="k">return</span> <span class="n">txt</span>

<span class="n">text_bag</span> <span class="o">=</span> <span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;body_text&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">body_merge</span><span class="p">)</span>
<span class="n">string</span> <span class="o">=</span> <span class="n">text_bag</span><span class="o">.</span><span class="n">take</span><span class="p">(</span><span class="mi">1</span><span class="p">)[</span><span class="mi">0</span><span class="p">]</span>
<span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>    
<span class="n">remove_symbols</span> <span class="o">=</span><span class="s2">&quot;1 2 3 4 5 6 9 8 7 0 . / * - + ! &#39; ? ^ } @ #  ] { [ ) ( = !   $ % &amp; / &lt; &gt; \ | , ; . : - _ &lt; &gt;&quot;</span>
<span class="n">remove_symbols</span> <span class="o">=</span> <span class="n">remove_symbols</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
<span class="k">for</span> <span class="n">symbol</span> <span class="ow">in</span> <span class="n">remove_symbols</span><span class="p">:</span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">symbol</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[34]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="o">%</span><span class="k">timeit</span> string.split()
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>15.1 s  97.4 ns per loop (mean  std. dev. of 7 runs, 100000 loops each)
</pre>
</div>
</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[35]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="o">%</span><span class="k">timeit</span> word_tokenize(string)
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>1.42 ms  6.6 s per loop (mean  std. dev. of 7 runs, 1000 loops each)
</pre>
</div>
</div>

</div>

</div>

</div>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h2 id="Grid-search-number-of-workers-and-partitions">Grid-search number of workers and partitions<a class="anchor-link" href="#Grid-search-number-of-workers-and-partitions">&#182;</a></h2>
</div>
</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[2]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">if</span> <span class="n">WARM_START</span><span class="p">:</span>
    <span class="n">time_matrix_univ</span>    <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">load</span><span class="p">(</span><span class="s2">&quot;./univ.npy&quot;</span><span class="p">)</span>
    <span class="n">time_matrix_counts</span>  <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">load</span><span class="p">(</span><span class="s2">&quot;./counts.npy&quot;</span><span class="p">)</span>
    <span class="n">time_matrix_country</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">load</span><span class="p">(</span><span class="s2">&quot;./country.npy&quot;</span><span class="p">)</span>
    
<span class="k">else</span><span class="p">:</span>
    <span class="n">time_matrix_univ</span>    <span class="o">=</span> <span class="p">[]</span>
    <span class="n">time_matrix_counts</span>  <span class="o">=</span> <span class="p">[]</span>
    <span class="n">time_matrix_country</span> <span class="o">=</span> <span class="p">[]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[30]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">client</span> <span class="o">=</span> <span class="n">Client</span><span class="p">(</span><span class="s2">&quot;tcp://10.67.22.115:8786&quot;</span><span class="p">)</span>
<span class="n">client</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt">Out[30]:</div>



<div class="jp-RenderedHTMLCommon jp-RenderedHTML jp-OutputArea-output jp-OutputArea-executeResult" data-mime-type="text/html">
<div>
    <div style="width: 24px; height: 24px; background-color: #e1e1e1; border: 3px solid #9D9D9D; border-radius: 5px; position: absolute;"> </div>
    <div style="margin-left: 48px;">
        <h3 style="margin-bottom: 0px;">Client</h3>
        <p style="color: #9D9D9D; margin-bottom: 0px;">Client-f3d78098-0f10-11ec-9305-1913593babe3</p>
        <table style="width: 100%; text-align: left;">

        <tr>
        
            <td style="text-align: left;"><strong>Connection method:</strong> Direct</td>
            <td style="text-align: left;"></td>
        
        </tr>

        
            <tr>
                <td style="text-align: left;">
                    <strong>Dashboard: </strong> <a href="http://10.67.22.115:8787/status" target="_blank">http://10.67.22.115:8787/status</a>
                </td>
                <td style="text-align: left;"></td>
            </tr>
        

        </table>

        
            <details>
            <summary style="margin-bottom: 20px;"><h3 style="display: inline;">Scheduler Info</h3></summary>
            <div style="">
    <div>
        <div style="width: 24px; height: 24px; background-color: #FFF7E5; border: 3px solid #FF6132; border-radius: 5px; position: absolute;"> </div>
        <div style="margin-left: 48px;">
            <h3 style="margin-bottom: 0px;">Scheduler</h3>
            <p style="color: #9D9D9D; margin-bottom: 0px;">Scheduler-76aca3ab-88cd-45c8-91c0-1594c5447510</p>
            <table style="width: 100%; text-align: left;">
                <tr>
                    <td style="text-align: left;">
                        <strong>Comm:</strong> tcp://10.67.22.115:8786
                    </td>
                    <td style="text-align: left;">
                        <strong>Workers:</strong> 6
                    </td>
                </tr>
                <tr>
                    <td style="text-align: left;">
                        <strong>Dashboard:</strong> <a href="http://10.67.22.115:8787/status" target="_blank">http://10.67.22.115:8787/status</a>
                    </td>
                    <td style="text-align: left;">
                        <strong>Total threads:</strong> 24
                    </td>
                </tr>
                <tr>
                    <td style="text-align: left;">
                        <strong>Started:</strong> Just now
                    </td>
                    <td style="text-align: left;">
                        <strong>Total memory:</strong> 45.83 GiB
                    </td>
                </tr>
            </table>
        </div>
    </div>

    <details style="margin-left: 48px;">
        <summary style="margin-bottom: 20px;">
            <h3 style="display: inline;">Workers</h3>
        </summary>

        
        <div style="margin-bottom: 20px;">
            <div style="width: 24px; height: 24px; background-color: #DBF5FF; border: 3px solid #4CC9FF; border-radius: 5px; position: absolute;"> </div>
            <div style="margin-left: 48px;">
            <details>
                <summary>
                    <h4 style="margin-bottom: 0px; display: inline;">Worker: tcp://10.67.22.115:44687</h4>
                </summary>
                <table style="width: 100%; text-align: left;">
                    <tr>
                        <td style="text-align: left;">
                            <strong>Comm: </strong> tcp://10.67.22.115:44687
                        </td>
                        <td style="text-align: left;">
                            <strong>Total threads: </strong> 4
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Dashboard: </strong> <a href="http://10.67.22.115:41646/status" target="_blank">http://10.67.22.115:41646/status</a>
                        </td>
                        <td style="text-align: left;">
                            <strong>Memory: </strong> 7.64 GiB
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Nanny: </strong> tcp://10.67.22.115:41162
                        </td>
                        <td style="text-align: left;"></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="text-align: left;">
                            <strong>Local directory: </strong> /root/dask-worker-space/worker-lpw1c9dd
                        </td>
                    </tr>

                    

                    
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks executing: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in memory: </strong> 0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks ready: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in flight: </strong>0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>CPU usage:</strong> 2.0%
                        </td>
                        <td style="text-align: left;">
                            <strong>Last seen: </strong> Just now
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Memory usage: </strong> 78.51 MiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Spilled bytes: </strong> 0 B
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Read bytes: </strong> 45.82 kiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Write bytes: </strong> 48.53 kiB
                        </td>
                    </tr>
                    

                </table>
            </details>
            </div>
        </div>
        
        <div style="margin-bottom: 20px;">
            <div style="width: 24px; height: 24px; background-color: #DBF5FF; border: 3px solid #4CC9FF; border-radius: 5px; position: absolute;"> </div>
            <div style="margin-left: 48px;">
            <details>
                <summary>
                    <h4 style="margin-bottom: 0px; display: inline;">Worker: tcp://10.67.22.115:46540</h4>
                </summary>
                <table style="width: 100%; text-align: left;">
                    <tr>
                        <td style="text-align: left;">
                            <strong>Comm: </strong> tcp://10.67.22.115:46540
                        </td>
                        <td style="text-align: left;">
                            <strong>Total threads: </strong> 4
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Dashboard: </strong> <a href="http://10.67.22.115:39781/status" target="_blank">http://10.67.22.115:39781/status</a>
                        </td>
                        <td style="text-align: left;">
                            <strong>Memory: </strong> 7.64 GiB
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Nanny: </strong> tcp://10.67.22.115:44167
                        </td>
                        <td style="text-align: left;"></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="text-align: left;">
                            <strong>Local directory: </strong> /root/dask-worker-space/worker-_ekzd0sb
                        </td>
                    </tr>

                    

                    
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks executing: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in memory: </strong> 0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks ready: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in flight: </strong>0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>CPU usage:</strong> 4.0%
                        </td>
                        <td style="text-align: left;">
                            <strong>Last seen: </strong> Just now
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Memory usage: </strong> 78.34 MiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Spilled bytes: </strong> 0 B
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Read bytes: </strong> 53.87 kiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Write bytes: </strong> 56.73 kiB
                        </td>
                    </tr>
                    

                </table>
            </details>
            </div>
        </div>
        
        <div style="margin-bottom: 20px;">
            <div style="width: 24px; height: 24px; background-color: #DBF5FF; border: 3px solid #4CC9FF; border-radius: 5px; position: absolute;"> </div>
            <div style="margin-left: 48px;">
            <details>
                <summary>
                    <h4 style="margin-bottom: 0px; display: inline;">Worker: tcp://10.67.22.125:35895</h4>
                </summary>
                <table style="width: 100%; text-align: left;">
                    <tr>
                        <td style="text-align: left;">
                            <strong>Comm: </strong> tcp://10.67.22.125:35895
                        </td>
                        <td style="text-align: left;">
                            <strong>Total threads: </strong> 4
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Dashboard: </strong> <a href="http://10.67.22.125:37396/status" target="_blank">http://10.67.22.125:37396/status</a>
                        </td>
                        <td style="text-align: left;">
                            <strong>Memory: </strong> 7.64 GiB
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Nanny: </strong> tcp://10.67.22.125:36624
                        </td>
                        <td style="text-align: left;"></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="text-align: left;">
                            <strong>Local directory: </strong> /root/dask-worker-space/worker-f37bo_yq
                        </td>
                    </tr>

                    

                    
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks executing: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in memory: </strong> 0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks ready: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in flight: </strong>0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>CPU usage:</strong> 4.0%
                        </td>
                        <td style="text-align: left;">
                            <strong>Last seen: </strong> Just now
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Memory usage: </strong> 80.16 MiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Spilled bytes: </strong> 0 B
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Read bytes: </strong> 572.163151533421 B
                        </td>
                        <td style="text-align: left;">
                            <strong>Write bytes: </strong> 1.89 kiB
                        </td>
                    </tr>
                    

                </table>
            </details>
            </div>
        </div>
        
        <div style="margin-bottom: 20px;">
            <div style="width: 24px; height: 24px; background-color: #DBF5FF; border: 3px solid #4CC9FF; border-radius: 5px; position: absolute;"> </div>
            <div style="margin-left: 48px;">
            <details>
                <summary>
                    <h4 style="margin-bottom: 0px; display: inline;">Worker: tcp://10.67.22.125:38075</h4>
                </summary>
                <table style="width: 100%; text-align: left;">
                    <tr>
                        <td style="text-align: left;">
                            <strong>Comm: </strong> tcp://10.67.22.125:38075
                        </td>
                        <td style="text-align: left;">
                            <strong>Total threads: </strong> 4
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Dashboard: </strong> <a href="http://10.67.22.125:42055/status" target="_blank">http://10.67.22.125:42055/status</a>
                        </td>
                        <td style="text-align: left;">
                            <strong>Memory: </strong> 7.64 GiB
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Nanny: </strong> tcp://10.67.22.125:35807
                        </td>
                        <td style="text-align: left;"></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="text-align: left;">
                            <strong>Local directory: </strong> /root/dask-worker-space/worker-0hwlvqhc
                        </td>
                    </tr>

                    

                    
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks executing: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in memory: </strong> 0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks ready: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in flight: </strong>0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>CPU usage:</strong> 6.0%
                        </td>
                        <td style="text-align: left;">
                            <strong>Last seen: </strong> Just now
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Memory usage: </strong> 78.23 MiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Spilled bytes: </strong> 0 B
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Read bytes: </strong> 571.1143875178299 B
                        </td>
                        <td style="text-align: left;">
                            <strong>Write bytes: </strong> 1.89 kiB
                        </td>
                    </tr>
                    

                </table>
            </details>
            </div>
        </div>
        
        <div style="margin-bottom: 20px;">
            <div style="width: 24px; height: 24px; background-color: #DBF5FF; border: 3px solid #4CC9FF; border-radius: 5px; position: absolute;"> </div>
            <div style="margin-left: 48px;">
            <details>
                <summary>
                    <h4 style="margin-bottom: 0px; display: inline;">Worker: tcp://10.67.22.202:36191</h4>
                </summary>
                <table style="width: 100%; text-align: left;">
                    <tr>
                        <td style="text-align: left;">
                            <strong>Comm: </strong> tcp://10.67.22.202:36191
                        </td>
                        <td style="text-align: left;">
                            <strong>Total threads: </strong> 4
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Dashboard: </strong> <a href="http://10.67.22.202:45045/status" target="_blank">http://10.67.22.202:45045/status</a>
                        </td>
                        <td style="text-align: left;">
                            <strong>Memory: </strong> 7.64 GiB
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Nanny: </strong> tcp://10.67.22.202:35635
                        </td>
                        <td style="text-align: left;"></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="text-align: left;">
                            <strong>Local directory: </strong> /root/dask-worker-space/worker-ow2x5n0q
                        </td>
                    </tr>

                    

                    
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks executing: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in memory: </strong> 0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks ready: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in flight: </strong>0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>CPU usage:</strong> 4.0%
                        </td>
                        <td style="text-align: left;">
                            <strong>Last seen: </strong> Just now
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Memory usage: </strong> 77.18 MiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Spilled bytes: </strong> 0 B
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Read bytes: </strong> 872.370245771602 B
                        </td>
                        <td style="text-align: left;">
                            <strong>Write bytes: </strong> 1.21 kiB
                        </td>
                    </tr>
                    

                </table>
            </details>
            </div>
        </div>
        
        <div style="margin-bottom: 20px;">
            <div style="width: 24px; height: 24px; background-color: #DBF5FF; border: 3px solid #4CC9FF; border-radius: 5px; position: absolute;"> </div>
            <div style="margin-left: 48px;">
            <details>
                <summary>
                    <h4 style="margin-bottom: 0px; display: inline;">Worker: tcp://10.67.22.202:40092</h4>
                </summary>
                <table style="width: 100%; text-align: left;">
                    <tr>
                        <td style="text-align: left;">
                            <strong>Comm: </strong> tcp://10.67.22.202:40092
                        </td>
                        <td style="text-align: left;">
                            <strong>Total threads: </strong> 4
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Dashboard: </strong> <a href="http://10.67.22.202:43730/status" target="_blank">http://10.67.22.202:43730/status</a>
                        </td>
                        <td style="text-align: left;">
                            <strong>Memory: </strong> 7.64 GiB
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Nanny: </strong> tcp://10.67.22.202:41456
                        </td>
                        <td style="text-align: left;"></td>
                    </tr>
                    <tr>
                        <td colspan="2" style="text-align: left;">
                            <strong>Local directory: </strong> /root/dask-worker-space/worker-rfwkc0wm
                        </td>
                    </tr>

                    

                    
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks executing: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in memory: </strong> 0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Tasks ready: </strong> 0
                        </td>
                        <td style="text-align: left;">
                            <strong>Tasks in flight: </strong>0
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>CPU usage:</strong> 4.0%
                        </td>
                        <td style="text-align: left;">
                            <strong>Last seen: </strong> Just now
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Memory usage: </strong> 77.80 MiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Spilled bytes: </strong> 0 B
                        </td>
                    </tr>
                    <tr>
                        <td style="text-align: left;">
                            <strong>Read bytes: </strong> 1.79 kiB
                        </td>
                        <td style="text-align: left;">
                            <strong>Write bytes: </strong> 2.81 kiB
                        </td>
                    </tr>
                    

                </table>
            </details>
            </div>
        </div>
        

    </details>
</div>
            </details>
        

    </div>
</div>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h3 id="Word-count">Word count<a class="anchor-link" href="#Word-count">&#182;</a></h3>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[3]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">increment</span><span class="p">(</span><span class="n">tot</span><span class="p">,</span> <span class="n">x</span><span class="p">):</span>
    <span class="k">return</span> <span class="n">tot</span> <span class="o">+</span> <span class="n">x</span><span class="p">[</span><span class="s1">&#39;n_counts&#39;</span><span class="p">]</span>
<span class="k">def</span> <span class="nf">counts_of_word</span><span class="p">(</span><span class="n">body_text</span><span class="p">):</span>
    

    <span class="c1">##  Begin clean phase</span>
    <span class="n">string</span> <span class="o">=</span> <span class="s1">&#39;&#39;</span>
    <span class="k">for</span> <span class="n">txt</span> <span class="ow">in</span> <span class="n">body_text</span><span class="p">:</span>
        <span class="n">string</span> <span class="o">+=</span> <span class="n">txt</span><span class="p">[</span><span class="s2">&quot;text&quot;</span><span class="p">]</span>
        
    <span class="c1"># Now we have the string which contains the full body text of the documents in input, we &quot;lower&quot; it  </span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">lower</span><span class="p">()</span>
    
    <span class="c1"># We need to clean it up from the stop words and 1,2,3,4,5,6,7,8,9,0,?,^,:,.,-,_,!,&quot;,,$,%,&amp;,/,(,),=,?&lt;,&gt; and ,</span>
    <span class="n">remove_symbols</span> <span class="o">=</span><span class="s2">&quot;1 2 3 4 5 6 9 8 7 0 . / * - + ! &#39; ? ^ } @ #  ] { [ ` ) ( = !   $ % &amp; / &lt; &gt; \ | , ; . : - _ &lt; &gt;&quot;</span>
    <span class="n">remove_symbols</span> <span class="o">=</span> <span class="n">remove_symbols</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    
    <span class="k">for</span> <span class="n">symbol</span> <span class="ow">in</span> <span class="n">remove_symbols</span><span class="p">:</span>
        <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="n">symbol</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>
    
    <span class="c1"># The last symbol to clean is the &quot;, because we use it to create the string remove_symbols</span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">replace</span><span class="p">(</span><span class="s1">&#39;&quot;&#39;</span><span class="p">,</span><span class="s2">&quot;&quot;</span><span class="p">)</span>
    <span class="c1"># We have run the algorithm and we found out that some useless words appeare (also the alphabet)</span>
    <span class="c1"># however we remove it now </span>
    <span class="n">remove_words</span> <span class="o">=</span> <span class="n">stopwords</span><span class="o">.</span><span class="n">words</span><span class="p">(</span><span class="s2">&quot;english&quot;</span><span class="p">)</span> <span class="o">+</span> <span class="p">[</span><span class="s2">&quot;et&quot;</span><span class="p">,</span><span class="s2">&quot;al&quot;</span><span class="p">,</span><span class="s2">&quot;may&quot;</span><span class="p">,</span><span class="s2">&quot;figure&quot;</span><span class="p">,</span><span class="s2">&quot;results&quot;</span><span class="p">,</span><span class="s2">&quot;however&quot;</span><span class="p">,</span><span class="s2">&quot;fig&quot;</span><span class="p">]</span>
    <span class="n">remove_words</span> <span class="o">+=</span> <span class="s2">&quot;q w e r t y u i o p l k j h g f d s a z x c v b n m&quot;</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    <span class="n">string</span> <span class="o">=</span> <span class="n">string</span><span class="o">.</span><span class="n">split</span><span class="p">()</span>
    
    <span class="n">string</span> <span class="o">=</span> <span class="p">[</span><span class="n">word</span> <span class="k">for</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">string</span> <span class="k">if</span> <span class="ow">not</span> <span class="n">word</span> <span class="ow">in</span> <span class="n">remove_words</span><span class="p">]</span>
    
    <span class="c1">## End clean phase</span>
    
    <span class="c1">## Count phase</span>
    <span class="c1"># In this phase we count the single words using the numpy function unique</span>
    
    <span class="n">words</span><span class="p">,</span><span class="n">counts</span> <span class="o">=</span> <span class="n">np</span><span class="o">.</span><span class="n">unique</span><span class="p">(</span><span class="n">string</span><span class="p">,</span><span class="n">return_counts</span><span class="o">=</span><span class="kc">True</span><span class="p">)</span>
    <span class="c1">## The Output will be the follow : [(word1,frequencies1)...(wordn,frequenciesn)]</span>
    <span class="k">return</span> <span class="p">[{</span><span class="s2">&quot;word&quot;</span><span class="p">:</span><span class="n">i</span> <span class="p">,</span> <span class="s2">&quot;n_counts&quot;</span><span class="p">:</span> <span class="n">j</span><span class="p">}</span> <span class="k">for</span> <span class="n">i</span><span class="p">,</span><span class="n">j</span> <span class="ow">in</span> <span class="nb">zip</span><span class="p">(</span><span class="n">words</span><span class="p">,</span><span class="n">counts</span><span class="p">)]</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[92]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">grid_search_counts</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">):</span>

    <span class="n">start</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;../json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">)</span>
    <span class="n">words_counted_map</span> <span class="o">=</span> <span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;body_text&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">counts_of_word</span><span class="p">)</span>
    
    <span class="n">words_counted_reduce</span> <span class="o">=</span> <span class="n">words_counted_map</span><span class="o">.</span><span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">foldby</span><span class="p">(</span><span class="s1">&#39;word&#39;</span><span class="p">,</span> <span class="n">binop</span><span class="o">=</span><span class="n">increment</span><span class="p">,</span> 
                                      <span class="n">initial</span><span class="o">=</span><span class="mi">0</span><span class="p">,</span> <span class="n">combine</span> <span class="o">=</span> <span class="k">lambda</span> <span class="n">x</span><span class="p">,</span><span class="n">y</span><span class="p">:</span> <span class="n">x</span><span class="o">+</span><span class="n">y</span><span class="p">,</span> 
                                      <span class="n">combine_initial</span><span class="o">=</span><span class="mi">0</span><span class="p">)</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
    <span class="n">end</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">diff</span> <span class="o">=</span> <span class="n">end</span> <span class="o">-</span> <span class="n">start</span>
    
    <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;For </span><span class="si">{}</span><span class="s2"> partitions, computational time: </span><span class="si">{}</span><span class="s2">&quot;</span><span class="o">.</span><span class="n">format</span><span class="p">(</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="n">diff</span><span class="p">))</span>
    <span class="k">del</span> <span class="n">words_counted_map</span>
    <span class="k">del</span> <span class="n">words_counted_reduce</span>
    <span class="k">del</span> <span class="n">input_bag</span>
    <span class="k">return</span> <span class="n">diff</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[93]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">part</span> <span class="ow">in</span> <span class="n">n_partitions</span><span class="p">:</span>
    <span class="n">time_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">grid_search_counts</span><span class="p">(</span><span class="n">part</span><span class="p">))</span>
<span class="n">time_matrix_counts</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">time_list</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>For 1 partitions, computational time: 22.727080821990967
For 10 partitions, computational time: 12.804254293441772
For 20 partitions, computational time: 12.70289945602417
For 50 partitions, computational time: 13.307487487792969
For 100 partitions, computational time: 16.382213354110718
For 500 partitions, computational time: 15.22591257095337
</pre>
</div>
</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[3]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df_cm</span> <span class="o">=</span> <span class="n">pd</span><span class="o">.</span><span class="n">DataFrame</span><span class="p">(</span><span class="n">time_matrix_counts</span><span class="p">,</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span><span class="mi">2</span><span class="p">,</span><span class="mi">3</span><span class="p">,</span><span class="mi">4</span><span class="p">,</span><span class="mi">5</span><span class="p">,</span><span class="mi">6</span><span class="p">])</span>
<span class="n">plt</span><span class="o">.</span><span class="n">figure</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">16</span><span class="p">,</span><span class="mi">10</span><span class="p">))</span>
<span class="n">sn</span><span class="o">.</span><span class="n">set</span><span class="p">(</span><span class="n">font_scale</span><span class="o">=</span><span class="mf">1.7</span><span class="p">)</span> 
<span class="n">sn</span><span class="o">.</span><span class="n">heatmap</span><span class="p">(</span><span class="n">df_cm</span><span class="p">,</span> <span class="n">annot</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span> <span class="n">annot_kws</span><span class="o">=</span><span class="p">{</span><span class="s2">&quot;size&quot;</span><span class="p">:</span> <span class="mi">16</span><span class="p">},</span><span class="n">fmt</span><span class="o">=</span><span class="s2">&quot;.3f&quot;</span><span class="p">,</span>
               <span class="n">cbar_kws</span><span class="o">=</span><span class="p">{</span><span class="s1">&#39;label&#39;</span><span class="p">:</span><span class="s1">&#39;Execution time [s]&#39;</span><span class="p">},</span><span class="n">cmap</span><span class="o">=</span><span class="n">sn</span><span class="o">.</span><span class="n">color_palette</span><span class="p">(</span><span class="s2">&quot;inferno_r&quot;</span><span class="p">,</span><span class="mi">40</span><span class="p">))</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">&#39;workers&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">&#39;partitions&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">&quot;Computational time words counts algorithm search&quot;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">20</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
<span class="n">plt</span><span class="o">.</span><span class="n">style</span><span class="o">.</span><span class="n">use</span><span class="p">(</span><span class="s1">&#39;default&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h3 id="Countries">Countries<a class="anchor-link" href="#Countries">&#182;</a></h3>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[5]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">grid_search_countries</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">):</span>
    
    <span class="n">start</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;../json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">)</span>
    
    
    <span class="n">data_country</span> <span class="o">=</span> <span class="p">(</span><span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s2">&quot;metadata&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;authors&#39;</span><span class="p">)</span>
                   <span class="o">.</span><span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;affiliation&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="kc">None</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;location&#39;</span><span class="p">))</span>
    <span class="n">data_country</span> <span class="o">=</span> <span class="n">data_country</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
    
    <span class="n">country</span> <span class="o">=</span> <span class="n">data_country</span><span class="o">.</span><span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;country&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
    
    <span class="n">end</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">diff</span> <span class="o">=</span> <span class="n">end</span> <span class="o">-</span> <span class="n">start</span>
    
    <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;For </span><span class="si">{}</span><span class="s2"> partitions, computational time: </span><span class="si">{}</span><span class="s2">&quot;</span><span class="o">.</span><span class="n">format</span><span class="p">(</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="n">diff</span><span class="p">))</span>
    <span class="k">return</span> <span class="n">diff</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[31]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">part</span> <span class="ow">in</span> <span class="n">n_partitions</span><span class="p">:</span>
    <span class="n">time_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">grid_search_countries</span><span class="p">(</span><span class="n">part</span><span class="p">))</span>
<span class="n">time_matrix_country</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">time_list</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>For 1 partitions, computational time: 12.846150875091553
For 10 partitions, computational time: 3.831408977508545
For 20 partitions, computational time: 3.243894577026367
For 50 partitions, computational time: 3.040823459625244
For 100 partitions, computational time: 2.961162567138672
For 500 partitions, computational time: 3.3865442276000977
</pre>
</div>
</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[32]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df_cm</span> <span class="o">=</span> <span class="n">pd</span><span class="o">.</span><span class="n">DataFrame</span><span class="p">(</span><span class="n">time_matrix_country</span><span class="p">,</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span><span class="mi">2</span><span class="p">,</span><span class="mi">3</span><span class="p">,</span><span class="mi">4</span><span class="p">,</span><span class="mi">5</span><span class="p">,</span><span class="mi">6</span><span class="p">])</span>
<span class="n">plt</span><span class="o">.</span><span class="n">figure</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">16</span><span class="p">,</span><span class="mi">10</span><span class="p">))</span>
<span class="n">sn</span><span class="o">.</span><span class="n">set</span><span class="p">(</span><span class="n">font_scale</span><span class="o">=</span><span class="mf">1.7</span><span class="p">)</span> 
<span class="n">sn</span><span class="o">.</span><span class="n">heatmap</span><span class="p">(</span><span class="n">df_cm</span><span class="p">,</span> <span class="n">annot</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span> <span class="n">annot_kws</span><span class="o">=</span><span class="p">{</span><span class="s2">&quot;size&quot;</span><span class="p">:</span> <span class="mi">16</span><span class="p">},</span><span class="n">fmt</span><span class="o">=</span><span class="s2">&quot;.3f&quot;</span><span class="p">,</span>
               <span class="n">cbar_kws</span><span class="o">=</span><span class="p">{</span><span class="s1">&#39;label&#39;</span><span class="p">:</span><span class="s1">&#39;Execution time [s]&#39;</span><span class="p">},</span><span class="n">cmap</span><span class="o">=</span><span class="n">sn</span><span class="o">.</span><span class="n">color_palette</span><span class="p">(</span><span class="s2">&quot;inferno_r&quot;</span><span class="p">,</span><span class="mi">40</span><span class="p">))</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">&#39;workers&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">&#39;partitions&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">&quot;Computational time countries algorithm search&quot;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">20</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
<span class="n">plt</span><span class="o">.</span><span class="n">style</span><span class="o">.</span><span class="n">use</span><span class="p">(</span><span class="s1">&#39;default&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section>
<div class="jp-Cell-inputWrapper"><div class="jp-InputPrompt jp-InputArea-prompt">
</div><div class="jp-RenderedHTMLCommon jp-RenderedMarkdown jp-MarkdownOutput " data-mime-type="text/markdown">
<h3 id="Universities">Universities<a class="anchor-link" href="#Universities">&#182;</a></h3>
</div>
</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[96]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="k">def</span> <span class="nf">grid_search_univ</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">):</span>

    <span class="n">start</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">input_bag</span> <span class="o">=</span> <span class="n">db</span><span class="o">.</span><span class="n">read_text</span><span class="p">(</span><span class="s2">&quot;../json_singleline/*.json&quot;</span><span class="p">)</span><span class="o">.</span><span class="n">map</span><span class="p">(</span><span class="n">js</span><span class="o">.</span><span class="n">loads</span><span class="p">)</span><span class="o">.</span><span class="n">repartition</span><span class="p">(</span><span class="n">n_partitions</span><span class="p">)</span>
    
    <span class="n">data_univ</span> <span class="o">=</span> <span class="p">(</span><span class="n">input_bag</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;metadata&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;authors&#39;</span><span class="p">)</span><span class="o">.</span>
                 <span class="n">flatten</span><span class="p">()</span><span class="o">.</span><span class="n">pluck</span><span class="p">(</span><span class="s1">&#39;affiliation&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="kc">None</span><span class="p">))</span>
    <span class="n">data_univ</span> <span class="o">=</span> <span class="n">data_univ</span><span class="o">.</span><span class="n">to_dataframe</span><span class="p">()</span>
    <span class="n">univ</span> <span class="o">=</span> <span class="n">data_univ</span><span class="o">.</span><span class="n">groupby</span><span class="p">(</span><span class="s1">&#39;institution&#39;</span><span class="p">)</span><span class="o">.</span><span class="n">size</span><span class="p">()</span><span class="o">.</span><span class="n">compute</span><span class="p">()</span>
    
    <span class="n">end</span> <span class="o">=</span> <span class="n">time</span><span class="o">.</span><span class="n">time</span><span class="p">()</span>
    <span class="n">diff</span> <span class="o">=</span> <span class="n">end</span> <span class="o">-</span> <span class="n">start</span>
    
    <span class="nb">print</span><span class="p">(</span><span class="s2">&quot;For </span><span class="si">{}</span><span class="s2"> partitions, computational time: </span><span class="si">{}</span><span class="s2">&quot;</span><span class="o">.</span><span class="n">format</span><span class="p">(</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="n">diff</span><span class="p">))</span>
    
    <span class="k">return</span> <span class="n">diff</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[97]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">time_list</span> <span class="o">=</span> <span class="p">[]</span>
<span class="k">for</span> <span class="n">part</span> <span class="ow">in</span> <span class="n">n_partitions</span><span class="p">:</span>
    <span class="n">time_list</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">grid_search_univ</span><span class="p">(</span> <span class="n">part</span><span class="p">))</span>
<span class="n">time_matrix_univ</span><span class="o">.</span><span class="n">append</span><span class="p">(</span><span class="n">time_list</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>


<div class="jp-RenderedText jp-OutputArea-output" data-mime-type="text/plain">
<pre>For 1 partitions, computational time: 11.986531019210815
For 10 partitions, computational time: 3.139528274536133
For 20 partitions, computational time: 2.5777668952941895
For 50 partitions, computational time: 2.3963794708251953
For 100 partitions, computational time: 2.2514843940734863
For 500 partitions, computational time: 2.835209608078003
</pre>
</div>
</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell   ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[5]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">df_cm</span> <span class="o">=</span> <span class="n">pd</span><span class="o">.</span><span class="n">DataFrame</span><span class="p">(</span><span class="n">time_matrix_univ</span><span class="p">,</span> <span class="n">n_partitions</span><span class="p">,</span> <span class="p">[</span><span class="mi">1</span><span class="p">,</span><span class="mi">2</span><span class="p">,</span><span class="mi">3</span><span class="p">,</span><span class="mi">4</span><span class="p">,</span><span class="mi">5</span><span class="p">,</span><span class="mi">6</span><span class="p">])</span>
<span class="n">plt</span><span class="o">.</span><span class="n">figure</span><span class="p">(</span><span class="n">figsize</span><span class="o">=</span><span class="p">(</span><span class="mi">16</span><span class="p">,</span><span class="mi">10</span><span class="p">))</span>
<span class="n">sn</span><span class="o">.</span><span class="n">set</span><span class="p">(</span><span class="n">font_scale</span><span class="o">=</span><span class="mf">1.7</span><span class="p">)</span> 
<span class="n">sn</span><span class="o">.</span><span class="n">heatmap</span><span class="p">(</span><span class="n">df_cm</span><span class="p">,</span> <span class="n">annot</span><span class="o">=</span><span class="kc">True</span><span class="p">,</span> <span class="n">annot_kws</span><span class="o">=</span><span class="p">{</span><span class="s2">&quot;size&quot;</span><span class="p">:</span> <span class="mi">16</span><span class="p">},</span><span class="n">fmt</span><span class="o">=</span><span class="s2">&quot;.3f&quot;</span><span class="p">,</span>
               <span class="n">cbar_kws</span><span class="o">=</span><span class="p">{</span><span class="s1">&#39;label&#39;</span><span class="p">:</span><span class="s1">&#39;Execution time [s]&#39;</span><span class="p">},</span><span class="n">cmap</span><span class="o">=</span><span class="n">sn</span><span class="o">.</span><span class="n">color_palette</span><span class="p">(</span><span class="s2">&quot;inferno_r&quot;</span><span class="p">,</span><span class="mi">40</span><span class="p">))</span>
<span class="n">plt</span><span class="o">.</span><span class="n">xlabel</span><span class="p">(</span><span class="s1">&#39;workers&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">ylabel</span><span class="p">(</span><span class="s1">&#39;partitions&#39;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">16</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">title</span><span class="p">(</span><span class="s2">&quot;Computational time university algorithm search&quot;</span><span class="p">,</span><span class="n">fontsize</span><span class="o">=</span><span class="mi">20</span><span class="p">)</span>
<span class="n">plt</span><span class="o">.</span><span class="n">show</span><span class="p">()</span>
<span class="n">plt</span><span class="o">.</span><span class="n">style</span><span class="o">.</span><span class="n">use</span><span class="p">(</span><span class="s1">&#39;default&#39;</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

<div class="jp-Cell-outputWrapper">


<div class="jp-OutputArea jp-Cell-outputArea">

<div class="jp-OutputArea-child">

    
    <div class="jp-OutputPrompt jp-OutputArea-prompt"></div>




<div class="jp-RenderedImage jp-OutputArea-output ">
<img src="data:image/png;base64,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
"
>
</div>

</div>

</div>

</div>

</div></section><section><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[33]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span><span class="n">np</span><span class="o">.</span><span class="n">save</span><span class="p">(</span><span class="s2">&quot;counts&quot;</span><span class="p">,</span> <span class="n">time_matrix_counts</span><span class="p">)</span>
<span class="n">np</span><span class="o">.</span><span class="n">save</span><span class="p">(</span><span class="s2">&quot;univ&quot;</span><span class="p">,</span><span class="n">time_matrix_univ</span><span class="p">)</span>
<span class="n">np</span><span class="o">.</span><span class="n">save</span><span class="p">(</span><span class="s2">&quot;country&quot;</span><span class="p">,</span><span class="n">time_matrix_country</span><span class="p">)</span>
</pre></div>

     </div>
</div>
</div>
</div>

</div><div class="jp-Cell jp-CodeCell jp-Notebook-cell jp-mod-noOutputs  ">
<div class="jp-Cell-inputWrapper">
<div class="jp-InputArea jp-Cell-inputArea">
<div class="jp-InputPrompt jp-InputArea-prompt">In&nbsp;[&nbsp;]:</div>
<div class="jp-CodeMirrorEditor jp-Editor jp-InputArea-editor" data-type="inline">
     <div class="CodeMirror cm-s-jupyter">
<div class=" highlight hl-ipython3"><pre><span></span> 
</pre></div>

     </div>
</div>
</div>
</div>

</div></section></section>
</div>
</div>
</body>


<script>
require(
    {
      // it makes sense to wait a little bit when you are loading
      // reveal from a cdn in a slow connection environment
      waitSeconds: 15
    },
    [
      "https://unpkg.com/reveal.js@4.0.2/dist/reveal.js"
    ],

    function(Reveal){
        // Full list of configuration options available here: https://github.com/hakimel/reveal.js#configuration
        Reveal.initialize({
            controls: true,
            progress: true,
            history: true,
            transition: "slide",
        });

        var update = function(event){
          if(MathJax.Hub.getAllJax(Reveal.getCurrentSlide())){
            MathJax.Hub.Rerender(Reveal.getCurrentSlide());
          }
        };

        Reveal.addEventListener('slidechanged', update);

        function setScrollingSlide() {
            var scroll = true
            if (scroll === true) {
              var h = $('.reveal').height() * 0.95;
              $('section.present').find('section')
                .filter(function() {
                  return $(this).height() > h;
                })
                .css('height', 'calc(95vh)')
                .css('overflow-y', 'scroll')
                .css('margin-top', '20px');
            }
        }

        // check and set the scrolling slide every time the slide change
        Reveal.addEventListener('slidechanged', setScrollingSlide);
    }
);
</script>

</html>
